



Federal Register

1-6-06
Vol. 71 No. 4

Friday
Jan. 6, 2006

United States
Government
Printing Office


SUPERINTENDENT
OF DOCUMENTS
Washington, DC 20402

OFFICIAL BUSINESS
Penalty for Private Use, \$300

PERIODICALS

Postage and Fees Paid
U.S. Government Printing Office
(ISSN 0097-6326)

*****3-DIGIT 481
A FR BONN1346B MAR 07 R
BONNIE COLVIN
PROQUEST I & L
PO BOX 1346
ANN ARBOR MI 48106





Federal Register

1-6-06

Vol. 71 No. 4

Pages 873-1388

Friday

Jan. 6, 2006



The **FEDERAL REGISTER** (ISSN 0097-6326) is published daily, Monday through Friday, except official holidays, by the Office of the Federal Register, National Archives and Records Administration, Washington, DC 20408, under the Federal Register Act (44 U.S.C. Ch. 15) and the regulations of the Administrative Committee of the Federal Register (1 CFR Ch. I). The Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 is the exclusive distributor of the official edition. Periodicals postage is paid at Washington, DC.

The **FEDERAL REGISTER** provides a uniform system for making available to the public regulations and legal notices issued by Federal agencies. These include Presidential proclamations and Executive Orders, Federal agency documents having general applicability and legal effect, documents required to be published by act of Congress, and other Federal agency documents of public interest.

Documents are on file for public inspection in the Office of the Federal Register the day before they are published, unless the issuing agency requests earlier filing. For a list of documents currently on file for public inspection, see www.archives.gov.

The seal of the National Archives and Records Administration authenticates the Federal Register as the official serial publication established under the Federal Register Act. Under 44 U.S.C. 1507, the contents of the Federal Register shall be judicially noticed.

The Federal Register is published in paper and on 24x microfiche. It is also available online at no charge as one of the databases on GPO Access, a service of the U.S. Government Printing Office.

The online edition of the Federal Register www.gpoaccess.gov/nara, available through GPO Access, is issued under the authority of the Administrative Committee of the Federal Register as the official legal equivalent of the paper and microfiche editions (44 U.S.C. 4101 and 1 CFR 5.10). It is updated by 6 a.m. each day the Federal Register is published and includes both text and graphics from Volume 59, Number 1 (January 2, 1994) forward.

For more information about GPO Access, contact the GPO Access User Support Team, call toll free 1-888-293-6498; DC area 202-512-1530; fax at 202-512-1262; or via e-mail at gpoaccess@gpo.gov. The Support Team is available between 7:00 a.m. and 9:00 p.m. Eastern Time, Monday-Friday, except official holidays.

The annual subscription price for the Federal Register paper edition is \$749 plus postage, or \$808, plus postage, for a combined Federal Register, Federal Register Index and List of CFR Sections Affected (LSA) subscription; the microfiche edition of the Federal Register including the Federal Register Index and LSA is \$165, plus postage. Six month subscriptions are available for one-half the annual rate. The prevailing postal rates will be applied to orders according to the delivery method requested. The price of a single copy of the daily Federal Register, including postage, is based on the number of pages: \$11 for an issue containing less than 200 pages; \$22 for an issue containing 200 to 400 pages; and \$33 for an issue containing more than 400 pages. Single issues of the microfiche edition may be purchased for \$3 per copy, including postage. Remit check or money order, made payable to the Superintendent of Documents, or charge to your GPO Deposit Account, VISA, MasterCard, American Express, or Discover. Mail to: New Orders, Superintendent of Documents, P.O. Box 371954, Pittsburgh, PA 15250-7954; or call toll free 1-866-512-1800, DC area 202-512-1800; or go to the U.S. Government Online Bookstore site, see bookstore.gpo.gov.

There are no restrictions on the republication of material appearing in the Federal Register.

How To Cite This Publication: Use the volume number and the page number. Example: 71 FR 12345.

Postmaster: Send address changes to the Superintendent of Documents, Federal Register, U.S. Government Printing Office, Washington DC 20402, along with the entire mailing label from the last issue received.

SUBSCRIPTIONS AND COPIES

PUBLIC

Subscriptions:	
Paper or fiche	202-512-1800
Assistance with public subscriptions	202-512-1806
General online information	202-512-1530; 1-888-293-6498
Single copies/back copies:	
Paper or fiche	202-512-1800
Assistance with public single copies	1-866-512-1800 (Toll-Free)

FEDERAL AGENCIES

Subscriptions:	
Paper or fiche	202-741-6005
Assistance with Federal agency subscriptions	202-741-6005

FEDERAL REGISTER WORKSHOP

THE FEDERAL REGISTER: WHAT IT IS AND HOW TO USE IT

FOR:	Any person who uses the Federal Register and Code of Federal Regulations.
WHO:	Sponsored by the Office of the Federal Register.
WHAT:	Free public briefings (approximately 3 hours) to present: <ol style="list-style-type: none"> 1. The regulatory process, with a focus on the Federal Register system and the public's role in the development of regulations. 2. The relationship between the Federal Register and Code of Federal Regulations. 3. The important elements of typical Federal Register documents. 4. An introduction to the finding aids of the FR/CFR system.
WHY:	To provide the public with access to information necessary to research Federal agency regulations which directly affect them. There will be no discussion of specific agency regulations.
WHEN:	Wednesday, January 11, 2006 9:00 a.m.-Noon
WHERE:	Office of the Federal Register Conference Room, Suite 700 800 North Capitol Street, NW. Washington, DC 20002
RESERVATIONS:	(202) 741-6008



Contents

Federal Register

Vol. 70, No. 4

Friday, January 6, 2006

Agency for Healthcare Research and Quality

NOTICES

Meetings:

Citizens' Health Care Working Group, 934-935

Agriculture Department

See Animal and Plant Health Inspection Service

See Food and Nutrition Service

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 904

Animal and Plant Health Inspection Service

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 904-906

Environmental statements; availability, etc.:

Nonregulated status determinations—

Monsanto Co.; genetically engineered for insect resistance and glyphosate tolerance, 906-908

Army Department

See Engineers Corps

NOTICES

Environmental statements; availability, etc.:

Fort Bragg, NC; Overhills property integration into Fort Bragg Training Program, 920-921

Meetings:

Reserve Officers Training Corps Program Subcommittee, 921

Patent licenses; non-exclusive, exclusive, or partially exclusive:

Article of footwear with temperature regulation means, 921-922

Automated neurological assessment metrics (Anam), 922

Composition for treating sulfur mustard toxicity using same, 922

Method and apparatus for making body heating and cooling garments, 922

Method of prophylactically treating organophosphate poisoning, 922-923

Projectile launch assembly and method, 923

Blind or Severely Disabled, Committee for Purchase From People Who Are

See Committee for Purchase From People Who Are Blind or Severely Disabled

Centers for Disease Control and Prevention

NOTICES

Meetings:

Disease, Disability, and Injury Prevention and Control Special Emphasis Panels, 935

Centers for Medicare & Medicaid Services

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 935-937

Privacy Act; systems of records, 937-941

Commerce Department

See National Institute of Standards and Technology

See National Oceanic and Atmospheric Administration

Committee for Purchase From People Who Are Blind or Severely Disabled

NOTICES

Procurement list; additions and deletions, 909-910

Defense Department

See Army Department

See Engineers Corps

Energy Department

See Federal Energy Regulatory Commission

See National Nuclear Security Administration

Engineers Corps

NOTICES

Environmental statements; notice of intent:

Pike County, KY; Fishtrap Lake road construction project, 923-924

San Francisco Bay, CA; Shoreline study, Alviso Ponds and Santa Clara County Feasibility Report, 924-927

Environmental Protection Agency

RULES

Air pollutants, hazardous; national emission standards:

Metal cans; surface coating, 1378-1385

PROPOSED RULES

Air pollutants, hazardous; national emission standards:

Metal cans; surface coating, 1386-1387

Air quality implementation plans; approval and promulgation; various States:

Virginia, 890-894

Pesticides; tolerances in food, animal feeds, and raw agricultural commodities:

Iodomethane, 901-903

Water pollution control:

National Pollutant Discharge Elimination System—

Storm water discharges for oil and gas exploration, production, processing, or treatment operations, or transmission facilities, 894-901

Storm water discharges for oil and gas exploration, production, processing, or treatment operations, or transmission facilities, 894-901

NOTICES

Confidential business information and data transfer, 927-928

Environmental statements; availability, etc.:

Agency comment availability, 928

Agency weekly receipts, 928-929

Meetings:

Good Neighbor Environmental Board; teleconference, 929

Strategic approach to international chemicals management, 929-930

Pesticide programs:

Risk assessments—

Iodomethane, 930-933

Federal Aviation Administration

RULES

Airworthiness directives:

Airbus, 873-875

PROPOSED RULES

Class E airspace, 889-890

Federal Communications Commission**RULES**

Radio stations; table of assignments:
Minnesota, 877

NOTICES

Committees; establishment, renewal, termination, etc.:
Hurricane Katrina Impact on Communications Networks
Review Independent Panel, 933

Federal Energy Regulatory Commission**RULES**

Electric utilities (Federal Power Act):
Section 203 transactions; expeditious approval
procedures, 1348-1376

Federal Highway Administration**NOTICES**

Grants and cooperative agreements; availability, etc.:
Federal aid facilities; tolling authority for State and other
qualifying agencies, 965-969
Reports and guidance documents; availability, etc.:
Motor vehicle registration and licensed driver
information, 969-970
Value Pricing Pilot program; application guidelines, 970-
977

Federal Reserve System**NOTICES**

Banks and bank holding companies:
Formations, acquisitions, and mergers, 933-934
Permissible nonbanking activities, 934

Fish and Wildlife Service**NOTICES**

Environmental statements; availability, etc.:
Incidental take permits—
Guayanilla, PR; Puerto Rican nightjar, brown pelican,
and roseate tern, 951-953
Environmental statements; notice of intent:
San Francisco Bay, CA; Shoreline study, Alviso Ponds
and Santa Clara County Feasibility Report, 924-927

Food and Drug Administration**RULES**

Animal drugs, feeds, and related products:
Phenylbutazone powder, 875-876

NOTICES

Food for human consumption:
Food labeling—
Existing label stock use after trans fat labeling effective
date of January 1, 2006; extension request;
addendum, 941-942
Meetings:
Drug Safety and Risk Management Advisory Committee,
942
Oncological Drugs Advisory Committee, 942-943
Memorandum of understanding with Health Products and
Food Branch, Health Canada of Canada;
implementation, 944-950

Food and Nutrition Service**NOTICES**

Agency information collection activities; proposals,
submissions, and approvals, 908-909

General Services Administration**RULES**

Federal travel:
2006 privately owned vehicle mileage reimbursement,
876

NOTICES

Environmental statements; notice of intent:
Madawaska, ME; border station facility, 934

Health and Human Services Department

See Agency for Healthcare Research and Quality
See Centers for Disease Control and Prevention
See Centers for Medicare & Medicaid Services
See Food and Drug Administration
See Substance Abuse and Mental Health Services
Administration

Housing and Urban Development Department**NOTICES**

Homeless assistance; excess and surplus Federal properties,
950-951

Interior Department

See Fish and Wildlife Service
See Land Management Bureau

International Trade Commission**NOTICES**

Meetings; Sunshine Act, 954

Land Management Bureau**NOTICES**

Environmental statements; availability, etc.:
Agua Fria National Monument and Bradshaw-
Harquahala, AZ; resource management plan, 953-954

National Highway Traffic Safety Administration**RULES**

Motor vehicle safety standards:
Tires; performance requirements, 877-888

National Institute of Standards and Technology**NOTICES**

Agency information collection activities; proposals,
submissions, and approvals, 910-911

National Nuclear Security Administration**NOTICES**

Environmental statements; availability, etc.:
Y-12 National Security Complex, Anderson County, TN,
927

National Oceanic and Atmospheric Administration**NOTICES**

Agency information collection activities; proposals,
submissions, and approvals, 911-913
Fishery conservation and management:
Caribbean, Gulf, and South Atlantic fisheries—
Gulf of Mexico reef fish, 913-915
Meetings:
New England Fishery Management Council, 915-916
Scientific research permit determinations, etc., 916-920

Nuclear Regulatory Commission**NOTICES**

Applications, hearings, determinations, etc.:
PacifiCorp, 954-955

Pipeline and Hazardous Materials Safety Administration**NOTICES**

Meetings:

Pipeline safety—

Natural gas pipeline maximum allowable operating pressure for class locations reconsideration, 977–979

Securities and Exchange Commission**NOTICES**

Self-regulatory organizations; proposed rule changes:

Chicago Board Options Exchange, Inc., 955–958

Pacific Exchange, Inc., 958–959

Philadelphia Stock Exchange, Inc., 959–961

Social Security Administration**NOTICES**

Agency information collection activities; proposals, submissions, and approvals, 961–964

Representative fee assessment rate, 964

Substance Abuse and Mental Health Services Administration**NOTICES**

Meetings:

Substance Abuse Treatment Center National Advisory Council, 950

Surface Transportation Board**NOTICES**

Railroad operation, acquisition, construction, control, etc.:

Union Pacific Railroad Co., 979

Transportation Department

See Federal Aviation Administration

See Federal Highway Administration

See National Highway Traffic Safety Administration

See Pipeline and Hazardous Materials Safety Administration

See Surface Transportation Board

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 964–965

Veterans Affairs Department**NOTICES**

Medical benefits:

Medical care or services; reasonable charges; 2006 methodology changes, 982–1345

Separate Parts In This Issue**Part II**

Veterans Affairs Department, 982–1345

Part III

Energy Department, Federal Energy Regulatory Commission, 1348–1376

Part IV

Environmental Protection Agency, 1378–1387

Reader Aids

Consult the Reader Aids section at the end of this issue for phone numbers, online resources, finding aids, reminders, and notice of recently enacted public laws.

To subscribe to the Federal Register Table of Contents LISTSERV electronic mailing list, go to <http://listserv.access.gpo.gov> and select Online mailing list archives, FEDREGTOC-L, Join or leave the list (or change settings); then follow the instructions.

CFR PARTS AFFECTED IN THIS ISSUE

A cumulative list of the parts affected this month can be found in the Reader Aids section at the end of this issue.

14 CFR	
39.....	873
Proposed Rules:	
71.....	889
18 CFR	
2.....	1348
33.....	1348
21 CFR	
510.....	875
520.....	875
40 CFR	
63.....	1378
Proposed Rules:	
52 (2 documents).....	890, 892
63.....	1386
122.....	894
180.....	901
41 CFR	
301-10.....	876
47 CFR	
73.....	877
49 CFR	
571.....	877

Rules and Regulations

Federal Register

Vol. 71, No. 4

Friday, January 6, 2006

This section of the FEDERAL REGISTER contains regulatory documents having general applicability and legal effect, most of which are keyed to and codified in the Code of Federal Regulations, which is published under 50 titles pursuant to 44 U.S.C. 1510.

The Code of Federal Regulations is sold by the Superintendent of Documents. Prices of new books are listed in the first FEDERAL REGISTER issue of each week.

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. FAA-2005-21860; Directorate Identifier 2005-NM-032-AD; Amendment 39-14445; AD 2006-01-06]

RIN 2120-AA64

Airworthiness Directives; Airbus Model A330-200, A330-300, A340-200, and A340-300 Series Airplanes

AGENCY: Federal Aviation Administration (FAA), Department of Transportation (DOT).

ACTION: Final rule.

SUMMARY: The FAA is adopting a new airworthiness directive (AD) for certain Airbus Model A330-200, A330-300, A340-200, and A340-300 series airplanes. This AD requires operators to modify the hydraulic control block of the nose landing gear. This AD results from a report of an unexpected steering event (swerve) during the take-off roll of one affected airplane. We are issuing this AD to prevent loss of airplane steering while on the ground, which could result in the airplane going off the side of the runway.

DATES: This AD becomes effective February 10, 2006.

The Director of the Federal Register approved the incorporation by reference of certain publications listed in the AD as of February 10, 2006.

ADDRESSES: You may examine the AD docket on the Internet at <http://dms.dot.gov> or in person at the Docket Management Facility, U.S. Department of Transportation, 400 Seventh Street, SW., Nassif Building, room PL-401, Washington, DC.

Contact Airbus, 1 Rond Point Maurice Bellonte, 31707 Blagnac Cedex, France, for service information identified in this AD.

FOR FURTHER INFORMATION CONTACT: Tim Backman, Aerospace Engineer International Branch, ANM-116, FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington 98055-4056; telephone (425) 227-2797; fax (425) 227-1149.

SUPPLEMENTARY INFORMATION:

Examining the Docket

You may examine the airworthiness directive (AD) docket on the Internet at <http://dms.dot.gov> or in person at the Docket Management Facility office between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The Docket Management Facility office (telephone (800) 647-5227) is located on the plaza level of the Nassif Building at the street address stated in the ADDRESSES section.

Discussion

The FAA issued a notice of proposed rulemaking (NPRM) to amend 14 CFR part 39 to include an AD that would apply to certain Airbus Model A330-200, A330-300, A340-200, and A340-300 series airplanes. That NPRM was published in the *Federal Register* on July 19, 2005 (70 FR 41354). That NPRM proposed to require operators to modify the hydraulic control block of the nose landing gear.

Comments

We provided the public the opportunity to participate in the development of this AD. We have considered the comments received.

Request To Exclude Airplanes With Certain Modification From Applicability

The commenter requests that the applicability be revised to match the effectivity of French airworthiness directive F-2005-016, dated January 19, 2005. The French airworthiness directive excludes airplanes on which Airbus Modification 50650 has been embodied in production or Airbus Service Bulletin A330-32-3156 or A340-32-4194 has been embodied in service. The original issue of these service bulletins, both dated December 22, 2004, was referenced as the appropriate source of service information for accomplishing the actions proposed in the NPRM. The commenter states that this additional information in the applicability would be useful for compliance with the FAA

AD, particularly at the delivery level, and would help to avoid requests for alternate methods of compliance (AMOCs) once the AD is issued.

We partially agree with the commenter. We agree to revise the applicability to exclude airplanes on which Airbus Modification 50650 has been embodied in production. Airplanes on which Modification 50650 has been embodied are not subject to the identified unsafe condition. We disagree with including a reference to the service bulletins in the applicability. Paragraph (f) of the NPRM proposed to require accomplishing the actions in those service bulletins in order to ensure that the actions are accomplished on all affected airplanes. In addition, paragraph (e) of the NPRM and the final rule states, "You are responsible for having the actions required by this AD performed within the compliance times specified, unless the actions have already been done." If the service bulletins referenced in paragraph (f) are accomplished then, in accordance with paragraph (e), no further actions are necessary. Paragraph (e) accomplishes the purpose of the commenter's request regarding airplanes on which the service bulletins are embodied, without making an additional change to the applicability. Therefore, we have changed the applicability of the final rule to exclude airplanes on which Airbus Modification 50650 has been embodied in production, but we have not added a reference to the service bulletins in the applicability.

Request To Add Reference to Re-identified Parts

The commenter considers it useful to operators to add a new note at the end of paragraph (f) to state that "At the end of the modification: The hydraulic control block (HCB) part number (P/N) C24856000-9 will become P/N C24856000-11, and the HCB P/N C24856001-7 will become P/N C24856001-9."

We agree with the commenter. The information about the part numbers used for re-identifying the parts after the modification would be useful to operators. We have not added a new note, but have included this information in the existing Note 1 of the final rule. Note 1 refers to Messier-Bugatti Service Bulletin C24856-32-064, dated January 26, 2005, which is an additional source

of service information for doing the modification, and which also contains the references to the re-identified part numbers. We have also revised paragraph (g) of the final rule to remove the statement "unless it has been modified in accordance with paragraph (f) of this AD." The modified parts have a new part number, as specified in the revised Note 1.

Request To Add Airplanes to Applicability

The commenter requests that we add Airbus Model A330-302 and -303 airplanes to the applicability. The commenter points out that French airworthiness directive F-2005-016, dated January 19, 2005, and Airbus Service Bulletin A330-32-3156, dated December 22, 2004, which was referenced as a source of service information in the NPRM, both include these airplanes. The commenter acknowledges that Airbus Model A330-302 and -303 airplanes have not yet been certified by the FAA, but states that the certification is expected in the near future. The commenter suggests that, since the certification is expected and these airplane models are included in the mandated service information, they be included in the applicability of the final rule.

We do not agree with the commenter. AD actions are restricted to airplanes that are type certificated for operation in the United States under the provisions of section 21.29 of the Federal Aviation Regulations (14 CFR 21.29) and the applicable bilateral airworthiness agreement. However, should these airplanes be type certificated, we may consider further AD action. We have not changed the final rule in this regard.

Clarification of AMOC Paragraph

We have revised this action to clarify the appropriate procedure for notifying the principal inspector before using any approved AMOC on any airplane to which the AMOC applies.

Conclusion

We have carefully reviewed the available data, including the comments received, and determined that air safety and the public interest require adopting the AD with the changes described previously. We have determined that these changes will neither increase the economic burden on any operator nor increase the scope of the AD.

Costs of Compliance

This AD affects about 22 Model A330-200 and A330-300 airplanes of U.S. registry. The actions take about 39 work hours per airplane, at an average

labor rate of \$65 per work hour. There is no charge for required parts. Based on these figures, the estimated cost of this AD for U.S. operators is \$55,770, or \$2,535 per airplane.

There are currently no Model A340-200 or Model A340-300 airplanes on the U.S. Register. Should one of these airplanes be imported and placed on the U.S. Register in the future, the actions would take about 39 work hours per airplane, at an average labor rate of \$65 per work hour. Based on these figures, the estimated cost of this AD would be \$2,535 per airplane.

Authority for This Rulemaking

Title 49 of the United States Code specifies the FAA's authority to issue rules on aviation safety. Subtitle I, section 106, describes the authority of the FAA Administrator. Subtitle VII, Aviation Programs, describes in more detail the scope of the Agency's authority.

We are issuing this rulemaking under the authority described in subtitle VII, part A, subpart III, section 44701, "General requirements." Under that section, Congress charges the FAA with promoting safe flight of civil aircraft in air commerce by prescribing regulations for practices, methods, and procedures the Administrator finds necessary for safety in air commerce. This regulation is within the scope of that authority because it addresses an unsafe condition that is likely to exist or develop on products identified in this rulemaking action.

Regulatory Findings

We have determined that this AD will not have federalism implications under Executive Order 13132. This AD will not have a substantial direct effect on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government.

For the reasons discussed above, I certify that this AD:

- (1) Is not a "significant regulatory action" under Executive Order 12866;
- (2) Is not a "significant rule" under DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and
- (3) Will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

We prepared a regulatory evaluation of the estimated costs to comply with this AD and placed it in the AD docket. See the ADDRESSES section for a location to examine the regulatory evaluation.

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Incorporation by reference, Safety.

Adoption of the Amendment

Accordingly, under the authority delegated to me by the Administrator, the FAA amends 14 CFR part 39 as follows:

PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

2. The Federal Aviation Administration (FAA) amends § 39.13 by adding the following new airworthiness directive (AD):

2006-01-06 Airbus: Amendment 39-14445. Docket No. FAA-2005-21860; Directorate Identifier 2005-NM-032-AD.

Effective Date

(a) This AD becomes effective February 10, 2006.

Affected ADs

(b) None.

Applicability

(c) This AD applies to Airbus Model A330-201, -202, -203, -223, -243, -301, -321, -322, -323, -341, -342, and -343 airplanes; and Model A340-211, -212, -213, -311, -312, and -313 airplanes; certificated in any category; except airplanes on which Airbus Modification 50650 has been embodied in production.

Unsafe Condition

(d) This AD results from a report of an unexpected steering event (swerve) during the take-off roll of one affected airplane. We are issuing this AD to prevent loss of airplane steering while on the ground, which could result in the airplane going off the side of the runway.

Compliance

(e) You are responsible for having the actions required by this AD performed within the compliance times specified, unless the actions have already been done.

Modification

(f) Within 30 months after the effective date of this AD: Modify the hydraulic control block (HCB) in accordance with the Accomplishment Instructions of the applicable service bulletin in paragraph (f)(1) or (f)(2) of this AD.

(1) For Model A380-200 and A330-300 series airplanes: Airbus Service Bulletin A330-32-3156, dated December 22, 2004.

(2) For Model A340-200 and A340-300 series airplanes: Airbus Service Bulletin A340-32-4194, dated December 22, 2004.

Note 1: The Airbus service bulletins refer to Messier-Bugatti Service Bulletin C24856-

32-064, dated January 26, 2005, as an additional source of service information for doing the modification. At the end of the modification: The HCB part number (P/N) C24856000-9 will become P/N C24856000-11, and the HCB P/N C24856001-7 will become P/N C24856001-9.

Parts Installation

(g) After the effective date of this AD, no person may install on any airplane an HCB having P/N C24856000-9 or C24856001-7.

Alternative Methods of Compliance (AMOCs)

(h)(1) The Manager, ANM-116, Transport Airplane Directorate, FAA, has the authority to approve AMOCs for this AD, if requested in accordance with the procedures found in 14 CFR 39.19.

(2) Before using any AMOC approved in accordance with § 39.19 on any airplane to which the AMOC applies, notify the appropriate principal inspector in the FAA Flight Standards Certificate Holding District Office.

Related Information

(i) French airworthiness directive F-2005-016, dated January 19, 2005, also addresses the subject of this AD.

Material Incorporated by Reference

(j) You must use Airbus Service Bulletin A330-32-3156, dated December 22, 2004; or Airbus Service Bulletin A340-32-4194, dated December 22, 2004; as applicable; to perform the actions that are required by this AD, unless the AD specifies otherwise. The Director of the Federal Register approved the incorporation by reference of these documents in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Contact Airbus, 1 Rond Point Maurice Bellonte, 31707 Blagnac Cedex, France, for a copy of this service information. You may review copies at the Docket Management Facility, U.S. Department of Transportation, 400 Seventh Street SW., room PL-401, Nassif Building, Washington, DC; on the Internet at <http://dms.dot.gov>; or at the National Archives and Records Administration (NARA). For information on the availability of this material at the NARA, call (202) 741-6030, or go to http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html.

Issued in Renton, Washington, on December 27, 2005.

Ali Bahrami,

Manager, Transport Airplane Directorate, Aircraft Certification Service.

[FR Doc. 06-62 Filed 1-5-06; 8:45 am]

BILLING CODE 4910-13-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510 and 520

Oral Dosage Form New Animal Drugs; Phenylbutazone Powder

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by A & G Pharmaceuticals, Inc. The ANADA provides for the veterinary prescription use of phenylbutazone powder administered to horses in feed for the relief of inflammatory conditions associated with the musculoskeletal system.

DATES: This rule is effective January 6, 2006.

FOR FURTHER INFORMATION CONTACT: John K. Harshman, Center for Veterinary Medicine (HFV-104), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-276-9808, e-mail: john.harshman@fda.gov.

SUPPLEMENTARY INFORMATION: A & G Pharmaceuticals, Inc., 1030 West Commodore Blvd., Jackson, NJ 08527, filed ANADA 200-334 that provides for the veterinary prescription use of EQUIZONE 100 (phenylbutazone), a powder administered to horses in feed for the relief of inflammatory conditions associated with the musculoskeletal system. A & G Pharmaceuticals, Inc.'s, EQUIZONE 100 is approved as a generic copy of Phoenix Scientific, Inc.'s, Phenylbutazone Tablets, USP, approved under NADA 91-818. The ANADA is approved as of November 18, 2005, and the regulations are amended in 21 CFR part 520 by adding new § 520.1720e. The basis of approval is discussed in the freedom of information summary.

In addition, A & G Pharmaceuticals, Inc., has not been previously listed in the animal drug regulations as a sponsor of an approved application. At this time, 21 CFR 510.600(c) is being amended to add entries for the firm.

In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9

a.m. and 4 p.m., Monday through Friday.

FDA has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

List of Subjects

21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

21 CFR Part 520

Animal drugs.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 520 are amended as follows:

PART 510—NEW ANIMAL DRUGS

■ 1. The authority citation for 21 CFR part 510 continues to read as follows:

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

■ 2. Section 510.600 is amended in the table in paragraph (c)(1) by alphabetically adding a new entry for "A & G Pharmaceuticals, Inc." and in the table in paragraph (c)(2) by numerically adding a new entry for "057699" to read as follows:

§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.

* * * * *	
(c) * * *	
(1) * * *	
Firm name and address	Drug labeler code
A & G Pharmaceuticals, Inc., 1030 West Commodore Blvd., Jackson, NJ 08527.	057699
* * * * *	
(2) * * *	
Drug labeler code	Firm name and address
* * * * *	* * * * *

Drug labeler code	Firm name and address
057699	A & G Pharmaceuticals, Inc., 1030 West Commodore Blvd., Jackson, NJ 08527

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

■ 3. The authority citation for 21 CFR part 520 continues to read as follows:

Authority: 21 U.S.C. 360b.

■ 4. Section 520.1720e is added to read as follows:

§ 520.1720e Phenylbutazone powder.

(a) *Specifications.* Each 10 grams (g) of powder contains 1 g phenylbutazone.

(b) *Sponsor.* See No. 057699 in § 510.600(c) of this chapter.

(c) *Conditions of use in horses—(1) Amount.* Administer 1 to 2 g (1 to 2 level scoops, using the scoop provided) per 500 pounds of body weight on a small amount of palatable feed.

(2) *Indications for use.* For the relief of inflammatory conditions associated with the musculoskeletal system.

(3) *Limitations.* Do not exceed 4 g per animal daily. Administer at a relatively high dosage level for the first 48 hours, then reduce gradually to a maintenance dosage level with the lowest dosage maintained at the level capable of producing the desired clinical response. Do not use in horses intended for human consumption. Federal law prohibits the extralabel use of this product in female cattle 20 months of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dated: December 21, 2005.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 06–90 Filed 1–5–06; 8:45 am]

BILLING CODE 4160–01–S

GENERAL SERVICES ADMINISTRATION

41 CFR Part 301–10

[FTR Amendment 2005–07; FTR Case 2005–308]

RIN 3090–A121

Federal Travel Regulation; 2006 Privately Owned Vehicle Mileage Reimbursement

AGENCY: Office of Governmentwide Policy, General Services Administration (GSA).

ACTION: Final rule.

SUMMARY: This final rule amends the mileage reimbursement rate for use of a privately owned automobile (POA) on official travel to reflect the decrease in the single standard mileage rate established by the Internal Revenue Service (IRS). 5 U.S.C. 5704(a)(1) prohibits GSA from exceeding the single standard mileage rate established by the IRS. Accordingly, the FTR is revised to decrease the reimbursement of operating a POA from \$0.485 to \$0.445 per mile.

DATES: Effective date: This final rule is effective January 6, 2006. Applicability date: This final rule is effective for travel performed on and after January 1, 2006.

FOR FURTHER INFORMATION CONTACT: The Regulatory Secretariat, Room 4035, GS Building, Washington, DC, 20405, (202) 208–7312, for information pertaining to status or publication schedules. For clarification of content, contact Umeki Thorne, Office of Governmentwide Policy, email umeki.thorne@gsa.gov or by telephone at (202) 208–7636. Please cite FTR Amendment 2005–07, FTR case 2005–308.

SUPPLEMENTARY INFORMATION:

A. Background

Pursuant to 5 U.S.C 5707(b), the Administrator of General Services has the responsibility to prescribe the privately owned vehicle (POV) mileage reimbursement rates to which Federal employees are entitled when using their privately owned airplanes, automobiles, and motorcycles while engaged on official business. As provided for in 5 U.S.C. 5704(a)(1), the automobile reimbursement rate established by the Administrator of General Services cannot exceed the single standard mileage rate established by the Internal Revenue Service (IRS) for purposes of calculating the deductible costs of operating an automobile for business purposes. The IRS issued Revenue Procedure 2005–78 announcing the new single standard mileage rate for automobiles would be \$0.445 per mile effective on January 1, 2006. At this time, this change only affects the mileage reimbursement for privately owned automobiles. GSA is obtaining data from industry sources to determine if an increase or decrease in the mileage reimbursement allowances is warranted for motorcycles and airplanes.

B. Executive Order 12886

This is not a significant regulatory action and, therefore, was not subject to review under Section 6(b) of Executive Order 12866, Regulatory Planning and Review, dated September 30, 1993. This

final rule is not a major rule under 5 U.S.C. 804.

C. Regulatory Flexibility Act

This final rule is not required to be published in the *Federal Register* for notice and comment; therefore, the Regulatory Flexibility Act, 5 U.S.C. 601, *et seq.*, does not apply.

D. Paperwork Reduction Act

The Paperwork Reduction Act does not apply because the changes to the FTR do not impose recordkeeping or information collection requirements, or the collection of information from offerors, contractors, or members of the public which require the approval of the Office of Management and Budget (OMB) under 44 U.S.C. 3501, *et seq.*

E. Small Business Regulatory Enforcement Fairness Act

This final rule is also exempt from congressional review prescribed under 5 U.S.C. 801 since it relates solely to agency management and personnel.

List of Subjects in 41 CFR Part 301–10

Government employees, Travel and transportation expenses.

Dated: December 21, 2005.

David L. Bibb,

Acting Administrator of General Services.

■ For the reasons set forth in the preamble, under 5 U.S.C. 5701–5709, the General Services Administration (GSA) amends 41 CFR part 301–10 as set forth below:

PART 301–10—TRANSPORTATION EXPENSES

■ 1. The authority citation for 41 CFR part 301–10 is added to read as follows:

Authority: 5 U.S.C. 5707; 40 U.S.C. 121(c), 49 U.S.C. 40118, Office of Management and Budget Circular No. A–126, “Improving the Management and Use of Government Aircraft.” Revised May 22, 1992.

§ 301–10.303 [Amended]

■ 2. In § 301–10.303, in the table, in the second column, in the third entry under the heading “Your reimbursement is”, add “\$0.445”.

[FR Doc. 06–86 Filed 1–5–06; 8:45 am]

BILLING CODE 6820–14–S

FEDERAL COMMUNICATIONS COMMISSION**47 CFR Part 73**

[DA 05-3211; MB Docket No. 04-339, RM-11060]

Radio Broadcasting Services; Grand Portage, MN**AGENCY:** Federal Communications Commission.**ACTION:** Final rule.

SUMMARY: The Audio Division, at the request of Cook County Broadcasting of Minnesota, allots Channel 245C0 at Grand Portage, Minnesota, as the community's first local FM service. Channel 245C0 can be allotted to Grand Portage, Minnesota, in compliance with the Commission's minimum distance separation requirements at city reference coordinates without site restriction. The coordinates for Channel 245C0 at Grand Portage, Minnesota, are 47-57-50 North Latitude and 89-41-05 West Longitude. The Government of Canada has concurred in this allotment, which is located within 320 kilometers (199 miles) of the U.S.-Canadian border.

DATES: Effective January 30, 2006.**ADDRESSES:** Federal Communications Commission, 445 Twelfth Street, SW., Washington, DC 20554.**FOR FURTHER INFORMATION CONTACT:** Deborah Dupont, Media Bureau, (202) 418-2180.

SUPPLEMENTARY INFORMATION: This is a synopsis of the Commission's *Report and Order*, MB Docket No. 04-339, adopted December 14, 2005, and released December 16, 2005. The full text of this Commission decision is available for inspection and copying during normal business hours in the FCC Information Center, Portals II, 445 12th Street, SW., Room CY-A257, Washington, DC 20554. The complete text of this decision also may be purchased from the Commission's duplicating contractor, Best Copy and Printing, Inc., 445 12th Street, SW., Room CY-B402, Washington, DC 0554, (800) 378-3160, or via the company's Web site, www.bcpweb.com. The Commission will send a copy of this *Report and Order* in a report to be sent to Congress and the Government Accountability Office pursuant to the Congressional Review Act, see U.S.C. 801(a)(1)(A).

List of Subjects in 47 CFR Part 73

Radio, Radio broadcasting.

■ Part 73 of title 47 of the Code of Federal Regulations is amended as follows:

PART 73—RADIO BROADCAST SERVICES

■ 1. The authority citation for Part 73 continues to read as follows:

Authority: 47 U.S.C. 154, 303, 334 and 336.

§ 73.202 [Amended]

■ 2. Section 73.202(b), the Table of FM Allotments under Minnesota, is amended by adding Grand Portage, Channel 245C0.

Federal Communications Commission.

John A. Karousos,

Assistant Chief, Audio Division, Media Bureau.

[FR Doc. 06-111 Filed 1-5-06; 8:45 am]

BILLING CODE 6712-01-P

DEPARTMENT OF TRANSPORTATION**National Highway Traffic Safety Administration****49 CFR Part 571**

[Docket No. NHTSA-2005-23439]

RIN 2127-AJ65

Federal Motor Vehicle Safety Standards; Tires**AGENCY:** National Highway Traffic Safety Administration (NHTSA), Department of Transportation.**ACTION:** Final rule; response to petitions for reconsideration.

SUMMARY: In June 2003, NHTSA published a final rule establishing upgraded tire performance requirements for new tires for use on vehicles with a gross vehicle weight rating of 10,000 pounds or less. This document responds to petitions for reconsideration of that final rule. After carefully considering the petitions, the agency is modifying certain performance requirements to better address snow tires and certain specialty tires. Specifically, we are amending the performance requirements for snow tires used on light vehicles. Further, we decided that the safety performance of certain other specialty tires is better addressed through the requirements of a different Federal safety standard.

DATES: The amendments in this rule are effective June 1, 2007, and delay the effective date of the Final Rule published on June 26, 2003 (68 FR 38115) from June 1, 2007 until September 1, 2007. Voluntary compliance is permitted before that time. In addition, "snow tires," as defined in S3 of 49 CFR 571.139 need not comply with the requirements of 49

CFR 571.139 until September 1, 2008, if they comply with applicable requirements in effect as of the date of this Final Rule. The incorporation by reference of certain publications listed in the regulations is approved by the Director of the Federal Register as of September 1, 2007.

FOR FURTHER INFORMATION CONTACT: For technical and policy issues: George Soodoo, Office of Crash Avoidance Standards. Telephone: (202) 366-2720. Fax: (202) 366-4329. E-mail: George.Soodoo@nhtsa.dot.gov.

For legal issues: George Feygin, Attorney Advisor, Office of Chief Counsel. Telephone: (202) 366-2992. Fax: (202) 366-3820. E-mail: George.Feygin@nhtsa.dot.gov.

Both persons may be reached at the following address: NHTSA, 400 7th Street, SW., Washington, DC 20590.

SUPPLEMENTARY INFORMATION:**Table of Contents**

- I. Summary of Final Rule
- II. Background
- III. Petitions for Reconsideration
- IV. Discussion and Analysis
 - A. Endurance Test Failure Due to Tire Chunking
 - B. Deep Tread LT Specialty Tires
 - C. Tire Conditioning Prior to Low-Pressure Performance Test
 - D. Test Temperature Tolerance
 - E. Calculation of Vehicle Normal Load
 - F. Time Limit for Measuring Post-Test Inflation Pressure
 - G. Permissible Level of Tire Pressure Loss
- V. Miscellaneous Issues and Technical Corrections to the Regulatory Text
- VI. Effective Date
- VII. Rulemaking Notices and Analyses
- VIII. Regulatory Text

I. Summary of Final Rule

First, this final rule amends Federal Motor Vehicle Safety Standard (FMVSS) No. 139, "New pneumatic tires for light vehicles" to reduce the endurance and low-pressure test speeds from 120 km/h to 110 km/h for snow tires. Second, this rule amends the application of FMVSS No. 139 to exclude light truck radial tires with a tread depth of 18/32 inches or greater. Instead these tires will be subject to the requirements of FMVSS No. 119. Third, this rule makes several technical corrections and amendments to the regulatory texts of FMVSS Nos. 109, 110, 119, 120 and 139. For example, because a test laboratory may not be able to maintain a constant ambient temperature the agency is specifying a tolerance during certain tests. Finally, we have delayed the effective date of the upgraded tire safety requirements from June 1, 2007 until September 1, 2007. Voluntary compliance is permitted before that date.

II. Background

The Transportation Recall Enhancement, Accountability, and Documentation (TREAD) Act, Section 10, "Endurance and resistance standards for tires," required NHTSA to revise and update Federal Motor Vehicle Safety Standard (FMVSS) No. 109, *New Pneumatic Tires*, and FMVSS No. 119, *New Pneumatic Tires for Vehicles Other than Passenger Cars*.¹ In response to this mandate, NHTSA published a final rule on June 26, 2003, establishing a new FMVSS No. 139, *New Pneumatic Radial Tires for Light Vehicles*, which will apply to new tires used on light vehicles; *i.e.*, vehicles with a gross vehicle weight rating of 10,000 pounds or less, except motorcycles and low speed vehicles.²

The new standard is scheduled to become effective on June 1, 2007. It features substantially more stringent high speed and endurance tests, and a new low-pressure performance test. The purpose of the new and more stringent requirements is to improve the ability of tires to withstand the effects of tire heat build-up and severe under-inflation during highway travel in fully loaded conditions. Unlike the existing tire safety standards, which previously differentiated between light trucks and passenger cars,³ FMVSS No. 139 applies to tires used on both.

The June 2003 final rule deferred action on proposals to revise the existing strength and bead unseating resistance tests, and to add a new tire-aging test, because the agency believed that additional research should be undertaken before reaching decision in these areas. Finally, the final rule changed the applicability of FMVSS No. 109 and FMVSS No. 119. Beginning June 1, 2007, FMVSS No. 109 would apply only to bias-ply tires and certain other specialty tires used on light vehicles. FMVSS No. 119 would apply to tires used on motorcycles, low speed vehicles, and heavy vehicles; *i.e.*, vehicles with a gross vehicle weight rating of more than 10,000 pounds.

III. Petitions for Reconsideration

NHTSA received petitions for reconsideration of the June 2003 final rule from eight petitioners who requested that NHTSA reconsider or otherwise address 18 issues described

below.⁴ The petitioners were Denman Tire (Denman), the Rubber Manufacturers Association (RMA), Japan Automobile Tyre Manufacturers Association (JATMA), European Tyre and Rim Technical Organization (ETRTO), Specialty Equipment Market Association (SEMA), Alliance of Automobile Manufacturers (Alliance), Tire and Rim Association (TRA), and Strategy Safety. Two commenters, the Small Business Administration (SBA) and the Tire Industry Association (TIA) submitted letters in support of Denman's petition to exclude its tires from FMVSS No. 139. The issues or subject areas addressed by the petitioners include the following:

- RMA, ETRTO, and JATMA requested that NHTSA either redefine tire chunking or not consider tire chunking to be an indication of tire failure during endurance testing.
- Denman petitioned the agency to exclude tires manufactured in quantities of less than 15,000 tires from the requirements of FMVSS No. 139, and instead subject these tires to the requirements of FMVSS No. 119.
- RMA, ETRTO, and JATMA petitioned the agency to clarify which tire safety standard applies to spare tires.
- JATMA petitioned the agency to revise the test conditions and procedures specified for the low-pressure performance test.
- JATMA, ETRTO, and RMA petitioned the agency to include a temperature tolerance of ± 3 °C to the ambient temperature of 38 °C specified for endurance and low-pressure testing of FMVSS No. 139.
- The RMA and ETRTO petitioned the agency to amend the method by which vehicle manufacturers calculate the vehicle normal load on the tire.
- Exclude ST, FL, and 8-12 rim diameter code tires.
- Definition of passenger car tire.
- RMA petitioned the agency to delete CT tires from the requirements of FMVSS No. 139 and other tire safety standards because CT tires are no longer being offered for sale in the U.S.
- Alliance petitioned the agency to change the effective date of FMVSS No. 139 from June 1, 2007 to September 1, 2007 to coincide with the traditional start of the new model year introduction.
- Allow FMVSS No. 139 tires on vehicles over 10,000 pounds.
- De-rating requirement.
- Measuring post-test inflation pressure.

- RMA petitioned the agency to correct the test pressures for LT tires with a nominal cross section larger than 295 mm.

- JATMA petitioned the agency to clarify the bead unseating test conditions for light truck tires.

IV. Discussion and Analysis

A. Endurance Test Failure Due to Tire Chunking

Under the new requirements of FMVSS No. 139, tires are subjected to endurance testing under different loading conditions at the speed of 120 km/h, for a combined duration of 34 hours. After completing the endurance test, the same tire is then subjected to a low-pressure performance test for an additional 90 minutes. S6.3.2(a) and S6.4.2(a) of FMVSS No. 139, require that when the tire is tested for endurance and low-pressure performance, " * * * there shall be no visual evidence of tread, sidewall, ply, cord, belt or bead separation, chunking, open splices, cracking or broken cords." Chunking is defined as " * * * breaking away of pieces of the tread or sidewall."⁵

RMA, ETRTO, and JATMA requested that NHTSA either redefine tire chunking or not consider tire chunking to be an indication of tire failure during endurance testing because petitioners believe that endurance test failures due to chunking are not representative of tire failures occurring in the real world.

RMA recommended that we either delete "chunking" from Sections S6.3.2(a) and S6.4.2(a), or modify the definition of "chunking" as follows: "Chunking means the breaking away of pieces of the tread or sidewall rubber extending to the reinforcement cord or wire material." That is, chunking would only be considered to occur if the breakaway pieces of tread or sidewall were deep enough to reach reinforcement cord or wire material. JATMA also asked the agency to redefine chunking such that it would be permitted for deep tread, winter type snow tires, and on light truck tires so long as it did not expose reinforcement cords.

RMA argued that chunking mostly occurs during endurance testing and is rarely experienced in the real world. RMA believes that chunking occurs in testing because the test road-wheel artificially overheats the tire by

¹ Pub. L. 106-414, November 1, 2000, 114 Stat. 1800.

² 68 FR 38115; June 26, 2003.

³ Historically, FMVSS No. 109 applied to tires for use on passenger cars and FMVSS No. 119 applied to tires for use on all other vehicles, including light trucks.

⁴ To examine the petitions please see Docket No. NHTSA-03-15400 at <http://dms.dot.gov/search/searchFormSimple.cfm>.

⁵ The existing tire safety requirements, FMVSSs No. 109 and 119, contain the same definition of "chunking." Additionally, the European Union tire regulations, Economic Commission for Europe (ECE) Regulation 30 for light vehicle tires and ECE Regulation 54 for heavy vehicle tires also contain a similar definition.

deflecting the tire's outer edges.⁶ This deflection occurs because the tire's contact patch flexes when contacting the curved surface of the test road-wheel, which is typically 67 inches (1.7 meters) in diameter. The difference between flat and curved surface performance increases as the tire's outside diameter increases, and/or the tread depth increases. According to RMA, this results in more energy being transferred into the tire, resulting in higher running temperatures.

According to RMA and ETRTO, the test road-wheel temperature difference is more pronounced for deep tread snow tires and certain light truck tires because

deep tread snow tires depend on the traction characteristics of higher hysteretic tread compounds, molded in greater tread depth, and smaller tread blocks. These tread designs and compounds are adversely affected by the greater deflection on the road-wheel and consequently run at disproportionately higher temperatures. Petitioners argue that the resultant tread chunking is uncharacteristic of real-world tire performance.

RMA states that its members subjected 352 passenger car tires of various sizes, service descriptions, load ranges and types to endurance and low-pressure testing. We note that the

duration of these tests exceeded the duration of tests specified in FMVSS No. 139 by six hours.⁷ Thirteen of the 35 deep tread snow tires failed that endurance test. All 13 failures were attributed to tread chunking. Out of 129 light truck (LT) tires of various sizes, 38 tires failed the 40-hour endurance test. Tread chunking was attributed to 44 percent of failures.

After we issued the June 2003 final rule, RMA performed additional testing using the FMVSS No. 139 duration parameters.⁸ The data are summarized below:

Tire type	Number tested	Number chunked	Percent failure
PC tires	157	9	6
PC snow tires	67	33	49
LT tires	87	6	7
LT snow tires	2	1	50
Total	313	49	16

* PC means passenger car.

RMA believes that the "no chunking" requirement penalizes larger tires because of material thickness (heavier lugs, ribs, plies, and deeper tread depth), especially at higher speed and reduced inflation pressure. The petitioners argue that the "no chunking" requirement will force tire manufacturers to redesign deep tread winter type snow tires and LT tires and that these tire design changes will not improve but will, to the contrary, reduce snow traction and off-road traction performance.

As an alternative to redefining chunking, petitioners suggested that the agency subject light truck tires and deep tread snow tires to the performance requirements of FMVSS No. 119, instead of FMVSS No. 139.

Agency Testing. Before issuing the June 2003 final rule, we tested a select sample of tires to assess their performance under the more stringent high-speed and endurance tests, and the new low-pressure test. Our tire sample varied not only in size, but also in price. We found that 19 out of 20 sampled tires passed all tests being contemplated by the agency. All five LT tires subjected to this testing passed. Fourteen out of 15 passenger car (PC) tires passed all the tests. One snow tire failed the endurance testing due to chunking.⁹

To address the issues raised in the petitions for reconsideration, the agency conducted additional testing on a larger sample of tires. We focused on the tires selected by vehicle manufacturers as

original equipment for new light vehicles, and similar-sized tires readily available in the replacement market. We also tested certain specialty tires discussed in Section IV(B). The test results are summarized in Table I below.

In addition to FMVSS No. 139 testing, the agency performed modified testing to assess the effectiveness of cooling fans in reducing the incidence of tire chunking during testing. We used a circulating fan to simulate the airflow across the tire that would normally occur on the roadway. The addition of fan did not affect tire performance. The tires that failed FMVSS No. 139 endurance and low-pressure performance tests did not pass the modified tests.

TABLE 1.—SUMMARY OF ENDURANCE/LOW-PRESSURE TIRE TESTING RESULTS

Tire category	Number tested	Number passed (%)	Number failed (%)	Number failed due to chunking (%)
Passenger Car Tires (PC)				
Regular PC	19	11 (58%) 2 of 2 (Michelin, Yokohama, Uniroyal, and Cooper). 3 of 4 Kelly-Springfield.	8 (42%) 7 of 8 Cokers, 1 Kelly-Springfield.	4 (50%) 1 Kelly-Springfield, 3 Coker.
Snow PC	28	18 (64%)	10 (36%) 2 of 2 Bridgestone Blizzak.	10 (100%).

⁶ Road-wheel machine is curved test wheel pressed against the test tire, rotating it to the specified test speed.

⁷ RMA tested tires to the proposed requirements of FMVSS No. 139, which specified testing for a

combined duration of 40 hours. As explained above, the June 2003 final rule specifies endurance testing for a combined duration of 34 hours.

⁸ The test data is available at Docket No. NHTSA-15400-21.

⁹ The agency tested Bridgestone Blizzak tire with a Q speed rating. Bridgestone describes the Blizzak as a "dedicated winter tire."

TABLE 1.—SUMMARY OF ENDURANCE/LOW-PRESSURE TIRE TESTING RESULTS—Continued

Tire category	Number tested	Number passed (%)	Number failed (%)	Number failed due to chunking (%)
Light Truck Tires (LT)				
Regular LT	12	7 (58%)	5 (42%) 1 Michelin, 2 Cooper, & 2 Fisk (Uniroyal).	0 (0%).
Snow LT	4	2 (50%) 2 of 2 Dunlop	2 (50%) 2 of 2 Yokohama.	2 (100%) Both Yokohama.
Specialty LT *see Section IV(b).	16	5 (31%) 1 of 8 Denman & 4 of 4 Goodyear	11 (69%) 7 of 8 Denman & 4 of 4 Specialty Tires of America.	3 (27%).

Observations:

- Chunking: Half of the failures (19/36, 53%) were due to chunking.
- Specialty LT: All four Goodyear 31x10.50R15 passed, while all 4 Denman 31x10.50R15 failed.
- Effectiveness of fan is inconclusive: 1 Kelly-Springfield PC did better with the fan; however 1 Coker PC did better without the fan.

Transport Canada conducted testing of LT and PC snow tires to FMVSS No. 139 test requirements, except that the test speed was reduced from 120 km/h to 110 km/h. The tests were performed at the Standards Testing Labs (STL) and Smithers Scientific Services (Smithers). STL tested 13 tires and Smithers Scientific Services tested 20 tires, including six LT snow tires. Of the 13 tires tested by STL, none failed. Of the 20 tires tested by Smithers, two PC snow tires failed because of chunking.¹⁰ The overall tire failure rate was 6%, or 2 out of 33 tires.

Agency Decision. Based on analysis of agency research and testing, as well as testing conducted by RMA and Transport Canada, we decided to amend certain performance requirements of FMVSS No. 139 as they apply to PC snow tires and LT snow tires. Specifically, we decided to reduce the endurance and low pressure performance test speeds in S6.3.1.2.3 and S6.4.2.1 from 120 km/h to 110 km/h for all PC snow tires and LT snow tires with load ranges of C, D, and E. All of the other test parameters in S6.3 and S6.4 remain unchanged.

The agency decided against eliminating "chunking" as a test failure condition because we did not receive data demonstrating that some fixed percentage of a tire's tread could break away without detrimental effect on safe vehicle operation.

In real world driving conditions, operating a vehicle with chunked tires creates a potential safety hazard due to wheel imbalance and vehicle vibrations. Further, allowing tread chunking just short of exposing the reinforcement

could create an unacceptable risk of imminent tire failure. Finally, we note that international standards such as ECE R 30 and ECE R 54 also deem tire chunking to be an indication of a safety problem.

The agency believes that because of the nature of snow tire construction, the speed specified in certain current tests of FMVSS No. 139 are impracticable for special tires. Specifically, snow tires usually feature higher hysteretic tread compounds, molded in greater tread depth, and smaller tread blocks. This construction is used to provide special performance in snow conditions. These tread designs and compounds are disproportionately affected at high speeds when tested on the road wheel. The technical design challenges and the costs to redesign existing snow tires to pass the 120 km/h test would far outweigh the negligible safety benefits associated with that redesign. By reducing the endurance and low-pressure test speeds from 120 km/h to 110 km/h for all PC snow tires and LT snow tires with load ranges of C, D, and E we can ensure virtually all the safety benefits from upgrading the test speed for snow tires and eliminate practicability and cost concerns.


The agency has decided not to reduce the test speed for non-snow LT tires. These tires did not experience chunking in our tests, and we believe the higher test speed is practicable for non-snow LT tires. The test results provided by RMA also indicate that chunking occurs infrequently in non-snow LT tires when tested at speeds and duration specified in S6.3.1.2.3 and S6.4.1.2.1.

The tire industry classifies tires as "snow tires" if they attain a traction index equal to or greater than 110, compared to the ASTM E-1136 Standard Reference Test Tire, when

using the snow traction test as described in ASTM F-1805, Standard Test Method for Single Wheel Driving Traction in a Straight Line on Snow- and Ice-Covered Surfaces. We are incorporating this voluntary consensus standard by reference in order to insure that the tires that do not attain a certain level of traction are not labeled as snow tires and subjected to less stringent testing.

In order to enable the agency to ascertain which tires are to be tested at 110 km/h, the agency is adding a labeling requirement to all PC snow tires and LT snow tires with load ranges of C, D, and E that are certified at this test speed. The manufacturers must mark their snow tires with the Alpine Symbol if they wish to certify their snow tires to the special requirements applicable to snow tires. The use of the Alpine Symbol will have the added benefit of enabling consumers to identify snow tires that provide a higher level of snow traction compared to all-season tires. However, the tire manufacturers are not obligated to do so if they wish to certify their snow tires to the normal requirements of the Standard. Thus, only the snow tires certified to the reduced test speed requirements must display an Alpine symbol (as shown below), on at least one sidewall. The symbol is currently required in Canada as a means of identifying snow tires.

¹⁰The two snow tires that chunked during testing at Smithers are Kumho Izen Stud (P205/75R15, 97Q) and Bridgestone Dueler DM-Z2 (P235/75R15, 105Q).



If the manufacturers choose to mark their snow tires with the Alpine Symbol, the mountain profile must have a minimum base of 15 mm and a minimum height of 15 mm, and must contain three peaks with the middle peak being the tallest. Inside the mountain profile, there must be a six-sided snowflake having a minimum height of one-half the tallest peak.

B. Deep Tread LT Specialty Tires

Denman produces Radial Deep Tread On-road/Off-road LT specialty radial tires (deep tread tires) used for significant off-road operations necessitating extended mobility on harsh terrain. Denman petitioned the agency to exclude these deep tread tires from the requirements of FMVSS 139 because the costs of compliance testing and certification would, according to the petitioner, cause it to go out of business. Instead, Denman asked that the agency subject their deep tread tires to the less stringent requirements of FMVSS No. 109 or FMVSS No. 119. The agency received letters from the U.S. Congress, the Small Business Administration, the Tire Industry Association and SEMA in support of Denman's petition.

Denman stated it has not tested any of their deep tread tires to the new requirements of FMVSS No. 139, because such tests are cost prohibitive. Denman argued that when issuing the June 2003 final rule, the agency excluded bias-ply tires for the reasons of practicability, and the same rationale should exclude their deep tread tires from the requirements of FMVSS No. 139. Denman argued that mandating more stringent and expensive tire performance requirements for specialty deep tread radial tires, but not for bias ply tires would encourage manufacturing of bias ply deep tread tires instead of deep tread radial tires. Denman recommended that NHTSA exclude radial tires with a $20/32$ -inch tread depth or greater and a rubber-to-void ratio of $3/4$ or lower.

Agency Testing and Research

Because there is no standard industry definition of rubber-to-void ratio, the

agency has decided to consider only the tread depth, which is an easily measured parameter, in addressing the issues raised by the Denman petition.

NHTSA tested sixteen of Denman's deep tread tires ($\geq 19/32$ inch tread depth) to the FMVSS No. 139 performance parameters. Our test results showed a higher failure rate for deep tread tires compared to the failure rates for original equipment non-deep tread tires. We believe the deep tread tires experienced chunking because of their tread depth. The results are as follows:

Type of test	Number of Denman tires tested	Number and percentage of Denman tires that passed
FMVSS No. 139 endurance and low-pressure tests	8	2 (25%)
FMVSS No. 139 high speed test	5	2 (40%)
FMVSS No. 119 endurance test	3	3 (100%)

Our research indicates that, with one exception,¹¹ vehicle manufacturers typically do not install tires with tread depth exceeding $19/32$ inches on their vehicles either as standard or optional equipment.

Agency Decision

Based agency testing and analysis, we believe that a number of the requirements in FMVSS No. 139 are impracticable for deep tread specialty tires with tread depth of at least $19/32$ inches. Because the thickness of the tread rubber of these tires causes higher tire temperatures, we believe that it is more appropriate to subject these tires to the requirements of FMVSS No. 119.¹² We note that in a letter to the agency on October 4, 2004, RMA provided endurance test results on 16 deep tread tires with tread depths of $19/32$ -inch or greater; 62 percent (10 of 16) failed due to chunking. The agency believes that any potential countermeasures could be cost prohibitive, and could also negatively impact the utility of deep tread tires, which serve a special purpose of

¹¹ Jeep Wrangler Rubicon is equipped with 245/75R16 Goodyear Wrangler MT/R tires with a tread depth of $19/32$ inches.

¹² FMVSS No. 119 endurance test for load range E tires is conducted at 40 mph at loading conditions of 70 percent/88 percent/106 percent for 47 hours (7/16/24 hours) at an inflation pressure corresponding to the maximum load rating marked on the tire sidewall.

providing increased navigational capabilities for vehicles used off-road.

C. Tire Conditioning Prior to Low Pressure Performance Test

JATMA petitioned the agency to revise the test conditions and procedures specified for the low pressure performance test such that at the completion of the endurance test, all hot air would be purged from the test tire and refilled with cold air before beginning the low-pressure test. JATMA did not provide a rationale or data supporting this recommendation, but its petition suggests that the tire would cool down quicker if purged of its hot air and refilled with cold air.

The agency believes that complete deflation and re-inflation of the test tire is unnecessary. Instead, in order to ensure that the tire is sufficiently cooled-off after completion of the endurance test, we are amending the low-pressure test conditions and procedures to specify that the tire is conditioned for a period of at least 3 hours prior to beginning the low-pressure test.¹³

D. Test Temperature Tolerance

JATMA, ETRTO, and RMA petitioned the agency to include a temperature tolerance of ± 3 °C to the ambient temperature of 38 °C specified for endurance and low-pressure testing of FMVSS No. 139. The petitioners note that this tolerance is currently specified in FMVSS No. 109. The RMA also petitioned the agency to lower the ambient temperature for the tire dimensions test since this test is typically performed in an area with an ambient of 20 °C–30 °C.

Because a test laboratory may not be able to maintain a constant ambient temperature of 38 °C, the agency is specifying a tolerance of +0 °C, -6 °C. That is, the tires subject to the high speed, endurance, and low pressure performance tests of FMVSS No. 139 must meet the applicable requirements at the full range of temperatures between 32 °C and 38 °C. For the tire dimensions test, the agency is specifying an ambient room temperature of 20 °C to 30 °C.

E. Calculation of Vehicle Normal Load

RMA and ETRTO petitioned the agency to amend the method by which vehicle manufacturers calculate the vehicle normal load on the tire, as specified by S4.2.1.2, S4.2.2.2 and S4.2.2.3 of FMVSS No. 110.

¹³ The agency has also amended the conditioning procedure which precedes the endurance testing by adding a tolerance of ± 5 minutes.

Specifically, the petitioners suggested that the vehicle normal load on the tire should not exceed 88 percent of tire maximum load.

The agency revised the definition of vehicle normal load to change the frame of reference from a percentage of the tire's maximum load to the percentage of the tire's load at the manufacturer's recommended tire pressure. Specifically, the normal load is defined as 94 percent of the vehicle manufacturer's recommended cold inflation pressure.

We believe that it is not appropriate to define normal load as 88% of maximum load rating because the manufacturer's recommended tire pressure for some vehicles equipped with, for example, LT load range E tires, could be far below their maximum inflation pressure. If we were to require normal load calculation based on the maximum inflation pressure, the normal load calculation would be different. Accordingly, the agency is denying the petitioner's request.

F. Time Limit for Measuring Post-Test Inflation Pressure

RMA and ETRTO petitioned the agency to amend the time limit for checking post-test inflation pressure from "at least one hour" to "at least 15 minutes after the end of the test."¹⁴ RMA explained that when post-test time period exceeds one hour, inflation pressure in the tires often falls below pre-test levels. Petitioners argue that the tire inflation pressure should be measured when the tire temperature has stabilized, which occurs within one hour, but not sooner than 15 minutes.

In the June 2003 final rule, the agency specified that all post-test pressure measurements be taken at least one hour after the test is completed. We indicated that the one-hour period provides a sufficient time for tire cooling and would prevent superficially high tire temperatures from masking test-induced pressure losses that would not be detectable at an earlier time. Further, this time period reduces the risk of tire explosion, which RMA stated could occur if tire pressure measurement was taken immediately after testing.

The agency is amending the time limit for post-test pressure measurement from "at least one hour" to "at any time between 15 minutes and 25 minutes" after the tests are completed. This change ensures that the pressure measurement does not occur after 25 minutes have elapsed. For tires known to retain more heat and therefore, higher inflation pressure, the change offers

enough flexibility to allow measurement after the 15 minute time period, in order to address technician safety. The agency believes that if a rapid loss of pressure to a level below the initial test pressure is to occur, it is likely to occur during the test or within the first 15 minutes after the end of the test. Thus, this change will not affect the stringency of the upgraded tire safety performance requirements.

G. Permissible Level of Tire Pressure Loss

RMA and ETRTO petitioned the agency to amend FMVSS No. 139 to allow for a pressure loss of not greater than 10 percent below the initial test pressure. Petitioners noted that small air losses occur during and after tests as a result of air diffusion through the tire casing. Further, some air also escapes during pressure measurement. According to the petitioners, additional variability factors could include tire pressure gauge accuracy, and the "initial break-in" factor; *i.e.* testing of new tires could result in some small mechanical growth of the tire casing (increase in pressure vessel volume). As a result, some post-test tire pressure measurements will show small pressure losses below the initial test pressure, which should not be indicative of tire failure. RMA suggested that a minimum permissible tire pressure loss criteria be specified.

RMA submitted information, data, and graphs on its testing by RMA member companies. A total of 313 tires (224 passenger car and 89 light truck tires) were tested to the FMVSS No. 139 endurance and low pressure performance tests. Of the 313 tires tested, 42 percent (133) experienced pressure loss per the FMVSS No. 139 conditions and procedures. The loss of pressure was attributed to the longer cool-down time periods addressed above. RMA stated that the 42 percent estimate could be higher as some tire manufacturers did not report pressure loss data to the RMA.

The agency agrees that some small mechanical growth of the tire casing could occur during the initial break-in of new tires, which could result in post-test pressures being slightly lower than the initial test pressure once the tire has cooled to ambient temperature. Although our testing did not show significant losses in tire pressure at 15 to 25 minutes after the completion of endurance and low-pressure testing, we believe that it is reasonable to allow for a nominal amount of post-test pressure drop. Accordingly, the agency will require that the post-test pressure loss

be no greater than 5% of the specified initial inflation pressure.

V. Miscellaneous Issues and Technical Corrections to the Regulatory Text

1. JATMA, ETRTO, RMA petitioned the agency to remove references to T-Type spare tires from S6.1.1.1.2 of FMVSS No. 139. Petitioners noted that footnote 38 of the June 2003 final rule indicated that temporary spare tires would not be subject to the requirements of FMVSS No. 139.¹⁵

The agency did not intend to subject T-Type temporary spare tires to the requirements of FMVSS No. 139. Therefore, NHTSA is amending the regulatory text of FMVSS No. 139 to remove references to T-Type temporary spare tires.

2. The RMA and ETRTO petitioned the agency to replace the term "P-metric" with the term "passenger car" in the regulatory text of FMVSS Nos. 109, 110 and 139. The RMA stated that using "P-metric" as a generic term for "passenger car" tires is not correct since the use of this terminology could exclude "Hard" metric or any other radial passenger car tire that does not have "P-metric" size designation.

NHTSA has reviewed the tire industry Year Books (TRA, JATMA, and ETRTO) and notes that tires used on passenger cars are referred to as "passenger car" tires and not "P-metric" tires.¹⁶ Therefore, the agency is amending the regulatory text of the relevant tire safety standards by removing references to "P-metric tires" where it is more appropriate to use the term "passenger car." In conjunction with this change, we are adding a definition of passenger car tires to FMVSS No. 139.

3. Alliance petitioned the agency to amend FMVSS No. 120 to allow the use of tires meeting FMVSS 139 in addition to those meeting FMVSS No. 119 for vehicles with a GVWR over 10,000 pounds.

The agency agrees that FMVSS No. 120 should allow the use of tires that comply with FMVSS No. 139. For example, LT tires with a load range E are sometimes used on vehicles with a GVWR below 10,000 pounds. Since FMVSS No. 139 applies to LT tires load range E tires, a reference to this standard should have been included in S5.1.1 of FMVSS No. 120. NHTSA believes this reference was inadvertently omitted from the June 2003 final rule.

¹⁵ See 68 FR 38116 at 38145.

¹⁶ The TRA Year Book states that the prefix, "P", when used in tire size designations identifies a tire primarily intended for service on passenger cars. In addition to the P-Type passenger car tires, the Year Book also includes information on T-Type passenger car tires and other passenger car tires.

¹⁴ See Docket No. NHTSA-2003-15400-23.

Accordingly, the agency is amending the regulatory text of S5.1.1 of FMVSS No. 120 to add a reference to FMVSS No. 139.

4. RMA, TRA, and ETRTO petitioned the agency to amend the "application" sections of FMVSS No. 119, "New pneumatic tires for vehicles other than passenger cars," to indicate that it applies to Special Trailer (ST), Farm Implement (FI), and 8-12 rim diameter code and below tires. We note that in the June 2003 final rule, the agency decided to exclude bias, ST, FI, and 8-12 rim diameter tires from the requirements of FMVSS No. 139 and indicated that they would remain subject to the requirements of FMVSS Nos. 109 and 119.¹⁷ However, the petitioners indicate that all such tires have been, and remain subject to only FMVSS No. 119 because they are not used on passenger cars.

The agency is amending the application sections of FMVSS Nos. 109, 119, and 139 in order to clarify that ST, FI, and 8-12 rim diameter code and below tires are subject to the requirements of FMVSS No. 119.

5. When a passenger car tire is installed on a traditionally heavier vehicle such as an MPV, truck, bus, or trailer, the normal load rating is "de-rated" by a factor of 1.10. That is, the normal load rating is reduced by dividing it by 1.10. The Alliance petitioned the agency to clarify that the de-rating requirement in FMVSS No. 120 applies only to passenger car tires, and not to all tires.

The agency intended to apply the 1.10 de-rating requirement in FMVSS No. 120 only to passenger car tires when installed on vehicles other than passenger cars. The agency did not intend to subject other tires to the same requirements. Accordingly, the agency is amending S5.1.2 of FMVSS No. 120 to clarify the application of the de-rating requirement.

6. Safety Research and Strategies (SRS) submitted comments urging the agency to address tire aging.¹⁸ In short, SRS is asking the agency to require that tires be labeled with an "expiration date" that would inform consumers that their tires are no longer safe after an X number of years have elapsed since their manufacture.

The agency is currently conducting research on tire aging. When this research is complete, the agency will decide how to proceed.

7. This document amends the titles to FMVSS No. 109 and FMVSS No. 139 to

more accurately reflect their application. The new titles read as follows: § 571.109—Standard No. 109—New pneumatic and certain specialty tires, and § 571.139—Standard No. 139—New pneumatic radial tires for light vehicles.

8. This document amends the table located below Figure 1 in FMVSS No. 109 to add a 20 rim diameter code because the Tire & Rim Association's 2003 and newer Yearbooks now include LT tires of that size.

9. ETRTO and RMA petitioned the agency to remove references to CT Tires from FMVSS No. 139 because CT tires are not being manufactured for sale or distribution in the United States.¹⁹ The petitioners also indicated that this tire type is being withdrawn as an active classification in the ETRTO Standards Manual.

This rule amends FMVSS No. 139 by removing references to CT tires because these tires are not being sold in the United States.

10. RMA and ETRTO petitioned the agency to amend Tables I and II in FMVSS No. 119. Specifically, the petitioners requested that Table I include the plunger diameter for motorcycles. The petitioners also requested that Table II include the minimum static breaking energies for load ranges "A" through "E" tires used on 12 rim diameter code or smaller, and light truck tires, because FMVSS No. 119 applies to these types of tires.

NHTSA agrees with the petitioners that Tables I and II of FMVSS No. 119 should be revised to reflect the change in applicability of FMVSS No. 119. The agency has retained the current strength requirements of FMVSS No. 119 but since LT load range C, D, and E tires are now subject to the requirements of FMVSS No. 139, the tables need to reflect this change.

11. RMA petitioned the agency to correct the test pressures for LT tires with a nominal cross section larger than 295 mm. The petitioner indicated that these tires, as shown in the Tire and Rim Association Year Book, have a lower inflation pressure to attain the load range C, D, or E maximum load limits and do not follow the normal load range C, D, and E inflation pressures for tire maximum load limits. Therefore, to ensure that all LT tires within a single load range category are subject to the same level of performance requirements, the petitioners recommend that FMVSS

No. 139 be amended to specify correct inflation pressures for these tires.

NHTSA agrees with the petitioner that LT tires with a nominal cross section greater than 295 mm have a different load range for the same maximum inflation pressure as tires equal to or less than 295 mm wide and therefore amend S6.2.1.1.1, S6.3.1.1.1 and S6.4.1.1.1 accordingly.

12. JATMA petitioned the agency to clarify the bead unseating test conditions (inflation pressure and dimension "A") for light truck tires, since they were not stipulated in the June 2003 final rule. The current requirement in FMVSS No. 139, S6.6, reference FMVSS No. 109, which does not include test parameters for LT tires.

We are amending the regulatory text to specify the test inflation pressure for the LT tires undergoing resistance to bead unseating test. The pressure is the same for the endurance test. The dimension "A" parameters are the same as those specified in FMVSS No. 109.

VI. Effective Date

Alliance petitioned the agency to change the effective date of FMVSS No. 139 from June 1, 2007 to September 1, 2007 to coincide with the traditional start of the new model year introduction. Petitioners argue that an effective date of September 1, 2007 would help in the transition from the 2007 to 2008 model year. RMA petitioned the agency to extend the effective date for an additional 2 years to 2009 arguing that tire manufacturers are waiting for the agency's response to petitions for reconsideration.

In light of potential impact of mid-model year introduction of a new set of requirements, the agency is delaying the effective date of FMVSS No. 139 until September 1, 2007. Furthermore, we are delaying the effective date of applicability of FMVSS No. 139 to snow tires until September 1, 2008 because of changes to snow tire construction that may be necessitated by the more stringent performance requirements. However, we believe that a two-year delay in the effective date, as requested by the RMA is unwarranted. As indicated in 49 CFR § 553.35(d) a petition for reconsideration does not stay the effectiveness of the rule. Therefore, the manufacturers need to continue their efforts to comply with the new requirements while their petitions are being considered.

VII. Rulemaking Notices and Analyses

A. Executive Order 12866 and DOT Regulatory Policies and Procedures

Executive Order 12866, "Regulatory Planning and Review" (58 FR 51735,

¹⁷ See 68 FR 38116 at 38141.

¹⁸ See Docket No. NHTSA-2003-15400-12, 31, 32.

¹⁹ CT means a pneumatic tire with an inverted flange tire and rim system in which the rim is designed with rim flanges pointed radially inward and the tire is designed to fit on the underside of the rim in a manner that encloses the rim flanges inside the air cavity of the tire.

October 4, 1993), provides for making determinations whether a regulatory action is "significant" and therefore subject to Office of Management and Budget (OMB) review and to the requirements of the Executive Order. The Order defines a "significant regulatory action" as one that is likely to result in a rule that may:

(1) Have an annual effect on the economy of \$100 million or more or adversely affect in a material way the economy, a sector of the economy, productivity, competition, jobs, the environment, public health or safety, or State, local, or Tribal governments or communities;

(2) Create a serious inconsistency or otherwise interfere with an action taken or planned by another agency;

(3) Materially alter the budgetary impact of entitlements, grants, user fees, or loan programs or the rights and obligations of recipients thereof; or

(4) Raise novel legal or policy issues arising out of legal mandates, the President's priorities, or the principles set forth in the Executive Order.

This rulemaking action was not reviewed under Executive Order 12866. The rulemaking action is not significant under Department of Transportation regulatory policies and procedures. The agency is modifying certain performance requirements to better address snow tires and certain deep tread specialty tires. The effect of this change is a decreased regulatory burden on manufacturers of snow tires and deep tread specialty tires through more practicable tire safety performance requirements. This final rule also makes a number of technical corrections to the regulatory text of all Federal tire safety regulations. This action will not affect the impacts estimated in the final regulatory evaluation for the June 2003 final rule.

B. Regulatory Flexibility Act

The Regulatory Flexibility Act of 1980 (5 U.S.C. § 601 *et seq.*) requires agencies to evaluate the potential effects of their proposed and final rules on small business, small organizations and small governmental jurisdictions. I hereby certify that this rulemaking action will not have a significant economic impact on a substantial number of small entities.

This document decreases the regulatory burden on small entities by subjecting the specially manufactured deep-tread tires to more practicable tire safety performance requirements. According to the petitioners and the Small Business Administration, this rulemaking action will result in substantial cost savings for the one

small business that petitioned the agency to amend our regulations.

C. National Environmental Policy Act

NHTSA has analyzed this document for the purposes of the National Environmental Policy Act. The agency has determined that implementation of this rulemaking action does not have any significant impact on the quality of the human environment.

D. Executive Order 13132 (Federalism)

The agency has analyzed this rulemaking in accordance with the principles and criteria contained in Executive Order 13132 and has determined that it does not have sufficient federal implications to warrant consultation with State and local officials or the preparation of a federalism summary impact statement. The final rule does not have any substantial impact on the States, or on the current Federal-State relationship, or on the current distribution of power and responsibilities among the various local officials.

E. Unfunded Mandates Act

The Unfunded Mandates Reform Act of 1995 requires agencies to prepare a written assessment of the costs, benefits and other effects of proposed or final rules that include a Federal mandate likely to result in the expenditure by State, local or tribal governments, in the aggregate, or by the private sector, of more than \$100 million annually (\$120.7 million as adjusted annually for inflation with base year of 1995).

The agency previously estimated that the June 2003 final rule establishing more stringent tire performance requirements was likely to result in the expenditure by automobile manufacturers and/or tire manufacturers of more than \$109 million annually.²⁰

This document amends certain performance requirements to better address snow tires and certain specialty tires. This final rule also makes a number of technical corrections to the regulatory text of all Federal tire safety regulations. The effect of these changes is a decreased regulatory burden on manufacturers of snow tires and certain other specialty tires. Accordingly, this rulemaking action will not result in expenditures by State, local or tribal governments of more than \$120 million annually. Further this rulemaking action will not result in private sector expenditure of more than \$120 million annually.

²⁰ The written assessment of costs is available at Docket No. NHTSA-2003-15400-2 at <http://dms.dot.gov/search/searchResultsSimple.cfm>.

F. Civil Justice Reform

This final rule does not have any retroactive effect. Under 49 U.S.C. 21403, whenever a Federal motor vehicle safety standard is in effect, a State may not adopt or maintain a safety standard applicable to the same aspect of performance which is not identical to the Federal standard, except to the extent that the state requirement imposes a higher level of performance and applies only to vehicles procured for the State's use. 49 U.S.C. 21461 sets forth a procedure for judicial review of final rules establishing, amending or revoking Federal motor vehicle safety standards. That section does not require submission of a petition for reconsideration or other administrative proceedings before parties may file suit in court.

G. Paperwork Reduction Act

Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501, *et seq.*), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each "collection of information" they conduct, sponsor, or require through regulations. NHTSA has reviewed this final rule and determined that it does not contain collection of information requirements.

In order to enable the agency to ascertain which tires are to be tested to less stringent requirements, the agency is adding a labeling requirement to all PC snow tires and LT snow tires with load ranges of C, D, and E that are certified under the less stringent requirements. The manufacturers must mark their snow tires with the Alpine Symbol described in Section IV(A), if they wish to certify their snow tires to the requirements applicable to snow tires. However, the tire manufacturers are not obligated to do so if they wish to certify their snow tires to the normal requirements of the Standard. Thus, only the snow tires certified to the reduced test speed requirements must display an Alpine symbol (as shown below), on at least one sidewall. The use of the Alpine Symbol will have the added benefit of enabling consumers to identify snow tires that provide a higher level of snow traction compared to all-season tires.

Under CFR 1320.3(h)(1), "information" does not generally include certifications such as that described in the previous paragraph, which only identify tires certified to the less stringent requirements.

H. Privacy Act

Anyone is able to search the electronic form of all comments

received into any of our dockets by the name of the individual submitting the comment (or signing the comment, if submitted on behalf of an association, business, labor union, etc.). You may review DOT's complete Privacy Act Statement in the **Federal Register** published on April 11, 2000 (Volume 65, Number 70; Pages 19477-78) or you may visit <http://dms.dot.gov>.

VIII. Regulatory Text

List of Subjects in 49 CFR Part 571

Motor vehicle safety, Reporting and recordkeeping requirements. Tires.

■ In consideration of the foregoing, part 571 is amended as follows:

PART 571—FEDERAL MOTOR VEHICLE SAFETY STANDARDS

■ 1. The authority citation for part 571 continues to read as follows:

Authority: 49 U.S.C. 322, 30111, 30115, 30117, and 30166; delegation of authority at 49 CFR 1.50.

■ 2. Section 571.109 is amended by revising the section heading, S2, and the Table located below Figure 1:

§ 571.109 Standard No. 109—New pneumatic and certain specialty tires.

* * * * *

S2. *Application.* This standard applies to new pneumatic radial tires for use on passenger cars manufactured before 1975, and new pneumatic bias ply tires for use on passenger cars manufactured after 1948.

* * * * *

FIGURES FOR FMVSS No. 109

Wheel size	Dimension "A" for tires with maximum inflation pressure			
	Other than 60 psi (in)	Other than 420 kPa	60 psi (in)	420 kPa
20	13.50	345		
19	13.00	330	12.00	305
18	12.50	318	11.40	290
17	12.00	305	10.60	269
16	11.50	292	9.90	251
15	11.00	279	9.40	239
14	10.50	267	8.90	226
13	10.00	254	8.40	213
12	9.50	241		
11	9.00	229		
10	8.50	216		
320	8.50	216		
340	9.00	229		
345	9.25	235		
365	9.75	248		
370	10.00	254		
390	11.00	279		
415	11.50	292		

* * * * *

■ 3. Section 571.110 is amended by revising S4.2.2.2 and S4.2.2.3(a), to read as follows:

§ 571.110 Standard No. 110—Tire selection and rims for motor vehicles with a GVWR of 4,536 kilograms (10,000 pounds) or less.

* * * * *

S4.2.2.2 When passenger car tires are installed on an MPV, truck, bus, or trailer, each tire's load rating is reduced by dividing it by 1.10 before determining, under S4.2.2.1, the sum of the maximum load ratings of the tires fitted to an axle.

S4.2.2.3(a) For vehicles equipped with passenger car tires, the vehicle normal load on the tire shall be no greater than the value of 94 percent of the derated load rating at the vehicle manufacturer's recommended cold inflation pressure for that tire.

* * * * *

■ 4. Section 571.119 is amended by revising S3, and Tables I and II to read as follows:

§ 571.119 Standard No. 119—New pneumatic tires for motor vehicles with a GVWR of more than 4,536 kilograms (10,000 pounds) and motorcycles.

* * * * *

S3. *Application.* This standard applies to:

(a) New pneumatic tires for use on motor vehicles with a GVWR of more than 4,536 kilograms (10,000 pounds) manufactured after 1948;

(b) New pneumatic light truck tires with a tread depth of 18/32 inch or greater, for use on motor vehicles with a GVWR of 4,536 kilograms (10,000 pounds) or less manufactured after 1948;

(c) Tires for use on special-use trailers (ST, FI and 8-12 rim or lower diameter code); and

(d) Tires for use on motorcycles manufactured after 1948.

* * * * *

TABLE I.—STRENGTH TEST PLUNGER DIAMETER

Tire type	Plunger diameter	
	(mm)	(inches)
Light truck	19.05	3/4
Motorcycle	7.94	5/16
≤ 12 rim diameter code (except motorcycle)	19.05	3/4
Tubeless:		
≤ 17.5 rim diameter code ...	19.05	3/4
>17.5 rim diameter code, load range F or less	31.75	1 1/4
> 17.5 rim diameter code, load range over F	38.10	1 1/2
Tube-type:		
Load range F or less	31.75	1 1/4
Load range over F	38.10	1 1/2

TABLE II.—MINIMUM STATIC BREAKING ENERGY
[Joules (J) and Inch-Pounds (inch-lbs)]

Tire characteristic Plunger diameter (mm and inches)	Motorcycle		All 12 rim diameter code or smaller rim size except motorcycle		Light truck and 17.5 rim diameter code or smaller rim Tubeless		Tires other than Light Motorcycle, 12 rim diameter code or smaller								
	7.94 J mm	5/16"					Tube type		Tubeless greater than 17.5 rim diameter code		Tube type		Tubeless Greater than 17.5 rim diameter code		
	Breaking Energy	J	In-lbs	19.05 J mm	3/4"	19.05J mm	3/4"	31.75J mm	1 1/4"	31.75 mm	1 1/4"	38.10J mm	1 1/2"	38.10 mm	1 1/2"
				J	In-lbs	J	In-lbs	J	In-lbs	J	In-lbs	J	In-lbs	J	In-lbs
Load Range:															
A	16	150	67	600	225	2,000									
B	33	300	135	1,200	293	2,600									
C	45	400	203	1,800	361	3,200	768	6,800	576	5,100					
D			271	2,400	514	4,550	892	7,900	734	6,500					
E			338	3,000	576	5,100	1,412	12,500	971	8,600					
F			406	3,600	644	5,700	1,785	15,800	1,412	12,500					
G					711	6,300					2,282	20,200	1,694	15,000	
H					768	6,800					2,598	23,000	2,090	18,500	
J											2,824	25,000	2,203	19,500	
L											3,050	27,000			
M											3,220	28,500			
N											3,389	30,000			

* * * * *

■ 5. Section 571.120 is amended by revising S5.1.1 and S5.1.2 to read as follows:

§ 571.120—Standard No. 120—Tire selection and rims for motor vehicles with a GVWR of more than 4,536 kilograms (10,000 pounds).

* * * * *

S5.1.1 Except as specified in S5.1.3, each vehicle equipped with pneumatic tires for highway service shall be equipped with tires that meet the requirements of § 571.109, § 571.119 or § 571.139, and rims that are listed by the manufacturer of the tires as suitable for use with those tires, in accordance with S4.4 of § 571.109 or S5.1 of § 571.119, as applicable, except that vehicles may be equipped with a non-pneumatic spare tire assembly that meets the requirements of § 571.129. New non-pneumatic tires for passenger cars, and S8 of this standard. Vehicles equipped with such an assembly shall meet the requirements of S5.3.3, S7, and S9 of this standard.

S5.1.2 Except in the case of a vehicle which has a speed attainable in 3.2 kilometers of 80 kilometers per hour or less, the sum of the maximum load ratings of the tires fitted to an axle shall be not less than the gross axle weight rating (GAWR) of the axle system as specified on the vehicle's certification label required by 49 CFR part 567. Except in the case of a vehicle which has a speed attainable in 2 miles of 50 mph or less, the sum of the maximum load ratings of the tires fitted to an axle shall be not less than the gross axle weight rating (GAWR) of the axle system as specified on the vehicle's

certification label required by 49 CFR part 567. If the certification label shows more than one GAWR for the axle system, the sum shall be not less than the GAWR corresponding to the size designation of the tires fitted to the axle. If the size designation of the tires fitted to the axle does not appear on the certification label, the sum shall be not less than the lowest GAWR appearing on the label. When a passenger car tire is installed on a multipurpose passenger vehicle, truck, bus, or trailer, the tire's load rating shall be reduced by dividing by 1.10 before calculating the sum (i.e., the sum of the load ratings of the tires on each axle, when the tires' load carrying capacity at the recommended tire cold inflation pressure is reduced by dividing by 1.10, must be appropriate for the GAWR).

* * * * *

■ 6. Section 571.139 is amended by:

■ a. Adding new paragraphs S2.1 and S2.2 to S2; adding to S3, in alphabetical order, new definitions of "Passenger car tire" and "Snow tire" and adding a new paragraph (i) to S5.5;

■ b. Revising S2; the first sentence of S5.5; S6.1.1.1.2; S6.1.1.1.4; S6.2.1.1.1; S6.2.1.2.6; S6.2.1.2.8; S6.2.2; S6.3.1.1.1; S6.3.1.1.2; S6.3.1.2.2; S6.3.1.2.3; S6.3.1.2.5; S6.3.2; S6.4.1.1.1; S6.4.1.1.2; S6.4.1.2.1; S6.4.1.2.5; S6.4.1.2.6; S6.4.2; S6.5.1; and S6.6 as set forth below.

§ 571.139—Standard No. 139—New pneumatic radial tires for light vehicles.

* * * * *

S2 Application and Incorporation by Reference.

S2.1 Application. This standard applies to new pneumatic radial tires for use on motor vehicles that have a gross

vehicle weight rating (GVWR) of 10,000 pounds or less, and that were manufactured after 1975. This standard does not apply to tires for use on new pneumatic light truck tires with a tread depth of 1 3/32 inch or greater; ST, FI and 8-12 rim or lower diameter code tires; tires for use on low speed vehicles; and tires for use on motorcycles manufactured after 1948.

S2.2 Incorporation by reference. ASTM F-1805-00, Standard Test Method for Single Wheel Driving Traction in a Straight Line on Snow- and Ice-Covered Surfaces is incorporated by reference in S3 of this section. The Director of the Federal Register has approved the incorporation by reference of this material in accordance with 5 U.S.C. 552(a) and 1 CFR Part 51. A copy of ASTM F-1805-00 may be obtained from the ASTM Web site <http://www.astm.org/> or by contacting ASTM, 100 Barr Harbor Drive, West Conshohocken, PA 19428-2959. A copy of ASTM F-1805-00 may be obtained from the NHTSA docket at Docket No. 2005-23439, or at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html.

* * * * *

S3. Definitions.

* * * * *

Passenger car tire means a tire intended for use on passenger cars, multipurpose passenger vehicles, and

trucks, that have a gross vehicle weight rating (GVWR) of 10,000 pounds or less.

* * * * *


Snow tire means a tire that attains a traction index equal to or greater than 110, compared to the ASTM E-1136 Standard Reference Test Tire, when using the snow traction test as described in ASTM F-1805-00, Standard Test Method for Single Wheel Driving Traction in a Straight Line on Snow and Ice-Covered Surfaces, and which is marked with an Alpine Symbol specified in S5.5 (i) on at least one sidewall.

* * * * *

S5.5 *Tire Markings*. Except as specified in paragraphs (a) through (h) of S5.5, each tire must be marked on each sidewall with the information specified in S5.5 (a) through (d) and on one sidewall with the information specified in S5.5 (e) through (h) according to the phase-in schedule specified in S7 of this standard.

* * * * *

(i) *Alpine Symbol*. A tire meeting the definition of a snow tire as defined in paragraph S3 may, at the option of the manufacturer, show the pictograph of a mountain with a snowflake as shown below. If the manufacturer chooses to mark the snow tire with the alpine symbol, the mountain profile must have a minimum base of 15 mm and a minimum height of 15 mm, and must contain three peaks with the middle peak being the tallest. Inside the mountain, there must be a six-sided snowflake having a minimum height of one-half the tallest peak.



* * * * *

S6.1.1.1.2 For passenger car tires, inflate to the pressure specified in the following table:

Inflation pressure (kPa)	
Standard	Reinforced
180	220

* * * * *

S6.1.1.1.4 Condition the assembly at an ambient room temperature of 20 °C to 30 °C for not less than 24 hours.

* * * * *

S6.2.1.1.1 Mount the tire on a test rim and inflate it to the pressure specified for the tire in the following table:

Tire application	Test pressure (kPa)
Passenger car tires	
Standard load	220
Extra load	260
Load Range C	320
Load Range D	410
Load Range E	500

Light truck tires with a nominal cross section > 295 mm (11.5 inches)

Load Range C	230
Load Range D	320
Load Range E	410

* * * * *

S6.2.1.2.6 During the test, the ambient temperature, measured at a distance of not less than 150 mm and not more than 1 m from the tire, is maintained at not less than 32 °C or more than 38 °C.

* * * * *

S6.2.1.2.8 Allow the tire to cool for between 15 minutes and 25 minutes. Measure its inflation pressure. Then, deflate the tire, remove it from the test rim, and inspect it for the conditions specified in S6.2.2(a).

* * * * *

S6.2.2 Performance requirements. When the tire is tested in accordance with S6.2.1:

(a) There shall be no visual evidence of tread, sidewall, ply, cord, innerliner, belt or bead separation, chunking, open splices, cracking, or broken cords.

(b) The tire pressure, when measured at any time between 15 minutes and 25 minutes after the end of the test, shall not be less than 95% of the initial pressure specified in S6.2.1.1.1.

* * * * *

S6.3.1.1.1 Mount the tire on a test rim and inflate it to the pressure specified for the tire in the following table:

Tire application	Test pressure (kPa)
Passenger car tires	
Standard load	180
Extra load	220
Load Range C	260
Load Range D	340
Load Range E	410

Tire application	Test pressure (kPa)
------------------	---------------------

Light truck tires with a nominal cross section > 295 mm (11.5 inches)

Load Range C	190
Load Range D	260
Load Range E	340

S6.3.1.1.2 Condition the assembly at 32 to 38 °C for not less than 3 hours.

* * * * *

S6.3.1.2.2 During the test, the ambient temperature, at a distance of not less than 150 mm and not more than 1 m from the tire, is maintained at not less than 32 °C or more than 38 °C.

S6.3.1.2.3 Conduct the test, without interruptions, at the test speed of not less than 120 km/h with loads and test periods not less than those shown in the following table. For snow tires, conduct the test at not less than 110 km/h.

Test period	Duration (hours)	Load as a percentage of tire maximum load rating
1	4	85
2	6	90
3	24	100

* * * * *

S6.3.1.2.5 Allow the tire to cool for between 15 minutes and 25 minutes after running the tire for the time specified in the table in S6.3.1.2.3, measure its inflation pressure. Inspect the tire externally on the test rim for the conditions specified in S6.3.2(a).

* * * * *

S6.3.2 Performance requirements. When the tire is tested in accordance with S6.3.1:

(a) There shall be no visual evidence of tread, sidewall, ply, cord, belt or bead separation, chunking, open splices, cracking or broken cords.

(b) The tire pressure, when measured at any time between 15 minutes and 25 minutes after the end of the test, shall not be less than 95% of the initial pressure specified in S6.3.1.1.1.

* * * * *

S6.4.1.1.1 This test is conducted following completion of the tire endurance test using the same tire and rim assembly tested in accordance with S6.3 with the tire deflated to the following appropriate pressure:

Tire application	Test pressure (kPa)
Passenger car tires	
Standard load	140
Extra load	160

Tire application	Test pressure (kPa)
Load Range C	200
Load Range D	260
Load Range E	320

Light truck tires with a nominal cross section > 295 mm (11.5 inches)

Load Range C	150
Load Range D	200
Load Range E	260

S6.4.1.1.2 Condition the assembly at 32 to 38 °C for not less than 2 hours.

* * * * *

S6.4.1.2.1 The test is conducted for ninety minutes at the end of the test specified in S6.3, continuous and uninterrupted, at a speed of 120 km/h (75 mph). For snow tires, conduct the test at not less than 110 km/h.

* * * * *

S6.4.1.2.5 During the test, the ambient temperature, at a distance of not less than 150 mm and not more than 1 m from the tire, is maintained at not less than 32 °C or more than 38 °C.

S6.4.1.2.6 Allow the tire to cool for between 15 minutes and 25 minutes. Measure its inflation pressure. Then, deflate the tire, remove it from the test rim, and inspect it for the conditions specified in S6.4.2(a).

S6.4.2 Performance requirements. When the tire is tested in accordance with S6.4.1:

(a) There shall be no visual evidence of tread, sidewall, ply, cord, innerliner, belt or bead separation, chunking, open splices, cracking, or broken cords, and

(b) The tire pressure, when measured at any time between 15 minutes and 25 minutes after the end of the test, shall not be less than 95% of the initial pressure specified in S6.4.1.1.1.

* * * * *

S6.5.1 Tire strength for passenger car tires. Each tire shall comply with the requirements of S5.3 of § 571.109.

* * * * *

S6.6 Tubeless tire bead unseating resistance. Each tire shall comply with the requirements of S5.2 of § 571.109. For light truck tires, the maximum permissible inflation pressure to be used for the bead unseating test is as follows:

Load Range C	260 kPa.
Load Range D	340 kPa.
Load Range E	410 kPa.

* * * * *

Issued on: December 21, 2005.

Jacqueline Glassman,

Deputy Administrator.

[FR Doc. 06-137 Filed 1-5-06; 8:45 am]

BILLING CODE 4910-59-P

Proposed Rules

Federal Register

Vol. 71, No. 4

Friday, January 6, 2006

This section of the FEDERAL REGISTER contains notices to the public of the proposed issuance of rules and regulations. The purpose of these notices is to give interested persons an opportunity to participate in the rule making prior to the adoption of the final rules.

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 71

[Docket No. FAA-2005-23184; Airspace Docket No. 05-AWP-14]

Proposed Modification of Class E Airspace; Palm Springs, CA

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of proposed rulemaking.

SUMMARY: This notice proposes to modify the Class E airspace area at Palm Springs, CA. The establishment of an Area Navigation (RNAV) Required Navigation Performance (RNP) Y Instrument Approach Procedures (IAP) to Runway (RWY) 13R and 31R at Palm Springs International Airport, Palm Springs, CA has made this proposal necessary. Additional controlled airspace extending upward from 700 feet or more above the surface of the earth is needed to contain aircraft executing the RNAV (RNP) Y IAP to RWY 13R at Palm Springs International Airport. The intended effect to this proposal is to provide adequate controlled airspace for Instrument Flight Rules (IFR) operations at Palm Springs International Airport, Palm Springs, CA.

DATES: Comments must be received on or before February 21, 2006.

ADDRESSES: Send comments on this proposal to the Docket Management System, U.S. Department of Transportation, Room Plaza 401, 400 Seventh Street, SW., Washington, DC 20590-0001. You must identify the docket number FAA-2005-23184/Airspace Docket No. 05-AWP-14 at the beginning of your comments. You may also submit comments on the Internet at <http://dms.dot.gov>. You may review the public docket containing the proposal, any comments received, and any final dispositions in person in the Docket Office between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. The Docket Office (telephone

1-800-647-5527) is on the plaza level of the Department of Transportation NASSIF Building at the above address.

An informal docket may also be examined during normal business hours at the Office of the Regional Western Terminal Operations, Federal Aviation Administration, at 15000 Aviation Boulevard, Lawndale, California 90261, telephone number (310) 725-6613.

SUPPLEMENTARY INFORMATION:

Comments Invited

Interested parties are invited to participate in this proposed rulemaking by submitting such written data, views, or arguments, as they may desire. Comments that provide the factual basis supporting the views and suggestions presented are particularly helpful in developing reasoned regulatory decisions on the proposal. Comments are specifically invited on the overall regulatory, aeronautical, economic, environmental, and energy-related aspects of the proposal. Communications should identify both docket numbers and be submitted in triplicate to the address listed above. Commenters wishing the FAA to acknowledge receipt of their comments on this notice must submit with the comments a self-addressed, stamped postcard on which the following statement is made: "Comments to Docket No. FAA-2005-23184/Airspace Docket No. 05-AWP-14." The postcard will be date/time stamped and returned to the commenter.

Availability of NPRM

An electronic copy of this document may be downloaded through the Internet at <http://dms.dot.gov>. Recently published rulemaking documents can also be accessed through the FAA's web page at <http://www.faa.gov> or the Superintendent of Document's web page at <http://www.access.gpo.gov/nara>.

Additionally any person may obtain a copy of this notice by submitting a request to the Federal Aviation Administration, Office of Air Traffic Airspace Management, ATA-400, 800 Independence Avenue, SW., Washington, DC 20591, or by calling (202) 267-8783. Communications must identify both document numbers for this notice. Persons interested in being placed on a mailing list for future NPRM's should contact the FAA's Office of Rulemaking, (202) 267-9677,

to request a copy of Advisory Circular No. 11-2A, Notice of Proposed Rulemaking Distribution System, which describes the application procedures.

The Proposal

The FAA is considering an amendment to 14 CFR part 71 by modifying the Class E airspace area at Palm Springs International Airport, Palm Springs, CA. The establishment of a RNAV (RNP) Y IAP to RWY 13R at Palm Springs International Airport has made this proposal necessary. Additional controlled airspace extending upward from 700 feet above the surface is needed to contain aircraft executing the RNAV (RNP) Y IAP to RWY 13R at Palm Springs International Airport has made this proposal necessary. The intended effect of this proposal is to provide adequate controlled airspace for aircraft executing the RNAV (RNP) Y IAP to RWY 13R at Palm Springs International Airport, Palm Springs, CA. Class E airspace designations are published in paragraph 6005 of FAA Order 7400.9N dated September 1, 2005, and effective September 16, 2005, which is incorporated by reference in 14 CFR 71.1. The Class E airspace designation listed in this document would be published subsequently in this Order.

The FAA has determined that this proposed regulation only involves an established body of technical regulations for which frequent and routine amendments are necessary to keep them operationally current. Therefore, this proposed regulation—(1) is not a "significant regulatory action" under Executive Order 12866; (2) is not a "significant rule" under DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and (3) does not warrant preparation of a regulatory evaluation as the anticipated impact is so minimal. Since this is a routine matter that will only affect air traffic procedures and air navigation, it is certified that this proposed rule would not have a significant economic impact on a substantial number of small entities under the criteria of the Regulatory Flexibility Act.

List of Subjects in 14 CFR Part 71

Airspace, Incorporation by reference, Navigation (air).

Adoption of the Amendment

In consideration of the foregoing, the Federal Aviation Administration amends 14 CFR part 71 as follows:

PART 71—DESIGNATION OF CLASS A, CLASS B, CLASS C, CLASS D, AND CLASS E AIRSPACE AREAS; ROUTES; AND REPORTING POINTS

1. The authority citation for 14 CFR part 71 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40103, 40113, 40120; E.O. 10854, 24 FR 9565, 3 CFR, 1959–1963 Comp., p. 389.

§ 71.1 [Amended]

2. The incorporation by reference in 14 CFR 71.1 of the Federal Aviation Administration Order 7400.9N, Airspace Designations and Reporting Points, dated September 1, 2005, and Effective, September 16, 2005, is amended as follows:

Paragraph 6005 Class E airspace areas extending upward from 700 feet or more above the surface of the earth.

* * * * *

AWP CA E5 Palm Springs, CA [Amended]

Palm Springs International Airport
(Lat. 33°49'46" N, long. 116°30'24" W)

That airspace extending upward from 700 feet above the surface beginning at lat. 34°05'00" N, long. 116°34'03" W; to lat. 34°08'00" N, long. 116°30'00" W; to lat. 34°06'42" N, long. 116°28'49" W; to lat. 34°03'00" N, long. 116°31'00" W; to lat. 33°42'45" N, long. 115°53'34" W; to lat. 33°26'00" N, long. 116°09'33" W; to lat. 33°55'00" N, long. 116°46'03" W, to the point of beginning.

* * * * *

Issued in Los Angeles, California, on December 22, 2005.

Stephen J. Lloyd,

Acting Area Director, Western Terminal Operations.

[FR Doc. 06–97 Filed 1–5–06; 8:45 am]

BILLING CODE 4910–13–M

ENVIRONMENTAL PROTECTION AGENCY**40 CFR Part 52**

[EPA–R03–OAR–2005–VA–0015; FRL–8019–8]

Approval and Promulgation of Air Quality Implementation Plans; Virginia; NSR in the Ozone Transport Region

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

SUMMARY: This action is being taken under the Clean Air Act (CAA) or the

Act). EPA is proposing to approve a State Implementation Plan (SIP) revision submitted by the Commonwealth of Virginia. This revision pertains to changes in the State's regulations that require implementation of nonattainment New Source Review (NSR) in the Ozone Transport Region (OTR) locations in Virginia.

DATES: Written comments must be received on or before February 6, 2006.

ADDRESSES: Submit your comments, identified by Docket ID Number EPA–R03–OAR–2005–VA–0015 by one of the following methods:

A. <http://www.regulations.gov>. Follow the on-line instructions for submitting comments.

B. E-mail: campbell.dave@epa.gov.
C. Mail: EPA–R03–OAR–2005–VA–0015, David Campbell, Chief, Permits and Technical Assessment Branch, Mailcode 3AP11, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103.

D. Hand Delivery: At the previously-listed EPA Region III address. Such deliveries are only accepted during the Docket's normal hours of operation, and special arrangements should be made for deliveries of boxed information.

Instructions: Direct your comments to Docket ID No. EPA–R03–OAR–2005–VA–0015. EPA's policy is that all comments received will be included in the public docket without change, and may be made available online at <http://www.regulations.gov>, including any personal information provided, unless the comment includes information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. Do not submit information that you consider to be CBI or otherwise protected through www.regulations.gov or e-mail. The www.regulations.gov Web site is an "anonymous access" system, which means EPA will not know your identity or contact information unless you provide it in the body of your comment. If you send an e-mail comment directly to EPA without going through www.regulations.gov, your e-mail address will be automatically captured and included as part of the comment that is placed in the public docket and made available on the Internet. If you submit an electronic comment, EPA recommends that you include your name and other contact information in the body of your comment and with any disk or CD-ROM you submit. If EPA cannot read your comment due to technical difficulties and cannot contact you for clarification,

EPA may not be able to consider your comment. Electronic files should avoid the use of special characters, any form of encryption, and be free of any defects or viruses.

Docket: All documents in the electronic docket are listed in the www.regulations.gov index. Although listed in the index, some information is not publicly available, i.e., CBI or other information whose disclosure is restricted by statute. Certain other material, such as copyrighted material, is not placed on the Internet and will be publicly available only in hard copy form. Publicly available docket materials are available either electronically in <http://www.regulations.gov> or in hard copy during normal business hours at the Air Protection Division, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103. Copies of the State submittal are available at the Virginia Department of Environmental Quality, 629 East Main Street, Richmond, Virginia 23219.

FOR FURTHER INFORMATION CONTACT: Sharon McCauley, (215) 814–3376, or by e-mail at mccauley.sharon@epa.gov.

SUPPLEMENTARY INFORMATION: On March 28, 2005, the Virginia Department of Environmental Quality submitted a SIP revision approval request entitled, "NSR in the Ozone Transport Region (OTR)." The applicable regulations requiring implementation of nonattainment NSR in the Virginia portion of the OTR were adopted by the Virginia State Air Pollution Control Board on September 29, 2004.

I. Background

The Clean Air Act requires that 13 states including the District of Columbia submit revisions to their State Implementation Plans that will require major new and major modified sources of volatile organic compounds (VOC) or nitrogen oxides (NO_x) to meet certain new source review (NSR) requirements if they are located (or are proposing to locate) in the Ozone Transport Region.

Section 184 of the Act establishes the OTR, which consists of the states of Connecticut, Delaware, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, and the Consolidated Metropolitan Statistical Area that includes the District of Columbia and portions of Virginia. The areas designated as in the Virginia portion of the OTR are as follows: Arlington County, Fairfax County, Loudoun County, Prince William County, Stafford County, Alexandria

City, Fairfax City, Falls Church City, Manassas City, and Manassas Park City.

II. Summary of SIP Revision

The Commonwealth of Virginia amended its regulations to clarify that areas located in the Virginia portion of the OTR must meet the requirements of Virginia Code Article 9 VAC 5 Chapter 80 (Permits for Major Stationary Sources and Major Modifications Locating in Nonattainment Areas) as if they were classified as moderate nonattainment for ozone, except that the threshold for major stationary sources of VOCs would be 50 tons instead of 100 tons. The changes that are reflected in this requested SIP revision are those that identify and define the OTR locations in Virginia while providing direction to what State regulations sources will need to follow when they are either planning to locate in or are already located in the Virginia portion of the OTR. Changes were made to the State provisions at 9 VAC 5-80-2000, Applicability and 9 VAC 5-80-2010, Definitions.

Sources in the Virginia portion of the OTR are also required to meet offset requirements in 9 VAC 5-80-2120 B 2 for areas classified as moderate nonattainment for ozone. These provisions require all increases of VOC and/or NO_x emissions attributable to the new or modified source to be offset with emission reductions elsewhere in the Virginia portion of the OTR at a ratio of 1.15 to 1.00.

The SIP revision will amend the SIP to add new regulatory language indicating that sources in the Virginia portion of the OTR are subject to the requirements of 9 VAC 5-80-2000, *et seq.* regardless of the nonattainment status of the area where the source is located. The SIP revision also provides that sources located or planning to locate in areas within the OTR that are classified as "serious" or "severe" nonattainment areas are required to meet the respective emission thresholds listed within the State's definition of a "major stationary source" at 9 VAC 5-80-2010 C Section a(1) and (2) and the more restrictive offset requirements located in 9 VAC 5-80-2120 B 3 and B 4, respectively.

III. General Information Pertaining to SIP Submittals From the Commonwealth of Virginia

In 1995, Virginia adopted legislation that provides, subject to certain conditions, for an environmental assessment (audit) "privilege" for voluntary compliance evaluations performed by a regulated entity. The legislation further addresses the relative burden of proof for parties either

asserting the privilege or seeking disclosure of documents for which the privilege is claimed. Virginia's legislation also provides, subject to certain conditions, for a penalty waiver for violations of environmental laws when a regulated entity discovers such violations pursuant to a voluntary compliance evaluation and voluntarily discloses such violations to the Commonwealth and takes prompt and appropriate measures to remedy the violations. Virginia's Voluntary Environmental Assessment Privilege Law, Va. Code Sec. 10.1-1198, provides a privilege that protects from disclosure documents and information about the content of those documents that are the product of a voluntary environmental assessment. The Privilege Law does not extend to documents or information (1) that are generated or developed before the commencement of a voluntary environmental assessment; (2) that are prepared independently of the assessment process; (3) that demonstrate a clear, imminent and substantial danger to the public health or environment; or (4) that are required by law.

On January 12, 1998, the Commonwealth of Virginia Office of the Attorney General provided a legal opinion that states that the Privilege law, Va. Code Sec. 10.1-1198, precludes granting a privilege to documents and information "required by law," including documents and information "required by Federal law to maintain program delegation, authorization or approval," since Virginia must "enforce Federally authorized environmental programs in a manner that is no less stringent than their Federal counterparts * * *." The opinion concludes that "[r]egarding § 10.1-1198, therefore, documents or other information needed for civil or criminal enforcement under one of these programs could not be privileged because such documents and information are essential to pursuing enforcement in a manner required by Federal law to maintain program delegation, authorization or approval."

Virginia's Immunity law, Va. Code Sec. 10.1-1199, provides that "[t]o the extent consistent with requirements imposed by Federal law," any person making a voluntary disclosure of information to a state agency regarding a violation of an environmental statute, regulation, permit, or administrative order is granted immunity from administrative or civil penalty. The Attorney General's January 12, 1998 opinion states that the quoted language renders this statute inapplicable to enforcement of any Federally authorized programs, since "no immunity could be

afforded from administrative, civil, or criminal penalties because granting such immunity would not be consistent with Federal law, which is one of the criteria for immunity." Therefore, EPA has determined that Virginia's Privilege and Immunity statutes will not preclude the Commonwealth from enforcing its NSR program consistent with the Federal requirements. In any event, because EPA has also determined that a state audit privilege and immunity law can affect only state enforcement and cannot have any impact on Federal enforcement authorities, EPA may at any time invoke its authority under the Clean Air Act, including, for example, sections 113, 167, 205, 211 or 213, to enforce the requirements or prohibitions of the state plan, independently of any state enforcement effort. In addition, citizen enforcement under section 304 of the Clean Air Act is likewise unaffected by this, or any, state audit privilege or immunity law.

IV. Proposed Action

EPA's review of this material indicates this action will have a beneficial effect on air quality by reducing emissions in the Ozone Transport Region. EPA is proposing to approve the Virginia SIP revision for NSR in the Ozone Transport Region, which was submitted on March 28, 2005. EPA is soliciting public comments on the issues discussed in this document. These comments will be considered before taking final action.

V. Statutory and Executive Order Reviews

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this proposed action is not a "significant regulatory action" and therefore is not subject to review by the Office of Management and Budget. For this reason, this action is also not subject to Executive Order 13211, "Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use" (66 FR 28355 (May 22, 2001)). This action merely proposes to approve state law as meeting Federal requirements and imposes no additional requirements beyond those imposed by state law. Accordingly, the Administrator certifies that this proposed rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*). Because this rule proposes to approve pre-existing requirements under state law and does not impose any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or significantly or uniquely affect small

governments, as described in the Unfunded Mandates Reform Act of 1995 (Pub. L. 104-4). This proposed rule also does not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes, as specified by Executive Order 13175 (65 FR 67249, November 9, 2000), nor will it have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999), because it merely proposes to approve a state rule implementing a Federal requirement, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This proposed rule also is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997), because it is not economically significant.

In reviewing SIP submissions, EPA's role is to approve state choices, provided that they meet the criteria of the Clean Air Act. In this context, in the absence of a prior existing requirement for the State to use voluntary consensus standards (VCS), EPA has no authority to disapprove a SIP submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a SIP submission, to use VCS in place of a SIP submission that otherwise satisfies the provisions of the Clean Air Act. Thus, the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. As required by section 3 of Executive Order 12988 (61 FR 4729, February 7, 1996), in issuing this proposed rule, EPA has taken the necessary steps to eliminate drafting errors and ambiguity, minimize potential litigation, and provide a clear legal standard for affected conduct. EPA has complied with Executive Order 12630 (53 FR 8859, March 15, 1988) by examining the takings implications of the rule in accordance with the "Attorney General's Supplemental Guidelines for the Evaluation of Risk and Avoidance of Unanticipated Takings" issued under the executive order. This proposed rule, to approve the Virginia Department of Environmental Quality State Implementation Plan revision request requiring implementation of NSR in the Virginia portion of the Ozone Transport

Region, does not impose an information collection burden under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*).

List of Subjects in 40 CFR Part 52

Environmental protection, Air pollution control, Carbon monoxide, Intergovernmental relations, Nitrogen dioxide, Ozone, Particulate matter, Reporting and recordkeeping requirements, Sulfur oxides, Volatile organic compounds.

Authority: 42 U.S.C. 7401 *et seq.*

Dated: December 28, 2005.

Donald S. Welsh,

Regional Administrator, Region III.

[FR Doc. E6-37 Filed 1-5-06; 8:45 am]

BILLING CODE 6560-50-P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[EPA-R03-OAR-2005-VA-0016; FRL-8019-7]

Approval and Promulgation of Air Quality Implementation Plans; Virginia; Amendments to the Ambient Air Quality Standards

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

SUMMARY: EPA is proposing to approve a State Implementation Plan (SIP) revision submitted by the Commonwealth of Virginia. This revision pertains to the amendments of the Commonwealth's existing ambient air quality standards. This action is being taken under the Clean Air Act (CAA or the Act).

DATES: Written comments must be received on or before February 6, 2006.

ADDRESSES: Submit your comments, identified by Docket ID Number EPA-R03-OAR-2005-VA-0016 by one of the following methods:

A. www.regulations.gov. Follow the on-line instructions for submitting comments.

B. E-mail: morris.makeba@epa.gov.

C. Mail: EPA-R03-OAR-2005-VA-0016, Makeba Morris, Chief, Air Quality Planning Branch, Mailcode 3AP21, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103.

D. Hand Delivery: At the previously-listed EPA Region III address. Such deliveries are only accepted during the Docket's normal hours of operation, and special arrangements should be made for deliveries of boxed information.

Instructions: Direct your comments to Docket ID No. EPA-R03-OAR-2005-VA-0016. EPA's policy is that all comments received will be included in the public docket without change, and may be made available online at www.regulations.gov, including any personal information provided, unless the comment includes information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. Do not submit information that you consider to be CBI or otherwise protected through www.regulations.gov or e-mail. The www.regulations.gov Web site is a "anonymous access" system, which means EPA will not know your identity or contact information unless you provide it in the body of your comment. If you send an e-mail comment directly to EPA without going through www.regulations.gov, your e-mail address will be automatically captured and included as part of the comment that is placed in the public docket and made available on the Internet. If you submit an electronic comment, EPA recommends that you include your name and other contact information in the body of your comment and with any disk or CD-ROM you submit. If EPA cannot read your comment due to technical difficulties and cannot contact you for clarification, EPA may not be able to consider your comment. Electronic files should avoid the use of special characters, any form of encryption, and be free of any defects or viruses.

Docket: All documents in the electronic docket are listed in the www.regulations.gov index. Although listed in the index, some information is not publicly available, *i.e.*, CBI or other information whose disclosure is restricted by statute. Certain other material, such as copyrighted material, is not placed on the Internet and will be publicly available only in hard copy form. Publicly available docket materials are available either electronically in www.regulations.gov or in hard copy during normal business hours at the Air Protection Division, U.S. Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103. Copies of the State submittal are available at the Virginia Department of Environmental Quality, 629 East Main Street, Richmond, Virginia 23219.

FOR FURTHER INFORMATION CONTACT: Rose Quinto, (215) 814-2182, or by e-mail at quinto.rose@epa.gov.

SUPPLEMENTARY INFORMATION:

I. Background

In 1997, EPA adopted an 8-hour ozone national ambient air quality standard (NAAQS) with a level of 0.08 parts per million (ppm) to provide greater protection to public health than the previous standard of 0.12 ppm averaged over a 1-hour block of time (62 FR 38894, July 18, 1997). At the same time, EPA established a new standard for fine particulate matter (PM_{2.5}) that applies to particles 2.5 microns in diameter or less (62 FR 38711, July 18, 1997). These standards became effective on September 16, 1997 and are located in 40 CFR part 50.

On September 26, 2005, the Commonwealth submitted a SIP revision that amends the existing Virginia Regulations for the Control and Abatement of Air Pollution (9 VAC 5 Chapter 30, Ambient Air Quality Standards). This amendment includes the NAAQS for the 8-hour ozone and PM_{2.5}, as well as general revisions to the Commonwealth's regulations consistent with 40 CFR part 50.

II. Summary of SIP Revision

The Commonwealth's revision incorporates the 1997 NAAQS for the 8-hour ozone and PM_{2.5} standards into 9 VAC 5 Chapter 30. This SIP revision provides that the 8-hour primary and secondary ozone ambient air quality standards are met when the average of the fourth highest daily maximum 8-hour average ozone concentration is less than or equal to 0.08 ppm, averaged over three consecutive years. In addition, the SIP revision adds a new PM_{2.5} ambient air quality standard. The standards incorporated in this SIP revision are 65 micrograms per cubic meter based on a 24-hour average concentration and 15.0 micrograms per cubic meter annual arithmetic mean concentration.

The other SIP revisions incorporated into 9 VAC 5 Chapter 30, are amendments to the ambient air quality standards for sulfur dioxide, carbon monoxide, ozone (1-hour), PM₁₀, nitrogen dioxide, and lead, to make the state regulation consistent with 40 CFR part 50.

III. General Information Pertaining to SIP Submittals From the Commonwealth of Virginia

In 1995, Virginia adopted legislation that provides, subject to certain conditions, for an environmental assessment (audit) "privilege" for voluntary compliance evaluations performed by a regulated entity. The legislation further addresses the relative burden of proof for parties either

asserting the privilege or seeking disclosure of documents for which the privilege is claimed. Virginia's legislation also provides, subject to certain conditions, for a penalty waiver for violations of environmental laws when a regulated entity discovers such violations pursuant to a voluntary compliance evaluation and voluntarily discloses such violations to the Commonwealth and takes prompt and appropriate measures to remedy the violations. Virginia's Voluntary Environmental Assessment Privilege Law, Va. Code Sec. 10.1-1198, provides a privilege that protects from disclosure documents and information about the content of those documents that are the product of a voluntary environmental assessment. The Privilege Law does not extend to documents or information (1) that is generated or developed before the commencement of a voluntary environmental assessment; (2) that is prepared independently of the assessment process; (3) that demonstrates a clear, imminent and substantial danger to the public health or environment; or (4) that is required by law.

On January 12, 1998, the Commonwealth of Virginia Office of the Attorney General provided a legal opinion that states that the Privilege Law, Va. Code Sec. 10.1-1198, precludes granting a privilege to documents and information "required by law," including documents and information "required by Federal law to maintain program delegation, authorization or approval," since Virginia must "enforce Federally authorized environmental programs in a manner that is no less stringent than their Federal counterparts. * * * The opinion concludes that "[r]egarding §10.1-1198, therefore, documents or other information needed for civil or criminal enforcement under one of these programs could not be privileged because such documents and information are essential to pursuing enforcement in a manner required by Federal law to maintain program delegation, authorization or approval."

Virginia's Immunity law, Va. Code Sec. 10.1-1199, provides that "[t]o the extent consistent with requirements imposed by Federal law," any person making a voluntary disclosure of information to a state agency regarding a violation of an environmental statute, regulation, permit, or administrative order is granted immunity from administrative or civil penalty. The Attorney General's January 12, 1998 opinion states that the quoted language renders this statute inapplicable to enforcement of any Federally authorized

programs, since "no immunity could be afforded from administrative, civil, or criminal penalties because granting such immunity would not be consistent with Federal law, which is one of the criteria for immunity."

Therefore, EPA has determined that Virginia's Privilege and Immunity statutes will not preclude the Commonwealth from enforcing its program consistent with the Federal requirements. In any event, because EPA has also determined that a state audit privilege and immunity law can affect only state enforcement and cannot have any impact on Federal enforcement authorities, EPA may at any time invoke its authority under the Clean Air Act, including, for example, sections 113, 167, 205, 211 or 213, to enforce the requirements or prohibitions of the state plan, independently of any state enforcement effort. In addition, citizen enforcement under section 304 of the Clean Air Act is likewise unaffected by this, or any, state audit privilege or immunity law.

IV. Proposed Action

EPA's review of this material indicates that the amendments to 9 VAC 5 Chapter 30 are consistent with 40 CFR part 50. EPA is proposing to approve the Virginia SIP revision for 9 VAC 5 Chapter 30, which was submitted on September 26, 2005. EPA is soliciting public comments on the issues discussed in this document. These comments will be considered before taking final action.

V. Statutory and Executive Order Reviews

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this proposed action is not a "significant regulatory action" and therefore is not subject to review by the Office of Management and Budget. For this reason, this action is also not subject to Executive Order 13211, "Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use" (66 FR 28355 (May 22, 2001)). This action merely proposes to approve state law as meeting Federal requirements and imposes no additional requirements beyond those imposed by state law. Accordingly, the Administrator certifies that this proposed rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*). Because this rule proposes to approve pre-existing requirements under state law and does not impose any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or

significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Pub. L. 104-4). This proposed rule also does not have a substantial direct effect on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes, as specified by Executive Order 13175 (65 FR 67249, November 9, 2000), nor will it have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999), because it merely proposes to approve a state rule implementing a Federal requirement, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This proposed rule also is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997), because it is not economically significant.

In reviewing SIP submissions, EPA's role is to approve state choices, provided that they meet the criteria of the Clean Air Act. In this context, in the absence of a prior existing requirement for the State to use voluntary consensus standards (VCS), EPA has no authority to disapprove a SIP submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a SIP submission, to use VCS in place of a SIP submission that otherwise satisfies the provisions of the Clean Air Act. Thus, the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. As required by section 3 of Executive Order 12988 (61 FR 4729, February 7, 1996), in issuing this proposed rule, EPA has taken the necessary steps to eliminate drafting errors and ambiguity, minimize potential litigation, and provide a clear legal standard for affected conduct. EPA has complied with Executive Order 12630 (53 FR 8859, March 15, 1988) by examining the takings implications of the rule in accordance with the "Attorney General's Supplemental Guidelines for the Evaluation of Risk and Avoidance of Unanticipated Takings" issued under the executive order.

This proposed rule pertaining to the amendments of Virginia's ambient air quality standards, does not impose an information collection burden under the

provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*).

List of Subjects in 40 CFR Part 52

Environmental protection, Air pollution control, Carbon monoxide, Nitrogen dioxide, Ozone, Particulate matter, Reporting and recordkeeping requirements, Sulfur oxides, Volatile organic compounds.

Authority: 42 U.S.C. 7401 *et seq.*

Dated: December 28, 2005.

Donald S. Welsh,

Regional Administrator, Region III.

[FR Doc. E6-30 Filed 1-5-06; 8:45 am]

BILLING CODE 6560-50-P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 122

[OW-2002-0068; FRL-8019-6]

RIN 2040-AE81

Amendments to the National Pollutant Discharge Elimination System (NPDES) Regulations for Storm Water Discharges Associated With Oil and Gas Exploration, Production, Processing, or Treatment Operations, or Transmission Facilities

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice of proposed rulemaking.

SUMMARY: Today EPA proposes action to codify in the Agency's regulations changes to the Federal Water Pollution Control Act resulting from the Energy Policy Act of 2005. This proposed action would modify National Pollutant Discharge Elimination System regulations to provide that certain storm water discharges from field activities, including construction, associated with oil and gas exploration, production, processing, or treatment operations, or transmission facilities would be exempt from National Pollutant Discharge Elimination System permit requirements. This action also encourages voluntary application of best management practices for oil and gas field activities and operations to minimize the discharge of pollutants in storm water runoff and protect water quality.

DATES: Comments must be received on or before February 21, 2006.

ADDRESSES: Submit your comments, identified by Docket ID No. EPA-HQ-OW-2002-0068 by one of the following methods:

- www.regulations.gov: Follow the on-line instructions for submitting comments.

- E-mail: ow-docket@epa.gov
- Mail: Water Docket, Environmental Protection Agency, Mailcode: 4101T, 1200 Pennsylvania Ave., NW., Washington, DC 20460. Please include a total of three copies.

• Hand Delivery: EPA Docket Center, EPA West, Room B102, 1301 Constitution Ave., NW., Washington, DC 20004. Such deliveries are only accepted during the Docket's normal hours of operation, and special arrangements should be made for deliveries of boxed information.

Instructions: Direct your comments to Docket ID No. EPA-HQ-OW-2002-0068. EPA's policy is that all comments received will be included in the public docket without change and may be made available online at www.regulations.gov, including any personal information provided, unless the comment includes information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. Do not submit information that you consider to be CBI or otherwise protected through www.regulations.gov or e-mail. The www.regulations.gov Web site is an "anonymous access" system, which means EPA will not know your identity or contact information unless you provide it in the body of your comment. If you send an e-mail comment directly to EPA without going through www.regulations.gov, your e-mail address will be automatically captured and included as part of the comment that is placed in the public docket and made available on the Internet. If you submit an electronic comment, EPA recommends that you include your name and other contact information in the body of your comment and with any disk or CD ROM you submit. If EPA cannot read your comment due to technical difficulties and cannot contact you for clarification, EPA may not be able to consider your comment. Electronic files should avoid the use of special characters, any form of encryption, and be free of any defects or viruses. For additional information about EPA's public docket, visit the EPA Docket Center homepage at www.epa.gov/epahome/dockets.htm. For additional instructions on submitting comments, go to Unit I.C of the **SUPPLEMENTARY INFORMATION** section of the document.

Docket: All documents in the docket are listed in the www.regulations.gov index. Although listed in the index, some information is not publicly available, e.g., CBI or other information whose disclosure is restricted by statute. Certain other material, such as copyrighted material, will be publicly

available only in hard copy. Publicly available docket materials are available either electronically in www.regulations.gov or in hard copy at the Water Docket, EPA/DC, EPA West, Room B102, 1301 Constitution Ave., NW., Washington, DC 20004. This Docket Facility is open from 8:00 a.m. to 4:30 p.m., Monday through Friday, excluding legal holidays. The Docket telephone number is (202) 566-2426. The Public Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday through Friday, excluding legal holidays. The telephone number for the Public Reading Room is (202) 566-1744.

FOR FURTHER INFORMATION CONTACT: Jeff Smith, Office of Wastewater Management, Office of Water, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460; telephone number: (202) 564-0652; fax number: (202) 564-6431; e-mail address: smith.jeff@epa.gov.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does This Action Apply to Me?

Entities potentially affected by this action include operators of oil and gas exploration, production, processing and treatment, and transmission facilities and associated construction activities at oil and gas sites that generally are defined in the following North American Industrial Classification System (NAICS) codes and titles: 211—Oil and Gas Extraction, 21311—Drilling Oil and Gas Wells, 21312—Support Activities for Oil and Gas Operations, 48611—Pipeline Transportation of Crude Oil and 48621—Pipeline Transportation of Natural Gas.

This description is not intended to be exhaustive, but rather provides a guide for readers regarding entities likely to be affected by this action. This description identifies the types of entities that EPA is aware could potentially be affected by this action. Other types of entities not identified could also be affected. To determine whether your facility or company is affected by this action, you should carefully examine the applicability criteria in 40 CFR 122.26(a)(2), (b)(14)(x), (b)(15) and (e)(8). If you have questions regarding the applicability of this action to a particular entity, consult the person listed in the preceding **FOR FURTHER INFORMATION CONTACT** section.

B. What Should I Consider as I Prepare My Comments for EPA?

1. *Submitting CBI.* Do not submit this information to EPA through www.regulations.gov or e-mail. Clearly

mark the part or all of the information that you claim to be CBI. For CBI information in a disk or CD ROM that you mail to EPA, mark the outside of the disk or CD ROM as CBI and then identify electronically within the disk or CD ROM the specific information that is claimed as CBI. In addition to one complete version of the comment that includes information claimed as CBI, a copy of the comment that does not contain the information claimed as CBI must be submitted for inclusion in the public docket. Information so marked will not be disclosed except in accordance with procedures set forth in 40 CFR part 2.

2. *Tips for Preparing Your Comments.* When submitting comments, remember to:

- Identify the rulemaking by docket number and other identifying information (subject heading, Federal Register date and page number).
- Follow directions—The agency may ask you to respond to specific questions or organize comments by referencing a Code of Federal Regulations (CFR) part or section number.
- Explain why you agree or disagree; suggest alternatives and substitute language for your requested changes.
- Describe any assumptions and provide any technical information and/or data that you used.
- If you estimate potential costs or burdens, explain how you arrived at your estimate in sufficient detail to allow for it to be reproduced.
- Provide specific examples to illustrate your concerns, and suggest alternatives.
- Explain your views as clearly as possible.
- Make sure to submit your comments by the comment period deadline identified.

II. Background Information

A. NPDES Program

In 1972, Congress amended the Federal Water Pollution Control Act (more commonly referred to as the Clean Water Act or CWA) to prohibit the discharge of any pollutant to waters of the United States from a point source except in compliance with specified provisions of the CWA, including section 402. The principal means by which one may lawfully discharge pollutants into waters of the United States is by obtaining authorization in a NPDES permit issued under CWA section 402. Initial efforts to improve water quality under the NPDES program focused primarily on reducing pollutants in industrial process wastewater and municipal sewage.

As pollution control measures for industrial process wastewater and municipal sewage were implemented and refined, it became increasingly evident that more diffuse sources of water pollution were also significant causes of water quality impairment. Specifically, storm water runoff draining large surface areas, such as agricultural and urban land, was found to be a major cause of water quality impairment, including the non-attainment of designated beneficial uses. As a result, in 1987, Congress added Section 402(p) of the CWA, which directs EPA to develop a two-phased approach to regulate storm water discharges under the NPDES program.

The first phase of the national program for controlling storm water, commonly referred to as "Phase I," was promulgated on November 16, 1990 (55 FR 47990). Phase I requires NPDES permits for storm water discharges from a large number of priority sources, including municipal separate storm sewer systems (MS4s) generally serving populations of 100,000 or more and industrial activity. EPA defined the term "storm water discharge associated with industrial activity" in a manner that covered a wide variety of facilities, including construction activities that disturb at least five acres of land (40 CFR 122.26(b)(14)(x)).

The second phase of the storm water program, "Phase II," was promulgated on December 8, 1999 (64 FR 68722). Phase II expanded the existing program to include discharges of storm water from smaller municipalities in urbanized areas and from construction sites that disturb between one and five acres of land. (40 CFR 122.26(b)(15)(i)). Discharges from these sources have generally needed permit authorization since March 10, 2003 (40 CFR 122.26(e)(8)). Phase II allows certain sources to be excluded from the national program based on a demonstrable lack of impact on water quality. The Phase II rule also allows for other sources not automatically regulated on a national basis to be designated for inclusion based on increased likelihood for localized adverse impact on water quality.

B. NPDES Program Provisions Specific to Oil and Gas Activities

The 1987 amendments to the CWA also added language at section 402(l)(2) that exempts from NPDES permitting requirements certain storm water discharges from oil and gas exploration, production, processing, or treatment operations or transmission facilities. That provision states that "[t]he Administrator shall not require a permit

under this section, nor shall the Administrator directly or indirectly require any State to require a permit, for discharges of storm water runoff from mining operations or oil and gas exploration, production, processing, or treatment operations or transmission facilities, composed entirely of flows which are from conveyances or systems of conveyances (including but not limited to pipes, conduits, ditches, and channels) used for collecting and conveying precipitation runoff and which are not contaminated by contact with, or do not come into contact with, any overburden, raw material, intermediate products, finished product, byproduct, or waste products located on the site of such operations."

On January 4, 1989, EPA promulgated a rule [National Pollutant Discharge Elimination System Permit Regulations] that, among other actions, codified the CWA section 402(l)(2) exemption at what was then 40 CFR 122.26(a)(3). (See 54 FR 246). The preamble to that rule explained that the legislative history of CWA section 402(l)(2) suggests that, with respect to oil or grease or hazardous substances, the determination of whether storm water is contaminated by contact with such materials, as established by the Administrator, shall take into consideration whether these materials are present in such storm water runoff in excess of reportable quantities under section 311 of the CWA or section 102 of CERCLA.

The 1990 NPDES Phase I storm water regulations also codified the CWA section 402(l)(2) exemption, this time moving the regulatory exemption to 40 CFR 122.26(a)(2) for uncontaminated storm water discharges from oil and gas activities while also imposing permit requirements for storm water discharges associated with industrial activities, including construction sites disturbing at least five acres (40 CFR 122.26(b)(14)(x)). The Phase I rule recodification of the CWA section 402(l)(2) provision also revised the regulatory language to specify that the "Director may not require a permit" rather than the section 402(l)(2) language that specifies that the "Administrator shall not require a permit under this section, nor shall the Administrator directly or indirectly require any State to require a permit" for these discharges. This change helped clarify that States may not require permits for these discharges under the NPDES program.

The rule also codified at § 122.26(c)(1)(iii) the conditions which would be considered indicative of contamination by contact with

overburden, raw material, intermediate products, finished product, byproduct, or waste products located on the site and would thus necessitate an NPDES storm water permit application by oil and gas exploration, production, processing or treatment operations or transmission facilities. Section 122.26(c)(1)(iii) provides as follows:

(iii) The operator of an existing or new discharge composed entirely of storm water from an oil or gas exploration, production, processing, or treatment operation, or transmission facility is not required to submit a permit application in accordance with paragraph (c)(1)(i) of this section, unless the facility:

(A) Has had a discharge of storm water resulting in the discharge of a reportable quantity for which notification is or was required pursuant to 40 CFR 117.21 or 40 CFR 302.6 at anytime since November 16, 1987; or

(B) Has had a discharge of storm water resulting in the discharge of a reportable quantity for which notification is or was required pursuant to 40 CFR 110.6 at any time since November 16, 1987; or

(C) Contributes to a violation of a water quality standard.

EPA based this interpretation of contamination on the legislative history of section 402(l)(2), which directed EPA to consider whether reportable quantities (RQs) of oil or grease or hazardous substances under either the CWA or CERCLA had been exceeded in determining whether storm water from oil and gas operations had been contaminated by contact with overburden, raw material, intermediate products, finished products, byproduct, or waste products.

Shortly after issuance of EPA's first general permit specific to storm water discharges associated with construction activity (Final NPDES General Permits for Storm Water Discharges From Construction Sites, September 9, 1992, 57 FR 41176), EPA Region 8 raised a question to EPA Headquarters about the applicability of the permit requirements for oil and gas-related construction activities. On December 10, 1992, EPA Headquarters sent a memorandum to EPA Region 8 stating that all construction activities that disturb five or more acres must apply for a permit, including those construction activities associated with oil and gas activities.

This memorandum was legally challenged by a collection of trade associations who asserted that the memorandum was unlawful and requested that the court set it aside as inconsistent with the CWA. The United States Court of Appeals for the Fourth Circuit dismissed this challenge on the grounds that the internal EPA memorandum itself did not constitute

an action reviewable by the courts. *Appalachian Energy Group v. EPA*, 33 F.3d 319, 322 (4th Cir. 1994).

As noted previously, EPA promulgated the final Phase II storm water rule on December 8, 1999 with a requirement that storm water discharges from small construction activities (those disturbing between one and five acres) obtain NPDES permit coverage beginning on March 10, 2003. Based on public comments on the January 9, 1998, proposed Phase II rule, EPA had considered including oil and gas exploration sites in its economic analysis for the rulemaking, but further analysis suggested that few, if any, of these sites would actually disturb more than one acre of land. Economic Analysis of the Final Phase II Storm Water Rule, October 1999 (see p 4-2). Accordingly, EPA decided that separate analysis of this sector was unnecessary. After promulgating the final Phase II rule, EPA became aware that close to 30,000 oil and gas sites annually may, in fact, be affected. EPA now believes that the majority of such sites may exceed one acre when the acreage attributed to lease roads, pipeline right-of-ways and other infrastructure facilities is apportioned to each site.

In light of this new information, on March 10, 2003, EPA published a rule (the "deferral rule") that postponed until March 10, 2005, the permit authorization deadline for NPDES storm water permits for oil and gas construction activity that disturbs one to five acres of land. This extension allowed EPA to analyze and better evaluate (1) the impact of the permit requirements on the oil and gas industry, (2) the appropriate best management practices (BMPs) for preventing contamination of storm water runoff resulting from construction associated with oil and gas exploration, production, processing, or treatment operations or transmission facilities, and (3) the scope and effect of section 402(l)(2) and other storm water provisions of the Clean Water Act. 68 FR 11325.

Between 2003 and 2005, EPA gathered information on size, location and other site characteristics to better evaluate compliance costs associated with the control of storm water runoff from oil and gas construction activities. EPA met with various stakeholders and visited a number of oil and gas sites with construction-related activities, to discuss and review existing BMPs for preventing contamination of storm water runoff resulting from construction associated with these oil and gas activities. Additionally, EPA gathered economic data for the industry and

initiated an economic impact analysis of the existing Phase II regulations specific to the oil and gas industry. EPA's preliminary analysis indicated that there could be significant and potentially costly administrative delays in the permitting process for oil and gas construction sites that were not considered in the original economic analysis for the 1999 Phase II rulemaking. As a result, on March 9, 2005, EPA further postponed the date for NPDES regulation for an additional 15 months until June 12, 2006, to provide additional time for the Agency to complete its evaluation of the economic and legal issues that were raised and to assess appropriate procedures and methods for controlling storm water discharges from these sources to mitigate impacts on water quality.

A collection of trade associations petitioned the United States Court of Appeals for the Fifth Circuit for review of the March 10, 2003 deferral rule. The petitioners asserted that the deferral rule represents the Agency's first acknowledgment that the NPDES regulations apply to construction activities associated with oil and gas activities, but that such regulations are inconsistent with CWA section 402(l)(2). On June 16, 2005, the Fifth Circuit dismissed the petition on the grounds that the issue is not ripe for review. Specifically, the Court acknowledged EPA's ongoing analysis of this issue and indicated that "any interpretation [of CWA section 402(l)(2)] we would provide would necessarily prematurely cut off EPA's interpretive process." *Texas Independent Producers and Royalty Owners Ass'n, et al. v. EPA*, 413 F.3d 479, 483 (5th Cir. 2005).

III. Description of Proposed NPDES Program Modifications

A. Objectives EPA Seeks To Achieve in Today's Proposal

The primary purpose of today's proposed rule is to propose modifications to the NPDES regulations in 40 CFR part 122 based on changes to the Clean Water Act (CWA) resulting from the Energy Policy Act of 2005 language (See Pub. L. 109-58, 119 Stat. 694 (codified as amended at 33 U.S.C. 1362 (2005))). A second purpose is to encourage voluntary application of best management practices (BMPs) for oil and gas field activities and operations, including construction, to provide additional protection of water quality from potential storm water discharges.

On August 8, 2005, the President signed into law the Energy Policy Act of 2005. Section 323 of the Energy Policy

Act of 2005 added a new paragraph (24) to section 502 of the CWA to define the term "oil and gas exploration, production, processing, or treatment, or transmission facilities" to mean "all field activities or operations associated with exploration, production, processing, or treatment operations, or transmission facilities, including activities necessary to prepare a site for drilling and for the movement and placement of drilling equipment, whether or not such field activities or operations may be considered to be construction activities." This term is used in CWA section 402(l)(2) of the CWA to identify oil and gas activities for which EPA shall not require NPDES permit coverage for certain storm water discharges. The effect of this statutory change is to make construction activities at oil and gas sites eligible for the exemption established by CWA section 402(l)(2). EPA interprets this extension of the statutory exemption to include construction of drilling sites, drilling waste management pits, and access roads as well as construction of the transportation and treatment infrastructure such as pipelines, natural gas treatment plants, natural gas pipeline compressor stations and crude oil pumping stations.

The action is being published in the **Federal Register** as a proposed rule to provide the public and interested stakeholders with the opportunity to comment on this rulemaking.

B. Today's Regulatory Approach

1. Requirements for Regulated Entities Under Today's Proposal

Today's action proposes to codify changes to section 502, subpart (24) ("Oil and Gas Exploration and Production Defined") of the Clean Water Act (CWA) into EPA regulations in 40 CFR part 122 ("EPA-Administered Permit Programs: The National Pollutant Discharge Elimination System [NPDES]"). Specifically, the language in the Energy Policy Act of 2005, signed by the President on August 8, 2005, states that section 502 of the CWA is amended by adding the following subparagraph at the end of the current section: "(24) OIL AND GAS EXPLORATION AND PRODUCTION.—The term 'oil and gas exploration, production, processing, or treatment operations or transmission facilities' means all field activities or operations associated with exploration, production, processing, or treatment operations, or transmission facilities, including activities necessary to prepare a site for drilling and for the movement and placement of drilling equipment, whether or not such field activities or

operations may be considered to be construction activities."

In extending this statutory exemption at CWA section 402(l)(2) to oil and gas construction activities, Congress did not differentiate among operations on the basis of the size of the disturbed acreage. Accordingly, there is no distinction in today's proposal as to whether the amount of disturbed acreage is less than 1 acre, between 1 and 5 acres, or greater than 5 acres. Hence, discharges from "large" construction activity (disturbing at least 5 acres) at oil and gas facilities would be eligible for the exemption from NPDES permitting requirements under today's proposal to the same extent as discharges from small construction activity at such facilities.

In addition to the construction of drilling sites, drilling waste management pits, and access roads, EPA also interprets the specific phrase in the statutory language "*all field activities or operations*" [emphasis added] as being applicable to construction of in-field treatment plants and the transportation infrastructure (e.g., crude oil and natural gas pipelines, natural gas treatment plants and both natural gas pipeline compressor and crude oil pump stations) necessary for the operation of most producing oil and gas fields. Such construction activities would thus be eligible for the CWA section 402(l)(2) exemption from NPDES permitting requirements.

This proposed regulation would implement Congress' intention, in the Energy Policy Act of 2005, to exclude virtually all oil and gas construction activities from regulation under the NPDES storm water program. However, consistent with the language of CWA section 402(l)(2), the proposed regulatory changes would not exclude oil and gas construction activities from regulation under the NPDES storm water program when such field activities or operations discharge storm water that has been contaminated by contact with " * * * any overburden, raw material, intermediate products, finished product, byproduct or waste products located on the site of such operations." [CWA section 402(l)(2)].

The legislative history of CWA section 402(l)(2) provided guidance to EPA in interpreting the phrase "contaminated by contact with." It provides as follows:

The substitute [final version of the bill] provides that permits are not required where stormwater runoff is diverted around mining operations or oil and gas operations and does not come in contact with overburden, raw material, product, or process waste. In addition, where stormwater runoff is not contaminated by contact with such materials,

as determined by the Administrator, permits are also not required. With respect to oil or grease or hazardous substances, the determination of whether stormwater is 'contaminated by contact with' such materials, as established by the Administrator, shall take into consideration runoff in excess of reportable quantities under section 311 of the Clean Water Act or section 102 of the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, or in the case of mining operations, above natural background levels.

Based on this language, EPA codified its interpretation of "contaminated by contact with" at § 122.26(c)(1)(iii). It provides that oil and gas operations are exempt except where their discharges contribute reportable quantities of oil or grease or hazardous substances to waters of the United States or contribute to a violation of a water quality standard.

However, a plain reading of CWA section 402(l)(2) suggests that oil and gas sites where runoff is not contaminated by contact with raw material, intermediate products, finished product, byproduct or waste products located at the site are not required to obtain NPDES permits, even in situations where the runoff might be contributing to a violation of water quality standards (the term overburden is applicable only to mining). At the time that EPA promulgated § 122.26(c)(1)(iii), EPA believed it reasonable to presume that causing or contributing to a violation of water quality standards was an indication of contamination as envisioned in the statute. However, now that Congress has explicitly extended the exemption to construction activities associated with oil and gas operations, EPA believes this presumption may no longer be valid in some instances. For example, sediment in runoff related to the clearing of ground or construction of an access road could cause or contribute to a water quality standard violation even where the runoff does not come into contact with raw material, intermediate products, finished product, byproduct or waste products located at the site.

For this reason, EPA is proposing to clarify in § 122.26(a)(2)(ii) that a water quality standard violation for sediment alone does not trigger a permitting requirement. Because most substances for which an RQ has been established are the types of materials (e.g., oil, grease, toxic or hazardous chemicals) that would likely not be present in storm water discharge from an oil or gas site other than through contact with exposed raw material, intermediate products, finished product, byproduct or waste products, EPA would generally consider an exceedance of an RQ as

indicative of contamination. This would be true whether such contact occurred during or after construction. Sediment, in contrast, could easily be present in the discharge even without such contact, and thus in and of itself would not lead to a determination of contamination through contact. Sediment could serve as a vehicle for discharges of oil or grease or hazardous substances (e.g., heavy metals) and if an RQ is exceeded or a water quality standard violated for such a pollutant, such contamination could trigger permitting requirements. EPA believes that this interpretation is fully consistent with Congress' intent in enacting the 2005 Energy Policy Act, which specifically included within the scope of the section 404(l)(2) exemption construction activities associated with oil and gas sites.

Finally, EPA proposes to reorganize regulatory language in § 122.26(a)(2) to create two new paragraphs: (i) and (ii). EPA believes this change is consistent with the existing regulatory framework provided in § 122.26(c)(1)(iii) and (iv) which separates mining and oil and gas requirements. Proposed paragraph (i) merely recodifies existing requirements at § 122.26(c)(1)(iv) for storm water discharges from mining operations that come into contact with, any overburden, raw material, intermediate products, finished products, byproduct, or waste products located on the site of such operations." Proposed paragraph (ii) clarifies permit requirements for storm water discharges from oil and gas sites consistent with the discussion provided above. In addition, EPA is proposing to add a note to the regulations *encouraging* operators of oil and gas field activities or operations to implement and maintain Best Management Practices (BMPs) to minimize the discharges of pollutants, including sediment, in storm water both during and after construction activities to help protect surface water quality during storm events. Additional discussion of the importance of these activities is provided in section III.B.3.

Today's proposed rulemaking would apply to all States, Federal lands and Indian Country regardless of whether EPA is the NPDES permitting authority. Discharges that would be exempted from NPDES permit requirements in today's proposal would be exempted from such NPDES requirements regardless of whether EPA or a State is the permitting authority. EPA wishes to clarify, however, that today's proposal is not intended to interfere with the States' ability to regulate any discharges through a State's non-NPDES program. However, if a State were to require a

permit for discharges exempt from the Clean Water Act NPDES program requirements, the State's permit requirement would not be considered part of the State's EPA-approved NPDES program. See 40 CFR 123.1(i)(2).

EPA requests comment on all aspects of this proposed rule.

2. Timeframe for Final Rule

EPA intends to issue a final rulemaking in advance of the June 12, 2006 deadline by which oil and gas construction sites that disturb one to five acres of land are currently scheduled to obtain NPDES permits for their discharges. If finalized as proposed, EPA's final rulemaking would effectively exempt all field activities or operations associated with oil and gas exploration, production, processing or treatment and transmission construction activities from regulation under the NPDES storm water permitting program, except in accordance with § 122.26(a)(2)(ii) and (c)(1)(iii).

3. Best Management Practices (BMPs)

In accordance with CWA section 402(l)(2), today's proposed rule does not *require* that operators select, install, and maintain Best Management Practices (BMPs) to minimize discharges of pollutants (including sediment) in storm water; however, the Agency is adding a note within the regulatory text *encouraging* operators of oil and gas field activities or operations to institute these practices both during and after construction activities whenever practicable.

Installation of effective BMPs would provide additional measures to help protect surface water during storm events. Appropriate controls would be those suitable to the site conditions, both during and after the period of construction, and consistent with generally accepted engineering design criteria and manufacturer specifications. Selection of BMPs could also be affected by seasonal or climate conditions.

Most storm water controls for construction activities can be grouped into three classes: (a) Erosion and sediment controls; (b) storm water management measures; and (c) good housekeeping practices. Erosion and sediment controls address pollutants (e.g., sediment) in storm water generated from the site during active construction-related work. Storm water management measures result in reductions of pollutants in storm water discharged from the site after the construction has been completed. Good housekeeping measures are those practices employed to manage materials on the site and control litter. While not explicitly

required by regulation, some good housekeeping practices may be necessary to ensure that runoff satisfies the conditions in § 122.26(a)(2)(ii) and (c)(1)(iii) for eligibility for the permitting exemption.

Effective soil erosion and sedimentation control typically is accomplished through the use of a suite of BMPs. Operators should design control measures that collectively address the multiple needs of holding soil in place, diverting storm water around active areas with bare soil, slowing water down as it crosses the site, and providing settling areas for soil that has become mobilized.

The value of EPA's recommended oil and gas construction site BMPs has already been recognized by many oil and gas site operators. Under the sponsorship of the Independent Petroleum Association of America, the oil and gas industry developed guidance entitled "Guidance Document: Reasonable and Prudent Practices for Stabilization (RAPPS) of Oil and Gas Construction Sites," Horizon Environmental Services, Inc., April 2004, that describes the application of appropriate BMPs based on general geographical location and the distance, slope, and amount of vegetative cover between the construction activity and the nearest water body. This document is a relatively simple, common sense approach to mitigating environmental consequences arising from a variety of oil and gas construction activities. The document has been widely publicized and a large number of independent oil and gas operating companies have informed EPA that they have adopted the practices outlined in the document in their day-to-day field construction activities.

4. Other Federal, State, Tribal, and/or Local Controls

EPA expects that operators will comply with applicable Federal, State, Tribal, and/or local controls on oil and gas construction activities. For example, today's action does not affect existing requirements established under section 404 of the CWA for discharges of dredge and fill materials to waters of the United States, including requirements as they apply to wetlands. Similarly, the proposed rule does not affect decisions made at the local level on the need for enhanced protection of local water resources. As such, this proposed rulemaking would not curtail the ability of an appropriate environmental management agency (e.g., State, Tribal or local government) from imposing specific discharge conditions on an oil and gas operator that would otherwise

be exempted under today's proposed rule so long as these requirements are imposed pursuant to authority other than an EPA-approved NPDES program. For example, a State or tribe could choose, under its own authorities, to set limits or require that an operator meet certain discharge conditions in sensitive watersheds.

IV. Statutory and Executive Order Reviews

A. Executive Order 12866: Regulatory Planning and Review

Under Executive Order 12866, (58 FR 51735 (October 4, 1993)) the Agency must determine whether the regulatory action is "significant" and therefore subject to OMB review and the requirements of the Executive Order. The Order defines "significant regulatory action" as one that is likely to result in a rule that may:

(1) Have an annual effect on the economy of \$100 million or more or adversely affect in a material way the economy, a sector of the economy, productivity, competition, jobs, the environment, public health or safety, or State, local, or tribal governments or communities;

(2) Create a serious inconsistency or otherwise interfere with an action taken or planned by another agency;

(3) Alter materially the budgetary impact of entitlements, grants, user fees, or loan programs or the rights and obligations of recipients thereof; or

(4) Raise novel legal or policy issues arising out of legal mandates, the President's priorities, or the principles set forth in the Executive Order.

Pursuant to the terms of Executive Order 12866, EPA has determined that this is a "significant regulatory action" within the meaning of the Executive Order. EPA has submitted this action to OMB for review. Changes made in response to OMB suggestions or recommendations will be documented in the public record.

B. Paperwork Reduction Act

This proposed rule would not impose an information collection burden under the provisions of the Paperwork Reduction Act, 44 U.S.C. 3501, *et seq.*, as this rulemaking is deregulatory and imposes no new requirements.

Burden means the total time, effort, or financial resources expended by persons to generate, maintain, retain, or disclose or provide information to or for a Federal agency. This includes the time needed to review instructions; develop, acquire, install, and utilize technology and systems for the purposes of collecting, validating, and verifying

information; processing and maintaining information, and disclosing and providing information; adjust the existing ways to comply with any previously applicable instructions and requirements; train personnel to be able to respond to a collection of information; search data sources; complete and review the collection of information; and transmit or otherwise disclose the information.

An Agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The OMB control numbers for EPA's regulations are listed in 40 CFR part 9.

C. Regulatory Flexibility Act

The Regulatory Flexibility Act (RFA), 5 U.S.C. 601 *et seq.*, generally requires an agency to prepare a regulatory flexibility analysis of any rule subject to notice and comment rulemaking requirements under the Administrative Procedure Act or any other statute unless the agency certifies that the rule will not have a significant economic impact on a substantial number of small entities. Small entities include small businesses, small organizations, and small governmental jurisdictions. For purposes of assessing the impacts of today's final rule on small entities, small entity is defined as: (1) A small business based on Small Business Administration size standards; (2) a small governmental jurisdiction that is a government of a city, county, town, school district or special district with a population of less than 50,000; and (3) a small organization that is any not-for-profit enterprise which is independently owned and operated and is not dominant in its field.

After considering the economic impacts of today's proposed rule on small entities, I certify that this action would not have a significant economic impact on a substantial number of small entities. In determining whether a rule would have a significant economic impact on a substantial number of small entities, the impact of concern is any significant adverse economic impact on small entities, since the primary purpose of the regulatory flexibility analyses is to identify and address regulatory alternatives "which minimize any significant economic impact of the rule on small entities." 5 U.S.C. 603 and 604. Thus, an agency may certify that a rule will not have a significant economic impact on a substantial number of small entities if the rule relieves regulatory burden, or otherwise has a positive economic effect on all of the small entities subject to the rule.

Today's proposed rule, by expanding the universe of oil and gas operations eligible for the NPDES permit exemption created by CWA section 402(f)(2), would relieve the regulatory burden for certain discharges associated with construction activity at exploration, production, processing, or treatment operations, or transmission facilities to obtain an NPDES storm water permit. We have therefore concluded that today's proposed rule would relieve a regulatory burden for all affected small entities.

D. Unfunded Mandates Reform Act

Title II of the Unfunded Mandates Reform Act of 1995 (UMRA), Public Law 104-4, establishes requirements for Federal agencies to assess the effects of their regulatory actions on State, local, and tribal governments and the private sector. Under section 202 of the UMRA, EPA generally must prepare a written statement, including a cost-benefit analysis, for proposed and final rules with "Federal mandates" that may result in expenditures to State, local, and tribal governments, in the aggregate, or to the private sector, of \$100 million or more in any one year. Before promulgating an EPA rule for which a written statement is needed, section 205 of the UMRA generally requires EPA to identify and consider a reasonable number of regulatory alternatives and adopt the least costly, most cost-effective or least burdensome alternative that achieves the objectives of the rule. The provisions of section 205 do not apply when they are inconsistent with applicable law. Moreover, section 205 allows EPA to adopt an alternative other than the least costly, most cost-effective or least burdensome alternative if the Administrator publishes with the final rule an explanation why that alternative was not adopted.

Before EPA establishes any regulatory requirements that may significantly or uniquely affect small governments, including tribal governments, it must have developed under section 203 of the UMRA a small government agency plan. The plan must provide for notifying potentially affected small governments, enabling officials of affected small governments to have meaningful and timely input in the development of EPA regulatory proposals with significant Federal intergovernmental mandates, and informing, educating, and advising small governments on compliance with the regulatory requirements.

Today's proposed rule contains no Federal mandates (under the regulatory provisions of Title II of the UMRA) for State, local, or tribal governments or the private sector. The proposed rule

imposed no enforceable duty on any State, local or tribal governments or the private sector. Thus, today's proposed rule is not subject to the requirements of sections 202 and 205 of the UMRA.

E. Executive Order 13132: Federalism

Executive Order 13132, entitled "Federalism" (64 FR 43255, August 10, 1999), requires EPA to develop an accountable process to ensure "meaningful and timely input by State and local officials in the development of regulatory policies that have federalism implications." The phrase "Policies that have federalism implications" is defined in the Executive Order to include regulations that have "substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government."

This proposed rule does not have federalism implications. It would not have substantial, direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132. Thus, Executive Order 13132 does not apply to this rule.

F. Executive Order 13175: Consultation and Coordination With Indian Tribal Governments

Executive Order 13175, entitled, "Consultation and Coordination with Indian Tribal Governments" (65 FR 67249, November 9, 2000), requires EPA to develop an accountable process to ensure "meaningful and timely input by tribal officials in the development of regulatory policies that have tribal implications." This proposed rule does not have any Tribal implications as specified in Executive Order 13175. It would not have substantial direct effects on Tribal governments, on the relationship between the Federal government and Indian tribes, or on the distribution of power and responsibilities between the Federal government and Indian tribes, as specified in Executive Order 13175. Thus, Executive Order 13175 does not apply to this rule. EPA specifically solicits additional comment on this proposed rule from tribal officials.

G. Executive Order 13045: Protection of Children From Environmental Health and Safety Risks

Executive Order 13045, "Protection of Children from Environmental Health Risks and Safety Risks" (62 FR 19885, April 23, 1997), applies to any rule that:

(1) Is determined to be "economically significant" as defined under Executive Order 12866, and (2) concerns an environmental health or safety risk that EPA has reason to believe may have a disproportionate effect on children. If the regulatory action meets both criteria, the Agency must evaluate the environmental health or safety effects of the planned rule on children, and explain why the planned regulation is preferable to other potentially effective and reasonably feasible alternatives considered by the Agency. This proposed rule is not subject to the Executive Order because it is not economically significant as defined under Executive Order 12866, and because the Agency does not have reason to believe the environmental health or safety risks addressed by this action present a disproportionate risk to children.

H. Executive Order 13211: Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use

This proposed rule is not a "significant energy action" as defined in Executive Order 13211, "Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use (66 FR 28355 (May 22, 2001))" because it is not likely to have a significant adverse effect on the supply, distribution, or use of energy.

I. National Technology Transfer and Advancement Act

Section 12(d) of the National Technology Transfer and Advancement Act of 1995 ("NTTAA"), Public Law 104-113, section 12(d) (15 U.S.C. 272 note) directs EPA to use voluntary consensus standards in its regulatory activities unless to do so would be inconsistent with applicable law or otherwise impractical. Voluntary consensus standards are technical standards (e.g., materials specifications, test methods, sampling procedures, and business practices) that are developed or adopted by voluntary consensus standard bodies. The NTTAA directs EPA to provide Congress, through OMB, explanations when the Agency decides not to use available and applicable voluntary consensus standards.

This proposed rulemaking does not involve technical standards. Therefore, EPA is not considering the use of any voluntary consensus standards.

List of Subjects in 40 CFR Part 122

Environmental protection, Administrative practice and procedure, Confidential business information, Hazardous substances, Reporting and

recordkeeping requirements, Water pollution control.

Dated: December 30, 2005.

Stephen L. Johnson,
Administrator.

For the reasons set forth in the preamble, Chapter I of Title 40 of the Code of Federal Regulations is proposed to be amended as follows:

PART 122—EPA ADMINISTERED PERMIT PROGRAMS: THE NATIONAL POLLUTANT DISCHARGE ELIMINATION SYSTEM

1. The authority citation for part 122 continues to read as follows:

Authority: The Clean Water Act, 33 U.S.C. 1251 *et seq.*

Subpart B—[Amended]

2. Section 122.26 is amended by revising paragraphs (a)(2) and (e)(8) to read as follows:

§ 122.26 Storm water discharges (applicable to State NPDES programs, see 122.35).

(a) * * *

(2) The Director may not require a permit for discharges of storm water runoff from the following:

(i) Mining operations composed entirely of flows which are from conveyances or systems of conveyances (including but not limited to pipes, conduits, ditches, and channels) used for collecting and conveying precipitation runoff and which are not contaminated by contact with or that have not come into contact with, any overburden, raw material, intermediate products, finished product, byproduct or waste products located on the site of such operations, except in accordance with § 122.26(c)(1)(iv).

(ii) All field activities or operations associated with oil and gas exploration, production, processing, or treatment operations, or transmission facilities, including activities necessary to prepare a site for drilling and for the movement and placement of drilling equipment, whether or not such field activities or operations may be considered to be construction activities, except in accordance with § 122.26(c)(1)(iii). Discharges of sediment from construction activities associated with oil and gas exploration, production, processing, or treatment operations, or transmission facilities are not subject to the provisions of § 122.26(c)(1)(iii)(C).

Note to § 122.26(a)(2)(ii): EPA encourages operators of oil and gas field activities or operations to implement and maintain Best Management Practices (BMPs) to minimize discharges of pollutants, including sediment,

in storm water both during and after construction activities to help ensure protection of surface water quality during storm events. Appropriate controls would be those suitable to the site conditions and consistent with generally accepted engineering design criteria and manufacturer specifications. Selection of BMPs could also be affected by seasonal or climate conditions.

* * * * *

(e) * * *

(8) For any storm water discharge associated with small construction activities identified in paragraph (b)(15)(i) of this section, see § 122.21(c)(1). Discharges from these sources require permit authorization by March 10, 2003, unless designated for coverage before then.

* * * * *

[FR Doc. E6-36 Filed 1-5-06; 8:45 am]

BILLING CODE 6560-50-P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 180

[EPA-HQ-OPP-2005-0252; FRL-7755-6]

Iodomethane; Pesticide Chemical Not Requiring a Tolerance or an Exemption from Tolerance

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

SUMMARY: EPA is proposing to designate the use of the active ingredient, iodomethane as a non-food use pesticide when applied as a pre-plant soil fumigant for peppers, strawberries and tomatoes by adding an entry to 40 CFR 180.2020 noting the non-food use determination. This determination is based on the Agency's evaluation of data which indicates that residues of iodomethane (CH₃I) are quickly degraded or metabolized into non-toxic degradates and subsequently incorporated into natural plant constituents. The effect of this proposed designation is that EPA does not require that a tolerance or exemption from tolerance under section 408 of the Federal Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. 346a, be established as a condition of registration of the pesticide under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), 7 U.S.C. 136 *et seq.*

DATES: Comments must be received on or before February 6, 2006.

ADDRESSES: Submit your comments, identified by docket identification (ID) number EPA-HQ-OPP-2005-0252, by one of the following methods:

• **Federal eRulemaking Portal:** <http://www.regulations.gov/>. Follow the on-

line instructions for submitting comments.

• **Agency Website:** EDOCKET, EPA's electronic public docket and comment system was replaced on November 25, 2005 by an enhanced federal-wide electronic docket management and comment system located at <http://www.regulations.gov/>. Follow the on-line instructions.

• **E-mail:** Comments may be sent by e-mail to opp-docket@epa.gov, Attention: Docket ID Number EPA-HQ-OPP-2005-0252.

• **Mail:** Public Information and Records Integrity Branch (PIRIB) (7502C), Office of Pesticide Programs (OPP), Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460-0001, Attention: Docket ID Number EPA-HQ-OPP-2005-0252.

• **Hand Delivery:** Public Information and Records Integrity Branch (PIRIB), Office of Pesticide Programs (OPP), Environmental Protection Agency, Rm. 119, Crystal Mall #2, 1801 S. Bell St., Arlington, VA, Attention: Docket ID Number EPA-HQ-OPP-2005-0252. Such deliveries are only accepted during the Docket's normal hours of operation, and special arrangements should be made for deliveries of boxed information.

Instructions: Direct your comments to docket ID number EPA-HQ-OPP-2005-0252. EPA's policy is that all comments received will be included in the public docket without change and may be made available online at <http://www.epa.gov/edocket/>, including any personal information provided, unless the comment includes information claimed to be Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. Do not submit information that you consider to be CBI or otherwise protected through EDOCKET, www.regulations.gov, or e-mail. The EPA EDOCKET and the www.regulations.gov websites are "anonymous access" systems, which means EPA will not know your identity or contact information unless you provide it in the body of your comment. If you send an e-mail comment directly to EPA without going through EDOCKET or www.regulations.gov, your e-mail address will be automatically captured and included as part of the comment that is placed in the public docket and made available on the Internet. If you submit an electronic comment, EPA recommends that you include your name and other contact information in the body of your comment and with any disk or CD ROM you submit. If EPA cannot read your comment due to

technical difficulties and cannot contact you for clarification, EPA may not be able to consider your comment. Electronic files should avoid the use of special characters, any form of encryption, and be free of any defects or viruses. For additional information about EPA's public docket visit EDOCKET on-line or see the **Federal Register** of May 31, 2002 (67 FR 38102) (FRL-7181-7).

Docket: All documents in the docket are listed in the EDOCKET index at <http://www.epa.gov/edocket/>. Although listed in the index, some information is not publicly available, i.e., CBI or other information whose disclosure is restricted by statute. Certain other material, such as copyrighted material, is not placed on the Internet and will be publicly available only in hard copy form. Publicly available docket materials are available either electronically in EDOCKET or in hard copy at the Public Information and Records Integrity Branch (PIRIB), Rm. 119, Crystal Mall #2, 1801 S. Bell St., Arlington, VA. This Docket Facility is open from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The Docket telephone number is (703) 305-5805.

FOR FURTHER INFORMATION CONTACT: Mary L. Waller, Registration Division (7505C), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460-0001; telephone number: (703) 308-9354; e-mail address: waller.mary@epa.gov.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

You may be potentially affected by this action if you are an agricultural producer, food manufacturer, or pesticide manufacturer. Potentially affected entities may include, but are not limited to:

- Crop production (NAICS code 111)
- Animal production (NAICS code 112)
- Food manufacturing (NAICS code 311)
- Pesticide manufacturing (NAICS code 32532)

This listing is not intended to be exhaustive, but rather provides a guide for readers regarding entities likely to be affected by this action. Other types of entities not listed in this unit could also be affected. The North American Industrial Classification System (NAICS) codes have been provided to assist you and others in determining whether this action might apply to certain entities. If you have any

questions regarding the applicability of this action to a particular entity, consult the person listed under **FOR FURTHER INFORMATION CONTACT**.

B. How Can I Access Electronic Copies of this Document and Other Related Information?

In addition to using EDOCKET (<http://www.epa.gov/edocket/>), you may access this **Federal Register** document electronically through the EPA Internet under the "**Federal Register**" listings at <http://www.epa.gov/fedrgstr/>. A frequently updated electronic version of 40 CFR part 180 is available at E-CFR Beta Site Two at <http://www.gpoaccess.gov/ecfr/>.

C. What Should I Consider as I Prepare My Comments for EPA?

1. **Submitting CBI.** Do not submit this information to EPA through EDOCKET, [regulations.gov](http://www.regulations.gov), or e-mail. Clearly mark the part or all of the information that you claim to be CBI. For CBI information in a disk or CD ROM that you mail to EPA, mark the outside of the disk or CD ROM as CBI and then identify electronically within the disk or CD ROM the specific information that is claimed as CBI. In addition to one complete version of the comment that includes information claimed as CBI, a copy of the comment that does not contain the information claimed as CBI must be submitted for inclusion in the public docket. Information so marked will not be disclosed except in accordance with procedures set forth in 40 CFR part 2.

2. **Tips for preparing your comments.** When submitting comments, remember to:

- i. Identify the rulemaking by docket ID number and other identifying information (subject heading, **Federal Register** date, and page number).
- ii. Follow directions. The Agency may ask you to respond to specific questions or organize comments by referencing a Code of Federal Regulations (CFR) part or section number.
- iii. Explain why you agree or disagree; suggest alternatives and substitute language for your requested changes.
- iv. Describe any assumptions and provide any technical information and/or data that you used.
- v. If you estimate potential costs or burdens, explain how you arrived at your estimate in sufficient detail to allow for it to be reproduced.
- vi. Provide specific examples to illustrate your concerns, and suggest alternatives.
- vii. Explain your views as clearly as possible, avoiding the use of profanity or personal threats.

viii. Make sure to submit your comments by the comment period deadline identified.

II. Background and Statutory Findings

On February 4, 2002 and February 18, 2005, the Agency received applications to register pesticide products containing the new active ingredient, iodomethane as a pre-plant fumigant for peppers, strawberries, and tomatoes. The registrant, Arysta LifeScience North America, Corp. (formerly known as Arvesta Corp.) asserted that the uses should be considered non-food uses based on data submitted with the applications.

EPA on its own initiative, under section 408 of the FFDCA, 21 U.S.C. 346a, is proposing to add an entry to 40 CFR 180.2020 noting the non-food use determination for iodomethane when used as a pre-plant fumigant for peppers, strawberries and tomatoes. This determination is based on the Agency's evaluation of metabolism and crop field trial data which included analysis for residues of iodomethane (CH₃I) and free iodide (I⁻). Analytical method descriptions and validations used to measure iodomethane and free iodide were also submitted to the Agency.

The Agency does not believe that there is a reasonable expectation of iodomethane residues *per se* in peppers, strawberries and tomatoes at harvest. Iodomethane is quickly metabolized/degraded into iodide at levels lower than those which would cause toxic effects, and into other non-toxic degradates which are incorporated into natural plant constituents. Iodide, the major degradate, is an ubiquitous, naturally-occurring component of all soils, plants, and animals, and as such, there is an existing background level of iodine and iodide in the environment which varies depending on the naturally-occurring sources of iodine chemicals in the region. As a result, enforcement of tolerances would not be possible since no iodide-free samples are available and residue field trials showed evidence of control samples with higher iodide residues than iodomethane treated samples. Additionally, iodine is an essential human dietary nutrient, and iodomethane residues must dissipate in the soil prior to planting as the chemical is phytotoxic. Therefore, the Agency concludes that tolerances are not required for iodomethane.

EPA lists in 40 CFR 180.2020 pesticide chemical uses EPA has determined do not need a tolerance or exemption from the requirement of a tolerance based on EPA's finding that

they are not likely to result in residues in or on food. It is under these provisions that the EPA proposes to designate the pre-plant fumigant use of iodomethane on peppers, strawberries and tomatoes as a non-food use because the use is not likely to result in residues in or on food for the reasons described in Unit II of this document.

III. Conclusion

A nonfood use determination is proposed for iodomethane when applied as a pre-plant soil fumigant for peppers, strawberries, and tomatoes.

IV. Statutory and Executive Order Reviews

This proposed rule establishes a non-food use determination under section 408(e) of the FFDCA in response to an application for registration of a pesticide product submitted to the Agency. The Office of Management and Budget (OMB) has exempted these types of actions from review under Executive Order 12866, entitled *Regulatory Planning and Review* (58 FR 51735, October 4, 1993). Because this proposed rule has been exempted from review under Executive Order 12866 due to its lack of significance, this proposed rule is not subject to Executive Order 13211, *Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use* (66 FR 28355, May 22, 2001). This proposed rule does not contain any information collections subject to OMB approval under the Paperwork Reduction Act (PRA), 44 U.S.C. 3501 *et seq.*, or impose any enforceable duty or contain any unfunded mandate as described under Title II of the Unfunded Mandates Reform Act of 1995 (UMRA) (Public Law 104-4). Nor does it require any special considerations under Executive Order 12898, entitled *Federal Actions to Address Environmental Justice in Minority Populations and Low-Income Populations* (59 FR 7629, February 16, 1994); or OMB review or any Agency action under Executive Order 13045, entitled *Protection of Children from Environmental Health Risks and Safety*

Risks (62 FR 19885, April 23, 1997). This action does not involve any technical standards that would require Agency consideration of voluntary consensus standards pursuant to section 12(d) of the National Technology Transfer and Advancement Act of 1995 (NTTAA), Public Law 104-113, section 12(d) (15 U.S.C. 272 note). Pursuant to the requirements of the Regulatory Flexibility Act (RFA) (5 U.S.C. 601 *et seq.*), the Agency hereby certifies that this proposed action will not have significant negative economic impact on a substantial number of small entities. Listing a pesticide use as not requiring a tolerance or exemption from tolerance clarifies that regulation under the FFDCA is unnecessary as to that use and thus has no negative economic impact. In addition, the Agency has determined that this action will not have a substantial direct effect on States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132, entitled *Federalism* (64 FR 43255, August 10, 1999). Executive Order 13132 requires EPA to develop an accountable process to ensure "meaningful and timely input by State and local officials in the development of regulatory policies that have federalism implications." "Policies that have federalism implications" is defined in the Executive order to include regulations that have "substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government." This proposed rule directly regulates growers, food processors, food handlers and food retailers, not States. This action does not alter the relationships or distribution of power and responsibilities established by Congress in the preemption provisions of section 408(n)(4) of the FFDCA. For these same reasons, the Agency has determined that this proposed rule does not have any "tribal

implications" as described in Executive Order 13175, entitled *Consultation and Coordination with Indian Tribal Governments* (65 FR 67249, November 6, 2000). Executive Order 13175, requires EPA to develop an accountable process to ensure "meaningful and timely input by tribal officials in the development of regulatory policies that have tribal implications." "Policies that have tribal implications" is defined in the Executive order to include regulations that have "substantial direct effects on one or more Indian tribes, on the relationship between the Federal Government and the Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes." This proposed rule will not have substantial direct effects on tribal governments, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes, as specified in Executive Order 13175. Thus, Executive Order 13175 does not apply to this proposed rule.

List of Subjects in 40 CFR Part 180

Environmental protection, Administrative practice and procedure, Agricultural commodities, Pesticides and pests, Reporting and recordkeeping requirements.

Dated: December 30, 2005.

Donald R. Stubbs,

Acting Director, Registration Division, Office of Pesticide Programs.

Therefore, it is proposed that 40 CFR chapter I be amended as follows:

PART 180—[AMENDED]

1. The authority citation for part 180 continues to read as follows:

Authority: 21 U.S.C. 321(q), 346a and 371.

2. In § 180.2020 the table is amended by adding alphabetically the following entry to read as follows:

§ 180.2020 Non-food determinations:

* * * * *

Pesticide Chemical	CAS Reg. No.	Limits	Uses
Iodomethane (CH ₃ I)	74-88-4	When applied as a pre-plant fumigant	Peppers, strawberries and tomatoes

Notices

Federal Register

Vol. 71, No. 4

Friday, January 6, 2006

This section of the FEDERAL REGISTER contains documents other than rules or proposed rules that are applicable to the public. Notices of hearings and investigations, committee meetings, agency decisions and rulings, delegations of authority, filing of petitions and applications and agency statements of organization and functions are examples of documents appearing in this section.

DEPARTMENT OF AGRICULTURE

Office of the Secretary

Notice of Request for Extension of a Currently Approved Information Collection

AGENCY: Office of the Secretary, USDA.

ACTION: Proposed collection; comments requested.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995, this notice announces the Office of Community Development's intention to request an extension for a currently approved information collection in support of the program for 7 CFR part 25 Rural Empowerment Zones and Enterprise Communities (EZ/EC).

DATES: Comments on this notice must be received by March 7, 2006 to be assured of consideration.

FOR FURTHER INFORMATION CONTACT: Yvette Butler, Program Specialist, Office of Community Development, U.S. Department of Agriculture, STOP 3203, 1400 Independence Avenue, SW., Washington, DC 20250-3203, or by e-mail: Yvette.Butler@wdc.usda.gov. Telephone: 202-690-4743.

SUPPLEMENTARY INFORMATION:

Title: Rural Empowerment Zones and Enterprise Communities (EZ/EC).

OMB Number: 0570-0027.

Expiration Date of Approval: May 31, 2006.

Type of Request: Extension for a currently approved information collection.

Abstract: USDA Rural Development's Office of Community Development administers the rural Empowerment Zones and Enterprise Communities (EZ/EC) program, an initiative designed to provide economically depressed rural areas and communities with real opportunities for growth and revitalization. Its mission: To create self-sustaining, long-term economic development in areas of pervasive

poverty, unemployment, and general distress, and to demonstrate how distressed communities can achieve self-sufficiency through innovative and comprehensive strategic plans developed and implemented by alliances among private, public, and nonprofit entities.

Estimate of Burden: Public reporting burden for this collection of information is estimated to average 11 hours per response.

Respondents: Rural Empowerment Zones, Rural Enterprise Communities and Champion Communities.

Estimated Number of Respondents: 110.

Estimated Number of Responses per Respondent: 2.

Estimated Number of Responses: 220.

Estimated Total Annual Burden on Respondents: 2,402 hours.

Copies of this information collection can be obtained from Cheryl Thompson, Regulations and Paperwork Management Branch, Support Services Division at (202) 692-0043.

Comments

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the Office of the Secretary, including whether the information will have practical utility; (b) the accuracy of the Office of the Secretary's estimate of the burden of the proposed collection of information including the validity of the methodology and assumptions used; (c) ways to enhance the quality, utility and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

Comments may be sent to Cheryl Thompson, Regulations and Paperwork Management Branch, Support Services Division, U.S. Department of Agriculture, Rural Development, STOP 0742, 1400 Independence Ave., SW., Washington, DC 20250-0742. All responses to this notice will be summarized and included in the request for OMB approval. All comments will also become a matter of public record.

Dated: December 27, 2005.

Allan Johnson,

Acting Under Secretary, Rural Development.

[FR Doc. E6-35 Filed 1-5-06; 8:45 am]

BILLING CODE 3410-01-P

DEPARTMENT OF AGRICULTURE

Animal and Plant Health Inspection Service

[Docket No. 05-049-1]

Notice of Request for Extension of Approval of an Information Collection; National Veterinary Accreditation Program

AGENCY: Animal and Plant Health Inspection Service, USDA.

ACTION: Extension of approval of an information collection; comment request.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995, this notice announces the Animal and Plant Health Inspection Service's intention to request an extension of approval of an information collection associated with the National Veterinary Accreditation Program.

DATES: We will consider all comments that we receive on or before March 7, 2006.

ADDRESSES: You may submit comments by either of the following methods:

- Federal eRulemaking Portal: Go to <http://www.regulations.gov> and, in the "Search for Open Regulations" box, select "Animal and Plant Health Inspection Service" from the agency drop-down menu, then click on "Submit." In the Docket ID column, select APHIS-2005-0114 to submit or view public comments and to view supporting and related materials available electronically. After the close of the comment period, the docket can be viewed using the "Advanced Search" function in Regulations.gov.

- Postal Mail/Commercial Delivery: Please send four copies of your comment (an original and three copies) to Docket No. 05-049-1, Regulatory Analysis and Development, PPD, APHIS, Station 3A-03.8, 4700 River Road Unit 118, Riverdale, MD 20737-1238. Please state that your comment refers to Docket No. 05-049-1.

Reading Room: You may read any comments that we receive on this

docket in our reading room. The reading room is located in Room 1141 of the USDA South Building, 14th Street and Independence Avenue SW., Washington, DC. Normal reading room hours are 8 a.m. to 4:30 p.m., Monday through Friday, except holidays. To be sure someone is there to help you, please call (202) 690-2817 before coming.

Other Information: Additional information about APHIS and its programs is available on the Internet at <http://www.aphis.usda.gov>.

FOR FURTHER INFORMATION CONTACT: For information regarding the National Veterinary Accreditation Program, contact Ms. Lynn Thomas, Management Analyst, Surveillance and Identification Programs, National Center for Animal Health Programs, VS, APHIS, 4700 River Road Unit 200, Riverdale, MD 20737-1231; (301) 734-5777. For copies of more detailed information on the information collection, contact Mrs. Celeste Sickles, APHIS' Information Collection Coordinator, at (301) 734-7477.

SUPPLEMENTARY INFORMATION:

Title: National Veterinary Accreditation Program.

OMB Number: 0579-0032.

Type of Request: Extension of approval of an information collection.

Abstract: The Animal and Plant Health Inspection Service (APHIS) of the U.S. Department of Agriculture is responsible for, among other things, protecting the health of our Nation's livestock and poultry populations by preventing the introduction and spread of serious diseases and pests of livestock and poultry and for eradicating such diseases and pests from the United States when feasible.

To help us accomplish our mission, APHIS' Veterinary Services administers the National Veterinary Accreditation Program. This program certifies private veterinary practitioners to work cooperatively with Federal veterinarians, as well as with State animal health officials, to conduct certain activities for us. Accredited veterinarians are instrumental in increasing our capacity to perform health certifications and conduct extensive disease surveillance and monitoring.

Operating this program requires a number of information gathering activities, including:

- Conducting veterinary accreditation orientation and training.
- Completing animal health certificates.
- Applying and removing official seals.

- Completing test reports.
- Reviewing applications for veterinary accreditation and reaccreditation.
- Recordkeeping.
- Updating information on accredited veterinarians.

We are asking the Office of Management and Budget (OMB) to approve our use of these information collection activities for an additional 3 years.

The purpose of this notice is to solicit comments from the public (as well as affected agencies) concerning our information collection. These comments will help us:

- (1) Evaluate whether the collection of information is necessary for the proper performance of the functions of the Agency, including whether the information will have practical utility;
- (2) Evaluate the accuracy of our estimate of the burden of the information collection, including the validity of the methodology and assumptions used;
- (3) Enhance the quality, utility, and clarity of the information to be collected; and
- (4) Minimize the burden of the information collection on those who are to respond, through use, as appropriate, of automated, electronic, mechanical, and other collection technologies, e.g., permitting electronic submission of responses.

Estimate of burden: The public reporting burden for this collection of information is estimated to average 0.477348 hours per response.

Respondents: Accredited veterinarians, candidates for the National Veterinary Accreditation Program, and State animal health officials who review applications for veterinary accreditation and reaccreditation.

Estimated annual number of respondents: 63,000.

Estimated annual number of responses per respondent: 2.095936.

Estimated annual number of responses: 132,044.

Estimated total annual burden on respondents: 63,031 hours. (Due to averaging, the total annual burden hours may not equal the product of the annual number of responses multiplied by the reporting burden per response.)

All responses to this notice will be summarized and included in the request for OMB approval. All comments will also become a matter of public record.

Done in Washington, DC, this 29th day of December 2005.

Kevin Shea,

Acting Administrator, Animal and Plant Health Inspection Service.

[FR Doc. 06-87 Filed 1-5-06; 8:45 am]

BILLING CODE 3410-34-P

DEPARTMENT OF AGRICULTURE

Animal and Plant Health Inspection Service

[Docket No. 05-085-1]

Notice of Request for Extension of Approval of an Information Collection; Requirements for Recognizing the Animal Health Status of Foreign Regions

AGENCY: Animal and Plant Health Inspection Service, USDA.

ACTION: Extension of approval of an information collection; comment request.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995, this notice announces the Animal and Plant Health Inspection Service's intention to request an extension of approval of an information collection associated with requirements for recognizing the animal health status of foreign regions.

DATES: We will consider all comments that we receive on or before March 7, 2006.

ADDRESSES: You may submit comments by either of the following methods:

- Federal eRulemaking Portal: Go to <http://www.regulations.gov> and, in the "Search for Open Regulations" box, select "Animal and Plant Health Inspection Service" from the agency drop-down menu, then click on "Submit." In the Docket ID column, select APHIS-2005-0115 to submit or view public comments and to view supporting and related materials available electronically. After the close of the comment period, the docket can be viewed using the "Advanced Search" function in Regulations.gov.

- Postal Mail/Commercial Delivery: Please send four copies of your comment (an original and three copies) to Docket No. 05-085-1, Regulatory Analysis and Development, PPD, APHIS, Station 3A-03.8, 4700 River Road Unit 118, Riverdale, MD 20737-1238. Please state that your comment refers to Docket No. 05-085-1.

Reading Room: You may read any comments that we receive on this docket in our reading room. The reading room is located in Room 1141 of the USDA South Building, 14th Street and

Independence Avenue, SW., Washington, DC. Normal reading room hours are 8 a.m. to 4:30 p.m., Monday through Friday, except holidays. To be sure someone is there to help you, please call (202) 690-2817 before coming.

Other Information: Additional information about APHIS and its programs is available on the Internet at <http://www.aphis.usda.gov>.

FOR FURTHER INFORMATION CONTACT: For information on regulations for recognizing the animal health status of foreign regions, contact Dr. Gary Colgrove, Director, National Center for Import and Export, VS, APHIS, 4700 River Road Unit 38, Riverdale, MD 20737-1231; (301) 734-4356. For copies of more detailed information on the information collection, contact Mrs. Celeste Sickles, APHIS' Information Collection Coordinator, at (301) 734-7477.

SUPPLEMENTARY INFORMATION:

Title: Requirements for Recognizing the Animal Health Status of Foreign Regions.

OMB Number: 0579-0219.

Type of Request: Extension of approval of an information collection.

Abstract: The Animal and Plant Health Inspection Service (APHIS) of the U.S. Department of Agriculture is responsible for, among other things, protecting the health of our Nation's livestock and poultry populations by preventing the introduction and spread of serious diseases and pests of livestock and poultry and for eradicating such diseases and pests from the United States when feasible.

The regulations in 9 CFR part 92, Importation of Animals and Animal Products: Procedures for Requesting Recognition of Regions, set out the process by which a foreign government may request recognition of the animal health status of a region or approval to export animals or animal products to the United States based on the risk associated with animals or animal products from that region. Each request must include information about the region, including information on the veterinary services organization of the region; the extent to which movement of animals and animal products is controlled from regions of higher risk, and the level of biosecurity for such movements; livestock demographics and marketing practices in the region; diagnostic laboratory capabilities in the region; and the region's policies and infrastructure for animal disease control. Specifically, in § 92.2, we require regions that have been granted status under the regulations to provide

information, or allow us to access information, to confirm the regions' animal health status when we request it. The types of information collected will vary based on the information required to adequately assess a region's animal health status.

We are asking the Office of Management and Budget (OMB) to approve our use of this information collection activity for an additional 3 years.

The purpose of this notice is to solicit comments from the public (as well as affected agencies) concerning our information collection. These comments will help us:

(1) Evaluate whether the collection of information is necessary for the proper performance of the functions of the Agency, including whether the information will have practical utility;

(2) Evaluate the accuracy of our estimate of the burden of the information collection, including the validity of the methodology and assumptions used;

(3) Enhance the quality, utility, and clarity of the information to be collected; and

(4) Minimize the burden of the information collection on those who are to respond, through use, as appropriate, of automated, electronic, mechanical, and other collection technologies, e.g., permitting electronic submission of responses.

Estimate of burden: The public reporting burden for this collection of information is estimated to average 40 hours per response.

Respondents: Veterinary authorities in regions that have been granted a particular animal health status for a specified animal disease.

Estimated annual number of respondents: 3.

Estimated annual number of responses per respondent: 1.

Estimated annual number of responses: 3.

Estimated total annual burden on respondents: 120 hours. (Due to averaging, the total annual burden hours may not equal the product of the annual number of responses multiplied by the reporting burden per response.)

All responses to this notice will be summarized and included in the request for OMB approval. All comments will also become a matter of public record.

Done in Washington, DC, this 29th day of December, 2005.

Kevin Shea,

Acting Administrator, Animal and Plant Health Inspection Service.

[FR Doc. 06-89 Filed 1-5-06; 8:45 am]

BILLING CODE 3410-34-P

DEPARTMENT OF AGRICULTURE

Animal and Plant Health Inspection Service

[Docket No. 04-114-2]

Monsanto Company; Availability of Determination of Nonregulated Status for Corn Genetically Engineered for Insect Resistance and Glyphosate Tolerance

AGENCY: Animal and Plant Health Inspection Service, USDA.

ACTION: Notice.

SUMMARY: We are advising the public of our determination that the Monsanto corn line designated as transformation event MON 88017, which has been genetically engineered for resistance to a corn rootworm complex and for tolerance to the herbicide glyphosate, is no longer considered a regulated article under our regulations governing the introduction of certain genetically engineered organisms. Our determination is based on our evaluation of data submitted by Monsanto in their petition for a determination of nonregulated status, our analysis of other scientific data, and comments received from the public in response to a previous notice announcing the availability of the petition for nonregulated status and an environmental assessment. This notice also announces the availability of our written determination and our finding of no significant impact.

DATES: *Effective Date:* December 14, 2005.

ADDRESSES: You may read the petition, the environmental assessment, the determination, the finding of no significant impact, and the comments that we received on Docket No. 04-114-1 in our reading room. The reading room is located in room 1141 of the USDA South Building, 14th Street and Independence Avenue SW., Washington, DC. Normal reading room hours are 8 a.m. to 4:30 p.m., Monday through Friday, except holidays. To be sure someone is there to help you, please call (202) 690-2817 before coming.

FOR FURTHER INFORMATION CONTACT: Dr. Robyn Rose, Biotechnology Regulatory Services, APHIS, 4700 River Road Unit 147, Riverdale, MD 20737-1236; (301) 734-0489. To obtain copies of the petition, EA, determination, FONSI, or response to comments, contact Ms. Ingrid Berlander at (301) 734-4885; e-mail: Ingrid.E.Berlander@aphis.usda.gov. The petition and the draft environmental

assessment (EA) and the final EA with the determination, finding of no significant impact, and response to comments are also available on the Internet at: http://www.aphis.usda.gov/brs/aphisdocs/04_12501p.pdf, http://www.aphis.usda.gov/brs/aphisdocs/04_12501p_pea.pdf, and http://www.aphis.usda.gov/brs/aphisdocs2/04_12501p_com.pdf.

SUPPLEMENTARY INFORMATION:

Background

The regulations in 7 CFR part 340, "Introduction of Organisms and Products Altered or Produced Through Genetic Engineering Which Are Plant Pests or Which There Is Reason to Believe Are Plant Pests," regulate, among other things, the introduction (importation, interstate movement, or release into the environment) of organisms and products altered or produced through genetic engineering that are plant pests or that there is reason to believe are plant pests. Such genetically engineered organisms and products are considered "regulated articles."

The regulations in § 340.6(a) provide that any person may submit a petition to the Animal and Plant Health Inspection Service (APHIS) seeking a determination that an article should not be regulated under 7 CFR part 340. Paragraphs (b) and (c) of § 340.6 describe the form that a petition for a determination of nonregulated status must take and the information that must be included in the petition.

On May 4, 2004, APHIS received a petition (APHIS Petition Number 04-125-01p) from Monsanto Company (Monsanto) of St. Louis, MO, requesting a determination of nonregulated status under 7 CFR part 340 for corn (*Zea mays* L.) designated as transformation event MON 88017 which has been genetically engineered for resistance to corn rootworm and for tolerance to the herbicide glyphosate. The Monsanto petition states that the subject corn should not be regulated by APHIS because it does not present a plant pest risk.

In a notice published in the **Federal Register** on August 12, 2005 (70 FR 47168-47169, Docket No. 04-114-1), APHIS announced the availability of the Monsanto petition and an environmental assessment (EA). APHIS solicited comments on whether the subject corn would present a plant pest risk and on the EA. The August 2005 notice also discussed the role of APHIS, the Environmental Protection Agency (EPA), and the Food and Drug Administration (FDA) in regulating the

subject corn and products developed from it.

APHIS received 19 comments by the close of the 60-day comment period, which ended on October 11, 2005. Comments were submitted by university professionals, growers associations, and private individuals. Eight comments supported granting nonregulated status to corn line MON 88017. These comments cited corn rootworm as a significant problem and supported the use of technologies to help combat the problem. One commenter submitted a request to "treat MON 88017 with suspicion until proven otherwise [safe]," but provided no basis for the concern and neither requested the petition be approved nor denied. Ten comments were opposed to the action. Several of those comments reflected a general disapproval of genetically engineered crops. Several other comments cited the similarity of MON 88017 to MON 863 and cited an article that reviewed the acute toxicology studies commissioned by European Food Safety Agency and did not address a plant-pest risk. APHIS conferred with both FDA and EPA about the results of that study. The response to these comments can be found in an attachment to the finding of no significant impact (FONSI).

APHIS has amended the EA. A list of changes is included as an attachment to the EA. The changes correct typographical errors and provide clarity to the reader; these changes are not substantive and do not change the analysis described in the EA.

As described in the petition, event MON 88017 corn has been genetically engineered to express a Cry3Bb1 insecticidal protein derived from *Bacillus thuringiensis* (*Bt*) subspecies *kumamotoensis* strain EG4691. This gene has been modified to encode six specific amino acid substitutions when compared to strain EG4691. Cry3Bb1 expression is regulated by the enhanced 35S promoter (e35S) from cauliflower mosaic virus, the rice actin intron (*ract1* intron), 5' leader sequence from wheat chlorophyll a/b-binding protein (wt CAB), and the 3' nontranslated region of the 17.3 kDa heat shock protein from wheat. Event MON 88017 has also been genetically engineered to express a 5-enolpyruvylshikimate-3-phosphate synthase protein from *Agrobacterium* sp. strain CP4 (CP4 EPSPS), which confers tolerance to the herbicide glyphosate. Expression of *cp4 epsps* is regulated by the rice actin 1 (*ract1*) 5' untranslated region containing the promoter and first intron and nopaline synthase 3' polyadenylation signal (NOS 3') from *Agrobacterium tumefaciens*. A

construct containing both genes was delivered to the recipient corn variety, A xHi-II, through *Agrobacterium*-mediated gene transfer. The petitioner states that the Cry3Bb1 protein expressed in MON 88017 is 99.8 percent identical to the Cry3Bb1 protein expressed in nonregulated corn line MON 863. The CP4 EPSPS protein is identical to corn line NK603.

Determination

Based on its analysis of the data submitted by Monsanto, a review of other scientific data, field tests of the subject corn, and the comments submitted by the public, APHIS has determined that corn line MON 88017 is no longer a regulated article under APHIS' regulations at 7 CFR part 340 for the following reasons: (1) It exhibits no plant pathogenic properties (although a plant pathogen was used in the development of this corn, these plants are not infected by this organism, nor do they contain genetic material from this pathogen that can cause plant disease); (2) it exhibits no characteristics that would cause it to be weedier than the nontransgenic parent corn line or other cultivated corn; (3) gene introgression from MON 88017 corn into wild relatives in the United States and its territories is extremely unlikely and is not likely to increase the weediness potential of any resulting progeny nor adversely affect genetic diversity of related plants any more than would introgression from traditional corn hybrids; (4) disease and susceptibility and compositional profiles of the plants of MON 88017 are similar to those of its parent variety and other corn cultivars grown in the United States; therefore, no direct or indirect plant pest effect on raw or processed plant commodities is expected; (5) field observations, compositional analyses, and data on the safety of the engineered EPSPS and Cry3Bb1 proteins all indicate that MON 88017 should not have greater potential than other cultivated corn to damage or harm organisms beneficial to agriculture; (6) compared to current corn pest and weed management practices, cultivation of MON 88017 should not reduce the ability to control pests and weeds in corn or other crops. In addition to our finding of no plant pest risk, there will be no effect on the threatened or endangered species resulting from a determination of nonregulated status for MON 88017 and its progeny.

Therefore, APHIS has concluded that the subject corn and any progeny derived from hybrid crosses with other nontransformed corn varieties will be as safe to grow as corn varieties in

traditional breeding programs that are not subject to regulation under 7 CFR part 340. The effect of this determination is that Monsanto corn line MON 88017 is no longer considered a regulated article under APHIS' regulations in 7 CFR part 340.

Therefore, the requirements pertaining to regulated articles under those regulations no longer apply to the subject corn or its progeny. However, the importation of corn line MON 88017 and seeds capable of propagation is still subject to the restrictions found in APHIS' foreign quarantine notices in 7 CFR part 319 and imported seed regulations in 7 CFR part 361.

National Environmental Policy Act

An EA was prepared to examine any potential environmental impacts and plant pest risk associated with the determination of nonregulated status for the Monsanto corn line MON 88017. The EA was prepared in accordance with: (1) The National Environmental Policy Act of 1969 (NEPA), as amended (42 U.S.C. 4321 *et seq.*), (2) regulations of the Council on Environmental Quality for implementing the procedural provisions of NEPA (40 CFR parts 1500-1508), (3) USDA regulations implementing NEPA (7 CFR part 1b), and (4) APHIS' NEPA Implementing Procedures (7 CFR part 372).

Based on that EA, APHIS has reached a FONSI with regard to the determination that Monsanto corn line MON 88017 and lines developed from it are no longer regulated articles under its regulations in 7 CFR part 340. Copies of the EA and FONSI are available from the individual listed under **FOR FURTHER INFORMATION CONTACT**.

Authority: 7 U.S.C. 7701-7772 and 7781-7786; 31 U.S.C. 9701; 7 CFR 2.22, 2.80, and 371.3.

Done in Washington, DC, this 29th day of December, 2005.

Kevin Shea,

Acting Administrator, Animal and Plant Health Inspection Service.

[FR Doc. 06-88 Filed 1-5-06; 8:45 am]

BILLING CODE 3410-34-P

DEPARTMENT OF AGRICULTURE

Food and Nutrition Service

Agency Information Collection Activities: Proposed Collections; Comment Request—A Case Study: Modernization of the Food Stamp Program in Florida

AGENCY: Food and Nutrition Service, USDA.

ACTION: Notice.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995, this notice invites the general public and other public agencies to comment on proposed information collections.

This notice announces the Food and Nutrition Service's (FNS) intent to request approval from the Office of Management and Budget (OMB) for new information collection in the state of Florida. The Food and Nutrition Service (FNS) plans to systematically examine Florida's modernization model in order to understand better the relationship between Food Stamp Program structure, operations, costs, and performance. This review will consist of both a quantitative study using extant data and a qualitative study relying on the responses of state and local food stamp staff, community partners, food stamp applicants and participants and eligible non-participants. Project results will inform FNS policy discussion, provide technical information to States, and offer Florida's Department of Children and Family Services a tool for responding efficiently to the variety of stakeholder queries received.

DATES: Written comments must be received on or before March 7, 2006.

ADDRESSES: Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on those who are to respond, including use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

Comments may be sent to Erika Jones, Project Officer, Food and Nutrition Service, U.S. Department of Agriculture, 3101 Park Center Drive, Alexandria, VA 22302. Comments may also be submitted via fax to the attention of Erika Jones at 703-305-2576 or via e-mail to erika.jones@fns.usda.gov.

All written comments will be open for public inspection at the office of the Food and Nutrition Service, through prior arrangement with the project officer, during regular business hours (8:30 a.m. to 5 p.m., Monday through Friday) at 3101 Park Center Drive, Alexandria, Virginia 22302, Room 1014.

All responses to this notice will be summarized and included in the request

for OMB approval. All comments will be a matter of public record.

FOR FURTHER INFORMATION CONTACT: Requests for additional information or copies of this information collection should be directed to Erika Jones on 703-305-2124.

SUPPLEMENTARY INFORMATION:

Title: A Case Study: Modernization of the Food Stamp Program in Florida.

OMB Number: Not Yet Assigned.

Form Number: N/A.

Expiration Date: To be determined.

Type of Request: New collection of information.

Abstract: The Florida Department of Family and Children's Services (DCFS) is implementing organizational changes, simplifying policies, streamlining procedures and introducing a variety of technology improvements to improve access and customer service while improving administrative efficiency. DCFS is in the process of modernizing its program districts which are at different stages of implementation. Key features of the State's organizational changes include toll-free phone access to regional call centers, an interactive voice response system, an Internet-based application, document scanning, and automated support for some verification procedures. DCFS also is developing partnerships with community-based service providers to engage them in client application support and other customer assistance activities.

In an effort to understand outcomes associated with program modernization, The Food and Nutrition Service (FNS) plans to systematically examine Florida's modernization model in order to understand better the relationship between Food Stamp Program structure, operations, costs and performance. Project results will inform FNS policy discussions, provide technical and procedurally relevant information to States, and offer Florida DCFS a tool for assessing potential model enhancements and responding efficiently to the variety of stakeholder queries received.

Specifically, the project will be guided by following objectives: (1) Developing a description of changes to food stamp policies and procedures that have been made in support of Automated Community Connection to Economic Self-Sufficiency Florida (ACCESS Florida), (2) Identifying how technology is used to support the range of food stamp eligibility determination and case management functions; (3) Describing the roles and experiences of State food stamp staff, vendors, and community partners working at different levels; (4) Understanding the

experiences and satisfaction of food stamp participants, applicants and eligible non-participants; and (5) Describing Food Stamp Program performance overtime.

A descriptive case study, incorporating both qualitative and quantitative data, will be implemented to address these objectives. The study will rely on extant data to describe FSP performance before and after the State's modernization initiative with respect to participation rates, payment accuracy, administrative costs and other outcomes. Data will also be obtained through interviews with local, regional and state-level staff as well as community partners; and include discussion groups with food stamp participants and eligible non-participants.

While state-level performance data will be collected, along with interviews of state program staff, there will be a special focus on 6 of the 13 program districts providing food stamp services. Districts will be chosen to reflect diversity of modernization implementation across Florida. In each of these districts, a combination of in-person and telephone interviews will be conducted with FSP staff and community partners. In each region, the study will also conduct focus groups with participants, applicants, and eligible non-participants.

Interview and focus group questions will be kept as simple and respondent-friendly as possible. Responses to all questions will be voluntary. The contractor will take the following steps to treat the data provided in a confidential manner: (1) No data will be released in a form that identifies individual respondents by name and (2) information collected through interviews will be combined across other respondents in the same category and reported only in aggregate form. Respondents will be notified of these confidentiality measures during data collection.

Respondents: Staff associated with ACCESS Florida at the state and regional level, including regional call centers; staff from local food stamp service and case maintenance centers, state, regional and local staff from community partners assisting with the modernization efforts; and food stamp participants, applicants, and eligible non-participants.

Estimated Number of Respondents: The study will collect data from a total of 118 respondents. This number represents the sum of 23 State, districts and phone center staff (composed of 7 phone interviews and 16 in-person interviews); 33 local FSP staff

(including 17 phone interviews and 16 in-person interviews); 26 staff members from community partners involved in modernization (12 phone interviews and 14 in-person interviews); 24 FSP participants and applicants and 12 eligible non-participants.

Number of Responses per Respondent: 1.

Estimated Time per Response: All burden estimates include respondents' time to prepare for and complete interviews or focus groups. In-person interviews: 1.5 hours each; Phone interviews: 1.5 hours each; and Focus groups: 1.5 hours per participant.

Estimated Total Annual Burden on Respondents: Total of 177 hours, including: State, regional and phone center staff, 34.5 hours; local ACCESS Florida staff, 49.5 hours; community partners, 39 hours; FSP applicants-participants and eligible non-participants, 54 hours.

Dated: December 30, 2005.

Steven N. Christensen,

Acting Administrator, Food and Nutrition Service.

[FR Doc. E6-33 Filed 1-5-06; 8:45 am]

BILLING CODE 3410-30-P

COMMITTEE FOR PURCHASE FROM PEOPLE WHO ARE BLIND OR SEVERELY DISABLED

Procurement List Proposed Deletions

AGENCY: Committee for Purchase from People Who Are Blind or Severely Disabled.

ACTION: Proposed Addition to and Deletions from Procurement List.

SUMMARY: The Committee is proposing to delete products previously furnished by such agencies.

DATES: *Comments Must Be Received On or Before:* February 5, 2006.

ADDRESSES: Committee for Purchase From People Who Are Blind or Severely Disabled, Jefferson Plaza 2, Suite 10800, 1421 Jefferson Davis Highway, Arlington, Virginia 22202-3259.

FOR FURTHER INFORMATION OR TO SUBMIT COMMENTS CONTACT: Sheryl D. Kennerly, Telephone: (703) 603-7740, Fax: (703) 603-0655, or e-mail SKennerly@jwod.gov.

SUPPLEMENTARY INFORMATION: This notice is published pursuant to 41 U.S.C 47(a)(2) and 41 CFR 51-2.3. Its purpose is to provide interested persons an opportunity to submit comments on the proposed actions.

Deletions

Regulatory Flexibility Act Certification

I certify that the following action will not have a significant impact on a substantial number of small entities. The major factors considered for this certification were:

1. If approved, the action may result in additional reporting, recordkeeping or other compliance requirements for small entities.
2. If approved, the action may result in authorizing small entities to furnish the products to the Government.
3. There are no known regulatory alternatives which would accomplish the objectives of the Javits-Wagner-O'Day Act (41 U.S.C. 46-48c) in connection with the products proposed for deletion from the Procurement List.

End of Certification

The following products are proposed for deletion from the Procurement List:

Products

Product/NSN: Bag, Produce, Star Bottom. NSN: 8105-00-NIB-1046—Bag, Produce, Star Bottom.

NPA: Envision, Inc., Wichita, Kansas.

Contracting Activity: Defense Commissary Agency, Fort Lee, Virginia.

Product/NSN: Pen, Rollerball, Executive and Refill.

NSN: 7520-01-424-4882—Pen, Rollerball, Executive and Refill.

NPA: San Antonio Lighthouse for the Blind, San Antonio, Texas.

Contracting Activity: Office Supplies & Paper Products Acquisition Center, New York, NY.

Patrick Rowe,

Executive Deputy Director.

[FR Doc. E6-3 Filed 1-5-06; 8:45 am]

BILLING CODE 6353-01-P

COMMITTEE FOR PURCHASE FROM PEOPLE WHO ARE BLIND OR SEVERELY DISABLED

Procurement List Additions

AGENCY: Committee for Purchase from People Who Are Blind or Severely Disabled.

ACTION: Additions to Procurement List.

SUMMARY: This action adds to the Procurement List services to be furnished by nonprofit agencies employing persons who are blind or have other severe disabilities.

EFFECTIVE DATE: February 5, 2006.

ADDRESSES: Committee for Purchase From People Who Are Blind or Severely Disabled, Jefferson Plaza 2, Suite 10800, 1421 Jefferson Davis Highway, Arlington, Virginia 22202-3259.

FOR FURTHER INFORMATION CONTACT: Sheryl D. Kennerly, Telephone: (703) 603-7740, Fax: (703) 603-0655, or e-mail SKennerly@jwod.gov.

SUPPLEMENTARY INFORMATION: On October 28, and November 4, 2005, the Committee for Purchase From People Who Are Blind or Severely Disabled published notice (70 FR 62092 and 67136) of proposed additions to the Procurement List.

After consideration of the material presented to it concerning capability of qualified nonprofit agencies to provide the services and impact of the additions on the current or most recent contractors, the Committee has determined that the services listed below are suitable for procurement by the Federal Government under 41 U.S.C. 46-48c and 41 CFR 51-2.4.

Regulatory Flexibility Act Certification

I certify that the following action will not have a significant impact on a substantial number of small entities. The major factors considered for this certification were:

1. The action will not result in any additional reporting, recordkeeping or other compliance requirements for small entities other than the small organizations that will furnish the services to the Government.
2. The action will result in authorizing small entities to furnish the services to the Government.
3. There are no known regulatory alternatives which would accomplish the objectives of the Javits-Wagner-O'Day Act (41 U.S.C. 46-48c) in connection with the services proposed for addition to the Procurement List.

End of Certification

Accordingly, the following services are added to the Procurement List:

Services

Service Type/Location: Catering Service, Military Entrance Processing Station, 111 W. Huron Street, Buffalo, New York.
NPA: Phoenix Frontier, Inc., Buffalo, New York.

Contracting Activity: Directorate of Contracting, Fort Knox, Kentucky.

Service Type/Location: Custodial Services, U.S. Army Reserve Center, Building 5003, Rural Route 2, San Antonio, Texas.
NPA: Professional Contract Services, Inc., Austin, Texas.

Contracting Activity: Army Contracting Agency, Southern Region, Fort Sam Houston, Texas.

This action does not affect current contracts awarded prior to the effective

date of this addition or options that may be exercised under those contracts.

Patrick Rowe,

Executive Deputy Director.

[FR Doc. E6-4 Filed 1-5-06; 8:45 am]

BILLING CODE 6353-01-P

DEPARTMENT OF COMMERCE

National Institute of Standards and Technology

Proposed Information Collection; Comment Request; SURF (Summer Undergraduate Research Fellowship) Program Student Applicant Information

AGENCY: National Institute of Standards and Technology.

ACTION: Notice.

SUMMARY: The Department of Commerce (DOC), as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to comment on the continuing and proposed information collection, as required by the Paperwork Reduction Act of 1995, Public Law 104-13 (44 U.S.C. 3506(c)(2)(A)).

DATES: Written comments must be submitted on or before March 7, 2006.

ADDRESSES: Direct all written comments to Diana Hynek, Departmental Forms Clearance Officer, Department of Commerce, Room 6625, 14th and Constitution Avenue, NW., Washington, DC 20230 (or via the Internet at dHynek@doc.gov).

FOR FURTHER INFORMATION CONTACT: Requests for additional information should be directed to the attention of Terrell Vanderah, NIST, 100 Bureau Drive, Stop 8520, Gaithersburg, MD 20899, tel. (301) 975-5785 or via e-mail to terrell.vanderah@nist.gov.

SUPPLEMENTARY INFORMATION

I. Abstract

The purpose of this collection is to gather information needed for the SURF (Summer Undergraduate Research Fellowship) Program. The information will be provided by student applicants and will be described in the Proposal Review Process and Evaluation Criteria sections of the **Federal Register** Notice for the SURF Program. The information will be used by the Program Directors and technical evaluators and is needed to determine eligible students, select students for the program using the Evaluation Criteria described in the **Federal Register** Notice, and place

selected students in appropriate research projects that match their needs, interests, and academic preparation. The information includes: Student name, host institution, e-mail address/contact information, home address, class standing, first- and second-choice NIST laboratories they wish to apply to, academic major/minor, current overall GPA, need for housing and gender (for housing purposes only), availability dates, resume, personal statement of commitment and research interests, two letters of recommendation, academic transcripts, ability to verify U.S. citizenship or permanent legal residency, and ability to verify health coverage.

II. Method of Collection

The Student Application Information form will be available on the web for downloading only; can be submitted as hard copy or scanned and submitted electronically.

III. Data

OMB Number: 0693-0042.

Form Number: None.

Type of Review: Regular submission.

Affected Public: Individuals or households.

Estimated Number of Respondents: 200.

Estimated Time Per Response: 2 hours.

Estimated Total Annual Burden Hours: 400.

Estimated Total Annual Respondent Cost Burden: \$0.

IV. Request for Comments

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) the accuracy of the agency's estimate of the burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, e.g., the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized or included in the request for OMB approval of this information collection; they also will become a matter of public record.

Dated: December 30, 2005.

Gwellnar Banks,

Management Analyst, Office of the Chief Information Officer.

[FR Doc. E5-8323 Filed 1-5-06; 8:45 am]

BILLING CODE 3510-13-P

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

Proposed Information Collection; Comment Request; Capital Construction Fund—Deposit/Withdrawal Report

AGENCY: National Oceanic and Atmospheric Administration (NOAA).

ACTION: Notice.

SUMMARY: The Department of Commerce, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995.

DATES: Written comments must be submitted on or before March 7, 2006.

ADDRESSES: Direct all written comments to Diana Hynek, Departmental Paperwork Clearance Officer, Department of Commerce, Room 6625, 14th and Constitution Avenue, NW., Washington, DC 20230 (or via the Internet at dHynek@doc.gov).

FOR FURTHER INFORMATION CONTACT: Requests for additional information or copies of the information collection instrument and instructions should be directed to Patsy A. Bearden, 907-586-7008 or patsy.bearden@noaa.gov.

SUPPLEMENTARY INFORMATION:

I. Abstract

The respondents will be commercial fishing industry individuals, partnerships, and corporations, which entered into Capital Construction Fund agreements with the Secretary of Commerce allowing deferral of Federal taxation on fishing vessel income, deposited into the fund for use in the acquisition, construction, or reconstruction of fishing vessels. Deferred taxes are recaptured by reducing an agreement vessel's basis for depreciation by the amount withdrawn from the fund for its acquisition, construction, or reconstruction. The deposit/withdrawal information collected from agreement holders are required pursuant to 50 CFR Part 259.35 and Public Law 99-514 (The Tax Reform Act, 1986). The information

collected is required to ensure that agreement holders are complying with fund deposit/withdrawal requirements established in program regulations and properly accounting for fund activity on their Federal income tax returns. The information collected must also be reported annually to the Secretary of Treasury in accordance with the Tax Reform Act, 1986.

II. Method of Collection

The information will be collected by mail.

III. Data

OMB Number: 0648-0041.

Form Number: NOAA Form 38-42.

Type of Review: Regular submission.

Affected Public: Business or other for-profit organizations.

Estimated Number of Respondents: 3,600.

Estimated Time Per Response: 20 minutes.

Estimated Total Annual Burden Hours: 1,200.

Estimated Total Annual Cost to Public: \$2,500.

IV. Request for Comments

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval of this information collection; they also will become a matter of public record.

Dated: December 30, 2005.

Gwellnar Banks,

Management Analyst, Office of the Chief Information Officer.

[FR Doc. E5-8319 Filed 1-5-06; 8:45 am]

BILLING CODE 3510-22-P

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

Proposed Information Collection; Comment Request; Designation of Fishery Management Council Members and Application for Reinstatement of State Authority

AGENCY: National Oceanic and Atmospheric Administration (NOAA).

ACTION: Notice.

SUMMARY: The Department of Commerce, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995.

DATES: Written comments must be submitted on or before March 7, 2006.

ADDRESSES: Direct all written comments to Diana Hynek, Departmental Paperwork Clearance Officer, Department of Commerce, Room 6625, 14th and Constitution Avenue, NW., Washington, DC 20230 (or via the Internet at dHynek@doc.gov).

FOR FURTHER INFORMATION CONTACT: Requests for additional information or copies of the information collection instrument and instructions should be directed to Linda Moon, 301-713-2337 or Linda.Moon@noaa.gov.

SUPPLEMENTARY INFORMATION:

I. Abstract

The Magnuson-Stevens Fishery Conservation and Management Act (Magnuson-Stevens Act), as amended in 1996, provides for the nomination for members of Fishery Management Councils by state governors and Indian treaty tribes, for the designation of a principal state fishery official who will perform duties under the Magnuson-Stevens Act, and for a request by a state for reinstatement of state authority over a managed fishery. Nominees for council membership must provide the governor or tribe with background documentation, which is then submitted to NOAA with the nomination. The information submitted with these actions will be used to ensure that the requirements of the Magnuson-Stevens Act are being met.

II. Method of Collection

State governors and Indian treaty tribes submit written nominations to the Secretary of Commerce, together with recommendations and statements of candidates' qualifications. Designations

of state officials and requests for reinstatement of state authority are also made in writing in response to regulations. No forms are used.

III. Data

OMB Number: 0648-0314.

Form Number: None.

Type of Review: Regular submission.

Affected Public: State, Local or Tribal government.

Estimated Number of Respondents: 275.

Estimated Time Per Response: 1 hour to designate a principal state fishery official(s); 80 hours for a nomination for a Council appointment; 16 hours for background documentation for nominees; and 1 hour for a request to reinstate state authority.

Estimated Total Annual Burden Hours: 4,607 hours.

Estimated Total Annual Cost to Public: \$700.

IV. Request for Comments

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval of this information collection; they also will become a matter of public record.

Dated: December 30, 2005.

Gwellnar Banks,

Management Analyst, Office of the Chief Information Officer.

[FR Doc. E5-8320 Filed 1-5-06; 8:45 am]

BILLING CODE 3510-22-P

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

Proposed Information Collection; Comment Request; Survey Form for Feedback for Annual Tsunami Warning Communications Test

AGENCY: National Oceanic and Atmospheric Administration (NOAA).

ACTION: Notice.

SUMMARY: The Department of Commerce, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995.

DATES: Written comments must be submitted on or before March 7, 2006.

ADDRESSES: Direct all written comments to Diana Hynek, Departmental Paperwork Clearance Officer, Department of Commerce, Room 6625, 14th and Constitution Avenue, NW., Washington, DC 20230 (or via the Internet at dHynek@doc.gov).

FOR FURTHER INFORMATION CONTACT: Requests for additional information or copies of the information collection instrument and instructions should be directed to Jeff Lorens, 801-524-4000 or Jeffrey.Lorens@noaa.gov.

SUPPLEMENTARY INFORMATION:

I. Abstract

The NOAA/National Weather Service Western Region and West Coast/Alaska Tsunami Warning Center conduct test to assess the effectiveness of their Tsunami Warning communications system. This survey is required to gather specific feedback immediately following testing, which is conducted annually in September. Post-test feedback will be requested from emergency managers, the media, law enforcement officials, local government agencies/officials, and the general public. This will be a web-based survey. The responses will be solicited for a limited period immediately following completion of this test, not to exceed two weeks. This web-based survey will allow for a rapid and efficient collection of information regarding the effectiveness of the Tsunami Warning System, particularly with respect to communications systems and related processes.

II. Method of Collection

Web-based survey.

III. Data

OMB Number: None.

Form Number: None.

Type of Review: Regular submission.

Affected Public: Federal Government; State, Local, or Tribal Government; and individuals or households.

Estimated Number of Respondents: 600.

Estimated Time Per Response: 5 minutes.

Estimated Total Annual Burden Hours: 50.

Estimated Total Annual Cost to Public: \$0.

IV. Request for Comments

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval of this information collection; they also will become a matter of public record.

Dated: December 30, 2005.

Gwellnar Banks,

Management Analyst, Office of the Chief Information Officer.

[FR Doc. E5-8322 Filed 1-5-06; 8:45 am]

BILLING CODE 3510-KE-P

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

Proposed Information Collection; Comment Request; Northeast Multispecies Days-At-Sea Leasing Program

AGENCY: National Oceanic and Atmospheric Administration (NOAA).

ACTION: Notice.

SUMMARY: The Department of Commerce, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995.

DATES: Written comments must be submitted on or before March 7, 2006.

ADDRESSES: Direct all written comments to Diana Hynek, Departmental Paperwork Clearance Officer, Department of Commerce, Room 6625, 14th and Constitution Avenue, NW., Washington, DC 20230 (or via the Internet at dHynek@doc.gov).

FOR FURTHER INFORMATION CONTACT: Requests for additional information or

copies of the information collection instrument and instructions should be directed to Moira C. Kelly, National Marine Fisheries Service, 1 Blackburn Drive, Gloucester, MA 01930 (or Moira.Kelly@noaa.gov).

SUPPLEMENTARY INFORMATION:

I. Abstract

A proposed emergency rule for the NE Multispecies Fishery Management Plan (FMP) was published in the **Federal Register** on April 24, 2003 (68 FR 20096). The emergency rule was used to continue management measures specified in the Settlement Agreement Among Certain Parties (Settlement Agreement), which were implemented as ordered by the U.S. District Court for the District of Columbia (Court) in a Remedial Order issued on May 23, 2002 (Order). The emergency rule included several management measures designed to reduce overfishing on species managed under the NE Multispecies FMP, including a Days-At-Sea (DAS) Leasing Program, and was published in order to continue the measures until the implementation of Amendment 13.

The final rule for Amendment 13 to the NE Multispecies FMP was published in the **Federal Register** on April 27, 2004 (69 FR 22906). Amendment 13 was developed by the New England Fishery Management Council (Council) primarily to end overfishing on all groundfish stocks and to rebuild all groundfish stocks that are overfished. Amendment 13 included substantial reductions in the amount of effort available to target groundfish stocks. Therefore, Amendment 13 resulted in considerable reductions in the number of DAS for NE multispecies vessels.

The reduction in the DAS allocated to NE multispecies permit holders limited the ability of some vessels to participate in the fishery, resulting in a loss of revenue and/or the ability to operate at a profit. In order to mitigate some of the adverse economic impacts of the effort reductions, the DAS Leasing Program was established by the Council, among other provisions, in Amendment 13. The DAS Leasing Program enables vessels to increase their revenue by either leasing additional DAS from another vessel or using them to increase their participation in the fishery, or by leasing their allocated DAS that they may not use to another vessel.

II. Method of Collection

Applications will be submitted by mail.

III. Data

OMB Number: 0648-0475.
Form Number: None.

Type of Review: Regular submission.

Affected Public: Business or other for-profit organizations; individuals or households.

Estimated Number of Respondents: 1,400.

Estimated Time per Response: 5 minutes.

Estimated Total Annual Burden Hours: 233.

Estimated Total Annual Cost to Public: \$1,176.

IV. Request for Comments

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval of this information collection; they also will become a matter of public record.

Dated: December 30, 2005.

Gwellnar Banks,

Management Analyst, Office of the Chief Information Officer.

[FR Doc. E5-8324 Filed 1-5-06; 8:45 am]

BILLING CODE 3510-22-P

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 122905A]

Fisheries of the Caribbean, Gulf of Mexico, and South Atlantic; Reef Fish Fishery of the Gulf of Mexico; Second Referendum Procedures for a Potential Gulf of Mexico Red Snapper Individual Fishing Quota Program

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice of referendum schedule.

SUMMARY: NMFS issues this notice to announce information about the schedule for participating in a referendum to determine whether an individual fishing quota (IFQ) program

for the Gulf of Mexico commercial red snapper fishery should be submitted to the Secretary of Commerce (Secretary) for review. The intended effect of the IFQ program would be to reduce overcapacity in the commercial red snapper fishery and end the current derby-type conditions that have resulted from increasingly restrictive regulation.

ADDRESSES: Copies of supporting documentation including the final rule implementing these procedures (69 FR 6921, February 12, 2004), which includes a regulatory impact review and a Regulatory Flexibility Act Analysis, are available from NMFS, Southeast Regional Office, 263 13th Avenue S., St. Petersburg, FL 33701.

FOR FURTHER INFORMATION CONTACT: Phil Steele, telephone: 727-551-5784, fax: 727-824-5308, e-mail: phil.steele@noaa.gov.

SUPPLEMENTARY INFORMATION: Under section 407(c) of the Magnuson-Stevens Fishery Conservation and Management Act (Magnuson-Stevens Act), the Gulf of Mexico Fishery Management Council (Council) is authorized to prepare and submit a plan amendment and regulations to implement an IFQ program for the commercial red snapper fishery, but only if certain conditions are met. First, the preparation of such a plan amendment and regulations must be approved in a referendum of certain fishery participants. Second, the submission of the plan amendment and regulations to the Secretary for review and approval or disapproval must be approved in a subsequent referendum. Both referendums must be conducted in accordance with section 407(c)(2). Section 407(c)(2) also specifies that:

Prior to each referendum, the Secretary, in consultation with the Council, shall: (A) identify and notify all such persons holding permits with red snapper endorsements and all such vessel captains; and (B) make available to all such persons and vessel captains information about the schedule, procedures, and eligibility requirements for the referendum and the proposed individual fishing quota program.

On February 12, 2004, NMFS issued the final rule (69 FR 6921) to provide information about the schedule, procedures, and eligibility requirements for participating in both referendums to determine whether an IFQ program should be prepared and, if so, whether it should be submitted to the Secretary for review. The intended effect of the final rule was to implement procedures for the referendums consistent with the requirements of the Magnuson-Stevens Act.

At the request of the Council, NMFS conducted the first referendum in early

2004 and presented the results to the Council at its March 2004 meeting. The voters approved preparation of an IFQ plan amendment in that referendum, and the Council began preparation of the amendment. The Council is scheduled to take final action on the amendment at its March 2006 meeting, and therefore NMFS needs to complete the second referendum prior to that meeting.

The procedures, criteria, and vote weighting formula for this referendum were established in the final rule published February 12, 2004 (69 FR 6921) and are repeated here pursuant to section 407(c)(2) of the Magnuson-Stevens Act.

Referendum Processes

Who Will Be Eligible to Vote in the Referendums?

Section 407(c)(2) of the Magnuson-Stevens Act establishes criteria regarding eligibility of persons to vote in the referendums. Those criteria are subject to various interpretations. After careful consideration of those criteria, the practicality and fairness of several possible interpretations, and public comments, NMFS has determined the following persons will be eligible to vote in the referendum.

I. For the second referendum:

A. A person who according to NMFS permit records has continuously held his or her Gulf red snapper endorsement/Class 1 license from September 1, 1996, through the date of publication in the **Federal Register** of this notice announcing the second referendum;

B. In the case of a Class 1 license that has been transferred through sale since September 1, 1996, the person who according to NMFS' permit records holds such Class 1 license as of the date of publication in the **Federal Register** of this notice announcing the second referendum;

C. In the case of a Class 1 license that has been transferred through lease since September 1, 1996, both the final lessor and final lessee as of the date of publication in the **Federal Register** of this notice announcing the second referendum, as determined by NMFS' permit records; and

D. A vessel captain who harvested red snapper under a red snapper endorsement in each red snapper commercial fishing season occurring between January 1, 1993, and September 1, 1996.

A person will only receive voting eligibility under one of the eligibility criteria, i.e., a person will not receive dual voting eligibility by being both a

qualifying vessel captain and a qualifying holder of an endorsement/Class 1 license.

NMFS has sufficient information in the Southeast Regional Office fisheries permit database to identify those persons who will be eligible to vote in the referendums based on their having held a red snapper endorsement/Class 1 license during the required periods. However, NMFS did not have sufficient information to identify vessel captains whose eligibility would be based on the harvest of red snapper under a red snapper endorsement in each red snapper commercial fishing season occurring between January 1, 1993, and September 1, 1996. To obtain that information prior to the first referendum, NMFS prepared and distributed a fishery bulletin that described the general referendum procedures and provided a 20-day period (ending August 18, 2003) for submittal of detailed information by those vessel captains. That fishery bulletin was widely distributed to all Gulf reef fish permittees, including dealers, and to major fishing organizations, state fisheries directors, and others. Information received from that solicitation has been used to identify vessel captains whose eligibility to vote in the referendums is based on the red snapper harvest criterion.

How Will Votes Be Weighted?

Section 407(c)(2) of the Magnuson-Stevens Act requires that NMFS develop a formula to weight votes based on the proportional harvests under each eligible endorsement and by each eligible captain between the period January 1, 1993, and September 1, 1996. NMFS will obtain applicable red snapper landings data from the Southeast Fisheries Science Center reef fish logbook database. Information from NMFS' Southeast Regional Office permit database will be used to assign applicable landings to each eligible voter (red snapper endorsement/Class 1 license holder, lessee/lessor, or vessel captain). In cases where only one eligible voter has eligibility tied to a particular license, all applicable landings associated with that license accrue to that voter, and the voter will be assigned a vote-weighting factor of one vote per pound. In cases where more than one eligible voter has eligibility tied to a particular license, e.g., lessee and lessor, or a qualifying vessel captain and a license holder, all eligible voters associated with that license will have their vote weighted equally such that their combined vote will equal one vote per pound of

landings applicable to that license. For example, if a qualifying captain is eligible based on his or her landings under a specific license during the relevant time period, and that license is now held by a license holder who is not involved with lease arrangements with that license, but who is not the same qualifying captain, then each would get one-half of a vote per pound of landings associated with the license. In this example, should the current holder lease the same license, then each participant would have their vote weighted as one-third of a vote per pound, so that their combined vote would equal the total number of pounds associated with the license.

The weighting procedure is complicated somewhat by requirements to protect the confidentiality of landings data, when the applicable landings history involves landings by different entities. To address confidentiality concerns, NMFS will establish a series of categories (ranges) of red snapper landings based on 5,000-lb (2,268-kg) intervals, e.g., 0-5,000 lb (0-2,268 kg); 5,001-10,000 lb (2,268-4,536 kg); etc., concluding with the interval that includes the highest documented landings. The total landings between the period January 1, 1993, and September 1, 1996, associated with each license, will be attributed to the appropriate category. The overall average pounds landed attributed to each category will be determined. That average number of pounds will be the base applied to the vote-weighting factor for each eligible voter whose landings fall within that category.

For example, if the overall average number of pounds attributed to the 5,001-10,000-lb (2,268-4,536-kg) category is 8,150 lb (3,697 kg), each eligible voter within that category would receive votes equal to 8,150 multiplied by the applicable vote-weighting factor, e.g., $8,150 \times 1.0 = 8,150$ votes if only one voter was associated with the license; $8,150 \times 0.5 = 4,075$ votes each for a lessee and lessor associated with the same license; $8,150 \times 0.33 = 2,690$ votes each for a qualifying vessel captain, lessee, and lessor all associated with the same license.

How Will the Vote Be Conducted?

On or about January 17, 2006, NMFS will mail each eligible voter a ballot that would specify the number of votes (weighting) that voter is assigned. NMFS will mail the ballots and associated explanatory information, via certified mail return receipt requested, to the address of record indicated in NMFS' permit database for endorsement/Class 1

license holders and, for vessel captains, to the address provided to NMFS by the captains during the prior information solicitation that ended August 18, 2003. All votes assigned to an eligible voter must be cast for the same decision, i.e., either all to approve or all to disapprove the applicable referendum question. The ballot must be signed by the eligible voter. Ballots must be mailed to Phil Steele, Southeast Regional Office, NMFS, 263 13th Avenue South, St. Petersburg, FL 33701. Ballots for the second referendum must be received at that address by 4:30 p.m., eastern time, February 21, 2006; ballots received after that deadline will not be considered in determining the outcome of the initial referendum. Although it will not be required, voters may want to consider submitting their ballots by registered mail.

How Will the Outcome of the Second Referendum Be Determined?

Vote counting will be conducted by NMFS. Approval or disapproval of the referendums will be determined by a majority (i.e., a number greater than half of a total) of the weighted votes cast. NMFS will prepare a fishery bulletin announcing the results of the second referendum that is conducted and will distribute the bulletin to all Gulf reef fish permittees, including dealers, and to other interested parties. The results will also be posted on NMFS' Southeast Regional Office's Web site at <http://sero.nmfs.noaa.gov>.

What Will Happen After the Second Referendum?

NMFS will present the results of the second referendum at the March 2006 Council meeting. If the second referendum fails, the Council cannot proceed with implementation an IFQ program for the commercial red snapper fishery in the Gulf of Mexico. If the second referendum is approved, the Council would be authorized, if it so decides, to submit the finalized plan amendment and regulations to the Secretary for review and approval or disapproval. The proposed IFQ program was developed through the usual Council and rulemaking processes that involved extensive opportunities for industry and public review and input at various Council meetings, public hearings, and during public comment periods on the plan amendment and regulations. The plan amendment and regulations could only be submitted to the Secretary for review and approval or disapproval if, in a second referendum, approval of the submission was passed by a majority (i.e., a number greater than

half of a total) of the votes cast by the eligible voters as described above.

Authority: 16 U.S.C. 1801 *et seq.*

Dated: December 30, 2005.

Margo Schulze-Haugen,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.

[FR Doc. 06-109 Filed 1-3-06; 2:49 pm]

BILLING CODE 3510-22-S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 123005B]

New England Fishery Management Council; Public Meeting

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice of a public meeting.

SUMMARY: The New England Fishery Management Council (Council) is scheduling a public meeting of its Scallop Committee in January, 2006 to consider actions affecting New England fisheries in the exclusive economic zone (EEZ). Recommendations from this group will be brought to the full Council for formal consideration and action, if appropriate.

DATES: The meeting will be held on Monday, January 23, 2006, at 9 a.m.

ADDRESSES: The meeting will be held at the Hilton Garden Inn, One Thurber Street, Warwick, RI 02886; telephone: (401) 734-9600; fax: (401) 734-9700.

Council address: New England Fishery Management Council, 50 Water Street, Mill 2, Newburyport, MA 01950.
FOR FURTHER INFORMATION CONTACT: Paul J. Howard, Executive Director, New England Fishery Management Council; telephone: (978) 465-0492.

SUPPLEMENTARY INFORMATION: The Committee will meet to begin development of a draft Amendment 11 to the Atlantic Sea Scallop Fishery Management Plan. The primary purpose of this amendment is to improve the effectiveness of management in the general category fishery. In addition, it will address the allocation of scallops between the limited access and general category permit holders as well as consider options to change the scallop fishing year. The committee will review and develop issues to present for public comment at scoping meetings scheduled for spring 2006. Draft management alternatives will be developed at future meetings based on scoping comments

and specific policy direction from the Council. The committee will also have a closed door session to discuss the formation of an ad-hoc industry advisory panel for general category management.

Although non-emergency issues not contained in this agenda may come before this group for discussion, those issues may not be the subject of formal action during this meeting. Action will be restricted to those issues specifically listed in this notice and any issues arising after publication of this notice that require emergency action under section 305(c) of the Magnuson-Stevens Act, provided the public has been notified of the Council's intent to take final action to address the emergency.

Special Accommodations

This meeting is physically accessible to people with disabilities. Requests for sign language interpretation or other auxiliary aids should be directed to Paul J. Howard, Executive Director, at (978) 465-0492, at least 5 days prior to the meeting date.

Dated: December 30, 2005.

Tracey L. Thompson,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.

[FR Doc. E5-8310 Filed 1-5-06; 8:45 am]

BILLING CODE 3510-22-S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 123005C]

New England Fishery Management Council; Public Meeting

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice of a public meeting

SUMMARY: The New England Fishery Management Council (Council) is scheduling a joint public meeting of its Scientific and Statistical and Social Sciences Advisory Committees in January, 2006 to consider actions affecting New England fisheries in the exclusive economic zone (EEZ). Recommendations from this group will be brought to the full Council for formal consideration and action, if appropriate.

DATES: The meeting will be held on Friday, January 27, 2006, at 9 a.m.

ADDRESSES: The meeting will be held at the Holiday Inn, 225 McClellan Highway, E. Boston, MA 02128; telephone: (617) 569-5250; fax: (617) 561-0971.

Council address: New England Fishery Management Council, 50 Water Street, Mill 2, Newburyport, MA 01950.
FOR FURTHER INFORMATION CONTACT: Paul J. Howard, Executive Director, New England Fishery Management Council; telephone: (978) 465-0492.

SUPPLEMENTARY INFORMATION: The Committees will meet to review and provide input on topics relevant to the Council's Ecosystems Pilot Project including, but not limited to, a review of the elements of the project including non-fishing marine resource uses; marine pollution and governance under an ecosystem approach. The committee will review the recent stakeholder workshops; provide advice for integrating, as necessary, ecosystems approaches with the current management structures and may consider other topics at their discretion.

Although non-emergency issues not contained in this agenda may come before this group for discussion, those issues may not be the subject of formal action during this meeting. Action will be restricted to those issues specifically listed in this notice and any issues arising after publication of this notice that require emergency action under section 305(c) of the Magnuson-Stevens Act, provided the public has been notified of the Council's intent to take final action to address the emergency.

Special Accommodations

This meeting is physically accessible to people with disabilities. Requests for sign language interpretation or other auxiliary aids should be directed to Paul J. Howard, Executive Director, at (978) 465-0492, at least 5 days prior to the meeting date.

Dated: December 30, 2005.

Tracey L. Thompson,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.

[FR Doc. E5-8311 Filed 1-5-06; 8:45 am]

BILLING CODE 3510-22-S.

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 123005A]

Endangered and Threatened Species; Take of Anadromous Fish

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Extension of scientific research permit 1376 - Modification 1.

SUMMARY: Notice is hereby given that NMFS has received a request to extend the duration of a scientific research permit that currently allows Pacific salmon to be taken. The research is designed to increase knowledge of salmonids listed under the Endangered Species Act (ESA) and help guide management and conservation efforts.

DATES: Comments or requests for a public hearing on the application must be received no later than 5 p.m. Pacific time on February 6, 2006.

ADDRESSES: Written comments on the application should be sent to Protected Resources Division, NMFS, 1201 NE Lloyd Blvd., Suite 1100, Portland, OR 97232-1274. Comments may also be sent via fax to 503-230-5441 or by e-mail to resapps.nwr@NOAA.gov.

FOR FURTHER INFORMATION CONTACT: Garth Griffin, Portland, OR (ph.: 503-231-2005, Fax: 503-230-5435, e-mail: Garth.Griffin@noaa.gov). Permit application instructions are available at <http://www.nwr.noaa.gov>.

SUPPLEMENTARY INFORMATION:

Species Covered in This Notice

The following listed species (evolutionarily significant unit) is covered in this notice:

Chinook salmon (*O. tshawytscha*): threatened naturally produced and artificially propagated Puget Sound (PS).

Authority

Scientific research permits are issued in accordance with section 10(a)(1)(A) of the ESA (16 U.S.C. 1531 et. seq) and regulations governing listed fish and wildlife permits (50 CFR Parts 222-226). NMFS issues permits based on findings that such permits: (1) Are applied for in good faith; (2) if granted and exercised, would not operate to the disadvantage of the listed species that are the subject of the permit; and (3) are consistent with the purposes and policy of section 2 of the ESA. The authority to take listed species is subject to conditions set forth in the permits.

Anyone requesting a hearing on this extension request should set out the specific reasons why such a hearing would be appropriate (see **ADDRESSES**). Hearings are held at the discretion of the Assistant Administrator for Fisheries, NOAA.

Extension Request

Permit 1376 - Modification 1

Permit 1376 currently authorizes the Washington Cooperative Fish and Wildlife Research Unit (University of Washington, School of Aquatic and Fisheries Sciences) to take juvenile and

adult PS Chinook salmon in Lakes Washington and Sammamish, Washington. The purpose of the research is to understand food web interactions, identify sources of mortality, and determine the energetic requirements for sustaining fish and zooplankton communities in each lake. The study helps researchers identify and quantify factors limiting survival and growth of juvenile salmon and other species. The UW captures (using gillnets, trawls, hook-and-line, trot lines, minnow traps, beach seines, and backpack electrofishing equipment), anesthetizes, handles, measures, weighs, and releases juvenile PS Chinook salmon and examines their stomach contents. The permittee is asking NMFS to allow the research to continue until December 31, 2006. No other changes are proposed. Further information on the actions covered by this permit may be obtained from previous notices, from the biological opinion analyzing the effects of the research (2002/01919C - which is still in effect), and on the web at <http://www.nwr.noaa.gov/>.

This notice is provided pursuant to section 10(c) of the ESA. NMFS will evaluate the request, associated documents, and comments submitted to determine whether the request meets the requirements of section 10(a) of the ESA and Federal regulations. The final permit decision will not be made until after the end of the 30-day comment period. NMFS will publish notice of its final action in the **Federal Register**.

Dated: December 30, 2005.

Susan Pultz,

Acting Chief, Endangered Species Division, Office of Protected Resources, National Marine Fisheries Service.

[FR Doc. E6-16 Filed 1-5-06; 8:45 am]

BILLING CODE 3510-22-S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 122005B]

Endangered Species; File No. 1557

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice; receipt of application.

SUMMARY: Notice is hereby given that Molly Lutcavage, Department of Biology, 177 A Spaulding Hall, University of New Hampshire, Durham, NH 03824-2617, has applied in due form for a permit to take leatherback

(*Dermochelys coriacea*) sea turtles for purposes of scientific research.

DATES: Written, telefaxed, or e-mail comments must be received on or before February 6, 2006.

ADDRESSES: The application and related documents are available for review upon written request or by appointment in the following office(s):

Permits, Conservation and Education Division, Office of Protected Resources, NMFS, 1315 East-West Highway, Room 13705, Silver Spring, MD 20910; phone (301) 713-2289; fax (301) 427-2521; and Northeast Region, NMFS, One Blackburn Drive, Gloucester, MA 01930-2298; phone (978) 281-9328; fax (978) 281-9394.

Written comments or requests for a public hearing on this application should be mailed to the Chief, Permits, Conservation and Education Division, F/PR1, Office of Protected Resources, NMFS, 1315 East-West Highway, Room 13705, Silver Spring, MD 20910. Those individuals requesting a hearing should set forth the specific reasons why a hearing on this particular request would be appropriate.

Comments may also be submitted by facsimile at (301) 427-2521, provided the facsimile is confirmed by hard copy submitted by mail and postmarked no later than the closing date of the comment period.

Comments may also be submitted by e-mail. The mailbox address for providing e-mail comments is *NMFS.Pr1Comments@noaa.gov*. Include in the subject line of the e-mail comment the following document identifier: File No. 1557.

FOR FURTHER INFORMATION CONTACT: Patrick Opay or Kate Swails, (301) 713-2289.

SUPPLEMENTARY INFORMATION: The subject permit is requested under the authority of the Endangered Species Act of 1973, as amended (ESA; 16 U.S.C. 1531 *et seq.*) and the regulations governing the taking, importing, and exporting of endangered and threatened species (50 CFR 222-226).

The primary purpose of the proposed research would be to investigate leatherback sea turtle behavior and movements in near-shore waters off the northeastern United States and to identify their dispersal in relation to oceanographic conditions and fishing activities. The research would also help establish baseline health assessments, genetic identities, sex ratios, and stable isotope composition of leatherback sea turtle tissues and prey. Researchers propose to conduct research on up to 12 leatherback sea turtles annually. Researchers would use animals that

have been disentangled from fishing gear by the stranding network or they would capture the animals using a breakaway hoopnet. Turtles would be measured, weighed, photographed and video taped, flipper and passive integrated transponder (PIT) tagged, blood sampled, cloacal swabbed, skin sampled, tagged with electronic instruments (e.g., satellite transmitters), and released. The research permit would be issued for 5 years.

Dated: December 30, 2005.

Shane Guan,

Acting Chief, Permits, Conservation and Education Division, Office of Protected Resources, National Marine Fisheries Service.

[FR Doc. E6-17 Filed 1-5-06; 8:45 am]

BILLING CODE 3510-22-S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 122705A]

Marine Mammals; File Nos. 781-1824, 965-1821, 532-1822, 540-1811, 774-1714, 782-1719, 731-1774

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice; receipt of applications and amendment requests; request for comments.

SUMMARY: Notice is hereby given that the following seven entities have applied in due form for permits and permit amendments to conduct scientific research on marine mammal species and import marine mammal part specimens for scientific research purposes:

Northwest Fisheries Science Center (NWFSC, Dr. Linda Jones, Principle Investigator), 2725 Montlake Blvd., East, Seattle, Washington 98112-2097 (File No. 781-1824);

Dr. David E. Bain, Friday Harbor Laboratories, University of Washington, 620 University Road, Friday Harbor, Washington 98250 (File No. 965-1821);

Center for Whale Research (CWR, Mr. Kenneth C. Balcomb III, Principle Investigator), 355 Smuggler's Cove Road, Friday Harbor, Washington 98250 (File No. 532-1822);

Mr. John Calambokidis, Cascadia Research, Waterstreet Bldg., 218 1/2 W. 4th Avenue, Olympia, Washington 98501 (File No. 540-1811);

Southwest Fisheries Science Center (SWFSC, Dr. Stephen B. Reilly, Principle Investigator), 8604 La Jolla

Shores Drive, La Jolla, California 92037 (Permit No. 774-1714);

National Marine Mammal Laboratory, Alaska Fisheries Science Center, (NMML, Dr. John L. Bengtson, Principle Investigator), 7600 Sand Point Way, NE., Seattle, Washington 98115-6349 (Permit No. 782-1719); and

Dr. Robin W. Baird, Cascadia Research, Waterstreet Bldg., 218 1/2 W. 4th Avenue, Olympia, Washington 98501 (Permit No. 731-1774).

DATES: Written, telefaxed, or e-mail comments must be received on or before February 6, 2006.

ADDRESSES: The application and related documents are available for review upon written request, online at <http://www.nmfs.noaa.gov/pr/permits/review.htm>, or by appointment in the following offices:

Permits, Conservation and Education Division, Office of Protected Resources, NMFS, 1315 East-West Highway, Room 13705, Silver Spring, MD 20910; phone (301) 713-2289; fax (301) 427-2521;

Northwest Region, NMFS, 7600 Sand Point Way NE, BIN C15700, Bldg. 1, Seattle, WA 98115-0070; phone (206) 526-6150; fax (206) 526-6426;

Southwest Region, NMFS, 501 West Ocean Blvd., Suite 4200, Long Beach, CA 90802-4213; phone (562) 980-4001; fax (562) 980-4018; and

Alaska Region, NMFS, P.O. Box 21668, Juneau, AK 99802-1668; phone (907) 586-7221; fax (907) 586-7249.

Written comments or requests for a public hearing on this application should be mailed to the Chief, Permits, Conservation and Education Division, F/PR1, Office of Protected Resources, NMFS, 1315 East-West Highway, Room 13705, Silver Spring, MD 20910. Those individuals requesting a hearing should set forth the specific reasons why a hearing on this particular request would be appropriate.

Comments may also be submitted by facsimile at (301) 427-2521, provided the facsimile is confirmed by hard copy submitted by mail and postmarked no later than the closing date of the comment period.

Comments may also be submitted by e-mail. The mailbox address for providing email comments is *NMFS.Pr1Comments@noaa.gov*. Include in the subject line of the e-mail comment the following document identifier: either File No. 781-1824, or 965-1821, or 532-1822, or 540-1811, or Permit Nos. 774-1714, or 782-1719, or 731-1774.

FOR FURTHER INFORMATION CONTACT: Shane Guan or Kelsey Abbott, (301) 713-2289.

SUPPLEMENTARY INFORMATION: The subject permits and amendment requests are requested under the authority of the Marine Mammal Protection Act of 1972, as amended (MMPA; 16 U.S.C. 1361 *et seq.*), the Regulations Governing the Taking and Importing of Marine Mammals (50 CFR part 216), the Endangered Species Act of 1973, as amended (ESA; 16 U.S.C. 1531 *et seq.*), the regulations governing the taking, importing, and exporting of endangered and threatened species (50 CFR 222–226), and the Fur Seal Act of 1966, as amended (16 U.S.C. 1151 *et seq.*).

File No. 781–1824: The NWFSC proposes to conduct a five-year study to determine the abundance, distribution, movement patterns, habitat use, contaminant levels, prey choice, behavior, energetics, and stock structure of cetacean species in the eastern North Pacific off the coast of Washington, Oregon, and California. The applicant proposes to take 20 cetacean species, including endangered blue whales (*Balaenoptera musculus*), fin whales (*Balaenoptera physalus*), humpback whales (*Megaptera novaeangliae*), sperm whales (*Physeter macrocephalus*), and the distinct population segment (DPS) of the Southern Resident killer whale (*Orcinus orca*). These studies would be carried out through vessel surveys, photo-identification from large and small vessels, focal follows to collect behavioral data, photogrammetry, passive acoustic monitoring, biological sample collection, satellite/radio and data log/time-depth tagging and tracking, and health assessments. The applicant proposes to utilize video photogrammetry from an unmanned tethered airship to document cetacean behavior and assess body condition. The airship would be tethered to a small boat (20–40 feet) and would be flown at an altitude of 250–400 feet. Passive acoustic data may be collected using a towed hydrophone array and/or sonobuoys. On an opportunistic basis, prey remains, sloughed skin, or feces would be collected from the water column and biopsy samples would be collected from both free-ranging and stranded cetaceans. Biopsy samples would undergo genetic, contaminant, stable isotope, and fatty acid analyses. To track the movements and diving behavior of cetaceans, both data logging tags and satellite or radio tags would be attached to the animals. These tags may use either suction cup or implantable attachments. To assess the health of the animals, breath samples would be collected by placing a funnel over the

blowhole of a surfacing animal and manually opening the attached vacuum cylinder as the animal exhales. To further assess the health of cetaceans, the applicant proposes using a 0.5MHz ultrasound transducer to determine the blubber thickness of Alaska resident killer whales, humpback whales, and gray whales (*Eschrichtius robustus*). The proposed research would also include the salvage and import/export of cetacean parts, specimens, and biological samples. All proposed activities would target adult and juvenile males and females as well as females accompanying calves. No calves would be taken. The applicant requests a total of 215 annual takes of Southern Resident killer whales (SRKW) for close approach for vessel and aerial surveys, photo-id, photogrammetry, focal follows, and collection of prey and fecal material. Additionally, NWFSC proposes to take 5 breath samples and 25 biopsy samples from SRKW each year. Using only suction cup attachment, the applicant proposes to attach 10 data logging tags to SRKW annually. In addition, the applicant requests authorization to engage in the worldwide import, export, re-export and/or salvage of 30 biological samples, specimens, or parts from SRKW annually. Each year, up to 300 Southern Resident killer whales may be incidentally harassed by the above research activities.

File No. 965–1821: Dr. David Bain requests a five-year permit to study killer whales, including the Southern Resident DPS. Research would focus on the inland waters of Washington, with comparative data collected from central California to central Alaska. The study is designed to examine killer whale distribution and movement patterns; diet and energetic requirements; reproduction and mortality patterns; health; social structure; and the effects of anthropogenic disturbances, including noise, on the whales. The applicant proposes to utilize a variety of platforms including boats, unmanned vessels, and blimps. Unmanned vessels would be used to carry instrumentation as an alternative to the use of a small manned vessel. Standard manned blimps (50–60 meters or 164–197 feet in length) would be operated at 1,000–1,500 feet. Smaller unmanned blimps (10–15 meters or 33–49 feet in length) would be operated via remote control at an altitude no higher than 400 feet and potentially 200–250 feet. Video and photographs would be collected from all survey platforms for use in photo-identification and photogrammetry. The applicant proposes to conduct health

assessments of each Southern Resident once per year. These health assessments would consist of underwater photography, respiratory samples, infrared imaging, and acoustic recordings of blows. Underwater video would be taken to assess body condition, including possible pregnancies, injuries, and body girth. To collect baseline information about upper respiratory tract microbes, a researcher would sweep a culture plate attached to a lightweight telescoping pole through the exhaled air of a whale surfacing near the research vessel. The acoustic properties of whale blows would be recorded using a directional microphone and parabolic reflector. A thermal imaging camera would be utilized to examine the spatial characteristics of blows as well as any bodily wounds. A laser range finder would be employed to measure the distance to a whale for calibrating images and recordings. To study killer whale diet, samples of prey and feces would be collected for analysis. A Splashcam camera towed in the upper 10 meters (33 feet) of the water column would be employed on some occasions to monitor potential prey. Multi-beam sonar images operated at a high frequency level of 200 kHz would be used to determine the relative density of potential prey in the water column. Both tetrahedral and linear towed arrays may be used to collect passive acoustic data. Focal follows of individual animals would be conducted to examine behavior, social structure, and energetics. The applicant requests 50 thirty-minute focal follow samples annually, focusing on one age/sex class each year. Adult males, adult females, and juveniles would be sampled in this manner. Annually, 300 SRKW and 320 killer whales of other stocks would be harassed during the above research activities. The applicant has also requested takes of other cetacean and pinniped species that may be incidentally harassed during the killer whale research. These species include humpback whales, fin whales, harbor seals (*Phoca vitulina*), northern fur seals (*Callorhinus ursinus*), and Steller sea lions (*Eumetopias jubatus*).

File No. 532–1822: The Center for Whale Research (CWR, Ken Balcomb, Principal Investigator) requests a five-year permit to study Southern Resident killer whales throughout their range, from Monterey Bay, California to the Queen Charlotte Islands, Canada. The goal of the research would be to continue conducting annual photo-identification studies on this population in order to monitor population size and

demographics, movements and distribution, social structure, and individual health and body condition. To achieve these goals, CWR requests 500 annual takes of SRKW by close approach for photo-identification and 1,000 takes annually by close approach for vessel and aerial surveys. During vessel surveys, the applicant would collect passive acoustic information. The applicant also requests authority to collect photo-identification data from other killer whale stocks that are encountered opportunistically, including the eastern North Pacific Offshore stock, eastern North Pacific Northern Resident stock, and the eastern North Pacific Transient stock. Takes would occur by close approach by vessel survey for photo-identification, and by incidental harassment by aerial and vessel surveys. In addition, the researcher would like to collect non-marine mammal prey remains after the killer whales have left an area.

File No. 540-1811: John Calambokidis (Cascadia Research) requests a five-year permit to study marine mammals in the North Pacific Ocean including the waters off California, Oregon, and Washington. The applicant requests the authority to: (1) Use photo-identification activities to determine the abundance, movements, and population structure of cetaceans; (2) collect skin biopsies to determine sex and relatedness, and to evaluate stock structure of cetaceans; (3) conduct suction cup tagging activities to examine the diving behavior, feeding, movements, and vocal behavior of cetacean species; (4) conduct aerial, vessel, and shore-based surveys to examine distribution, abundance, habitat, and feeding behavior; and (5) to recover dead harbor seals for contaminant analysis. To conduct this research, the applicant requests takes of five species of pinnipeds and 27 cetacean species, including humpback whales, blue whales, fin whales, and gray whales. The principal research activities of this study would be to survey, photo-id, and biopsy sample gray, humpback, and blue whales in the Pacific Northwest; to tag humpback, blue, and fin whales off the coast of California; to perform aerial surveys for harbor porpoises, humpback, and blue whales; and to perform shore-based censuses of harbor seals in Washington. The applicant plans to tag and biopsy all age and sex classes except calves less than one year of age and females accompanying such calves. Tagging packages would contain a combination of the following instruments and devices: hydrophone and recording system for underwater vocalizations,

pressure sensor to record water depth, sensor to monitor and record water temperature, 3-axis accelerometers to measure pitch and roll of animal, 3-axis solid state magnetometers to measure heading, VHF tag to provide local positioning information, satellite tag to record long-range movements, and underwater video camera to record behavior and prey. The applicant also requests 150 annual takes of Southern Resident killer whales by close approach for photo-identification and 150 annual SRKW takes by close approach for aerial and vessel surveys.

Amendment Requests

Permit No. 774-1714-04: The SWFSC proposes to amend their existing scientific research permit (Permit No. 774-1714, issued on June 30, 2004 and most recently amended on September 16, 2005) to allow takes of the recently ESA-listed Southern Resident killer whale DPS. The purpose of the research is to document the range of the SRKW within 300 nm of the California, Oregon, and Washington outer coasts, which is outside their relatively well studied distribution in inland and coastal waters. The research would be carried out opportunistically during SWFSC's line-transect surveys designed to provide data for Stock Assessment Reports on abundance and stock identity of all cetacean species in these areas. Photo-identification activities would be conducted from small boats at a distance of 10-20 meters (approximately 33-65 feet) from the animals. Biopsy sampling would only be done at the request of the NWFSC. The SWFSC is requesting to amend Permit No. 774-1714-03 to allow takes of 20 SRKW and 180 non-SRKW for photo-identification, and 10 SRKW and 130 non-SRKW for biopsy sampling annually. Each year, up to 20 SRKW may be incidentally harassed by the above research activities. The current permit allows the SWFSC to take 500 killer whales for biopsy and 500 for photo-identification, with no distinction between SRKW and non-SRKW. The amended permit, if issued, would be valid until the permit expires on June 30, 2009.

Permit No. 782-1719-03: Permit No. 782-1719-00, issued to NMML on June 30, 2004 (69 FR 44514) and most recently amended on September 16, 2005 authorizes the Permit Holder to take all species of cetaceans under NMFS jurisdiction during stock assessment activities throughout U.S. territorial waters and the high seas of the North Pacific Ocean, Southern Ocean, Arctic Ocean, and the territorial waters of Mexico (Gulf of California

only), Canada, Russia, Japan, and the Philippines. The permit authorizes close approach during Level B harassment (aerial surveys, vessel-based surveys, observations, and photo-identification) and Level A harassment (biopsy sampling and attachment of scientific instruments) for all age and sex classes. The Holder now requests authority to opportunistically sample SRKW when encountered during stock assessment surveys. The Holder asks to biopsy sample 10 SRKW (excluding calves and accompanying females) per year. These samples will undergo fatty acid, stable isotope, and contaminant analyses to determine the diet and nutrition of the animals. In addition, NMML requests 100 takes of SRKW by close approach for photo-identification and 1,000 annual takes by vessel and aerial surveys. The amended permit, if issued, would be valid until the permit expires on June 30, 2009.

Permit No. 731-1774-01: Permit No. 731-1774, issued to Robin Baird, Ph.D. (Cascadia Research) on September 16, 2005, authorizes takes by close approach, including vessel approaches, aerial over-flights, and suction cup tagging of cetacean species in all U.S. and international waters in the Pacific, including Alaska, Washington, Oregon, California, Hawaii, and other U.S. territories. The objectives of the research are to assess cetacean populations and to study diving and night-time behavior, social organization, and inter-specific interactions. The Permit Holder now requests authority to suction cup tag 15 Southern Resident killer whales per year to assess inter-annual variability in diving patterns. Males and females of all ages would be tagged, with the exception of calves under six months of age and females attending such calves. Furthermore, the Holder requests 100 takes of all age and sex classes of SRKW annually by harassment during close approach for vessel and aerial surveys, photo-identification, behavioral observations, video and acoustic recordings, and incidental harassment. The proposed research would primarily occur in the waters of Washington, but may also occur in the waters of California and Oregon. The current permit authorizes the Holder to import/export five parts/samples from killer whales. The Holder requests authority to import/export one part or sample from SRKW and four from other killer whales annually. The amended permit, if issued, would be valid until the permit expires on August 31, 2010.

Concurrent with the publication of this notice in the **Federal Register**, NMFS is forwarding copies of this application to the Marine Mammal

Commission and its Committee of Scientific Advisors.

Dated: December 30, 2005.

Shane Guan,

Acting Chief, Permits, Conservation and Education Division, Office of Protected Resources, National Marine Fisheries Service.

[FR Doc. E6-18 Filed 1-5-06; 8:45 am]

BILLING CODE 3510-22-S

DEPARTMENT OF DEFENSE

Department of the Army

Final Environmental Impact Statement To Fully Integrate the Overhills Property Into the Fort Bragg Training Program, Fort Bragg, NC

AGENCY: Department of the Army, DOD.
ACTION: Notice of availability.

SUMMARY: The Department of the Army announces the availability of the Final Environmental Impact Statement (FEIS) to fully integrate the Overhills property into the Fort Bragg Training Program, Fort Bragg, Cumberland and Harnett Counties, NC. Presently, realistic training in Fort Bragg's Northern Training Area (NTA), one of Fort Bragg's largest training areas, is hampered by the two sets of training rules that govern training in the units. Though no physical barriers separate the Overhills training units, NTA V-VIII, from NTA units I-IV, the Overhills Standard Operating Procedures (SOP) limits the number of personnel and types of activities during training exercises, effectively creating a training barrier. Applying the same training regulation to the Overhills that governs training on the rest of the installation would allow Fort Bragg to fully incorporate the Overhills into the installation's training program, and maximize training possibilities throughout the NTA.

DATES: Written comments on the FEIS must be received no later than 30 days after publication of the notice of availability (NOA) in the **Federal Register** by the U.S. Environmental Protection Agency to be considered in preparation of the Record of Decision.

ADDRESSES: Please direct written comments or requests for copies of the FEIS to David A. Heins, Chief, Environmental Sustainment Division, Public Works Business Center, ATTN: AFZA-PW-E, Fort Bragg, NC 28310, or e-mail to david.a.heins@us.army.mil.

FOR FURTHER INFORMATION CONTACT: David A. Heins, (910) 396-8207 or e-mail david.a.heins@us.army.mil.

SUPPLEMENTARY INFORMATION: Fort Bragg serves as headquarters for the XVIII

Airborne Corps and Army Special Operations Command, and is home to the 82nd Airborne Division. The primary mission of Fort Bragg is the training and deployment of military units. Fort Bragg supports the most intensive and varied training program in the continental United States. An average of 2.5 million personnel days of training is conducted at Fort Bragg and Camp Mackall (a sub-installation to Fort Bragg) each year. Training to sustain readiness is Fort Bragg's primary activity.

Land upon which to train personnel is vital to Fort Bragg's mission. In 1995, Fort Bragg directed a study that identified a shortfall of maneuver land of 81,876 acres, and a weapons range and impact area shortfall of 43,636 acres. In order to reduce this training land deficit, the Department of the Army purchased the Overhills property from the Rockefeller family in 1997.

The Overhills property comprises 10,580 acres in Cumberland and Harnett Counties, NC, and adjoins the northern boundaries of Fort Bragg and Pope Air Force Base. An Environmental Assessment was prepared in 1999 to adopt an Interim Training Program (ITP) on the Overhills tract. Under the ITP, training was restricted to company-level, low impact (limited) military training.

Presently, the maneuver/training areas at Fort Bragg are so heavily utilized that the land to support training needs to be used to its fullest extent. These factors, in conjunction with the training land deficit identified by Fort Bragg, demonstrate the need to make maximum use of available training lands on Fort Bragg. Fully incorporating the Overhills tract, which represents the eastern part of the NTA and comprises almost half of the training area, into the installation's training program would enhance training throughout the NTA, and help sustain environmental resources in other training areas on Fort Bragg.

The Army proposes to fully integrate the Overhills into Fort Bragg's training program. The FEIS analyzes the No Action/Status Quo alternative as well as three action alternatives. Alternatives considered in detail in the FEIS are:

Alternative 1. (No Action)—Continue limited training, existing recreation, and preservation of the Overhills Historic District (the District). Fort Bragg would conduct this training in accordance with existing Fort Bragg Standing Operating Procedure (SOP) for training on the Overhills. This SOP limits training exercises to company-sized units (approximately 250 personnel, including exercise support personnel)

and prescribes the procedures for use of the Overhills for training. Company-size exercises generally require fewer than 75 vehicles per exercise. Exercises would be scheduled 4-6 times per month. The following types of exercises are permitted under the Overhills SOP:

Dismounted movement; Air mobile insertions; Firing of blank small arms ammunition (up to .50 caliber) and simulators; Movement of wheeled vehicles on maintained roads and trails; Fixed activities limited to bivouac, signal, or medical in existing clearings; Military operations on urbanized terrain training in buildings, but only on non-contributing elements within the District and non-eligible resources outside the District; hasty hand-dug personnel fighting positions; Use of flame-producing munitions of any type. Hunting and fishing would continue to be allowed subject to restrictions imposed on public access by military training schedules.

The District would be preserved in accordance with the "Standards for Preservation" in the Secretary of Interior's Standards for the Treatment of Historic Properties (38 CFR Part 68). Training in buildings considered contributing elements would not be permitted, but maneuvers in open areas within the historic district boundary would continue.

Alternative 2. Limited training, additional recreation, and adaptive reuse and/or layaway of selected contributing elements within the District. Training units would be limited to company-size (250 personnel plus support personnel), but training would be conducted in accordance with the Installation Range Regulation (IRR), not the Overhills SOP. The following additional training would be permitted:

Ground and air maneuvers involving both mechanized and light infantry with attached combat support and combat service support; Operation of wheeled and tracked vehicles off road; River crossing, bridging, and waterborne operations (including water drops); Construction of fortifications and obstacles; Helicopter landing zones; Excavations (in addition to hand-dug positions) for survivability emplacements, such as vehicle fighting positions; and use of tear gas and obscurant smoke.

A youth golf program and a horse stables program would be added to the recreational programs at Fort Bragg. These programs would utilize several of the historic buildings and structures on Overhills such as the Donald Ross golf course, the polo barn, and riding stables. New facilities would also be constructed. Hunting and fishing would

continue as discussed under Alternative 1.

This alternative would maintain the historic integrity of 15 of the 56 contributing elements of the historic district. The remaining buildings and structures would be incorporated into the Fort Bragg training program after mitigating for the loss of historical integrity by fulfilling all requirements under the National Historic Preservation Act (NHPA), the Fort Bragg Integrated Cultural Resource Management Plan (ICRMP) and Army Regulation (AR) 200-4, Cultural Resources Management.

Alternative 3. Intermediate training, additional recreation, and adaptive reuse and/or layaway of selected contributing elements within the District. Under this alternative, the level of activity on the Overhills would be increased to accommodate battalion-sized units (approximately 1,000 personnel), plus support personnel. Training would occur in accordance with the IRR. There are 40 battalions at Fort Bragg. Battalion-size field exercises typically use 75 or fewer vehicles per exercise, including support vehicles. Each battalion holds one or two 3-day field exercises per year. Movement between NTA units I-IV and Overhills (NTA V-VIII) would be fluid with no training restrictions other than the number of personnel permitted on the Overhills. Additional recreation would consist of the youth golf and horse stables programs described for Alternative 2. Hunting and fishing would continue to be permitted, as discussed in Alternative 1. This alternative would treat the District as discussed under Alternative 2.

Alternative 4. (Preferred Alternative)—Maximum training, existing recreation, and no preservation of the District. Under this alternative, the level of training would be increased to accommodate brigade-sized units (up to approximately 5,000 personnel); the Overhills would be fully incorporated into the installation's training program, and used in the same manner as the other training areas on Fort Bragg. Units up to, and including brigade size, would train in accordance with the IRR. Hunting and fishing would continue as discussed under Alternative 1. No additional recreational use of the Overhills would occur under maximum training due to the need for maneuver frontage and flexibility.

After mitigating for the loss of historical integrity by fulfillment of all legal requirements under the NHPA, the Fort Bragg ICRMP, and AR 200-4, the 56 contributing elements would be integrated into the training program. All contributing and non-contributing

elements as well as standing structures determined not eligible for the NRHP would be evaluated for use in training exercises. The buildings that could be incorporated into the training program would remain; the non-essential buildings and structures would be demolished.

The Overhills FEIS provides an analysis of both the beneficial and adverse environmental impacts of the different use alternatives for the Overhills, and analyzes quantitatively and qualitatively the potential environmental impacts of the proposed alternatives. The resource areas discussed and evaluated are: Soils, surface waters, groundwater, wetlands, vegetation, wildlife, protected species, hazardous materials/waste management, solid waste management, air quality, noise, safety, land use, demographics and economy, recreation, archaeological resources, and the historic district. The FEIS indicates that Alternative 1 (No Action) has the fewest potential impacts because no new training types would be added, and all of the historic buildings and structures would be preserved. Alternatives 2, 3 and 4 would have some potential adverse impacts to several of the analyzed resources; however, mitigations to reduce those impacts are identified in the FEIS.

Minimal comments were received during the 45-day DEIS comment period and changes made to the document were exclusively clarifications and minor factual changes. Therefore, in accordance with 32 CFR 651.45(h), only the DEIS comments, responses to the comments and the errata sheet are being circulated. Copies of the comments, responses and the errata sheet are available for review at major libraries in the study area. A copy of the DEIS, comments and responses, and the errata sheet may be viewed at: http://www.bragg.army.mil/envbr/nepa_review.htm.

Thomas M. Jordan,
Brigadier General, USA, Assistant Deputy
Chief of Staff, G-3/5/7 (Readiness), U.S. Army
Forces Command.

[FR Doc. 06-100 Filed 1-5-06; 8:45 am]
BILLING CODE 3710-08-M

DEPARTMENT OF DEFENSE

Department of the Army

Reserve Officers' Training Corps (ROTC) Program Subcommittee

AGENCY: Department of the Army, DoD.

ACTION: Notice of open meeting.

SUMMARY: In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (5 U.S.C., App. 2), announcement is made of the following Committee meeting:

Name of Committee: Reserve Officers' Training Corps (ROTC) Program Subcommittee.

Dates of Meeting: January 24-25, 2006.

Location: Radisson Hotel Hampton, 700 Settlers Landing Road, Hampton, VA 23669.

Time: 0800-1700 hours, January 24, 2006; 0800-1030 hours, January 25, 2006.

Proposed Agenda: Review and discuss the Junior and Senior Reserve Officers' Training Corps programs; incentive-based scholarships initiatives; academic accreditation agencies and procedures; curriculum review, revision and validation; and the growth of Military Science and Leadership as a college minor.

FOR FURTHER INFORMATION CONTACT: Mr. Pierre Blackwell, U.S. Army Cadet Command (ATCC-TR), Fort Monroe, VA 23651 at (757) 788-4522.

SUPPLEMENTARY INFORMATION: This meeting is open to the public. Any interested person may attend, appear before, or file statements with the committee.

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 06-99 Filed 1-5-06; 8:45 am]
BILLING CODE 3710-08-M

DEPARTMENT OF DEFENSE

Department of the Army

Availability of Non-Exclusive, Exclusive License or Partially Exclusive Licensing of U.S. Patent Concerning Article of Footwear With Temperature Regulation Means

AGENCY: Department of the Army, DoD.

ACTION: Notice.

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent No. US 6,981,339 entitled "Article of Footwear with Temperature Regulation Means" issued January 3, 2006. This patent has been assigned to the United States Government as represented by the Secretary of the Army.

FOR FURTHER INFORMATION CONTACT: Mr. Robert Rosenkrans at U.S. Army Soldier Systems Center, Kansas Street, Natick, MA 01760; Phone: (508) 233-4928 or E-mail: Robert.Rosenkrans@natick.army.mil.

SUPPLEMENTARY INFORMATION: Any licenses granted shall comply with 35 U.S.C. 209 and 37 CFR part 404.

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 06-104 Filed 1-5-06; 8:45 am]
BILLING CODE 3710-08-M

DEPARTMENT OF DEFENSE

Department of the Army

Intent To Grant an Exclusive License of a U.S. Government-Owned Patent

AGENCY: Department of the Army, DoD.
ACTION: Notice.

SUMMARY: In accordance with 35 U.S.C. 209 and 37 CFR 404.7(a)(1)(i), announcement is made of the intent to grant an exclusive, royalty-bearing, revocable license within the geographic area of the United States of America and its territories and possessions to U.S. Patent 6,669,481, issued December 30, 2003 entitled "Neurocognitive Assessment Apparatus And Method," Continuation-in-part U.S. Patent Application 10/614,758, filed July 8, 2003 entitled "Automated Neurological Assessment Metrics (Anam)," U.S. Provisional Patent Application 60/289,125, filed May 8, 2001 entitled "Automated Neurological Assessment Metrics," U.S. Provisional Patent Application 60/663,765, filed March 22, 2005 entitled "System, Method, And Computer Program Product For An Automated Neuropsychological Test;" U.S. Patent Application 10/340,473, filed December 27, 2002, to The University of Oklahoma with its principal place of business at 350 David L. Boren Boulevard, Suite 1510, Norman, Oklahoma 73072-7264.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-ZA-J, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: Anyone wishing to object to the grant of this license can file written objections along with supporting evidence, if any, within 15 days from the date of this publication. Written objections are to be filed with the Command Judge Advocate, U.S. Army Medical Research

and Materiel Command, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 06-106 Filed 1-5-06; 8:45 am]
BILLING CODE 3710-08-M

DEPARTMENT OF DEFENSE

Department of the Army

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Application Concerning Composition for Treating Sulfur Mustard Toxicity and Methods of Using Same

AGENCY: Department of the Army, DoD.
ACTION: Notice.

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 60/632,834 entitled "Composition for Treating Sulfur Mustard Toxicity and Methods of Using Same," filed December 3, 2004. Foreign rights are also available. The United States Government, as represented by the Secretary of the Army, has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-ZA-J, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: The present invention relates to the areas of medicine, biology, and chemistry. More specifically, the present invention relates to a treatment of skin damage caused by exposure to sulfur mustard (mustard gas).

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 06-107 Filed 1-5-06; 8:45 am]
BILLING CODE 3710-08-M

DEPARTMENT OF DEFENSE

Department of the Army

Availability of Non-Exclusive License or Partially Exclusive Licensing of U.S. Patent Concerning Method and Apparatus for Making Body Heating and Cooling Garments

AGENCY: Department of the Army, DoD.
ACTION: Notice.

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent No. US 6,979,382 entitled "Method and apparatus for making body heating and cooling garments" issued December 27, 2005. This patent has been assigned to the United States Government as represented by the Secretary of the Army.

FOR FURTHER INFORMATION CONTACT: Mr. Robert Rosenkrans at U.S. Army Soldier Systems Center, Kansas Street, Natick, MA 01760, Phone; (508) 233-4928 or E-mail: Robert.Rosenkrans@natick.army.mil.

SUPPLEMENTARY INFORMATION: Any licenses granted shall comply with 35 U.S.C. 209 and 37 CFR part 404.

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 06-105 Filed 1-5-06; 8:45 am]
BILLING CODE 3710-08-M

DEPARTMENT OF DEFENSE

Department of the Army

Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Application Concerning Method of Prophylactically Treating Organophosphate Poisoning

AGENCY: Department of the Army, DoD.
ACTION: Notice.

SUMMARY: In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 60/613,121 entitled "Method of Prophylactically Treating Organophosphate Poisoning," filed September 24, 2004. Foreign rights are also available. The United States Government, as represented by the Secretary of the Army, has rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-ZA-J, 504 Scott

Street, Fort Detrick, Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: The invention relates to a method of prophylactically treating organophosphate poisoning in an animal, in particular a mammal, specifically a human.

Brenda S. Bowen,

Army Federal Register Liaison Officer

[FR Doc. 06-108 Filed 1-5-06; 8:45 am]

BILLING CODE 3710-08-M

DEPARTMENT OF DEFENSE

Department of the Army

Availability of Non-Exclusive, Exclusive License or Partially Exclusive Licensing of U.S. Patent Concerning Projectile Launch Assembly and Method

AGENCY: Department of the Army, DoD.

ACTION: Notice.

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent No. US 6,981,449 entitled "Projectile Launch Assembly and Method" issued January 3, 2006. This patent has been assigned to the United States Government as represented by the Secretary of the Army.

FOR FURTHER INFORMATION CONTACT: Mr. Robert Rosenkrans at U.S. Army Soldier Systems Center, Kansas Street, Natick, MA 01760; Phone: (508) 233-4928 or e-mail:

Robert.Rosenkrans@natick.army.mil.

SUPPLEMENTARY INFORMATION: Any licenses granted shall comply with 35 U.S.C. 209 and 37 CFR part 404.

Brenda S. Bowen,

Army Federal Register Liaison Officer.

[FR Doc. 06-103 Filed 1-5-06; 8:45 am]

BILLING CODE 3710-08-M

DEPARTMENT OF DEFENSE

Department of the Army; Corps of Engineers

Notice of Intent To Prepare an Environmental Impact Statement and Conduct Public Scoping Meetings for the Fishtrap Lake Road Project, Fishtrap Lake, Pike County, KY

AGENCY: Department of the Army, U.S. Army Corps of Engineers, DoD.

ACTION: Notice.

SUMMARY: Pursuant to the National Environmental Policy Act (NEPA), the Huntington District, U.S. Army Corps of Engineers, DoD, will prepare an Environmental Impact Statement (EIS). The EIS will evaluate potential direct, indirect and cumulative impacts to the natural, physical, and human environment resulting from construction of one or more roads proposed to serve recreational development and community access needs at the Fishtrap Lake Project near Millard, Pike County, KY.

ADDRESSES: Send written comments and suggestions concerning this proposed project to Peter K. Dodgion PD-R, U.S. Army Corps of Engineers, Huntington District, 502 Eighth Street, Huntington, WV 25701-2070. Telephone: 304-399-5873. Electronic mail: *peter.k.dodgion@usace.army.mil.* Requests to be placed on the mailing list should also be sent to this address.

FOR FURTHER INFORMATION CONTACT: To obtain additional information about the proposed project, contact Beth A. Cade PD-F, U.S. Army Corps of Engineers, Huntington District, 502 Eighth Street, Huntington, WV 25701-2070. Telephone: 304-399-5848. Electronic mail: *beth.a.cade@usace.army.mil.*

SUPPLEMENTARY INFORMATION:

1. Public Participation:

a. The Corps of Engineers will conduct public scoping workshops to gain input from interested agencies, organizations, and the general public concerning the content of the EIS, issues and impacts to be addressed in the EIS, and alternatives that should be analyzed. Three public scoping workshops are scheduled as follows:

(1) January 23, 2006, from 6-8:30 p.m., Kimper Grade School, 8151 State Highway 194, East Kimper, KY;

(2) January 24, 2006, from 12-2:30 p.m., Pike County Courthouse, Fiscal Courtroom, 146 Main Street, Pikesville, KY; and,

(3) January 24, 2006 from 6-8:30 p.m., Millard Grade School, 20 Rocky Road, Pikesville, KY.

b. The Corps invites full public participation to promote open communication and better decision-making. All persons and organizations that have an interest in the community access and recreation at and around Fishtrap Lake are urged to participate in this NEPA environmental analysis process. Assistance will be provided upon request to anyone having difficulty with learning how to participate.

c. Public comments are welcomed anytime throughout the NEPA process. Formal opportunities for public participation include: (1) Public meetings to be held near the Fishtrap Lake Project; (2) Anytime during the NEPA process via mail, telephone, fax, or e-mail; (3) During Review and Comment on the Draft EIS—approximately Fall 2006; and, (4) Review of the Final EIS—approximately Spring 2007. Schedules and locations will be announced in local news media. Interested parties may also request to be included on the mailing list for public distribution of meeting announcements and documents. (See **ADDRESSES**).

d. To ensure that all issues related to the proposed project are addressed, the Corps will conduct an open process to define the scope of the EIS. Recommendations from interested agencies, local and regional stakeholders and the general public are encouraged to provide input into regional recreational needs, community access, and other issues and concerns that should be considered in formulation and evaluation of project alternatives and documented in the EIS. Scoping for the EIS will continue to build upon the knowledge and information developed in the approximately 40 years the Corps of Engineer has managed the Fishtrap Lake Project.

2. Background:

a. The Fishtrap Lake Project (Project), which became operational in 1969, includes a 2,631-acre impoundment of the Levisa Fork, a tributary of the Big Sandy River. The dam is located 103.3 miles above the mouth of the Levisa Fork. The Project consists of 15,786 acres in this rugged mountainous area of Southeastern Kentucky. In addition to flood control, Congressionally authorized project purposes include recreation, low-flow augmentation, and fish and wildlife conservation. About 12,000 acres are currently leased to the Kentucky Division of Fish and Wildlife for wildlife management.

b. The proposed road at Fishtrap Lake was named in the Consolidated Appropriations Act of 2004 (Act). The Act also provided under the General

Provisions for Federal Highway Administration (FHWA) that "funds made available under this section may, at the request of a State, be transferred by the Secretary to another Federal agency to carry out a project funded under this section, such funds to be then administered by the procedures of the Federal agency to which such funds may be transferred". Pursuant to this provision, FHWA transferred the funding to the Huntington District U.S. Army Corps of Engineers to execute the project. FHWA will participate in the EIS development as a cooperating agency.

c. An evaluation of current and reasonably foreseeable future recreation demands of the region that could be served by the Fishtrap Project will be conducted within this study. Pike County has long been interested in development of the recreation potential of the Project as a means to diversify the region's predominately coal extraction-based economy. Inundation to create Fishtrap Lake affected access of certain communities adjacent to the project. An array of acceptable recreation alternatives as well as community access needs will provide the basis for road alternatives.

d. Alternatives to be considered will include the No Action alternative, or no road development; and alternatives formulated to address the results of the assessments of recreational needs and community access with input through internal and external scoping.

William E. Bulen,

Colonel, Corps of Engineers, District Engineer, Huntington.

[FR Doc. 06-101 Filed 1-5-06; 8:45 am]

BILLING CODE 3710-GM-M

DEPARTMENT OF DEFENSE

Department of the Army, Corps of Engineers

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Notice of Intent To Prepare an Integrated Environmental Impact Statement/Environmental Impact Report/Feasibility Report for the South San Francisco Bay Shoreline Study: Alviso Ponds and Santa Clara County Interim Feasibility Study

AGENCY: Department of the Army, U.S. Army Corps of Engineers; Department of Defense; U.S. Fish and Wildlife Service, Department of the Interior.

ACTION: Notice of intent.

SUMMARY: Pursuant to the National Environmental Policy Act (NEPA) of 1969, as amended, the U.S. Army Corps of Engineers (Corps) and the U.S. Fish and Wildlife Service (USFWS) intend to prepare a joint project-level integrated Environmental Impact Statement (EIS)/Environmental Impact Report (EIR)/Feasibility Report, hereafter called the Report, to address the potential impacts of the first Interim Feasibility Study component of the South San Francisco Bay Shoreline Study, San Francisco Bay, CA. This study is closely interrelated with the ongoing South Bay Salt Ponds Restoration Project, discussed in the Notice of Intent dated November 9, 2004. It will function as a project-level EIS/EIR tiered under that programmatic EIS/EIR and will be issued subsequently to the programmatic document. The California State Coastal Conservancy (Conservancy) will be the lead agency under the California Environmental Quality Act (CEQA).

Federal Lead Agencies Proposed Actions and Related Programmatic EIS/EIR. The Corps, in cooperation with the USFWS, is proposing to study flood protection and ecosystem restoration for the Alviso portion of the South San Francisco Bay (South Bay) Salt Ponds and adjacent areas to determine whether there is a federal interest in constructing a project with flood protection and/or ecosystem restoration components in this area, and if so, to determine the optimum project to recommend to Congress for authorization. The Report will recommend a plan which will provide for long-term restoration for these salt ponds and adjacent areas as well as flood protection and recreation components, if these actions are justified under Federal criteria. The Report and its alternatives will be tiered to the programmatic EIS/EIR for the South Bay Salt Ponds Restoration Project.

One public scoping meeting will be held to solicit comments on the environmental effects of the range of potential projects and the appropriate scope of the Report. The public is invited to comment during this meeting on environmental issues to be addressed in the Report.

DATES: Written comments from all interested parties are encouraged and must be received on or before February 7, 2006.

ADDRESSES: Written comments and requests for information should be sent to Yvonne LeTellier, Project Manager, U.S. Army Corps of Engineers, 333 Market Street, 8th Floor, San Francisco, CA 94105-2197, or to Mendel Stewart,

Refuge Manager, U.S. Fish and Wildlife Service, San Francisco Bay NWR Complex, P.O. Box 524, Newark, CA 94560.

FOR FURTHER INFORMATION CONTACT: Yvonne LeTellier, Project Manager, U.S. Army Corps of Engineers (415-977-8466) or Mendel Stewart, Refuge Manager, U.S. Fish and Wildlife Service, San Francisco Bay NWR Complex (510-792-0222). For questions concerning the CEQA aspects of the study, contact Brenda Buxton, California State Coastal Conservancy, 1330 Broadway, 11th Floor, Oakland, CA 94612, telephone: 510-286-0753.

SUPPLEMENTARY INFORMATION: On November 9, 2004, the USFWS and the Corps issued a Notice of Intent for the proposed South Bay Salt Ponds Restoration Project programmatic EIS/EIR. The Corps and the USFWS propose to integrate the planning process for the Alviso Pond and Santa Clara County Interim Feasibility Study component of the South San Francisco Bay Shoreline Study with the planning process for the South Bay Salt Ponds Restoration Project. The two projects include ecosystem restoration, flood protection, and public access components. However, the current Interim Feasibility Study is a project-level component of the South Bay Salt Pond Restoration Study and it will be tiered to the above-mentioned programmatic EIS/EIR. This Interim Feasibility Study and the Report to be prepared will only cover a portion of the larger geographic area addressed in the South Bay Salt Ponds programmatic EIS/EIR.

Project Description. *South Bay Salt Ponds Restoration Project.* The South Bay Salt Ponds Restoration Project area comprises 15,100 acres of salt ponds and adjacent habitats in South San Francisco Bay the USFWS and California Department of Fish and Game (CDFG) acquired from the Cargill Salt Company in 2003. USFWS owns and manages the 8,000-acre Alviso pond complex and the 1,600-acre Ravenswood pond complex. CDFG owns and manages the 5,500-acre Eden Landing pond complex.

The overarching goal of the South Bay Salt Ponds Restoration Project is to restore and enhance wetlands in the South San Francisco Bay while providing for flood protection and wildlife-oriented public access and recreation. The following project objectives were adopted by the South Bay Salt Ponds Restoration Project's Stakeholder Forum which includes representatives of local governments, environmental organizations,

neighboring landowners, businesses, and community organizations:

1. Create, restore, or enhance habitats of sufficient size, function, and appropriate structure to:

a. Promote restoration of native special-status plants and animals that depend on South San Francisco Bay habitat for all or part of their life cycles.

b. Maintain current migratory bird species that utilize existing salt ponds and associated structures such as levees.

c. Support increased abundance and diversity of native species in various South San Francisco Bay aquatic and terrestrial ecosystem components, including plants, invertebrates, fish, mammals, birds, reptiles and amphibians.

2. Maintain or improve existing levels of flood protection in the South Bay area.

3. Provide public access and recreational opportunities compatible with wildlife and habitat goals.

4. Protect or improve existing levels of water and sediment quality in the South Bay, and fully evaluate ecological risks that could be caused by restoration.

5. Implement design and management measures to maintain or improve current levels of vector management, control predation on special-status species, and manage the spread of non-native species.

6. Protect the services provided by existing infrastructure (e.g., power lines, railroads).

USFWS and CDFG reviewed the proposed project objectives to ensure compliance with legal mandates, such as compatibility of wildlife with public access. Two additional evaluation factors were identified in the Alternatives Development Framework for comparative analysis:

7. Cost Effectiveness: Consider costs of implementation, management, and monitoring so that planned activities can be effectively executed with available funding.

8. Environmental Impact: Promote environmental benefit and reduce impacts to the human environment.

The South Bay salt ponds are now being managed by the U.S. Fish and Wildlife Service and the California Department of Fish and Game under an Initial Stewardship Plan which was evaluated in a March 2004 Final EIS/EIR. The long-term restoration plan currently under evaluation in the ongoing programmatic NEPA/CEQA process may include general plans for the entire project area as well as detailed design plans for a specific Phase I project.

South San Francisco Bay Shoreline Study. The Corps plans to prepare a

Feasibility Report integrated with an salt ponds of EIS/EIR for the South San Francisco Bay Shoreline Study: Alviso Ponds and Santa Clara County Interim Feasibility Study, pursuant to the following resolution by the U.S. House of Representatives Transportation and Infrastructure Committee, adopted July 24, 2002:

"Resolved by the Committee on Transportation and Infrastructure of the United States House of Representatives, that the Secretary of the Army is requested to review the Final Letter Report for the San Francisco Bay Shoreline Study, California, dated July 1992, and all related interims and other pertinent reports to determine whether modifications to the recommendations contained therein are advisable at the present time in the interest of tidal and fluvial flood damage reduction, environmental restoration and protection and related purposes along the South San Francisco Bay shoreline for the counties of San Mateo, Santa Clara and Alameda, California."

The South San Francisco Bay Shoreline Study area extends along South San Francisco Bay and includes the Alviso, Ravenswood, and Eden Landing pond complexes which are described above, as well as additional shoreline and floodplain areas in the counties of Alameda, San Mateo, and Santa Clara. The Report referenced in this Notice of Intent would propose implementation of the findings of the first Interim Feasibility Study component of the Shoreline Study.

The area to be examined in the first Interim Study consists of 25 ponds in the Alviso pond complex on the shores of the South Bay in Fremont, San Jose, Sunnyvale and Mountain View, located in Santa Clara and Alameda counties, plus substantial adjacent areas which may need flood protection or which may be affected by flood protection or ecosystem restoration measures. The study area is bordered by San Francisco Bay and the operational salt ponds of Alameda County to the north and San Francisquito Creek on the west. To the south and east, the study area extends beyond the salt ponds to include all lands subject to inundation from a 100-year tidal flooding event. These additional lands are primarily urbanized areas in Palo Alto, Mountain View, Sunnyvale, and San Jose to the south, and urbanized lands in Milpitas and Fremont to the east. These lands are generally delineated on maps which are on file with the Corps of Engineers, San Francisco District. During the course of the study the exact delineation of which lands are subject to tidal inundation may be modified based on technical studies.

The Corps proposes to conduct the South San Francisco Bay Shoreline

Study: Alviso Ponds and Santa Clara County Interim Feasibility Study in coordination with the South Bay Salt Ponds Restoration Project and in partnership with the USFWS, CDFG, Conservancy, and the Santa Clara Valley Water District. It is expected that the Corps's Report for the first Interim Feasibility Study component of the Shoreline Study will be released after the completion of the South Bay Salt Ponds Restoration Project programmatic EIS/EIR, so the EIS/EIR components of the Report for the Shoreline Study will tier off from the joint programmatic South Bay Salt Ponds EIS/EIR.

Public Involvement. The public scoping meeting will be held on Wednesday, January 25, 2006 at the Milpitas Library Community Room located at 40 North Milpitas Blvd., Milpitas, CA 95035 (408-262-1171), from 5:30-8:30 p.m. Persons needing reasonable accommodation in order to attend and participate in the public scoping meeting should contact Bill DeJager at 415-977-8670 at least one week in advance of the meeting to allow time for arrangements to be made.

Written comments may be sent to the addresses indicated in the Addresses section above, by facsimile to 415-977-8695, or via e-mail through the public comments link on the South Bay Salt Ponds Restoration Project Web site, located at http://www.southbayrestoration.org/Question_Comment.html. All comments received, including names and addresses, will become part of the administrative record and will be available to the public unless commenters request that this information not be released.

Alternatives. The Report will consider a range of alternatives and their impacts, including the No Action Alternative. Scoping will be an early and open process designed to determine the issues and alternatives to be addressed in the Report. For example, the range of alternatives may include varying mixes of managed ponds and tidal marsh habitat, varying levels and means of flood protection, and varying levels and means of recreation and public access components which respond to the Shoreline Study objectives.

Content of the Report. The Report will identify the anticipated effects of the project alternatives (detrimental and beneficial) and describe and analyze direct, indirect, and cumulative environmental impacts of the project alternatives, including the No Action Alternative, in accordance with NEPA (40 CFR 1500-1508) and CEQA. For each issue listed below, the EIS/EIR will include discussion of: The parameters

used in evaluating the impacts as well as recommended mitigation; the effectiveness of mitigation measures proposed to be implemented; and any additional measures that would reduce the impacts to a less-than-significant level.

The list of issues presented below is preliminary both in scope and number. These issues are presented to facilitate public comment on the scope of the Report, and are not intended to be all-inclusive or a predetermination of impact topics to be considered.

Biological Resources. The Report will address the following issues and potential detrimental and beneficial impacts related to biological resources:

- Effects on population sizes of endangered species and other species of concern, including California clapper rail, snowy plover, California least tern, salt marsh harvest mouse, Chinook salmon and steelhead trout.
- Shift in populations and effects on population sizes of migratory waterfowl and shorebirds.
- Increased habitat connectivity for all organisms that use multiple marsh and/or aquatic habitats, including birds, mammals, and fish.
- Potential for improved habitat connectivity with adjacent upland habitats.
- Potential loss of hypersaline wetlands and their unique communities.
- Reduction in predation for species of concern with larger habitat blocks.
- Increased nursery habitat in wetlands for fish.
- Potential for salmonid entrainment into managed ponds.
- Effects of *Spartina alterniflora* and the hybrids of this species, and other invasive species.
- Effects of flood control structures on existing ecosystem attributes and functions including aquatic and terrestrial species.
- Effects of public access and recreation on aquatic and terrestrial species.

Hydrology and Flood Protection. The Report will address the following issues and potential detrimental and beneficial impacts related to hydrology and flood protection:

- Existing and future without-project tidal flood hazards as affected by fluvial inputs.
- Effects on the tidal regime and tidal mixing from project components, and related effects on salinity of Bay waters.
- Effects on high-tide water levels and resulting effects on flood hazards.
- Changes in tidal hydrodynamics, including tidal prism and tidal range in tidal sloughs, resulting changes in channel geometry and changes in tidal

flood risks (including during project implementation).

- Effects on flood flow conveyance as a result of converting salt ponds to tidal marsh.
- Potential decrease in wave energy associated with tidal marsh restoration and reduced erosion of flood protection levees.
- Impacts on tidal flooding frequency and extent, and flood protection due to breaches in salt pond levees, improvement of existing levees, and construction of new levees.
- Impacts on groundwater quality.

Water and Sediment Quality. The Report will address the following issues and potential detrimental and beneficial impacts related to water and sediment quality:

- Effects of salt pond levee breaches, including changes in salinity, turbidity, dissolved oxygen, biochemical and biological oxygen demand, metals, polychlorinated biphenyls (PCBs), and other pollutants of concern.
- Changes in residence time of water in the South Bay and related effects on water quality.
- Changes in mercury and/or methyl mercury concentrations, and other pollutants of concern, in Bay and slough waters.
- Potential to mobilize existing sediment contaminants, including mercury, PCBs, and other pollutants of concern.
- Potential contamination from outside sources, including urban runoff, wastewater discharges, imported sediment and atmospheric deposition.

Recreation and Public Access. The Report will address the project's effects on existing recreation facilities and their use as well as the potential effects of expansion or creation of new facilities. The benefits and impacts of increased or decreased public access on biological resources and achievement of other project objectives will also be addressed.

Economics. The Report will evaluate the economic effects of the alternatives, including costs and benefits of flood protection, recreation, and effects on commercial fishing.

Cumulative Impacts. The Report will examine the cumulative impacts of past, ongoing, and reasonably foreseeable future projects affecting tidal marsh and estuarine habitats in the South Bay, as well as effects on adjacent urban and rural lands and communities.

Environmental Analysis Process. The Report will be prepared in compliance with NEPA and Council on Environmental Quality Regulations, contained in 40 CFR parts 1500-1508, and with CEQA, Public Resources Code

Sec 21000 *et seq.* and the CEQA Guidelines as amended. Because requirements for NEPA and CEQA are somewhat different, the document must be prepared to comply with whichever requirements are more stringent. The Corps and the USFWS will be Joint Lead Agencies for the NEPA process and the Conservancy will be the Lead Agency for the CEQA process. In accordance with both CEQA and NEPA, these Lead Agencies are responsible for the scope, content, and legal adequacy of the document. The SCVWD will be a Responsible Agency under the provisions of CEQA. Therefore, all aspects of the Report scope and process will be fully coordinated between these four agencies.

The scoping process will include the opportunity for public input during one public meeting and by written comments submitted during the 30-day scoping period.

The draft Report will address public concerns associated with the issues identified in the scoping process and in subsequent public involvement and will be distributed for at least a 45-day public review and comment period. During this time, both written and verbal comments will be solicited on the adequacy of the draft Report. The final Report will address the comments received on the draft during public review and will be made available to all commenters on the draft Report. Copies of the draft and final reports will be posted on the Internet as part of the public review process.

The final step in the NEPA process is the preparation of a Record of Decision (ROD). This document is a concise summary of the decisions made by the Corps and the USFWS. The ROD will identify the alternative selected by the agencies and other alternatives that were considered. It also will discuss the mitigation measures that were adopted. Because there are two lead agencies, it is possible that each agency will prepare its own ROD.

The Record, or Records, of Decision may be published no earlier than thirty days after publication of the Notice of Availability of the final EIS/EIR. The final step in the CEQA process is certification of the CEQA document, which includes preparation of a Mitigation, Monitoring, and Reporting Plan and adoption of its findings, should the project be approved.

This notice is provided pursuant to regulations for implementing the National Environmental Policy Act of 1969 (40 CFR 1501.7 and 1506.6).

Dated: December 23, 2005.

John Engring,

Acting Manager, California/Nevada Operations Office, U.S. Fish and Wildlife Service.

Philip T. Feir,

Lieutenant Colonel, Commanding, San Francisco District, U.S. Army Corps of Engineers.

[FR Doc. 06-102 Filed 1-5-06; 8:45 am]

BILLING CODE 3710-19-M

DEPARTMENT OF ENERGY

National Nuclear Security Administration

Extension of Scoping Period for the Notice of Intent to Prepare a Site-Wide Environmental Impact Statement

AGENCY: National Nuclear Security Administration, DOE.

SUMMARY: The National Nuclear Security Administration (NNSA), an agency within the U.S. Department of Energy (DOE), is extending the scoping period for the Site-Wide Environmental Impact Statement (SWEIS) for the Y-12 National Security Complex (Y-12), located at the junction of Bear Creek Road and Scarboro Road in Anderson County, Tennessee, near the City of Oak Ridge, Tennessee.

DATES: The scoping period for the SWEIS is extended from January 9, 2006 to January 31, 2006. Comments received after that date will be considered to the extent practicable.

ADDRESSES: For information concerning the SWEIS, please contact Ms. Pam Gorman, Y-12 SWEIS Document Manager at (865) 576-9903 or e-mail at: gormanpl@yso.doe.gov. Written comments on the scope of SWEIS can be sent to: Y-12 SWEIS Document Manager, 800 Oak Ridge Turnpike, Suite A-500, Oak Ridge, Tennessee 37830; by facsimile to: (865) 482-6052 or by e-mail to: comments@y-12sweis.com.

FOR FURTHER INFORMATION CONTACT: For information about the DOE NEPA process, please contact: Ms. Carol Borgstrom, Director, Office of NEPA Policy and Compliance (EH-42), U.S. Department of Energy, 1000 Independence Avenue, SW., Washington, DC 20585, (202) 586-4600, or leave a message at 1-800-472-2756.

SUPPLEMENTARY INFORMATION: On November 28, 2005 (70 FR 71270), NNSA issued a Notice of Intent (NOI) to prepare an SWEIS for the Y-12 National Security Complex. As originally announced in the NOI, DOE has conducted public scoping meetings on the SWEIS in Oak Ridge, Tennessee

on December 15, 2005. The original public scoping period was to continue until January 9, 2006. However, in response to public comments, DOE is extending the public scoping period until January 31, 2006.

Issued in Washington, DC on January 3, 2006.

Alice C. Williams,

NNSA NEPA Compliance Officer.

[FR Doc. E6-32 Filed 1-5-06; 8:45 am]

BILLING CODE 6450-01-P

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPP-2005-0257; FRL-7756-6]

Lockheed Martin; Transfer of Data

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: This notice announces that pesticide related information submitted to EPA's Office of Pesticide Programs (OPP) pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) and the Federal Food, Drug, and Cosmetic Act (FFDCA), including information that may have been claimed as Confidential Business Information (CBI) by the submitter, will be transferred to Lockheed Martin in accordance with 40 CFR 2.307(h)(3) and 2.308(i)(2). Lockheed Martin has been awarded multiple contracts to perform work for OPP, and access to this information will enable Lockheed Martin to fulfill the obligations of the contract.

DATES: Lockheed Martin will be given access to this information on or before January 13, 2006.

FOR FURTHER INFORMATION CONTACT: Felicia Croom, Information Technology and Resources Management Division (7502C), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460-0001; telephone number: (703) 305-0786; e-mail address: croom.felicia@epa.gov.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

This action applies to the public in general. As such, the Agency has not attempted to describe all the specific entities that may be affected by this action. If you have any questions regarding the applicability of this action to a particular entity, consult the person listed under **FOR FURTHER INFORMATION CONTACT**.

B. How Can I Get Copies of this Document and Other Related Information?

1. **Docket.** EPA has established an official public docket for this action under docket identification (ID) number EPA-HQ-OPP-2005-0257. The official public docket consists of the documents specifically referenced in this action, any public comments received, and other information related to this action. Although a part of the official docket, the public docket does not include Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. The official public docket is the collection of materials that is available for public viewing at the Public Information and Records Integrity Branch (PIRIB), Rm. 119, Crystal Mall #2, 1801 S. Bell St., Arlington, VA. This docket facility is open from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The docket telephone number is (703) 305-5805.

2. **Electronic access.** You may access this **Federal Register** document electronically through the EPA Internet under the "**Federal Register**" listings at <http://www.epa.gov/fedrgstr/>.

EDOCKET, EPA's electronic public docket and comment system was replaced on November 25, 2005 by an enhanced federal-wide electronic docket management and comment system located at <http://www.regulations.gov/>. Follow the on-line instructions.

An electronic version of the public docket is available through EPA's electronic public docket and comment system, EPA Dockets. You may use EPA Dockets at <http://www.epa.gov/edocket/> to submit or view public comments, access the index listing of the contents of the official public docket, and to access those documents in the public docket that are available electronically. Although not all docket materials may be available electronically, you may still access any of the publicly available docket materials through the docket facility identified in Unit I.B.1. Once in the system, select "search," then key in the appropriate docket ID number.

II. Contractor Requirements

Under contract number 68-W-04-005, the contractor will perform the following:

1. Establish individual chemical identity records including systematic chemical name, CAS registry number, and other chemical name synonyms;
2. Establish inert ingredient mixture composition records;
3. Respond to internal OPP requests for elucidation of chemical identities in

and acceptability status of chemicals in inert mixtures;

4. Maintain existing files of all inert ingredient mixture compositional data submitted to the Agency;

5. Receive new compositional information from suppliers;

6. Scan an image pesticide inert ingredient master file submission documents into an image database.

This contract involves no subcontractors.

The OPP has determined that the contracts described in this document involve work that is being conducted in connection with FIFRA, in that pesticide chemicals will be the subject of certain evaluations to be made under this contract. These evaluations may be used in subsequent regulatory decisions under FIFRA.

Some of this information may be entitled to confidential treatment. The information has been submitted to EPA under sections 3, 4, 6, and 7 of FIFRA and under sections 408 and 409 of FFDCA.

In accordance with the requirements of 40 CFR 2.307(h)(3), the contracts with Lockheed Martin, prohibits use of the information for any purpose not specified in these contracts; prohibits disclosure of the information to a third party without prior written approval from the Agency; and requires that each official and employee of the contractor sign an agreement to protect the information from unauthorized release and to handle it in accordance with the *FIFRA Information Security Manual*. In addition, Lockheed Martin is required to submit for EPA approval a security plan under which any CBI will be secured and protected against unauthorized release or compromise. No information will be provided to Lockheed Martin until the requirements in this document have been fully satisfied. Records of information provided to Lockheed Martin will be maintained by EPA Project Officers for these contracts. All information supplied to Lockheed Martin by EPA for use in connection with these contracts will be returned to EPA when Lockheed Martin has completed its work.

List of Subjects

Environmental protection, Business and industry, Government contracts, Government property, Security measures.

Dated: December 29, 2005.

Brenda Despanza,

Acting Director, Information Technology and Resources Management Division, Office of Pesticide Programs.

[FR Doc. E6-27 Filed 1-5-06; 8:45 am]

BILLING CODE 6560-50-S

ENVIRONMENTAL PROTECTION AGENCY

[ER-FRL-6671-1]

Environmental Impact Statements and Regulations; Availability of EPA Comments

Availability of EPA comments prepared pursuant to the Environmental Review Process (ERP), under section 309 of the Clean Air Act and section 102(2)(c) of the National Environmental Policy Act as amended. Requests for copies of EPA comments can be directed to the Office of Federal Activities at 202-564-7167. An explanation of the ratings assigned to draft environmental impact statements (EISs) was published in FR dated April 1, 2005 (70 FR 16815).

Draft EISs

EIS No. 20050389, ERP No. D-FHW-140171-CO, US Highway 160, Transportation Improvements from Junction U.S. 160/550 Durango—East to Bayfield, US Army COE Section 404 Permit, La Plata County, CO.

Summary: EPA has environmental concerns with the proposed project regarding impacts to wetlands and cumulative impacts to air quality. Rating EC2.

EIS No. 20050433, ERP No. D-FHW-F40433-WI, US Highway 12, Improvement from US12/WI-26 North Fort Atkinson Interchange to Whitewater Bypass, Funding, Rock and Jefferson Counties, WI.

Summary: EPA has environmental concerns with the proposed project regarding impacts to wetlands and water quality as well as secondary and cumulative impacts. Rating EC2.

Final EISs

EIS No. 20050461, ERP No. F-AFS-165416-WY, Bighorn National Forest Revised Land and Resource Management Plan, Implementation, Big Horn Mountain Range, Bighorn National Forest, Johnson, Sheridan, Bighorn, and Washakie Counties, WY.

Summary: While the Final EIS and selected alternative improve monitoring for grazing activities, EPA continues to have environmental concerns with potential adverse environmental impacts, including cumulative impacts to water quality, fisheries and wildlife habitat from new road construction, timber harvest and an 85% reduction of roadless areas.

EIS No. 20050486, ERP No. F-AFS-L65479-OR, Timberline Express Project, To Improve the Winter Recreational Opportunities, Implementation, Zigzag Ranger

District, Mt. Hood National Forest, Clackamas County, OR.

Summary: The final EIS addressed EPA's environmental concerns about water resources, habitat fragmentation, and infrastructure constraints.

Dated: January 3, 2006.

Clifford Rader,

Environmental Protection Specialist, Office of Federal Activities.

[FR Doc. E6-25 Filed 1-5-06; 8:45 am]

BILLING CODE 6560-50-P

ENVIRONMENTAL PROTECTION AGENCY

[ER-FRL-6670-9]

Environmental Impacts Statements; Notice of Availability

Responsible Agency: Office of Federal Activities, General Information (202) 564-7167 or <http://www.epa.gov/compliance/nepa/>.

Weekly receipt of Environmental Impact Statements

Filed 12/27/2005 through 12/30/2005 Pursuant to 40 CFR 1506.9.

EIS No. 20050548, Draft EIS, NPS, NC, North Shore Road, Great Smoky Mountains National Park, General Management Plan, Implementation, Fontana Dam, Swain County, NC, Comment Period Ends: 02/21/2006, Contact: Imelda Wegwerth 865-436-1302.

EIS No. 20050549, Draft EIS, BLM, AZ, Aqua Fria National Monument and Bradshaw-Harquahala, Proposed Resource Management Plan, Implementation, Yavapai County, AZ, Comment Period Ends: 04/07/2006, Contact: Chris Horyza 623-580-5628.

EIS No. 20050550, Final EIS, AFS, CA, North Fork Eel Grazing Allotment Management Project, Proposing to Authorize Cattle Grazing on Four Allotment, Six Rivers National Forest, Mad River Ranger District, North Fork Eel River and Upper Mad River, Trinity County, CA, Wait Period Ends: 02/06/2006, Contact: Julie Ranieri 707-441-3673.

EIS No. 20050551, Draft EIS, NAS, 00, Programmatic—Development of Advanced Radioisotope Power Systems, Two New Advanced RPS's: Multi-Mission Radioisotope Thermoelectric Generator (MMRTG) and Stirling Radioisotope Generator (SRG), Comment Period Ends: 02/21/2006, Contact: Dr. Ajay Misra 202-358-1588.

EIS No. 20050552, Draft EIS, FRC, FL, Cypress Pipeline Project and Phase VII Expansion Project, Construction and Operation, U.S. Army COE

Section 10 and 404 Permits, Northern and Central Florida, Comment Period Ends: 02/21/2006, Contact: Thomas Russo 1-866-208-3372.

EIS No. 20050553, Final Supplement, STB, 00, Powder River Basin Expansion Project, New Information, Addressing Four Environmental Issues Remanded by the 8th Circuit Court of Appeals, Finance Docket No. 33407—Dakota, Minnesota, Eastern Railroad, SD, WY and MN, Wait Period Ends: 02/06/2006, Contact: Victoria Rutson 202-565-1545.

EIS No. 20050554, Draft EIS, IBR, ND, Red River Valley Water Supply Project, Development and Delivery of a Bulk Water Supply to meet Long-Term Water Needs of the Red River Valley, Implementation, ND, Comment Period Ends: 02/21/2006, Contact: Signe Snortland 701-250-4242, ext. 3619.

Amended Notices

EIS No. 20050542, Final Supplement, AFS, WA, Upper Charley Subwatershed Ecosystem Restoration Projects, Proposing to Amend the Umatilla National Forests Land and Resource Management Plan to Incorporate Management for Canada Lynx, Pomeroy Ranger District, Umatilla National Forest, Garfield County, WA, Wait Period Ends: 01/30/2006, Contact: Allen J. Ollila 701-227-7735. Revision of FR Notice Published on 12/30/2005: Correction to Wait Period from 02/13/2006 to 01/30/2006.

- Dated: January 3, 2006.

Clifford Rader,

Environmental Protection Specialist, Office of Federal Activities.

[FR Doc. E6-24 Filed 1-5-06; 8:45 am]

BILLING CODE 6560-50-P

ENVIRONMENTAL PROTECTION AGENCY

[FRL-8019-9]

Good Neighbor Environmental Board; Notification of Public Advisory Committee Teleconference Meeting

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notification of Public Advisory Committee Teleconference Meeting.

SUMMARY: Pursuant to the Federal Advisory Committee Act, Public Law 92-463, notice is hereby given that the Good Neighbor Environmental Board will meet in a public teleconference on January 25, 2005, from 2 p.m. to 3:30 p.m. Eastern Time. The meeting will be

hosted out of the main conference room, U.S. EPA, 655 15th Street, NW., Suite 800, Washington, DC 20005. The meeting is open to the public, however, due to limited space, seating will be on a registration-only basis. For further information regarding the teleconference meeting, please contact the individual listed below.

Background: The Good Neighbor Environmental Board (GNEB) is a Federal advisory committee based at the Environmental Protection Agency that reports to the United States President and Congress on Good Neighbor environmental practices along the U.S. border with Mexico. The GNEB consists of representatives from eight Federal government agencies, each of the four U.S. border states, and private and public sector organizations. Each year, the GNEB prepares an annual report to the President and Congress.

Purpose of Meeting: The Board has prepared its latest draft annual report, its Ninth Report. The purpose of this teleconference is for the Board to review, discuss, and decide whether to approve the recommendations in the report.

Availability of Review Materials: If you wish to receive a copy of the draft recommendations, please contact Ms. Elaine Koerner, Designated Federal Officer for the Board, at the number below.

SUPPLEMENTARY INFORMATION: Members of the public wishing to gain access to the conference room on the day of the meeting must contact Ms. Elaine Koerner, Designated Federal Officer for the Good Neighbor Environmental Board, U.S. Environmental Protection Agency (1601E), Office of Cooperative Environmental Management, 655 15th Street, NW., Suite 800, Washington, DC 20005; telephone/voice mail at (202) 233-0069 or via e-mail at koerner.elaine@epa.gov. If you wish to make oral comments or to submit written comments to the Board, please contact Ms. Koerner by January 18, 2005.

General Information: Additional information concerning the Good Neighbor Environmental Board can be found on its Web site (<http://www.epa.gov/ocem/gneb>).

Meeting Access: For information on access or services for individuals with disabilities, please contact Elaine Koerner at 202-233-0069 or koerner.elaine@epa.gov. To request accommodation of a disability, please contact Elaine Koerner, preferably at least 10 days prior to the meeting, to give EPA as much time as possible to process your request.

Dated: December 22, 2005.

Elaine Koerner,
Designated Federal Officer.

[FR Doc. E6-29 Filed 1-5-06; 8:45 am]

BILLING CODE 6560-50-P

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPPT-2005 0029; FRL-7755-7]

Strategic Approach to International Chemicals Management (SAICM); Notice of Public Meeting

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: This notice is to announce that the EPA and the State Department will be hosting a stakeholder meeting to inform U.S. Government viewpoints for the upcoming International Conference on Chemicals Management (ICCM), where participants are expected to agree to the Strategic Approach to International Chemicals Management (SAICM). See the website listed under Unit II. The United States is seeking comments to guide us as we work with other countries and participants to develop a SAICM that promotes the sound management of chemicals while facilitating the movement of chemicals and their products across borders without compromising human health or the environment. There are several working documents that will serve as a basis for the SAICM. This meeting will serve as an opportunity for stakeholders to share their views on these documents before they are finalized at the International Conference on Chemicals Management (ICCM) in February 2006.

DATES: The meeting will be held on Tuesday, January 17, 2006, 2 p.m.-4 p.m.

Requests to participate in the meeting, identified by docket identification (ID) number OPPT-2005-0029, must be received on or before January 17, 2006.

ADDRESSES: The meeting will be held at 1201 Constitution Ave. NW, Room 1153 EPA East (1st Floor) Washington, D.C. 20460

Requests to participate in the meeting may be submitted to the technical person listed under FOR FURTHER INFORMATION CONTACT.

FOR FURTHER INFORMATION CONTACT: For general information contact: Colby Lintner, Regulatory Coordinator, Environmental Assistance Division (7408M), Office of Pollution Prevention and Toxics, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460-0001; telephone

number: (202) 554-1404; e-mail address: TSCA-Hotline@epa.gov.

For technical information contact: John Shoaff, OPPT International Team Leader, Environmental Assistance Division (7408M), Office of Pollution Prevention and Toxics, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460-0001; telephone number: (202) 564-0531; e-mail address: shaaff.john@epa.gov.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

This action is directed to the public in general, and may be of particular interest to industry, trade associations, and non-governmental organizations that deal with and are interested in international chemicals management. If you have any questions regarding the applicability of this action to a particular entity, consult the technical person listed under **FOR FURTHER INFORMATION CONTACT**.

B. How Can I Get Copies of this Document and Other Related Information?

1. **Docket.** EPA has established an official public docket for this action under docket ID number EPA-HQ-OPP-2005-0029. The official public docket consists of the documents specifically referenced in this action, any public comments received, and other information related to this action. Although, a part of the official docket, the public docket does not include Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. The official public docket is the collection of materials that is available for public viewing at the EPA Docket Center, Rm. B102-Reading Room, EPA West, 1301 Constitution Ave., NW., Washington, DC. The EPA Docket Center is open from 8:30 a.m. to 4:30 p.m., Monday through Friday, excluding legal holidays. The EPA Docket Center Reading Room telephone number is (202) 566-1744 and the telephone number for the OPPT Docket, which is located in EPA Docket Center, is (202) 566-0280.

2. **Electronic access.** You may access this **Federal Register** document electronically through the EPA Internet under the "**Federal Register**" listings at <http://www.epa.gov/fedrgstr/>.

EDOCKET, EPA's electronic public docket and comment system was replaced on November 25, 2005, by an enhanced Federal-wide electronic docket, management and comment system located at <http://www.regulations.gov/>. Follow the on-line instructions.

An electronic version of the public docket is available through EPA's electronic public docket and comment system, EPA Dockets. You may use EPA Dockets at <http://www.epa.gov/edocket/> to submit or view public comments, access the index listing of the contents of the official public docket, and to access those documents in the public docket that are available electronically. Although, not all docket materials may be available electronically, you may still access any of the publicly available docket materials through the docket facility identified in Unit I.B.1. Once in the system, select "search," then key in the appropriate docket ID number.

Although, not all docket materials may be available electronically, you may still access any of the publicly available docket materials through the docket facility identified in Unit I.B.1. Once in the system, select "search," then key in the appropriate docket ID number.

II. Background

An agenda for the stakeholder meeting will be available two weeks prior to the meeting. This meeting is open to the public.

The agenda and meeting documents for the ICCM are available at:

http://www.chem.unep.ch/ICCM/meeting_docs/ For general and background information on the SAICM including the report and documents from the most recent Preparatory Committee meeting (PrepCom3), see <http://www.chem.unep.ch/saicm/>.

III. How Can I Request to Participate in this Meeting?

You may submit a request to participate in this meeting to the technical person listed under **FOR FURTHER INFORMATION CONTACT**. Do not submit any information in your request that is considered CBI. Requests to participate in the meeting, identified by docket ID number OPPT-2005-0029, must be received on or before January 17, 2006.

List of Subjects

Environmental protection, International chemicals management, Toxic chemicals, Risk reduction, Pollution prevention

Dated: December 27, 2005.

Wendy C. Hamnett,

Acting Director Office of Pollution Prevention and Toxics

[FR Doc. 06-92 Filed 1-5-06; 8:45 am]

BILLING CODE 5560-50-S

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPP-2005-0252; FRL-7756-7]

Iodomethane Risk Assessment; Notice of Availability

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: This notice announces the availability of EPA's human health risk assessment and related documents for the pesticide iodomethane and opens a public comment period on these documents. EPA has completed a human health risk assessment for the fumigant, iodomethane and wants to provide the public an opportunity to comment on the risk assessment. Iodomethane is a new chemical under consideration by the Agency for registration and has been identified as a potential partial replacement for methyl bromide.

DATES: Comments, identified by docket identification (ID) number EPA-HQ-OPP-2005-0252, must be received on or before February 6, 2006.

ADDRESSES: Comments may be submitted electronically, by mail, or through hand delivery/courier. Follow the detailed instructions as provided in Unit I. of the **SUPPLEMENTARY INFORMATION**.

FOR FURTHER INFORMATION CONTACT: Mary L. Waller, Registration Division (7505C), Office of Pesticide Programs, Environmental Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460-0001; telephone number: (703) 308-9354; fax number: (703) 308-1825; e-mail address: waller.mary@epa.gov.

SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

This action is directed to the public in general, and may be of interest to a wide range of stakeholders including environmental, human health, and agricultural advocates; the chemical industry; pesticide users; and members of the public interested in the sale, distribution, or use of pesticides. Since others may also be interested, the Agency has not attempted to describe all the specific entities that may be affected by this action. If you have any questions regarding the applicability of this action to a particular entity, consult the person listed under **FOR FURTHER INFORMATION CONTACT**.

B. How Can I Get Copies of this Document and Other Related Information?

1. *Docket.* EPA has established an official public docket for this action under docket ID number EPA-HQ-OPP-2005-0252. The official public docket consists of the documents specifically referenced in this action, any public comments received, and other information related to this action. Although, a part of the official docket, the public docket does not include Confidential Business Information (CBI) or other information whose disclosure is restricted by statute. The official public docket is the collection of materials that is available for public viewing at the Public Information and Records Integrity Branch (PIRIB), Rm. 119, Crystal Mall #2, 1801 S. Bell St., Arlington, VA. This docket facility is open from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The docket telephone number is (703) 305-5805.

2. *Electronic access.* You may access this **Federal Register** document electronically through the EPA Internet under the "**Federal Register**" listings at <http://www.epa.gov/fedrgstr/>. EDOCKET, EPA's electronic public docket and comment system was replaced on November 25, 2005, by an enhanced Federal-wide electronic docket management and comment system located at <http://www.regulations.gov/>. Follow the online instruction.

An electronic version of the public docket is available through EPA's electronic public docket and comment system, EPA Dockets. You may use EPA Dockets at <http://www.epa.gov/edocket/> to submit or view public comments, access the index listing of the contents of the official public docket, and to access those documents in the public docket that are available electronically. Once in the system, select "search," then key in the appropriate docket ID number.

Certain types of information will not be placed in the EPA Dockets. Information claimed as CBI and other information whose disclosure is restricted by statute, which is not included in the official public docket, will not be available for public viewing in EPA's electronic public docket. EPA's policy is that copyrighted material will not be placed in EPA's electronic public docket but will be available only in printed, paper form in the official public docket. To the extent feasible, publicly available docket materials will be made available in EPA's electronic public docket. When a document is selected

from the index list in EPA Dockets, the system will identify whether the document is available for viewing in EPA's electronic public docket. Although, not all docket materials may be available electronically, you may still access any of the publicly available docket materials through the docket facility identified in Unit I.B.1. EPA intends to work towards providing electronic access to all of the publicly available docket materials through EPA's electronic public docket.

For public commenters, it is important to note that EPA's policy is that public comments, whether submitted electronically or on paper, will be made available for public viewing in EPA's electronic public docket as EPA receives them and without change, unless the comment contains copyrighted material, CBI, or other information whose disclosure is restricted by statute. When EPA identifies a comment containing copyrighted material, EPA will provide a reference to that material in the version of the comment that is placed in EPA's electronic public docket. The entire printed comment, including the copyrighted material, will be available in the public docket.

Public comments submitted on computer disks that are mailed or delivered to the docket will be transferred to EPA's electronic public docket. Public comments that are mailed or delivered to the docket will be scanned and placed in EPA's electronic public docket. Where practical, physical objects will be photographed, and the photograph will be placed in EPA's electronic public docket along with a brief description written by the docket staff.

C. How and to Whom Do I Submit Comments?

You may submit comments electronically, by mail, or through hand delivery/courier. To ensure proper receipt by EPA, identify the appropriate docket ID number in the subject line on the first page of your comment. Please ensure that your comments are submitted within the specified comment period. Comments received after the close of the comment period will be marked "late." EPA is not required to consider these late comments. If you wish to submit CBI or information that is otherwise protected by statute, please follow the instructions in Unit I.D. Do not use EPA Dockets or e-mail to submit CBI or information protected by statute.

1. *Electronically.* If you submit an electronic comment as prescribed in this unit, EPA recommends that you include your name, mailing address, and an e-

mail address or other contact information in the body of your comment. Also, include this contact information on the outside of any disk or CD ROM you submit, and in any cover letter accompanying the disk or CD ROM. This ensures that you can be identified as the submitter of the comment and allows EPA to contact you in case EPA cannot read your comment due to technical difficulties or needs further information on the substance of your comment. EPA's policy is that EPA will not edit your comment, and any identifying or contact information provided in the body of a comment will be included as part of the comment that is placed in the official public docket, and made available in EPA's electronic public docket. If EPA cannot read your comment due to technical difficulties and cannot contact you for clarification, EPA may not be able to consider your comment.

i. *EPA Dockets.* Your use of EPA's electronic public docket to submit comments to EPA electronically is EPA's preferred method for receiving comments. Go directly to EPA Dockets at <http://www.epa.gov/edocket/>, and follow the online instructions for submitting comments. Once in the system, select "search," and then key in docket ID number EPA-HQ-OPP-2005-0252. The system is an "anonymous access" system, which means EPA will not know your identity, e-mail address, or other contact information unless you provide it in the body of your comment.

ii. *E-mail.* Comments may be sent by e-mail to opp-docket@epa.gov, Attention: Docket ID number EPQ-HQ-OPP-2005-0252. In contrast to EPA's electronic public docket, EPA's e-mail system is not an "anonymous access" system. If you send an e-mail comment directly to the docket without going through EPA's electronic public docket, EPA's e-mail system automatically captures your e-mail address. E-mail addresses that are automatically captured by EPA's e-mail system are included as part of the comment that is placed in the official public docket, and made available in EPA's electronic public docket.

iii. *Disk or CD ROM.* You may submit comments on a disk or CD ROM that you mail to the mailing address identified in Unit I.C.2. These electronic submissions will be accepted in WordPerfect or ASCII file format. Avoid the use of special characters and any form of encryption.

2. *By mail.* Send your comments to: Public Information and Records Integrity Branch (PIRIB) (7502C), Office of Pesticide Programs (OPP), Environmental Protection Agency, 1200

Pennsylvania Ave., NW., Washington, DC 20460-0001, Attention: Docket ID number EPQ-HQ-OPP-2005-0252.

3. *By hand delivery or courier.* Deliver your comments to: Public Information and Records Integrity Branch (PIRIB), Office of Pesticide Programs (OPP), Environmental Protection Agency, Rm. 119, Crystal Mall #2, 1801 S. Bell St., Arlington, VA, Attention: Docket ID number EPA-HQ-OPP-2005-0252. Such deliveries are only accepted during the docket's normal hours of operation as identified in Unit I.B.1.

D. How Should I Submit CBI to the Agency?

Do not submit information that you consider to be CBI electronically through EPA's electronic public docket or by e-mail. You may claim information that you submit to EPA as CBI by marking any part or all of that information as CBI (if you submit CBI on disk or CD ROM, mark the outside of the disk or CD ROM as CBI and then identify electronically within the disk or CD ROM the specific information that is CBI). Information so marked will not be disclosed except in accordance with procedures set forth in 40 CFR part 2.

In addition to one complete version of the comment that includes any information claimed as CBI, a copy of the comment that does not contain the information claimed as CBI must be submitted for inclusion in the public docket and EPA's electronic public docket. If you submit the copy that does not contain CBI on disk or CD ROM, mark the outside of the disk or CD ROM clearly that it does not contain CBI. Information not marked as CBI will be included in the public docket and EPA's electronic public docket without prior notice. If you have any questions about CBI or the procedures for claiming CBI, please consult the person listed under **FOR FURTHER INFORMATION CONTACT**.

E. What Should I Consider as I Prepare My Comments for EPA?

You may find the following suggestions helpful for preparing your comments:

1. Explain your views as clearly as possible.
2. Describe any assumptions that you used.
3. Provide any technical information and/or data you used that support your views.
4. If you estimate potential burden or costs, explain how you arrived at your estimate.
5. Provide specific examples to illustrate your concerns.
6. Offer alternatives.

7. Make sure to submit your comments by the comment period deadline identified.

8. To ensure proper receipt by EPA, identify the appropriate docket ID number in the subject line on the first page of your response. It would also be helpful if you provided the name, date, and **Federal Register** citation related to your comments.

II. Background

A. What Action is the Agency Taking?

EPA is making available the human health risk assessment for iodomethane. Iodomethane is a new chemical proposed for use as a pre-plant fumigant to control soil borne pests including weed seeds, nematodes, insects, and diseases in fields intended for commercial production of strawberries, tomatoes, peppers, turf, ornamentals (flowers grown for cutting, bulbs, and nursery plants), trees and vines. The Agency developed this risk assessment as part of the registration decision process. EPA is ensuring that all new pesticides proposed for use meet current standards under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) and the Federal Food, Drug, and Cosmetic Act (FFDCA), as amended by the Food Quality Protection Act of 1996 (FQPA).

The risk assessment for iodomethane addresses exposures to workers and the general population which are expected to occur primarily via inhalation. Dermal exposure is not expected due to the high vapor pressure of iodomethane. Potential general population exposures via inhalation are those in proximity to treated fields (i.e., bystanders). These exposure scenarios are plausible considering the volatility of fumigants, in general, and the potential for fumigant off-gassing into the air and transport off-site by winds to bystanders in proximity to treated fields. Exposures to iodomethane may be acute (less than 24 hours), short-term (one to thirty days), intermediate-term (one month to six months) or long-term in duration. Acute exposures have been quantitatively assessed because this duration is the key concern due to the anticipated use pattern of iodomethane, its emission profile and the nature of its toxicity. Additionally, for these same reasons, it is believed that the human health assessment of acute exposures are protective of other durations of exposure. Iodomethane is considered a nonfood use chemical, and a dietary risk assessment was not conducted. The general population may be exposed to iodomethane through drinking water. Therefore, a qualitative drinking water

risk assessment was conducted, and no risks were identified from this potential source of exposure.

EPA is providing an opportunity, through this notice, for interested parties to provide comments and input on the Agency's risk assessment for iodomethane. Such comments and input could address, for example, the availability of additional data to further refine the risk assessments, such as meteorological data for probabilistic modeling purposes and projections for product use by major use regions, frequency or application parameters, etc., or could address the Agency's risk assessment methodologies and assumptions, air dispersion models, or physiologically-based pharmacokinetic models as applied to this specific pesticide.

EPA seeks to achieve environmental justice, the fair treatment and meaningful involvement of all people, regardless of race, color, national origin, or income, in the development, implementation, and enforcement of environmental laws, regulations, and policies. To help address potential environmental justice issues, the Agency seeks information on any groups or segments of the population who, as a result of their location, cultural practices, or other factors, may have potentially atypical, unusually high exposure to iodomethane, compared to the general population.

Comments should be limited to issues raised within the risk assessment and associated documents or to environmental justice issues discussed above. All comments should be submitted using the methods in Unit I. of the **SUPPLEMENTARY INFORMATION**, and must be received by EPA on or before the closing date. Comments will become part of the Agency Docket for iodomethane. Comments received after the close of the comment period will be marked "late." EPA is not required to consider these late comments.

B. What is the Agency's Authority for Taking this Action?

Section 3 of FIFRA directs that "the Administrator may by regulation limit the distribution, sale, or use in any State of any pesticide that is not registered under this Act and that is not the subject of an experimental use permit under section 5 or an emergency exemption under section 18."

List of Subjects

Environmental protection, Pesticides and pests.

Dated: December 30, 2005.

Donald R. Stubbs,

Acting Director, Registration Division, Office of Pesticide Programs.

[FR Doc. E6-28 Filed 1-5-06; 8:45 am]

BILLING CODE 6560-50-S

FEDERAL COMMUNICATIONS COMMISSION

Federal Advisory Committee Act

AGENCY: Federal Communications Commission.

ACTION: Notice.

SUMMARY: In accordance with the Federal Advisory Committee Act, the purpose of this notice is to announce that a Federal Advisory Committee, known as the "Independent Panel Reviewing the Impact of Hurricane Katrina on Communications Networks" (hereinafter the "Independent Panel") is being established.

ADDRESSES: Federal Communications Commission, Enforcement Bureau, 445 12th Street, SW., Washington, DC 20554, Attn: Lisa M. Fowlkes, 445 12th Street, SW., Washington, DC 20554.

FOR FURTHER INFORMATION CONTACT: Lisa M. Fowlkes, Federal Communications Commission, 445 12th St., SW., Washington, DC 20554. Telephone (202) 418-7452, e-mail lisa.fowlkes@fcc.gov.

SUPPLEMENTARY INFORMATION: The Chairman of the Federal Communications Commission has determined that the establishment of the Panel is necessary and in the public interest in connection with the performance of duties imposed upon the Federal Communications Commission ("FCC" or "Commission") by law. The Committee Management Secretariat, General Services Administration concurs with the establishment of the Independent Panel. The purpose of the Independent Panel is to review the impact of Hurricane Katrina on the telecommunications and media infrastructure in the areas affected by the hurricane. Specifically, the Independent Panel will study the impact of Hurricane Katrina on all sectors of the telecommunications and media industries, including public safety communications. The Independent Panel will also review the sufficiency and effectiveness of the recovery effort with respect to this infrastructure. The Independent Panel will then make recommendations to the FCC by June 15, 2006 regarding ways to improve disaster preparedness, network reliability, and communications among first responders such as police,

firefighters, and emergency medical personnel.

Federal Communications Commission.

Lisa M. Fowlkes,

Assistant Chief, Enforcement Bureau.

[FR Doc. 06-150 Filed 1-5-06; 8:45 am]

BILLING CODE 6712-01-P

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than January 30, 2006.

A. Federal Reserve Bank of Cleveland (Cindy West, Manager) 1455 East Sixth Street, Cleveland, Ohio 44101-2566:

1. *National City Corporation*, Columbus, Ohio; to merge with Forbes First Financial Corp., St. Louis, Missouri; and thereby indirectly acquire Pioneer Bank and Trust Company, Maplewood, Missouri.

Board of Governors of the Federal Reserve System, December 29, 2005.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. E6-2 Filed 1-5-06; 8:45 am]

BILLING CODE 6210-01-S

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center Web site at <http://www.ffiec.gov/nic/>.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than February 2, 2006.

A. Federal Reserve Bank of St. Louis (Glenda Wilson, Community Affairs Officer) 411 Locust Street, St. Louis, Missouri 63166-2034:

1. *M&P Community Bancshares, Inc. 401(k) Employee Stock Ownership Plan*, Newport, Arkansas; to become a bank holding company by acquiring an additional 1.63 percent, for a total of 26.58 percent, of the voting shares of M&P Community Bancshares, Inc., Newport, Arkansas, and thereby indirectly acquire voting shares of

Greens Ferry Lake State Bank, Heber Springs, Arkansas, and Merchants & Planters Bank, Newport, Arkansas.

Board of Governors of the Federal Reserve System, January 3, 2006.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. E6-23 Filed 1-5-06; 8:45 am]

BILLING CODE 6210-01-S

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than January 30, 2006.

A. Federal Reserve Bank of San Francisco (Tracy Basinger, Director, Regional and Community Bank Group) 101 Market Street, San Francisco, California 94105-1579:

1. *Cathay General Bancorp*, Los Angeles, California; to acquire up to 14.9 percent of the voting shares of Broadway Financial Corporation, Los Angeles, California, and thereby indirectly acquire voting shares of Broadway Federal Bank, FSB, Los Angeles, California, and thereby engage in operating a savings association, pursuant to section 225.28(b)(4)(ii) of Regulation Y.

Board of Governors of the Federal Reserve System, December 29, 2005.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. E6-1 Filed 1-5-06; 8:45 am]

BILLING CODE 6210-01-S

GENERAL SERVICES ADMINISTRATION

[PBS-N01]

Notice of Intent to Prepare an Environmental Impact Statement and Hold a Public Scoping Meeting for the Construction of a New Border Station Facility in Madawaska, Maine

AGENCY: Public Buildings Service, GSA.

ACTION: Notice of Intent.

SUMMARY: The General Services Administration (GSA) announces its intent to prepare an Environmental Impact Statement (EIS) under the National Environmental Policy Act (NEPA) of 1969 to assess the potential impacts of the construction of a New Border Station Facility in Madawaska, Maine (the "Proposed Action"). At the request of Customs and Border Protection (CBP), the GSA is proposing to construct a new border station facility which meets their needs, and the design requirements of the GSA.

The existing facilities are undersized and obsolete, and consequently incapable of providing the level of security now required. The Proposed Action has been defined and will likely include: (a) identification of land requirements, including acquisition of adjoining land; (b) demolition of existing government structures at the border station; (c) construction of a main administration building and ancillary support buildings; and (d) consequent potential alterations to secondary roads.

Alternatives to be studied will identify alternative locations for the components of the border station including the main administration and ancillary support buildings, the associated roadway network and parking. A No Action alternative will also be studied that will evaluate the consequences of not constructing the new border station facility. This alternative is included to provide a basis for comparison to the action alternatives described above as required by NEPA regulations (40 CFR 1002.14(d)).

GSA invites individuals, organizations and agencies to submit comments concerning the scope of the EIS. The public scoping period starts with the publication of this notice in the

Federal Register and will continue for forty five (45) days from the date of this notice. GSA will consider all comments received or postmarked by that date in defining the scope of the EIS. GSA expects to issue a Draft EIS by June 2006 at which time its availability will be announced in the **Federal Register** and local media. A public comment period will commence upon publication of the Notice of Availability. The GSA will consider and respond to comments received on the Draft EIS in preparing the Final EIS.

ADDRESSES: Written comments or suggestions concerning the scope of the EIS should be sent to David M. Drevinsky P.E., PMP, Regional Environmental Quality Advocate (REQA), U.S. General Services Administration, 10 Causeway Street, Room 975, Boston, MA 02222; Fax (617) 565-5967.

FOR FURTHER INFORMATION CONTACT: David M. Drevinsky by phone at (617) 565-6596 or by email at david.drevinsky@gsa.gov.

SUPPLEMENTARY INFORMATION: Public Scoping Meeting:

A public scoping meeting will provide the public with an opportunity to present comments, ask questions, and discuss concerns regarding the scope of the EIS for the Proposed Action with GSA representatives. GSA will hold a public scoping meeting at the Middle / High School Library located on 135 Seventh Avenue in Madawaska on January 10, 2006 from 6 p.m. to 8 p.m. In case of inclement weather, this public scoping meeting will be held on January 11, 2006 at the same location and with the same time.

Dated: December 29, 2005

Dennis R. Smith

Regional Administrator, New England Region
[FR Doc. E5-8328 Filed 1-5-06; 8:45 am]

BILLING CODE 6820-A8-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Meeting of the Citizens' Health Care Working Group

AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.

ACTION: Notice of public meeting.

SUMMARY: In accordance with section 10(a) of the Federal Advisory Committee Act, this notice announces a meeting of the Citizens' Health Care Working Group (the Working Group) mandated

by section 1014 of the Medicare Modernization Act.

DATES: The business meeting of the Working Group will be held on Wednesday, January 18, 2006, from 9 a.m. to 4:30 p.m. and Thursday, January 19, 2006 from 9 a.m. to 2 p.m.

ADDRESSES: The meeting will take place in the conference room of the United Food and Commercial Workers International Union, in Washington, DC. The office is located at 1775 K Street NW. The main receptionist area is located on the 7th floor; the conference room is located on the 11th floor.

The meeting is open to the public.

FOR FURTHER INFORMATION CONTACT: Caroline Taplin, Citizens' Health Care Working Group, at (301) 443-1514 or ctaplin@ahrq.gov. If sign language interpretation or other reasonable accommodation for a disability is needed, please contact Mr. Donald L. Inniss, Director, Office of Equal Employment Opportunity Program, Program Support Center, on (301) 443-1144.

The agenda for this Working Group meeting will be available on the Citizens' Working Group Web site, www.citizenshealthcare.gov. Also available at that site is a roster of Working Group members. When summaries of the meeting are completed, they will also be available on the Web site.

SUPPLEMENTARY INFORMATION: Section 1014 of Pub. L. 108-173, (known as the Medicare Modernization Act) directs the Secretary of the Department of Health and Human Services (DHHS), acting through the Agency for Healthcare Research and Quality, to establish a Citizens' Health Care Working Group (Citizen Group). This statutory provision, codified at 42 U.S.C. 299 n., directs the Working Group to: (1) Identify options for changing our health care system so that every American has the ability to obtain quality, affordable health care coverage; (2) provide for a nationwide public debate about improving the health care system; and (3) submit its recommendations to the President and the Congress.

The Citizens' Health Care Working Group is composed of 15 members: the Secretary of DHHS is designated as a member by statute and the Comptroller General of the U.S. Government Accountability Office (GAO) was directed to name the remaining 14 members whose appointments were announced on February 28, 2005.

Working Group Meeting Agenda

The Working Group business meeting on January 18th and 19th will be

devoted to ongoing Working Group business. Topics to be addressed are expected to include: an update on community meetings; background information on public perceptions on health care quality and efficiency; discussion of data from various sources including community meetings, Web site questions, Web casts, the citizen survey and other sources of public input; and broad concepts relating to the Working Group's recommendation report.

Submission of Written Information

The Working Group invites written submissions on those topics to be addressed at the Working Group business meetings listed above. In general, individuals or organizations wishing to provide written information for consideration by the Citizens' Health Care Working Group should submit information electronically to citizenshealth@ahrq.gov. Since all electronic submissions will be posted on the Working Group Web site, separate submissions by topic will facilitate review of ideas submitted on each topic by the Working Group and the public.

This notice is published less than 15 days in advance of the meeting due to logistical difficulties.

Dated: December 30, 2005.

Carolyn M. Clancy,

Director.

[FR Doc. 06-91 Filed 1-5-06; 8:45 am]

BILLING CODE 4160-90-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panels (SEP): In-Country Development of H5N1 Influenza Vaccines in Vietnam, Program Announcement Number C106-008

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): In-Country Development of H5N1 Influenza Vaccines in Vietnam, Program Announcement Number C106-008.

Times and Dates: 11 a.m.-1 p.m., January 23, 2006 (Closed).

Place: Teleconference.

Status: The meeting will be closed to the public in accordance with provisions set forth in section 5523b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to: In-Country Development of H5N1 Influenza Vaccines in Vietnam, Program Announcement Number C106-008.

FOR FURTHER INFORMATION CONTACT:

Mary Lerchen, Dr.P.H., Associate Director, Office of Public Health Research, Centers for Disease Control and Prevention, 1600 Clifton Road, NE., Mailstop D-72, Atlanta, GA 30030, Telephone (404) 639-4897.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: December 30, 2005.

Alvin Hall,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 06-98 Filed 1-5-06; 8:45 am]

BILLING CODE 4163-18-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[Document Identifier: CMS-R-250]

Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Centers for Medicare & Medicaid Services.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Centers for Medicare & Medicaid Services (CMS) is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated

burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

1. Type of Information Collection

Request: Extension of a currently approved collection; **Title of Information Collection:** Skilled Nursing Facility Resident Assessment MDS Data and Supporting Regulations in 42 CFR 413.337, 413.343, 424.32, and 483.20; **Form Number:** CMS-R-250 (OMB#: 0938-0739); **Use:** Skilled Nursing Facilities (SNFs) are required to submit the resident assessment data as described at 42 CFR 483.20 in the manner necessary to administer the payment rate methodology described in 42 CFR 413.337. Pursuant to sections 4204(b) and 4214(d) of Omnibus Budget Reconciliation Act (OBRA) 1987, the current requirements related to the submission and retention of resident assessment data for the 5th, 30th, 60th and 90th days following admission, necessary to administer the payment rate methodology described in 42 CFR 413.337, are subject to the Paperwork Reduction Act. The burden associated with information collection is the sum of the SNF staff time required to complete the Minimum Data Set (MDS), SNF staff time to encode the data, and SNF staff time spent in transmitting the data.; **Frequency:** Reporting—Other, 5th, 14th, 30th, 60th, and 90th days of stay; **Affected Public:** Business or other for-profit, Not-for-profit institutions; **Number of Respondents:** 15,352; **Total Annual Responses:** 4,719,118; **Total Annual Hours:** 3,284,247.

To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, access CMS' Web site address at <http://www.cms.hhs.gov/regulations/pral/>, or E-mail your request, including your address, phone number, OMB number, and CMS document identifier, to Paperwork@cms.hhs.gov, or call the Reports Clearance Office on (410) 786-1326.

To be assured consideration, comments and recommendations for the proposed information collections must be received at the address below, no later than 5 p.m. on March 7, 2006.

CMS, Office of Strategic Operations and Regulatory Affairs, Division of Regulations Development—B, Attention: William N. Parham, III, Room C4-26-05, 7500 Security Boulevard, Baltimore, Maryland 21244-1850.

Dated: December 28, 2005.

Michelle Shortt,

*Director, Regulations Development Group,
Office of Strategic Operations and Regulatory
Affairs.*

[FR Doc. E6-14 Filed 1-5-06; 8:45 am]

BILLING CODE 4120-01-P

**DEPARTMENT OF HEALTH AND
HUMAN SERVICES**

**Centers for Medicare & Medicaid
Services**

[Document Identifier: CMS-10165 and CMS-10149]

**Agency Information Collection
Activities: Submission for OMB
Review; Comment Request**

AGENCY: Centers for Medicare & Medicaid Services.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services, is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the Agency's function; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

1. Type of Information Collection

Request: Extension of a currently approved collection; **Title of Information Collection:** Application for Participation in the Medicare Care Management Performance Demonstration; **Form Number:** CMS-10165 (OMB#: 0938-0965); **Use:** The Medicare Care Management Performance (MCMP) Demonstration and its corresponding Report to Congress are mandated by the section 649 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA). Section 649 of the MMA provides for the implementation of a "pay for performance" demonstration under which Medicare would pay incentive payments to physicians who (1) adopt and use health information technology; and (2) meet established standards on clinical performance

measures. This demonstration will be held in four States, Arkansas, California, Massachusetts, and Utah. Providers that are enrolled in the Doctors' Office Quality—Information Technology (DOQ-IT) project are eligible to participate in the demonstration. To enroll in the MCMP Demonstration, a physician/provider must submit an application form. The information collected will be used to assess eligibility for the demonstration; **Frequency:** Reporting—One-time only; **Affected Public:** Business or other for-profit; **Number of Respondents:** 800; **Total Annual Responses:** 800; **Total Annual Hours:** 133.

2. Type of Information Collection

Request: Extension of a currently approved collection; **Title of Information Collection:** Health Insurance Reform: Security Standards Final Rule; **Form Number:** CMS-10149 (OMB#: 0938-0949); **Use:** The Department of Health and Human Services (HHS) Medicare Program, other Federal agencies operating health plans or providing health care, State Medicaid agencies, private health plans, health care providers, and health care clearinghouses must assure their customers (for example, patients, insured individuals, providers, and health plans) that the integrity, confidentiality, and availability of electronic protected health information they collect, maintain, use, or transmit is protected. The confidentiality of health information is threatened not only by the risk of improper access to stored information, but also by the risk of interception during electronic transmission of the information. The use of the security standards will improve the Medicare and Medicaid programs, other Federal health programs, and private health programs; in addition, it will improve the effectiveness and efficiency of the health care industry in general by establishing a level of protection for certain electronic health information.; **Frequency:** Recordkeeping and Reporting—On occasion; **Affected Public:** Business or other for-profit, Not-for-profit institutions, Federal Government, and State, Local or Tribal Government; **Number of Respondents:** 4,000,000; **Total Annual Responses:** 4,000,000; **Total Annual Hours:** 64,539,263.

To obtain copies of the supporting statement and any related forms for these paperwork collections referenced above, access CMS Web site address at <http://www.cms.hhs.gov/PaperworkReductionActof1995>, or E-mail your request, including your address, phone number, OMB number, and CMS document identifier, to

Paperwork@cms.hhs.gov, or call the Reports Clearance Office on (410) 786-1326.

To be assured consideration, comments and recommendations for the proposed information collections must be received by the OMB Desk Officer at the address below, no later than 5 p.m. on February 6, 2006.

OMB Human Resources and Housing Branch, Attention: Carolyn Lovett, CMS Desk Officer, New Executive Office Building, Room 10235, Washington, DC 20503.

Dated: December 28, 2005.

Michelle Shortt,

Director, Regulations Development Group, Office of Strategic Operations and Regulatory Affairs.

[FR Doc. E6-15 Filed 1-5-06; 8:45 am]

BILLING CODE 4120-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

Privacy Act of 1974; Report of a New System of Records

AGENCY: Department of Health and Human Services (HHS), Centers for Medicare & Medicaid Services (CMS).

ACTION: Notice of a new System of Records (SOR).

SUMMARY: In accordance with the requirements of the Privacy Act of 1974, we are proposing to establish a new SOR titled, "Medicare Bariatric Surgery System (MBSS), System No. 09-70-0570." National coverage determinations (NCDs) are determinations made by the Secretary of HHS with respect to whether or not a particular item or service is covered nationally under title XVIII of the Social Security Act (the Act) section 1869(f)(1)(B). In order to be covered by Medicare, an item or service must fall within one or more benefit categories contained within Part A or Part B, and must not be otherwise excluded from coverage. Moreover, with limited exceptions, the expenses incurred for items or services must be "reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member," section 1862(a)(1)(A). CMS has determined that the evidence is adequate to conclude that bariatric surgery is reasonable and necessary in several patient groups where certain criteria for these patients have been met. The reasonable and necessary determination requires that patients

meet the MBSS criteria set forth in the decision memorandum and are consistent with the trials discussed. Bariatric surgery is reasonable and necessary only when facilities performing the surgery have full accreditation based on standards equivalent to or exceeding the CMS minimum standards. Collection of data elements related to bariatric surgery allows that determination to be made.

The purpose of this system is to provide reimbursement for bariatric surgery, and assist in the collection of data on patients receiving bariatric surgery, for a data collection process to assure patient safety and protection, and to determine that the bariatric surgery is reasonable and necessary. Information retrieved from this system will also be disclosed to: (1) Support regulatory, reimbursement, and policy functions performed within the agency or by a contractor or consultant; (2) assist another Federal or state agency with information to enable such agency to administer a Federal health benefits program, or to enable such agency to fulfill a requirement of Federal statute or regulation that implements a health benefits program funded in whole or in part with Federal funds; (3) assist an individual or organization for a research project or in support of an evaluation project related to the prevention of disease or disability, the restoration or maintenance of health, or payment related projects; (4) support constituent requests made to a congressional representative; (5) support litigation involving the agency; and (6) combat fraud and abuse in certain Federally-funded health benefits programs. We have provided background information about the modified system in the **SUPPLEMENTARY INFORMATION** section below. Although the Privacy Act requires only that CMS provide an opportunity for interested persons to comment on the proposed routine uses, CMS invites comments on all portions of this notice. See **EFFECTIVE DATES** section for comment period.

EFFECTIVE DATE: CMS filed a new SOR report with the Chair of the House Committee on Government Reform and Oversight, the Chair of the Senate Committee on Governmental Affairs, and the Administrator, Office of Information and Regulatory Affairs, Office of Management and Budget (OMB) on 12/29/2005. We will not disclose any information under a routine use until 30 days after publication. We may defer implementation of this system or one or more of the routine use statements listed

below if we receive comments that persuade us to defer implementation.

ADDRESSES: The public should address comment to the CMS Privacy Officer, Mail Stop N2-04-27, 7500 Security Boulevard, Baltimore, Maryland 21244-1850. Comments received will be available for review at this location, by appointment, during regular business hours, Monday through Friday from 9 a.m.-3 p.m., eastern daylight time.

FOR FURTHER INFORMATION CONTACT: Rosemarie Hakim, Epidemiologist, Office of Clinical Standards and Quality, CMS, Mail Stop C1-09-06, 7500 Security Boulevard, Baltimore, Maryland 21244-1849. She may be contacted via telephone at (410) 786-3934, or via e-mail at Rosemarie.Hakim@cms.hhs.gov.

SUPPLEMENTARY INFORMATION: Obesity is a growing epidemic in the United States with over 60% of the population classified as overweight or obese. One form of treatment for obesity is bariatric surgery. In May 2005 CMS began a reconsideration of the NCD on BS for Medicare beneficiaries submitted by the American Society for bariatric surgery, the American Obesity Association, and others. The requestors included the following bariatric surgery procedures in their request for reconsideration: (1) Roux-en-y Gastric Bypass, (2) Biliopancreatic Diversion, (3) Laparoscopic Adjustable Gastric Banding, and (4) Vertical Gastric Banding. CMS has determined that the evidence is adequate to conclude that bariatric surgery is reasonable and necessary for Medicare beneficiaries who have a Body Mass Index ≥ 35 , at least one co-morbidity related to morbid obesity, and have been unsuccessful with medical treatment for obesity.

I. Description of the Proposed System of Records

A. Statutory and Regulatory Basis for SOR

The statutory authority for linking coverage decisions to the collection of additional data is derived from section 1862(a)(1)(A) of the Act, which states that Medicare may not provide payment for items and services unless they are "reasonable and necessary" for the treatment of illness or injury. In some cases, CMS will determine that an item or service is only reasonable and necessary when specific data collections accompany the provisions of the service. In these cases, the collection of data is required to ensure that the care provided to individual patients will improve health outcomes.

B. Collection and Maintenance of Data in the System

The data collection should include baseline patient characteristics. The information collected will include but is not limited to: Name, address, telephone number, Health Insurance Claim Number (HICN), geographic location, race/ethnicity, gender, and date of birth, as well as, background information relating to Medicare or Medicaid issues.

II. Agency Policies, Procedures, and Restrictions on the Routine Use

A. Agency Policies, Procedures, and Restrictions on the Routine Use

The Privacy Act permits us to disclose information without an individual's consent if the information is to be used for a purpose that is compatible with the purpose(s) for which the information was collected. Any such disclosure of data is known as a "routine use." The government will only release MBSS information that can be associated with an individual as provided for under "Section III. Proposed Routine Use Disclosures of Data in the System." Both identifiable and non-identifiable data may be disclosed under a routine use.

We will only collect the minimum personal data necessary to achieve the purpose of MBSS. CMS has the following policies and procedures concerning disclosures of information that will be maintained in the system. Disclosure of information from the system will be approved only to the extent necessary to accomplish the purpose of the disclosure and only after CMS:

1. Determines that the use or disclosure is consistent with the reason that the data is being collected, e.g., to provide reimbursement for bariatric surgery, and assist in the collection of data on patients receiving bariatric surgery, for a data collection process to assure patient safety and protection, and to determine that the bariatric surgery is reasonable and necessary.

2. Determines that:

- a. The purpose for which the disclosure is to be made can only be accomplished if the record is provided in individually identifiable form;
- b. The purpose for which the disclosure is to be made is of sufficient importance to warrant the effect and/or risk on the privacy of the individual that additional exposure of the record might bring; and

- c. There is a strong probability that the proposed use of the data would in fact accomplish the stated purpose(s).

3. Requires the information recipient to:

- a. Establish administrative, technical, and physical safeguards to prevent unauthorized use of disclosure of the record;

- b. Remove or destroy at the earliest time all patient-identifiable information; and

- c. Agree to not use or disclose the information for any purpose other than the stated purpose under which the information was disclosed.

4. Determines that the data are valid and reliable.

III. Proposed Routine Use Disclosures of Data in the System

A. The Privacy Act allows us to disclose information without an individual's consent if the information is to be used for a purpose that is compatible with the purpose(s) for which the information was collected. Any such compatible use of data is known as a "routine use." The proposed routine uses in this system meet the compatibility requirement of the Privacy Act. We are proposing to establish the following routine use disclosures of information maintained in the system:

1. To agency contractors or consultants who have been engaged by the agency to assist in the performance of a service related to this system and who need to have access to the records in order to perform the activity.

We contemplate disclosing information under this routine use only in situations in which CMS may enter into a contractual or similar agreement with a third party to assist in accomplishing CMS function relating to purposes for this system.

CMS occasionally contracts out certain of its functions when doing so would contribute to effective and efficient operations. CMS must be able to give a contractor or consultant whatever information is necessary for the contractor or consultant to fulfill its duties. In these situations, safeguards are provided in the contract prohibiting the contractor or consultant from using or disclosing the information for any purpose other than that described in the contract and requires the contractor or consultant to return or destroy all information at the completion of the contract.

2. To another Federal or state agency to:

- a. Provide reimbursement for bariatric surgery, and assist in the collection of data on patients receiving bariatric surgery for a data collection process to assure patient safety and protection, and to determine that the bariatric surgery is reasonable and necessary,

- b. Contribute to the accuracy of CMS's proper payment of Medicare benefits, and/or

- c. Enable such agency to administer a Federal health benefits program, or as necessary to enable such agency to fulfill a requirement of a Federal statute or regulation that implements a health benefits program funded in whole or in part with Federal funds.

Other Federal or state agencies in their administration of a Federal health program may require MBSS information in order to provide reimbursement for bariatric surgery, and assist in the collection of data on patients receiving bariatric surgery for a data collection process to assure patient safety and protection, and to determine that the bariatric surgery is reasonable and necessary.

3. To an individual or organization for a research project or in support of an evaluation project related to the prevention of disease or disability, the restoration or maintenance of health, or payment related projects.

The MBSS data will provide for research or in support of evaluation projects, a broader, national perspective of the status of Medicare beneficiaries. CMS anticipates that many researchers will have legitimate requests to use these data in projects that could ultimately improve the care provided to Medicare beneficiaries and the policy that governs the care.

4. To a member of Congress or to a Congressional staff member in response to an inquiry of the Congressional office made at the written request of the constituent about whom the record is maintained.

Beneficiaries sometimes request the help of a member of Congress in resolving an issue relating to a matter before CMS. The member of Congress then writes CMS, and CMS must be able to give sufficient information to be responsive to the inquiry.

5. To the Department of Justice (DOJ), court or adjudicatory body when:

- a. The agency or any component thereof, or

- b. Any employee of the agency in his or her official capacity, or

- c. Any employee of the agency in his or her individual capacity where the DOJ has agreed to represent the employee, or

- d. The United States Government is a party to litigation or has an interest in such litigation, and by careful review, CMS determines that the records are both relevant and necessary to the litigation and that the use of such records by the DOJ, court or adjudicatory body is compatible with

the purpose for which the agency collected the records.

Whenever CMS is involved in litigation, and occasionally when another party is involved in litigation and CMS' policies or operations could be affected by the outcome of the litigation, CMS would be able to disclose information to the DOJ, court or adjudicatory body involved.

6. To a CMS contractor (including, but not necessarily limited to fiscal intermediaries and carriers) that assists in the administration of a CMS-administered health benefits program, or to a grantee of a CMS-administered grant program, when disclosure is deemed reasonably necessary by CMS to prevent, deter, discover, detect, investigate, examine, prosecute, sue with respect to, defend against, correct, remedy, or otherwise combat fraud or abuse in such program.

We contemplate disclosing information under this routine use only in situations in which CMS may enter into a contractual relationship or grant with a third party to assist in accomplishing CMS functions relating to the purpose of combating fraud and abuse.

CMS occasionally contracts out certain of its functions and makes grants when doing so would contribute to effective and efficient operations. CMS must be able to give a contractor or grantee whatever information is necessary for the contractor or grantee to fulfill its duties. In these situations, safeguards are provided in the contract prohibiting the contractor or grantee from using or disclosing the information for any purpose other than that described in the contract and requiring the contractor or grantee to return or destroy all information.

7. To another Federal agency or to an instrumentality of any governmental jurisdiction within or under the control of the United States (including any State or local governmental agency), that administers, or that has the authority to investigate potential fraud or abuse in, a health benefits program funded in whole or in part by Federal funds, when disclosure is deemed reasonably necessary by CMS to prevent, deter, discover, detect, investigate, examine, prosecute, sue with respect to, defend against, correct, remedy, or otherwise combat fraud or abuse in such programs.

Other agencies may require MBSS information for the purpose of combating fraud and abuse in such Federally-funded programs.

B. Additional Provisions Affecting Routine Use Disclosures

To the extent this system contains Protected Health Information (PHI) as defined by HHS regulation "Standards for Privacy of Individually Identifiable Health Information" (45 CFR Parts 160 and 164, 65 FR 82462 (12-28-00), Subparts A and E) disclosures of such PHI that are otherwise authorized by these routine uses may only be made if, and as, permitted or required by the "Standards for Privacy of Individually Identifiable Health Information."

In addition, our policy will be to prohibit release even of data not directly identifiable, except pursuant to one of the routine uses or if required by law, if we determine there is a possibility that an individual can be identified through implicit deduction based on small cell sizes (instances where the patient population is so small that individuals who are familiar with the enrollees could, because of the small size, use this information to deduce the identity of the beneficiary).

IV. Safeguards

CMS has safeguards in place for authorized users and monitors such users to ensure against excessive or unauthorized use. Personnel having access to the system have been trained in the Privacy Act and information security requirements. Employees who maintain records in this system are instructed not to release data until the intended recipient agrees to implement appropriate management, operational and technical safeguards sufficient to protect the confidentiality, integrity and availability of the information and information systems and to prevent unauthorized access.

This system will conform to all applicable Federal laws and regulations and Federal, HHS, and CMS policies and standards as they relate to information security and data privacy. These laws and regulations may apply but are not limited to: The Privacy Act of 1974; the Federal Information Security Management Act of 2002; the Computer Fraud and Abuse Act of 1986; the Health Insurance Portability and Accountability Act of 1996; the E-Government Act of 2002, the Clinger-Cohen Act of 1996; the Medicare Modernization Act of 2003, and the corresponding implementing regulations. OMB Circular A-130, Management of Federal Resources, Appendix III, Security of Federal Automated Information Resources also applies. Federal, HHS, and CMS policies and standards include but are not limited to: All pertinent National

Institute of Standards and Technology publications; the HHS Information Systems Program Handbook and the CMS Information Security Handbook.

V. Effects of the Proposed System of Records on Individual Rights

CMS proposes to establish this system in accordance with the principles and requirements of the Privacy Act and will collect, use, and disseminate information only as prescribed therein. Data in this system will be subject to the authorized releases in accordance with the routine uses identified in this system of records.

CMS will take precautionary measures (see item IV above) to minimize the risks of unauthorized access to the records and the potential harm to individual privacy or other personal or property rights of patients whose data are maintained in the system. CMS will collect only that information necessary to perform the system's functions. In addition, CMS will make disclosure from the proposed system only with consent of the subject individual, or his/her legal representative, or in accordance with an applicable exception provision of the Privacy Act. CMS, therefore, does not anticipate an unfavorable effect on individual privacy as a result of information relating to individuals.

Dated: December 27, 2005.

Lori Davis,

Acting Chief Operating Officer, Centers for Medicare & Medicaid Services.

System No. 09-70-0570

SYSTEM NAME:

"Medicare Bariatric Surgery System (MBSS);" HHS/CMS/OCSQ.

SECURITY CLASSIFICATION:

Level Three Privacy Act Sensitive Data.

SYSTEM LOCATION:

Centers for Medicare & Medicaid Services (CMS) Data Center, 7500 Security Boulevard, North Building, First Floor, Baltimore, Maryland 21244-1850 and at various co-locations of CMS contractors.

CATEGORIES OF INDIVIDUALS COVERED BY THE SYSTEM:

CMS has determined that the evidence is adequate to conclude that bariatric surgery is reasonable and necessary for Medicare beneficiaries who have a Body Mass Index ≥ 35 , at least one co-morbidity related to morbid obesity, and have been unsuccessful with medical treatment for obesity.

CATEGORIES OF RECORDS IN THE SYSTEM:

The data collection should include baseline patient characteristics. The information collected will include but is not limited to: name, address, telephone number, Health Insurance Claim Number (HICN), geographic location, race/ethnicity, gender, and date of birth, as well as, background information relating to Medicare or Medicaid issues.

AUTHORITY FOR MAINTENANCE OF THE SYSTEM:

The statutory authority for linking coverage decisions to the collection of additional data is derived from Sec. 1862(a)(1)(A) of the Social Security Act (the Act), which states that Medicare may not provide payment for items and services unless they are "reasonable and necessary" for the treatment of illness or injury. In some cases, CMS will determine that an item or service is only reasonable and necessary when specific data collections accompany the provision of the service. In these cases, the collection of data is required to ensure that the care provided to individual patients will improve health outcomes.

PURPOSE(S) OF THE SYSTEM:

The purpose of this system is to provide reimbursement for bariatric surgery, and assist in the collection of data on patients receiving bariatric surgery, for a data collection process to assure patient safety and protection, and to determine that the bariatric surgery is reasonable and necessary. Information retrieved from this system will also be disclosed to: (1) Support regulatory, reimbursement, and policy functions performed within the agency or by a contractor or consultant; (2) assist another Federal or state agency with information to enable such agency to administer a Federal health benefits program, or to enable such agency to fulfill a requirement of Federal statute or regulation that implements a health benefits program funded in whole or in part with Federal funds; (3) assist an individual or organization for a research project or in support of an evaluation project related to the prevention of disease or disability, the restoration or maintenance of health, or payment related projects; (4) support constituent requests made to a congressional representative; (5) support litigation involving the agency; and (6) combat fraud and abuse in certain Federally-funded health benefits programs.

ROUTINE USES OF RECORDS MAINTAINED IN THE SYSTEM, INCLUDING CATEGORIES OF USERS AND THE PURPOSES OF SUCH USES:

A. The Privacy Act allows us to disclose information without an

individual's consent if the information is to be used for a purpose that is compatible with the purpose(s) for which the information was collected. Any such compatible use of data is known as a "routine use." The proposed routine uses in this system meet the compatibility requirement of the Privacy Act. We are proposing to establish the following routine use disclosures of information maintained in the system:

1. To agency contractors or consultants who have been engaged by the agency to assist in the performance of a service related to this system of records and who need to have access to the records in order to perform the activity.

2. To another Federal or State agency to:

A. Provide reimbursement for bariatric surgery, and assist in the collection of data on patients receiving bariatric surgery, for a data collection process to assure patient safety and protection, and to determine that the bariatric surgery is reasonable and necessary,

b. Contribute to the accuracy of CMS's proper payment of Medicare benefits, and/or

c. Enable such agency to administer a Federal health benefits program, or as necessary to enable such agency to fulfill a requirement of a Federal statute or regulation that implements a health benefits program funded in whole or in part with Federal funds.

3. To an individual or organization for a research project or in support of an evaluation project related to the prevention of disease or disability, the restoration or maintenance of health, or payment related projects.

4. To a member of Congress or to a Congressional staff member in response to an inquiry of the Congressional office made at the written request of the constituent about whom the record is maintained.

5. To the Department of Justice (DOJ), court or adjudicatory body when:

a. The agency or any component thereof, or

b. Any employee of the agency in his or her official capacity, or

c. Any employee of the agency in his or her individual capacity where the DOJ has agreed to represent the employee, or

d. The United States Government is a party to litigation or has an interest in such litigation, and by careful review, CMS determines that the records are both relevant and necessary to the litigation and that the use of such records by the DOJ, court or adjudicatory body is compatible with

the purpose for which the agency collected the records.

6. To a CMS contractor (including, but not necessarily limited to fiscal intermediaries and carriers) that assists in the administration of a CMS-administered health benefits program, or to a grantee of a CMS-administered grant program, when disclosure is deemed reasonably necessary by CMS to prevent, deter, discover, detect, investigate, examine, prosecute, sue with respect to, defend against, correct, remedy, or otherwise combat fraud or abuse in such program.

7. To another Federal agency or to an instrumentality of any governmental jurisdiction within or under the control of the United States (including any State or local governmental agency), that administers, or that has the authority to investigate potential fraud or abuse in, a health benefits program funded in whole or in part by Federal funds, when disclosure is deemed reasonably necessary by CMS to prevent, deter, discover, detect, investigate, examine, prosecute, sue with respect to, defend against, correct, remedy, or otherwise combat fraud or abuse in such programs.

B. Additional Provisions Affecting Routine Use Disclosures.

To the extent this system contains Protected Health Information (PHI) as defined by HHS regulation "Standards for Privacy of Individually Identifiable Health Information" (45 CFR parts 160 and 164, 65 FR 82462 (12-28-00), subparts A and E. Disclosures of such PHI that are otherwise authorized by these routine uses may only be made if, and as, permitted or required by the "Standards for Privacy of Individually Identifiable Health Information."

In addition, our policy will be to prohibit release even of data not directly identifiable, except pursuant to one of the routine uses or if required by law, if we determine there is a possibility that an individual can be identified through implicit deduction based on small cell sizes (instances where the patient population is so small that individuals who are familiar with the enrollees could, because of the small size, use this information to deduce the identity of the beneficiary).

POLICIES AND PRACTICES FOR STORING, RETRIEVING, ACCESSING, RETAINING, AND DISPOSING OF RECORDS IN THE SYSTEM:**STORAGE:**

All records are stored electronically.

RETRIEVABILITY:

The data are retrieved by an individual identifier *i.e.*, name of beneficiary or provider.

SAFEGUARDS:

CMS has safeguards in place for authorized users and monitors such users to ensure against excessive or unauthorized use. Personnel having access to the system have been trained in the Privacy Act and information security requirements. Employees who maintain records in this system are instructed not to release data until the intended recipient agrees to implement appropriate management, operational and technical safeguards sufficient to protect the confidentiality, integrity and availability of the information and information systems and to prevent unauthorized access.

This system will conform to all applicable Federal laws and regulations and Federal, HHS, and CMS policies and standards as they relate to information security and data privacy. These laws and regulations may apply but are not limited to: The Privacy Act of 1974; the Federal Information Security Management Act of 2002; the Computer Fraud and Abuse Act of 1986; the Health Insurance Portability and Accountability Act of 1996; the E-Government Act of 2002, the Clinger-Cohen Act of 1996; the Medicare Modernization Act of 2003, and the corresponding implementing regulations. OMB Circular A-130, Management of Federal Resources, Appendix III, Security of Federal Automated Information Resources also applies. Federal, HHS, and CMS policies and standards include but are not limited to: All pertinent National Institute of Standards and Technology publications; the HHS Information Systems Program Handbook and the CMS Information Security Handbook.

RETENTION AND DISPOSAL:

CMS will retain information for a total period of 6 years and 3 months. All claims-related records are encompassed by the document preservation order and will be retained until notification is received from DOJ.

SYSTEM MANAGER AND ADDRESS:

Director, Office of Clinical Standards and Quality, CMS, Room S2-26-17, 7500 Security Boulevard, Baltimore, Maryland 21244-1850.

NOTIFICATION PROCEDURE:

For the purpose of access, the subject individual should write to the system manager who will require the system name, address, age, gender, and for verification purposes, the subject individual's name (woman's maiden name, if applicable).

RECORD ACCESS PROCEDURE:

For the purpose of access, use the same procedures outlines in Notification Procedures above. Requestors should also reasonably specify the record contents being sought. (These procedures are in accordance with Department regulation 45 CFR 5b.5).

CONTESTING RECORDS PROCEDURES:

The subject individual should contact the system manager named above and reasonably identify the records and specify the information to be contested. State the corrective action sought and the reasons for the correction with supporting justification. (These procedures are in accordance with Department regulation 45 CFR 5b.7).

RECORD SOURCE CATEGORIES:

Records maintained in this system are derived from Carrier and Fiscal Intermediary Systems of Records, Common Working File System of Records, clinics, institutions, hospitals and group practices performing the procedures, and outside registries and professional interest groups.

SYSTEMS EXEMPTED FROM CERTAIN PROVISIONS OF THE ACT:

None.

[FR Doc. E5-8331 Filed 1-5-06; 8:45 am]

BILLING CODE 4120-03-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Food and Drug Administration**

[Docket No. 2005D-0483]

Guidance for Industry and Food and Drug Administration: Requesting an Extension to Use Existing Label Stock After the Trans Fat Labeling Effective Date of January 1, 2006; Addendum December 30, 2005; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) published a notice in the *Federal Register* of December 14, 2005 (70 FR 74020) announcing the availability of a guidance document entitled, "Requesting an Extension to Use Existing Label Stock After the *Trans* Fat Labeling Effective Date of January 1, 2006." The guidance document provided guidance to FDA and the food industry about when and how businesses may request the agency to consider enforcement discretion for the

use, on products introduced into interstate commerce on or after the January 1, 2006, effective date for the *trans* fat labeling final rule, of some or all existing label stock that does not declare *trans* fat labeling in compliance with the final rule. This is to notify all interested persons of an addendum to that guidance.

DATES: This guidance is final upon the date of publication. Submit written or electronic comments on the guidance at any time.

ADDRESSES: Submit written requests for single copies of the guidance document to the Office of Nutritional Products, Labeling and Dietary Supplements (HFS-800), Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740. Include a self-addressed adhesive label to assist that office in processing your request. Submit written comments on the guidance to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to <http://www.fda.gov/dockets/ecomments>. To ensure a timelier processing of comments, FDA is no longer accepting comments submitted to the agency by e-mail. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the guidance document.

FOR FURTHER INFORMATION CONTACT: Julie Moss, Center for Food Safety and Applied Nutrition (HFS-830), Food and Drug Administration, 5100 Paint Branch Pkwy., College Park, MD 20740-3835, 301-436-2373, FAX: 301-436-2636.

SUPPLEMENTARY INFORMATION:**I. Background**

FDA announced the availability of a guidance document for industry and FDA entitled, "Requesting an Extension to Use Existing Label Stock After the *Trans* Fat Labeling Effective Date of January 1, 2006," in the *Federal Register* of December 14, 2005 (70 FR 74020). Based on the number of requests the agency received asking it to consider enforcement discretion, FDA decided to incorporate an addendum into that guidance. Thus, FDA is issuing this notice to inform all interested persons of the addendum to that guidance.

In compliance with section 212 of the Small Business Regulatory Enforcement Fairness Act (Public Law 104-121), we are making available this guidance that states in plain language the factors the agency intends to consider concerning requests for enforcement discretion by small and other businesses regarding compliance with this regulation.

FDA is issuing this guidance as a level 1 guidance consistent with FDA's good guidance practices regulation § 10.115 (21 CFR 10.115). Consistent with FDA's good guidance practices regulation, the agency will accept comment, but is implementing the guidance document immediately in accordance with § 10.115 (g)(2), because the agency has determined that prior public participation is not feasible or appropriate. This document affects the *trans fat* labeling effective date of January 1, 2006, so it is urgent that FDA explains its new enforcement policy before that date. This guidance represents the agency's current thinking on the subject. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You may use an alternative approach if such approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance (see **FOR FURTHER INFORMATION CONTACT**).

II. Paperwork Reduction Act of 1995

This final guidance contains information collection provisions that are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The collection of information in this guidance was approved under OMB control number 0910-0571.

III. Comments

Interested persons may submit to the Division of Dockets Management (see **ADDRESSES**) written or electronic comments regarding this document at any time. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. The guidance and received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

IV. Electronic Access

Persons with access to the Internet may obtain the guidance document at <http://www.cfsan.fda.gov/guidance.html>.

Dated: January 3, 2006.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. 06-116 Filed 1-3-06; 3:14 pm]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Drug Safety and Risk Management Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Drug Safety and Risk Management Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on February 9, 2006, from 8 a.m. to 5 p.m. and February 10, 2006, from 8 a.m. to 3 p.m.

Location: Holiday Inn Gaithersburg, Two Montgomery Village Ave., Gaithersburg, MD.

Contact Person: Victoria Ferretti-Aceto, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7001, FAX: 301-827-6776, e-mail: ferrettiv@cder.fda.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512535. Please call the Information Line for up-to-date information on this meeting.

Agenda: Cases of sudden death and serious adverse events including hypertension, myocardial infarction, and stroke have been reported to the agency in association with therapeutic doses of drugs used to treat Attention Deficit Hyperactivity Disorder (ADHD) in both pediatric and adult populations. The few controlled clinical studies of longer term drug treatment of ADHD provided little information on cardiovascular risks. On February 9, 2006, the committee will be asked to discuss approaches that could be used to study whether these products increase the risk of adverse cardiovascular outcomes. On February 10, 2006, the committee will be briefed on developments in the Office of Drug Safety and will receive updates on the Drug Safety Oversight Board and agency actions for the COX-2 selective Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and the risk management program for the isotretinoin products.

Background materials for this meeting will be posted 1 business day before the

meeting on FDA's Web site at <http://www.fda.gov/ohrms/dockets/ac/acmenu.htm> (click on the year 2006 and scroll down to Drug Safety and Risk Management Advisory Committee).

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by February 2, 2006. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. on February 9, 2006, and between approximately 8:15 a.m. and 9:15 a.m. on February 10, 2006. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before February 2, 2006, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Victoria Ferretti-Aceto at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: December 27, 2005.

Jason Brodsky,

Acting Associate Commissioner for External Relations.

[FR Doc. E6-6 Filed 1-5-06; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held March 14, 2006, from 8 a.m. to 5 p.m.

Location: Gaithersburg Hilton, The Ballrooms, 620 Perry Pkwy., Gaithersburg, MD.

Contact Person: Johanna M. Clifford, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, (for express delivery, 5630 Fishers Lane, rm. 1093) Rockville, MD 20857, 301-827-7001, FAX: 301-827-6776, e-mail: cliffordj@cder.fda.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512542. Please call the Information Line for up-to-date information on this meeting.

Agenda: The subcommittee will discuss the following: (1) Clinical studies of methotrexate and daunomycin to be conducted under the Best Pharmaceuticals for Children Act; (2) phase 4 requirements for Deferasirox, Novartis Pharmaceuticals, as mandated under accelerated approval; and (3) the Center for Drug Evaluation and Research's process for handling drug shortages. The background material will become available no later than the day before the meeting and will be posted on FDA's Web site at <http://www.fda.gov/ohrms/dockets/ac/acmenu.htm> under the heading "Oncologic Drugs Advisory Committee; Pediatric Oncology" (click on the year 2006 and scroll down to the previously named committee).

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the subcommittee. Written submissions may be made to the contact person by March 7, 2006. Oral presentations from the public will be scheduled between approximately 2 p.m. to 3 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before March 7, 2006, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the

agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Johanna M. Clifford at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: December 27, 2005.

Jason Brodsky,

Acting Associate Commissioner for External Relations.

[FR Doc. E5-8332 Filed 1-5-06; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Oncologic Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Oncologic Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held March 15, 2006, from 8 a.m. to 5 p.m.

Location: Gaithersburg Hilton, The Ballrooms, 620 Perry Pkwy., Gaithersburg, MD.

Contact Person: Johanna M. Clifford, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, (for express delivery, 5630 Fishers Lane, rm. 1093) Rockville, MD 20857, 301-827-7001, FAX: 301-827-6776, e-mail: cliffordj@cder.fda.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512542. Please call the Information Line for up-to-date information on this meeting. The background material will become available no later than the day before the meeting and will be posted on FDA's Web site at <http://www.fda.gov/ohrms/dockets/ac/>

[acmenu.htm](#) under the heading "Oncologic Drugs Advisory Committee" (click on the year 2006 and scroll down to the above named committee meeting).

Agenda: The committee will discuss the following: (1) Receive and discuss pediatric update from the October 20, 2005, meeting of the Pediatric Oncology Subcommittee; (2) discuss pre-clinical requirements and phase 1 trial design issues for the development of oncologic products; and (3) discuss new drug application (NDA) 20-509, S-039, GEMZAR (gemcitabine hydrochloride) for Injection, Eli Lilly & Co., proposed indication for use in combination with carboplatin for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by March 7, 2006. Oral presentations from the public will be scheduled between approximately 10:30 a.m. to 11 a.m. and 2:30 p.m. to 3 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before March 7, 2006, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Johanna Clifford at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: December 27, 2005.

Jason Brodsky,

Acting Associate Commissioner for External Relations.

[FR Doc. E5-8333 Filed 1-5-06; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Food and Drug Administration**

[FDA 225-05-8007]

Implementation Plan for the Memorandum of Understanding Regarding the Sharing and Exchange of Information About Therapeutic Products Between the Food and Drug Administration Department of Health and Human Services of the United States of America and Health Products and Food Branch, Health Canada of Canada**AGENCY:** Food and Drug Administration, HHS.**ACTION:** Notice.**SUMMARY:** The Food and Drug Administration (FDA) is providing notice of an Implementation Plan

(Implementation Plan) for the Memorandum of Understanding (MOU) Regarding the Sharing and Exchange of Information About Therapeutic Products Between the Food and Drug Administration Department of Health and Human Services of the United States of America and the Health Products and Food Branch, Health Canada of Canada. The purpose of the Implementation Plan is to establish the following: A governance structure for directing and monitoring the implementation of the MOU; clear process by which each party will undertake the exchange of otherwise not public information; and the process for setting and monitoring mutually agreed upon annual priorities for cooperation.

DATES: The Implementation Plan became effective December 1, 2005.**FOR FURTHER INFORMATION CONTACT:** Matthew E. Eckel, Office of

International Programs, (HFG-1), 5600 Fishers Lane, Rockville MD, 20857, 301-827-4480, FAX: 301-480-0716.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 20.108(a) and (c), which states that all written agreements and understandings signed by FDA and other departments, agencies, and organizations shall be published in the **Federal Register**, except those agreements and memoranda of understanding between FDA and State or local government agencies that are cooperative work-sharing agreements, the agency is publishing notice of this Implementation Plan.

Dated: December 30, 2005.

Jeffrey Shuren,*Assistant Commissioner for Policy.*

BILLING CODE 4160-01-S

IMPLEMENTATION PLAN

**For
The Memorandum of Understanding
Regarding the Sharing and Exchange of Information
about Therapeutic Products**

**Between the
Food and Drug Administration
Department of Health and Human Services
of the United States of America**

**and the
Health Products and Food Branch
Health Canada
of Canada**

I. Introduction

On November 18, 2003, the Health Products and Food Branch (HPFB) of Health Canada and the U.S. Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services concluded a Memorandum of Understanding (MOU) and respective Confidentiality Commitments. The intent of this implementation plan is to confirm the necessary governance and management elements to facilitate cooperation and the successful exchange of otherwise not public information between FDA and HPFB in accordance with the terms of the MOU and respective Confidentiality Commitments. The duration of this implementation plan is the same as that of the MOU.

The specific objectives of this Implementation Plan are to establish: (a) a governance structure for directing and monitoring the implementation of the MOU; (b) clear process by which each party will undertake the exchange of otherwise not public information; and (c) the process for setting and monitoring mutually agreed upon annual priorities for cooperation.

II. Governance

In order to ensure the smooth implementation of the MOU, an appropriate governance structure is required. The agreed governance structure for the MOU includes Senior Officials, a Steering Committee, and Coordinators.

Senior Officials

The Assistant Deputy Minister of HPFB and the Deputy Commissioner for International and Special Programs of the FDA will meet as needed, but will hold one formal Senior Officials' Meeting in January of each year. Each country will host the meeting on an annual rotating basis (starting with Canada hosting the 2006 meeting and so on). The objectives of these meetings are to:

- review progress in the implementation of the MOU in the previous year;
- set priorities for the year; and
- if deemed necessary, host policy discussions with key senior managers from both organizations.

Steering Committee

The Steering Committee will be co-chaired by the Director General, Office of Regulatory and International Affairs (ORIA) of HPFB, and the Assistant Commissioner, Office of International Program (OIP) of the FDA. In addition to the above, the Steering Committee will consist of the:

- Director of International Affairs, ORIA, HPFB
- coordinator from each organization; and
- senior managers of the centres/directorates of both organizations as appropriate.

The Steering Committee will hold quarterly discussions (either in-person meetings, teleconferences or videoconferences). During the discussions, the presiding chair will be the co-chair from the country hosting the Senior Officials' Meeting. The key responsibilities of the Steering Committee are:

- Recommendation of an annual work plan with priorities and strategic directions to the Senior Officials.
- Management of significant issues arising from the implementation of the MOU and Confidentiality Commitments not adequately addressed by the Coordinators.
- Evaluation and communication of the MOU implementation.
- Discussion of any request for disclosure of non-public information to third parties prior to the release of such information. Clearly such discussion will need to occur on an ad hoc basis as the situations arise. These discussions will by necessity occur most often outside the routinely scheduled discussions of the committee.

Coordinators

Each organization will identify a **coordinator** to track and monitor the implementation of the MOU. The coordinators will be the **Senior Policy Analyst, International Affairs, ORIA of HPPFB**, and the **Associate Director for the Americas, OIP of the FDA**. The key responsibilities of the coordinators are to:

- Be the primary point of contact for each organization for all requests for non-public information to be shared or exchanged and for all other activities under the MOU (*see Section III*).
- Support, and provide advice to the Steering Committee and Senior Officials as required.
- Provide advice within their organization on what may or may not be exchanged under the auspices of the MOU (*see Section III*).
- Draft annual (calendar year) work plans with key priorities that will be presented for discussion at the Steering Committee, and ultimately presented for approval by Senior Officials.
- Create, within his/her own organization, a working group to help draft and monitor the implementation of the annual work plan as deemed appropriate.

III. Process for the Exchange of Otherwise Not Public Information

The process for the exchange of otherwise not public information will consist of the following three key elements:

3.1. The establishment of focal point of contacts

The coordinators are to be considered as the primary points of contact for all requests for otherwise not public information to be shared or exchanged and for all other activities under the MOU.

The main purpose of the focal points is to be able to track and monitor all non-public information exchanges (functionary) and to oversee the requests in order to assure they fall under the MOU and that they are handled procedurally in an appropriate manner (substantive) as stipulated in the procedures in *Section 3.2*.

3.2. The establishment of procedures for the exchange of information and documents

Procedures will be developed to ensure that all requests for otherwise not public information is shared or exchanged in accordance with the terms of the respective Confidentiality Commitments. These procedures will also:

- Delineate the steps for tracking priorities and activities.
- Confirm the officials in each organization who are able to authorize the sharing of non-public information.
- Identify key individuals within each organization who will be responsible, with the coordinators, for sharing non-public information.

3.3. *The establishment of an orientation session*

An orientation session will be established, and held on a regular basis to promote the goals and advantages of strengthening and the conditions for implementing regulatory cooperation between the two organizations. The session should be presented to the key officials from HPFB and the FDA who will be responsible for managing and coordinating the flow of information and work of the MOU. It will also address the general principles, responsibilities, and implications of the agreement, and the procedures highlighted in *Section 3.2*.

IV. **Process for Establishing and Monitoring Mutually Agreed-Upon Priorities for Cooperation**

The process for establishing mutual agreed-upon priorities for cooperation will include the following two elements:

4.1. *The establishment of annual work plan with priorities*

The Senior Officials will approve an annual (calendar year) work plan with key priorities based on the areas of cooperation highlighted in *Section V* during their meeting in January of each year (*see Section II*).

This work plan may include activities established by specific program areas through their own cooperation frameworks (e.g., draft cooperation frameworks on product quality (TPD/CDER) and on medical devices (TPD/CDRH)).

4.2. *The establishment of a tool to assess progress*

The Steering Committee (*see Section II*) will establish a tool for assessing results and performance of annual priorities and other cooperation under the MOU. The assessment will include a summary of achievements realized to date and identification of areas where further improvements can be made. Based on this assessment, consideration may be given to either broadening or narrowing the scope of interaction between the organizations.

V. Areas of Cooperation and Types of Activities

In accordance with the scope of the MOU, the annual priorities should focus on the following four areas of cooperation, which will be reviewed by the Senior Officials on a regular basis:

- pre-market product review (e.g., applications reviews);
- post-market product safety (e.g., pharmacovigilance, compliance and enforcement);
- regulatory and public health policy and approaches (e.g., regulations, international policy and emerging public health issues); and
- regulatory infrastructure (e.g., E-review, regulatory databases, procedures for sharing information under the MOU).

In general, the types of activities to be undertaken under the above-mentioned areas of cooperation will include:

A) *Information Exchange:*

Regular exchange:

Regularly scheduled sharing of agreed routine quantitative and qualitative information on applications (both pre- and post-authorization) and status of regulatory documents under development.

Ad-hoc exchange:


Ad-hoc exchanges, while they may not be predicted, can be important for specific issues arising. Regardless of their frequency, they should be tracked for accountability and performance measurement. Examples of these kinds of information that might be exchanged include encountered difficulties in evaluating applications, significant safety issues that arise pre- and post-marketing, and significant advisories and warnings.

B) *Scientific Meetings and Collaboration:*

Invitations to staff members of HPFB and FDA to attend each other's scientific meetings, including advisory committees, and training sessions will be extended to the extent possible. Staff exchanges to study respective review processes and joint projects will also be explored.

Signed at Ottawa, Ontario, Canada, on this 1st day of December 2005 in duplicate in the English language.

FOR THE FOOD AND DRUG ADMINISTRATION
DEPARTMENT OF HEALTH AND HUMAN SERVICES
OF THE UNITED STATES OF AMERICA



Murray M. Lumpkin, M.D.
Deputy Commissioner (International and Special Programs)

FOR THE HEALTH PRODUCTS AND FOOD BRANCH
HEALTH CANADA
OF CANADA



Diane C. Gorman
Assistant Deputy Minister

[FR Doc. 06-113 Filed 1-5-06; 8:45 am]
BILLING CODE 4160-01-C

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

Substance Abuse and Mental Health
Services Administration

Center for Substance Abuse
Treatment; Notice of Meeting

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the Center for Substance Abuse Treatment (CSAT) National Advisory Council in February 2006.

The meeting is open and will include discussion of the Center's policy issues, current administrative, legislative, and program developments.

Attendance by the public will be limited to space available. Public comments are welcome. Please communicate with the individual listed below as contact to make arrangements to comment or to request special accommodations for persons with disabilities.

Substantive program information and a roster of Council members may be obtained by accessing the SAMHSA Advisory Council Web site (<http://www.samhsa.gov>) after the meeting or by communicating with the contact whose name and telephone number are listed below. The transcript for the open session will also be available on the

SAMHSA Advisory Council Web site by February 27, 2005.

Committee Name: Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment National Advisory Council.

Meeting Dates: February 2-9 a.m.-5 p.m.; February 3-9 a.m.-1 p.m.

Place: 1 Choke Cherry Road, Sugar Loaf and Seneca Conference Rooms, Rockville, Maryland 20857.

Type: Open: February 2-9 a.m.-5 p.m.; Open: February 3-9 a.m.-1 p.m.

Contact: Cynthia Graham, M.S., Executive Secretary, SAMHSA/CSAT National Advisory Council, 1 Choke Cherry Road, Room 5-1036, Rockville, MD 20857, Telephone: (240) 276-1692, Fax: (240) 276-1690, E-mail: cynthia.graham@samhsa.hhs.gov.

Dated: December 28, 2005.

Toian Vaughn,

Committee Management Officer, Substance Abuse and Mental Health Services Administration.

[FR Doc. E6-7 Filed 1-5-06; 8:45 am]

BILLING CODE 4162-20-P

DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT

[Docket No. FR-5045-N-01]

Federal Property Suitable as Facilities
to Assist the Homeless

AGENCY: Office of the Assistant Secretary for Community Planning and Development, HUD.

ACTION: Notice.

SUMMARY: This Notice identifies unutilized, underutilized, excess, and surplus Federal property reviewed by HUD for suitability for possible use to assist the homeless.

EFFECTIVE DATE: January 6, 2006.

FOR FURTHER INFORMATION CONTACT: Kathy Ezzell, Department of Housing and Urban Development, Room 7262, 451 Seventh Street, SW., Washington, DC 20410; telephone (202) 708-1234; TTY number for the hearing- and speech-impaired (202) 708-2565, (these telephone numbers are not toll-free), or call the toll-free Title V information line at 1-800-927-7588.

SUPPLEMENTARY INFORMATION: In accordance with the December 12, 1988 court order in *National Coalition for the Homeless v. Veterans Administration*, No. 88-2503-OG (D.D.C.), HUD publishes a Notice, on a weekly basis, identifying unutilized, underutilized, excess and surplus Federal buildings and real property that HUD has reviewed for suitability for use to assist

the homeless. Today's Notice is for the purpose of announcing that no additional properties have been determined suitable or unsuitable this week.

Dated: December 29, 2005.

Mark R. Johnston,

Director, Office of Special Needs, Assistance Programs.

[FR Doc. 06-39 Filed 1-5-06; 8:45 am]

BILLING CODE 4210-29-M

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Receipt of an Application and Availability of an Environmental Assessment for an Incidental Take Permit for a Commercial Wind-Energy Project in Guayanilla, PR

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Notice.

SUMMARY: WindMar RE (Applicant) requests an incidental take permit (ITP) pursuant to section 10(a)(1)(B) of the Endangered Species Act of 1973 (U.S.C. 1531 *et seq.*), as amended (Act). The Applicant anticipates taking Puerto Rican nightjar (*Caprimulgus noctitherus*) (nightjar), brown pelican (*Pelecanus occidentalis occidentalis*), and roseate tern (*Sterna dougallii*), incidental to the construction and operation, over a 40-year term of a commercial wind-energy project in Punta Verraco, Cerro Toro, and Punta Ventana in Guayanilla, Puerto Rico (Project).

The Applicant's Habitat Conservation Plan (HCP) describes the mitigation and minimization measures proposed to address the effects of the Project on nightjars, brown pelicans, and roseate terns. These measures are described further in the **SUPPLEMENTARY INFORMATION** section below. The Service announces the availability of the HCP and our Environmental Assessment (EA) for the incidental take permit application. Copies of the HCP and EA may be obtained by making a request to the Regional Office (see **ADDRESSES**). Requests must be in writing to be processed. This notice is provided pursuant to section 10 of the Endangered Species Act and National Environmental Policy Act regulations (40 CFR 1506.6).

DATES: Written comments on the permit application, EA, and HCP should be sent to the Service's Regional Office (see **ADDRESSES**) and should be received on or before March 7, 2006.

ADDRESSES: Persons wishing to review the application, HCP, and EA may obtain copies by writing the Service's Southeast Regional Office, Atlanta, Georgia. Documents will also be available for public inspection by appointment during normal business hours at the Regional Office, 1875 Century Boulevard, Suite 200, Atlanta, Georgia 30345 (Attn: Endangered Species Permits), or Caribbean Field Office, U.S. Fish and Wildlife Service, Road 301 Km. 5.1, P.O. Box 491, Boquerón, Puerto Rico 00622. Written data or comments concerning the application, supporting documentation, EA, or HCP should be submitted to the Regional Office. Requests for the documentation must be in writing to be processed. Comments must be submitted in writing to be adequately considered in the Service's decision-making process.

FOR FURTHER INFORMATION CONTACT: Mr. David Dell, Regional Permit Coordinator, (see **ADDRESSES** above), telephone: 404/679-7313; or Ms. Marelisa Rivera, Fish and Wildlife Biologist, Boquerón Field Office, (see **ADDRESSES** above), telephone: 787/851-7297, extension 231.

SUPPLEMENTARY INFORMATION: If you wish to comment, you may submit comments by any one of several methods. Please reference permit number TE104073-0 in such comments. You may mail comments to the Service's Regional Office (see **ADDRESSES**). You may also comment via the internet to david_dell@fws.gov. Please submit comments over the internet as an ASCII file avoiding the use of special characters and any form of encryption. Please also include your name and return address in your internet message. If you do not receive a confirmation from the Service that we have received your Internet message, contact us directly at either of the telephone numbers listed below (see **FOR FURTHER INFORMATION CONTACT**). Finally, you may hand deliver comments to either of the Service offices listed above, (see **ADDRESSES**). Our practice is to make comments, including names and home addresses of respondents, available for public review during regular business hours. Individual respondents may request that we withhold their home address from the administrative record. We will honor such requests to the extent allowable by law. There may also be other circumstances in which we would withhold from the administrative record a respondent's identity, as allowable by law. If you wish us to withhold your name and address, you must state this

prominently at the beginning of your comments. We will not, however, consider anonymous comments. We will make all submissions from organizations or businesses, and from individuals identifying themselves as representatives or officials of organizations or businesses, available for public inspection in their entirety.

The endangered nightjar is an endemic bird of Puerto Rico belonging to the family Caprimulgidae. This insectivorous and nocturnal bird nests from late February through early July, but the peak period is from April to June. The nightjar does not construct a nest, but rather the eggs are laid directly on leaf litter under vegetation having a canopy 4 to 6 m (13 to 20 feet) in height. The species is presently found in the dry limestone forests of the southwestern coast of Puerto Rico, and in the lower cordillera forest in Susúa area. The species' current distribution includes the Peñones de Melones area in Cabo Rojo, the Sierra Bermeja forested hills in Cabo Rojo-Lajas area, the Guánica—Yauco area including the Guánica Commonwealth Forest, the Guayanilla—Peñuelas hills, Ponce, and Susúa-Maricao area including the Susúa Commonwealth Forest. Approximately 712 singing male nightjars have been estimated in 9,839 ha (24,598 acres) in Susúa, Guánica and Guayanilla. The species is threatened by habitat modification and destruction for urban, industrial, and tourism development, and by predation by exotic species such as mongoose (*Herpestes auropunctatus*) and cats (*Felis catus*).

The Applicant conducted an intensive study of the Puerto Rican nightjar during the 2003 and 2004 breeding seasons and recorded approximately 33 singing male nightjars in 2003, and approximately 42 singing male nightjars in 2004, both studies conducted on 250 hectares (625 acres) of dry forest.

The brown pelican is found along North American coasts from California through Mexico, around the Gulf of Mexico, and through North Carolina, as well as the West Indies, many Caribbean islands, and Guyana and Venezuela in South America. It is considered endangered throughout its range, except on the U.S. Atlantic coast and the Gulf coast of Florida and Alabama.

Brown pelicans nest in colonies, mostly on small coastal islands. In Puerto Rico, brown pelicans have nested in Añasco, Cayo Frío (Lajas), Cayo Don Luis (Guánica), Cayo Conejo (Vieques), Montalva Bay (Guánica-Parguera), Aguadilla, Guanajibo (Mayagüez), Cayo Ratonés (Cabo Rojo), Cayos Fríos (Ponce), and Cayo Morrillito (Ponce). In the U.S. Virgin Islands, brown pelicans

nest in Dutch Cap Cay (St. Thomas), Congo Cay (St. John), Mary Point (St. John), Whistling Key (St. John), Buck Island (St. Croix), and Green Cay (St. Croix). In the U.S. Caribbean, the species is threatened by low food abundance; die-offs; poaching of eggs, young, and adults; human disturbance of nesting colonies; entanglement in fishing gear; and loss or degradation of coastal forests.

The Applicant conducted pelican censuses at Guayanilla Bay, and a study on flight patterns of pelicans through the project site. Based on the study's results, brown pelicans use the wind to move as effortlessly as possible near the project site. The pelican's predominant flight pattern is along the immediate coast, where there are updrafts. To enter Guayanilla Bay, where they roost and feed, pelicans use three principal routes: (1) Around the tip of the peninsula (2.2 birds/hr), (2) gliding "downhill" out of the updraft elevator at Cerro Toro (1.4 birds/hr), and (3) at any point across the main part of the peninsula (0.2 birds/hr, but at 0.06 birds/hr at rotor height). Departing Guayanilla Bay for the Caribbean, where they also feed, most pelicans go around the peninsula tip (3.9 birds/hr), but some birds cross the main part of the peninsula (0.1 birds/hr, 0.08 birds/hr at rotor height) and some use the Cerro Toro crossing (0.1 birds/hr). Based on observations at Cerro Toro and Punta Verraco, observers have estimated that it is likely that between 12 and 20 pelicans regularly fly and feed around the project site. Surveys of Guayanilla Bay and adjacent areas have recorded as many as 100 individuals, though half this number or less at the study period.

The roseate tern is a migratory species that is listed as threatened in the Caribbean. This species is distributed throughout the Caribbean, with the largest populations occurring in the Lesser Antilles. In general, roseate terns in the Caribbean begin egg laying in May, and have downy chicks in June which fledge in July. Roseate terns breed primarily on small offshore islands, rocks, cays, and islets. Roseate terns have been reported nesting near vegetation or jagged rock, on open sandy beaches, close to waterline on narrow ledges of emerging rocks, or among coral rubble. Total population numbers are not known, but between 3,000 and 6,000 breeding pairs have been estimated for the Caribbean region. It has been suggested that eggging, human disturbance, predation, and netting of adults in Guyana, South America, are the main factors affecting the Caribbean roseate tern. The Applicant did not record roseate terns during its flight-use

study or in recent years. We have recorded the nesting of this species (four times in fourteen years) on Cayo Guayanilla, a small coral islet 600 m (2,000 feet) south of the tip of Punta Verraco peninsula.

The Project would erect twenty-five 1.65 megawatt (MW) wind turbines on Punta Verraco, Cerro Toro, and Punta Ventana, the site's three upland areas. The widening of 8.7 kilometers (km) (5.4 miles) of existing roads, siting of 1.4 km (0.87 mile) of new roads, and preparation of construction areas to erect the wind turbines would affect a maximum of 12.2 ha (30.6 acres) of dry forest (4.2 percent of the entire property, and 4.9 percent of the property's dry forest). Incidental to affecting a maximum of 12.2 ha (30.6) the Project would permanently eliminate 1.7 ha (4.3 acres) of nightjar habitat and cause the temporary loss of 10.5 ha (26.3 acres) of nightjar habitat, and may result in harm of 12 nightjar singing territories. The operation of the wind-energy project may result in mortality of one brown pelican every 5 years, and one roseate tern every 20 years. No mortality of nightjars is anticipated from collisions with operating wind turbines.

Under section 9 of the Act and its implementing regulations, "taking" of endangered and threatened wildlife is prohibited. However, the Service, under limited circumstances, may issue permits to take such wildlife, if the taking is incidental to and not the purpose of otherwise lawful activities. The Applicant has developed an HCP as required for their incidental take permit application.

The HCP describes measures the Applicant will take to avoid, minimize and mitigate taking at the Project site. To avoid impacts to nightjars from construction activities the Applicant will clear the vegetation outside of the nightjar nesting season. However, in emergency situations, if vegetation needs to be cleared during the nesting season, the Applicant will use experienced and qualified biologists to search for nightjar nests before any clearing activity is conducted. In the event that nests are found, the Applicant will avoid them by redesigning the road or construction area, or by delaying the activity until the nightjars fledge their young.

To minimize impacts to listed species from construction and operation of the project, the Applicant will:

1. Widen and use 8.7 km (5.4 miles) of existing roads rather than constructing the needed 10.1 km (6.18 miles) of roads along entirely new alignments.

2. Use fewer, larger turbines rather than a greater number of smaller turbines.

3. Clear vegetation using small to midsize bulldozers to scrape the vegetation at the surface and leave the rootstalks intact to encourage regrowth.

4. Paint rotor blades to make them more visible to birds.

5. Establish a predator control program. The Applicant will institute a permanent program to trap mongoose, rats, and feral animals on the site in order to decrease predation pressure on the nightjars, the dry forest lizard (*Anolis cooki*), and other native animals.
6. Establish roads as fire brakes. The Applicant will maintain access roads to the wind turbines as fire brakes to decrease the threat of fire to the nightjar and its habitat.

7. Implement Avian Power Line Interaction Committee (APLIC) guidelines. The Applicant will bury all electrical transmission lines on the site out to PR-335, where they will run aboveground along existing transmission line poles to the Puerto Rico Electric Power Authority (PREPA) substation.

To mitigate the effects of permanently eliminating 1.7 ha (4.3 acres) of nightjar habitat and causing the temporary loss of 10.5 ha (26.3 acres) that would result in take of 12 nightjar singing male territories, the take of one brown pelican every 5 years, and the take of one roseate tern every 20 years, the Applicant will:

1. Establish a conservation easement on 245 ha (612.5 acres) of the Project site. The Applicant will grant a conservation easement that protects 85 percent of the Project site. The conservation easement will compensate for Project impacts at a rate of approximately 17 acres conserved to 1 acre of direct impact. The easement is being drafted in accordance with a law approved on December 27, 2001, by the Legislature of the Commonwealth of Puerto Rico (Law Number 183, Puerto Rico Conservation Law). The easement will be offered to a qualifying non-profit organization.

2. Restore at least 2.6 ha (6.5 acres) of the 3.1 ha (7.8 acres) of the previous Texaco quarry at the base of Punta Verraco with dry forest vegetation. This activity will restore 21 percent of the dry forest lost due to construction impacts. This restoration will fill in a key habitat gap at the base of the Verraco peninsula, allowing nightjars to establish territories in an area that is presently too fragmented for viable territories to be established. This restoration may allow for two or more additional nightjar territories, once dry

forest with good structure has been established.

3. Restore a 10-hectare (25-acre) mangrove area by improving drainage. The Applicant will restore this mangrove area destroyed by the construction of the causeway to Punta Verraco and subsequent silting in of its culverts. This restoration will likely improve foraging resources for the endangered brown pelican and threatened roseate tern.

4. Support brown pelican research. The Applicant will contract with experts and scientists to work with pelican biologists to develop a research program that meets the priorities identified in studies conducted by the Applicant and in the species recovery plan. The Applicant will provide a \$100,000 grant to accomplish the actions prioritized in the research program.

5. Establish an environmental education program. The Applicant will educate visitors about renewable energy and the plants and wildlife of southwest Puerto Rico. The Applicant will control site access, schedule visiting hours, and lead visitors on regularly scheduled tours. The Applicant will produce a brochure to be handed out in schools, community centers, and hotels. The Applicant will also finance environmental education projects in surrounding communities. One priority project will be to educate residents and tourists about the marine environment and the measures required to improve its health. This project will focus on the plight of the brown pelican. In addition, the Applicant will provide facilities at the Ventana beach area for local visitors, including an informational kiosk with environmental education materials.

The Service has made a preliminary determination that the ITP is not a major Federal action significantly affecting the quality of the human environment, within the meaning of section 102(2)(C) of NEPA. This preliminary information may be revised due to public comments received in response to this notice, and it is based on information contained in the EA and HCP.

The Service will evaluate the HCP and comments submitted thereon, to determine whether the application meets the issuance criteria requirements of section 10(a)(1)(B) of the Act. By conducting an intra-Service section 7 consultation, the Service will also evaluate whether issuance of the section 10(a)(1)(B) ITP would comply with section 7 of the Act. The results of this consultation, in combination with the above findings, will be used in the final analysis to determine whether or not to

issue the ITP for the nightjar, the brown pelican, and the roseate tern.

Dated: December 12, 2005.

Cynthia K. Dohner,

Acting Regional Director, Southeast Region.

[FR Doc. E6-8 Filed 1-5-06; 8:45 am]

BILLING CODE 4310-55-P

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[AZ 210-05-1610-DP-081A-241E]

Notice of Availability of Agua Fria National Monument and Bradshaw-Harquahala Draft Resource Management Plan and Draft Environmental Impact Statement

AGENCY: Bureau of Land Management, Department of the Interior.

ACTION: Notice of availability of Agua Fria National Monument and Bradshaw-Harquahala Draft Resource Management Plan and Draft Environmental Impact Statement.

SUMMARY: In compliance with the Bureau of Land Management (BLM) planning regulations, Title 43 Code of Federal Regulations (CFR) 1610.2(f)(3) and the National Environmental Policy Act (NEPA) Regulations, Title 40 CFR 1502.9(a), the BLM hereby gives notice that the Agua Fria National Monument and Bradshaw-Harquahala Draft Resource Management Plan and Draft Environmental Impact Statement (DRMP/DEIS) is available for public review and comment. The National Monument encompasses 71,000 acres, and the Bradshaw-Harquahala planning area includes another 895,900 acres of the BLM-administered lands.

DATES: Written comments on the DRMP/DEIS will be accepted for 90 days following the date the Environmental Protection Agency publishes the Notice of Availability in the *Federal Register*. Future meetings or hearings and any other public involvement activities will be announced at least 15 days in advance through local media.

ADDRESSES: Written comments may be mailed to Teri Raml, Phoenix Field Manager, Agua Fria National Monument and Bradshaw-Harquahala Resource Management Plan, Phoenix Field Office, 21605 North 7th Avenue, Phoenix, Arizona 85027. You may also comment via the Internet using the comment tool of the interactive document, which can be accessed from a link on the Arizona Bureau of Land Management web page at <http://www.az.blm.gov>. Please submit Internet comments using this comment tool. The comment tool requires

entering your name and address for comment submission. If you do not receive a confirmation from the system that we have received your Internet message, contact Chris Horyza at (623) 580-5500. Finally, you may hand-deliver comments to the address listed above. Oral comments will be accepted and recorded at any of seven public meetings to be held within 90 days of publication of this Notice. Exact dates, places, and times of public meetings will be posted on the Arizona BLM web page, or you may contact Chris Horyza at (623) 580-5500 for further information.

Public comments, including names and street addresses of respondents, will be available for public review at, Bureau of Land Management, 21605 North 7th Avenue, Phoenix, Arizona 85027 during regular business hours (7:30 a.m. to 4:25 p.m.), Monday through Friday, except holidays. Individual respondents may request confidentiality. If you wish to withhold your name or street address from public review or from disclosure under the Freedom of Information Act, you must state this prominently at the beginning of your comments. Such requests will be honored to the extent allowed by law. All submissions from organizations or businesses, and from individuals identifying themselves as representatives or officials of organizations or businesses, will be made available for public inspection in their entirety.

FOR FURTHER INFORMATION CONTACT: Chris Horyza, Bureau of Land Management, 21605 North 7th Avenue, Phoenix, Arizona 85027; telephone (623) 580-5500.

SUPPLEMENTARY INFORMATION: A copy of the Agua Fria National Monument and Bradshaw-Harquahala Draft Resource Management Plan and Draft Environmental Impact Statement is available for review via the internet from a link at <http://www.az.blm.gov> (subject to change); electronic (on CD-ROM) and paper may be obtained from the Bureau of Land Management, Phoenix Field Office. Electronic (on CD-ROM) and paper copies may also be obtained by contacting Chris Horyza at the aforementioned address and telephone number. The Agua Fria National Monument and Bradshaw-Harquahala Draft Resource Management Plan and Draft Environmental Impact Statement is being developed by BLM. The DRMP/DEIS includes strategies for protecting and preserving the biological, cultural, recreational, geological, educational, scientific, and scenic values that the Monument was established to protect, and strategies

that balance multiple uses of the BLM-administered lands in the Bradshaw-Harquahala planning area. The preferred alternative attempts to accomplish the above while achieving consistency between Forest Service, Arizona State Land Department, Arizona Game and Fish Department, the BLM, and other land managing agencies within the boundaries of both planning areas. The range of alternatives in this draft evaluates planning decisions brought forward from the current BLM planning documents, including the Lower Gila North Management Framework Plan and the Phoenix Resource Management Plan.

The preferred alternative identifies four potential Areas of Critical Environmental Concern (ACEC): Tule Creek ACEC, 640 acres to protect wildlife, riparian, and cultural resources; Vulture Mountain ACEC, 6,120 acres to protect high value raptor nesting habitat; Black Butte Outstanding Natural Area (ONA) ACEC, 8,260 acres to protect high value raptor nesting sites, rare cultural resources, and scenic values; and Harquahala Mountains ONA ACEC, 74,950 acres to protect unique biological assemblages, high value cultural resources, and outstanding scenic and primitive landscapes. The following types of use limitations would generally apply: (1) Except for Tule Creek, areas would be closed to mineral material disposal but open to other types of mineral development. Tule Creek would be withdrawn from all mineral development; (2) recreation uses would generally be dispersed and undeveloped and may be limited by season or location if ACEC values are threatened; (3) motorized and mechanized travel would be limited to designated routes; (4) vehicle routes that threaten ACEC values would be mitigated or closed; (5) visual resources would be allocated to VRM Class II. For detailed information, see the Special Area Designations sections of Chapter 2.

Records of Decision will be prepared by the BLM for the Agua Fria National Monument Resource Management Plan and the Bradshaw-Harquahala Resource Management Plan in accordance with planning regulations 43 CFR part 1610 and NEPA at 40 CFR part 1502. The Agua Fria National Monument was established by Presidential Proclamation 7263 in January 2000. The Agua Fria National Monument Proclamation of 2000 affects only Federal lands and Federal interests located within the established boundaries.

Dated: September 9, 2005.

Elaine Y. Zielinski,
Arizona State Director.
[FR Doc. 06-115 Filed 1-5-06; 8:45 am]
BILLING CODE 4310-32-M

INTERNATIONAL TRADE COMMISSION

[USITC SE-06-001]

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: United States International Trade Commission.

TIME AND DATE: January 13, 2006 at 1 p.m.

PLACE: Room 101, 500 E Street, SW., Washington, DC 20436, Telephone: (202) 205-2000.

STATUS: Open to the public.

MATTERS TO BE CONSIDERED:

1. Agenda for future meetings: None.
2. Minutes.
3. Ratification List.
4. Inv. Nos. 701-TA-302 and 731-TA-454 (Second Review) (Fresh and Chilled Atlantic Salmon from Norway)—briefing and vote. (The Commission is currently scheduled to transmit its determination and Commissioners' opinions to the Secretary of Commerce on or before January 27, 2006.)
5. *Outstanding action jackets:* None. In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting.

By order of the Commission.

Issued: January 3, 2006.

Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. 06-165 Filed 1-4-06; 12:53 pm]
BILLING CODE 7020-02-P

NUCLEAR REGULATORY COMMISSION

[Docket No. 72-17; License No. SNM-2509]

In the Matter of PacifiCorp (Trojan Nuclear Plant Independent Spent Fuel Storage Installation); Order Approving Application Regarding Proposed Acquisition Indirect Transfer of Materials License SNM-2509

I

By application dated June 30, 2005, and supplemented on August 12, 2005, PacifiCorp, together with PacifiCorp Holdings, Inc., and MidAmerican Energy Holdings Company (MEHC), requested approval of the indirect

transfer of control of Materials License No. SNM-2509 for the Trojan Independent Spent Fuel Storage Installation (ISFSI), with regard to PacifiCorp's 2.5 percent interest in the Trojan ISFSI, to MEHC. PacifiCorp is a non-operating licensee of the Trojan ISFSI, and will continue to hold the license. The request was in connection with the sale of PacifiCorp, which will become an indirect wholly-owned subsidiary of MEHC. The supplemental letter cited above did not expand the scope of the application beyond that noticed in the *Federal Register* on July 27, 2005 (70 FR 43461).

The U.S. Nuclear Regulatory Commission (NRC) 10 CFR Part 50 license for the Trojan Nuclear Plant (License No. NPF-1) was terminated on May 23, 2005, after completion of the radiological decommissioning of the nuclear plant. The Trojan ISFSI holds spent fuel from the former Trojan Nuclear Plant.

PacifiCorp is a wholly owned subsidiary of PacifiCorp Holdings, Inc. (PHI), which in turn is an indirect, wholly-owned subsidiary of Scottish Power, plc. PacifiCorp will be sold to PPW, LLC, a Delaware limited liability corporation and a wholly-owned subsidiary of MEHC. The name of the MEHC subsidiary that will acquire PacifiCorp was changed from NWQ Holdings, LLC to PPW Holdings, LLC. PacifiCorp operates an electric utility in six western states of the United States, serving approximately 1.6 million retail customers with annual revenues of approximately \$3 billion per year. PacifiCorp will remain an electric utility after the sale to MEHC.

MEHC, a global electric and natural gas utility operating in the United States, the United Kingdom, and the Philippines, serves approximately 4.4 million electric customers and 680,000 natural gas customers. Its annual operating revenue is approximately \$6.5 billion.

MEHC will purchase all the outstanding shares of PacifiCorp from PHI for a value of approximately \$9.4 billion, consisting of approximately \$5.1 billion in cash and approximately \$4.3 billion in net debt and preferred stock which will remain outstanding at PacifiCorp.

The Trojan ISFSI is jointly owned by three licensees: Portland General Electric Company (PGE) (67.5%); Eugene Water & Electric Board (30%); and PacifiCorp (2.5%). PGE has always been the sole operator of the Trojan ISFSI and will remain the sole operator. The Eugene Water & Electric Board and PacifiCorp are non-operating licensees. PacifiCorp has no right of access to the

ISFSI. No physical changes will occur to the Trojan ISFSI as a result of the change in ownership of PacifiCorp. Thus, both the management and operation of the ISFSI will remain unchanged.

II

The applicant requested approval of the indirect transfer of the Trojan ISFSI license, to the extent held by PacifiCorp, to MEHC, pursuant to 10 CFR 72.50(a) which states:

No license or any part included in a license issued under this part for an ISFSI [Independent Spent Fuel Storage Installation] or MRS [Monitored Retrievable Storage Installation] shall be transferred, assigned, or in any manner disposed of, either voluntarily or involuntarily, directly or indirectly, through transfer of control of the license to any person, unless the Commission gives its consent in writing.

The Commission will approve an application for the indirect transfer of a license, if, after appropriate notice and observance of required procedures, the Commission determines that: (1) The underlying transaction effecting the indirect transfer will not affect the qualifications of the holder of the license; and (2) the indirect transfer of the license is consistent with applicable provisions of the law, and the regulations and orders issued by the Commission.

Upon review of the information in the application, and other information before the Commission, the NRC staff has determined that MEHC's proposed purchase of all the outstanding shares of PacifiCorp from PHI will not affect the qualifications of PacifiCorp as holder of Materials License No. SNM-2509, and that the indirect transfer of the license, to the extent effected by the proposed acquisition, is otherwise consistent with applicable provisions of law, regulations, and orders issued by the Commission, subject to the conditions set forth herein. These findings are supported by "Safety Evaluation by the Office of Nuclear Materials Safety and Safeguards, PacifiCorp, Trojan Independent Spent Fuel Storage Installation, Docket No. 72-17," dated October 27, 2005.

III

In view of the foregoing, the Commission finds that the acquisition of PacifiCorp by MEHC will not affect the qualifications of PacifiCorp to hold the Trojan ISFSI Materials License to the extent now held by PacifiCorp, and the indirect transfer of control of the license to MEHC is otherwise consistent with the applicable provisions of law,

regulations, and orders issued by the Commission pursuant thereto.

Accordingly, pursuant to Sections 161b, 161i, 161o, and 184 of the Atomic Energy Act of 1954, as amended (the Act), 42 U.S.C. 2201(b), 2201(i), 2201(o), and 2234; and 10 CFR 72.50, *it is hereby ordered* that the application regarding the indirect license transfer related to the proposed acquisition is approved, subject to the following conditions:

(1) PacifiCorp shall provide the Director of the Office of Nuclear Material Safety and Safeguards a copy of any application, at the time it is filed, to transfer (excluding grants of security interests or liens) from PacifiCorp to its direct or indirect parent, or to any affiliated company, facilities for the production, transmission, or distribution of electric energy having a depreciated book value exceeding 10 percent (10%) of PacifiCorp's net utility plant, as recorded on its books of account.

(2) Should the proposed indirect license transfer not be completed by December 31, 2006, this Order shall become null and void, provided, however, upon application and for good cause shown, such a date may be extended.

This Order is effective upon issuance.

For further details with respect to this Order, see the application dated June 30, 2005, and supplement dated August 12, 2005, and the safety evaluation report dated October 27, 2005, which are available for public inspection at the Commission's Public Document Room (PDR), located at One White Flint North, Public File Area O1 F21, 11555 Rockville Pike (first floor), Rockville, Maryland. Publicly available records will be accessible electronically from the Agencywide Documents Access and Management System's (ADAMS) Public Electronic Reading Room on the Internet at the NRC Web site, <http://www.nrc.gov/reading-rm/adams.html>. Persons who do not have access to ADAMS or who encounter problems in accessing the documents located in ADAMS, should contact the NRC PDR Reference staff by telephone at 1-800-397-4209, 301-415-4737 or by e-mail to pdr@nrc.gov.

Dated at Rockville, Maryland this 29th day of December, 2005.

For the Nuclear Regulatory Commission.

Robert C. Pierson,

Acting Director, Office of Nuclear Material Safety and Safeguards.

[FR Doc. E6-9 Filed 1-5-06; 8:45 am]

BILLING CODE 7590-01-P

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-53040; File No. SR-CBOE-2005-116]

Self-Regulatory Organizations; Chicago Board Options Exchange, Incorporated; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Extend a Pilot Program Relating to Electronic DPMs and Affiliated Market-Makers

December 28, 2005.

Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 ("Act"),¹ and Rule 19b-4 thereunder,² notice is hereby given that on December 23, 2005, the Chicago Board Options Exchange, Incorporated ("Exchange" or "CBOE") filed with the Securities and Exchange Commission ("Commission") the proposed rule change as described in Items I and II below, which Items have been prepared by the Exchange. The Exchange filed the proposal as a "non-controversial" proposed rule change pursuant to Section 19(b)(3)(A)(iii) of the Act³ and Rule 19b-4(f)(6) thereunder.⁴ The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.

I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

CBOE proposes to extend the pilot allowing Electronic DPMs ("e-DPMs") to have up to one affiliated Market-Maker trade in classes assigned to the e-DPM. The text of the proposed rule change is available on the Exchange's Web site (<http://www.cboe.com>), at the Exchange's Office of the Secretary, and at the Commission.

II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, the CBOE included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of those statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant parts of such statements.

¹ 15 U.S.C. 78s(b)(1).

² 17 CFR 240.19b-4.

³ 15 U.S.C. 78s(b)(3)(A)(iii).

⁴ 17 CFR 240.19b-4(f)(6).

A. Self-Regulatory Organization's Statement of the Purpose of, and the Statutory Basis for, the Proposed Rule Change

1. Purpose

The Exchange proposes to amend CBOE Rule 8.93(vii) to extend the pilot program allowing an e-DPM the option to have up to one separate affiliated Market-Maker physically present in the trading crowds where it operates as an e-DPM (such Market-Makers would be required to trade on a separate membership). The pilot would be extended from January 12, 2006 until September 14, 2006.

In July of 2004, the SEC approved File No. SR-CBOE-2004-24, which established the e-DPM program, including the pilot program.⁵ The pilot allows e-DPM firms to maintain a physical presence in the trading crowd through an affiliated Market-Maker, who would also be able to electronically stream a quote. The pilot, however, limits the number of separate affiliates per trading crowd to one.

CBOE will be sending the Commission, under separate cover, data relating to: (1) The size of the orders that e-DPM's and affiliated Market-Makers both trade with electronically; (2) the price and size of the e-DPM's and the affiliated Market-Maker's respective quotes; (3) the price and size of quotes of other participants in the classes where an e-DPM and an affiliate are quoting; and (4) a breakdown of how orders are allocated to the e-DPM, the affiliated Market-Maker, and any other participants.

The date chosen to extend the pilot program corresponds with the ending date of a matching pilot program for Remote Market-Makers (RMMs) found in CBOE Rule 8.4(c)(i). Thus, the date chosen would allow the Commission to evaluate both pilot programs simultaneously.

2. Statutory Basis

CBOE believes the proposed rule change is consistent with the Act and the rules and regulations under the Act applicable to a national securities exchange and, in particular, the requirements of Section 6(b) of the Act.⁶ Specifically, the Exchange believes the proposed rule change is consistent with the Section 6(b)(5)⁷ requirements that the rules of an exchange be designed to promote just and equitable principles of

trade, and to protect investors and the public interest.

B. Self-Regulatory Organization's Statement on Burden on Competition

CBOE does not believe that the proposed rule change will impose any burden on competition not necessary or appropriate in furtherance of the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others

The Exchange neither solicited nor received comments on the proposal.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

Because the foregoing proposed rule does not (i) significantly affect the protection of investors or the public interest; (ii) impose any significant burden on competition; and (iii) become operative for 30 days from the date on which it was filed, or such shorter time as the Commission may designate if consistent with the protection of investors and the public interest, provided that the Exchange has given the Commission written notice of its intent to file the proposed rule change at least five business days prior to the date of filing of the proposed rule change or such shorter time as designated by the Commission, the proposed rule change has become effective pursuant to Section 19(b)(3)(A) of the Act⁸ and Rule 19b-4(f)(6) thereunder.⁹ At any time within 60 days of the filing of such proposed rule change, the Commission may summarily abrogate such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act.

Under Rule 19b-4(f)(6)(iii) of the Act,¹⁰ the proposal does not become operative for 30 days after the date of its filing, or such shorter time as the Commission may designate if consistent with the protection of investors and the public interest. The Exchange has requested that the Commission accelerate the 30-day operative date and waive the five day pre-filing requirement. The Commission, consistent with the protection of investors and the public interest, has determined to accelerate the 30-day operative date and waive the five day

pre-filing requirement, so that the e-DPM pilot program may continue without interruption.¹¹

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:

Electronic Comments

- Use the Commission's Internet comment form (<http://www.sec.gov/rules/sro.shtml>); or
- Send an e-mail to rule-comments@sec.gov. Please include File Number SR-CBOE-2005-116 on the subject line.

Paper Comments

- Send paper comments in triplicate to Jonathan G. Katz, Secretary, Securities and Exchange Commission, 100 F Street, NE., Washington, DC 20549-9303.

All submissions should refer to File Number SR-CBOE-2005-116. This file number should be included on the subject line if e-mail is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's Internet Web site (<http://www.sec.gov/rules/sro.shtml>). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Section, 100 F Street, NE., Washington, DC 20549. Copies of such filing also will be available for inspection and copying at the principal office of the CBOE. All comments received will be posted without change; the Commission does not edit personal identifying information from submissions. You should submit only information that you wish to make available publicly. All submissions should refer to File Number SR-CBOE-2005-116 and

⁵ See Securities Exchange Act Release No. 50003 (July 12, 2004), 69 FR 43028 (July 19, 2004).

⁶ 15 U.S.C. 78f(b).

⁷ 15 U.S.C. 78f(b)(5).

⁸ 15 U.S.C. 78s(b)(3)(A).

⁹ 17 CFR 240.19b-4(f)(6).

¹⁰ 17 CFR 240.19b-4(f)(6)(iii).

¹¹ For purposes only of accelerating the 30-day operative period for this proposal, the Commission has considered the proposed rule's impact on efficiency, competition, and capital formation. 15 U.S.C. 78c(f).

should be submitted on or before January 27, 2006.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.¹²

Jonathan G. Katz,

Secretary.

[FR Doc. E6-19 Filed 1-5-06; 8:45 am]

BILLING CODE 8010-01-P

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-53044; File No. SR-CBOE-2005-114]

Self-Regulatory Organizations; Chicago Board Options Exchange, Incorporated; Notice of Filing and Immediate Effectiveness of Proposed Rule Change and Amendment No. 1 Thereto Relating to Extension of the Prospective Fee Reduction and DPM Linkage Fee Credit Programs

December 30, 2005.

Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 ("Act")¹ and Rule 19b-4 thereunder,² notice is hereby given that on December 16, 2005, the Chicago Board Options Exchange, Incorporated ("CBOE" or "Exchange") filed with the Securities and Exchange Commission ("Commission") the proposed rule change as described in Items I, II, and III below, which Items have been prepared by the Exchange. On December 22, 2005, CBOE filed Amendment No. 1 to the proposed rule change.³ CBOE has designated this proposal as one establishing or changing a due, fee, or other charge imposed by a self-regulatory organization pursuant to Section 19(b)(3)(A) of the Act,⁴ and Rule 19b-4(f)(2) thereunder,⁵ which renders the proposal effective upon filing with the Commission. The Commission is publishing this notice to solicit comments on the proposed rule change, as amended, from interested persons.

I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

CBOE proposes to amend its Fees Schedule to extend through January 31, 2006 the Prospective Fee Reduction Program and the DPM Linkage Fees Credit Program. The text of the

proposed rule change is available on CBOE's Web site, <http://www.cboe.com>, at CBOE's principal office, and at the Commission's Public Reference Room.

II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, CBOE included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposal. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and the Statutory Basis for, the Proposed Rule Change

1. Purpose

The Exchange proposes to extend two Exchange-fee related programs through the end of January 2006: The Prospective Fee Reduction Program and the DPM Linkage Fees Credit Program.⁶ Each program is currently due to expire at the end of 2005. The Exchange has determined to extend each of these programs for an additional month because the Exchange's 2006 budget is expected to be approved in January 2006.

Prospective Fee Reduction Program. The Exchange proposes to continue the Prospective Fee Reduction Program ("PFRP") through January 31, 2006. No other changes to the PFRP are proposed. The current PFRP took effect on August 1, 2004.⁷ The PFRP is intended to reduce Market-Maker and DPM transaction fees in periods of high volume. The Exchange will determine as part of its annual budget review process whether the PFRP should be continued, modified or eliminated in the future. Any proposed changes to the PFRP would be filed with the Commission.

DPM Linkage Fees Credit Program. The Exchange proposes to continue the DPM Linkage Fees Credit Program ("Linkage Fees Credit") through January 31, 2006. No other changes to the Linkage Fees Credit are proposed. The Linkage Fees Credit took effect on

February 2, 2004 and was amended twice.⁸ The Linkage Fees Credit is a program that credits DPMs for transaction fees they incur related to the execution of outbound P/A orders, as defined in the Plan for the Purpose of Creating and Operating an Intermarket Option Linkage, to assist DPMs in offsetting the additional costs they incur in routing orders to other exchanges in order to obtain the National Best Bid or Offer. The Exchange will determine as part of its annual budget review process whether the Linkage Fees Credit should be continued, modified or eliminated in the future. Any proposed changes to the Linkage Fees Credit would be filed with the Commission.

2. Statutory Basis

The Exchange believes that the proposed rule change is consistent with Section 6(b) of the Act⁹ in general, and furthers the objectives of Section 6(b)(4) of the Act¹⁰ in particular, in that it is designed to provide for the equitable allocation of reasonable dues, fees, and other charges among its members.

B. Self-Regulatory Organization's Statement on Burden on Competition

CBOE believes that the proposed rule change would impose no burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others

CBOE did not solicit or receive any written comments with respect to the proposal.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

The foregoing proposed rule change has been designated as a fee change pursuant to Section 19(b)(3)(A)(ii) of the Act¹¹ and Rule 19b-4(f)(2)¹² thereunder. Accordingly, the proposal is effective upon filing with the Commission. At any time within 60 days of the filing of the proposed rule change, the Commission may summarily abrogate such rule change if it appears to the Commission that such action is necessary or appropriate in the public

⁸ See Securities Exchange Act Release Nos. 49341 (March 1, 2004), 69 FR 10492 (March 5, 2004) (SR-CBOE-2004-08); 49769 (May 25, 2004), 69 FR 31145 (June 2, 2004) (SR-CBOE-2004-13); and 52660 (October 24, 2005), 70 FR 62355 (October 31, 2005) (SR-CBOE-2005-80).

⁹ 15 U.S.C. 78f(b).

¹⁰ 15 U.S.C. 78f(b)(4).

¹¹ 15 U.S.C. 78s(b)(3)(A)(ii).

¹² 17 CFR 240.19b-4(f)(2).

¹² 17 CFR 200.30-3(a)(12).

¹ 15 U.S.C. 78s(b)(1).

² 17 CFR 240.19b-4.

³ In Amendment No. 1, CBOE deleted all references to an extension of the Fixed Annual Fee Program.

⁴ 15 U.S.C. 78s(b)(3)(A).

⁵ 17 CFR 240.19b-4(f)(2).

⁶ See Sections 19 and 21 of the CBOE Fees Schedule, respectively.

⁷ See Securities Exchange Act Release No. 50175 (August 10, 2004), 69 FR 51129 (August 17, 2004) (SR-CBOE-2004-38). See also Securities Exchange Act Release No. 52111 (July 22, 2005), 70 FR 43729 (July 28, 2005) (SR-CBOE-2005-52) (extension of PFRP through the end of 2005).

interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act.¹³

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change, as amended, is consistent with the Act. Comments may be submitted by any of the following methods:

Electronic Comments

- Use the Commission's Internet comment form (<http://www.sec.gov/rules/sro.shtml>); or
- Send an e-mail to rule-comments@sec.gov. Please include File Number SR-CBOE-2005-114 on the subject line.

Paper Comments

- Send paper comments in triplicate to Jonathan G. Katz, Secretary, Securities and Exchange Commission, Station Place, 100 F Street NE., Washington, DC 20549-9303.

All submissions should refer to File Number SR-CBOE-2005-114. This file number should be included on the subject line if e-mail is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's Internet Web site (<http://www.sec.gov/rules/sro.shtml>). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Room. Copies of such filing also will be available for inspection and copying at the principal office of the Exchange. All comments received will be posted without change; the Commission does not edit personal identifying information from submissions. You should submit only information that you wish to make available publicly. All

¹³ The effective date of the original proposed rule change is December 16, 2005, and the effective date of Amendment No. 1 is December 22, 2005. For purposes of calculating the 60-day period within which the Commission may summarily abrogate the proposed rule change, as amended, under Section 19(b)(3)(C) of the Act, the Commission considers the period to commence on December 22, 2005, the date on which CBOE submitted Amendment No. 1. See 15 U.S.C. 78s(b)(3)(C).

submissions should refer to File Number SR-CBOE-2005-114 and should be submitted on or before January 27, 2006.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.¹⁴

Jonathan G. Katz,
Secretary.

[FR Doc. E6-22 Filed 1-5-06; 8:45 am]

BILLING CODE 8010-01-P

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-53045; File No. SR-PCX-2005-132]

Self-Regulatory Organizations; Pacific Exchange, Inc.; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Relating to Obligations of Lead Market Makers

December 30, 2005.

Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 ("Act"),¹ and Rule 19b-4 thereunder,² notice is hereby given that on December 30, 2005, the Pacific Exchange, Inc. ("Exchange" or "PCX") filed with the Securities and Exchange Commission ("Commission") the proposed rule change as described in Items I and II below, which Items have been substantially prepared by the Exchange. The Exchange filed the proposed rule change as a "non-controversial" rule change under Rule 19b-4(f)(6) under the Act,³ which rendered the proposal effective upon filing with the Commission. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.

I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

The Exchange proposes to delete PCX Rule 6.82(c)(15) in its entirety. The Exchange also proposes to amend Commentary .02 to PCX Rule 6.82. The text of the proposed rule change is available on PCX's Web site, <http://www.pacificex.com>, at PCX's Office of the Secretary, and at the Commission's Public Reference Section.

¹⁴ 17 CFR 200.30-3(a)(12).

¹ 15 U.S.C. 78s(b)(1).

² 17 CFR 240.19b-4.

³ 17 CFR 240.19b-4(f)(6).

II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, the Exchange included statements concerning the purpose of, and basis for, the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in Sections A, B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

1. Purpose

The purpose of this filing is to delete PCX Rule 6.82(c)(15), a sub-paragraph of Obligations of Lead Market Makers. Along with the deletion of PCX Rule 6.82(c)(15), the PCX proposes to amend Commentary .02 to PCX Rule 6.82, which addresses PCX Rule 6.82(c)(15). This rule, dealing with the handling of public customer orders that are not automatically executed on the PCX because there is a better-displayed bid or offer on another exchange, is scheduled to be operative on January 1, 2006.

Under PCX Rule 6.82(c)(15), when a public customer order is not automatically executed on the PCX due to a better bid or ask price being displayed on another exchange, a Lead Market Maker ("LMM") is obligated, as soon as practical, to address the order by either executing the public customer order at a price that matches the best available price displayed at any other exchange or by routing the public customer order via intermarket linkage ("Linkage") for execution at any other exchange displaying the best price in the market at the time. Outbound Linkage orders on the PCX are still handled via manual interaction with the Linkage system. Manual interaction with the Linkage system can be a time consuming process that potentially could result in the delay of a public customer order being executed at a better price available at a competing exchange. By deleting PCX Rule 6.82(c)(15), in the event that an LMM does not execute the order at the better price displayed on another exchange, the LMM would not be required to send the order to the competing exchange via Linkage. Public customer orders that are not executed on the PCX could still be

rejected to the initiating brokerage firm for rerouting to a competing exchange.

Due to delays in technology development, the PCX has not been able to implement an automated outbound Linkage function into the PCX Plus trading system. The PCX is presently developing a new enhanced options trading system, called the OX System. Included in the design plans for the OX System is functionality that will route outbound Linkage orders to other exchanges via an automated process.

2. Statutory Basis

The Exchange believes that the proposed rule change is consistent with Section 6(b) of the Act⁴ in general, and furthers the objectives of section 6(b)(5) of the Act⁵ in particular, in that it is designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, to foster cooperation and coordination with persons engaged in facilitating transactions in securities, and to remove impediments to and perfect the mechanism of a free and open market and a national market system.

B. Self-Regulatory Organization's Statement on Burden on Competition

The Exchange does not believe that the proposed rule change will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others

The Exchange has neither solicited nor received written comments on the proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

Because the proposed rule change: (i) Does not significantly affect the protection of investors or the public interest; (ii) does not impose any significant burden on competition; and (iii) by its terms, does not become operative for 30 days after the date of filing, or such shorter time as the Commission may designate, if consistent with the protection of investors and the public interest, the proposed rule change has become effective pursuant to Section 19(b)(3)(A) of the Act⁶ and subparagraph (f)(6) of Rule 19b-4 thereunder.⁷

The Exchange has requested that the Commission waive the 30-day operative delay period for "non-controversial" proposals and make the proposed rule change effective and operative upon filing. The Commission believes that waiver of the 30-day operative delay is consistent with the protection of investors and the public interest, because PCX Rule 6.82(c)(15) has never become operative (as its operative date was January 1, 2006), and deleting a rule that has never become operative has no real effect and thus raises no issues of regulatory concern. For this reason, the Commission designates the proposal to be effective and operative upon filing with the Commission.⁸

At any time within 60 days of the filing of the proposed rule change, the Commission may summarily abrogate such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in the furtherance of the purposes of the Act.

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:

Electronic Comments

- Use the Commission's Internet comment form (<http://www.sec.gov/rules/sro.shtml>); or
- Send an e-mail to rule-comments@sec.gov. Please include File Number SR-PCX-2005-132 on the subject line.

Paper Comments

- Send paper comments in triplicate to Jonathan G. Katz, Secretary, Securities and Exchange Commission, 100 F Street, NE., Washington, DC 20549-9303.

All submissions should refer to File Number SR-PCX-2005-132. This file number should be included on the subject line if e-mail is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's Internet Web site (<http://www.sec.gov/rules/sro.shtml>). Copies of the submission, all subsequent amendments, all written statements

with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Section, 100 F Street, NE., Washington, DC 20549. Copies of such filing also will be available for inspection and copying at the principal office of the Exchange. All comments received will be posted without change; the Commission does not edit personal identifying information from submissions. You should submit only information that you wish to make available publicly. All submissions should refer to File Number SR-PCX-2005-132 and should be submitted on or before January 27, 2006.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.⁹

Jonathan G. Katz,
Secretary.

[FR Doc. E6-20 Filed 1-5-06; 8:45 am]

BILLING CODE 8010-01-P

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-53043; File No. SR-Phlx-2005-72]

Self-Regulatory Organizations; Philadelphia Stock Exchange, Inc.; Notice of Filing and Immediate Effectiveness of Proposed Rule Change and Amendment No. 1 Thereto Relating to Remote Streaming Quote Trader Permit Fees

December 29, 2005.

Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 ("Act")¹ and Rule 19b-4 thereunder,² notice is hereby given that on November 10, 2005, the Philadelphia Stock Exchange, Inc. ("Phlx" or "Exchange") filed with the Securities and Exchange Commission ("Commission") the proposed rule change as described in Items I, II, and III below, which Items have been prepared by the Phlx. On December 19, 2005, the Phlx submitted Amendment No. 1 to the proposed rule change.³ The Exchange has designated

¹ 17 CFR 200.30-3(a)(12).

² 15 U.S.C. 78s(b)(1).

³ 17 CFR 240.19b-4.

⁴ In Amendment No. 1, the Exchange revised the proposed rule text to clarify that RSQTs and SQTs

Continued

⁴ 15 U.S.C. 78f(b).

⁵ 15 U.S.C. 78f(b)(5).

⁶ 15 U.S.C. 78s(b)(3)(A).

⁷ 17 CFR 240.19b-4(f)(6).

⁸ For the purposes only of accelerating the operative date of this proposal, the Commission has considered the proposed rule's impact on efficiency, competition and capital formation. 15 U.S.C. 78c(f).

the proposed rule change as one establishing or changing a due, fee, or other charge imposed by the Phlx pursuant to Section 19(b)(3)(A)(ii) of the Act⁴ and Rule 19b-4(f)(2) thereunder,⁵ which renders the proposal effective upon filing with the Commission.⁶ The Commission is publishing this notice to solicit comments on the proposed rule change, as amended, from interested persons.

I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

The Phlx proposes to amend its permit fee schedule to assess a permit fee on Remote Streaming Quote Traders ("RSQTs")⁷ under the Registered Options Trader ("ROT") permit fee category. In addition, the Exchange proposes to amend its permit fee schedule to clarify that Streaming Quote Traders ("SQTs")⁸ are currently included in the ROT permit fee category.⁹ The text of the proposed rule change is available on the Exchange's Web site (<http://www.phlx.com>), at the Phlx, and at the Commission's Public Reference Room.

will be included in the ROT permit fee category. The Exchange also amended the purpose section to clarify that, by including RSQTs in the ROT permit fee category, the Exchange will be assessing a new permit fee on RSQTs.

⁴ 15 U.S.C. 78s(b)(3)(A)(ii).

⁵ 17 CFR 240.19b-4(f)(2).

⁶ The effective date of the original proposed rule change is November 10, 2005, and the effective date of Amendment No. 1 is December 19, 2005. For purposes of calculating the 60-day period within which the Commission may summarily abrogate the proposed rule change under Section 19(b)(3)(C) of the Act, the Commission considers the period to commence on December 19, 2005, the date on which the Exchange submitted Amendment No. 1. See 15 U.S.C. 78s(b)(3)(C).

⁷ An RSQT is an Exchange ROT that is a member or member organization of the Exchange with no physical trading floor presence who has received permission from the Exchange to generate and submit option quotations electronically through the Exchange's Automated Options Market in eligible options in which such RSQT has been assigned. An RSQT may only trade in a market making capacity in classes of options in which he is assigned. An RSQT may only submit such quotations electronically from off the floor of the Exchange. See Phlx Rule 1014(b)(ii)(B).

⁸ An SQT is a ROT who has received permission from the Exchange to generate and submit option quotations electronically through an electronic interface with the Exchange's automated options market ("AUTOM") via an Exchange approved proprietary electronic quoting device in eligible options to which the SQT is assigned. See Exchange Rule 1014(b)(iii).

⁹ Currently, SQTs are assessed a permit fee under the ROT (on any trading floor) category, but are not specifically referred to on the Exchange's fee schedule.

II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, the Phlx included statements concerning the purpose of, and basis for, the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Phlx has prepared summaries, set forth in Sections A, B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

1. Purpose

Phlx recently adopted equity option fees applicable to RSQTs.¹⁰ In addition to the equity options fees assessed on RSQTs, RSQTs must also pay a monthly permit fee. Presently, RSQTs do not pay a ROT permit fee because they are not on any trading floor¹¹ and are thus not included in the ROT permit fee category on the Exchange's fee schedule. However, RSQTs pay a permit fee under another category of permit fees such as a specialist or an order flow provider.¹² Currently, monthly permit fees are assessed as follows:

Permit Fees¹³ Order Flow Provider Permit Fee¹⁴

¹⁰ See Securities Exchange Act Release No. 51428 (March 24, 2005), 70 FR 16325 (March 30, 2005) (SR-Phlx-2005-12).

¹¹ See definition of "RSQT," *supra* note 7.

¹² The Exchange assesses permit fees on its members. Monthly permit fees are assessed based on how each permit is used, for example, order flow provider, specialist or floor broker. However, any member who qualifies a member organization in more than one category of permit fees pays the higher of the applicable fees for such permit. For example, if an RSQT permit holder qualifies a member organization as an order flow provider and the RSQT permit holder associated with the member organization then registered as a floor broker on the Exchange for that or another member organization, that RSQT permit holder would be subject to a permit fee of \$1,200, the higher of \$200 (the order flow provider permit fee) and \$1,200 (the floor broker permit fee), but not both fees.

¹³ The Exchange has established the date of notification of termination of a permit as the date that permit fee billing will cease. Additionally, a permit holder will be billed only one monthly permit fee if the holder transfers from one member organization to another previously unrelated member organization as a result of a merger, partial sale or other business combination during a monthly permit fee period in order to avoid double billing in the month the merger or business combination occurred. If the permit holder transfers from one member organization to another unrelated member organization in the same month, both member organizations are assessed a permit fee in the same billing period.

¹⁴ This fee applies to a permit held by a permit holder who does not have physical access to the

a. Permits used only to submit orders to the equity, foreign currency options, or options trading floor (one floor only): \$200.00 per month.

b. Permits used only to submit orders to more than one trading floor: \$300.00 per month.

Floor Broker, Specialist, or ROT (on any trading floor) or Off-Floor Trader Permit Fee

a. First Permit: \$1,200.00 per month.

b. Additional permits for members in the same organization: \$1,000.00 per month.

Excess Permit Holders: \$200.00 per month.

Other Permit Holders:¹⁵ \$200.00 per month.

Any member who is associated with one or more member organizations and uses a permit in more than one category pays the higher of the applicable fees for such permit.

Because RSQTs do not have a physical presence on the trading floor, but are a subset of ROTs, the Exchange proposes to assess the same permit fees on RSQTs as ROTs on any trading floor. As such, the Exchange proposes to replace the words "on any trading floor" that appear after the ROT category with "including RSQTs and SQTs."¹⁶

In addition, although SQTs have a physical presence on the trading floor and are thus currently included in the ROT (on any trading floor) permit fee

Exchange's trading floor, is not registered as a Floor Broker, Specialist or ROT (on any trading floor) or Off-Floor trader, and whose member organization submits orders to the Exchange. Phlx Rule 620(a) requires such registration.

¹⁵ A permit holder or the member organization they solely qualify must apply for "other" status in writing to the Membership Services Department. This status requires that a permit holder or the member organization have no transaction activity for the applicable monthly billing period. Should a permit holder actively transact business during a particular month, the highest applicable monthly permit fee will apply to such permit holder and member organization for that monthly period. The "other" status only applies to permit holders who solely qualify their member organization. These policies were effective as of February 2, 2004.

¹⁶ As a practical matter, the effect of including RSQTs in the ROT permit fee category should not increase overall costs to the RSQTs due to the fact that RSQTs receive a permit credit, which is applied against a member organization's RSQT fees. Specifically, pursuant to the Exchange's fee schedule, RSQTs are assessed an RSQT fee based on the number and type of option issues in which an RSQT is assigned. A credit is given to RSQTs based on the total number of permits held by the RSQT in a particular calendar month. For example, currently an RSQT may receive a monthly credit of \$200 (which is the same amount as the permit fee) because the permit holder qualifies a member organization as an order flow provider. Now, under this proposal, the RSQT will be charged a higher permit fee of \$1,200, but receive a permit credit of \$1,200 to be applied against the RSQT fee. See Securities Exchange Act Release No. 51428 (March 24, 2005), 70 FR 16325 (March 30, 2005) (SR-Phlx-2005-12).

category, the Exchange proposes to specifically refer to SQTs on the fee schedule in order to help clarify that SQTs are also included in the ROT category.

2. Statutory Basis

The Exchange believes that its proposal to amend its schedule of fees is consistent with Section 6(b) of the Act,¹⁷ in general, and furthers the objectives of Section 6(b)(4) of the Act,¹⁸ in particular, in that it is an equitable allocation of reasonable fees among Exchange members.

B. Self-Regulatory Organization's Statement on Burden on Competition

The Exchange does not believe that the proposed rule change will impose any burden on competition not necessary or appropriate in furtherance of the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others

No written comments were either solicited or received.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

The foregoing proposed rule change has been designated as a fee change pursuant to Section 19(b)(3)(A)(ii) of the Act¹⁹ and Rule 19b-4(f)(2)²⁰ thereunder. Accordingly, the proposal will take effect upon filing with the Commission. At any time within 60 days of the filing of Amendment No. 1 to the proposed rule change, the Commission may summarily abrogate such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act.²¹

IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Comments may be submitted by any of the following methods:

Electronic Comments

- Use the Commission's Internet comment form (<http://www.sec.gov/rules/sro.shtml>); or

¹⁷ 15 U.S.C. 78f(b).

¹⁸ 15 U.S.C. 78f(b)(4).

¹⁹ 15 U.S.C. 78s(b)(3)(A)(ii).

²⁰ 17 CFR 240.19b-4(f)(2).

²¹ See *supra* note 6.

- Send an e-mail to rule-comments@sec.gov: Please include File Number SR-Phlx-2005-72 on the subject line.

Paper Comments

- Send paper comments in triplicate to Jonathan G. Katz, Secretary, Securities and Exchange Commission, 100 F Street, NE., Washington, DC 20549-9303.

All submissions should refer to File Number SR-Phlx-2005-72. This file number should be included on the subject line if e-mail is used. To help the Commission process and review your comments more efficiently, please use only one method. The Commission will post all comments on the Commission's Internet Web site (<http://www.sec.gov/rules/sro.shtml>). Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Room. Copies of the filing also will be available for inspection and copying at the principal office of the Exchange. All comments received will be posted without change; the Commission does not edit personal identifying information from submissions. You should submit only information that you wish to make available publicly. All submissions should refer to File Number SR-Phlx-2005-72 and should be submitted on or before January 27, 2006.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.²²

Jonathan G. Katz,

Secretary.

[FR Doc. E6-21 Filed 1-5-06; 8:45 am]

BILLING CODE 8010-01-P

SOCIAL SECURITY ADMINISTRATION

Agency Information Collection Activities: Proposed Request and Comment Request

The Social Security Administration (SSA) publishes a list of information collection packages that will require clearance by the Office of Management and Budget (OMB) in compliance with

²² 17 CFR 200.30-3(a)(12).

Public Law 104-13, the Paperwork Reduction Act of 1995, effective October 1, 1995. The information collection packages that may be included in this notice are for new information collections, approval of existing information collections, revisions to OMB-approved information collections, and extensions (no change) of OMB-approved information collections.

SSA is soliciting comments on the accuracy of the agency's burden estimate; the need for the information; its practical utility; ways to enhance its quality, utility, and clarity; and on ways to minimize burden on respondents, including the use of automated collection techniques or other forms of information technology. Written comments and recommendations regarding the information collection(s) should be submitted to the OMB Desk Officer and the SSA Reports Clearance Officer. The information can be mailed and/or faxed to the individuals at the addresses and fax numbers listed below:

(OMB) Office of Management and Budget, Attn: Desk Officer for SSA, Fax: 202-395-6974.

(SSA) Social Security Administration, DCFAM, Attn: Reports Clearance Officer, 1333 Annex Building, 6401 Security Blvd., Baltimore, MD 21235. Fax: 410-965-6400.

I. The information collections listed below are pending at SSA and will be submitted to OMB within 60 days from the date of this notice. Therefore, your comments should be submitted to SSA within 60 days from the date of this publication. You can obtain copies of the collection instruments by calling the SSA Reports Clearance Officer at 410-965-0454 or by writing to the address listed above.

1. Work Activity Report—Employee—20 CFR 404.1520(b), 404.1571-.1576, 404.1584-.1593, and 416.971-.976—0960-0059. Form SSA-821-BK collects information that provides evidence necessary to determine initial or continuing eligibility for Supplemental Security Income (SSI) or Social Security disability benefits. An individual's entitlement to benefits ends if he/she demonstrates an ability to perform substantial gainful activity (SGA). This form is used to determine whether work an individual performs in employment is at the SGA level. The respondents are Social Security disability applicants and beneficiaries; and SSI applicants.

Type of Request: Extension of an OMB-approved information collection.

Number of Respondents: 300,000.

Frequency of Response: 1.

Average Burden per Response: 45 minutes.

Estimated Annual Burden: 225,000 hours.

2. Homeless Outreach Project and Evaluation (HOPE)—0960-0704. *Background.* Congress passed the McKinney Act of 1987 in recognition of and in an effort to address situations and conditions facing people without permanent shelter. The Act funded 15 emergency services and nine individual titles to authorize the provision of specific programs by Federal agencies. The Act also established the Interagency Council on Homelessness (ICH) composed of leaders from 15 Federal agencies who are in charge of coordinating efforts to assist people who are homeless. During the past decade, SSA and other ICH agencies have compiled important data about people who are homeless and have carried out evaluations of services which have generated evidence about "best" or "promising practices" well suited to combating homelessness.

In fiscal year 2003, President George W. Bush announced an initiative to end chronic homelessness in 10 years. As a result, SSA developed Project HOPE

and in May 2004 awarded 34 Cooperative Agreements to organizations which provide outreach, support services and benefit application assistance to the chronically homeless and other underserved populations. An additional 7 cooperative agreements were awarded in November 2004 for a total of 41. The goal of Project HOPE is to improve both the quantity and quality of applications for disability benefits. Project HOPE gives focused support to Cooperative (co-op) awardees via a training program and ongoing technical assistance.

Evaluation of Project HOPE. SSA uses the project HOPE evaluation to determine the effectiveness and the efficiency of the program. To obtain the information needed for the evaluation, SSA has developed an interactive Web site that is used by co-op awardees to input client and program data, and by SSA to communicate project-wide announcements to the awardees. The respondents are HOPE grantees/non-profit social services organizations serving people who are homeless and disabled.

Type of Request: Extension of an OMB-approved information collection.

Number of Respondents: 41.

Frequency of Response: 12.

Average Burden Per Response: 65 minutes.

Estimated Annual Burden: 533 hours.

3. Report to United States Social Security Administration by Person Receiving Benefits for a Child or for an Adult Unable to Handle Funds and Report to United States Social Security Administration—0960-0049. SSA needs the information on Form SSA-7161-OCR-SM to monitor the performance of representative payees outside the U.S. and the information on SSA-7162-OCR-SM to determine continuing entitlement to Social Security benefits and correct benefit amounts for beneficiaries outside the U.S. The respondents are individuals outside the U.S. who are receiving benefits either for someone else, or on their own behalf under title II of the Social Security Act.

Type of Request: Revision of an OMB-approved information collection.

Forms	Number of respondents	Frequency of response	Average burden per response (in minutes)	Burden hours
SSA-7161-OCR-SM	30,000	1	15	7,500
SSA-7162-OCR-SM	227,000	1	5	18,917
Totals	257,000	26,417

II. The information collections listed below have been submitted to OMB for clearance. Your comments on the information collections would be most useful if received by OMB and SSA within 30 days from the date of this publication. You can obtain a copy of the OMB clearance packages by calling the SSA Reports Clearance Officer at 410-965-0454, or by writing to the address listed above.

1. Report of New Information in Disability Cases—20 CFR 404.460, 404.468, 404.408, and 404.1588—0960-0071. The information collected on the form SSA-612 is used to update the disability records of a respondent based on reported changes contained in the form. These changes may affect the respondent's Title II disability benefits. The respondents are applicants for Title II disability benefits.

Type of Request: Extension of an OMB-approved information collection.

Number of Respondents: 27,000.

Frequency of Response: 1.

Average Burden per Response: 5 minutes.

Estimated Annual Burden: 2,250 hours.

2. Statement of Marital Relationship (By one of the parties)—20 CFR 404.726—0960-0038. SSA uses the information collected on Form SSA-754-F4 to determine whether the conditions for establishing a common-law marriage under state law are met. The respondents are applicants for spouse's benefits.

Type of Request: Extension of an OMB-approved information collection.

Number of Respondents: 30,000.

Frequency of Response: 1.

Average Burden per Response: 30 minutes.

Estimated Annual Burden: 15,000 hours.

3. Employee Verification Service (EVS)—0960-0669. *Background.* Under Internal Revenue Service regulations, employers are required to provide wage and tax data to SSA using form W-2, Wage and Tax Statement or its electronic equivalent. As part of this process, the employer must furnish the employee's name and Social Security Number (SSN). This information must

match SSA's records in order for the employee's wage and tax data to be properly posted to the earnings record. Information that is incorrectly provided to the Agency must be corrected by the employer using an amended reporting form, which is a labor-intensive and time-consuming process for both SSA and the employer. Therefore, to help ensure that employers provide accurate name and SSN information on their wage reports, SSA offers the EVS service whereby employers can verify, via magnetic tape, cartridge, diskette, paper, and telephone, if the reported name and SSN of their employee matches SSA's records.

EVS Collection. SSA will use the information collected through the EVS to verify that the employee name and SSN information, provided by employers, matches SSA records. SSA will respond to the employer informing them only of matches and mismatches of submitted information. Respondents are employers who provide wage and tax data to SSA who elect to use EVS

to verify their employees' names and SSNs.

Type of Request: Extension of an OMB-Approved Information Collection.

Number of Respondents: 50,000.

Frequency of Response: 12.

Average Burden per Response: 10 minutes.

Estimated Annual Burden: 100,000 hours.

4. Application for Parent's Insurance Benefits—20 CFR 404.370–404.374, 20

CFR 404.601–404.603—0960–0012.

Form SSA–7–F6 collects information to entitle an individual to his parent's insurance benefits. The respondents are individuals who wish to apply to receive their parent's insurance benefits.

Type of Request: Revision of an OMB-approved information collection.

Number of Respondents: 1,400.

Frequency of Response: 1.

Average Burden per Response: 15 minutes.

Estimated Annual Burden: 350 hours.

5. Application for Supplemental Security Income—20 CFR 416.305–416.335—0960–0444. The information collected on the SSA–8001–BK is needed and used to determine eligibility for SSI, and the amount of SSI benefits payable to the applicant. Respondents are applicants for SSI benefits.

Type of Request: Revision of an OMB-approved information collection.

Title of collection	Number of respondents	Frequency of response	Average burden per response (in minutes)	Burden hours
MISSICS	840,088	1	16	224,023
MISSICS/Signature Proxy	280,029	1	15	70,007
Paper	25,982	1	19	8,228
Paper/Signature Proxy	8,661	1	18	2,598
Totals	1,154,760			304,856

6. Medical Source Statement of Ability To Do Work Related Activities (Physical and Mental)—20 CFR 404.1512–404.1514, 404.912–404.914, 404.1517, 416.917, 404.1519–404.1520, 416.919–416.920, 404.946, 416.946—0960–0662. The HA–1151 and HA–1152 are used to collect data that is required

to determine the residual functional capacity (RFC) of individuals who are appealing denied claims for benefits based on disability. RFC must be determined to decide cases that cannot be decided based on current work activity or on medical facts alone. The respondents are medical sources that are

paid by SSA to provide reports based either on existing medical evidence or on consultative examinations conducted for the purposes of the report. We estimate each respondent will submit approximately 20 responses per year.

Type of Request: Revision of an OMB-approved information collection.

Forms	Number of respondents	Frequency of response	Average burden per response (in minutes)	Burden hours
HA–1151	5,000	20	15	25,000
HA–1152	5,000	20	15	25,000
Totals	10,000			50,000

Dated: December 30, 2005.

Elizabeth A. Davidson,

Reports Clearance Officer, Social Security Administration.

[FR Doc. E6–34 Filed 1–5–06; 8:45 am]

BILLING CODE 4191–02–P

SOCIAL SECURITY ADMINISTRATION

Agency Information Collection Activities: Proposed Request

The Social Security Administration (SSA) publishes a list of information collection packages that will require clearance by the Office of Management and Budget (OMB) in compliance with Public Law 104–13, the Paperwork Reduction Act of 1995, effective October 1, 1995. The information collection request included in this notice is for a revision to an existing information collection.

SSA is soliciting comments on the accuracy of the agency's burden estimate; the need for the information; its practical utility; ways to enhance its quality, utility, and clarity; and on ways to minimize burden on respondents, including the use of automated collection techniques or other forms of information technology. Written comments and recommendations regarding the information collection should be submitted to the SSA Reports Clearance Officer. The information can be mailed and/or faxed to the individuals at the addresses and fax number listed below:

Social Security Administration, DCFAM, (SSA), Attn: Reports Clearance Officer, 1333 Annex Building, 6401 Security Blvd., Baltimore, MD 21235. Fax: 410–965–6400.

The information collection listed below is pending at SSA and will be

submitted to OMB within 60 days from the date of this notice. Therefore, your comments should be submitted to SSA within 60 days from the date of this publication. You can obtain a copy of the OMB clearance package by calling the SSA Reports Clearance Officer at 410–965–0454, or by writing to the address listed above.

Application for a Social Security Card—20 CFR 422.103–.110—0960–0066. Forms SS–5 (used in the United States) and SS–5–FS (used outside the United States) are used to apply for original and replacement Social Security cards. Changes are being made to these forms to reflect new statutory limits on the number of allowable replacement cards. The respondents are requestors of new or replacement Social Security cards.

Note: This Notice is for the full clearance of the collection, which received a temporary emergency clearance through April 2006.

Application scenario	Number of annual respondents	Completion time (in minutes)	Burden hours
Respondents who do not have to provide parents' SSNs	13,000,000	8½	1,841,667
Respondents who are asked to provide parents' SSNs (for application for original SSN cards for children under age 18)	540,000	9	81,000
Applicants age 12 or older who need to answer additional questions so SSA can determine whether an SSN was previously assigned	40,000	9½	6,333
Applicants asking for a replacement SSN card beyond the new allowable limits (i.e., who must provide additional documentation to accompany the application)	4,000	60	4,000
Totals	13,584,000	1,933,000

Dated: December 30, 2005.

Elizabeth A. Davidson,
Reports Clearance Officer, Social Security Administration.

[FR Doc. E6-38 Filed 1-5-06; 8:45 am]

BILLING CODE 4191-02-P

SOCIAL SECURITY ADMINISTRATION

Rate for Assessment on Direct Payment of Fees to Representatives in 2006

AGENCY: Social Security Administration (SSA).

ACTION: Notice.

SUMMARY: The Social Security Administration is announcing that the assessment percentage rate under section 206(d) and 1631(d)(2)(C) of the Social Security Act (the Act), 42 U.S.C. 406(d), and 1383(d)(2)(C) is 6.3 percent for 2006.

FOR FURTHER INFORMATION CONTACT: James A. Winn, Associate General Counsel for Program Law, Office of the General Counsel, Social Security Administration, Phone: (410) 965-3137, e-mail jim.winn@ssa.gov.

SUPPLEMENTARY INFORMATION: Section 406 of Public Law No. 106-170, the Ticket to Work and Work Incentives Improvement Act of 1999, established an assessment for the services required to determine and certify payments to attorneys from the benefits due claimants under Title II of the Act. This provision is codified in section 206 of the Act (42 U.S.C. 406). That legislation set the assessment for the calendar year 2000 at 6.3 percent of the amount that would be required to be certified for direct payment to the attorney under section 206(a)(4) or 206(b)(1) before the application of the assessment. For subsequent years, the legislation requires the Commissioner of Social Security to determine the percentage rate necessary to achieve full recovery of the costs of determining and certifying fees to attorneys, but not in excess of 6.3 percent.

Beginning in 2005, sections 302 and 303 of Public Law 108-203, the Social Security Protection Act of 2004 (SSPA) extended the direct payment of fees to attorneys in cases under Title XVI of the Act and to eligible non-attorney representatives in cases under Title II and/or Title XVI of the Act. Fees directly paid under these provisions are subject to the same assessment. In addition, sections 301 and 302 of the SSPA imposed a dollar cap on the amount of the assessment, so that the assessment may not exceed the lesser of that dollar cap or the amount determined using the assessment percentage rate.

The Commissioner of Social Security has determined, based on the best available data that the current assessment percentage rate of 6.3 percent will continue for 2006. We will continue to review our costs on a yearly basis.

Dated: December 23, 2005.

Dale W. Sopper,
Deputy Commissioner for Finance,
Assessment and Management.

[FR Doc. E6-31 Filed 1-5-06; 8:45 am]

BILLING CODE 4191-02-P

DEPARTMENT OF TRANSPORTATION

Office of the Secretary

[Docket No. OST-95-950]

Notice of Request for Extension of a Previously Approved Collection

AGENCY: Office of the Secretary, DOT.

ACTION: Notice and request for comments.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*), this notice announces that the Information Collection Request (ICR) abstracted below has been forwarded to the Office of Management and Budget (OMB) for renewal and comment. The ICR describes the nature of the information collection and its expected cost and

burden. The Federal Register Notice with a 60-day comment period soliciting comments on the following collection of information was published on October 19, 2005 [FR Vol. 70, No. 201, page 60869]. No comments were received.

DATES: Comments on this notice must be received by February 6, 2006 and sent to the attention of the DOT/OST Desk Officer, Office of Information and Regulatory Affairs, Office of Management and Budget, Docket library, Room 10102, 725 17th Street, NW., Washington, DC 20503.

FOR FURTHER INFORMATION CONTACT: Jack Schmidt, (202) 366-5420, Office of Aviation Analysis, Office of the Assistant Secretary for Aviation and International Affairs, Office of the Secretary, U.S. Department of Transportation, 400 Seventh Street, SW., Washington, DC 20590.

SUPPLEMENTARY INFORMATION:

Title: Passenger Manifest Information.

OMB Control Number: 2105-0534.

Affected Public: All U.S. air carriers and foreign air carriers operating international flights to and from the United States, travel agents doing business in the U.S. and the traveling public.

Annual Estimated Burden Hours: 833,464. In the 60-day notice mentioned above, the annual burden hours were shown as 1.05 million. Since the time of that notice, the methodology used to calculate the burden hours was updated to reflect international travel growth as well as improved efficiencies resulting from technological changes especially from an increased use of the Internet.

Comments are invited on: (a) Whether this collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) the accuracy of the agency's estimate of the burden of the continued collection of information; (c) ways to enhance the quality, utility, and clarity of the information collected; and (d) ways to minimize the burden of the collection of information on the respondents, including the use of

automated collection techniques or other forms of information technology.

All responses to this notice will be summarized and included in the request for OMB approval. All comments will also become a matter of public record.

Issued in Washington, DC, on December 29, 2005.

Steven B. Lott,

Manager, Strategic Integration IT Investment Management Office.

[FR Doc. E6-10 Filed 1-5-06; 8:45 am]

BILLING CODE 4910-62-P

DEPARTMENT OF TRANSPORTATION

Federal Highway Administration

Safe, Accountable, Flexible, Efficient Transportation Equity Act: A Legacy for Users (SAFETEA-LU); Opportunities for State and Other Qualifying Agencies To Gain Authority to Toll Facilities Constructed Using Federal Funds

AGENCY: Federal Highway Administration (FHWA), DOT.

ACTION: Notice; process to solicit participation in various programs that grant authority to toll Federal-aid facilities.

SUMMARY: This notice provides summary information on all of the various non-grant tolling and pricing opportunities available in the Safe, Accountable, Flexible, Efficient Transportation Equity Act: A Legacy for Users (SAFETEA-LU). This notice and a companion notice, which refers to the Value Pricing Pilot (VPP) program, are both in today's **Federal Register**. Together they are intended to explain all of the opportunities for States and other qualifying transportation agencies requesting permission to toll their respective facilities. In addition to describing each of the relevant programs, this notice also describes the initial review process that will help to identify which of the programs are candidate for a States' particular project, and of those, which is most appropriate to gain successful approval. That process applies to every program contained in this notice and also to the VPP program. The process is initiated with an Expression of Interest, which is fully defined later in this notice.

Due to the nature of the deadlines required to solicit, review, and award the grant funds annually, the VPP program requires its own **Federal Register** notice, and is published in its entirety elsewhere in today's **Federal Register** under the title "Safe, Accountable, Flexible, Efficient

Transportation Equity Act: A Legacy for Users (SAFETEA-LU); Value Pricing Pilot Program Participation."

Finally, this notice announces the availability of a website that will serve as a clearinghouse of information on all of the tolling and pricing programs and their respective program tenets.

DATES: Of the non-grant programs described herein, only two have deadlines stipulated in the legislation. The Interstate System Construction Toll Pilot Program has a deadline for applications of August 10, 2015, and the Express Lanes Demonstration Program has a window of fiscal years 2005 to 2009. For the other programs discussed herein, there are no annual or recurring submittal deadlines for States or other qualifying public agencies to request authority to toll their federally funded public highway facilities. However, States are advised that some programs discussed herein have a finite number of available slots permitted by legislation, meaning that participation in these programs will not be allowed once all slots are allotted.

FOR FURTHER INFORMATION CONTACT: For questions about the programs discussed herein, please contact Mr. Wayne Berman, Tolling and Pricing Team, FHWA Office of Operations, (202) 366-4069, or via e-mail at wayne.berman@fhwa.dot.gov. For legal questions, interpretations and counsel, please contact Mr. Michael Harkins, Attorney Advisor, FHWA Office of the Chief Counsel, (202) 366-4928, or via email at michael.harkins@fhwa.dot.gov. Office hours for the FHWA are from 7:45 a.m. to 4:15 p.m., EST, Monday through Friday, except Federal holidays.

SUPPLEMENTARY INFORMATION:

Electronic Access

You may submit or retrieve comments online through the Document Management System (DMS) at: <http://dms.dot.gov/submit>. The DMS is available 24 hours each day, 365 days each year. Electronic submission and retrieval help and guidelines are available under the help section of the Web site.

An electronic copy of this document may be downloaded from the Federal Register's home page at: <http://www.archives.gov/> and the Government Printing Office's database at: <http://www.access.gpo.gov/nara>.

Anyone is able to search the electronic form of all comments received into any of our dockets by the name of the individual submitting the comment (or signing the comment, if submitted on behalf of an association, business, labor union, etc.). You may

review DOT's complete Privacy Act Statement in a **Federal Register** published on April 11, 2000 (70 FR 19477), or you may visit <http://dms.dot.gov>.

Background

In the recently passed SAFETEA-LU legislation (Pub. L. 109-59, August 10, 2005) Congress enabled three new exceptions, and modified one existing exception, to Title 23 of the United States Code, Section 301, which otherwise generally prohibits the imposition of tolls on facilities that use Federal funds. These actions now provide States and other qualifying transportation agencies or compacts of States more opportunities to enact tolls as a means of financing various operating, construction, or reconstruction projects, or of addressing debt reduction. Along with the three new programs and the one modification, there already exist other specific exceptions to federal authority to enact tolls. This notice and the VPP program notice elsewhere in today's **Federal Register** intend to explain the sum of all opportunities for States and other qualifying transportation agencies requesting permission to toll their respective facilities. The FHWA Office of Operations has been designated to coordinate both notices and serves as the office point of contact for both notices.

In addition to describing each of the non-grant tolling and pricing opportunities available in SAFETEA-LU, this notice also describes the two-step process necessary to submit an application. Briefly, the first step is to submit an Expression of Interest to the Tolling and Pricing Team (fully described later in this notice). The Expression of Interest is a document that will enable FHWA to assist the applicant in identifying the range of options and will help direct the application to the most appropriate program office. The Tolling and Pricing Team will not approve projects, but will serve as a clearinghouse for all applications, with intent to properly and fairly facilitate the completeness of the application. The second step is for the applicant to respond to FHWA's comments on the Expression of Interest, and then formally apply to the selected program office that offers the desired tolling or pricing authority. This approach will help direct public authorities to the most appropriate program among the many options available. This approach will also help the FHWA to coordinate and manage the limited number of participation slots

that are available for the different tolling and pricing programs.

Tolling and pricing strategies (e.g., strategies that set the price of a toll to rise and fall or impose parking charges to reduce congestion) are increasingly emerging as necessary and useful tools to finance projects, manage congestion, improve air quality, and facilitate the creation of public-private partnerships. The term "tolling" refers to any imposition of a fee for the use of a facility. Classic examples of this term would be fixed fees that motorists pay (usually per number of axles or vehicle weight) to cross a bridge or tunnel, or enter or exit an express toll facility at a particular location. While tolling involves the collection of a fee from motorists for their use of a highway facility, the term "toll pricing" specifically refers to strategies that vary the price of the toll by time of day or traffic volume level in a way to manage congestion or use of that facility.

Probably the most well known application of toll pricing is "High Occupancy Toll" (HOT) lanes that offer single-occupant vehicles the ability to use High Occupancy Vehicle (HOV) lanes that they would otherwise be restricted from using. By paying a fee to use the HOV lane (thereby justifying the renamed "HOT lane" designation) the motorist benefits by gaining a degree of trip-time reliability over the adjacent congested general-purpose lanes, while the general-purpose lanes benefit from the reduction of vehicles that have transferred into the HOT lane.

All tolling and pricing of Federal-aid highway system facilities requires legal authority from the Federal government, but some pricing strategies unrelated to tolling, such as parking charges or pay-per-mile car insurance, do not. As such, the latter do not apply to this notice and are not discussed herein. Although 23 U.S.C. 301 generally prohibits the imposition of tolls on facilities that have been constructed with Federal funds, SAFETEA-LU includes the aforementioned three new exceptions, and one modified exception. Along with some prior authority granted in various sections of the United States Code, this notice is intended to identify and describe the various options.

The SAFETEA-LU legislation offers States, compacts of States, and in one case, "public or private entities designated by States" (hereafter, collectively referred to as "public authorities") three new opportunities and one modified opportunity to toll motor vehicles to finance Interstate construction and/or reconstruction, promote efficiency in the use of

highways, reduce traffic congestion and/or improve air quality.

First, section 1121, amended 23 U.S.C. 166 to permit the conversion of HOV lanes into HOT lanes.

Next, sections 1604(b), the Express Lanes Demonstration program, and 1604(c), the Interstate System Construction Toll Pilot program, are new programs providing tolling authority opportunities. The Express Lanes Demonstration program permits tolling authority for up to fifteen demonstration projects for existing HOV facilities or where toll capacity is added, and the Interstate System Construction Toll Pilot program authorizes up to three toll pilot facilities on the Interstate system for the purpose of constructing new Interstate highways.

Finally, section 1604(a), the VPP program, modifies and extends an existing program that was first enacted as the "Congestion Pricing Pilot" program by Section 1012(b) of the Intermodal Surface Transportation Efficiency Act of 1991 (ISTEA), and amended by 1216(a) of the Transportation Equity Act for the 21st Century (TEA-21). Because of its unique standing as the only grant program discussed herein, and because there exists annual deadlines for solicitation, review, and award, the VPP program has its own notice published elsewhere in today's *Federal Register*. However, the request to submit an initial Expression of Interest is the same as the one described herein for the remaining programs.

In addition to the SAFETEA-LU provisions, there are other pre-existing provisions that permit the tolling of federally funded highway facilities. First, and most notably, 23 U.S.C. 129 permits the imposition of tolls on free non-Interstate highways, bridges, and tunnels and on free Interstate bridges and tunnels in accordance with Title 23 U.S.C. 129(a)(1). Also, the Interstate System Reconstruction and Rehabilitation Pilot Program, section 1216(b) of TEA-21, permits the collection of tolls on three Interstate facilities for the purpose of reconstruction and rehabilitation.

Purpose of This Notice

The purpose of this notice is to explain the legislative programs that grant permission to public authorities to enact tolls, to invite Expressions of Interest to participate in these programs, and to introduce a website that will serve as a clearinghouse of information on the programs, the process, and the questions that might arise. Concurrent with this notice is the companion notice published elsewhere in today's *Federal*

Register pertaining to the VPP program, which is the only grant program that is available.

The primary audience for this notice is expected to be State departments of transportation and associated public authorities (e.g., metropolitan planning organizations, public/private transportation entities, etc.) that will seek permission from the Federal government, through FHWA, to enact tolls.

The Web site resource offers general descriptions of all the programs, points of contact, a way to submit questions electronically, and instructions on how to submit an Expression of Interest via the Internet. This Web page is located on the FHWA Office of Operations website at the Tolling and Pricing Opportunities page at http://www.ops.fhwa.dot.gov/tolling_pricing/index.htm.

Program Coordination and Assistance—The Tolling and Pricing Team

The Federal Highway Administration, Office of Operations is responsible for coordinating all tolling and pricing programs that now exist under the Federal-aid Highway Program. The many programs described in this notice can be potentially confusing because of their number and range of specific purposes. In an effort to minimize this potential confusion, the Office of Operations has formed a working group known as the "Tolling and Pricing Team."

The key role for the Tolling and Pricing Team is to assist public authorities by directing them to the most appropriate program (or programs) among the many options available. Members of the Tolling and Pricing Team represent the FHWA Offices of Operations, Policy and Governmental Affairs, and Infrastructure—the primary offices responsible for administering each of the tolling and pricing programs—and other oversight offices within the U.S. Department of Transportation, including, but not limited to the Office of the Secretary and the FHWA Offices of the Administrator and Office of Chief Counsel. Members participate on the Tolling and Pricing Team because of their direct program responsibilities or because they are interested stakeholders for tolling and pricing programs within the U.S. Department of Transportation.

The Tolling and Pricing Team has six purposes:

1. Coordinate all tolling and pricing activity within FHWA to facilitate the implementation and advancement of

tolling and pricing projects and standards in the United States;

2. Receive and review all Expressions of Interest submitted to the FHWA from a public authority;

3. Direct the public authority or partnerships designated by the State to the tolling and pricing program (or programs) that can enable them to accomplish the goals set forth in the "Expression of Interest";

4. Assist the Office of Operations in the promulgation of a final rule including requirements, standards, or performance specifications for the interoperability of automated toll collection systems as directed by SAFETEA-LU Section 1604(b)(6);

5. Support each of the FHWA Program Offices, that have responsibility for a tolling and pricing program, in advancing formal proposals to gain approval to toll or price motor vehicles and facilitating coordination with the appropriate FHWA Division Office; and

6. Establish program performance goals; monitor achievements, and prepare an annual report to Congress on the status and progress of all tolling and pricing programs, including describing program successes in meeting congestion reduction and other performance goals.

The Tolling and Pricing Team reviews all "Expression of Interest" for the various tolling opportunities contained in current law but does not have responsibility to approve or disapprove specific projects. That responsibility will remain with each of the respective FHWA program offices responsible for administering a specific tolling and pricing program. By requesting and reviewing all Expressions of Interest, the Tolling and Pricing Team can effectively guide an applicant to the most appropriate program.

The "Expression of Interest"

A public authority that wants to request tolling or pricing authority, or funding, is asked to submit an Expression of Interest to the Tolling and Pricing Team in care of the FHWA Office of Operations in Washington, DC. An Expression of Interest template can be downloaded via the Internet by going to the Tolling and Pricing Opportunities webpage within the FHWA Office of Operations Web site at http://www.ops.fhwa.dot.gov/tolling_pricing/index.htm. Use of the template is optional. The Expression of Interest may be attached as an e-mail to TollingandPricingTeam@fhwa.dot.gov, or a hardcopy can be mailed to Mr. Wayne Berman, FHWA Office of Operations, Room 3404, 400 Seventh Street, SW., Washington DC 20590.

Concurrently, the Expression of Interest should be copied to the respective State FHWA Division Office.

The Expression of Interest is a document—in letter, memo, or report format—that provides the rationale for funding or tolling authority and information about the intended project. A complete Expression of Interest, based upon the information items listed below, will enable the Tolling and Pricing Team to provide the best assistance and identify the range of options possible to meet intended goals and timeframes.

The information items requested for a complete Expression of Interest are as follows:

(a) A description of the agency or requesting authority or authorities that is/are requesting this tolling authority where applicable;

(b) The name, title, email, and phone number of the person who will act as the point of contact on behalf of the requesting authority or authorities;

(c) A statement concerning the action being sought:

(i) Funding and/or tolling authority via the Value Pricing Pilot program to support either pre-project study activities or implementation activities as permitted; or

(ii) Only authority to toll either existing or planned facilities;

(d) A description of the subject facility or facilities proposed to be tolled;

(e) Whether the subject facility is an Interstate or non-Interstate facility;

(f) Whether construction is involved and, if so, whether this is new construction, expansion, rehabilitation, reconstruction, or other;

(g) Whether an HOV lane or lanes currently exist on the facility;

(h) A timetable to enact tolling (or modify tolling) on the subject facility;

(i) Any expressions or declarations of support from public officials or the public. If no public meetings or expressions of support are available, please indicate if there are project plans for ensuring adequate public involvement and support prior to implementation;

(j) A plan for implementing tolls on the facility, where applicable. Where known, the range of anticipated tolls and the strategies to vary toll rates (*i.e.*, the formulae for variable pricing);

(k) The reasons for implementing tolls, such as financing construction, reducing congestion, or improving air quality;

(l) A description of the public agency or agencies that will be responsible for operating, maintaining, and enforcing the tolling program; and

(m) A description of how, if at all, any private entities are involved either in the up-front costs to enact tolling, or the cost sharing or debt retirement associated with revenues.

Program Participation—Overview of the Process

Submitting an Expression of Interest initiates a review process by the Tolling and Pricing Team that leads to a recommendation as to which tolling or pricing program (or programs) will be appropriate and available to meet the goals of the public authority. In some cases, if more than one tolling program is available, the Tolling and Pricing Team will work with the public authority to help select the one program that is most appropriate and is most likely to lead to project approval. If, in some cases, the public authority prefers a tolling program other than the one recommended, the Tolling and Pricing Team will defer to this request; however, the Tolling and Pricing Team will also provide advice as to the pros and cons of the decision.

Once there is agreement between the public authority and the Tolling and Pricing Team as to the most appropriate program, the applicant will be referred to the specific FHWA program office responsible for administering that tolling and pricing initiative. The FHWA program office will then provide the public authority with the necessary information on how to formally apply for authority to toll motor vehicles.

Once a formal application is submitted, the appropriate FHWA program office will review the application and determine whether or not to approve the proposed project. The public authority will then be notified as to the determination. If approved, a formal tolling agreement and/or cooperative agreement will be prepared between the FHWA and the public authority. The toll agreement must be executed with the FHWA and address the use of revenues that are collected from the operation of the toll facility. While program elements may vary, the restrictions generally require the revenues to be used first for debt service, reasonable return on the investment for private parties, and the operations and maintenance of the facility. In addition, if the facility is being adequately maintained, any revenues in excess of these uses may be used for other title 23 U.S.C. eligible purposes. The FHWA, the State Department of Transportation, and the relevant toll authority or local governmental entity, if any, will execute the toll agreement.

Summary of the Two-Step Review Process

The entire review process, resulting in the execution of a toll agreement and/or a cooperative agreement, can be summarized in two steps as follows:

Step #1: Submit an Expression of Interest to the Tolling and Pricing Team. The Tolling and Pricing Team will review the Expression of Interest, advise the applicant which program or programs are eligible, and will also provide counsel as to which program is most appropriate to pursue. The State or public authority making application will be directed to contact the selected program office, wherein, the program office will then inform the public authority as to the procedures required for submitting a formal application for tolling authority and/or value pricing funding.

Step #2: Submit a formal application for tolling and pricing authority or value pricing funding to the FHWA program office for formal review, ultimately leading to a decision on approval. The public authority will then be notified of the decision. If the project is approved, a formal tolling agreement will then be prepared.

Tolling and Pricing Opportunities Available Under the Federal-Aid Highway Program (Title 23, U.S.C.) HOV Facilities—Section 1121

Section 1121 of SAFETEA-LU removed section 102(a) of Title 23 of the United States Code (23 U.S.C.) and replaced it with a new section 166 that clarifies the operation requirements of HOV facilities and provides more exceptions to their minimum vehicle occupancy requirements. Other non-tolling related issues are addressed in this section (e.g., low emission and energy efficient vehicles) that are irrelevant to the purpose of this notice. Specific to tolling and the creation of HOT lanes, the new legislation allows States to charge tolls to vehicles that do not meet the established occupancy requirements to use an HOV lane, provided the agency meets certain criteria to enroll participants, collect fees electronically, manage demand by varying tolls, and enforce against violations. Tolling under this section may be charged on both Interstate and non-Interstate facilities. There is no limit on the number of projects or the number of States that can participate. For more information, refer to the document "Federal-aid Highway Program Guidance on High Occupancy Vehicle (HOV) Lanes" which can be accessed from the HOV Facilities program section of the Tolling and Pricing Web site at

http://www.ops.fhwa.dot.gov/tolling_pricing/index.htm.

Express Lanes Demonstration Program—Section 1604(b)

This program permits tolling on selected demonstration projects to manage high levels of congestion, reduce emissions in a nonattainment or maintenance air quality area, or finance additional Interstate lanes for the purpose of reducing congestion. Fifteen projects are authorized nationwide from 2005 through 2009 to allow "States, authorities, or public or private entities designated by States" to collect a toll from motor vehicles at an eligible toll facility for any highway, bridge, or tunnel, including on the Interstate system. The State must vary the price of tolls according to the time of day or level of traffic, as appropriate, to manage congestion or improve air quality.

Unique to this program is the term "demonstration project." For purposes of tracking the fifteen slots allowed in section 1604(b), each agreement executed between an authority and the FHWA will constitute one "demonstration project." Either one facility, or, at the FHWA's discretion, a group of interrelated facilities in a region (so long as they are all operated under the auspices of the same oversight agency or agencies) may constitute one demonstration project, provided that all candidate facilities meet program criteria at the time of the agreement. Facilities located elsewhere in the State would require new and separate agreements.

Interstate System Construction Toll Pilot Program—Section 1604(c)

This new program authorizes up to three facilities on the Interstate System to toll for the purpose of financing the construction of new Interstate highways. A State or an interstate "compact of States" may submit a single candidate project under this program. Each applicant or applicants must demonstrate that financing the construction of the facility with the collection of tolls is the most efficient and economical way to advance the project. The State must agree not to enter into a noncompete agreement with a private party under which the State is prevented from improving or expanding the capacity of public roads in the vicinity of the toll facility to address conditions resulting from traffic diverted to nearby roads from the toll facility. There is no special funding authorized for this program. By law, Interstate maintenance funds may not be used on a facility for which tolls are

being collected under this program. All applications submitted under this program must be received by FHWA before August 10, 2015. This date is specifically cited for this program in section 1604(c)(8) of SAFETEA-LU.

23 U.S.C. 129

Under 23 U.S.C. 129, Federal participation is allowed in the following five types of toll activities.

- Initial construction (except on the Interstate System) of toll highways, bridges, and tunnels, including the approaches to these facilities;
- Reconstructing, resurfacing, restoring, and rehabilitation work on any existing toll facility;
- Reconstruction or replacement of free bridges or tunnels and conversion to toll facilities;
- Reconstruction of a free Federal-aid highway (except on the Interstate System) and conversion to a toll facility; and
- Preliminary studies to determine the feasibility of the above toll construction activities.

If Federal-aid funds are used for construction of or improvements to a toll facility or the approach to a toll facility or if a State plans to reconstruct and convert a free highway, bridge or tunnel previously constructed with Federal-aid funds to a toll facility, a toll agreement under section 129(a)(3) must be executed. There is no limit to the number of agreements that may be executed.

Interstate System Reconstruction and Rehabilitation Pilot Program

SAFETEA-LU continued the authority initially provided in section 1216(b) of TEA-21, by allowing up to three existing Interstate facilities (highway, bridge, or tunnel) to be tolled to fund needed reconstruction or rehabilitation on Interstate highway corridors that could not otherwise be adequately maintained or functionally improved without the collection of tolls. Each of the three facilities must be in a different State. There is no special funding authorized for this program. By law, Interstate maintenance funds may not be used on a facility for which tolls are being collected under this program. Currently, only one open slot remains.

Value Pricing Pilot Program—Section 1604(a)

As previously noted, a separate notice announcing this program's solicitation is published elsewhere in today's **Federal Register** due to the fact that this program is unique in offering grant funds, and the requirements for timely solicitation, review, and award of

grants. The existence of this program is mentioned herein solely as a means to complete the perspective of all tolling opportunity programs.

Frequently Asked Questions

1. *Why can't a State (or "public authority") simply apply directly to one specific program?* Technically, there is nothing to restrict an agency from doing this; however, since there are so many programs, some with limited participation slots, FHWA prefers to screen each project application. This is to ensure that (a) The agency is aware of the full range of available options; (b) the FHWA can effectively manage the very limited number of participation slots authorized for each program; and (c) other program offices are made aware that an application has been made, as each program will have a representative on the Tolling and Pricing Team.

2. *Who will make up the Tolling and Pricing Team?* The Office of Operations is the lead office and will undertake responsibility to gather and distribute the Expressions of Interest for preliminary evaluation and to maintain the aforementioned website. The Tolling and Pricing Team has representation from all of the relevant program offices that have tolling and pricing oversight responsibilities, including the FHWA Offices of Operations, Policy and Governmental Affairs, and Infrastructure. In addition, other stakeholder offices within FHWA and the U.S. Department of Transportation are represented, including the FHWA Offices of Public Affairs and Chief Counsel, and the Office of the Secretary of Transportation.

3. *How often will the Tolling and Pricing Team meet?* The group will meet as often as necessary in person, but mostly will communicate via email contact and access to a File Transfer Protocol (FTP) Web site, which will serve to post the Expressions of Interest for private review by the team almost immediately upon submittal. The Office of Operations will act promptly to engage the Tolling and Pricing Team to review a project proposal discuss project eligibility under different programs, and recommend the project for further consideration under the most appropriate program.

4. *If I have any questions, whom should I contact?* Any general questions concerning the tolling and pricing programs should be directed to Mr. Wayne Berman, Transportation Specialist, in the Office of Operations at 202-366-4069. His e-mail address is wayne.berman@fhwa.dot.gov. Alternatively, there is an e-mail "mailbox" on the tolling and pricing

Web site (address below). At the time of this notice, the direct points of contact are:

- a. Web site: http://www.ops.fhwa.dot.gov/tolling_pricing/index.htm.
- b. Tolling and Pricing Team—Wayne Berman, HOP. (202) 366-4069; wayne.berman@fhwa.dot.gov.
- c. Value Pricing (SAFETEA—LU 1604(a))—Patrick DeCorla-Souza. (202) 366-4076; patrick.decorla-souza@fhwa.dot.gov.
- d. HOV to HOT lane (1121)—Jessie Yung. (202) 366-4672; jessie.yung@fhwa.dot.gov.
- e. Express Lanes Demonstration (SAFETEA—LU 1604(b))—Wayne Berman (contact info above).
- f. Interstate System Construction (SAFETEA—LU 1604(c))—Greg Wolf. (202) 366-4655; greg.wolf@fhwa.dot.gov.
- g. Interstate Reconstruction and Rehabilitation (TEA-21 1216(b))—Greg Wolf (contact info above).
- h. 23 U.S.C. Section 129 Agreements—Greg Wolf (contact info above).

Authority: 23 U.S.C. 315; sec. 1216(a), Pub. L. 105-178, 112 Stat. 107; Pub. L. 109-59; 117 Stat. 1144 49 CFR 1.48.

Issued on: December 28, 2005.

J. Richard Capka,
Acting Federal Highway Administrator.
[FR Doc. E6-13 Filed 1-5-06; 8:45 am]
BILLING CODE 4910-22-P

DEPARTMENT OF TRANSPORTATION

Federal Highway Administration

[FHWA Docket No. FHWA-05-22706]

Motor Vehicle Registration and Licensed Driver Information

AGENCY: Federal Highway Administration (FHWA), DOT.

ACTION: Notice; request for comments.

SUMMARY: The Federal Highway Administration (FHWA) annually analyzes and publishes motor vehicle registration and licensed driver information obtained from the States, the District of Columbia, and Puerto Rico. This notice seeks public input from users on the quality, timeliness, comprehensiveness, and other characteristics of these data. Based on this input and other information, the FHWA will determine whether it is necessary to change the motor vehicle registration and licensed driver information collected. The FHWA is considering various options for these data programs including investigating alternative sources of data from the

public or private sector, developing enhanced software to capture and process the data more efficiently, and maintaining the status quo.

DATES: Comments should be received on or before March 7, 2006.

ADDRESSES: Mail or hand deliver comments for the docket number that appears in the heading of this document to the U.S. Department of Transportation, Dockets Management Facility, Room PL-401, 400 Seventh Street, SW., Washington, DC 20590-0001, or submit electronically at <http://dms.dot.gov/submit> or fax comments to (202) 493-2251.

Alternatively, comments may be submitted to the Federal rulemaking portal at <http://www.regulations.gov>. All comments must include the docket number that appears in the heading of this document. All comments received will be available for examination and copying at the above address from 9 a.m. to 5 p.m., e.t., Monday through Friday, except Federal holidays. Those desiring notification of receipt of comments must include a self-addressed, stamped postcard or you may print the acknowledgement page that appears after submitting comments electronically. Anyone is able to search the electronic form of all comments in any one of our dockets by the name of the individual submitting the comment (or signing the comment, if submitted on behalf of an association, business, or labor union). Anyone may review DOT's complete Privacy Act Statement in the Federal Register published on April 11, 2000 (Volume 65, Number 70, Pages 19477-78) or you may visit <http://dms.dot.gov>.

FOR FURTHER INFORMATION CONTACT: Mr. Tom Howard, 202-366-2833, Office of Highway Policy Information, HPPI-10, or Mr. Milton Hsieh, Office of Chief Counsel, HCC-40, 202-366-1397. Office hours are from 7:45 a.m. to 4:15 p.m., e.t., Monday through Friday, except Federal holidays.

SUPPLEMENTARY INFORMATION:

Electronic Access and Filing: You may submit or retrieve comments online through the Document Management System (DMS) at: <http://dms.dot.gov/submit>. Electronic submission and retrieval help and guidelines are available under the help section. Alternatively, Internet users may access all comments received by the U.S. DOT Docket Facility by using the universal resource locator (URL) <http://dms.dot.gov>. It is available 24 hours each day, 365 days each year. Please follow the instructions. An electronic copy of this document may also be downloaded by accessing the Office of

the Federal Register's home page at <http://www.archives.gov> and from the Government Printing Office's Web page at <http://www.gpoaccess.gov/nara>.

Background: The FHWA collects and publishes motor vehicle registration and licensed driver information obtained from the States, the District of Columbia, and Puerto Rico. This information is collected from State departments of transportation pursuant to 23 CFR 420.105 and is published in *Highway Statistics*.¹

The information in *Highway Statistics* is used in the development of highway legislation at the Federal level. The information is also used in preparing legislatively required reports to Congress, in keeping State governments informed, and, in general, as an aid to highway planning, programming, budgeting, forecasting, and fiscal management. This information is also used extensively in the evaluation of Federal, State, and local highway programs. The FHWA has re-assessed DOT internal needs for these data and has preliminarily determined that the information in *Highway Statistics* meets the Federal need of providing a national perspective on highway program activities.

This notice seeks public input from users on the quality, timeliness, comprehensiveness, and other characteristics of the motor vehicle registration and licensed driver data collected by the FHWA and published in *Highway Statistics*. Based on this input and other information, the FHWA will determine whether it is necessary to change the motor vehicle registration and licensed driver information collected. The motor vehicle registration data currently collected by the FHWA can be found in *Highway Statistics* tables MV-1, MV-2, MV-7, MV-9, MV-10 and MV-11. The licensed driver data currently collected by the FHWA can be found in *Highway Statistics* tables DL-1C, DL-20 and DL-22.

Motor vehicle registration: The motor vehicle registration data collection practices vary among the States. States register specific vehicle types on a calendar year or fiscal year basis. States may use some form of a "staggered" system to register motor vehicles to permit a distribution of the renewal workload throughout all months. In addition, most States allow pre-

registration or permit "grace periods" to better distribute the annual registration workload.

States report motor vehicle registrations by major vehicle classes: automobiles, buses, trucks, and motorcycles. The truck category includes light trucks to the extent they can be identified and separated from automobiles. Data on trucks, buses, trailers, and semitrailers are given in tables MV-9, MV-10, and MV-11, respectively. Although the detail of motor-vehicle data has improved in recent years, it is not yet possible to obtain from all States separate data on single-unit trucks and combinations. Some States provide data for light trucks and truck tractors, but for many States the FHWA estimates this information using other data sources, such as the Vehicle Inventory and Use Survey conducted by the Bureau of the Census.² The table MV-9 light truck category includes pickups, vans (full-size and mini), utility-type vehicles, as well as other vehicles (panel trucks and delivery vans generally of 10,000 pounds or less gross vehicle weight). Registrations of publicly owned motor vehicles are reported in table MV-7.

Registration practices for commercial vehicles also differ greatly among the States. Some States register a tractor-semi-trailer combination as a single unit; others register the tractor and the semi-trailer separately. Regardless of how they were registered, only the power units have been included in the truck count in table MV-1. Some States register buses with trucks or automobiles; many States do not report light utility trailers separately from commercial trailers or semi-trailers; and some States do not require registration of car or light utility trailers.

Drivers' License: Each State, the District of Columbia, and Puerto Rico administers its own driver licensing system. Since 1954 all States have required drivers to be licensed, and since 1959 all States have required examination prior to licensing. Tests of knowledge of State driving laws and practices, vision, and driving proficiency are now required for new licensees. The State distribution of total U.S. licensed drivers, by sex and age group, is shown in table DL-1C.

The distribution of total U.S. licensed drivers, by sex and age group, is shown in table DL-20.

DL-22 displays the number of drivers by sex and age groups for each State. For the States that do not provide the driver license data broken out to the top age

bracket of 85 and over, we have redistributed the last age bracket provided by each State according to the Census population data for those particular age brackets in that particular State.

Conclusion: This notice seeks public input from users on the quality, timeliness, comprehensiveness, and other characteristics of these data. Based on this input and other information, the FHWA will determine whether it is necessary to change the motor vehicle registration and licensed driver information collected, and the steps needed to ensure the quality of the information.

Specifically, the FHWA is interested in comments from users of motor vehicle registration and licensed driver information on data uses, data quality, data timeliness, data availability, and how well data meets user needs. Currently, the FHWA is considering various options for these data programs including investigating alternative sources of data from the public or private sector, developing enhanced software to capture and process the data more efficiently, and maintaining the status quo.

Issued on: December 28, 2005.

J. Richard Capka,

Acting Federal Highway Administrator.

[FR Doc. E6-11 Filed 1-5-06; 8:45 am]

BILLING CODE 4910-22-P

DEPARTMENT OF TRANSPORTATION

Federal Highway Administration

Safe, Accountable, Flexible, Efficient Transportation Equity Act: A Legacy for Users (SAFETEA-LU); Value Pricing Pilot Program Participation

AGENCY: Federal Highway Administration (FHWA), DOT.

ACTION: Notice; solicitation for participation.

SUMMARY: This notice invites State and local governments and other public authorities to apply to participate in the Value Pricing Pilot (VPP) program and presents guidelines for program applications. This notice describes the statutory basis for the VPP program and updates a notice published in the *Federal Register* on May 7, 2001 (66 FR 23077), by providing revised procedures, process timelines, and guidance for program participation.

A companion notice referring to non-grant programs, entitled "Safe, Accountable, Flexible, Efficient Transportation Equity Act: A Legacy for Users (SAFETEA-LU); Opportunities for

¹ *Highway Statistics* is an annual report containing analyzed data on motor fuel, motor vehicles, driver licensing, highway user taxation, State and local highway finance, highway mileage, and other selected data. This report has been published each year since 1945. It is available at the following URL: <http://www.fhwa.dot.gov/policy/ohpi/hss/>.

² This report is available at the following URL: <http://www.census.gov/svsd/www/tiusview.html>.

States and Other Qualifying Agencies to Gain Authority to Toll Facilities Constructed Using Federal Funds" is published elsewhere in today's edition of the **Federal Register**. Both of these notices are intended to cover all of the opportunities for States and other qualifying transportation agencies to obtain approval to toll their respective facilities and to secure funding to implement tolling and pricing.

DATES: Formal grant applications must be submitted no later than March 31, 2006, for FY 2006 funds, October 1, 2006, for FY 2007 funds, and each subsequent October 1 for funding through and including FY 2009. To be assured of the maximum amount of constructive assistance from FHWA in preparing a formal application, Expressions of Interest must be submitted two months prior, i.e., by January 31, 2006, for FY 2006 funds, August 1, 2006, for FY 2007 funds, and each subsequent August 1 covering the funding period.

FOR FURTHER INFORMATION CONTACT: For questions about this notice, please contact Mr. Wayne Berman, Office of Operations, (202) 366-4069, or via email at <mailto:wayne.berman@fhwa.dot.gov>, FHWA, 400 Seventh Street, SW., Washington, DC 20590. For specific information about the Value Pricing Pilot Program, please contact Mr. Patrick DeCorla-Souza, Office of Policy and Governmental Affairs, Highway Pricing and System Analysis Team Leader, (202) 366-4076, or via e-mail at patrick.decorla-souza@fhwa.dot.gov. For legal questions, interpretations and counsel, please contact Mr. Michael Harkins, Attorney Advisor, FHWA Office of the Chief Counsel, (202) 366-4928, or via e-mail at michael.harkins@fhwa.dot.gov. Office hours for the FHWA are from 7:45 a.m. to 4:15 p.m., e.s.t., Monday through Friday, except Federal holidays.

SUPPLEMENTARY INFORMATION:

Electronic Access

An electronic copy of this document may be downloaded from the **Federal Register's** home page at: <http://www.archives.gov> and the Government Printing Office's database at: <http://www.access.gpo.gov/nara>.

Background

Section 1012(b) of the Intermodal Surface Transportation Efficiency Act (ISTEA) (Pub. L. 102-240; 105 Stat. 1914), as amended by section 1216(a) of the Transportation Equity Act (TEA-21) (Pub. L. 105-178; 112 Stat. 107), and section 1604(a) of Safe, Accountable, Flexible, Efficient Transportation Equity

Act: A Legacy for Users (SAFETEA-LU) (Pub. L. 109-59; 119 Stat. 1144), authorizes the Secretary of Transportation (the Secretary) to create a Value Pricing Pilot Program. Value pricing encompasses a variety of strategies to manage congestion on highways, including tolling of highway facilities, as well as other strategies that do not involve tolls, such as mileage-based charges for insurance, taxes, leasing fees, and car sharing. The value pricing concept of assessing relatively higher prices for travel during peak periods is the same as that used in many other sectors of the economy to respond to peak-use demands. For example, airlines, hotels, and theaters often charge more for peak than non-peak times.

The FHWA is seeking applications for the FY 2006 VPP program. According to statute, the FHWA may enter into cooperative agreements with up to fifteen State or local governments or other public authorities (hereafter, States) to establish, maintain, and monitor value pricing pilot programs, each including an unlimited number of projects. The FHWA invites interested States to apply to participate in the VPP program for FY 2006. There are already fourteen State-led programs currently in the VPP program: California, Colorado, Florida, Georgia, Illinois, Maryland, Minnesota, New Jersey, North Carolina, Oregon, Pennsylvania, Texas, Virginia, and Washington. Therefore, only one new State is eligible to participate. Any value pricing project included under these programs may involve the use of tolls on the Interstate system. This is an exception to the general provisions prohibiting tolls on the Interstate system as contained in 23 U.S.C. 129 and 301.

A maximum of \$12 million is authorized for each of the fiscal years 2006 through 2009 to be made available to carry out the VPP program requirements. A set-aside of \$3 million per fiscal years 2006 through 2009 is authorized only for value pricing pilot projects that do not involve highway tolls. The Federal share payable under the program is 80 percent of the cost of the project. Funds allocated by the Secretary to a State or other public entity under this section shall remain available for obligation by the State for a period of three years after the last day of the fiscal year for which funds are authorized. If, on September 30 of any year, the amount of funds made available for the VPP program, but not allocated, exceeds \$8 million, the excess amount will be apportioned to all States as Surface Transportation Program funds.

Funds available for the VPP program can be used to support pre-implementation study activities as well as to pay for implementation costs of value pricing projects. Section 1012(b)(6) of ISTEA provides that a State may permit toll-paying vehicles with fewer than two occupants to operate in high occupancy vehicle (HOV) lanes if the vehicles are part of a local value pricing pilot program under this section. SAFETEA-LU Section 1121, "HOV Facilities," among other things, also allows for the conversion of HOV lanes to high occupancy toll (HOT) lanes. Given that the VPP program has only one more slot available for a new program partner to participate, Section 1121 authority should be used, instead of VPP program authority, for HOV-to-HOT lane conversions if an application comes from a State that is not already in the VPP program.

Potential financial effects of value pricing projects on low-income drivers shall be considered and, where such effects are expected to be significant, possible mitigation measures should be identified, such as providing new or expanded transit service as an integral part of the value pricing project, toll discounts or credits for low-income motorists who do not have viable transit options, or fare or toll credits earned by motorists on regular lanes which can be used to pay for tolls on priced lanes. Mitigation measures can be included as part of the value pricing project implementation costs.

The Secretary is required to report to Congress every two years on the effects of all value pricing pilot programs. Annual evaluation data and reports shall be provided to the FHWA for use in reports to Congress.

The VPP program is a continuation of the Congestion Pricing Pilot Program authorized by section 1012(b) of the ISTEA and amended by section 1216(a) of TEA-21. To obtain up-to-date information on the status of current projects, please go to: http://www.ops.fhwa.dot.gov/tolling_pricing/index.htm and go to "Resources" and click on "Value Pricing Pilot Program Knowledge Exchange".

In addition to the VPP program, SAFETEA-LU offers States broader authority to use tolling on a pilot or demonstration basis to finance Interstate construction and reconstruction, promote efficiency in the use of highways, and support congestion reduction by providing expanded flexibility under the following programs: HOV facilities; Interstate System Reconstruction & Rehabilitation Pilot; Interstate System Construction

Toll Pilot; and Express Lanes Demonstration Program. For more information on those programs, please refer to the companion notice in today's **Federal Register** entitled "Safe, Accountable, Flexible, Efficient Transportation Equity Act: A Legacy for Users (SAFETEA-LU); Opportunities for State and Other Qualifying Agencies to Gain Authority to Toll Facilities Constructed Using Federal Funds."

What Is Value Pricing?

"Value pricing," "congestion pricing," "peak-period pricing," "variable pricing," and "variable tolling" are all terms used to refer to direct non-constant charges for road use, possibly varying by location, time of day, severity of congestion, vehicle occupancy, or type of facility. By shifting some trips to off-peak periods, to mass transit or other higher-occupancy vehicles, or to routes away from congested facilities, or by encouraging consolidation of trips, value pricing charges are intended to promote economic efficiency both generally and within the commercial freight sector. They also achieve congestion reduction, improved air quality, energy conservation, and transit productivity goals.

A "value pricing project" means any implementation of value pricing concepts or techniques discussed in the "Potential Project Types" section of this notice and included under a State or local "value pricing pilot program," where such a program includes one or more value pricing projects serving a single geographic area, such as a metropolitan area or State. By definition, an entity with one or more approved value pricing projects must have a value pricing program. While the distinction between "project" and "program" may appear to be merely a technical one, it is significant in that, as described in the "Background" section of this notice, the number of total VPP programs is statutorily limited to fifteen, while there is no limit to the number of VPP projects allowed under each VPP program.

"Cooperative agreement" means the agreement signed between the FHWA and a State to implement local value pricing pilot programs (See 49 CFR Part 18). "Toll agreement" means the agreement signed between the FHWA and a State to grant the authority to collect tolls.

Program Objective

The overall objective of the VPP program is to support efforts by State and local governments or other public authorities to establish local value

pricing pilot programs, to provide for the monitoring and evaluation of value pricing projects included in such programs, and to report on these effects. The VPP program's primary focus is on value pricing with road tolls, with a secondary focus on other market-based approaches for congestion relief that do not involve road tolls, such as parking pricing or pay-as-you-drive insurance. All projects should incorporate significant pricing mechanisms intended to reduce the level of congestion.

Potential Project Types

The FHWA is seeking applications to use value pricing projects to reduce congestion, improve system performance, and promote mobility. Value pricing charges are expected to accomplish this purpose by encouraging the use of alternative times, modes, routes, or trip patterns. As such, value pricing charges need to be targeted at vehicles causing congestion, and prices must be set at levels significant enough to encourage drivers to use alternative times, routes, modes, or trip patterns during congested periods. Conversely, proposed projects that contemplate value pricing charges that are not significant enough to influence demand, such as minor increases in fees during peak-periods, or moderate toll increases instituted primarily for financing purposes, will be given low priority. Similarly, value pricing concepts that have become mainstream and have been adopted as common practice, such as HOV-to-HOT lane conversions, will not be funded. To increase the likelihood of generating information on a variety of useful value pricing strategies, proposed projects having as many of the following characteristics as possible will receive priority for Federal support. Projects of interest include:

1. Applications of value pricing which are comprehensive and include pricing of currently free facilities, such as area wide pricing, pricing of multiple facilities or corridors, and/or combinations of road pricing and parking pricing. The size or extent of road pricing programs, ranging from single facilities, to sections of, or complete corridors, to comprehensive area- or region-wide applications, are of interest, along with their relative effect on reducing congestion, altering travel behavior, and encouraging the use of other transportation modes. Region-wide pricing applications that use technologies that provide drivers with real-time congestion and pricing information on alternative routes are especially encouraged.

2. Pricing at key traffic bottlenecks, of multiple facilities in a single travel corridor, or on single highway facilities, including bridges and tunnels. Applications to shift from a fixed to a variable toll schedule on existing toll facilities are encouraged (i.e., combinations of peak-period surcharges and off-peak discounts). Pricing of queue jumps is also eligible. A queue jump is defined as a facility that can be used by certain types of traffic to bypass points on the transportation network where congestion is particularly severe and occurs in a predictable pattern (colloquially called "bottlenecks"). Queue jumps can be as elaborate as an elevated facility or as simple as an at-grade lane addition.

3. Innovative parking pricing strategies, including time-of-day pricing and charges reflective of congestion conditions, provided the level and coverage of proposed parking charges is sufficient to reduce congestion. Parking pricing strategies that are integrated with other pricing strategies are encouraged. Parking pricing strategies should be designed to influence trip-making behavior, and might include surcharges for entering or exiting a parking facility during or near peak periods, or a range of parking cash-out policies, where cash is offered to employees in lieu of subsidized parking, parking operators reimburse monthly patrons for unused parking days, or renters or purchasers in multi-family housing developments are provided direct financial saving for not availing of car parking spaces. Pricing of a single parking facility, coverage of a few employee spaces, or pricing of parking spaces in a small area, for example, are unlikely to receive priority, unless they incorporate a truly unique element which might facilitate broader applications of value pricing across local areas or States.

4. Pay-as-you-drive pricing, including car insurance premiums set on a per-mile basis and innovative car ownership, leasing, and usage arrangements that reduce fixed costs and increase variable usage costs.

5. Projects that are likely to add to the base of knowledge about the various design, implementation, effectiveness, operational, and acceptability dimensions of value pricing. The FHWA is seeking information related to the impacts of value pricing on the following: Travel behavior (e.g., trip lengths, mode use, time-of-travel, trip destinations, and trip generation by private and commercial trip makers); traffic conditions (e.g., speeds and levels of service); implementation issues (e.g., technology, innovative pricing).

techniques, public acceptance, administration, operation, enforcement, and legal and institutional issues); revenues, their uses and financial plans; different types of users and businesses; and low-income motorists, including possible mitigation measures and their effectiveness. These diverse information needs mean that the FHWA may fund different types of value pricing applications in different local contexts to maximize the potential of the pilot program.

6. Projects that do not have adverse effects on alternative routes or modes, or on low-income or other transportation-disadvantaged groups are encouraged under the VPP program. If such effects are anticipated, proposed pricing programs should incorporate measures to mitigate any major adverse impacts, including enhancement of transportation alternatives for peak period travelers, services such as "life-line" toll rates aimed at low income travelers, and credit-based tolling programs such as toll credits earned by motorists in regular lanes which can be used to pay tolls on priced lanes.

7. Pricing projects that lead to substantial congestion reduction and supplant or supplement existing tax-based approaches for generating surface transportation revenues.

8. Pricing projects that result in free-flow peak period roadway conditions, and where motorists earn or are provided with limited monetary credit for their discretionary use, thereby allowing them a limited amount of free or discounted rush hour roadway access or transit trips before having to pay full fees.

While the FHWA is seeking applications that incorporate some or all of these project characteristics, these guidelines are intended only to illustrate selection priorities, not to limit potential program participants from proposing new and innovative pricing approaches for incorporation in the program.

Pre-Implementation Studies

The VPP program funds may also be used to assist State and local governments in carrying out pre-implementation study activities designed to lead to implementation of a value pricing project. The intent of the pre-implementation study phase is to support efforts to identify and evaluate value pricing project alternatives, and to prepare the necessary groundwork for possible future implementation. Purely academic studies of value pricing (not designed to lead to possible project implementation), or broad, area wide planning studies which incorporate

value pricing only as one option, will not be funded under this program. Broad planning studies can be funded with regular Federal-aid highway or transit planning funds. Applications for pre-implementation studies will be selected based on the likelihood that they will lead to implementation of pilot tests of value pricing conforming to the objectives described in the previous section.

In cases where the FHWA has made funds available to a State for pre-implementation studies, but the State decides not to implement the project and has no other value pricing projects, the FHWA may proceed to remove that State from the program and replace it with another State in the pilot program. Since section 1012(b)(1) of ISTEA limits participation in the pilot program to only fifteen slots (specifically, "States, local governments or public authorities," colloquially termed States), the fifteen participating States must intend to implement value pricing projects and proceed accordingly.

Project Costs Eligible for Grant Funding

The FHWA will provide up to the statutorily allowable 80 percent share of the estimated costs of an approved project. Funds available for the VPP program can be used to support pre-implementation study activities and also to pay for implementation costs of value-pricing projects. Costs eligible for reimbursement include costs of planning for, setting up, managing, operating, monitoring, evaluating, and reporting on local value pricing pilot projects. Costs cannot be reimbursed for longer than three years. The three-year funding limitation will begin on the date of the first disbursement of Federal funds for project activities. Examples of specific costs eligible for reimbursement include the following:

1. Pre-Implementation Study Costs—Allowable pre-implementation study costs include: Planning, public participation, consensus building, marketing, impact assessment, modeling, financial planning, technology assessments and specifications, and other pre-implementation work that relates to the establishment of the value pricing project including meeting Federal or State environmental or other planning requirements.

2. Implementation Costs—Allowable costs include those for setting up, managing, operating, evaluating, and reporting on a value pricing project, including:

a. Necessary salaries and expenses, or other administrative and operational costs, such as installation of equipment

for operation of a pilot project (e.g., Electronic Toll Collection (ETC)) technology, video equipment for traffic monitoring, and other instrumentation), enforcement costs, costs of monitoring and evaluating project operations, and costs of continuing public relations activities during the period of implementation.

b. Costs of providing transportation alternatives, such as new or expanded transit or ridesharing services provided as an integral part of the value pricing project. Funds are not available to replace existing sources of support for these services.

Project implementation costs can be supported until such time that sufficient revenues are being generated by the project to fund such activities without Federal support, but in any case for no longer than three years. Each implementation project included in a local value pricing pilot program will be considered separately for this purpose.

Funds may not be used to pay for activities conducted prior to approval for VPP program participation. Also, funds made available through the VPP program may not be used to construct new highway lanes or bridges, even if those facilities are to be priced, but toll ramps or minor pavement additions needed to facilitate toll collection or enforcement are eligible.

Complementary actions, such as lane construction or the implementation of traffic control systems or transit projects can be funded through other highway and transit programs eligible under SAFETEA-LU and from new revenues raised as a result of a pilot. Those interested in participating in the VPP program are encouraged to explore opportunities for combining funds from these other programs with VPP program funds. Nevertheless, Federal funds may not be used to match VPP program funds unless permitted under specific statutory authority.

Eligible Uses of Revenues

Sections 1012(b)(2) and (3) of ISTEA provide that revenues generated by any value pricing pilot project must be used for the project's operating costs and for projects that are eligible for assistance under Title 23, United States Code. Also, since section 1012(b)(2) requires the Secretary to fund a pilot project until such time that sufficient revenues are being generated to fund its operating costs, any revenues generated by a pilot project must be applied first to pay for pilot project operating costs. Any project revenues in excess of pilot project operating costs may be used for any projects eligible under Title 23, U.S. Code. A project's operating (or

implementation) costs include any costs necessary for a project's implementation; mitigation measures to deal with adverse financial effects on low-income drivers; the proper maintenance of the facility; any construction (including reconstruction, rehabilitation, restoration, or resurfacing) of the facility; any debt service incurred in implementing the project; and a reasonable return on investment by any private entity financing the project. Uses of revenue are encouraged which will support the goals of the VPP program, particularly uses designed to provide benefits to those traveling in the corridor where the project is being implemented.

Furthermore, for toll projects, the FHWA and the public authority (including the State transportation department) having jurisdiction over a facility shall enter into a toll agreement concerning the use of toll revenue to be generated under a value pricing project. The toll agreement will merely provide for the public authority's commitment to use the revenues in accordance with the applicable statutory requirements of the VPP program and to annually audit its use of toll revenues for compliance with such requirements. The execution of a toll agreement is consistent with the requirements of other toll programs, such as contained in 23 U.S.C. 129, and will facilitate adequate oversight of a State's compliance with revenue use requirements of the VPP program. The FHWA Division Administrator, in coordination with the Office of Policy and Governmental Affairs and Office of Chief Counsel, will execute value pricing toll agreements.

Who Is Eligible To Apply?

Qualified applicants include local, regional and State government agencies, as well as public tolling authorities. The VPP program term "States" and the Tolling and Pricing Team term "public authorities" may be used interchangeably for purposes of identifying that a responsible entity will enter into process of applying to the VPP program or another tolling program. Although project agreements must be with public authorities, a local VPP program partnership may also include private tolling authorities and non-profit organizations.

Program Coordination and Assistance—The Tolling and Pricing Team

The Federal Highway Administration, Office of Operations is responsible for coordinating all tolling and pricing programs that now exist under the Federal-aid Highway Program. In order

to reduce confusion among interested applicants, given both the number and differing structures of the various tolling and pricing programs, the Office of Operations has formed a working group known as the "Tolling and Pricing Team."

The key role for the Tolling and Pricing Team is to assist public authorities by directing them to the most appropriate program (or programs), including to the VPP program, among the many options available. Members of the Tolling and Pricing Team represent the FHWA Offices of Operations, Policy and Governmental Affairs, and Infrastructure—the primary offices responsible for administering each of the tolling and pricing programs—and other oversight offices within the U.S. DOT and the FHWA, including, but not limited to the Office of the Secretary, and the FHWA Office of the Administrator and Office of Chief Counsel. Members participate on the Tolling and Pricing Team because of their direct program responsibilities or because they are interested stakeholders in tolling and pricing programs within the U.S. DOT.

The Tolling and Pricing Team has six purposes:

1. Coordinate all tolling and pricing activity within FHWA to facilitate the implementation and advancement of tolling and pricing projects and standards in the United States;
2. Receive and review all Expressions of Interest submitted to the FHWA from public authorities;
3. Direct the public authority or partnerships designated by the State to the tolling and pricing program (or programs) that can enable them to accomplish the goals set forth in the "Expression of Interest" section of this notice;
4. Assist the Office of Operations in the promulgation of a final rule including requirements, standards, or performance specifications for the interoperability of automated toll collection systems as directed by SAFETEA-LU Section 1604(b)(6);
5. Support each of the FHWA program offices that have responsibility for a tolling and pricing program, in advancing formal proposals to gain approval to toll or price motor vehicles and facilitating coordination with the appropriate FHWA Division Office; and
6. Establish program performance goals; monitor achievements, and prepare an annual report to Congress on the status and progress of all tolling and pricing programs, including describing program successes in meeting congestion reduction and other performance goals.

The Tolling and Pricing Team reviews all Expressions of Interest for the various tolling opportunities contained in current law but does not have responsibility to approve or disapprove specific projects. That responsibility will remain with each of the respective FHWA program offices responsible for administering a specific tolling or pricing program. By requesting and reviewing all Expressions of Interest, the Tolling and Pricing Team can effectively guide an applicant to the most appropriate program.

The "Expression of Interest"

A public authority that wants to request tolling or pricing authority, or funding, is asked to submit an Expression of Interest to the Tolling and Pricing Team in care of the FHWA Office of Operations in Washington, DC. An Expression of Interest template can be downloaded via the Internet by going to the Tolling and Pricing Opportunities webpage within the FHWA Office of Operations Web site at http://www.ops.fhwa.dot.gov/tolling_pricing/index.htm. Use of the template is optional. The Expression of Interest may be attached as an e-mail to TollingandPricingTeam@fhwa.dot.gov, or a hardcopy can be mailed to Mr. Wayne Berman, FHWA Office of Operations, Room 3404, 400 Seventh Street, SW., Washington, DC 20590. Concurrently, the Expression of Interest should be copied to the respective State FHWA Division Office.

The Expression of Interest is a document—in letter, memo, or report format—that provides the rationale for funding or tolling authority and information about the intended project. A complete Expression of Interest, based upon the information items listed below, will enable the Tolling and Pricing Team to provide the best assistance and identify the range of options possible to meet intended goals and timeframes.

The information items requested for a complete Expression of Interest are as follows:

- (a) A description of the agency or requesting authority or authorities that is/are requesting this tolling authority where applicable;
- (b) The name, title, email address, and phone number of the person who will act as the point of contact on behalf of the requesting authority or authorities;
- (c) A statement concerning the action being sought:
 - (i) Funding and/or tolling authority via the Value Pricing Pilot program to support either pre-project study activities or implementation activities as permitted; or

(ii) Only authority to toll either existing or planned facilities;

(d) A description of the subject facility or facilities proposed to be tolled;

(e) Whether the subject facility is an Interstate or non-Interstate facility;

(f) Whether construction is involved and, if so, whether this is new construction, expansion, rehabilitation, reconstruction, or other;

(g) Whether an HOV lane or lanes currently exist on the facility;

(h) A timetable to enact tolling (or modify tolling) on the subject facility;

(i) Any expressions or declarations of support from public officials or the public, i.e., specifically, any public meetings that were held. If no public meetings or expressions of support are available, please indicate if there are project plans for ensuring adequate public involvement and support prior to implementation;

(j) A plan for implementing tolls on the facility, where applicable. Where known, the range of anticipated tolls and the strategies to vary toll rates (i.e., the formulae for variable pricing);

(k) The reasons for implementing tolls, such as financing construction, reducing congestion, or improving air quality;

(l) A description of the public agency or agencies that will be responsible for operating, maintaining, and enforcing the tolling program; and

(m) A description of how, if at all, any private entities are involved either in the up-front costs to enact tolling, or the cost sharing or debt retirement associated with revenues.

Program Participation—Overview of the Process

Submitting an Expression of Interest initiates a review process by the Tolling and Pricing Team that leads to a recommendation as to which tolling or pricing program (or programs) will be appropriate and available to meet the goals of the public authority. In some cases, if more than one tolling program is available, the Tolling and Pricing Team will work with the public authority to help select the one program that is most appropriate and is most likely to lead to project approval. If the public authority prefers applying to a tolling program other than the one recommended, the Tolling and Pricing Team will defer to this request; however, the Tolling and Pricing Team will also provide advice as to the pros and cons of the decision.

Once there is agreement between the public authority and the Tolling and Pricing Team as to the most appropriate program, the applicant will be referred

to the specific FHWA program office responsible for administering that tolling and pricing initiative. The FHWA program office will then provide the public authority with the necessary information on how to formally apply for authority to toll motor vehicles and, in the case of the VPP program, request funding.

Once a formal application is submitted, the appropriate FHWA program office will review the application and determine whether or not to approve the proposed project. The public authority will then be notified as to the determination. If approved, a formal tolling agreement and/or cooperative agreement will be prepared between the FHWA and the public authority. The toll agreement must be executed with the FHWA and address the use of revenues that are collected from the operation of the toll facility. While program elements may vary, the restrictions generally require the revenues to be used first for debt service, reasonable return on the investment for private parties, and the operations and maintenance of the facility. In addition, if the facility is being adequately maintained, any revenues in excess of these uses may be used for other title 23 U.S.C. eligible purposes. The FHWA, the State Department of Transportation, and the relevant toll authority or local governmental entity, if any, will execute the toll agreement, and in the case of the VPP, also a "cooperative agreement" that defines the scope of work that will be funded.

Summary of the Two-Step Review Process

The entire review process, resulting in the execution of a toll agreement and/or a cooperative agreement, can be summarized in two steps as follows:

Step #1: Submit an Expression of Interest to the Tolling and Pricing Team. The Tolling and Pricing Team will review the Expression of Interest, advise the applicant as to which program or programs are candidate to their project, and provide counsel as to which of those is most appropriate to pursue. The applicant will be directed to contact the selected program office, wherein, the program office will then inform the public authority as to the procedures required for submitting a formal application for tolling authority and/or value pricing funding.

Step #2: Submit a formal application for tolling or pricing authority or value pricing funding to the FHWA program office for formal review, ultimately leading to a decision on approval. The public authority will then be notified of

the decision. If the project is approved, a formal tolling agreement (and in the case of the VPP program, also a cooperative agreement) will then be prepared.

The Value Pricing Pilot Program Application

As stated under the **DATES** section in this notice, in order to be assured of the maximum amount of constructive assistance from FHWA in preparing a formal application, Expressions of Interest for tolling and pricing projects seeking VPP program funding must be submitted two months prior to the application deadline that applies to the fiscal year for which funds are being sought. Once the Tolling and Pricing Team provides feedback on the Expression of Interest submittal, and once the public authority has confirmed its course of action is to pursue VPP program approval, the formal application should be submitted directly through the State Department of Transportation to the appropriate FHWA Division Administrator, with a copy sent concurrently to Mr. Patrick DeCorla-Souza, FHWA's Highway Pricing and System Analysis Team Leader, c/o the Office of Policy and Governmental Affairs, 400 Seventh Street, SW., Washington, DC 20590, or via e-mail at <mailto:patrick.decorla-souza@fhwa.dot.gov>.

Formal VPP program applications (i.e., step #2) will be reviewed by a Federal Interagency Review Group,¹ which provides support to the FHWA in evaluating program applications (see the "VPP Program Application Review Process" section below). Ideally, the refined formal application will include:

1. A description of the congestion problem being addressed (current and projected);
2. A description of the proposed pricing program and its goals, including description of facilities included, and, for implementation projects, expected pricing schedules, technology to be used, enforcement programs, and operating details;
3. Preliminary estimates of the social and economic effects of the pricing program, including potential equity impacts, and a plan or methodology for further refining these estimates for all

¹ The Federal Interagency Review Group was established to assist the FHWA in assessing the likelihood that proposed local value pricing programs will provide valid and useful tests of value pricing concepts. The Review Group is composed of representatives of the Tolling and Pricing Team, along with representatives of the Federal Transit Administration, the U.S. Environmental Protection Agency, and the U.S. Department of Energy.

pricing project(s) included in the program;

4. The role of alternative transportation modes in the project, and anticipated enhancements proposed to be included in the pricing program;

5. A time line for the pre-implementation study and implementation phases of the project (applications indicating early implementation of pricing projects that will allow evaluation during the life of SAFETEA-LU will receive priority);

6. A description of tasks to be carried out as part of each phase of the project, and an estimate of costs associated with each;

7. Plans for monitoring and evaluating value pricing implementation projects, including plans for data collection and analysis, before and after assessment, and long term monitoring and documenting of project effects;

8. A detailed finance and revenue plan, including (for implementation projects) a budget for capital and operating costs; a description of all funding sources, planned expenditures, proposed uses of revenues, and a plan for projects to become financially self-sustaining (without Federal support) within three years of implementation.

9. Plans for involving key affected parties, coalition building, media relations, and related matters, including either demonstration of previous public involvement in the development of the proposed pricing program or plans to ensure adequate public involvement prior to implementation;

10. Plans for meeting all Federal, State and local legal and administrative requirements for project implementation, including relevant Federal-aid planning and environmental requirements. Priority will be given to applications where projects are included as a part of (or are consistent with) a broad program addressing congestion, mobility, air quality and energy conservation, where an area has congestion management systems (CMS) for Transportation Management Areas (urbanized areas with over 200,000 population or those designated by the Secretary).

11. An explanation about how ETC project components will be compatible with other ETC systems in the region:

If some of these items are not available or fully developed at the time the formal application is submitted, applications will still be considered for support if they meet some of the priority interests of the FHWA, and related project characteristics, as described earlier in the section entitled "Potential Project Types," and if there is a strong

indication that these items will be completed within a short time.

VPP Program Application Review Process

A. Requests for Funding

After completion of an Expression of Interest, and upon subsequent receipt of the formal, refined application, the FHWA's Office of Policy and Governmental Affairs will engage the Federal Interagency Review Group and proceed with final evaluation.

To ensure that all projects receive equal and fair consideration for the limited available funds, the FHWA requires formal grant applications to be submitted no later than March 31, 2006, for FY 2006 funds, October 1, 2006, for FY 2007 funds, and each subsequent October 1 for funding through and including FY 2009. To be assured of the maximum amount of constructive assistance from FHWA in preparing a formal application, Expressions of Interest must be submitted by January 31, 2006, for FY 2006 funds, August 1, 2006, for FY 2007 funds, and each subsequent August 1 thereafter. This timeline will allow for a fair comparison among formal applications received and will also allow the FHWA to make timely recommendations to the Secretary with regard to allocation of available funds in accordance with the criteria discussed in this notice. Based on the recommendations of the Federal Interagency Review Group, the U.S. DOT will identify those VPP program applications that have the greatest potential for promoting the objectives of the VPP program, including demonstrating the effects of value pricing on congestion, driver behavior, traffic volume, ridesharing, transit ridership, air quality, and availability of funds for transportation programs. The Secretary will make selections of applications based on the recommendations of the Federal Interagency Review Group and criteria contained in this notice.

B. Projects for Which No Funds Are Requested

Although most projects under the VPP program involve requests for value pricing funds, some projects do not. In such cases, and especially where a State is not already part of the VPP program, the FHWA recommends that the public authority investigate the other opportunities to gain authority to toll that are listed in the companion notice in today's **Federal Register**, entitled "Safe, Accountable, Flexible, Efficient Transportation Equity Act: A Legacy for Users (SAFETEA-LU); Opportunities for

State and Other Qualifying Agencies to Gain Authority to Toll Facilities Constructed Using Federal Funds."

Cooperative Agreement

The VPP program candidates approved for funding will be invited to enter into negotiations with the FHWA to develop a cooperative agreement under which the scope of work for the value pricing project will be defined. Federal statutes will govern the cooperative agreement. Regulations cited in the agreement, and 49 CFR part 18, Uniform Administrative Requirements for Grants and Cooperative Agreements to State and Local Governments, will also govern as they relate to the acceptance and use of Federal funds for this program. As a practical matter, each VPP program project should have a separate cooperative agreement. Although, in the past, the FHWA has allowed some States to have a master cooperative agreement that is subsequently amended for each approved project, in the future the FHWA will execute a separate agreement for each project. For value pricing projects that do not involve requests for Federal funds, a cooperative agreement must still be executed. The FHWA Division Administrator will sign the cooperative agreement on behalf of FHWA.

Other Requirements

Prior to the FHWA approval of pricing project implementation, value-pricing programs must be shown to be consistent with Federal metropolitan and statewide planning requirements (23 U.S.C. 135 (c)(1), (e)(2)(B), (f)(1)(B)(i)(I) and (II), (f)(3)(A) and (B); 49 U.S.C. 5323(1)).

Implementation projects involving tolls outside metropolitan areas must be included in the approved statewide transportation improvement program and be selected in accordance with the requirements set forth in section 1204(f)(3) of the TEA-21.

Implementation projects involving tolls in metropolitan areas must be: (a) Included in, or consistent with, the approved metropolitan transportation plan (if the area is in nonattainment for a transportation related pollutant, the metropolitan plan must be in conformance with the State air quality implementation plan); (b) included in the approved metropolitan and statewide transportation improvement programs (if the metropolitan area is in a nonattainment area for a transportation related pollutant, the metropolitan transportation improvement program must be in conformance with the State air quality

implementation plan); (c) selected in accordance with the requirements in Section 1203(h)(5) or (i)(2) of TEA-21; and (d) consistent with any existing congestion management system in Transportation Management areas, developed pursuant to 23 U.S.C. 134(i)(3).

Frequently Asked Questions

1. *Who will make up the Tolling and Pricing Team?* The Office of Operations is the lead office and will undertake responsibility to gather and distribute the Expressions of Interest for preliminary evaluation and to maintain the aforementioned website. The Tolling and Pricing Team has representation from all of the relevant program offices that have tolling and pricing oversight responsibilities, including the FHWA Offices of Operations, Policy and Governmental Affairs, and Infrastructure. In addition, other stakeholder offices within FHWA and the U.S. Department of Transportation are represented, including the FHWA Offices of Public Affairs and Chief Counsel, and the Office of the Secretary of Transportation.

2. *How often will the Tolling and Pricing Team meet?* The group will meet as often as necessary in person, but mostly will communicate via e-mail contact and access to a File Transfer Protocol (FTP) Web site, which will serve to post the Expressions of Interest for private review by the team almost immediately upon submittal. The Office of Operations will act promptly to engage the Tolling and Pricing Team to review a project proposal, discuss project eligibility under different programs, and recommend the project for further consideration under the most appropriate program.

3. *If I have any questions, whom should I contact?* Any general questions concerning the tolling and pricing programs should be directed to Mr. Wayne Berman, Transportation Specialist, in the Office of Operations at 202-366-4069. His e-mail address is wayne.berman@fhwa.dot.gov. Alternatively, there is an e-mail "mailbox" on the tolling and pricing Web site (address below). At the time of this notice, the direct points of contact are:

a. Web site: http://www.ops.fhwa.dot.gov/tolling_pricing/index.htm

b. Tolling and Pricing Team—Wayne Berman, HOP. (202) 366-4069; wayne.berman@fhwa.dot.gov.

c. Value Pricing (SAFETEA-LU 1604(a))—Patrick DeCorla-Souza. (202) 366-4076; patrick.decorla-souza@fhwa.dot.gov.

d. HOV to HOT lane (1121)—Jessie Yung. (202) 366-4672; jessie.yung@fhwa.dot.gov.

e. Express Lanes Demonstration (SAFETEA-LU 1604(b))—Wayne Berman (contact info above).

f. Interstate System Construction (SAFETEA-LU 1604(c))—Greg Wolf. (202) 366-4655; greg.wolf@fhwa.dot.gov.

g. Interstate Reconstruction and Rehabilitation (TEA-21 1216(b))—Greg Wolf (contact info above).

h. 23 U.S.C. 129 Agreements—Greg Wolf (contact info above).

Authority 23 U.S.C. 315; sec. 1216(a), Pub. L. 105-178, 112 Stat. 107; Pub. L. 109-59; 117 Stat. 1144 49 CFR 1.48.

Issued on: December 28, 2005.

J. Richard Capka,

Acting Federal Highway Administrator.

[FR Doc. E6-12 Filed 1-5-06; 8:45 am]

BILLING CODE 4910-22-P

DEPARTMENT OF TRANSPORTATION

Pipeline and Hazardous Materials Safety Administration

[Docket No. PHMSA-05-23447]

Pipeline Safety: Reconsideration of Natural Gas Pipeline Maximum Allowable Operating Pressure for Class Locations

AGENCY: Pipeline and Hazardous Materials Safety Administration, DOT.

ACTION: Notice of meeting; call for papers.

SUMMARY: On March 21, 2006, the Pipeline and Hazardous Materials Safety Administration (PHMSA) will hold a public meeting to discuss raising the allowable operating pressure on certain natural gas transmission pipelines. Pipelines are the energy highways of the Nation that provide the most efficient means to transport vast volumes of natural gas on which we depend. Raising the maximum allowable operating pressures (MAOP) for natural gas pipelines would allow more gas to flow through these pipelines. This notice is designed to announce a public meeting and to invite papers on relevant technical subjects.

Over the past 20 years, there has been a drastic improvement in technology pertaining to materials, metallurgy, controls, operations, and maintenance of the pipeline network. Based on these and other advances, PHMSA believes that certain pipelines in certain locations could be safely and reliably operated above the operating pressure established in current Federal pipeline safety regulation.

There are three categories of pipelines that could realize an immediate benefit from such an increase in the MAOP: the proposed Alaska Natural Gas Transmission System; new natural gas pipelines that are being certificated by the Federal Energy Regulatory Commission; and pipelines constructed since 1980 with line pipe of known metallurgical and mechanical properties.

This meeting provides the pipeline industry, Federal and State regulators, and interested members of the public an opportunity to share their knowledge and experience about the impact of increasing the MAOP to increase pipeline efficiency. Individuals that would like to make presentations should notify the individual listed under **FOR FURTHER INFORMATION CONTACT** by February 7, 2006, and submit papers at this meeting.

ADDRESSES: The March 21, 2006, meeting will be held at the Hyatt Regency Reston Hotel, 1800 Presidents Street, Reston, VA 20190. The telephone number for reservations at the Hyatt Regency Reston Hotel is (703) 709-1234. The hotel will post the particular meeting room the day of the meeting.

FOR FURTHER INFORMATION CONTACT: Mr. Joy Kadnar, Director, Engineering and Emergency Support at (202) 366-4595 or joy.kadnar@dot.gov about the subject matter in this notice.

SUPPLEMENTARY INFORMATION:

Introduction

Pipeline operators continually explore ways to reduce the cost of new pipelines, or increase the efficiency of existing pipelines, without affecting reliability and safety. One way to achieve cost reductions is to use high-grade line pipe and employ new welding methods. Another method to increase cost-effectiveness and to make the pipeline more efficient is to operate pipelines at higher stress levels.

International pipeline regulations generally limit design stresses to 72% specified minimum yield strength (SMYS). Under highly selective conditions, some pipelines in the United States and Canada operate at hoop stresses up to 80% SMYS. Notwithstanding, the current United States Code of Federal Pipeline Safety Regulations (CFR) (49 CFR part 192) limits the stress to 72% SMYS for Class 1 locations, while Canada limits it to 80%. There are a lot of other countries considering operating at higher levels. Therefore, PHMSA believes it is appropriate to explore the reliability and integrity implications of operating pipelines at stress levels above 72%

SMYS, but not to exceed 80% SMYS for Class 1 locations.

The benefits of an increase in MAOP for natural gas pipelines are tremendous, mainly because of the increase in capacity and fuel efficiency. For new pipelines operated at a higher MAOP, operators might realize an initial cost savings, primarily in materials. A capacity increase in existing pipelines will have an auxiliary benefit by avoiding the construction of new pipelines or costly modifications that have the potential to damage the environment. Historical problems associated with seam failures are non-existent with new materials. Most new pipelines have been configured to accept inline inspection tools to monitor the pipeline's condition. Pipeline operators have improved their ability to manage internal corrosion. By allowing pipeline companies to safely increase the MAOP of existing pipelines that meet certain criteria, they could avoid new construction that can impact the environment.

Research by the Pipeline Research Council International concluded that pipeline operations can be safe and reliable at stress levels of up to 80% SMYS if the pipeline has well-established metallurgical properties and can be managed to protect it against known threats, such as corrosion and mechanical damage. Additionally, independent studies demonstrate the benefits of risk and reliability-based principles that strengthen safety.

Background

The class location regulations require that pipelines routed through areas with higher local population density operate at lower pressures. This is intended to provide an extra safety margin in those areas.

The gas transmission integrity management program addresses protections in high consequence areas. The cost-benefit analysis included in the final rule noted that a significant benefit to implementing integrity management is reduced cost to the pipeline industry for ensuring safety in populated areas along pipelines. Improved knowledge of pipeline integrity provides a technical basis for considering alternatives to regulation, for example whether to replace pipe or to reduce operating stresses in pipelines when population near them increases, (i.e., when the class location increases to either Class 2 from Class 1 or to Class 3 from Class 2). A class location change results from new construction near a pipeline segment and unless a waiver is granted triggers a requirement that the MAOP be confirmed or revised.

On June 24, 2004, PHMSA issued criteria for granting class location waivers based on integrity management principles. The criteria provide information and guidance to pipeline operators concerning the specific pipe design and operating parameters within which PHMSA is likely to consider a class location waiver application to be consistent with pipeline safety. Class location waivers that are granted allow a pipeline operator to perform alternative risk control activities based on the principles and requirements of the integrity management program in lieu of pipe replacement or pressure reduction. These waivers allow operators to continue to operate pipelines at existing hoop stresses although the MAOP is no longer commensurate with the class location requirements.

Specified Minimum Yield Strength

In the early 1950s, the American Standards Association's (ASA) pipeline committee developed ASA Standard B31.8 and the concept of basing design stress on a percentage of the specified minimum yield strength (SMYS): The committee determined that 72% SMYS was an acceptable design factor. Thereafter, PHMSA incorporated this standard by reference into its pipeline regulations. In the late 1980s, ASME International (ASME) revisited the SMYS issue and determined that pipelines could operate safely at up to 80% SMYS. The committee then modified ASME B31.8 to include that provision.

The United States Federal pipeline safety regulations allow a maximum operating pressure of 72% SMYS. The Canadian regulations allow a maximum operating pressure of 80% SMYS. Currently, there are pipelines in the United States that have been "grandfathered" to operate at an MAOP above 72% SMYS. PHMSA statistics show that these pipelines have an equivalent safety record when compared with pipelines that operate according to the design factors in the pipeline safety regulations. Further, the pipeline safety regulations already allow pipelines to continue to operate at the original design factor when the class location increases by one Class, providing certain criteria are met. For example, a pipeline in a Class 2 location is allowed to continue operating at 60% of SMYS when it changes to a Class 3.

Preliminary Meeting Agenda

The public meeting will examine policies and technical issues that are central to understanding and improving pipeline safety. While providing

opportunities for improved efficiency, the meeting will highlight contributed papers and studies and will provide opportunities to discuss and exchange views.

The agenda for this meeting will include discussion on:

- Existing pipelines operating above 72% SMYS.
- Evolution of the 72% SMYS ceiling.
- Class Location.
- Regulatory Requirements in the United States, Canada, and the United Kingdom.
- Engineering and Technical Considerations for 80% SMYS Operation.
- Waiver requests submitted to PHMSA. See DOT Docket Numbers: PHMSA-05-23448, and PHMSA-05-23387.

During the meeting, PHMSA would like participants to discuss their views on the MAOP and any experience they have had operating pipelines beyond 72% SMYS. PHMSA also would like participants to provide information on reliability and how moving beyond 72% SMYS would impact pipeline safety.

Call for Papers

We invite papers to address reasons why PHMSA should or should not provide relief from the class location requirements to pipelines that meet certain stringent operating criteria. PHMSA is interested in engineering and technical considerations. Papers may discuss the impact on public safety, the environment, the economy, and the State pipeline programs. All papers, whether presented at the public meeting or not, will be included in the public docket. PHMSA solicits papers on relevant policy and technical topics in the following areas:

- The impact of operating pipelines at pressures greater than 72% SMYS.
- The impact on pipeline threats at 80% SMYS operation.
- The role of ongoing integrity assessment in managing the safety of pipelines designed to operate at pressures up to 80% SMYS.
- The benefits of 80% SMYS operation on natural gas commodity movements and energy flows.
- A qualitative assessment of the pipeline capacity increase across the grid that could result from such pressure uprating.
- A comparison of failure histories, national and international, of pipelines operating up to 72% SMYS versus those operating above 72% SMYS.
- Regulatory harmonization between the United States and Canada.
- Role of initial hydrostatic testing for initial design integrity validation.

- Review of pipe robustness and resistance to excavation damage.
- Impact on fatigue life of pipelines operating up to 80% SMYS.
- Fracture control design parameters for 80% SMYS operation.
- Evaluation of integrity re-assessment intervals for 80% SMYS operation.
- Optimization of conditioning, monitoring, and mitigation programs for 80% SMYS operation.
- Review of existing compressor station equipment relative to 80% SMYS operation.
- Review of operations and controls for 80% SMYS.
- Emerging approaches for reliability analysis, integrity management, and risk analysis in high stress pipelines.
- Line pipe characteristics and flaws that preclude pipelines from higher operating stresses.

Authors must submit abstracts of their papers in 250 words or less to the docket by February 7, 2006. PHMSA will notify authors by February 14, 2006, whether their papers were accepted for presentation at the meeting. Each author of an accepted paper will have the choice of providing either a short paper (6–10 pages) or an extended abstract (3–5 pages) that will be due before the public meeting.

You may submit papers or comments by mail or deliver them to the Dockets Facility, U.S. Department of Transportation, Room PL-401, 400 Seventh Street, SW., Washington, DC 20590-0001. The Dockets Facility is open from 9 a.m. to 5 p.m., Monday through Friday, except Federal holidays. You also may submit papers or comments to the docket electronically by logging onto the following Internet Web address: <http://dms.dot.gov>. Click on "Help & Information" for instructions on how to file a document electronically. All papers or comments should reference docket number

PHMSA-05-23447. Anyone who would like confirmation of mailed papers or comments must include a self-addressed stamped postcard.

Privacy Act Statement: Anyone may search the electronic form of all comments received for any of our dockets. You may review DOT's complete Privacy Act Statement in the **Federal Register** published on April 11, 2000 (65 FR 19477) or you may visit <http://dms.dot.gov>.

Information on Services for Individuals With Disabilities: For information on facilities or services for individuals with disabilities, or to request special assistance at the meeting, please contact Cheryl Whetsel at (202) 366-4431 by March 6, 2006.

Authority: 49 U.S.C. 60102 and 60133.

Issued in Washington, DC, on December 30, 2005.

Stacey L. Gerard,

Associate Administrator for Pipeline Safety.

[FR Doc. 06-110 Filed 1-5-06; 8:45 am]

BILLING CODE 4910-60-P

DEPARTMENT OF TRANSPORTATION

Surface Transportation Board

[STB Finance Docket No. 34812]

BNSF Railway Company—Temporary Trackage Rights Exemption —Union Pacific Railroad Company

Union Pacific Railroad Company (UP) has agreed to grant temporary overhead trackage rights to BNSF Railway Company (BNSF) over UP's Chester Subdivision between milepost 131.3, Rockview Junction, MO, and milepost 0.0, Valley Junction, IL, a distance of approximately 132 miles.

The transaction was scheduled to be consummated on December 28, 2005, the effective date of this notice, and the temporary rights will expire on March

21, 2006. The purpose of the temporary rights is for bridging BNSF's train service while BNSF's main lines are out of service due to certain programmed track, roadbed and structural maintenance.

As a condition to this exemption, any employee affected by the acquisition of the temporary rights will be protected by the conditions imposed in *Norfolk and Western Ry. Co.—Trackage Rights—BN*, 354 I.C.C. 605 (1978), as modified in *Mendocino Coast Ry., Inc.—Lease and Operate*, 360 I.C.C. 653 (1980), and any employee affected by the discontinuance of those trackage rights will be protected by the conditions set out in *Oregon Short Line R. Co.—Abandonment—Goshen*, 360 I.C.C. 91 (1979).

This notice is filed under 49 CFR 1180.2(d)(8). If it contains false or misleading information, the exemption is void *ab initio*. Petitions to revoke the exemption under 49 U.S.C. 10502(d) may be filed at any time. The filing of a petition to revoke will not automatically stay the transaction.

An original and 10 copies of all pleadings, referring to STB Finance Docket No. 34812, must be filed with the Surface Transportation Board, 1925 K Street, NW., Washington, DC 20423-0001. In addition, a copy of each pleading must be served on Sidney L. Strickland, Jr., Sidney Strickland and Associates, PLLC, 3050 K Street, NW., Suite 101, Washington, DC 20007.

Board decisions and notices are available on our Web site at "<http://www.stb.dot.gov>."

Decided: December 28, 2005.


By the Board, David M. Konschnik,
Director, Office of Proceedings.

Vernon A. Williams,

Secretary.

[FR Doc. 06-15 Filed 1-5-06; 8:45 am]

BILLING CODE 4915-01-P





Federal Register

Friday,
January 6, 2006

Part II

Department of Veterans Affairs

Reasonable Charges for Medical Care or
Services; 2006 Calendar Year Update;
Notice

DEPARTMENT OF VETERANS AFFAIRS

Reasonable Charges for Medical Care or Services; 2006 Calendar Year Update

AGENCY: Department of Veterans Affairs.

ACTION: Notice.

SUMMARY: Section 17.101 of Title 38 of the Code of Federal Regulations sets forth the Department of Veterans Affairs (VA) medical regulations concerning "reasonable charges" for medical care or services provided or furnished by VA to a veteran:

- For a nonservice-connected disability for which the veteran is entitled to care (or the payment of expenses of care) under a health plan contract;
- For a nonservice-connected disability incurred incident to the veteran's employment and covered under a worker's compensation law or plan that provides reimbursement or indemnification for such care and services; or
- For a nonservice-connected disability incurred as a result of a motor vehicle accident in a State that requires automobile accident reparations insurance.

The regulations include methodologies for establishing billed amounts for the following types of charges: Acute inpatient facility charges; skilled nursing facility/sub-acute inpatient facility charges; partial hospitalization facility charges; outpatient facility charges; physician and other professional charges, including professional charges for anesthesia services and dental services; pathology and laboratory charges; observation care facility charges; ambulance and other emergency transportation charges; and charges for durable medical equipment, drugs, injectables, and other medical services, items, and supplies identified by Healthcare Common Procedure Coding System (HCPCS) Level II codes. The

regulations also provide that data for calculating actual charge amounts at individual VA facilities based on these methodologies will either be published in a notice in the **Federal Register** or will be posted on the Internet site of the Veterans Health Administration Chief Business Office, currently at <http://www.va.gov/cbo>, under "Charge Data." Some of these charges are hereby updated as described in the **SUPPLEMENTARY INFORMATION** section of this notice. These changes are effective January 1, 2006.

When charges for medical care or services provided or furnished at VA expense by either VA or non-VA providers have not been established under other provisions of the regulations, the method for determining VA's charges is set forth at 38 CFR 17.101(a)(8).

FOR FURTHER INFORMATION CONTACT: Romona Greene, Chief Business Office (168), Veterans Health Administration, Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 254-0361. (This is not a toll free number.)

SUPPLEMENTARY INFORMATION: Of the charge types listed in the Summary section of this notice, acute inpatient facility charges and skilled nursing facility/sub-acute inpatient facility charges are not being changed. Acute inpatient facility charges remain the same as set forth in a notice published in the **Federal Register** on September 28, 2005 (70 FR 56772). Skilled nursing facility/sub-acute inpatient facility charges remain the same as set forth in a notice published in the **Federal Register** on September 28, 2005 (70 FR 56772).

Based on the methodologies set forth in 38 CFR 17.101, this document provides an update to charges for 2006 HCPCS Level II and Current Procedural Technology (CPT) codes. Charges are also being updated based on more recent versions of data sources for the following charge types: Partial

hospitalization facility charges; outpatient facility charges; physician and other professional charges, including professional charges for anesthesia services and dental services; pathology and laboratory charges; observation care facility charges; ambulance and other emergency transportation charges; and charges for durable medical equipment, drugs, injectables, and other medical services, items, and supplies identified by HCPCS Level II codes. These updated charges are effective January 1, 2006.

In this update, we are retaining the table designations used in the notice published in the **Federal Register** on April 11, 2005 (70 FR 18466). Accordingly, the tables identified as being updated by this notice correspond to the applicable tables published in the notice, beginning with Table C.

We have updated the list of data sources presented in Supplementary Table 1 to reflect the updated data sources used to establish the updated charges described in this notice.

As a reminder, in Supplementary Table 3 published in the **Federal Register** dated September 28, 2005, we set forth the list of VA medical facility locations, which includes their three-digit Zip Codes and provider based/non-provider based designations. In accordance with the final rule, subsequent updates to Supplementary Table 3 will be posted on the Internet site of the Veterans Health Administration Chief Business Office.

Consistent with the regulations, the updated data tables and supplementary tables containing the changes described are published with this notice. The updated data tables and supplementary tables containing the changes described will be effective until changed by a subsequent **Federal Register** notice.

Approved: December 20, 2005.

Gordon H. Mansfield,
Deputy Secretary of Veterans Affairs.

BILLING CODE 8320-01-P

TABLE C. — OBSERVATION CARE FACILITY NATIONWIDE BASE AND HOURLY CHARGES

Description	Base Charge	Hourly Charge
Observation Facility Care	\$209.44	\$42.69

TABLE D. — PARTIAL HOSPITALIZATION FACILITY NATIONWIDE PER DIEM CHARGE

Description	All-Inclusive Per Diem Charge
Partial Hospitalization Facility	\$504.78

TABLE E. — AMBULANCE AND OTHER EMERGENCY TRANSPORTATION CHARGES BY HCPCS CODE

HCPCS Code	Description	Charge
A0380	Basic Life Support Mileage (Per Mile)	\$11.63
A0390	Advanced Life Support Mileage (Per Mile)	\$10.74
A0425	Ground Mileage, Per Statute Mile	\$11.83
A0426	Ambulance Service, Advanced Life Support, Non-Emergency Transport, Level 1 (ALS 1)	\$742.80
A0427	Ambulance Service, Advanced Life Support, Emergency Transport, Level 1 (ALS1-Emergency)	\$813.86
A0428	Ambulance Service, Basic Life Support, Non-Emergency Transport, (BLS)	\$484.44
A0429	Ambulance Service, Basic Life Support, Emergency Transport (BLS-Emergency)	\$542.58
A0430	Ambulance Service, Conventional Air Services, Transport, One Way (Fixed Wing)	\$5,232.43
A0431	Ambulance Service, Conventional Air Services, Transport, One Way (Rotary Wing)	\$6,253.75
A0435	Fixed Wing Air Mileage, Per Statute Mile	\$49.10
A0436	Rotary Wing Air Mileage, Per Statute Mile	\$75.17

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 1 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
10021	Fna w/o image		+	\$243.49	
10022	Fna w/image		+	\$457.00	
10040	Acne surgery		+	\$195.23	
10060	Drainage of skin abscess		+	\$497.85	
10061	Drainage of skin abscess		+	\$497.85	
10080	Drainage of pilonidal cyst		+	\$497.85	
10081	Drainage of pilonidal cyst		+	\$3,544.82	
10120	Remove foreign body		+	\$497.85	
10121	Remove foreign body		+	\$4,293.63	
10140	Drainage of hematoma/fluid		+	\$3,544.82	
10160	Puncture drainage of lesion		+	\$276.50	
10180	Complex drainage, wound		+	\$3,544.82	
11000	Debride infected skin		+	\$480.57	
11001	Debride infected skin add-on		+	\$229.30	
11010	Debride skin, fx		+	\$1,188.19	
11011	Debride skin/muscle, fx		+	\$1,188.19	
11012	Debride skin/muscle/bone, fx		+	\$1,188.19	
11040	Debride skin, partial		+	\$480.57	
11041	Debride skin, full		+	\$480.57	
11042	Debride skin/tissue		+	\$774.62	
11043	Debride tissue/muscle		+	\$774.62	
11044	Debride tissue/muscle/bone		+	\$2,425.17	
11055	Trim skin lesion		+	\$229.30	
11056	Trim skin lesions, 2 to 4		+	\$229.30	
11057	Trim skin lesions, over 4		+	\$337.02	
11100	Biopsy, skin lesion		+	\$276.50	
11101	Biopsy, skin add-on		+	\$276.50	
11200	Removal of skin tags		+	\$337.02	
11201	Remove skin tags add-on		+	\$480.57	
11300	Shave skin lesion		+	\$229.30	
11301	Shave skin lesion		+	\$229.30	
11302	Shave skin lesion		+	\$229.30	
11303	Shave skin lesion		+	\$480.57	
11305	Shave skin lesion		+	\$337.02	
11306	Shave skin lesion		+	\$337.02	
11307	Shave skin lesion		+	\$337.02	
11308	Shave skin lesion		+	\$337.02	
11310	Shave skin lesion		+	\$337.02	
11311	Shave skin lesion		+	\$337.02	
11312	Shave skin lesion		+	\$337.02	
11313	Shave skin lesion		+	\$774.62	
11400	Removal of skin lesion		+	\$1,188.19	
11401	Removal of skin lesion		+	\$1,188.19	
11402	Removal of skin lesion		+	\$1,188.19	
11403	Removal of skin lesion		+	\$2,131.88	
11404	Removal of skin lesion		+	\$4,293.63	
11406	Removal of skin lesion		+	\$4,293.63	
11420	Removal of skin lesion		+	\$2,131.88	
11421	Removal of skin lesion		+	\$2,131.88	
11422	Removal of skin lesion		+	\$2,131.88	
11423	Removal of skin lesion		+	\$2,131.88	
11424	Removal of skin lesion		+	\$4,293.63	
11426	Removal of skin lesion		+	\$5,653.51	
11440	Removal of skin lesion		+	\$1,188.19	
11441	Removal of skin lesion		+	\$1,188.19	
11442	Removal of skin lesion		+	\$2,131.88	
11443	Removal of skin lesion		+	\$2,131.88	
11444	Removal of skin lesion		+	\$2,131.88	
11446	Removal of skin lesion		+	\$5,653.51	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 2 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
11450	Removal, sweat gland lesion		+	\$5,653.51	
11451	Removal, sweat gland lesion		+	\$5,653.51	
11462	Removal, sweat gland lesion		+	\$5,653.51	
11463	Removal, sweat gland lesion		+	\$5,653.51	
11470	Removal, sweat gland lesion		+	\$5,653.51	
11471	Removal, sweat gland lesion		+	\$5,653.51	
11600	Removal of skin lesion		+	\$1,188.19	
11601	Removal of skin lesion		+	\$1,188.19	
11602	Removal of skin lesion		+	\$1,188.19	
11603	Removal of skin lesion		+	\$2,131.88	
11604	Removal of skin lesion		+	\$2,131.88	
11606	Removal of skin lesion		+	\$4,293.63	
11620	Removal of skin lesion		+	\$2,131.88	
11621	Removal of skin lesion		+	\$1,188.19	
11622	Removal of skin lesion		+	\$2,131.88	
11623	Removal of skin lesion		+	\$4,293.63	
11624	Removal of skin lesion		+	\$4,293.63	
11626	Removal of skin lesion		+	\$5,653.51	
11640	Removal of skin lesion		+	\$2,131.88	
11641	Removal of skin lesion		+	\$2,131.88	
11642	Removal of skin lesion		+	\$2,131.88	
11643	Removal of skin lesion		+	\$2,131.88	
11644	Removal of skin lesion		+	\$4,293.63	
11646	Removal of skin lesion		+	\$5,653.51	
11719	Trim nail(s)		+	\$200.15	
11720	Debride nail, 1-5		+	\$200.15	
11721	Debride nail, 6 or more		+	\$200.15	
11730	Removal of nail plate		+	\$337.02	
11732	Remove nail plate, add-on		+	\$229.30	
11740	Drain blood from under nail		+	\$200.15	
11750	Removal of nail bed		+	\$1,188.19	
11752	Remove nail bed/finger tip		+	\$5,653.51	
11755	Biopsy, nail unit		+	\$1,188.19	
11760	Repair of nail bed		+	\$503.72	
11762	Reconstruction of nail bed		+	\$503.72	
11765	Excision of nail fold, toe		+	\$480.57	
11770	Removal of pilonidal lesion		+	\$5,653.51	
11771	Removal of pilonidal lesion		+	\$5,653.51	
11772	Removal of pilonidal lesion		+	\$5,653.51	
11900	Injection into skin lesions		+	\$229.30	
11901	Added skin lesions injection		+	\$229.30	
11920	Correct skin color defects		+	\$503.72	
11921	Correct skin color defects		+	\$503.72	
11922	Correct skin color defects		+	\$503.72	
11950	Therapy for contour defects		+	\$503.72	
11951	Therapy for contour defects		+	\$503.72	
11952	Therapy for contour defects		+	\$503.72	
11954	Therapy for contour defects		+	\$503.72	
11960	Insert tissue expander(s)		+	\$4,779.12	
11970	Replace tissue expander		+	\$4,779.12	
11971	Remove tissue expander(s)		+	\$5,653.51	
11976	Removal of contraceptive cap		+	\$1,188.19	
11980	Implant hormone pellet(s)			\$190.09	
11981	Insert drug implant device			\$190.09	
11982	Remove drug implant device			\$190.09	
11983	Remove/insert drug implant			\$190.09	
12001	Repair superficial wound(s)		+	\$503.72	
12002	Repair superficial wound(s)		+	\$503.72	
12004	Repair superficial wound(s)		+	\$503.72	
12005	Repair superficial wound(s)		+	\$503.72	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 3 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
12006	Repair superficial wound(s)		+	\$503.72	
12007	Repair superficial wound(s)		+	\$503.72	
12011	Repair superficial wound(s)		+	\$503.72	
12013	Repair superficial wound(s)		+	\$503.72	
12014	Repair superficial wound(s)		+	\$503.72	
12015	Repair superficial wound(s)		+	\$503.72	
12016	Repair superficial wound(s)		+	\$503.72	
12017	Repair superficial wound(s)		+	\$503.72	
12018	Repair superficial wound(s)		+	\$503.72	
12020	Closure of split wound		+	\$503.72	
12021	Closure of split wound		+	\$503.72	
12031	Layer closure of wound(s)		+	\$503.72	
12032	Layer closure of wound(s)		+	\$503.72	
12034	Layer closure of wound(s)		+	\$503.72	
12035	Layer closure of wound(s)		+	\$503.72	
12036	Layer closure of wound(s)		+	\$503.72	
12037	Layer closure of wound(s)		+	\$1,558.31	
12041	Layer closure of wound(s)		+	\$503.72	
12042	Layer closure of wound(s)		+	\$503.72	
12044	Layer closure of wound(s)		+	\$503.72	
12045	Layer closure of wound(s)		+	\$503.72	
12046	Layer closure of wound(s)		+	\$503.72	
12047	Layer closure of wound(s)		+	\$1,558.31	
12051	Layer closure of wound(s)		+	\$503.72	
12052	Layer closure of wound(s)		+	\$503.72	
12053	Layer closure of wound(s)		+	\$503.72	
12054	Layer closure of wound(s)		+	\$503.72	
12055	Layer closure of wound(s)		+	\$503.72	
12056	Layer closure of wound(s)		+	\$503.72	
12057	Layer closure of wound(s)		+	\$1,558.31	
13100	Repair of wound or lesion		+	\$1,558.31	
13101	Repair of wound or lesion		+	\$1,558.31	
13102	Repair wound/lesion add-on		+	\$503.72	
13120	Repair of wound or lesion		+	\$503.72	
13121	Repair of wound or lesion		+	\$503.72	
13122	Repair wound/lesion add-on		+	\$503.72	
13131	Repair of wound or lesion		+	\$503.72	
13132	Repair of wound or lesion		+	\$503.72	
13133	Repair wound/lesion add-on		+	\$503.72	
13150	Repair of wound or lesion		+	\$1,558.31	
13151	Repair of wound or lesion		+	\$503.72	
13152	Repair of wound or lesion		+	\$1,558.31	
13153	Repair wound/lesion add-on		+	\$503.72	
13160	Late closure of wound		+	\$4,779.12	
14000	Skin tissue rearrangement		+	\$4,779.12	
14001	Skin tissue rearrangement		+	\$4,779.12	
14020	Skin tissue rearrangement		+	\$4,779.12	
14021	Skin tissue rearrangement		+	\$4,779.12	
14040	Skin tissue rearrangement		+	\$4,779.12	
14041	Skin tissue rearrangement		+	\$4,779.12	
14060	Skin tissue rearrangement		+	\$4,779.12	
14061	Skin tissue rearrangement		+	\$4,779.12	
14300	Skin tissue rearrangement		+	\$4,779.12	
14350	Skin tissue rearrangement		+	\$4,779.12	
15000	Skin graft		+	\$1,558.31	
15001	Skin graft add-on		+	\$1,558.31	
15040	Harvest cultured skin graft	c	+	\$98.78	OPPS
15050	Skin pinch graft		+	\$1,558.31	
15100	Skin split graft		+	\$4,779.12	
15101	Skin split graft add-on		+	\$4,779.12	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 4 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
15110	Epidrm autogrft trnk/arm/leg	c	+	\$1,158.64	OPPS
15111	Epidrm autogrft t/a/l add-on	c	+	\$1,158.64	OPPS
15115	Epidrm a-grft face/hck/hf/q	c	+	\$1,158.64	OPPS
15116	Epidrm a-grft t/n/hf/q addl	c	+	\$1,158.64	OPPS
15120	Skin split graft		+	\$4,779.12	
15121	Skin split graft add-on		+	\$4,779.12	
15130	Derm autograft, trnk/arm/leg	c	+	\$1,158.64	OPPS
15131	Derm autograft t/a/l add-on	c	+	\$1,158.64	OPPS
15135	Derm autograft face/hck/hf/q	c	+	\$1,158.64	OPPS
15136	Derm autograft, t/n/hf/q add	c	+	\$1,158.64	OPPS
15150	Cult epiderm grft t/arm/leg	c	+	\$1,158.64	OPPS
15151	Cult epiderm grft t/a/l addl	c	+	\$1,158.64	OPPS
15152	Cult epiderm graft t/a/l +%	c	+	\$1,158.64	OPPS
15155	Cult epiderm graft, t/n/hf/q	c	+	\$1,158.64	OPPS
15156	Cult epidrm grft t/n/hf/q add	c	+	\$1,158.64	OPPS
15157	Cult epiderm grft t/n/hf/q +%	c	+	\$1,158.64	OPPS
15170	Cell graft trunk/arms/legs	c	+	\$98.78	OPPS
15171	Cell graft t/arm/leg add-on	c	+	\$98.78	OPPS
15175	Acellular graft, t/n/hf/q	c	+	\$98.78	OPPS
15176	Acell graft, t/n/hf/q add-on	c	+	\$98.78	OPPS
15200	Skin full graft		+	\$4,779.12	
15201	Skin full graft add-on		+	\$1,558.31	
15220	Skin full graft		+	\$4,779.12	
15221	Skin full graft add-on		+	\$1,558.31	
15240	Skin full graft		+	\$4,779.12	
15241	Skin full graft add-on		+	\$1,558.31	
15260	Skin full graft		+	\$4,779.12	
15261	Skin full graft add-on		+	\$1,558.31	
15300	Apply sknallogrft, t/arm/leg	c	+	\$1,158.64	OPPS
15301	Apply sknallogrft t/a/l addl	c	+	\$337.81	OPPS
15320	Apply skin allogrft t/n/hf/q	c	+	\$337.81	OPPS
15321	Aply sknallogrft t/n/hf/q add	c	+	\$337.81	OPPS
15330	Aply acell alogrft t/arm/leg	c	+	\$337.81	OPPS
15331	Aply acell grft t/a/l add-on	c	+	\$337.81	OPPS
15335	Apply acell graft, t/n/hf/q	c	+	\$337.81	OPPS
15336	Aply acell grft t/n/hf/q add	c	+	\$337.81	OPPS
15340	Apply cult skin substitute	c	+	\$98.78	OPPS
15341	Apply cult skin sub add-on	c	+	\$98.78	OPPS
15360	Apply cult derm sub, t/a/l	c	+	\$98.78	OPPS
15361	Apply cult derm sub t/a/l add	c	+	\$98.78	OPPS
15365	Apply cult derm sub t/n/hf/q	c	+	\$98.78	OPPS
15366	Apply cult derm t/hf/q add	c	+	\$98.78	OPPS
15400	Skin heterograft		+	\$1,558.31	
15401	Skin heterograft add-on		+	\$1,558.31	
15420	Apply skin xgraft, t/n/hf/q	c	+	\$337.81	OPPS
15421	Apply skn xgrft t/n/hf/q add	c	+	\$337.81	OPPS
15430	Apply acellular xenograft	c	+	\$337.81	OPPS
15431	Apply acellular xgraft add	c	+	\$337.81	OPPS
15570	Form skin pedicle flap		+	\$4,779.12	
15572	Form skin pedicle flap		+	\$4,779.12	
15574	Form skin pedicle flap		+	\$4,779.12	
15576	Form skin pedicle flap		+	\$4,779.12	
15600	Skin graft		+	\$4,779.12	
15610	Skin graft		+	\$4,779.12	
15620	Skin graft		+	\$4,779.12	
15630	Skin graft		+	\$4,779.12	
15650	Transfer skin pedicle flap		+	\$4,779.12	
15732	Muscle-skin graft, head/neck		+	\$4,779.12	
15734	Muscle-skin graft, trunk		+	\$4,779.12	
15736	Muscle-skin graft, arm		+	\$4,779.12	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 5 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
15738	Muscle-skin graft, leg		+	\$4,779.12	
15740	Island pedicle flap graft		+	\$4,779.12	
15750	Neurovascular pedicle graft		+	\$4,779.12	
15760	Composite skin graft		+	\$4,779.12	
15770	Derma-fat-fascia graft		+	\$4,779.12	
15775	Hair transplant punch grafts		+	\$1,558.31	
15776	Hair transplant punch grafts		+	\$1,558.31	
15780	Abrasion treatment of skin		+	\$5,653.51	
15781	Abrasion treatment of skin		+	\$1,188.19	
15782	Dressing change not for burn		+	\$1,188.19	
15783	Abrasion treatment of skin		+	\$774.62	
15786	Abrasion, lesion, single		+	\$229.30	
15787	Abrasion, lesions, add-on		+	\$337.02	
15788	Chemical peel, face, epiderm		+	\$229.30	
15789	Chemical peel, face, dermal		+	\$480.57	
15792	Chemical peel, nonfacial		+	\$229.30	
15793	Chemical peel, nonfacial		+	\$229.30	
15819	Plastic surgery, neck		+	\$1,558.31	
15820	Revision of lower eyelid		+	\$4,779.12	
15821	Revision of lower eyelid		+	\$4,779.12	
15822	Revision of upper eyelid		+	\$4,779.12	
15823	Revision of upper eyelid		+	\$4,779.12	
15824	Removal of forehead wrinkles		+	\$4,779.12	
15825	Removal of neck wrinkles		+	\$4,779.12	
15826	Removal of brow wrinkles		+	\$4,779.12	
15828	Removal of face wrinkles		+	\$4,779.12	
15829	Removal of skin wrinkles		+	\$4,779.12	
15831	Excise excessive skin tissue		+	\$5,653.51	
15832	Excise excessive skin tissue		+	\$5,653.51	
15833	Excise excessive skin tissue		+	\$5,653.51	
15834	Excise excessive skin tissue		+	\$5,653.51	
15835	Excise excessive skin tissue		+	\$1,558.31	
15836	Excise excessive skin tissue		+	\$4,293.63	
15837	Excise excessive skin tissue		+	\$4,293.63	
15838	Excise excessive skin tissue		+	\$4,293.63	
15839	Excise excessive skin tissue		+	\$4,293.63	
15840	Graft for face nerve palsy		+	\$4,779.12	
15841	Graft for face nerve palsy		+	\$4,779.12	
15842	Flap for face nerve palsy		+	\$4,779.12	
15845	Skin and muscle repair, face		+	\$4,779.12	
15850	Removal of sutures		+	\$774.62	
15851	Removal of sutures		+	\$774.62	
15852	Dressing change not for burn			\$190.09	
15860	Test for blood flow in graft			\$122.25	
15876	Suction assisted lipectomy		+	\$4,779.12	
15877	Suction assisted lipectomy		+	\$4,779.12	
15878	Suction assisted lipectomy		+	\$4,779.12	
15879	Suction assisted lipectomy		+	\$4,779.12	
15920	Removal of tail bone ulcer		+	\$1,188.19	
15922	Removal of tail bone ulcer		+	\$4,779.12	
15931	Remove sacrum pressure sore		+	\$5,653.51	
15933	Remove sacrum pressure sore		+	\$5,653.51	
15934	Remove sacrum pressure sore		+	\$4,779.12	
15935	Remove sacrum pressure sore		+	\$4,779.12	
15936	Remove sacrum pressure sore		+	\$4,779.12	
15937	Remove sacrum pressure sore		+	\$4,779.12	
15940	Remove hip pressure sore		+	\$5,653.51	
15941	Remove hip pressure sore		+	\$5,653.51	
15944	Remove hip pressure sore		+	\$4,779.12	
15945	Remove hip pressure sore		+	\$4,779.12	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

1. See end of this table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 6 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
15946	Remove hip pressure sore		+	\$4,779.12	
15950	Remove thigh pressure sore		+	\$5,653.51	
15951	Remove thigh pressure sore		+	\$5,653.51	
15952	Remove thigh pressure sore		+	\$4,779.12	
15953	Remove thigh pressure sore		+	\$4,779.12	
15956	Remove thigh pressure sore		+	\$4,779.12	
15958	Remove thigh pressure sore		+	\$4,779.12	
15999	Removal of pressure sore		+	\$5,653.51	
16000	Initial treatment of burn(s)		+	\$229.30	
16020	Treatment of burn(s)		+	\$337.02	
16025	Treatment of burn(s)		+	\$229.30	
16030	Treatment of burn(s)		+	\$480.57	
17000	Destroy benign/premalignant lesion		+	\$195.23	
17003	Destroy lesions, 2-14		+	\$195.23	
17004	Destroy lesions, 15 or more		+	\$669.27	
17106	Destruction of skin lesions		+	\$669.27	
17107	Destruction of skin lesions		+	\$669.27	
17108	Destruction of skin lesions		+	\$669.27	
17110	Destruct lesion, 1-14		+	\$195.23	
17111	Destruct lesion, 15 or more		+	\$195.23	
17250	Chemical cautery, tissue		+	\$337.02	
17260	Destruction of skin lesions		+	\$480.57	
17261	Destruction of skin lesions		+	\$480.57	
17262	Destruction of skin lesions		+	\$480.57	
17263	Destruction of skin lesions		+	\$480.57	
17264	Destruction of skin lesions		+	\$480.57	
17266	Destruction of skin lesions		+	\$774.62	
17270	Destruction of skin lesions		+	\$480.57	
17271	Destruction of skin lesions		+	\$337.02	
17272	Destruction of skin lesions		+	\$480.57	
17273	Destruction of skin lesions		+	\$480.57	
17274	Destruction of skin lesions		+	\$774.62	
17276	Destruction of skin lesions		+	\$774.62	
17280	Destruction of skin lesions		+	\$480.57	
17281	Destruction of skin lesions		+	\$480.57	
17282	Destruction of skin lesions		+	\$480.57	
17283	Destruction of skin lesions		+	\$480.57	
17284	Destruction of skin lesions		+	\$774.62	
17285	Destruction of skin lesions		+	\$480.57	
17304	Chemotherapy of skin lesion		+	\$896.25	
17305	2 stage mohs, up to 5 spec		+	\$896.25	
17306	3 stage mohs, up to 5 spec		+	\$896.25	
17307	Mohs add'l stage up to 5 spec		+	\$896.25	
17310	Extensive skin chemotherapy		+	\$896.25	
17340	Cryotherapy of skin		+	\$229.30	
17360	Skin peel therapy		+	\$229.30	
17380	Hair removal by electrolysis		+	\$229.30	
17999	Skin tissue procedure		+	\$497.85	
19000	Drainage of breast lesion		+	\$478.42	
19001	Drain breast lesion add-on		+	\$478.42	
19020	Incision of breast lesion		+	\$3,544.82	
19100	Bx breast percut w/o image		+	\$984.98	
19101	Biopsy of breast, open		+	\$5,292.54	
19102	Bx breast percut w/image		+	\$984.98	
19103	Bx breast percut w/device		+	\$1,680.31	
19110	Nipple exploration		+	\$5,292.54	
19112	Excise breast duct fistula		+	\$5,292.54	
19120	Removal of breast lesion		+	\$5,292.54	
19125	Excision, breast lesion		+	\$5,292.54	
19126	Excision, add'l breast lesion		+	\$5,292.54	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
 1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 7 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
19140	Removal of breast tissue		+	\$5,292.54	
19160	Removal of breast tissue		+	\$5,292.54	
19162	Remove breast tissue, nodes		+	\$11,648.28	
19180	Removal of breast		+	\$9,006.23	
19182	Removal of breast		+	\$9,006.23	
19240	Removal of breast		+	\$11,238.73	
19260	Removal of chest wall lesion		+	\$4,293.63	
19295	Place breast clip, percut			\$454.94	
19296	Place po breast cath for rad			\$3,477.50	
19297	Place breast cath for rad			\$2,942.50	
19298	Place breast rad tube/caths			\$3,477.50	
19316	Suspension of breast		+	\$9,006.23	
19318	Reduction of large breast		+	\$11,648.28	
19324	Enlarge breast		+	\$11,648.28	
19325	Enlarge breast with implant		+	\$16,271.88	
19328	Removal of breast implant		+	\$9,006.23	
19330	Removal of implant material		+	\$9,006.23	
19340	Immediate breast prosthesis		+	\$11,238.73	
19342	Delayed breast prosthesis		+	\$16,271.88	
19350	Breast reconstruction		+	\$5,292.54	
19355	Correct inverted nipple(s)		+	\$9,006.23	
19357	Breast reconstruction		+	\$16,271.88	
19366	Breast reconstruction		+	\$9,006.23	
19370	Surgery of breast capsule		+	\$9,006.23	
19371	Removal of breast capsule		+	\$9,006.23	
19380	Revise breast reconstruction		+	\$11,238.73	
19396	Design custom breast implant		+	\$9,006.23	
19499	Breast surgery procedure		+	\$5,292.54	
20000	Incision of abscess		+	\$497.85	
20005	Incision of deep abscess		+	\$5,897.27	
20100	Explore wound, neck		+	\$847.72	
20101	Explore wound, chest		+	\$4,779.12	
20102	Explore wound, abdomen		+	\$4,779.12	
20103	Explore wound, extremity		+	\$847.72	
20150	Excise epiphyseal bar		+	\$10,324.87	
20200	Muscle biopsy		+	\$4,293.63	
20205	Deep muscle biopsy		+	\$4,293.63	
20206	Needle biopsy, muscle		+	\$984.98	
20220	Bone biopsy, trocar/needle		+	\$1,188.19	
20225	Bone biopsy, trocar/needle		+	\$2,131.88	
20240	Bone biopsy, excisional		+	\$5,653.51	
20245	Bone biopsy, excisional		+	\$5,653.51	
20250	Open bone biopsy		+	\$5,897.27	
20251	Open bone biopsy		+	\$5,897.27	
20500	Injection of sinus tract		+	\$538.65	
20520	Removal of foreign body		+	\$1,188.19	
20525	Removal of foreign body		+	\$5,653.51	
20526	Ther injection, carp tunnel		+	\$652.44	
20550	Inject tendon/ligament/cyst		+	\$652.44	
20551	Inj tendon origin/insertion		+	\$652.44	
20552	Inj trigger point, 1/2 muscl		+	\$652.44	
20553	Inject trigger points, > 3		+	\$652.44	
20600	Drain/inject, joint/bursa		+	\$652.44	
20605	Drain/inject, joint/bursa		+	\$652.44	
20610	Drain/inject, joint/bursa		+	\$652.44	
20612	Aspirate/inj ganglion cyst		+	\$662.44	
20615	Treatment of bone cyst		+	\$478.42	
20650	Insert and remove bone pin		+	\$5,897.27	
20665	Removal of fixation device			\$190.09	
20670	Removal of support implant		+	\$4,293.63	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for notes regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 8 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
20680	Removal of support implant		+	\$5,653.51	
20690	Apply bone fixation device		+	\$7,473.47	
20692	Apply bone fixation device		+	\$7,473.47	
20693	Adjust bone fixation device		+	\$5,897.27	
20694	Remove bone fixation device		+	\$5,897.27	
20900	Removal of bone for graft		+	\$7,473.47	
20902	Removal of bone for graft		+	\$7,473.47	
20910	Remove cartilage for graft		+	\$4,779.12	
20912	Remove cartilage for graft		+	\$4,779.12	
20920	Removal of fascia for graft		+	\$4,779.12	
20922	Removal of fascia for graft		+	\$4,779.12	
20924	Removal of tendon for graft		+	\$7,473.47	
20926	Removal of tissue for graft		+	\$4,779.12	
20950	Fluid pressure, muscle		+	\$497.85	
20975	Electrical bone stimulation			\$5,897.27	
20982	Ablate, bone tumor(s) perq		+	\$9,046.13	
20999	Musculoskeletal surgery		+	\$5,897.27	
21010	Incision of jaw joint		+	\$6,567.70	
21015	Resection of facial tumor		+	\$4,583.99	
21025	Excision of bone, lower jaw		+	\$10,471.26	
21026	Excision of facial bone(s)		+	\$10,471.26	
21029	Contour of face bone lesion		+	\$10,471.26	
21030	Removal of face bone lesion		+	\$6,567.70	
21031	Remove exostosis, mandible		+	\$6,567.70	
21032	Remove exostosis, maxilla		+	\$6,567.70	
21034	Removal of face bone lesion		+	\$10,471.26	
21040	Removal of jaw bone lesion		+	\$6,567.70	
21044	Removal of jaw bone lesion		+	\$10,471.26	
21046	Remove mandible cyst complex		+	\$10,471.26	
21047	Excise lwr jaw cyst w/repair		+	\$10,471.26	
21048	Remove maxilla cyst complex		+	\$10,471.26	
21049	Excis uppr jaw cyst w/repair		+	\$10,471.26	
21050	Removal of jaw joint		+	\$10,471.26	
21060	Remove jaw joint cartilage		+	\$10,471.26	
21070	Remove coronoid process		+	\$10,471.26	
21076	Prepare face/oral prosthesis		+	\$6,567.70	
21077	Prepare face/oral prosthesis		+	\$10,471.26	
21079	Prepare face/oral prosthesis		+	\$10,471.26	
21080	Prepare face/oral prosthesis		+	\$10,471.26	
21081	Prepare face/oral prosthesis		+	\$10,471.26	
21082	Prepare face/oral prosthesis		+	\$10,471.26	
21083	Prepare face/oral prosthesis		+	\$10,471.26	
21084	Prepare face/oral prosthesis		+	\$10,471.26	
21085	Prepare face/oral prosthesis		+	\$4,583.99	
21086	Prepare face/oral prosthesis		+	\$10,471.26	
21087	Prepare face/oral prosthesis		+	\$10,471.26	
21088	Prepare face/oral prosthesis		+	\$10,471.26	
21089	Prepare face/oral prosthesis		+	\$4,583.99	
21100	Maxillofacial fixation		+	\$10,471.26	
21110	Interdental fixation		+	\$1,939.62	
21120	Reconstruction of chin		+	\$6,567.70	
21121	Reconstruction of chin		+	\$6,567.70	
21122	Reconstruction of chin		+	\$6,567.70	
21123	Reconstruction of chin		+	\$6,567.70	
21125	Augmentation, lower jaw bone		+	\$6,567.70	
21127	Augmentation, lower jaw bone		+	\$10,471.26	
21137	Reduction of forehead		+	\$6,567.70	
21138	Reduction of forehead		+	\$10,471.26	
21139	Reduction of forehead		+	\$10,471.26	
21181	Contour cranial bone lesion		+	\$6,567.70	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

1 - See end of the table for note regarding Charge Methodology

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 9 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
21198	Reconstr lwr jaw segment		+	\$10,471.26	
21199	Reconstr lwr jaw w/advance		+	\$10,471.26	
21206	Reconstruct upper jaw bone		+	\$10,471.26	
21208	Augmentation of facial bones		+	\$10,471.26	
21209	Reduction of facial bones		+	\$10,471.26	
21210	Face bone graft		+	\$10,471.26	
21215	Lower jaw bone graft		+	\$10,471.26	
21230	Rib cartilage graft		+	\$10,471.26	
21235	Ear cartilage graft		+	\$6,567.70	
21240	Reconstruction of jaw joint		+	\$10,471.26	
21242	Reconstruction of jaw joint		+	\$10,471.26	
21243	Reconstruction of jaw joint		+	\$10,471.26	
21244	Reconstruction of lower jaw		+	\$10,471.26	
21245	Reconstruction of jaw		+	\$10,471.26	
21246	Reconstruction of jaw		+	\$10,471.26	
21248	Reconstruction of jaw		+	\$10,471.26	
21249	Reconstruction of jaw		+	\$10,471.26	
21260	Revise eye sockets		+	\$10,471.26	
21261	Revise eye sockets		+	\$10,471.26	
21263	Revise eye sockets		+	\$10,471.26	
21267	Revise eye sockets		+	\$10,471.26	
21270	Augmentation, cheek bone		+	\$10,471.26	
21275	Revision, orbitofacial bones		+	\$10,471.26	
21280	Revision of eyelid		+	\$10,471.26	
21282	Revision of eyelid		+	\$4,583.99	
21295	Revision of jaw muscle/bone		+	\$1,939.62	
21296	Revision of jaw muscle/bone		+	\$6,567.70	
21299	Cranio/maxillofacial surgery		+	\$4,583.99	
21300	Treatment of skull fracture		+	\$4,583.99	
21310	Treatment of nose fracture		+	\$190.09	
21315	Treatment of nose fracture		+	\$190.09	
21320	Treatment of nose fracture		+	\$190.09	
21325	Treatment of nose fracture		+	\$6,567.70	
21330	Treatment of nose fracture		+	\$6,567.70	
21335	Treatment of nose fracture		+	\$6,567.70	
21336	Treat nasal septal fracture		+	\$9,739.05	
21337	Treat nasal septal fracture		+	\$4,583.99	
21338	Treat nasoethmoid fracture		+	\$6,567.70	
21339	Treat nasoethmoid fracture		+	\$6,567.70	
21340	Treatment of nose fracture		+	\$10,471.26	
21345	Treat nose/jaw fracture		+	\$6,567.70	
21355	Treat cheek bone fracture		+	\$10,471.26	
21356	Treat cheek bone fracture		+	\$11,444.60	
21390	Treat eye socket fracture		+	\$10,471.26	
21400	Treat eye socket fracture		+	\$1,939.62	
21401	Treat eye socket fracture		+	\$4,583.99	
21406	Treat eye socket fracture		+	\$10,471.26	
21407	Treat eye socket fracture		+	\$10,471.26	
21421	Treat mouth roof fracture		+	\$6,567.70	
21440	Treat dental ridge fracture		+	\$6,567.70	
21445	Treat dental ridge fracture		+	\$6,567.70	
21450	Treat lower jaw fracture		+	\$538.65	
21451	Treat lower jaw fracture		+	\$1,939.62	
21452	Treat lower jaw fracture		+	\$4,583.99	
21453	Treat lower jaw fracture		+	\$10,471.26	
21454	Treat lower jaw fracture		+	\$6,567.70	
21461	Treat lower jaw fracture		+	\$10,471.26	
21462	Treat lower jaw fracture		+	\$10,471.26	
21465	Treat lower jaw fracture		+	\$10,471.26	
21470	Treat lower jaw fracture		+	\$10,471.26	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 10 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
21480	Reset dislocated jaw		+	\$538.65	
21485	Reset dislocated jaw		+	\$4,583.99	
21490	Repair dislocated jaw		+	\$10,471.26	
21497	Interdental wiring		+	\$4,583.99	
21499	Head surgery procedure		+	\$4,583.99	
21501	Drain neck/chest lesion		+	\$5,869.10	
21502	Drain chest lesion		+	\$5,897.27	
21550	Biopsy of neck/chest		+	\$4,293.63	
21555	Remove lesion, neck/chest		+	\$5,653.51	
21556	Remove lesion, neck/chest		+	\$5,653.51	
21557	Remove tumor, neck/chest		+	\$1,181.02	
21600	Partial removal of rib		+	\$7,473.47	
21610	Partial removal of rib		+	\$7,473.47	
21685	Hyoid myotomy & suspension		+	\$1,939.62	
21700	Revision of neck muscle		+	\$5,897.27	
21720	Revision of neck muscle		+	\$5,897.27	
21725	Revision of neck muscle		+	\$497.85	
21742	Repair stern/nuss w/o scope		+	\$10,324.87	
21743	Repair sternum/nuss w/scope		+	\$10,324.87	
21800	Treatment of rib fracture		+	\$574.59	
21805	Treatment of rib fracture		+	\$9,739.05	
21820	Treat sternum fracture		+	\$574.59	
21899	Neck/chest surgery procedure		+	\$1,939.62	
21920	Biopsy soft tissue of back		+	\$2,131.88	
21925	Biopsy soft tissue of back		+	\$5,653.51	
21930	Remove lesion, back or flank		+	\$5,653.51	
21935	Remove tumor, back		+	\$5,653.51	
22100	Remove part of neck vertebra		+	\$12,016.14	
22101	Remove part, thorax vertebra		+	\$12,016.14	
22102	Remove part, lumbar vertebra		+	\$12,016.14	
22103	Remove extra spine segment		+	\$12,016.14	
22222	Revision of thorax spine		+	\$2,595.57	
22305	Treat spine process fracture		+	\$574.59	
22310	Treat spine fracture		+	\$574.59	
22315	Treat spine fracture		+	\$574.59	
22505	Manipulation of spine		+	\$4,047.77	
22520	Percut vertebroplasty thor		+	\$7,473.47	
22521	Percut vertebroplasty lumb		+	\$7,473.47	
22522	Percut vertebroplasty add'l		+	\$7,473.47	
22523	Percut kyphoplasty, thor	c	+	\$2,773.47	OPPS
22524	Percut kyphoplasty, lumbar	c	+	\$2,773.47	OPPS
22525	Percut kyphoplasty, add-on	c	+	\$2,773.47	OPPS
22612	Lumbar spine fusion		+	\$12,016.14	
22614	Spine fusion, extra segment		+	\$12,016.14	
22899	Spine surgery procedure		+	\$574.59	
22900	Remove abdominal wall lesion		+	\$5,653.51	
22999	Abdomen surgery procedure		+	\$5,653.51	
23000	Removal of calcium deposits		+	\$4,293.63	
23020	Release shoulder joint		+	\$10,324.87	
23030	Drain shoulder lesion		+	\$5,869.10	
23031	Drain shoulder bursa		+	\$5,869.10	
23035	Drain shoulder bone lesion		+	\$5,897.27	
23040	Exploratory shoulder surgery		+	\$7,473.47	
23044	Exploratory shoulder surgery		+	\$7,473.47	
23065	Biopsy shoulder tissues		+	\$4,293.63	
23066	Biopsy shoulder tissues		+	\$5,653.51	
23075	Removal of shoulder lesion		+	\$4,293.63	
23076	Removal of shoulder lesion		+	\$5,653.51	
23077	Remove tumor of shoulder		+	\$5,653.51	
23100	Biopsy of shoulder joint		+	\$5,897.27	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
 1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPSC CODE

PAGE 11 of 96

CPT/ HCPSC Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
23101	Shoulder joint surgery		+	\$7,473.47	
23105	Remove shoulder joint lining		+	\$7,473.47	
23106	Incision of collarbone joint		+	\$7,473.47	
23107	Explore treat shoulder joint		+	\$7,473.47	
23120	Partial removal, collar bone		+	\$10,324.87	
23125	Removal of collar bone		+	\$10,324.87	
23130	Remove shoulder bone, part		+	\$10,324.87	
23140	Removal of bone lesion		+	\$5,897.27	
23146	Removal of bone lesion		+	\$7,473.47	
23146	Removal of bone lesion		+	\$7,473.47	
23150	Removal of humerus lesion		+	\$7,473.47	
23155	Removal of humerus lesion		+	\$7,473.47	
23156	Removal of humerus lesion		+	\$7,473.47	
23170	Remove collar bone lesion		+	\$7,473.47	
23172	Remove shoulder blade lesion		+	\$7,473.47	
23174	Remove humerus lesion		+	\$7,473.47	
23180	Remove collar bone lesion		+	\$7,473.47	
23182	Remove shoulder blade lesion		+	\$7,473.47	
23184	Remove humerus lesion		+	\$7,473.47	
23190	Partial removal of scapula		+	\$7,473.47	
23195	Removal of head of humerus		+	\$7,473.47	
23330	Remove shoulder foreign body		+	\$2,131.88	
23331	Remove shoulder foreign body		+	\$5,653.51	
23395	Muscle transfer, shoulder/arm		+	\$10,324.87	
23397	Muscle transfers		+	\$12,517.27	
23400	Fixation of shoulder blade		+	\$7,473.47	
23405	Incision of tendon & muscle		+	\$7,473.47	
23406	Incise tendon(s) & muscle(s)		+	\$7,473.47	
23410	Repair of tendon(s)		+	\$12,517.27	
23412	Repair rotator cuff, chronic		+	\$12,517.27	
23415	Release of shoulder ligament		+	\$10,324.87	
23420	Repair of shoulder		+	\$12,517.27	
23430	Repair biceps tendon		+	\$12,517.27	
23440	Remove/transplant tendon		+	\$12,517.27	
23450	Repair shoulder capsule		+	\$12,517.27	
23455	Repair shoulder capsule		+	\$12,517.27	
23460	Repair shoulder capsule		+	\$12,517.27	
23462	Repair shoulder capsule		+	\$12,517.27	
23465	Repair shoulder capsule		+	\$12,517.27	
23466	Repair shoulder capsule		+	\$12,517.27	
23470	Reconstruct shoulder joint		+	\$15,450.09	
23480	Revision of collar bone		+	\$10,324.87	
23485	Revision of collar bone		+	\$10,324.87	
23490	Reinforce clavicle		+	\$10,324.87	
23491	Reinforce shoulder bones		+	\$10,324.87	
23500	Treat clavicle fracture		+	\$574.59	
23505	Treat clavicle fracture		+	\$574.59	
23515	Treat clavicle fracture		+	\$9,739.05	
23520	Treat clavicle dislocation		+	\$574.59	
23525	Treat clavicle dislocation		+	\$574.59	
23530	Treat clavicle dislocation		+	\$9,739.05	
23532	Treat clavicle dislocation		+	\$9,739.05	
23540	Treat clavicle dislocation		+	\$574.59	
23545	Treat clavicle dislocation		+	\$574.59	
23550	Treat clavicle dislocation		+	\$9,739.05	
23552	Treat clavicle dislocation		+	\$9,739.05	
23570	Treat shoulder blade fx		+	\$574.59	
23575	Treat shoulder blade fx		+	\$574.59	
23585	Treat scapula fracture		+	\$9,739.05	
23600	Treat humerus fracture		+	\$574.59	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 12 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
23605	Treat humerus fracture		+	\$574.59	
23615	Treat humerus fracture		+	\$9,739.05	
23616	Treat humerus fracture		+	\$9,739.05	
23620	Treat humerus fracture		+	\$574.59	
23625	Treat humerus fracture		+	\$574.59	
23630	Treat humerus fracture		+	\$9,739.05	
23650	Treat shoulder dislocation		+	\$574.59	
23655	Treat shoulder dislocation		+	\$4,047.77	
23660	Treat shoulder dislocation		+	\$9,739.05	
23665	Treat dislocation/fracture		+	\$574.59	
23670	Treat dislocation/fracture		+	\$9,739.05	
23675	Treat dislocation/fracture		+	\$574.59	
23680	Treat dislocation/fracture		+	\$9,739.05	
23700	Fixation of shoulder		+	\$4,047.77	
23800	Fusion of shoulder joint		+	\$10,324.87	
23802	Fusion of shoulder joint		+	\$10,324.87	
23921	Amputation follow-up surgery		+	\$1,558.31	
23929	Shoulder surgery procedure		+	\$574.59	
23930	Drainage of arm lesion		+	\$5,869.10	
23931	Drainage of arm bursa		+	\$3,544.82	
23935	Drain arm/elbow bone lesion		+	\$5,897.27	
24000	Exploratory elbow surgery		+	\$7,473.47	
24006	Release elbow joint		+	\$7,473.47	
24065	Biopsy arm/elbow soft tissue		+	\$4,293.63	
24066	Biopsy arm/elbow soft tissue		+	\$4,293.63	
24075	Remove arm/elbow lesion		+	\$5,653.51	
24076	Remove arm/elbow lesion		+	\$5,653.51	
24077	Remove tumor of arm/elbow		+	\$5,897.27	
24100	Biopsy elbow joint lining		+	\$5,897.27	
24101	Explore/treat elbow joint		+	\$7,473.47	
24102	Remove elbow joint lining		+	\$7,473.47	
24105	Removal of elbow bursa		+	\$5,897.27	
24110	Remove humerus lesion		+	\$5,897.27	
24115	Remove/graft bone lesion		+	\$7,473.47	
24116	Remove/graft bone lesion		+	\$7,473.47	
24120	Remove elbow lesion		+	\$5,897.27	
24125	Remove/graft bone lesion		+	\$7,473.47	
24126	Remove/graft bone lesion		+	\$7,473.47	
24130	Removal of head of radius		+	\$7,473.47	
24134	Removal of arm bone lesion		+	\$7,473.47	
24136	Remove radius bone lesion		+	\$7,473.47	
24138	Remove elbow bone lesion		+	\$7,473.47	
24140	Partial removal of arm bone		+	\$7,473.47	
24145	Partial removal of radius		+	\$7,473.47	
24147	Partial removal of elbow		+	\$7,473.47	
24149	Radical resection of elbow		+	\$1,499.92	
24150	Extensive humerus surgery		+	\$12,517.27	
24151	Extensive humerus surgery		+	\$12,517.27	
24152	Extensive radius surgery		+	\$12,517.27	
24153	Extensive radius surgery		+	\$12,517.27	
24155	Removal of elbow joint		+	\$10,324.87	
24160	Remove elbow joint implant		+	\$7,473.47	
24164	Remove radius head implant		+	\$7,473.47	
24200	Removal of arm foreign body		+	\$1,188.19	
24201	Removal of arm foreign body		+	\$4,293.63	
24300	Manipulate elbow w/anesth		+	\$4,047.77	
24301	Muscle/tendon transfer		+	\$7,473.47	
24305	Arm tendon lengthening		+	\$7,473.47	
24310	Revision of arm tendon		+	\$5,897.27	
24320	Repair of arm tendon		+	\$10,324.87	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 13 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
24330	Revision of arm muscles		+	\$10,324.87	
24331	Revision of arm muscles		+	\$10,324.87	
24332	Tenolysis, triceps		+	\$5,897.27	
24340	Repair of biceps tendon		+	\$10,324.87	
24341	Repair arm tendon/muscle		+	\$10,324.87	
24342	Repair of ruptured tendon		+	\$10,324.87	
24343	Repr elbow lat ligmnt w/tiss		+	\$7,473.47	
24344	Reconstruct elbow lat ligmnt		+	\$10,324.87	
24345	Repr elbow med ligmnt w/tissu		+	\$7,473.47	
24346	Reconstruct elbow med ligmnt		+	\$10,324.87	
24350	Repair of tennis elbow		+	\$7,473.47	
24351	Repair of tennis elbow		+	\$7,473.47	
24352	Repair of tennis elbow		+	\$7,473.47	
24354	Repair of tennis elbow		+	\$7,473.47	
24356	Revision of tennis elbow		+	\$7,473.47	
24360	Reconstruct elbow joint		+	\$9,010.40	
24361	Reconstruct elbow joint		+	\$15,450.09	
24362	Reconstruct elbow joint		+	\$15,450.09	
24363	Replace elbow joint		+	\$15,450.09	
24365	Reconstruct head of radius		+	\$9,010.40	
24366	Reconstruct head of radius		+	\$15,450.09	
24400	Revision of humerus		+	\$7,473.47	
24410	Revision of humerus		+	\$7,473.47	
24420	Revision of humerus		+	\$10,324.87	
24430	Repair of humerus		+	\$10,324.87	
24435	Repair humerus with graft		+	\$10,324.87	
24470	Revision of elbow joint		+	\$10,324.87	
24495	Decompression of forearm		+	\$7,473.47	
24498	Reinforce humerus		+	\$10,324.87	
24500	Treat humerus fracture		+	\$574.59	
24505	Treat humerus fracture		+	\$574.59	
24515	Treat humerus fracture		+	\$9,739.05	
24516	Treat humerus fracture		+	\$9,739.05	
24530	Treat humerus fracture		+	\$574.59	
24535	Treat humerus fracture		+	\$574.59	
24538	Treat humerus fracture		+	\$9,739.05	
24545	Treat humerus fracture		+	\$9,739.05	
24546	Treat humerus fracture		+	\$9,739.05	
24560	Treat humerus fracture		+	\$574.59	
24565	Treat humerus fracture		+	\$574.59	
24566	Treat humerus fracture		+	\$9,739.05	
24575	Treat humerus fracture		+	\$9,739.05	
24576	Treat humerus fracture		+	\$574.59	
24577	Treat humerus fracture		+	\$574.59	
24579	Treat humerus fracture		+	\$9,739.05	
24582	Treat humerus fracture		+	\$9,739.05	
24586	Treat elbow fracture		+	\$9,739.05	
24587	Treat elbow fracture		+	\$9,739.05	
24600	Treat elbow dislocation		+	\$574.59	
24605	Treat elbow dislocation		+	\$4,047.77	
24615	Treat elbow dislocation		+	\$9,739.05	
24620	Treat elbow fracture		+	\$574.59	
24635	Treat elbow fracture		+	\$9,739.05	
24640	Treat elbow dislocation		+	\$574.59	
24650	Treat radius fracture		+	\$574.59	
24655	Treat radius fracture		+	\$574.59	
24665	Treat radius fracture		+	\$9,739.05	
24666	Treat radius fracture		+	\$9,739.05	
24670	Treat ulnar fracture		+	\$574.59	
24675	Treat ulnar fracture		+	\$574.59	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
 1 - See end of the table for note regarding Charge Methodology

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 14 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
24685	Treat ulnar fracture		+	\$9,739.05	
24800	Fusion of elbow joint		+	\$10,324.87	
24802	Fusion/graft of elbow joint		+	\$10,324.87	
24925	Amputation follow-up surgery		+	\$5,897.27	
24935	Revision of amputation		+	\$12,517.27	
24999	Upper arm/elbow surgery		+	\$574.59	
25000	Incision of tendon sheath		+	\$5,897.27	
25001	Incise flexor carpi radialis		+	\$5,897.27	
25020	Decompress forearm 1 space		+	\$5,897.27	
25023	Decompress forearm 1 space		+	\$7,473.47	
25024	Decompress forearm 2 spaces		+	\$7,473.47	
25025	Decompress forearm 2 spaces		+	\$7,473.47	
25028	Drainage of forearm lesion		+	\$5,897.27	
25031	Drainage of forearm bursa		+	\$5,897.27	
25035	Treat forearm bone lesion		+	\$5,897.27	
25040	Explore/treat wrist joint		+	\$7,473.47	
25065	Biopsy forearm soft tissues		+	\$4,293.63	
25066	Biopsy forearm soft tissues		+	\$5,653.51	
25075	Removal forearm lesion subcu		+	\$4,293.63	
25076	Removal forearm lesion deep		+	\$5,653.51	
25077	Remove tumor, forearm/wrist		+	\$5,653.51	
25085	Incision of wrist capsule		+	\$5,897.27	
25100	Biopsy of wrist joint		+	\$5,897.27	
25101	Explore/treat wrist joint		+	\$7,473.47	
25105	Remove wrist joint lining		+	\$7,473.47	
25107	Remove wrist joint cartilage		+	\$7,473.47	
25110	Remove wrist tendon lesion		+	\$5,897.27	
25111	Remove wrist tendon lesion		+	\$4,477.45	
25112	Remove wrist tendon lesion		+	\$4,477.45	
25115	Remove wrist/forearm lesion		+	\$5,897.27	
25116	Remove wrist/forearm lesion		+	\$5,897.27	
25118	Excise wrist tendon sheath		+	\$7,473.47	
25119	Partial removal of ulna		+	\$7,473.47	
25120	Removal of forearm lesion		+	\$7,473.47	
25125	Remove/graft forearm lesion		+	\$7,473.47	
25126	Remove/graft forearm lesion		+	\$7,473.47	
25130	Removal of wrist lesion		+	\$7,473.47	
25135	Remove & graft wrist lesion		+	\$7,473.47	
25136	Remove & graft wrist lesion		+	\$7,473.47	
25145	Remove forearm bone lesion		+	\$7,473.47	
25150	Partial removal of ulna		+	\$7,473.47	
25151	Partial removal of radius		+	\$7,473.47	
25170	Extensive forearm surgery		+	\$12,517.27	
25210	Removal of wrist bone		+	\$7,265.78	
25215	Removal of wrist bones		+	\$7,265.78	
25230	Partial removal of radius		+	\$7,473.47	
25240	Partial removal of ulna		+	\$7,473.47	
25248	Remove forearm foreign body		+	\$5,897.27	
25250	Removal of wrist prosthesis		+	\$7,473.47	
25251	Removal of wrist prosthesis		+	\$7,473.47	
25259	Manipulate wrist w/anesthes		+	\$574.59	
25260	Repair forearm tendon/muscle		+	\$7,473.47	
25263	Repair forearm tendon/muscle		+	\$7,473.47	
25265	Repair forearm tendon/muscle		+	\$7,473.47	
25270	Repair forearm tendon/muscle		+	\$7,473.47	
25272	Repair forearm tendon/muscle		+	\$7,473.47	
25274	Repair forearm tendon/muscle		+	\$7,473.47	
25275	Repair forearm tendon sheath		+	\$7,473.47	
25280	Revise wrist/forearm tendon		+	\$7,473.47	
25290	Incise wrist/forearm tendon		+	\$7,473.47	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F.—OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE¹

PAGE 15 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
25295	Release wrist/forearm tendon		+	\$5,897.27	
25300	Fusion of tendons at wrist		+	\$7,473.47	
25301	Fusion of tendons at wrist		+	\$7,473.47	
25310	Transplant forearm tendon		+	\$10,324.87	
25312	Transplant forearm tendon		+	\$10,324.87	
25315	Revise palsy hand tendon(s)		+	\$10,324.87	
25316	Revise palsy hand tendon(s)		+	\$10,324.87	
25320	Repair/revise wrist joint		+	\$10,324.87	
25332	Revise wrist joint		+	\$9,010.40	
25335	Realignment of hand		+	\$10,324.87	
25337	Reconstruct ulna/radioulnar		+	\$10,324.87	
25350	Revision of radius		+	\$10,324.87	
25355	Revision of radius		+	\$10,324.87	
25360	Revision of ulna		+	\$7,473.47	
25365	Revise radius & ulna		+	\$7,473.47	
25370	Revise radius or ulna		+	\$10,324.87	
25375	Revise radius & ulna		+	\$10,324.87	
25390	Shorten radius or ulna		+	\$7,473.47	
25391	Lengthen radius or ulna		+	\$10,324.87	
25392	Shorten radius & ulna		+	\$7,473.47	
25393	Lengthen radius & ulna		+	\$10,324.87	
25394	Repair carpal bone, shorten		+	\$4,477.45	
25400	Repair radius or ulna		+	\$7,473.47	
25405	Repair/graft radius or ulna		+	\$7,473.47	
25415	Repair radius & ulna		+	\$7,473.47	
25420	Repair/graft radius & ulna		+	\$10,324.87	
25425	Repair/graft radius or ulna		+	\$10,324.87	
25426	Repair/graft radius & ulna		+	\$10,324.87	
25430	Vasc graft into carpal bone		+	\$7,265.78	
25431	Repair non union carpal bone		+	\$7,265.78	
25440	Repair/graft wrist bone		+	\$10,324.87	
25441	Reconstruct wrist joint		+	\$15,450.09	
25442	Reconstruct wrist joint		+	\$15,450.09	
25443	Reconstruct wrist joint		+	\$15,450.09	
25444	Reconstruct wrist joint		+	\$15,450.09	
25445	Reconstruct wrist joint		+	\$15,450.09	
25446	Wrist replacement		+	\$15,450.09	
25447	Repair wrist joint(s)		+	\$9,010.40	
25449	Remove wrist joint implant		+	\$9,010.40	
25450	Revision of wrist joint		+	\$10,324.87	
25455	Revision of wrist joint		+	\$10,324.87	
25490	Reinforce radius		+	\$10,324.87	
25491	Reinforce ulna		+	\$10,324.87	
25492	Reinforce radius and ulna		+	\$10,324.87	
25500	Treat fracture of radius		+	\$574.59	
25505	Treat fracture of radius		+	\$574.59	
25515	Treat fracture of radius		+	\$9,739.05	
25520	Treat fracture of radius		+	\$574.59	
25525	Treat fracture of radius		+	\$9,739.05	
25526	Treat fracture of radius		+	\$9,739.05	
25530	Treat fracture of ulna		+	\$574.59	
25535	Treat fracture of ulna		+	\$574.59	
25545	Treat fracture of ulna		+	\$9,739.05	
25560	Treat fracture radius & ulna		+	\$574.59	
25565	Treat fracture radius & ulna		+	\$574.59	
25574	Treat fracture radius & ulna		+	\$9,739.05	
25575	Treat fracture radius/ulna		+	\$9,739.05	
25600	Treat fracture radius/ulna		+	\$574.59	
25605	Treat fracture radius/ulna		+	\$574.59	
25611	Treat fracture radius/ulna		+	\$9,739.05	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 16 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
25620	Treat fracture radius/ulna		+	\$9,739.05	
25622	Treat wrist bone fracture		+	\$574.59	
25624	Treat wrist bone fracture		+	\$574.59	
25628	Treat wrist bone fracture		+	\$9,739.05	
25630	Treat wrist bone fracture		+	\$574.59	
25635	Treat wrist bone fracture		+	\$574.59	
25645	Treat wrist bone fracture		+	\$9,739.05	
25650	Treat wrist bone fracture		+	\$574.59	
25651	Pin ulnar styloid fracture		+	\$9,739.05	
25652	Treat fracture ulnar styloid		+	\$9,739.05	
25660	Treat wrist dislocation		+	\$574.59	
25670	Treat wrist dislocation		+	\$9,739.05	
25671	Pin radioulnar dislocation		+	\$9,739.05	
25675	Treat wrist dislocation		+	\$574.59	
25676	Treat wrist dislocation		+	\$9,739.05	
25680	Treat wrist fracture		+	\$574.59	
25685	Treat wrist fracture		+	\$9,739.05	
25690	Treat wrist dislocation		+	\$574.59	
25695	Treat wrist dislocation		+	\$9,739.05	
25800	Fusion of wrist joint		+	\$10,324.87	
25805	Fusion/graft of wrist joint		+	\$10,324.87	
25810	Fusion/graft of wrist joint		+	\$10,324.87	
25820	Fusion of hand bones		+	\$4,477.45	
25825	Fuse hand bones with graft		+	\$7,265.78	
25830	Fusion, radioulnar int/ulna		+	\$10,324.87	
25907	Amputation follow-up surgery		+	\$5,897.27	
25922	Amputate hand at wrist		+	\$5,897.27	
25929	Amputation follow-up surgery		+	\$4,779.12	
25999	Forearm or wrist surgery		+	\$574.59	
26010	Drainage of finger abscess		+	\$497.85	
26011	Drainage of finger abscess		+	\$3,544.82	
26020	Drain hand tendon sheath		+	\$4,477.45	
26025	Drainage of palm bursa		+	\$4,477.45	
26030	Drainage of palm bursa(s)		+	\$4,477.45	
26034	Treat hand bone lesion		+	\$4,477.45	
26035	Decompress fingers/hand		+	\$4,477.45	
26037	Decompress fingers/hand		+	\$4,477.45	
26040	Release palm contracture		+	\$7,265.78	
26045	Release palm contracture		+	\$7,265.78	
26055	Incise finger tendon sheath		+	\$4,477.45	
26060	Incision of finger tendon		+	\$4,477.45	
26070	Explore/treat hand joint		+	\$4,477.45	
26075	Explore/treat finger joint		+	\$4,477.45	
26080	Explore/treat finger joint		+	\$4,477.45	
26100	Biopsy hand joint lining		+	\$4,477.45	
26105	Biopsy finger joint lining		+	\$4,477.45	
26110	Biopsy finger joint lining		+	\$4,477.45	
26115	Remove hand lesion subcut		+	\$5,653.51	
26116	Remove hand lesion, deep		+	\$5,653.51	
26117	Remove tumor, hand/finger		+	\$5,653.51	
26121	Release palm contracture		+	\$7,265.78	
26123	Release palm contracture		+	\$7,265.78	
26125	Release palm contracture		+	\$7,265.78	
26130	Remove wrist joint lining		+	\$4,477.45	
26135	Revise finger joint, each		+	\$7,265.78	
26140	Revise finger joint, each		+	\$4,477.45	
26145	Tendon excision, palm/finger		+	\$4,477.45	
26160	Remove tendon sheath lesion		+	\$4,477.45	
26170	Removal of palm tendon, each		+	\$4,477.45	
26180	Removal of finger tendon		+	\$4,477.45	

NOTES: CPT codes and descriptions only copyright 2005 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 17 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
26185	Remove finger bone		+	\$4,477.45	
26200	Remove hand bone lesion		+	\$4,477.45	
26205	Remove/graft bone lesion		+	\$7,265.78	
26210	Removal of finger lesion		+	\$4,477.45	
26215	Remove/graft finger lesion		+	\$4,477.45	
26230	Partial removal of hand bone		+	\$4,477.45	
26235	Partial removal, finger bone		+	\$4,477.45	
26236	Partial removal, finger bone		+	\$4,477.45	
26250	Extensive hand surgery		+	\$4,477.45	
26255	Extensive hand surgery		+	\$7,265.78	
26260	Extensive finger surgery		+	\$4,477.45	
26261	Extensive finger surgery		+	\$4,477.45	
26262	Partial removal of finger		+	\$4,477.45	
26320	Removal of implant from hand		+	\$4,293.63	
26340	Manipulate finger w/anesth		+	\$574.59	
26350	Repair finger/hand tendon		+	\$7,265.78	
26352	Repair/graft hand tendon		+	\$7,265.78	
26356	Repair finger/hand tendon		+	\$7,265.78	
26357	Repair finger/hand tendon		+	\$7,265.78	
26358	Repair/graft hand tendon		+	\$7,265.78	
26370	Repair finger/hand tendon		+	\$7,265.78	
26372	Repair/graft hand tendon		+	\$7,265.78	
26373	Repair finger/hand tendon		+	\$7,265.78	
26390	Revise hand/finger tendon		+	\$7,265.78	
26392	Repair/graft hand tendon		+	\$7,265.78	
26410	Repair hand tendon		+	\$4,477.45	
26412	Repair/graft hand tendon		+	\$7,265.78	
26415	Excision, hand/finger tendon		+	\$7,265.78	
26416	Graft hand or finger tendon		+	\$7,265.78	
26418	Repair finger tendon		+	\$4,477.45	
26420	Repair/graft finger tendon		+	\$7,265.78	
26426	Repair finger/hand tendon		+	\$7,265.78	
26428	Repair/graft finger tendon		+	\$7,265.78	
26432	Repair finger tendon		+	\$4,477.45	
26433	Repair finger tendon		+	\$4,477.45	
26434	Repair/graft finger tendon		+	\$7,265.78	
26437	Realignment of tendons		+	\$4,477.45	
26440	Release palm/finger tendon		+	\$4,477.45	
26442	Release palm & finger tendon		+	\$7,265.78	
26445	Release hand/finger tendon		+	\$4,477.45	
26449	Release forearm/hand tendon		+	\$7,265.78	
26450	Incision of palm tendon		+	\$4,477.45	
26455	Incision of finger tendon		+	\$4,477.45	
26460	Incise hand/finger tendon		+	\$4,477.45	
26471	Fusion of finger tendons		+	\$4,477.45	
26474	Fusion of finger tendons		+	\$4,477.45	
26476	Tendon lengthening		+	\$4,477.45	
26477	Tendon shortening		+	\$4,477.45	
26478	Lengthening of hand tendon		+	\$4,477.45	
26479	Shortening of hand tendon		+	\$4,477.45	
26480	Transplant hand tendon		+	\$7,265.78	
26483	Transplant/graft hand tendon		+	\$7,265.78	
26485	Transplant palm tendon		+	\$7,265.78	
26489	Transplant/graft palm tendon		+	\$7,265.78	
26490	Revise thumb tendon		+	\$7,265.78	
26492	Tendon transfer with graft		+	\$7,265.78	
26494	Hand tendon/muscle transfer		+	\$7,265.78	
26496	Revise thumb tendon		+	\$7,265.78	
26497	Finger tendon transfer		+	\$7,265.78	
26498	Finger tendon transfer		+	\$7,265.78	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 18 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
26499	Revision of finger		+	\$7,265.78	
26500	Hand tendon reconstruction		+	\$4,477.45	
26502	Hand tendon reconstruction		+	\$7,265.78	
26504	Hand tendon reconstruction		+	\$7,265.78	
26508	Release thumb contracture		+	\$4,477.45	
26510	Thumb tendon transfer		+	\$7,265.78	
26516	Fusion of knuckle joint		+	\$7,265.78	
26517	Fusion of knuckle joints		+	\$7,265.78	
26518	Fusion of knuckle joints		+	\$7,265.78	
26520	Release knuckle contracture		+	\$4,477.45	
26525	Release finger contracture		+	\$4,477.45	
26530	Revise knuckle joint		+	\$9,010.40	
26531	Revise knuckle with implant		+	\$15,450.09	
26535	Revise finger joint		+	\$9,010.40	
26536	Revise/implant finger joint		+	\$15,450.09	
26540	Repair hand joint		+	\$4,477.45	
26541	Repair hand joint with graft		+	\$7,265.78	
26542	Repair hand joint with graft		+	\$4,477.45	
26545	Reconstruct finger joint		+	\$7,265.78	
26546	Repair nonunion hand		+	\$7,265.78	
26548	Reconstruct finger joint		+	\$7,265.78	
26550	Construct thumb replacement		+	\$7,265.78	
26555	Positional change of finger		+	\$7,265.78	
26560	Repair of web finger		+	\$4,477.45	
26561	Repair of web finger		+	\$7,265.78	
26562	Repair of web finger		+	\$7,265.78	
26565	Correct metacarpal flaw		+	\$7,265.78	
26567	Correct finger deformity		+	\$7,265.78	
26568	Lengthen metacarpal/finger		+	\$7,265.78	
26580	Repair hand deformity		+	\$7,265.78	
26587	Reconstruct extra finger		+	\$4,477.45	
26590	Repair finger deformity		+	\$7,265.78	
26591	Repair muscles of hand		+	\$7,265.78	
26593	Release muscles of hand		+	\$4,477.45	
26596	Excision constricting tissue		+	\$7,265.78	
26600	Treat metacarpal fracture		+	\$574.59	
26605	Treat metacarpal fracture		+	\$574.59	
26607	Treat metacarpal fracture		+	\$574.59	
26608	Treat metacarpal fracture		+	\$9,739.05	
26615	Treat metacarpal fracture		+	\$9,739.05	
26641	Treat thumb dislocation		+	\$574.59	
26645	Treat thumb fracture		+	\$574.59	
26650	Treat thumb fracture		+	\$9,739.05	
26665	Treat thumb fracture		+	\$9,739.05	
26670	Treat hand dislocation		+	\$574.59	
26675	Treat hand dislocation		+	\$574.59	
26676	Pin hand dislocation		+	\$9,739.05	
26685	Treat hand dislocation		+	\$9,739.05	
26686	Treat hand dislocation		+	\$9,739.05	
26700	Treat knuckle dislocation		+	\$574.59	
26705	Treat knuckle dislocation		+	\$574.59	
26706	Pin knuckle dislocation		+	\$574.59	
26715	Treat knuckle dislocation		+	\$9,739.05	
26720	Treat finger fracture, each		+	\$574.59	
26725	Treat finger fracture, each		+	\$574.59	
26727	Treat finger fracture, each		+	\$9,739.05	
26735	Treat finger fracture, each		+	\$9,739.05	
26740	Treat finger fracture, each		+	\$574.59	
26742	Treat finger fracture, each		+	\$574.59	
26746	Treat finger fracture, each		+	\$9,739.05	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

1 - See end of the table for note regarding Charge Methodology

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

-PAGE 19 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
26750	Treat finger fracture, each		+	\$574.59	
26755	Treat finger fracture, each		+	\$574.59	
26756	Pin finger fracture, each		+	\$9,739.05	
26765	Treat finger fracture, each		+	\$9,739.05	
26770	Treat finger dislocation		+	\$574.59	
26775	Treat finger dislocation		+	\$4,047.77	
26776	Pin finger dislocation		+	\$9,739.05	
26785	Treat finger dislocation		+	\$9,739.05	
26820	Thumb fusion with graft		+	\$7,265.78	
26841	Fusion of thumb		+	\$7,265.78	
26842	Thumb fusion with graft		+	\$7,265.78	
26843	Fusion of hand joint		+	\$7,265.78	
26844	Fusion/graft of hand joint		+	\$7,265.78	
26850	Fusion of knuckle		+	\$7,265.78	
26852	Fusion of knuckle with graft		+	\$7,265.78	
26860	Fusion of finger joint		+	\$7,265.78	
26861	Fusion of finger jnt, add-on		+	\$7,265.78	
26862	Fusion/graft of finger joint		+	\$7,265.78	
26863	Fuse/graft added joint		+	\$7,265.78	
26910	Amputate metacarpal bone		+	\$7,265.78	
26951	Amputation of finger/thumb		+	\$4,477.45	
26952	Amputation of finger/thumb		+	\$4,477.45	
26989	Hand/finger surgery		+	\$574.59	
26990	Drainage of pelvis lesion		+	\$5,897.27	
26991	Drainage of pelvis bursa		+	\$5,897.27	
27000	Incision of hip tendon		+	\$5,897.27	
27001	Incision of hip tendon		+	\$7,473.47	
27003	Incision of hip tendon		+	\$7,473.47	
27033	Exploration of hip joint		+	\$10,324.87	
27035	Denervation of hip joint		+	\$12,517.27	
27040	Biopsy of soft tissues		+	\$2,131.88	
27041	Biopsy of soft tissues		+	\$1,188.19	
27047	Remove hip/pelvis lesion		+	\$5,653.51	
27048	Remove hip/pelvis lesion		+	\$5,653.51	
27049	Remove tumor, hip/pelvis		+	\$5,653.51	
27050	Biopsy of sacroiliac joint		+	\$5,897.27	
27052	Biopsy of hip joint		+	\$5,897.27	
27060	Removal of ischial bursa		+	\$5,897.27	
27062	Remove femur lesion/bursa		+	\$5,897.27	
27065	Removal of hip bone lesion		+	\$5,897.27	
27066	Removal of hip bone lesion		+	\$7,473.47	
27067	Remove/graft hip bone lesion		+	\$7,473.47	
27080	Removal of tail bone		+	\$7,473.47	
27086	Remove hip foreign body		+	\$2,131.88	
27087	Remove hip foreign body		+	\$5,897.27	
27096	Inject sacroiliac joint		+	\$1,125.40	
27097	Revision of hip tendon		+	\$7,473.47	
27098	Transfer tendon to pelvis		+	\$7,473.47	
27100	Transfer of abdominal muscle		+	\$10,324.87	
27105	Transfer of spinal muscle		+	\$10,324.87	
27110	Transfer of iliopsoas muscle		+	\$10,324.87	
27111	Transfer of iliopsoas muscle		+	\$10,324.87	
27193	Treat pelvic ring fracture		+	\$574.59	
27194	Treat pelvic ring fracture		+	\$4,047.77	
27200	Treat tail bone fracture		+	\$574.59	
27202	Treat tail bone fracture		+	\$9,739.05	
27216	Treat pelvic ring fracture		+	\$7,473.47	
27220	Treat hip socket fracture		+	\$574.59	
27230	Treat thigh fracture		+	\$574.59	
27235	Treat thigh fracture		+	\$7,473.47	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPSC CODE

PAGE 20 of 96

CPT/ HCPSC Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
27238	Treat thigh fracture		+	\$574.59	
27246	Treat thigh fracture		+	\$574.59	
27250	Treat hip dislocation		+	\$574.59	
27252	Treat hip dislocation		+	\$4,047.77	
27256	Treat hip dislocation		+	\$574.59	
27257	Treat hip dislocation		+	\$4,047.77	
27265	Treat hip dislocation		+	\$574.59	
27266	Treat hip dislocation		+	\$4,047.77	
27275	Manipulation of hip joint		+	\$4,047.77	
27299	Pelvis/hip joint surgery		+	\$574.59	
27301	Drain thigh/knee lesion		+	\$5,869.10	
27305	Incise thigh tendon & fascia		+	\$5,897.27	
27306	Incision of thigh tendon		+	\$5,897.27	
27307	Incision of thigh tendons		+	\$5,897.27	
27310	Exploration of knee joint		+	\$7,473.47	
27315	Partial removal, thigh nerve		+	\$4,983.20	
27320	Partial removal, thigh nerve		+	\$4,983.20	
27323	Biopsy, thigh soft tissues		+	\$4,293.63	
27324	Biopsy, thigh soft tissues		+	\$5,653.51	
27327	Removal of thigh lesion		+	\$5,653.51	
27328	Removal of thigh lesion		+	\$5,653.51	
27329	Remove tumor, thigh/knee		+	\$5,653.51	
27330	Biopsy, knee joint lining		+	\$7,473.47	
27331	Explore/treat knee joint		+	\$7,473.47	
27332	Removal of knee cartilage		+	\$7,473.47	
27333	Removal of knee cartilage		+	\$7,473.47	
27334	Remove knee joint lining		+	\$7,473.47	
27335	Remove knee joint lining		+	\$7,473.47	
27340	Removal of kneecap bursa		+	\$5,897.27	
27345	Removal of knee cyst		+	\$5,897.27	
27347	Remove knee cyst		+	\$5,897.27	
27350	Removal of kneecap		+	\$7,473.47	
27355	Remove femur lesion		+	\$7,473.47	
27356	Remove femur lesion/graft		+	\$7,473.47	
27357	Remove femur lesion/graft		+	\$7,473.47	
27358	Remove femur lesion/fixation		+	\$7,473.47	
27360	Partial removal, leg bone(s)		+	\$7,473.47	
27372	Removal of foreign body		+	\$5,653.51	
27380	Repair of kneecap tendon		+	\$5,897.27	
27381	Repair/graft kneecap tendon		+	\$5,897.27	
27385	Repair of thigh muscle		+	\$5,897.27	
27386	Repair/graft of thigh muscle		+	\$5,897.27	
27390	Incision of thigh tendon		+	\$5,897.27	
27391	Incision of thigh tendons		+	\$5,897.27	
27392	Incision of thigh tendons		+	\$5,897.27	
27393	Lengthening of thigh tendon		+	\$7,473.47	
27394	Lengthening of thigh tendons		+	\$7,473.47	
27395	Lengthening of thigh tendons		+	\$10,324.87	
27396	Transplant of thigh tendon		+	\$7,473.47	
27397	Transplants of thigh tendons		+	\$10,324.87	
27400	Revise thigh muscles/tendons		+	\$10,324.87	
27403	Repair of knee cartilage		+	\$7,473.47	
27405	Repair of knee ligament		+	\$10,324.87	
27407	Repair of knee ligament		+	\$10,324.87	
27409	Repair of knee ligaments		+	\$10,324.87	
27412	Autochondrocyte implant knee		+	\$2,657.16	
27415	Osteochondral knee allograft		+	\$2,657.16	
27418	Repair degenerated kneecap		+	\$10,324.87	
27420	Revision of unstable kneecap		+	\$10,324.87	
27422	Revision of unstable kneecap		+	\$10,324.87	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 21 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
27424	Revision/removal of kneecap		+	\$10,324.87	
27425	Lateral retinacular release		+	\$7,473.47	
27427	Reconstruction, knee		+	\$12,517.27	
27428	Reconstruction, knee		+	\$12,517.27	
27429	Reconstruction, knee		+	\$12,517.27	
27430	Revision of thigh muscles		+	\$10,324.87	
27435	Incision of knee joint		+	\$10,324.87	
27437	Revise kneecap		+	\$9,010.40	
27438	Revise kneecap with implant		+	\$15,450.09	
27440	Revision of knee joint		+	\$9,010.40	
27441	Revision of knee joint		+	\$9,010.40	
27442	Revision of knee joint		+	\$9,010.40	
27443	Revision of knee joint		+	\$9,010.40	
27446	Revision of knee joint		+	\$24,383.19	
27496	Decompression of thigh/knee		+	\$5,897.27	
27497	Decompression of thigh/knee		+	\$5,897.27	
27498	Decompression of thigh/knee		+	\$5,897.27	
27499	Decompression of thigh/knee		+	\$5,897.27	
27500	Treatment of thigh fracture		+	\$574.59	
27501	Treatment of thigh fracture		+	\$574.59	
27502	Treatment of thigh fracture		+	\$574.59	
27503	Treatment of thigh fracture		+	\$574.59	
27508	Treatment of thigh fracture		+	\$574.59	
27509	Treatment of thigh fracture		+	\$9,739.05	
27510	Treatment of thigh fracture		+	\$574.59	
27516	Treat thigh fx growth plate		+	\$574.59	
27517	Treat thigh fx growth plate		+	\$574.59	
27520	Treat kneecap fracture		+	\$574.59	
27524	Treat kneecap fracture		+	\$9,739.05	
27530	Treat knee fracture		+	\$574.59	
27532	Treat knee fracture		+	\$574.59	
27538	Treat knee fracture(s)		+	\$574.59	
27550	Treat knee dislocation		+	\$574.59	
27552	Treat knee dislocation		+	\$4,047.77	
27560	Treat kneecap dislocation		+	\$574.59	
27562	Treat kneecap dislocation		+	\$4,047.77	
27566	Treat kneecap dislocation		+	\$9,739.05	
27570	Fixation of knee joint		+	\$4,047.77	
27594	Amputation follow-up surgery		+	\$5,897.27	
27599	Leq surgery procedure		+	\$574.59	
27600	Decompression of lower leg		+	\$5,897.27	
27601	Decompression of lower leg		+	\$5,897.27	
27602	Decompression of lower leg		+	\$5,897.27	
27603	Drain lower leg lesion		+	\$3,544.82	
27604	Drain lower leg bursa		+	\$5,897.27	
27605	Incision of achilles tendon		+	\$5,632.15	
27606	Incision of achilles tendon		+	\$5,897.27	
27607	Treat lower leg bone lesion		+	\$5,897.27	
27610	Explore/treat ankle joint		+	\$7,473.47	
27612	Exploration of ankle joint		+	\$7,473.47	
27613	Biopsy lower leg soft tissue		+	\$2,131.88	
27614	Biopsy lower leg soft tissue		+	\$5,653.51	
27615	Remove tumor, lower leg		+	\$9,739.05	
27618	Remove lower leg lesion		+	\$4,293.63	
27619	Remove lower leg lesion		+	\$5,653.51	
27620	Explore/treat ankle joint		+	\$7,473.47	
27625	Remove ankle joint lining		+	\$7,473.47	
27626	Remove ankle joint lining		+	\$7,473.47	
27630	Removal of tendon lesion		+	\$5,897.27	
27635	Remove lower leg bone lesion		+	\$7,473.47	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 22 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
27637	Remove/graft leg bone lesion		+	\$7,473.47	
27638	Remove/graft leg bone lesion		+	\$7,473.47	
27640	Partial removal of tibia		+	\$10,324.87	
27641	Partial removal of fibula		+	\$7,473.47	
27647	Extensive ankle/heel surgery		+	\$10,324.87	
27650	Repair achilles tendon		+	\$10,324.87	
27652	Repair/graft achilles tendon		+	\$10,324.87	
27654	Repair of achilles tendon		+	\$10,324.87	
27656	Repair leg fascia defect		+	\$5,897.27	
27658	Repair of leg tendon, each		+	\$5,897.27	
27659	Repair of leg tendon, each		+	\$5,897.27	
27664	Repair of leg tendon, each		+	\$5,897.27	
27665	Repair of leg tendon, each		+	\$7,473.47	
27675	Repair lower leg tendons		+	\$5,897.27	
27676	Repair lower leg tendons		+	\$7,473.47	
27680	Release of lower leg tendon		+	\$7,473.47	
27681	Release of lower leg tendons		+	\$7,473.47	
27685	Revision of lower leg tendon		+	\$7,473.47	
27686	Revise lower leg tendons		+	\$7,473.47	
27687	Revision of calf tendon		+	\$7,473.47	
27690	Revise lower leg tendon		+	\$10,324.87	
27691	Revise lower leg tendon		+	\$10,324.87	
27692	Revise additional leg tendon		+	\$10,324.87	
27695	Repair of ankle ligament		+	\$7,473.47	
27696	Repair of ankle ligaments		+	\$7,473.47	
27698	Repair of ankle ligament		+	\$7,473.47	
27700	Revision of ankle joint		+	\$9,010.40	
27704	Removal of ankle implant		+	\$5,897.27	
27705	Incision of tibia		+	\$10,324.87	
27707	Incision of fibula		+	\$5,897.27	
27709	Incision of tibia & fibula		+	\$7,473.47	
27730	Repair of tibia epiphysis		+	\$7,473.47	
27732	Repair of fibula epiphysis		+	\$7,473.47	
27734	Repair lower leg epiphyses		+	\$7,473.47	
27740	Repair of leg epiphyses		+	\$7,473.47	
27742	Repair of leg epiphyses		+	\$10,324.87	
27745	Reinforce tibia		+	\$10,324.87	
27750	Treatment of tibia fracture		+	\$574.59	
27752	Treatment of tibia fracture		+	\$574.59	
27756	Treatment of tibia fracture		+	\$9,739.05	
27758	Treatment of tibia fracture		+	\$9,739.05	
27759	Treatment of tibia fracture		+	\$9,739.05	
27760	Treatment of ankle fracture		+	\$574.59	
27762	Treatment of ankle fracture		+	\$574.59	
27766	Treatment of ankle fracture		+	\$9,739.05	
27780	Treatment of fibula fracture		+	\$574.59	
27781	Treatment of fibula fracture		+	\$574.59	
27784	Treatment of fibula fracture		+	\$9,739.05	
27786	Treatment of ankle fracture		+	\$574.59	
27788	Treatment of ankle fracture		+	\$574.59	
27792	Treatment of ankle fracture		+	\$9,739.05	
27808	Treatment of ankle fracture		+	\$574.59	
27810	Treatment of ankle fracture		+	\$574.59	
27814	Treatment of ankle fracture		+	\$9,739.05	
27816	Treatment of ankle fracture		+	\$574.59	
27818	Treatment of ankle fracture		+	\$574.59	
27822	Treatment of ankle fracture		+	\$9,739.05	
27823	Treatment of ankle fracture		+	\$9,739.05	
27824	Treat lower leg fracture		+	\$574.59	
27825	Treat lower leg fracture		+	\$574.59	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 23 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
27826	Treat lower leg fracture		+	\$9,739.05	
27827	Treat lower leg fracture		+	\$9,739.05	
27828	Treat lower leg fracture		+	\$9,739.05	
27829	Treat lower leg joint		+	\$9,739.05	
27830	Treat lower leg dislocation		+	\$574.59	
27831	Treat lower leg dislocation		+	\$574.59	
27832	Treat lower leg dislocation		+	\$9,739.05	
27840	Treat ankle dislocation		+	\$574.59	
27842	Treat ankle dislocation		+	\$4,047.77	
27846	Treat ankle dislocation		+	\$9,739.05	
27848	Treat ankle dislocation		+	\$9,739.05	
27860	Fixation of ankle joint		+	\$4,047.77	
27870	Fusion of ankle joint		+	\$10,324.87	
27871	Fusion of tibiofibular joint		+	\$10,324.87	
27884	Amputation follow-up surgery		+	\$5,897.27	
27889	Amputation of foot at ankle		+	\$7,473.47	
27892	Decompression of leg		+	\$5,897.27	
27893	Decompression of leg		+	\$5,897.27	
27894	Decompression of leg		+	\$5,897.27	
27899	Leg/ankle surgery procedure		+	\$574.59	
28001	Drainage of bursa of foot		+	\$3,544.82	
28002	Treatment of foot infection		+	\$5,897.27	
28003	Treatment of foot infection		+	\$5,897.27	
28005	Treat foot bone lesion		+	\$5,632.15	
28008	Incision of foot fascia		+	\$5,632.15	
28010	Incision of toe tendon		+	\$5,632.15	
28011	Incision of toe tendons		+	\$5,632.15	
28020	Exploration of foot joint		+	\$5,632.15	
28022	Exploration of foot joint		+	\$5,632.15	
28024	Exploration of toe joint		+	\$5,632.15	
28030	Removal of foot nerve		+	\$4,983.20	
28035	Decompression of tibia nerve		+	\$4,983.20	
28043	Excision of foot lesion		+	\$4,293.63	
28045	Excision of foot lesion		+	\$5,632.15	
28046	Resection of tumor, foot		+	\$5,632.15	
28050	Biopsy of foot joint lining		+	\$5,632.15	
28052	Biopsy of foot joint lining		+	\$5,632.15	
28054	Biopsy of toe joint lining		+	\$5,632.15	
28060	Partial removal, foot fascia		+	\$7,606.70	
28062	Removal of foot fascia		+	\$7,606.70	
28070	Removal of foot joint lining		+	\$7,606.70	
28072	Removal of foot joint lining		+	\$7,606.70	
28080	Removal of foot lesion		+	\$5,632.15	
28086	Excise foot tendon sheath		+	\$5,632.15	
28088	Excise foot tendon sheath		+	\$5,632.15	
28090	Removal of foot lesion		+	\$5,632.15	
28092	Removal of toe lesions		+	\$5,632.15	
28100	Removal of ankle/heel lesion		+	\$5,632.15	
28102	Remove/graft foot lesion		+	\$7,606.70	
28103	Remove/graft foot lesion		+	\$7,606.70	
28104	Removal of foot lesion		+	\$5,632.15	
28106	Remove/graft foot lesion		+	\$7,606.70	
28107	Remove/graft foot lesion		+	\$7,606.70	
28108	Removal of toe lesions		+	\$5,632.15	
28110	Part removal of metatarsal		+	\$7,606.70	
28111	Part removal of metatarsal		+	\$5,632.15	
28112	Part removal of metatarsal		+	\$5,632.15	
28113	Part removal of metatarsal		+	\$5,632.15	
28114	Removal of metatarsal heads		+	\$5,632.15	
28116	Revision of foot		+	\$5,632.15	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/OFARS apply.
1 - See end of the table for note regarding Charge Methodology

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 24 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
28118	Removal of heel bone		+	\$5,632.15	
28119	Removal of heel spur		+	\$5,632.15	
28120	Part removal of ankle/heel		+	\$5,632.15	
28122	Partial removal of foot bone		+	\$5,632.15	
28124	Partial removal of toe		+	\$5,632.15	
28126	Partial removal of toe		+	\$5,632.15	
28130	Removal of ankle bone		+	\$5,632.15	
28140	Removal of metatarsal		+	\$5,632.15	
28150	Removal of toe		+	\$5,632.15	
28153	Partial removal of toe		+	\$5,632.15	
28160	Partial removal of toe		+	\$5,632.15	
28171	Extensive foot surgery		+	\$5,632.15	
28173	Extensive foot surgery		+	\$5,632.15	
28175	Extensive foot surgery		+	\$5,632.15	
28190	Removal of foot foreign body		+	\$1,188.19	
28192	Removal of foot foreign body		+	\$4,293.63	
28193	Removal of foot foreign body		+	\$2,131.88	
28200	Repair of foot tendon		+	\$5,632.15	
28202	Repair/graft of foot tendon		+	\$7,606.70	
28208	Repair of foot tendon		+	\$5,632.15	
28210	Repair/graft of foot tendon		+	\$7,606.70	
28220	Release of foot tendon		+	\$5,632.15	
28222	Release of foot tendons		+	\$5,632.15	
28225	Release of foot tendon		+	\$5,632.15	
28226	Release of foot tendons		+	\$5,632.15	
28230	Incision of foot tendon(s)		+	\$5,632.15	
28232	Incision of toe tendon		+	\$5,632.15	
28234	Incision of foot tendon		+	\$5,632.15	
28238	Revision of foot tendon		+	\$7,606.70	
28240	Release of big toe		+	\$5,632.15	
28250	Revision of foot fascia		+	\$7,606.70	
28260	Release of midfoot joint		+	\$7,606.70	
28261	Revision of foot tendon		+	\$7,606.70	
28262	Revision of foot and ankle		+	\$7,606.70	
28264	Release of midfoot joint		+	\$7,606.70	
28270	Release of foot contracture		+	\$5,632.15	
28272	Release of toe joint, each		+	\$5,632.15	
28280	Fusion of toes		+	\$5,632.15	
28285	Repair of hammertoe		+	\$5,632.15	
28286	Repair of hammertoe		+	\$5,632.15	
28288	Partial removal of foot bone		+	\$7,606.70	
28289	Repair hallux rigidus		+	\$7,606.70	
28290	Correction of bunion		+	\$7,606.70	
28292	Correction of bunion		+	\$7,670.42	
28293	Correction of bunion		+	\$7,670.42	
28294	Correction of bunion		+	\$7,606.70	
28296	Correction of bunion		+	\$7,606.70	
28297	Correction of bunion		+	\$7,670.42	
28298	Correction of bunion		+	\$7,606.70	
28299	Correction of bunion		+	\$7,670.42	
28300	Incision of heel bone		+	\$7,606.70	
28302	Incision of ankle bone		+	\$7,606.70	
28304	Incision of midfoot bones		+	\$7,606.70	
28305	Incise/graft midfoot bones		+	\$7,606.70	
28306	Incision of metatarsal		+	\$7,606.70	
28307	Incision of metatarsal		+	\$7,606.70	
28308	Incision of metatarsal		+	\$7,606.70	
28309	Incision of metatarsals		+	\$7,606.70	
28310	Revision of big toe		+	\$5,632.15	
28312	Revision of toe		+	\$5,632.15	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 25 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
28313	Repair deformity of toe		+	\$5,632.15	
28315	Removal of sesamoid bone		+	\$5,632.15	
28320	Repair of foot bones		+	\$7,606.70	
28322	Repair of metatarsals		+	\$7,606.70	
28340	Resect enlarged toe tissue		+	\$5,632.15	
28341	Resect enlarged toe		+	\$5,632.15	
28344	Repair extra toe(s)		+	\$7,606.70	
28345	Repair webbed toe(s)		+	\$7,606.70	
28360	Reconstruct cleft foot		+	\$7,606.70	
28400	Treatment of heel fracture		+	\$574.59	
28405	Treatment of heel fracture		+	\$574.59	
28406	Treatment of heel fracture		+	\$9,739.05	
28415	Treat heel fracture		+	\$9,739.05	
28420	Treat/graft heel fracture		+	\$9,739.05	
28430	Treatment of ankle fracture		+	\$574.59	
28435	Treatment of ankle fracture		+	\$574.59	
28436	Treatment of ankle fracture		+	\$9,739.05	
28445	Treat ankle fracture		+	\$9,739.05	
28450	Treat midfoot fracture, each		+	\$574.59	
28455	Treat midfoot fracture, each		+	\$574.59	
28456	Treat midfoot fracture		+	\$9,739.05	
28465	Treat midfoot fracture, each		+	\$9,739.05	
28470	Treat metatarsal fracture		+	\$574.59	
28475	Treat metatarsal fracture		+	\$574.59	
28476	Treat metatarsal fracture		+	\$9,739.05	
28485	Treat metatarsal fracture		+	\$9,739.05	
28490	Treat big toe fracture		+	\$574.59	
28495	Treat big toe fracture		+	\$574.59	
28496	Treat big toe fracture		+	\$9,739.05	
28505	Treat big toe fracture		+	\$9,739.05	
28510	Treatment of toe fracture		+	\$574.59	
28515	Treatment of toe fracture		+	\$574.59	
28525	Treat toe fracture		+	\$9,739.05	
28530	Treat sesamoid bone fracture		+	\$574.59	
28531	Treat sesamoid bone fracture		+	\$9,739.05	
28540	Treat foot dislocation		+	\$574.59	
28545	Treat foot dislocation		+	\$4,047.77	
28546	Treat foot dislocation		+	\$9,739.05	
28555	Repair foot dislocation		+	\$9,739.05	
28570	Treat foot dislocation		+	\$574.59	
28575	Treat foot dislocation		+	\$574.59	
28576	Treat foot dislocation		+	\$9,739.05	
28585	Repair foot dislocation		+	\$9,739.05	
28600	Treat foot dislocation		+	\$574.59	
28605	Treat foot dislocation		+	\$574.59	
28606	Treat foot dislocation		+	\$9,739.05	
28615	Repair foot dislocation		+	\$9,739.05	
28630	Treat toe dislocation		+	\$574.59	
28635	Treat toe dislocation		+	\$4,047.77	
28636	Treat toe dislocation		+	\$9,739.05	
28645	Repair toe dislocation		+	\$9,739.05	
28660	Treat toe dislocation		+	\$574.59	
28665	Treat toe dislocation		+	\$4,047.77	
28666	Treat toe dislocation		+	\$9,739.05	
28675	Repair of toe dislocation		+	\$9,739.05	
28705	Fusion of foot bones		+	\$7,606.70	
28715	Fusion of foot bones		+	\$7,606.70	
28725	Fusion of foot bones		+	\$7,606.70	
28730	Fusion of foot bones		+	\$7,606.70	
28735	Fusion of foot bones		+	\$7,606.70	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 1 - See end of the table for note regarding Charge Methodology.

TABLE F.—OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 26 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
28737	Revision of foot bones		+	\$7,606.70	
28740	Fusion of foot bones		+	\$7,606.70	
28750	Fusion of big toe joint		+	\$7,606.70	
28755	Fusion of big toe joint		+	\$5,632.15	
28760	Fusion of big toe joint		+	\$7,606.70	
28810	Amputation toe & metatarsal		+	\$5,632.15	
28820	Amputation of toe		+	\$5,632.15	
28825	Partial amputation of toe		+	\$5,632.15	
28890	High energy eswt, plantar f	c	+	\$909.50	OPPS
28899	Foot/toes surgery procedure		+	\$574.59	
29000	Application of body cast			\$329.29	
29010	Application of body cast			\$329.29	
29015	Application of body cast			\$329.29	
29020	Application of body cast			\$329.29	
29025	Application of body cast			\$329.29	
29035	Application of body cast			\$329.29	
29040	Application of body cast			\$329.29	
29044	Application of body cast			\$329.29	
29046	Application of body cast			\$329.29	
29049	Application of figure eight			\$329.29	
29055	Application of shoulder cast			\$329.29	
29058	Application of shoulder cast			\$329.29	
29065	Application of long arm cast			\$329.29	
29075	Application of forearm cast			\$329.29	
29085	Apply hand/wrist cast			\$329.29	
29086	Apply finger cast			\$329.29	
29105	Apply long arm splint			\$329.29	
29125	Apply forearm splint			\$329.29	
29126	Apply forearm splint			\$329.29	
29130	Application of finger splint			\$329.29	
29131	Application of finger splint			\$329.29	
29200	Strapping of chest			\$329.29	
29220	Strapping of low back			\$329.29	
29240	Strapping of shoulder			\$329.29	
29260	Strapping of elbow or wrist			\$329.29	
29280	Strapping of hand or finger			\$329.29	
29305	Application of hip cast			\$329.29	
29325	Application of hip casts			\$329.29	
29345	Application of long leg cast			\$329.29	
29355	Application of long leg cast			\$329.29	
29358	Apply long leg cast brace			\$329.29	
29365	Application of long leg cast			\$329.29	
29405	Apply short leg cast			\$329.29	
29425	Apply short leg cast			\$329.29	
29435	Apply short leg cast			\$329.29	
29440	Addition of walker to cast			\$329.29	
29445	Apply rigid leg cast			\$329.29	
29450	Application of leg cast			\$329.29	
29505	Application, long leg splint			\$329.29	
29515	Application lower leg splint			\$329.29	
29520	Strapping of hip			\$329.29	
29530	Strapping of knee			\$329.29	
29540	Strapping of ankle			\$329.29	
29550	Strapping of toes			\$329.29	
29580	Application of paste boot			\$329.29	
29590	Application of foot splint			\$329.29	
29700	Removal/revision of cast			\$329.29	
29705	Removal/revision of cast			\$329.29	
29710	Removal/revision of cast			\$329.29	
29715	Removal/revision of cast			\$329.29	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
 1. See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 27 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
29720	Repair of body cast			\$329.29	
29730	Windowing of cast			\$329.29	
29740	Wedging of cast			\$329.29	
29750	Wedging of clubfoot cast			\$329.29	
29799	Casting/strapping procedure			\$329.29	
29800	Jaw arthroscopy/surgery		+	\$8,234.70	
29804	Jaw arthroscopy/surgery		+	\$8,234.70	
29805	Shoulder arthroscopy, dx		+	\$8,234.70	
29806	Shoulder arthroscopy/surgery		+	\$8,234.70	
29807	Shoulder arthroscopy/surgery		+	\$8,234.70	
29819	Shoulder arthroscopy/surgery		+	\$8,234.70	
29820	Shoulder arthroscopy/surgery		+	\$8,234.70	
29821	Shoulder arthroscopy/surgery		+	\$8,234.70	
29822	Shoulder arthroscopy/surgery		+	\$8,234.70	
29823	Shoulder arthroscopy/surgery		+	\$8,234.70	
29824	Shoulder arthroscopy/surgery		+	\$8,234.70	
29825	Shoulder arthroscopy/surgery		+	\$8,234.70	
29826	Shoulder arthroscopy/surgery		+	\$12,957.17	
29827	Arthroscop rotator cuff repr		+	\$8,234.70	
29830	Elbow arthroscopy		+	\$8,234.70	
29834	Elbow arthroscopy/surgery		+	\$8,234.70	
29835	Elbow arthroscopy/surgery		+	\$12,957.17	
29836	Elbow arthroscopy/surgery		+	\$12,957.17	
29837	Elbow arthroscopy/surgery		+	\$8,234.70	
29838	Elbow arthroscopy/surgery		+	\$8,234.70	
29840	Wrist arthroscopy		+	\$8,234.70	
29843	Wrist arthroscopy/surgery		+	\$8,234.70	
29844	Wrist arthroscopy/surgery		+	\$8,234.70	
29845	Wrist arthroscopy/surgery		+	\$8,234.70	
29846	Wrist arthroscopy/surgery		+	\$8,234.70	
29847	Wrist arthroscopy/surgery		+	\$8,234.70	
29848	Wrist endoscopy/surgery		+	\$8,234.70	
29850	Knee arthroscopy/surgery		+	\$8,234.70	
29851	Knee arthroscopy/surgery		+	\$8,234.70	
29855	Tibial arthroscopy/surgery		+	\$12,957.17	
29856	Tibial arthroscopy/surgery		+	\$8,234.70	
29860	Hip arthroscopy, dx		+	\$8,234.70	
29861	Hip arthroscopy/surgery		+	\$8,234.70	
29862	Hip arthroscopy/surgery		+	\$12,957.17	
29863	Hip arthroscopy/surgery		+	\$12,957.17	
29866	Autgrft implnt, knee w/scope		+	\$2,657.16	
29867	Allgrft implnt, knee w/scope		+	\$2,657.16	
29868	Meniscal tm spl, knee w/scpe		+	\$2,657.16	
29870	Knee arthroscopy, dx		+	\$8,234.70	
29871	Knee arthroscopy/drainage		+	\$8,234.70	
29873	Knee arthroscopy/surgery		+	\$8,234.70	
29874	Knee arthroscopy/surgery		+	\$8,234.70	
29875	Knee arthroscopy/surgery		+	\$8,234.70	
29876	Knee arthroscopy/surgery		+	\$8,234.70	
29877	Knee arthroscopy/surgery		+	\$8,234.70	
29879	Knee arthroscopy/surgery		+	\$8,234.70	
29880	Knee arthroscopy/surgery		+	\$8,234.70	
29881	Knee arthroscopy/surgery		+	\$8,234.70	
29882	Knee arthroscopy/surgery		+	\$8,234.70	
29883	Knee arthroscopy/surgery		+	\$8,234.70	
29884	Knee arthroscopy/surgery		+	\$8,234.70	
29885	Knee arthroscopy/surgery		+	\$8,234.70	
29886	Knee arthroscopy/surgery		+	\$8,234.70	
29887	Knee arthroscopy/surgery		+	\$8,234.70	
29888	Knee arthroscopy/surgery		+	\$12,957.17	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 28 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
29889	Knee arthroscopy/surgery		+	\$12,957.17	
29891	Ankle arthroscopy/surgery		+	\$8,234.70	
29892	Ankle arthroscopy/surgery		+	\$8,234.70	
29893	Scope, plantar fasciotomy		+	\$5,632.15	
29894	Ankle arthroscopy/surgery		+	\$8,234.70	
29895	Ankle arthroscopy/surgery		+	\$8,234.70	
29897	Ankle arthroscopy/surgery		+	\$8,234.70	
29898	Ankle arthroscopy/surgery		+	\$8,234.70	
29899	Ankle arthroscopy/surgery		+	\$8,234.70	
29900	Mcp joint arthroscopy, dx		+	\$4,477.45	
29901	Mcp joint arthroscopy, surq		+	\$4,477.45	
29902	Mcp joint arthroscopy, surq		+	\$4,477.45	
29999	Arthroscopy of joint		+	\$8,234.70	
30000	Drainage of nose lesion		+	\$538.65	
30020	Drainage of nose lesion		+	\$538.65	
30100	Intranasal biopsy		+	\$1,939.62	
30110	Removal of nose polyp(s)		+	\$4,583.99	
30115	Removal of nose polyp(s)		+	\$4,583.99	
30117	Removal of intranasal lesion		+	\$4,583.99	
30118	Removal of intranasal lesion		+	\$6,567.70	
30120	Revision of nose		+	\$4,583.99	
30124	Removal of nose lesion		+	\$1,939.62	
30125	Removal of nose lesion		+	\$10,471.26	
30130	Removal of turbinate bones		+	\$4,583.99	
30140	Removal of turbinate bones		+	\$6,567.70	
30150	Partial removal of nose		+	\$10,471.26	
30160	Removal of nose		+	\$10,471.26	
30200	Injection treatment of nose		+	\$4,583.99	
30210	Nasal sinus therapy		+	\$1,939.62	
30220	Insert nasal septal button		+	\$1,939.62	
30300	Remove nasal foreign body		+	\$190.09	
30310	Remove nasal foreign body		+	\$4,583.99	
30320	Remove nasal foreign body		+	\$4,583.99	
30400	Reconstruction of nose		+	\$10,471.26	
30410	Reconstruction of nose		+	\$10,471.26	
30420	Reconstruction of nose		+	\$10,471.26	
30430	Revision of nose		+	\$6,567.70	
30435	Revision of nose		+	\$10,471.26	
30450	Revision of nose		+	\$10,471.26	
30460	Revision of nose		+	\$10,471.26	
30462	Revision of nose		+	\$10,471.26	
30465	Repair nasal stenosis		+	\$10,471.26	
30520	Repair of nasal septum		+	\$6,567.70	
30540	Repair nasal defect		+	\$10,471.26	
30545	Repair nasal defect		+	\$10,471.26	
30560	Release of nasal adhesions		+	\$538.65	
30580	Repair upper jaw fistula		+	\$10,471.26	
30600	Repair mouth/nose fistula		+	\$10,471.26	
30620	Intranasal reconstruction		+	\$10,471.26	
30630	Repair nasal septum defect		+	\$6,567.70	
30801	Cauterization, inner nose		+	\$1,939.62	
30802	Cauterization, inner nose		+	\$4,583.99	
30901	Control of nosebleed		+	\$436.05	
30903	Control of nosebleed		+	\$436.05	
30905	Control of nosebleed		+	\$436.05	
30906	Repeat control of nosebleed		+	\$436.05	
30915	Ligation, nasal sinus artery		+	\$8,635.42	
30920	Ligation, upper jaw artery		+	\$7,546.45	
30930	Therapy, fracture of nose		+	\$4,583.99	
30999	Nasal surgery procedure		+	\$538.65	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
 1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 29 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
31000	Irrigation, maxillary sinus		+	\$538.65	
31002	Irrigation, sphenoid sinus		+	\$1,939.62	
31020	Exploration, maxillary sinus		+	\$6,567.70	
31030	Exploration, maxillary sinus		+	\$10,471.26	
31032	Explore sinus, remove polyps		+	\$10,471.26	
31040	Exploration behind upper jaw		+	\$6,567.70	
31050	Exploration, sphenoid sinus		+	\$10,471.26	
31051	Sphenoid sinus surgery		+	\$10,471.26	
31070	Exploration of frontal sinus		+	\$6,567.70	
31075	Exploration of frontal sinus		+	\$10,471.26	
31080	Removal of frontal sinus		+	\$10,471.26	
31081	Removal of frontal sinus		+	\$10,471.26	
31084	Removal of frontal sinus		+	\$10,471.26	
31085	Removal of frontal sinus		+	\$10,471.26	
31086	Removal of frontal sinus		+	\$10,471.26	
31087	Removal of frontal sinus		+	\$10,471.26	
31090	Exploration of sinuses		+	\$10,471.26	
31200	Removal of ethmoid sinus		+	\$10,471.26	
31201	Removal of ethmoid sinus		+	\$10,471.26	
31205	Removal of ethmoid sinus		+	\$10,471.26	
31231	Nasal endoscopy, dx		+	\$256.70	
31233	Nasal/sinus endoscopy, dx		+	\$530.59	
31235	Nasal/sinus endoscopy, dx		+	\$4,180.20	
31237	Nasal/sinus endoscopy, surq		+	\$6,139.75	
31238	Nasal/sinus endoscopy, surq		+	\$4,180.20	
31239	Nasal/sinus endoscopy, surq		+	\$6,139.75	
31240	Nasal/sinus endoscopy, surq		+	\$4,180.20	
31254	Revision of ethmoid sinus		+	\$6,139.75	
31255	Removal of ethmoid sinus		+	\$6,139.75	
31256	Exploration maxillary sinus		+	\$6,139.75	
31267	Endoscopy, maxillary sinus		+	\$6,139.75	
31276	Sinus endoscopy, surgical		+	\$6,139.75	
31287	Nasal/sinus endoscopy, surq		+	\$6,139.75	
31288	Nasal/sinus endoscopy, surq		+	\$6,139.75	
31292	Nasal/sinus endoscopy, surq		+	\$1,276.52	
31299	Sinus surgery procedure		+	\$1,939.62	
31300	Removal of larynx lesion		+	\$6,567.70	
31320	Diagnostic incision, larynx		+	\$10,471.26	
31400	Revision of larynx		+	\$10,471.26	
31420	Removal of epiglottis		+	\$10,471.26	
31500	Insert emergency airway			\$914.26	
31502	Change of windpipe airway		+	\$633.47	
31505	Diagnostic laryngoscopy		+	\$256.70	
31510	Laryngoscopy with biopsy		+	\$4,180.20	
31511	Remove foreign body, larynx		+	\$530.59	
31512	Removal of larynx lesion		+	\$4,180.20	
31513	Injection into vocal cord		+	\$530.59	
31515	Laryngoscopy for aspiration		+	\$4,180.20	
31520	Diagnostic laryngoscopy		+	\$530.59	
31525	Diagnostic laryngoscopy		+	\$4,180.20	
31526	Diagnostic laryngoscopy		+	\$6,139.75	
31527	Laryngoscopy for treatment		+	\$6,139.75	
31528	Laryngoscopy and dilation		+	\$4,180.20	
31529	Laryngoscopy and dilation		+	\$4,180.20	
31530	Operative laryngoscopy		+	\$6,139.75	
31531	Operative laryngoscopy		+	\$6,139.75	
31535	Operative laryngoscopy		+	\$6,139.75	
31536	Operative laryngoscopy		+	\$6,139.75	
31540	Operative laryngoscopy		+	\$6,139.75	
31541	Operative laryngoscopy		+	\$6,139.75	

NOTES: CPT codes and descriptions only copyright 2005 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPSCS CODE

PAGE 30 of 96

CPT/ HCPSCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
31545	Remove vc lesion w/scope		+	\$1,276.52	
31546	Remove vc lesion scope/graft		+	\$1,276.52	
31560	Operative laryngoscopy		+	\$6,139.75	
31561	Operative laryngoscopy		+	\$6,139.75	
31570	Laryngoscopy with injection		+	\$4,180.20	
31571	Laryngoscopy with injection		+	\$6,139.75	
31575	Diagnostic laryngoscopy		+	\$530.59	
31576	Laryngoscopy with biopsy		+	\$6,139.75	
31577	Remove foreign body, larynx		+	\$1,040.52	
31578	Removal of larynx lesion		+	\$6,139.75	
31579	Diagnostic laryngoscopy		+	\$1,040.52	
31580	Revision of larynx		+	\$10,471.26	
31582	Revision of larynx		+	\$10,471.26	
31588	Revision of larynx		+	\$10,471.26	
31590	Reinnervate larynx		+	\$10,471.26	
31595	Larynx nerve surgery		+	\$10,471.26	
31599	Larynx surgery procedure		+	\$6,567.70	
31600	Incision of windpipe		+	\$6,567.70	
31601	Incision of windpipe		+	\$6,567.70	
31603	Incision of windpipe		+	\$1,939.62	
31605	Incision of windpipe		+	\$4,583.99	
31610	Incision of windpipe		+	\$6,567.70	
31611	Surgery/speech prosthesis		+	\$6,567.70	
31612	Puncture/clear windpipe		+	\$6,567.70	
31613	Repair windpipe opening		+	\$6,567.70	
31614	Repair windpipe opening		+	\$10,471.26	
31615	Visualization of windpipe		+	\$2,779.84	
31620	Endobronchial us add-on		+	\$1,852.43	
31622	Dx bronchoscope/wash		+	\$2,779.84	
31623	Dx bronchoscope/brush		+	\$2,779.84	
31624	Dx bronchoscope/lavage		+	\$2,779.84	
31625	Bronchoscopy w/biopsy(s)		+	\$2,779.84	
31628	Bronchoscopy/lung bx, each		+	\$2,779.84	
31629	Bronchoscopy/needle bx, each		+	\$2,779.84	
31630	Bronchoscopy dilate/fix repr		+	\$6,229.28	
31631	Bronchoscopy, dilate w/stent		+	\$6,229.28	
31632	Bronchoscopy/lung bx, add'l		+	\$2,779.84	
31633	Bronchoscopy/needle bx add'l		+	\$2,779.84	
31635	Bronchoscopy w/fb removal		+	\$2,779.84	
31636	Bronchoscopy, bronch stents		+	\$1,340.84	
31637	Bronchoscopy, stent add-on		+	\$575.40	
31638	Bronchoscopy, revise stent		+	\$1,340.84	
31640	Bronchoscopy w/tumor excise		+	\$6,229.28	
31641	Bronchoscopy, treat blockage		+	\$6,229.28	
31643	Diag bronchoscope/catheter		+	\$2,779.84	
31645	Bronchoscopy, clear airways		+	\$2,779.84	
31646	Bronchoscopy, reclear airway		+	\$2,779.84	
31656	Bronchoscopy, inj for x-ray		+	\$2,779.84	
31700	Insertion of airway catheter		+	\$530.59	
31717	Bronchial brush biopsy		+	\$1,040.52	
31720	Clearance of airways		+	\$256.70	
31730	Intro, windpipe wire/tube		+	\$1,040.52	
31750	Repair of windpipe		+	\$10,471.26	
31755	Repair of windpipe		+	\$10,471.26	
31785	Remove windpipe lesion		+	\$6,567.70	
31820	Closure of windpipe lesion		+	\$4,583.99	
31825	Repair of windpipe defect		+	\$6,567.70	
31830	Revise windpipe scar		+	\$6,567.70	
31899	Airways surgical procedure		+	\$2,779.84	
32000	Drainage of chest		+	\$924.87	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 31 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
32002	Treatment of collapsed lung		+	\$924.87	
32005	Treat lung lining chemically		+	\$924.87	
32019	Insert pleural catheter		+	\$202.22	
32020	Insertion of chest tube		+	\$924.87	
32201	Drain, percut, lung lesion		+	\$924.87	
32400	Needle biopsy chest lining		+	\$984.98	
32405	Biopsy, lung or mediastinum		+	\$1,435.53	
32420	Puncture/clear lung		+	\$924.87	
32601	Thoracoscopy, diagnostic		+	\$8,717.62	
32602	Thoracoscopy, diagnostic		+	\$8,717.62	
32603	Thoracoscopy, diagnostic		+	\$8,717.62	
32604	Thoracoscopy, diagnostic		+	\$8,717.62	
32605	Thoracoscopy, diagnostic		+	\$8,717.62	
32606	Thoracoscopy, diagnostic		+	\$8,717.62	
32960	Therapeutic pneumothorax		+	\$924.87	
32999	Chest surgery procedure		+	\$924.87	
33010	Drainage of heart sac		+	\$924.87	
33011	Repeat drainage of heart sac		+	\$924.87	
33206	Insertion of heart pacemaker		+	\$25,780.51	
33207	Insertion of heart pacemaker		+	\$25,780.51	
33208	Insertion of heart pacemaker		+	\$25,957.34	
33210	Insertion of heart electrode		+	\$17,764.69	
33211	Insertion of heart electrode		+	\$17,764.69	
33212	Insertion of pulse generator		+	\$24,084.66	
33213	Insertion of pulse generator		+	\$25,548.02	
33214	Upgrade of pacemaker system		+	\$25,957.34	
33215	Reposition pacing-defib lead		+	\$5,773.21	
33216	Revise eltrd pacing-defib		+	\$17,764.69	
33217	Insert lead pace-defib, dual		+	\$17,764.69	
33218	Repair lead pace-defib, one		+	\$17,764.69	
33220	Repair lead pace-defib, dual		+	\$17,764.69	
33222	Revise pocket, pacemaker		+	\$4,779.12	
33223	Revise pocket, pacing-defib		+	\$4,779.12	
33224	Insert pacing lead & connect		+	\$4,156.33	
33225	L ventric pacing lead add-on		+	\$5,623.27	
33226	Reposition I ventric lead		+	\$5,773.21	
33233	Removal of pacemaker system		+	\$5,773.21	
33234	Removal of pacemaker system		+	\$5,773.21	
33235	Removal pacemaker electrode		+	\$5,773.21	
33241	Remove pulse generator		+	\$5,773.21	
33244	Remove eltrd, transven		+	\$5,773.21	
33282	Implant pat-active ht record		+	\$18,920.24	
33284	Remove pat-active ht record		+	\$2,248.50	
33999	Cardiac surgery procedure		+	\$924.87	
34101	Removal of artery clot		+	\$10,406.88	
34111	Removal of arm artery clot		+	\$10,406.88	
34201	Removal of artery clot		+	\$10,406.88	
34203	Removal of leg artery clot		+	\$10,406.88	
34421	Removal of vein clot		+	\$10,406.88	
34471	Removal of vein clot		+	\$10,406.88	
34490	Removal of vein clot		+	\$10,406.88	
34501	Repair valve, femoral vein		+	\$10,406.88	
34510	Transposition of vein valve		+	\$10,406.88	
34520	Cross-over vein graft		+	\$10,406.88	
34530	Leg vein fusion		+	\$10,406.88	
35011	Repair defect of artery		+	\$8,903.37	
35180	Repair blood vessel lesion		+	\$6,311.41	
35184	Repair blood vessel lesion		+	\$6,311.41	
35188	Repair blood vessel lesion		+	\$10,406.88	
35190	Repair blood vessel lesion		+	\$6,311.41	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 32 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
35201	Repair blood vessel lesion		+	\$6,311.41	
35206	Repair blood vessel lesion		+	\$6,311.41	
35207	Repair blood vessel lesion		+	\$10,406.88	
35226	Repair blood vessel lesion		+	\$6,311.41	
35231	Repair blood vessel lesion		+	\$6,311.41	
35236	Repair blood vessel lesion		+	\$6,311.41	
35256	Repair blood vessel lesion		+	\$6,311.41	
35261	Repair blood vessel lesion		+	\$8,903.37	
35266	Repair blood vessel lesion		+	\$8,903.37	
35286	Repair blood vessel lesion		+	\$8,903.37	
35321	Rechannelling of artery		+	\$6,311.41	
35458	Repair arterial blockage		+	\$10,536.99	
35459	Repair arterial blockage		+	\$10,536.99	
35460	Repair venous blockage		+	\$10,536.99	
35470	Repair arterial blockage		+	\$10,536.99	
35471	Repair arterial blockage		+	\$10,536.99	
35472	Repair arterial blockage		+	\$10,536.99	
35473	Repair arterial blockage		+	\$10,536.99	
35474	Repair arterial blockage		+	\$10,536.99	
35475	Repair arterial blockage		+	\$10,536.99	
35476	Repair venous blockage		+	\$10,536.99	
35484	Atherectomy, open		+	\$10,536.99	
35485	Atherectomy, open		+	\$10,536.99	
35490	Atherectomy, percutaneous		+	\$10,536.99	
35491	Atherectomy, percutaneous		+	\$10,536.99	
35492	Atherectomy, percutaneous		+	\$10,536.99	
35493	Atherectomy, percutaneous		+	\$10,536.99	
35494	Atherectomy, percutaneous		+	\$10,536.99	
35495	Atherectomy, percutaneous		+	\$10,536.99	
35500	Harvest vein for bypass		+	\$10,536.99	
35685	Bypass graft patency/patrch		+	\$6,311.41	
35686	Bypass graft/av fist patency		+	\$6,311.41	
35761	Exploration of artery/vein		+	\$7,705.57	
35860	Explore limb vessels		+	\$6,311.41	
35875	Removal of clot in graft		+	\$10,406.88	
35876	Removal of clot in graft		+	\$10,406.88	
35879	Revise graft w/vein		+	\$10,406.88	
35881	Revise graft w/vein		+	\$10,406.88	
35903	Excision, graft, extremity		+	\$7,705.57	
36002	Pseudoaneurysm injection trt			\$727.77	
36260	Insertion of infusion pump		+	\$26,110.97	
36261	Revision of infusion pump		+	\$6,956.09	
36262	Removal of Infusion pump		+	\$6,956.09	
36415	Drawing blood			\$14.93	
36420	Vein access cutdown < 1 yr		+	\$44.20	
36425	Vein access cutdown > 1 yr		+	\$44.20	
36430	Blood transfusion service			\$1,104.90	
36440	Bl push transfuse, 2 yr or <			\$1,104.90	
36450	Bl exchange/transfuse, nb			\$1,104.90	
36455	Bl exchange/transfuse non-nb			\$1,104.90	
36460	Transfusion service, fetal			\$1,104.90	
36468	Injection(s), spider veins		+	\$323.21	
36469	Injection(s), spider veins		+	\$323.21	
36470	Injection therapy of vein		+	\$323.21	
36471	Injection therapy of veins		+	\$323.21	
36475	Endovenous rf, 1st vein		+	\$1,645.95	
36476	Endovenous rf, vein add-on		+	\$1,645.95	
36478	Endovenous laser, 1st vein		+	\$1,645.95	
36479	Endovenous laser vein add-on		+	\$1,645.95	
36511	Apheresis wbc			\$3,967.89	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for notes regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 33 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
36512	Apheresis rbc			\$3,967.89	
36513	Apheresis platelets			\$3,967.89	
36514	Apheresis plasma			\$3,967.89	
36515	Apheresis, adsorp/reinfuse			\$11,321.56	
36516	Apheresis, selective			\$11,321.56	
36522	Photopheresis			\$11,321.56	
36550	Declot vascular device		+	\$653.86	
36555	Insert non-tunnel cv cath		+	\$3,455.33	
36556	Insert non-tunnel cv cath		+	\$3,455.33	
36557	Insert tunneled cv cath		+	\$3,455.33	
36558	Insert tunneled cv cath		+	\$3,455.33	
36560	Insert tunneled cv cath		+	\$7,705.57	
36561	Insert tunneled cv cath		+	\$7,705.57	
36563	Insert tunneled cv cath		+	\$7,705.57	
36565	Insert tunneled cv cath		+	\$7,705.57	
36566	Insert tunneled cv cath		+	\$23,068.40	
36568	Insert tunneled cv cath		+	\$3,455.33	
36569	Insert tunneled cv cath		+	\$3,455.33	
36570	Insert tunneled cv cath		+	\$3,455.33	
36571	Insert tunneled cv cath		+	\$3,455.33	
36575	Repair tunneled cv cath		+	\$1,436.55	
36576	Repair tunneled cv cath		+	\$1,436.55	
36578	Replace tunneled cv cath		+	\$1,436.55	
36580	Replace tunneled cv cath		+	\$3,455.33	
36581	Replace tunneled cv cath		+	\$3,455.33	
36582	Replace tunneled cv cath		+	\$7,705.57	
36583	Replace tunneled cv cath		+	\$7,705.57	
36584	Replace tunneled cv cath		+	\$3,455.33	
36585	Replace tunneled cv cath		+	\$3,455.33	
36589	Removal tunneled cv cath		+	\$1,436.55	
36590	Removal tunneled cv cath		+	\$2,248.50	
36595	Mech remov tunneled cv cath		+	\$1,222.45	
36596	Mech remov tunneled cv cath		+	\$1,222.45	
36597	Reposition venous catheter		+	\$1,436.55	
36598	Inj w/fluor, eval cv device	c		\$39.08	OPPS
36640	Insertion catheter, artery		+	\$3,455.33	
36680	Insert needle, bone cavity		+	\$743.38	
36800	Insertion of cannula		+	\$7,705.57	
36810	Insertion of cannula		+	\$7,705.57	
36815	Insertion of cannula		+	\$7,705.57	
36818	Av fuse, uppr arm, cephalic		+	\$2,196.70	
36819	Av fusion/uppr arm vein		+	\$10,406.88	
36820	Av fusion/forearm vein		+	\$10,406.88	
36821	Av fusion direct any site		+	\$10,406.88	
36825	Artery-vein autograft		+	\$10,406.88	
36830	Artery-vein graft		+	\$10,406.88	
36831	Open thrombect av fistula		+	\$10,406.88	
36832	Av fistula revision, open		+	\$10,406.88	
36833	Av fistula revision		+	\$10,406.88	
36834	Repair A-V aneurysm		+	\$10,406.88	
36835	Artery to vein shunt		+	\$7,705.57	
36838	Dist revas ligation, hemo		+	\$10,406.88	
36860	External cannula declotting		+	\$3,500.46	
36861	Cannula declotting		+	\$7,705.57	
36870	Percut thrombect av fistula		+	\$8,903.37	
37184	Prim art mech thrombectomy	c	+	\$2,352.40	OPPS
37185	Prim art m-thrombect add-on	c	+	\$957.87	OPPS
37186	Sec art m-thrombect add-on	c	+	\$957.87	OPPS
37187	Venous mech thrombectomy	c	+	\$2,352.40	OPPS
37188	Venous m-thrombectomy add-on	c	+	\$2,352.40	OPPS

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 1 - See end of the table for note regarding Charge Methodology.

TABLE F.—OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 34 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
37195	Thrombolytic therapy, stroke	c	+	\$144.81	OPPS
37200	Transcatheter biopsy		+	\$1,435.53	
37201	Transcatheter therapy infuse		+	\$939.74	
37202	Transcatheter therapy infuse		+	\$653.86	
37203	Transcatheter retrieval		+	\$3,500.46	
37204	Transcatheter occlusion		+	\$7,705.57	
37205	Transcatheter stent		+	\$18,673.69	
37206	Transcatheter stent add-on		+	\$18,673.69	
37207	Transcatheter stent		+	\$18,673.69	
37208	Transcatheter stent add-on		+	\$18,673.69	
37209	Exchange arterial catheter		+	\$3,500.46	
37250	Iv us first vessel add-on			\$9,525.53	
37251	Iv us each add vessel add-on			\$9,525.53	
37500	Endoscopy ligate perf veins		+	\$7,546.45	
37501	Vascular endoscopy procedure		+	\$7,546.45	
37565	Ligation of neck vein		+	\$6,311.41	
37600	Ligation of neck artery		+	\$6,311.41	
37605	Ligation of neck artery		+	\$8,635.42	
37606	Ligation of neck artery		+	\$8,635.42	
37607	Ligation of a-v fistula		+	\$7,546.45	
37609	Temporal artery procedure		+	\$4,293.63	
37615	Ligation of neck artery		+	\$8,635.42	
37620	Revision of major vein		+	\$8,635.42	
37650	Revision of major vein		+	\$8,635.42	
37700	Revise leg vein		+	\$8,635.42	
37718	Ligate/strip short leg vein	c	+	\$1,688.10	OPPS
37722	Ligate/strip long leg vein	c	+	\$1,688.10	OPPS
37735	Removal of leg veins/lesion		+	\$7,546.45	
37760	Revision of leg veins		+	\$8,635.42	
37765	Phleb veins - extrem - to 20		+	\$8,635.42	
37766	Phleb veins - extrem 20+		+	\$8,635.42	
37780	Revision of leg vein		+	\$8,635.42	
37785	Ligate/divide/excise vein		+	\$8,635.42	
37790	Penile venous occlusion		+	\$8,862.99	
37799	Vascular surgery procedure		+	\$44.20	
38120	Laparoscopy, splenectomy		+	\$12,159.93	
38129	Laparoscopy proc, spleen		+	\$9,807.60	
38205	Harvest allogenic stem cells			\$3,967.89	
38206	Harvest auto stem cells			\$3,967.89	
38220	Bone marrow aspiration		+	\$681.63	
38221	Bone marrow biopsy		+	\$681.63	
38230	Bone marrow collection			\$3,967.89	
38240	Bone marrow/stem transplant			\$1,852.57	
38241	Bone marrow/stem transplant			\$1,852.57	
38242	Lymphocyte infuse transplant			\$3,967.89	
38300	Drainage, lymph node lesion		+	\$5,869.10	
38305	Drainage, lymph node lesion		+	\$5,869.10	
38308	Incision of lymph channels		+	\$5,996.11	
38500	Biopsy/removal, lymph nodes		+	\$5,996.11	
38505	Needle biopsy, lymph nodes		+	\$984.98	
38510	Biopsy/removal, lymph nodes		+	\$5,996.11	
38520	Biopsy/removal, lymph nodes		+	\$5,996.11	
38525	Biopsy/removal, lymph nodes		+	\$5,996.11	
38530	Biopsy/removal, lymph nodes		+	\$5,996.11	
38542	Explore deep node(s), neck		+	\$11,091.92	
38550	Removal, neck/axilla lesion		+	\$5,996.11	
38555	Removal, neck/axilla lesion		+	\$5,996.11	
38570	Laparoscopy, lymph node biop		+	\$12,159.93	
38571	Laparoscopy, lymphadenectomy		+	\$16,693.95	
38572	Laparoscopy, lymphadenectomy		+	\$12,159.93	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 35 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
38589	Laparoscope proc, lymphatic		+	\$9,807.60	
38700	Removal of lymph nodes, neck		+	\$5,996.11	
38720	Removal of lymph nodes, neck		+	\$5,996.11	
38740	Remove armpit lymph nodes		+	\$11,091.92	
38745	Remove armpit lymph nodes		+	\$11,091.92	
38760	Remove groin lymph nodes		+	\$5,996.11	
38999	Blood/lymph system procedure			\$1,104.90	
39400	Visualization of chest		+	\$8,717.62	
40490	Biopsy of lip		+	\$538.65	
40500	Partial excision of lip		+	\$4,583.99	
40510	Partial excision of lip		+	\$6,567.70	
40520	Partial excision of lip		+	\$4,583.99	
40525	Reconstruct lip with flap		+	\$6,567.70	
40527	Reconstruct lip with flap		+	\$6,567.70	
40530	Partial removal of lip		+	\$6,567.70	
40650	Repair lip		+	\$1,939.62	
40652	Repair lip		+	\$1,939.62	
40654	Repair lip		+	\$1,939.62	
40700	Repair cleft lip/nasal		+	\$10,471.26	
40701	Repair cleft lip/nasal		+	\$10,471.26	
40702	Repair cleft lip/nasal		+	\$10,471.26	
40720	Repair cleft lip/nasal		+	\$10,471.26	
40761	Repair cleft lip/nasal		+	\$10,471.26	
40799	Lip surgery procedure		+	\$4,583.99	
40800	Drainage of mouth lesion		+	\$538.65	
40801	Drainage of mouth lesion		+	\$1,939.62	
40804	Removal, foreign body, mouth		+	\$190.09	
40805	Removal, foreign body, mouth		+	\$1,939.62	
40806	Incision of lip fold		+	\$538.65	
40808	Biopsy of mouth lesion		+	\$538.65	
40810	Excision of mouth lesion		+	\$4,583.99	
40812	Excise/repair mouth lesion		+	\$4,583.99	
40814	Excise/repair mouth lesion		+	\$4,583.99	
40816	Excision of mouth lesion		+	\$6,567.70	
40818	Excise oral mucosa for graft		+	\$538.65	
40819	Excise lip or cheek fold		+	\$1,939.62	
40820	Treatment of mouth lesion		+	\$4,583.99	
40830	Repair mouth laceration		+	\$538.65	
40831	Repair mouth laceration		+	\$1,939.62	
40840	Reconstruction of mouth		+	\$6,567.70	
40842	Reconstruction of mouth		+	\$6,567.70	
40843	Reconstruction of mouth		+	\$6,567.70	
40844	Reconstruction of mouth		+	\$10,471.26	
40845	Reconstruction of mouth		+	\$10,471.26	
40899	Mouth surgery procedure		+	\$1,939.62	
41000	Drainage of mouth lesion		+	\$4,583.99	
41005	Drainage of mouth lesion		+	\$538.65	
41006	Drainage of mouth lesion		+	\$6,567.70	
41007	Drainage of mouth lesion		+	\$4,583.99	
41008	Drainage of mouth lesion		+	\$4,583.99	
41009	Drainage of mouth lesion		+	\$538.65	
41010	Incision of tongue fold		+	\$4,583.99	
41015	Drainage of mouth lesion		+	\$538.65	
41016	Drainage of mouth lesion		+	\$1,939.62	
41017	Drainage of mouth lesion		+	\$1,939.62	
41018	Drainage of mouth lesion		+	\$1,939.62	
41100	Biopsy of tongue		+	\$1,939.62	
41105	Biopsy of tongue		+	\$4,583.99	
41108	Biopsy of floor of mouth		+	\$1,939.62	
41110	Excision of tongue lesion		+	\$4,583.99	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 1 - See end of the table for note regarding Charge Methodology

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 36 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
41112	Excision of tongue lesion		+	\$4,583.99	
41113	Excision of tongue lesion		+	\$4,583.99	
41114	Excision of tongue lesion		+	\$6,567.70	
41115	Excision of tongue fold		+	\$1,939.62	
41116	Excision of mouth lesion		+	\$4,583.99	
41120	Partial removal of tongue		+	\$6,567.70	
41250	Repair tongue laceration		+	\$538.65	
41251	Repair tongue laceration		+	\$538.65	
41252	Repair tongue laceration		+	\$1,939.62	
41500	Fixation of tongue		+	\$6,567.70	
41510	Tongue to lip surgery		+	\$4,583.99	
41520	Reconstruction, tongue fold		+	\$1,939.62	
41599	Tongue and mouth surgery		+	\$538.65	
41800	Drainage of gum lesion		+	\$538.65	
41805	Removal foreign body, gum		+	\$6,567.70	
41806	Removal foreign body, jawbone		+	\$4,583.99	
41820	Excision, gum, each quadrant		+	\$1,939.62	
41821	Excision of gum flap		+	\$1,939.62	
41822	Excision of gum lesion		+	\$4,583.99	
41823	Excision of gum lesion		+	\$6,567.70	
41825	Excision of gum lesion		+	\$4,583.99	
41826	Excision of gum lesion		+	\$4,583.99	
41827	Excision of gum lesion		+	\$6,567.70	
41828	Excision of gum lesion		+	\$4,583.99	
41830	Removal of gum tissue		+	\$4,583.99	
41850	Treatment of gum lesion		+	\$4,583.99	
41870	Gum graft		+	\$6,567.70	
41872	Repair gum		+	\$4,583.99	
41874	Repair tooth socket		+	\$6,567.70	
41899	Dental surgery procedure		+	\$4,583.99	
42000	Drainage mouth roof lesion		+	\$538.65	
42100	Biopsy roof of mouth		+	\$1,939.62	
42104	Excision lesion, mouth roof		+	\$4,583.99	
42106	Excision lesion, mouth roof		+	\$4,583.99	
42107	Excision lesion, mouth roof		+	\$6,567.70	
42120	Remove palate/lesion		+	\$10,471.26	
42140	Excision of uvula		+	\$1,939.62	
42145	Repair palate, pharynx/uvula		+	\$6,567.70	
42160	Treatment mouth roof lesion		+	\$4,583.99	
42180	Repair palate		+	\$538.65	
42182	Repair palate		+	\$10,471.26	
42200	Reconstruct cleft palate		+	\$10,471.26	
42205	Reconstruct cleft palate		+	\$10,471.26	
42210	Reconstruct cleft palate		+	\$10,471.26	
42215	Reconstruct cleft palate		+	\$10,471.26	
42220	Reconstruct cleft palate		+	\$10,471.26	
42225	Reconstruct cleft palate		+	\$10,471.26	
42226	Lengthening of palate		+	\$10,471.26	
42227	Lengthening of palate		+	\$10,471.26	
42235	Repair palate		+	\$4,583.99	
42260	Repair nose to lip fistula		+	\$6,567.70	
42280	Preparation, palate mold		+	\$538.65	
42281	Insertion, palate prosthesis		+	\$4,583.99	
42299	Palate/uvula surgery		+	\$538.65	
42300	Drainage of salivary gland		+	\$4,583.99	
42305	Drainage of salivary gland		+	\$4,583.99	
42310	Drainage of salivary gland		+	\$538.65	
42320	Drainage of salivary gland		+	\$538.65	
42330	Removal of salivary stone		+	\$4,583.99	
42335	Removal of salivary stone		+	\$4,583.99	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 37 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
42340	Removal of salivary stone		+	\$4,583.99	
42400	Biopsy of salivary gland		+	\$984.98	
42405	Biopsy of salivary gland		+	\$4,583.99	
42408	Excision of salivary cyst		+	\$4,583.99	
42409	Drainage of salivary cyst		+	\$4,583.99	
42410	Excise parotid gland/lesion		+	\$10,471.26	
42415	Excise parotid gland/lesion		+	\$10,471.26	
42420	Excise parotid gland/lesion		+	\$10,471.26	
42425	Excise parotid gland/lesion		+	\$10,471.26	
42440	Excise submaxillary gland		+	\$10,471.26	
42450	Excise sublingual gland		+	\$6,567.70	
42500	Repair salivary duct		+	\$6,567.70	
42505	Repair salivary duct		+	\$10,471.26	
42507	Parotid duct diversion		+	\$10,471.26	
42508	Parotid duct diversion		+	\$10,471.26	
42509	Parotid duct diversion		+	\$10,471.26	
42510	Parotid duct diversion		+	\$10,471.26	
42600	Closure of salivary fistula		+	\$4,583.99	
42650	Dilation of salivary duct		+	\$1,939.62	
42660	Dilation of salivary duct		+	\$538.65	
42665	Ligation of salivary duct		+	\$6,567.70	
42699	Salivary surgery procedure		+	\$4,583.99	
42700	Drainage of tonsil abscess		+	\$538.65	
42720	Drainage of throat abscess		+	\$4,583.99	
42725	Drainage of throat abscess		+	\$10,471.26	
42800	Biopsy of throat		+	\$4,583.99	
42802	Biopsy of throat		+	\$4,583.99	
42804	Biopsy of upper nose/throat		+	\$4,583.99	
42806	Biopsy of upper nose/throat		+	\$6,567.70	
42808	Excise pharynx lesion		+	\$4,583.99	
42809	Remove pharynx foreign body			\$190.09	
42810	Excision of neck cyst		+	\$6,567.70	
42815	Excision of neck cyst		+	\$10,471.26	
42820	Remove tonsils and adenoids		+	\$6,213.51	
42821	Remove tonsils and adenoids		+	\$6,213.51	
42825	Removal of tonsils		+	\$6,213.51	
42826	Removal of tonsils		+	\$6,213.51	
42830	Removal of adenoids		+	\$6,213.51	
42831	Removal of adenoids		+	\$6,213.51	
42835	Removal of adenoids		+	\$6,213.51	
42836	Removal of adenoids		+	\$6,213.51	
42842	Extensive surgery of throat		+	\$6,567.70	
42844	Extensive surgery of throat		+	\$10,471.26	
42860	Excision of tonsil tags		+	\$6,213.51	
42870	Excision of lingual tonsil		+	\$6,213.51	
42890	Partial removal of pharynx		+	\$10,471.26	
42892	Revision of pharyngeal walls		+	\$10,471.26	
42900	Repair throat wound		+	\$1,939.62	
42950	Reconstruction of throat		+	\$6,567.70	
42955	Surgical opening of throat		+	\$6,567.70	
42960	Control throat bleeding		+	\$436.05	
42962	Control throat bleeding		+	\$10,471.26	
42970	Control nose/throat bleeding		+	\$436.05	
42972	Control nose/throat bleeding		+	\$4,583.99	
42999	Throat surgery procedure		+	\$1,939.62	
43020	Incision of esophagus		+	\$1,939.62	
43030	Throat muscle surgery		+	\$4,583.99	
43130	Removal of esophagus pouch		+	\$6,567.70	
43200	Esophagus endoscopy		+	\$2,461.65	
43201	Esoph scope w/submucous inj		+	\$2,461.65	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 38 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
43202	Esophagus endoscopy, biopsy		+	\$2,461.65	
43204	Esoph scope w/sclerosis inj		+	\$2,461.65	
43205	Esophagus endoscopy/ligation		+	\$2,461.65	
43215	Esophagus endoscopy		+	\$2,461.65	
43216	Esophagus endoscopy/lesion		+	\$2,461.65	
43217	Esophagus endoscopy		+	\$2,461.65	
43219	Esophagus endoscopy		+	\$10,989.52	
43220	Esoph endoscopy, dilation		+	\$2,461.65	
43226	Esoph endoscopy, dilation		+	\$2,461.65	
43227	Esoph endoscopy, repair		+	\$2,461.65	
43228	Esoph endoscopy, ablation		+	\$2,461.65	
43231	Esoph endoscopy w/us exam		+	\$2,461.65	
43232	Esoph endoscopy w/us fn bx		+	\$2,461.65	
43234	Upper GI endoscopy, exam		+	\$2,461.65	
43235	Uppr gi endoscopy, diagnosis		+	\$2,461.65	
43236	Uppr gi scope w/submuc inj		+	\$2,461.65	
43237	Endoscopic us exam, esoph		+	\$2,461.65	
43238	Uppr gi endoscopy w/us fn bx		+	\$2,461.65	
43239	Upper GI endoscopy, biopsy		+	\$2,461.65	
43240	Esoph endoscope w/drain cyst		+	\$2,461.65	
43241	Upper GI endoscopy with tube		+	\$2,461.65	
43242	Uppr gi endoscopy w/us fn bx		+	\$2,461.65	
43243	Upper gi endoscopy & inject		+	\$2,461.65	
43244	Upper GI endoscopy/ligation		+	\$2,461.65	
43245	Uppr gi scope dilate strictr		+	\$2,461.65	
43246	Place gastrostomy tube		+	\$2,461.65	
43247	Operative upper GI endoscopy		+	\$2,461.65	
43248	Uppr gi endoscopy/guide wire		+	\$2,461.66	
43249	Esoph endoscopy, dilation		+	\$2,461.65	
43250	Upper GI endoscopy/tumor		+	\$2,461.65	
43251	Operative upper GI endoscopy		+	\$2,461.65	
43255	Operative upper GI endoscopy		+	\$2,461.65	
43256	Uppr gi endoscopy w stent		+	\$10,989.52	
43257	Uppr gi scope w/hml txmnt		+	\$1,353.33	
43258	Operative upper GI endoscopy		+	\$2,461.65	
43259	Endoscopic ultrasound exam		+	\$2,461.65	
43260	Endo cholangiopancreatograph		+	\$5,377.75	
43261	Endo cholangiopancreatograph		+	\$5,377.75	
43262	Endo cholangiopancreatograph		+	\$5,377.75	
43263	Endo cholangiopancreatograph		+	\$5,377.75	
43264	Endo cholangiopancreatograph		+	\$5,377.75	
43265	Endo cholangiopancreatograph		+	\$5,377.75	
43267	Endo cholangiopancreatograph		+	\$5,377.75	
43268	Endo cholangiopancreatograph		+	\$10,989.52	
43269	Endo cholangiopancreatograph		+	\$10,989.52	
43271	Endo cholangiopancreatograph		+	\$5,377.75	
43272	Endo cholangiopancreatograph		+	\$5,377.75	
43280	Laparoscopy, fundoplasty		+	\$16,693.95	
43289	Laparoscope proc, esoph		+	\$9,807.60	
43450	Dilate esophagus		+	\$1,930.95	
43453	Dilate esophagus		+	\$1,930.95	
43456	Dilate esophagus		+	\$1,930.95	
43458	Dilate esophagus		+	\$1,930.95	
43499	Esophagus surgery procedure		+	\$2,461.65	
43510	Surgical opening of stomach		+	\$492.20	
43600	Biopsy of stomach		+	\$2,461.65	
43651	Laparoscopy, vagus nerve		+	\$16,693.95	
43652	Laparoscopy, vagus nerve		+	\$16,693.95	
43653	Laparoscopy, gastrostomy		+	\$12,159.93	
43659	Laparoscope proc, stom		+	\$9,807.60	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1. See end of the table for note regarding Charge Methodology

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 39 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
43750	Place gastrostomy tube		+	\$2,461.65	
43752	Nasal/orogastric w/stent			\$633.47	
43760	Change gastrostomy tube		+	\$633.47	
43761	Reposition gastrostomy tube		+	\$633.47	
43830	Place gastrostomy tube		+	\$2,461.65	
43831	Place gastrostomy tube		+	\$2,461.65	
43870	Repair stomach opening		+	\$2,461.65	
43999	Stomach surgery procedure		+	\$2,461.65	
44100	Biopsy of bowel		+	\$2,461.65	
44180	Lap, enterolysis	c	+	\$2,741.28	OPPS
44186	Lap, jejunostomy	c	+	\$2,741.28	OPPS
44206	Lap part colectomy w/stoma		+	\$16,693.95	
44207	L colectomy/coloproctostomy		+	\$16,693.95	
44208	L colectomy/coloproctostomy		+	\$16,693.95	
44213	Lap, mobil splenic fl add-on	c	+	\$2,029.72	OPPS
44238	Laparoscope proc, intestine		+	\$9,807.60	
44312	Revision of ileostomy		+	\$4,779.12	
44340	Revision of colostomy		+	\$4,779.12	
44360	Small bowel endoscopy		+	\$2,649.66	
44361	Small bowel endoscopy/biopsy		+	\$2,649.66	
44363	Small bowel endoscopy		+	\$2,649.66	
44364	Small bowel endoscopy		+	\$2,649.66	
44365	Small bowel endoscopy		+	\$2,649.66	
44366	Small bowel endoscopy		+	\$2,649.66	
44369	Small bowel endoscopy		+	\$2,649.66	
44370	Small bowel endoscopy/stent		+	\$10,989.52	
44372	Small bowel endoscopy		+	\$2,649.66	
44373	Small bowel endoscopy		+	\$2,649.66	
44376	Small bowel endoscopy		+	\$2,649.66	
44377	Small bowel endoscopy/biopsy		+	\$2,649.66	
44378	Small bowel endoscopy		+	\$2,649.66	
44379	S bowel endoscope w/stent		+	\$10,989.52	
44380	Small bowel endoscopy		+	\$2,649.66	
44382	Small bowel endoscopy		+	\$2,649.66	
44383	Ileoscopy w/stent		+	\$10,989.52	
44385	Endoscopy of bowel pouch		+	\$2,342.98	
44386	Endoscopy, bowel pouch/biop		+	\$2,342.98	
44388	Colonoscopy		+	\$2,342.98	
44389	Colonoscopy with biopsy		+	\$2,342.98	
44390	Colonoscopy for foreign body		+	\$2,342.98	
44391	Colonoscopy for bleeding		+	\$2,342.98	
44392	Colonoscopy & polypectomy		+	\$2,342.98	
44393	Colonoscopy, lesion removal		+	\$2,342.98	
44394	Colonoscopy w/snare		+	\$2,342.98	
44397	Colonoscopy w/stent		+	\$10,989.52	
44500	Intro, gastrointestinal tube		+	\$633.47	
44799	Unlisted procedure intestine		+	\$2,649.66	
44901	Drain abscess, percut		+	\$569.60	
44970	Laparoscopy, appendectomy		+	\$9,807.60	
44979	Laparoscope proc, app		+	\$9,807.60	
45000	Drainage of pelvic abscess		+	\$1,154.37	
45005	Drainage of rectal abscess		+	\$1,154.37	
45020	Drainage of rectal abscess		+	\$1,154.37	
45100	Biopsy of rectum		+	\$5,152.27	
45108	Removal of anorectal lesion		+	\$6,571.98	
45150	Excision of rectal stricture		+	\$5,152.27	
45160	Excision of rectal lesion		+	\$6,571.98	
45170	Excision of rectal lesion		+	\$6,571.98	
45190	Destruction, rectal tumor		+	\$6,571.98	
45300	Proctosigmoidoscopy dx		+	\$1,192.86	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCCPS CODE

PAGE 40 of 96

CPT/ HCCPS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
45303	Proctosigmoidoscopy dilate		+	\$1,192.86	
45305	Proctosigmoidoscopy w/bx		+	\$1,192.86	
45307	Proctosigmoidoscopy fb		+	\$1,192.86	
45308	Proctosigmoidoscopy removal		+	\$2,312.00	
45309	Proctosigmoidoscopy removal		+	\$2,312.00	
45315	Proctosigmoidoscopy removal		+	\$2,312.00	
45317	Proctosigmoidoscopy bleed		+	\$2,312.00	
45320	Proctosigmoidoscopy ablate		+	\$2,312.00	
45321	Proctosigmoidoscopy volvul		+	\$2,312.00	
45327	Proctosigmoidoscopy w/stent		+	\$10,989.52	
45330	Diagnostic sigmoidoscopy		+	\$1,192.86	
45331	Sigmoidoscopy and biopsy		+	\$1,192.86	
45332	Sigmoidoscopy w/fb removal		+	\$1,192.86	
45333	Sigmoidoscopy & polypectomy		+	\$2,312.00	
45334	Sigmoidoscopy for bleeding		+	\$2,312.00	
45335	Sigmoidoscopy w/submuc inj		+	\$2,312.00	
45337	Sigmoidoscopy & decompress		+	\$2,312.00	
45338	Sigmoidoscopy w/tumr remove		+	\$2,312.00	
45339	Sigmoidoscopy w/ablate tumr		+	\$2,312.00	
45340	Sig w/balloon dilatation		+	\$2,312.00	
45341	Sigmoidoscopy w/ultrasound		+	\$2,312.00	
45342	Sigmoidoscopy w/us guide bx		+	\$2,312.00	
45345	Sigmoidoscopy w/stent		+	\$10,989.52	
45355	Surgical colonoscopy		+	\$2,342.98	
45378	Diagnostic colonoscopy	c	+	\$2,342.98	
45379	Colonoscopy w/fb removal		+	\$2,342.98	
45380	Colonoscopy and biopsy		+	\$2,342.98	
45381	Colonoscopy, submucous inj		+	\$2,342.98	
45382	Colonoscopy/control bleeding		+	\$2,342.98	
45383	Lesion removal colonoscopy		+	\$2,342.98	
45384	Lesion remove colonoscopy		+	\$2,342.98	
45385	Lesion removal colonoscopy		+	\$2,342.98	
45386	Colonoscopy dilate stricture		+	\$2,342.98	
45387	Colonoscopy w/stent		+	\$10,989.52	
45391	Colonoscopy w/endscope us		+	\$524.31	
45392	Colonoscopy w/endoscopic fnb		+	\$524.31	
45499	Laparoscope proc, rectum	c	+	\$2,029.72	OPPS
45500	Repair of rectum		+	\$5,152.27	
45505	Repair of rectum		+	\$6,571.98	
45520	Treatment of rectal prolapse		+	\$323.21	
45541	Correct rectal prolapse		+	\$1,413.67	
45560	Repair of rectocele		+	\$6,571.98	
45900	Reduction of rectal prolapse		+	\$1,154.37	
45905	Dilation of anal sphincter		+	\$5,152.27	
45910	Dilation of rectal narrowing		+	\$5,152.27	
45915	Remove rectal obstruction		+	\$1,154.37	
45990	Surq dx exam, anorectal	c	+	\$223.17	OPPS
45999	Rectum surgery procedure		+	\$1,154.37	
46020	Placement of seton		+	\$1,154.37	
46030	Removal of rectal marker		+	\$1,154.37	
46040	Incision of rectal abscess		+	\$5,152.27	
46045	Incision of rectal abscess		+	\$6,571.98	
46050	Incision of anal abscess		+	\$1,154.37	
46060	Incision of rectal abscess		+	\$6,571.98	
46070	Incision of anal septum		+	\$3,036.76	
46080	Incision of anal sphincter		+	\$5,152.27	
46083	Incise external hemorrhoid		+	\$1,154.37	
46200	Removal of anal fissure		+	\$6,571.98	
46210	Removal of anal crypt		+	\$5,152.27	
46211	Removal of anal crypts		+	\$6,571.98	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 41 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
46220	Removal of anal tag		+	\$5,152.27	
46221	Ligation of hemorrhoid(s)		+	\$1,154.37	
46230	Removal of anal tags		+	\$5,152.27	
46250	Hemorrhoidectomy		+	\$6,571.98	
46255	Hemorrhoidectomy		+	\$6,571.98	
46257	Remove hemorrhoids & fissure		+	\$6,571.98	
46258	Remove hemorrhoids & fistula		+	\$6,571.98	
46260	Hemorrhoidectomy		+	\$6,571.98	
46261	Remove hemorrhoids & fissure		+	\$6,571.98	
46262	Remove hemorrhoids & fistula		+	\$6,571.98	
46270	Removal of anal fistula		+	\$6,571.98	
46275	Removal of anal fistula		+	\$6,571.98	
46280	Removal of anal fistula		+	\$6,571.98	
46285	Removal of anal fistula		+	\$6,571.98	
46288	Repair anal fistula		+	\$6,571.98	
46320	Removal of hemorrhoid clot		+	\$1,154.37	
46500	Injection into hemorrhoid(s)		+	\$3,036.76	
46505	Chemodenervation anal musc	C	+	\$223.17	OPPS
46600	Diagnostic anoscopy			\$190.09	
46604	Anoscopy and dilation		+	\$2,312.00	
46606	Anoscopy and biopsy		+	\$2,312.00	
46608	Anoscopy, remove for body		+	\$2,312.00	
46610	Anoscopy, remove lesion		+	\$2,312.00	
46611	Anoscopy		+	\$2,312.00	
46612	Anoscopy, remove lesions		+	\$2,312.00	
46614	Anoscopy, control bleeding		+	\$2,312.00	
46615	Anoscopy		+	\$2,312.00	
46700	Repair of anal stricture		+	\$6,571.98	
46706	Repr of anal fistula w/glue		+	\$1,154.37	
46750	Repair of anal sphincter		+	\$6,571.98	
46753	Reconstruction of anus		+	\$6,571.98	
46754	Removal of suture from anus		+	\$5,152.27	
46760	Repair of anal sphincter		+	\$6,571.98	
46761	Repair of anal sphincter		+	\$6,571.98	
46762	Implant artificial sphincter		+	\$6,571.98	
46900	Destruction, anal lesion(s)		+	\$774.62	
46910	Destruction, anal lesion(s)		+	\$4,931.21	
46916	Cryosurgery, anal lesion(s)		+	\$337.02	
46917	Laser surgery, anal lesions		+	\$5,779.26	
46922	Excision of anal lesion(s)		+	\$5,779.26	
46924	Destruction, anal lesion(s)		+	\$5,779.26	
46934	Destruction of hemorrhoids		+	\$3,036.76	
46935	Destruction of hemorrhoids		+	\$3,036.76	
46936	Destruction of hemorrhoids		+	\$5,152.27	
46937	Cryotherapy of rectal lesion		+	\$5,152.27	
46938	Cryotherapy of rectal lesion		+	\$6,571.98	
46940	Treatment of anal fissure		+	\$5,152.27	
46942	Treatment of anal fissure		+	\$1,154.37	
46945	Ligation of hemorrhoids		+	\$3,036.76	
46946	Ligation of hemorrhoids		+	\$3,036.76	
46947	Hemorrhoidopexy by stapling		+	\$1,413.67	
46999	Anus surgery procedure		+	\$1,154.37	
47000	Needle biopsy of liver		+	\$1,435.53	
47011	Percut drain, liver lesion		+	\$2,979.88	
47370	Laparo ablate liver tumor rf		+	\$12,159.93	
47371	Laparo ablate liver cryosurg		+	\$12,159.93	
47379	Laparoscope procedure, liver		+	\$9,807.60	
47382	Percut ablate liver rf		+	\$9,046.13	
47399	Liver surgery procedure		+	\$2,979.88	
47490	Incision of gallbladder		+	\$2,535.05	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 42 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
47510	Insert catheter, bile duct		+	\$2,535.05	
47511	Insert bile duct drain		+	\$2,535.05	
47525	Change bile duct catheter		+	\$2,623.11	
47530	Revise/reinsert bile tube		+	\$2,623.11	
47552	Biliary endoscopy thru skin		+	\$2,535.05	
47553	Biliary endoscopy thru skin		+	\$2,535.05	
47554	Biliary endoscopy thru skin		+	\$2,535.05	
47555	Biliary endoscopy thru skin		+	\$2,535.05	
47556	Biliary endoscopy thru skin		+	\$2,535.05	
47560	Laparoscopy w/cholangio		+	\$9,807.60	
47561	Laparo w/cholangio/biopsy		+	\$9,807.60	
47562	Laparoscopic cholecystectomy		+	\$12,159.93	
47563	Laparo cholecystectomy/graph		+	\$12,159.93	
47564	Laparo cholecystectomy/explr		+	\$12,159.93	
47579	Laparoscope proc, biliary		+	\$9,807.60	
47630	Remove bile duct stone		+	\$2,535.05	
47999	Bile tract surgery procedure		+	\$2,535.05	
48102	Needle biopsy, pancreas		+	\$1,435.53	
48511	Drain pancreatic pseudocyst		+	\$2,979.88	
48999	Pancreas surgery procedure		+	\$984.98	
49021	Drain abdominal abscess		+	\$7,382.82	
49041	Drain, percut, abdom abscess		+	\$569.60	
49061	Drain, percut, retroper abs		+	\$569.60	
49080	Puncture, peritoneal cavity		+	\$924.87	
49081	Removal of abdominal fluid		+	\$924.87	
49085	Remove abdomen foreign body		+	\$6,239.46	
49180	Biopsy, abdominal mass		+	\$1,435.53	
49200	Removal of abdominal lesion		+	\$9,807.60	
49250	Excision of umbilicus		+	\$6,239.46	
49320	Diag laparo separate proc		+	\$9,807.60	
49321	Laparoscopy, biopsy		+	\$9,807.60	
49322	Laparoscopy, aspiration		+	\$9,807.60	
49323	Laparo drain lymphocele		+	\$9,807.60	
49329	Laparo proc, abdm/per/oment		+	\$9,807.60	
49419	Insrt abdom cath for chemotx		+	\$26,110.97	
49420	Insert abdom drain, temp		+	\$8,093.27	
49421	Insert abdom drain, perm		+	\$8,093.27	
49422	Remove perm cannula/catheter		+	\$5,773.21	
49423	Exchange drainage catheter		+	\$2,535.05	
49426	Revise abdomen-venous shunt		+	\$6,239.46	
49429	Removal of shunt		+	\$5,773.21	
49491	Rpr hern preemie reduc		+	\$8,086.36	
49492	Rpr inq hern preemie, blocked		+	\$8,086.36	
49495	Rpr inq hernia baby, reduc		+	\$8,086.36	
49496	Rpr inq hernia baby, blocked		+	\$8,086.36	
49500	Rpr inq hernia, init, reduce		+	\$8,086.36	
49501	Rpr inq hernia, init blocked		+	\$8,086.36	
49505	Prp i/hem init reduc>5 yr		+	\$8,086.36	
49507	Prp i/hem init block>5 yr		+	\$8,086.36	
49520	Rerepair inq hernia, reduce		+	\$8,086.36	
49521	Rerepair inq hernia, blocked		+	\$8,086.36	
49525	Repair inq hernia, sliding		+	\$8,086.36	
49540	Repair lumbar hernia		+	\$8,086.36	
49550	Rpr rem hernia, init, reduce		+	\$8,086.36	
49553	Rpr fem hernia, init blocked		+	\$8,086.36	
49555	Rerepair fem hernia, reduce		+	\$8,086.36	
49557	Rerepair fem hernia, blocked		+	\$8,086.36	
49560	Rpr ventral hern init, reduc		+	\$8,086.36	
49561	Rpr ventral hern init, block		+	\$8,086.36	
49565	Rerepair ventrl hern, reduce		+	\$8,086.36	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 43 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction- Applies	Charge	Charge Method- ology (1)
49566	Rerepair ventrl hern, block		+	\$8,086.36	
49568	Hernia repair w/mesh		+	\$8,086.36	
49570	Rpr epigastric hern, reduce		+	\$8,086.36	
49572	Rpr epigastric hern, blocked		+	\$8,086.36	
49580	Rpr umbil hern, reduc < 5 yr		+	\$8,086.36	
49582	Rpr umbil hern, block < 5 yr		+	\$8,086.36	
49585	Rpr umbil hern, reduc > 5 yr		+	\$8,086.36	
49587	Rpr umbil hern, block > 5 yr		+	\$8,086.36	
49590	Repair spigilliaq hernia		+	\$8,086.36	
49600	Repair umbilical lesion		+	\$8,086.36	
49650	Laparo hernia repair initial		+	\$12,159.93	
49651	Laparo hernia repair recur		+	\$12,159.93	
49659	Laparo proc, hernia repair		+	\$12,159.93	
49999	Abdomen surgery procedure		+	\$6,239.46	
50020	Renal abscess, open drain		+	\$1,403.47	
50021	Renal abscess, percut drain		+	\$2,979.88	
50080	Removal of kidney stone		+	\$10,025.80	
50081	Removal of kidney stone		+	\$10,025.80	
50200	Biopsy of kidney		+	\$1,435.53	
50382	Change ureter stent, percut	c	+	\$1,183.14	OPPS
50384	Remove ureter stent, percut	c	+	\$1,183.14	OPPS
50387	Change ext/int ureter stent	c	+	\$440.51	OPPS
50389	Remove renal tube w/fluoro	c	+	\$166.34	OPPS
50390	Drainage of kidney lesion		+	\$1,435.53	
50391	Instill rx agnt into mal tub		+	\$151.11	
50392	Insert kidney drain		+	\$5,062.42	
50393	Insert ureteral tube		+	\$5,062.42	
50395	Create passage to kidney		+	\$5,062.42	
50396	Measure kidney pressure		+	\$345.56	
50398	Change kidney tube		+	\$2,623.11	
50541	Laparo ablate renal cyst		+	\$9,807.60	
50542	Laparo ablate renal mass		+	\$12,159.93	
50543	Laparo partial nephrectomy		+	\$12,159.93	
50544	Laparoscopy, pyeloplasty		+	\$9,807.60	
50549	Laparoscopy proc, renal		+	\$9,807.60	
50551	Kidney endoscopy		+	\$2,068.83	
50553	Kidney endoscopy		+	\$5,062.42	
50555	Kidney endoscopy & biopsy		+	\$2,068.83	
50557	Kidney endoscopy & treatment		+	\$6,575.81	
50561	Kidney endoscopy & treatment		+	\$5,062.42	
50562	Renal scope w/tumor resect		+	\$2,068.83	
50570	Kidney endoscopy		+	\$412.62	
50572	Kidney endoscopy		+	\$412.62	
50574	Kidney endoscopy & biopsy		+	\$412.62	
50575	Kidney endoscopy		+	\$7,538.92	
50576	Kidney endoscopy & treatment		+	\$1,090.49	
50590	Fragmenting of kidney stone		+	\$13,583.31	
50592	Percut ablate renal tumor	c	+	\$2,520.85	OPPS
50686	Measure ureter pressure		+	\$345.56	
50688	Change of ureter tube		+	\$2,623.11	
50945	Laparoscopy ureterolithotomy		+	\$12,159.93	
50947	Laparo new ureter/bladder		+	\$12,159.93	
50948	Laparo new ureter/bladder		+	\$12,159.93	
50949	Laparoscopy proc, ureter		+	\$9,807.60	
50951	Endoscopy of ureter		+	\$2,068.83	
50953	Endoscopy of ureter		+	\$2,068.83	
50955	Ureter endoscopy & biopsy		+	\$5,062.42	
50957	Ureter endoscopy & treatment		+	\$5,062.42	
50961	Ureter endoscopy & treatment		+	\$5,062.42	
50970	Ureter endoscopy		+	\$2,068.83	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 44 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
50972	Ureter endoscopy & catheter		+	\$2,068.83	
50974	Ureter endoscopy & biopsy		+	\$5,062.42	
50976	Ureter endoscopy & treatment		+	\$5,062.42	
50980	Ureter endoscopy & treatment		+	\$5,062.42	
51000	Drainage of bladder		+	\$345.56	
51005	Drainage of bladder		+	\$345.56	
51010	Drainage of bladder		+	\$4,423.33	
51020	Incise & treat bladder		+	\$6,575.81	
51030	Incise & treat bladder		+	\$6,575.81	
51040	Incise & drain bladder		+	\$6,575.81	
51045	Incise bladder/drain ureter		+	\$2,068.83	
51050	Removal of bladder stone		+	\$6,575.81	
51065	Remove ureter calculus		+	\$6,575.81	
51080	Drainage of bladder abscess		+	\$3,544.82	
51500	Removal of bladder cyst		+	\$8,086.36	
51520	Removal of bladder lesion		+	\$6,575.81	
51700	Irrigation of bladder		+	\$345.56	
51705	Change of bladder tube		+	\$633.47	
51710	Change of bladder tube		+	\$2,623.11	
51715	Endoscopic injection/implant		+	\$9,016.92	
51720	Treatment of bladder lesion		+	\$745.48	
51725	Simple cystometrogram	b	+	\$745.48	
51726	Complex cystometrogram	b	+	\$745.48	
51736	Urine flow measurement	b	+	\$345.56	
51741	Electro-uroflowmetry, first	b	+	\$345.56	
51772	Urethra pressure profile	b	+	\$345.56	
51784	Anal/urinary muscle study	b	+	\$345.56	
51785	Anal/urinary muscle study	b	+	\$345.56	
51792	Urinary reflex study	b	+	\$345.56	
51795	Urine voiding pressure study	b	+	\$345.56	
51797	Intraabdominal pressure test	b	+	\$345.56	
51798	Us urine capacity measure			\$190.09	
51880	Repair of bladder opening		+	\$6,575.81	
51990	Laparo urethral suspension		+	\$12,159.93	
51992	Laparo sling operation		+	\$16,693.95	
51999	Laparoscopy proc, bladder	c	+	\$2,029.72	OPPS
52000	Cystoscopy		+	\$2,068.83	
52001	Cystoscopy, removal of clots		+	\$2,068.83	
52005	Cystoscopy & ureter catheter		+	\$5,062.42	
52007	Cystoscopy and biopsy		+	\$5,062.42	
52010	Cystoscopy & duct catheter		+	\$2,068.83	
52204	Cystoscopy		+	\$5,062.42	
52214	Cystoscopy and treatment		+	\$6,575.81	
52224	Cystoscopy and treatment		+	\$6,575.81	
52234	Cystoscopy and treatment		+	\$6,575.81	
52235	Cystoscopy and treatment		+	\$6,575.81	
52240	Cystoscopy and treatment		+	\$6,575.81	
52250	Cystoscopy and radiotracer		+	\$6,575.81	
52260	Cystoscopy and treatment		+	\$5,062.42	
52265	Cystoscopy and treatment		+	\$2,068.83	
52270	Cystoscopy & revise urethra		+	\$5,062.42	
52275	Cystoscopy & revise urethra		+	\$5,062.42	
52276	Cystoscopy and treatment		+	\$5,062.42	
52277	Cystoscopy and treatment		+	\$6,575.81	
52281	Cystoscopy and treatment		+	\$5,062.42	
52282	Cystoscopy, implant stent		+	\$19,495.73	
52283	Cystoscopy and treatment		+	\$5,062.42	
52285	Cystoscopy and treatment		+	\$5,062.42	
52290	Cystoscopy and treatment		+	\$5,062.42	
52300	Cystoscopy and treatment		+	\$5,062.42	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology

TABLE F.—OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 45 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
52301	Cystoscopy and treatment		+	\$5,062.42	
52305	Cystoscopy and treatment		+	\$5,062.42	
52310	Cystoscopy and treatment		+	\$2,068.83	
52315	Cystoscopy and treatment		+	\$5,062.42	
52317	Remove bladder stone		+	\$6,575.81	
52318	Remove bladder stone		+	\$6,575.81	
52320	Cystoscopy and treatment		+	\$6,575.81	
52325	Cystoscopy, stone removal		+	\$6,575.81	
52327	Cystoscopy, inject material		+	\$6,575.81	
52330	Cystoscopy and treatment		+	\$6,575.81	
52332	Cystoscopy and treatment		+	\$6,575.81	
52334	Create passage to kidney		+	\$6,575.81	
52341	Cysto w/ureter stricture tx		+	\$6,575.81	
52342	Cysto w/up stricture tx		+	\$6,575.81	
52343	Cysto w/renal stricture tx		+	\$6,575.81	
52344	Cysto/uretero, stone remove		+	\$6,575.81	
52345	Cysto/uretero w/up stricture		+	\$6,575.81	
52346	Cystouretero w/renal strict		+	\$6,575.81	
52351	Cystouretero & or pyeloscope		+	\$5,062.42	
52352	Cystouretero w/stone remove		+	\$6,575.81	
52353	Cystouretero w/lithotripsy		+	\$10,025.80	
52354	Cystouretero w/biopsy		+	\$6,575.81	
52355	Cystouretero w/excise tumor		+	\$6,575.81	
52400	Cystouretero w/congen repr		+	\$6,575.81	
52402	Cystourethro cut eiaacul duct		+	\$1,403.47	
52450	Incision of prostate		+	\$6,575.81	
52500	Revision of bladder neck		+	\$6,575.81	
52510	Dilation prostatic urethra		+	\$5,062.42	
52601	Prostatectomy (TURP)		+	\$10,025.80	
52606	Control postop bleeding		+	\$6,575.81	
52612	Prostatectomy, first stage		+	\$10,025.80	
52614	Prostatectomy, second stage		+	\$10,025.80	
52620	Remove residual prostate		+	\$10,025.80	
52630	Remove prostate regrowth		+	\$10,025.80	
52640	Relieve bladder contracture		+	\$6,575.81	
52647	Laser surgery of prostate		+	\$10,025.80	
52648	Laser surgery of prostate		+	\$10,025.80	
52700	Drainage of prostate abscess		+	\$6,575.81	
53000	Incision of urethra		+	\$5,058.36	
53010	Incision of urethra		+	\$5,058.36	
53020	Incision of urethra		+	\$5,058.36	
53025	Incision of urethra		+	\$5,058.36	
53040	Drainage of urethra abscess		+	\$9,016.92	
53060	Drainage of urethra abscess		+	\$5,058.36	
53080	Drainage of urinary leakage		+	\$5,058.36	
53085	Drainage of urinary leakage		+	\$1,083.43	
53200	Biopsy of urethra		+	\$5,058.36	
53210	Removal of urethra		+	\$8,628.67	
53215	Removal of urethra		+	\$5,058.36	
53220	Treatment of urethra lesion		+	\$8,628.67	
53230	Removal of urethra lesion		+	\$8,628.67	
53235	Removal of urethra lesion		+	\$5,058.36	
53240	Surgery for urethra pouch		+	\$8,628.67	
53250	Removal of urethra gland		+	\$5,058.36	
53260	Treatment of urethra lesion		+	\$5,058.36	
53265	Treatment of urethra lesion		+	\$5,058.36	
53270	Removal of urethra gland		+	\$9,016.92	
53275	Repair of urethra defect		+	\$5,058.36	
53400	Revise urethra, stage 1		+	\$8,628.67	
53405	Revise urethra, stage 2		+	\$8,628.67	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 46 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
53410	Reconstruction of urethra		+	\$8,628.67	
53420	Reconstruct urethra, stage 1		+	\$8,628.67	
53425	Reconstruct urethra, stage 2		+	\$8,628.67	
53430	Reconstruction of urethra		+	\$8,628.67	
53431	Reconstruct urethra/bladder		+	\$8,628.67	
53440	Correct bladder function			\$19,495.73	
53442	Remove perineal prosthesis		+	\$9,016.92	
53444	Insert tandem cuff			\$19,495.73	
53445	Insert uro/ves nck sphincter			\$25,547.47	
53446	Remove uro sphincter		+	\$8,628.67	
53447	Remove/replace ur sphincter			\$25,547.47	
53449	Repair uro sphincter		+	\$8,628.67	
53450	Revision of urethra		+	\$8,628.67	
53460	Revision of urethra		+	\$5,058.36	
53500	Urethrlvs, transvaq w/ scope		+	\$8,628.67	
53502	Repair of urethra injury		+	\$5,058.36	
53505	Repair of urethra injury		+	\$9,016.92	
53510	Repair of urethra injury		+	\$5,058.36	
53515	Repair of urethra injury		+	\$8,628.67	
53520	Repair of urethra defect		+	\$8,628.67	
53600	Dilate urethra stricture		+	\$745.48	
53601	Dilate urethra stricture		+	\$345.56	
53605	Dilate urethra stricture		+	\$5,062.42	
53620	Dilate urethra stricture		+	\$4,423.33	
53621	Dilate urethra stricture		+	\$345.56	
53660	Dilation of urethra		+	\$345.56	
53661	Dilation of urethra		+	\$345.56	
53665	Dilation of urethra		+	\$5,058.36	
53850	Prostatic microwave thermox		+	\$14,824.38	
53852	Prostatic rf thermox		+	\$14,824.38	
53853	Prostatic water thermother		+	\$5,623.27	
53899	Urology surgery procedure		+	\$345.56	
54000	Slitting of prepuce		+	\$5,058.36	
54001	Slitting of prepuce		+	\$5,058.36	
54015	Drain penis lesion		+	\$3,544.82	
54050	Destruction, penis lesion(s)		+	\$337.02	
54055	Destruction, penis lesion(s)		+	\$4,931.21	
54056	Cryosurgery, penis lesion(s)		+	\$229.30	
54057	Laser surg, penis lesion(s)		+	\$4,931.21	
54060	Excision of penis lesion(s)		+	\$4,931.21	
54065	Destruction, penis lesion(s)		+	\$5,779.26	
54100	Biopsy of penis		+	\$4,293.63	
54105	Biopsy of penis		+	\$5,653.51	
54110	Treatment of penis lesion		+	\$8,862.99	
54111	Treat penis lesion, graft		+	\$8,862.99	
54112	Treat penis lesion, graft		+	\$8,862.99	
54115	Treatment of penis lesion		+	\$5,869.10	
54120	Partial removal of penis		+	\$8,862.99	
54150	Circumcision		+	\$5,589.53	
54152	Circumcision		+	\$5,589.53	
54160	Circumcision		+	\$5,589.53	
54161	Circumcision		+	\$5,589.53	
54162	Lysis penit circumic lesion		+	\$5,589.53	
54163	Repair of circumcision		+	\$5,589.53	
54164	Frenulotomy of penis		+	\$5,589.53	
54200	Treatment of penis lesion		+	\$745.48	
54205	Treatment of penis lesion		+	\$8,862.99	
54220	Treatment of penis lesion		+	\$745.48	
54231	Dynamic cavemosometry		+	\$4,423.33	
54235	Penile injection		+	\$345.56	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 47 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
54240	Penis study	b	+	\$345.56	
54250	Penis study	b	+	\$345.56	
54300	Revision of penis		+	\$8,862.99	
54304	Revision of penis		+	\$8,862.99	
54308	Reconstruction of urethra		+	\$8,862.99	
54312	Reconstruction of urethra		+	\$8,862.99	
54316	Reconstruction of urethra		+	\$8,862.99	
54318	Reconstruction of urethra		+	\$8,862.99	
54322	Reconstruction of urethra		+	\$8,862.99	
54324	Reconstruction of urethra		+	\$8,862.99	
54326	Reconstruction of urethra		+	\$8,862.99	
54328	Revise penis/urethra		+	\$8,862.99	
54340	Secondary urethral surgery		+	\$8,862.99	
54344	Secondary urethral surgery		+	\$8,862.99	
54348	Secondary urethral surgery		+	\$8,862.99	
54352	Reconstruct urethra/penis		+	\$8,862.99	
54360	Penis plastic surgery		+	\$8,862.99	
54380	Repair penis		+	\$8,862.99	
54385	Repair penis		+	\$8,862.99	
54400	Insert semi-rigid prosthesis			\$19,495.73	
54401	Insert self-contd prosthesis			\$25,547.47	
54405	Insert multi-comp penis pros			\$25,547.47	
54406	Remove multi-comp penis pros		+	\$8,862.99	
54408	Repair multi-comp penis pros		+	\$8,862.99	
54410	Remove/replace penis prosth			\$25,547.47	
54415	Remove self-contd penis pros		+	\$8,862.99	
54416	Remv/repl penis contain pros			\$19,495.73	
54420	Revision of penis		+	\$8,862.99	
54435	Revision of penis		+	\$8,862.99	
54440	Repair of penis		+	\$8,862.99	
54450	Preputial stretching		+	\$745.48	
54500	Biopsy of testis		+	\$2,979.88	
54505	Biopsy of testis		+	\$6,501.62	
54512	Excise lesion testis		+	\$6,501.62	
54520	Removal of testis		+	\$6,501.62	
54522	Orchiectomy, partial		+	\$6,501.62	
54530	Removal of testis		+	\$8,086.36	
54550	Exploration for testis		+	\$8,086.36	
54600	Reduce testis torsion		+	\$6,501.62	
54620	Suspension of testis		+	\$6,501.62	
54640	Suspension of testis		+	\$8,086.36	
54660	Revision of testis		+	\$6,501.62	
54670	Repair testis injury		+	\$6,501.62	
54680	Relocation of testis(es)		+	\$6,501.62	
54690	Laparoscopy, orchiectomy		+	\$12,159.93	
54692	Laparoscopy, orchiopexy		+	\$16,693.95	
54699	Laparoscope proc, testis		+	\$9,807.60	
54700	Drainage of scrotum		+	\$6,501.62	
54800	Biopsy of epididymis		+	\$478.42	
54820	Exploration of epididymis		+	\$6,501.62	
54830	Remove epididymis lesion		+	\$6,501.62	
54840	Remove epididymis lesion		+	\$6,501.62	
54860	Removal of epididymis		+	\$6,501.62	
54861	Removal of epididymis		+	\$6,501.62	
54900	Fusion of spermatic ducts		+	\$6,501.62	
54901	Fusion of spermatic ducts		+	\$6,501.62	
55000	Drainage of hydrocele		+	\$478.42	
55040	Removal of hydrocele		+	\$8,086.36	
55041	Removal of hydroceles		+	\$8,086.36	
55060	Repair of hydrocele		+	\$6,501.62	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 48 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
55100	Drainage of scrotum abscess		+	\$3,544.82	
55110	Explore scrotum		+	\$6,501.62	
55120	Removal of scrotum lesion		+	\$6,501.62	
55150	Removal of scrotum		+	\$6,501.62	
55175	Revision of scrotum		+	\$6,501.62	
55180	Revision of scrotum		+	\$6,501.62	
55200	Incision of sperm duct		+	\$6,501.62	
55250	Removal of sperm duct(s)		+	\$6,501.62	
55300	Prepare, sperm duct x-ray			\$53.13	
55400	Repair of sperm duct		+	\$6,501.62	
55450	Ligation of sperm duct		+	\$6,501.62	
55500	Removal of hydrocele		+	\$6,501.62	
55520	Removal of sperm cord lesion		+	\$6,501.62	
55530	Revise spermatic cord veins		+	\$6,501.62	
55535	Revise spermatic cord veins		+	\$8,086.36	
55540	Revise hemia & sperm veins		+	\$8,086.36	
55550	Laparo ligate spermatic vein		+	\$12,199.93	
55559	Laparo proc, spermatic cord		+	\$9,807.60	
55680	Remove sperm pouch lesion		+	\$6,501.62	
55700	Biopsy of prostate		+	\$1,170.93	
55705	Biopsy of prostate		+	\$1,170.93	
55720	Drainage of prostate abscess		+	\$6,575.81	
55725	Drainage of prostate abscess		+	\$6,575.81	
55859	Percut/needle insert, pros		+	\$10,025.80	
55860	Surgical exposure, prostate		+	\$4,423.33	
55870	Electroejaculation		+	\$1,454.39	
55873	Cryoablate prostate		+	\$25,894.27	
55899	Genital surgery procedure		+	\$345.56	
56405	I & D of vulva/perineum		+	\$816.97	
56420	Drainage of gland abscess		+	\$816.97	
56440	Surgery for vulva lesion		+	\$5,551.41	
56441	Lysis of labial lesion(s)		+	\$4,532.26	
56501	Destroy, vulva lesions, sim		+	\$4,931.21	
56515	Destroy vulva lesion/s compl		+	\$5,779.26	
56605	Biopsy of vulva/perineum		+	\$1,188.19	
56606	Biopsy of vulva/perineum		+	\$1,188.19	
56620	Partial removal of vulva		+	\$7,432.07	
56625	Complete removal of vulva		+	\$7,432.07	
56700	Partial removal of hymen		+	\$5,551.41	
56720	Incision of hymen		+	\$4,532.26	
56740	Remove vagina gland lesion		+	\$5,551.41	
56800	Repair of vagina		+	\$5,551.41	
56805	Repair clitoris		+	\$5,551.41	
56810	Repair of perineum		+	\$5,551.41	
56820	Exam of vulva w/scope		+	\$342.38	
56821	Exam/biopsy of vulva w/scope		+	\$428.72	
57000	Exploration of vagina		+	\$5,551.41	
57010	Drainage of pelvic abscess		+	\$5,551.41	
57020	Drainage of pelvic fluid		+	\$816.97	
57022	I & d vaginal hematoma, pp		+	\$3,544.82	
57023	I & d vag hematoma, non-ob		+	\$3,544.82	
57061	Destroy vag lesions, simple		+	\$5,551.41	
57065	Destroy vag lesions, complex		+	\$5,551.41	
57100	Biopsy of vagina		+	\$816.97	
57105	Biopsy of vagina		+	\$5,551.41	
57106	Remove vagina wall, partial		+	\$5,551.41	
57107	Remove vagina tissue, part		+	\$7,432.07	
57109	Vaginectomy partial w/nodes		+	\$7,432.07	
57120	Closure of vagina		+	\$7,432.07	
57130	Remove vagina lesion		+	\$5,551.41	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 1 - See end of the table for note regarding Charge Methodology.

TABLE F — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 49 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
57135	Remove vagina lesion		+	\$5,551.41	
57150	Treat vagina infection		+	\$62.57	
57155	Insert uteri tandems/ovoids		+	\$4,532.26	
57160	Insert pessary/other device		+	\$342.38	
57170	Fitting of diaphragm/cap		+	\$62.57	
57180	Treat vaginal bleeding		+	\$816.97	
57200	Repair of vagina		+	\$5,551.41	
57210	Repair vagina/penneum		+	\$5,551.41	
57220	Revision of urethra		+	\$7,432.07	
57230	Repair of urethral lesion		+	\$7,432.07	
57240	Repair bladder & vagina		+	\$7,432.07	
57250	Repair rectum & vagina		+	\$7,432.07	
57260	Repair of vagina		+	\$7,432.07	
57265	Extensive repair of vagina		+	\$7,432.07	
57267	Insert mesh/pelvic flr addon		+	\$1,711.84	
57268	Repair of bowel bulge		+	\$7,432.07	
57284	Repair paravaginal defect		+	\$7,432.07	
57287	Revise/remove sling repair		+	\$11,596.50	
57288	Repair bladder defect		+	\$11,596.50	
57289	Repair bladder & vagina		+	\$7,432.07	
57291	Construction of vagina		+	\$7,432.07	
57295	Change vaginal graft	C	+	\$1,315.39	OPPS
57300	Repair rectum-vagina fistula		+	\$7,432.07	
57310	Repair urethrovaginal lesion		+	\$7,432.07	
57320	Repair bladder-vagina lesion		+	\$7,432.07	
57330	Repair bladder-vagina lesion		+	\$7,432.07	
57400	Dilation of vagina		+	\$5,551.41	
57410	Pelvic examination		+	\$5,551.41	
57415	Remove vaginal foreign body		+	\$5,551.41	
57420	Exam of vagina w/scope		+	\$816.97	
57421	Exam/biopsy of vaq w/scope		+	\$816.97	
57425	Laparoscopy, surq, colpopexy		+	\$9,807.60	
57452	Examination of vagina		+	\$428.72	
57454	Vagina examination & biopsy		+	\$816.97	
57455	Biopsy of cervix w/scope		+	\$816.97	
57456	Endocerv curettage w/scope		+	\$816.97	
57460	Cervix excision		+	\$4,532.26	
57461	Conz of cervix w/scope, leep		+	\$5,551.41	
57500	Biopsy of cervix		+	\$816.97	
57505	Endocervical curettage		+	\$816.97	
57510	Cauterization of cervix		+	\$4,532.26	
57511	Cryocautery of cervix		+	\$428.72	
57513	Laser surgery of cervix		+	\$4,532.26	
57520	Conization of cervix		+	\$5,551.41	
57522	Conization of cervix		+	\$7,432.07	
57530	Removal of cervix		+	\$7,432.07	
57550	Removal of residual cervix		+	\$7,432.07	
57555	Remove cervix/repair vagina		+	\$7,432.07	
57556	Remove cervix, repair bowel		+	\$7,432.07	
57700	Revision of cervix		+	\$5,551.41	
57720	Revision of cervix		+	\$5,551.41	
57800	Dilation of cervical canal		+	\$4,532.26	
57820	D & c of residual cervix		+	\$4,856.58	
58100	Biopsy of uterus lining		+	\$342.38	
58110	Bx done w/colposcopy add-on	C	+	\$80.32	OPPS
58120	Dilation and curettage		+	\$4,856.58	
58145	Myomectomy vaq method		+	\$7,432.07	
58300	Insert intrauterine device		+	\$809.40	
58301	Remove intrauterine device		+	\$428.72	
58321	Artificial insemination		+	\$1,454.39	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
1. See end of the table for note regarding Charge Methodology

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 50 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
58322	Artificial insemination		+	\$1,454.39	
58323	Sperm washing		+	\$1,454.39	
58345	Reopen fallopian tube		+	\$5,551.41	
58346	Insert heyman uteri capsule		+	\$4,532.26	
58350	Reopen fallopian tube		+	\$5,551.41	
58353	Endometr ablate, thermal		+	\$7,432.07	
58356	Endometrial cryoablation		+	\$2,418.60	
58545	Laparoscopic myomectomy		+	\$9,807.60	
58546	Laparo-myomectomy, complex		+	\$12,159.93	
58550	Laparo-assst vaq hysterectomy		+	\$16,693.95	
58552	Laparo-vaq hyst incl t/o		+	\$12,159.93	
58553	Laparo-vaq hyst, complex		+	\$12,159.93	
58554	Laparo-vaq hyst w/lo, compl		+	\$12,159.93	
58555	Hysteroscopy, dx, sep proc		+	\$5,932.10	
58558	Hysteroscopy, biopsy		+	\$5,932.10	
58559	Hysteroscopy, lysis		+	\$5,932.10	
58560	Hysteroscopy, resect septum		+	\$8,479.27	
58561	Hysteroscopy, remove myoma		+	\$8,479.27	
58562	Hysteroscopy, remove fb		+	\$5,932.10	
58563	Hysteroscopy, ablation		+	\$8,479.27	
58565	Hysteroscopy, sterilization		+	\$2,418.60	
58578	Laparo proc, uterus		+	\$9,807.60	
58579	Hysteroscope procedure		+	\$5,932.10	
58600	Division of fallopian tube		+	\$7,432.07	
58615	Occlude fallopian tube(s)		+	\$5,551.41	
58660	Laparoscopy, lysis		+	\$12,159.93	
58661	Laparoscopy, remove adnexa		+	\$12,159.93	
58662	Laparoscopy, excise lesions		+	\$12,159.93	
58670	Laparoscopy, tubal cautery		+	\$12,159.93	
58671	Laparoscopy, tubal block		+	\$12,159.93	
58672	Laparoscopy, fimbrioplasty		+	\$12,159.93	
58673	Laparoscopy, salpingostomy		+	\$12,159.93	
58679	Laparo proc, oviduct-ovary		+	\$9,807.60	
58770	Create new tubal opening		+	\$1,613.15	
58800	Drainage of ovarian cyst(s)		+	\$4,532.26	
58820	Drain ovary abscess, open		+	\$7,432.07	
58823	Drain pelvic abscess, percut		+	\$4,532.26	
58900	Biopsy of ovary(s)		+	\$4,532.26	
58920	Partial removal of ovary(s)		+	\$7,432.07	
58925	Removal of ovarian cyst(s)		+	\$7,432.07	
58970	Retrieval of oocyte		+	\$5,551.41	
58974	Transfer of embryo		+	\$1,454.39	
58976	Transfer of embryo		+	\$1,454.39	
58999	Genital surgery procedure		+	\$62.57	
59000	Amniocentesis, diagnostic		+	\$285.85	
59001	Amniocentesis, therapeutic		+	\$285.85	
59012	Fetal cord puncture, prenatal		+	\$285.85	
59015	Chorion biopsy		+	\$285.85	
59020	Fetal contract stress test		+	\$285.85	
59025	Fetal non-stress test	b	+	\$285.85	
59030	Fetal scalp blood sample	b	+	\$285.85	
59050	Fetal monitor w/report		+	\$14.20	
59070	Transabdom amniocinfus w/ us		+	\$285.85	
59072	Umbilical cord occlud w/ us		+	\$285.85	
59074	Fetal fluid drainage w/ us		+	\$285.85	
59076	Fetal shunt placement, w/ us		+	\$285.85	
59150	Treat ectopic pregnancy		+	\$12,159.93	
59151	Treat ectopic pregnancy		+	\$12,159.93	
59160	D & c after delivery		+	\$4,856.58	
59200	Insert cervical dilator		+	\$428.72	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
1 - See end of the table for note regarding Charge Methodology

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 51 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
59300	Episiotomy or vaginal repair		+	\$4,532.26	
59320	Revision of cervix		+	\$5,551.41	
59409	Obstetrical care		+	\$4,610.98	
59412	Antepartum manipulation		+	\$648.48	
59414	Deliver placenta		+	\$4,610.98	
59612	Vbac delivery only		+	\$4,610.98	
59812	Treatment of miscarriage		+	\$4,499.75	
59820	Care of miscarriage		+	\$4,499.75	
59821	Treatment of miscarriage		+	\$4,499.75	
59840	Abortion		+	\$4,800.13	
59841	Abortion		+	\$4,800.13	
59866	Abortion (mpr)		+	\$285.85	
59870	Evacuate mole of uterus		+	\$4,499.75	
59871	Remove cerclage suture		+	\$5,551.41	
59897	Fetal invas px w/ us		+	\$285.85	
59898	Laparo proc, ob care/deliver		+	\$9,807.60	
59899	Maternity care procedure		+	\$285.85	
60000	Drain thyroid/tongue cyst		+	\$1,939.62	
60001	Aspirate/inject thyroid cyst		+	\$478.42	
60100	Biopsy of thyroid		+	\$478.42	
60200	Remove thyroid lesion		+	\$11,091.92	
60210	Partial thyroid excision		+	\$11,091.92	
60212	Partial thyroid excision		+	\$11,091.92	
60220	Partial removal of thyroid		+	\$11,091.92	
60225	Partial removal of thyroid		+	\$11,091.92	
60240	Removal of thyroid		+	\$11,091.92	
60252	Removal of thyroid		+	\$10,471.26	
60260	Repeat thyroid surgery		+	\$10,471.26	
60280	Remove thyroid duct lesion		+	\$11,091.92	
60281	Remove thyroid duct lesion		+	\$11,091.92	
60500	Explore parathyroid glands		+	\$10,471.26	
60512	Autotransplant parathyroid		+	\$5,653.51	
60659	Laparo proc, endocrine		+	\$9,807.60	
60699	Endocrine surgery procedure		+	\$11,091.92	
61000	Remove cranial cavity fluid		+	\$895.87	
61001	Remove cranial cavity fluid		+	\$895.87	
61020	Remove brain cavity fluid		+	\$895.87	
61026	Injection into brain canal		+	\$895.87	
61050	Remove brain canal fluid		+	\$895.87	
61055	Injection into brain canal		+	\$895.87	
61070	Brain canal shunt procedure		+	\$895.87	
61215	Insert brain-fluid device		+	\$9,309.48	
61330	Decompress eye socket		+	\$10,471.26	
61623	Endovasc tempory vessel occl		+	\$8,068.17	
61626	Transcath occlusion, non-cns		+	\$10,536.99	
61790	Treat trigeminal nerve		+	\$4,983.20	
61791	Treat trigeminal tract		+	\$652.44	
61795	Brain surgery usinq computer			\$1,905.92	
61880	Revise/remove neuroelectrode		+	\$6,157.80	
61885	Implant neurostim one array			\$28,531.49	
61886	Implant neurostim arrays		+	\$28,169.46	
61888	Revise/remove neuroreceiver		+	\$13,965.40	
62194	Replace/irrigate catheter		+	\$633.47	
62225	Replace/irrigate catheter		+	\$2,623.11	
62230	Replace/revise brain shunt		+	\$9,309.48	
62252	Csf shunt reprogram			\$845.45	
62263	Lysis epidural adhesions	b	+	\$3,489.84	
62264	Epidural lysis on single day		+	\$3,489.84	
62268	Drain spinal cord cyst		+	\$895.87	
62269	Needle biopsy, spinal cord		+	\$984.98	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 52 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
62270	Spinal fluid tap, diagnostic		+	\$1,548.29	
62272	Drain cerebro spinal fluid		+	\$1,548.29	
62273	Treat epidural spine lesion		+	\$1,548.29	
62280	Treat spinal cord lesion		+	\$1,943.33	
62281	Treat spinal cord lesion		+	\$1,943.33	
62282	Treat spinal canal lesion		+	\$1,943.33	
62287	Percutaneous discectomy		+	\$4,983.20	
62291	Inject for spine disk x-ray			\$49.88	
62292	Injection into disk lesion		+	\$895.87	
62294	Injection into spinal artery		+	\$895.87	
62310	Inject spine ct		+	\$1,548.29	
62311	Inject spine l/s (cd)		+	\$1,548.29	
62318	Inject spine w/cath, ct		+	\$1,548.29	
62319	Inject spine w/cath l/s (cd)		+	\$1,548.29	
62350	Implant spinal canal cath		+	\$7,623.27	
62351	Implant spinal canal cath		+	\$12,016.14	
62355	Remove spinal canal catheter		+	\$3,489.84	
62360	Insert spine infusion device		+	\$25,193.97	
62361	Implant spine infusion pump		+	\$24,779.22	
62362	Implant spine infusion pump		+	\$24,779.22	
62365	Remove spine infusion device		+	\$3,489.84	
62367	Analyze spine infusion pump	b		\$845.45	
62368	Analyze spine infusion pump	b		\$845.45	
63001	Removal of spinal lamina		+	\$12,016.14	
63003	Removal of spinal lamina		+	\$12,016.14	
63005	Removal of spinal lamina		+	\$12,016.14	
63011	Removal of spinal lamina		+	\$12,016.14	
63012	Removal of spinal lamina		+	\$12,016.14	
63015	Removal of spinal lamina		+	\$12,016.14	
63016	Removal of spinal lamina		+	\$12,016.14	
63017	Removal of spinal lamina		+	\$12,016.14	
63020	Neck spine disk surgery		+	\$12,016.14	
63030	Low back disk surgery		+	\$12,016.14	
63035	Spinal disk surgery add-on		+	\$12,016.14	
63040	Laminotomy, single cervical		+	\$12,016.14	
63042	Laminotomy, single lumbar		+	\$12,016.14	
63045	Removal of spinal lamina		+	\$12,016.14	
63046	Removal of spinal lamina		+	\$12,016.14	
63047	Removal of spinal lamina		+	\$12,016.14	
63048	Remove spinal lamina add-on		+	\$12,016.14	
63055	Decompress spinal cord		+	\$12,016.14	
63056	Decompress spinal cord		+	\$12,016.14	
63057	Decompress spine cord add-on		+	\$12,016.14	
63064	Decompress spinal cord		+	\$12,016.14	
63066	Decompress spine cord add-on		+	\$12,016.14	
63600	Remove spinal cord lesion		+	\$4,983.20	
63610	Stimulation of spinal cord		+	\$4,983.20	
63615	Remove lesion of spinal cord		+	\$4,983.20	
63650	Implant neuroelectrodes			\$15,694.64	
63655	Implant neuroelectrodes			\$24,991.14	
63660	Revise/remove neuroelectrode		+	\$6,157.80	
63685	Implant neuroreceiver		+	\$28,169.46	
63688	Revise/remove neuroreceiver		+	\$13,965.40	
63741	Install spinal shunt		+	\$15,751.23	
63744	Revision of spinal shunt		+	\$15,751.23	
63746	Removal of spinal shunt		+	\$2,248.50	
64400	N block inj, ingeminal		+	\$652.44	
64402	N block inj, facial		+	\$652.44	
64405	N block inj, occipital		+	\$652.44	
64408	N block inj, vaqus		+	\$652.44	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
 1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 53 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
64410	N block inj, phrenic		+	\$652.44	
64412	N block inj, spinal accessor		+	\$652.44	
64413	N block inj, cervical plexus		+	\$652.44	
64415	Injection for nerve block		+	\$652.44	
64416	N block cont infuse, b plex		+	\$652.44	
64417	N block inj, axillary		+	\$652.44	
64418	N block inj, suprascapular		+	\$652.44	
64420	N block inj, intercost, snq		+	\$1,943.33	
64421	N block inj, intercost, mlt		+	\$1,943.33	
64425	N block inj ilio-inq/hypoqi		+	\$652.44	
64430	N block inj, pudendal		+	\$652.44	
64435	N block inj, paracervical		+	\$652.44	
64445	Injection for nerve block		+	\$652.44	
64446	N blk inj, sciatic, cont inf		+	\$652.44	
64447	N block inj fem, single		+	\$652.44	
64448	N block inj fem, cont inf		+	\$652.44	
64449	N block inj, lumbar plexus		+	\$652.44	
64450	N block, other peripheral		+	\$652.44	
64470	Inj paravertebral c/t		+	\$1,943.33	
64472	Inj paravertebral c/t add-on		+	\$1,943.33	
64475	Inj paravertebral l/s		+	\$1,943.33	
64476	Inj paravertebral l/s add-on		+	\$1,943.33	
64479	Inj foramen epidural c/t		+	\$1,943.33	
64480	Inj foramen epidural add-on		+	\$1,943.33	
64483	Inj foramen epidural l/s		+	\$1,943.33	
64484	Inj foramen epidural add-on		+	\$1,943.33	
64505	N block, sphenopalatine gangl		+	\$652.44	
64508	N block, carotid sinus s/p		+	\$652.44	
64510	N block, stellate ganglion		+	\$1,943.33	
64517	N block inj, hypogas plxs		+	\$652.44	
64520	N block, lumbar/thoracic		+	\$1,943.33	
64530	N block inj, celiac pelus		+	\$1,943.33	
64550	Apply neurostimulator			\$344.49	
64553	Implant neuroelectrodes			\$24,991.14	
64555	Implant neuroelectrodes			\$15,694.64	
64560	Implant neuroelectrodes			\$15,694.64	
64561	Implant neuroelectrodes			\$15,694.64	
64565	Implant neuroelectrodes			\$15,694.64	
64573	Implant neuroelectrodes			\$24,991.14	
64575	Implant neuroelectrodes			\$15,694.64	
64577	Implant neuroelectrodes			\$24,991.14	
64580	Implant neuroelectrodes			\$24,991.14	
64581	Implant neuroelectrodes			\$15,694.64	
64585	Revise/remove neuroelectrode		+	\$6,157.80	
64590	Implant neuroreceiver		+	\$28,169.46	
64595	Revise/remove neuroreceiver		+	\$13,965.40	
64600	Injection treatment of nerve		+	\$3,489.84	
64605	Injection treatment of nerve		+	\$3,489.84	
64610	Injection treatment of nerve		+	\$3,489.84	
64612	Destroy nerve, face muscle		+	\$652.44	
64613	Destroy nerve, spine muscle		+	\$652.44	
64614	Destroy nerve, extrem musc		+	\$652.44	
64620	Injection treatment of nerve		+	\$3,489.84	
64622	Destr paravertebr nerve l/s		+	\$3,489.84	
64623	Destr paravertebral n add-on		+	\$3,489.84	
64626	Destr paravertebr nerve c/t		+	\$3,489.84	
64627	Destr paravertebral n add-on		+	\$3,489.84	
64630	Injection treatment of nerve		+	\$1,943.33	
64640	Injection treatment of nerve		+	\$1,943.33	
64650	Chemodenerv eccrine glands	C	+	\$144.33	OPPS

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 54 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
64653	Chemodenerve eccrine glands	c	+	\$144.33	OPPS
64680	Injection treatment of nerve		+	\$3,489.84	
64681	Injection treatment of nerve		+	\$3,489.84	
64702	Revise finger/toe nerve		+	\$4,983.20	
64704	Revise hand/foot nerve		+	\$4,983.20	
64708	Revise arm/leg nerve		+	\$4,983.20	
64712	Revision of sciatic nerve		+	\$4,983.20	
64713	Revision of arm nerve(s)		+	\$4,983.20	
64714	Revise low back nerve(s)		+	\$4,983.20	
64716	Revision of cranial nerve		+	\$4,983.20	
64718	Revise ulnar nerve at elbow		+	\$4,983.20	
64719	Revise ulnar nerve at wrist		+	\$4,983.20	
64721	Carpal tunnel surgery		+	\$4,983.20	
64722	Relieve pressure on nerve(s)		+	\$4,983.20	
64726	Release foot/toe nerve		+	\$4,983.20	
64727	Internal nerve revision		+	\$4,983.20	
64732	Incision of brow nerve		+	\$4,983.20	
64734	Incision of cheek nerve		+	\$4,983.20	
64736	Incision of chin nerve		+	\$4,983.20	
64738	Incision of jaw nerve		+	\$4,983.20	
64740	Incision of tongue nerve		+	\$4,983.20	
64742	Incision of facial nerve		+	\$4,983.20	
64744	Incise nerve, back of head		+	\$4,983.20	
64746	Incise diaphragm nerve		+	\$4,983.20	
64761	Incision of pelvis nerve		+	\$4,983.20	
64771	Sever cranial nerve		+	\$4,983.20	
64772	Incision of spinal nerve		+	\$4,983.20	
64774	Remove skin nerve lesion		+	\$4,983.20	
64776	Remove digit nerve lesion		+	\$4,983.20	
64778	Digit nerve surgery add-on		+	\$4,983.20	
64782	Remove limb nerve lesion		+	\$4,983.20	
64783	Limb nerve surgery add-on		+	\$4,983.20	
64784	Remove nerve lesion		+	\$4,983.20	
64786	Remove sciatic nerve lesion		+	\$7,497.12	
64787	Implant nerve end		+	\$4,983.20	
64788	Remove skin nerve lesion		+	\$4,983.20	
64790	Removal of nerve lesion		+	\$4,983.20	
64792	Removal of nerve lesion		+	\$7,497.12	
64795	Biopsy of nerve		+	\$4,983.20	
64802	Remove sympathetic nerves		+	\$4,983.20	
64820	Remove sympathetic nerves		+	\$4,983.20	
64821	Remove sympathetic nerves		+	\$7,265.78	
64822	Remove sympathetic nerves		+	\$7,265.78	
64823	Remove sympathetic nerves		+	\$7,265.78	
64831	Repair of digit nerve		+	\$7,497.12	
64832	Repair nerve add-on		+	\$7,497.12	
64834	Repair of hand or foot nerve		+	\$7,497.12	
64835	Repair of hand or foot nerve		+	\$7,497.12	
64836	Repair of hand or foot nerve		+	\$7,497.12	
64837	Repair nerve add-on		+	\$7,497.12	
64840	Repair of leg nerve		+	\$7,497.12	
64856	Repair/transpose nerve		+	\$7,497.12	
64857	Repair arm/leg nerve		+	\$7,497.12	
64858	Repair sciatic nerve		+	\$7,497.12	
64859	Nerve surgery		+	\$7,497.12	
64861	Repair of arm nerves		+	\$7,497.12	
64862	Repair of low back nerves		+	\$7,497.12	
64864	Repair of facial nerve		+	\$7,497.12	
64865	Repair of facial nerve		+	\$7,497.12	
64870	Fusion of facial/other nerve		+	\$7,497.12	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 55 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
64872	Subsequent repair of nerve		+	\$7,497.12	
64874	Repair & revise nerve add-on		+	\$7,497.12	
64876	Repair nerve/shorten bone		+	\$7,497.12	
64885	Nerve graft, head or neck		+	\$7,497.12	
64886	Nerve graft, head or neck		+	\$7,497.12	
64890	Nerve graft, hand or foot		+	\$7,497.12	
64891	Nerve graft, hand or foot		+	\$7,497.12	
64892	Nerve graft, arm or leg		+	\$7,497.12	
64893	Nerve graft, arm or leg		+	\$7,497.12	
64895	Nerve graft, hand or foot		+	\$7,497.12	
64896	Nerve graft, hand or foot		+	\$7,497.12	
64897	Nerve graft, arm or leg		+	\$7,497.12	
64898	Nerve graft, arm or leg		+	\$7,497.12	
64901	Nerve graft add-on		+	\$7,497.12	
64902	Nerve graft add-on		+	\$7,497.12	
64905	Nerve pedicle transfer		+	\$7,497.12	
64907	Nerve pedicle transfer		+	\$7,497.12	
64999	Nervous system surgery		+	\$652.44	
65091	Revise eye		+	\$8,799.92	
65093	Revise eye with implant		+	\$6,686.61	
65101	Removal of eye		+	\$8,799.92	
65103	Remove eye/insert implant		+	\$8,799.92	
65105	Remove eye/attach implant		+	\$8,799.92	
65110	Removal of eye		+	\$8,799.92	
65112	Remove eye/revise socket		+	\$8,799.92	
65114	Remove eye/revise socket		+	\$8,799.92	
65125	Revise ocular implant		+	\$5,249.03	
65130	Insert ocular implant		+	\$6,686.61	
65135	Insert ocular implant		+	\$6,686.61	
65140	Attach ocular implant		+	\$8,799.92	
65150	Revise ocular implant		+	\$6,686.61	
65155	Reinsert ocular implant		+	\$8,799.92	
65175	Removal of ocular implant		+	\$5,249.03	
65205	Remove foreign body from eye			\$256.08	
65210	Remove foreign body from eye			\$659.23	
65220	Remove foreign body from eye			\$659.23	
65222	Remove foreign body from eye			\$659.23	
65235	Remove foreign body from eye		+	\$4,322.28	
65260	Remove foreign body from eye		+	\$5,605.58	
65265	Remove foreign body from eye		+	\$5,605.58	
65270	Repair of eye wound		+	\$5,249.03	
65272	Repair of eye wound		+	\$4,322.28	
65275	Repair of eye wound		+	\$4,322.28	
65280	Repair of eye wound		+	\$6,452.58	
65285	Repair of eye wound		+	\$6,452.58	
65286	Repair of eye wound		+	\$4,322.28	
65290	Repair of eye socket wound		+	\$6,546.65	
65400	Removal of eye lesion		+	\$4,322.28	
65410	Biopsy of cornea		+	\$4,322.28	
65420	Removal of eye lesion		+	\$4,322.28	
65426	Removal of eye lesion		+	\$6,452.58	
65430	Corneal smear			\$203.28	
65435	Curette/treat cornea		+	\$1,847.55	
65436	Curette/treat cornea		+	\$4,322.28	
65450	Treatment of corneal lesion			\$659.23	
65600	Revision of cornea		+	\$5,249.03	
65710	Corneal transplant		+	\$11,296.81	
65730	Corneal transplant		+	\$11,296.81	
65750	Corneal transplant		+	\$11,296.81	
65755	Corneal transplant		+	\$11,296.81	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 56 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
65770	Revise cornea with implant		+	\$11,296.81	
65771	Radial keratotomy			\$2,607.98	
65772	Correction of astigmatism		+	\$4,322.28	
65775	Correction of astigmatism		+	\$4,322.28	
65780	Ocular reconst, transplant		+	\$11,296.81	
65781	Ocular reconst, transplant		+	\$11,296.81	
65782	Ocular reconst, transplant		+	\$11,296.81	
65800	Drainage of eye		+	\$4,322.28	
65805	Drainage of eye		+	\$4,322.28	
65810	Drainage of eye		+	\$6,452.58	
65815	Drainage of eye		+	\$6,452.58	
65820	Relieve inner eye pressure		+	\$1,482.26	
65850	Incision of eye		+	\$6,452.58	
65855	Laser surgery of eye		+	\$1,490.21	
65860	Incise inner eye adhesions		+	\$1,490.21	
65865	Incise inner eye adhesions		+	\$4,322.28	
65870	Incise inner eye adhesions		+	\$6,452.58	
65875	Incise inner eye adhesions		+	\$6,452.58	
65880	Incise inner eye adhesions		+	\$4,322.28	
65900	Remove eye lesion		+	\$4,322.28	
65920	Remove implant of eye		+	\$4,322.28	
65930	Remove blood clot from eye		+	\$6,452.58	
66020	Injection treatment of eye		+	\$4,322.28	
66030	Injection treatment of eye		+	\$4,322.28	
66130	Remove eye lesion		+	\$6,452.58	
66150	Glaucoma surgery		+	\$4,322.28	
66155	Glaucoma surgery		+	\$6,452.58	
66160	Glaucoma surgery		+	\$6,452.58	
66165	Glaucoma surgery		+	\$6,452.58	
66170	Glaucoma surgery		+	\$6,452.58	
66172	Incision of eye		+	\$8,067.12	
66180	Implant eye shunt		+	\$8,067.12	
66185	Revise eye shunt		+	\$8,067.12	
66220	Repair eye lesion		+	\$5,605.58	
66225	Repair/graft eye lesion		+	\$8,067.12	
66250	Follow-up surgery of eye		+	\$4,322.28	
66500	Incision of iris		+	\$1,482.26	
66505	Incision of iris		+	\$1,482.26	
66600	Remove iris and lesion		+	\$4,322.28	
66605	Removal of iris		+	\$6,452.58	
66625	Removal of iris		+	\$4,322.28	
66630	Removal of iris		+	\$4,322.28	
66635	Removal of iris		+	\$6,452.58	
66680	Repair iris & ciliary body		+	\$6,452.58	
66682	Repair iris & ciliary body		+	\$6,452.58	
66700	Destruction, ciliary body		+	\$4,322.28	
66710	Destruction, ciliary body		+	\$4,322.28	
66711	Ciliary endoscopic ablation		+	\$895.35	
66720	Destruction, ciliary body		+	\$4,322.28	
66740	Destruction, ciliary body		+	\$4,322.28	
66761	Revision of iris		+	\$1,490.21	
66762	Revision of iris		+	\$1,490.21	
66770	Removal of inner eye lesion		+	\$1,490.21	
66820	Incision, secondary cataract		+	\$1,482.26	
66821	After cataract laser surgery		+	\$1,490.21	
66825	Reposition intraocular lens		+	\$6,452.58	
66830	Removal of lens lesion		+	\$1,482.26	
66840	Removal of lens material		+	\$3,704.43	
66850	Removal of lens material		+	\$8,356.54	
66852	Removal of lens material		+	\$8,356.54	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 57 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method— ology (1)
66920	Extraction of lens		+	\$8,356.54	
66930	Extraction of lens		+	\$8,356.54	
66940	Extraction of lens		+	\$3,704.43	
66982	Cataract surgery, complex		+	\$5,946.03	
66983	Cataract surg w/ocl, 1 stage		+	\$5,946.03	
66984	Cataract surg w/ocl, 1 stage		+	\$5,946.03	
66985	Insert lens prosthesis		+	\$5,946.03	
66986	Exchange lens prosthesis		+	\$5,946.03	
66999	Eye surgery procedure		+	\$1,482.26	
67005	Partial removal of eye fluid		+	\$10,278.45	
67010	Partial removal of eye fluid		+	\$10,278.45	
67015	Release of eye fluid		+	\$10,278.45	
67025	Replace eye fluid		+	\$5,605.58	
67027	Implant eye drug system		+	\$10,278.45	
67028	Injection eye drug		+	\$1,528.75	
67030	Incise inner eye strands		+	\$5,605.58	
67031	Laser surgery, eye strands		+	\$1,490.21	
67036	Removal of inner eye fluid		+	\$10,278.45	
67038	Strip retinal membrane		+	\$10,278.45	
67039	Laser treatment of retina		+	\$10,278.45	
67040	Laser treatment of retina		+	\$11,710.69	
67101	Repair detached retina		+	\$1,528.75	
67105	Repair detached retina		+	\$1,452.67	
67107	Repair detached retina		+	\$11,710.69	
67108	Repair detached retina		+	\$11,710.69	
67110	Repair detached retina		+	\$5,605.58	
67112	Rerepair detached retina		+	\$11,710.69	
67115	Release encircling material		+	\$5,605.58	
67120	Remove eye implant material		+	\$5,605.58	
67121	Remove eye implant material		+	\$10,278.45	
67141	Treatment of retina		+	\$1,528.75	
67145	Treatment of retina		+	\$1,452.67	
67208	Treatment of retinal lesion		+	\$1,528.75	
67210	Treatment of retinal lesion		+	\$1,452.67	
67218	Treatment of retinal lesion		+	\$5,605.58	
67220	Treatment of choroid lesion		+	\$1,528.75	
67221	Ocular photodynamic ther		+	\$1,528.75	
67225	Eye photodynamic ther add-on		+	\$1,528.75	
67227	Treatment of retinal lesion		+	\$1,528.75	
67228	Treatment of retinal lesion		+	\$1,452.67	
67250	Reinforce eye wall		+	\$5,249.03	
67255	Reinforce/graft eye wall		+	\$10,278.45	
67299	Eye surgery procedure		+	\$1,528.75	
67311	Revise eye muscle		+	\$6,546.65	
67312	Revise two eye muscles		+	\$6,546.65	
67314	Revise eye muscle		+	\$6,546.65	
67316	Revise two eye muscles		+	\$6,546.65	
67318	Revise eye muscle(s)		+	\$6,546.65	
67320	Revise eye muscle(s) add-on		+	\$6,546.65	
67331	Eye surgery follow-up add-on		+	\$6,546.65	
67332	Rerevise eye muscles add-on		+	\$6,546.65	
67334	Revise eye muscle w/suture		+	\$6,546.65	
67335	Eye suture during surgery		+	\$6,546.65	
67340	Revise eye muscle add-on		+	\$6,546.65	
67343	Release eye tissue		+	\$6,546.65	
67345	Destroy nerve of eye muscle		+	\$962.56	
67350	Biopsy eye muscle		+	\$671.87	
67399	Eye muscle surgery procedure		+	\$6,546.65	
67400	Explore/biopsy eye socket		+	\$6,686.61	
67405	Explore/drain eye socket		+	\$6,686.61	

NOTES: CPT codes and descriptions only copyright 2005 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 58 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
67412	Explore/treat eye socket		+	\$6,686.61	
67413	Explore/treat eye socket		+	\$6,686.61	
67414	Explr/decompress eye socket		+	\$8,799.92	
67415	Aspiration, orbital contents		+	\$1,847.55	
67420	Explore/treat eye socket		+	\$8,799.92	
67430	Explore/treat eye socket		+	\$8,799.92	
67440	Explore/drain eye socket		+	\$8,799.92	
67445	Explr/decompress eye socket		+	\$8,799.92	
67450	Explore/biopsy eye socket		+	\$8,799.92	
67500	Inject/treat eye socket			\$659.23	
67505	Inject/treat eye socket		+	\$962.56	
67515	Inject/treat eye socket		+	\$1,847.55	
67550	Insert eye socket implant		+	\$8,799.92	
67560	Revise eye socket implant		+	\$6,686.61	
67570	Decompress optic nerve		+	\$8,799.92	
67599	Orbit surgery procedure		+	\$1,847.55	
67700	Drainage of eyelid abscess		+	\$962.56	
67710	Incision of eyelid		+	\$1,847.55	
67715	Incision of eyelid fold		+	\$5,249.03	
67800	Remove eyelid lesion		+	\$962.56	
67801	Remove eyelid lesions		+	\$1,847.55	
67805	Remove eyelid lesions		+	\$962.56	
67808	Remove eyelid lesion(s)		+	\$5,249.03	
67810	Biopsy of eyelid		+	\$962.56	
67820	Revise eyelashes			\$256.08	
67825	Revise eyelashes		+	\$962.56	
67830	Revise eyelashes		+	\$1,847.55	
67835	Revise eyelashes		+	\$5,249.03	
67840	Remove eyelid lesion		+	\$1,847.55	
67850	Treat eyelid lesion		+	\$1,847.55	
67875	Closure of eyelid by suture		+	\$1,847.55	
67880	Revision of eyelid		+	\$4,322.28	
67882	Revision of eyelid		+	\$5,249.03	
67900	Repair brow defect		+	\$5,249.03	
67901	Repair eyelid defect		+	\$5,249.03	
67902	Repair eyelid defect		+	\$5,249.03	
67903	Repair eyelid defect		+	\$5,249.03	
67904	Repair eyelid defect		+	\$5,249.03	
67906	Repair eyelid defect		+	\$5,249.03	
67908	Repair eyelid defect		+	\$5,249.03	
67909	Revise eyelid defect		+	\$5,249.03	
67911	Revise eyelid defect		+	\$5,249.03	
67912	Correction eyelid w/ implant		+	\$1,847.55	
67914	Repair eyelid defect		+	\$5,249.03	
67915	Repair eyelid defect		+	\$1,847.55	
67916	Repair eyelid defect		+	\$5,249.03	
67917	Repair eyelid defect		+	\$5,249.03	
67921	Repair eyelid defect		+	\$5,249.03	
67922	Repair eyelid defect		+	\$5,249.03	
67923	Repair eyelid defect		+	\$5,249.03	
67924	Repair eyelid defect		+	\$5,249.03	
67930	Repair eyelid wound		+	\$5,249.03	
67935	Repair eyelid wound		+	\$5,249.03	
67938	Remove eyelid foreign body			\$256.08	
67950	Revision of eyelid		+	\$5,249.03	
67961	Revision of eyelid		+	\$5,249.03	
67966	Revision of eyelid		+	\$5,249.03	
67971	Reconstruction of eyelid		+	\$6,686.61	
67973	Reconstruction of eyelid		+	\$6,686.61	
67974	Reconstruction of eyelid		+	\$6,686.61	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
 1. See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPSC CODE

PAGE 59 of 96

CPT/ HCPSC Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
67975	Reconstruction of eyelid		+	\$5,249.03	
67999	Revision of eyelid		+	\$5,249.03	
68020	Incise/drain eyelid lining		+	\$5,249.03	
68040	Treatment of eyelid lesions			\$256.08	
68100	Biopsy of eyelid lining		+	\$1,482.26	
68110	Remove eyelid lining lesion		+	\$671.87	
68115	Remove eyelid lining lesion		+	\$1,847.55	
68130	Remove eyelid lining lesion		+	\$4,322.28	
68135	Remove eyelid lining lesion		+	\$1,847.55	
68200	Treat eyelid by injection			\$256.08	
68320	Revise/graft eyelid lining		+	\$5,249.03	
68325	Revise/graft eyelid lining		+	\$8,799.92	
68326	Revise/graft eyelid lining		+	\$6,686.61	
68328	Revise/graft eyelid lining		+	\$6,686.61	
68330	Revise eyelid lining		+	\$4,322.28	
68335	Revise/graft eyelid lining		+	\$6,686.61	
68340	Separate eyelid adhesions		+	\$5,249.03	
68360	Revise eyelid lining		+	\$6,452.58	
68362	Revise eyelid lining		+	\$6,452.58	
68371	Harvest eye tissue, allograft		+	\$4,322.28	
68399	Eyelid lining surgery		+	\$1,847.55	
68400	Incise/drain tear gland		+	\$962.56	
68420	Incise/drain tear sac		+	\$5,249.03	
68440	Incise tear duct opening		+	\$962.56	
68500	Removal of tear gland		+	\$6,686.61	
68505	Partial removal, tear gland		+	\$6,686.61	
68510	Biopsy of tear gland		+	\$5,249.03	
68520	Removal of tear sac		+	\$6,686.61	
68525	Biopsy of tear sac		+	\$5,249.03	
68530	Clearance of tear duct		+	\$5,249.03	
68540	Remove tear gland lesion		+	\$6,686.61	
68550	Remove tear gland lesion		+	\$8,799.92	
68700	Repair tear ducts		+	\$6,686.61	
68705	Revise tear duct opening		+	\$962.56	
68720	Create tear sac drain		+	\$8,799.92	
68745	Create tear duct drain		+	\$6,686.61	
68750	Create tear duct drain		+	\$8,799.92	
68760	Close tear duct opening			\$256.08	
68761	Close tear duct opening			\$659.23	
68770	Close tear system fistula		+	\$5,249.03	
68801	Dilate tear duct opening			\$659.23	
68810	Probe nasolacrimal duct			\$671.87	
68811	Probe nasolacrimal duct		+	\$5,249.03	
68815	Probe nasolacrimal duct		+	\$5,249.03	
68840	Explore/irrigate tear ducts			\$671.87	
68850	Injection for tear sac x-ray			\$27.58	
68899	Tear duct system surgery			\$671.87	
69000	Drain external ear lesion		+	\$497.85	
69005	Drain external ear lesion		+	\$3,544.82	
69020	Drain outer ear canal lesion		+	\$497.85	
69100	Biopsy of external ear		+	\$1,188.19	
69105	Biopsy of external ear canal		+	\$4,583.99	
69110	Remove external ear, partial		+	\$4,293.63	
69120	Removal of external ear		+	\$6,567.70	
69140	Remove ear canal lesion(s)		+	\$6,567.70	
69145	Remove ear canal lesion(s)		+	\$4,293.63	
69150	Extensive ear canal surgery		+	\$1,939.62	
69200	Clear outer ear canal			\$190.09	
69205	Clear outer ear canal		+	\$5,653.51	
69210	Remove impacted ear wax			\$190.09	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 60 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
69220	Clean out mastoid cavity		+	\$229.30	
69222	Clean out mastoid cavity		+	\$4,583.99	
69300	Revise external ear		+	\$6,567.70	
69310	Rebuild outer ear canal		+	\$10,471.26	
69320	Rebuild outer ear canal		+	\$10,471.26	
69399	Outer ear surgery procedure		+	\$538.65	
69400	Inflate middle ear canal		+	\$538.65	
69401	Inflate middle ear canal		+	\$538.65	
69405	Catheterize middle ear canal		+	\$1,939.62	
69420	Incision of eardrum		+	\$1,939.62	
69421	Incision of eardrum		+	\$4,583.99	
69424	Remove ventilating tube		+	\$1,939.62	
69433	Create eardrum opening		+	\$1,939.62	
69436	Create eardrum opening		+	\$4,583.99	
69440	Exploration of middle ear		+	\$6,567.70	
69450	Eardrum revision		+	\$10,471.26	
69501	Mastoidectomy		+	\$10,471.26	
69502	Mastoidectomy		+	\$6,567.70	
69505	Remove mastoid structures		+	\$10,471.26	
69511	Extensive mastoid surgery		+	\$10,471.26	
69530	Extensive mastoid surgery		+	\$10,471.26	
69540	Remove ear lesion		+	\$4,583.99	
69550	Remove ear lesion		+	\$10,471.26	
69552	Remove ear lesion		+	\$10,471.26	
69601	Mastoid surgery revision		+	\$10,471.26	
69602	Mastoid surgery revision		+	\$10,471.26	
69603	Mastoid surgery revision		+	\$10,471.26	
69604	Mastoid surgery revision		+	\$10,471.26	
69605	Mastoid surgery revision		+	\$10,471.26	
69610	Repair of eardrum		+	\$6,567.70	
69620	Repair of eardrum		+	\$6,567.70	
69631	Repair eardrum structures		+	\$10,471.26	
69632	Rebuild eardrum structures		+	\$10,471.26	
69633	Rebuild eardrum structures		+	\$10,471.26	
69635	Repair eardrum structures		+	\$10,471.26	
69636	Rebuild eardrum structures		+	\$10,471.26	
69637	Rebuild eardrum structures		+	\$10,471.26	
69641	Revise middle ear & mastoid		+	\$10,471.26	
69642	Revise middle ear & mastoid		+	\$10,471.26	
69643	Revise middle ear & mastoid		+	\$10,471.26	
69644	Revise middle ear & mastoid		+	\$10,471.26	
69645	Revise middle ear & mastoid		+	\$10,471.26	
69646	Revise middle ear & mastoid		+	\$10,471.26	
69650	Release middle ear bone		+	\$6,567.70	
69660	Revise middle ear bone		+	\$10,471.26	
69661	Revise middle ear bone		+	\$10,471.26	
69662	Revise middle ear bone		+	\$10,471.26	
69666	Repair middle ear structures		+	\$10,471.26	
69667	Repair middle ear structures		+	\$10,471.26	
69670	Remove mastoid air cells		+	\$10,471.26	
69676	Remove middle ear nerve		+	\$10,471.26	
69700	Close mastoid fistula		+	\$10,471.26	
69711	Remove/repair hearing aid		+	\$10,471.26	
69714	Implant temple bone w/stimul		+	\$10,471.26	
69715	Temple bone implant w/stimulat		+	\$10,471.26	
69717	Temple bone implant revision		+	\$10,471.26	
69718	Revise temple bone implant		+	\$10,471.26	
69720	Release facial nerve		+	\$10,471.26	
69725	Release facial nerve		+	\$10,471.26	
69740	Repair facial nerve		+	\$10,471.26	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1. See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 61 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
69745	Repair facial nerve		+	\$10,471.26	
69799	Middle ear surgery procedure		+	\$4,583.99	
69801	Incise inner ear		+	\$10,471.26	
69802	Incise inner ear		+	\$10,471.26	
69805	Explore inner ear		+	\$10,471.26	
69806	Explore inner ear		+	\$10,471.26	
69820	Establish inner ear window		+	\$10,471.26	
69840	Revise inner ear window		+	\$10,471.26	
69905	Remove inner ear		+	\$10,471.26	
69910	Remove inner ear & mastoid		+	\$10,471.26	
69915	Incise inner ear nerve		+	\$10,471.26	
69930	Implant cochlear device		+	\$47,659.76	
69949	Inner ear surgery procedure		+	\$4,583.99	
69955	Release facial nerve		+	\$10,471.26	
69960	Release inner ear canal		+	\$10,471.26	
69979	Temporal bone surgery		+	\$538.65	
70010	Contrast x-ray of brain	b		\$1,157.09	
70015	Contrast x-ray of brain	b		\$1,157.09	
70030	X-ray eye for foreign body	b		\$231.26	
70100	X-ray exam of jaw	b		\$231.26	
70110	X-ray exam of jaw	b		\$231.26	
70120	X-ray exam of mastoids	b		\$231.26	
70130	X-ray exam of mastoids	b		\$231.26	
70134	X-ray exam of middle ear	b		\$422.95	
70140	X-ray exam of facial bones	b		\$231.26	
70150	X-ray exam of facial bones	b		\$231.26	
70160	X-ray exam of nasal bones	b		\$231.26	
70170	X-ray exam of tear duct	b		\$709.31	
70190	X-ray exam of eye sockets	b		\$231.26	
70200	X-ray exam of eye sockets	b		\$231.26	
70210	X-ray exam of sinuses	b		\$231.26	
70220	X-ray exam of sinuses	b		\$231.26	
70240	X-ray exam, pituitary saddle	b		\$231.26	
70250	X-ray exam of skull	b		\$231.26	
70260	X-ray exam of skull	b		\$422.95	
70300	X-ray exam of teeth	b		\$244.58	
70310	X-ray exam of teeth	b		\$244.58	
70320	Full mouth x-ray of teeth	b		\$244.58	
70328	X-ray exam of jaw joint	b		\$231.26	
70330	X-ray exam of jaw joints	b		\$231.26	
70332	X-ray exam of jaw joint	b		\$1,063.09	
70336	Magnetic image, jaw joint	b		\$2,059.71	
70350	X-ray head for orthodontia	b		\$231.26	
70355	Panoramic x-ray of jaws	b		\$231.26	
70360	X-ray exam of neck	b		\$231.26	
70370	Throat x-ray & fluoroscopy	b		\$459.16	
70371	Speech evaluation, complex	b		\$459.16	
70373	Contrast x-ray of larynx	b		\$709.31	
70380	X-ray exam of salivary gland	b		\$231.26	
70390	X-ray exam of salivary duct	b		\$977.13	
70450	Ct head/brain w/o dye	b		\$1,322.54	
70460	Ct head/brain w/dye	b		\$1,768.76	
70470	Ct head/brain w/o & w/ dye	b		\$2,097.84	
70480	Ct orbit/ear/fossa w/o dye	b		\$1,322.54	
70481	Ct orbit/ear/fossa w/dye	b		\$1,768.76	
70482	Ct orbit/ear/fossa w/o&w dye	b		\$2,097.84	
70486	Ct maxillofacial w/o dye	b		\$1,322.54	
70487	Ct maxillofacial w/dye	b		\$1,768.76	
70488	Ct maxillofacial w/o & w dye	b		\$2,097.84	
70490	Ct soft tissue neck w/o dye	b		\$1,322.54	

NOTES: CPT codes and descriptions only copyright 2005 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1. See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 62 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
70491	Ct soft tissue neck w/dye	b		\$1,768.76	
70492	Ct soft tissue neck w/o & w/dye	b		\$2,097.84	
70496	Ct angiography, head	b		\$1,906.27	
70498	Ct angiography, neck	b		\$1,906.27	
70540	Mri orbit/face/neck w/o dye	b		\$2,210.11	
70542	Mri orbit/face/neck w/dye	b		\$2,308.32	
70543	Mri orbit/face/neck w/o & w dye	b		\$3,333.23	
70544	Mr angiography head w/o dye	b		\$2,210.11	
70545	Mr angiography head w/dye	b		\$2,308.32	
70546	Mr angiography head w/o & w dye	b		\$3,333.23	
70547	Mr angiography neck w/o dye	b		\$2,210.11	
70548	Mr angiography neck w/dye	b		\$2,308.32	
70549	Mr angiography neck w/o & w dye	b		\$3,333.23	
70551	Mri brain w/o dye	b		\$2,210.11	
70552	Mri brain w/dye	b		\$2,308.32	
70553	Mri brain w/o & w/dye	b		\$3,333.23	
70557	Mri brain w/o dye	b		\$2,210.11	
70558	Mri brain w/dye	b		\$2,308.32	
70559	Mri brain w/o & w/dye	b		\$3,333.23	
71010	Chest x-ray	b		\$231.26	
71015	Chest x-ray	b		\$231.26	
71020	Chest x-ray	b		\$231.26	
71021	Chest x-ray	b		\$231.26	
71022	Chest x-ray	b		\$231.26	
71023	Chest x-ray and fluoroscopy	b		\$459.16	
71030	Chest x-ray	b		\$231.26	
71034	Chest x-ray and fluoroscopy	b		\$459.16	
71035	Chest x-ray	b		\$231.26	
71040	Contrast x-ray of bronchi	b		\$709.31	
71060	Contrast x-ray of bronchi	b		\$977.13	
71090	X-ray & pacemaker insertion	b		\$459.16	
71100	X-ray exam of ribs	b		\$231.26	
71101	X-ray exam of ribs/chest	b		\$231.26	
71110	X-ray exam of ribs	b		\$231.26	
71111	X-ray exam of ribs/chest	b		\$422.95	
71120	X-ray exam of breastbone	b		\$231.26	
71130	X-ray exam of breastbone	b		\$231.26	
71250	Ct thorax w/o dye	b		\$1,322.54	
71260	Ct thorax w/dye	b		\$1,768.76	
71270	Ct thorax w/o & w/dye	b		\$2,097.84	
71275	Ct angiography, chest	b		\$1,906.27	
71550	Mri chest w/o dye	b		\$2,210.11	
71551	Mri chest w/dye	b		\$2,308.32	
71552	Mri chest w/o & w/dye	b		\$3,333.23	
71555	Mri anqio chest w or w/o dye	b		\$3,541.18	
72010	X-ray exam of spine	b		\$422.95	
72020	X-ray exam of spine	b		\$231.26	
72040	X-ray exam of neck spine	b		\$231.26	
72050	X-ray exam of neck spine	b		\$422.95	
72052	X-ray exam of neck spine	b		\$422.95	
72069	X-ray exam of trunk spine	b		\$231.26	
72070	X-ray exam of thoracic spine	b		\$231.26	
72072	X-ray exam of thoracic spine	b		\$231.26	
72074	X-ray exam of thoracic spine	b		\$231.26	
72080	X-ray exam of trunk spine	b		\$231.26	
72090	X-ray exam of trunk spine	b		\$422.95	
72100	X-ray exam of lower spine	b		\$231.26	
72110	X-ray exam of lower spine	b		\$422.95	
72114	X-ray exam of lower spine	b		\$422.95	
72120	X-ray exam of lower spine	b		\$231.26	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1. See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 63 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
72125	Ct neck spine w/o dye	b		\$1,322.54	
72126	Ct neck spine w/dye	b		\$1,768.76	
72127	Ct neck spine w/o & w/dye	b		\$2,097.84	
72128	Ct chest spine w/o dye	b		\$1,322.54	
72129	Ct chest spine w/dye	b		\$1,768.76	
72130	Ct chest spine w/o & w/dye	b		\$2,097.84	
72131	Ct lumbar spine w/o dye	b		\$1,322.54	
72132	Ct lumbar spine w/dye	b		\$1,768.76	
72133	Ct lumbar spine w/o & w/dye	b		\$2,097.84	
72141	Mri neck spine w/o dye	b		\$2,210.11	
72142	Mri neck spine w/dye	b		\$2,308.32	
72146	Mri chest spine w/o dye	b		\$2,210.11	
72147	Mri chest spine w/dye	b		\$2,308.32	
72148	Mri lumbar spine w/o dye	b		\$2,210.11	
72149	Mri lumbar spine w/dye	b		\$2,308.32	
72156	Mri neck spine w/o & w/dye	b		\$3,333.23	
72157	Mri chest spine w/o & w/dye	b		\$3,333.23	
72158	Mri lumbar spine w/o & w/dye	b		\$3,333.23	
72159	Mr angio spine w/o&w/dye	b		\$3,683.97	
72170	X-ray exam of pelvis	b		\$231.26	
72190	X-ray exam of pelvis	b		\$231.26	
72191	Ct angiograph pelv w/o&w/dye	b		\$1,906.27	
72192	Ct pelvis w/o dye	b		\$1,322.54	
72193	Ct pelvis w/dye	b		\$1,768.76	
72194	Ct pelvis w/o & w/dye	b		\$2,097.84	
72195	Mri pelvis w/o dye	b		\$2,210.11	
72196	Mri pelvis w/dye	b		\$2,308.32	
72197	Mri pelvis w/o & w/dye	b		\$3,333.23	
72198	Mr angio pelvis w/o & w/dye	b		\$3,455.22	
72200	X-ray exam sacroiliac joints	b		\$231.26	
72202	X-ray exam sacroiliac joints	b		\$231.26	
72220	X-ray exam of tailbone	b		\$231.26	
72240	Contrast x-ray of neck spine	b		\$1,157.09	
72255	Contrast x-ray, thorax spine	b		\$1,157.09	
72265	Contrast x-ray, lower spine	b		\$1,157.09	
72270	Contrast x-ray, spine	b		\$1,157.09	
72275	Epidurography	b		\$1,157.09	
72285	X-ray c/t spine disk	b		\$3,766.96	
72295	X-ray of lower spine disk	b		\$3,766.96	
73000	X-ray exam of collar bone	b		\$231.26	
73010	X-ray exam of shoulder blade	b		\$231.26	
73020	X-ray exam of shoulder	b		\$231.26	
73030	X-ray exam of shoulder	b		\$231.26	
73040	Contrast x-ray of shoulder	b		\$1,063.09	
73050	X-ray exam of shoulders	b		\$231.26	
73060	X-ray exam of humerus	b		\$231.26	
73070	X-ray exam of elbow	b		\$231.26	
73080	X-ray exam of elbow	b		\$231.26	
73085	Contrast x-ray of elbow	b		\$1,063.09	
73090	X-ray exam of forearm	b		\$231.26	
73092	X-ray exam of arm, infant	b		\$231.26	
73100	X-ray exam of wrist	b		\$231.26	
73110	X-ray exam of wrist	b		\$231.26	
73115	Contrast x-ray of wrist	b		\$1,063.09	
73120	X-ray exam of hand	b		\$231.26	
73130	X-ray exam of hand	b		\$231.26	
73140	X-ray exam of finger(s)	b		\$231.26	
73200	Ct upper extremity w/o dye	b		\$1,322.54	
73201	Ct upper extremity w/dye	b		\$1,768.76	
73202	Ct uppr extremity w/o&w/dye	b		\$2,097.84	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 64 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
73206	Ct anqio upr extrm w/o&w/dye	b		\$1,906.27	
73218	Mri upper extremity w/o dye	b		\$2,210.11	
73219	Mri upper extremity w/dye	b		\$2,308.32	
73220	Mri uppr extremity w/o&w/dye	b		\$3,333.23	
73221	Mri joint upr extrem w/o dye	b		\$2,210.11	
73222	Mri joint upr extrem w/dye	b		\$2,308.32	
73223	Mri joint upr extr w/o&w/dye	b		\$3,333.23	
73225	Mr anqio upr extr w/o&w/dye	b		\$2,443.36	
73500	X-ray exam of hip	b		\$231.26	
73510	X-ray exam of hip	b		\$231.26	
73520	X-ray exam of hips	b		\$231.26	
73525	Contrast x-ray of hip	b		\$1,063.09	
73530	X-ray exam of hip	b		\$422.95	
73540	X-ray exam of pelvis & hips	b		\$231.26	
73542	X-ray exam, sacroiliac joint	b		\$1,063.09	
73550	X-ray exam of thigh	b		\$231.26	
73560	X-ray exam of knee, 1 or 2	b		\$231.26	
73562	X-ray exam of knee, 3	b		\$231.26	
73564	X-ray exam, knee, 4 or more	b		\$231.26	
73565	X-ray exam of knees	b		\$231.26	
73580	Contrast x-ray of knee joint	b		\$1,063.09	
73590	X-ray exam of lower leg	b		\$231.26	
73592	X-ray exam of leg, infant	b		\$231.26	
73600	X-ray exam of ankle	b		\$231.26	
73610	X-ray exam of ankle	b		\$231.26	
73615	Contrast x-ray of ankle	b		\$1,063.09	
73620	X-ray exam of foot	b		\$231.26	
73630	X-ray exam of foot	b		\$231.26	
73650	X-ray exam of heel	b		\$231.26	
73660	X-ray exam of toe(s)	b		\$231.26	
73700	Ct lower extremity w/o dye	b		\$1,322.54	
73701	Ct lower extremity w/dye	b		\$1,768.76	
73702	Ct lwr extremity w/o&w/dye	b		\$2,097.84	
73706	Ct anqio lwr extr w/o&w/dye	b		\$1,906.27	
73718	Mri lower extremity w/o dye	b		\$2,210.11	
73719	Mri lower extremity w/dye	b		\$2,308.32	
73720	Mri lwr extremity w/o&w/dye	b		\$3,333.23	
73721	Mri jnt of lwr extre w/o dye	b		\$2,210.11	
73722	Mri joint of lwr extr w/dye	b		\$2,308.32	
73723	Mri joint lwr extr w/o&w/dye	b		\$3,333.23	
73725	Mr anq lwr ext w or w/o dye	b		\$2,426.17	
74000	X-ray exam of abdomen	b		\$231.26	
74010	X-ray exam of abdomen	b		\$231.26	
74020	X-ray exam of abdomen	b		\$231.26	
74022	X-ray exam series, abdomen	b		\$422.95	
74150	Ct abdomen w/o dye	b		\$1,322.54	
74160	Ct abdomen w/dye	b		\$1,768.76	
74170	Ct abdomen w/o & w /dye	b		\$2,097.84	
74175	Ct anqio abdom w/o & w/dye	b		\$1,906.27	
74181	Mri abdomen w/o dye	b		\$2,210.11	
74182	Mri abdomen w/dye	b		\$2,308.32	
74183	Mri abdomen w/o & w/dye	b		\$3,333.23	
74185	Mri anqio, abdom w orw/o dye	b		\$4,071.44	
74190	X-ray exam of peritoneum	b		\$709.31	
74210	Contrst x-ray exam of throat	b		\$539.46	
74220	Contrast x-ray, esophagus	b		\$539.46	
74230	Cine/vid x-ray, throat/esoph	b		\$539.46	
74235	Remove esophagus obstruction	b		\$928.85	
74240	X-ray exam, upper qi tract	b		\$539.46	
74241	X-ray exam, upper qi tract	b		\$539.46	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 1 - See end of the table for note regarding Charge Methodology

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 65 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
74245	X-ray exam, upper qi tract	b		\$792.63	
74246	Contrst x-ray uppr qi tract	b		\$539.46	
74247	Contrst x-ray uppr qi tract	b		\$539.46	
74249	Contrst x-ray uppr qi tract	b		\$792.63	
74250	X-ray exam of small bowel	b		\$539.46	
74251	X-ray exam of small bowel	b		\$792.63	
74260	X-ray exam of small bowel	b		\$792.63	
74270	Contrast x-ray exam of colon	b		\$539.46	
74280	Contrast x-ray exam of colon	b		\$792.63	
74283	Contrast x-ray exam of colon	b		\$539.46	
74290	Contrast x-ray, gallbladder	b		\$539.46	
74291	Contrast x-rays, gallbladder	b		\$539.46	
74300	X-ray bile ducts/pancreas	b		\$709.31	
74301	X-rays at surgery add-on	b		\$709.31	
74305	X-ray bile ducts/pancreas	b		\$709.31	
74320	Contrast x-ray of bile ducts	b		\$977.13	
74327	X-ray bile stone removal	b		\$928.85	
74329	X-ray for pancreas endoscopy			\$93.56	
74340	X-ray guide for GI tube	b		\$459.16	CALC
74350	X-ray guide, stomach tube	b		\$709.31	
74355	X-ray guide, intestinal tube	b		\$709.31	
74360	X-ray guide, GI dilation	b		\$928.85	
74363	X-ray, bile duct dilation	b		\$2,502.31	
74400	Contrst x-ray, urinary tract	b		\$875.41	
74410	Contrst x-ray, urinary tract	b		\$875.41	
74415	Contrst x-ray, urinary tract	b		\$875.41	
74420	Contrst x-ray, urinary tract	b		\$875.41	
74425	Contrst x-ray, urinary tract	b		\$875.41	
74430	Contrast x-ray, bladder	b		\$875.41	
74440	X-ray, male genital tract	b		\$875.41	
74445	X-ray exam of penis	b		\$875.41	
74450	X-ray, urethra/bladder	b		\$875.41	
74455	X-ray, urethra/bladder	b		\$875.41	
74470	X-ray exam of kidney lesion	b		\$977.13	
74475	X-ray control, cath insert	b		\$2,502.31	
74480	X-ray control, cath insert	b		\$928.85	
74485	X-ray guide, GU dilation	b		\$928.85	
74710	X-ray measurement of pelvis	b		\$231.26	
74740	X-ray, female genital tract	b		\$977.13	
74742	X-ray, fallopian tube	b		\$709.31	
74775	X-ray exam of penneum	b		\$875.41	
75552	Heart mri for morph w/o dye	b		\$2,210.11	
75553	Heart mri for morph w/dye	b		\$2,308.32	
75554	Cardiac MRI/function	b		\$2,059.71	
75555	Cardiac MRI/limited study	b		\$2,059.71	
75600	Contrast x-ray exam of aorta	b		\$6,151.16	
75605	Contrast x-ray exam of aorta	b		\$6,151.16	
75625	Contrast x-ray exam of aorta	b		\$6,151.16	
75630	X-ray aorta, leg arteries	b		\$6,151.16	
75635	Ct anqio abdominal arteries	b		\$1,906.27	
75650	Artery x-rays, head & neck	b		\$6,151.16	
75658	Artery x-rays, arm	b		\$6,151.16	
75660	Artery x-rays, head & neck	b		\$3,473.06	
75662	Artery x-rays, head & neck	b		\$3,473.06	
75665	Artery x-rays, head & neck	b		\$6,151.16	
75671	Artery x-rays, head & neck	b		\$6,151.16	
75676	Artery x-rays, neck	b		\$6,151.16	
75680	Artery x-rays, neck	b		\$6,151.16	
75685	Artery x-rays, spine	b		\$3,473.06	
75705	Artery x-rays, spine	b		\$3,473.06	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 66 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
75710	Artery x-rays, arm/leg	b		\$6,151.16	
75716	Artery x-rays, arms/legs	b		\$6,151.16	
75722	Artery x-rays, kidney	b		\$6,151.16	
75724	Artery x-rays, kidneys	b		\$6,151.16	
75726	Artery x-rays, abdomen	b		\$6,151.16	
75731	Artery x-rays, adrenal gland	b		\$6,151.16	
75733	Artery x-rays, adrenals	b		\$6,151.16	
75736	Artery x-rays, pelvis	b		\$6,151.16	
75741	Artery x-rays, lung	b		\$3,473.06	
75743	Artery x-rays, lungs	b		\$6,151.16	
75746	Artery x-rays, lung	b		\$3,473.06	
75756	Artery x-rays, chest	b		\$3,473.06	
75774	Artery x-ray, each vessel	b		\$3,329.90	
75790	Visualize A-V shunt	b		\$2,141.24	
75801	Lymph vessel x-ray, arm/leg	b		\$977.13	
75803	Lymph vessel x-ray, arms/legs	b		\$977.13	
75805	Lymph vessel x-ray, trunk	b		\$977.13	
75807	Lymph vessel x-ray, trunk	b		\$977.13	
75809	Nonvascular shunt, x-ray	b		\$709.31	
75810	Vein x-ray, spleen/liver	b		\$3,473.06	
75820	Vein x-ray, arm/leg	b		\$2,141.24	
75822	Vein x-ray, arms/legs	b		\$2,141.24	
75825	Vein x-ray, trunk	b		\$3,473.06	
75827	Vein x-ray, chest	b		\$3,473.06	
75831	Vein x-ray, kidney	b		\$2,105.90	
75833	Vein x-ray, kidneys	b		\$3,473.06	
75840	Vein x-ray, adrenal gland	b		\$2,105.90	
75842	Vein x-ray, adrenal glands	b		\$2,105.90	
75860	Vein x-ray, neck	b		\$2,105.90	
75870	Vein x-ray, skull	b		\$2,105.90	
75872	Vein x-ray, skull	b		\$2,105.90	
75880	Vein x-ray, eye socket	b		\$2,105.90	
75885	Vein x-ray, liver	b		\$3,473.06	
75887	Vein x-ray, liver	b		\$6,151.16	
75889	Vein x-ray, liver	b		\$3,473.06	
75891	Vein x-ray, liver	b		\$3,473.06	
75894	X-rays, transcath therapy	b		\$2,502.31	
75896	X-rays, transcath therapy	b		\$2,502.31	
75898	Follow-up angiography	b		\$977.13	
75901	Remove cva device obstruct	b		\$977.13	
75902	Remove cva lumen obstruct	b		\$709.31	
75940	X-ray placement, vein filter	b		\$1,436.55	
75945	Intravascular us	b		\$727.77	
75946	Intravascular us add-on	b		\$727.77	
75960	Transcatheter intro, stent	b		\$6,151.16	
75961	Retrieval, broken catheter	b		\$6,151.16	
75962	Repair arterial blockage	b		\$6,151.16	
75964	Repair artery blockage, each	b		\$6,151.16	
75966	Repair arterial blockage	b		\$6,151.16	
75968	Repair artery blockage, each	b		\$6,151.16	
75970	Vascular biopsy	b		\$6,151.16	
75978	Repair venous blockage	b		\$3,329.90	
75980	Contrast xray exam bile duct	b		\$928.85	
75982	Contrast xray exam bile duct	b		\$2,502.31	
75984	Xray control catheter change	b		\$977.13	
75992	Atherectomy, x-ray exam	b		\$6,151.16	
75993	Atherectomy, x-ray exam	b		\$6,151.16	
75994	Atherectomy, x-ray exam	b		\$6,151.16	
75995	Atherectomy, x-ray exam	b		\$6,151.16	
75996	Atherectomy, x-ray exam	b		\$6,151.16	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 67 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
76000	Fluoroscope examination	b		\$459.16	
76006	X-ray stress view			\$231.26	
76010	X-ray, nose to rectum	b		\$231.26	
76012	Percut vertebroplasty fluor	b		\$1,157.09	
76013	Percut vertebroplasty, ct	b		\$1,157.09	
76020	X-rays for bone age	b		\$231.26	
76040	X-rays, bone evaluation	b		\$231.26	
76061	X-rays, bone survey	b		\$422.95	
76062	X-rays, bone survey	b		\$422.95	
76065	X-rays, bone evaluation	b		\$422.95	
76066	Joint survey, single view	b		\$231.26	
76070	CT scan, bone density study	b		\$377.88	
76071	Ct bone density, peripheral	b		\$660.65	
76075	Dexa, axial skeleton study	b		\$377.88	
76076	Dexa, peripheral study	b		\$235.37	
76077	Dxa bone density/v-fracture	b		\$46.94	
76078	Radiographic absorptiometry	b		\$422.95	
76080	X-ray exam of fistula	b		\$709.31	
76082	Computer mammogram add-on	b		\$49.41	
76086	X-ray of mammary duct	b		\$709.31	
76088	X-ray of mammary ducts	b		\$709.31	
76090	Mammogram, one breast	b		\$203.55	
76091	Mammogram, both breasts	b		\$203.55	
76093	Magnetic image, breast	b		\$4,126.03	
76094	Magnetic image, both breasts	b		\$5,420.07	
76095	Stereotactic breast biopsy	b		\$1,436.55	
76096	X-ray of needle wire, breast	b		\$1,132.05	
76098	X-ray exam, breast specimen	b		\$231.26	
76100	X-ray exam of body section	b		\$422.95	
76101	Complex body section x-ray	b		\$977.13	
76102	Complex body section x-rays	b		\$977.13	
76120	Cine/video x-rays	b		\$459.16	
76125	Cine/video x-rays add-on	b		\$231.26	
76150	X-ray exam, dry process	e		\$231.26	
76355	Ct scan for localization	b		\$1,768.76	
76360	Ct scan for needle biopsy	b		\$1,768.76	
76362	Ct guide for tissue ablation	b		\$1,322.54	
76370	Ct scan for therapy guide	b		\$660.65	
76376	3d render w/o postprocess	c		\$39.08	OPPS
76377	3d rendering w/postprocess	c		\$101.46	OPPS
76380	CAT scan follow-up study	b		\$660.65	
76390	Mr spectroscopy	b		\$1,674.22	
76393	Mr guidance for needle place	b		\$2,059.71	
76394	Mri for tissue ablation	b		\$2,059.71	
76400	Magnetic image, bone marrow	b		\$2,059.71	
76496	Fluoroscopic procedure			\$459.16	
76497	Ct procedure			\$660.65	
76498	Mri procedure			\$2,059.71	
76499	Radiographic procedure			\$231.26	
76506	Echo exam of head	b		\$622.69	
76510	Ophth us, b & quant a	b		\$99.23	
76511	Echo exam of eye	b		\$622.69	
76512	Echo exam of eye	b		\$622.69	
76513	Echo exam of eye, water bath	b		\$404.73	
76514	Echo exam of eye, thickness	b		\$404.73	
76516	Echo exam of eye	b		\$622.69	
76519	Echo exam of eye	b		\$622.69	
76529	Echo exam of eye	b		\$404.73	
76536	Us exam of head and neck	b		\$622.69	
76604	Us exam, chest, b-scan	b		\$622.69	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 68 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
76645	Us exam, breast(s)	b		\$404.73	
76700	Us exam, abdom, complete	b		\$622.69	
76705	Echo exam of abdomen	b		\$622.69	
76770	Us exam abdo back wall, comp	b		\$622.69	
76775	Us exam abdo back wall, lim	b		\$622.69	
76778	Us exam kidney transplant	b		\$622.69	
76800	Us exam, spinal canal	b		\$622.69	
76801	Ob us < 14 wks, single fetus	b		\$404.73	
76802	Ob us < 14 wks, add'l fetus	b		\$404.73	
76805	Us exam, pq uterus, compl	b		\$622.69	
76810	Us exam, pq uterus, mult	b		\$404.73	
76811	Ob us, detailed, snql fetus	b		\$727.77	
76812	Ob us, detailed, add'l fetus	b		\$622.69	
76815	Us exam, pq uterus limit	b		\$404.73	
76816	Us exam pq uterus repeat	b		\$404.73	
76817	Transvaginal us, obstetric	b		\$404.73	
76818	Fetal biophys profile w/nst	b		\$622.69	
76819	Fetal biophys profil w/o nst	b		\$622.69	
76820	Umbilical artery echo	b		\$103.86	
76821	Middle cerebral artery echo	b		\$103.86	
76825	Echo exam of fetal heart	b		\$500.71	
76826	Echo exam of fetal heart	b		\$438.66	
76827	Echo exam of fetal heart	b		\$500.71	
76828	Echo exam of fetal heart	b		\$438.66	
76830	Transvaginal us, non-ob	b		\$622.69	
76831	Echo exam, uterus	b		\$622.69	
76856	Us exam, pelvic, complete	b		\$622.69	
76857	Us exam, pelvic, limited	b		\$404.73	
76870	Us exam, scrotum	b		\$622.69	
76872	Us, transrectal	b		\$622.69	
76873	Echograp trans r, pros study	b		\$622.69	
76880	Us exam, extremity	b		\$622.69	
76885	Us exam infant hips, dynamic	b		\$622.69	
76886	Us exam infant hips, static	b		\$622.69	
76930	Echo guide, cardiocentesis	b		\$423.86	
76932	Echo guide for heart biopsy	b		\$423.86	
76936	Echo guide-for artery repair	b		\$423.86	
76940	Us guide, tissue ablation	b		\$423.86	
76941	Echo guide for transfusion	b		\$423.86	
76942	Echo guide for biopsy	b		\$423.86	
76945	Echo guide, villus sampling	b		\$423.86	
76946	Echo guide for amniocentesis	b		\$423.86	
76948	Echo guide, ova aspiration	b		\$423.86	
76950	Echo quidance radiotherapy	b		\$423.86	
76965	Echo quidance radiotherapy	b		\$423.86	
76970	Ultrasound exam follow-up	b		\$404.73	
76975	GI endoscopic ultrasound	b		\$622.69	
76977	Us bone density measure	b		\$190.09	
76986	Ultrasound guide intraoper	b		\$622.69	
76999	Echo examination procedure	b		\$404.73	
77280	Set radiation therapy field	b		\$481.26	
77285	Set radiation therapy field	b		\$1,139.95	
77290	Set radiation therapy field	b		\$1,139.95	
77295	Set radiation therapy field	b		\$4,449.17	
77300	Radiation therapy dose plan	b		\$481.26	
77301	Radiotherapy dose plan, imrt	b		\$4,156.33	
77305	Teletx isodose plan simple	b		\$481.26	
77310	Teletx isodose plan intermed	b		\$481.26	
77315	Teletx isodose plan complex	b		\$1,139.95	
77321	Special teletx port plan	b		\$1,139.95	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

1. See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 69 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
77326	Radiation therapy dose plan	b		\$1,139.95	
77327	Brachytx isodose calc interm	b		\$1,139.95	
77328	Brachytx isodose plan compl	b		\$1,139.95	
77331	Special radiation dosimetry	b		\$481.26	
77332	Radiation treatment aid(s)	b		\$851.99	
77333	Radiation treatment aid(s)	b		\$851.99	
77334	Radiation treatment aid(s)	b		\$851.99	
77336	Radiation physics consult	e		\$481.26	
77370	Radiation physics consult	e		\$1,139.95	
77399	External radiation dosimetry			\$481.26	
77401	Radiation treatment delivery	e		\$420.78	
77402	Radiation treatment delivery	e		\$420.78	
77403	Radiation treatment delivery	e		\$420.78	
77404	Radiation treatment delivery	e		\$420.78	
77406	Radiation treatment delivery	e		\$420.78	
77407	Radiation treatment delivery	e		\$420.78	
77408	Radiation treatment delivery	e		\$420.78	
77409	Radiation treatment delivery	e		\$420.78	
77411	Radiation treatment delivery	e		\$420.78	
77412	Radiation treatment delivery	e		\$615.50	
77413	Radiation treatment delivery	e		\$615.50	
77414	Radiation treatment delivery	e		\$615.50	
77416	Radiation treatment delivery	e		\$615.50	
77417	Radiology port film(s)	e		\$231.26	
77418	Radiation tx delivery, imrt	e		\$1,748.48	
77421	Stereoscopic x-ray guidance	c		\$80.25	OPPS
77422	Neutron beam tx, simple	c		\$140.45	OPPS
77423	Neutron beam tx, complex	c		\$140.45	OPPS
77470	Special radiation treatment	b		\$1,868.93	
77520	Proton trmt, simple w/o comp	e		\$3,155.90	
77522	Proton trmt, simple w/comp	e		\$3,155.90	
77523	Proton trmt, intermediate	c		\$4,645.31	
77525	Proton treatment, complex	c		\$4,645.31	
77600	Hyperthermia treatment	b		\$1,493.38	
77605	Hyperthermia treatment	b		\$1,493.38	
77610	Hyperthermia treatment	b		\$1,493.38	
77615	Hyperthermia treatment	b		\$1,493.38	
77620	Hyperthermia treatment	b		\$1,493.38	
77750	Infuse radioactive materials	b		\$420.78	
77761	Apply intrcav radiat simple	b		\$1,188.41	
77762	Apply intrcav radiat interm	b		\$1,188.41	
77763	Apply intrcav radiat compl	b		\$1,188.41	
77776	Apply intersit radiat simpl	b		\$1,188.41	
77777	Apply intersit radiat inter	b		\$1,188.41	
77778	Apply intersit radiat compl	b		\$3,318.73	
77781	High intensity brachytherapy	b		\$4,478.60	
77782	High intensity brachytherapy	b		\$4,478.60	
77783	High intensity brachytherapy	b		\$4,478.60	
77784	High intensity brachytherapy	b		\$4,478.60	
77789	Apply surface radiation	b		\$420.78	
77799	Radium/radioisotope therapy			\$4,478.60	
78000	Thyroid, single uptake	b		\$529.64	
78001	Thyroid, multiple uptakes	b		\$529.64	
78003	Thyroid suppress/stimul	b		\$529.64	
78006	Thyroid imaging with uptake	b		\$905.19	
78007	Thyroid image, mult uptakes	b		\$1,036.57	
78010	Thyroid imaging	b		\$905.19	
78011	Thyroid imaging with flow	b		\$905.19	
78015	Thyroid met imaging	b		\$1,425.73	
78016	Thyroid met imaging/studies	b		\$1,425.73	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPSC CODE

PAGE 70 of 96

CPT/ HCPSC Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
78018	Thyroid met imaging, body	b		\$1,425.73	
78020	Thyroid met uptake	b		\$599.70	
78070	Parathyroid nuclear imaging	b		\$1,036.57	
78075	Adrenal nuclear imaging	b		\$1,036.57	
78099	Endocrine nuclear procedure			\$905.19	
78102	Bone marrow imaging, ltd	b		\$1,233.64	
78103	Bone marrow imaging, mult	b		\$1,233.64	
78104	Bone marrow imaging, body	b		\$1,233.64	
78110	Plasma volume, single	b		\$1,438.69	
78111	Plasma volume, multiple	b		\$1,438.69	
78120	Red cell mass, single	b		\$1,438.69	
78121	Red cell mass, multiple	b		\$1,438.69	
78122	Blood volume	b		\$1,438.69	
78130	Red cell survival study	b		\$1,438.69	
78135	Red cell survival kinetics	b		\$1,438.69	
78140	Red cell sequestration	b		\$1,438.69	
78185	Spleen imaging	b		\$1,233.64	
78190	Platelet survival, kinetics	b		\$529.64	
78191	Platelet survival	b		\$529.64	
78195	Lymph system imaging	b		\$1,233.64	
78199	Blood/lymph nuclear exam			\$1,233.64	
78201	Liver imaging	b		\$1,417.94	
78202	Liver imaging with flow	b		\$1,417.94	
78205	Liver imaging (3D)	b		\$1,417.94	
78206	Liver image (3d) with flow	b		\$1,417.94	
78215	Liver and spleen imaging	b		\$1,417.94	
78216	Liver & spleen image/flow	b		\$1,417.94	
78220	Liver function study	b		\$1,417.94	
78223	Hepatobiliary imaging	b		\$1,417.94	
78230	Salivary gland imaging	b		\$1,281.46	
78231	Serial salivary imaging	b		\$1,281.46	
78232	Salivary gland function exam	b		\$1,281.46	
78258	Esophageal motility study	b		\$1,281.46	
78261	Gastric mucosa imaging	b		\$1,281.46	
78262	Gastroesophageal reflux exam	b		\$1,281.46	
78264	Gastric emptying study	b		\$1,281.46	
78270	Vit B-12 absorption exam	b		\$529.64	
78271	Vit B-12 absorp exam, int fac	b		\$529.64	
78272	Vit B-12 absorp, combined	b		\$529.64	
78278	Acute GI blood loss imaging	b		\$1,281.46	
78282	GI protein loss exam	b		\$1,281.46	
78290	Meckel's divert exam	b		\$1,281.46	
78291	Leveen/shunt patency exam	b		\$1,281.46	
78299	GI nuclear procedure			\$1,281.46	
78300	Bone imaging, limited area	b		\$1,281.45	
78305	Bone imaging, multiple areas	b		\$1,281.45	
78306	Bone imaging, whole body	b		\$1,281.45	
78315	Bone imaging, 3 phase	b		\$1,281.45	
78320	Bone imaging (3D)	b		\$1,281.45	
78350	Bone mineral, single photon	b		\$422.95	
78351	Bone mineral, dual photon	b		\$611.92	
78399	Musculoskeletal nuclear exam			\$1,281.45	
78414	Non-imaging heart function	b		\$1,462.58	
78428	Cardiac shunt imaging	b		\$1,462.58	
78445	Vascular flow imaging	b		\$719.53	
78456	Acute venous thrombus image	b		\$719.53	
78457	Venous thrombosis imaging	b		\$719.53	
78458	Ven thrombosis images, bilat	b		\$719.53	
78459	Heart muscle imaging (PET)	b		\$4,590.00	
78460	Heart muscle blood, single	b		\$1,462.58	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

1. See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 71 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
78461	Heart muscle blood, multiple	b		\$2,276.91	
78464	Heart image (3d), single	b		\$1,462.58	
78465	Heart image (3d), multiple	b		\$2,276.91	
78466	Heart infarct image	b		\$1,462.58	
78468	Heart infarct image (ef)	b		\$1,462.58	
78469	Heart infarct image (3D)	b		\$1,462.58	
78472	Gated heart, planar, single	b		\$1,462.58	
78473	Gated heart, multiple	b		\$1,443.74	
78478	Heart wall motion add-on	b		\$599.70	
78480	Heart function add-on	b		\$599.70	
78481	Heart first pass, single	b		\$1,462.58	
78483	Heart first pass, multiple	b		\$1,443.74	
78491	Heart image (pet), single	b		\$23.93	
78494	Heart image, spect	b		\$1,462.58	
78496	Heart first pass add-on	b		\$599.70	
78499	Cardiovascular nuclear exam			\$1,500.02	
78580	Lung perfusion imaging	b		\$1,094.29	
78584	Lung V/Q image single breath	b		\$1,779.22	
78585	Lung V/Q imaging	b		\$1,779.22	
78586	Aerosol lung image, single	b		\$1,094.29	
78587	Aerosol lung image, multiple	b		\$1,094.29	
78588	Perfusion lung image	b		\$1,779.22	
78591	Vent image, 1 breath, 1 proj	b		\$1,094.29	
78593	Vent image, 1 proj, gas	b		\$1,094.29	
78594	Vent image, mult proj, gas	b		\$1,094.29	
78596	Lung differential function	b		\$1,779.22	
78599	Respiratory nuclear exam			\$1,094.29	
78600	Brain imaging, ltd static	b		\$1,753.59	
78601	Brain imaging, ltd w/flow	b		\$1,753.59	
78605	Brain imaging, complete	b		\$1,753.59	
78606	Brain imaging, compl w/flow	b		\$1,753.59	
78607	Brain imaging (3D)	b		\$1,753.59	
78610	Brain flow imaging only	b		\$1,753.59	
78615	Cerebral vascular flow image	b		\$1,753.59	
78630	Cerebrospinal fluid scan	b		\$1,225.56	
78635	CSF ventriculography	b		\$1,225.56	
78645	CSF shunt evaluation	b		\$1,225.56	
78647	Cerebrospinal fluid scan	b		\$1,225.56	
78650	CSF leakage imaging	b		\$1,225.56	
78660	Nuclear exam of tear flow	b		\$1,225.56	
78699	Nervous system nuclear exam			\$1,753.59	
78700	Kidney imaging, static	b		\$1,209.99	
78701	Kidney imaging with flow	b		\$1,209.99	
78704	Imaging renogram	b		\$1,209.99	
78707	Kidney flow/function image	b		\$1,209.99	
78708	Kidney flow/function image	b		\$1,408.79	
78709	Kidney flow/function image	b		\$1,408.79	
78710	Kidney imaging (3D)	b		\$1,209.99	
78715	Renal vascular flow exam	b		\$1,209.99	
78725	Kidney function study	b		\$529.64	
78730	Urinary bladder retention	b		\$1,209.99	
78740	Ureteral reflux study	b		\$1,209.99	
78760	Testicular imaging	b		\$1,209.99	
78761	Testicular imaging/flow	b		\$1,209.99	
78799	Genitourinary nuclear exam			\$1,209.99	
78800	Tumor imaging, limited area	b		\$1,425.73	
78801	Tumor imaging, mult areas	b		\$1,425.73	
78802	Tumor imaging, whole body	b		\$1,425.73	
78803	Tumor imaging (3D)	b		\$1,425.73	
78804	Tumor imaging, whole body	b		\$3,178.37	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
 1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 72 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
78805	Abscess imaging, ltd area	b		\$1,425.73	
78806	Abscess imaging, whole body	b		\$1,425.73	
78807	Nuclear localization/abscess	b		\$1,425.73	
78999	Nuclear diagnostic exam			\$529.64	
79005	Nuclear rx, oral admin	b		\$248.99	
79101	Nuclear rx, iv admin	b		\$248.99	
79200	Intracavitary nuclear trmt	b		\$1,159.95	
79300	Interstitial nuclear therapy	b		\$1,159.95	
79403	Hematopoietic nuclear therapy	b		\$2,689.39	
79440	Nuclear joint therapy	b		\$1,159.95	
79445	Nuclear rx, intra-arterial	b, c		\$248.99	
79999	Nuclear medicine therapy			\$1,159.95	
80050	General health panel			\$332.11	
80500	Lab pathology consultation			\$139.22	
80502	Lab pathology consultation			\$84.74	
85060	Blood smear interpretation			\$84.74	
85097	Bone marrow interpretation			\$139.22	
86077	Physician blood bank service			\$26.40	
86078	Physician blood bank service			\$26.40	
86079	Physician blood bank service			\$26.40	
86485	Skin test, candida			\$46.11	
86490	Coccidioidomycosis skin test	e		\$46.11	
86510	Histoplasmosis skin test	e		\$46.11	
86580	TB intradermal test	e		\$46.11	
86586	Skin test, unlisted			\$46.11	
86850	RBC antibody screen			\$88.64	
86860	RBC antibody elution			\$132.94	
86870	RBC antibody identification			\$132.94	
86880	Coombs test, direct			\$54.61	
86885	Coombs test, indirect, qual			\$54.61	
86886	Coombs test, indirect, titer			\$54.61	
86890	Autologous blood process			\$324.47	
86891	Autologous blood, op salvage			\$88.64	
86900	Blood typing, ABO			\$54.61	
86901	Blood typing, Rh (D)			\$54.61	
86903	Blood typing, antigen screen			\$88.64	
86904	Blood typing, patient serum			\$88.64	
86905	Blood typing, RBC antigens			\$88.64	
86906	Blood typing, Rh phenotype			\$88.64	
86911	Blood typing, antigen system			\$87.81	
86920	Compatibility test			\$132.94	
86921	Compatibility test			\$88.64	
86922	Compatibility test			\$132.94	
86923	Compatibility test, electric	d		\$13.81	OPPS
86927	Plasma, fresh frozen			\$132.94	
86930	Frozen blood prep			\$324.47	
86931	Frozen blood thaw			\$324.47	
86932	Frozen blood freeze/thaw			\$324.47	
86945	Blood product/irradiation			\$132.94	
86950	Leukocyte transfusion			\$324.47	
86960	Vol reduction of blood/prod	d		\$13.81	OPPS
86965	Pooling blood platelets			\$132.94	
86970	RBC pretreatment			\$88.64	
86971	RBC pretreatment			\$88.64	
86972	RBC pretreatment			\$88.64	
86975	RBC pretreatment, serum			\$88.64	
86976	RBC pretreatment, serum			\$88.64	
86977	RBC pretreatment, serum			\$88.64	
86978	RBC pretreatment, serum			\$88.64	
86985	Split blood or products			\$324.47	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 73 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
86999	Transfusion procedure			\$88.64	
88104	Cytopathology, fluids	b		\$139.22	
88106	Cytopathology, fluids	b		\$139.22	
88107	Cytopathology, fluids	b		\$139.22	
88108	Cytopath, concentrate tech	b		\$139.22	
88112	Cytopath, cell enhance tech	b		\$139.22	
88125	Forensic cytopathology	b		\$84.74	
88160	Cytopath smear, other source	b		\$84.74	
88161	Cytopath smear, other source	b		\$139.22	
88162	Cytopath smear, other source	b		\$139.22	
88172	Cytopathology eval of fna	b		\$139.22	
88173	Cytopath eval, fna, report	b		\$139.22	
88182	Cell marker study	b		\$212.40	
88184	Flowcytometry/ tc, 1 marker	e		\$12.60	
88185	Flowcytometry/tc, add-on	e		\$12.60	
88187	Flowcytometry/read, 2-8	e		\$12.60	
88188	Flowcytometry/read, 9-15	e		\$12.60	
88189	Flowcytometry/read, 16 & >	e		\$37.26	
88299	Cytogenetic study			\$84.74	
88300	Surgical path, gross	b		\$84.74	
88302	Tissue exam by pathologist	b		\$84.74	
88304	Tissue exam by pathologist	b		\$139.22	
88305	Tissue exam by pathologist	b		\$139.22	
88307	Tissue exam by pathologist	b		\$212.40	
88309	Tissue exam by pathologist	b		\$212.40	
88311	Decalcify tissue	b		\$84.74	
88312	Special stains	b		\$84.74	
88313	Special stains	b		\$84.74	
88314	Histochemical stain	b		\$84.74	
88318	Chemical histochemistry	b		\$84.74	
88319	Enzyme histochemistry	b		\$84.74	
88321	Microslide consultation			\$84.74	
88323	Microslide consultation	b		\$139.22	
88325	Comprehensive review of data			\$212.40	
88329	Path consult introsp			\$84.74	
88331	Path consult intraop, 1 bloc	b		\$139.22	
88332	Path consult intraop, add'l	b		\$84.74	
88333	Intraop cyto path consult, 1	c		\$29.00	OPPS
88334	Intraop cyto path consult, 2	c		\$15.88	OPPS
88342	Immunohistochemistry	b		\$212.40	
88346	Immunofluorescent study	b		\$139.22	
88347	Immunofluorescent study	b		\$212.40	
88348	Electron microscopy	b		\$1,099.94	
88349	Scanning electron microscopy	b		\$1,099.94	
88355	Analysis, skeletal muscle	b		\$212.40	
88356	Analysis, nerve	b		\$212.40	
88358	Analysis, tumor	b		\$212.40	
88360	Tumor immunohistochem/manual	b		\$37.26	
88361	Immunohistochemistry, tumor	b		\$212.40	
88362	Nerve teasing preparations	b		\$212.40	
88365	Tissue hybridization	b		\$212.40	
88367	In situ hybridization, auto	b		\$37.26	
88368	In situ hybridization, manual	b		\$37.26	
88384	Eval molecular probes, 11-50	c		\$15.88	OPPS
88385	Eval molecu probes, 51-250	c		\$29.00	OPPS
88386	Eval molecu probes, 251-500	c		\$48.29	OPPS
89049	Chct for mal hyperthermia	c		\$29.00	OPPS
89100	Sample intestinal contents			\$461.90	
89105	Sample intestinal contents			\$461.90	
89130	Sample stomach contents			\$461.90	

NOTES: CPT codes and descriptions only copyright 2005 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 74 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
89132	Sample stomach contents			\$461.90	
89135	Sample stomach contents			\$461.90	
89136	Sample stomach contents			\$461.90	
89140	Sample stomach contents			\$461.90	
89141	Sample stomach contents			\$461.90	
89220	Sputum specimen collection			\$139.22	
89230	Collect sweat for test			\$212.40	
89250	Cultr oocyte/embryo <4 days			\$276.69	
89251	Cultr oocyte/embryo <4 days			\$276.69	
89253	Embryo hatching			\$276.69	
89254	Oocyte identification			\$276.69	
89255	Prepare embryo for transfer			\$276.69	
89257	Sperm identification			\$276.69	
89258	Cryopreservation; embryo(s)			\$276.69	
89259	Cryopreservation, sperm			\$276.69	
89260	Sperm isolation, simple			\$276.69	
89261	Sperm isolation, complex			\$276.69	
89264	Identify sperm tissue			\$276.69	
89268	Insemination of oocytes			\$276.69	
89272	Extended culture of oocytes			\$276.69	
89280	Assist oocyte fertilization			\$276.69	
89281	Assist oocyte fertilization			\$276.69	
89290	Biopsy, oocyte polar body			\$276.69	
89291	Biopsy, oocyte polar body			\$276.69	
89335	Cryopreserve testicular tiss			\$276.69	
89342	Storage/year; embryo(s)			\$276.69	
89343	Storage/year; sperm/semen			\$276.69	
89344	Storage/year; reprod tissue			\$276.69	
89346	Storage/year; oocyte			\$276.69	
89352	Thawing cryopresvrd; embryo			\$276.69	
89353	Thawing cryopresvrd; sperm			\$276.69	
89354	Thaw cryoprsvrd; reprod tiss			\$276.69	
89356	Thawing cryopresvrd; oocyte			\$276.69	
90291	Cmv iq, iv	d		\$462.03	CALC
90375	Rabies iq, im/sc			\$221.27	
90376	Rabies iq, heat treated			\$221.27	
90379	Rsv iq, iv			\$221.27	
90385	Rh iq, minidose, im			\$221.27	
90393	Vaccina iq, im			\$221.27	
90396	Varicella-zoster iq, im			\$221.27	
90467	Immune admin o or n, < 8 yrs			\$5.35	CALC
90468	Immune admin o/n, addl < 8 y			\$0.30	CALC
90586	Bcg vaccine, intravesical			\$221.27	
90636	Hep a/hep b vacc, adult im			\$79.24	
90655	Flu vaccine, 6-35 mo, im			\$20.73	
90657	Flu vaccine, 6-35 mo, im			\$20.73	
90658	Flu vaccine, 3 yrs, im			\$19.38	
90675	Rabies vaccine, im			\$221.27	
90676	Rabies vaccine, id			\$221.27	
90693	Typhoid vaccine, akd, sc			\$221.27	
90714	Td vaccine no prsv >= 7 im	d		\$37.45	OPPS
90716	Chicken pox vaccine, sc			\$79.24	
90723	Dtap-hep b-ipv vaccine, im			\$221.27	
90725	Cholera vaccine, injectable			\$79.24	
90732	Pneumococcal vaccine			\$40.39	
90740	Hepb vacc, ill pat 3 dose im			\$221.27	
90743	Hep b vacc, adol, 2 dose, im			\$221.27	
90744	Hepb vacc ped/adol 3 dose im			\$221.27	
90746	Hep b vaccine, adult, im			\$221.27	
90747	Hepb vacc, ill pat 4 dose im			\$221.27	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 75 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
90748	Hep b/hib vaccine, im			\$79.24	
90772	Ther/proph/diaq inj, sc/im	c		\$24.94	OPPS
90773	Ther/proph/diaq inj, ia	c		\$51.17	OPPS
90779	Ther/proph/diaq inj/inf proc	c		\$8.71	OPPS
90801	Psy dx interview			\$190.02	
90802	Intac psy dx interview			\$190.02	
90804	Psytx, office, 20-30 min			\$220.25	
90805	Psytx, off, 20-30 min w/e&m			\$220.25	
90806	Psytx, off, 45-50 min			\$190.02	
90807	Psytx, off, 45-50 min w/e&m			\$190.02	
90808	Psytx, office, 75-80 min			\$190.02	
90809	Psytx, off, 75-80, w/e&m			\$190.02	
90810	Intac psytx, off, 20-30 min			\$220.25	
90811	Intac psytx, 20-30, w/e&m			\$220.25	
90812	Intac psytx, off, 45-50 min			\$190.02	
90813	Intac psytx, 45-50 min w/e&m			\$190.02	
90814	Intac psytx, off, 75-80 min			\$190.02	
90815	Intac psytx, 75-80 w/e&m			\$190.02	
90816	Psytx, hosp, 20-30 min			\$220.25	
90817	Psytx, hosp, 20-30 min w/e&m			\$220.25	
90818	Psytx, hosp, 45-50 min			\$190.02	
90819	Psytx, hosp, 45-50 min w/e&m			\$190.02	
90821	Psytx, hosp, 75-80 min			\$190.02	
90822	Psytx, hosp, 75-80 min w/e&m			\$190.02	
90823	Intac psytx, hosp, 20-30 min			\$220.25	
90824	Intac psytx, hsp 20-30 w/e&m			\$220.25	
90826	Intac psytx, hosp, 45-50 min			\$190.02	
90827	Intac psytx, hsp 45-50 w/e&m			\$190.02	
90828	Intac psytx, hosp, 75-80 min			\$190.02	
90829	Intac psytx, hsp 75-80 w/e&m			\$190.02	
90845	Psychoanalysis			\$190.02	
90846	Family psytx w/o patient			\$288.04	
90847	Family psytx w/patient			\$288.04	
90849	Multiple family group psytx			\$171.36	
90853	Group psychotherapy			\$171.36	
90857	Intac group psytx			\$171.36	
90862	Medication management			\$113.69	
90865	Narcosynthesis			\$190.02	
90870	Electroconvulsive therapy			\$625.03	
90875	Psychophysiological therapy			\$72.34	
90880	Hypnotherapy			\$190.02	
90899	Psychiatric service/therapy			\$220.25	
90901	Biofeedback train, any meth			\$173.77	
90911	Biofeedback peri/uro/rectal			\$395.29	
90925	Esrd related services, day			\$803.00	
90935	Hemodialysis, one evaluation			\$1,590.81	
90937	Hemodialysis, repeated eval			\$452.74	
90945	Dialysis, one evaluation			\$1,590.81	
90947	Dialysis, repeated eval			\$103.27	
90989	Dialysis training, complete			\$466.23	
90993	Dialysis training, incompl			\$397.91	
90997	Hemoperfusion			\$26.77	
90999	Dialysis procedure			\$371.91	
91000	Esophageal intubation	b		\$945.60	
91010	Esophagus motility study	b		\$945.60	
91011	Esophagus motility study	b		\$945.60	
91012	Esophagus motility study	b		\$945.60	
91020	Gastric motility	b		\$945.60	
91022	Duodenal motility study	c		\$227.14	OPPS
91030	Acid perfusion of esophagus	b		\$945.60	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 76 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
91034	Gastroesophageal reflux test	b		\$221.98	
91035	G-esoph reflx tst w/electrod	b		\$481.50	
91037	Esoph impeded function test	b		\$221.98	
91038	Esoph impeded function test > 1h	b		\$221.98	
91040	Esoph balloon distension test	b		\$101.94	
91052	Gastric analysis test	b		\$945.60	
91055	Gastric intubation for smear	b		\$461.90	
91060	Gastric saline load test	b		\$461.90	
91065	Breath hydrogen test	b		\$461.90	
91100	Pass intestine bleeding tube			\$461.90	
91105	Gastric intubation treatment			\$461.90	
91110	GI tract capsule endoscopy	b	+	\$3,178.37	
91120	Rectal sensation test	b	+	\$151.11	
91122	Anal pressure record	b	+	\$745.48	
91132	Electrogastrography	b, c		\$461.90	
91133	Electrogastrography w/test	b, c		\$461.90	
91299	Gastroenterology procedure			\$461.90	
92002	Eye exam, new patient			\$98.89	
92004	Eye exam, new patient			\$168.36	
92012	Eye exam established patient			\$103.43	
92014	Eye exam & treatment			\$168.36	
92015	Refraction			\$37.60	
92018	New eye exam & treatment		+	\$671.87	
92019	Eye exam & treatment		+	\$671.87	
92020	Special eye evaluation			\$203.28	
92060	Special eye evaluation	b		\$203.28	
92065	Orthoptic/pleoptic training	b		\$203.28	
92081	Visual field examination(s)	b		\$203.28	
92082	Visual field examination(s)	b		\$256.08	
92083	Visual field examination(s)	b		\$256.08	
92120	Tonography & eye evaluation			\$203.28	
92130	Water provocation tonography			\$256.08	
92135	Ophthalmic dx imaging	b		\$203.28	
92136	Ophthalmic biometry	b		\$203.28	
92140	Glaucoma provocative tests			\$256.08	
92225	Special eye exam, initial			\$256.08	
92226	Special eye exam, subsequent			\$256.08	
92230	Eye exam with photos		+	\$671.87	
92235	Eye exam with photos	b		\$671.87	
92240	Icga angiography	b		\$659.23	
92250	Eye exam with photos	b		\$203.28	
92260	Ophthalmoscopy/dynamometry			\$203.28	
92265	Eye muscle evaluation	b		\$659.23	
92270	Electro-oculography	b		\$256.08	
92275	Electroretinography	b		\$659.23	
92283	Color vision examination	b		\$203.28	
92284	Dark adaptation eye exam	b		\$256.08	
92285	Eye photography	b		\$203.28	
92286	Internal eye photography	b		\$256.08	
92287	Internal eye photography	b		\$659.23	
92311	Contact lens fitting			\$719.93	
92312	Contact lens fitting			\$719.93	
92313	Contact lens fitting			\$719.93	
92315	Prescription of contact lens			\$719.93	
92316	Prescription of contact lens			\$719.93	
92317	Prescription of contact lens			\$719.93	
92325	Modification of contact lens			\$719.93	
92326	Replacement of contact lens			\$719.93	
92352	Special spectacles fitting			\$719.93	
92353	Special spectacles fitting			\$719.93	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 77 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
92354	Special spectacles fitting			\$719.93	
92355	Special spectacles fitting			\$719.93	
92358	Eye prosthesis service			\$719.93	
92371	Repair & adjust spectacles			\$719.93	
92499	Eye service or procedure			\$203.28	
92502	Ear and throat examination		+	\$538.65	
92511	Nasopharyngoscopy		+	\$256.70	
92512	Nasal function studies			\$230.55	
92516	Facial nerve function test			\$462.98	
92520	Laryngeal function studies			\$462.98	
92541	Spontaneous nystagmus test	b		\$230.55	
92542	Positional nystagmus test	b		\$230.55	
92543	Caloric vestibular test	b		\$230.55	
92544	Optokinetic nystagmus test	b		\$230.55	
92545	Oscillating tracking test	b		\$230.55	
92546	Sinusoidal rotational test	b		\$462.98	
92547	Supplemental electrical test	e		\$230.55	
92548	Posturography	b		\$462.98	
92552	Pure tone audiometry, air	e		\$118.97	
92553	Audiometry, air & bone	e		\$323.66	
92555	Speech threshold audiometry	e		\$118.97	
92556	Speech audiometry, complete	e		\$118.97	
92557	Comprehensive hearing test	e		\$323.66	
92561	Bekeesy audiometry, diagnosis	e		\$323.66	
92562	Loudness balance test	e		\$118.97	
92563	Tone decay hearing test	e		\$118.97	
92564	Sisi hearing test	e		\$118.97	
92565	Stenger test, pure tone	e		\$118.97	
92567	Tympanometry	e		\$118.97	
92568	Acoustic reflex testing	e		\$118.97	
92569	Acoustic reflex decay test	e		\$118.97	
92571	Filtered speech hearing test	e		\$118.97	
92572	Staggered spondaic word test	e		\$118.97	
92573	Lombard test	e		\$118.97	
92575	Sensorineural acuity test	e		\$323.66	
92576	Synthetic sentence test	e		\$118.97	
92577	Stenger test, speech	e		\$323.66	
92579	Visual audiometry (vra)	e		\$323.66	
92582	Conditioning play audiometry	e		\$323.66	
92583	Select picture audiometry	e		\$118.97	
92584	Electrocochleography	e		\$462.98	
92585	Auditor evoke potent, compre	b		\$761.29	
92586	Auditor evoke potent, limit	e		\$304.25	
92587	Evoked auditory test	b		\$230.55	
92588	Evoked auditory test	b		\$230.55	
92590	Hearing aid exam, one ear			\$193.78	
92591	Hearing aid exam, both ears			\$229.95	
92592	Hearing aid check, one ear			\$108.52	
92593	Hearing aid check, both ears			\$114.08	
92596	Ear protector evaluation	e		\$323.66	
92601	Cochlear implt f/up exam < 7			\$323.66	
92602	Reprogram cochlear implt < 7			\$323.66	
92603	Cochlear implt f/up exam 7 >			\$323.66	
92604	Reprogram cochlear implt 7 >			\$323.66	
92620	Auditory function, 60 min			\$29.06	
92625	Tinnitus assessment			\$29.06	
92626	Eval aud rehab status	c		\$75.95	OPPS
92700	Ent procedure/service			\$118.97	
92950	Heart/lung resuscitation cpr			\$914.26	
92953	Temporary external pacing			\$914.26	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 78 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
92960	Cardioversion electric, ext			\$1,893.97	
92961	Cardioversion, electric, int	b		\$1,893.97	
92973	Percut coronary thrombectomy		+	\$1,222.45	
92974	Cath place, cardio brachytx		+	\$11,002.05	
92977	Dissolve clot, heart vessel		+	\$939.74	
92978	Intravasc us, heart add-on	b	-	\$9,525.53	
92979	Intravasc us, heart add-on	b		\$9,525.53	
92980	Insert intracoronary stent		+	\$22,447.41	
92981	Insert intracoronary stent		+	\$22,447.41	
92982	Coronary artery dilation		+	\$17,565.11	
92984	Coronary artery dilation		+	\$17,565.11	
92986	Revision of aortic valve		+	\$17,565.11	
92987	Revision of mitral valve		+	\$17,565.11	
92990	Revision of pulmonary valve		+	\$17,565.11	
92995	Coronary atherectomy		+	\$25,394.15	
92996	Coronary atherectomy add-on		+	\$25,394.15	
92997	Pul art balloon repr, percut		+	\$10,536.99	
92998	Pul art balloon repr, percut		+	\$10,536.99	
93005	Electrocardiogram, tracing	e		\$144.02	
93017	Cardiovascular stress test	e		\$622.38	
93024	Cardiac drug stress test	b		\$622.38	
93025	Microvolt t-wave assess	b		\$622.38	
93041	Rhythm ECG, tracing	e		\$144.02	
93225	ECG monitor/record, 24 hrs	e		\$418.26	
93226	ECG monitor/report, 24 hrs	e		\$418.26	
93231	ECG monitor/record, 24 hrs	e		\$418.26	
93236	ECG monitor/report, 24 hrs	e		\$418.26	
93270	ECG recording	e		\$418.26	
93271	ECG/monitoring and analysis	e		\$418.26	
93278	ECG/signal-averaged	b		\$144.02	
93303	Echo transthoracic	b		\$953.48	
93304	Echo transthoracic	b		\$438.66	
93307	Echo exam of heart	b		\$953.48	
93308	Echo exam of heart	b		\$438.66	
93312	Echo transesophageal	b		\$2,025.47	
93313	Echo transesophageal			\$2,025.47	
93315	Echo transesophageal	b		\$2,025.47	
93316	Echo transesophageal			\$2,025.47	
93318	Echo transesophageal intraop	b		\$2,025.47	
93320	Doppler echo exam, heart	b		\$500.71	
93321	Doppler echo exam, heart	b		\$438.66	
93325	Doppler color flow add-on	b		\$438.66	
93350	Echo transthoracic	b		\$953.48	
93501	Right heart catheterization	b	+	\$10,807.90	
93503	Insert/place heart catheter		+	\$3,500.46	
93505	Biopsy of heart lining	b	+	\$3,500.46	
93508	Cath placement, angiography	b	+	\$10,807.90	
93510	Left heart catheterization	b	+	\$10,807.90	
93511	Left heart catheterization	b	+	\$10,807.90	
93514	Left heart catheterization	b	+	\$10,807.90	
93524	Left heart catheterization	b	+	\$10,807.90	
93526	Rt & Lt heart catheters	b	+	\$10,807.90	
93527	Rt & Lt heart catheters	b	+	\$10,807.90	
93528	Rt & Lt heart catheters	b	+	\$10,807.90	
93529	Rt, lt heart catheterization	b	+	\$10,807.90	
93530	Rt heart cath, congenital	b	+	\$10,807.90	
93531	R & l heart cath, congenital	b	+	\$10,807.90	
93532	R & l heart cath, congenital	b	+	\$10,807.90	
93533	R & l heart cath, congenital	b	+	\$10,807.90	
93571	Heart flow reserve measure	c		\$1,852.43	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 79 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
93572	Heart flow reserve measure	c		\$293.78	
93580	Transcath closure of asd		+	\$11,002.05	
93581	Transcath closure of vsd		+	\$11,002.05	
93600	Bundle of His recording		+	\$13,358.69	
93602	Intra-atrial recording	b	+	\$13,358.69	
93603	Right ventricular recording	b	+	\$13,358.69	
93609	Map tachycardia, add-on	b	+	\$13,358.69	
93610	Intra-atrial pacing	b	+	\$13,358.69	
93612	Intraventricular pacing	b	+	\$13,358.69	
93613	Electrophys map 3d, add-on	b	+	\$13,358.69	
93615	Esophageal recording	b	+	\$13,358.69	
93616	Esophageal recording	b	+	\$13,358.69	
93618	Heart rhythm pacing	b	+	\$13,358.69	
93619	Electrophysiology evaluation	b	+	\$12,079.75	
93620	Electrophysiology evaluation	b	+	\$12,079.75	
93621	Electrophysiology evaluation	b	+	\$12,079.75	
93622	Electrophysiology evaluation	b	+	\$12,079.75	
93623	Stimulation, pacing heart	b	+	\$13,358.69	
93624	Electrophysiologic study	b	+	\$3,649.96	
93631	Heart pacing, mapping	b	+	\$13,358.69	
93640	Evaluation heart device	b		\$3,649.96	
93641	Electrophysiology evaluation	b		\$3,649.96	
93642	Electrophysiology evaluation	b		\$3,649.96	
93650	Ablate heart dysrhythm focus		+	\$14,733.71	
93651	Ablate heart dysrhythm focus		+	\$14,733.71	
93652	Ablate heart dysrhythm focus		+	\$14,733.71	
93660	Tilt table evaluation			\$1,528.37	
93662	Intracardiac ecg (ice)	b		\$9,525.53	
93668	Peripheral vascular rehab			\$912.08	
93701	Bioimpedance, thoracic	b		\$144.02	
93721	Plethysmography tracing	e		\$322.99	
93724	Analyze pacemaker system	b		\$131.11	
93727	Analyze iir system			\$131.11	
93731	Analyze pacemaker system	b		\$131.11	
93732	Analyze pacemaker system	b		\$131.11	
93733	Telephone analy, pacemaker	b		\$131.11	
93734	Analyze pacemaker system	b		\$131.11	
93735	Analyze pacemaker system	b		\$131.11	
93736	Telephonic analy, pacemaker	b		\$131.11	
93740	Temperature gradient studies	b		\$197.42	
93741	Analyze ht pace device snq1	b		\$191.74	
93742	Analyze ht pace device snq1	b		\$191.74	
93743	Analyze ht pace device dual	b		\$191.74	
93744	Analyze ht pace device dual	b		\$191.74	
93745	Set-up cardiovert-defibrill			\$35.68	
93760	Cephalic thermogram	b		\$869.11	
93786	Ambulatory BP recording	e		\$418.26	
93788	Ambulatory BP analysis	e		\$893.84	
93797	Cardiac rehab			\$146.29	
93798	Cardiac rehab/monitor			\$146.29	
93799	Cardiovascular procedure			\$527.21	
93875	Extracranial study	b		\$527.21	
93880	Extracranial study	b		\$727.77	
93882	Extracranial study	b		\$727.77	
93886	Intracranial study	b		\$727.77	
93888	Intracranial study	b		\$622.69	
93890	Tcd, vasoreactivity study	b		\$99.23	
93892	Tcd, emboli detect w/o inj	b		\$99.23	
93893	Tcd, emboli detect w/inj	b		\$99.23	
93922	Extremity study	b		\$527.21	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 80 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
93923	Extremity study	b		\$527.21	
93924	Extremity study	b		\$527.21	
93925	Lower extremity study	b		\$727.77	
93926	Lower extremity study	b		\$727.77	
93930	Upper extremity study	b		\$727.77	
93931	Upper extremity study	b		\$622.69	
93965	Extremity study	b		\$527.21	
93970	Extremity study	b		\$727.77	
93971	Extremity study	b		\$727.77	
93975	Vascular study	b		\$727.77	
93976	Vascular study	b		\$727.77	
93978	Vascular study	b		\$727.77	
93979	Vascular study	b		\$727.77	
93980	Penile vascular study	b		\$727.77	
93981	Penile vascular study	b		\$727.77	
93990	Doppler flow testing	b		\$727.77	
94010	Breathing capacity test	b		\$322.99	
94014	Patient recorded spirometry			\$197.42	
94015	Patient recorded spirometry	e		\$666.59	
94060	Evaluation of wheezing	b		\$322.99	
94070	Evaluation of wheezing	b		\$666.59	
94150	Vital capacity test	b		\$197.42	
94200	Lung function test (MBC/MVV)	b		\$197.42	
94240	Residual lung capacity	b		\$322.99	
94250	Expired gas collection	b		\$197.42	
94260	Thoracic gas volume	b		\$322.99	
94350	Lung nitrogen washout curve	b		\$322.99	
94360	Measure airflow resistance	b		\$197.42	
94370	Breath airway closing volume	b		\$197.42	
94375	Respiratory flow volume loop	b		\$197.42	
94400	CO2 breathing response curve	b		\$197.42	
94450	Hypoxia response curve	b		\$197.42	
94452	Hast w/report	b		\$57.71	
94453	Hast w/oxygen titrate	b		\$57.71	
94620	Pulmonary stress test/simple	b		\$322.99	
94621	Pulm stress test/complex	b		\$666.59	
94640	Airway inhalation treatment			\$74.81	
94642	Aerosol inhalation treatment			\$211.25	
94656	Initial ventilator mgmt			\$573.43	
94657	Continued ventilator mgmt			\$573.43	
94660	Pos airway pressure, CPAP			\$280.30	
94662	Neg press ventilation, cnp			\$573.43	
94664	Aerosol or vapor inhalations			\$74.81	
94667	Chest wall manipulation			\$74.81	
94668	Chest wall manipulation			\$74.81	
94680	Exhaled air analysis, o2	b		\$197.42	
94681	Exhaled air analysis, o2/co2	b		\$322.99	
94690	Exhaled air analysis	b		\$197.42	
94720	Monoxide diffusing capacity	b		\$322.99	
94725	Membrane diffusion capacity	b		\$322.99	
94750	Pulmonary compliance study	b		\$197.42	
94770	Exhaled carbon dioxide test	b		\$197.42	
94772	Breath recording, infant			\$666.59	
94799	Pulmonary service/procedure			\$197.42	
95004	Percut allergy skin tests			\$264.73	
95010	Percut allergy titrate test			\$264.73	
95015	Id allergy titrate-drug/buq			\$264.73	
95024	Id allergy test, drug/buq			\$264.73	
95027	Skin end point titration	e		\$264.73	
95028	Id allergy test-delayed type	e		\$264.73	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

1 - See end of the table for note regarding Charge Methodology.

TABLE F.—OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCCPS CODE

PAGE 81 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
95044	Allergy patch tests			\$264.73	
95052	Photo patch test			\$264.73	
95056	Photosensitivity tests			\$264.73	
95060	Eye allergy tests			\$264.73	
95065	Nose allergy test	e		\$264.73	
95070	Bronchial allergy tests	e		\$666.59	
95071	Bronchial allergy tests	e		\$666.59	
95075	Ingestion challenge test			\$945.60	
95078	Provocative testing	e		\$264.73	
95115	Immunotherapy, one injection			\$34.14	
95117	Immunotherapy injections			\$95.03	
95125	Immunotherapy, many antigens			\$175.65	
95144	Antigen therapy services			\$118.34	
95145	Antigen therapy services			\$118.34	
95146	Antigen therapy services			\$118.34	
95147	Antigen therapy services			\$118.34	
95148	Antigen therapy services			\$118.34	
95149	Antigen therapy services			\$118.34	
95165	Antigen therapy services			\$118.34	
95170	Antigen therapy services			\$118.34	
95180	Rapid desensitization			\$264.73	
95199	Allergy immunology services			\$264.73	
95250	Glucose monitoring, cont	e		\$733.49	
95805	Multiple sleep latency test	b		\$3,078.89	
95806	Sleep study, unattended	b		\$775.18	
95807	Sleep study, attended	b		\$3,078.89	
95808	Polysomnography, 1-3	b		\$3,078.89	
95810	Polysomnography, 4 or more	b		\$3,078.89	
95811	Polysomnography w/cpap	b		\$3,078.89	
95812	Electroencephalogram (EEG)	b		\$775.18	
95813	Eeg, over 1 hour	b		\$775.18	
95816	Electroencephalogram (EEG)	b		\$590.98	
95819	Electroencephalogram (EEG)	b		\$590.98	
95822	Sleep electroencephalogram	b		\$590.98	
95824	Eeg, cerebral death only	b		\$590.98	
95827	night electroencephalogram	b		\$3,078.89	
95829	Surgery electrocorticogram	b		\$590.98	
95857	Tensilon test			\$304.25	
95860	Muscle test, one limb	b		\$304.25	
95861	Muscle test, 2 limbs	b		\$304.25	
95863	Muscle test, 3 limbs	b		\$304.25	
95864	Muscle test, 4 limbs	b		\$304.25	
95865	Muscle test, larynx	c		\$70.92	OPPS
95866	Muscle test, hemidiaphragm	c		\$70.92	OPPS
95867	Muscle test, head or neck	b		\$304.25	
95868	Muscle test cran nerve bilat	b		\$304.25	
95869	Muscle test, thor paraspinal	b		\$144.19	
95870	Muscle test, nonparaspinal	b		\$144.19	
95872	Muscle test, one fiber	b		\$304.25	
95873	Guide nerv destr, elec stim	c		\$38.37	OPPS
95874	Guide nerv destr, needle emg	c		\$38.37	OPPS
95875	Limb exercise test	b		\$144.19	
95900	Motor nerve conduction test	b		\$144.19	
95903	Motor nerve conduction test	b		\$144.19	
95904	Sense nerve conduction test	b		\$144.19	
95920	Intraop nerve test add-on	b		\$761.29	
95921	Autonomic nerv function test	b		\$304.25	
95922	Autonomic nerv function test	b		\$304.25	
95923	Autonomic nerv function test	b		\$144.19	
95925	Somatosensory testing	b		\$761.29	

NOTES. CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply

1 - See end of the table for note regarding Charge Methodology

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 82 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
95926	Somatosensory testing	b		\$761.29	
95927	Somatosensory testing	b		\$761.29	
95928	C motor evoked, uppr limbs	b		\$69.76	
95929	C motor evoked, lwr limbs	b		\$69.76	
95930	Visual evoked potential test	b		\$304.25	
95933	Blink reflex test	b		\$144.19	
95934	H-reflex test	b		\$144.19	
95936	H-reflex test	b		\$144.19	
95937	Neuromuscular junction test	b		\$304.25	
95950	Ambulatory eeg monitoring	b		\$775.18	
95951	EEG monitoring/videorecord	b		\$3,078.89	
95953	EEG monitoring/computer	b		\$3,078.89	
95954	EEG monitoring/giving drugs	b		\$590.98	
95955	EEG during surgery	b		\$775.18	
95956	Eeg monitoring, cable/radio	b		\$590.98	
95957	EEG digital analysis	b		\$590.98	
95958	EEG monitoring/function test	b		\$775.18	
95961	Electrode stimulation, brain	b		\$761.29	
95962	Electrode stim, brain add-on	b		\$761.29	
95965	Meq, spontaneous	b	+	\$24,180.13	
95966	Meq, evoked, single	b	+	\$7,090.21	
95967	Meq, evoked, each add'l	b	+	\$4,645.31	
95970	Analyze neurostim, no prog			\$295.00	
95971	Analyze neurostim, simple			\$295.00	
95972	Analyze neurostim, complex			\$295.00	
95973	Analyze neurostim, complex			\$295.00	
95974	Cranial neurostim, complex			\$295.00	
95975	Cranial neurostim, complex			\$295.00	
95978	Analyze neurostim brain/lh			\$125.50	
95979	Analyz neurostim brain addon			\$125.50	
95990	Spin/brain pump refill & main		+	\$576.42	
95991	Spin/brain pump refill & main		+	\$576.42	
95999	Neurological procedure			\$144.19	
96000	Motion analysis, video/3d			\$733.49	
96001	Motion test w/ft press meas			\$733.49	
96002	Dynamic surface emg			\$733.49	
96003	Dynamic fine wire emg			\$733.49	
96101	Psycho testing by psych/phys	c		\$79.68	OPPS
96102	Psycho testing by technician	c		\$217.31	OPPS
96103	Psycho testing admin by comp	c		\$79.68	OPPS
96105	Assessment of aphasia			\$137.82	
96110	Developmental test, lim			\$621.31	
96111	Developmental test, extend			\$621.31	
96116	Neurobehavioral status exam	c		\$79.68	OPPS
96118	Neuropsych tst by psych/phys	c		\$79.68	OPPS
96119	Neuropsych testing by tech	c		\$217.31	OPPS
96120	Neuropsych tst admin w/comp	c		\$79.68	OPPS
96150	Assess hlt/behav, init			\$220.25	
96151	Assess hlt/behav, subseq			\$220.25	
96152	Intervene hlt/behav, indiv			\$220.25	
96153	Intervene hlt/behav, group			\$220.25	
96154	Interv hlt/behav, fam w/pt			\$220.25	
96155	Interv hlt/behav fam no pt			\$220.25	
96401	Chemo, anti-neopl, sq/im	c		\$73.16	OPPS
96402	Chemo hormon antineopl sq/im	c		\$73.16	OPPS
96416	Chemo prolong infuse w/pump	c		\$202.27	OPPS
96521	Refill/maint, portable pump	c	+	\$121.12	OPPS
96522	Refill/maint pump/resvr syst	c	+	\$121.12	OPPS
96523	Imiq drug delivery device	c		\$121.12	CALC
96567	Photodynamic tx, skin		+	\$733.49	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPSC CODE

PAGE 83 of 96

CPT/ HCPSC Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
96570	Photodynamic tx, 30 min		+	\$1,222.45	
96571	Photodynamic tx, addl 15 min		+	\$1,222.45	
96900	Ultraviolet light therapy			\$113.06	
96910	Photochemotherapy with UV-B			\$113.06	
96912	Photochemotherapy with UV-A			\$113.06	
96913	Photochemotherapy, UV-A or B			\$413.24	
96920	Laser tx, skin < 250 sq cm		+	\$229.30	
96921	Laser tx, skin 250-500 sq cm		+	\$229.30	
96922	Laser tx, skin > 500 sq cm		+	\$337.02	
96999	Dermatological procedure		+	\$195.23	
97014	Electric stimulation therapy			\$65.49	
98925	Osteopathic manipulation			\$74.38	
98926	Osteopathic manipulation			\$74.38	
98927	Osteopathic manipulation			\$74.38	
98928	Osteopathic manipulation			\$74.38	
98929	Osteopathic manipulation			\$74.38	
98940	Chiropractic manipulation			\$74.38	
98941	Chiropractic manipulation			\$74.38	
98942	Chiropractic manipulation			\$74.38	
99000	Specimen handling			\$33.71	
99001	Specimen handling			\$29.54	
99002	Device handling			\$151.15	
99050	Medical services after hrs			\$193.78	
99058	Office emergency care			\$52.12	
99170	Anogenital exam, child		+	\$62.57	
99172	Ocular function screen	b		\$212.34	
99183	Hyperbaric oxygen therapy			\$3,153.14	
99195	Phlebotomy			\$149.07	
99199	Special service/proc/report			\$599.36	
99201	Office/outpatient visit, new	a		\$103.43	
99202	Office/outpatient visit, new	a		\$103.43	
99203	Office/outpatient visit, new	a		\$98.89	
99204	Office/outpatient visit, new	a		\$168.36	
99205	Office/outpatient visit, new	a		\$168.36	
99211	Office/outpatient visit, est	a		\$103.43	
99212	Office/outpatient visit, est	a		\$103.43	
99213	Office/outpatient visit, est	a		\$98.89	
99214	Office/outpatient visit, est	a		\$168.36	
99215	Office/outpatient visit, est	a		\$168.36	
99241	Office consultation			\$103.43	
99242	Office consultation			\$103.43	
99243	Office consultation			\$98.89	
99244	Office consultation			\$168.36	
99245	Office consultation			\$168.36	
99281	Emergency dept visit	f		\$239.49	
99282	Emergency dept visit	f		\$239.49	
99283	Emergency dept visit	f		\$493.16	
99284	Emergency dept visit	f		\$783.75	
99285	Emergency dept visit	f		\$783.75	
99291	Critical care, first hour			\$2,396.46	
99385	Prev visit, new, age 18-39			\$164.50	
99386	Prev visit, new, age 40-64			\$94.04	
99387	Prev visit, new, 65 & over			\$169.76	
99391	Prev visit, est, infant			\$215.00	
99395	Prev visit, est, age 18-39			\$198.71	
99396	Prev visit, est, age 40-64			\$143.33	
99397	Prev visit, est, 65 & over			\$98.12	
99401	Preventive counseling, indiv			\$80.24	
99402	Preventive counseling, indiv			\$213.15	
99404	Preventive counseling, indiv			\$211.73	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPSCS CODE

PAGE 84 of 96

CPT/ HCPSCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
99412	Preventive counseling, group			\$148.22	
99431	Initial care, normal newborn			\$103.43	
99440	Newborn resuscitation			\$914.26	
99499	Unlisted e&m service			\$2,800.46	
0003T	Cervicography			\$122.25	
0008T	Upper qi endoscopy w/suture		+	\$1,353.33	
0016T	Thermox choroid vasc lesion		+	\$1,528.75	
0017T	Photocoagulat macular drusen	c	+	\$305.17	OPPS
0018T	Transcranial magnetic stimul			\$144.19	
0027T	Endoscopic epidural lysis		+	\$4,156.33	
0028T	Dexa body composition study	c		\$377.88	CALC
0042T	Ct perfusion w/contrast, cbf	c		\$1,768.76	CALC
0044T	Whole body photography	c		\$195.23	CALC
0045T	Whole body photography	c		\$195.23	CALC
0046T	Cath lavage, mammary duct(s)		+	\$276.50	
0047T	Cath lavage, mammary duct(s)		+	\$276.50	
0058T	Cryopreservation, ovary tiss			\$276.69	
0059T	Cryopreservation, oocyte			\$276.69	
0062T	Rep intradisc annulus;1 lev		+	\$666.00	
0063T	Rep intradisc annulus;>1lev		+	\$666.00	
0066T	Ct colonography;screen			\$206.76	CALC
0067T	Ct colonography;dx	c		\$206.76	
0071T	U/s leiomyomata ablate <200		+	\$811.24	
0072T	U/s leiomyomata ablate >200		+	\$811.24	
0073T	Delivery, comp imit			\$330.84	
0082T	Stereotactic rad delivery			\$5,623.27	CALC
0084T	Temp prostate urethral stent		+	\$76.60	
0085T	Breath test heart reject			\$38.58	
0087T	Sperm eval hyaluronan			\$46.79	
0088T	Rf tongue base vol reductn		+	\$974.80	
0089T	Actigraphy testing, 3-day			\$70.92	OPPS
0099T	Implant corneal ring		+	\$933.79	OPPS
0100T	Prosth retina receive&gen		+	\$2,348.23	OPPS
0101T	Extracorp shockwv bx,hi enrq		+	\$909.50	OPPS
0102T	Extracorp shockwv bx,anesth		+	\$909.50	OPPS
0106T	Touch quant sensory test			\$6.59	OPPS
0107T	Vibrate quant sensory test			\$6.59	OPPS
0108T	Cool quant sensory test			\$6.59	OPPS
0109T	Heat quant sensory test			\$6.59	OPPS
0110T	Nos quant sensory test			\$6.59	OPPS
0120T	Fibroadenoma cryoablate, ea		+	\$2,004.71	OPPS
0123T	Scleral fistulization		+	\$1,404.20	OPPS
0124T	Conjunctival drug placement		+	\$440.67	OPPS
0133T	Esophageal Implant Injxn		+	\$1,872.50	OPPS
0135T	Perq cryoablate renal tumor		+	\$2,139.30	OPPS
0137T	Prostate Saturation Sampling		+	\$282.93	OPPS
0144T	Ct Heart W/ Dye; Qual Calc			\$267.68	OPPS
0145T	Ct Heart W/Wo Dye Funct			\$320.39	OPPS
0146T	Ccta W/Wo Dye			\$320.39	OPPS
0147T	Ccta W/Wo, Quan Calcium			\$320.39	OPPS
0148T	Ccta W/Wo, Strxr			\$424.91	OPPS
0149T	Ccta W/Wo, Strxr Quan Calc			\$424.91	OPPS
0150T	Ccta W/Wo, Disease Strxr			\$267.68	OPPS
0151T	Ct Heart Funct Add-On			\$101.46	OPPS
0154T	Implant Aneur Sensor Study			\$65.02	OPPS
A4209	5+ CC sterile syringe&needle			\$4.53	
A4221	Maint drug infus cath per wk			\$61.43	
A4222	Drug infusion pump supplies			\$90.44	
A4232	Syringe w/needle insulin 3cc			\$0.55	
A4253	Blood glucose/reaqent strips			\$6.46	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 85 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
A4259	Lancets per box			\$3.23	
A4550	Surgical trays			\$138.88	
A4554	Disposable underpads			\$2.91	
A4556	Electrodes, pair			\$25.84	
A4590	Special-casting material			\$49.09	
A4624	Tracheal suction tube			\$7.21	
A4628	Oropharyngeal suction cath			\$12.02	
A4642	Satumomab pendetide per dose			\$8,762.90	
A7000	Disposable canister for pump			\$53.94	
A7002	Tubing used w suction pump			\$31.01	
A7015	Aerosol mask used w nebulize			\$2.02	
A9270	Non-covered item or service			\$96.89	
A9300	Exercise equipment			\$19.38	
A9500	Technetium TC 99m sestamibi			\$421.36	
A9502	Technetium TC99m tetrofosmin			\$3,955.08	
A9505	Thallous chloride TL 201/mci			\$132.18	
A9507	Indium/111 capromab pendetid			\$12,071.88	
A9508	Iobenguane sulfate I-131, per 0.5 mCi			\$985.80	
A9517	Th I131 so iodide cap millic			\$32.58	
A9521	Technetiumtc-99m exametazine			\$4,904.61	
A9524	Iodinated I-131 serumalbumin, per 5uci			\$288.79	
A9526	Ammonia N-13, per dose			\$117.55	
A9528	Dx I131 so iodide cap millic			\$32.58	
A9529	Dx I131 so iodide sol millic			\$38.59	
A9530	Th I131 so iodide sol millic			\$38.59	
A9535	Injection, methylene blue	d		\$3.26	OPPS
A9600	Strontium-89 chloride			\$5,305.48	
A9605	Samarium sm 153 lexidronamm			\$2,936.19	
C1178	BUSULFAN IV, 6 mg	d		\$117.95	
C1300	HYPERBARIC Oxygen	d		\$497.88	
C1713	Anchor/screw bn/bn,tis/bn	d		\$152.64	CALC
C1721	AICD, dual chamber	d		\$13,743.30	CALC
C1722	AICD, single chamber	d		\$12,183.28	CALC
C1750	Cath, hemodialysis, long-term	d		\$508.59	CALC
C1752	Cath, hemodialysis, short-term	d		\$549.20	CALC
C1753	Cath, intravas ultrasound	d		\$14.34	CALC
C1755	Catheter, intraspinal	d		\$14.24	CALC
C1756	Cath, pacing, transesoph	d		\$140.79	CALC
C1758	Catheter, ureteral	d		\$127.31	CALC
C1760	Closure dev, vasc	d		\$1,038.66	CALC
C1763	Conn tiss, non-human	d		\$856.41	CALC
C1764	Event recorder, cardiac	d		\$3,008.44	CALC
C1767	Generator, neurostim, imp	d		\$5,880.24	CALC
C1768	Graft, vascular	d		\$2,771.61	CALC
C1769	Guide wire	d		\$544.75	CALC
C1772	Infusion pump, programmable	d		\$14,625.07	CALC
C1777	Lead, AICD, endo single coil	d		\$3,708.06	CALC
C1778	Lead, neurostimulator	d		\$48.66	CALC
C1779	Lead, pmkr, transvenous VDD	d		\$1,727.19	CALC
C1781	Mesh (implantable)	d		\$491.31	CALC
C1783	Ocular imp, aqueous drain de	d		\$415.02	CALC
C1784	Ocular dev, intraop, det ret	d		\$0.94	CALC
C1785	Pmkr, dual, rate-resp	d		\$6,128.16	CALC
C1786	Pmkr, single, rate-resp	d		\$4,594.55	CALC
C1787	Patient progr, neurostim	d		\$31,545.40	CALC
C1788	Port, indwelling, imp	d		\$14.34	CALC
C1789	Prosthesis, breast, imp	d		\$255.45	CALC
C1813	Prosthesis, penile, inflatab	d		\$2,073.50	CALC
C1815	Pros, urinary sph, imp	d		\$1,187.48	CALC
C1874	Stent, coated/cov w/del sys	d		\$1,819.68	CALC

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 86 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
C1875	Stent, coated/cov w/o del sy	d		\$1,811.45	CALC
C1876	Stent, non-coat/non-cov w/del	d		\$1,557.78	CALC
C1877	Stent, non-coat/cov w/o del	d		\$813.91	CALC
C1878	Matrl for vocal cord	d		\$229.81	CALC
C1879	Tissue marker, implantable	d		\$640.13	CALC
C1880	Vena cava filter	d		\$1,308.76	CALC
C1882	AICD, other than sing/dual	d		\$8,896.25	CALC
C1887	Catheter, quiding	d		\$33.22	CALC
C1891	Infusion pump, non-prog, perm	d		\$14.24	CALC
C1895	Lead, AICD, endo dual coil	d		\$6,735.01	CALC
C1896	Lead, AICD, non sing/dual	d		\$1,203.94	CALC
C1897	Lead, neurostim test kit	d		\$14.34	CALC
C1898	Lead, pmkr, other than trans	d		\$1,065.72	CALC
C1899	Lead, pmkr/AICD combination	d		\$433.61	CALC
C1900	Lead coronary venous	d		\$1,258.96	CALC
C2617	Stent, non-cor, tem w/o del	d		\$70.77	CALC
C2619	Pmkr, dual, non rate-resp	d		\$1,464.54	CALC
C2620	Pmkr, single, non rate-resp	d		\$6,316.83	CALC
C2621	Pmkr, other than sing/dual	d		\$6,924.01	CALC
C2622	Prosthesis, penile, non-inf	d		\$1,199.35	CALC
C2625	Stent, non-cor, tem w/del sy	d		\$1,764.26	CALC
C2628	Catheter, occlusion	d		\$18.41	CALC
C8900	MRA w/cont, abd	d		\$2,308.32	
C8901	MRA w/o cont, abd	d		\$2,210.11	
C8902	MRA w/o fol w/cont, abd	d		\$3,333.23	
C8903	MRI w/cont, breast, uni	d		\$2,308.32	
C8904	MRI w/o cont, breast, uni	d		\$2,210.11	
C8905	MRI w/o fol w/cont, brst, un	d		\$3,333.23	
C8906	MRI w/cont, breast, bi	d		\$2,308.32	
C8907	MRI w/o cont, breast, bi	d		\$2,210.11	
C8908	MRI w/o fol w/cont, breast,	d		\$3,333.23	
C8909	MRA w/cont, chest	d		\$2,308.32	
C8910	MRA w/o cont, chest	d		\$2,210.11	
C8911	MRA w/o fol w/cont, chest	d		\$3,333.23	
C8912	MRA w/cont, hwr ext	d		\$2,308.32	
C8913	MRA w/o cont, hwr ext	d		\$2,210.11	
C8914	MRA w/o fol w/cont, hwr ext	d		\$3,333.23	
C8918	MRA w/cont, pelvis	d		\$2,308.32	
C8919	MRA w/o cont, pelvis	d		\$2,210.11	
C8920	MRA w/o fol w/cont, pelvis	d		\$3,333.23	
C8950	IV inf, b/dx, up to 1 hr	d		\$129.22	OPPS
C8951	IV inf, b/dx, each addl hr	d		\$70.46	RBRVS
C8952	Tx, prophyl, dx IV push	d		\$51.17	OPPS
C8953	Chemotx adm, IV push	d		\$73.16	OPPS
C8954	Chemotx adm, IV inf up to 1h	d		\$202.27	OPPS
C8955	Chemotx adm, IV inf, addl hr	d		\$168.91	RBRVS
C8956	Refill/maint port/impl pump	d	+	\$121.12	OPPS
C8957	Prolonged IV inf, req pump	d		\$129.22	OPPS
C9003	Palivizumab, per 50 mg	d		\$2,988.83	
C9113	Inj pantoprazole sodium, via	d		\$98.30	
C9121	Injection, argatroban	d		\$61.92	
C9220	Sodium hyaluronate	d		\$255.05	
C9221	Graftjacket Ring Matrix	d		\$1,143.56	
C9222	Graftjacket StTis	d		\$795.42	
C9224	Injection, qalsulfase	d		\$1,628.70	OPPS
C9225	Fluocinolone acetoneide	d		\$20,699.15	OPPS
C9716	Radiofrequency energy to anu	d		\$1,872.50	
C9723	Dyn IR Perf Imq	d		\$80.25	OPPS
C9724	EPS gast cardia plic	d	+	\$1,531.59	OPPS
C9725	Place endorectal app	d		\$588.50	OPPS

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 87 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
D0150	Comprehensive oral evaluation			\$153.30	
D0240	Intraoral occlusal film			\$153.30	
D0250	Extraoral first film			\$153.30	
D0260	Extraoral ea additional film			\$153.30	
D0270	Dental bitewing single film			\$153.30	
D0272	Dental bitewings two films			\$153.30	
D0274	Dental bitewings four films			\$153.30	
D0277	Vert bitewings-sev to eight			\$153.30	
D0460	Pulp vitality test			\$153.30	
D0472	Gross exam, prep & report			\$153.30	
D0473	Micro exam, prep & report			\$153.30	
D0474	Micro w exam of surg margins			\$153.30	
D0475	Decalcification procedure			\$9.91	CALC
D0476	Spec stains for microorganis			\$16.39	CALC
D0477	Spec stains not for microorg			\$16.39	CALC
D0478	Immunohistochemical stains			\$30.39	CALC
D0479	Tissue in-situ hybridization			\$50.77	CALC
D0480	Cytopath smear prep & report			\$153.30	
D0481	Electron microscopy diagnost			\$214.46	CALC
D0482	Direct immunofluorescence			\$30.39	CALC
D0483	Indirect immunofluorescence			\$30.39	CALC
D0484	Consult slides prep elsewhere			\$16.39	CALC
D0485	Consult inc prep of slides			\$30.39	CALC
D0502	Other oral pathology procedu			\$153.30	
D0999	Unspecified diagnostic proce			\$153.30	
D1510	Space maintainer fxd unilat			\$153.30	
D1515	Fixed bilat space maintainer			\$153.30	
O1520	Remove unilat space maintai			\$153.30	
D1525	Remove bilat space maintain			\$153.30	
D1550	Recement space maintainer			\$153.30	
D2999	Dental unspec restorative pr			\$153.30	
D3460	Endodontic endosseous implan			\$153.30	
D3999	Endodontic procedure			\$153.30	
D4260	Osseous surgery per quadrant			\$153.30	
D4263	Bone replce graft first site			\$153.30	
D4264	Bone replce graft each add			\$153.30	
D4268	Surgical revision procedure			\$153.30	
D4270	Pedicle soft tissue graft pr			\$153.30	
D4271	Free soft tissue graft proc			\$153.30	
D4273	Subepithelial tissue graft			\$153.30	
D4355	Full mouth debridement			\$153.30	
D4381	Localized chemo delivery			\$153.30	
D5911	Facial moulage sectional			\$153.30	
D5912	Facial moulage complete			\$153.30	
D5983	Radiation applicator			\$153.30	
D5984	Radiation shield			\$153.30	
D5985	Radiation cone locator			\$153.30	
D5987	Commissure splint			\$153.30	
D6190	Radio/surgical implant index			\$47.97	CALC
D6920	Dental connector bar			\$153.30	
D7111	Coronal remnants deciduous t			\$153.30	
D7140	Extraction erupted tooth/exr			\$153.30	
D7210	Rem imp tooth w mucoper flap			\$153.30	
D7220	Impact tooth remov soft tiss			\$153.30	
D7230	Impact tooth remov part bony			\$153.30	
D7240	Impact tooth remov comp bony			\$153.30	
D7241	Impact tooth rem bony w/comp			\$153.30	
D7250	Tooth root removal			\$153.30	
D7260	Oral antral fistula closure			\$153.30	
D7261	Primary closure sinus perf			\$153.30	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 88 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
D7288	Brush biopsy			\$132.38	CALC
D7291	Transseptal fibrotomy			\$153.30	
D7311	Alveoloplasty w/extract 1-3			\$1,486.08	CALC
D7321	Alveoloplasty not w/extracts			\$1,486.08	CALC
D7511.	Incision/drain abscess intra			\$1,024.57	CALC
D7521	Incision/drain abscess extra			\$127.64	CALC
D7940	Reshaping bone orthognathic			\$153.30	
D7953	Bone replacement graft			\$475.95	CALC
D7963	Frenuloplasty			\$499.55	CALC
D9630	Other drugs/medicaments			\$153.30	
D9930	Treatment of complications			\$153.30	
D9940	Dental occlusal guard			\$153.30	
D9950	Occlusion analysis			\$153.30	
D9951	Limited occlusal adjustment			\$153.30	
D9952	Complete occlusal adjustment			\$153.30	
G0008	Admin influenza virus vac			\$17.92	
G0009	Admin pneumococcal vaccine			\$19.38	
G0010	Admin hepatitis b vaccine			\$79.24	
G0101	CA screen;pelvic/breast exam			\$103.43	
G0104	CA screen;flexi sigmoidscope			\$838.17	
G0105	Colorectal scm; hi risk ind		+	\$2,235.53	
G0106	Colon CA screen;barium enema	b		\$773.96	
G0117	Glaucoma scm hgh risk direc			\$203.28	
G0118	Glaucoma scm hgh risk direc			\$203.28	
G0120	Colon ca scm; barium enema	b		\$773.96	
G0121	Colon ca scm not hi rsk ind		+	\$2,235.53	
G0127	Trim nail(s)		+	\$200.15	
G0128	CORF skilled nursing service			\$38.76	
G0130	Single energy x-ray study	b		\$231.26	
G0166	Extrl counterpulse, per tx		+	\$551.18	
G0168	Wound closure by adhesive			\$190.09	
G0173	Stereo radioisurgery,complete			\$24,180.13	
G0175	OPPS Service,sched team conf			\$168.36	
G0179	MD recertification HHA PT			\$96.89	
G0186	Dstry eye lesn,for vssl tech		+	\$1,528.75	
G0204	Diagnosticmammothographydigital	b		\$292.21	
G0206	Diagnosticmammothographydigital	b		\$292.21	
G0219	PET imq wholbod melano nonco			\$1,230.50	CALC
G0235	PET not otherwise specified			\$1,230.50	CALC
G0237	Therapeutic procd strq endur			\$116.52	
G0238	Oth resp proc, indiv			\$116.52	
G0239	Oth resp proc, group			\$116.52	
G0243	Multisour photon stero treat			\$24,180.13	
G0245	Initial Foot Exam PTLOPS			\$103.43	
G0246	Followup eval of foot pt lop			\$103.43	
G0247	Routine footcare pt w lops		+	\$200.15	
G0248	Demonstrate use home inr mon	e		\$733.49	
G0249	Provide test material,equpm	e		\$733.49	
G0251	Linear acc based stero radio			\$5,623.27	
G0257	Unsched dialysis ESRD pt hos			\$1,590.81	
G0259	Inject for sacroiliac joint	d		\$5.89	CALC
G0260	Inj for sacroiliac jt anesth		+	\$652.44	
G0267	Bone marrow or psc harvest			\$1,104.90	
G0268	Removal of impacted wax md			\$190.09	
G0288	Recon, CTA for pre & post suq	e		\$2,200.42	
G0290	Drug-eluting stents, single		+	\$24,883.56	
G0291	Drug-eluting stents,each add		+	\$24,883.56	
G0293	Non-cov surq proc,clin trial			\$1,711.43	
G0294	Non-cov proc, clinical trial			\$366.74	
G0297	Insert single chamber/cd		+	\$40,898.71	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

1. See end of the table for note regarding Charge Methodology.

TABLE F.—OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 89 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
G0298	Insert dual chamber/cd		+	\$40,898.71	
G0299	insert/repos single icd+heads		+	\$54,918.88	
G0300	insert reposit lead dual+gen		+	\$54,918.88	
G0302	Pre-op service LVRS complete			\$3,667.36	
G0303	Pre-op service LVRS 10-15dos			\$2,689.39	
G0304	Pre-op service LVRS 1-9 dos			\$1,222.45	
G0305	Post op service LVRS min 6			\$1,222.45	
G0332	Preadmin IV immunoglobulin	d		\$80.25	OPPS
G0339	Robot lin-radsurg com, first			\$24,180.13	
G0340	Robt lin-radsurg fractx 2-5			\$18,336.75	
G0344	Initial preventive exam	a		\$60.04	
G0364	Bone marrow aspirate & biopsy	b		\$12.60	
G0365	Vessel mapping hemo access	b		\$147.85	
G0367	EKG tracing for initial prev	d		\$23.24	
G0375	Smoke/tobacco counseling 3-10	c		\$5.35	OPPS
G0376	Smoke/tobacco counseling >10	c		\$5.35	OPPS
G0378	Hospital observation per hr	d		\$454.84	OPPS
G0379	Direct admit hospital observ	d		\$56.04	OPPS
G3001	Admin + supply, tositumomab			\$11,002.05	
G9016	Demo-smoking cessation coun			\$26.75	CALC
J0128	Abarelix injection			\$72.35	
J0130	Abciximab injection			\$2,010.90	
J0135	Adalimumab injection			\$664.08	
J0150	Injection adenosine 6 MG			\$81.94	
J0152	Adenosine injection			\$239.97	
J0180	Aqalsidase beta injection			\$129.62	
J0205	Alglucerase injection			\$157.13	
J0207	Amifostine			\$1,775.52	
J0215	Alefacept	d		\$28.42	OPPS
J0256	Alpha 1 proteinase inhibitor			\$14.52	
J0287	Amphotericin b lipid complex			\$88.28	
J0288	Ampho b cholesteryl sulfate			\$88.28	
J0289	Amphotericin b liposome inj			\$88.28	
J0350	Injection anistreplase 30 u			\$10,558.96	
J0395	Arbutamine HCl injection			\$72.85	
J0583	Bivalirudin			\$6.82	
J0585	Botulinum toxin a per unit			\$9.04	
J0587	Botulinum toxin type B			\$34.44	
J0595	Butorphanol tartrate 1 mg			\$5.35	
J0637	Caspofungin acetate			\$129.15	
J0850	Cytomegalovirus imm IV /vial			\$2,791.14	
J0878	Daptomycin injection			\$0.30	
J1190	Dexrazoxane HCl injection			\$475.97	
J1245	Dipyridamole injection			\$58.32	
J1327	Eptifibatid injection			\$50.28	
J1330	Ergonovine maleate injection	d		\$35.43	OPPS
J1335	Ertapenem injection			\$93.06	
J1438	Etanercept injection			\$608.20	
J1440	Filgrastim 300 mcg injection			\$728.67	
J1441	Filgrastim 480 mcg injection			\$1,231.07	
J1457	Gallium nitrate injection			\$0.25	
J1565	RSV-ivig			\$70.03	
J1570	Ganciclovir sodium injection			\$136.64	
J1595	Injection qlatiramer acetate	d		\$704.65	CALC
J1626	Granisetron HCl injection			\$66.08	
J1745	Infliximab injection			\$134.18	
J1785	Injection imiglucerase /unit			\$5.24	
J1825	Interferon beta-1a			\$523.73	
J1830	Interferon beta-1b / .25 MG			\$284.45	
J1931	Laronidase injection			\$24.33	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F.—OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPSCS CODE

PAGE 90 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
J1950	Leuprolide acetate /3.75 MG			\$2,027.77	
J2020	Linezolid injection			\$144.27	
J2185	Meropenem			\$38.80	
J2260	Inj mirifnone lactate / 5 MG			\$43.37	
J2280	Inj, moxifloxacin 100 mg			\$9.36	
J2353	Octreotide injection, depot			\$311.53	
J2354	Octreotide inj, non-depot			\$16.69	
J2355	Oprelvekin injection			\$1,050.10	
J2357	Omalizumab injection			\$16.31	
J2430	Pamidronate disodium /30 MG			\$517.63	
J2469	Palonosetron HCl			\$19.53	
J2505	Injection, pegfilgrastim 6mg			\$10,985.03	
J2545	Pentamidine isethionate/300mg			\$312.63	
J2783	Rasburicase			\$113.46	
J2788	Rho d immune globulin 50 mcg			\$136.30	
J2790	Rho d immune globulin inj			\$393.24	
J2792	Rho(D) immune globulin h, sd			\$80.55	
J2794	Risperidone, long acting			\$4.90	
J2820	Sargramostim injection			\$113.91	
J2941	Somatropin injection			\$1,260.12	
J2993	Retepase injection			\$5,348.22	
J2995	Inj streptokinase /250000 IU			\$363.24	
J2997	Alteplase recombinant			\$61.89	
J3100	Tenecteplase injection			\$10,547.49	
J3110	Teriparatide injection	d		\$368.20	CALC
J3240	Thyrotropin injection			\$2,420.43	
J3246	Tirofiban HCl			\$8.82	
J3305	Inj trimetrexate glucuronate			\$558.56	
J3315	Triptorelin pamoate			\$1,509.22	
J3365	Urokinase 250,000 IU inj			\$873.98	
J3396	Verteporfin injection			\$9.08	
J3411	Thiamine hcl 100 mg			\$1.02	
J3415	Pyridoxine hcl 100 mg			\$2.82	
J3465	Injection, voriconazole			\$4.86	
J3486	Ziprasidone mesylate			\$78.72	
J3487	Zoledronic acid			\$893.15	
J3530	Nasal vaccine inhalation			\$98.88	
J7190	Factor viii			\$0.57	
J7191	Factor VIII (porcine)			\$8.01	
J7192	Factor viii recombinant			\$2.60	
J7193	Factor IX non-recombinant			\$2.16	
J7194	Factor ix complex			\$0.76	
J7195	Factor IX recombinant			\$1.18	
J7198	Anti-inhibitor			\$1.89	
J7310	Ganciclovir long act implant			\$366.20	
J7343	Nonmetabolic act d/e tissue	d		\$11.44	OPPS
J7344	Nonmetabolic active tissue	d		\$67.81	OPPS
J7350	Injectable human tissue			\$8.61	
J7502	Cyclosporine oral 100 mg			\$8.35	
J7504	Lymphocyte immune globulin			\$1,092.44	
J7505	Monoclonal antibodies			\$3,154.69	
J7507	Tacrolimus oral per 1 MG			\$4.71	
J7511	Antithymocyte globulin rabbit			\$1,401.61	
J7513	Daclizumab, parenteral			\$1,666.29	
J7517	Mycophenolate mofetil oral			\$3.78	
J7518	Mycophenolic acid			\$2.60	
J7520	Sirolimus, oral			\$11.09	
J7525	Tacrolimus injection			\$465.65	
J7643	Glycopyrrolate inhal sol u d			\$24.55	
J7644	Ipratropium brom inh sol u d			\$14.51	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

1- See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 91 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
J7674	Methacholine chloride, neb			\$0.50	
J7699	Inhalation solution for DME			\$91.88	
J7799	Non-inhalation drug for DME			\$48.58	
J8499	Oral prescrip drug non chemo			\$6.46	
J8501	Oral aprepitant	d		\$4.96	OPPS.
J8510	Oral busulfan			\$8.16	
J8520	Capecitabine, oral, 150 mg			\$13.30	
J8521	Capecitabine, oral, 500 mg			\$16.51	
J8560	Etoposide oral 50 MG			\$92.74	
J8565	Gefitinib oral	d		\$1,267.69	CALC
J8700	Temozolomide			\$28.84	
J9000	Doxorubic hcl 10 MG vl chemo			\$18.16	
J9001	Doxorubicin hcl liposome inj			\$1,542.34	
J9010	Alemtuzumab injection			\$2,291.22	
J9015	Aldesleukin/single use vial			\$2,878.92	
J9017	Arsenic trioxide			\$145.23	
J9020	Asparaginase injection			\$153.40	
J9031	Bcg live intravesical vac			\$328.12	
J9035	Bevacizumab injection			\$61.13	
J9040	Bleomycin sulfate injection			\$328.79	
J9041	Bortezomib injection			\$29.46	
J9045	Carboplatin injection			\$583.06	
J9055	Cetuximab injection			\$53.36	
J9060	Cisplatin 10 MG injection			\$32.70	
J9065	Inj cladribine per 1 MG			\$105.12	
J9070	Cyclophosphamide 100 MG inj			\$11.75	
J9093	Cyclophosphamide lyophilized			\$9.61	
J9096	Cyclophosphamide lyophilized			\$399.04	
J9098	Cytarabine liposome			\$1,455.98	
J9100	Cytarabine hcl 100 MG inj			\$6.54	
J9130	Dacarbazine 100 mg inj			\$22.47	
J9150	Daunorubicin			\$152.10	
J9151	Daunorubicin citrate liposom			\$273.35	
J9160	Denileukin diftitox, 300 mcg			\$5,216.97	
J9170	Docetaxel			\$1,402.89	
J9178	Inj, epirubicin hcl, 2 mg			\$108.34	
J9181	Etoposide 10 MG inj			\$3.51	
J9182	Etoposide 100 MG inj			\$317.80	
J9185	Fludarabine phosphate inj			\$1,395.71	
J9200	Floxuridine injection,			\$280.31	
J9201	Gemcitabine HCl			\$474.33	
J9202	Goserelin acetate implant			\$1,750.12	
J9206	Ininotecan injection			\$571.27	
J9208	Ifosfomide injection			\$308.12	
J9209	Mesna injection			\$74.74	
J9211	Idarubicin hcl injection			\$754.10	
J9213	Interferon alfa-2a inj			\$136.74	
J9214	Interferon alfa-2b inj			\$58.32	
J9215	Interferon alfa-n3 inj			\$34.58	
J9216	Interferon gamma 1-b inj			\$1,230.10	
J9217	Leuprolide acetate suspnsion			\$2,439.35	
J9218	Leuprolide acetate injection			\$61.28	
J9219	Leuprolide acetate implant			\$21,165.73	
J9245	Inj melphalan hydrochl 50 MG			\$1,646.68	
J9260	Methotrexate sodium inj			\$27.14	
J9263	Oxaliplatin	d		\$9.13	OPPS
J9265	Paclitaxel injection			\$334.46	
J9268	Pentostatin injection			\$7,551.74	
J9270	Plitacmycin (mithramycin) inj			\$367.68	
J9280	Mitomycin 5 MG inj			\$130.81	

NOTES: CPT codes and descriptions only copyright 2005 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for notes regarding Charge Methodology

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPSC CODE

PAGE 92 of 96

CPT/ HCPSC Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
J9293	Mitoxantrone hydrochl / 5 MG			\$1,398.64	
J9300	Gemtuzumab ozogamicin			\$8,559.95	
J9305	Pemetrexed injection			\$43.38	
J9310	Rituximab cancer treatment			\$1,953.61	
J9320	Streptozocin injection			\$554.55	
J9340	Thiotepa injection			\$191.73	
J9350	Topotecan			\$3,130.48	
J9355	Trastuzumab			\$227.87	
J9357	Valrubicin, 200 mg			\$2,064.45	
J9390	Vinorelbine tartrate/10 mg			\$427.26	
J9395	Injection, Fulvestrant			\$331.59	
J9600	Porfimer sodium			\$10,090.91	
M0064	Visit for drug monitoring			\$113.69	
P3001	Screening pap smear by phys			\$245.94	
P9010	Whole blood for transfusion			\$429.97	
P9011	Blood split unit			\$202.64	
P9012	Cryoprecipitate each unit			\$143.33	
P9016	RBC leukocytes reduced			\$582.06	
P9017	Plasma 1 donor frz w/in 8 hr			\$459.83	
P9019	Platelets, each unit			\$202.64	
P9020	Platelet rich plasma unit			\$261.90	
P9021	Red blood cells unit			\$421.25	
P9022	Washed red blood cells unit			\$785.74	
P9023	Frozen plasma, pooled, sd			\$607.86	
P9031	Platelets leukocytes reduced			\$221.32	
P9032	Platelets, irradiated			\$365.70	
P9033	Platelets leukoreduced irradi			\$582.06	
P9034	Platelets, pheresis			\$1,989.75	
P9035	Platelet pheres leukoreduced			\$1,989.75	
P9036	Platelet pheresis irradiated			\$2,169.51	
P9037	Plate pheres leukoredu irradi			\$1,986.64	
P9038	RBC irradiated			\$531.28	
P9039	RBC deglycerolized			\$896.99	
P9040	RBC leukoreduced irradiated			\$896.99	
P9041	Albumin (human), 5%, 50ml			\$74.77	
P9043	Plasma protein fract, 5%, 50ml			\$454.65	
P9044	Cryoprecipitatereducedplasma			\$182.83	
P9045	Albumin (human), 5%, 250 ml			\$290.85	
P9046	Albumin (human), 25%, 20 ml			\$99.81	
P9047	Albumin (human), 25%, 50ml			\$224.10	
P9048	Plasmaprotein fract, 5%, 250ml			\$2,273.27	
P9050	Granulocytes, pheresis unit			\$6,105.71	
P9051	Blood, l/r, cmv-neq			\$179.46	
P9052	Platelets, hla-m, l/r, unit			\$607.94	
P9053	Plt, pher, l/r cmv-neq, irr			\$596.69	
P9054	Blood, l/r, froz/degly/wash			\$287.08	
P9055	Plt, aph/pher, l/r, cmv-neq			\$509.64	
P9056	Blood, l/r, irradiated			\$195.50	
P9057	RBC, frz/deq/wsh, l/r, irradi			\$340.59	
P9058	RBC, l/r, cmv-neq, irradi			\$292.53	
P9059	Plasma, frz between 8-24hour			\$459.83	
P9060	Fr frz plasma donor retested			\$81.68	
Q0035	Cardiokymography	b		\$622.38	
Q0081	Infusion ther other than che			\$743.38	
Q0083	Chemo by other than infusion	d		\$184.06	
Q0084	Chemotherapy by infusion	d		\$700.76	
Q0085	Chemo by both infusion and o	d		\$474.92	
Q0091	Obtaining screen pap smear		+	\$62.57	
Q0166	Granisetron HCl 1 mg oral			\$726.87	
Q0180	Dolasetron mesylate oral			\$644.80	

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F.—OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 93 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
Q0480	Driver pneumatic vad, rep	d		\$92,612.14	DMEPOS
Q0481	Microprcsr cu elec vad, rep	d		\$14,941.90	DMEPOS
Q0482	Microprcsr cu combo vad, rep	d		\$4,680.07	DMEPOS
Q0483	Monitor elec vad, rep	d		\$19,279.83	DMEPOS
Q0484	Monitor elec or comb vad rep	d		\$3,744.08	DMEPOS
Q0485	Monitor cable elec vad, rep	d		\$361.49	DMEPOS
Q0486	Mon cable elec/pneum vad rep	d		\$300.86	DMEPOS
Q0487	Leads any type vad, rep only	d		\$351.00	DMEPOS
Q0489	Pwr pck base combo vad, rep	d		\$16,714.58	DMEPOS
Q0490	Emr pwr source elec vad, rep	d		\$722.99	DMEPOS
Q0491	Emr pwr source combo vad rep	d		\$1,136.62	DMEPOS
Q0492	Emr pwr cbl elec vad, rep	d		\$91.58	DMEPOS
Q0493	Emr pwr cbl combo vad, rep	d		\$260.74	DMEPOS
Q0494	Emr hd pmp elec/combo, rep	d		\$220.63	DMEPOS
Q0495	Charger elec/combo vad, rep	d		\$4,295.23	DMEPOS
Q0496	Battery elec/combo vad, rep	d		\$1,541.62	DMEPOS
Q0497	Bat clips elec/comb vad, rep	d		\$481.38	DMEPOS
Q0498	Holster elec/combo vad, rep	d		\$528.18	DMEPOS
Q0499	Belt/vest elec/combo vad rep	d		\$171.61	DMEPOS
Q0500	Filters elec/combo vad, rep	d		\$31.39	DMEPOS
Q0501	Shwr cov elec/combo vad, rep	d		\$525.15	DMEPOS
Q0502	Mobility cart pneum vad, rep	d		\$668.57	DMEPOS
Q0503	Battery pneum vad replacemnt	d		\$1,337.17	DMEPOS
Q0504	Pwr adpt pneum vad, rep veh	d		\$705.59	DMEPOS
Q2009	Fosphenytoin, 50 mg			\$29.76	
Q2017	Teniposide, 50 mg			\$1,259.89	
Q3025	IM inj interferon beta 1-a			\$56.55	
Q3031	Collagen skin test	a, c		\$264.73	CALC
Q4051	Splint supplies misc			\$76.23	
Q4079	Injection, Natalizumab, 1 MG	d		\$6.84	OPPS
Q9955	Inj perftexane lip micros,ml	d		\$14.18	OPPS
Q9957	Inj perflutren lip micros,ml	d		\$66.21	OPPS
S0078	Injection Fosphenytoin Sodium 750 mg			\$332.87	CALC
S0107	Injection Omalizumab 25 mg			\$349.59	CALC
S0114	Injection Treprostinil Sodium 05 mg			\$4,092.74	CALC
S0116	Bevacizumab 100 mg			\$440.51	CALC
S0118	Injection Ziconotide Intrathecal Infusion 1 mcg			\$479.61	CALC
S0132	Injection Ganirelix Acetate 250 mcg			\$33.10	CALC
S0133	Histeretin Implant 50 mg			\$2,312.00	CALC
S0136	Clozapine 25 mg			\$31.46	CALC
S0137	Didanosine 25 mg			\$114.60	CALC
S0157	Becaplermin Gel 0.01% 0.5 gm			\$342.75	CALC
S0158	Injection Laronidase 0.58 mg			\$439.99	CALC
S0159	Injection Agalsidase Beta 35 mg			\$3,082.41	CALC
S0161	Calcitrol 0.25 mg			\$78.04	CALC
S0164	Injection Pantoprazole Sodium 40 mg			\$64.52	CALC
S0167	Injection Apomorphine Hydrochloride 1 mg			\$63.43	CALC
S0168	Injection Azacitidine 100 mg			\$297.42	CALC
S0195	Pneumococcl Coniugat Vac Im 5-9 Yr Not Prev Recvd			\$243.87	CALC
S0198	Injection Pegaptanib Sodium 0.3 mg			\$813.18	CALC
S0201	Partial Hospitalization Services < 24 Hr Per Diem			\$504.78	CALC
S0220	Med Conf Phys W/Team Hlth Prof Pt Care; 30 Min			\$1.53	CALC
S0221	Med Conf Phys W/Team Hlth Prof Pt Care; 60 Min			\$1.53	CALC
S0255	By Nurse Social Worker Or Other Designated Staff			\$80.24	CALC
S0257	Cnstl&Discuss Adv Dirctv/Eol Care Pt&Surrogate			\$112.34	CALC
S0260	History And Physical Related To Surgical Proc			\$55.07	CALC
S0265	Genetic Counseling Phys Supervision Ea 15 Mins			\$55.07	CALC
S0315	Disease Management Progm; Init Assess&Init Progm			\$55.07	CALC
S0316	Disease Management Program; Follow-Up/Reassess			\$55.07	CALC
S0390	Routine Foot Care; Per Visit			\$47.84	CALC

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F.—OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 94 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
S0400	Global Fee Xtracorp Shock Wave Lith Kidney Stone			\$13,583.31	CALC
S0592	Comprehensive Contact Lens Evaluation			\$719.93	*CALC
S0601	Screening Proctoscopy			\$190.09	CALC
S0613	Annual Gyn Exam Clin Breast Exam W/O Pelv Exam			\$55.07	CALC
S0618	Audiometry For Hearing Aid Evaluation			\$33.65	CALC
S0622	Physical Exam College New Or Established Patient			\$55.07	CALC
S0625	Retinal Telescr Digtl Imaq Mx Diff Fundus Areas			\$48.89	CALC
S0810	Photorefractive Keratectomy			\$1,847.55	CALC
S0812	Phototherapeutic Keratectomy			\$1,847.55	CALC
S2070	Cysto W/Ureterscopy&/Pyelscopy;Lasr Tx Uretri Calc			\$6,575.81	CALC
S2080	Laser-Assisted Uvulopalatoplasty			\$6,567.70	CALC
S2082	Lap Surg; Adj Gastric Band Incl Plcmt Subq Port			\$9,807.60	CALC
S2090	Ablation Open 1/More Renal Tumor; Cryosurgical			\$1,403.47	CALC
S2091	Ablat Perq 1/More Renal Tumor; Cryosurgical			\$1,435.53	CALC
S2095	Trnscath Occl/Emboliz Tumor Destruct Perq Meth Usi			\$7,705.57	CALC
S2120	Ldl Apheres Heparn-Induced Xtracorp Ldl Precip			\$11,321.56	CALC
S2135	Neurolysis Inj Mt Neuroma/Interdigtl Neuritis			\$652.44	CALC
S2140	Cord Blood Harvesting Transplantation Alloqeneic			\$775.92	CALC
S2142	Cord Bld-Derived Stem-Cell Tplnt Alloqeneic			\$1,852.57	CALC
S2150	Bn Marrow/Bld Derivd Stem Cells Harv Tplnt&Comp;			\$650.90	CALC
S2202	Echosclectotherapy			\$81.84	CALC
S2215	Uqi Endo; Inj Impl Mat Low Esoph Sphnctr Tx Gerd			\$492.20	CALC
S2225	Myringotomy Laser-Assisted			\$4,583.99	CALC
S2230	Impl Magnct Cmpnt Semi-Impl Hearing Devc Mid Ear			\$3,031.77	CALC
S2235	Implantation Of Auditory Brain Stem Implant			\$28,169.46	CALC
S2250	Uterine Artery Embolization For Uterine Fibroids			\$2,502.31	CALC
S2300	Arthroscope Shldr Surg; W/Therm-Induced Cpslstr			\$8,234.70	CALC
S2340	Chemodenevation Abductor Muscle Vocal Cord			\$4,180.20	CALC
S2341	Chemodenevation Adductor Muscle Vocal Cord			\$4,180.20	CALC
S2342	Nasal Endoscopic Postop Debridement Uni/Bil			\$6,139.75	CALC
S2348	Decomp Perq Intervert Disc Rt Energy 1/Mx Lumb			\$4,983.20	CALC
S2360	Perq Vertolsty 1 Vert Bdy Unilat/Bilat Inj; Cerv			\$7,473.47	CALC
S2361	Each Additional Cervical Vertebral Body			\$1,518.09	CALC
S2362	Kyphoplasty 1 Vert Body Unilat/Bilat Injection			\$112.35	CALC
S2363	Kypholsty 1 Vert Bdy Unilat/Bilat Inj; Ea Add Ve			\$574.59	CALC
S2370	Intradiscal Electrothrm Therapy; Single Intrsp			\$666.00	CALC
S2371	Each Additional Interspace			\$666.00	CALC
S3005	Performance Msr Eval Pt Self Assess Depression			\$55.07	CALC
S3708	Gastrointestinal Fat Absorption Study			\$242.78	CALC
S3900	Surface Electromyography			\$733.49	CALC
S4005	Internm Labor Facility Global			\$82.33	CALC
S4981	Insrtn Levonorgestrel-Releasing Intrautem Sys			\$809.40	CALC
S5190	Wellness Assessment Performed By Non-Physician			\$80.24	CALC
S8030	Scleral Application Tantalum Ring Proton Beam Tx			\$5,249.03	CALC
S8037	Magnetic Resonance Cholangiopancreatography			\$2,059.71	CALC
S8040	Topographic Brain Mapping			\$761.29	CALC
S8049	Intraoperative Radiation Therapy			\$420.78	CALC
S8055	Ultrasound Guid Multifetal Pg Rduc Tech Cmpnt			\$622.69	CALC
S8075	Cmpnt Anly Full-Field Digtl Mammoqm&Further Phys			\$49.41	CALC
S8080	Scintimammography Uni Incl Supply Radiopharm			\$529.64	CALC
S8093	Ct Angiography Coronary Art W/Contrst Material			\$342.69	CALC
S9024	Paranasal Sinus Ultrasound			\$404.73	CALC
S9034	Extracorporeal Shockwave Lithotripsy Gall Stones			\$2,535.05	CALC
S9083	Global Fee Urgent Care Centers			\$82.58	CALC
S9092	Canolith Repositioning Per Visit			\$55.07	CALC
S9117	Back School Per Visit			\$55.07	CALC
S9401	Anticoagulat Clin Incl All Serv No Lab Per Sess			\$55.07	CALC
S9452	Nutrition Classes Non-Physician Per Session			\$86.00	CALC
S9453	Smoking Cessation Classes Non-Physician Per Sess			\$26.75	CALC
S9474	Entrstml Tx Registered Nrs Cert Entrstml Tx-Diem			\$132.40	CALC

NOTES: CPT codes and descriptions only copyright 2005 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 95 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
S9475	Amb Set Substance Abs Tx/Detoxification Svc-Diem			\$78.75	CALC
S9480	Intensive Op Psychiatric Services Per Diem			\$107.25	CALC
S9484	Crisis Interven Mental Health Services Per Hour			\$107.25	CALC
S9485	Crisis Intervent Mental Health Serv			\$107.25	CALC

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
 1 - See end of the table for note regarding Charge Methodology.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE

PAGE 96 of 96

CPT/ HCPCS Code	Description	Status/ Usage Indicator	Multiple Surgery Reduction Applies	Charge	Charge Method- ology (1)
-----------------------	-------------	-------------------------------	---	--------	--------------------------------

Key to Status/Usage Indicators for new items:

- a: Cannot be billed by VA non-provider-based clinics because the charge is included in the associated professional charge.
- b: Cannot be billed by VA non-provider-based clinics because a technical component charge from the professional charge table applies.
- c: Can be billed by VA non-provider-based clinics.
- d: Cannot be billed by VA non-provider-based clinics because a different code is used for professional billing.
- e: Cannot be billed by VA non-provider-based clinics because a stand-alone charge from the professional charge table applies.
- f: Can be billed for patients who are subsequently admitted to the hospital.
- All other procedures cannot be billed by VA non-provider-based clinics because the service is generally considered "facility only" or the facility charge is included in the professional non-facility practice expense units.
- For all CPT/HCPCS codes retained from V2.4, the status/usage indicator was retained from V2.4.

Charge Methodology:

- No entry: Charge based upon Version 2.4 fees trended forward.
- CALC: Charge based upon a calculation or data provided by VA (e.g., cost).
- DMEPOS: Charge based upon 8-18-2005 DMEPOS fee schedule.
- OPPS: Charge based upon 1-1-2006 OPPS Addendum B.
- RBRVS: Charge based upon 1-1-2006 RBRVS fee schedule.
- All other entries: See Supplementary Table 1, Reasonable Charges Data Sources - V2.6.

NOTES: CPT codes and descriptions only copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
1 - See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 1 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
10021		Fna w/o image	Surgery		1.27	0.54	2.16		
10022		Fna w/image	Surgery		1.27	0.42	2.55		
10040		Acne surgery	Surgery		1.18	0.79	1.01		
10060		Drainage of skin abscess	Surgery		1.17	0.93	1.21		
10061		Drainage of skin abscess	Surgery		2.40	1.50	1.83		
10080		Drainage of pilonidal cyst	Surgery		1.17	1.11	3.11		
10081		Drainage of pilonidal cyst	Surgery		2.45	1.50	4.08		
10120		Remove foreign body	Surgery		1.22	0.97	2.18		
10121		Remove foreign body	Surgery		2.69	1.79	3.52		
10140		Drainage of hematoma/fluid	Surgery		1.53	1.29	1.78		
10160		Puncture drainage of lesion	Surgery		1.20	1.08	1.60		
10180		Complex drainage, wound	Surgery		2.25	1.99	2.99		
11000		Debride infected skin	Surgery		0.60	0.22	0.58		
11001		Debride infected skin add-on	Surgery		0.30	0.11	0.23		
11004		Debride genitalia & perineum	Surgery		10.31	3.91	3.91		
11005		Debride abdom wall	Surgery		13.75	5.58	5.58		
11006		Debride genit/per/abdom wall	Surgery		12.61	4.86	4.86		
11008		Remove mesh from abd wall	Surgery		5.00	2.03	2.03		
11010		Debride skin, fx	Surgery		4.19	2.63	6.89		
11011		Debride skin/muscle, fx	Surgery		4.94	2.35	8.18		
11012		Debride skin/muscle/bone, fx	Surgery		6.87	3.85	12.14		
11040		Debride skin, partial	Surgery		0.50	0.21	0.52		
11041		Debride skin, full	Surgery		0.82	0.33	0.66		
11042		Debride skin/tissue	Surgery		1.12	0.44	0.97		
11043		Debride tissue/muscle	Surgery		2.38	2.60	3.39		
11044		Debride tissue/muscle/bone	Surgery		3.06	3.76	4.46		
11055		Trim skin lesion	Surgery		0.43	0.17	0.56		
11056		Trim skin lesions, 2 to 4	Surgery		0.61	0.23	0.64		
11057		Trim skin lesions, over 4	Surgery		0.79	0.30	0.74		
11100		Biopsy of skin lesion	Surgery		0.81	0.37	1.25		
11101		Biopsy, skin add-on	Surgery		0.41	0.19	0.33		
11200		Removal of skin tags	Surgery		0.77	0.76	1.04		
11201		Remove skin tags add-on	Surgery		0.29	0.12	0.16		
11300		Shave skin lesion	Surgery		0.51	0.21	0.99		
11301		Shave skin lesion	Surgery		0.85	0.38	1.11		
11302		Shave skin lesion	Surgery		1.05	0.46	1.30		
11303		Shave skin lesion	Surgery		1.24	0.52	1.58		
11305		Shave skin lesion	Surgery		0.67	0.27	0.85		
11306		Shave skin lesion	Surgery		0.99	0.42	1.10		
11307		Shave skin lesion	Surgery		1.14	0.49	1.29		
11308		Shave skin lesion	Surgery		1.41	0.59	1.45		
11310		Shave skin lesion	Surgery		0.73	0.32	1.11		
11311		Shave skin lesion	Surgery		1.05	0.49	1.23		
11312		Shave skin lesion	Surgery		1.20	0.55	1.42		
11313		Shave skin lesion	Surgery		1.62	0.72	1.81		
11400		Exc tr-ext b9+marq 0.5 < cm	Surgery		0.85	0.88	2.00		
11401		Exc tr-ext b9+marq 0.6-1 cm	Surgery		1.23	1.02	2.06		
11402		Exc tr-ext b9+marq 1.1-2 cm	Surgery		1.51	1.08	2.23		
11403		Exc tr-ext b9+marq 2.1-3 cm	Surgery		1.79	1.32	2.40		
11404		Exc tr-ext b9+marq 3.1-4 cm	Surgery		2.06	1.40	2.71		
11406		Exc tr-ext b9+marq > 4.0 cm	Surgery		2.76	1.65	3.07		
11420		Exc h-fnk-sp b9+marq 0.5 <	Surgery		0.98	0.93	1.77		
11421		Exc h-fnk-sp b9+marq 0.6-1	Surgery		1.42	1.11	2.07		
11422		Exc h-fnk-sp b9+marq 1.1-2	Surgery		1.63	1.33	2.26		
11423		Exc h-fnk-sp b9+marq 2.1-3	Surgery		2.01	1.45	2.59		
11424		Exc h-fnk-sp b9+marq 3.1-4	Surgery		2.43	1.60	2.81		
11426		Exc h-fnk-sp b9+marq > 4 cm	Surgery		3.77	2.11	3.49		
11440		Exc face-mm b9+marq 0.5 < cm	Surgery		1.06	1.31	2.21		
11441		Exc face-mm b9+marq 0.6-1 cm	Surgery		1.48	1.49	2.34		
11442		Exc face-mm b9+marq 1.1-2 cm	Surgery		1.72	1.57	2.55		
11443		Exc face-mm b9+marq 2.1-3 cm	Surgery		2.29	1.82	2.92		
11444		Exc face-mm b9+marq 3.1-4 cm	Surgery		3.14	2.19	3.48		
11446		Exc face-mm b9+marq > 4 cm	Surgery		4.48	2.78	4.05		
11450		Removal, sweat gland lesion	Surgery		2.73	2.03	5.04		
11451		Removal, sweat gland lesion	Surgery		3.94	2.55	6.62		
11462		Removal, sweat gland lesion	Surgery		2.51	2.02	5.12		
11463		Removal, sweat gland lesion	Surgery		3.94	2.69	6.84		
11470		Removal, sweat gland lesion	Surgery		3.25	2.27	5.07		
11471		Removal, sweat gland lesion	Surgery		4.40	2.77	6.72		

NOTES: CPT Codes and descriptions only are copyright© 2006 American Medical Association. All rights reserved. Applicable FARS/OFARS apply. See end of the table for notes regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 2 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
11600		Exc tr-ext mlg+marq 0.5 < cm	Surgery		1.31	0.97	2.64		
11601		Exc tr-ext mlg+marq 0.6-1 cm	Surgery		1.80	1.22	2.71		
11602		Exc tr-ext mlg+marq 1.1-2 cm	Surgery		1.95	1.26	2.83		
11603		Exc tr-ext mlg+marq 2.1-3 cm	Surgery		2.19	1.33	3.08		
11604		Exc tr-ext mlg+marq 3.1-4 cm	Surgery		2.40	1.39	3.38		
11606		Exc tr-ext mlg+marq > 4 cm	Surgery		3.42	1.74	4.07		
11620		Exc h-f-nk-sp mlg+marq 0.5 <	Surgery		1.19	0.95	2.60		
11621		Exc h-f-nk-sp mlg+marq 0.6-1	Surgery		1.76	1.24	2.71		
11622		Exc h-f-nk-sp mlg+marq 1.1-2	Surgery		2.09	1.39	2.97		
11623		Exc h-f-nk-sp mlg+marq 2.1-3	Surgery		2.61	1.58	3.34		
11624		Exc h-f-nk-sp mlg+marq 3.1-4	Surgery		3.06	1.78	3.75		
11626		Exc h-f-nk-sp mlg+marq > 4 cm	Surgery		4.29	2.40	4.64		
11640		Exc face-mm malg+marq 0.5 <	Surgery		1.35	1.11	2.66		
11641		Exc face-mm malg+marq 0.6-1	Surgery		2.16	1.53	3.03		
11642		Exc face-mm malg+marq 1.1-2	Surgery		2.59	1.71	3.41		
11643		Exc face-mm malg+marq 2.1-3	Surgery		3.10	1.97	3.81		
11644		Exc face-mm malg+marq 3.1-4	Surgery		4.02	2.46	4.69		
11646		Exc face-mm mlg+marq > 4 cm	Surgery		5.94	3.48	5.77		
11719		Trim nail(s)	Surgery		0.17	0.07	0.25		
11720		Debride nail, 1-5	Surgery		0.32	0.12	0.34		
11721		Debride nail, 6 or more	Surgery		0.54	0.21	0.44		
11730		Removal of nail plate	Surgery		1.13	0.43	1.03		
11732		Remove nail plate, add-on	Surgery		0.57	0.22	0.44		
11740		Drain blood from under nail	Surgery		0.37	0.35	0.55		
11750		Removal of nail bed	Surgery		1.86	1.76	2.17		
11752		Remove nail bed/finger tip	Surgery		2.67	3.00	3.00		
11755		Biopsy, nail unit	Surgery		1.31	0.77	1.57		
11760		Repair of nail bed	Surgery		1.58	1.79	2.63		
11762		Reconstruction of nail bed	Surgery		2.89	2.35	2.89		
11765		Excision of nail fold, toe	Surgery		0.69	0.76	1.79		
11770		Removal of pilonidal lesion	Surgery		2.61	1.50	3.49		
11771		Removal of pilonidal lesion	Surgery		5.73	3.32	5.66		
11772		Removal of pilonidal lesion	Surgery		6.97	5.08	7.52		
11900		Injection into skin lesions	Surgery		0.52	0.21	0.65		
11901		Added skin lesions injection	Surgery		0.80	0.35	0.66		
11920		Correct skin color defects	Surgery		1.61	1.09	3.71		
11921		Correct skin color defects	Surgery		1.93	1.27	3.97		
11922		Correct skin color defects	Surgery		0.49	0.25	1.14		
11950		Therapy for contour defects	Surgery		0.84	0.39	1.14		
11951		Therapy for contour defects	Surgery		1.19	0.51	1.49		
11952		Therapy for contour defects	Surgery		1.69	0.68	1.86		
11954		Therapy for contour defects	Surgery		1.85	0.90	2.45		
11960		Insert tissue expander(s)	Surgery		9.07	10.42	10.42		
11970		Replace tissue expander	Surgery		7.05	6.15	6.15		
11971		Remove tissue expander(s)	Surgery		2.13	3.80	9.14		
11975		Insert contraceptive cap	Surgery		1.48	0.57	1.42		
11976		Removal of contraceptive cap	Surgery		1.78	0.68	1.72		
11977		Removal/reinsert contra cap	Surgery		3.30	1.26	2.28		
11980		Implant hormone pellet(s)	Surgery		1.48	0.54	1.08		
11981		Insert drug implant device	Surgery		1.48	0.68	1.70		
11982		Remove drug implant device	Surgery		1.78	0.83	1.95		
11983		Remove/insert drug implant	Surgery		3.30	1.47	2.29		
12001		Repair superficial wound(s)	Surgery		1.70	0.77	1.99		
12002		Repair superficial wound(s)	Surgery		1.86	0.90	2.05		
12004		Repair superficial wound(s)	Surgery		2.24	1.01	2.33		
12005		Repair superficial wound(s)	Surgery		2.86	1.20	2.83		
12006		Repair superficial wound(s)	Surgery		3.66	1.51	3.40		
12007		Repair superficial wound(s)	Surgery		4.11	1.82	3.83		
12011		Repair superficial wound(s)	Surgery		1.76	0.78	2.14		
12013		Repair superficial wound(s)	Surgery		1.99	0.93	2.28		
12014		Repair superficial wound(s)	Surgery		2.46	1.06	2.58		
12015		Repair superficial wound(s)	Surgery		3.19	1.25	3.14		
12016		Repair superficial wound(s)	Surgery		3.92	1.52	3.56		
12017		Repair superficial wound(s)	Surgery		4.70	1.90	1.90		
12018		Repair superficial wound(s)	Surgery		5.52	2.26	2.26		
12020		Closure of split wound	Surgery		2.82	1.93	3.83		
12021		Closure of split wound	Surgery		1.84	1.41	1.83		
12031		Layer closure of wound(s)	Surgery		2.15	0.96	2.29		
12032		Layer closure of wound(s)	Surgery		2.47	1.80	3.85		
12034		Layer closure of wound(s)	Surgery		2.92	1.45	3.20		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 3 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
12035		Layer closure of wound(s)	Surgery		3.42	2.16	5.21		
12036		Layer closure of wound(s)	Surgery		4.04	2.55	5.57		
12037		Layer closure of wound(s)	Surgery		4.66	2.97	6.11		
12041		Layer closure of wound(s)	Surgery		2.37	1.13	2.55		
12042		Layer closure of wound(s)	Surgery		2.74	1.46	3.27		
12044		Layer closure of wound(s)	Surgery		3.14	1.60	3.22		
12045		Layer closure of wound(s)	Surgery		3.63	2.29	5.28		
12046		Layer closure of wound(s)	Surgery		4.24	2.76	6.52		
12047		Layer closure of wound(s)	Surgery		4.64	3.09	6.36		
12051		Layer closure of wound(s)	Surgery		2.47	1.45	3.28		
12052		Layer closure of wound(s)	Surgery		2.77	1.43	3.23		
12053		Layer closure of wound(s)	Surgery		3.12	1.53	3.25		
12054		Layer closure of wound(s)	Surgery		3.45	1.63	3.57		
12055		Layer closure of wound(s)	Surgery		4.42	2.13	4.49		
12056		Layer closure of wound(s)	Surgery		5.23	3.06	6.77		
12057		Layer closure of wound(s)	Surgery		5.95	3.76	6.15		
13100		Repair of wound or lesion	Surgery		3.12	2.31	4.06		
13101		Repair of wound or lesion	Surgery		3.91	2.69	4.67		
13102		Repair wound/lesion add-on	Surgery		1.24	0.57	1.17		
13120		Repair of wound or lesion	Surgery		3.30	2.35	4.15		
13121		Repair of wound or lesion	Surgery		4.32	2.80	4.86		
13122		Repair wound/lesion add-on	Surgery		1.44	0.63	1.51		
13131		Repair of wound or lesion	Surgery		3.78	2.69	4.37		
13132		Repair of wound or lesion	Surgery		5.94	4.17	5.92		
13133		Repair wound/lesion add-on	Surgery		2.19	1.03	1.66		
13150		Repair of wound or lesion	Surgery		3.80	2.77	4.88		
13151		Repair of wound or lesion	Surgery		4.44	3.15	4.81		
13152		Repair of wound or lesion	Surgery		6.32	4.05	6.05		
13153		Repair wound/lesion add-on	Surgery		2.38	1.14	1.94		
13160		Late closure of wound	Surgery		10.46	7.18	7.18		
14000		Skin tissue rearrangement	Surgery		5.88	5.48	7.87		
14001		Skin tissue rearrangement	Surgery		8.46	7.09	9.44		
14020		Skin tissue rearrangement	Surgery		6.58	6.55	8.63		
14021		Skin tissue rearrangement	Surgery		10.04	8.30	10.01		
14040		Skin tissue rearrangement	Surgery		7.86	7.22	8.83		
14041		Skin tissue rearrangement	Surgery		11.47	8.70	10.62		
14060		Skin tissue rearrangement	Surgery		8.49	7.45	8.81		
14061		Skin tissue rearrangement	Surgery		12.27	9.53	11.63		
14300		Skin tissue rearrangement	Surgery		11.74	9.20	11.16		
14350		Skin tissue rearrangement	Surgery		9.60	7.16	7.16		
15000		Skin graft	Surgery		3.99	2.19	3.80		
15001		Skin graft add-on	Surgery		1.00	0.41	1.35		
15040		Harvest cultured skin graft	Surgery	a	2.00	1.13	4.57		RBRVS
15050		Skin pinch graft	Surgery		4.29	5.12	6.93		
15100		Skin split graft	Surgery		9.04	7.84	12.62		
15101		Skin split graft add-on	Surgery		1.72	1.17	3.74		
15110		Epidrm autogrtf tmk/arm/leg	Surgery	a	9.50	7.02	10.70		RBRVS
15111		Epidrm autogrtf v/af add-on	Surgery	a	1.85	0.79	1.29		RBRVS
15115		Epidrm a-grft face/nck/h/q	Surgery	a	9.81	7.37	9.25		RBRVS
15116		Epidrm a-grft t/n/h/q addl	Surgery	a	2.50	1.12	1.58		RBRVS
15120		Skin split graft	Surgery		9.82	7.80	10.75		
15121		Skin split graft add-on	Surgery		2.67	1.85	4.51		
15130		Derm autograft, tmk/arm/leg	Surgery	a	7.00	6.36	9.89		RBRVS
15131		Derm autograft v/af add-on	Surgery	a	1.50	0.64	1.07		RBRVS
15135		Derm autograft face/nck/h/q	Surgery	a	10.50	8.15	9.90		RBRVS
15136		Derm autograft, t/n/h/q add	Surgery	a	1.50	0.67	0.89		RBRVS
15150		Cult epiderm grft v/arm/leg	Surgery	a	8.25	6.46	8.48		RBRVS
15151		Cult epiderm grft v/af addl	Surgery	a	2.00	0.85	1.31		RBRVS
15152		Cult epiderm grft v/af +%	Surgery	a	2.50	1.06	1.56		RBRVS
15155		Cult epiderm grft, t/n/h/q	Surgery	a	9.00	6.98	7.84		RBRVS
15156		Cult epidrm grft t/n/h/q add	Surgery	a	2.75	1.24	1.56		RBRVS
15157		Cult epiderm grft t/n/h/q +%	Surgery	a	3.00	1.35	1.78		RBRVS
15170		Cell graft trunk/arms/legs	Surgery	a	5.00	2.37	3.84		RBRVS
15171		Cell graft v/arm/leg add-on	Surgery	a	1.55	0.62	0.68		RBRVS
15175		Acellular graft, t/n/h/q	Surgery	a	7.00	4.01	5.44		RBRVS
15176		Acell graft, t/n/h/q add-on	Surgery	a	2.45	0.99	1.11		RBRVS
15200		Skin full graft	Surgery		8.02	6.22	9.43		
15201		Skin full graft add-on	Surgery		1.32	0.62	2.57		
15220		Skin full graft	Surgery		7.86	6.70	9.21		
15221		Skin full graft add-on	Surgery		1.19	0.56	2.33		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARSD/FARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 4 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
15240		Skin full graft	Surgery		9.03	7.97	10.23		
15241		Skin full graft add-on	Surgery		1.86	0.91	2.45		
15260		Skin full graft	Surgery		10.04	8.60	10.24		
15261		Skin full graft add-on	Surgery		2.23	1.40	2.70		
15300		Apply skinallgrft, 1/4arm/1q	Surgery	a	3.99	2.24	3.21		RBRVS
15301		Apply skinallgrft 1/4a1 add1	Surgery	a	1.00	0.40	0.47		RBRVS
15320		Apply skin allgrft 1/4n/1q	Surgery	a	4.70	2.54	3.63		RBRVS
15321		Apply skinallgrft 1/4n/1q add	Surgery	a	1.50	0.59	0.69		RBRVS
15330		Apply acell allgrft 1/4arm/1q	Surgery	a	3.99	2.23	3.20		RBRVS
15331		Apply acell grft 1/4a1 add-on	Surgery	a	1.00	0.40	0.46		RBRVS
15335		Apply acell graft, 1/4n/1q	Surgery	a	4.50	2.45	3.48		RBRVS
15336		Apply acell grft 1/4n/1q add	Surgery	a	1.43	0.57	0.69		RBRVS
15340		Apply cult skin substitute	Surgery	a	3.72	2.76	4.01		RBRVS
15341		Apply cult skin sub add-on	Surgery	a	0.50	0.20	0.61		RBRVS
15360		Apply cult derm sub, 1/4a1	Surgery	a	3.87	3.09	4.48		RBRVS
15361		Apply cult derm sub 1/4a1 add	Surgery	a	1.15	0.46	0.58		RBRVS
15365		Apply cult derm sub 1/4n/1q	Surgery	a	4.15	3.20	4.56		RBRVS
15366		Apply cult derm 1/4n/1q add	Surgery	a	1.45	0.58	0.70		RBRVS
15400		Skin heterograft	Surgery		3.99	4.02	4.02		
15401		Skin heterograft add-on	Surgery		1.00	0.44	1.90		
15420		Apply skin xgrft, 1/4n/1q	Surgery	a	4.50	3.80	4.79		RBRVS
15421		Apply skin xgrft 1/4n/1q add	Surgery	a	1.50	0.62	1.32		RBRVS
15430		Apply acellular xenograft	Surgery	a	5.75	6.63	6.92		RBRVS
15570		Form skin pedicle flap	Surgery		9.20	6.78	11.33		
15572		Form skin pedicle flap	Surgery		9.26	6.47	9.52		
15574		Form skin pedicle flap	Surgery		9.87	7.81	10.71		
15576		Form skin pedicle flap	Surgery		8.68	6.90	9.78		
15600		Skin graft	Surgery		1.91	3.07	7.62		
15610		Skin graft	Surgery		2.42	3.43	4.70		
15620		Skin graft	Surgery		2.94	3.89	7.80		
15630		Skin graft	Surgery		3.27	4.16	7.06		
15650		Transfer skin pedicle flap	Surgery		3.96	4.22	7.16		
15732		Muscle-skin graft, head/neck	Surgery		17.81	12.25	18.09		
15734		Muscle-skin graft, trunk	Surgery		17.76	12.41	18.16		
15736		Muscle-skin graft, arm	Surgery		16.25	11.25	18.28		
15738		Muscle-skin graft, leg	Surgery		17.89	11.75	18.02		
15740		Island pedicle flap graft	Surgery		10.23	8.28	10.16		
15750		Neurovascular pedicle graft	Surgery		11.39	9.07	9.07		
15756		Free myo/skin flap microvasc	Surgery		35.18	20.62	20.62		
15757		Free skin flap, microvasc	Surgery		35.18	21.65	21.65		
15758		Free fascial flap, microvasc	Surgery		35.05	21.63	21.63		
15760		Composite skin graft	Surgery		8.73	7.28	10.05		
15770		Derma-fat-fascia graft	Surgery		7.51	6.70	6.70		
15775		Hair transplant punch grafts	Surgery		3.95	1.30	4.24		
15776		Hair transplant punch grafts	Surgery		5.53	2.81	5.37		
15780		Abrasion treatment of skin	Surgery		7.28	8.27	11.55		
15781		Abrasion treatment of skin	Surgery		4.84	5.38	6.93		
15782		Abrasion treatment of skin	Surgery		4.31	6.57	9.88		
15783		Abrasion treatment of skin	Surgery		4.28	4.19	6.89		
15786		Abrasion, lesion, single	Surgery		2.03	1.32	3.36		
15787		Abrasion, lesions, add-on	Surgery		0.33	0.16	1.09		
15788		Chemical peel, face, epiderm	Surgery		2.09	3.09	6.73		
15789		Chemical peel, face, dermal	Surgery		4.91	4.81	8.11		
15792		Chemical peel, nonfacial	Surgery		1.86	4.46	7.11		
15793		Chemical peel, nonfacial	Surgery		3.73	4.39	6.30		
15819		Plastic surgery, neck	Surgery		9.37	7.20	7.20		
15820		Revision of lower eyelid	Surgery		5.14	5.58	6.99		
15821		Revision of lower eyelid	Surgery		5.71	5.73	7.37		
15822		Revision of upper eyelid	Surgery		4.44	4.50	5.85		
15823		Revision of upper eyelid	Surgery		7.04	6.45	7.87		
15824		Removal of forehead wrinkles	Surgery					17.87	
15825		Removal of neck wrinkles	Surgery					20.42	
15826		Removal of brow wrinkles	Surgery					17.87	
15828		Removal of face wrinkles	Surgery					47.23	
15829		Removal of skin wrinkles	Surgery					52.34	
15831		Excise excessive skin tissue	Surgery		12.38	8.18	8.18		
15832		Excise excessive skin tissue	Surgery		11.57	8.36	8.36		
15833		Excise excessive skin tissue	Surgery		10.62	8.23	8.23		
15834		Excise excessive skin tissue	Surgery		10.83	7.71	7.71		
15835		Excise excessive skin tissue	Surgery		11.65	7.56	7.56		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for notes regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 5 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
15836		Excise excessive skin tissue	Surgery		9.33	6.80	6.80		
15837		Excise excessive skin tissue	Surgery		8.42	7.39	8.57		
15838		Excise excessive skin tissue	Surgery		7.12	6.08	6.08		
15839		Excise excessive skin tissue	Surgery		9.37	6.41	8.85		
15840		Graft for face nerve palsy	Surgery		13.24	10.00	10.00		
15841		Graft for face nerve palsy	Surgery		23.23	15.03	15.03		
15842		Flap for face nerve palsy	Surgery		37.90	22.98	22.98		
15845		Skin and muscle repair, face	Surgery		12.55	9.33	9.33		
15850		Removal of sutures	Surgery		0.78	0.30	1.56		
15851		Removal of sutures	Surgery		0.86	0.31	1.68		
15852		Dressing change, not for burn	Surgery		0.86	0.33	1.85		
15860		Test for blood flow in graft	Surgery		1.95	0.78	0.83		
15876		Suction assisted lipectomy	Surgery					11.19	
15877		Suction assisted lipectomy	Surgery					15.70	
15878		Suction assisted lipectomy	Surgery					14.19	
15879		Suction assisted lipectomy	Surgery					13.98	
15920		Removal of tail bone ulcer	Surgery		7.94	5.57	5.57		
15922		Removal of tail bone ulcer	Surgery		9.89	7.23	7.23		
15931		Remove sacrum pressure sore	Surgery		9.23	5.70	5.70		
15933		Remove sacrum pressure sore	Surgery		10.83	7.87	7.87		
15934		Remove sacrum pressure sore	Surgery		12.67	8.06	8.06		
15935		Remove sacrum pressure sore	Surgery		14.55	10.35	10.35		
15936		Remove sacrum pressure sore	Surgery		12.36	8.24	8.24		
15937		Remove sacrum pressure sore	Surgery		14.19	9.85	9.85		
15940		Remove hip pressure sore	Surgery		9.33	6.19	6.19		
15941		Remove hip pressure sore	Surgery		11.41	9.48	9.48		
15944		Remove hip pressure sore	Surgery		11.44	8.62	8.62		
15945		Remove hip pressure sore	Surgery		12.67	9.67	9.67		
15946		Remove hip pressure sore	Surgery		21.54	14.41	14.41		
15950		Remove thigh pressure sore	Surgery		7.53	5.43	5.43		
15951		Remove thigh pressure sore	Surgery		10.70	7.88	7.88		
15952		Remove thigh pressure sore	Surgery		11.37	7.77	7.77		
15953		Remove thigh pressure sore	Surgery		12.61	9.02	9.02		
15956		Remove thigh pressure sore	Surgery		15.50	10.80	10.80		
15958		Remove thigh pressure sore	Surgery		15.46	11.07	11.07		
15999		Removal of pressure sore	Surgery					20.99	
16000		Initial treatment of burn(s)	Surgery		0.89	0.26	0.86		
16020		Treatment of burn(s)	Surgery		0.80	0.58	1.29		
16025		Treatment of burn(s)	Surgery		1.85	0.96	1.77		
16030		Treatment of burn(s)	Surgery		2.08	1.12	2.18		
16035		Incision of burn scab, initi	Surgery		3.74	1.58	1.58		
16036		Incise burn scab, addl incis	Surgery		1.50	0.60	0.60		
17000		Destroy benign/premali lesion	Surgery		0.60	0.54	0.97		
17003		Destroy lesions, 2-14	Surgery		0.15	0.07	0.11		
17004		Destroy lesions, 15 or more	Surgery		2.79	1.59	2.31		
17106		Destruction of skin lesions	Surgery		4.58	3.34	4.61		
17107		Destruction of skin lesions	Surgery		9.15	5.47	7.22		
17108		Destruction of skin lesions	Surgery		13.18	7.68	9.29		
17110		Destruct lesion, 1-14	Surgery		0.65	0.70	1.62		
17111		Destruct lesion, 15 or more	Surgery		0.92	0.81	1.67		
17250		Chemical cautery, tissue	Surgery		0.50	0.34	1.22		
17260		Destruction of skin lesions	Surgery		0.91	0.67	1.28		
17261		Destruction of skin lesions	Surgery		1.17	0.83	1.61		
17262		Destruction of skin lesions	Surgery		1.58	1.02	1.89		
17263		Destruction of skin lesions	Surgery		1.79	1.09	2.06		
17264		Destruction of skin lesions	Surgery		1.94	1.12	2.23		
17266		Destruction of skin lesions	Surgery		2.34	1.22	2.51		
17270		Destruction of skin lesions	Surgery		1.32	0.87	1.70		
17271		Destruction of skin lesions	Surgery		1.49	0.98	1.78		
17272		Destruction of skin lesions	Surgery		1.77	1.11	2.00		
17273		Destruction of skin lesions	Surgery		2.05	1.21	2.21		
17274		Destruction of skin lesions	Surgery		2.59	1.44	2.57		
17276		Destruction of skin lesions	Surgery		3.20	1.68	2.95		
17280		Destruction of skin lesions	Surgery		1.17	0.81	1.61		
17281		Destruction of skin lesions	Surgery		1.72	1.09	1.91		
17282		Destruction of skin lesions	Surgery		2.04	1.24	2.16		
17283		Destruction of skin lesions	Surgery		2.64	1.49	2.55		
17284		Destruction of skin lesions	Surgery		3.21	1.76	2.93		
17286		Destruction of skin lesions	Surgery		4.43	2.45	3.68		
17304		1 stage mohs, up to 5 spec	Surgery		7.59	3.57	8.26		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 6 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
17305		2 stage mchs. up to 5 spec	Surgery		2.85	1.34	3.90		
17306		3 stage mchs. up to 5 spec	Surgery		2.85	1.35	3.92		
17307		Mchs addl stage up to 5 spec	Surgery		2.85	1.36	3.57		
17310		Mchs any stage > 5 spec each	Surgery		0.95	0.46	1.62		
17340		Cryotherapy of skin	Surgery		0.76	0.36	0.37		
17360		Skin peel therapy	Surgery		1.43	0.87	1.44		
17380		Hair removal by electrolysis	Surgery					0.76	
17999		Skin tissue procedure	Surgery					1.74	
19000		Drainage of breast lesion	Surgery		0.84	0.31	1.99		
19001		Drain breast lesion add-on	Surgery		0.42	0.14	0.25		
19020		Incision of breast lesion	Surgery		3.56	2.68	6.35		
19030		Injection for breast x-ray	Surgery		1.53	0.50	2.87		
19100		Bx breast percut w/o image	Surgery		1.27	0.42	2.09		
19101		Biopsy of breast, open	Surgery		3.18	1.92	4.51		
19102		Bx breast percut w/image	Surgery		2.00	0.66	3.84		
19103		Bx breast percut w/device	Surgery		3.69	1.23	11.52		
19110		Nipple exploration	Surgery		4.29	2.87	5.81		
19112		Excise breast duct fistula	Surgery		3.66	2.69	6.08		
19120		Removal of breast lesion	Surgery		5.55	3.07	4.55		
19125		Excision, breast lesion	Surgery		6.05	3.29	4.79		
19126		Excision, addl breast lesion	Surgery		2.93	1.00	1.00		
19140		Removal of breast tissue	Surgery		5.13	3.40	7.16		
19160		Removal of breast tissue	Surgery		5.98	3.43	3.43		
19162		Remove breast tissue, nodes	Surgery		13.51	6.35	6.35		
19180		Removal of breast	Surgery		8.79	5.03	5.03		
19182		Removal of breast	Surgery		7.72	4.76	4.76		
19200		Removal of breast	Surgery		15.47	7.98	7.98		
19220		Removal of breast	Surgery		15.70	8.25	8.25		
19240		Removal of breast	Surgery		15.98	8.22	8.22		
19260		Removal of chest wall lesion	Surgery		15.42	11.18	11.18		
19271		Revision of chest wall	Surgery		18.87	18.00	18.00		
19272		Extensive chest wall surgery	Surgery		21.52	18.98	18.98		
19290		Place needle wire, breast	Surgery		1.27	0.42	2.86		
19291		Place needle wire, breast	Surgery		0.63	0.21	1.21		
19295		Place breast clip, percut	Surgery		0.00	2.70	2.70		
19296		Place po breast cath for rad	Surgery		3.63	1.53	125.75		
19297		Place breast cath for rad	Surgery		1.72	0.64	0.64		
19298		Place breast rad tube/caths	Surgery		6.00	2.42	42.28		
19316		Suspension of breast	Surgery		10.67	7.53	7.53		
19318		Reduction of large breast	Surgery		15.60	11.20	11.20		
19324		Enlarge breast	Surgery		5.84	4.90	4.90		
19325		Enlarge breast with implant	Surgery		8.44	6.54	6.54		
19328		Removal of breast implant	Surgery		5.67	5.03	5.03		
19330		Removal of implant material	Surgery		7.58	6.05	6.05		
19340		Immediate breast prosthesis	Surgery		6.32	3.12	3.12		
19342		Delayed breast prosthesis	Surgery		11.18	8.95	8.95		
19350		Breast reconstruction	Surgery		8.91	7.19	13.88		
19355		Correct inverted nipple(s)	Surgery		7.56	4.71	10.28		
19357		Breast reconstruction	Surgery		18.13	15.66	15.66		
19361		Breast reconstruction	Surgery		19.23	12.47	12.47		
19364		Breast reconstruction	Surgery		40.94	23.61	23.61		
19366		Breast reconstruction	Surgery		21.25	11.61	11.61		
19367		Breast reconstruction	Surgery		25.69	16.74	16.74		
19368		Breast reconstruction	Surgery		32.37	18.97	18.97		
19369		Breast reconstruction	Surgery		29.78	18.45	18.45		
19370		Surgery of breast capsule	Surgery		8.04	6.92	6.92		
19371		Removal of breast capsule	Surgery		9.34	7.84	7.84		
19380		Revise breast reconstruction	Surgery		9.13	7.72	7.72		
19396		Design custom breast implant	Surgery		2.17	0.99	1.08		
19499		Breast surgery procedure	Surgery					8.77	
20000		Incision of abscess	Surgery		2.12	1.74	2.70		
20005		Incision of deep abscess	Surgery		3.41	2.26	3.50		
20100		Explore wound, neck	Surgery		10.06	4.47	4.47		
20101		Explore wound, chest	Surgery		3.22	1.62	5.94		
20102		Explore wound, abdomen	Surgery		3.93	1.91	7.48		
20103		Explore wound, extremity	Surgery		5.29	3.40	8.60		
20150		Excise epiphyseal bar	Surgery		13.67	7.05	7.05		
20200		Muscle biopsy	Surgery		1.46	0.75	3.04		
20205		Deep muscle biopsy	Surgery		2.35	1.19	3.90		
20206		Needle biopsy, muscle	Surgery		0.99	0.63	6.52		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPSC CODE

PAGE 7 of 119

CPT/ HCPSC Code	Modifier	CPT/HCPSC Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
20220		Bone biopsy, trocar/needle	Surgery		1.27	0.79	4.57		
20225		Bone biopsy, trocar/needle	Surgery		1.87	1.13	24.52		
20240		Bone biopsy, excisional	Surgery		3.23	2.56	2.56		
20245		Bone biopsy, excisional	Surgery		7.77	6.59	6.59		
20250		Open bone biopsy	Surgery		5.02	3.51	3.51		
20251		Open bone biopsy	Surgery		5.55	4.17	4.17		
20500		Injection of sinus tract	Surgery		1.23	1.53	2.27		
20501		Inject sinus tract for x-ray	Surgery		0.76	0.25	2.92		
20520		Removal of foreign body	Surgery		1.85	1.77	2.92		
20525		Removal of foreign body	Surgery		3.49	2.63	9.17		
20526		Ther injection, carp tunnel	Surgery		0.94	0.52	0.97		
20550		Inj tendon sheath/ligament	Surgery		0.75	0.23	0.71		
20551		Inject tendon origin/insert	Surgery		0.75	0.33	0.68		
20552		Inject trigger point, 1 or 2	Surgery		0.66	0.20	0.72		
20553		Inject trigger points, => 3	Surgery		0.75	0.22	0.82		
20600		Drain/inject, joint/bursa	Surgery		0.66	0.35	0.65		
20605		Drain/inject, joint/bursa	Surgery		0.68	0.36	0.76		
20610		Drain/inject, joint/bursa	Surgery		0.79	0.42	0.95		
20612		Aspirate/inj ganglion cyst	Surgery		0.70	0.36	0.71		
20615		Treatment of bone cyst	Surgery		2.28	1.85	3.52		
20650		Insert and remove bone pin	Surgery		2.23	1.55	2.37		
20660		Apply, rem fixation device	Surgery		2.51	1.61	3.06		
20661		Application of head brace	Surgery		4.88	4.92	4.92		
20662		Application of pelvis brace	Surgery		6.06	5.54	5.54		
20663		Application of thigh brace	Surgery		5.42	4.84	4.84		
20664		Halo brace application	Surgery		8.05	7.06	7.06		
20665		Removal of fixation device	Surgery		1.31	1.35	2.16		
20670		Removal of support implant	Surgery		1.74	2.11	11.57		
20680		Removal of support implant	Surgery		3.34	3.73	8.81		
20690		Apply bone fixation device	Surgery		3.51	2.52	2.52		
20692		Apply bone fixation device	Surgery		6.40	3.78	3.78		
20693		Adjust bone fixation device	Surgery		5.85	5.46	5.46		
20694		Remove bone fixation device	Surgery		4.15	4.05	7.16		
20802		Replantation, arm, complete	Surgery		41.09	21.01	21.01		
20805		Replant forearm, complete	Surgery		49.93	34.41	34.41		
20808		Replantation hand, complete	Surgery		61.56	42.34	42.34		
20816		Replantation digit, complete	Surgery		30.89	37.90	37.90		
20822		Replantation digit, complete	Surgery		25.55	34.69	34.69		
20824		Replantation thumb, complete	Surgery		30.89	36.65	36.65		
20827		Replantation thumb, complete	Surgery		26.37	36.58	36.58		
20838		Replantation foot, complete	Surgery		41.35	22.34	22.34		
20900		Removal of bone for graft	Surgery		5.57	5.69	8.45		
20902		Removal of bone for graft	Surgery		7.54	6.90	6.90		
20910		Remove cartilage for graft	Surgery		5.33	5.20	5.20		
20912		Remove cartilage for graft	Surgery		6.34	5.81	5.81		
20920		Removal of fascia for graft	Surgery		5.30	4.23	4.23		
20922		Removal of fascia for graft	Surgery		6.60	4.88	7.56		
20924		Removal of tendon for graft	Surgery		6.47	5.90	5.90		
20926		Removal of tissue for graft	Surgery		5.52	4.76	4.76		
20930		Spinal bone allograft	Surgery					3.65	
20931		Spinal bone allograft	Surgery		1.81	0.93	0.93		
20936		Spinal bone autograft	Surgery					5.55	
20937		Spinal bone autograft	Surgery		2.79	1.45	1.45		
20938		Spinal bone autograft	Surgery		3.02	1.56	1.56		
20950		Fluid pressure, muscle	Surgery		1.26	0.99	6.86		
20955		Fibula bone graft, microvasc	Surgery		39.15	24.34	24.34		
20956		Iliac bone graft, microvasc	Surgery		39.21	24.81	24.81		
20957		Mt bone graft, microvasc	Surgery		40.59	18.99	18.99		
20962		Other bone graft, microvasc	Surgery		39.21	26.60	26.60		
20969		Bone/skin graft, microvasc	Surgery		43.85	26.71	26.71		
20970		Bone/skin graft, iliac crest	Surgery		43.00	25.45	25.45		
20972		Bone/skin graft, metatarsal	Surgery		42.53	20.64	20.64		
20973		Bone/skin graft, great toe	Surgery		45.69	25.23	25.23		
20974		Electrical bone stimulation	Surgery		0.62	0.54	0.69		
20975		Electrical bone stimulation	Surgery		2.60	1.71	1.71		
20979		Us bone stimulation	Surgery		0.62	0.34	0.80		
20982		Ablate, bone tumor(s) perq	Surgery		7.27	2.98	109.86		
20999		Musculoskeletal surgery	Surgery					1.41	
21010		Incision of jaw joint	Surgery		10.12	7.11	7.11		
21015		Resection of facial tumor	Surgery		5.28	5.02	5.02		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 8 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
21025		Excision of bone, lower jaw	Surgery		10.04	9.38	12.28		
21026		Excision of facial bone(s)	Surgery		4.84	6.34	7.88		
21029		Contour of face bone lesion	Surgery		7.70	7.03	9.40		
21030		Excise max/zygoma b9 tumor	Surgery		4.49	5.04	6.35		
21031		Remove exostosis, mandible	Surgery		3.24	3.63	5.18		
21032		Remove exostosis, maxilla	Surgery		3.24	3.52	5.36		
21034		Excise max/zygoma mlq tumor	Surgery		16.15	12.70	15.97		
21040		Excise mandible lesion	Surgery		4.49	4.73	6.41		
21044		Removal of jaw bone lesion	Surgery		11.84	9.40	9.40		
21045		Extensive jaw surgery	Surgery		16.15	12.39	12.39		
21046		Remove mandible cyst complex	Surgery		12.98	11.93	11.93		
21047		Excise lwr jaw cyst w/repair	Surgery		18.72	13.48	13.48		
21048		Remove maxilla cyst complex	Surgery		13.48	12.17	12.17		
21049		Excis uppr jaw cyst w/repair	Surgery		17.97	13.06	13.06		
21050		Removal of jaw joint	Surgery		10.75	9.47	9.47		
21060		Remove jaw joint cartilage	Surgery		10.21	8.63	8.63		
21070		Remove coronoid process	Surgery		8.19	7.12	7.12		
21076		Prepare face/oral prosthesis	Surgery		13.40	10.03	12.39		
21077		Prepare face/oral prosthesis	Surgery		33.70	26.08	31.42		
21079		Prepare face/oral prosthesis	Surgery		22.31	17.20	21.56		
21080		Prepare face/oral prosthesis	Surgery		25.06	19.42	24.56		
21081		Prepare face/oral prosthesis	Surgery		22.85	17.54	22.36		
21082		Prepare face/oral prosthesis	Surgery		20.84	15.78	19.40		
21083		Prepare face/oral prosthesis	Surgery		19.27	14.47	18.84		
21084		Prepare face/oral prosthesis	Surgery		22.48	17.75	22.50		
21085		Prepare face/oral prosthesis	Surgery		8.99	6.80	8.31		
21086		Prepare face/oral prosthesis	Surgery		24.68	19.49	23.81		
21087		Prepare face/oral prosthesis	Surgery		24.68	19.25	23.35		
21088		Prepare face/oral prosthesis	Surgery					10.85	
21089		Prepare face/oral prosthesis	Surgery					16.97	
21100		Maxillofacial fixation	Surgery		4.21	4.75	11.56		
21110		Interdental fixation	Surgery		5.20	8.38	9.59		
21116		Injection, jaw joint x-ray	Surgery		0.81	0.33	4.34		
21120		Reconstruction of chin	Surgery		4.92	7.51	10.61		
21121		Reconstruction of chin	Surgery		7.63	7.84	9.76		
21122		Reconstruction of chin	Surgery		8.51	8.64	8.64		
21123		Reconstruction of chin	Surgery		11.14	10.83	10.83		
21125		Augmentation, lower jaw bone	Surgery		10.60	8.34	55.38		
21127		Augmentation, lower jaw bone	Surgery		11.10	9.48	42.92		
21137		Reduction of forehead	Surgery		9.81	7.75	7.75		
21138		Reduction of forehead	Surgery		12.17	9.56	9.56		
21139		Reduction of forehead	Surgery		14.59	11.09	11.09		
21141		Reconstruct midface, left	Surgery		18.07	13.69	13.69		
21142		Reconstruct midface, left	Surgery		18.78	12.86	12.86		
21143		Reconstruct midface, left	Surgery		19.55	14.35	14.35		
21145		Reconstruct midface, left	Surgery		19.91	13.94	13.94		
21146		Reconstruct midface, left	Surgery		20.68	15.37	15.37		
21147		Reconstruct midface, left	Surgery		21.74	15.09	15.09		
21150		Reconstruct midface, left	Surgery		25.20	16.81	16.81		
21151		Reconstruct midface, left	Surgery		28.26	23.02	23.02		
21154		Reconstruct midface, left	Surgery		30.47	23.19	23.19		
21155		Reconstruct midface, left	Surgery		34.40	23.96	23.96		
21159		Reconstruct midface, left	Surgery		42.32	29.16	29.16		
21160		Reconstruct midface, left	Surgery		46.37	27.55	27.55		
21172		Reconstruct orbit/forehead	Surgery		27.76	13.79	13.79		
21175		Reconstruct orbit/forehead	Surgery		33.12	17.84	17.84		
21179		Reconstruct entire forehead	Surgery		22.22	14.17	14.17		
21180		Reconstruct entire forehead	Surgery		25.15	15.42	15.42		
21181		Contour cranial bone lesion	Surgery		9.89	7.48	7.48		
21182		Reconstruct cranial bone	Surgery		32.14	19.17	19.17		
21183		Reconstruct cranial bone	Surgery		35.26	20.89	20.89		
21184		Reconstruct cranial bone	Surgery		38.18	22.00	22.00		
21188		Reconstruction of midface	Surgery		22.43	18.92	18.92		
21193		Reconst lwr jaw w/o graft	Surgery		17.12	12.69	12.69		
21194		Reconst lwr jaw w/graft	Surgery		19.81	13.79	13.79		
21195		Reconst lwr jaw w/o fixation	Surgery		17.21	14.86	14.86		
21196		Reconst lwr jaw w/fixation	Surgery		18.88	15.74	15.74		
21198		Reconst lwr jaw segment	Surgery		14.14	12.74	12.74		
21199		Reconst lwr jaw w/advance	Surgery		15.98	9.14	9.14		
21206		Reconstruct upper jaw bone	Surgery		14.08	12.67	12.67		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/OFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 9 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
21208		Augmentation of facial bones	Surgery		10.21	9.61	22.39		
21209		Reduction of facial bones	Surgery		6.71	8.09	10.83		
21210		Face bone graft	Surgery		10.21	9.38	24.94		
21215		Lower jaw bone graft	Surgery		10.75	9.39	42.00		
21230		Rib cartilage graft	Surgery		10.75	8.06	8.06		
21235		Ear cartilage graft	Surgery		6.71	6.43	9.87		
21240		Reconstruction of jaw joint	Surgery		14.03	12.08	12.08		
21242		Reconstruction of jaw joint	Surgery		12.93	11.54	11.54		
21243		Reconstruction of jaw joint	Surgery		20.76	17.48	17.48		
21244		Reconstruction of lower jaw	Surgery		11.84	12.13	12.13		
21245		Reconstruction of jaw	Surgery		11.84	9.88	14.44		
21246		Reconstruction of jaw	Surgery		12.45	9.07	9.07		
21247		Reconstruct lower jaw bone	Surgery		22.60	17.40	17.40		
21248		Reconstruction of jaw	Surgery		11.46	9.43	12.17		
21249		Reconstruction of jaw	Surgery		17.49	12.73	16.77		
21255		Reconstruct lower jaw bone	Surgery		16.59	16.18	16.18		
21256		Reconstruction of orbit	Surgery		16.17	11.85	11.85		
21260		Revise eye sockets	Surgery		16.50	12.80	12.80		
21261		Revise eye sockets	Surgery		31.44	24.30	24.30		
21263		Revise eye sockets	Surgery		28.38	19.13	19.13		
21267		Revise eye sockets	Surgery		18.87	19.83	19.83		
21268		Revise eye sockets	Surgery		24.44	20.27	20.27		
21270		Augmentation, cheek bone	Surgery		10.21	7.27	11.68		
21275		Revision, orbitofacial bones	Surgery		11.22	8.18	8.18		
21280		Revision of eyelid	Surgery		6.02	5.94	5.94		
21282		Revision of eyelid	Surgery		3.48	4.49	4.49		
21295		Revision of jaw muscle/bone	Surgery		1.53	2.54	2.54		
21296		Revision of jaw muscle/bone	Surgery		4.24	4.92	4.92		
21299		Cranio/maxillofacial surgery	Surgery					20.01	
21300		Treatment of skull fracture	Surgery		0.72	0.26	2.37		
21310		Treatment of nose fracture	Surgery		0.58	0.15	2.29		
21315		Treatment of nose fracture	Surgery		1.51	1.89	4.24		
21320		Treatment of nose fracture	Surgery		1.85	1.62	3.92		
21325		Treatment of nose fracture	Surgery		3.76	8.64	8.64		
21330		Treatment of nose fracture	Surgery		5.37	9.73	9.73		
21335		Treatment of nose fracture	Surgery		8.60	9.65	9.65		
21336		Treat nasal septal fracture	Surgery		5.71	9.64	9.64		
21337		Treat nasal septal fracture	Surgery		2.70	3.58	6.14		
21338		Treat nasosethmoid fracture	Surgery		6.45	14.06	14.06		
21339		Treat nasosethmoid fracture	Surgery		8.08	13.94	13.94		
21340		Treatment of nose fracture	Surgery		10.75	8.42	8.42		
21343		Treatment of sinus fracture	Surgery		12.93	15.51	15.51		
21344		Treatment of sinus fracture	Surgery		19.69	16.55	16.55		
21345		Treat nose/faw fracture	Surgery		8.15	7.19	9.87		
21346		Treat nose/faw fracture	Surgery		10.59	12.24	12.24		
21347		Treat nose/faw fracture	Surgery		12.67	16.24	16.24		
21348		Treat nose/faw fracture	Surgery		16.66	11.14	11.14		
21355		Treat cheek bone fracture	Surgery		3.76	3.49	6.25		
21356		Treat cheek bone fracture	Surgery		4.14	4.56	7.14		
21360		Treat cheek bone fracture	Surgery		6.45	5.95	5.95		
21365		Treat cheek bone fracture	Surgery		14.93	10.86	10.86		
21366		Treat cheek bone fracture	Surgery		17.74	11.36	11.36		
21385		Treat eye socket fracture	Surgery		9.15	8.30	8.30		
21386		Treat eye socket fracture	Surgery		9.15	7.09	7.09		
21387		Treat eye socket fracture	Surgery		9.69	8.98	8.98		
21390		Treat eye socket fracture	Surgery		10.11	7.82	7.82		
21395		Treat eye socket fracture	Surgery		12.66	9.05	9.05		
21400		Treat eye socket fracture	Surgery		1.40	1.88	2.62		
21401		Treat eye socket fracture	Surgery		3.26	3.50	8.01		
21406		Treat eye socket fracture	Surgery		7.00	6.10	6.10		
21407		Treat eye socket fracture	Surgery		8.60	6.88	6.88		
21408		Treat eye socket fracture	Surgery		12.36	8.91	8.91		
21421		Treat mouth roof fracture	Surgery		5.13	8.33	9.36		
21422		Treat mouth roof fracture	Surgery		8.31	8.10	8.10		
21423		Treat mouth roof fracture	Surgery		10.38	9.35	9.35		
21431		Treat craniofacial fracture	Surgery		7.04	9.55	9.55		
21432		Treat craniofacial fracture	Surgery		8.60	8.08	8.08		
21433		Treat craniofacial fracture	Surgery		25.31	16.45	16.45		
21435		Treat craniofacial fracture	Surgery		17.22	12.74	12.74		
21436		Treat craniofacial fracture	Surgery		28.00	18.27	18.27		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 10 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
21440		Treat dental ridge fracture	Surgery		2.70	6.18	7.12		
21445		Treat dental ridge fracture	Surgery		5.37	8.39	9.78		
21450		Treat lower jaw fracture	Surgery		2.97	6.89	7.40		
21451		Treat lower jaw fracture	Surgery		4.86	8.42	9.38		
21452		Treat lower jaw fracture	Surgery		1.98	4.62	13.06		
21453		Treat lower jaw fracture	Surgery		5.53	10.76	10.77		
21454		Treat lower jaw fracture	Surgery		6.45	6.28	6.28		
21455		Treat lower jaw fracture	Surgery		8.08	12.70	24.53		
21461		Treat lower jaw fracture	Surgery		9.78	12.75	27.69		
21462		Treat lower jaw fracture	Surgery		11.89	9.84	9.84		
21465		Treat lower jaw fracture	Surgery		15.32	12.05	12.05		
21470		Treat lower jaw fracture	Surgery		0.61	0.19	1.78		
21480		Reset dislocated jaw	Surgery		3.98	7.68	8.24		
21485		Reset dislocated jaw	Surgery		11.84	9.72	9.72		
21490		Repair dislocated jaw	Surgery		5.68	8.44	8.44		
21495		Treat hyoid bone fracture	Surgery		3.85	7.66	8.47		
21497		Interdental wiring	Surgery					7.51	
21499		Head surgery procedure	Surgery						
21501		Drain neck/chest lesion	Surgery		3.80	3.83	6.44		
21502		Drain chest lesion	Surgery		7.11	5.65	5.65		
21510		Drainage of bone lesion	Surgery		5.73	5.68	5.68		
21550		Biopsy of neck/chest	Surgery		2.06	1.72	3.59		
21555		Remove lesion, neck/chest	Surgery		4.34	3.20	5.53		
21556		Remove lesion, neck/chest	Surgery		5.56	4.11	4.11		
21557		Remove tumor, neck/chest	Surgery		8.87	5.37	5.37		
21600		Partial removal of rib	Surgery		6.88	5.75	5.75		
21610		Partial removal of rib	Surgery		14.59	8.89	8.89		
21615		Removal of rib	Surgery		9.86	6.70	6.70		
21616		Removal of rib and nerves	Surgery		12.02	8.04	8.04		
21620		Partial removal of sternum	Surgery		6.78	5.99	5.99		
21627		Sternal debridement	Surgery		6.80	6.32	6.32		
21630		Extensive sternum surgery	Surgery		17.35	11.87	11.87		
21632		Extensive sternum surgery	Surgery		18.11	11.14	11.14		
21685		Hyoid myotomy & suspension	Surgery		12.98	10.00	10.00		
21700		Revision of neck muscle	Surgery		6.18	4.45	4.45		
21705		Revision of neck muscle/rib	Surgery		9.59	5.60	5.60		
21720		Revision of neck muscle	Surgery		5.67	2.47	2.47		
21725		Revision of neck muscle	Surgery		6.98	5.46	5.46		
21740		Reconstruction of sternum	Surgery		16.48	8.54	8.54		
21742		Repair sternum w/o scope	Surgery					25.36	
21743		Repair sternum w/scope	Surgery					33.37	
21750		Repair of sternum separation	Surgery		10.75	6.13	6.13		
21800		Treatment of rib fracture	Surgery		0.96	1.34	1.34		
21805		Treatment of rib fracture	Surgery		2.75	3.21	3.21		
21810		Treatment of rib fracture(s)	Surgery		6.85	4.98	4.98		
21820		Treat sternum fracture	Surgery		1.28	1.77	1.83		
21825		Treat sternum fracture	Surgery		7.40	6.41	6.41		
21899		Neck/chest surgery procedure	Surgery					7.88	
21920		Biopsy soft tissue of back	Surgery		2.06	1.47	3.29		
21925		Biopsy soft tissue of back	Surgery		4.48	3.25	5.18		
21930		Remove lesion, back or flank	Surgery		4.99	3.41	5.73		
21935		Remove tumor, back	Surgery		17.93	9.65	9.65		
22010		l&d, p-spine, c/cerv-thor	Surgery		11.05	8.91	8.91		RBRVS
22015		l&d, p-spine, l/s/l	Surgery		10.94	8.85	8.85		RBRVS
22100		Remove part of neck vertebra	Surgery		9.72	7.55	7.55		
22101		Remove part, thorax vertebra	Surgery		9.80	7.77	7.77		
22102		Remove part, lumbar vertebra	Surgery		9.80	8.13	8.13		
22103		Remove extra spine segment	Surgery		2.34	1.21	1.21		
22110		Remove part of neck vertebra	Surgery		12.72	9.19	9.19		
22112		Remove part, thorax vertebra	Surgery		12.79	9.30	9.30		
22114		Remove part, lumbar vertebra	Surgery		12.79	9.28	9.28		
22116		Remove extra spine segment	Surgery		2.32	1.17	1.17		
22210		Revision of neck spine	Surgery		23.78	15.45	15.45		
22212		Revision of thorax spine	Surgery		19.39	13.31	13.31		
22214		Revision of lumbar spine	Surgery		19.42	13.85	13.85		
22216		Revis, extra spine segment	Surgery		6.03	3.14	3.14		
22220		Revision of neck spine	Surgery		21.34	13.66	13.66		
22222		Revision of thorax spine	Surgery		21.49	11.16	11.16		
22224		Revision of lumbar spine	Surgery		21.49	14.26	14.26		
22226		Revis, extra spine segment	Surgery		6.03	3.10	3.10		
22305		Treat spine process fracture	Surgery		2.05	1.93	2.32		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 11 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
22310		Treat spine fracture	Surgery		2.61	2.36	2.81		
22315		Treat spine fracture	Surgery		8.83	7.35	9.71		
22318		Treat odontoid fx w/o graft	Surgery		21.47	13.42	13.42		
22319		Treat odontoid fx w/graft	Surgery		23.96	14.75	14.75		
22325		Treat spine fracture	Surgery		18.27	12.11	12.11		
22326		Treat neck spine fracture	Surgery		19.56	12.74	12.74		
22327		Treat thorax spine fracture	Surgery		19.17	12.40	12.40		
22328		Treat each add spine fx	Surgery		4.60	2.27	2.27		
22505		Manipulation of spine	Surgery		1.87	0.94	0.94		
22520		Percut vertebroplasty thor	Surgery		8.90	5.11	61.84		
22521		Percut vertebroplasty lumb	Surgery		8.33	4.96	56.13		
22522		Percut vertebroplasty addl	Surgery		4.30	1.68	1.68		
22523		Percut kyphoplasty, thor	Surgery		8.94	5.92	5.92		RBRVS
22524		Percut kyphoplasty, lumbar	Surgery	a	8.54	5.71	5.71		RBRVS
22525		Percut kyphoplasty, add-on	Surgery	a	4.47	2.28	2.28		RBRVS
22532		Lat thorax spine fusion	Surgery		23.96	14.86	14.86		
22533		Lat lumbar spine fusion	Surgery		23.09	13.63	13.63		
22534		Lat thor/lumb, add'l seq	Surgery		5.99	3.04	3.04		
22548		Neck spine fusion	Surgery		25.78	15.85	15.85		
22554		Neck spine fusion	Surgery		18.59	12.38	12.38		
22556		Thorax spine fusion	Surgery		23.42	14.77	14.77		
22558		Lumbar spine fusion	Surgery		22.25	13.33	13.33		
22585		Additional spinal fusion	Surgery		5.52	2.80	2.80		
22590		Spine & skull spinal fusion	Surgery		20.48	13.36	13.36		
22595		Neck spinal fusion	Surgery		19.36	12.87	12.87		
22600		Neck spine fusion	Surgery		16.12	11.22	11.22		
22610		Thorax spine fusion	Surgery		16.00	11.44	11.44		
22612		Lumbar spine fusion	Surgery		20.97	14.24	14.24		
22614		Spine fusion, extra segment	Surgery		6.43	3.36	3.36		
22630		Lumbar spine fusion	Surgery		20.81	13.64	13.64		
22632		Spine fusion, extra segment	Surgery		5.22	2.67	2.67		
22800		Fusion of spine	Surgery		18.22	12.81	12.81		
22802		Fusion of spine	Surgery		30.83	19.65	19.65		
22804		Fusion of spine	Surgery		36.22	22.76	22.76		
22808		Fusion of spine	Surgery		26.23	16.35	16.35		
22810		Fusion of spine	Surgery		30.22	18.41	18.41		
22812		Fusion of spine	Surgery		32.65	20.12	20.12		
22818		Kyphectomy, 1-2 segments	Surgery		31.78	18.92	18.92		
22819		Kyphectomy, 3 or more	Surgery		36.39	20.11	20.11		
22830		Exploration of spinal fusion	Surgery		10.83	7.98	7.98		
22840		Insert spine fixation device	Surgery		12.52	6.51	6.51		
22841		Insert spine fixation device	Surgery					9.26	
22842		Insert spine fixation device	Surgery		12.56	6.52	6.52		
22843		Insert spine fixation device	Surgery		13.44	6.62	6.62		
22844		Insert spine fixation device	Surgery		16.42	8.78	8.78		
22845		Insert spine fixation device	Surgery		11.94	6.09	6.09		
22846		Insert spine fixation device	Surgery		12.40	6.35	6.35		
22847		Insert spine fixation device	Surgery		13.78	7.04	7.04		
22848		Insert pelv fixation device	Surgery		5.99	3.19	3.19		
22849		Reinsert spinal fixation	Surgery		18.48	11.76	11.76		
22850		Remove spine fixation device	Surgery		9.51	7.01	7.01		
22851		Apply spine prosth device	Surgery		6.70	3.37	3.37		
22852		Remove spine fixation device	Surgery		9.00	6.81	6.81		
22855		Remove spine fixation device	Surgery		15.11	9.69	9.69		
22899		Spine surgery procedure	Surgery					19.09	
22900		Remove abdominal wall lesion	Surgery		5.79	3.23	3.23		
22999		Abdomen surgery procedure	Surgery					9.07	
23000		Removal of calcium deposits	Surgery		4.35	4.43	8.55		
23020		Release shoulder joint	Surgery		8.92	7.58	7.58		
23030		Drain shoulder lesion	Surgery		3.42	2.91	7.41		
23031		Drain shoulder bursa	Surgery		2.74	2.73	7.88		
23035		Drain shoulder bone lesion	Surgery		8.60	8.29	8.29		
23040		Exploratory shoulder surgery	Surgery		9.19	7.88	7.88		
23044		Exploratory shoulder surgery	Surgery		7.11	6.45	6.45		
23065		Biopsy shoulder tissues	Surgery		2.27	1.52	2.49		
23066		Biopsy shoulder tissues	Surgery		4.15	3.99	7.69		
23075		Removal of shoulder lesion	Surgery		2.39	1.79	3.67		
23076		Removal of shoulder lesion	Surgery		7.62	5.57	5.57		
23077		Remove tumor of shoulder	Surgery		16.07	10.24	10.24		
23100		Biopsy of shoulder joint	Surgery		6.02	5.67	5.67		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCCPS CODE

PAGE 12 of 119

CPT/ HCCPS Code	Modifier	CPT/HCCPS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
23101		Shoulder joint surgery	Surgery		5.57	5.35	5.35		
23105		Remove shoulder joint lining	Surgery		8.22	7.14	7.14		
23106		Incision of collarbone joint	Surgery		5.95	5.72	5.72		
23107		Explore treat shoulder joint	Surgery		8.61	7.41	7.41		
23120		Partial removal, collar bone	Surgery		7.10	6.48	6.48		
23125		Removal of collar bone	Surgery		9.38	7.58	7.58		
23130		Remove shoulder bone, part	Surgery		7.54	7.15	7.15		
23140		Removal of bone lesion	Surgery		6.88	5.24	5.24		
23145		Removal of bone lesion	Surgery		9.08	7.46	7.46		
23146		Removal of bone lesion	Surgery		7.82	7.13	7.13		
23150		Removal of humerus lesion	Surgery		8.47	6.94	6.94		
23155		Removal of humerus lesion	Surgery		10.33	8.35	8.35		
23156		Removal of humerus lesion	Surgery		8.67	7.40	7.40		
23170		Remove collar bone lesion	Surgery		6.85	6.04	6.04		
23172		Remove shoulder blade lesion	Surgery		6.89	6.30	6.30		
23174		Remove humerus lesion	Surgery		9.50	8.38	8.38		
23180		Remove collar bone lesion	Surgery		8.52	9.02	9.02		
23182		Remove shoulder blade lesion	Surgery		8.14	8.57	8.57		
23184		Remove humerus lesion	Surgery		9.37	9.34	9.34		
23190		Partial removal of scapula	Surgery		7.23	6.19	6.19		
23195		Removal of head of humerus	Surgery		9.80	7.75	7.75		
23200		Removal of collar bone	Surgery		12.06	8.75	8.75		
23210		Removal of shoulder blade	Surgery		12.47	9.02	9.02		
23220		Partial removal of humerus	Surgery		14.54	10.85	10.85		
23221		Partial removal of humerus	Surgery		17.71	11.75	11.75		
23222		Partial removal of humerus	Surgery		23.88	15.83	15.83		
23330		Remove shoulder foreign body	Surgery		1.85	1.89	3.69		
23331		Remove shoulder foreign body	Surgery		7.37	6.81	6.81		
23332		Remove shoulder foreign body	Surgery		11.60	9.35	9.35		
23350		Injection for shoulder x-ray	Surgery		1.00	0.33	3.47		
23395		Muscle transfer, shoulder/arm	Surgery		16.82	12.90	12.90		
23397		Muscle transfers	Surgery		16.11	11.40	11.40		
23400		Fixation of shoulder blade	Surgery		13.52	10.10	10.10		
23405		Incision of tendon & muscle	Surgery		8.36	6.94	6.94		
23406		Incise tendon(s) & muscle(s)	Surgery		10.77	8.36	8.36		
23410		Repair rotator cuff, acute	Surgery		12.43	9.43	9.43		
23412		Repair rotator cuff, chronic	Surgery		13.29	9.92	9.92		
23415		Release of shoulder ligament	Surgery		9.96	8.01	8.01		
23420		Repair of shoulder	Surgery		13.28	10.87	10.87		
23430		Repair biceps tendon	Surgery		9.97	8.12	8.12		
23440		Remove/transplant tendon	Surgery		10.46	8.28	8.28		
23450		Repair shoulder capsule	Surgery		13.38	9.87	9.87		
23455		Repair shoulder capsule	Surgery		14.35	10.47	10.47		
23460		Repair shoulder capsule	Surgery		15.35	11.40	11.40		
23462		Repair shoulder capsule	Surgery		15.28	10.78	10.78		
23465		Repair shoulder capsule	Surgery		15.83	11.21	11.21		
23466		Repair shoulder capsule	Surgery		14.20	11.40	11.40		
23470		Reconstruct shoulder joint	Surgery		17.12	12.29	12.29		
23472		Reconstruct shoulder joint	Surgery		21.07	14.45	14.45		
23480		Revision of collar bone	Surgery		11.16	8.80	8.80		
23485		Revision of collar bone	Surgery		13.41	9.92	9.92		
23490		Reinforce clavicle	Surgery		11.84	8.72	8.72		
23491		Reinforce shoulder bones	Surgery		14.19	10.74	10.74		
23500		Treat clavicle fracture	Surgery		2.08	2.53	2.88		
23505		Treat clavicle fracture	Surgery		3.68	3.85	4.42		
23515		Treat clavicle fracture	Surgery		7.40	6.57	6.57		
23520		Treat clavicle dislocation	Surgery		2.16	2.75	2.86		
23525		Treat clavicle dislocation	Surgery		3.59	3.95	4.55		
23530		Treat clavicle dislocation	Surgery		7.30	5.95	5.95		
23532		Treat clavicle dislocation	Surgery		8.00	6.99	6.99		
23540		Treat clavicle dislocation	Surgery		2.23	2.37	2.87		
23545		Treat clavicle dislocation	Surgery		3.25	3.37	4.20		
23550		Treat clavicle dislocation	Surgery		7.23	6.39	6.39		
23552		Treat clavicle dislocation	Surgery		8.44	7.34	7.34		
23570		Treat shoulder blade fx	Surgery		2.23	2.90	3.02		
23575		Treat shoulder blade fx	Surgery		4.05	4.32	4.89		
23585		Treat scapula fracture	Surgery		8.95	7.66	7.66		
23600		Treat humerus fracture	Surgery		2.93	3.56	4.56		
23605		Treat humerus fracture	Surgery		4.86	5.12	6.17		
23615		Treat humerus fracture	Surgery		9.34	8.86	8.86		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 13 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
23616		Treat humerus fracture	Surgery		21.24	14.18	14.18		
23620		Treat humerus fracture	Surgery		2.40	2.99	3.62		
23625		Treat humerus fracture	Surgery		3.92	4.29	4.95		
23630		Treat humerus fracture	Surgery		7.34	6.65	6.65		
23650		Treat shoulder dislocation	Surgery		3.38	2.77	3.78		
23655		Treat shoulder dislocation	Surgery		4.56	4.18	4.18		
23660		Treat shoulder dislocation	Surgery		7.48	6.40	6.40		
23665		Treat dislocation/fracture	Surgery		4.46	4.73	5.35		
23670		Treat dislocation/fracture	Surgery		7.89	6.85	6.85		
23675		Treat dislocation/fracture	Surgery		6.04	5.85	6.85		
23680		Treat dislocation/fracture	Surgery		10.04	8.13	8.13		
23700		Fixation of shoulder	Surgery		2.52	2.18	2.18		
23800		Fusion of shoulder joint	Surgery		14.14	10.44	10.44		
23802		Fusion of shoulder joint	Surgery		16.58	10.20	10.20		
23900		Amputation of arm & girdle	Surgery		19.69	11.74	11.74		
23920		Amputation at shoulder joint	Surgery		14.59	9.95	9.95		
23921		Amputation follow-up surgery	Surgery		5.48	5.09	5.09		
23929		Shoulder surgery procedure	Surgery					13.58	
23930		Drainage of arm lesion	Surgery		2.94	2.32	6.34		
23931		Drainage of arm bursa	Surgery		1.79	2.18	5.93		
23935		Drain arm/elbow bone lesion	Surgery		6.08	5.93	5.93		
24000		Exploratory elbow surgery	Surgery		5.81	5.43	5.43		
24006		Release elbow joint	Surgery		9.30	7.77	7.77		
24065		Biopsy arm/elbow soft tissue	Surgery		2.08	1.75	3.22		
24066		Biopsy arm/elbow soft tissue	Surgery		5.20	4.14	8.96		
24075		Remove arm/elbow lesion	Surgery		3.91	3.41	7.37		
24076		Remove arm/elbow lesion	Surgery		6.29	4.87	4.87		
24077		Remove tumor of arm/elbow	Surgery		11.74	7.76	7.76		
24100		Biopsy elbow joint lining	Surgery		4.92	4.53	4.53		
24101		Explore/treat elbow joint	Surgery		6.12	5.95	5.95		
24102		Remove elbow joint lining	Surgery		8.02	6.88	6.88		
24105		Removal of elbow bursa	Surgery		3.60	4.40	4.40		
24110		Remove humerus lesion	Surgery		7.38	6.68	6.68		
24115		Remove/graft bone lesion	Surgery		9.62	7.23	7.23		
24116		Remove/graft bone lesion	Surgery		11.79	9.10	9.10		
24120		Remove elbow lesion	Surgery		6.64	5.94	5.94		
24125		Remove/graft bone lesion	Surgery		7.88	6.18	6.18		
24126		Remove/graft bone lesion	Surgery		8.30	7.04	7.04		
24130		Removal of head of radius	Surgery		6.24	6.04	6.04		
24134		Removal of arm bone lesion	Surgery		9.72	8.88	8.88		
24136		Remove radius bone lesion	Surgery		7.98	7.24	7.24		
24138		Remove elbow bone lesion	Surgery		8.04	7.80	7.80		
24140		Partial removal of arm bone	Surgery		9.17	9.13	9.13		
24145		Partial removal of radius	Surgery		7.57	8.08	8.08		
24147		Partial removal of elbow	Surgery		7.53	8.62	8.62		
24149		Radical resection of elbow	Surgery		14.18	11.65	11.65		
24150		Extensive humerus surgery	Surgery		13.25	10.02	10.02		
24151		Extensive humerus surgery	Surgery		15.56	11.54	11.54		
24152		Extensive radius surgery	Surgery		10.04	7.75	7.75		
24153		Extensive radius surgery	Surgery		11.52	5.59	5.59		
24155		Removal of elbow joint	Surgery		11.71	8.42	8.42		
24160		Remove elbow joint implant	Surgery		7.82	6.91	6.91		
24164		Remove radius head implant	Surgery		6.22	5.79	5.79		
24200		Removal of arm foreign body	Surgery		1.76	1.63	3.42		
24201		Removal of arm foreign body	Surgery		4.55	4.24	9.84		
24220		Injection for elbow x-ray	Surgery		1.31	0.44	3.64		
24300		Manipulate elbow w/ anesth	Surgery		3.74	5.73	5.73		
24301		Muscle/tendon transfer	Surgery		10.18	8.20	8.20		
24305		Arm tendon lengthening	Surgery		7.44	6.73	6.73		
24310		Revision of arm tendon	Surgery		5.97	5.60	5.60		
24320		Repair of arm tendon	Surgery		10.54	7.55	7.55		
24330		Revision of arm muscles	Surgery		9.59	7.90	7.90		
24331		Revision of arm muscles	Surgery		10.63	8.70	8.70		
24332		Tenolysis, biceps	Surgery		7.44	6.79	6.79		
24340		Repair of biceps tendon	Surgery		7.88	7.00	7.00		
24341		Repair arm tendon/muscle	Surgery		7.89	7.94	7.94		
24342		Repair of ruptured tendon	Surgery		10.60	8.54	8.54		
24343		Repr elbow lat ligmnt w/ bss	Surgery		8.64	8.17	8.17		
24344		Reconstruct elbow lat ligmnt	Surgery		13.98	11.55	11.55		
24345		Repr elbow med ligmnt w/ bss	Surgery		8.64	8.04	8.04		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 14 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
24346		Reconstruct elbow med ligmnt	Surgery		13.98	11.37	11.37		
24350		Repair of tennis elbow	Surgery		5.24	5.60	5.60		
24351		Repair of tennis elbow	Surgery		5.90	5.94	5.94		
24352		Repair of tennis elbow	Surgery		6.42	6.20	6.20		
24354		Repair of tennis elbow	Surgery		6.47	6.17	6.17		
24356		Revision of tennis elbow	Surgery		6.67	6.33	6.33		
24360		Reconstruct elbow joint	Surgery		12.32	9.50	9.50		
24361		Reconstruct elbow joint	Surgery		14.06	10.61	10.61		
24362		Reconstruct elbow joint	Surgery		14.97	10.07	10.07		
24363		Replace elbow joint	Surgery		18.46	13.75	13.75		
24365		Reconstruct head of radius	Surgery		8.38	7.22	7.22		
24366		Reconstruct head of radius	Surgery		9.12	7.56	7.56		
24400		Revision of humerus	Surgery		11.04	8.88	8.88		
24410		Revision of humerus	Surgery		14.80	10.34	10.34		
24420		Revision of humerus	Surgery		13.42	10.57	10.57		
24430		Repair of humerus	Surgery		12.79	9.77	9.77		
24435		Repair humerus with graft	Surgery		13.15	10.91	10.91		
24470		Revision of elbow joint	Surgery		8.73	7.74	7.74		
24495		Decompression of forearm	Surgery		8.11	8.77	8.77		
24498		Reinforce humerus	Surgery		11.90	9.29	9.29		
24500		Treat humerus fracture	Surgery		3.21	3.69	4.86		
24505		Treat humerus fracture	Surgery		5.16	5.41	6.62		
24515		Treat humerus fracture	Surgery		11.63	9.41	9.41		
24516		Treat humerus fracture	Surgery		11.63	9.14	9.14		
24530		Treat humerus fracture	Surgery		3.49	4.05	5.22		
24535		Treat humerus fracture	Surgery		6.86	6.64	7.86		
24538		Treat humerus fracture	Surgery		9.42	8.73	8.73		
24545		Treat humerus fracture	Surgery		10.44	8.47	8.47		
24546		Treat humerus fracture	Surgery		15.67	11.35	11.35		
24560		Treat humerus fracture	Surgery		2.80	3.20	4.49		
24565		Treat humerus fracture	Surgery		5.55	5.54	6.63		
24566		Treat humerus fracture	Surgery		7.78	8.18	8.18		
24575		Treat humerus fracture	Surgery		10.64	8.42	8.42		
24576		Treat humerus fracture	Surgery		2.86	3.72	4.77		
24577		Treat humerus fracture	Surgery		5.78	5.86	6.95		
24579		Treat humerus fracture	Surgery		11.58	8.86	8.86		
24582		Treat humerus fracture	Surgery		8.54	9.14	9.14		
24586		Treat elbow fracture	Surgery		15.19	11.26	11.26		
24587		Treat elbow fracture	Surgery		15.14	11.05	11.05		
24600		Treat elbow dislocation	Surgery		4.22	3.51	4.87		
24605		Treat elbow dislocation	Surgery		5.41	5.38	5.38		
24615		Treat elbow dislocation	Surgery		9.41	7.84	7.84		
24620		Treat elbow fracture	Surgery		6.97	6.27	6.27		
24635		Treat elbow fracture	Surgery		13.17	14.09	14.09		
24640		Treat elbow dislocation	Surgery		1.20	0.80	1.85		
24650		Treat radius fracture	Surgery		2.16	2.76	3.79		
24655		Treat radius fracture	Surgery		4.39	4.80	5.97		
24665		Treat radius fracture	Surgery		8.13	7.53	7.53		
24666		Treat radius fracture	Surgery		9.48	8.09	8.09		
24670		Treat ulnar fracture	Surgery		2.54	3.08	4.12		
24675		Treat ulnar fracture	Surgery		4.71	4.98	6.02		
24685		Treat ulnar fracture	Surgery		8.79	7.54	7.54		
24800		Fusion of elbow joint	Surgery		11.18	8.77	8.77		
24802		Fusion/graft of elbow joint	Surgery		13.67	10.41	10.41		
24900		Amputation of upper arm	Surgery		9.59	7.08	7.08		
24920		Amputation of upper arm	Surgery		9.53	6.96	6.96		
24925		Amputation follow-up surgery	Surgery		7.06	6.10	6.10		
24930		Amputation follow-up surgery	Surgery		10.23	7.26	7.26		
24931		Amputate upper arm & implant	Surgery		12.70	5.74	5.74		
24935		Revision of amputation	Surgery		15.54	8.04	8.04		
24940		Revision of upper arm	Surgery					23.19	
24999		Upper arm/elbow surgery	Surgery					8.53	
25000		Incision of tendon sheath	Surgery		3.37	6.89	6.89		
25001		Incise flexor carpi radialis	Surgery		3.37	4.24	4.24		
25020		Decompress forearm 1 space	Surgery		5.91	9.59	9.59		
25023		Decompress forearm 1 space	Surgery		12.94	14.98	14.98		
25024		Decompress forearm 2 spaces	Surgery		9.49	7.49	7.49		
25025		Decompress forearm 2 spaces	Surgery		16.52	10.00	10.00		
25028		Drainage of forearm lesion	Surgery		5.24	8.18	8.18		
25031		Drainage of forearm bursa	Surgery		4.13	7.94	7.94		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for notes regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 15 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
25035		Treat forearm bone lesion	Surgery		7.35	13.63	13.63		
25040		Explore/treat wrist joint	Surgery		7.17	7.32	7.32		
25065		Biopsy forearm soft tissues	Surgery		1.99	1.91	3.23		
25066		Biopsy forearm soft tissues	Surgery		4.12	7.08	7.08		
25075		Remove forearm lesion subcu	Surgery		3.73	5.91	5.91		
25076		Remove forearm lesion deep	Surgery		4.91	9.57	9.57		
25077		Remove tumor, forearm/wrist	Surgery		9.75	12.12	12.12		
25085		Incision of wrist capsule	Surgery		5.49	7.14	7.14		
25100		Biopsy of wrist joint	Surgery		3.89	5.29	5.29		
25101		Explore/treat wrist joint	Surgery		4.68	5.91	5.91		
25105		Remove wrist joint lining	Surgery		5.84	7.32	7.32		
25107		Remove wrist joint cartilage	Surgery		6.42	8.36	8.36		
25110		Remove wrist tendon lesion	Surgery		3.91	7.07	7.07		
25111		Remove wrist tendon lesion	Surgery		3.38	4.71	4.71		
25112		Reremove wrist tendon lesion	Surgery		4.52	5.27	5.27		
25115		Remove wrist/forearm lesion	Surgery		8.81	14.07	14.07		
25116		Remove wrist/forearm lesion	Surgery		7.10	13.18	13.18		
25118		Excise wrist tendon sheath	Surgery		4.36	5.76	5.76		
25119		Partial removal of ulna	Surgery		6.03	7.62	7.62		
25120		Removal of forearm lesion	Surgery		6.09	12.12	12.12		
25125		Remove/graft forearm lesion	Surgery		7.47	12.88	12.88		
25126		Remove/graft forearm lesion	Surgery		7.54	13.05	13.05		
25130		Removal of wrist lesion	Surgery		5.25	6.44	6.44		
25135		Remove & graft wrist lesion	Surgery		6.88	7.53	7.53		
25136		Remove & graft wrist lesion	Surgery		5.96	6.61	6.61		
25145		Remove forearm bone lesion	Surgery		6.36	12.09	12.09		
25150		Partial removal of ulna	Surgery		7.08	8.23	8.23		
25151		Partial removal of radius	Surgery		7.38	12.76	12.76		
25170		Extensive forearm surgery	Surgery		11.07	15.19	15.19		
25210		Removal of wrist bone	Surgery		5.94	6.81	6.81		
25215		Removal of wrist bones	Surgery		7.88	8.78	8.78		
25230		Partial removal of radius	Surgery		5.22	6.16	6.16		
25240		Partial removal of ulna	Surgery		5.16	6.97	6.97		
25245		Injection for wrist x-ray	Surgery		1.45	0.48	3.45		
25248		Remove forearm foreign body	Surgery		5.13	8.54	8.54		
25250		Removal of wrist prosthesis	Surgery		6.59	6.12	6.12		
25251		Removal of wrist prosthesis	Surgery		9.56	7.94	7.94		
25259		Manipulate wrist w/anesthes	Surgery		3.74	5.74	5.74		
25260		Repair forearm tendon/muscle	Surgery		7.79	13.35	13.35		
25263		Repair forearm tendon/muscle	Surgery		7.61	13.30	13.30		
25265		Repair forearm tendon/muscle	Surgery		9.87	14.35	14.35		
25270		Repair forearm tendon/muscle	Surgery		5.99	12.06	12.06		
25272		Repair forearm tendon/muscle	Surgery		7.03	12.83	12.83		
25274		Repair forearm tendon/muscle	Surgery		8.74	13.66	13.66		
25275		Repair forearm tendon sheath	Surgery		8.49	7.60	7.60		
25280		Revise wrist/forearm tendon	Surgery		7.21	12.67	12.67		
25290		Incise wrist/forearm tendon	Surgery		5.28	15.03	15.03		
25295		Release wrist/forearm tendon	Surgery		6.54	12.19	12.19		
25300		Fusion of tendons at wrist	Surgery		8.79	8.47	8.47		
25301		Fusion of tendons at wrist	Surgery		8.39	8.08	8.08		
25310		Transplant forearm tendon	Surgery		8.13	13.07	13.07		
25312		Transplant forearm tendon	Surgery		9.56	13.98	13.98		
25315		Revise palsy hand tendon(s)	Surgery		10.18	14.44	14.44		
25316		Revise palsy hand tendon(s)	Surgery		12.31	16.27	16.27		
25320		Repair/revise wrist joint	Surgery		10.75	11.42	11.42		
25332		Revise wrist joint	Surgery		11.39	9.20	9.20		
25335		Realignment of hand	Surgery		12.86	11.62	11.62		
25337		Reconstruct ulna/radioulnar	Surgery		10.15	11.11	11.11		
25350		Revision of radius	Surgery		8.77	14.01	14.01		
25355		Revision of radius	Surgery		10.15	14.65	14.65		
25360		Revision of ulna	Surgery		8.42	13.91	13.91		
25365		Revise radius & ulna	Surgery		12.38	15.69	15.69		
25370		Revise radius or ulna	Surgery		13.34	16.12	16.12		
25375		Revise radius & ulna	Surgery		13.02	16.47	16.47		
25390		Shorten radius or ulna	Surgery		10.38	14.62	14.62		
25391		Lengthen radius or ulna	Surgery		13.63	16.60	16.60		
25392		Shorten radius & ulna	Surgery		13.93	16.01	16.01		
25393		Lengthen radius & ulna	Surgery		15.85	17.63	17.63		
25394		Repair carpal bone, shorten	Surgery		10.38	8.08	8.08		
25400		Repair radius or ulna	Surgery		10.90	15.23	15.23		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 16 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
25405		Repair/graft radius or ulna	Surgery		14.36	17.32	17.32		
25415		Repair radius & ulna	Surgery		13.33	16.56	16.56		
25420		Repair/graft radius & ulna	Surgery		16.31	18.32	18.32		
25425		Repair/graft radius or ulna	Surgery		13.19	21.45	21.45		
25426		Repair/graft radius & ulna	Surgery		15.80	16.60	16.60		
25430		Vasc graft into carpal bone	Surgery		9.24	7.36	7.36		
25431		Repair nonunion carpal bone	Surgery		10.42	8.42	8.42		
25440		Repair/graft wrist bone	Surgery		10.42	9.43	9.43		
25441		Reconstruct wrist joint	Surgery		12.88	10.03	10.03		
25442		Reconstruct wrist joint	Surgery		10.83	8.91	8.91		
25443		Reconstruct wrist joint	Surgery		10.37	8.80	8.80		
25444		Reconstruct wrist joint	Surgery		11.13	9.06	9.06		
25445		Reconstruct wrist joint	Surgery		9.68	8.01	8.01		
25446		Wrist replacement	Surgery		16.53	11.95	11.95		
25447		Repair wrist joint(s)	Surgery		10.35	8.68	8.68		
25449		Remove wrist joint implant	Surgery		14.47	10.70	10.70		
25450		Revision of wrist joint	Surgery		7.86	10.22	10.22		
25455		Revision of wrist joint	Surgery		9.48	10.89	10.89		
25490		Reinforce radius	Surgery		9.53	13.77	13.77		
25491		Reinforce ulna	Surgery		9.95	14.50	14.50		
25492		Reinforce radius and ulna	Surgery		12.31	15.34	15.34		
25500		Treat fracture of radius	Surgery		2.45	2.72	3.58		
25505		Treat fracture of radius	Surgery		5.20	5.44	6.56		
25515		Treat fracture of radius	Surgery		9.17	7.48	7.48		
25520		Treat fracture of radius	Surgery		6.25	6.08	6.88		
25525		Treat fracture of radius	Surgery		12.22	10.02	10.02		
25526		Treat fracture of radius	Surgery		12.96	13.54	13.54		
25530		Treat fracture of ulna	Surgery		2.09	2.87	3.77		
25535		Treat fracture of ulna	Surgery		5.13	5.31	6.03		
25545		Treat fracture of ulna	Surgery		8.89	7.68	7.68		
25560		Treat fracture radius & ulna	Surgery		2.44	2.61	3.70		
25565		Treat fracture radius & ulna	Surgery		5.62	5.44	6.72		
25574		Treat fracture radius & ulna	Surgery		7.00	7.22	7.22		
25575		Treat fracture radius/ulna	Surgery		10.43	9.54	9.54		
25600		Treat fracture radius/ulna	Surgery		2.63	2.98	4.10		
25605		Treat fracture radius/ulna	Surgery		5.80	6.24	7.25		
25611		Treat fracture radius/ulna	Surgery		7.76	8.99	8.99		
25620		Treat fracture radius/ulna	Surgery		8.54	7.28	7.28		
25622		Treat wrist bone fracture	Surgery		2.61	3.11	4.28		
25624		Treat wrist bone fracture	Surgery		4.52	5.08	6.32		
25628		Treat wrist bone fracture	Surgery		8.42	7.84	7.84		
25630		Treat wrist bone fracture	Surgery		2.88	2.95	4.19		
25635		Treat wrist bone fracture	Surgery		4.38	3.91	5.96		
25645		Treat wrist bone fracture	Surgery		7.24	6.55	6.55		
25650		Treat wrist bone fracture	Surgery		3.05	3.18	4.32		
25651		Pin ulnar styloid fracture	Surgery		5.35	5.50	5.50		
25652		Treat fracture ulnar styloid	Surgery		7.59	7.02	7.02		
25660		Treat wrist dislocation	Surgery		4.75	4.72	4.72		
25670		Treat wrist dislocation	Surgery		7.91	7.01	7.01		
25671		Pin radioulnar dislocation	Surgery		5.99	6.17	6.17		
25675		Treat wrist dislocation	Surgery		4.66	4.66	5.67		
25676		Treat wrist dislocation	Surgery		8.03	7.32	7.32		
25680		Treat wrist fracture	Surgery		5.98	4.75	4.75		
25685		Treat wrist fracture	Surgery		9.77	7.82	7.82		
25690		Treat wrist dislocation	Surgery		5.49	5.52	5.52		
25695		Treat wrist dislocation	Surgery		8.33	7.11	7.11		
25800		Fusion of wrist joint	Surgery		9.75	9.12	9.12		
25805		Fusion/graft of wrist joint	Surgery		11.26	10.28	10.28		
25810		Fusion/graft of wrist joint	Surgery		10.55	9.93	9.93		
25820		Fusion of hand bones	Surgery		7.44	7.87	7.87		
25825		Fuse hand bones with graft	Surgery		9.26	9.26	9.26		
25830		Fusion, radioulnar int/ulna	Surgery		10.04	14.45	14.45		
25900		Amputation of forearm	Surgery		9.00	12.60	12.60		
25905		Amputation of forearm	Surgery		9.11	12.33	12.33		
25907		Amputation follow-up surgery	Surgery		7.79	11.79	11.79		
25909		Amputation follow-up surgery	Surgery		8.95	12.31	12.31		
25915		Amputation of forearm	Surgery		17.05	18.93	18.93		
25920		Amputate hand at wrist	Surgery		8.67	7.87	7.87		
25922		Amputate hand at wrist	Surgery		7.41	7.07	7.07		
25924		Amputation follow-up surgery	Surgery		8.45	8.11	8.11		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/OFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 17 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
25927		Amputation of hand	Surgery		8.79	11.71	11.71	8.21	
25929		Amputation follow-up surgery	Surgery		7.58	5.89	5.89		
25931		Amputation follow-up surgery	Surgery		7.80	11.49	11.49		
25999		Forearm or wrist surgery	Surgery						
26010		Drainage of finger abscess	Surgery		1.54	1.63	5.58		
26011		Drainage of finger abscess	Surgery		2.19	2.33	8.84		
26020		Drain hand tendon sheath	Surgery		4.66	5.37	5.37		
26025		Drainage of palm bursa	Surgery		4.81	5.13	5.13		
26030		Drainage of palm bursae(s)	Surgery		5.92	5.74	5.74		
26034		Treat hand bone lesion	Surgery		6.22	6.37	6.37		
26035		Decompress fingers/hand	Surgery		9.50	7.89	7.89		
26037		Decompress fingers/hand	Surgery		7.24	6.34	6.34		
26040		Release palm contracture	Surgery		3.33	4.06	4.06		
26045		Release palm contracture	Surgery		5.55	5.66	5.66		
26055		Incise finger tendon sheath	Surgery		2.69	3.95	14.39		
26060		Incision of finger tendon	Surgery		2.81	3.52	3.52		
26070		Explore/treat hand joint	Surgery		3.68	3.37	3.37		
26075		Explore/treat finger joint	Surgery		3.78	3.79	3.79		
26080		Explore/treat finger joint	Surgery		4.23	4.86	4.86		
26100		Biopsy hand joint lining	Surgery		3.66	4.14	4.14		
26105		Biopsy finger joint lining	Surgery		3.70	4.24	4.24		
26110		Biopsy finger joint lining	Surgery		3.52	4.05	4.05		
26115		Remove hand lesion subcut	Surgery		3.85	4.78	13.13		
26116		Remove hand lesion, deep	Surgery		5.52	6.02	6.02		
26117		Remove tumor, hand/finger	Surgery		8.54	7.08	7.08		
26121		Release palm contracture	Surgery		7.53	6.98	6.98		
26123		Release palm contracture	Surgery		9.28	8.88	8.88		
26125		Release palm contracture	Surgery		4.60	2.45	2.45		
26130		Remove wrist joint lining	Surgery		5.41	5.36	5.36		
26135		Revise finger joint, each	Surgery		6.95	6.48	6.48		
26140		Revise finger joint, each	Surgery		6.16	6.06	6.06		
26145		Tendon excision, palm/finger	Surgery		6.31	6.07	6.07		
26160		Remove tendon sheath lesion	Surgery		3.15	4.13	12.41		
26170		Removal of palm tendon, each	Surgery		4.76	4.95	4.95		
26180		Removal of finger tendon	Surgery		5.17	5.43	5.43		
26185		Remove finger bone	Surgery		5.24	6.05	6.05		
26200		Remove hand bone lesion	Surgery		5.90	5.37	5.37		
26205		Remove/graft bone lesion	Surgery		7.69	6.91	6.91		
26210		Removal of finger lesion	Surgery		5.14	5.44	5.44		
26215		Remove/graft finger lesion	Surgery		7.09	6.33	6.33		
26230		Partial removal of hand bone	Surgery		6.32	5.93	5.93		
26235		Partial removal, finger bone	Surgery		6.18	5.83	5.83		
26236		Partial removal, finger bone	Surgery		5.31	5.34	5.34		
26250		Extensive hand surgery	Surgery		7.54	6.45	6.45		
26255		Extensive hand surgery	Surgery		12.41	9.40	9.40		
26260		Extensive finger surgery	Surgery		7.02	6.20	6.20		
26261		Extensive finger surgery	Surgery		9.08	6.19	6.19		
26262		Partial removal of finger	Surgery		5.66	5.35	5.35		
26320		Removal of implant from hand	Surgery		3.97	4.32	4.32		
26340		Manipulate finger w/ anesth	Surgery		2.50	4.89	4.89		
26350		Repair finger/hand tendon	Surgery		5.98	14.65	14.65		
26352		Repair/graft hand tendon	Surgery		7.67	15.40	15.40		
26356		Repair finger/hand tendon	Surgery		8.06	18.42	18.42		
26357		Repair finger/hand tendon	Surgery		8.57	15.68	15.68		
26358		Repair/graft hand tendon	Surgery		9.13	16.69	16.69		
26370		Repair finger/hand tendon	Surgery		7.10	15.15	15.15		
26372		Repair/graft hand tendon	Surgery		8.75	16.58	16.58		
26373		Repair finger/hand tendon	Surgery		8.15	16.09	16.09		
26390		Revise hand/finger tendon	Surgery		9.18	13.32	13.32		
26392		Repair/graft hand tendon	Surgery		10.24	16.77	16.77		
26410		Repair hand tendon	Surgery		4.62	11.97	11.97		
26412		Repair/graft hand tendon	Surgery		6.30	13.31	13.31		
26415		Excision, hand/finger tendon	Surgery		8.33	11.81	11.81		
26416		Graft hand or finger tendon	Surgery		9.36	14.63	14.63		
26418		Repair finger tendon	Surgery		4.24	12.36	12.36		
26420		Repair/graft finger tendon	Surgery		6.76	13.67	13.67		
26426		Repair finger/hand tendon	Surgery		6.14	13.20	13.20		
26428		Repair/graft finger tendon	Surgery		7.20	13.90	13.90		
26432		Repair finger tendon	Surgery		4.01	10.29	10.29		
26433		Repair finger tendon	Surgery		4.55	10.82	10.82		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 18 of 119

GPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
26434		Repair/graft finger tendon	Surgery		6.08	11.57	11.57		
26437		Realignment of tendons	Surgery		5.81	11.60	11.60		
26440		Release palm/finger tendon	Surgery		5.01	13.47	13.47		
26442		Release palm & finger tendon	Surgery		8.15	15.99	15.99		
26445		Release hand/finger tendon	Surgery		4.30	13.18	13.18		
26449		Release forearm/hand tendon	Surgery		6.99	15.82	15.82		
26450		Incision of palm tendon	Surgery		3.66	7.35	7.35		
26455		Incision of finger tendon	Surgery		3.63	7.30	7.30		
26460		Incise hand/finger tendon	Surgery		3.45	7.16	7.16		
26471		Fusion of finger tendons	Surgery		5.72	11.27	11.27		
26474		Fusion of finger tendons	Surgery		5.31	11.42	11.42		
26476		Tendon lengthening	Surgery		5.17	10.96	10.96		
26477		Tendon shortening	Surgery		5.14	11.09	11.09		
26478		Lengthening of hand tendon	Surgery		5.79	11.87	11.87		
26479		Shortening of hand tendon	Surgery		5.73	11.59	11.59		
26480		Transplant hand tendon	Surgery		6.68	15.08	15.08		
26483		Transplant/graft hand tendon	Surgery		8.28	15.54	15.54		
26485		Transplant palm tendon	Surgery		7.69	15.40	15.40		
26489		Transplant/graft palm tendon	Surgery		9.54	12.09	12.09		
26490		Revise thumb tendon	Surgery		8.40	12.86	12.86		
26492		Tendon transfer with graft	Surgery		9.61	13.64	13.64		
26494		Hand tendon/muscle transfer	Surgery		8.46	13.01	13.01		
26496		Revise thumb tendon	Surgery		9.58	13.27	13.27		
26497		Finger tendon transfer	Surgery		9.56	13.61	13.61		
26498		Finger tendon transfer	Surgery		13.98	16.21	16.21		
26499		Revision of finger	Surgery		8.97	13.08	13.08		
26500		Hand tendon reconstruction	Surgery		5.95	11.47	11.47		
26502		Hand tendon reconstruction	Surgery		7.13	12.05	12.05		
26504		Hand tendon reconstruction	Surgery		7.46	12.62	12.62		
26508		Release thumb contracture	Surgery		6.00	11.71	11.71		
26510		Thumb tendon transfer	Surgery		5.42	11.37	11.37		
26516		Fusion of knuckle joint	Surgery		7.14	12.27	12.27		
26517		Fusion of knuckle joints	Surgery		8.82	13.54	13.54		
26518		Fusion of knuckle joints	Surgery		9.01	13.43	13.43		
26520		Release knuckle contracture	Surgery		5.29	13.93	13.93		
26525		Release finger contracture	Surgery		5.32	14.01	14.01		
26530		Revise knuckle joint	Surgery		6.68	6.16	6.16		
26531		Revise knuckle with implant	Surgery		7.90	7.14	7.14		
26535		Revise finger joint	Surgery		5.23	3.75	3.75		
26536		Revise/implant finger joint	Surgery		6.36	9.68	9.68		
26540		Repair hand joint	Surgery		6.42	11.90	11.90		
26541		Repair hand joint with graft	Surgery		8.61	13.43	13.43		
26542		Repair hand joint with graft	Surgery		6.77	12.06	12.06		
26545		Reconstruct finger joint	Surgery		6.91	12.17	12.17		
26546		Repair nonunion hand	Surgery		8.91	15.07	15.07		
26548		Reconstruct finger joint	Surgery		8.02	12.89	12.89		
26550		Construct thumb replacement	Surgery		21.21	17.63	17.63		
26551		Great toe-hand transfer	Surgery		46.51	32.53	32.53		
26553		Single transfer, toe-hand	Surgery		46.20	22.75	22.75		
26554		Double transfer, toe-hand	Surgery		54.87	37.64	37.64		
26555		Positional change of finger	Surgery		16.61	18.23	18.23		
26556		Toe joint transfer	Surgery		47.19	33.42	33.42		
26560		Repair of web finger	Surgery		5.37	9.83	9.83		
26561		Repair of web finger	Surgery		10.90	12.38	12.38		
26562		Repair of web finger	Surgery		14.98	17.19	17.19		
26565		Correct metacarpal flaw	Surgery		6.73	12.04	12.04		
26567		Correct finger deformity	Surgery		6.81	11.98	11.98		
26568		Lengthen metacarpal/finger	Surgery		9.07	15.47	15.47		
26580		Repair hand deformity	Surgery		18.15	13.68	13.68		
26587		Reconstruct extra finger	Surgery		14.03	9.24	9.24		
26590		Repair finger deformity	Surgery		17.93	13.98	13.98		
26591		Repair muscles of hand	Surgery		3.25	9.65	9.65		
26593		Release muscles of hand	Surgery		5.30	11.16	11.16		
26596		Excision constricting tissue	Surgery		8.94	8.85	8.85		
26600		Treat metacarpal fracture	Surgery		1.96	2.66	3.62		
26605		Treat metacarpal fracture	Surgery		2.85	3.66	4.57		
26607		Treat metacarpal fracture	Surgery		5.35	6.29	6.29		
26608		Treat metacarpal fracture	Surgery		5.35	6.27	6.27		
26615		Treat metacarpal fracture	Surgery		5.32	5.32	5.32		
26641		Treat thumb dislocation	Surgery		3.93	3.54	4.58		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 19 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
26645		Treat thumb fracture	Surgery		4.40	4.20	5.18		
26650		Treat thumb fracture	Surgery		5.71	6.71	6.71		
26655		Treat thumb fracture	Surgery		7.59	6.63	6.63		
26670		Treat hand dislocation	Surgery		3.68	2.95	4.27		
26675		Treat hand dislocation	Surgery		4.63	4.48	5.49		
26676		Pin hand dislocation	Surgery		5.51	6.71	6.71		
26685		Treat hand dislocation	Surgery		6.97	6.16	6.16		
26686		Treat hand dislocation	Surgery		7.93	6.92	6.92		
26700		Treat knuckle dislocation	Surgery		3.68	2.87	3.77		
26705		Treat knuckle dislocation	Surgery		4.18	4.31	5.35		
26706		Pin knuckle dislocation	Surgery		5.11	5.10	5.10		
26715		Treat knuckle dislocation	Surgery		5.73	5.53	5.53		
26720		Treat finger fracture, each	Surgery		1.66	2.06	2.79		
26725		Treat finger fracture, each	Surgery		3.33	3.51	4.78		
26727		Treat finger fracture, each	Surgery		5.22	6.25	6.25		
26735		Treat finger fracture, each	Surgery		5.97	5.57	5.57		
26740		Treat finger fracture, each	Surgery		1.94	2.71	3.14		
26742		Treat finger fracture, each	Surgery		3.84	3.09	5.00		
26746		Treat finger fracture, each	Surgery		5.80	5.58	5.58		
26750		Treat finger fracture, each	Surgery		1.70	2.02	2.49		
26755		Treat finger fracture, each	Surgery		3.10	3.01	4.43		
26756		Pin finger fracture, each	Surgery		4.38	5.74	5.74		
26765		Treat finger fracture, each	Surgery		4.16	4.40	4.40		
26770		Treat finger dislocation	Surgery		3.02	2.42	3.44		
26775		Treat finger dislocation	Surgery		3.70	3.82	5.21		
26776		Pin finger dislocation	Surgery		4.79	6.02	6.02		
26785		Treat finger dislocation	Surgery		4.20	4.54	4.54		
26820		Thumb fusion with graft	Surgery		8.25	13.29	13.29		
26841		Fusion of thumb	Surgery		7.12	13.27	13.27		
26842		Thumb fusion with graft	Surgery		8.23	13.41	13.41		
26843		Fusion of hand joint	Surgery		7.60	12.39	12.39		
26844		Fusion/graft of hand joint	Surgery		8.72	13.40	13.40		
26850		Fusion of knuckle	Surgery		6.96	12.24	12.24		
26852		Fusion of knuckle with graft	Surgery		8.45	12.93	12.93		
26860		Fusion of finger joint	Surgery		4.68	11.22	11.22		
26861		Fusion of finger int, add-on	Surgery		1.74	0.93	0.93		
26862		Fusion/graft of finger joint	Surgery		7.36	12.38	12.38		
26863		Fuse/graft added joint	Surgery		3.89	2.12	2.12		
26910		Amputate metacarpal bone	Surgery		7.59	11.25	11.25		
26951		Amputation of finger/thumb	Surgery		4.58	10.18	10.18		
26952		Amputation of finger/thumb	Surgery		6.30	11.69	11.69		
26989		Hand/finger surgery	Surgery					7.89	
26990		Drainage of pelvis lesion	Surgery		7.47	7.23	7.23		
26991		Drainage of pelvis bursa	Surgery		6.67	5.45	11.19		
26992		Drainage of bone lesion	Surgery		13.00	10.41	10.41		
27000		Incision of hip tendon	Surgery		5.61	5.30	5.30		
27001		Incision of hip tendon	Surgery		6.93	6.11	6.11		
27003		Incision of hip tendon	Surgery		7.33	6.50	6.50		
27005		Incision of hip tendon	Surgery		9.65	7.84	7.84		
27006		Incision of hip tendons	Surgery		9.67	8.00	8.00		
27025		Incision of hip/ thigh fascia	Surgery		11.14	8.57	8.57		
27030		Drainage of hip joint	Surgery		12.99	9.67	9.67		
27033		Exploration of hip joint	Surgery		13.37	9.95	9.95		
27035		Denerivation of hip joint	Surgery		16.66	11.26	11.26		
27036		Excision of hip joint/muscle	Surgery		12.86	10.03	10.03		
27040		Biopsy of soft tissues	Surgery		2.87	2.02	5.25		
27041		Biopsy of soft tissues	Surgery		9.88	6.66	6.66		
27047		Remove hip/pelvis lesion	Surgery		7.44	4.78	7.13		
27048		Remove hip/pelvis lesion	Surgery		6.24	4.81	4.81		
27049		Remove tumor, hip/pelvis	Surgery		13.64	8.42	8.42		
27050		Biopsy of sacroiliac joint	Surgery		4.35	4.43	4.43		
27052		Biopsy of hip joint	Surgery		6.22	5.90	5.90		
27054		Removal of hip joint lining	Surgery		8.53	7.36	7.36		
27060		Removal of ischial bursa	Surgery		5.42	4.38	4.38		
27062		Remove femur lesion/bursa	Surgery		5.36	5.21	5.21		
27065		Removal of hip bone lesion	Surgery		5.89	5.46	5.46		
27066		Removal of hip bone lesion	Surgery		10.31	8.46	8.46		
27067		Remove/graft hip bone lesion	Surgery		13.81	10.69	10.69		
27070		Partial removal of hip bone	Surgery		10.70	9.16	9.16		
27071		Partial removal of hip bone	Surgery		11.44	10.15	10.15		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 20 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
27075		Extensive hip surgery	Surgery		34.95	19.26	19.26		
27076		Extensive hip surgery	Surgery		22.09	14.55	14.55		
27077		Extensive hip surgery	Surgery		39.94	22.73	22.73		
27078		Extensive hip surgery	Surgery		13.42	9.97	9.97		
27079		Extensive hip surgery	Surgery		13.73	9.57	9.57		
27080		Removal of tail bone	Surgery		6.38	4.84	4.84		
27086		Remove hip foreign body	Surgery		1.87	1.83	4.56		
27087		Remove hip foreign body	Surgery		8.53	6.68	6.68		
27090		Removal of hip prosthesis	Surgery		11.13	8.81	8.81		
27091		Removal of hip prosthesis	Surgery		22.11	14.03	14.03		
27093		Injection for hip x-ray	Surgery		1.30	0.48	4.47		
27095		Injection for hip x-ray	Surgery		1.50	0.52	5.74		
27096		Inject sacroiliac joint	Surgery		1.40	0.33	4.26		
27097		Revision of hip tendon	Surgery		8.79	6.43	6.43		
27098		Transfer tendon to pelvis	Surgery		8.82	7.04	7.04		
27100		Transfer of abdominal muscle	Surgery		11.06	8.69	8.69		
27105		Transfer of spinal muscle	Surgery		11.75	9.19	9.19		
27110		Transfer of iliopectus muscle	Surgery		13.24	9.14	9.14		
27111		Transfer of iliopectus muscle	Surgery		12.13	9.16	9.16		
27120		Reconstruction of hip socket	Surgery		17.98	11.87	11.87		
27122		Reconstruction of hip socket	Surgery		14.96	11.07	11.07		
27125		Partial hip replacement	Surgery		14.67	10.65	10.65		
27130		Total hip arthroplasty	Surgery		20.09	13.34	13.34		
27132		Total hip arthroplasty	Surgery		23.27	15.68	15.68		
27134		Revise hip joint replacement	Surgery		28.48	17.84	17.84		
27137		Revise hip joint replacement	Surgery		21.14	13.97	13.97		
27138		Revise hip joint replacement	Surgery		22.14	14.43	14.43		
27140		Transplant femur ridge	Surgery		12.22	9.44	9.44		
27146		Incision of hip bone	Surgery		17.40	12.17	12.17		
27147		Revision of hip bone	Surgery		20.55	13.29	13.29		
27151		Incision of hip bones	Surgery		22.48	7.97	7.97		
27156		Revision of hip bones	Surgery		24.59	16.11	16.11		
27158		Revision of pelvis	Surgery		19.71	11.00	11.00		
27161		Incision of neck of femur	Surgery		16.68	12.14	12.14		
27165		Incision/fixation of femur	Surgery		17.88	12.95	12.95		
27170		Repair/graft femur head/neck	Surgery		16.06	11.33	11.33		
27175		Treat slipped epiphysis	Surgery		8.45	6.69	6.69		
27176		Treat slipped epiphysis	Surgery		12.03	9.04	9.04		
27177		Treat slipped epiphysis	Surgery		15.06	10.92	10.92		
27178		Treat slipped epiphysis	Surgery		11.97	8.44	8.44		
27179		Revise head/neck of femur	Surgery		12.96	10.02	10.02		
27181		Treat slipped epiphysis	Surgery		14.66	10.23	10.23		
27185		Revision of femur epiphysis	Surgery		9.17	7.54	7.54		
27187		Reinforce hip bones	Surgery		13.52	10.35	10.35		
27193		Treat pelvic ring fracture	Surgery		5.55	5.10	5.10		
27194		Treat pelvic ring fracture	Surgery		9.64	7.67	7.67		
27200		Treat tail bone fracture	Surgery		1.84	2.16	2.23		
27202		Treat tail bone fracture	Surgery		7.03	16.91	16.91		
27215		Treat pelvic fracture(s)	Surgery		10.03	7.10	7.10		
27216		Treat pelvic ring fracture	Surgery		15.17	9.62	9.62		
27217		Treat pelvic ring fracture	Surgery		14.09	10.17	10.17		
27218		Treat pelvic ring fracture	Surgery		20.12	11.43	11.43		
27220		Treat hip socket fracture	Surgery		6.17	5.65	5.74		
27222		Treat hip socket fracture	Surgery		12.68	10.00	10.00		
27226		Treat hip wall fracture	Surgery		14.89	7.83	7.83		
27227		Treat hip fracture(s)	Surgery		23.41	15.44	15.44		
27228		Treat hip fracture(s)	Surgery		27.12	17.67	17.67		
27230		Treat thigh fracture	Surgery		5.49	5.11	5.53		
27232		Treat thigh fracture	Surgery		10.66	7.19	7.19		
27235		Treat thigh fracture	Surgery		12.14	9.48	9.48		
27236		Treat thigh fracture	Surgery		15.58	11.08	11.08		
27238		Treat thigh fracture	Surgery		5.51	5.15	5.15		
27240		Treat thigh fracture	Surgery		12.48	9.50	9.50		
27244		Treat thigh fracture	Surgery		15.92	11.33	11.33		
27245		Treat thigh fracture	Surgery		20.28	13.78	13.78		
27246		Treat thigh fracture	Surgery		4.70	4.43	4.47		
27248		Treat thigh fracture	Surgery		10.43	8.23	8.23		
27250		Treat hip dislocation	Surgery		6.94	4.63	4.63		
27252		Treat hip dislocation	Surgery		10.37	7.45	7.45		
27253		Treat hip dislocation	Surgery		12.90	9.81	9.81		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 21 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
27254		Treat hip dislocation	Surgery		18.23	12.05	12.05		
27256		Treat hip dislocation	Surgery		4.11	2.09	3.53		
27257		Treat hip dislocation	Surgery		5.21	2.82	2.82		
27258		Treat hip dislocation	Surgery		15.41	10.90	10.90		
27259		Treat hip dislocation	Surgery		21.52	14.16	14.16		
27265		Treat hip dislocation	Surgery		5.04	4.80	4.80		
27266		Treat hip dislocation	Surgery		7.48	6.36	6.36		
27275		Manipulation of hip joint	Surgery		2.27	2.11	2.11		
27280		Fusion of sacroiliac joint	Surgery		13.37	10.29	10.29		
27282		Fusion of pubic bones	Surgery		11.32	8.02	8.02		
27284		Fusion of hip joint	Surgery		23.41	14.80	14.80		
27286		Fusion of hip joint	Surgery		23.41	15.84	15.84		
27290		Amputation of leg at hip	Surgery		23.25	14.10	14.10		
27295		Amputation of leg at hip	Surgery		18.62	11.34	11.34		
27299		Pelvis/hip joint surgery	Surgery					33.30	
27301		Drain thigh/knee lesion	Surgery		6.48	5.15	10.10		
27303		Drainage of bone lesion	Surgery		8.27	7.00	7.00		
27305		Incise thigh tendon & fascia	Surgery		5.91	5.20	5.20		
27306		Incision of thigh tendon	Surgery		4.61	4.73	4.73		
27307		Incision of thigh tendons	Surgery		5.79	5.40	5.40		
27310		Exploration of knee joint	Surgery		9.26	7.60	7.60		
27315		Partial removal, thigh nerve	Surgery		6.96	4.96	4.96		
27320		Partial removal, thigh nerve	Surgery		6.29	5.25	5.25		
27323		Biopsy, thigh soft tissues	Surgery		2.28	1.89	3.52		
27324		Biopsy, thigh soft tissues	Surgery		4.89	4.19	4.19		
27327		Removal of thigh lesion	Surgery		4.46	3.73	6.01		
27328		Removal of thigh lesion	Surgery		5.66	4.38	4.38		
27329		Remove tumor, thigh/knee	Surgery		14.12	9.05	9.05		
27330		Biopsy, knee joint lining	Surgery		4.96	4.58	4.58		
27331		Explore/treat knee joint	Surgery		5.87	5.54	5.54		
27332		Removal of knee cartilage	Surgery		8.26	7.14	7.14		
27333		Removal of knee cartilage	Surgery		7.29	6.69	6.69		
27334		Remove knee joint lining	Surgery		8.69	7.43	7.43		
27335		Remove knee joint lining	Surgery		9.99	8.24	8.24		
27340		Removal of kneecap bursa	Surgery		4.17	4.57	4.57		
27345		Removal of knee cyst	Surgery		5.91	5.64	5.64		
27347		Remove knee cyst	Surgery		5.77	5.44	5.44		
27350		Removal of kneecap	Surgery		8.16	7.26	7.26		
27355		Remove femur lesion	Surgery		7.64	6.79	6.79		
27356		Remove femur lesion/graft	Surgery		9.47	7.87	7.87		
27357		Remove femur lesion/graft	Surgery		10.51	8.73	8.73		
27358		Remove femur lesion/fixation	Surgery		4.73	2.53	2.53		
27360		Partial removal, leg bone(s)	Surgery		10.48	9.58	9.58		
27365		Extensive leg surgery	Surgery		16.25	11.71	11.71		
27370		Injection for knee x-ray	Surgery		0.96	0.32	3.73		
27372		Removal of foreign body	Surgery		5.06	4.70	10.08		
27380		Repair of kneecap tendon	Surgery		7.15	7.30	7.30		
27381		Repair/graft kneecap tendon	Surgery		10.32	9.12	9.12		
27385		Repair of thigh muscle	Surgery		7.75	7.65	7.65		
27386		Repair/graft of thigh muscle	Surgery		10.54	9.54	9.54		
27390		Incision of thigh tendon	Surgery		5.32	5.12	5.12		
27391		Incision of thigh tendons	Surgery		7.19	6.58	6.58		
27392		Incision of thigh tendons	Surgery		9.19	7.61	7.61		
27393		Lengthening of thigh tendon	Surgery		6.38	5.85	5.85		
27394		Lengthening of thigh tendons	Surgery		8.49	7.24	7.24		
27395		Lengthening of thigh tendons	Surgery		11.71	9.35	9.35		
27396		Transplant of thigh tendon	Surgery		7.85	7.02	7.02		
27397		Transplants of thigh tendons	Surgery		11.26	9.07	9.07		
27400		Revise thigh muscles/tendons	Surgery		9.01	7.27	7.27		
27403		Repair of knee cartilage	Surgery		8.32	7.20	7.20		
27405		Repair of knee ligament	Surgery		8.64	7.51	7.51		
27407		Repair of knee ligament	Surgery		10.26	8.34	8.34		
27409		Repair of knee ligaments	Surgery		12.88	9.98	9.98		
27412		Autochondrocyte implant knee	Surgery		23.23	14.84	14.84		
27415		Osteochondral knee allograft	Surgery		18.49	12.59	12.59		
27418		Repair degenerated kneecap	Surgery		10.83	8.93	8.93		
27420		Revision of unstable kneecap	Surgery		9.82	8.13	8.13		
27422		Revision of unstable kneecap	Surgery		9.77	8.14	8.14		
27424		Revision/removal of kneecap	Surgery		9.80	8.11	8.11		
27425		Lat retinacular release open	Surgery		5.21	5.54	5.54		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 22 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
27427		Reconstruction, knee	Surgery		9.35	7.82	7.82		
27428		Reconstruction, knee	Surgery		13.98	11.27	11.27		
27429		Reconstruction, knee	Surgery		15.50	12.45	12.45		
27430		Revision of thigh muscles	Surgery		9.66	8.02	8.02		
27435		Incision of knee joint	Surgery		9.48	8.50	8.50		
27437		Revise kneecap	Surgery		8.45	7.26	7.26		
27438		Revise kneecap with implant	Surgery		11.21	8.56	8.56		
27440		Revision of knee joint	Surgery		10.41	6.01	6.01		
27441		Revision of knee joint	Surgery		10.80	6.73	6.73		
27442		Revision of knee joint	Surgery		11.87	8.94	8.94		
27443		Revision of knee joint	Surgery		10.91	8.75	8.75		
27445		Revision of knee joint	Surgery		17.65	12.39	12.39		
27446		Revision of knee joint	Surgery		15.82	11.30	11.30		
27447		Total knee arthroplasty	Surgery		21.45	14.64	14.64		
27448		Incision of thigh	Surgery		11.04	8.62	8.62		
27450		Incision of thigh	Surgery		13.96	10.61	10.61		
27454		Realignment of thigh bone	Surgery		17.53	12.54	12.54		
27455		Realignment of knee	Surgery		12.80	9.91	9.91		
27457		Realignment of knee	Surgery		13.43	9.95	9.95		
27465		Shortening of thigh bone	Surgery		13.85	10.25	10.25		
27466		Lengthening of thigh bone	Surgery		16.31	11.86	11.86		
27468		Shorten/lengthen thighs	Surgery		18.94	12.39	12.39		
27470		Repair of thigh	Surgery		16.05	11.82	11.82		
27472		Repair/graft of thigh	Surgery		17.69	12.72	12.72		
27475		Surgery to stop leg growth	Surgery		8.63	7.23	7.23		
27477		Surgery to stop leg growth	Surgery		9.84	7.75	7.75		
27479		Surgery to stop leg growth	Surgery		12.78	9.67	9.67		
27485		Surgery to stop leg growth	Surgery		8.83	7.42	7.42		
27486		Revise/replace knee joint	Surgery		19.24	13.53	13.53		
27487		Revise/replace knee joint	Surgery		25.23	16.60	16.60		
27488		Removal of knee prosthesis	Surgery		15.72	11.73	11.73		
27495		Reinforce thigh	Surgery		15.53	11.44	11.44		
27496		Decompression of thigh/knee	Surgery		6.10	5.62	5.62		
27497		Decompression of thigh/knee	Surgery		7.16	5.45	5.45		
27498		Decompression of thigh/knee	Surgery		7.98	5.97	5.97		
27499		Decompression of thigh/knee	Surgery		8.99	6.84	6.84		
27500		Treatment of thigh fracture	Surgery		5.91	5.00	6.14		
27501		Treatment of thigh fracture	Surgery		5.91	5.40	5.81		
27502		Treatment of thigh fracture	Surgery		10.56	8.13	8.13		
27503		Treatment of thigh fracture	Surgery		10.56	8.31	8.31		
27506		Treatment of thigh fracture	Surgery		17.42	12.82	12.82		
27507		Treatment of thigh fracture	Surgery		13.97	9.87	9.87		
27508		Treatment of thigh fracture	Surgery		5.82	5.50	6.48		
27509		Treatment of thigh fracture	Surgery		7.70	7.98	7.98		
27510		Treatment of thigh fracture	Surgery		9.12	7.35	7.35		
27511		Treatment of thigh fracture	Surgery		13.62	11.23	11.23		
27513		Treatment of thigh fracture	Surgery		17.89	13.92	13.92		
27514		Treatment of thigh fracture	Surgery		17.27	13.39	13.39		
27516		Treat thigh fx growth plate	Surgery		5.36	5.53	6.37		
27517		Treat thigh fx growth plate	Surgery		8.77	7.47	7.47		
27519		Treat thigh fx growth plate	Surgery		15.00	11.62	11.62		
27520		Treat kneecap fracture	Surgery		2.86	3.45	4.55		
27524		Treat kneecap fracture	Surgery		9.99	8.25	8.25		
27530		Treat knee fracture	Surgery		3.77	4.43	5.33		
27532		Treat knee fracture	Surgery		7.29	6.47	7.38		
27535		Treat knee fracture	Surgery		11.48	10.14	10.14		
27536		Treat knee fracture	Surgery		15.63	11.64	11.64		
27538		Treat knee fracture(s)	Surgery		4.86	5.21	6.15		
27540		Treat knee fracture	Surgery		13.08	9.54	9.54		
27550		Treat knee dislocation	Surgery		5.75	4.94	6.03		
27552		Treat knee dislocation	Surgery		7.89	6.97	6.97		
27556		Treat knee dislocation	Surgery		14.39	11.68	11.68		
27557		Treat knee dislocation	Surgery		16.74	13.16	13.16		
27558		Treat knee dislocation	Surgery		17.69	13.08	13.08		
27560		Treat kneecap dislocation	Surgery		3.81	3.19	4.85		
27562		Treat kneecap dislocation	Surgery		5.78	4.78	4.78		
27566		Treat kneecap dislocation	Surgery		12.21	9.35	9.35		
27570		Fixation of knee joint	Surgery		1.74	1.78	1.78		
27580		Fusion of knee	Surgery		19.34	14.84	14.84		
27590		Amputate leg at thigh	Surgery		12.01	6.69	6.69		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE G -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPSC CODE

PAGE 23 of 119

CPT/ HCPSC Code	Modifier	CPT/HCPSC Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
27591		Amputate leg at thigh	Surgery		12.66	8.67	8.67		
27592		Amputate leg at thigh	Surgery		10.00	6.19	6.19		
27594		Amputation follow-up surgery	Surgery		6.91	5.18	5.18		
27596		Amputation follow-up surgery	Surgery		10.58	6.63	6.63		
27598		Amputate lower leg at knee	Surgery		10.51	7.04	7.04		
27599		Leg surgery procedure	Surgery					.19	68
27600		Decompression of lower leg	Surgery		5.64	4.54	4.54		
27601		Decompression of lower leg	Surgery		5.63	4.86	4.86		
27602		Decompression of lower leg	Surgery		7.34	5.14	5.14		
27603		Drain lower leg lesion	Surgery		4.93	4.17	4.17		
27604		Drain lower leg bursa	Surgery		4.46	3.97	3.97		
27605		Incision of achilles tendon	Surgery		2.87	2.33	2.33		
27606		Incision of achilles tendon	Surgery		4.13	3.37	3.37		
27607		Treat lower leg bone lesion	Surgery		7.96	6.19	6.19		
27610		Explore/treat ankle joint	Surgery		8.33	7.02	7.02		
27612		Exploration of ankle joint	Surgery		7.32	6.11	6.11		
27613		Biopsy lower leg soft tissue	Surgery		2.17	1.81	1.81		
27614		Biopsy lower leg soft tissue	Surgery		5.65	4.45	4.45		
27615		Remove tumor, lower leg	Surgery		12.54	9.42	9.42		
27618		Remove lower leg lesion	Surgery		5.08	4.00	4.00		
27619		Remove lower leg lesion	Surgery		8.39	5.97	5.97		
27620		Explore/treat ankle joint	Surgery		5.97	5.48	5.48		
27625		Remove ankle joint lining	Surgery		8.29	6.48	6.48		
27626		Remove ankle joint lining	Surgery		8.90	6.94	6.94		
27630		Removal of tendon lesion	Surgery		4.79	4.39	4.39		
27635		Remove lower leg bone lesion	Surgery		7.77	6.76	6.76		
27637		Remove/graft leg bone lesion	Surgery		9.84	8.31	8.31		
27638		Remove/graft leg bone lesion	Surgery		10.55	8.31	8.31		
27640		Partial removal of tibia	Surgery		11.35	10.34	10.34		
27641		Partial removal of fibula	Surgery		9.23	8.36	8.36		
27645		Extensive lower leg surgery	Surgery		14.15	12.08	12.08		
27646		Extensive lower leg surgery	Surgery		12.64	11.06	11.06		
27647		Extensive ankle/heel surgery	Surgery		12.22	7.63	7.63		
27648		Injection for ankle x-ray	Surgery		0.96	0.33	0.33		
27650		Repair achilles tendon	Surgery		9.68	7.53	7.53		
27652		Repair/graft achilles tendon	Surgery		10.31	8.05	8.05		
27654		Repair of achilles tendon	Surgery		10.00	7.16	7.16		
27656		Repair leg fascia defect	Surgery		4.56	3.78	3.78		
27658		Repair of leg tendon, each	Surgery		4.97	4.57	4.57		
27659		Repair of leg tendon, each	Surgery		6.80	5.66	5.66		
27664		Repair of leg tendon, each	Surgery		4.58	4.56	4.56		
27665		Repair of leg tendon, each	Surgery		5.39	4.98	4.98		
27675		Repair lower leg tendons	Surgery		7.17	5.75	5.75		
27676		Repair lower leg tendons	Surgery		8.41	6.77	6.77		
27680		Release of lower leg tendon	Surgery		5.73	5.12	5.12		
27681		Release of lower leg tendons	Surgery		6.81	5.93	5.93		
27685		Revision of lower leg tendon	Surgery		6.49	5.48	5.48		
27686		Revise lower leg tendons	Surgery		7.45	6.51	6.51		
27687		Revision of calf tendon	Surgery		6.23	5.33	5.33		
27690		Revise lower leg tendon	Surgery		8.70	6.37	6.37		
27691		Revise lower leg tendon	Surgery		9.95	7.78	7.78		
27692		Revise additional leg tendon	Surgery		1.87	0.93	0.93		
27695		Repair of ankle ligament	Surgery		6.50	5.89	5.89		
27696		Repair of ankle ligaments	Surgery		8.26	6.45	6.45		
27698		Repair of ankle ligament	Surgery		9.35	6.96	6.96		
27700		Revision of ankle joint	Surgery		9.28	5.70	5.70		
27702		Reconstruct ankle joint	Surgery		13.65	10.49	10.49		
27703		Reconstruction, ankle joint	Surgery		15.85	11.26	11.26		
27704		Removal of ankle implant	Surgery		7.61	5.51	5.51		
27705		Incision of tibia	Surgery		10.36	8.19	8.19		
27707		Incision of fibula	Surgery		4.36	4.95	4.95		
27709		Incision of tibia & fibula	Surgery		9.94	8.15	8.15		
27712		Realignment of lower leg	Surgery		14.23	10.77	10.77		
27715		Revision of lower leg	Surgery		14.37	10.80	10.80		
27720		Repair of tibia	Surgery		11.77	9.43	9.43		
27722		Repair/graft of tibia	Surgery		11.80	9.16	9.16		
27724		Repair/graft of tibia	Surgery		18.17	12.40	12.40		
27725		Repair of lower leg	Surgery		15.57	11.94	11.94		
27727		Repair of lower leg	Surgery		13.99	10.37	10.37		
27730		Repair of tibia epiphysis	Surgery		7.40	6.44	6.44		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 24 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code, Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
27732		Repair of fibula epiphysis	Surgery		5.31	4.94	4.94		
27734		Repair lower leg epiphyses	Surgery		8.47	6.30	6.30		
27740		Repair of leg epiphyses	Surgery		9.29	8.01	8.01		
27742		Repair of leg epiphyses	Surgery		10.28	5.58	5.58		
27745		Reinforce tibia	Surgery		10.05	8.19	8.19		
27750		Treatment of tibia fracture	Surgery		3.19	3.86	4.77		
27752		Treatment of tibia fracture	Surgery		5.83	5.69	6.67		
27756		Treatment of tibia fracture	Surgery		6.77	6.48	6.48		
27758		Treatment of tibia fracture	Surgery		11.65	9.21	9.21		
27759		Treatment of tibia fracture	Surgery		13.74	10.34	10.34		
27760		Treatment of ankle fracture	Surgery		3.01	3.60	4.69		
27762		Treatment of ankle fracture	Surgery		5.24	5.29	6.35		
27766		Treatment of ankle fracture	Surgery		8.35	7.24	7.24		
27780		Treatment of fibula fracture	Surgery		2.65	3.22	4.19		
27781		Treatment of fibula fracture	Surgery		4.39	4.65	5.51		
27784		Treatment of fibula fracture	Surgery		7.10	6.49	6.49		
27786		Treatment of ankle fracture	Surgery		2.84	3.34	4.47		
27788		Treatment of ankle fracture	Surgery		4.44	4.66	5.66		
27792		Treatment of ankle fracture	Surgery		7.65	6.98	6.98		
27808		Treatment of ankle fracture	Surgery		2.83	3.71	4.81		
27810		Treatment of ankle fracture	Surgery		5.12	5.16	6.26		
27814		Treatment of ankle fracture	Surgery		10.66	8.58	8.58		
27816		Treatment of ankle fracture	Surgery		2.89	3.42	4.39		
27818		Treatment of ankle fracture	Surgery		5.49	5.18	6.39		
27822		Treatment of ankle fracture	Surgery		10.98	10.68	10.68		
27823		Treatment of ankle fracture	Surgery		12.98	11.50	11.50		
27824		Treat lower leg fracture	Surgery		2.89	3.57	4.07		
27825		Treat lower leg fracture	Surgery		6.18	5.40	6.62		
27826		Treat lower leg fracture	Surgery		8.53	8.85	8.85		
27827		Treat lower leg fracture	Surgery		14.04	12.80	12.80		
27828		Treat lower leg fracture	Surgery		16.21	13.97	13.97		
27829		Treat lower leg joint	Surgery		5.48	6.80	6.80		
27830		Treat lower leg dislocation	Surgery		3.78	3.86	4.40		
27831		Treat lower leg dislocation	Surgery		4.55	4.47	4.47		
27832		Treat lower leg dislocation	Surgery		6.48	6.19	6.19		
27840		Treat ankle dislocation	Surgery		4.57	3.77	3.77		
27842		Treat ankle dislocation	Surgery		6.20	5.13	5.13		
27846		Treat ankle dislocation	Surgery		9.78	7.95	7.95		
27848		Treat ankle dislocation	Surgery		11.18	9.74	9.74		
27860		Fixation of ankle joint	Surgery		2.34	1.99	1.99		
27870		Fusion of ankle joint, open	Surgery		13.89	10.55	10.55		
27871		Fusion of tibiofibular joint	Surgery		9.16	7.60	7.60		
27880		Amputation of lower leg	Surgery		11.83	7.15	7.15		
27881		Amputation of lower leg	Surgery		12.32	8.87	8.87		
27882		Amputation of lower leg	Surgery		8.93	6.50	6.50		
27884		Amputation follow-up surgery	Surgery		6.20	5.77	5.77		
27886		Amputation follow-up surgery	Surgery		9.31	6.53	6.53		
27888		Amputation of foot at ankle	Surgery		9.66	7.52	7.52		
27889		Amputation of foot at ankle	Surgery		9.97	6.49	6.49		
27892		Decompression of leg	Surgery		7.38	5.61	5.61		
27893		Decompression of leg	Surgery		7.34	5.48	5.48		
27894		Decompression of leg	Surgery		10.47	7.79	7.79		
27899		Leg/ankle surgery procedure	Surgery					11.65	
28001		Drainage of bursa of foot	Surgery		2.73	1.96	2.99		
28002		Treatment of foot infection	Surgery		4.61	3.78	5.00		
28003		Treatment of foot infection	Surgery		8.40	5.24	6.25		
28005		Treat foot bone lesion	Surgery		8.67	6.06	6.06		
28008		Incision of foot fascia	Surgery		4.44	3.21	4.56		
28010		Incision of toe tendon	Surgery		2.84	2.38	2.38		
28011		Incision of toe tendons	Surgery		4.13	3.31	3.31		
28020		Exploration of foot joint	Surgery		5.00	4.14	6.03		
28022		Exploration of foot joint	Surgery		4.66	3.86	5.21		
28024		Exploration of toe joint	Surgery		4.37	3.93	5.23		
28030		Removal of foot nerve	Surgery		6.14	3.66	3.66		
28035		Decompression of tibia nerve	Surgery		5.08	4.10	5.87		
28043		Excision of foot lesion	Surgery		3.53	3.18	3.82		
28045		Excision of foot lesion	Surgery		4.71	3.61	5.39		
28046		Resection of tumor, foot	Surgery		10.16	6.49	8.79		
28050		Biopsy of foot joint lining	Surgery		4.24	3.60	4.90		
28052		Biopsy of foot joint lining	Surgery		3.93	3.44	4.92		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARSIDFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 25 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology ⁽¹⁾
28054		Biopsy of toe joint lining	Surgery		3.44	3.24	4.73		
28060		Partial removal, foot fascia	Surgery		5.22	3.88	5.49		
28062		Removal of foot fascia	Surgery		6.51	4.02	6.53		
28070		Removal of foot joint lining	Surgery		5.09	3.82	5.23		
28072		Removal of foot joint lining	Surgery		4.57	4.31	5.54		
28080		Removal of foot lesion	Surgery		3.57	3.69	5.12		
28086		Excise foot tendon sheath	Surgery		4.77	4.69	8.00		
28088		Excise foot tendon sheath	Surgery		3.85	3.90	5.77		
28090		Removal of foot lesion	Surgery		4.40	3.46	5.15		
28092		Removal of toe lesions	Surgery		3.63	3.53	5.23		
28100		Removal of ankle/heel lesion	Surgery		5.65	4.70	7.98		
28102		Remove/graft foot lesion	Surgery		7.72	5.96	5.96		
28103		Remove/graft foot lesion	Surgery		6.49	4.62	4.62		
28104		Removal of foot lesion	Surgery		5.11	3.93	5.50		
28106		Remove/graft foot lesion	Surgery		7.15	4.44	4.44		
28107		Remove/graft foot lesion	Surgery		5.55	4.21	6.54		
28108		Removal of toe lesions	Surgery		4.15	3.26	4.60		
28110		Part removal of metatarsal	Surgery		4.07	3.23	5.23		
28111		Part removal of metatarsal	Surgery		5.00	3.66	6.29		
28112		Part removal of metatarsal	Surgery		4.48	3.58	5.82		
28113		Part removal of metatarsal	Surgery		4.78	4.32	6.07		
28114		Removal of metatarsal heads	Surgery		9.78	8.39	11.65		
28116		Revision of foot	Surgery		7.74	5.18	6.81		
28118		Removal of heel bone	Surgery		5.95	4.35	6.26		
28119		Removal of heel spur	Surgery		5.38	3.73	5.44		
28120		Part removal of ankle/heel	Surgery		5.39	4.42	7.30		
28122		Partial removal of foot bone	Surgery		7.28	5.28	6.85		
28124		Partial removal of toe	Surgery		4.80	3.66	5.00		
28126		Partial removal of toe	Surgery		3.51	3.00	4.22		
28130		Removal of ankle bone	Surgery		8.10	6.73	6.73		
28140		Removal of metatarsal	Surgery		6.90	4.77	7.24		
28150		Removal of toe	Surgery		4.08	3.29	4.84		
28153		Partial removal of toe	Surgery		3.65	2.69	4.32		
28160		Partial removal of toe	Surgery		3.73	3.34	4.57		
28171		Extensive foot surgery	Surgery		9.59	5.44	5.44		
28173		Extensive foot surgery	Surgery		8.79	5.21	7.61		
28175		Extensive foot surgery	Surgery		6.04	3.71	5.72		
28190		Removal of foot foreign body	Surgery		1.96	1.48	3.40		
28192		Removal of foot foreign body	Surgery		4.63	3.65	5.49		
28193		Removal of foot foreign body	Surgery		5.72	3.93	5.62		
28200		Repair of foot tendon	Surgery		4.59	3.56	5.10		
28202		Repair/graft of foot tendon	Surgery		6.83	4.50	7.23		
28208		Repair of foot tendon	Surgery		4.36	3.31	4.82		
28210		Repair/graft of foot tendon	Surgery		6.34	4.03	6.23		
28220		Release of foot tendon	Surgery		4.52	3.43	4.68		
28222		Release of foot tendons	Surgery		5.61	4.13	5.25		
28225		Release of foot tendon	Surgery		3.65	2.91	4.29		
28226		Release of foot tendons	Surgery		4.52	3.75	4.80		
28230		Incision of foot tendon(s)	Surgery		4.23	3.68	4.68		
28232		Incision of toe tendon	Surgery		3.38	3.32	4.53		
28234		Incision of foot tendon	Surgery		3.36	3.36	4.68		
28238		Revision of foot tendon	Surgery		7.72	4.94	7.26		
28240		Release of big toe	Surgery		4.35	3.49	4.64		
28250		Revision of foot fascia	Surgery		5.91	4.14	5.64		
28260		Release of midfoot joint	Surgery		7.95	5.00	6.34		
28261		Revision of foot tendon	Surgery		11.71	7.32	8.63		
28262		Revision of foot and ankle	Surgery		15.81	10.94	13.59		
28264		Release of midfoot joint	Surgery		10.33	7.30	7.75		
28270		Release of foot contracture	Surgery		4.75	3.74	4.90		
28272		Release of toe joint, each	Surgery		3.79	2.86	4.19		
28280		Fusion of toes	Surgery		5.18	4.49	6.26		
28285		Repair of hammertoe	Surgery		4.58	3.43	4.87		
28286		Repair of hammertoe	Surgery		4.55	3.26	4.80		
28288		Partial removal of foot bone	Surgery		4.73	4.89	5.95		
28289		Repair hallux rigidus	Surgery		7.03	5.78	8.00		
28290		Correction of bunion	Surgery		5.65	4.73	6.27		
28292		Correction of bunion	Surgery		7.03	5.55	7.48		
28293		Correction of bunion	Surgery		9.14	6.12	10.77		
28294		Correction of bunion	Surgery		8.55	4.72	7.45		
28296		Correction of bunion	Surgery		9.17	5.43	8.17		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 26 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
28297		Correction of bunion	Surgery		9.17	6.27	8.97		
28298		Correction of bunion	Surgery		7.93	5.01	7.23		
28299		Correction of bunion	Surgery		10.56	6.08	8.79		
28300		Incision of heel bone	Surgery		9.53	7.05	7.05		
28302		Incision of ankle bone	Surgery		9.54	6.90	6.90		
28304		Incision of midfoot bones	Surgery		9.15	5.75	7.96		
28305		Incise/graft midfoot bones	Surgery		10.48	6.74	6.74		
28306		Incision of metatarsal	Surgery		5.85	4.18	6.85		
28307		Incision of metatarsal	Surgery		6.32	5.30	11.05		
28308		Incision of metatarsal	Surgery		5.28	3.69	5.76		
28309		Incision of metatarsals	Surgery		12.76	7.97	7.97		
28310		Revision of big toe	Surgery		5.42	3.56	5.76		
28312		Revision of toe	Surgery		4.54	3.64	5.45		
28313		Repair deformity of toe	Surgery		5.00	4.84	5.29		
28315		Removal of sesamoid bone	Surgery		4.85	3.34	4.90		
28320		Repair of foot bones	Surgery		9.17	6.73	6.73		
28322		Repair of metatarsals	Surgery		8.33	6.35	9.20		
28340		Resect enlarged toe tissue	Surgery		6.97	4.25	6.46		
28341		Resect enlarged toe	Surgery		8.40	4.82	6.95		
28344		Repair extra toe(s)	Surgery		4.25	3.64	5.76		
28345		Repair webbed toe(s)	Surgery		5.91	4.69	6.21		
28360		Reconstruct cleft foot	Surgery		13.32	10.52	10.52		
28400		Treatment of heel fracture	Surgery		2.16	3.06	3.64		
28405		Treatment of heel fracture	Surgery		4.56	4.63	4.84		
28406		Treatment of heel fracture	Surgery		6.30	6.81	6.81		
28415		Treat heel fracture	Surgery		15.95	13.32	13.32		
28420		Treat/graft heel fracture	Surgery		16.62	12.95	12.95		
28430		Treatment of ankle fracture	Surgery		2.09	2.57	3.40		
28435		Treatment of ankle fracture	Surgery		3.39	3.75	3.89		
28436		Treatment of ankle fracture	Surgery		4.70	5.93	5.93		
28445		Treat ankle fracture	Surgery		15.60	11.06	11.06		
28450		Treat midfoot fracture, each	Surgery		1.90	2.48	3.12		
28455		Treat midfoot fracture, each	Surgery		3.09	3.43	3.43		
28456		Treat midfoot fracture	Surgery		2.68	4.16	4.16		
28465		Treat midfoot fracture, each	Surgery		7.00	6.33	6.33		
28470		Treat metatarsal fracture	Surgery		1.99	2.45	3.13		
28475		Treat metatarsal fracture	Surgery		2.97	3.22	3.34		
28476		Treat metatarsal fracture	Surgery		3.37	4.99	4.99		
28485		Treat metatarsal fracture	Surgery		5.70	5.46	5.46		
28490		Treat big toe fracture	Surgery		1.09	1.64	2.02		
28495		Treat big toe fracture	Surgery		1.58	2.07	2.18		
28496		Treat big toe fracture	Surgery		2.33	3.20	8.27		
28505		Treat big toe fracture	Surgery		3.80	3.91	8.12		
28510		Treatment of toe fracture	Surgery		1.09	1.53	1.53		
28515		Treatment of toe fracture	Surgery		1.46	1.90	1.90		
28525		Treat toe fracture	Surgery		3.32	3.44	7.53		
28530		Treat sesamoid bone fracture	Surgery		1.06	1.44	1.44		
28531		Treat sesamoid bone fracture	Surgery		2.35	2.07	7.28		
28540		Treat foot dislocation	Surgery		2.04	2.41	2.41		
28545		Treat foot dislocation	Surgery		2.45	2.35	2.35		
28546		Treat foot dislocation	Surgery		3.20	4.39	6.93		
28555		Repair foot dislocation	Surgery		6.29	5.69	9.93		
28570		Treat foot dislocation	Surgery		1.66	2.34	2.43		
28575		Treat foot dislocation	Surgery		3.31	3.73	3.73		
28576		Treat foot dislocation	Surgery		4.16	4.18	4.18		
28585		Repair foot dislocation	Surgery		7.98	5.85	7.34		
28600		Treat foot dislocation	Surgery		1.89	2.69	2.82		
28605		Treat foot dislocation	Surgery		2.71	3.13	3.13		
28606		Treat foot dislocation	Surgery		4.89	4.70	4.70		
28615		Repair foot dislocation	Surgery		7.76	8.06	8.06		
28630		Treat toe dislocation	Surgery		1.70	1.00	1.57		
28635		Treat toe dislocation	Surgery		1.91	1.53	2.03		
28636		Treat toe dislocation	Surgery		2.77	2.63	3.88		
28645		Repair toe dislocation	Surgery		4.21	3.28	4.96		
28660		Treat toe dislocation	Surgery		1.23	0.79	1.26		
28665		Treat toe dislocation	Surgery		1.92	1.43	1.43		
28666		Treat toe dislocation	Surgery		2.66	2.59	5.90		
28675		Repair of toe dislocation	Surgery		2.92	3.35	7.16		
28705		Fusion of foot bones	Surgery		18.77	12.47	12.47		
28715		Fusion of foot bones	Surgery		13.08	9.78	9.78		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 27 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
28725		Fusion of foot bones	Surgery		11.59	8.26	8.26		
28730		Fusion of foot bones	Surgery		10.74	8.50	8.50		
28735		Fusion of foot bones	Surgery		10.83	7.84	7.84		
28737		Revision of foot bones	Surgery		9.63	6.82	6.82		
28740		Fusion of foot bones	Surgery		8.01	6.48	10.89		
28750		Fusion of big toe joint	Surgery		7.29	6.68	11.94		
28755		Fusion of big toe joint	Surgery		4.73	3.76	6.12		
28760		Fusion of big toe joint	Surgery		7.74	5.53	7.99		
28800		Amputation of midfoot	Surgery		8.20	5.81	5.81		
28805		Amputation thru metatarsal	Surgery		8.38	5.66	5.66		
28810		Amputation toe & metatarsal	Surgery		6.20	4.48	4.48		
28820		Amputation of toe	Surgery		4.40	3.79	7.57		
28825		Partial amputation of toe	Surgery		3.58	3.49	7.01		
28890		High energy eswt, plantar f	Surgery	a	3.30	2.09	5.73		
28899		Foot/toes surgery procedure	Surgery					9.04	RRVS
29000		Application of body cast	Surgery		2.25	1.74	2.97		
29010		Application of body cast	Surgery		2.06	1.78	3.29		
29015		Application of body cast	Surgery		2.41	1.60	2.98		
29020		Application of body cast	Surgery		2.11	1.41	3.19		
29025		Application of body cast	Surgery		2.40	1.86	3.15		
29035		Application of body cast	Surgery		1.77	1.58	3.62		
29040		Application of body cast	Surgery		2.22	1.51	2.47		
29044		Application of body cast	Surgery		2.12	1.91	3.98		
29046		Application of body cast	Surgery		2.41	2.10	3.24		
29049		Application of figure eight	Surgery		0.89	0.53	1.30		
29055		Application of shoulder cast	Surgery		1.78	1.47	2.99		
29058		Application of shoulder cast	Surgery		1.31	0.72	1.56		
29065		Application of long arm cast	Surgery		0.87	0.75	1.33		
29075		Application of forearm cast	Surgery		0.77	0.68	1.26		
29085		Apply hand/wrist cast	Surgery		0.87	0.63	1.28		
29086		Apply finger cast	Surgery		0.62	0.49	0.96		
29105		Apply long arm splint	Surgery		0.87	0.51	1.23		
29125		Apply forearm splint	Surgery		0.59	0.39	1.02		
29126		Apply forearm splint	Surgery		0.77	0.46	1.21		
29130		Application of finger splint	Surgery		0.50	0.17	0.47		
29131		Application of finger splint	Surgery		0.55	0.24	0.74		
29200		Strapping of chest	Surgery		0.65	0.34	0.72		
29220		Strapping of low back	Surgery		0.64	0.39	0.72		
29240		Strapping of shoulder	Surgery		0.71	0.36	0.85		
29260		Strapping of elbow or wrist	Surgery		0.55	0.32	0.74		
29280		Strapping of hand or finger	Surgery		0.51	0.32	0.80		
29305		Application of hip cast	Surgery		2.03	1.77	3.35		
29325		Application of hip casts	Surgery		2.32	1.96	3.54		
29345		Application of long leg cast	Surgery		1.40	1.06	1.77		
29355		Application of long leg cast	Surgery		1.53	1.12	1.71		
29358		Apply long leg cast brace	Surgery		1.43	1.09	2.07		
29365		Application of long leg cast	Surgery		1.18	0.95	1.66		
29405		Apply short leg cast	Surgery		0.86	0.71	1.22		
29425		Apply short leg cast	Surgery		1.01	0.74	1.23		
29435		Apply short leg cast	Surgery		1.18	0.93	1.56		
29440		Addition of walker to cast	Surgery		0.57	0.27	0.69		
29445		Apply rigid leg cast	Surgery		1.78	0.96	1.81		
29450		Application of leg cast	Surgery		2.08	1.09	1.47		
29505		Application; long leg splint	Surgery		0.69	0.45	1.18		
29515		Application lower leg splint	Surgery		0.73	0.46	0.87		
29520		Strapping of hip	Surgery		0.54	0.47	0.85		
29530		Strapping of knee	Surgery		0.57	0.33	0.79		
29540		Strapping of ankle and/or ft	Surgery		0.51	0.31	0.42		
29550		Strapping of toes	Surgery		0.47	0.28	0.42		
29580		Application of paste boot	Surgery		0.57	0.35	0.65		
29590		Application of foot splint	Surgery		0.76	0.29	0.51		
29700		Removal/revision of cast	Surgery		0.57	0.28	0.89		
29705		Removal/revision of cast	Surgery		0.76	0.38	0.82		
29710		Removal/revision of cast	Surgery		1.34	0.70	1.53		
29715		Removal/revision of cast	Surgery		0.94	0.40	1.17		
29720		Repair of body cast	Surgery		0.68	0.39	1.16		
29730		Windowing of cast	Surgery		0.75	0.35	0.81		
29740		Wedging of cast	Surgery		1.12	0.49	1.15		
29750		Wedging of clubfoot cast	Surgery		1.26	0.58	1.06		
29799		Casting/strapping procedure	Surgery					1.43	

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 28 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
29800		Jaw arthroscopy/surgery	Surgery		6.42	6.99	6.99		
29804		Jaw arthroscopy/surgery	Surgery		8.13	7.64	7.64		
29805		Shoulder arthroscopy, dx	Surgery		5.88	5.69	5.69		
29806		Shoulder arthroscopy/surgery	Surgery		14.35	11.19	11.19		
29807		Shoulder arthroscopy/surgery	Surgery		13.88	11.02	11.02		
29819		Shoulder arthroscopy/surgery	Surgery		7.61	6.81	6.81		
29820		Shoulder arthroscopy/surgery	Surgery		7.06	6.24	6.24		
29821		Shoulder arthroscopy/surgery	Surgery		7.71	6.82	6.82		
29822		Shoulder arthroscopy/surgery	Surgery		7.42	6.71	6.71		
29823		Shoulder arthroscopy/surgery	Surgery		8.16	7.24	7.24		
29824		Shoulder arthroscopy/surgery	Surgery		8.24	7.55	7.55		
29825		Shoulder arthroscopy/surgery	Surgery		7.61	6.78	6.78		
29826		Shoulder arthroscopy/surgery	Surgery		8.98	7.55	7.55		
29827		Arthroscop rotator cuff repr	Surgery		15.34	11.56	11.56		
29830		Elbow arthroscopy	Surgery		5.75	5.36	5.36		
29834		Elbow arthroscopy/surgery	Surgery		6.27	5.85	5.85		
29835		Elbow arthroscopy/surgery	Surgery		6.47	5.90	5.90		
29836		Elbow arthroscopy/surgery	Surgery		7.54	6.81	6.81		
29837		Elbow arthroscopy/surgery	Surgery		6.86	6.15	6.15		
29838		Elbow arthroscopy/surgery	Surgery		7.70	6.91	6.91		
29840		Wrist arthroscopy	Surgery		5.53	5.34	5.34		
29843		Wrist arthroscopy/surgery	Surgery		6.00	5.64	5.64		
29844		Wrist arthroscopy/surgery	Surgery		6.36	5.84	5.84		
29845		Wrist arthroscopy/surgery	Surgery		7.51	6.49	6.49		
29846		Wrist arthroscopy/surgery	Surgery		6.74	6.07	6.07		
29847		Wrist arthroscopy/surgery	Surgery		7.07	6.21	6.21		
29848		Wrist endoscopy/surgery	Surgery		5.43	5.62	5.62		
29850		Knee arthroscopy/surgery	Surgery		8.18	5.05	5.05		
29851		Knee arthroscopy/surgery	Surgery		13.08	9.82	9.82		
29855		Tibial arthroscopy/surgery	Surgery		10.60	8.79	8.79		
29856		Tibial arthroscopy/surgery	Surgery		14.12	10.70	10.70		
29860		Hip arthroscopy, dx	Surgery		8.04	6.97	6.97		
29861		Hip arthroscopy/surgery	Surgery		9.14	7.36	7.36		
29862		Hip arthroscopy/surgery	Surgery		9.89	8.58	8.58		
29863		Hip arthroscopy/surgery	Surgery		9.89	8.53	8.53		
29866		Autqrrt implnt, knee w/scope	Surgery		13.88	11.38	11.38		
29867		Autqrrt implnt, knee w/scope	Surgery		17.00	13.26	13.26		
29868		Meniscal tm脾, knee w/scope	Surgery		23.59	16.84	16.84		
29870		Knee arthroscopy, dx	Surgery		5.06	4.90	4.90		
29871		Knee arthroscopy/drainage	Surgery		6.54	5.89	5.89		
29873		Knee arthroscopy/surgery	Surgery		5.99	6.59	6.59		
29874		Knee arthroscopy/surgery	Surgery		7.04	6.09	6.09		
29875		Knee arthroscopy/surgery	Surgery		6.30	5.87	5.87		
29876		Knee arthroscopy/surgery	Surgery		7.91	7.04	7.04		
29877		Knee arthroscopy/surgery	Surgery		7.34	6.76	6.76		
29879		Knee arthroscopy/surgery	Surgery		8.03	7.14	7.14		
29880		Knee arthroscopy/surgery	Surgery		8.49	7.38	7.38		
29881		Knee arthroscopy/surgery	Surgery		7.75	6.98	6.98		
29882		Knee arthroscopy/surgery	Surgery		8.64	7.26	7.26		
29883		Knee arthroscopy/surgery	Surgery		11.03	9.09	9.09		
29884		Knee arthroscopy/surgery	Surgery		7.32	6.72	6.72		
29885		Knee arthroscopy/surgery	Surgery		9.08	7.99	7.99		
29886		Knee arthroscopy/surgery	Surgery		7.53	6.87	6.87		
29887		Knee arthroscopy/surgery	Surgery		9.03	7.95	7.95		
29888		Knee arthroscopy/surgery	Surgery		13.88	10.23	10.23		
29889		Knee arthroscopy/surgery	Surgery		15.98	12.47	12.47		
29891		Ankle arthroscopy/surgery	Surgery		8.39	7.53	7.53		
29892		Ankle arthroscopy/surgery	Surgery		8.99	7.76	7.76		
29893		Scope, plantar fasciotomy	Surgery		5.21	4.00	6.30		
29894		Ankle arthroscopy/surgery	Surgery		7.20	5.49	5.49		
29895		Ankle arthroscopy/surgery	Surgery		6.98	5.49	5.49		
29897		Ankle arthroscopy/surgery	Surgery		7.17	5.90	5.90		
29898		Ankle arthroscopy/surgery	Surgery		8.31	6.21	6.21		
29899		Ankle arthroscopy/surgery	Surgery		13.89	10.57	10.57		
29900		Mcp joint arthroscopy, dx	Surgery		5.41	5.88	5.88		
29901		Mcp joint arthroscopy, surq	Surgery		6.12	6.28	6.28		
29902		Mcp joint arthroscopy, surq	Surgery		6.69	6.56	6.56		
29999		Arthroscopy of joint	Surgery					14.57	
30000		Drainage of nose lesion	Surgery		1.43	1.39	4.08		
30020		Drainage of nose lesion	Surgery		1.43	1.47	3.28		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 29 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
30100		Intranasal biopsy	Surgery		0.94	0.82	1.98		
30110		Removal of nose polyp(s)	Surgery		1.63	1.57	3.25		
30115		Removal of nose polyp(s)	Surgery		4.34	5.78	5.78		
30117		Removal of intranasal lesion	Surgery		3.16	4.64	13.18		
30118		Removal of intranasal lesion	Surgery		9.68	9.22	9.22		
30120		Revision of nose	Surgery		5.26	6.02	6.51		
30124		Removal of nose lesion	Surgery		3.10	3.62	3.62		
30125		Removal of nose lesion	Surgery		7.15	8.34	8.34		
30130		Removal of turbinate bones	Surgery		3.37	5.61	5.61		
30140		Removal of turbinate bones	Surgery		3.42	6.21	6.21		
30150		Partial removal of nose	Surgery		9.13	11.04	11.04		
30160		Removal of nose	Surgery		9.57	10.24	10.24		
30200		Injection treatment of nose	Surgery		0.78	0.74	1.62		
30210		Nasal sinus therapy	Surgery		1.08	1.31	2.11		
30220		Insert nasal septal button	Surgery		1.54	1.53	4.24		
30300		Remove nasal foreign body	Surgery		1.04	1.92	4.64		
30310		Remove nasal foreign body	Surgery		1.96	3.11	3.11		
30320		Remove nasal foreign body	Surgery		4.51	7.06	7.06		
30400		Reconstruction of nose	Surgery		9.82	15.53	15.53		
30410		Reconstruction of nose	Surgery		12.96	18.42	18.42		
30420		Reconstruction of nose	Surgery		15.86	17.96	17.96		
30430		Revision of nose	Surgery		7.20	16.06	16.06		
30435		Revision of nose	Surgery		11.69	19.41	19.41		
30450		Revision of nose	Surgery		18.62	21.95	21.95		
30460		Revision of nose	Surgery		9.95	9.97	9.97		
30462		Revision of nose	Surgery		19.54	20.30	20.30		
30465		Repair nasal stenosis	Surgery		11.62	12.00	12.00		
30520		Repair of nasal septum	Surgery		5.69	6.68	6.68		
30540		Repair nasal defect	Surgery		7.74	9.30	9.30		
30545		Repair nasal defect	Surgery		11.36	11.93	11.93		
30560		Release of nasal adhesions	Surgery		1.26	2.14	4.78		
30580		Repair upper jaw fistula	Surgery		6.68	5.81	7.79		
30600		Repair mouth/nose fistula	Surgery		6.01	5.03	7.54		
30620		Intranasal reconstruction	Surgery		5.96	8.86	8.86		
30630		Repair nasal septum defect	Surgery		7.11	7.97	7.97		
30801		Cauterization, inner nose	Surgery		1.09	1.93	4.14		
30802		Cauterization, inner nose	Surgery		2.03	2.37	4.62		
30901		Control of nosebleed	Surgery		1.21	0.32	1.36		
30903		Control of nosebleed	Surgery		1.54	0.50	2.72		
30905		Control of nosebleed	Surgery		1.97	0.76	3.52		
30906		Repeat control of nosebleed	Surgery		2.45	1.20	3.90		
30915		Ligation, nasal sinus artery	Surgery		7.19	6.71	6.71		
30920		Ligation, upper jaw artery	Surgery		9.82	9.00	9.00		
30930		Therapy, fracture of nose	Surgery		1.26	1.62	1.62		
30999		Nasal surgery procedure	Surgery					6.88	
31000		Irrigation, maxillary sinus	Surgery		1.15	1.40	2.85		
31002		Irrigation, sphenoid sinus	Surgery		1.91	3.25	3.25		
31020		Exploration, maxillary sinus	Surgery		2.94	5.20	8.55		
31030		Exploration, maxillary sinus	Surgery		5.91	6.68	11.53		
31032		Explore sinus, remove polyps	Surgery		6.56	7.25	7.25		
31040		Exploration behind upper jaw	Surgery		9.41	9.85	9.85		
31050		Exploration, sphenoid sinus	Surgery		5.27	6.37	6.37		
31051		Sphenoid sinus surgery	Surgery		7.10	8.26	8.26		
31070		Exploration of frontal sinus	Surgery		4.27	5.95	5.95		
31075		Exploration of frontal sinus	Surgery		9.15	9.76	9.76		
31080		Removal of frontal sinus	Surgery		11.40	13.57	13.57		
31081		Removal of frontal sinus	Surgery		12.73	14.04	14.04		
31084		Removal of frontal sinus	Surgery		13.49	13.54	13.54		
31085		Removal of frontal sinus	Surgery		14.18	14.00	14.00		
31086		Removal of frontal sinus	Surgery		12.84	13.32	13.32		
31087		Removal of frontal sinus	Surgery		13.08	12.57	12.57		
31090		Exploration of sinuses	Surgery		9.52	12.59	12.59		
31200		Removal of ethmoid sinus	Surgery		4.96	9.24	9.24		
31201		Removal of ethmoid sinus	Surgery		8.36	9.20	9.20		
31205		Removal of ethmoid sinus	Surgery		10.22	11.91	11.91		
31225		Removal of upper jaw	Surgery		19.20	17.87	17.87		
31230		Removal of upper jaw	Surgery		21.91	19.42	19.42		
31231		Nasal endoscopy, dx	Surgery		1.10	0.88	3.39		
31233		Nasal/sinus endoscopy, dx	Surgery		2.18	1.48	4.31		
31235		Nasal/sinus endoscopy, dx	Surgery		2.64	1.72	4.92		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 30 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
31237		Nasal/sinus endoscopy, surq	Surgery		2.98	1.89	5.21		
31238		Nasal/sinus endoscopy, surq	Surgery		3.26	2.10	5.25		
31239		Nasal/sinus endoscopy, surq	Surgery		8.69	8.02	8.02		
31240		Nasal/sinus endoscopy, surq	Surgery		2.61	1.74	1.74		
31254		Revision of ethmoid sinus	Surgery		4.64	2.86	2.86		
31255		Removal of ethmoid sinus	Surgery		6.95	4.12	4.12		
31256		Exploration maxillary sinus	Surgery		3.29	2.12	2.12		
31267		Endoscopy, maxillary sinus	Surgery		5.45	3.30	3.30		
31276		Sinus endoscopy, surgical	Surgery		8.84	5.13	5.13		
31287		Nasal/sinus endoscopy, surq	Surgery		3.91	2.46	2.46		
31288		Nasal/sinus endoscopy, surq	Surgery		4.57	2.82	2.82		
31290		Nasal/sinus endoscopy, surq	Surgery		17.21	12.08	12.08		
31291		Nasal/sinus endoscopy, surq	Surgery		18.16	12.51	12.51		
31292		Nasal/sinus endoscopy, surq	Surgery		14.74	10.64	10.64		
31293		Nasal/sinus endoscopy, surq	Surgery		16.19	11.41	11.41		
31294		Nasal/sinus endoscopy, surq	Surgery		19.03	12.91	12.91		
31299		Sinus surgery procedure	Surgery					5.43	
31300		Removal of larynx lesion	Surgery		14.27	15.02	15.02		
31320		Diagnostic incision, larynx	Surgery		5.25	10.33	10.33		
31360		Removal of larynx	Surgery		17.05	16.77	16.77		
31365		Removal of larynx	Surgery		24.12	20.42	20.42		
31367		Partial removal of larynx	Surgery		21.83	21.95	21.95		
31368		Partial removal of larynx	Surgery		27.05	25.56	25.56		
31370		Partial removal of larynx	Surgery		21.35	22.32	22.32		
31375		Partial removal of larynx	Surgery		20.18	20.44	20.44		
31380		Partial removal of larynx	Surgery		20.18	20.66	20.66		
31382		Partial removal of larynx	Surgery		20.49	21.67	21.67		
31390		Removal of larynx & pharynx	Surgery		27.49	24.45	24.45		
31395		Reconstruct larynx & pharynx	Surgery		31.04	28.38	28.38		
31400		Revision of larynx	Surgery		10.29	13.81	13.81		
31420		Removal of epiglottis	Surgery		19.20	9.57	9.57		
31500		Insert emergency airway	Surgery		2.33	0.55	0.55		
31502		Change of windpipe airway	Surgery		0.65	0.28	0.31		
31505		Diagnostic laryngoscopy	Surgery		0.61	0.61	1.45		
31510		Laryngoscopy with biopsy	Surgery		1.92	1.25	3.31		
31511		Remove foreign body, larynx	Surgery		2.16	1.06	3.13		
31512		Removal of larynx lesion	Surgery		2.07	1.36	3.21		
31513		Injection into vocal cord	Surgery		2.10	1.46	1.46		
31515		Laryngoscopy for aspiration	Surgery		1.80	1.06	3.55		
31520		Diagnostic laryngoscopy	Surgery		2.56	1.56	1.56		
31525		Diagnostic laryngoscopy	Surgery		2.63	1.66	3.65		
31526		Diagnostic laryngoscopy	Surgery		2.57	1.72	1.72		
31527		Laryngoscopy for treatment	Surgery		3.27	1.88	1.88		
31528		Laryngoscopy and dilation	Surgery		2.37	1.46	1.46		
31529		Laryngoscopy and dilation	Surgery		2.68	1.71	1.71		
31530		Operative laryngoscopy	Surgery		3.38	1.96	1.96		
31531		Operative laryngoscopy	Surgery		3.58	2.28	2.28		
31535		Operative laryngoscopy	Surgery		3.16	2.00	2.00		
31536		Operative laryngoscopy	Surgery		3.55	2.26	2.26		
31540		Operative laryngoscopy	Surgery		4.12	2.55	2.55		
31541		Operative laryngoscopy	Surgery		4.52	2.79	2.79		
31545		Remove vc lesion w/scope	Surgery		6.30	3.48	3.48		
31546		Remove vc lesion scope/graft	Surgery		9.73	4.98	4.98		
31560		Operative laryngoscopy	Surgery		5.45	3.16	3.16		
31561		Operative laryngoscopy	Surgery		5.99	3.38	3.38		
31570		Laryngoscopy with injection	Surgery		3.86	2.39	5.69		
31571		Laryngoscopy with injection	Surgery		4.26	2.61	2.61		
31575		Diagnostic laryngoscopy	Surgery		1.10	0.89	1.91		
31576		Laryngoscopy with biopsy	Surgery		1.97	1.29	3.67		
31577		Remove foreign body, larynx	Surgery		2.47	1.53	3.77		
31578		Removal of larynx lesion	Surgery		2.84	1.52	4.29		
31579		Diagnostic laryngoscopy	Surgery		2.26	1.48	3.79		
31590		Revision of larynx	Surgery		12.36	15.96	15.96		
31582		Revision of larynx	Surgery		21.59	25.87	25.87		
31584		Treat larynx fracture	Surgery		19.61	18.20	18.20		
31587		Revision of larynx	Surgery		11.97	9.29	9.29		
31588		Revision of larynx	Surgery		13.09	13.65	13.65		
31590		Reinnervate larynx	Surgery		6.96	15.58	15.58		
31595		Larynx nerve surgery	Surgery		8.33	10.58	10.58		
31599		Larynx surgery procedure	Surgery					2.88	

NOTES: CPT Codes and descriptions only are copyright © 2006 American Medical Association. All rights reserved. Applicable FARS/OFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 31 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
31600		Incision of windpipe	Surgery		7.17	3.20	3.20		
31601		Incision of windpipe	Surgery		4.44	2.41	2.41		
31603		Incision of windpipe	Surgery		4.14	1.71	1.71		
31605		Incision of windpipe	Surgery		3.57	1.19	1.19		
31610		Incision of windpipe	Surgery		8.75	8.28	8.28		
31611		Surgery/speech prosthesis	Surgery		5.63	7.08	7.08		
31612		Puncture/deer windpipe	Surgery		0.91	0.35	1.10		
31613		Repair windpipe opening	Surgery		4.58	6.01	6.01		
31614		Repair windpipe opening	Surgery		7.11	8.74	8.74		
31615		Visualization of windpipe	Surgery		2.09	1.20	2.60		
31620		Endobronchial us add-on	Surgery		1.40	0.55	5.66		
31622		Dx bronchoscope/wash	Surgery		2.78	1.06	5.67		
31623		Dx bronchoscope/brush	Surgery		2.88	1.05	6.44		
31624		Dx bronchoscope/svage	Surgery		2.88	1.05	5.79		
31625		Bronchoscopy w/biopsy(s)	Surgery		3.36	1.21	5.83		
31628		Bronchoscopy/lung bx, each	Surgery		3.80	1.30	7.04		
31629		Bronchoscopy/needle bx, each	Surgery		4.09	1.40	14.29		
31630		Bronchoscopy dilate/fix reor	Surgery		3.81	1.72	1.72		
31631		Bronchoscopy, dilate w/stent	Surgery		4.36	1.77	1.77		
31632		Bronchoscopy/lung bx, add'l	Surgery		1.03	0.31	0.81		
31633		Bronchoscopy/needle bx add'l	Surgery		1.32	0.40	0.92		
31635		Bronchoscopy w/fo removal	Surgery		3.67	1.43	6.13		
31636		Bronchoscopy, bronch stents	Surgery		4.30	1.77	1.77		
31637		Bronchoscopy, stent add-on	Surgery		1.58	0.56	0.56		
31638		Bronchoscopy, revise stent	Surgery		4.88	1.98	1.98		
31640		Bronchoscopy w/tumor excise	Surgery		4.93	2.08	2.08		
31641		Bronchoscopy, treat blockage	Surgery		5.02	1.89	1.89		
31643		Diag bronchoscope/catheter	Surgery		3.49	1.23	1.23		
31645		Bronchoscopy, clear airways	Surgery		3.16	1.12	5.15		
31646		Bronchoscopy, reclear airway	Surgery		2.72	1.00	4.87		
31656		Bronchoscopy, inj for x-ray	Surgery		2.17	0.83	7.31		
31700		Insertion of airway catheter	Surgery		1.34	0.68	2.16		
31708		Instill airway contrast dye	Surgery		1.41	0.46	2.04		
31710		Insertion of airway catheter	Surgery		1.30	0.41	0.41		
31715		Injection for bronchus x-ray	Surgery		1.11	0.34	0.34		
31717		Bronchial brush biopsy	Surgery		2.12	0.79	8.27		
31720		Clearance of airways	Surgery		1.06	0.33	0.33		
31725		Clearance of airways	Surgery		1.96	0.58	0.65		
31730		Intro, windpipe wire/tube	Surgery		2.85	1.00	2.20		
31750		Repair of windpipe	Surgery		13.00	17.60	17.60		
31755		Repair of windpipe	Surgery		15.91	24.59	24.59		
31760		Repair of windpipe	Surgery		22.32	10.74	10.74		
31766		Reconstruction of windpipe	Surgery		30.38	13.69	13.69		
31770		Repair/graft of bronchus	Surgery		22.48	10.27	10.27		
31775		Reconstruct bronchus	Surgery		23.50	11.82	11.82		
31780		Reconstruct windpipe	Surgery		17.69	11.08	11.08		
31781		Reconstruct windpipe	Surgery		23.49	12.16	12.16		
31785		Remove windpipe lesion	Surgery		17.20	10.21	10.21		
31786		Remove windpipe lesion	Surgery		23.94	13.13	13.13		
31800		Repair of windpipe injury	Surgery		7.42	9.27	9.27		
31805		Repair of windpipe injury	Surgery		13.11	7.23	7.23		
31820		Closure of windpipe lesion	Surgery		4.48	3.66	5.68		
31825		Repair of windpipe defect	Surgery		6.80	5.39	7.68		
31830		Revise windpipe scar	Surgery		4.49	3.99	5.78		
31899		Airways surgical procedure	Surgery					4.39	
32000		Drainage of chest	Surgery		1.54	0.48	3.06		
32002		Treatment of collapsed lung	Surgery		2.19	1.06	3.22		
32005		Treat lung lining chemically	Surgery		2.19	0.70	6.47		
32019		Insert pleural catheter	Surgery		4.17	1.65	20.02		
32020		Insertion of chest tube	Surgery		3.97	1.35	1.35		
32035		Exploration of chest	Surgery		8.66	5.87	5.87		
32036		Exploration of chest	Surgery		9.67	6.45	6.45		
32095		Biopsy through chest wall	Surgery		8.35	5.38	5.38		
32100		Exploration/biopsy of chest	Surgery		15.22	7.84	7.84		
32110		Explore/repair chest	Surgery		22.97	10.76	10.76		
32120		Re-exploration of chest	Surgery		11.52	7.09	7.09		
32124		Explore chest free adhesions	Surgery		12.70	7.23	7.23		
32140		Removal of lung lesion(s)	Surgery		13.91	7.70	7.70		
32141		Remove/treat lung lesions	Surgery		13.98	7.57	7.57		
32150		Removal of lung lesion(s)	Surgery		14.13	7.62	7.62		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/OFARS apply. See end of the table for notes regarding Charge Methodology.

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 32 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
32151		Remove lung foreign body	Surgery		14.19	8.02	8.02		
32160		Open chest heart massage	Surgery		9.29	5.28	5.28		
32200		Drain, open, lung lesion	Surgery		15.27	8.63	8.63		
32201		Drain, percut, lung lesion	Surgery		3.99	1.30	20.76		
32215		Treat chest lining	Surgery		11.31	6.92	6.92		
32220		Release of lung	Surgery		23.96	12.99	12.99		
32225		Partial release of lung	Surgery		13.94	7.67	7.67		
32310		Removal of chest lining	Surgery		13.42	7.41	7.41		
32320		Free/remove chest lining	Surgery		23.96	12.19	12.19		
32400		Needle biopsy chest lining	Surgery		1.76	0.55	2.13		
32402		Open biopsy chest lining	Surgery		7.55	5.12	5.12		
32405		Biopsy, lung or mediastinum	Surgery		1.93	0.63	0.67		
32420		Puncture/clear lung	Surgery		2.18	0.68	0.68		
32440		Removal of lung	Surgery		24.96	12.93	12.93		
32442		Sleeve pneumonectomy	Surgery		26.20	14.80	14.80		
32445		Removal of lung	Surgery		25.05	14.10	14.10		
32480		Partial removal of lung	Surgery		23.71	12.09	12.09		
32482		Bilobectomy	Surgery		24.96	12.95	12.95		
32484		Segmentectomy	Surgery		20.66	11.41	11.41		
32486		Sleeve lobectomy	Surgery		23.88	13.28	13.28		
32488		Completion pneumonectomy	Surgery		25.67	13.82	13.82		
32491		Lung volume reduction	Surgery		21.22	12.66	12.66		
32500		Partial removal of lung	Surgery		21.97	12.39	12.39		
32501		Repair bronchus add-on	Surgery		4.68	1.54	1.54		
32503		Resect apical lung tumor	Surgery		30.00	15.11	15.11		RBRVS
32504		Resect apical lung tum/chest	Surgery		34.80	16.72	16.72		RBRVS
32540		Removal of lung lesion	Surgery		14.62	9.66	9.66		
32601		Thoracoscopy, diagnostic	Surgery		5.45	2.36	2.36		
32602		Thoracoscopy, diagnostic	Surgery		5.95	2.53	2.53		
32603		Thoracoscopy, diagnostic	Surgery		7.80	3.04	3.04		
32604		Thoracoscopy, diagnostic	Surgery		8.77	3.46	3.46		
32605		Thoracoscopy, diagnostic	Surgery		6.92	2.91	2.91		
32606		Thoracoscopy, diagnostic	Surgery		8.39	3.34	3.34		
32650		Thoracoscopy, surgical	Surgery		10.73	6.78	6.78		
32651		Thoracoscopy, surgical	Surgery		12.89	7.25	7.25		
32652		Thoracoscopy, surgical	Surgery		18.63	10.17	10.17		
32653		Thoracoscopy, surgical	Surgery		12.85	6.99	6.99		
32654		Thoracoscopy, surgical	Surgery		12.42	7.55	7.55		
32655		Thoracoscopy, surgical	Surgery		13.08	7.26	7.26		
32656		Thoracoscopy, surgical	Surgery		12.89	7.96	7.96		
32657		Thoracoscopy, surgical	Surgery		13.63	7.70	7.70		
32658		Thoracoscopy, surgical	Surgery		11.61	7.37	7.37		
32659		Thoracoscopy, surgical	Surgery		11.57	7.47	7.47		
32660		Thoracoscopy, surgical	Surgery		17.40	9.51	9.51		
32661		Thoracoscopy, surgical	Surgery		13.23	7.81	7.81		
32662		Thoracoscopy, surgical	Surgery		16.42	8.85	8.85		
32663		Thoracoscopy, surgical	Surgery		18.44	10.79	10.79		
32664		Thoracoscopy, surgical	Surgery		14.18	7.65	7.65		
32665		Thoracoscopy, surgical	Surgery		15.52	8.15	8.15		
32800		Repair lung hernia	Surgery		13.67	7.43	7.43		
32810		Close chest after drainage	Surgery		13.03	7.54	7.54		
32815		Close bronchial fistula	Surgery		23.12	11.00	11.00		
32820		Reconstruct injured chest	Surgery		21.45	12.20	12.20		
32851		Lung transplant, single	Surgery		38.57	27.74	27.74		
32852		Lung transplant with bypass	Surgery		41.74	33.26	33.26		
32853		Lung transplant, double	Surgery		47.74	31.84	31.84		
32854		Lung transplant with bypass	Surgery		50.90	34.83	34.83		
32900		Removal of rib(s)	Surgery		20.24	9.91	9.91		
32905		Revise & repair chest wall	Surgery		20.72	10.16	10.16		
32906		Revise & repair chest wall	Surgery		26.73	12.09	12.09		
32940		Revision of lung	Surgery		19.40	9.50	9.50		
32960		Therapeutic pneumothorax	Surgery		1.84	0.56	1.74		
32997		Total lung lavage	Surgery		5.99	1.92	1.92		
32999		Chest surgery procedure	Surgery					5.42	
33010		Drainage of heart sac	Surgery		2.24	0.78	0.78		
33011		Repeat drainage of heart sac	Surgery		2.24	0.81	0.81		
33015		Incision of heart sac	Surgery		6.79	4.96	4.96		
33020		Incision of heart sac	Surgery		12.59	6.80	6.80		
33025		Incision of heart sac	Surgery		12.07	6.37	6.37		
33030		Partial removal of heart sac	Surgery		18.68	9.55	9.55		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 33 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
33031		Partial removal of heart sac	Surgery		21.76	10.06	10.06		
33050		Removal of heart sac lesion	Surgery		14.34	7.86	7.86		
33120		Removal of heart lesion	Surgery		24.52	11.61	11.61		
33130		Removal of heart lesion	Surgery		21.36	10.14	10.14		
33140		Heart revascularize (tmr)	Surgery		19.97	10.91	10.91		
33141		Heart tmr w/other procedure	Surgery		4.83	1.58	1.58		
33200		Insertion of heart pacemaker	Surgery		12.46	6.86	6.86		
33201		Insertion of heart pacemaker	Surgery		10.16	6.60	6.60		
33206		Insertion of heart pacemaker	Surgery		6.66	4.47	4.47		
33207		Insertion of heart pacemaker	Surgery		8.03	4.67	4.67		
33208		Insertion of heart pacemaker	Surgery		8.12	4.78	4.78		
33210		Insertion of heart electrode	Surgery		3.30	1.25	1.25		
33211		Insertion of heart electrode	Surgery		3.39	1.31	1.31		
33212		Insertion of pulse generator	Surgery		5.51	3.37	3.37		
33213		Insertion of pulse generator	Surgery		6.36	3.73	3.73		
33214		Upgrade of pacemaker system	Surgery		7.74	4.90	4.90		
33215		Reposition pacing-defib lead	Surgery		4.75	3.19	3.19		
33216		Insert lead pace-defib, one	Surgery		5.77	4.21	4.21		
33217		Insert lead pace-defib, dual	Surgery		5.74	4.24	4.24		
33218		Repair lead pace-defib, one	Surgery		5.43	4.31	4.31		
33220		Repair lead pace-defib, dual	Surgery		5.51	4.28	4.28		
33222		Revise pocket, pacemaker	Surgery		4.95	4.30	4.30		
33223		Revise pocket, pacing-defib	Surgery		6.45	4.60	4.60		
33224		Insert pacing lead & connect	Surgery		9.04	4.01	4.01		
33225		L ventric pacing lead add-on	Surgery		8.33	3.26	3.26		
33226		Reposition l ventric lead	Surgery		8.68	3.83	3.83		
33233		Removal of pacemaker system	Surgery		3.29	3.28	3.28		
33234		Removal of pacemaker system	Surgery		7.81	4.92	4.92		
33235		Removal pacemaker electrode	Surgery		9.39	6.83	6.83		
33236		Remove electrode/thoracotomy	Surgery		12.58	7.45	7.45		
33237		Remove electrode/thoracotomy	Surgery		13.69	7.80	7.80		
33238		Remove electrode/thoracotomy	Surgery		15.20	8.22	8.22		
33240		Insert pulse generator	Surgery		7.59	4.59	4.59		
33241		Remove pulse generator	Surgery		3.24	2.97	2.97		
33243		Remove eltrd/thoracotomy	Surgery		22.61	11.49	11.49		
33244		Remove eltrd, transven	Surgery		13.74	8.92	8.92		
33245		Insert epic eltrd pace-defib	Surgery		14.28	7.92	7.92		
33246		Insert epic eltrd/generator	Surgery		20.68	10.31	10.31		
33249		Eltrd/insert pace-defib	Surgery		14.21	8.38	8.38		
33250		Ablate heart dysrhythm focus	Surgery		21.82	11.05	11.05		
33251		Ablate heart dysrhythm focus	Surgery		24.84	11.69	11.69		
33253		Reconstruct atria	Surgery		31.01	13.86	13.86		
33261		Ablate heart dysrhythm focus	Surgery		24.84	11.80	11.80		
33282		Implant pat-active ht record	Surgery		4.16	4.03	4.03		
33284		Remove pat-active ht record	Surgery		2.50	3.54	3.54		
33300		Repair of heart wound	Surgery		17.89	9.26	9.26		
33305		Repair of heart wound	Surgery		21.41	10.64	10.64		
33310		Exploratory heart surgery	Surgery		18.48	9.61	9.61		
33315		Exploratory heart surgery	Surgery		22.34	10.91	10.91		
33320		Repair major blood vessel(s)	Surgery		16.76	8.24	8.24		
33321		Repair major vessel	Surgery		20.17	9.81	9.81		
33322		Repair major blood vessel(s)	Surgery		20.59	10.39	10.39		
33330		Insert major vessel graft	Surgery		21.40	10.29	10.29		
33332		Insert major vessel graft	Surgery		23.92	10.54	10.54		
33335		Insert major vessel graft	Surgery		29.96	13.37	13.37		
33400		Repair of aortic valve	Surgery		28.46	15.71	15.71		
33401		Valvuloplasty, open	Surgery		23.87	13.54	13.54		
33403		Valvuloplasty, w/cp bypass	Surgery		24.85	14.34	14.34		
33404		Prepare heart-aorta conduit	Surgery		28.50	14.58	14.58		
33405		Replacement of aortic valve	Surgery		34.95	18.34	18.34		
33406		Replacement of aortic valve	Surgery		37.44	19.18	19.18		
33410		Replacement of aortic valve	Surgery		32.41	16.63	16.63		
33411		Replacement of aortic valve	Surgery		36.20	18.79	18.79		
33412		Replacement of aortic valve	Surgery		41.94	20.46	20.46		
33413		Replacement of aortic valve	Surgery		43.43	20.87	20.87		
33414		Repair of aortic valve	Surgery		30.30	14.17	14.17		
33415		Revision, subvalvular tissue	Surgery		27.11	12.05	12.05		
33416		Revise ventricle muscle	Surgery		30.30	13.54	13.54		
33417		Repair of aortic valve	Surgery		28.49	13.65	13.65		
33420		Revision of mitral valve	Surgery		22.67	9.59	9.59		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 34 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
33422		Revision of mitral valve	Surgery		25.90	13.69	13.69		
33425		Repair of mitral valve	Surgery		26.96	13.09	13.09		
33426		Repair of mitral valve	Surgery		32.95	17.18	17.18		
33427		Repair of mitral valve	Surgery		39.94	19.42	19.42		
33430		Replacement of mitral valve	Surgery		33.45	17.34	17.34		
33460		Revision of tricuspid valve	Surgery		23.56	11.33	11.33		
33463		Valvuloplasty, tricuspid	Surgery		25.58	12.95	12.95		
33464		Valvuloplasty, tricuspid	Surgery		27.29	13.56	13.56		
33485		Replace tricuspid valve	Surgery		28.75	13.00	13.00		
33488		Revision of tricuspid valve	Surgery		30.07	13.69	13.69		
33470		Revision of pulmonary valve	Surgery		20.78	10.72	10.72		
33471		Valvotomy, pulmonary valve	Surgery		22.22	9.78	9.78		
33472		Revision of pulmonary valve	Surgery		22.22	11.69	11.69		
33474		Revision of pulmonary valve	Surgery		23.01	10.91	10.91		
33475		Replacement, pulmonary valve	Surgery		32.95	15.41	15.41		
33476		Revision of heart chamber	Surgery		25.73	11.99	11.99		
33478		Revision of heart chamber	Surgery		26.70	13.09	13.09		
33496		Repair, prosth valve clot	Surgery		27.21	12.78	12.78		
33500		Repair heart vessel fistula	Surgery		25.51	11.49	11.49		
33501		Repair heart vessel fistula	Surgery		17.75	8.30	8.30		
33502		Coronary artery correction	Surgery		21.01	11.10	11.10		
33503		Coronary artery graft	Surgery		21.75	9.76	9.76		
33504		Coronary artery graft	Surgery		24.62	11.84	11.84		
33505		Repair artery w/tunnel	Surgery		26.80	12.94	12.94		
33506		Repair artery, translocation	Surgery		35.45	14.60	14.60		
33507		Repair art, intramural	Surgery		30.00	13.68	13.68		RBRVS
33508		Endoscopic vein harvest	Surgery		0.31	0.10	0.10		
33510		CABG, vein, single	Surgery		28.96	16.38	16.38		
33511		CABG, vein, two	Surgery		29.96	17.12	17.12		
33512		CABG, vein, three	Surgery		31.75	17.65	17.65		
33513		CABG, vein, four	Surgery		31.95	17.83	17.83		
33514		CABG, vein, five	Surgery		32.70	18.10	18.10		
33516		Cabg, vein, six or more	Surgery		34.95	18.85	18.85		
33517		CABG, artery-vein, single	Surgery		2.57	0.84	0.84		
33518		CABG, artery-vein, two	Surgery		4.84	1.58	1.58		
33519		CABG, artery-vein, three	Surgery		7.11	2.33	2.33		
33521		CABG, artery-vein, four	Surgery		9.39	3.08	3.08		
33522		CABG, artery-vein, five	Surgery		11.65	3.82	3.82		
33523		Cabg, art-vein, six or more	Surgery		13.93	4.54	4.54		
33530		Coronary artery, bypass/reop	Surgery		5.85	1.92	1.92		
33533		CABG, arterial, single	Surgery		29.96	16.51	16.51		
33534		CABG, arterial, two	Surgery		32.15	17.76	17.76		
33535		CABG, arterial, three	Surgery		34.45	18.18	18.18		
33536		Cabg, arterial, four or more	Surgery		37.44	18.34	18.34		
33542		Removal of heart lesion	Surgery		28.81	13.03	13.03		
33545		Repair of heart damage	Surgery		36.72	15.67	15.67		
33548		Restore/remodel, ventricle	Surgery		37.97	19.35	19.35		RBRVS
33572		Open coronary endarterectomy	Surgery		4.44	1.45	1.45		
33600		Closure of valve	Surgery		29.47	12.55	12.55		
33602		Closure of valve	Surgery		28.50	12.48	12.48		
33606		Anastomosis/artery-aorta	Surgery		30.69	13.71	13.71		
33608		Repair anomaly w/conduit	Surgery		31.04	14.14	14.14		
33610		Repair by enlargement	Surgery		30.56	13.64	13.64		
33611		Repair double ventricle	Surgery		33.95	14.17	14.17		
33612		Repair double ventricle	Surgery		34.95	15.19	15.19		
33615		Repair, modified fontan	Surgery		33.95	13.18	13.18		
33617		Repair single ventricle	Surgery		36.94	16.04	16.04		
33619		Repair single ventricle	Surgery		44.93	20.86	20.86		
33641		Repair heart septum defect	Surgery		21.36	9.60	9.60		
33645		Revision of heart veins	Surgery		24.78	11.80	11.80		
33647		Repair heart septum defects	Surgery		28.69	13.81	13.81		
33660		Repair of heart defects	Surgery		29.96	13.52	13.52		
33665		Repair of heart defects	Surgery		28.56	13.87	13.87		
33670		Repair of heart chambers	Surgery		34.95	13.21	13.21		
33681		Repair heart septum defect	Surgery		30.56	14.72	14.72		
33684		Repair heart septum defect	Surgery		29.61	13.66	13.66		
33688		Repair heart septum defect	Surgery		30.57	10.50	10.50		
33690		Reinforce pulmonary artery	Surgery		19.52	10.19	10.19		
33692		Repair of heart defects	Surgery		30.70	13.96	13.96		
33694		Repair of heart defects	Surgery		33.95	14.26	14.26		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 35 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
33697		Repair of heart defects	Surgery		35.95	14.91	14.91		
33702		Repair of heart defects	Surgery		26.50	12.60	12.60		
33710		Repair of heart defects	Surgery		29.67	14.00	14.00		
33720		Repair of heart defect	Surgery		26.52	12.32	12.32		
33722		Repair of heart defect	Surgery		28.37	13.89	13.89		
33730		Repair heart-vein defect(s)	Surgery		34.20	14.16	14.16		
33732		Repair heart-vein defect	Surgery		28.12	13.42	13.42		
33735		Revision of heart chamber	Surgery		21.36	8.98	8.98		
33736		Revision of heart chamber	Surgery		23.48	11.88	11.88		
33737		Revision of heart chamber	Surgery		21.73	10.96	10.96		
33750		Major vessel shunt	Surgery		21.38	10.24	10.24		
33755		Major vessel shunt	Surgery		21.76	8.83	8.83		
33762		Major vessel shunt	Surgery		21.76	10.18	10.18		
33764		Major vessel shunt & graft	Surgery		21.76	10.25	10.25		
33766		Major vessel shunt	Surgery		22.73	11.70	11.70		
33767		Major vessel shunt	Surgery		24.46	11.75	11.75		
33768		Cardiopulmonary Shunting	Surgery		8.00	2.67	2.67		RBRVS
33770		Repair great vessels defect	Surgery		36.94	14.72	14.72		
33771		Repair great vessels defect	Surgery		34.60	12.42	12.42		
33774		Repair great vessels defect	Surgery		30.93	14.70	14.70		
33775		Repair great vessels defect	Surgery		32.15	15.03	15.03		
33776		Repair great vessels defect	Surgery		33.99	15.85	15.85		
33777		Repair great vessels defect	Surgery		33.41	15.66	15.66		
33778		Repair great vessels defect	Surgery		39.94	16.94	16.94		
33779		Repair great vessels defect	Surgery		36.16	15.41	15.41		
33780		Repair great vessels defect	Surgery		41.69	19.14	19.14		
33781		Repair great vessels defect	Surgery		36.40	13.37	13.37		
33786		Repair arterial trunk	Surgery		38.94	16.76	16.76		
33788		Revision of pulmonary artery	Surgery		26.58	11.98	11.98		
33800		Aortic suspension	Surgery		16.22	8.13	8.13		
33802		Repair vessel defect	Surgery		17.63	9.25	9.25		
33803		Repair vessel defect	Surgery		19.57	9.79	9.79		
33813		Repair septal defect	Surgery		29.62	10.94	10.94		
33814		Repair septal defect	Surgery		25.73	12.68	12.68		
33820		Revise major vessel	Surgery		16.27	8.38	8.38		
33822		Revise major vessel	Surgery		17.29	8.98	8.98		
33824		Revise major vessel	Surgery		19.49	10.01	10.01		
33840		Remove aorta constriction	Surgery		20.60	10.32	10.32		
33845		Remove aorta constriction	Surgery		22.09	11.38	11.38		
33851		Remove aorta constriction	Surgery		21.24	10.71	10.71		
33852		Repair septal defect	Surgery		23.67	11.39	11.39		
33853		Repair septal defect	Surgery		31.67	14.86	14.86		
33860		Ascending aortic graft	Surgery		37.94	16.50	16.50		
33861		Ascending aortic graft	Surgery		41.94	17.76	17.76		
33863		Ascending aortic graft	Surgery		44.93	18.74	18.74		
33870		Transverse aortic arch graft	Surgery		43.93	18.43	18.43		
33875		Thoracic aortic graft	Surgery		33.01	14.13	14.13		
33877		Thoracoabdominal graft	Surgery		42.54	16.36	16.36		
33880		Endovasc taa repr ind subcl	Surgery		33.00	13.51	13.51		RBRVS
33881		Endovasc taa repr w/o subcl	Surgery		28.00	11.99	11.99		RBRVS
33883		Insert endovasc prosth, taa	Surgery		20.00	9.21	9.21		RBRVS
33884		Endovasc prosth, taa, add-on	Surgery		8.20	2.58	2.58		RBRVS
33886		Endovasc prosth, delayed	Surgery		17.00	8.25	8.25		RBRVS
33889		Artery transpose/endovasc taa	Surgery		15.92	5.19	5.19		RBRVS
33891		Car-car bp graft/endovasc taa	Surgery		20.00	6.98	6.98		RBRVS
33910		Remove lung artery emboli	Surgery		24.55	11.46	11.46		
33915		Remove lung artery emboli	Surgery		20.99	9.66	9.66		
33916		Surgery of great vessel	Surgery		25.79	11.37	11.37		
33917		Repair pulmonary artery	Surgery		24.46	12.22	12.22		
33920		Repair pulmonary atresia	Surgery		31.90	13.86	13.86		
33922		Transect pulmonary artery	Surgery		23.48	10.93	10.93		
33924		Remove pulmonary shunt	Surgery		5.49	1.85	1.85		
33925		Rpr pul art unifocal w/o cpb	Surgery		29.50	14.70	14.70		RBRVS
33926		Rpr pul art, unifocal w/cpb	Surgery		42.00	17.73	17.73		RBRVS
33935		Transplantation, heart/lung	Surgery		60.87	28.85	28.85		
33940		Removal of donor heart	Surgery					46.15	
33945		Transplantation of heart	Surgery		42.04	21.45	21.45		
33960		External circulation assist	Surgery		19.33	4.92	4.92		
33961		External circulation assist	Surgery		10.91	3.62	3.62		
33967		Insert ia percut device	Surgery		4.84	1.85	1.85		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for notes regarding Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 36 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
33968		Remove aortic assist device	Surgery		0.64	0.23	0.23		
33970		Aortic circulation assist	Surgery		6.74	2.29	2.29		
33971		Aortic circulation assist	Surgery		9.68	6.02	6.02		
33973		Insert balloon device	Surgery		9.75	3.32	3.32		
33974		Remove intra-aortic balloon	Surgery		14.39	7.90	7.90		
33975		Implant ventricular device	Surgery		20.97	6.30	6.30		
33976		Implant ventricular device	Surgery		22.97	7.57	7.57		
33977		Remove ventricular device	Surgery		19.26	11.10	11.10		
33978		Remove ventricular device	Surgery		21.70	11.78	11.78		
33979		Insert intracorporeal device	Surgery		45.93	14.96	14.96		
33980		Remove intracorporeal device	Surgery		56.17	25.31	25.31		
33999		Cardiac surgery procedure	Surgery					40.06	
34001		Removal of artery clot	Surgery		12.89	6.73	6.73		
34051		Removal of artery clot	Surgery		15.19	7.80	7.80		
34101		Removal of artery clot	Surgery		9.99	5.37	5.37		
34111		Removal of arm artery clot	Surgery		9.99	5.37	5.37		
34151		Removal of artery clot	Surgery		24.96	10.43	10.43		
34201		Removal of artery clot	Surgery		10.01	5.43	5.43		
34203		Removal of leg artery clot	Surgery		16.48	8.08	8.08		
34401		Removal of vein clot	Surgery		24.96	10.69	10.69		
34421		Removal of vein clot	Surgery		11.98	6.31	6.31		
34451		Removal of vein clot	Surgery		26.96	11.47	11.47		
34471		Removal of vein clot	Surgery		10.16	5.32	5.32		
34490		Removal of vein clot	Surgery		9.85	5.44	5.44		
34501		Repair valve, femoral vein	Surgery		15.98	8.51	8.51		
34502		Reconstruct vena cava	Surgery		26.91	12.33	12.33		
34510		Transposition of vein valve	Surgery		18.92	9.44	9.44		
34520		Cross-over vein graft	Surgery		17.92	8.47	8.47		
34530		Leg vein fusion	Surgery		16.62	8.63	8.63		
34600		Endovasc abdo repair w/tube	Surgery		20.72	9.19	9.19		
34602		Endovasc abdo repr w/device	Surgery		22.97	9.81	9.81		
34603		Endovasc aas repr w/3-p part	Surgery		24.00	10.24	10.24		
34604		Endovasc abdo repr w/device	Surgery		22.97	9.83	9.83		
34605		Endovasc abdo repair w/pros	Surgery		21.85	9.67	9.67		
34608		Endovasc abdo occlud device	Surgery		4.12	1.37	1.37		
34612		Xpose for endoprosth, femorl	Surgery		6.74	2.24	2.24		
34613		Femoral endovas graft add-on	Surgery		4.79	1.57	1.57		
34620		Xpose for endoprosth, iliac	Surgery		9.74	3.24	3.24		
34625		Endovasc extend prosth, nit	Surgery		11.98	6.16	6.16		
34626		Endovasc exten prosth, addl	Surgery		4.12	1.37	1.37		
34630		Open aortic tube prosth repr	Surgery		32.54	13.73	13.73		
34631		Open aortiliac prosth repr	Surgery		35.29	11.76	11.76		
34632		Open aortofemor prosth repr	Surgery		35.29	14.66	14.66		
34633		Xpose for endoprosth, iliac	Surgery		11.98	4.44	4.44		
34634		Xpose, endoprosth, brachial	Surgery		5.34	2.20	2.20		
34900		Endovasc iliac repr w/graft	Surgery		16.36	7.60	7.60		
35001		Repair defect of artery	Surgery		19.61	9.58	9.58		
35002		Repair artery rupture, neck	Surgery		20.97	9.72	9.72		
35005		Repair defect of artery	Surgery		18.09	8.87	8.87		
35011		Repair defect of artery	Surgery		17.97	8.00	8.00		
35013		Repair artery rupture, erm	Surgery		21.97	9.70	9.70		
35021		Repair defect of artery	Surgery		19.62	9.44	9.44		
35022		Repair artery rupture, chest	Surgery		23.15	9.88	9.88		
35045		Repair defect of arm artery	Surgery		17.54	7.52	7.52		
35081		Repair defect of artery	Surgery		27.97	11.49	11.49		
35082		Repair artery rupture, aorte	Surgery		38.44	15.33	15.33		
35091		Repair defect of artery	Surgery		35.35	13.60	13.60		
35092		Repair artery rupture, aorta	Surgery		44.93	17.68	17.68		
35102		Repair defect of artery	Surgery		30.71	12.39	12.39		
35103		Repair artery rupture, groin	Surgery		40.44	15.89	15.89		
35111		Repair defect of artery	Surgery		24.96	10.49	10.49		
35112		Repair artery rupture, spleen	Surgery		29.96	11.99	11.99		
35121		Repair defect of artery	Surgery		29.96	12.40	12.40		
35122		Repair artery rupture, belly	Surgery		34.95	13.84	13.84		
35131		Repair defect of artery	Surgery		24.96	10.77	10.77		
35132		Repair artery rupture, groin	Surgery		29.96	12.41	12.41		
35141		Repair defect of artery	Surgery		19.97	8.94	8.94		
35142		Repair artery rupture, thigh	Surgery		23.27	10.39	10.39		
35151		Repair defect of artery	Surgery		22.61	10.01	10.01		
35152		Repair artery rupture, knee	Surgery		25.58	11.40	11.40		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPSC CODE

PAGE 37 of 119

CPT/ HCPSC Code	Modifier	CPT/HCPSC Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
35180		Repair blood vessel lesion	Surgery		13.60	6.96	6.96		
35182		Repair blood vessel lesion	Surgery		29.96	12.83	12.83		
35184		Repair blood vessel lesion	Surgery		17.97	8.31	8.31		
35188		Repair blood vessel lesion	Surgery		14.26	7.65	7.65		
35189		Repair blood vessel lesion	Surgery		27.96	11.98	11.98		
35190		Repair blood vessel lesion	Surgery		12.73	6.49	6.49		
35201		Repair blood vessel lesion	Surgery		16.12	8.01	8.01		
35206		Repair blood vessel lesion	Surgery		13.23	6.57	6.57		
35207		Repair blood vessel lesion	Surgery		10.13	7.37	7.37		
35211		Repair blood vessel lesion	Surgery		22.09	10.64	10.64		
35216		Repair blood vessel lesion	Surgery		18.72	9.00	9.00		
35221		Repair blood vessel lesion	Surgery		24.35	9.96	9.96		
35226		Repair blood vessel lesion	Surgery		14.48	7.45	7.45		
35231		Repair blood vessel lesion	Surgery		19.97	9.79	9.79		
35236		Repair blood vessel lesion	Surgery		17.08	7.90	7.90		
35241		Repair blood vessel lesion	Surgery		23.09	11.15	11.15		
35246		Repair blood vessel lesion	Surgery		26.41	11.45	11.45		
35251		Repair blood vessel lesion	Surgery		30.15	11.82	11.82		
35256		Repair blood vessel lesion	Surgery		18.33	8.37	8.37		
35261		Repair blood vessel lesion	Surgery		17.77	8.03	8.03		
35266		Repair blood vessel lesion	Surgery		14.89	7.02	7.02		
35271		Repair blood vessel lesion	Surgery		22.09	10.54	10.54		
35276		Repair blood vessel lesion	Surgery		24.21	11.23	11.23		
35281		Repair blood vessel lesion	Surgery		27.96	11.73	11.73		
35286		Repair blood vessel lesion	Surgery		16.14	8.07	8.07		
35301		Rechanneling of artery	Surgery		18.67	8.45	8.45		
35311		Rechanneling of artery	Surgery		26.96	11.77	11.77		
35321		Rechanneling of artery	Surgery		15.98	7.40	7.40		
35331		Rechanneling of artery	Surgery		26.16	11.26	11.26		
35341		Rechanneling of artery	Surgery		25.07	10.89	10.89		
35351		Rechanneling of artery	Surgery		22.97	9.62	9.62		
35355		Rechanneling of artery	Surgery		18.47	8.10	8.10		
35361		Rechanneling of artery	Surgery		28.16	11.73	11.73		
35363		Rechanneling of artery	Surgery		30.15	12.62	12.62		
35371		Rechanneling of artery	Surgery		14.70	6.97	6.97		
35372		Rechanneling of artery	Surgery		17.97	8.06	8.06		
35381		Rechanneling of artery	Surgery		15.79	7.83	7.83		
35390		Reoperation, carotid add-on	Surgery		3.19	1.06	1.06		
35400		Angioscopy	Surgery		3.00	1.11	1.11		
35450		Repair arterial blockage	Surgery		10.05	3.57	3.57		
35452		Repair arterial blockage	Surgery		6.90	2.61	2.61		
35454		Repair arterial blockage	Surgery		6.03	2.32	2.32		
35456		Repair arterial blockage	Surgery		7.34	2.77	2.77		
35458		Repair arterial blockage	Surgery		9.48	3.48	3.48		
35459		Repair arterial blockage	Surgery		8.62	3.18	3.18		
35460		Repair venous blockage	Surgery		6.03	2.28	2.28		
35470		Repair arterial blockage	Surgery		8.62	3.36	89.12		
35471		Repair arterial blockage	Surgery		10.05	3.96	100.55		
35472		Repair arterial blockage	Surgery		6.90	2.75	64.54		
35473		Repair arterial blockage	Surgery		6.03	2.43	60.01		
35474		Repair arterial blockage	Surgery		7.35	2.90	87.98		
35475		Repair arterial blockage	Surgery		9.48	3.57	56.26		
35476		Repair venous blockage	Surgery		6.03	2.36	44.86		
35480		Atherectomy, open	Surgery		11.06	4.05	4.05		
35481		Atherectomy, open	Surgery		7.60	2.88	2.88		
35482		Atherectomy, open	Surgery		6.64	2.57	2.57		
35483		Atherectomy, open	Surgery		8.09	3.03	3.03		
35484		Atherectomy, open	Surgery		10.42	3.78	3.78		
35485		Atherectomy, open	Surgery		9.48	3.54	3.54		
35490		Atherectomy, percutaneous	Surgery		11.06	4.71	4.71		
35491		Atherectomy, percutaneous	Surgery		7.60	3.30	3.30		
35492		Atherectomy, percutaneous	Surgery		6.64	3.20	3.20		
35493		Atherectomy, percutaneous	Surgery		8.09	3.81	3.81		
35494		Atherectomy, percutaneous	Surgery		10.42	4.47	4.47		
35495		Atherectomy, percutaneous	Surgery		9.48	4.40	4.40		
35500		Harvest vein for bypass	Surgery		6.44	2.03	2.03		
35501		Artery bypass graft	Surgery		19.16	8.48	8.48		
35506		Artery bypass graft	Surgery		19.64	9.49	9.49		
35507		Artery bypass graft	Surgery		19.64	9.45	9.45		
35508		Artery bypass graft	Surgery		18.62	9.47	9.47		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for notes regarding Charge Methodology.

TABLE G -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 38 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
35509		Artery bypass graft	Surgery		18.04	8.79	8.79		
35510		Artery bypass graft	Surgery		22.97	10.20	10.20		
35511		Artery bypass graft	Surgery		21.17	9.38	9.38		
35512		Artery bypass graft	Surgery		22.47	10.03	10.03		
35515		Artery bypass graft	Surgery		18.62	9.31	9.31		
35516		Artery bypass graft	Surgery		16.30	6.82	6.82		
35518		Artery bypass graft	Surgery		21.17	9.00	9.00		
35521		Artery bypass graft	Surgery		22.47	9.86	9.86		
35522		Artery bypass graft	Surgery		21.73	9.78	9.78		
35525		Artery bypass graft	Surgery		20.60	9.40	9.40		
35526		Artery bypass graft	Surgery		29.91	12.54	12.54		
35531		Artery bypass graft	Surgery		36.15	14.51	14.51		
35533		Artery bypass graft	Surgery		27.96	11.75	11.75		
35536		Artery bypass graft	Surgery		31.65	12.98	12.98		
35541		Artery bypass graft	Surgery		25.76	11.23	11.23		
35546		Artery bypass graft	Surgery		25.50	10.89	10.89		
35548		Artery bypass graft	Surgery		21.54	9.45	9.45		
35549		Artery bypass graft	Surgery		23.31	10.40	10.40		
35551		Artery bypass graft	Surgery		26.63	11.52	11.52		
35556		Artery bypass graft	Surgery		21.73	9.75	9.75		
35558		Artery bypass graft	Surgery		21.17	9.57	9.57		
35560		Artery bypass graft	Surgery		31.95	13.35	13.35		
35563		Artery bypass graft	Surgery		24.16	10.55	10.55		
35565		Artery bypass graft	Surgery		23.47	10.16	10.16		
35566		Artery bypass graft	Surgery		26.88	11.41	11.41		
35571		Artery bypass graft	Surgery		24.02	10.87	10.87		
35572		Harvest femoropopliteal vein	Surgery		6.81	2.25	2.25		
35583		Vein bypass graft	Surgery		22.34	10.18	10.18		
35585		Vein bypass graft	Surgery		28.35	12.25	12.25		
35587		Vein bypass graft	Surgery		24.71	11.48	11.48		
35600		Harvest artery for cabg	Surgery		4.94	1.62	1.62		
35601		Artery bypass graft	Surgery		17.47	8.64	8.64		
35606		Artery bypass graft	Surgery		18.68	9.04	9.04		
35612		Artery bypass graft	Surgery		15.74	7.90	7.90		
35616		Artery bypass graft	Surgery		15.68	8.12	8.12		
35621		Artery bypass graft	Surgery		19.97	8.70	8.70		
35623		Bypass graft, not vein	Surgery		23.96	10.52	10.52		
35626		Artery bypass graft	Surgery		27.71	12.00	12.00		
35631		Artery bypass graft	Surgery		33.95	13.87	13.87		
35636		Artery bypass graft	Surgery		29.46	12.33	12.33		
35641		Artery bypass graft	Surgery		24.53	11.09	11.09		
35642		Artery bypass graft	Surgery		17.95	8.71	8.71		
35645		Artery bypass graft	Surgery		17.44	8.29	8.29		
35646		Artery bypass graft	Surgery		30.95	13.14	13.14		
35647		Artery bypass graft	Surgery		27.96	11.80	11.80		
35650		Artery bypass graft	Surgery		18.97	8.38	8.38		
35651		Artery bypass graft	Surgery		25.00	10.75	10.75		
35654		Artery bypass graft	Surgery		24.96	10.68	10.68		
35656		Artery bypass graft	Surgery		19.50	8.62	8.62		
35661		Artery bypass graft	Surgery		18.97	8.95	8.95		
35663		Artery bypass graft	Surgery		21.97	10.00	10.00		
35665		Artery bypass graft	Surgery		20.97	9.47	9.47		
35666		Artery bypass graft	Surgery		22.16	10.67	10.67		
35671		Artery bypass graft	Surgery		19.30	9.39	9.39		
35681		Composite bypass graft	Surgery		1.60	0.53	0.53		
35682		Composite bypass graft	Surgery		7.19	2.39	2.39		
35683		Composite bypass graft	Surgery		8.49	2.83	2.83		
35685		Bypass graft patency/patch	Surgery		4.04	1.35	1.35		
35686		Bypass graft/av fist patency	Surgery		3.34	1.13	1.13		
35691		Arterial transposition	Surgery		18.02	8.42	8.42		
35693		Arterial transposition	Surgery		15.34	7.74	7.74		
35694		Arterial transposition	Surgery		19.13	8.62	8.62		
35695		Arterial transposition	Surgery		19.13	8.57	8.57		
35697		Reimplant artery each	Surgery		3.00	1.02	1.02		
35700		Reoperation, bypass graft	Surgery		3.08	1.02	1.02		
35701		Exploration, carotid artery	Surgery		8.49	5.16	5.16		
35721		Exploration, femoral artery	Surgery		7.17	4.44	4.44		
35741		Exploration popliteal artery	Surgery		7.99	4.67	4.67		
35761		Exploration of artery/vein	Surgery		5.36	4.02	4.02		
35800		Explore neck vessels	Surgery		7.01	4.66	4.66		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 39 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
35820		Explore chest vessels	Surgery		12.86	7.22	7.22		
35840		Explore abdominal vessels	Surgery		9.76	5.30	5.30		
35860		Explore limb vessels	Surgery		5.54	4.04	4.04		
35870		Repair vessel graft defect	Surgery		22.14	9.79	9.79		
35875		Removal of clot in graft	Surgery		10.11	5.20	5.20		
35876		Removal of clot in graft	Surgery		16.97	7.53	7.53		
35879		Revise graft w/vein	Surgery		15.98	7.71	7.71		
35881		Revise graft w/vein	Surgery		17.97	8.69	8.69		
35901		Excision, graft, neck	Surgery		8.18	5.32	5.32		
35903		Excision, graft, extremity	Surgery		9.38	6.17	6.17		
35905		Excision, graft, thorax	Surgery		31.20	13.22	13.22		
35907		Excision, graft, abdomen	Surgery		34.95	14.20	14.20		
36000		Place needle in vein	Surgery		0.18	0.05	0.57		
36002		Pseudoaneurysm injection trt	Surgery		1.96	0.97	2.87		
36005		Injection ext venography	Surgery		0.95	0.31	7.67		
36010		Place catheter in vein	Surgery		2.43	0.79	19.36		
36011		Place catheter in vein	Surgery		3.14	1.06	27.90		
36012		Place catheter in vein	Surgery		3.51	1.19	19.00		
36013		Place catheter in artery	Surgery		2.52	0.69	21.42		
36014		Place catheter in artery	Surgery		3.02	1.03	20.18		
36015		Place catheter in artery	Surgery		3.51	1.19	23.73		
36100		Establish access to artery	Surgery		3.02	1.11	12.11		
36120		Establish access to artery	Surgery		2.01	0.65	10.73		
36140		Establish access to artery	Surgery		2.01	0.64	12.81		
36145		Artery to vein shunt	Surgery		2.01	0.66	12.59		
36160		Establish access to aorta	Surgery		2.52	0.84	13.52		
36200		Place catheter in aorta	Surgery		3.02	1.01	16.56		
36215		Place catheter in artery	Surgery		4.67	1.61	27.11		
36216		Place catheter in artery	Surgery		5.27	1.80	29.16		
36217		Place catheter in artery	Surgery		6.29	2.18	55.60		
36218		Place catheter in artery	Surgery		1.01	0.34	5.10		
36245		Place catheter in artery	Surgery		4.67	1.68	32.18		
36246		Place catheter in artery	Surgery		5.27	1.83	30.05		
36247		Place catheter in artery	Surgery		6.29	2.15	49.65		
36248		Place catheter in artery	Surgery		1.01	0.34	4.05		
36260		Insertion of infusion pump	Surgery		9.70	4.89	4.89		
36261		Revision of infusion pump	Surgery		5.44	3.67	3.67		
36262		Removal of infusion pump	Surgery		4.01	2.76	2.76		
36299		Vessel injection procedure	Surgery					4.04	
36400		Bl draw < 3 yrs fem/axular	Surgery		0.38	0.09	0.28		
36405		Bl draw < 3 yrs scalp vein	Surgery		0.31	0.08	0.26		
36406		Bl draw < 3 yrs other vein	Surgery		0.18	0.05	0.28		
36410		Non-routine bl draw > 3 yrs	Surgery		0.18	0.05	0.29		
36415		Routine venipuncture	Miscellaneous Medical	b				0.19	
36416		Capillary blood draw	Miscellaneous Medical	b				0.19	
36420		Vein access cutdown < 1 yr	Surgery		1.01	0.27	0.34		
36425		Vein access cutdown > 1 yr	Surgery		0.76	0.22	0.22		
36430		Blood transfusion service	Surgery		0.00	1.01	1.01		
36440		Bl push transfuse, 2 yr or <	Surgery		1.03	0.29	0.29		
36450		Bl exchange/transfuse, nb	Surgery		2.23	0.71	0.71		
36455		Bl exchange/transfuse non-nb	Surgery		2.43	1.01	1.01		
36460		Transfusion service, fetal	Surgery		6.58	2.25	2.25		
36468		Injection(s), spider veins	Surgery					1.97	
36469		Injection(s), spider veins	Surgery					2.10	
36470		Injection therapy of vein	Surgery		1.09	0.73	2.69		
36471		Injection therapy of veins	Surgery		1.57	0.96	3.08		
36475		Endovenous rf, 1st vein	Surgery		6.72	2.54	51.54		
36476		Endovenous rf, vein add-on	Surgery		3.38	1.14	7.90		
36478		Endovenous laser, 1st vein	Surgery		6.72	2.54	46.91		
36479		Endovenous laser vein add-on	Surgery		3.38	1.14	8.01		
36481		Insertion of catheter, vein	Surgery		6.98	2.60	5.75		
36500		Insertion of catheter, vein	Surgery		3.51	1.37	1.37		
36510		Insertion of catheter, vein	Surgery		1.09	0.61	3.90		
36511		Apheresis wbc	Surgery		1.74	0.73	0.73		
36512		Apheresis rbc	Surgery		1.74	0.74	0.74		
36513		Apheresis platelets	Surgery		1.74	0.73	0.73		
36514		Apheresis plasma	Surgery		1.74	0.71	17.02		
36515		Apheresis, adsorp/reinfuse	Surgery		1.74	0.66	66.49		
36516		Apheresis, selective	Surgery		1.22	0.48	84.29		
36522		Photopheresis	Surgery		1.67	0.96	32.46		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 40 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
36540		Collect blood venous device	Surgery					0.45	
36550		Declot vascular device	Surgery		0.00	0.39	0.39		
36555		Insert non-tunnel cv cath	Surgery		2.68	0.80	5.77		
36556		Insert non-tunnel cv cath	Surgery		2.50	0.74	5.64		
36557		Insert tunneled cv cath	Surgery		5.09	2.66	21.20		
36558		Insert tunneled cv cath	Surgery		4.79	2.56	21.10		
36560		Insert tunneled cv cath	Surgery		6.24	3.04	29.76		
36561		Insert tunneled cv cath	Surgery		5.99	2.96	29.67		
36563		Insert tunneled cv cath	Surgery		6.19	2.99	26.82		
36565		Insert tunneled cv cath	Surgery		5.99	2.96	24.77		
36566		Insert tunneled cv cath	Surgery		6.49	3.12	25.57		
36568		Insert tunneled cv cath	Surgery		1.92	0.58	7.55		
36569		Insert tunneled cv cath	Surgery		1.82	0.57	7.36		
36570		Insert tunneled cv cath	Surgery		5.31	2.73	33.27		
36571		Insert tunneled cv cath	Surgery		5.29	2.72	33.34		
36575		Repair tunneled cv cath	Surgery		0.67	0.26	4.06		
36576		Repair tunneled cv cath	Surgery		3.19	1.85	6.96		
36578		Replace tunneled cv cath	Surgery		3.49	2.31	11.16		
36580		Replace tunneled cv cath	Surgery		1.31	0.41	6.96		
36581		Replace tunneled cv cath	Surgery		3.43	1.93	19.55		
36582		Replace tunneled cv cath	Surgery		5.19	2.87	26.09		
36583		Replace tunneled cv cath	Surgery		5.24	2.89	26.11		
36584		Replace tunneled cv cath	Surgery		1.20	0.55	6.99		
36585		Replace tunneled cv cath	Surgery		4.79	2.74	27.90		
36589		Removal tunneled cv cath	Surgery		2.27	1.39	2.25		
36590		Removal tunneled cv cath	Surgery		3.30	1.72	3.38		
36595		Mech remov tunneled cv cath	Surgery		3.59	1.45	17.30		
36596		Mech remov tunneled cv cath	Surgery		0.75	0.50	3.70		
36597		Reposition venous catheter	Surgery		1.21	0.44	2.41		
36598		Inj w/fluor, eval cv device	Surgery	a	0.74	2.65	2.65		RBRVS
36600		Withdrawal of arterial blood	Surgery		0.32	0.09	0.49		
36620		Insertion catheter, artery	Surgery		1.15	0.23	0.23		
36625		Insertion catheter, artery	Surgery		2.11	0.53	0.53		
36640		Insertion catheter, artery	Surgery		2.10	1.04	1.04		
36660		Insertion catheter, artery	Surgery		1.40	0.44	0.44		
36680		Insert needle, bone cavity	Surgery		1.20	0.49	0.49		
36800		Insertion of cannula	Surgery		2.43	1.81	1.81		
36810		Insertion of cannula	Surgery		3.96	1.68	1.68		
36815		Insertion of cannula	Surgery		2.62	1.17	1.17		
36818		Av fuse, uppr arm, cephalic	Surgery		11.52	6.05	6.05		
36819		Av fusion/uppr arm vein	Surgery		13.98	6.39	6.39		
36820		Av fusion/forearm vein	Surgery		13.98	6.40	6.40		
36821		Av fusion direct any site	Surgery		8.92	4.66	4.66		
36822		Insertion of cannula(s)	Surgery		5.41	4.39	4.39		
36823		Insertion of cannula(s)	Surgery		20.97	9.40	9.40		
36825		Artery-vein autograft	Surgery		9.63	5.06	5.06		
36830		Artery-vein nonautograft	Surgery		11.98	5.25	5.25		
36831		Open thrombect av fistula	Surgery		7.99	3.95	3.95		
36832		Av fistula revision, open	Surgery		10.48	4.73	4.73		
36833		Av fistula revision	Surgery		11.93	5.22	5.22		
36834		Repair A-V aneurysm	Surgery		9.92	4.80	4.80		
36835		Artery to vein shunt	Surgery		7.14	4.33	4.33		
36838		Dist revas ligation, hemo	Surgery		20.60	9.41	9.41		
36860		External cannula declotting	Surgery		2.01	0.68	1.78		
36861		Cannula declotting	Surgery		2.52	1.49	1.49		
36870		Percut thrombect av fistula	Surgery		5.15	3.16	53.18		
37140		Revision of circulation	Surgery		23.56	10.51	10.51		
37145		Revision of circulation	Surgery		24.57	10.89	10.89		
37160		Revision of circulation	Surgery		21.57	9.28	9.28		
37180		Revision of circulation	Surgery		24.57	10.32	10.32		
37181		Splice spleen/kidney veins	Surgery		26.64	11.03	11.03		
37182		Insert hepatic shunt (tips)	Surgery		16.97	6.08	6.08		
37183		Remove hepatic shunt (tips)	Surgery		7.99	3.02	3.02		
37184		Prim art mech thrombectomy	Surgery	a	8.66	3.36	71.90		RBRVS
37185		Prim art m-thrombect add-on	Surgery	a	3.28	1.11	22.95		RBRVS
37186		Sec art m-thrombect add-on	Surgery	a	4.92	1.66	49.53		RBRVS
37187		Venous mech thrombectomy	Surgery	a	8.03	3.15	70.38		RBRVS
37188		Venous m-thrombectomy add-on	Surgery	a	5.71	2.37	62.15		RBRVS
37195		Thrombolytic therapy, stroke	Surgery	a	4.99	2.55	2.55		CALC
37200		Transcatheter biopsy	Surgery		4.55	1.50	1.50		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 41 OF 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
37201		Transcatheter therapy infuse	Surgery		4.99	2.55	2.55		
37202		Transcatheter therapy infuse	Surgery		5.67	3.04	3.04		
37203		Transcatheter retrieval	Surgery		5.02	2.04	32.97		
37204		Transcatheter occlusion	Surgery		18.11	5.92	5.92		
37205		Transcatheter stent	Surgery		8.27	3.76	3.76		
37206		Transcatheter stent add-on	Surgery		4.12	1.43	1.43		
37207		Transcatheter stent	Surgery		8.27	3.17	3.17		
37208		Transcatheter stent add-on	Surgery		4.12	1.38	1.38		
37209		Exchange arterial catheter	Surgery		2.27	0.74	0.74		
37215		Transcath stent, cca w/eps	Surgery		18.71	9.12	9.12		
37216		Transcath stent, cca w/o eps	Surgery		17.98	8.84	8.84		
37250		Iv us first vessel add-on	Surgery		2.10	0.75	0.75		
37251		Iv us each add vessel add-on	Surgery		1.60	0.55	0.55		
37500		Endoscopy ligate perf veins	Surgery		10.98	6.87	6.87		
37501		Vascular endoscopy procedure	Surgery					18.10	
37565		Ligation of neck vein	Surgery		10.86	5.64	5.64		
37600		Ligation of neck artery	Surgery		11.23	6.65	6.65		
37605		Ligation of neck artery	Surgery		13.09	6.92	6.92		
37606		Ligation of neck artery	Surgery		6.27	4.57	4.57		
37607		Ligation of a-v fistula	Surgery		6.15	3.57	3.57		
37609		Temporal artery procedure	Surgery		3.00	1.97	4.51		
37615		Ligation of neck artery	Surgery		5.72	4.12	4.12		
37616		Ligation of chest artery	Surgery		16.47	8.10	8.10		
37617		Ligation of abdomen artery	Surgery		22.03	9.20	9.20		
37618		Ligation of extremity artery	Surgery		4.83	3.62	3.62		
37620		Revision of major vein	Surgery		10.54	5.73	5.73		
37650		Revision of major vein	Surgery		7.79	4.69	4.69		
37660		Revision of major vein	Surgery		20.97	9.08	9.08		
37700		Revise leg vein	Surgery		3.72	2.80	2.80		
37718		Ligate/strip short leg vein	Surgery	a	6.76	4.07	4.07		RBRVS
37722		Ligate/strip long leg vein	Surgery	a	7.79	4.42	4.42		RBRVS
37735		Removal of leg veins/lesion	Surgery		10.51	5.52	5.52		
37760		Ligation, leg veins, open	Surgery		10.45	5.36	5.36		
37765		Phleb veins - extrem - to 20	Surgery		7.34	4.63	4.63		
37766		Phleb veins - extrem 20+	Surgery		9.29	5.34	5.34		
37780		Revision of leg vein	Surgery		3.83	2.86	2.86		
37785		Revise secondary varicosity	Surgery		3.83	2.73	5.21		
37788		Revascularization, penis	Surgery		21.98	9.11	9.11		
37790		Penile venous occlusion	Surgery		8.33	4.38	4.38		
37799		Vascular surgery procedure	Surgery					0.11	
38100		Removal of spleen, total	Surgery		14.48	6.19	6.19		
38101		Removal of spleen, partial	Surgery		15.29	6.54	6.54		
38102		Removal of spleen, total	Surgery		4.79	1.64	1.64		
38115		Repair of ruptured spleen	Surgery		15.80	6.66	6.66		
38120		Laparoscopy, splenectomy	Surgery		16.97	7.40	7.40		
38129		Laparoscope proc, spleen	Surgery					24.40	
38200		Injection for spleen x-ray	Surgery		2.64	0.89	0.89		
38205		Harvest allogenic stem cells	Surgery		1.50	0.67	0.67		
38206		Harvest auto stem cells	Surgery		1.50	0.67	0.67		
38207		Cryopreserve stem cells	Surgery					1.75	
38208		Thaw preserved stem cells	Surgery					1.91	
38209		Wash harvest stem cells	Surgery					1.68	
38210		T-cell depletion of harvest	Surgery					1.83	
38211		Tumor cell deplete of harvest	Surgery					1.83	
38212		Rbc depletion of harvest	Surgery					1.83	
38213		Platelet deplete of harvest	Surgery					1.83	
38214		Volume deplete of harvest	Surgery					1.52	
38215		Harvest stem cell concentrate	Surgery					1.83	
38220		Bone marrow aspiration	Surgery		1.08	0.52	3.73		
38221		Bone marrow biopsy	Surgery		1.37	0.65	3.94		
38230		Bone marrow collection	Surgery		4.53	3.23	3.23		
38240		Bone marrow/stem transplant	Surgery		2.24	1.03	1.03		
38241		Bone marrow/stem transplant	Surgery		2.24	1.04	1.04		
38242		Lymphocyte infuse transplant	Surgery		1.71	0.78	0.78		
38300		Drainage, lymph node lesion	Surgery		1.99	2.06	4.31		
38305		Drainage, lymph node lesion	Surgery		5.99	4.45	4.45		
38308		Incision of lymph channels	Surgery		6.44	3.75	3.75		
38380		Thoracic duct procedure	Surgery		7.45	5.70	5.70		
38381		Thoracic duct procedure	Surgery		12.86	6.90	6.90		
38382		Thoracic duct procedure	Surgery		10.06	5.77	5.77		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/OFARS apply. See end of the table for notes regarding Charge Methodology

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 42 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
38500		Biopsy/removal, lymph nodes	Surgery		3.74	2.09	3.70		
38505		Needle biopsy, lymph nodes	Surgery		1.14	0.78	2.06		
38510		Biopsy/removal, lymph nodes	Surgery		6.42	3.49	5.56		
38520		Biopsy/removal, lymph nodes	Surgery		6.66	4.06	4.06		
38525		Biopsy/removal, lymph nodes	Surgery		6.06	3.30	3.30		
38530		Biopsy/removal, lymph nodes	Surgery		7.97	4.40	4.40		
38542		Explora deep node(s), neck	Surgery		5.90	4.49	4.49		
38550		Removal, neck/arm/pit lesion	Surgery		6.91	3.92	3.92		
38555		Removal, neck/arm/pit lesion	Surgery		14.12	8.55	8.55		
38562		Removal, pelvic lymph nodes	Surgery		10.47	5.79	5.79		
38564		Removal, abdomen lymph nodes	Surgery		10.81	5.26	5.26		
38570		Laparoscopy, lymph node biop	Surgery		9.24	3.98	3.98		
38571		Laparoscopy, lymphadenectomy	Surgery		14.66	5.66	5.66		
38572		Laparoscopy, lymphadenectomy	Surgery		16.57	7.09	7.09		
38589		Laparoscope proc, lymphatic	Surgery					13.18	
38700		Removal of lymph nodes, neck	Surgery		8.23	6.25	6.25		
38720		Removal of lymph nodes, neck	Surgery		13.59	9.38	9.38		
38724		Removal of lymph nodes, neck	Surgery		14.52	9.86	9.86		
38740		Remove armpit lymph nodes	Surgery		10.01	4.95	4.95		
38745		Remove armpit lymph nodes	Surgery		13.08	6.09	6.09		
38746		Remove thoracic lymph nodes	Surgery		4.88	1.61	1.61		
38747		Remove abdominal lymph nodes	Surgery		4.88	1.67	1.67		
38760		Remove groin lymph nodes	Surgery		12.93	6.14	6.14		
38765		Remove groin lymph nodes	Surgery		19.95	8.83	8.83		
38770		Remove pelvis lymph nodes	Surgery		13.21	5.76	5.76		
38780		Remove abdomen lymph nodes	Surgery		16.57	8.22	8.22		
38790		Inject for lymphatic x-ray	Surgery		1.29	0.76	7.37		
38792		Identify sentinel node	Surgery		0.52	0.44	0.44		
38794		Access thoracic lymph duct	Surgery		4.44	3.46	3.46		
38999		Blood/lymph system procedure	Surgery					5.81	
39000		Exploration of chest	Surgery		6.09	4.66	4.66		
39010		Exploration of chest	Surgery		11.77	7.56	7.56		
39200		Removal chest lesion	Surgery		13.60	7.55	7.55		
39220		Removal chest lesion	Surgery		17.39	9.39	9.39		
39400		Visualization of chest	Surgery		5.60	4.86	4.86		
39499		Chest procedure	Surgery					10.47	
39501		Repair diaphragm laceration	Surgery		13.17	6.47	6.47		
39502		Repair paraesophageal hernia	Surgery		16.31	7.16	7.16		
39503		Repair of diaphragm hernia	Surgery		94.86	33.47	33.47		
39520		Repair of diaphragm hernia	Surgery		16.08	8.06	8.06		
39530		Repair of diaphragm hernia	Surgery		15.39	7.15	7.15		
39531		Repair of diaphragm hernia	Surgery		16.40	7.40	7.40		
39540		Repair of diaphragm hernia	Surgery		13.30	6.24	6.24		
39541		Repair of diaphragm hernia	Surgery		14.39	6.60	6.60		
39545		Revision of diaphragm	Surgery		13.35	7.56	7.56		
39560		Resect diaphragm, simple	Surgery		11.98	6.30	6.30		
39561		Resect diaphragm, complex	Surgery		17.47	9.36	9.36		
39599		Diaphragm surgery procedure	Surgery					21.04	
40490		Biopsy of lip	Surgery		1.22	0.61	1.63		
40500		Partial excision of lip	Surgery		4.27	4.34	6.91		
40510		Partial excision of lip	Surgery		4.69	4.02	6.63		
40520		Partial excision of lip	Surgery		4.66	4.12	7.56		
40525		Reconstruct lip with flap	Surgery		7.54	6.32	6.32		
40527		Reconstruct lip with flap	Surgery		9.12	7.37	7.37		
40530		Partial removal of lip	Surgery		5.39	4.59	7.83		
40650		Repair lip	Surgery		3.63	3.30	6.81		
40652		Repair lip	Surgery		4.25	4.27	7.76		
40654		Repair lip	Surgery		5.30	4.94	8.62		
40700		Repair cleft lip/nasal	Surgery		12.77	9.10	9.10		
40701		Repair cleft lip/nasal	Surgery		15.83	11.36	11.36		
40702		Repair cleft lip/nasal	Surgery		13.02	8.27	8.27		
40720		Repair cleft lip/nasal	Surgery		13.53	9.92	9.92		
40761		Repair cleft lip/nasal	Surgery		14.70	10.30	10.30		
40799		Lip surgery procedure	Surgery					2.91	
40800		Drainage of mouth lesion	Surgery		1.17	1.78	2.97		
40801		Drainage of mouth lesion	Surgery		2.53	2.75	4.03		
40804		Removal, foreign body, mouth	Surgery		1.24	1.86	3.40		
40805		Removal, foreign body, mouth	Surgery		2.69	2.82	4.49		
40806		Incision of lip fold	Surgery		0.31	0.50	1.84		
40808		Biopsy of mouth lesion	Surgery		0.96	1.48	2.66		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARSOFARS apply.
See end of the table for notes regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 43 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
40810		Excision of mouth lesion	Surgery		1.31	1.66	2.89		
40812		Excise/repair mouth lesion	Surgery		2.31	2.41	3.73		
40814		Excise/repair mouth lesion	Surgery		3.41	3.90	4.95		
40816		Excision of mouth lesion	Surgery		3.66	4.01	5.18		
40818		Excise oral mucosa for graft	Surgery		2.41	3.98	5.18		
40819		Excise lip or cheek fold	Surgery		2.41	3.10	4.09		
40820		Treatment of mouth lesion	Surgery		1.28	2.45	3.94		
40830		Repair mouth laceration	Surgery		1.76	2.10	3.73		
40831		Repair mouth laceration	Surgery		2.46	3.06	4.67		
40840		Reconstruction of mouth	Surgery		8.72	6.99	9.81		
40842		Reconstruction of mouth	Surgery		8.72	6.80	10.09		
40843		Reconstruction of mouth	Surgery		12.08	7.83	11.98		
40844		Reconstruction of mouth	Surgery		15.99	11.59	15.81		
40845		Reconstruction of mouth	Surgery		18.55	13.25	17.11		
40899		Mouth surgery procedure	Surgery					5.25	
41000		Drainage of mouth lesion	Surgery		1.30	1.41	2.32		
41005		Drainage of mouth lesion	Surgery		1.26	1.72	3.34		
41006		Drainage of mouth lesion	Surgery		3.24	3.18	4.80		
41007		Drainage of mouth lesion	Surgery		3.10	3.03	5.15		
41008		Drainage of mouth lesion	Surgery		3.36	3.21	4.69		
41009		Drainage of mouth lesion	Surgery		3.58	3.58	4.98		
41010		Incision of tongue fold	Surgery		1.05	1.60	3.43		
41015		Drainage of mouth lesion	Surgery		3.95	4.15	5.42		
41016		Drainage of mouth lesion	Surgery		4.06	4.23	5.63		
41017		Drainage of mouth lesion	Surgery		4.06	4.31	5.65		
41018		Drainage of mouth lesion	Surgery		5.09	4.58	6.15		
41100		Biopsy of tongue	Surgery		1.63	1.42	2.43		
41105		Biopsy of tongue	Surgery		1.42	1.32	2.31		
41108		Biopsy of floor of mouth	Surgery		1.05	1.13	2.08		
41110		Excision of tongue lesion	Surgery		1.51	1.64	2.99		
41112		Excision of tongue lesion	Surgery		2.73	3.23	4.48		
41113		Excision of tongue lesion	Surgery		3.19	3.48	4.75		
41114		Excision of tongue lesion	Surgery		8.46	7.21	7.21		
41115		Excision of tongue fold	Surgery		1.74	1.86	3.30		
41116		Excision of mouth lesion	Surgery		2.44	2.81	4.36		
41120		Partial removal of tongue	Surgery		9.76	15.35	15.35		
41130		Partial removal of tongue	Surgery		11.13	16.24	16.24		
41135		Tongue and neck surgery	Surgery		23.06	23.29	23.29		
41140		Removal of tongue	Surgery		25.46	26.75	26.75		
41145		Tongue removal, neck surgery	Surgery		30.01	30.63	30.63		
41150		Tongue, mouth, jaw surgery	Surgery		23.01	24.78	24.78		
41153		Tongue, mouth, neck surgery	Surgery		23.73	25.09	25.09		
41155		Tongue, jaw, & neck surgery	Surgery		27.68	26.88	26.88		
41250		Repair tongue laceration	Surgery		1.91	1.18	2.75		
41251		Repair tongue laceration	Surgery		2.27	1.55	3.28		
41252		Repair tongue laceration	Surgery		2.97	2.26	3.90		
41500		Fixation of tongue	Surgery		3.70	7.47	7.47		
41510		Tongue to lip surgery	Surgery		3.41	7.95	7.95		
41520		Reconstruction, tongue fold	Surgery		2.73	3.63	4.63		
41599		Tongue and mouth surgery	Surgery					4.52	
41800		Drainage of gum lesion	Surgery		1.17	1.28	2.60		
41805		Removal foreign body, gum	Surgery		1.24	2.22	2.68		
41806		Removal foreign body, jawbone	Surgery		2.69	3.04	3.59		
41820		Excision, gum, each quadrant	Surgery					4.89	
41821		Excision of gum flap	Surgery					1.10	
41822		Excision of gum lesion	Surgery		2.31	1.88	3.90		
41823		Excision of gum lesion	Surgery		3.30	4.02	5.58		
41825		Excision of gum lesion	Surgery		1.31	2.25	3.07		
41826		Excision of gum lesion	Surgery		2.31	2.11	2.44		
41827		Excision of gum lesion	Surgery		3.41	3.67	5.53		
41828		Excision of gum lesion	Surgery		3.09	2.97	3.81		
41830		Removal of gum tissue	Surgery		3.34	3.63	4.97		
41850		Treatment of gum lesion	Surgery					2.45	
41870		Gum graft	Surgery					6.12	
41872		Repair gum	Surgery		2.59	3.47	5.03		
41874		Repair tooth socket	Surgery		3.09	3.18	4.85		
41899		Dental surgery procedure	Surgery					5.92	
42000		Drainage mouth roof lesion	Surgery		1.23	1.25	2.57		
42100		Biopsy roof of mouth	Surgery		1.31	1.36	2.09		
42104		Excision lesion, mouth roof	Surgery		1.64	1.55	2.55		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 44 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
42106		Excision lesion, mouth roof	Surgery		2.10	2.45	3.23		
42107		Excision lesion, mouth roof	Surgery		4.43	3.96	5.73		
42120		Remove palate/lesion	Surgery		6.16	11.80	11.80		
42140		Excision of uvula	Surgery		1.62	2.10	3.73		
42145		Repair palate, pharynx/uvula	Surgery		8.04	7.51	7.51		
42160		Treatment mouth roof lesion	Surgery		1.80	2.30	4.26		
42180		Repair palate	Surgery		2.50	2.11	3.08		
42182		Repair palata	Surgery		3.82	3.04	3.88		
42200		Reconstruct cleft palate	Surgery		11.98	10.24	10.24		
42205		Reconstruct cleft palate	Surgery		13.27	10.10	10.10		
42210		Reconstruct cleft palate	Surgery		14.48	11.49	11.49		
42215		Reconstruct cleft palate	Surgery		8.81	9.10	9.10		
42220		Reconstruct cleft palate	Surgery		7.01	6.80	6.80		
42225		Reconstruct cleft palate	Surgery		9.53	17.11	17.11		
42226		Lengthening of palate	Surgery		9.99	14.74	14.74		
42227		Lengthening of palate	Surgery		9.51	15.59	15.59		
42235		Repair palate	Surgery		7.86	11.89	11.89		
42260		Repair nose to lip fistula	Surgery		9.79	7.08	10.22		
42280		Preparation, palate mold	Surgery		1.54	1.14	1.97		
42281		Insertion, palate prosthesis	Surgery		1.93	1.88	2.64		
42299		Palate/uvula surgery	Surgery					14.65	
42300		Drainage of salivary gland	Surgery		1.93	1.82	2.83		
42305		Drainage of salivary gland	Surgery		6.06	4.73	4.73		
42310		Drainage of salivary gland	Surgery		1.56	1.54	2.27		
42320		Drainage of salivary gland	Surgery		2.35	2.10	3.28		
42330		Removal of salivary stone	Surgery		2.21	1.85	3.15		
42335		Removal of salivary stone	Surgery		3.31	3.15	4.91		
42340		Removal of salivary stone	Surgery		4.59	3.94	6.06		
42400		Biopsy of salivary gland	Surgery		0.78	0.72	1.65		
42405		Biopsy of salivary gland	Surgery		3.29	2.46	4.01		
42408		Excision of salivary cyst	Surgery		4.53	3.62	5.93		
42409		Drainage of salivary cyst	Surgery		2.81	2.77	4.53		
42410		Excise parotid gland/lesion	Surgery		9.33	6.24	6.24		
42415		Excise parotid gland/lesion	Surgery		16.86	10.89	10.89		
42420		Excise parotid gland/lesion	Surgery		19.56	12.41	12.41		
42425		Excise parotid gland/lesion	Surgery		13.00	8.63	8.63		
42426		Excise parotid gland/lesion	Surgery		21.23	13.05	13.05		
42440		Excise submaxillary gland	Surgery		6.96	4.80	4.80		
42450		Excise sublingual gland	Surgery		4.61	4.26	5.92		
42500		Repair salivary duct	Surgery		4.29	4.19	5.70		
42505		Repair salivary duct	Surgery		6.17	5.38	7.14		
42507		Parotid duct diversion	Surgery		6.10	6.55	6.55		
42508		Parotid duct diversion	Surgery		9.09	8.36	8.36		
42509		Parotid duct diversion	Surgery		11.52	10.22	10.22		
42510		Parotid duct diversion	Surgery		8.14	7.81	7.81		
42550		Injection for salivary x-ray	Surgery		1.25	0.41	3.22		
42600		Closure of salivary fistula	Surgery		4.81	4.13	6.60		
42650		Dilation of salivary duct	Surgery		0.77	0.71	1.10		
42660		Dilation of salivary duct	Surgery		1.13	0.85	1.35		
42665		Ligation of salivary duct	Surgery		2.53	2.60	4.18		
42699		Salivary surgery procedure	Surgery					12.02	
42700		Drainage of tonsil abscess	Surgery		1.62	1.70	2.66		
42720		Drainage of throat abscess	Surgery		5.41	3.80	4.84		
42725		Drainage of throat abscess	Surgery		10.70	8.24	8.24		
42800		Biopsy of throat	Surgery		1.39	1.40	2.19		
42802		Biopsy of throat	Surgery		1.54	2.07	4.77		
42804		Biopsy of upper nose/throat	Surgery		1.24	1.74	3.75		
42806		Biopsy of upper nose/throat	Surgery		1.58	1.94	4.08		
42808		Excise pharynx lesion	Surgery		2.30	1.94	3.10		
42809		Remove pharynx foreign body	Surgery		1.81	1.33	2.34		
42810		Excision of neck cyst	Surgery		3.25	3.55	5.73		
42815		Excision of neck cyst	Surgery		7.06	6.43	6.43		
42820		Remove tonsils and adenoids	Surgery		3.90	3.30	3.30		
42821		Remove tonsils and adenoids	Surgery		4.28	3.51	3.51		
42825		Removal of tonsils	Surgery		3.41	3.18	3.18		
42826		Removal of tonsils	Surgery		3.37	3.04	3.04		
42830		Removal of adenoids	Surgery		2.57	2.57	2.57		
42831		Removal of adenoids	Surgery		2.71	2.85	2.85		
42835		Removal of adenoids	Surgery		2.30	2.47	2.47		
42836		Removal of adenoids	Surgery		3.18	2.97	2.97		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 45 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
42842		Extensive surgery of throat	Surgery		8.75	11.02	11.02		
42844		Extensive surgery of throat	Surgery		14.29	16.28	16.28		
42845		Extensive surgery of throat	Surgery		24.25	23.25	23.25		
42860		Excision of tonsil tags	Surgery		2.22	2.41	2.41		
42870		Excision of lingual tonsil	Surgery		5.39	8.59	8.59		
42890		Partial removal of pharynx	Surgery		12.92	14.19	14.19		
42892		Revision of pharyngeal walls	Surgery		15.81	17.22	17.22		
42894		Revision of pharyngeal walls	Surgery		22.85	22.08	22.08		
42900		Repair throat wound	Surgery		5.24	3.67	3.67		
42950		Reconstruction of throat	Surgery		8.09	11.90	11.90		
42953		Repair throat, esophagus	Surgery		8.95	17.38	17.38		
42955		Surgical opening of throat	Surgery		7.38	10.70	10.70		
42960		Control throat bleeding	Surgery		2.33	1.97	1.97		
42961		Control throat bleeding	Surgery		5.58	4.97	4.97		
42962		Control throat bleeding	Surgery		7.13	5.93	5.93		
42970		Control nose/throat bleeding	Surgery		5.42	4.19	4.19		
42971		Control nose/throat bleeding	Surgery		6.20	5.13	5.13		
42972		Control nose/throat bleeding	Surgery		7.19	5.72	5.72		
42999		Throat surgery procedure	Surgery					7.37	
43020		Incision of esophagus	Surgery		8.08	5.43	5.43		
43030		Throat muscle surgery	Surgery		7.68	5.51	5.51		
43045		Incision of esophagus	Surgery		20.09	10.73	10.73		
43100		Excision of esophagus lesion	Surgery		9.18	6.24	6.24		
43101		Excision of esophagus lesion	Surgery		16.22	7.90	7.90		
43107		Removal of esophagus	Surgery		39.94	18.31	18.31		
43108		Removal of esophagus	Surgery		34.14	14.25	14.25		
43112		Removal of esophagus	Surgery		43.43	19.42	19.42		
43113		Removal of esophagus	Surgery		35.22	15.15	15.15		
43116		Partial removal of esophagus	Surgery		31.17	16.74	16.74		
43117		Partial removal of esophagus	Surgery		39.94	17.32	17.32		
43118		Partial removal of esophagus	Surgery		33.15	13.82	13.82		
43121		Partial removal of esophagus	Surgery		29.15	13.71	13.71		
43122		Partial removal of esophagus	Surgery		39.94	17.44	17.44		
43123		Partial removal of esophagus	Surgery		33.15	14.14	14.14		
43124		Removal of esophagus	Surgery		27.28	13.12	13.12		
43130		Removal of esophagus pouch	Surgery		11.73	7.58	7.58		
43135		Removal of esophagus pouch	Surgery		16.08	8.11	8.11		
43200		Esophagus endoscopy	Surgery		1.59	1.07	4.14		
43201		Esoph scope w/submucous inj	Surgery		2.09	1.10	4.64		
43202		Esophagus endoscopy, biopsy	Surgery		1.89	0.94	5.56		
43204		Esoph scope w/sclerosis inj	Surgery		3.76	1.52	1.52		
43205		Esophagus endoscopy/ligation	Surgery		3.78	1.52	1.52		
43215		Esophagus endoscopy	Surgery		2.60	1.20	1.20		
43216		Esophagus endoscopy/lesion	Surgery		2.40	1.06	1.06		
43217		Esophagus endoscopy	Surgery		2.90	1.19	6.97		
43219		Esophagus endoscopy	Surgery		2.80	1.35	1.35		
43220		Esoph endoscopy, dilation	Surgery		2.10	0.97	0.97		
43226		Esoph endoscopy, dilation	Surgery		2.34	1.03	1.03		
43227		Esoph endoscopy, repair	Surgery		3.59	1.45	1.45		
43228		Esoph endoscopy, ablation	Surgery		3.76	1.55	1.55		
43231		Esoph endoscopy w/us exam	Surgery		3.19	1.31	1.31		
43232		Esoph endoscopy w/us fn bx	Surgery		4.47	1.82	1.82		
43234		Upper GI endoscopy, exam	Surgery		2.01	0.87	5.34		
43235		Uppr gi endoscopy, diagnosis	Surgery		2.39	1.02	5.18		
43236		Uppr gi scope w/submuc inj	Surgery		2.92	1.22	6.42		
43237		Endoscopic us exam, esoph	Surgery		3.98	1.59	1.59		
43238		Uppr gi endoscopy w/us fn bx	Surgery		5.02	1.97	1.97		
43239		Upper GI endoscopy, biopsy	Surgery		2.87	1.19	5.73		
43240		Esoph endoscope w/drain cyst	Surgery		6.85	2.61	2.61		
43241		Upper GI endoscopy with tube	Surgery		2.59	1.10	1.10		
43242		Uppr gi endoscopy w/us fn bx	Surgery		7.30	2.74	2.74		
43243		Upper gi endoscopy & inject	Surgery		4.56	1.80	1.80		
43244		Upper GI endoscopy/ligation	Surgery		5.04	1.97	1.97		
43245		Uppr gi scope dilate strict	Surgery		3.18	1.30	1.30		
43246		Place gastrostomy tube	Surgery		4.32	1.69	1.69		
43247		Operative upper GI endoscopy	Surgery		3.38	1.37	1.37		
43248		Uppr gi endoscopy/guide wire	Surgery		3.15	1.31	1.31		
43249		Esoph endoscopy, dilation	Surgery		2.90	1.21	1.21		
43250		Upper GI endoscopy/tumor	Surgery		3.20	1.31	1.31		
43251		Operative upper GI endoscopy	Surgery		3.69	1.48	1.48		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 46 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
43255		Operative upper GI endoscopy	Surgery		4.81	1.89	1.89		
43256		Uppr gi endoscopy w stent	Surgery		4.34	1.71	1.71		
43257		Uppr gi scope w/triml bsmnt	Surgery		5.50	2.21	2.21		
43258		Operative upper GI endoscopy	Surgery		4.54	1.79	1.79		
43259		Endoscopic ultrasound exam	Surgery		5.19	2.00	2.00		
43260		Endo cholangiopancreatograph	Surgery		5.95	2.29	2.29		
43261		Endo cholangiopancreatograph	Surgery		6.26	2.40	2.40		
43262		Endo cholangiopancreatograph	Surgery		7.38	2.79	2.79		
43263		Endo cholangiopancreatograph	Surgery		7.28	2.77	2.77		
43264		Endo cholangiopancreatograph	Surgery		8.89	3.32	3.32		
43265		Endo cholangiopancreatograph	Surgery		10.00	3.70	3.70		
43267		Endo cholangiopancreatograph	Surgery		7.38	2.79	2.79		
43268		Endo cholangiopancreatograph	Surgery		7.38	2.89	2.89		
43269		Endo cholangiopancreatograph	Surgery		8.20	3.08	3.08		
43271		Endo cholangiopancreatograph	Surgery		7.38	2.79	2.79		
43272		Endo cholangiopancreatograph	Surgery		7.38	2.79	2.79		
43280		Laparoscopy, fundopasty	Surgery		17.22	7.29	7.29		
43289		Laparoscope proc, esoph	Surgery					24.55	
43300		Repair of esophagus	Surgery		9.13	6.39	6.39		
43305		Repair esophagus and fistula	Surgery		17.36	10.72	10.72		
43310		Repair of esophagus	Surgery		25.35	11.09	11.09		
43312		Repair esophagus and fistula	Surgery		28.38	11.92	11.92		
43313		Esophagoplasty congenital	Surgery		45.21	18.86	18.86		
43314		Tracheo-esophagoplasty cong	Surgery		50.19	19.24	19.24		
43320		Fuse esophagus & stomach	Surgery		19.90	9.23	9.23		
43324		Revise esophagus & stomach	Surgery		20.54	8.79	8.79		
43325		Revise esophagus & stomach	Surgery		20.03	8.81	8.81		
43326		Revise esophagus & stomach	Surgery		19.71	9.32	9.32		
43330		Repair of esophagus	Surgery		19.74	8.55	8.55		
43331		Repair of esophagus	Surgery		20.10	9.81	9.81		
43340		Fuse esophagus & intestine	Surgery		19.58	8.99	8.99		
43341		Fuse esophagus & Intestine	Surgery		20.82	10.04	10.04		
43350		Surgical opening, esophagus	Surgery		15.76	8.46	8.46		
43351		Surgical opening, esophagus	Surgery		18.32	9.82	9.82		
43352		Surgical opening, esophagus	Surgery		15.24	8.40	8.40		
43360		Gastrointestinal repair	Surgery		35.65	15.11	15.11		
43361		Gastrointestinal repair	Surgery		40.44	16.93	16.93		
43400		Ligate esophagus veins	Surgery		21.17	9.46	9.46		
43401		Esophagus surgery for veins	Surgery		22.06	9.51	9.51		
43405		Ligate/staple esophagus	Surgery		19.98	9.61	9.61		
43410		Repair esophagus wound	Surgery		13.45	7.65	7.65		
43415		Repair esophagus wound	Surgery		24.96	11.77	11.77		
43420		Repair esophagus opening	Surgery		14.33	7.42	7.42		
43425		Repair esophagus opening	Surgery		21.00	10.00	10.00		
43450		Dilate esophagus	Surgery		1.38	0.69	2.64		
43453		Dilate esophagus	Surgery		1.51	0.73	6.08		
43456		Dilate esophagus	Surgery		2.57	1.10	13.78		
43458		Dilate esophagus	Surgery		3.06	1.28	6.67		
43460		Pressure treatment esophagus	Surgery		3.79	1.49	1.49		
43496		Free jejunum flap, microvasc	Surgery					4.58	
43499		Esophagus surgery procedure	Surgery					4.58	CALC
43500		Surgical opening of stomach	Surgery		11.03	4.98	4.98		
43501		Surgical repair of stomach	Surgery		20.01	8.32	8.32		
43502		Surgical repair of stomach	Surgery		23.10	9.48	9.48		
43510		Surgical opening of stomach	Surgery		13.06	6.60	6.60		
43520		Incision of pyloric muscle	Surgery		9.98	5.27	5.27		
43600		Biopsy of stomach	Surgery		1.91	0.66	0.66		
43605		Biopsy of stomach	Surgery		11.96	5.30	5.30		
43610		Excision of stomach lesion	Surgery		14.58	6.16	6.16		
43611		Excision of stomach lesion	Surgery		17.81	7.58	7.58		
43620		Removal of stomach	Surgery		29.99	11.82	11.82		
43621		Removal of stomach	Surgery		30.68	12.00	12.00		
43622		Removal of stomach	Surgery		32.48	12.62	12.62		
43631		Removal of stomach, partial	Surgery		22.56	9.18	9.18		
43632		Removal of stomach, partial	Surgery		22.56	9.18	9.18		
43633		Removal of stomach, partial	Surgery		23.07	9.35	9.35		
43634		Removal of stomach, partial	Surgery		25.08	10.11	10.11		
43635		Removal of stomach, partial	Surgery		2.06	0.70	0.70		
43640		Vagotomy & pylorus repair	Surgery		16.99	7.27	7.27		
43641		Vagotomy & pylorus repair	Surgery		17.24	7.38	7.38		

NOTES: CPT Codes and descriptions only are copyright 2005 American Medical Association. All rights reserved. Applicable FARS/DARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 47 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usege Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
43644		Lap gastric bypass/roux-en-y	Surgery		27.83	11.24	11.24	14.93	RBRVS
43645		Lap gastr bypass incl small i	Surgery		29.96	12.04	12.04		
43651		Laparoscopy, vagus nerve	Surgery		10.13	4.77	4.77		
43652		Laparoscopy, vagus nerve	Surgery		12.13	5.77	5.77		
43653		Laparoscopy, gastrostomy	Surgery		7.72	4.19	4.19		
43659		Laparoscope proc, stom	Surgery						
43750		Place gastrostomy tube	Surgery		4.48	2.20	2.20		
43752		Nasal/orogastric w/stent	Surgery		0.81	0.26	0.26		
43760		Change gastrostomy tube	Surgery		1.10	0.45	2.09		
43761		Reposition gastrostomy tube	Surgery		2.01	0.66	1.17		
43770		Lap, place gastr adjust band	Surgery		16.71	7.73	7.73		
43771		Lap, revise adjust gast band	Surgery		19.50	8.61	8.61		
43772		Lap, remove adjust gast band	Surgery		15.00	6.44	6.44		
43773		Lap, change adjust gast band	Surgery		19.50	8.61	8.61		
43774		Lap remov adj gast band/port	Surgery		15.00	6.58	6.58		
43800		Reconstruction of pylorus	Surgery		13.67	5.91	5.91		
43810		Fusion of stomach and bowel	Surgery		14.63	6.19	6.19		
43820		Fusion of stomach and bowel	Surgery		15.35	6.42	6.42		
43825		Fusion of stomach and bowel	Surgery		19.19	8.03	8.03		
43830		Place gastrostomy tube	Surgery		9.52	4.85	4.85		
43831		Place gastrostomy tube	Surgery		7.83	4.52	4.52		
43832		Place gastrostomy tube	Surgery		15.58	6.86	6.86		
43840		Repair of stomach lesion	Surgery		15.54	6.78	6.78		
43842		Gastroplasty for obesity	Surgery		18.44	7.81	7.81		
43843		Gastroplasty for obesity	Surgery		18.62	7.78	7.78		
43845		Gastroplasty duodenal switch	Surgery		31.00	10.80	10.80		
43846		Gastric bypass for obesity	Surgery		24.01	10.05	10.05		
43847		Gastric bypass for obesity	Surgery		26.88	10.92	10.92		
43848		Revision gastroplasty	Surgery		29.35	11.84	11.84		
43850		Revise stomach-bowel fusion	Surgery		24.68	9.84	9.84		
43855		Revise stomach-bowel fusion	Surgery		26.12	10.35	10.35		
43860		Revise stomach-bowel fusion	Surgery		24.96	9.99	9.99		
43865		Revise stomach-bowel fusion	Surgery		26.48	10.53	10.53		
43870		Repair stomach opening	Surgery		9.68	4.52	4.52		
43880		Repair stomach-bowel fistula	Surgery		24.61	9.92	9.92		
43999		Stomach surgery procedure	Surgery					21.80	RBRVS
44005		Freeing of bowel adhesion	Surgery		16.21	6.73	6.73		
44010		Incision of small bowel	Surgery		12.50	5.46	5.46		
44015		Insert needle cath bowel	Surgery		2.62	0.88	0.88		
44020		Explore small intestine	Surgery		13.97	5.95	5.95		
44021		Decompress small bowel	Surgery		14.06	5.98	5.98		
44025		Incision of large bowel	Surgery		14.26	6.04	6.04		
44050		Reduce bowel obstruction	Surgery		14.01	5.97	5.97		
44055		Correct malrotation of bowel	Surgery		21.97	8.75	8.75		
44100		Biopsy of bowel	Surgery		2.01	0.71	0.71		
44110		Excise intestine lesion(s)	Surgery		11.79	5.24	5.24		
44111		Excision of bowel lesion(s)	Surgery		14.27	6.12	6.12		
44120		Removal of small intestine	Surgery		16.97	7.09	7.09		
44121		Removal of small intestine	Surgery		4.44	1.52	1.52		
44125		Removal of small intestine	Surgery		17.51	7.27	7.27		
44126		Enterectomy w/o taper, cong	Surgery		35.45	14.15	14.15		
44127		Enterectomy w/taper, cong	Surgery		40.94	15.76	15.76		
44128		Enterectomy cong, add-on	Surgery		4.44	1.53	1.53		
44130		Bowel to bowel fusion	Surgery		14.47	6.23	6.23		
44132		Enterectomy, cadaver donor	Surgery		4.44	1.52	1.52		
44133		Enterectomy, live donor	Surgery		4.44	1.52	1.52		
44139		Mobilization of colon	Surgery		2.23	0.76	0.76		
44140		Partial removal of colon	Surgery		20.97	8.67	8.67		
44141		Partial removal of colon	Surgery		19.48	10.07	10.07		
44143		Partial removal of colon	Surgery		22.96	10.71	10.71		
44144		Partial removal of colon	Surgery		21.50	9.64	9.64		
44145		Partial removal of colon	Surgery		26.38	10.83	10.83		
44146		Partial removal of colon	Surgery		27.50	12.89	12.89		
44147		Partial removal of colon	Surgery		20.68	8.71	8.71		
44150		Removal of colon	Surgery		23.91	12.05	12.05		
44151		Removal of colon/ileostomy	Surgery		26.84	13.43	13.43		
44152		Removal of colon/ileostomy	Surgery		27.79	11.62	11.62		
44153		Removal of colon/ileostomy	Surgery		30.54	14.41	14.41		
44155		Removal of colon/ileostomy	Surgery		27.82	13.34	13.34		
44158		Removal of colon/ileostomy	Surgery		30.74	15.07	15.07	CALC CALC	

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCP/PCS CODE

PAGE 48 of 119

CPT/ HCP/PCS Code	Modifier	CPT/HCP/PCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
44160		Removal of colon	Surgery		18.99	7.76	7.76		
44180		Lap, enterocolysis	Surgery	a	14.42	6.25	6.25		RBRVS
44186		Lap, jejunostomy	Surgery	a	9.77	4.80	4.80		RBRVS
44187		Lap, ileo/jejuno-stomy	Surgery		15.93	8.29	8.29		RBRVS
44188		Lap, colostomy	Surgery		17.61	8.87	8.87		RBRVS
44202		Lap resect s/intestine singt	Surgery		22.01	8.95	8.95		
44203		Lap resect s/intestine, adtl	Surgery		4.44	1.50	1.50		
44204		Laparo partial colectomy	Surgery		25.04	9.98	9.98		
44205		Lap colectomy part w/ileum	Surgery		22.20	8.87	8.87		
44206		Lap part colectomy w/stoma	Surgery		26.96	11.28	11.28		
44207		L colectomy/coloproctostomy	Surgery		29.96	11.51	11.51		
44208		L colectomy/coloproctostomy	Surgery		31.95	13.17	13.17		
44210		Laparo total proctocolectomy	Surgery		27.96	11.90	11.90		
44211		Laparo total proctocolectomy	Surgery		34.95	14.71	14.71		
44212		Laparo total proctocolectomy	Surgery		32.45	13.72	13.72		
44213		Lap, mobil splenic fl add-on	Surgery	a	3.50	1.22	1.22		
44227		Lap, close enterostomy	Surgery		26.50	10.65	10.65		RBRVS
44238		Laparoscope proc, intestine	Surgery					20.65	RBRVS
44300		Open bowel to skin	Surgery		12.09	5.50	5.50		
44310		Ileostomy/jejunostomy	Surgery		15.93	6.71	6.71		
44312		Revision of ileostomy	Surgery		8.01	4.00	4.00		
44314		Revision of ileostomy	Surgery		15.03	6.57	6.57		
44316		Devise bowel pouch	Surgery		21.06	8.56	8.56		
44320		Colostomy	Surgery		17.61	7.67	7.67		
44322		Colostomy with biopsies	Surgery		11.96	8.59	8.59		
44340		Revision of colostomy	Surgery		7.71	4.27	4.27		
44345		Revision of colostomy	Surgery		15.41	6.90	6.90		
44346		Revision of colostomy	Surgery		16.96	7.40	7.40		
44360		Small bowel endoscopy	Surgery		2.59	1.10	1.10		
44361		Small bowel endoscopy/biopsy	Surgery		2.87	1.20	1.20		
44363		Small bowel endoscopy	Surgery		3.49	1.38	1.38		
44364		Small bowel endoscopy	Surgery		3.73	1.49	1.49		
44365		Small bowel endoscopy	Surgery		3.31	1.36	1.36		
44366		Small bowel endoscopy	Surgery		4.40	1.74	1.74		
44369		Small bowel endoscopy	Surgery		4.51	1.74	1.74		
44370		Small bowel endoscopy/stent	Surgery		4.79	1.98	1.98		
44372		Small bowel endoscopy	Surgery		4.40	1.74	1.74		
44373		Small bowel endoscopy	Surgery		3.49	1.42	1.42		
44376		Small bowel endoscopy	Surgery		5.25	2.03	2.03		
44377		Small bowel endoscopy/biopsy	Surgery		5.52	2.14	2.14		
44378		Small bowel endoscopy	Surgery		7.12	2.70	2.70		
44379		S bowel endoscope w/stent	Surgery		7.46	2.92	2.92		
44380		Small bowel endoscopy	Surgery		1.05	0.55	0.55		
44382		Small bowel endoscopy	Surgery		1.27	0.63	0.63		
44383		Ileoscopy w/stent	Surgery		2.94	1.27	1.27		
44385		Endoscopy of bowel pouch	Surgery		1.82	0.75	0.75		
44386		Endoscopy, bowel pouch/biop	Surgery		2.12	0.88	0.88		
44388		Colon endoscopy	Surgery		2.82	1.15	1.15		
44389		Colonoscopy with biopsy	Surgery		3.13	1.27	1.27		
44390		Colonoscopy for foreign body	Surgery		3.82	1.49	1.49		
44391		Colonoscopy for bleeding	Surgery		4.31	1.69	1.69		
44392		Colonoscopy & polypectomy	Surgery		3.81	1.49	1.49		
44393		Colonoscopy, lesion removal	Surgery		4.83	1.87	1.87		
44394		Colonoscopy w/snare	Surgery		4.42	1.72	1.72		
44397		Colonoscopy w/stent	Surgery		4.70	1.80	1.80		
44500		Intr, gastrointestinal tube	Surgery		0.49	0.16	0.16		
44602		Suture, small intestine	Surgery		16.01	6.41	6.41		
44603		Suture, small intestine	Surgery		18.63	7.29	7.29		
44604		Suture, large intestine	Surgery		16.01	6.47	6.47		
44605		Repair of bowel lesion	Surgery		19.50	8.41	8.41		
44615		Intestinal stricturoplasty	Surgery		15.91	6.69	6.69		
44620		Repair bowel opening	Surgery		12.18	5.34	5.34		
44625		Repair bowel opening	Surgery		15.03	6.32	6.32		
44626		Repair bowel opening	Surgery		25.32	9.84	9.84		
44640		Repair bowel-skin fistula	Surgery		21.62	8.59	8.59		
44650		Repair bowel fistula	Surgery		22.54	8.91	8.91		
44650		Repair bowel-bladder fistula	Surgery		21.33	8.36	8.36		
44651		Repair bowel-bladder fistula	Surgery		24.77	9.58	9.58		
44680		Surgical revision, intestine	Surgery		15.38	6.46	6.46		
44700		Suspend bowel w/prosthesis	Surgery		16.09	6.68	6.68		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for notes regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 49 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
44701		Intraop colon lavage add-on	Surgery		3.10	1.06	1.06		
44720		Prep donor intestine/venous	Surgery		5.00	1.71	1.71		
44721		Prep donor intestine/artery	Surgery		7.00	2.40	2.40		
44799		Intestine surgery procedure	Surgery					24.09	
44800		Excision of bowel pouch	Surgery		11.21	5.40	5.40		
44820		Excision of mesentery lesion	Surgery		12.07	5.50	5.50		
44850		Repair of mesentery	Surgery		10.72	5.01	5.01		
44899		Bowel surgery procedure	Surgery					16.64	
44900		Drain abs abscess, open	Surgery		10.12	4.70	4.70		
44901		Drain abs abscess, percut	Surgery		3.37	1.11	27.97		
44950		Appendectomy	Surgery		9.99	4.32	4.32		
44955		Appendectomy add-on	Surgery		1.53	0.54	0.54		
44960		Appendectomy	Surgery		12.32	5.35	5.35		
44970		Laparoscopy, appendectomy	Surgery		8.69	4.09	4.09		
44979		Laparoscopy proc, app	Surgery					12.92	
45000		Drainage of pelvic abscess	Surgery		4.51	2.97	2.97		
45005		Drainage of rectal abscess	Surgery		1.99	1.58	4.06		
45020		Drainage of rectal abscess	Surgery		4.71	3.28	3.28		
45100		Biopsy of rectum	Surgery		3.67	2.37	2.37		
45108		Removal of anorectal lesion	Surgery		4.75	2.78	2.78		
45110		Removal of rectum	Surgery		27.96	12.43	12.43		
45111		Partial removal of rectum	Surgery		16.46	7.18	7.18		
45112		Removal of rectum	Surgery		30.49	11.79	11.79		
45113		Partial proctectomy	Surgery		30.53	12.63	12.63		
45114		Partial removal of rectum	Surgery		27.28	10.90	10.90		
45116		Partial removal of rectum	Surgery		24.54	10.05	10.05		
45119		Remove rectum w/reservoir	Surgery		30.79	12.49	12.49		
45120		Removal of rectum	Surgery		24.56	10.15	10.15		
45121		Removal of rectum and colon	Surgery		27.00	11.13	11.13		
45123		Partial proctectomy	Surgery		16.68	6.87	6.87		
45126		Pelvic exenteration	Surgery		45.09	19.26	19.26		
45130		Excision of rectal prolapse	Surgery		16.42	6.78	6.78		
45135		Excision of rectal prolapse	Surgery		19.25	8.43	8.43		
45136		Excise ileoanal reservoir	Surgery		27.26	12.55	12.55		
45150		Excision of rectal stricture	Surgery		5.66	2.97	2.97		
45160		Excision of rectal lesion	Surgery		15.30	6.66	6.66		
45170		Excision of rectal lesion	Surgery		11.47	5.25	5.25		
45190		Destruction, rectal tumor	Surgery		9.73	4.63	4.63		
45300		Proctosigmoidoscopy dx	Surgery		0.38	0.28	1.53		
45303		Proctosigmoidoscopy dilate	Surgery		0.44	0.33	18.73		
45305		Proctosigmoidoscopy w/bx	Surgery		1.01	0.50	2.64		
45307		Proctosigmoidoscopy fb	Surgery		0.94	0.48	3.04		
45308		Proctosigmoidoscopy removal	Surgery		0.83	0.44	2.00		
45309		Proctosigmoidoscopy removal	Surgery		2.01	0.84	2.82		
45315		Proctosigmoidoscopy removal	Surgery		1.40	0.63	2.87		
45317		Proctosigmoidoscopy bleed	Surgery		1.50	0.66	2.44		
45320		Proctosigmoidoscopy ablate	Surgery		1.58	0.71	2.92		
45321		Proctosigmoidoscopy volvul	Surgery		1.17	0.56	0.56		
45327		Proctosigmoidoscopy w/stent	Surgery		1.65	0.69	0.69		
45330		Diagnostic sigmoidoscopy	Surgery		0.96	0.50	2.28		
45331		Sigmoidoscopy and biopsy	Surgery		1.15	0.59	3.08		
45332		Sigmoidoscopy w/fb removal	Surgery		1.79	0.80	5.01		
45333		Sigmoidoscopy & polypectomy	Surgery		1.79	0.80	4.88		
45334		Sigmoidoscopy for bleeding	Surgery		2.73	1.14	1.14		
45335		Sigmoidoscopy w/submuc inj	Surgery		1.46	0.69	3.22		
45337		Sigmoidoscopy & decompress	Surgery		2.36	1.00	1.00		
45338		Sigmoidoscopy w/tumor remove	Surgery		2.34	1.00	5.23		
45339		Sigmoidoscopy w/ablate tumor	Surgery		3.14	1.28	3.47		
45340		Sig w/balloon dilation	Surgery		1.89	0.83	6.19		
45341		Sigmoidoscopy w/ultrasound	Surgery		2.60	1.07	1.07		
45342		Sigmoidoscopy w/ultrasound bx	Surgery		4.05	1.54	1.54		
45345		Sigmoidoscopy w/stent	Surgery		2.92	1.16	1.16		
45355		Surgical colonoscopy	Surgery		3.51	1.38	1.38		
45378		Diagnostic colonoscopy	Surgery		3.69	1.47	6.16		
45379		Colonoscopy w/fb removal	Surgery		4.68	1.82	7.68		
45380		Colonoscopy and biopsy	Surgery		4.43	1.74	7.21		
45381		Colonoscopy, submucous inj	Surgery		4.19	1.65	7.13		
45382		Colonoscopy/control bleeding	Surgery		5.68	2.19	9.97		
45383		Lesion removal colonoscopy	Surgery		5.86	2.23	7.94		
45384		Lesion remove colonoscopy	Surgery		4.69	1.83	6.82		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/SOARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPSC CODE

PAGE 50 of 119

CPT/ HCPSC Code	Modifier	CPT/HCPSC Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
45385		Lesion removal colonoscopy	Surgery		5.30	2.04	7.82		
45386		Colonoscope dilate stricture	Surgery		4.57	1.79	12.44		
45387		Colonoscopy w/stent	Surgery		5.90	2.34	2.34		
45391		Colonoscopy w/endscope us	Surgery		5.09	1.98	1.98		
45392		Colonoscopy w/endscopic fib	Surgery		6.54	2.49	2.49		
45395		Lap, removal of rectum	Surgery		30.50	13.71	13.71		RBRVS
45397		Lap, remove rectum w/pouch	Surgery		34.00	14.30	14.30		RBRVS
45400		Laparoscopic proctopexy	Surgery		18.06	7.85	7.85		RBRVS
45402		Lap proctopexy w/siq resect	Surgery		25.04	10.01	10.01		RBRVS
45500		Repair of rectum	Surgery		7.28	3.54	3.54		
45505		Repair of rectum	Surgery		7.57	3.86	3.86		
45520		Treatment of rectal prolapse	Surgery		0.55	0.37	1.64		
45540		Correct rectal prolapse	Surgery		16.25	6.81	6.81		
45541		Correct rectal prolapse	Surgery		13.38	5.96	5.96		
45550		Repair rectum/remove sigmoid	Surgery		22.97	9.24	9.24		
45560		Repair of rectocele	Surgery		10.56	5.06	5.06		
45562		Exploration/repair of rectum	Surgery		15.36	7.00	7.00		
45563		Exploration/repair of rectum	Surgery		23.43	10.54	10.54		
45800		Repair rect/bladder fistula	Surgery		17.74	7.44	7.44		
45805		Repair fistula w/colostomy	Surgery		20.75	9.53	9.53		
45820		Repair rectourethral fistula	Surgery		18.45	7.64	7.64		
45825		Repair fistula w/colostomy	Surgery		21.22	9.84	9.84		
45900		Reduction of rectal prolapse	Surgery		2.61	1.50	1.50		
45905		Dilation of anal sphincter	Surgery		2.30	1.43	1.43		
45910		Dilation of rectal narrowing	Surgery		2.80	1.66	1.66		
45915		Remove rectal obstruction	Surgery		3.14	2.10	4.33		RBRVS
45990		Surg dx exam, anorectal	Surgery	a	1.80	0.79	0.79	5.83	
45999		Rectum surgery procedure	Surgery						
46020		Placement of seton	Surgery		2.90	1.86	2.34		
46030		Removal of rectal marker	Surgery		1.23	0.71	1.35		
46040		Incision of rectal abscess	Surgery		4.95	3.59	5.51		
46045		Incision of rectal abscess	Surgery		4.31	2.90	2.90		
46050		Incision of anal abscess	Surgery		1.19	0.84	2.55		
46060		Incision of rectal abscess	Surgery		5.68	3.25	3.25		
46070		Incision of anal septum	Surgery		2.71	1.84	1.84		
46080		Incision of anal sphincter	Surgery		2.49	1.13	2.37		
46083		Incise external hemorrhoid	Surgery		1.40	0.92	2.53		
46200		Removal of anal fissure	Surgery		3.41	2.87	3.86		
46210		Removal of anal crypt	Surgery		2.67	2.63	5.12		
46211		Removal of anal crypts	Surgery		4.24	3.51	5.42		
46220		Removal of anal tag	Surgery		1.56	0.95	2.30		
46221		Ligation of hemorrhoid(s)	Surgery		2.04	1.75	2.65		
46230		Removal of anal tags	Surgery		2.57	1.29	3.08		
46250		Hemorrhoidectomy	Surgery		3.88	2.62	5.32		
46255		Hemorrhoidectomy	Surgery		4.59	2.84	5.85		
46257		Remove hemorrhoids & fissure	Surgery		5.39	2.88	2.88		
46258		Remove hemorrhoids & fistula	Surgery		5.72	3.28	3.28		
46260		Hemorrhoidectomy	Surgery		6.36	3.19	3.19		
46261		Remove hemorrhoids & fissure	Surgery		7.07	3.61	3.61		
46262		Remove hemorrhoids & fistula	Surgery		7.49	3.74	3.74		
46270		Removal of anal fistula	Surgery		3.71	2.84	5.00		
46275		Removal of anal fistula	Surgery		4.55	2.98	4.64		
46280		Removal of anal fistula	Surgery		5.97	3.26	3.26		
46285		Removal of anal fistula	Surgery		4.08	2.75	3.77		
46288		Repair anal fistula	Surgery		7.12	3.68	3.68		
46320		Removal of hemorrhoid clot	Surgery		1.61	0.85	2.13		
46500		Injection into hemorrhoid(s)	Surgery		1.61	1.15	2.12		
46505		Chemodenervation anal musc	Surgery	a	2.86	1.97	3.05		RBRVS
46600		Diagnostic anoscopy	Surgery		0.50	0.34	1.56		
46604		Anoscopy and dilation	Surgery		1.31	0.62	9.15		
46606		Anoscopy and biopsy	Surgery		0.81	0.43	3.79		
46608		Anoscopy, remove for body	Surgery		1.51	0.65	4.41		
46610		Anoscopy, remove lesion	Surgery		1.32	0.61	4.04		
46611		Anoscopy	Surgery		1.81	0.78	3.34		
46612		Anoscopy, remove lesions	Surgery		2.34	0.98	5.20		
46614		Anoscopy, control bleeding	Surgery		2.01	0.84	2.33		
46615		Anoscopy	Surgery		2.68	1.07	2.49		
46700		Repair of anal stricture	Surgery		9.12	4.21	4.21		
46705		Repair of anal stricture	Surgery		6.89	3.69	3.69		
46706		Repr of anal fistula w/plue	Surgery		2.39	1.25	1.25		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for notes regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 51 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ -Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
46710		Repr per/vag pouch snj/ proc	Surgery		16.00	7.77	7.77		RBRVS
46712		Repr per/vag pouch dbl proc	Surgery		34.00	15.08	15.08		RBRVS
46715		Repair of anovaginal fistula	Surgery		7.19	3.58	3.58		
46716		Repair of anovaginal fistula	Surgery		15.05	7.99	7.99		
46730		Construction of absent anus	Surgery		26.71	12.05	12.05		
46735		Construction of absent anus	Surgery		32.12	13.58	13.58		
46740		Construction of absent anus	Surgery		29.96	13.26	13.26		
46742		Repair of imperforated anus	Surgery		35.75	17.43	17.43		
46744		Repair of cloacal anomaly	Surgery		52.55	21.17	21.17		
46746		Repair of cloacal anomaly	Surgery		58.13	25.21	25.21		
46748		Repair of cloacal anomaly	Surgery		64.11	23.70	23.70		
46750		Repair of anal sphincter	Surgery		10.23	5.06	5.06		
46751		Repair of anal sphincter	Surgery		8.76	5.43	5.43		
46753		Reconstruction of anus	Surgery		8.28	3.85	3.85		
46754		Removal of suture from anus	Surgery		2.20	1.67	3.60		
46760		Repair of anal sphincter	Surgery		14.41	7.10	7.10		
46761		Repair of anal sphincter	Surgery		13.82	6.02	6.02		
46762		Implant artificial sphincter	Surgery		12.69	5.53	5.53		
46900		Destruction, anal lesion(s)	Surgery		1.91	1.27	2.59		
46910		Destruction, anal lesion(s)	Surgery		1.86	1.06	2.91		
46916		Cryosurgery, anal lesion(s)	Surgery		1.86	1.39	3.16		
46917		Laser surgery, anal lesions	Surgery		1.86	1.12	9.15		
46922		Excision of anal lesion(s)	Surgery		1.86	1.07	3.28		
46924		Destruction, anal lesion(s)	Surgery		2.76	1.35	8.71		
46934		Destruction of hemorrhoids	Surgery		3.50	2.96	5.08		
46935		Destruction of hemorrhoids	Surgery		2.43	1.21	3.47		
46936		Destruction of hemorrhoids	Surgery		3.68	2.50	4.88		
46937		Cryotherapy of rectal lesion	Surgery		2.69	1.22	2.78		
46938		Cryotherapy of rectal lesion	Surgery		4.65	3.06	4.00		
46940		Treatment of anal fissure	Surgery		2.32	1.09	2.00		
46942		Treatment of anal fissure	Surgery		2.04	1.02	1.84		
46945		Ligation of hemorrhoids	Surgery		1.84	2.48	3.27		
46946		Ligation of hemorrhoids	Surgery		2.58	2.40	3.73		
46947		Hemorrhoidopexy by stapling	Surgery		5.20	2.72	2.72		
46999		Anus surgery procedure	Surgery					3.55	
47000		Needle biopsy of liver	Surgery		1.90	0.63	3.08		
47001		Needle biopsy, liver add-on	Surgery		1.90	0.65	0.65		
47010		Open drainage, liver lesion	Surgery		15.99	8.41	8.41		
47011		Percut drain, liver lesion	Surgery		3.69	1.21	1.21		
47015		Inject/aspirate liver cyst	Surgery		15.09	7.50	7.50		
47100		Wedge biopsy of liver	Surgery		11.65	6.05	6.05		
47120		Partial removal of liver	Surgery		35.45	15.18	15.18		
47122		Extensive removal of liver	Surgery		55.05	21.50	21.50		
47125		Partial removal of liver	Surgery		49.12	19.56	19.56		
47130		Partial removal of liver	Surgery		53.27	21.02	21.02		
47135		Transplantation of liver	Surgery		81.40	31.59	31.59		
47136		Transplantation of liver	Surgery		68.50	27.09	27.09		
47140		Partial removal, donor liver	Surgery		54.92	22.33	22.33		
47141		Partial removal, donor liver	Surgery		67.40	26.98	26.98		
47142		Partial removal, donor liver	Surgery		74.89	29.55	29.55		
47146		Prep donor liver/venous	Surgery		6.00	2.06	2.06		
47147		Prep donor liver/arterial	Surgery		7.00	2.40	2.40		
47300		Surgery for liver lesion	Surgery		15.06	7.24	7.24		
47350		Repair liver wound	Surgery		19.53	8.89	8.89		
47360		Repair liver wound	Surgery		26.88	11.60	11.60		
47361		Repair liver wound	Surgery		47.05	18.56	18.56		
47362		Repair liver wound	Surgery		18.48	8.74	8.74		
47370		Lapero ablate liver tumor rf	Surgery		19.66	8.15	8.15		
47371		Lapero ablate liver cryosurg	Surgery		19.66	8.16	8.16		
47379		Lapero scope procedure, liver	Surgery					27.85	
47380		Open ablate liver tumor rf	Surgery		22.97	9.38	9.38		
47381		Open ablate liver tumor cryo	Surgery		23.24	9.61	9.61		
47382		Percut ablate liver rf	Surgery		15.17	6.09	6.09		
47399		Liver surgery procedure	Surgery					2.66	
47400		Incision of liver duct	Surgery		32.44	13.47	13.47		
47420		Incision of bile duct	Surgery		19.85	8.78	8.78		
47425		Incision of bile duct	Surgery		19.80	8.83	8.83		
47460		Incise bile duct sphincter	Surgery		18.01	8.38	8.38		
47480		Incision of gallbladder	Surgery		10.80	5.92	5.92		
47490		Incision of gallbladder	Surgery		7.22	5.58	5.58		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPSC CODE

PAGE 52 of 119

CPT/ HCPSC Code	Modifier	CPT/HCPSC Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
47500		Injection for liver x-rays	Surgery		1.96	0.64	0.64		
47505		Injection for liver x-rays	Surgery		0.76	0.25	0.25		
47510		Insert catheter, bile duct	Surgery		7.82	5.02	5.02		
47511		Insert bile duct drain	Surgery		10.48	5.09	5.09		
47525		Change bile duct catheter	Surgery		5.54	2.81	15.13		
47530		Revise/reinsert bile tube	Surgery		5.84	3.72	33.88		
47550		Bile duct endoscopy add-on	Surgery		3.02	1.02	1.02		
47552		Biliary endoscopy thru skin	Surgery		6.03	2.38	2.38		
47553		Biliary endoscopy thru skin	Surgery		6.34	2.07	2.07		
47554		Biliary endoscopy thru skin	Surgery		9.05	3.36	3.36		
47555		Biliary endoscopy thru skin	Surgery		7.55	2.47	2.47		
47556		Biliary endoscopy thru skin	Surgery		8.55	2.79	2.79		
47560		Laparoscopy w/cholangio	Surgery		4.88	1.67	1.67		
47561		Laparo w/cholangio/biopsy	Surgery		5.17	1.92	1.92		
47562		Laparoscopic cholecystectomy	Surgery		11.07	4.99	4.99		
47563		Laparo cholecystectomy/graph	Surgery		11.92	5.31	5.31		
47564		Laparo cholecystectomy/explr	Surgery		14.21	5.96	5.96		
47570		Laparo cholecystoenterotomy	Surgery		12.56	5.38	5.38		
47579		Laparoscope proc, biliary	Surgery					16.07	
47600		Removal of gallbladder	Surgery		13.56	6.14	6.14		
47605		Removal of gallbladder	Surgery		14.67	6.51	6.51		
47610		Removal of gallbladder	Surgery		18.79	7.94	7.94		
47612		Removal of gallbladder	Surgery		18.75	7.89	7.89		
47620		Removal of gallbladder	Surgery		20.61	8.53	8.53		
47630		Remove bile duct stone	Surgery		9.10	4.89	4.89		
47700		Exploration of bile ducts	Surgery		15.60	7.42	7.42		
47701		Bile duct revision	Surgery		27.77	11.50	11.50		
47711		Excision of bile duct tumor	Surgery		23.00	9.94	9.94		
47712		Excision of bile duct tumor	Surgery		30.19	12.44	12.44		
47715		Excision of bile duct cyst	Surgery		18.77	8.44	8.44		
47716		Fusion of bile duct cyst	Surgery		16.42	7.83	7.83		
47720		Fuse gallbladder & bowel	Surgery		15.89	7.48	7.48		
47721		Fuse upper gi structures	Surgery		19.09	8.57	8.57		
47740		Fuse gallbladder & bowel	Surgery		18.45	8.38	8.38		
47741		Fuse gallbladder & bowel	Surgery		21.31	9.30	9.30		
47760		Fuse bile ducts and bowel	Surgery		25.81	10.86	10.86		
47765		Fuse liver ducts & bowel	Surgery		24.84	10.81	10.81		
47780		Fuse bile ducts and bowel	Surgery		26.46	11.22	11.22		
47785		Fuse bile ducts and bowel	Surgery		31.13	12.93	12.93		
47800		Reconstruction of bile ducts	Surgery		23.27	10.07	10.07		
47801		Placement, bile duct support	Surgery		15.15	8.16	8.16		
47802		Fuse liver duct & intestine	Surgery		21.52	9.68	9.68		
47900		Suture bile duct injury	Surgery		19.87	8.88	8.88		
47999		Bile tract surgery procedure	Surgery					19.76	
48000		Drainage of abdomen	Surgery		28.03	11.52	11.52		
48001		Placement of drain, pancreas	Surgery		35.40	13.90	13.90		
48005		Resect/debride pancreas	Surgery		42.11	16.59	16.59		
48020		Removal of pancreatic stone	Surgery		15.68	7.31	7.31		
48100		Biopsy of pancreas, open	Surgery		12.21	5.60	5.60		
48102		Needle biopsy, pancreas	Surgery		4.67	1.95	7.97		
48120		Removal of pancreas lesion	Surgery		15.83	6.86	6.86		
48140		Partial removal of pancreas	Surgery		22.91	9.55	9.55		
48145		Partial removal of pancreas	Surgery		23.98	9.84	9.84		
48146		Pancreatectomy	Surgery		26.36	12.00	12.00		
48148		Removal of pancreatic duct	Surgery		17.31	7.61	7.61		
48150		Partial removal of pancreas	Surgery		47.93	19.54	19.54		
48152		Pancreatectomy	Surgery		43.68	18.23	18.23		
48153		Pancreatectomy	Surgery		47.82	19.58	19.58		
48154		Pancreatectomy	Surgery		44.03	18.26	18.26		
48155		Removal of pancreas	Surgery		24.60	11.68	11.68		
48160		Pancreas removal/transplant	Surgery					56.97	
48180		Fuse pancreas and bowel	Surgery		24.68	10.17	10.17		
48400		Injection, intraop add-on	Surgery		1.95	0.64	0.64		
48500		Surgery of pancreatic cyst	Surgery		15.26	7.34	7.34		
48510		Drain pancreatic pseudocyst	Surgery		14.29	7.45	7.45		
48511		Drain pancreatic pseudocyst	Surgery		3.99	1.31	20.95		
48520		Fuse pancreas cyst and bowel	Surgery		15.57	6.71	6.71		
48540		Fuse pancreas cyst and bowel	Surgery		19.69	8.12	8.12		
48545		Pancreatorrhaphy	Surgery		18.15	7.99	7.99		
48547		Duodenal exclusion	Surgery		25.79	10.50	10.50		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable F/R/S/D/FARS apply
See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 53 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
48552		Prep donor pancreas/venous	Surgery		4.30	1.46	1.46		
48554		Transpl allograft pancreas	Surgery		34.12	18.30	18.30		
48556		Removal, allograft pancreas	Surgery		15.69	8.08	8.08		
48999		Pancreas surgery procedure	Surgery					34.90	
49000		Exploration of abdomen	Surgery		11.66	5.39	5.39		
49002		Reopening of abdomen	Surgery		10.47	5.02	5.02		
49010		Exploration behind abdomen	Surgery		12.26	5.91	5.91		
49020		Drain abdominal abscess	Surgery		22.81	10.21	10.21		
49021		Drain abdominal abscess	Surgery		3.37	1.11	21.11		
49040		Drain, open, abdom abscess	Surgery		13.50	6.43	6.43		
49041		Drain, percut, abdom abscess	Surgery		3.99	1.31	19.57		
49060		Drain, open, retroper abscess	Surgery		15.84	7.44	7.44		
49061		Drain, percut, retroper abscc	Surgery		3.69	1.21	19.68		
49062		Drain to peritoneal cavity	Surgery		11.34	5.44	5.44		
49080		Puncture, peritoneal cavity	Surgery		1.35	0.46	3.99		
49081		Removal of abdominal fluid	Surgery		1.26	0.43	2.59		
49085		Remove abdomen foreign body	Surgery		12.12	5.51	5.51		
49180		Biopsy, abdominal mass	Surgery		1.73	0.57	3.11		
49200		Removal of abdominal lesion	Surgery		10.23	5.03	5.03		
49201		Remove abdom lesion, complex	Surgery		14.82	7.04	7.04		
49215		Excise sacral spine tumor	Surgery		33.45	14.08	14.08		
49220		Multiple surgery, abdomen	Surgery		14.86	6.64	6.64		
49250		Excision of umbilicus	Surgery		8.34	4.27	4.27		
49255		Removal of omentum	Surgery		11.12	5.62	5.62		
49320		Diag laparo separate proc	Surgery		5.09	2.64	2.64		
49321		Laparoscopy, biopsy	Surgery		5.39	2.65	2.65		
49322		Laparoscopy, aspiration	Surgery		5.69	3.00	3.00		
49323		Laparo drain lymphocele	Surgery		9.47	4.50	4.50		
49329		Laparo proc, abdm/pero/oment	Surgery					7.73	
49400		Air injection into abdomen	Surgery		1.88	0.52	3.08		
49419		Insert abdom cath for chemotr	Surgery		6.64	3.57	3.57		
49420		Insert abdom drain, temp	Surgery		2.22	1.09	1.09		
49421		Insert abdom drain, perm	Surgery		5.53	3.16	3.16		
49422		Remove perm cannula/catheter	Surgery		6.24	2.90	2.90		
49423		Exchange drainage catheter	Surgery		1.46	0.52	14.11		
49424		Assess cyst, contrast inject	Surgery		0.76	0.29	3.72		
49425		Insert abdomen-venous drain	Surgery		11.35	5.61	5.61		
49426		Revise abdomen-venous shunt	Surgery		9.62	4.77	4.77		
49427		Injection, abdominal shunt	Surgery		0.89	0.30	0.30		
49428		Ligation of shunt	Surgery		6.05	3.93	3.93		
49429		Removal of shunt	Surgery		7.39	3.43	3.43		
49491		Rpr hern preemie reduc	Surgery		11.11	5.06	5.06		
49492		Rpr ing hern preemie, blocked	Surgery		14.01	6.12	6.12		
49495		Rpr ing hernia baby, reduc	Surgery		5.88	2.96	2.96		
49496		Rpr ing hernia baby, blocked	Surgery		8.78	4.28	4.28		
49500		Rpr ing hernia, init, reduce	Surgery		5.47	3.12	3.12		
49501		Rpr ing hernia, init blocked	Surgery		8.87	4.21	4.21		
49505		Prp i/hem init reduc>5 yr	Surgery		7.59	3.75	3.75		
49507		Prp i/hem init block>5 yr	Surgery		9.56	4.46	4.46		
49520		Rerepair ing hernia, reduce	Surgery		9.62	4.44	4.44		
49521		Rerepair ing hernia, blocked	Surgery		11.95	5.25	5.25		
49525		Repair ing hernia, sliding	Surgery		8.56	4.08	4.08		
49540		Repair lumbar hernia	Surgery		10.37	4.75	4.75		
49550		Rpr rem hernia, init, reduce	Surgery		8.62	4.13	4.13		
49553		Rpr fem hernia, init blocked	Surgery		9.43	4.42	4.42		
49555		Rerepair fem hernia, reduce	Surgery		9.02	4.27	4.27		
49557		Rerepair fem hernia, blocked	Surgery		11.13	4.99	4.99		
49560		Rpr ventral hem init, reduc	Surgery		11.55	5.15	5.15		
49561		Rpr ventral hem init, block	Surgery		14.23	6.07	6.07		
49565		Rerepair ventri hem, reduce	Surgery		11.55	5.23	5.23		
49566		Rerepair ventri hem, block	Surgery		14.38	6.14	6.14		
49568		Hernia repair w/mesh	Surgery		4.88	1.67	1.67		
49570		Rpr epigastric hem, reduce	Surgery		5.68	3.17	3.17		
49572		Rpr epigastric hem, blocked	Surgery		6.72	3.47	3.47		
49580		Rpr umbil hern, reduc < 5 yr	Surgery		4.10	2.60	2.60		
49582		Rpr umbil hern, block < 5 yr	Surgery		6.64	3.47	3.47		
49585		Rpr umbil hern, reduc > 5 yr	Surgery		6.22	3.30	3.30		
49587		Rpr umbil hern, block > 5 yr	Surgery		7.55	3.74	3.74		
49590		Repair spigilian hernia	Surgery		8.53	4.09	4.09		
49600		Repair umbilical lesion	Surgery		10.94	5.34	5.34		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for notes regarding Charge Methodology

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPSC CODE

PAGE 54 of 119

CPT/ HCPSC Code	Modifier	CPT/HCPSC Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
49605		Repair umbilical lesion	Surgery		75.89	28.58	28.58		
49606		Repair umbilical lesion	Surgery		18.57	7.70	7.70		
49610		Repair umbilical lesion	Surgery		10.48	5.21	5.21		
49611		Repair umbilical lesion	Surgery		8.91	6.99	6.99		
49650		Laparo hernia repair initial	Surgery		6.26	3.20	3.20		
49651		Laparo hernia repair recur	Surgery		8.23	4.05	4.05		
49659		Laparo proc, hernia repair	Surgery					9.49	
49900		Repair of abdominal wall	Surgery		12.26	6.24	6.24		
49904		Omental flap, extra-abdom	Surgery		19.97	15.25	15.25		
49905		Omental flap, intra-abdom	Surgery		6.54	2.30	2.30		
49999		Abdomen surgery procedure	Surgery					11.47	
50010		Exploration of kidney	Surgery		10.96	5.23	5.23		
50020		Renal abscess, open drain	Surgery		14.64	7.76	7.76		
50021		Renal abscess, percut drain	Surgery		3.37	1.10	21.71		
50040		Drainage of kidney	Surgery		14.92	6.82	6.82		
50045		Exploration of kidney	Surgery		15.44	6.61	6.61		
50060		Removal of kidney stone	Surgery		19.27	7.84	7.84		
50065		Incision of kidney	Surgery		20.76	6.09	6.09		
50070		Incision of kidney	Surgery		20.29	8.23	8.23		
50075		Removal of kidney stone	Surgery		25.30	9.92	9.92		
50080		Removal of kidney stone	Surgery		14.69	6.29	6.29		
50081		Removal of kidney stone	Surgery		21.77	8.78	8.78		
50100		Revise kidney blood vessels	Surgery		16.07	7.80	7.80		
50120		Exploration of kidney	Surgery		15.89	6.78	6.78		
50125		Explore and drain kidney	Surgery		16.50	6.98	6.98		
50130		Removal of kidney stone	Surgery		17.26	7.18	7.18		
50135		Exploration of kidney	Surgery		19.15	7.79	7.79		
50200		Biopsy of kidney	Surgery		2.63	1.29	1.29		
50205		Biopsy of kidney	Surgery		11.29	5.02	5.02		
50220		Remove kidney, open	Surgery		17.12	7.25	7.25		
50225		Removal kidney open, complex	Surgery		20.20	8.16	8.16		
50230		Removal kidney open, radical	Surgery		22.04	8.59	8.59		
50234		Removal of kidney & ureter	Surgery		22.37	8.85	8.85		
50236		Removal of kidney & ureter	Surgery		24.82	10.27	10.27		
50240		Partial removal of kidney	Surgery		21.97	9.03	9.03		
50250		Cryoblate renal mass open	Surgery		19.97	9.18	9.18		RBRVS
50280		Removal of kidney lesion	Surgery		15.65	6.70	6.70		
50290		Removal of kidney lesion	Surgery		14.71	6.47	6.47		
50300		Removal of donor kidney	Surgery					26.89	
50320		Removal of donor kidney	Surgery		22.18	10.68	10.68		
50323		Prep cadaver renal allograft	Surgery		4.00	1.35	1.35		CALC
50325		Prep donor renal graft	Surgery		4.00	1.35	1.35		CALC
50327		Prep renal graft/venous	Surgery		4.00	1.35	1.35		
50328		Prep renal graft/arterial	Surgery		3.50	1.18	1.18		
50329		Prep renal graft/ureteral	Surgery		3.34	1.13	1.13		
50340		Removal of kidney	Surgery		12.13	6.51	6.51		
50360		Transplantation of kidney	Surgery		31.48	15.51	15.51		
50365		Transplantation of kidney	Surgery		36.75	18.24	18.24		
50370		Remove transplanted kidney	Surgery		13.70	7.16	7.16		
50380		Reimplantation of kidney	Surgery		20.73	12.05	12.05		
50382		Change ureter stent, percut	Surgery		5.50	1.87	36.22		RBRVS
50384		Remove ureter stent, percut	Surgery	a	5.00	1.71	35.32		RBRVS
50387		Change ext/int ureter stent	Surgery	a	2.00	0.67	18.26		RBRVS
50389		Remove renal tube w/fluoro	Surgery	a	1.10	0.37	12.78		RBRVS
50390		Drainage of kidney lesion	Surgery		1.96	0.64	0.64		
50391		Instill rx agent into mal tub	Surgery		1.96	0.63	1.58		
50392		Insert kidney drain	Surgery		3.37	1.52	1.52		
50393		Insert ureteral tube	Surgery		4.15	1.79	1.79		
50394		Injection for kidney x-ray	Surgery		0.76	0.66	2.69		
50395		Create passage to kidney	Surgery		3.37	1.50	1.50		
50396		Measure kidney pressure	Surgery		2.09	1.08	1.08		
50398		Change kidney tube	Surgery		1.46	0.52	16.36		
50400		Revision of kidney/ureter	Surgery		19.47	7.89	7.89		
50405		Revision of kidney/ureter	Surgery		23.89	9.05	9.05		
50500		Repair of kidney wound	Surgery		19.54	8.40	8.40		
50520		Close kidney-skin fistula	Surgery		17.20	7.44	7.44		
50525		Repair renal-abdomen fistula	Surgery		22.24	9.02	9.02		
50526		Repair renal-abdomen fistula	Surgery		23.98	9.88	9.88		
50540		Revision of horseshoe kidney	Surgery		19.90	8.34	8.34		
50541		Laparo ablate renal cyst	Surgery		15.98	6.50	6.50		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 55 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
50542		Laparo ablate renal mass	Surgery		19.97	8.15	8.15		
50543		Laparo partial nephrectomy	Surgery		25.46	10.22	10.22		
50544		Laparoscopy, pyeloplasty	Surgery		22.37	8.54	8.54		
50545		Laparo radical nephrectomy	Surgery		23.96	9.21	9.21		
50546		Laparoscopic nephrectomy	Surgery		20.45	8.38	8.38		
50547		Laparo removal donor kidney	Surgery		25.46	11.13	11.13		
50548		Laparo remove ureter	Surgery		24.36	9.20	9.20		
50549		Laparoscope proc, renal	Surgery					28.75	
50551		Kidney endoscopy	Surgery		5.59	1.98	4.15		
50553		Kidney endoscopy	Surgery		5.98	2.18	4.37		
50555		Kidney endoscopy & biopsy	Surgery		6.52	2.34	4.82		
50557		Kidney endoscopy & treatment	Surgery		6.61	2.30	4.59		
50561		Kidney endoscopy & treatment	Surgery		7.58	2.65	5.09		
50562		Renal scope w/tumor resect	Surgery		10.90	4.32	4.32		
50570		Kidney endoscopy	Surgery		9.53	3.22	3.22		
50572		Kidney endoscopy	Surgery		10.33	3.51	3.51		
50574		Kidney endoscopy & biopsy	Surgery		11.00	3.75	3.75		
50575		Kidney endoscopy	Surgery		13.96	4.64	4.64		
50576		Kidney endoscopy & treatment	Surgery		10.97	3.67	3.67		
50580		Kidney endoscopy & treatment	Surgery		11.84	3.97	3.97		
50590		Fragmenting of kidney stone	Surgery		9.08	4.12	12.43		
50592		Perc r/ ablate renal tumor	Surgery	a	6.75	2.99	149.45		RBRVS
50600		Exploration of ureter	Surgery		15.82	6.68	6.68		
50605		Insert ureteral support	Surgery		15.44	6.75	6.75		
50610		Removal of ureter stone	Surgery		15.90	6.98	6.98		
50620		Removal of ureter stone	Surgery		15.14	6.35	6.35		
50630		Removal of ureter stone	Surgery		14.92	6.29	6.29		
50650		Removal of ureter	Surgery		17.38	7.24	7.24		
50660		Removal of ureter	Surgery		19.52	7.97	7.97		
50684		Injection for ureter x-ray	Surgery		0.76	0.47	4.98		
50686		Measure ureter pressure	Surgery		1.51	0.82	3.45		
50688		Change of ureter tube	Surgery		1.17	1.06	1.06		
50690		Injection for ureter x-ray	Surgery		1.16	0.72	1.83		
50700		Revision of ureter	Surgery		15.19	7.13	7.13		
50715		Release of ureter	Surgery		18.87	8.76	8.76		
50722		Release of ureter	Surgery		16.33	7.82	7.82		
50725		Release/revise ureter	Surgery		18.46	8.06	8.06		
50727		Revise ureter	Surgery		8.17	4.28	4.28		
50728		Revise ureter	Surgery		12.00	5.57	5.57		
50740		Fusion of ureter & kidney	Surgery		18.39	7.75	7.75		
50750		Fusion of ureter & kidney	Surgery		19.48	8.00	8.00		
50760		Fusion of ureters	Surgery		18.39	7.69	7.69		
50770		Splicing of ureters	Surgery		19.48	7.99	7.99		
50780		Reimplant ureter in bladder	Surgery		18.33	7.60	7.60		
50782		Reimplant ureter in bladder	Surgery		19.51	8.79	8.79		
50783		Reimplant ureter in bladder	Surgery		20.52	8.23	8.23		
50785		Reimplant ureter in bladder	Surgery		20.49	8.31	8.31		
50800		Implant ureter in bowel	Surgery		14.50	6.48	6.48		
50810		Fusion of ureter & bowel	Surgery		20.02	9.11	9.11		
50815		Urine shunt to intestine	Surgery		19.90	8.46	8.46		
50820		Construct bowel bladder	Surgery		21.86	8.66	8.66		
50825		Construct bowel bladder	Surgery		28.14	11.15	11.15		
50830		Revise urine flow	Surgery		31.23	12.20	12.20		
50840		Replace ureter by bowel	Surgery		19.97	8.44	8.44		
50845		Appendico-vesicostomy	Surgery		20.86	8.92	8.92		
50860		Transplant ureter to skin	Surgery		15.34	6.63	6.63		
50900		Repair of ureter	Surgery		13.60	6.15	6.15		
50920		Closure ureter/skin fistula	Surgery		14.31	6.58	6.58		
50930		Closure ureter/bowel fistula	Surgery		18.69	7.98	7.98		
50940		Release of ureter	Surgery		14.49	6.41	6.41		
50945		Laparoscopy ureterolithotomy	Surgery		16.97	7.05	7.05		
50947		Laparo new ureter/bladder	Surgery		24.46	9.71	9.71		
50948		Laparo new ureter/bladder	Surgery		22.47	8.71	8.71		
50949		Laparoscope proc, ureter	Surgery					31.09	
50951		Endoscopy of ureter	Surgery		5.83	2.06	4.30		
50953		Endoscopy of ureter	Surgery		6.23	2.37	4.41		
50955		Ureter endoscopy & biopsy	Surgery		6.74	2.69	6.43		
50957		Ureter endoscopy & treatment	Surgery		6.78	2.38	4.57		
50961		Ureter endoscopy & treatment	Surgery		6.04	2.19	4.37		
50970		Ureter endoscopy	Surgery		7.13	2.47	2.47		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 56 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
50972		Ureter endoscopy & catheter	Surgery		6.88	2.47	2.47		
50974		Ureter endoscopy & biopsy	Surgery		9.16	3.11	3.11		
50976		Ureter endoscopy & treatment	Surgery		9.03	3.07	3.07		
50980		Ureter endoscopy & treatment	Surgery		6.84	2.38	2.38		
51000		Drainage of bladder	Surgery		0.78	0.24	1.95		
51005		Drainage of bladder	Surgery		1.02	0.34	4.71		
51010		Drainage of bladder	Surgery		3.52	1.88	5.62		
51020		Incise & treat bladder	Surgery		6.70	3.86	3.86		
51030		Incise & treat bladder	Surgery		6.76	3.98	3.98		
51040		Incise & drain bladder	Surgery		4.39	2.77	2.77		
51045		Incise bladder/drain ureter	Surgery		6.76	3.93	3.93		
51050		Removal of bladder stone	Surgery		6.91	3.65	3.65		
51060		Removal of ureter stone	Surgery		8.84	4.51	4.51		
51065		Remove ureter calculus	Surgery		8.84	4.36	4.36		
51080		Drainage of bladder abscess	Surgery		5.95	3.55	3.55		
51500		Removal of bladder cyst	Surgery		10.12	5.01	5.01		
51520		Removal of bladder lesion	Surgery		9.28	4.68	4.68		
51525		Removal of bladder lesion	Surgery		13.95	6.14	6.14		
51530		Removal of bladder lesion	Surgery		12.36	5.76	5.76		
51535		Repair of ureter lesion	Surgery		12.55	6.12	6.12		
51550		Partial removal of bladder	Surgery		15.64	6.74	6.74		
51555		Partial removal of bladder	Surgery		21.20	8.68	8.68		
51565		Revise bladder & ureter(s)	Surgery		21.59	8.98	8.98		
51570		Removal of bladder	Surgery		24.20	9.76	9.76		
51575		Removal of bladder & nodes	Surgery		30.40	12.05	12.05		
51580		Remove bladder/revise tract	Surgery		31.03	12.52	12.52		
51585		Removal of bladder & nodes	Surgery		35.18	13.73	13.73		
51590		Remove bladder/revise tract	Surgery		32.61	12.64	12.64		
51595		Remove bladder/revise tract	Surgery		37.08	14.16	14.16		
51596		Remove bladder/create pouch	Surgery		39.46	15.26	15.26		
51597		Removal of pelvic structures	Surgery		38.29	14.86	14.86		
51600		Injection for bladder x-ray	Surgery		0.88	0.29	5.06		
51605		Preparation for bladder x-ray	Surgery		0.84	0.35	6.07		
51610		Injection for bladder x-ray	Surgery		1.05	0.60	2.29		
51700		Irrigation of bladder	Surgery		0.88	0.28	1.60		
51701		Insert bladder catheter	Surgery		0.50	0.19	1.58		
51702		Insert temp bladder cath	Surgery		0.50	0.24	2.09		
51703		Insert bladder cath, complex	Surgery		1.47	0.56	2.74		
51705		Change of bladder tube	Surgery		1.02	0.61	2.28		
51710		Change of bladder tube	Surgery		1.49	0.77	3.34		
51715		Endoscopic injection/implant	Surgery		3.73	1.35	3.91		
51720		Treatment of bladder lesion	Surgery		1.96	0.69	1.75		
51725	26	Simple cystometrogram	Surgery		1.51	0.49	0.49		
51725	TC	Simple cystometrogram	Surgery	a	0.00	5.11	5.11		
51726	26	Complex cystometrogram	Surgery		1.71	0.56	0.56		
51726	TC	Complex cystometrogram	Surgery	a	0.00	6.96	6.96		
51736	26	Urine flow measurement	Surgery		0.61	0.20	0.20		
51736	TC	Urine flow measurement	Surgery	a	0.00	0.38	0.38		
51741	26	Electro-uroflowmetry, first	Surgery		1.14	0.37	0.37		
51741	TC	Electro-uroflowmetry, first	Surgery	a	0.00	0.42	0.42		
51772	26	Urethra pressure profile	Surgery		1.61	0.55	0.55		
51772	TC	Urethra pressure profile	Surgery	a	0.00	5.04	5.04		
51784	26	Anal/urinary muscle study	Surgery		1.53	0.50	0.50		
51784	TC	Anal/urinary muscle study	Surgery	a	0.00	3.49	3.49		
51785	26	Anal/urinary muscle study	Surgery		1.53	0.50	0.50		
51785	TC	Anal/urinary muscle study	Surgery	a	0.00	3.95	3.95		
51792	26	Urinary reflex study	Surgery		1.10	0.41	0.41		
51792	TC	Urinary reflex study	Surgery	a	0.00	5.60	5.60		
51795	26	Urine voiding pressure study	Surgery		1.53	0.50	0.50		
51795	TC	Urine voiding pressure study	Surgery	a	0.00	6.81	6.81		
51797	26	Intraabdominal pressure test	Surgery		1.60	0.53	0.53		
51797	TC	Intraabdominal pressure test	Surgery	a	0.00	5.27	5.27		
51798		Us urine capacity measure	Surgery		0.00	0.34	0.34		
51800		Revision of bladder/urethra	Surgery		17.39	7.58	7.58		
51820		Revision of urinary tract	Surgery		17.86	8.30	8.30		
51840		Attach bladder/urethra	Surgery		10.69	5.58	5.58		
51841		Attach bladder/urethra	Surgery		13.01	6.39	6.39		
51845		Repair bladder neck	Surgery		9.72	4.75	4.75		
51850		Repair of bladder wound	Surgery		12.00	5.77	5.77		
51865		Repair of bladder wound	Surgery		15.02	6.69	6.69		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for notes regarding Charge Methodology.

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 57 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
51880		Repair of bladder opening	Surgery		7.65	3.96	3.96		
51900		Repair bladder/vagina lesion	Surgery		12.95	6.08	6.08		
51920		Close bladder-uterus fistula	Surgery		11.79	5.65	5.65		
51925		Hysterectomy/bladder repair	Surgery		15.56	8.63	8.63		
51940		Correction of bladder defect	Surgery		28.39	12.11	12.11		
51960		Revision of bladder & bowel	Surgery		22.98	9.66	9.66		
51980		Construct bladder opening	Surgery		11.34	5.39	5.39		
51990		Laparo urethral suspension	Surgery		12.48	6.16	6.16		
51992		Laparo sling operation	Surgery		13.99	6.22	6.22		
52000		Cystoscopy	Surgery		2.01	0.76	3.31		
52001		Cystoscopy, removal of clots	Surgery		5.44	1.87	5.08		
52005		Cystoscopy & ureter catheter	Surgery		2.37	0.89	5.58		
52007		Cystoscopy and biopsy	Surgery		3.02	1.15	16.49		
52010		Cystoscopy & duct catheter	Surgery		3.02	1.15	10.78		
52204		Cystoscopy	Surgery		2.37	0.90	14.55		
52214		Cystoscopy and treatment	Surgery		3.70	1.33	38.21		
52224		Cystoscopy and treatment	Surgery		3.14	1.15	36.56		
52234		Cystoscopy and treatment	Surgery		4.62	1.66	1.66		
52235		Cystoscopy and treatment	Surgery		5.44	1.94	1.94		
52240		Cystoscopy and treatment	Surgery		9.71	3.31	3.31		
52250		Cystoscopy and radiotracer	Surgery		4.49	1.65	1.65		
52260		Cystoscopy and treatment	Surgery		3.91	1.42	1.42		
52265		Cystoscopy and treatment	Surgery		2.94	1.11	13.38		
52270		Cystoscopy & revise urethra	Surgery		3.36	1.24	11.06		
52275		Cystoscopy & revise urethra	Surgery		4.69	1.66	15.60		
52276		Cystoscopy and treatment	Surgery		4.99	1.79	1.79		
52277		Cystoscopy and treatment	Surgery		6.16	2.23	2.23		
52281		Cystoscopy and treatment	Surgery		2.80	1.08	7.11		
52282		Cystoscopy, implant stent	Surgery		6.39	2.24	2.24		
52283		Cystoscopy and treatment	Surgery		3.73	1.38	3.95		
52285		Cystoscopy and treatment	Surgery		3.60	1.33	4.02		
52290		Cystoscopy and treatment	Surgery		4.58	1.65	1.65		
52300		Cystoscopy and treatment	Surgery		5.30	1.91	1.91		
52301		Cystoscopy and treatment	Surgery		5.50	1.99	1.99		
52305		Cystoscopy and treatment	Surgery		5.30	1.86	1.86		
52310		Cystoscopy and treatment	Surgery		2.81	1.03	4.70		
52315		Cystoscopy and treatment	Surgery		5.20	1.84	8.69		
52317		Remove bladder stone	Surgery		6.71	2.29	29.02		
52318		Remove bladder stone	Surgery		9.18	3.10	3.10		
52320		Cystoscopy and treatment	Surgery		4.69	1.63	1.63		
52325		Cystoscopy, stone removal	Surgery		6.15	2.12	2.12		
52327		Cystoscopy, inject material	Surgery		5.18	1.82	31.90		
52330		Cystoscopy and treatment	Surgery		5.03	1.76	38.93		
52332		Cystoscopy and treatment	Surgery		2.83	1.05	5.76		
52334		Create passage to kidney	Surgery		4.82	1.74	1.74		
52341		Cysto w/ureter stricture tx	Surgery		5.99	2.22	2.22		
52342		Cysto w/lup stricture tx	Surgery		6.49	2.35	2.35		
52343		Cysto w/renal stricture tx	Surgery		7.19	2.59	2.59		
52344		Cysto/uretero, stone remove	Surgery		7.69	2.80	2.80		
52345		Cysto/uretero w/lup stricture	Surgery		8.19	2.96	2.96		
52346		Cystouretero w/renal strict	Surgery		9.22	3.29	3.29		
52351		Cystouretero & or pyeloscope	Surgery		5.85	2.15	2.15		
52352		Cystouretero w/stone remove	Surgery		6.87	2.51	2.51		
52353		Cystouretero w/lithotripsy	Surgery		7.96	2.86	2.86		
52354		Cystouretero w/biopsy	Surgery		7.33	2.68	2.68		
52355		Cystouretero w/excise tumor	Surgery		8.81	3.15	3.15		
52400		Cystouretero w/congen repr	Surgery		9.67	3.74	3.74		
52402		Cystourethro cut ejacul duct	Surgery		5.27	1.70	1.70		
52450		Incision of prostate	Surgery		7.63	3.68	3.68		
52500		Revision of bladder neck	Surgery		8.46	3.93	3.93		
52510		Dilation prostatic urethra	Surgery		6.71	3.12	3.12		
52601		Prostatectomy (TURP)	Surgery		12.35	5.11	5.11		
52606		Control postop bleeding	Surgery		8.12	3.56	3.56		
52612		Prostatectomy, first stage	Surgery		7.97	3.74	3.74		
52614		Prostatectomy, second stage	Surgery		6.83	3.35	3.35		
52620		Remove residual prostate	Surgery		6.60	2.99	2.99		
52630		Remove prostate regrowth	Surgery		7.25	3.20	3.20		
52640		Relieve bladder contracture	Surgery		6.61	2.97	2.97		
52647		Laser surgery of prostate	Surgery		10.34	4.54	74.15		
52648		Laser surgery of prostate	Surgery		11.19	4.80	4.80		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for notes regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 58 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
52700		Drainage of prostatic abscess	Surgery		6.79	3.19	3.19		
53000		Incision of urethra	Surgery		2.28	1.54	1.54		
53010		Incision of urethra	Surgery		3.63	2.92	2.92		
53020		Incision of urethra	Surgery		1.77	0.67	3.01		
53025		Incision of urethra	Surgery		1.13	0.51	3.74		
53040		Drainage of urethra abscess	Surgery		6.39	3.44	3.44		
53060		Drainage of urethra abscess	Surgery		2.63	1.37	2.09		
53080		Drainage of urinary leakage	Surgery		6.28	5.97	5.97		
53085		Drainage of urinary leakage	Surgery		10.25	7.42	7.42		
53200		Biopsy of urethra	Surgery		2.59	0.98	1.32		
53210		Removal of urethra	Surgery		12.55	5.85	5.85		
53215		Removal of urethra	Surgery		15.56	6.64	6.64		
53220		Treatment of urethra lesion	Surgery		6.99	3.72	3.72		
53230		Removal of urethra lesion	Surgery		9.57	4.72	4.72		
53235		Removal of urethra lesion	Surgery		10.12	4.91	4.91		
53240		Surgery for urethra pouch	Surgery		6.44	3.53	3.53		
53250		Removal of urethra gland	Surgery		5.88	3.30	3.30		
53260		Treatment of urethra lesion	Surgery		2.98	1.42	2.25		
53265		Treatment of urethra lesion	Surgery		3.12	1.42	2.72		
53270		Removal of urethra gland	Surgery		3.09	1.54	2.21		
53275		Repair of urethra defect	Surgery		4.52	2.26	2.26		
53400		Revise urethra, stage 1	Surgery		12.75	6.04	6.04		
53405		Revise urethra, stage 2	Surgery		14.46	6.33	6.33		
53410		Reconstruction of urethra	Surgery		16.42	7.07	7.07		
53415		Reconstruction of urethra	Surgery		19.38	7.35	7.35		
53420		Reconstruct urethra, stage 1	Surgery		14.06	6.30	6.30		
53425		Reconstruct urethra, stage 2	Surgery		15.96	6.90	6.90		
53430		Reconstruction of urethra	Surgery		16.32	7.01	7.01		
53431		Reconstruct urethra/bladder	Surgery		19.86	8.07	8.07		
53440		Male sling procedure	Surgery		13.60	5.99	5.99		
53442		Remove/revise male sling	Surgery		11.55	5.45	5.45		
53444		Insert tandem cuff	Surgery		13.38	5.89	5.89		
53445		Insert uro/ves nck sphincter	Surgery		14.04	7.10	7.10		
53446		Remove uro sphincter	Surgery		10.21	5.23	5.23		
53447		Remove/replace ur sphincter	Surgery		13.47	6.44	6.44		
53448		Remove/replc ur sphinctr comp	Surgery		21.12	9.07	9.07		
53449		Repair uro sphincter	Surgery		9.69	4.73	4.73		
53450		Revision of urethra	Surgery		6.13	3.30	3.30		
53460		Revision of urethra	Surgery		7.11	3.70	3.70		
53500		Urethriys, transvag w/ scope	Surgery		12.19	6.22	6.22		
53502		Repair of urethra injury	Surgery		7.62	3.99	3.99		
53505		Repair of urethra injury	Surgery		7.62	3.87	3.87		
53510		Repair of urethra injury	Surgery		10.09	5.17	5.17		
53515		Repair of urethra injury	Surgery		13.29	5.94	5.94		
53520		Repair of urethra defect	Surgery		8.57	4.48	4.48		
53600		Dilate urethra stricture	Surgery		1.21	0.43	1.14		
53601		Dilate urethra stricture	Surgery		0.98	0.37	1.27		
53605		Dilate urethra stricture	Surgery		1.28	0.41	0.41		
53620		Dilate urethra stricture	Surgery		1.62	0.59	2.00		
53621		Dilate urethra stricture	Surgery		1.35	0.49	2.08		
53660		Dilation of urethra	Surgery		0.71	0.31	1.31		
53661		Dilation of urethra	Surgery		0.72	0.29	1.30		
53665		Dilation of urethra	Surgery		0.76	0.25	0.25		
53665		Prostatic microwave thermobx	Surgery		9.44	3.95	94.33		
53850		Prostatic rf thermobx	Surgery		9.87	4.38	89.03		
53852		Prostatic water thermother	Surgery		5.23	2.86	55.50		
53853		Urology surgery procedure	Surgery					4.60	
53899		Sitting of prepuce	Surgery		1.54	0.93	2.92		
54000		Sitting of prepuce	Surgery		2.19	1.11	3.19		
54001		Drain penis lesion	Surgery		5.31	2.56	2.56		
54015		Destruction, penis lesion(s)	Surgery		1.24	1.03	1.66		
54050		Destruction, penis lesion(s)	Surgery		1.22	0.80	1.57		
54055		Cryosurgery, penis lesion(s)	Surgery		1.24	1.13	1.69		
54056		Laser surg, penis lesion(s)	Surgery		1.24	0.83	2.22		
54057		Excision of penis lesion(s)	Surgery		1.93	1.06	3.11		
54060		Destruction, penis lesion(s)	Surgery		2.42	1.23	2.64		
54065		Biopsy of penis	Surgery		1.90	0.82	2.81		
54100		Biopsy of penis	Surgery		3.49	1.94	4.29		
54105		Treatment of penis lesion	Surgery		10.11	4.76	4.76		
54110		Treat penis lesion, graft	Surgery		13.55	5.78	5.78		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 59 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
54112		Treat penis lesion, graft	Surgery		15.84	6.81	6.81		
54115		Treatment of penis lesion	Surgery		6.14	3.46	4.38		
54120		Partial removal of penis	Surgery		9.96	4.68	4.68		
54125		Removal of penis	Surgery		13.51	5.84	5.84		
54130		Remove penis & nodes	Surgery		20.11	8.19	8.19		
54135		Remove penis & nodes	Surgery		26.32	10.19	10.19		
54150		Circumcision	Surgery		1.81	0.70	4.36		
54152		Circumcision	Surgery		2.31	1.20	1.20		
54160		Circumcision	Surgery		2.48	1.09	4.15		
54161		Circumcision	Surgery		3.27	1.56	1.56		
54162		Lysis penil circumic lesion	Surgery		3.00	1.44	4.66		
54163		Repair of circumcision	Surgery		3.00	2.01	2.01		
54164		Frenulotomy of penis	Surgery		2.50	1.84	1.84		
54200		Treatment of penis lesion	Surgery		1.06	0.97	1.80		
54205		Treatment of penis lesion	Surgery		7.92	4.69	4.69		
54220		Treatment of penis lesion	Surgery		2.42	0.95	3.85		
54230		Prepare penis study	Surgery		1.34	0.63	1.08		
54231		Dynamic cavernosometry	Surgery		2.04	0.87	1.37		
54235		Penile injection	Surgery		1.19	0.58	0.96		
54240	26	Penis study	Surgery		1.31	0.43	0.43		
54240	TC	Penis study	Surgery	a	0.00	0.60	0.60		
54250	26	Penis study	Surgery		2.22	0.71	0.71		
54250	TC	Penis study	Surgery	a	0.00	0.20	0.20		
54300		Revision of penis	Surgery		10.39	5.58	5.58		
54304		Revision of penis	Surgery		12.47	6.34	6.34		
54308		Reconstruction of urethra	Surgery		11.81	5.97	5.97		
54312		Reconstruction of urethra	Surgery		13.55	7.00	7.00		
54316		Reconstruction of urethra	Surgery		16.79	7.96	7.96		
54318		Reconstruction of urethra	Surgery		11.23	5.80	5.80		
54322		Reconstruction of urethra	Surgery		12.99	6.47	6.47		
54324		Reconstruction of urethra	Surgery		16.29	7.97	7.97		
54326		Reconstruction of urethra	Surgery		15.70	7.79	7.79		
54328		Revise penis/urethra	Surgery		15.63	7.26	7.26		
54332		Revise penis/urethra	Surgery		17.05	7.74	7.74		
54336		Revise penis/urethra	Surgery		20.01	10.31	10.31		
54340		Secondary urethral surgery	Surgery		8.90	5.04	5.04		
54344		Secondary urethral surgery	Surgery		15.92	7.76	7.76		
54348		Secondary urethral surgery	Surgery		17.12	8.36	8.36		
54352		Reconstruct urethra/penis	Surgery		24.70	11.20	11.20		
54360		Penis plastic surgery	Surgery		11.91	6.04	6.04		
54380		Repair penis	Surgery		13.16	6.62	6.62		
54385		Repair penis	Surgery		15.37	8.27	8.27		
54390		Repair penis and bladder	Surgery		21.58	9.43	9.43		
54400		Insert semi-rigid prosthesis	Surgery		8.98	4.35	4.35		
54401		Insert self-contd prosthesis	Surgery		10.26	5.74	5.74		
54405		Insert multi-comp penis pros	Surgery		13.41	5.93	5.93		
54406		Remove multi-comp penis pros	Surgery		12.08	5.43	5.43		
54408		Repair multi-comp penis pros	Surgery		12.73	5.74	5.74		
54410		Remove/replace penis prosth	Surgery		15.48	6.63	6.63		
54411		Remove/replc penis pros, comp	Surgery		15.98	7.05	7.05		
54415		Remove self-contd penis pros	Surgery		8.19	4.20	4.20		
54416		Remv/replc penis contain pros	Surgery		10.85	5.38	5.38		
54417		Remv/replc penis pros, compl	Surgery		14.17	6.18	6.18		
54420		Revision of penis	Surgery		11.40	5.58	5.58		
54430		Revision of penis	Surgery		10.13	5.11	5.11		
54435		Revision of penis	Surgery		6.11	3.62	3.62		
54440		Repair of penis	Surgery					14.95	
54450		Preputial stretching	Surgery		1.12	0.44	0.95		
54500		Biopsy of testis	Surgery		1.31	0.56	0.61		
54505		Biopsy of testis	Surgery		3.45	1.92	1.92		
54512		Excise lesion testis	Surgery		8.57	4.13	4.13		
54520		Removal of testis	Surgery		5.22	2.79	2.79		
54522		Orchiectomy, partial	Surgery		9.49	4.87	4.87		
54530		Removal of testis	Surgery		8.57	4.24	4.24		
54535		Extensive testis surgery	Surgery		12.14	5.55	5.55		
54550		Exploration for testis	Surgery		7.77	3.81	3.81		
54550		Exploration for testis	Surgery		11.11	5.16	5.16		
54600		Reduce testis torsion	Surgery		7.00	3.55	3.55		
54620		Suspension of testis	Surgery		4.89	2.44	2.44		
54640		Suspension of testis	Surgery		6.89	3.74	3.74		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 60 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
54650		Orchiopexy (Fowler-Stephens)	Surgery		11.43	5.41	5.41		
54660		Revision of testis	Surgery		5.10	3.00	3.00		
54670		Repair testis injury	Surgery		6.40	3.54	3.54		
54680		Relocation of testis(es)	Surgery		12.63	6.16	6.16		
54690		Laparoscopy, orchiectomy	Surgery		10.94	4.94	4.94		
54692		Laparoscopy, orchiopexy	Surgery		12.86	5.44	5.44		
54699		Laparoscope proc, testis	Surgery					18.31	
54700		Drainage of scrotum	Surgery		3.42	1.94	1.94		
54800		Biopsy of epididymis	Surgery		2.33	0.90	0.94		
54820		Exploration of epididymis	Surgery		5.13	2.94	2.94		
54830		Remove epididymis lesion	Surgery		5.37	3.02	3.02		
54840		Remove epididymis lesion	Surgery		5.19	2.78	2.78		
54860		Removal of epididymis	Surgery		6.31	3.31	3.31		
54861		Removal of epididymis	Surgery		8.89	4.31	4.31		
54900		Fusion of spermatic ducts	Surgery		13.18	5.80	5.80		
54901		Fusion of spermatic ducts	Surgery		17.91	7.53	7.53		
55000		Drainage of hydrocele	Surgery		1.43	0.65	2.07		
55040		Removal of hydrocele	Surgery		5.35	2.90	2.90		
55041		Removal of hydroceles	Surgery		7.73	3.97	3.97		
55060		Repair of hydrocele	Surgery		5.51	3.08	3.08		
55100		Drainage of scrotum abscess	Surgery		2.13	1.56	3.68		
55110		Explore scrotum	Surgery		5.69	3.13	3.13		
55120		Removal of scrotum lesion	Surgery		5.08	2.95	2.95		
55150		Removal of scrotum	Surgery		7.21	3.84	3.84		
55175		Revision of scrotum	Surgery		5.23	3.01	3.01		
55180		Revision of scrotum	Surgery		10.70	5.37	5.37		
55200		Incision of sperm duct	Surgery		4.23	2.38	12.35		
55250		Removal of sperm duct(s)	Surgery		3.29	2.22	11.50		
55300		Prepare, sperm duct x-ray	Surgery		3.50	1.31	1.31		
55400		Repair of sperm duct	Surgery		8.48	4.06	4.06		
55450		Ligation of sperm duct	Surgery		4.11	1.87	7.01		
55500		Removal of hydrocele	Surgery		5.58	3.09	3.09		
55520		Removal of sperm cord lesion	Surgery		6.02	3.25	3.25		
55530		Revise spermatic cord veins	Surgery		5.65	3.01	3.01		
55535		Revise spermatic cord veins	Surgery		6.55	3.40	3.40		
55540		Revise hernia & sperm veins	Surgery		7.66	3.80	3.80		
55550		Laparo ligate spermatic vein	Surgery		6.56	3.30	3.30		
55559		Laparo proc, spermatic cord	Surgery					9.88	
55600		Incise sperm duct pouch	Surgery		6.37	3.33	3.33		
55605		Incise sperm duct pouch	Surgery		7.95	4.29	4.29		
55650		Remove sperm duct pouch	Surgery		11.78	5.28	5.28		
55680		Remove sperm pouch lesion	Surgery		5.18	2.97	2.97		
55700		Biopsy of prostate	Surgery		1.57	0.64	4.20		
55705		Biopsy of prostate	Surgery		4.56	2.30	2.30		
55720		Drainage of prostate abscess	Surgery		7.63	3.82	3.82		
55725		Drainage of prostate abscess	Surgery		8.67	4.49	4.49		
55801		Removal of prostate	Surgery		17.77	7.62	7.62		
55810		Extensive prostate surgery	Surgery		22.55	8.95	8.95		
55812		Extensive prostate surgery	Surgery		27.47	10.99	10.99		
55815		Extensive prostate surgery	Surgery		30.41	11.90	11.90		
55815		Extensive prostate surgery	Surgery		14.23	6.21	6.21		
55821		Removal of prostate	Surgery		15.60	6.66	6.66		
55831		Removal of prostate	Surgery		22.66	9.29	9.29		
55840		Extensive prostate surgery	Surgery		24.34	9.85	9.85		
55842		Extensive prostate surgery	Surgery		28.51	10.94	10.94		
55845		Extensive prostate surgery	Surgery		12.50	5.85	5.85		
55859		Percut/needle insert, pros	Surgery		14.43	6.41	6.41		
55860		Surgical exposure, prostate	Surgery		18.36	7.85	7.85		
55862		Extensive prostate surgery	Surgery		22.84	9.27	9.27		
55865		Extensive prostate surgery	Surgery		30.69	11.73	11.73		
55866		Laparo radical prostatectomy	Surgery		2.58	1.08	1.53		
55870		Vag hyst w/enterocele repair	Surgery		19.44	8.96	8.96		
55873		Cryoablate prostate	Surgery					4.69	
55899		Genital surgery procedure	Surgery						
56405		I & D of vulva/perineum	Surgery		1.44	1.14	1.33		
56420		Drainage of gland abscess	Surgery		1.39	1.04	2.28		
56440		Surgery for vulva lesion	Surgery		2.84	1.71	1.71		
56441		Lysis of labial lesion(s)	Surgery		1.97	1.41	1.82		
56501		Destroy, vulva lesions, sim	Surgery		1.53	1.24	1.79		
56515		Destroy vulva lesion/s compl	Surgery		2.76	1.82	2.55		
56605		Biopsy of vulva/perineum	Surgery		1.10	0.46	1.07		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 61 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
56606		Biopsy of vulva/perineum	Surgery		0.55	0.22	0.49		
56620		Partial removal of vulva	Surgery		7.46	4.80	4.80		
56625		Complete removal of vulva	Surgery		8.39	5.33	5.33		
56630		Extensive vulva surgery	Surgery		12.34	6.85	6.85		
56631		Extensive vulva surgery	Surgery		16.18	8.83	8.83		
56632		Extensive vulva surgery	Surgery		20.26	9.54	9.54		
56633		Extensive vulva surgery	Surgery		16.45	8.61	8.61		
56634		Extensive vulva surgery	Surgery		17.85	9.45	9.45		
56637		Extensive vulva surgery	Surgery		21.94	11.09	11.09		
56640		Extensive vulva surgery	Surgery		22.14	10.64	10.64		
56700		Partial removal of hymen	Surgery		2.52	1.84	1.84		
56720		Incision of hymen	Surgery		0.68	0.51	0.51		
56740		Remove vagina gland lesion	Surgery		4.56	2.57	2.57		
56800		Repair of vagina	Surgery		3.88	2.20	2.20		
56805		Repair clitoris	Surgery		18.83	9.44	9.44		
56810		Repair of perineum	Surgery		4.12	2.30	2.30		
56820		Exam of vulva w/scope	Surgery		1.50	0.65	1.31		
56821		Exam/biopsy of vulva w/scope	Surgery		2.05	0.91	1.76		
57000		Exploration of vagina	Surgery		2.97	1.72	1.72		
57010		Drainage of pelvic abscess	Surgery		6.02	3.81	3.81		
57020		Drainage of pelvic fluid	Surgery		1.50	0.59	0.94		
57022		l & d vaginal hematoma, pp	Surgery		2.56	1.49	1.49		
57023		l & d vaq hematoma, non-ob	Surgery		4.74	2.58	2.58		
57061		Destroy vaq lesions, simple	Surgery		1.25	1.12	1.65		
57065		Destroy vaq lesions, complex	Surgery		2.61	1.67	2.30		
57100		Biopsy of vagina	Surgery		1.20	0.48	1.08		
57105		Biopsy of vagina	Surgery		1.69	1.42	1.80		
57106		Remove vagina wall, partial	Surgery		6.35	4.19	4.19		
57107		Remove vagina tissue, part	Surgery		22.97	10.49	10.49		
57109		Vaginectomy partial w/nodes	Surgery		26.96	11.27	11.27		
57110		Remove vagina wall, complete	Surgery		14.27	7.29	7.29		
57111		Remove vagina tissue, compl	Surgery		26.96	12.65	12.65		
57112		Vaginectomy w/nodes, compl	Surgery		28.96	12.13	12.13		
57120		Closure of vagina	Surgery		7.40	4.61	4.61		
57130		Remove vagina lesion	Surgery		2.43	1.54	2.16		
57135		Remove vagina lesion	Surgery		2.67	1.65	2.27		
57150		Treat vagina infection	Surgery		0.55	0.21	1.10		
57155		Insert uteri tandems/ovoids	Surgery		6.26	4.57	4.57		
57160		Insert pessary/other device	Surgery		0.89	0.34	1.01		
57170		Fitting of diaphragm/cap	Surgery		0.91	0.33	1.48		
57180		Treat vaginal bleeding	Surgery		1.58	1.26	2.17		
57200		Repair of vagina	Surgery		3.93	2.90	2.90		
57210		Repair vagina/perineum	Surgery		5.16	3.44	3.44		
57220		Revision of urethra	Surgery		4.30	3.11	3.11		
57230		Repair of urethral lesion	Surgery		5.63	3.41	3.41		
57240		Repair bladder & vagina	Surgery		6.06	3.82	3.82		
57250		Repair rectum & vagina	Surgery		5.52	3.58	3.58		
57260		Repair of vagina	Surgery		8.26	4.84	4.84		
57265		Extensive repair of vagina	Surgery		11.32	6.05	6.05		
57267		Insert mesh/pelvic flr addon	Surgery		4.88	1.98	1.98		
57268		Repair of bowel bulge	Surgery		6.75	4.20	4.20		
57270		Repair of bowel pouch	Surgery		12.09	6.26	6.26		
57280		Suspension of vagina	Surgery		15.02	7.38	7.38		
57282		Repair of vaginal prolapse	Surgery		6.86	4.51	4.51		
57283		Colpopexy, intraperitoneal	Surgery		10.84	5.93	5.93		
57284		Repair paravaginal defect	Surgery		12.68	7.16	7.16		
57287		Revise/remove sling repair	Surgery		10.69	5.49	5.49		
57288		Repair bladder defect	Surgery		13.00	5.92	5.92		
57289		Repair bladder & vagina	Surgery		11.56	6.05	6.05		
57291		Construction of vagina	Surgery		7.94	4.93	4.93		
57292		Construct vagina with graft	Surgery		13.07	6.95	6.95		
57295		Change vaginal graft	Surgery		7.45	4.44	4.44		
57300		Repair rectum-vagina fistula	Surgery		7.60	4.29	4.29		
57305		Repair rectum-vagina fistula	Surgery		13.75	6.28	6.28		
57307		Fistula repair & colostomy	Surgery		15.91	7.01	7.01		
57308		Fistula repair, transperine	Surgery		9.93	5.10	5.10		
57310		Repair urethrovaginal lesion	Surgery		6.77	3.84	3.84		
57311		Repair urethrovaginal lesion	Surgery		7.97	4.12	4.12		
57320		Repair bladder-vagina lesion	Surgery		8.00	4.37	4.37		
57330		Repair bladder-vagina lesion	Surgery		12.33	5.72	5.72		

RBRVS

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 62 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
57335		Repair vagina	Surgery		18.70	9.05	9.05		
57400		Dilation of vagina	Surgery		2.27	1.11	1.11		
57410		Pelvic examination	Surgery		1.75	0.89	2.02		
57415		Remove vaginal foreign body	Surgery		2.17	1.42	1.42		
57420		Exam of vagina w/scope	Surgery		1.60	0.67	1.35		
57421		Exam/biopsy of vag w/scope	Surgery		2.20	0.96	1.85		
57425		Laparoscopy, surg, colpopexy	Surgery		15.73	6.65	6.65		
57452		Exam of cervix w/scope	Surgery		1.50	0.76	1.28		
57454		Bx/curett of cervix w/scope	Surgery		2.33	1.15	1.64		
57455		Biopsy of cervix w/scope	Surgery		1.99	0.87	1.72		
57456		Endocerv curettage w/scope	Surgery		1.85	0.82	1.65		
57460		Bx of cervix w/scope, leep	Surgery		2.83	1.38	5.86		
57461		Conz of cervix w/scope, leep	Surgery		3.43	1.47	6.12		
57500		Biopsy of cervix	Surgery		0.97	0.63	2.55		
57505		Endocervical curettage	Surgery		1.14	1.10	1.46		
57510		Cauterization of cervix	Surgery		1.90	1.04	1.56		
57511		Cryocautery of cervix	Surgery		1.90	1.37	1.83		
57513		Laser surgery of cervix	Surgery		1.90	1.40	1.72		
57520		Conization of cervix	Surgery		4.03	2.88	3.94		
57522		Conization of cervix	Surgery		3.35	2.46	3.16		
57530		Removal of cervix	Surgery		4.78	3.39	3.39		
57531		Removal of cervix, radical	Surgery		27.96	13.20	13.20		
57540		Removal of residual cervix	Surgery		12.20	6.25	6.25		
57545		Remove cervix/repair pelvis	Surgery		13.01	6.69	6.69		
57550		Removal of residual cervix	Surgery		5.52	3.83	3.83		
57555		Remove cervix/repair vagina	Surgery		8.94	5.09	5.09		
57556		Remove cervix, repair bowel	Surgery		8.36	4.86	4.86		
57700		Revision of cervix	Surgery		3.54	3.11	3.11		
57720		Revision of cervix	Surgery		4.12	3.11	3.11		
57800		Dilation of cervical canal	Surgery		0.77	0.47	0.76		
57820		D & c of residual cervix	Surgery		1.67	1.14	1.47		
58100		Biopsy of uterus lining	Surgery		1.53	0.72	1.32		
58110		Bx done w/colposcopy add-on	Surgery	a	0.77	0.31	0.55		RBRVS
58120		Dilation and curettage	Surgery		3.27	1.88	2.31		
58140		Myomectomy abdom method	Surgery		14.58	7.12	7.12		
58145		Myomectomy vag method	Surgery		8.03	4.80	4.80		
58146		Myomectomy abdom complex	Surgery		18.97	9.03	9.03		
58150		Total hysterectomy	Surgery		15.22	7.50	7.50		
58152		Total hysterectomy	Surgery		20.57	9.88	9.88		
58180		Partial hysterectomy	Surgery		15.27	7.47	7.47		
58200		Extensive hysterectomy	Surgery		21.56	10.02	10.02		
58210		Extensive hysterectomy	Surgery		28.81	13.23	13.23		
58240		Removal of pelvis contents	Surgery		38.33	17.66	17.66		
58260		Vaginal hysterectomy	Surgery		12.96	6.71	6.71		
58262		Vag hyst including t/o	Surgery		14.75	7.40	7.40		
58263		Vag hyst w/t/o & vag repair	Surgery		16.04	7.90	7.90		
58267		Vag hyst w/urinary repair	Surgery		17.01	8.39	8.39		
58270		Vag hyst w/enterocele repair	Surgery		14.24	7.08	7.08		
58275		Hysterectomy/revise vagina	Surgery		15.74	7.79	7.79		
58280		Hysterectomy/revise vagina	Surgery		16.98	8.27	8.27		
58285		Extensive hysterectomy	Surgery		22.23	9.97	9.97		
58290		Vag hyst complex	Surgery		18.97	9.15	9.15		
58291		Vag hyst incl t/o, complex	Surgery		20.76	9.90	9.90		
58292		Vag hyst t/o & repair, compl	Surgery		22.05	10.39	10.39		
58293		Vag hyst w/uro repair, compl	Surgery		23.03	10.68	10.68		
58294		Vag hyst w/enterocele, compl	Surgery		20.25	9.58	9.58		
58300		Insert intrauterine device	Surgery		1.01	0.38	1.42		
58301		Remove intrauterine device	Surgery		1.27	0.48	1.32		
58321		Artificial insemination	Surgery		0.92	0.37	1.15		
58322		Artificial insemination	Surgery		1.10	0.42	1.20		
58323		Sperm washing	Surgery		0.23	0.09	0.53		
58340		Catheter for hystero-graphy	Surgery		0.88	0.65	3.17		
58345		Reopen fallopian tube	Surgery		4.65	2.44	2.44		
58346		Insert heyman uteri capsule	Surgery		6.74	3.93	3.93		
58350		Reopen fallopian tube	Surgery		1.01	0.92	1.49		
58353		Endometr ablate, thermal	Surgery		3.55	2.06	35.76		
58356		Endometrial cryoablation	Surgery		6.36	2.70	61.61		
58400		Suspension of uterus	Surgery		6.35	3.94	3.94		
58410		Suspension of uterus	Surgery		12.71	6.45	6.45		
58520		Repair of ruptured uterus	Surgery		11.90	6.05	6.05		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 63 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
58540		Revision of uterus	Surgery		14.62	6.97	6.97		
58545		Laparoscopic myomectomy	Surgery		14.58	7.20	7.20		
58546		Laparo-myomectomy, complex	Surgery		18.97	8.94	8.94		
58550		Laparo-assst vag hysterectomy	Surgery		14.17	7.31	7.31		
58552		Laparo-vag hyst incl t/o	Surgery		15.98	8.03	8.03		
58553		Laparo-vag hyst, complex	Surgery		18.97	8.94	8.94		
58554		Laparo-vag hyst w/t/o, compl	Surgery		21.97	10.42	10.42		
58555		Hysteroscopy, dx, sep proc	Surgery		3.33	1.55	2.20		
58558		Hysteroscopy, biopsy	Surgery		4.74	2.18	2.18		
58559		Hysteroscopy, lysis	Surgery		6.16	2.74	2.74		
58560		Hysteroscopy, resect septum	Surgery		6.99	3.09	3.09		
58561		Hysteroscopy, remove myoma	Surgery		9.99	4.29	4.29		
58562		Hysteroscopy, remove fb	Surgery		5.20	2.36	2.36		
58563		Hysteroscopy, ablation	Surgery		6.16	2.76	56.35		
58565		Hysteroscopy, sterilization	Surgery		7.02	3.91	49.70		
58578		Laparo proc, uterus	Surgery					21.48	
58579		Hysteroscope procedure	Surgery					6.80	
58600		Division of fallopian tube	Surgery		5.59	3.34	3.34		
58605		Division of fallopian tube	Surgery		4.99	3.12	3.12		
58611		Ligate oviduct(s) add-on	Surgery		1.45	0.57	0.57		
58615		Occlude fallopian tube(s)	Surgery		3.89	2.71	2.71		
58660		Laparoscopy, lysis	Surgery		11.27	5.27	5.27		
58661		Laparoscopy, remove adnexa	Surgery		11.03	5.13	5.13		
58662		Laparoscopy, excise lesions	Surgery		11.77	5.80	5.80		
58670		Laparoscopy, tubal cautery	Surgery		5.59	3.28	3.28		
58671		Laparoscopy, tubal block	Surgery		5.59	3.28	3.28		
58672		Laparoscopy, fimbrioplasty	Surgery		12.86	6.20	6.20		
58673		Laparoscopy, salpingostomy	Surgery		13.72	6.59	6.59		
58679		Laparo proc, oviduct-ovary	Surgery					16.17	
58700		Removal of fallopian tube	Surgery		12.03	6.00	6.00		
58720		Removal of ovary/tube(s)	Surgery		11.34	5.79	5.79		
58740		Revise fallopian tube(s)	Surgery		13.98	7.15	7.15		
58750		Repair oviduct	Surgery		14.82	7.38	7.38		
58752		Revise ovarian tube(s)	Surgery		14.82	6.96	6.96		
58760		Remove tubal obstruction	Surgery		13.11	6.73	6.73		
58770		Create new tubal opening	Surgery		13.95	6.92	6.92		
58800		Drainage of ovarian cyst(s)	Surgery		4.13	2.91	3.65		
58805		Drainage of ovarian cyst(s)	Surgery		5.87	3.51	3.51		
58820		Drain ovary abscess, open	Surgery		4.21	3.30	3.30		
58822		Drain ovary abscess, percut	Surgery		10.11	5.23	5.23		
58823		Drain pelvic abscess, percut	Surgery		3.37	1.12	21.38		
58825		Transposition, ovary(s)	Surgery		10.96	5.81	5.81		
58900		Biopsy of ovary(s)	Surgery		5.98	3.58	3.58		
58920		Partial removal of ovary(s)	Surgery		11.34	5.59	5.59		
58925		Removal of ovarian cyst(s)	Surgery		11.34	5.70	5.70		
58940		Removal of ovary(s)	Surgery		7.28	4.11	4.11		
58943		Removal of ovary(s)	Surgery		18.40	8.67	8.67		
58950		Resect ovarian malignancy	Surgery		16.90	8.42	8.42		
58951		Resect ovarian malignancy	Surgery		22.35	10.47	10.47		
58952		Resect ovarian malignancy	Surgery		24.97	11.78	11.78		
58953		Tah, rad dissect for debulk	Surgery		31.95	14.58	14.58		
58954		Tah rad debulk/lymph remove	Surgery		34.95	15.75	15.75		
58956		Bso, omentectomy w/tah	Surgery		20.78	10.34	10.34		
58960		Exploration of abdomen	Surgery		14.63	7.37	7.37		
58970		Retrieval of oocyte	Surgery		3.52	1.49	2.32		
58974		Transfer of embryo	Surgery					4.54	
58976		Transfer of embryo	Surgery		3.82	1.83	2.69		
58999		Genital surgery procedure	Surgery					4.00	
59000		Amniocentesis, diagnostic	Maternity - Non-Deliveries		1.30	0.67	2.08		
59001		Amniocentesis, therapeutic	Maternity - Non-Deliveries		3.00	1.41	1.41		
59012		Fetal cord puncture, prenatal	Maternity - Non-Deliveries		3.44	1.54	1.54		
59015		Chorion biopsy	Maternity - Non-Deliveries		2.20	1.04	1.55		
59020	26	Fetal contract stress test	Maternity - Non-Deliveries		0.66	0.26	0.26		
59020	TC	Fetal contract stress test	Maternity - Non-Deliveries	a	0.00	0.52	0.52		
59025	26	Fetal non-stress test	Maternity - Non-Deliveries		0.53	0.21	0.21		
59025	TC	Fetal non-stress test	Maternity - Non-Deliveries	a	0.00	0.23	0.23		
59030		Fetal scalp blood sample	Maternity - Non-Deliveries		1.99	0.77	0.77		
59050		Fetal monitor w/report	Maternity - Non-Deliveries		0.89	0.35	0.35		
59051		Fetal monitor/interpret only	Maternity - Non-Deliveries		0.74	0.29	0.29		
59070		Transabdom amniocentesis w/ us	Maternity - Non-Deliveries		5.24	2.32	5.16		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 64 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
59072		Umbilical cord occlud w/ us	Maternity - Non-Deliveries		8.99	3.13	3.13		
59074		Fetal fluid drainage w/ us	Maternity - Non-Deliveries		5.24	2.32	4.58		
59076		Fetal shunt placement, w/ us	Maternity - Non-Deliveries		8.99	3.13	3.13		
59100		Remove uterus lesion	Maternity - Non-Deliveries		12.33	6.47	6.47		
59120		Treat ectopic pregnancy	Maternity - Non-Deliveries		11.47	6.26	6.26		
59121		Treat ectopic pregnancy	Maternity - Non-Deliveries		11.65	6.34	6.34		
59130		Treat ectopic pregnancy	Maternity - Non-Deliveries		14.20	4.80	4.80		
59135		Treat ectopic pregnancy	Maternity - Non-Deliveries		13.86	7.24	7.24		
59136		Treat ectopic pregnancy	Maternity - Non-Deliveries		13.16	6.62	6.62		
59140		Treat ectopic pregnancy	Maternity - Non-Deliveries		5.45	2.22	2.22		
59150		Treat ectopic pregnancy	Maternity - Non-Deliveries		11.65	6.01	6.01		
59151		Treat ectopic pregnancy	Maternity - Non-Deliveries		11.47	6.07	6.07		
59160		D & c after delivery	Maternity - Non-Deliveries		2.71	2.14	3.30		
59200		Insert cervical dilator	Maternity - Non-Deliveries		0.79	0.30	1.19		
59300		Episiotomy or vaginal repair	Maternity - Non-Deliveries		2.41	0.96	2.18		
59320		Revision of cervix	Maternity - Non-Deliveries		2.48	1.24	1.24		
59325		Revision of cervix	Maternity - Non-Deliveries		4.06	1.90	1.90		
59350		Repair of uterus	Maternity - Non-Deliveries		4.94	1.88	1.88		
59400		Obstetrical care	Maternity - Normal Deliveries		23.03	15.36	15.36		
59409		Obstetrical care	Maternity - Normal Deliveries		13.48	5.32	5.32		
59410		Obstetrical care	Maternity - Normal Deliveries		14.76	6.32	6.32		
59412		Antepartum manipulation	Maternity - Normal Deliveries		1.71	0.81	0.81		
59414		Deliver placenta	Maternity - Normal Deliveries		1.61	0.64	0.64		
59425		Antepartum care only	Maternity - Normal Deliveries		4.80	1.86	4.21		
59426		Antepartum care only	Maternity - Normal Deliveries		8.27	3.23	7.56		
59430		Care after delivery	Maternity - Normal Deliveries		2.13	0.94	1.23		
59510		Cesarean delivery	Maternity - Cesarean Deliveries		26.18	17.31	17.31		
59514		Cesarean delivery only	Maternity - Cesarean Deliveries		15.95	6.23	6.23		
59515		Cesarean delivery	Maternity - Cesarean Deliveries		17.34	7.85	7.85		
59525		Remove uterus after cesarean	Surgery		8.53	3.31	3.31		
59610		Vbac delivery	Maternity - Normal Deliveries		24.58	15.91	15.91		
59612		Vbac delivery only	Maternity - Normal Deliveries		15.04	6.07	6.07		
59614		Vbac care after delivery	Maternity - Normal Deliveries		16.32	6.95	6.95		
59618		Attempted vbac delivery	Maternity - Cesarean Deliveries		27.74	18.28	18.28		
59620		Attempted vbac delivery only	Maternity - Cesarean Deliveries		17.50	6.78	6.78		
59622		Attempted vbac after care	Maternity - Cesarean Deliveries		18.90	8.66	8.66		
59812		Treatment of miscarriage	Maternity - Non-Deliveries		4.00	2.55	2.55		
59820		Care of miscarriage	Maternity - Non-Deliveries		4.00	3.57	4.43		
59821		Treatment of miscarriage	Maternity - Non-Deliveries		4.46	3.41	4.28		
59830		Treat uterus infection	Maternity - Non-Deliveries		6.10	3.99	3.99		
59840		Abortion	Maternity - Non-Deliveries		3.01	2.13	2.13		
59841		Abortion	Maternity - Non-Deliveries		5.23	2.98	3.50		
59850		Abortion	Maternity - Non-Deliveries		5.90	3.26	3.26		
59851		Abortion	Maternity - Non-Deliveries		5.92	3.75	3.75		
59852		Abortion	Maternity - Non-Deliveries		8.23	5.05	5.05		
59855		Abortion	Maternity - Non-Deliveries		6.11	3.55	3.55		
59856		Abortion	Maternity - Non-Deliveries		7.47	4.07	4.07		
59857		Abortion	Maternity - Non-Deliveries		9.28	4.72	4.72		
59866		Abortion (mpr)	Maternity - Non-Deliveries		3.99	1.90	1.90		
59870		Evacuate mole of uterus	Maternity - Non-Deliveries		6.00	4.49	4.49		
59871		Remove cerclage suture	Maternity - Non-Deliveries		2.13	1.13	1.75		
59897		Fetal invas px w/ us	Maternity - Non-Deliveries					0.98	
59898		Laparo proc, ob care/deliver	Maternity - Non-Deliveries					17.56	
59899		Maternity care procedure	Maternity - Non-Deliveries					20.51	
60000		Drain thyroid/tongue cyst	Surgery		1.76	1.71	1.93		
60001		Aspirate/inject thyroid cyst	Surgery		0.97	0.33	1.41		
60100		Biopsy of thyroid	Surgery		1.56	0.53	1.40		
60200		Remove thyroid lesion	Surgery		9.54	6.00	6.00		
60210		Partial thyroid excision	Surgery		10.86	5.65	5.65		
60212		Partial thyroid excision	Surgery		16.01	7.69	7.69		
60220		Partial removal of thyroid	Surgery		11.88	6.16	6.16		
60225		Partial removal of thyroid	Surgery		14.17	7.42	7.42		
60240		Removal of thyroid	Surgery		16.04	7.60	7.60		
60252		Removal of thyroid	Surgery		20.54	10.12	10.12		
60254		Extensive thyroid surgery	Surgery		26.95	14.18	14.18		
60260		Repeat thyroid surgery	Surgery		17.44	8.67	8.67		
60270		Removal of thyroid	Surgery		20.24	10.48	10.48		
60271		Removal of thyroid	Surgery		16.80	8.60	8.60		
60280		Remove thyroid duct lesion	Surgery		5.86	4.67	4.67		
60281		Remove thyroid duct lesion	Surgery		8.52	5.85	5.85		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 65 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
60500		Explore parathyroid glands	Surgery		16.21	7.42	7.42		
60502		Re-explore parathyroids	Surgery		20.32	9.38	9.38		
60505		Explore parathyroid glands	Surgery		21.46	10.95	10.95		
60512		Autotransplant parathyroid	Surgery		4.44	1.62	1.62		
60520		Removal of thymus gland	Surgery		16.78	8.31	8.31		
60521		Removal of thymus gland	Surgery		18.84	9.57	9.57		
60522		Removal of thymus gland	Surgery		23.06	11.29	11.29		
60540		Explore adrenal gland	Surgery		17.00	7.60	7.60		
60545		Explore adrenal gland	Surgery		19.85	8.55	8.55		
60600		Remove carotid body lesion	Surgery		17.90	10.99	10.99		
60605		Remove carotid body lesion	Surgery		20.21	12.29	12.29		
60650		Laparoscopy adrenalectomy	Surgery		19.97	8.00	8.00		
60659		Lapero proc, endocrine	Surgery					27.96	
60699		Endocrine surgery procedure	Surgery					18.18	
61000		Remove cranial cavity fluid	Surgery		1.58	0.95	0.95		
61001		Remove cranial cavity fluid	Surgery		1.49	1.06	1.06		
61020		Remove brain cavity fluid	Surgery		1.51	1.34	1.34		
61026		Injection into brain canal	Surgery		1.69	1.39	1.39		
61050		Remove brain canal fluid	Surgery		1.51	1.27	1.27		
61055		Injection into brain canal	Surgery		2.10	1.42	1.42		
61070		Brain canal shunt procedure	Surgery		0.89	1.01	1.01		
61105		Twist drill hole	Surgery		5.13	3.94	3.94		
61107		Drill skull for implantation	Surgery		4.99	2.54	2.54		
61108		Drill skull for drainage	Surgery		10.17	7.16	7.16		
61120		Burr hole for puncture	Surgery		8.75	6.01	6.01		
61140		Pierce skull for biopsy	Surgery		15.88	9.91	9.91		
61150		Pierce skull for drainage	Surgery		17.54	10.40	10.40		
61151		Pierce skull for drainage	Surgery		12.40	7.83	7.83		
61154		Pierce skull & remove clot	Surgery		14.97	9.51	9.51		
61156		Pierce skull for drainage	Surgery		16.30	9.86	9.86		
61210		Pierce skull, implant device	Surgery		5.83	2.92	2.92		
61215		Insert brain-fluid device	Surgery		4.88	4.01	4.01		
61250		Pierce skull & explore	Surgery		10.40	6.87	6.87		
61253		Pierce skull & explore	Surgery		12.34	7.74	7.74		
61304		Open skull for exploration	Surgery		21.93	12.87	12.87		
61305		Open skull for exploration	Surgery		26.57	15.35	15.35		
61312		Open skull for drainage	Surgery		24.53	15.08	15.08		
61313		Open skull for drainage	Surgery		24.89	14.84	14.84		
61314		Open skull for drainage	Surgery		24.19	13.07	13.07		
61315		Open skull for drainage	Surgery		27.64	16.06	16.06		
61316		Implt cran bone flap to abdo	Surgery		1.39	0.60	0.60		
61320		Open skull for drainage	Surgery		25.58	14.79	14.79		
61321		Open skull for drainage	Surgery		28.46	16.17	16.17		
61322		Decompressive craniotomy	Surgery		29.46	15.71	15.71		
61323		Decompressive lobectomy	Surgery		30.95	16.13	16.13		
61330		Decompress eye socket	Surgery		23.29	13.76	13.76		
61332		Explore/biopsy eye socket	Surgery		27.24	15.64	15.64		
61333		Explore orbit/remove lesion	Surgery		27.91	15.62	15.62		
61334		Explore orbit/remove object	Surgery		18.24	10.66	10.66		
61340		Subtemporal decompression	Surgery		18.63	11.15	11.15		
61343		Incise skull (press relief)	Surgery		29.73	16.85	16.85		
61345		Relieve cranial pressure	Surgery		27.16	15.43	15.43		
61440		Incise skull for surgery	Surgery		26.59	14.24	14.24		
61450		Incise skull for surgery	Surgery		25.91	14.32	14.32		
61458		Incise skull for brain wound	Surgery		27.25	15.55	15.55		
61460		Incise skull for surgery	Surgery		28.35	16.46	16.46		
61470		Incise skull for surgery	Surgery		26.02	13.89	13.89		
61480		Incise skull for surgery	Surgery		26.45	15.31	15.31		
61490		Incise skull for surgery	Surgery		25.62	14.36	14.36		
61500		Removal of skull lesion	Surgery		17.89	10.83	10.83		
61501		Remove infected skull bone	Surgery		14.82	9.23	9.23		
61510		Removal of brain lesion	Surgery		28.41	16.74	16.74		
61512		Remove brain lining lesion	Surgery		35.04	19.73	19.73		
61514		Removal of brain abscess	Surgery		25.22	14.47	14.47		
61516		Removal of brain lesion	Surgery		24.57	14.30	14.30		
61517		Implt brain chemobr add-on	Surgery		1.38	0.64	0.64		
61518		Removal of brain lesion	Surgery		37.26	21.15	21.15		
61519		Remove brain lining lesion	Surgery		41.33	22.71	22.71		
61520		Removal of brain lesion	Surgery		54.76	30.41	30.41		
61521		Removal of brain lesion	Surgery		44.41	24.28	24.28		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HPCPS CODE

PAGE 66 of 119

CPT/ HPCPS Code	Modifier	CPT/HPCPS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
61522		Removal of brain abscess	Surgery		29.41	16.46	16.46		
61524		Removal of brain lesion	Surgery		27.82	15.71	15.71		
61526		Removal of brain lesion	Surgery		52.09	29.57	29.57		
61530		Removal of brain lesion	Surgery		43.79	25.12	25.12		
61531		Implant brain electrodes	Surgery		14.61	9.15	9.15		
61533		Implant brain electrodes	Surgery		19.68	11.56	11.56		
61534		Removal of brain lesion	Surgery		20.94	12.12	12.12		
61535		Remove brain electrodes	Surgery		11.61	7.44	7.44		
61536		Removal of brain lesion	Surgery		35.47	19.84	19.84		
61537		Removal of brain tissue	Surgery		24.96	14.78	14.78		
61538		Removal of brain tissue	Surgery		26.77	15.35	15.35		
61539		Removal of brain tissue	Surgery		32.03	17.81	17.81		
61540		Removal of brain tissue	Surgery		29.96	17.29	17.29		
61541		Incision of brain tissue	Surgery		28.81	16.25	16.25		
61542		Removal of brain tissue	Surgery		30.97	17.87	17.87		
61543		Removal of brain tissue	Surgery		29.18	16.43	16.43		
61544		Remove & treat brain lesion	Surgery		25.46	13.86	13.86		
61545		Excision of brain tumor	Surgery		43.73	24.28	24.28		
61546		Removal of pituitary gland	Surgery		31.25	17.54	17.54		
61548		Removal of pituitary gland	Surgery		21.50	12.82	12.82		
61550		Release of skull seams	Surgery		14.63	6.95	6.95		
61552		Release of skull seams	Surgery		19.53	9.14	9.14		
61556		Incise skull/sutures	Surgery		22.23	11.39	11.39		
61557		Incise skull/sutures	Surgery		22.35	13.66	13.66		
61558		Excision of skull/sutures	Surgery		25.54	14.23	14.23		
61559		Excision of skull/sutures	Surgery		32.74	19.37	19.37		
61563		Excision of skull tumor	Surgery		26.79	15.28	15.28		
61564		Excision of skull tumor	Surgery		33.78	18.33	18.33		
61566		Removal of brain tissue	Surgery		30.95	17.82	17.82		
61567		Incision of brain tissue	Surgery		35.45	20.73	20.73		
61570		Remove foreign body, brain	Surgery		24.56	13.95	13.95		
61571		Incise skull for brain wound	Surgery		26.35	15.18	15.18		
61575		Skull base/brainstem surgery	Surgery		34.31	19.69	19.69		
61576		Skull base/brainstem surgery	Surgery		52.35	34.83	34.83		
61580		Craniofacial approach, skull	Surgery		30.30	25.65	25.65		
61581		Craniofacial approach, skull	Surgery		34.55	23.51	23.51		
61582		Craniofacial approach, skull	Surgery		31.61	27.38	27.38		
61583		Craniofacial approach, skull	Surgery		36.16	25.18	25.18		
61584		Orbitocranial approach/skull	Surgery		34.60	24.59	24.59		
61585		Orbitocranial approach/skull	Surgery		38.55	26.57	26.57		
61586		Resect nasopharynx, skull	Surgery		25.06	22.65	22.65		
61590		Infratemporal approach/skull	Surgery		41.72	28.70	28.70		
61591		Infratemporal approach/skull	Surgery		43.61	29.61	29.61		
61592		Orbitocranial approach/skull	Surgery		39.58	26.58	26.58		
61595		Transcranial approach/skull	Surgery		29.53	22.41	22.41		
61596		Transcochlear approach/skull	Surgery		35.58	24.51	24.51		
61597		Transcondylar approach/skull	Surgery		37.90	23.06	23.06		
61598		Transpetrosal approach/skull	Surgery		33.36	23.30	23.30		
61600		Resect/excise cranial lesion	Surgery		25.81	19.83	19.83		
61601		Resect/excise cranial lesion	Surgery		27.85	20.55	20.55		
61605		Resect/excise cranial lesion	Surgery		29.29	22.02	22.02		
61606		Resect/excise cranial lesion	Surgery		38.77	25.22	25.22		
61607		Resect/excise cranial lesion	Surgery		36.22	23.85	23.85		
61608		Resect/excise cranial lesion	Surgery		42.04	26.66	26.66		
61609		Transect artery, sinus	Surgery		9.88	4.86	4.86		
61610		Transect artery, sinus	Surgery		29.63	13.18	13.18		
61611		Transect artery, sinus	Surgery		7.41	3.83	3.83		
61612		Transect artery, sinus	Surgery		27.84	13.35	13.35		
61613		Remove aneurysm, sinus	Surgery		40.80	26.34	26.34		
61615		Resect/excise lesion, skull	Surgery		32.02	22.79	22.79		
61616		Resect/excise lesion, skull	Surgery		43.27	28.73	28.73		
61618		Repair dura	Surgery		16.96	10.47	10.47		
61619		Repair dura	Surgery		20.68	12.28	12.28		
61623		Endovasc temporary vessel occl	Surgery		9.95	4.09	4.09		
61624		Transcath occlusion, cns	Surgery		20.12	6.91	6.91		
61626		Transcath occlusion, non-cns	Surgery		16.60	5.53	5.53		
61680		Intracranial vessel surgery	Surgery		30.66	17.48	17.48		
61682		Intracranial vessel surgery	Surgery		61.48	32.30	32.30		
61684		Intracranial vessel surgery	Surgery		39.75	22.06	22.06		
61686		Intracranial vessel surgery	Surgery		64.39	34.82	34.82		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 67 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
61690		Intracranial vessel surgery	Surgery		29.27	16.77	16.77		
61692		Intracranial vessel surgery	Surgery		51.79	27.55	27.55		
61697		Brain aneurysm repr, complx	Surgery		50.44	28.09	28.09		
61698		Brain aneurysm repr, complx	Surgery		48.34	26.77	26.77		
61700		Brain aneurysm repr, simple	Surgery		50.44	27.88	27.88		
61702		Inner skull vessel surgery	Surgery		48.34	26.11	26.11		
61703		Clamp neck artery	Surgery		17.44	10.49	10.49		
61705		Revise circulation to head	Surgery		36.15	19.31	19.31		
61706		Revise circulation to head	Surgery		35.25	15.19	15.19		
61710		Revise circulation to head	Surgery		29.63	13.68	13.68		
61711		Fusion of skull arteries	Surgery		36.28	19.86	19.86		
61720		Incise skull/brain surgery	Surgery		16.74	10.00	10.00		
61735		Incise skull/brain surgery	Surgery		20.40	12.20	12.20		
61750		Incise skull/brain biopsy	Surgery		18.17	10.64	10.64		
61751		Brain biopsy w/cl/mr guide	Surgery		17.59	10.85	10.85		
61760		Implant brain electrodes	Surgery		22.24	8.74	8.74		
61770		Incise skull for treatment	Surgery		21.41	12.29	12.29		
61790		Treat trigeminal nerve	Surgery		10.84	5.93	5.93		
61791		Treat trigeminal tract	Surgery		14.59	8.94	8.94		
61793		Focus radiation beam	Surgery		17.21	10.15	10.15		
61795		Brain surgery using computer	Surgery		4.03	2.04	2.04		
61850		Implant neuroelectrodes	Surgery		12.37	7.69	7.69		
61860		Implant neuroelectrodes	Surgery		20.84	12.09	12.09		
61863		Implant neuroelectrode	Surgery		18.97	11.80	11.80		
61864		Implant neuroelectrode, add'l	Surgery		4.49	2.29	2.29		
61867		Implant neuroelectrode	Surgery		31.29	18.07	18.07		
61868		Implant neuroelectrode, add'l	Surgery		7.91	4.02	4.02		
61870		Implant neuroelectrodes	Surgery		14.92	9.73	9.73		
61875		Implant neuroelectrodes	Surgery		15.04	8.59	8.59		
61880		Revise/remove neuroelectrode	Surgery		6.28	4.58	4.58		
61885		Implant neurostim one array	Surgery		5.84	5.32	5.32		
61886		Implant neurostim arrays	Surgery		7.99	6.37	6.37		
61888		Revise/remove neuroreceiver	Surgery		5.06	3.68	3.68		
62000		Treat skull fracture	Surgery		12.51	5.53	5.53		
62005		Treat skull fracture	Surgery		16.15	8.82	8.82		
62010		Treatment of head injury	Surgery		19.78	11.74	11.74		
62100		Repair brain fluid leakage	Surgery		22.00	12.82	12.82		
62115		Reduction of skull defect	Surgery		21.63	11.67	11.67		
62116		Reduction of skull defect	Surgery		23.55	13.40	13.40		
62117		Reduction of skull defect	Surgery		26.56	15.41	15.41		
62120		Repair skull cavity lesion	Surgery		23.31	18.53	18.53		
62121		Incise skull repair	Surgery		21.55	15.49	15.49		
62140		Repair of skull defect	Surgery		13.49	8.34	8.34		
62141		Repair of skull defect	Surgery		14.89	9.07	9.07		
62142		Remove skull plate/flap	Surgery		10.77	7.01	7.01		
62143		Replace skull plate/flap	Surgery		13.03	8.06	8.06		
62145		Repair of skull & brain	Surgery		18.79	10.92	10.92		
62146		Repair of skull with graft	Surgery		16.10	9.66	9.66		
62147		Repair of skull with graft	Surgery		19.31	11.33	11.33		
62148		Retr bone flap to fix skull	Surgery		2.00	0.86	0.86		
62160		Neuroendoscopy add-on	Surgery		3.00	1.53	1.53		
62161		Dissect brain w/scope	Surgery		19.97	12.13	12.13		
62162		Remove colloid cyst w/scope	Surgery		25.21	14.89	14.89		
62163		Neuroendoscopy w/flb removal	Surgery		15.48	9.95	9.95		
62164		Remove brain tumor w/scope	Surgery		27.46	14.99	14.99		
62165		Remove pituit tumor w/scope	Surgery		21.97	13.42	13.42		
62180		Establish brain cavity shunt	Surgery		21.03	12.32	12.32		
62190		Establish brain cavity shunt	Surgery		11.05	7.10	7.10		
62192		Establish brain cavity shunt	Surgery		12.23	7.64	7.64		
62194		Replace/imqate catheter	Surgery		5.02	2.44	2.44		
62200		Establish brain cavity shunt	Surgery		18.29	10.87	10.87		
62201		Brain cavity shunt w/scope	Surgery		14.84	9.47	9.47		
62220		Establish brain cavity shunt	Surgery		12.98	8.00	8.00		
62223		Establish brain cavity shunt	Surgery		12.85	8.26	8.26		
62225		Replace/imqate catheter	Surgery		5.40	4.10	4.10		
62230		Replace/revise brain shunt	Surgery		10.52	6.50	6.50		
62252		Csf shunt reprogram	Surgery		0.74	1.47	1.47		
62252		Csf shunt reprogram	Surgery		0.74	1.47	1.47		
62256		Remove brain cavity shunt	Surgery		6.59	4.70	4.70		
62258		Replace brain cavity shunt	Surgery		14.52	8.74	8.74		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPSC CODE

PAGE 68 of 119

CPT/ HCPSC Code	Modifier	CPT/HCPSC Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
62263		Epidural lysis mult sessions	Surgery		6.13	3.20	12.73		
62264		Epidural lysis on single day	Surgery		4.42	1.42	7.75		
62268		Drain spinal cord cyst	Surgery		4.73	2.15	11.56		
62269		Needle biopsy, spinal cord	Surgery		5.01	1.98	14.72		
62270		Spinal fluid tap, diagnostic	Surgery		1.13	0.56	3.00		
62272		Drain cerebro spinal fluid	Surgery		1.35	0.71	3.62		
62273		Treat epidural spine lesion	Surgery		2.15	0.71	2.72		
62280		Treat spinal cord lesion	Surgery		2.63	1.01	6.95		
62281		Treat spinal cord lesion	Surgery		2.66	0.89	5.67		
62282		Treat spinal canal lesion	Surgery		2.33	0.92	8.38		
62284		Injection for myelogram	Surgery		1.54	0.68	4.97		
62287		Percutaneous discectomy	Surgery		8.07	5.57	5.57		
62290		Inject for spine disk x-ray	Surgery		3.00	1.38	7.15		
62291		Inject for spine disk x-ray	Surgery		2.91	1.23	5.95		
62292		Injection into disk lesion	Surgery		7.85	4.48	4.48		
62294		Injection into spinal artery	Surgery		11.81	5.60	5.60		
62310		Inject spine ct	Surgery		1.91	0.65	4.82		
62311		Inject spine l/s (cd)	Surgery		1.54	0.59	4.93		
62318		Inject spine w/cath, ct	Surgery		2.04	0.65	5.74		
62319		Inject spine w/cath l/s (cd)	Surgery		1.87	0.61	4.99		
62350		Implant spinal canal cath	Surgery		6.86	3.95	3.95		
62351		Implant spinal canal cath	Surgery		9.99	7.14	7.14		
62355		Remove spinal canal catheter	Surgery		5.44	3.17	3.17		
62360		Insert spine infusion device	Surgery		2.62	2.69	2.69		
62361		Implant spine infusion pump	Surgery		5.41	3.93	3.93		
62362		Implant spine infusion pump	Surgery		7.03	4.37	4.37		
62365		Remove spine infusion device	Surgery		5.41	3.59	3.59		
62367		Analyze spine infusion pump	Surgery		0.75	0.17	0.69	0.56	
62368		Analyze spine infusion pump	Surgery						
62368		Analyze spine infusion pump	Surgery					1.50	
63001		Removal of spinal lamina	Surgery		15.80	9.54	9.54		
63003		Removal of spinal lamina	Surgery		15.93	9.89	9.89		
63005		Removal of spinal lamina	Surgery		14.90	10.00	10.00		
63011		Removal of spinal lamina	Surgery		14.50	8.29	8.29		
63012		Removal of spinal lamina	Surgery		15.38	10.15	10.15		
63015		Removal of spinal lamina	Surgery		19.32	11.90	11.90		
63016		Removal of spinal lamina	Surgery		19.17	11.81	11.81		
63017		Removal of spinal lamina	Surgery		15.92	10.42	10.42		
63020		Neck spine disk surgery	Surgery		14.79	9.70	9.70		
63030		Low back disk surgery	Surgery		11.98	8.44	8.44		
63035		Spinal disk surgery add-on	Surgery		3.15	1.59	1.59		
63040		Laminotomy, single cervical	Surgery		18.78	11.53	11.53		
63042		Laminotomy, single lumbar	Surgery		17.44	11.37	11.37		
63043		Laminotomy, add cervical	Surgery					15.61	
63044		Laminotomy, add lumbar	Surgery					14.83	
63045		Removal of spinal lamina	Surgery		16.48	10.38	10.38		
63046		Removal of spinal lamina	Surgery		15.78	10.21	10.21		
63047		Removal of spinal lamina	Surgery		14.59	9.92	9.92		
63048		Remove spinal lamina add-on	Surgery		3.26	1.66	1.66		
63050		Cervical laminoplasty	Surgery		20.75	11.87	11.87		
63051		C-laminoplasty w/graft/plate	Surgery		24.25	13.51	13.51		
63055		Decompress spinal cord	Surgery		21.96	13.17	13.17		
63056		Decompress spinal cord	Surgery		20.33	12.60	12.60		
63057		Decompress spine cord add-on	Surgery		5.25	2.64	2.64		
63064		Decompress spinal cord	Surgery		24.57	14.46	14.46		
63066		Decompress spine cord add-on	Surgery		3.26	1.66	1.66		
63075		Neck spine disk surgery	Surgery		19.38	12.12	12.12		
63076		Neck spine disk surgery	Surgery		4.04	2.06	2.06		
63077		Spine disk surgery, thorax	Surgery		21.41	12.83	12.83		
63078		Spine disk surgery, thorax	Surgery		3.28	1.64	1.64		
63081		Removal of vertebral body	Surgery		23.69	14.36	14.36		
63082		Remove vertebral body add-on	Surgery		4.36	2.23	2.23		
63085		Removal of vertebral body	Surgery		26.88	15.51	15.51		
63086		Remove vertebral body add-on	Surgery		3.19	1.59	1.59		
63087		Removal of vertebral body	Surgery		35.52	19.51	19.51		
63088		Remove vertebral body add-on	Surgery		4.32	2.18	2.18		
63090		Removal of vertebral body	Surgery		28.12	16.08	16.08		
63091		Remove vertebral body add-on	Surgery		3.03	1.46	1.46		
63101		Removal of vertebral body	Surgery		31.95	19.33	19.33		
63102		Removal of vertebral body	Surgery		31.95	19.33	19.33		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply
See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 69 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
63103		Remove vertebral body add-on	Surgery		4.82	2.51	2.51		
63170		Incise spinal cord tract(s)	Surgery		19.80	11.89	11.89		
63172		Drainage of spinal cyst	Surgery		17.63	10.67	10.67		
63173		Drainage of spinal cyst	Surgery		21.96	12.84	12.84		
63180		Revise spinal cord ligaments	Surgery		18.24	11.01	11.01		
63182		Revise spinal cord ligaments	Surgery		20.47	10.98	10.98		
63185		Incise spinal column/nerves	Surgery		15.02	8.11	8.11		
63190		Incise spinal column/nerves	Surgery		17.42	10.16	10.16		
63191		Incise spinal column/nerves	Surgery		17.51	10.50	10.50		
63194		Incise spinal column & cord	Surgery		19.16	11.74	11.74		
63195		Incise spinal column & cord	Surgery		18.81	11.07	11.07		
63196		Incise spinal column & cord	Surgery		22.27	13.42	13.42		
63197		Incise spinal column & cord	Surgery		21.08	12.24	12.24		
63198		Incise spinal column & cord	Surgery		25.34	8.45	8.45		
63199		Incise spinal column & cord	Surgery		26.85	15.07	15.07		
63200		Release of spinal cord	Surgery		19.15	11.32	11.32		
63250		Revise spinal cord vessels	Surgery		40.70	19.98	19.98		
63251		Revise spinal cord vessels	Surgery		41.14	22.65	22.65		
63252		Revise spinal cord vessels	Surgery		41.13	22.29	22.29		
63265		Excise intraspinal lesion	Surgery		21.53	12.80	12.80		
63266		Excise intraspinal lesion	Surgery		22.27	13.21	13.21		
63267		Excise intraspinal lesion	Surgery		17.92	11.10	11.10		
63268		Excise intraspinal lesion	Surgery		18.49	10.39	10.39		
63270		Excise intraspinal lesion	Surgery		26.76	15.50	15.50		
63271		Excise intraspinal lesion	Surgery		26.88	15.61	15.61		
63272		Excise intraspinal lesion	Surgery		25.28	14.72	14.72		
63273		Excise intraspinal lesion	Surgery		24.25	14.37	14.37		
63275		Biopsy/excise spinal tumor	Surgery		23.64	13.80	13.80		
63276		Biopsy/excise spinal tumor	Surgery		23.41	13.71	13.71		
63277		Biopsy/excise spinal tumor	Surgery		20.80	12.55	12.55		
63278		Biopsy/excise spinal tumor	Surgery		20.53	12.42	12.42		
63280		Biopsy/excise spinal tumor	Surgery		28.31	16.35	16.35		
63281		Biopsy/excise spinal tumor	Surgery		28.01	16.21	16.21		
63282		Biopsy/excise spinal tumor	Surgery		26.35	15.36	15.36		
63283		Biopsy/excise spinal tumor	Surgery		24.96	14.69	14.69		
63285		Biopsy/excise spinal tumor	Surgery		35.95	19.99	19.99		
63286		Biopsy/excise spinal tumor	Surgery		35.58	19.95	19.95		
63287		Biopsy/excise spinal tumor	Surgery		36.64	20.47	20.47		
63290		Biopsy/excise spinal tumor	Surgery		37.32	20.64	20.64		
63295		Repair of laminectomy defect	Surgery		5.25	2.15	2.15		
63300		Removal of vertebral body	Surgery		24.39	14.33	14.33		
63301		Removal of vertebral body	Surgery		27.56	15.59	15.59		
63302		Removal of vertebral body	Surgery		27.77	15.89	15.89		
63303		Removal of vertebral body	Surgery		30.45	16.95	16.95		
63304		Removal of vertebral body	Surgery		30.28	17.31	17.31		
63305		Removal of vertebral body	Surgery		31.98	18.09	18.09		
63306		Removal of vertebral body	Surgery		32.17	17.84	17.84		
63307		Removal of vertebral body	Surgery		31.58	16.85	16.85		
63308		Remove vertebral body add-on	Surgery		5.24	2.61	2.61		
63600		Remove spinal cord lesion	Surgery		14.00	5.41	5.41		
63610		Stimulation of spinal cord	Surgery		8.72	2.26	59.85		
63615		Remove lesion of spinal cord	Surgery		16.26	9.29	9.29		
63650		Implant neuroelectrodes	Surgery		6.73	3.18	3.18		
63655		Implant neuroelectrodes	Surgery		10.27	6.91	6.91		
63660		Revise/remove neuroelectrode	Surgery		6.15	3.62	3.62		
63685		Implant neuroreceiver	Surgery		7.03	4.15	4.15		
63688		Revise/remove neuroreceiver	Surgery		5.38	3.56	3.56		
63700		Repair of spinal herniation	Surgery		16.51	10.33	10.33		
63702		Repair of spinal herniation	Surgery		18.45	11.06	11.06		
63704		Repair of spinal herniation	Surgery		21.15	12.95	12.95		
63706		Repair of spinal herniation	Surgery		24.07	13.61	13.61		
63707		Repair spinal fluid leakage	Surgery		11.24	7.72	7.72		
63709		Repair spinal fluid leakage	Surgery		14.30	9.42	9.42		
63710		Graft repair of spine defect	Surgery		14.05	9.06	9.06		
63740		Install spinal shunt	Surgery		11.34	7.36	7.36		
63741		Install spinal shunt	Surgery		8.24	4.76	4.76		
63744		Revision of spinal shunt	Surgery		8.09	5.27	5.27		
63746		Removal of spinal shunt	Surgery		6.42	3.78	3.78		
64400		N block inj, trigeminal	Surgery		1.11	0.43	1.90		
64402		N block inj, facial	Surgery		1.25	0.60	1.61		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 70 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
64405		N block inj, occipital	Surgery		1.32	0.46	1.46		
64408		N block inj, vagus	Surgery		1.41	0.85	1.58		
64410		N block inj, phrenic	Surgery		1.43	0.46	2.51		
64412		N block inj, spinal accessor	Surgery		1.18	0.43	2.66		
64413		N block inj, cervical plexus	Surgery		1.40	0.50	1.85		
64415		N block inj, brachial plexus	Surgery		1.48	0.46	2.81		
64416		N block cont infuse, b plex	Surgery		3.49	0.79	0.79		
64417		N block inj, axillary	Surgery		1.44	0.49	3.04		
64418		N block inj, suprascapular	Surgery		1.32	0.44	2.63		
64420		N block inj, intercost, snq	Surgery		1.18	0.42	3.89		
64421		N block inj, intercost, mt	Surgery		1.68	0.52	6.10		
64425		N block inj ilio-ingu/hypoqi	Surgery		1.75	0.54	1.65		
64430		N block inj, pudendal	Surgery		1.46	0.55	2.52		
64435		N block inj, paracervical	Surgery		1.45	0.69	2.53		
64445		N block inj, sciatic, snq	Surgery		1.48	0.50	2.68		
64446		N blk inj, sciatic, cont inf	Surgery		3.25	1.00	1.00		
64447		N block inj fem, single	Surgery		1.50	0.43	0.43		
64448		N block inj fem, cont inf	Surgery		3.00	0.81	0.81		
64449		N block inj, lumbar plexus	Surgery		3.00	0.96	0.96		
64450		N block, other peripheral	Surgery		1.27	0.48	1.24		
64470		Inj paravertebral c/t	Surgery		1.85	0.71	7.25		
64472		Inj paravertebral c/t add-on	Surgery		1.29	0.34	2.34		
64475		Inj paravertebral l/s	Surgery		1.41	0.63	6.90		
64476		Inj paravertebral l/s add-on	Surgery		0.98	0.24	2.13		
64479		Inj foramen epidural c/t	Surgery		2.20	0.89	7.51		
64480		Inj foramen epidural add-on	Surgery		1.54	0.47	2.85		
64483		Inj foramen epidural l/s	Surgery		1.90	0.83	7.91		
64484		Inj foramen epidural add-on	Surgery		1.33	0.37	3.29		
64505		N block, sphenopalatine gangl	Surgery		1.36	0.66	1.24		
64508		N block, carotid sinus s/p	Surgery		1.12	0.74	3.33		
64510		N block, stellate ganglion	Surgery		1.22	0.51	3.46		
64517		N block inj, hypogastric plex	Surgery		2.20	0.87	2.73		
64520		N block, lumbar/thoracic	Surgery		1.35	0.55	5.15		
64530		N block inj, celiac plexus	Surgery		1.58	0.65	4.46		
64550		Apply neurostimulator	Surgery		0.18	0.05	0.28		
64553		Implant neuroelectrodes	Surgery		2.31	1.86	2.84		
64555		Implant neuroelectrodes	Surgery		2.27	1.19	3.11		
64560		Implant neuroelectrodes	Surgery		2.36	1.28	2.64		
64561		Implant neuroelectrodes	Surgery		6.73	2.78	30.14		
64565		Implant neuroelectrodes	Surgery		1.76	1.26	3.29		
64573		Implant neuroelectrodes	Surgery		7.49	5.26	5.26		
64575		Implant neuroelectrodes	Surgery		4.34	2.68	2.68		
64577		Implant neuroelectrodes	Surgery		4.61	3.29	3.29		
64580		Implant neuroelectrodes	Surgery		4.11	3.56	3.56		
64581		Implant neuroelectrodes	Surgery		13.48	5.39	5.39		
64585		Revise/remove neuroelectrode	Surgery		2.06	2.14	11.31		
64590		Implant neuroreceiver	Surgery		2.40	2.29	7.16		
64595		Revise/remove neuroreceiver	Surgery		1.73	1.93	10.42		
64600		Injection treatment of nerve	Surgery		3.44	1.65	9.38		
64605		Injection treatment of nerve	Surgery		5.60	2.19	9.58		
64610		Injection treatment of nerve	Surgery		7.15	3.72	8.89		
64612		Destroy nerve, face muscle	Surgery		1.96	1.32	2.49		
64613		Destroy nerve, spine muscle	Surgery		1.96	1.22	2.94		
64614		Destroy nerve, extrem muscle	Surgery		2.20	1.31	3.23		
64620		Injection treatment of nerve	Surgery		2.84	1.33	5.07		
64622		Destr paravertebral nerve l/s	Surgery		3.00	1.37	7.78		
64623		Destr paravertebral n add-on	Surgery		0.99	0.22	2.97		
64626		Destr paravertebral nerve c/t	Surgery		3.28	1.97	7.80		
64627		Destr paravertebral n add-on	Surgery		1.16	0.27	4.54		
64630		Injection treatment of nerve	Surgery		3.00	1.41	2.74		
64640		Injection treatment of nerve	Surgery		2.76	1.85	4.19		
64650		Chemodenerv acrine glands	Surgery	a	0.70	0.30	0.87		RBRVS
64653		Chemodenerv acrine glands	Surgery	a	0.88	0.38	0.92		RBRVS
64680		Injection treatment of nerve	Surgery		2.62	1.43	6.73		
64681		Injection treatment of nerve	Surgery		3.54	2.07	9.32		
64702		Revise finger/Toe nerve	Surgery		4.22	3.87	3.87		
64704		Revise hand/foot nerve	Surgery		4.56	3.32	3.32		
64708		Revise arm/leg nerve	Surgery		6.11	4.87	4.87		
64712		Revision of sciatic nerve	Surgery		7.74	4.97	4.97		
64713		Revision of arm nerve(s)	Surgery		10.98	5.89	5.89		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPSC CODE

PAGE 71 of 119

CPT/ HCPSC Code	Modifier	CPT/HCPSC Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
64714		Revise low back nerve(s)	Surgery		10.31	4.21	4.21		
64716		Revision of cranial nerve	Surgery		6.30	5.99	5.99		
64718		Revise ulnar nerve at elbow	Surgery		5.98	6.01	6.01		
64719		Revise ulnar nerve at wrist	Surgery		4.84	4.53	4.53		
64721		Carpal tunnel surgery	Surgery		4.28	5.38	5.38		
64722		Relieve pressure on nerve(s)	Surgery		4.69	3.05	3.05		
64726		Release foot/Toe nerve	Surgery		4.17	2.80	2.80		
64727		Interal nerve revision	Surgery		3.10	1.50	1.50		
64732		Incision of brow nerve	Surgery		4.40	3.51	3.51		
64734		Incision of cheek nerve	Surgery		4.91	4.06	4.06		
64736		Incision of chin nerve	Surgery		4.59	4.03	4.03		
64738		Incision of jaw nerve	Surgery		5.72	4.62	4.62		
64740		Incision of tongue nerve	Surgery		5.58	5.13	5.13		
64742		Incision of facial nerve	Surgery		6.21	4.71	4.71		
64744		Incise nerve, back of head	Surgery		5.23	3.78	3.78		
64746		Incise diaphragm nerve	Surgery		5.92	4.51	4.51		
64752		Incision of vagus nerve	Surgery		7.05	4.29	4.29		
64755		Incision of stomach nerves	Surgery		13.50	5.65	5.65		
64760		Incision of vagus nerve	Surgery		6.95	3.46	3.46		
64761		Incision of pelvis nerve	Surgery		6.40	3.53	3.53		
64763		Incise hip/thigh nerve	Surgery		6.92	5.21	5.21		
64766		Incise hip/thigh nerve	Surgery		8.66	5.26	5.26		
64771		Sever cranial nerve	Surgery		7.34	5.57	5.57		
64772		Incision of spinal nerve	Surgery		7.20	4.93	4.93		
64774		Remove skin nerve lesion	Surgery		5.16	3.84	3.84		
64776		Remove digit nerve lesion	Surgery		5.11	3.69	3.69		
64778		Digit nerve surgery add-on	Surgery		3.11	1.50	1.50		
64782		Remove limb nerve lesion	Surgery		6.22	3.78	3.78		
64783		Limb nerve surgery add-on	Surgery		3.71	1.84	1.84		
64784		Remove nerve lesion	Surgery		9.81	6.61	6.61		
64786		Remove sciatic nerve lesion	Surgery		15.44	9.86	9.86		
64787		Implant nerve end	Surgery		4.29	2.13	2.13		
64788		Remove skin nerve lesion	Surgery		4.60	3.47	3.47		
64790		Removal of nerve lesion	Surgery		11.29	7.22	7.22		
64792		Removal of nerve lesion	Surgery		14.90	8.85	8.85		
64795		Biopsy of nerve	Surgery		3.01	1.56	1.56		
64802		Remove sympathetic nerves	Surgery		9.14	5.14	5.14		
64804		Remove sympathetic nerves	Surgery		14.62	7.18	7.18		
64809		Remove sympathetic nerves	Surgery		13.65	5.78	5.78		
64818		Remove sympathetic nerves	Surgery		10.28	5.30	5.30		
64820		Remove sympathetic nerves	Surgery		10.35	7.14	7.14		
64821		Remove sympathetic nerves	Surgery		8.74	7.36	7.36		
64822		Remove sympathetic nerves	Surgery		8.74	7.25	7.25		
64823		Remove sympathetic nerves	Surgery		10.35	8.15	8.15		
64831		Repair of digit nerve	Surgery		9.43	7.09	7.09		
64832		Repair nerve add-on	Surgery		5.65	2.94	2.94		
64834		Repair of hand or foot nerve	Surgery		10.17	7.11	7.11		
64835		Repair of hand or foot nerve	Surgery		10.92	7.71	7.71		
64836		Repair of hand or foot nerve	Surgery		10.92	7.68	7.68		
64837		Repair nerve add-on	Surgery		6.25	3.24	3.24		
64840		Repair of leg nerve	Surgery		13.00	8.27	8.27		
64856		Repair/transpose nerve	Surgery		13.78	9.21	9.21		
64857		Repair arm/leg nerve	Surgery		14.47	9.66	9.66		
64858		Repair sciatic nerve	Surgery		16.47	10.80	10.80		
64859		Nerve surgery	Surgery		4.25	2.20	2.20		
64861		Repair of arm nerves	Surgery		19.21	11.80	11.80		
64862		Repair of low back nerves	Surgery		19.41	11.96	11.96		
64864		Repair of facial nerve	Surgery		12.53	8.79	8.79		
64865		Repair of facial nerve	Surgery		15.22	13.56	13.56		
64866		Fusion of facial/other nerve	Surgery		15.72	13.20	13.20		
64868		Fusion of facial/other nerve	Surgery		14.02	11.46	11.46		
64870		Fusion of facial/other nerve	Surgery		15.97	8.75	8.75		
64872		Subsequent repair of nerve	Surgery		1.99	1.08	1.08		
64874		Repair & revise nerve add-on	Surgery		2.98	1.53	1.53		
64876		Repair nerve/shorten bone	Surgery		3.37	1.75	1.75		
64885		Nerve graft, head or neck	Surgery		17.50	11.63	11.63		
64886		Nerve graft, head or neck	Surgery		20.72	13.58	13.58		
64890		Nerve graft, hand or foot	Surgery		15.13	10.02	10.02		
64891		Nerve graft, hand or foot	Surgery		16.12	7.60	7.60		
64892		Nerve graft, arm or leg	Surgery		14.63	8.89	8.89		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G.—PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 72 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
64893		Nerve graft, arm or leg	Surgery		15.58	9.89	9.89		
64895		Nerve graft, hand or foot	Surgery		19.22	9.68	9.68		
64896		Nerve graft, hand or foot	Surgery		20.46	11.01	11.01		
64897		Nerve graft, arm or leg	Surgery		18.21	10.72	10.72		
64898		Nerve graft, arm or leg	Surgery		19.47	11.82	11.82		
64901		Nerve graft add-on	Surgery		10.20	5.28	5.28		
64902		Nerve graft add-on	Surgery		11.81	5.98	5.98		
64905		Nerve pedicle transfer	Surgery		14.00	8.51	8.51		
64907		Nerve pedicle transfer	Surgery		18.80	12.56	12.56		
64999		Nervous system surgery	Surgery					8.64	
65091		Revise eye	Surgery		6.45	8.37	8.37		
65093		Revise eye with implant	Surgery		6.86	8.74	8.74		
65101		Removal of eye	Surgery		7.02	9.55	9.55		
65103		Remove eye/insert implant	Surgery		7.56	9.76	9.76		
65105		Remove eye/attach implant	Surgery		8.48	10.49	10.49		
65110		Removal of eye	Surgery		13.93	13.71	13.71		
65112		Remove eye/revise socket	Surgery		16.36	16.18	16.18		
65114		Remove eye/revise socket	Surgery		17.50	16.39	16.39		
65125		Revise ocular implant	Surgery		3.12	3.61	8.83		
65130		Insert ocular implant	Surgery		7.14	9.19	9.19		
65135		Insert ocular implant	Surgery		7.32	9.34	9.34		
65140		Attach ocular implant	Surgery		8.01	9.90	9.90		
65150		Revise ocular implant	Surgery		6.25	7.99	7.99		
65155		Reinsert ocular implant	Surgery		8.65	10.51	10.51		
65175		Removal of ocular implant	Surgery		6.27	8.50	8.50		
65205		Remove foreign body from eye	Surgery		0.71	0.29	0.64		
65210		Remove foreign body from eye	Surgery		0.84	0.38	0.81		
65220		Remove foreign body from eye	Surgery		0.71	0.28	0.64		
65222		Remove foreign body from eye	Surgery		0.93	0.38	0.89		
65235		Remove foreign body from eye	Surgery		7.56	6.76	6.76		
65260		Remove foreign body from eye	Surgery		10.94	9.68	9.68		
65265		Remove foreign body from eye	Surgery		12.57	10.65	10.65		
65270		Repair of eye wound	Surgery		1.90	1.39	5.24		
65272		Repair of eye wound	Surgery		3.81	3.30	7.73		
65273		Repair of eye wound	Surgery		4.35	3.59	3.59		
65275		Repair of eye wound	Surgery		5.33	3.95	6.33		
65280		Repair of eye wound	Surgery		7.65	6.25	6.25		
65285		Repair of eye wound	Surgery		12.88	9.24	9.24		
65286		Repair of eye wound	Surgery		5.50	4.63	11.17		
65290		Repair of eye socket wound	Surgery		5.40	4.75	4.75		
65400		Removal of eye lesion	Surgery		6.05	6.14	8.35		
65410		Biopsy of cornea	Surgery		1.47	0.97	2.12		
65420		Removal of eye lesion	Surgery		4.16	4.45	8.88		
65426		Removal of eye lesion	Surgery		5.24	4.93	10.20		
65430		Corneal smear	Surgery		1.47	0.98	1.29		
65435		Curette/treat cornea	Surgery		0.92	0.71	1.00		
65436		Curette/treat cornea	Surgery		4.18	3.68	4.10		
65450		Treatment of corneal lesion	Surgery		3.27	3.95	4.08		
65600		Revision of cornea	Surgery		3.39	3.36	5.02		
65710		Corneal transplant	Surgery		12.33	11.23	11.23		
65730		Corneal transplant	Surgery		14.23	12.05	12.05		
65750		Corneal transplant	Surgery		14.98	12.00	12.00		
65755		Corneal transplant	Surgery		14.87	11.92	11.92		
65760		Revision of cornea	Surgery					30.91	
65765		Revision of cornea	Surgery					35.86	
65767		Corneal tissue transplant	Surgery					33.39	
65770		Revise cornea with implant	Surgery		17.53	13.24	13.24		
65771		Radial keratotomy	Surgery					18.18	
65772		Correction of astigmatism	Surgery		4.28	4.14	5.55		
65775		Correction of astigmatism	Surgery		5.78	5.97	5.97		
65780		Ocular reconst, transplant	Surgery		10.23	10.32	10.32		
65781		Ocular reconst, transplant	Surgery		17.64	13.71	13.71		
65782		Ocular reconst, transplant	Surgery		14.98	12.02	12.02		
65800		Drainage of eye	Surgery		1.91	1.18	1.80		
65805		Drainage of eye	Surgery		1.91	1.19	2.18		
65810		Drainage of eye	Surgery		4.86	4.71	4.71		
65815		Drainage of eye	Surgery		5.04	4.62	10.03		
65820		Relieve inner eye pressure	Surgery		8.12	9.08	9.08		
65850		Incision of eye	Surgery		10.50	8.46	8.46		
65855		Laser surgery of eye	Surgery		3.84	3.11	4.32		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 73 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
65860		Incise inner eye adhesions	Surgery		3.54	2.51	4.05		
65865		Incise inner eye adhesions	Surgery		5.59	5.64	5.64		
65870		Incise inner eye adhesions	Surgery		6.26	6.43	6.43		
65875		Incise inner eye adhesions	Surgery		6.53	6.81	6.81		
65880		Incise inner eye adhesions	Surgery		7.08	7.05	7.05		
65900		Remove eye lesion	Surgery		10.91	10.28	10.28		
65920		Remove implant of eye	Surgery		8.39	8.19	8.19		
65930		Remove blood clot from eye	Surgery		7.43	6.85	6.85		
66020		Injection treatment of eye	Surgery		1.59	1.44	3.13		
66030		Injection treatment of eye	Surgery		1.25	1.28	2.97		
66130		Remove eye lesion	Surgery		7.68	5.63	9.65		
66150		Glaucoma surgery	Surgery		8.29	9.43	9.43		
66155		Glaucoma surgery	Surgery		8.28	9.38	9.38		
66160		Glaucoma surgery	Surgery		10.15	10.22	10.22		
66165		Glaucoma surgery	Surgery		8.00	9.27	9.27		
66170		Glaucoma surgery	Surgery		12.14	12.26	12.26		
66172		Incision of eye	Surgery		15.02	15.24	15.24		
66180		Implant eye shunt	Surgery		14.53	10.79	10.79		
66185		Revise eye shunt	Surgery		8.13	7.40	7.40		
66220		Repair eye lesion	Surgery		7.76	7.12	7.12		
66225		Repair/graft eye lesion	Surgery		11.03	8.76	8.76		
66250		Follow-up surgery of eye	Surgery		5.97	5.50	11.72		
66500		Incision of iris	Surgery		3.70	4.65	4.65		
66505		Incision of iris	Surgery		4.07	5.00	5.00		
66600		Remove iris and lesion	Surgery		8.67	8.24	8.24		
66605		Removal of iris	Surgery		12.77	10.05	10.05		
66625		Removal of iris	Surgery		5.12	4.74	4.74		
66630		Removal of iris	Surgery		6.15	5.73	5.73		
66635		Removal of iris	Surgery		6.24	5.76	5.76		
66680		Repair iris & ciliary body	Surgery		5.43	5.29	5.29		
66682		Repair iris & ciliary body	Surgery		6.20	6.63	6.63		
66700		Destruction, ciliary body	Surgery		4.77	3.94	5.26		
66710		Destruction, ciliary body	Surgery		4.77	3.85	5.18		
66711		Ciliary endoscopic ablation	Surgery		6.60	6.49	6.49		
66720		Destruction, ciliary body	Surgery		4.77	4.73	5.81		
66740		Destruction, ciliary body	Surgery		4.77	3.98	5.10		
66761		Revision of iris	Surgery		4.06	4.32	5.61		
66762		Revision of iris	Surgery		4.57	4.30	5.67		
66770		Removal of inner eye lesion	Surgery		5.17	4.81	6.10		
66820		Incision, secondary cataract	Surgery		3.88	5.83	5.83		
66821		After cataract laser surgery	Surgery		2.35	3.63	4.10		
66825		Reposition intraocular lens	Surgery		8.22	9.09	9.09		
66830		Removal of lens lesion	Surgery		8.19	6.97	6.97		
66840		Removal of lens material	Surgery		7.90	6.88	6.88		
66850		Removal of lens material	Surgery		9.10	7.66	7.66		
66852		Removal of lens material	Surgery		9.96	8.12	8.12		
66920		Extraction of lens	Surgery		8.85	7.32	7.32		
66930		Extraction of lens	Surgery		10.16	8.16	8.16		
66940		Extraction of lens	Surgery		8.92	7.62	7.62		
66982		Cataract surgery, complex	Surgery		13.48	9.89	9.89		
66983		Cataract surg w/fof, 1 stage	Surgery		8.98	6.13	6.13		
66984		Cataract surg w/fof, 1 stage	Surgery		10.21	7.44	7.44		
66985		Insert lens prosthesis	Surgery		8.38	7.47	7.47		
66986		Exchange lens prosthesis	Surgery		12.26	9.20	9.20		
66990		Ophthalmic endoscope add-on	Surgery		1.51	0.69	0.69		
66999		Eye surgery procedure	Surgery					17.84	
67005		Partial removal of eye fluid	Surgery		5.69	4.87	4.87		
67010		Partial removal of eye fluid	Surgery		6.86	5.43	5.43		
67015		Release of eye fluid	Surgery		6.91	6.47	6.47		
67025		Replace eye fluid	Surgery		6.83	6.24	9.25		
67027		Implant eye drug system	Surgery		10.83	8.02	8.02		
67028		Injection eye drug	Surgery		2.52	1.46	2.71		
67030		Incise inner eye strands	Surgery		4.83	5.87	5.87		
67031		Laser surgery, eye strands	Surgery		3.66	3.65	4.61		
67036		Removal of inner eye fluid	Surgery		11.87	9.15	9.15		
67038		Strip retinal membrane	Surgery		21.21	15.53	15.53		
67039		Laser treatment of retina	Surgery		14.50	12.22	12.22		
67040		Laser treatment of retina	Surgery		17.20	13.72	13.72		
67101		Repair detached retina	Surgery		7.52	6.55	9.15		
67105		Repair detached retina	Surgery		7.40	6.17	8.10		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPSC CODE

PAGE 74 of 119

CPT/ HCPSC Code	Modifier	CPT/HCPSC Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
67107		Repair detached retina	Surgery		14.82	11.33	11.33		
67108		Repair detached retina	Surgery		20.79	14.46	14.46		
67110		Repair detached retina	Surgery		8.80	7.41	10.26		
67112		Rerepair detached retina	Surgery		16.83	11.84	11.84		
67115		Release encircling material	Surgery		4.98	5.09	5.09		
67120		Remove eye implant material	Surgery		5.97	5.55	8.60		
67121		Remove eye implant material	Surgery		10.65	8.55	8.55		
67141		Treatment of retina	Surgery		5.19	4.87	5.87		
67145		Treatment of retina	Surgery		5.36	4.94	5.74		
67208		Treatment of retinal lesion	Surgery		6.69	5.53	6.14		
67210		Treatment of retinal lesion	Surgery		8.81	5.90	6.59		
67218		Treatment of retinal lesion	Surgery		18.50	12.19	12.19		
67220		Treatment of choroid lesion	Surgery		13.11	9.04	10.45		
67221		Ocular photodynamic ther	Surgery		4.00	1.81	4.34		
67225		Eye photodynamic ther add-on	Surgery		0.47	0.21	0.25		
67227		Treatment of retinal lesion	Surgery		6.57	5.54	6.60		
67228		Treatment of retinal lesion	Surgery		12.72	8.56	11.51		
67250		Reinforce eye wall	Surgery		8.65	9.20	9.20		
67255		Reinforce/graft eye wall	Surgery		8.89	9.92	9.92		
67299		Eye surgery procedure	Surgery					21.22	
67311		Revise eye muscle	Surgery		6.64	6.04	6.04		
67312		Revise two eye muscles	Surgery		8.53	6.77	6.77		
67314		Revise eye muscle	Surgery		7.51	6.57	6.57		
67316		Revise two eye muscles	Surgery		9.65	7.52	7.52		
67318		Revise eye muscle(s)	Surgery		7.84	6.95	6.95		
67320		Revise eye muscle(s) add-on	Surgery		4.32	1.96	1.96		
67331		Eye surgery follow-up add-on	Surgery		4.05	1.84	1.84		
67332		Rerevise eye muscles add-on	Surgery		4.48	2.03	2.03		
67334		Revise eye muscle w/suture	Surgery		3.97	1.80	1.80		
67335		Eye suture during surgery	Surgery		2.49	1.12	1.12		
67340		Revise eye muscle add-on	Surgery		4.92	2.21	2.21		
67343		Release eye tissue	Surgery		7.34	6.53	6.53		
67345		Destroy nerve of eye muscle	Surgery		2.96	2.02	2.59		
67350		Biopsy eye muscle	Surgery		2.87	1.88	1.88		
67399		Eye muscle surgery procedure	Surgery					13.06	
67400		Explore/biopsy eye socket	Surgery		9.75	11.29	11.29		
67405		Explore/drain eye socket	Surgery		7.92	9.80	9.80		
67412		Explore/treat eye socket	Surgery		9.49	10.96	10.96		
67413		Explore/treat eye socket	Surgery		9.99	10.80	10.80		
67414		Aspir/decompress eye socket	Surgery		11.11	12.07	12.07		
67415		Aspiration, orbital contents	Surgery		1.76	0.76	0.76		
67420		Explore/treat eye socket	Surgery		20.03	17.44	17.44		
67430		Explore/treat eye socket	Surgery		13.37	14.93	14.93		
67440		Explore/drain eye socket	Surgery		13.07	14.30	14.30		
67445		Explr/decompress eye socket	Surgery		14.40	13.95	13.95		
67450		Explore/biopsy eye socket	Surgery		13.49	14.73	14.73		
67500		Inject/treat eye socket	Surgery		0.79	0.29	0.67		
67505		Inject/treat eye socket	Surgery		0.82	0.31	0.69		
67515		Inject/treat eye socket	Surgery		0.61	0.38	0.59		
67550		Insert eye socket implant	Surgery		10.17	11.33	11.33		
67560		Revise eye socket implant	Surgery		10.58	11.40	11.40		
67570		Decompress optic nerve	Surgery		13.56	13.62	13.62		
67599		Orbit surgery procedure	Surgery					1.38	
67700		Drainage of eyelid abscess	Surgery		1.35	1.27	6.04		
67710		Incision of eyelid	Surgery		1.02	1.21	5.39		
67715		Incision of eyelid fold	Surgery		1.22	1.29	5.39		
67800		Remove eyelid lesion	Surgery		1.38	1.04	1.62		
67801		Remove eyelid lesions	Surgery		1.88	1.26	1.97		
67805		Remove eyelid lesions	Surgery		2.22	1.65	2.53		
67806		Remove eyelid lesion(s)	Surgery		3.79	3.78	3.78		
67810		Biopsy of eyelid	Surgery		1.48	0.68	3.34		
67820		Revise eyelashes	Surgery		0.89	0.56	0.60		
67825		Revise eyelashes	Surgery		1.38	1.41	1.74		
67830		Revise eyelashes	Surgery		1.70	1.50	5.55		
67835		Revise eyelashes	Surgery		5.55	4.63	4.63		
67840		Remove eyelid lesion	Surgery		2.04	1.65	5.49		
67850		Treat eyelid lesion	Surgery		1.69	1.47	3.38		
67875		Closure of eyelid by suture	Surgery		1.35	0.94	3.31		
67880		Revision of eyelid	Surgery		3.79	3.81	6.63		
67882		Revision of eyelid	Surgery		5.06	4.82	7.65		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 75 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
67900		Repair brow defect	Surgery		6.13	5.27	9.09		
67901		Repair eyelid defect	Surgery		7.39	5.42	5.42		
67902		Repair eyelid defect	Surgery		9.35	5.48	5.48		
67903		Repair eyelid defect	Surgery		6.36	5.53	9.59		
67904		Repair eyelid defect	Surgery		6.25	5.25	9.66		
67906		Repair eyelid defect	Surgery		6.78	5.04	5.39		
67908		Repair eyelid defect	Surgery		5.12	5.36	6.65		
67909		Revise eyelid defect	Surgery		5.39	4.96	8.05		
67911		Revise eyelid defect	Surgery		5.26	4.79	4.79		
67912		Correction eyelid w/ implant	Surgery		5.67	5.55	18.98		
67914		Repair eyelid defect	Surgery		3.67	3.06	6.36		
67915		Repair eyelid defect	Surgery		3.18	2.81	6.00		
67916		Repair eyelid defect	Surgery		5.30	4.77	8.07		
67917		Repair eyelid defect	Surgery		6.01	5.08	8.48		
67921		Repair eyelid defect	Surgery		3.39	2.90	6.21		
67922		Repair eyelid defect	Surgery		3.06	2.76	5.93		
67923		Repair eyelid defect	Surgery		5.87	4.98	8.14		
67924		Repair eyelid defect	Surgery		5.78	4.69	8.95		
67930		Repair eyelid wound	Surgery		3.60	2.18	5.73		
67935		Repair eyelid wound	Surgery		6.21	4.42	8.54		
67938		Remove eyelid foreign body	Surgery		1.33	1.26	5.40		
67950		Revision of eyelid	Surgery		5.81	5.23	8.66		
67961		Revision of eyelid	Surgery		5.68	5.04	8.71		
67966		Revision of eyelid	Surgery		6.56	5.58	9.16		
67971		Reconstruction of eyelid	Surgery		9.78	7.30	7.30		
67973		Reconstruction of eyelid	Surgery		12.85	9.34	9.34		
67974		Reconstruction of eyelid	Surgery		12.82	9.26	9.26		
67975		Reconstruction of eyelid	Surgery		9.12	6.97	6.97		
67999		Revision of eyelid	Surgery					4.70	
68020		Incise/drain eyelid lining	Surgery		1.37	1.21	1.41		
68040		Treatment of eyelid lesions	Surgery		0.85	0.43	0.71		
68100		Biopsy of eyelid lining	Surgery		1.35	0.95	3.26		
68110		Remove eyelid lining lesion	Surgery		1.77	1.65	4.11		
68115		Remove eyelid lining lesion	Surgery		2.36	1.92	5.98		
68130		Remove eyelid lining lesion	Surgery		4.92	4.61	8.74		
68135		Remove eyelid lining lesion	Surgery		1.84	1.65	1.82		
68200		Treat eyelid by injection	Surgery		0.49	0.33	0.54		
68320		Revise/graft eyelid lining	Surgery		5.36	5.54	11.31		
68325		Revise/graft eyelid lining	Surgery		7.35	6.56	6.56		
68326		Revise/graft eyelid lining	Surgery		7.14	6.43	6.43		
68328		Revise/graft eyelid lining	Surgery		8.17	7.31	7.31		
68330		Revise/graft eyelid lining	Surgery		4.82	4.73	9.44		
68335		Revise eyelid lining	Surgery		7.18	6.40	6.40		
68340		Revise/graft eyelid lining	Surgery		4.16	4.11	8.90		
68360		Separate eyelid adhesions	Surgery		4.36	4.19	8.06		
68362		Revise eyelid lining	Surgery		7.33	6.42	6.42		
68371		Harvest eye tissue, allograft	Surgery		4.89	4.74	4.74		
68399		Eyelid lining surgery	Surgery					4.00	
68400		Incise/drain tear gland	Surgery		1.69	1.83	5.92		
68420		Incise/drain tear sac	Surgery		2.30	2.11	6.21		
68440		Incise tear duct opening	Surgery		0.94	1.27	2.09		
68500		Removal of tear gland	Surgery		11.00	9.76	9.76		
68505		Partial removal, tear gland	Surgery		10.92	10.68	10.68		
68510		Biopsy of tear gland	Surgery		4.60	2.10	7.35		
68520		Removal of tear sac	Surgery		7.50	7.44	7.44		
68525		Biopsy of tear sac	Surgery		4.42	2.03	2.03		
68530		Clearance of tear duct	Surgery		3.65	2.65	8.19		
68540		Remove tear gland lesion	Surgery		10.58	9.42	9.42		
68550		Remove tear gland lesion	Surgery		13.24	11.38	11.38		
68700		Repair tear ducts	Surgery		6.59	6.00	6.00		
68705		Revise tear duct opening	Surgery		2.06	1.80	4.18		
68720		Create tear sac drain	Surgery		8.95	7.88	7.88		
68745		Create tear duct drain	Surgery		8.62	7.88	7.88		
68750		Create tear duct drain	Surgery		8.65	8.29	8.29		
68760		Close tear duct opening	Surgery		1.73	1.63	3.55		
68761		Close tear duct opening	Surgery		1.36	1.32	2.28		
68770		Close tear system fistula	Surgery		7.01	3.19	3.19		
68801		Dilate tear duct opening	Surgery		0.94	1.48	1.95		
68810		Probe nasolacrimal duct	Surgery		1.90	2.68	3.67		
68811		Probe nasolacrimal duct	Surgery		2.35	2.42	2.42		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 76 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
68815		Probe nasolacrimal duct	Surgery		3.20	2.82	8.26		
68840		Explore/irrigate tear ducts	Surgery		1.25	1.12	1.60		
68850		Injection for tear sac x-ray	Surgery		0.80	0.68	0.88		
68899		Tear duct system surgery	Surgery					4.65	
69000		Drain external ear lesion	Surgery		1.45	1.36	2.89		
69005		Drain external ear lesion	Surgery		2.11	1.84	2.94		
69020		Drain outer ear canal lesion	Surgery		1.48	2.07	4.00		
69090		Pierce earlobes	Surgery					0.71	
69100		Biopsy of external ear	Surgery		0.81	0.39	1.71		
69105		Biopsy of external ear canal	Surgery		0.85	0.77	2.35		
69110		Remove external ear, partial	Surgery		3.43	4.48	6.76		
69120		Removal of external ear	Surgery		4.04	6.20	6.20		
69140		Remove ear canal lesion(s)	Surgery		7.96	13.32	13.32		
69145		Remove ear canal lesion(s)	Surgery		2.62	3.31	5.80		
69150		Extensive ear canal surgery	Surgery		13.41	13.44	13.44		
69155		Extensive ear/neck surgery	Surgery		20.77	19.60	19.60		
69200		Clear outer ear canal	Surgery		0.77	0.55	2.39		
69205		Clear outer ear canal	Surgery		1.20	1.36	1.36		
69210		Remove impacted ear wax	Surgery		0.61	0.23	0.63		
69220		Clean out mastoid cavity	Surgery		0.83	0.73	2.37		
69222		Clean out mastoid cavity	Surgery		1.40	2.07	3.86		
69300		Revise external ear	Surgery		6.35	4.23	4.23		
69310		Rebuild outer ear canal	Surgery		10.77	16.33	16.33		
69320		Rebuild outer ear canal	Surgery		16.93	21.90	21.90		
69399		Outer ear surgery procedure	Surgery					1.21	
69400		Inflate middle ear canal	Surgery		0.83	0.67	2.17		
69401		Inflate middle ear canal	Surgery		0.63	0.65	1.24		
69405		Catheterize middle ear canal	Surgery		2.63	2.32	3.51		
69420		Incision of eardrum	Surgery		1.33	1.59	3.16		
69421		Incision of eardrum	Surgery		1.73	2.17	2.17		
69424		Remove ventilating tube	Surgery		0.85	0.68	2.19		
69433		Create eardrum opening	Surgery		1.52	1.64	3.10		
69436		Create eardrum opening	Surgery		1.96	2.30	2.30		
69440		Exploration of middle ear	Surgery		7.56	8.80	8.80		
69450		Eardrum revision	Surgery		5.56	7.05	7.05		
69501		Mastoidectomy	Surgery		9.06	9.03	9.03		
69502		Mastoidectomy	Surgery		12.36	11.62	11.62		
69505		Remove mastoid structures	Surgery		12.97	17.24	17.24		
69511		Extensive mastoid surgery	Surgery		13.50	17.52	17.52		
69530		Extensive mastoid surgery	Surgery		19.16	21.69	21.69		
69535		Remove part of temporal bone	Surgery		36.09	32.05	32.05		
69540		Remove ear lesion	Surgery		1.20	1.98	3.75		
69550		Remove ear lesion	Surgery		10.97	14.90	14.90		
69552		Remove ear lesion	Surgery		19.43	20.73	20.73		
69554		Remove ear lesion	Surgery		33.11	30.42	30.42		
69601		Mastoid surgery revision	Surgery		13.22	12.71	12.71		
69602		Mastoid surgery revision	Surgery		13.56	13.27	13.27		
69603		Mastoid surgery revision	Surgery		14.00	18.41	18.41		
69604		Mastoid surgery revision	Surgery		14.00	13.73	13.73		
69605		Mastoid surgery revision	Surgery		18.46	21.01	21.01		
69610		Repair of eardrum	Surgery		4.42	3.28	5.57		
69620		Repair of eardrum	Surgery		5.88	6.31	11.15		
69631		Repair eardrum structures	Surgery		9.85	11.23	11.23		
69632		Rebuild eardrum structures	Surgery		12.73	13.51	13.51		
69633		Rebuild eardrum structures	Surgery		12.08	13.09	13.09		
69635		Repair eardrum structures	Surgery		13.31	16.79	16.79		
69636		Rebuild eardrum structures	Surgery		15.20	19.36	19.36		
69637		Rebuild eardrum structures	Surgery		15.09	19.28	19.28		
69641		Revise middle ear & mastoid	Surgery		12.69	12.82	12.82		
69642		Revise middle ear & mastoid	Surgery		16.81	16.33	16.33		
69643		Revise middle ear & mastoid	Surgery		15.30	14.86	14.86		
69644		Revise middle ear & mastoid	Surgery		16.94	20.46	20.46		
69645		Revise middle ear & mastoid	Surgery		16.36	20.08	20.08		
69646		Revise middle ear & mastoid	Surgery		17.96	20.82	20.82		
69650		Release middle ear bone	Surgery		9.65	9.94	9.94		
69660		Revise middle ear bone	Surgery		11.88	11.21	11.21		
69661		Revise middle ear bone	Surgery		15.72	14.74	14.74		
69662		Revise middle ear bone	Surgery		15.42	13.79	13.79		
69666		Repair middle ear structures	Surgery		9.74	10.00	10.00		
69667		Repair middle ear structures	Surgery		9.75	10.01	10.01		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 77 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
69670		Remove mastoid air cells	Surgery		11.49	11.74	11.74		
69676		Remove middle ear nerve	Surgery		9.51	10.78	10.78		
69700		Close mastoid fistula	Surgery		8.22	9.27	9.27		
69710		Implant/replace hearing aid	Surgery					18.06	
69711		Remove/repair hearing aid	Surgery		10.42	10.82	10.82		
69714		Implant temple bone w/stimul	Surgery		13.98	12.70	12.70		
69715		Temple bone implant w/stimul	Surgery		18.22	15.07	15.07		
69717		Temple bone implant revision	Surgery		14.96	14.51	14.51		
69718		Revise temple bone implant	Surgery		18.47	15.34	15.34		
69720		Release facial nerve	Surgery		14.36	14.56	14.56		
69725		Release facial nerve	Surgery		25.34	20.19	20.19		
69740		Repair facial nerve	Surgery		15.94	13.45	13.45		
69745		Repair facial nerve	Surgery		16.66	15.01	15.01		
69799		Middle ear surgery procedure	Surgery					4.18	
69801		Incise inner ear	Surgery		8.55	9.49	9.49		
69802		Incise inner ear	Surgery		13.08	12.36	12.36		
69805		Explore inner ear	Surgery		13.80	11.91	11.91		
69806		Explore inner ear	Surgery		12.33	11.07	11.07		
69820		Establish inner ear window	Surgery		10.32	11.25	11.25		
69840		Revise inner ear window	Surgery		10.24	13.21	13.21		
69905		Remove inner ear	Surgery		11.08	11.38	11.38		
69910		Remove inner ear & mastoid	Surgery		13.61	11.95	11.95		
69915		Incise inner ear nerve	Surgery		21.20	16.51	16.51		
69930		Implant cochlear device	Surgery		16.78	14.79	14.79		
69949		Inner ear surgery procedure	Surgery					21.50	
69950		Incise inner ear nerve	Surgery		25.60	18.95	18.95		
69955		Release facial nerve	Surgery		27.00	21.44	21.44		
69960		Release inner ear canal	Surgery		27.00	20.11	20.11		
69970		Remove inner ear lesion	Surgery		29.99	23.34	23.34		
69979		Temporal bone surgery	Surgery					41.64	
69990		Microsurgery add-on	Surgery		3.46	1.80	1.80		
70010		Contrast x-ray of brain	Radiology		1.19	0.39	0.39		
70010	TC	Contrast x-ray of brain	Radiology	a	0.00	4.34	4.34		
70015	26	Contrast x-ray of brain	Radiology		1.19	0.39	0.39		
70015	TC	Contrast x-ray of brain	Radiology	a	0.00	1.35	1.35		
70030	26	X-ray eye for foreign body	Radiology		0.17	0.06	0.06		
70030	TC	X-ray eye for foreign body	Radiology	a	0.00	0.42	0.42		
70100	26	X-ray exam of jaw	Radiology		0.18	0.06	0.06		
70100	TC	X-ray exam of jaw	Radiology	a	0.00	0.52	0.52		
70110	26	X-ray exam of jaw	Radiology		0.25	0.08	0.08		
70110	TC	X-ray exam of jaw	Radiology	a	0.00	0.62	0.62		
70120	26	X-ray exam of mastoids	Radiology		0.18	0.06	0.06		
70120	TC	X-ray exam of mastoids	Radiology	a	0.00	0.62	0.62		
70130	26	X-ray exam of mastoids	Radiology		0.34	0.11	0.11		
70130	TC	X-ray exam of mastoids	Radiology	a	0.00	0.78	0.78		
70134	26	X-ray exam of middle ear	Radiology		0.34	0.11	0.11		
70134	TC	X-ray exam of middle ear	Radiology	a	0.00	0.73	0.73		
70140	26	X-ray exam of facial bones	Radiology		0.19	0.06	0.06		
70140	TC	X-ray exam of facial bones	Radiology	a	0.00	0.62	0.62		
70150	26	X-ray exam of facial bones	Radiology		0.26	0.08	0.08		
70150	TC	X-ray exam of facial bones	Radiology	a	0.00	0.78	0.78		
70160	26	X-ray exam of nasal bones	Radiology		0.17	0.06	0.06		
70160	TC	X-ray exam of nasal bones	Radiology	a	0.00	0.52	0.52		
70170	26	X-ray exam of tear duct	Radiology		0.30	0.10	0.10		
70170	TC	X-ray exam of tear duct	Radiology	a	0.00	0.95	0.95		
70190	26	X-ray exam of eye sockets	Radiology		0.21	0.07	0.07		
70190	TC	X-ray exam of eye sockets	Radiology	a	0.00	0.62	0.62		
70200	26	X-ray exam of eye sockets	Radiology		0.26	0.09	0.09		
70200	TC	X-ray exam of eye sockets	Radiology	a	0.00	0.78	0.78		
70210	26	X-ray exam of sinuses	Radiology		0.17	0.06	0.06		
70210	TC	X-ray exam of sinuses	Radiology	a	0.00	0.62	0.62		
70220	26	X-ray exam of sinuses	Radiology		0.25	0.08	0.08		
70220	TC	X-ray exam of sinuses	Radiology	a	0.00	0.78	0.78		
70240	26	X-ray exam, pituitary saddle	Radiology		0.19	0.06	0.06		
70240	TC	X-ray exam, pituitary saddle	Radiology	a	0.00	0.42	0.42		
70250	26	X-ray exam of skull	Radiology		0.24	0.08	0.08		
70250	TC	X-ray exam of skull	Radiology	a	0.00	0.62	0.62		
70260	26	X-ray exam of skull	Radiology		0.34	0.11	0.11		
70260	TC	X-ray exam of skull	Radiology	a	0.00	0.89	0.89		
70300	26	X-ray exam of teeth	Radiology		0.10	0.05	0.05		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 78 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
70300	TC	X-ray exam of teeth	Radiology	a	0.00	0.26	0.26		
70310	26	X-ray exam of teeth	Radiology		0.16	0.08	0.08		
70310	TC	X-ray exam of teeth	Radiology	a	0.00	0.42	0.42		
70320	26	Full mouth x-ray of teeth	Radiology		0.22	0.08	0.08		
70320	TC	Full mouth x-ray of teeth	Radiology	a	0.00	0.78	0.78		
70328	26	X-ray exam of jaw joint	Radiology		0.18	0.06	0.06		
70328	TC	X-ray exam of jaw joint	Radiology	a	0.00	0.49	0.49		
70330	26	X-ray exam of jaw joints	Radiology		0.24	0.08	0.08		
70330	TC	X-ray exam of jaw joints	Radiology	a	0.00	0.84	0.84		
70332	26	X-ray exam of jaw joint	Radiology		0.54	0.20	0.20		
70332	TC	X-ray exam of jaw joint	Radiology	a	0.00	2.11	2.11		
70336	26	Magnetic image, jaw joint	Radiology		1.48	0.49	0.49		
70336	TC	Magnetic image, jaw joint	Radiology	a	0.00	11.23	11.23		
70350	26	X-ray head for orthodontia	Radiology		0.17	0.07	0.07		
70350	TC	X-ray head for orthodontia	Radiology	a	0.00	0.38	0.38		
70355	26	Panoramic x-ray of jaws	Radiology		0.20	0.07	0.07		
70355	TC	Panoramic x-ray of jaws	Radiology	a	0.00	0.57	0.57		
70360	26	X-ray exam of neck	Radiology		0.17	0.06	0.06		
70360	TC	X-ray exam of neck	Radiology	a	0.00	0.42	0.42		
70370	26	Throat x-ray & fluoroscopy	Radiology		0.32	0.10	0.10		
70370	TC	Throat x-ray & fluoroscopy	Radiology	a	0.00	1.31	1.31		
70371	26	Speech evaluation, complex	Radiology		0.84	0.28	0.28		
70371	TC	Speech evaluation, complex	Radiology	a	0.00	2.11	2.11		
70373	26	Contrast x-ray of larynx	Radiology		0.44	0.14	0.14		
70373	TC	Contrast x-ray of larynx	Radiology	a	0.00	1.79	1.79		
70380	26	X-ray exam of salivary gland	Radiology		0.17	0.06	0.06		
70380	TC	X-ray exam of salivary gland	Radiology	a	0.00	0.67	0.67		
70390	26	X-ray exam of salivary duct	Radiology		0.38	0.12	0.12		
70390	TC	X-ray exam of salivary duct	Radiology	a	0.00	1.79	1.79		
70450	26	Ct head/brain w/o dye	Radiology		0.85	0.28	0.28		
70450	TC	Ct head/brain w/o dye	Radiology	a	0.00	4.73	4.73		
70460	26	Ct head/brain w/dye	Radiology		1.13	0.37	0.37		
70460	TC	Ct head/brain w/dye	Radiology	a	0.00	5.68	5.68		
70470	26	Ct head/brain w/o&w dye	Radiology		1.27	0.42	0.42		
70470	TC	Ct head/brain w/o&w dye	Radiology	a	0.00	7.09	7.09		
70480	26	Ct orbit/ear/fossa w/o dye	Radiology		1.28	0.42	0.42		
70480	TC	Ct orbit/ear/fossa w/o dye	Radiology	a	0.00	4.73	4.73		
70481	26	Ct orbit/ear/fossa w/dye	Radiology		1.38	0.45	0.45		
70481	TC	Ct orbit/ear/fossa w/dye	Radiology	a	0.00	5.68	5.68		
70482	26	Ct orbit/ear/fossa w/o&w dye	Radiology		1.45	0.48	0.48		
70482	TC	Ct orbit/ear/fossa w/o&w dye	Radiology	a	0.00	7.09	7.09		
70486	26	Ct maxillofacial w/o dye	Radiology		1.14	0.37	0.37		
70486	TC	Ct maxillofacial w/o dye	Radiology	a	0.00	4.73	4.73		
70487	26	Ct maxillofacial w/dye	Radiology		1.30	0.43	0.43		
70487	TC	Ct maxillofacial w/dye	Radiology	a	0.00	5.68	5.68		
70488	26	Ct maxillofacial w/o&w dye	Radiology		1.42	0.46	0.46		
70488	TC	Ct maxillofacial w/o&w dye	Radiology	a	0.00	7.09	7.09		
70490	26	Ct soft tissue neck w/o dye	Radiology		1.28	0.42	0.42		
70490	TC	Ct soft tissue neck w/o dye	Radiology	a	0.00	4.73	4.73		
70491	26	Ct soft tissue neck w/dye	Radiology		1.38	0.45	0.45		
70491	TC	Ct soft tissue neck w/dye	Radiology	a	0.00	5.68	5.68		
70492	26	Ct soft tissue neck w/o & w/dye	Radiology		1.45	0.47	0.47		
70492	TC	Ct soft tissue neck w/o & w/dye	Radiology	a	0.00	7.09	7.09		
70496	26	Ct angiography, head	Radiology		1.75	0.57	0.57		
70496	TC	Ct angiography, head	Radiology	a	0.00	10.63	10.63		
70498	26	Ct angiography, neck	Radiology		1.75	0.57	0.57		
70498	TC	Ct angiography, neck	Radiology	a	0.00	10.63	10.63		
70540	26	Mri orbit/face/neck w/o dye	Radiology		1.35	0.44	0.44		
70540	TC	Mri orbit/face/neck w/o dye	Radiology	a	0.00	11.23	11.23		
70542	26	Mri orbit/face/neck w/dye	Radiology		1.62	0.53	0.53		
70542	TC	Mri orbit/face/neck w/dye	Radiology	a	0.00	13.48	13.48		
70543	26	Mri orbit/face/neck w/o&w dye	Radiology		2.15	0.71	0.71		
70543	TC	Mri orbit/face/neck w/o&w dye	Radiology	a	0.00	24.95	24.95		
70544	26	Mr angiography head w/o dye	Radiology		1.20	0.40	0.40		
70544	TC	Mr angiography head w/o dye	Radiology	a	0.00	11.23	11.23		
70545	26	Mr angiography head w/dye	Radiology		1.20	0.39	0.39		
70545	TC	Mr angiography head w/dye	Radiology	a	0.00	11.23	11.23		
70546	26	Mr angiograph head w/o&w dye	Radiology		1.80	0.59	0.59		
70546	TC	Mr angiograph head w/o&w dye	Radiology	a	0.00	22.47	22.47		
70547	26	Mr angiography neck w/o dye	Radiology		1.20	0.39	0.39		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 79 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
70547	TC	Mri angiography neck w/o dye	Radiology	a	0.00	11.23	11.23		
70548	26	Mri angiography neck w/dye	Radiology		1.20	0.39	0.39		
70548	TC	Mri angiography neck w/dye	Radiology	a	0.00	11.23	11.23		
70549	26	Mri angiograph neck w/o&w dye	Radiology		1.80	0.59	0.59		
70549	TC	Mri angiograph neck w/o&w dye	Radiology	a	0.00	22.47	22.47		
70551	26	Mri brain w/o dye	Radiology		1.48	0.49	0.49		
70551	TC	Mri brain w/o dye	Radiology	a	0.00	11.23	11.23		
70552	26	Mri brain w/dye	Radiology		1.78	0.59	0.59		
70552	TC	Mri brain w/dye	Radiology	a	0.00	13.48	13.48		
70553	26	Mri brain w/o&w dye	Radiology		2.36	0.78	0.78		
70553	TC	Mri brain w/o&w dye	Radiology	a	0.00	24.95	24.95		
70557	26	Mri brain w/o dye	Radiology		2.90	1.13	1.13		
70557	TC	Mri brain w/o dye	Radiology	a				15.52	
70558	26	Mri brain w/ dye	Radiology		3.20	1.24	1.24		
70558	TC	Mri brain w/ dye	Radiology	a				17.12	
70559	26	Mri brain w/o & w/ dye	Radiology		3.20	1.24	1.24		
70559	TC	Mri brain w/o & w/ dye	Radiology	a				17.12	
71010	26	Chest x-ray	Radiology		0.18	0.06	0.06		
71010	TC	Chest x-ray	Radiology	a	0.00	0.47	0.47		
71015	26	Chest x-ray	Radiology		0.21	0.07	0.07		
71015	TC	Chest x-ray	Radiology	a	0.00	0.52	0.52		
71020	26	Chest x-ray	Radiology		0.22	0.07	0.07		
71020	TC	Chest x-ray	Radiology	a	0.00	0.62	0.62		
71021	26	Chest x-ray	Radiology		0.27	0.09	0.09		
71021	TC	Chest x-ray	Radiology	a	0.00	0.73	0.73		
71022	26	Chest x-ray	Radiology		0.31	0.10	0.10		
71022	TC	Chest x-ray	Radiology	a	0.00	0.73	0.73		
71023	26	Chest x-ray and fluoroscopy	Radiology		0.38	0.13	0.13		
71023	TC	Chest x-ray and fluoroscopy	Radiology	a	0.00	0.78	0.78		
71030	26	Chest x-ray	Radiology		0.31	0.10	0.10		
71030	TC	Chest x-ray	Radiology	a	0.00	0.78	0.78		
71034	26	Chest x-ray and fluoroscopy	Radiology		0.46	0.16	0.16		
71034	TC	Chest x-ray and fluoroscopy	Radiology	a	0.00	1.44	1.44		
71035	26	Chest x-ray	Radiology		0.18	0.06	0.06		
71035	TC	Chest x-ray	Radiology	a	0.00	0.52	0.52		
71040	26	Contrast x-ray of bronchi	Radiology		0.58	0.19	0.19		
71040	TC	Contrast x-ray of bronchi	Radiology	a	0.00	1.46	1.46		
71060	26	Contrast x-ray of bronchi	Radiology		0.74	0.24	0.24		
71060	TC	Contrast x-ray of bronchi	Radiology	a	0.00	2.21	2.21		
71090	26	X-ray & pacemaker insertion	Radiology		0.54	0.21	0.21		
71090	TC	X-ray & pacemaker insertion	Radiology	a	0.00	1.68	1.68		
71100	26	X-ray exam of ribs	Radiology		0.22	0.07	0.07		
71100	TC	X-ray exam of ribs	Radiology	a	0.00	0.57	0.57		
71101	26	X-ray exam of ribs/chest	Radiology		0.27	0.09	0.09		
71101	TC	X-ray exam of ribs/chest	Radiology	a	0.00	0.67	0.67		
71110	26	X-ray exam of ribs	Radiology		0.27	0.09	0.09		
71110	TC	X-ray exam of ribs	Radiology	a	0.00	0.78	0.78		
71111	26	X-ray exam of ribs/ chest	Radiology		0.32	0.10	0.10		
71111	TC	X-ray exam of ribs/ chest	Radiology	a	0.00	0.89	0.89		
71120	26	X-ray exam of breastbone	Radiology		0.20	0.07	0.07		
71120	TC	X-ray exam of breastbone	Radiology	a	0.00	0.65	0.65		
71130	26	X-ray exam of breastbone	Radiology		0.22	0.07	0.07		
71130	TC	X-ray exam of breastbone	Radiology	a	0.00	0.71	0.71		
71250	26	Ct thorax w/o dye	Radiology		1.16	0.38	0.38		
71250	TC	Ct thorax w/o dye	Radiology	a	0.00	5.93	5.93		
71260	26	Ct thorax w/dye	Radiology		1.24	0.41	0.41		
71260	TC	Ct thorax w/dye	Radiology	a	0.00	7.09	7.09		
71270	26	Ct thorax w/o&w dye	Radiology		1.38	0.45	0.45		
71270	TC	Ct thorax w/o&w dye	Radiology	a	0.00	8.88	8.88		
71275	26	Ct angiography, chest	Radiology		1.92	0.63	0.63		
71275	TC	Ct angiography, chest	Radiology	a	0.00	12.42	12.42		
71550	26	Mri chest w/o dye	Radiology		1.46	0.48	0.48		
71550	TC	Mri chest w/o dye	Radiology	a	0.00	11.23	11.23		
71551	26	Mri chest w/dye	Radiology		1.73	0.57	0.57		
71551	TC	Mri chest w/dye	Radiology	a	0.00	13.48	13.48		
71552	26	Mri chest w/o&w/dye	Radiology		2.26	0.74	0.74		
71552	TC	Mri chest w/o&w/dye	Radiology	a	0.00	24.95	24.95		
71555	26	Mri angio chest w or w/o dye	Radiology		1.81	0.60	0.60		
71555	TC	Mri angio chest w or w/o dye	Radiology	a	0.00	11.23	11.23		
72010	26	X-ray exam of spine	Radiology		0.45	0.15	0.15		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 80 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
72010	TC	X-ray exam of spine	Radiology	a	0.00	1.02	1.02		
72020	26	X-ray exam of spine	Radiology		0.15	0.05	0.05		
72020	TC	X-ray exam of spine	Radiology	a	0.00	0.42	0.42		
72040	26	X-ray exam of neck spine	Radiology		0.22	0.07	0.07		
72040	TC	X-ray exam of neck spine	Radiology	a	0.00	0.60	0.60		
72050	26	X-ray exam of neck spine	Radiology		0.31	0.10	0.10		
72050	TC	X-ray exam of neck spine	Radiology	a	0.00	0.89	0.89		
72052	26	X-ray exam of neck spine	Radiology		0.36	0.12	0.12		
72052	TC	X-ray exam of neck spine	Radiology	a	0.00	1.13	1.13		
72069	26	X-ray exam of trunk spine	Radiology		0.22	0.08	0.08		
72069	TC	X-ray exam of trunk spine	Radiology	a	0.00	0.49	0.49		
72070	26	X-ray exam of thoracic spine	Radiology		0.22	0.07	0.07		
72070	TC	X-ray exam of thoracic spine	Radiology	a	0.00	0.65	0.65		
72072	26	X-ray exam of thoracic spine	Radiology		0.22	0.07	0.07		
72072	TC	X-ray exam of thoracic spine	Radiology	a	0.00	0.73	0.73		
72074	26	X-ray exam of thoracic spine	Radiology		0.22	0.07	0.07		
72074	-TC	X-ray exam of thoracic spine	Radiology	a	0.00	0.91	0.91		
72080	26	X-ray exam of trunk spine	Radiology		0.22	0.07	0.07		
72080	TC	X-ray exam of trunk spine	Radiology	e	0.00	0.67	0.67		
72090	26	X-ray exam of trunk spine	Radiology		0.28	0.09	0.09		
72090	TC	X-ray exam of trunk spine	Radiology	a	0.00	0.67	0.67		
72100	26	X-ray exam of lower spine	Radiology		0.22	0.07	0.07		
72100	TC	X-ray exam of lower spine	Radiology	a	0.00	0.67	0.67		
72110	26	X-ray exam of lower spine	Radiology		0.31	0.10	0.10		
72110	TC	X-ray exam of lower spine	Radiology	a	0.00	0.91	0.91		
72114	26	X-ray exam of lower spine	Radiology		0.36	0.12	0.12		
72114	TC	X-ray exam of lower spine	Radiology	a	0.00	1.19	1.19		
72120	26	X-ray exam of lower spine	Radiology		0.22	0.07	0.07		
72120	TC	X-ray exam of lower spine	Radiology	a	0.00	0.89	0.89		
72125	26	Ct neck spine w/o dye	Radiology		1.16	0.38	0.38		
72125	TC	Ct neck spine w/o dye	Radiology	a	0.00	5.93	5.93		
72126	26	Ct neck spine w/dye	Radiology		1.22	0.40	0.40		
72126	TC	Ct neck spine w/dye	Radiology	a	0.00	7.09	7.09		
72127	26	Ct neck spine w/o&w/dye	Radiology		1.27	0.42	0.42		
72127	TC	Ct neck spine w/o&w/dye	Radiology	a	0.00	8.88	8.88		
72128	26	Ct chest spine w/o dye	Radiology		1.16	0.38	0.38		
72128	TC	Ct chest spine w/o dye	Radiology	e	0.00	5.93	5.93		
72129	26	Ct chest spine w/dye	Radiology		1.22	0.40	0.40		
72129	TC	Ct chest spine w/dye	Radiology	a	0.00	7.09	7.09		
72130	26	Ct chest spine w/o&w/dye	Radiology		1.27	0.42	0.42		
72130	TC	Ct chest spine w/o&w/dye	Radiology	a	0.00	8.88	8.88		
72131	26	Ct lumbar spine w/o dye	Radiology		1.16	0.38	0.38		
72131	TC	Ct lumbar spine w/o dye	Radiology	a	0.00	5.93	5.93		
72132	26	Ct lumbar spine w/dye	Radiology		1.22	0.40	0.40		
72132	TC	Ct lumbar spine w/dye	Radiology	a	0.00	7.09	7.09		
72133	26	Ct lumbar spine w/o&w/dye	Radiology		1.27	0.42	0.42		
72133	TC	Ct lumbar spine w/o&w/dye	Radiology	a	0.00	8.88	8.88		
72141	26	Mri neck spine w/o dye	Radiology		1.60	0.53	0.53		
72141	TC	Mri neck spine w/o dye	Radiology	a	0.00	11.23	11.23		
72142	26	Mri neck spine w/dye	Radiology		1.92	0.64	0.64		
72142	TC	Mri neck spine w/dye	Radiology	a	0.00	13.48	13.48		
72146	26	Mri chest spine w/o dye	Radiology		1.60	0.53	0.53		
72146	TC	Mri chest spine w/o dye	Radiology	a	0.00	12.48	12.48		
72147	26	Mri chest spine w/dye	Radiology		1.92	0.63	0.63		
72147	TC	Mri chest spine w/dye	Radiology	a	0.00	13.48	13.48		
72148	26	Mri lumbar spine w/o dye	Radiology		1.48	0.49	0.49		
72148	TC	Mri lumbar spine w/o dye	Radiology	a	0.00	12.48	12.48		
72149	26	Mri lumbar spine w/dye	Radiology		1.78	0.60	0.60		
72149	TC	Mri lumbar spine w/dye	Radiology	a	0.00	13.48	13.48		
72156	26	Mri neck spine w/o&w/dye	Radiology		2.57	0.85	0.85		
72156	TC	Mri neck spine w/o&w/dye	Radiology	a	0.00	24.95	24.95		
72157	26	Mri chest spine w/o&w/dye	Radiology		2.57	0.84	0.84		
72157	TC	Mri chest spine w/o&w/dye	Radiology	a	0.00	24.95	24.95		
72158	26	Mri lumbar spine w/o&w/dye	Radiology		2.36	0.78	0.78		
72158	TC	Mri lumbar spine w/o&w/dye	Radiology	e	0.00	24.95	24.95		
72159	26	Mr angio spine w/o&w/dye	Radiology		1.80	0.69	0.69		
72159	TC	Mr angio spine w/o&w/dye	Radiology	a	0.00	12.27	12.27		
72170	26	X-ray exam of pelvis	Radiology		0.17	0.06	0.06		
72170	TC	X-ray exam of pelvis	Radiology	a	0.00	0.52	0.52		
72190	26	X-ray exam of pelvis	Radiology		0.21	0.07	0.07		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE G -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 81 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
72190	TC	X-ray exam of pelvis	Radiology	a	0.00	0.67	0.67		
72191	26	Ct angiograph pelv w/o&w/dye	Radiology		1.81	0.60	0.60		
72191	TC	Ct angiograph pelv w/o&w/dye	Radiology	a	0.00	12.06	12.06		
72192	26	Ct pelvis w/o dye	Radiology		1.09	0.36	0.36		
72192	TC	Ct pelvis w/o dye	Radiology	a	0.00	5.93	5.93		
72193	26	Ct pelvis w/dye	Radiology		1.16	0.38	0.38		
72193	TC	Ct pelvis w/dye	Radiology	a	0.00	6.86	6.86		
72194	26	Ct pelvis w/o&w/dye	Radiology		1.22	0.40	0.40		
72194	TC	Ct pelvis w/o&w/dye	Radiology	a	0.00	8.51	8.51		
72195	26	Mri pelvis w/o dya	Radiology		1.46	0.48	0.48		
72195	TC	Mri pelvis w/o dya	Radiology	a	0.00	11.23	11.23		
72196	26	Mri pelvis w/dye	Radiology		1.73	0.57	0.57		
72196	TC	Mri pelvis w/dye	Radiology	a	0.00	13.48	13.48		
72197	26	Mri pelvis w/o & w/dye	Radiology		2.26	0.74	0.74		
72197	TC	Mri pelvis w/o & w/dye	Radiology	a	0.00	24.95	24.95		
72198	26	Mri angio pelvis w/o&w/dya	Radiology		1.80	0.59	0.59		
72198	TC	Mri angio pelvis w/o&w/dya	Radiology	a	0.00	11.23	11.23		
72200	26	X-ray exam sacroiliac joints	Radiology		0.17	0.06	0.06		
72200	TC	X-ray exam sacroiliac joints	Radiology	a	0.00	0.52	0.52		
72202	26	X-ray exam sacroiliac joints	Radiology		0.19	0.06	0.06		
72202	TC	X-ray exam sacroiliac joints	Radiology	a	0.00	0.62	0.62		
72220	26	X-ray exam of tailbona	Radiology		0.17	0.06	0.06		
72220	TC	X-ray exam of tailbona	Radiology	a	0.00	0.57	0.57		
72240	26	Contrast x-ray of neck spine	Radiology		0.91	0.29	0.29		
72240	TC	Contrast x-ray of neck spine	Radiology	a	0.00	4.76	4.76		
72255	26	Contrast x-ray, thorax spine	Radiology		0.91	0.27	0.27		
72255	TC	Contrast x-ray, thorax spine	Radiology	a	0.00	4.34	4.34		
72265	26	Contrast x-ray, lower spina	Radiology		0.83	0.25	0.25		
72265	TC	Contrast x-ray, lower spine	Radiology	a	0.00	4.08	4.08		
72270	26	Contrast x-ray of spina	Radiology		1.33	0.42	0.42		
72270	TC	Contrast x-ray of spine	Radiology	a	0.00	6.12	6.12		
72275	26	Epidurography	Radiology		0.76	0.20	0.20		
72275	TC	Epidurography	Radiology	a	0.00	2.11	2.11		
72285	26	X-ray ct spine disk	Radiology		1.16	0.36	0.36		
72285	TC	X-ray ct spine disk	Radiology	a	0.00	8.40	8.40		
72295	26	X-ray of lower spine disk	Radiology		0.83	0.27	0.27		
72295	TC	X-ray of lower spine disk	Radiology	a	0.00	7.88	7.88		
73000	26	X-ray exam of collar bone	Radiology		0.16	0.05	0.05		
73000	TC	X-ray exam of collar bone	Radiology	a	0.00	0.52	0.52		
73010	26	X-ray exam of shoulder blade	Radiology		0.17	0.06	0.06		
73010	TC	X-ray exam of shoulder blade	Radiology	a	0.00	0.52	0.52		
73020	26	X-ray exam of shoulder	Radiology		0.15	0.05	0.05		
73020	TC	X-ray exam of shoulder	Radiology	a	0.00	0.47	0.47		
73030	26	X-ray exam of shoulder	Radiology		0.18	0.06	0.06		
73030	TC	X-ray exam of shoulder	Radiology	a	0.00	0.57	0.57		
73040	26	Contrast x-ray of shoulder	Radiology		0.54	0.18	0.18		
73040	TC	Contrast x-ray of shoulder	Radiology	a	0.00	2.11	2.11		
73050	26	X-ray exam of shoulders	Radiology		0.20	0.07	0.07		
73050	TC	X-ray exam of shoulders	Radiology	a	0.00	0.67	0.67		
73060	26	X-ray exam of humerus	Radiology		0.17	0.06	0.06		
73060	TC	X-ray exam of humerus	Radiology	a	0.00	0.57	0.57		
73070	26	X-ray exam of elbow	Radiology		0.15	0.05	0.05		
73070	TC	X-ray exam of elbow	Radiology	a	0.00	0.52	0.52		
73080	26	X-ray exam of elbow	Radiology		0.17	0.06	0.06		
73080	TC	X-ray exam of elbow	Radiology	a	0.00	0.57	0.57		
73085	26	Contrast x-ray of elbow	Radiology		0.54	0.19	0.19		
73085	TC	Contrast x-ray of elbow	Radiology	a	0.00	2.11	2.11		
73090	26	X-ray exam of forearm	Radiology		0.16	0.05	0.05		
73090	TC	X-ray exam of forearm	Radiology	a	0.00	0.52	0.52		
73092	26	X-ray exam of arm, infant	Radiology		0.16	0.05	0.05		
73092	TC	X-ray exam of arm, infant	Radiology	a	0.00	0.49	0.49		
73100	26	X-ray exam of wrist	Radiology		0.16	0.05	0.05		
73100	TC	X-ray exam of wrist	Radiology	a	0.00	0.49	0.49		
73110	26	X-ray exam of wrist	Radiology		0.17	0.06	0.06		
73110	TC	X-ray exam of wrist	Radiology	a	0.00	0.53	0.53		
73115	26	Contrast x-ray of wrist	Radiology		0.54	0.18	0.18		
73115	TC	Contrast x-ray of wrist	Radiology	a	0.00	1.58	1.58		
73120	26	X-ray exam of hand	Radiology		0.16	0.05	0.05		
73120	TC	X-ray exam of hand	Radiology	a	0.00	0.49	0.49		
73130	26	X-ray exam of hand	Radiology		0.17	0.06	0.06		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARSD/FARS apply.
See end of the table for note regarding Charge Methodology

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 82 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
73130	TC	X-ray exam of hand	Radiology	a	0.00	0.53	0.53		
73140	26	X-ray exam of finger(s)	Radiology		0.13	0.04	0.04		
73140	TC	X-ray exam of finger(s)	Radiology	a	0.00	0.42	0.42		
73200	26	Ct upper extremity w/o dye	Radiology		1.09	0.36	0.36		
73200	TC	Ct upper extremity w/o dye	Radiology	a	0.00	4.97	4.97		
73201	26	Ct upper extremity w/dye	Radiology		1.16	0.38	0.38		
73201	TC	Ct upper extremity w/dye	Radiology	a	0.00	5.93	5.93		
73202	26	Ct uppr extremity w/o&w/dye	Radiology		1.22	0.40	0.40		
73202	TC	Ct uppr extremity w/o&w/dye	Radiology	a	0.00	7.44	7.44		
73206	26	Ct angio upr extrm w/o&w/dye	Radiology		1.81	0.59	0.59		
73206	TC	Ct angio upr extrm w/o&w/dye	Radiology	a	0.00	10.99	10.99		
73218	26	Mri upper extremity w/o dye	Radiology		1.35	0.44	0.44		
73218	TC	Mri upper extremity w/o dye	Radiology	a	0.00	11.23	11.23		
73219	26	Mri upper extremity w/dye	Radiology		1.62	0.54	0.54		
73219	TC	Mri upper extremity w/dye	Radiology	a	0.00	13.48	13.48		
73220	26	Mri uppr extremity w/o&w/dye	Radiology		2.15	0.71	0.71		
73220	TC	Mri uppr extremity w/o&w/dye	Radiology	a	0.00	24.95	24.95		
73221	26	Mri joint upr extrem w/o dye	Radiology		1.35	0.44	0.44		
73221	TC	Mri joint upr extrem w/o dye	Radiology	a	0.00	11.23	11.23		
73222	26	Mri joint upr extrem w/dye	Radiology		1.62	0.53	0.53		
73222	TC	Mri joint upr extrem w/dye	Radiology	a	0.00	13.48	13.48		
73223	26	Mri joint upr extr w/o&w/dye	Radiology		2.15	0.71	0.71		
73223	TC	Mri joint upr extr w/o&w/dye	Radiology	a	0.00	24.95	24.95		
73225	26	Mri angio upr extr w/o&w/dye	Radiology		1.73	0.67	0.67		
73225	TC	Mri angio upr extr w/o&w/dye	Radiology	a	0.00	11.04	11.04		
73500	26	X-ray exam of hip	Radiology		0.17	0.06	0.06		
73500	TC	X-ray exam of hip	Radiology	a	0.00	0.47	0.47		
73510	26	X-ray exam of hip	Radiology		0.21	0.07	0.07		
73510	TC	X-ray exam of hip	Radiology	a	0.00	0.57	0.57		
73520	26	X-ray exam of hips	Radiology		0.26	0.09	0.09		
73520	TC	X-ray exam of hips	Radiology	a	0.00	0.67	0.67		
73525	26	Contrast x-ray of hip	Radiology		0.54	0.18	0.18		
73525	TC	Contrast x-ray of hip	Radiology	a	0.00	2.11	2.11		
73530	26	X-ray exam of hip	Radiology		0.29	0.10	0.10		
73530	TC	X-ray exam of hip	Radiology	a	0.00	0.52	0.52		
73540	26	X-ray exam of pelvis & hips	Radiology		0.20	0.07	0.07		
73540	TC	X-ray exam of pelvis & hips	Radiology	a	0.00	0.57	0.57		
73542	26	X-ray exam, sacroiliac joint	Radiology		0.59	0.16	0.16		
73542	TC	X-ray exam, sacroiliac joint	Radiology	a	0.00	2.11	2.11		
73550	26	X-ray exam of thigh	Radiology		0.17	0.06	0.06		
73550	TC	X-ray exam of thigh	Radiology	a	0.00	0.57	0.57		
73560	26	X-ray exam of knee, 1 or 2	Radiology		0.17	0.06	0.06		
73560	TC	X-ray exam of knee, 1 or 2	Radiology	a	0.00	0.52	0.52		
73562	26	X-ray exam of knee, 3	Radiology		0.18	0.06	0.06		
73562	TC	X-ray exam of knee, 3	Radiology	a	0.00	0.57	0.57		
73564	26	X-ray exam, knee, 4 or more	Radiology		0.22	0.07	0.07		
73564	TC	X-ray exam, knee, 4 or more	Radiology	a	0.00	0.62	0.62		
73565	26	X-ray exam of knees	Radiology		0.17	0.06	0.06		
73565	TC	X-ray exam of knees	Radiology	a	0.00	0.49	0.49		
73580	26	Contrast x-ray of knee joint	Radiology		0.54	0.17	0.17		
73580	TC	Contrast x-ray of knee joint	Radiology	a	0.00	2.63	2.63		
73590	26	X-ray exam of lower leg	Radiology		0.17	0.06	0.06		
73590	TC	X-ray exam of lower leg	Radiology	a	0.00	0.52	0.52		
73592	26	X-ray exam of leg, infant	Radiology		0.16	0.05	0.05		
73592	TC	X-ray exam of leg, infant	Radiology	a	0.00	0.49	0.49		
73600	26	X-ray exam of ankle	Radiology		0.16	0.05	0.05		
73600	TC	X-ray exam of ankle	Radiology	a	0.00	0.49	0.49		
73610	26	X-ray exam of ankle	Radiology		0.17	0.06	0.06		
73610	TC	X-ray exam of ankle	Radiology	a	0.00	0.53	0.53		
73615	26	Contrast x-ray of ankle	Radiology		0.54	0.18	0.18		
73615	TC	Contrast x-ray of ankle	Radiology	a	0.00	2.11	2.11		
73620	26	X-ray exam of foot	Radiology		0.16	0.05	0.05		
73620	TC	X-ray exam of foot	Radiology	a	0.00	0.49	0.49		
73630	26	X-ray exam of foot	Radiology		0.17	0.06	0.06		
73630	TC	X-ray exam of foot	Radiology	a	0.00	0.53	0.53		
73650	26	X-ray exam of heel	Radiology		0.16	0.05	0.05		
73650	TC	X-ray exam of heel	Radiology	a	0.00	0.47	0.47		
73660	26	X-ray exam of toe(s)	Radiology		0.13	0.04	0.04		
73660	TC	X-ray exam of toe(s)	Radiology	a	0.00	0.42	0.42		
73700	26	Ct lower extremity w/o dye	Radiology		1.09	0.36	0.36		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARSDFARS apply.
See end of the table for notes regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 83 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
73700	TC	Ct lower extremity w/o dye	Radiology	a	0.00	4.97	4.97		
73701	26	Ct lower extremity w/dye	Radiology		1.16	0.38	0.38		
73701	TC	Ct lower extremity w/dye	Radiology	a	0.00	5.93	5.93		
73702	26	Ct lwr extremity w/o&w/dye	Radiology		1.22	0.40	0.40		
73702	TC	Ct lwr extremity w/o&w/dye	Radiology	a	0.00	7.44	7.44		
73706	26	Ct angio lwr extr w/o&w/dye	Radiology		1.90	0.62	0.62		
73706	TC	Ct angio lwr extr w/o&w/dye	Radiology	a	0.00	10.99	10.99		
73718	26	Mri lower extremity w/o dye	Radiology		1.35	0.44	0.44		
73718	TC	Mri lower extremity w/o dye	Radiology	a	0.00	11.23	11.23		
73719	26	Mri lower extremity w/dye	Radiology		1.62	0.53	0.53		
73719	TC	Mri lower extremity w/dye	Radiology	a	0.00	13.48	13.48		
73720	26	Mri lwr extremity w/o&w/dye	Radiology		2.15	0.70	0.70		
73720	TC	Mri lwr extremity w/o&w/dye	Radiology	a	0.00	24.95	24.95		
73721	26	Mri jint of lwr extre w/o dye	Radiology		1.35	0.44	0.44		
73721	TC	Mri jint of lwr extre w/o dye	Radiology	a	0.00	11.23	11.23		
73722	26	Mri joint of lwr extr w/dye	Radiology		1.62	0.53	0.53		
73722	TC	Mri joint of lwr extr w/dye	Radiology	a	0.00	13.48	13.48		
73723	26	Mri joint lwr extr w/o&w/dye	Radiology		2.15	0.71	0.71		
73723	TC	Mri joint lwr extr w/o&w/dye	Radiology	a	0.00	24.95	24.95		
73725	26	Mri ang lwr ext w or w/o dye	Radiology		1.82	0.60	0.60		
73725	TC	Mri ang lwr ext w or w/o dye	Radiology	a	0.00	11.23	11.23		
74000	26	X-ray exam of abdomen	Radiology		0.18	0.06	0.06		
74000	TC	X-ray exam of abdomen	Radiology	a	0.00	0.52	0.52		
74010	26	X-ray exam of abdomen	Radiology		0.23	0.08	0.08		
74010	TC	X-ray exam of abdomen	Radiology	a	0.00	0.57	0.57		
74020	26	X-ray exam of abdomen	Radiology		0.27	0.09	0.09		
74020	TC	X-ray exam of abdomen	Radiology	a	0.00	0.62	0.62		
74022	26	X-ray exam series, abdomen	Radiology		0.32	0.10	0.10		
74022	TC	X-ray exam series, abdomen	Radiology	a	0.00	0.73	0.73		
74150	26	Ct abdomen w/o dye	Radiology		1.19	0.39	0.39		
74150	TC	Ct abdomen w/o dye	Radiology	a	0.00	5.68	5.68		
74160	26	Ct abdomen w/dye	Radiology		1.27	0.42	0.42		
74160	TC	Ct abdomen w/dye	Radiology	a	0.00	6.86	6.86		
74170	26	Ct abdomen w/o&w/dye	Radiology		1.40	0.46	0.46		
74170	TC	Ct abdomen w/o&w/dye	Radiology	a	0.00	8.51	8.51		
74175	26	Ct angio abdom w/o&w/dye	Radiology		1.90	0.62	0.62		
74175	TC	Ct angio abdom w/o&w/dye	Radiology	a	0.00	12.06	12.06		
74181	26	Mri abdomen w/o dye	Radiology		1.46	0.48	0.48		
74181	TC	Mri abdomen w/o dye	Radiology	a	0.00	11.23	11.23		
74182	26	Mri abdomen w/dye	Radiology		1.73	0.57	0.57		
74182	TC	Mri abdomen w/dye	Radiology	a	0.00	13.48	13.48		
74183	26	Mri abdomen w/o&w/dye	Radiology		2.26	0.74	0.74		
74183	TC	Mri abdomen w/o&w/dye	Radiology	a	0.00	24.95	24.95		
74185	26	Mri angio, abdom w or w/o dy	Radiology		1.80	0.59	0.59		
74185	TC	Mri angio, abdom w or w/o dy	Radiology	a	0.00	11.23	11.23		
74190	26	X-ray exam of peritoneum	Radiology		0.48	0.16	0.16		
74190	TC	X-ray exam of peritoneum	Radiology	a	0.00	1.31	1.31		
74210	26	Contrst x-ray exam of throat	Radiology		0.36	0.12	0.12		
74210	TC	Contrst x-ray exam of throat	Radiology	a	0.00	1.19	1.19		
74220	26	Contrast x-ray, esophagus	Radiology		0.46	0.15	0.15		
74220	TC	Contrast x-ray, esophagus	Radiology	a	0.00	1.19	1.19		
74230	26	Cine/vid x-ray, throat/esoph	Radiology		0.53	0.17	0.17		
74230	TC	Cine/vid x-ray, throat/esoph	Radiology	a	0.00	1.31	1.31		
74235	26	Remove esophagus obstruction	Radiology		1.19	0.39	0.39		
74240	26	X-ray exam, upper gi tract	Radiology		0.69	0.23	0.23		
74240	TC	X-ray exam, upper gi tract	Radiology	a	0.00	1.46	1.46		
74241	26	X-ray exam, upper gi tract	Radiology		0.69	0.23	0.23		
74241	TC	X-ray exam, upper gi tract	Radiology	a	0.00	1.49	1.49		
74245	26	X-ray exam, upper gi tract	Radiology		0.91	0.30	0.30		
74245	TC	X-ray exam, upper gi tract	Radiology	a	0.00	2.39	2.39		
74246	26	Contrst x-ray uppr gi tract	Radiology		0.69	0.23	0.23		
74246	TC	Contrst x-ray uppr gi tract	Radiology	a	0.00	1.64	1.64		
74247	26	Contrst x-ray uppr gi tract	Radiology		0.69	0.23	0.23		
74247	TC	Contrst x-ray uppr gi tract	Radiology	a	0.00	1.68	1.68		
74249	26	Contrst x-ray uppr gi tract	Radiology		0.91	0.30	0.30		
74249	TC	Contrst x-ray uppr gi tract	Radiology	- a	0.00	2.58	2.58		
74250	26	X-ray exam of small bowel	Radiology		0.47	0.15	0.15		
74250	TC	X-ray exam of small bowel	Radiology	a	0.00	1.31	1.31		
74251	26	X-ray exam of small bowel	Radiology		0.69	0.23	0.23		
74251	TC	X-ray exam of small bowel	Radiology	a	0.00	1.31	1.31		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPSC CODE

PAGE 84 of 119

CPT/ HCPSC Code	Modifier	CPT/HCPSC Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
74260	26	X-ray exam of small bowel	Radiology		0.50	0.16	0.16		
74260	TC	X-ray exam of small bowel,	Radiology	a	0.00	1.49	1.49		
74270	26	Contrast x-ray exam of colon	Radiology		0.69	0.23	0.23		
74270	TC	Contrast x-ray exam of colon	Radiology	a	0.00	1.70	1.70		
74280	26	Contrast x-ray exam of colon	Radiology		0.99	0.32	0.32		
74280	TC	Contrast x-ray exam of colon	Radiology	a	0.00	2.24	2.24		
74283	26	Contrast x-ray exam of colon	Radiology		2.02	0.66	0.66		
74283	TC	Contrast x-ray exam of colon	Radiology	a	0.00	2.57	2.57		
74290	26	Contrast x-ray, gallbladder	Radiology		0.32	0.10	0.10		
74290	TC	Contrast x-ray, gallbladder	Radiology	a	0.00	0.73	0.73		
74291	26	Contrast x-rays, gallbladder	Radiology		0.20	0.07	0.07		
74291	TC	Contrast x-rays, gallbladder	Radiology	a	0.00	0.42	0.42		
74300	26	X-ray bile ducts/pancreas	Radiology		0.36	0.12	0.12		
74300	TC	X-ray bile ducts/pancreas	Radiology	a				1.20	
74301	26	X-rays at surgery add-on	Radiology		0.21	0.07	0.07		
74301	TC	X-rays at surgery add-on	Radiology	a				0.69	
74305	26	X-ray bile ducts/pancreas	Radiology		0.42	0.14	0.14		
74305	TC	X-ray bile ducts/pancreas	Radiology	a	0.00	0.78	0.78		
74320	26	Contrast x-ray of bile ducts	Radiology		0.54	0.18	0.18		
74320	TC	Contrast x-ray of bile ducts	Radiology	a	0.00	3.16	3.16		
74327	26	X-ray bile stone removal	Radiology		0.70	0.23	0.23		
74327	TC	X-ray bile stone removal	Radiology	a	0.00	1.77	1.77		
74328	26	X-ray bile duct endoscopy	Radiology		0.70	0.23	0.23		
74328	TC	X-ray bile duct endoscopy	Radiology	a	0.00	3.16	3.16		
74329	26	X-ray for pancreas endoscopy	Radiology		0.70	0.23	0.23		
74330	26	X-ray bile/panc endoscopy	Radiology		0.90	0.29	0.29		
74330	TC	X-ray bile/panc endoscopy	Radiology	a	0.00	3.16	3.16		
74340	26	X-ray guide for GI tube	Radiology		0.54	0.18	0.18		
74340	TC	X-ray guide for GI tube	Radiology	a	0.00	2.63	2.63		
74350	26	X-ray guide, stomach tube	Radiology		0.76	0.25	0.25		
74350	TC	X-ray guide, stomach tube	Radiology	a	0.00	3.16	3.16		
74355	26	X-ray guide, intestinal tube	Radiology		0.76	0.25	0.25		
74355	TC	X-ray guide, intestinal tube	Radiology	a	0.00	2.63	2.63		
74360	26	X-ray guide, GI dilation	Radiology		0.54	0.19	0.19		
74360	TC	X-ray guide, GI dilation	Radiology	a	0.00	3.16	3.16		
74363	26	X-ray, bile duct dilation	Radiology		0.88	0.29	0.29		
74400	26	Contrst x-ray, urinary tract	Radiology		0.49	0.16	0.16		
74400	TC	Contrst x-ray, urinary tract	Radiology	a	0.00	1.68	1.68		
74410	26	Contrst x-ray, urinary tract	Radiology		0.49	0.16	0.16		
74410	TC	Contrst x-ray, urinary tract	Radiology	a	0.00	1.96	1.96		
74415	26	Contrst x-ray, urinary tract	Radiology		0.49	0.16	0.16		
74415	TC	Contrst x-ray, urinary tract	Radiology	a	0.00	2.13	2.13		
74420	26	Contrst x-ray, urinary tract	Radiology		0.36	0.12	0.12		
74420	TC	Contrst x-ray, urinary tract	Radiology	a	0.00	2.63	2.63		
74425	26	Contrst x-ray, urinary tract	Radiology		0.36	0.12	0.12		
74425	TC	Contrst x-ray, urinary tract	Radiology	a	0.00	1.31	1.31		
74430	26	Contrast x-ray, bladder	Radiology		0.32	0.10	0.10		
74430	TC	Contrast x-ray, bladder	Radiology	a	0.00	1.05	1.05		
74440	26	X-ray, male genital tract	Radiology		0.38	0.12	0.12		
74440	TC	X-ray, male genital tract	Radiology	a	0.00	1.13	1.13		
74445	26	X-ray exam of penis	Radiology		1.14	0.37	0.37		
74445	TC	X-ray exam of penis	Radiology	a	0.00	1.13	1.13		
74450	26	X-ray, urethra/bladder	Radiology		0.33	0.11	0.11		
74450	TC	X-ray, urethra/bladder	Radiology	a	0.00	1.46	1.46		
74455	26	X-ray, urethra/bladder	Radiology		0.33	0.11	0.11		
74455	TC	X-ray, urethra/bladder	Radiology	a	0.00	1.58	1.58		
74470	26	X-ray exam of kidney lesion	Radiology		0.54	0.18	0.18		
74470	TC	X-ray exam of kidney lesion	Radiology	a	0.00	1.25	1.25		
74475	26	X-ray control, cath insert	Radiology		0.54	0.18	0.18		
74475	TC	X-ray control, cath insert	Radiology	a	0.00	4.08	4.08		
74480	26	X-ray control, cath insert	Radiology		0.54	0.18	0.18		
74480	TC	X-ray control, cath insert	Radiology	a	0.00	4.08	4.08		
74485	26	X-ray guide, GU dilation	Radiology		0.54	0.17	0.17		
74485	TC	X-ray guide, GU dilation	Radiology	a	0.00	3.16	3.16		
74710	26	X-ray measurement of pelvis	Radiology		0.34	0.11	0.11		
74710	TC	X-ray measurement of pelvis	Radiology	a	0.00	1.05	1.05		
74740	26	X-ray, female genital tract	Radiology		0.38	0.13	0.13		
74740	TC	X-ray, female genital tract	Radiology	a	0.00	1.31	1.31		
74742	26	X-ray, fallopian tube	Radiology		0.61	0.20	0.20		
74775	26	X-ray exam of perineum	Radiology		0.62	0.21	0.21		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 85 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
74775	TC	X-ray exam of perineum	Radiology	a	0.00	1.46	1.46		
75552	26	Heart mri for morph w/o dye	Radiology		1.60	0.53	0.53		
75552	TC	Heart mri for morph w/o dye	Radiology	a	0.00	11.23	11.23		
75553	26	Heart mri for morph w/dye	Radiology		2.00	0.65	0.65		
75553	TC	Heart mri for morph w/dye	Radiology	a	0.00	11.23	11.23		
75554	26	Cardiac MRI/function	Radiology		1.83	0.64	0.64		
75554	TC	Cardiac MRI/function	Radiology	a	0.00	11.23	11.23		
75555	26	Cardiac MRI/limited study	Radiology		1.74	0.64	0.64		
75555	TC	Cardiac MRI/limited study	Radiology	a	0.00	11.23	11.23		
75556		Cardiac MRI/low mapping	Radiology					12.37	
75600	26	Contrast x-ray exam of aorta	Radiology		0.49	0.19	0.19		
75600	TC	Contrast x-ray exam of aorta	Radiology	a	0.00	12.64	12.64		
75605	26	Contrast x-ray exam of aorta	Radiology		1.14	0.40	0.40		
75605	TC	Contrast x-ray exam of aorta	Radiology	a	0.00	12.64	12.64		
75625	26	Contrast x-ray exam of aorta	Radiology		1.14	0.38	0.38		
75625	TC	Contrast x-ray exam of aorta	Radiology	a	0.00	12.64	12.64		
75630	26	X-ray aorta, leg arteries	Radiology		1.79	0.61	0.61		
75630	TC	X-ray aorta, leg arteries	Radiology	a	0.00	13.17	13.17		
75635	26	Ct angio abdominal arteries	Radiology		2.40	0.79	0.79		
75635	TC	Ct angio abdominal arteries	Radiology	a	0.00	15.96	15.96		
75650	26	Artery x-rays, head & neck	Radiology		1.49	0.49	0.49		
75650	TC	Artery x-rays, head & neck	Radiology	a	0.00	12.64	12.64		
75658	26	Artery x-rays, arm	Radiology		1.31	0.47	0.47		
75658	TC	Artery x-rays, arm	Radiology	a	0.00	12.64	12.64		
75660	26	Artery x-rays, head & neck	Radiology		1.31	0.44	0.44		
75660	TC	Artery x-rays, head & neck	Radiology	a	0.00	12.64	12.64		
75662	26	Artery x-rays, head & neck	Radiology		1.66	0.59	0.59		
75662	TC	Artery x-rays, head & neck	Radiology	a	0.00	12.64	12.64		
75665	26	Artery x-rays, head & neck	Radiology		1.31	0.44	0.44		
75665	TC	Artery x-rays, head & neck	Radiology	a	0.00	12.64	12.64		
75671	26	Artery x-rays, head & neck	Radiology		1.66	0.55	0.55		
75671	TC	Artery x-rays, head & neck	Radiology	a	0.00	12.64	12.64		
75676	26	Artery x-rays, neck	Radiology		1.31	0.44	0.44		
75676	TC	Artery x-rays, neck	Radiology	a	0.00	12.64	12.64		
75680	26	Artery x-rays, neck	Radiology		1.66	0.55	0.55		
75680	TC	Artery x-rays, neck	Radiology	a	0.00	12.64	12.64		
75685	26	Artery x-rays, spine	Radiology		1.31	0.43	0.43		
75685	TC	Artery x-rays, spine	Radiology	a	0.00	12.64	12.64		
75705	26	Artery x-rays, spine	Radiology		2.18	0.73	0.73		
75705	TC	Artery x-rays, spine	Radiology	a	0.00	12.64	12.64		
75710	26	Artery x-rays, arm/leg	Radiology		1.14	0.39	0.39		
75710	TC	Artery x-rays, arm/leg	Radiology	a	0.00	12.64	12.64		
75716	26	Artery x-rays, arms/legs	Radiology		1.31	0.43	0.43		
75716	TC	Artery x-rays, arms/legs	Radiology	a	0.00	12.64	12.64		
75722	26	Artery x-rays, kidney	Radiology		1.14	0.40	0.40		
75722	TC	Artery x-rays, kidney	Radiology	a	0.00	12.64	12.64		
75724	26	Artery x-rays, kidneys	Radiology		1.49	0.56	0.56		
75724	TC	Artery x-rays, kidneys	Radiology	a	0.00	12.64	12.64		
75726	26	Artery x-rays, abdomen	Radiology		1.14	0.37	0.37		
75726	TC	Artery x-rays, abdomen	Radiology	a	0.00	12.64	12.64		
75731	26	Artery x-rays, adrenal gland	Radiology		1.14	0.37	0.37		
75731	TC	Artery x-rays, adrenal gland	Radiology	a	0.00	12.64	12.64		
75733	26	Artery x-rays, adrenals	Radiology		1.31	0.44	0.44		
75733	TC	Artery x-rays, adrenals	Radiology	a	0.00	12.64	12.64		
75736	26	Artery x-rays, pelvis	Radiology		1.14	0.38	0.38		
75736	TC	Artery x-rays, pelvis	Radiology	a	0.00	12.64	12.64		
75741	26	Artery x-rays, lung	Radiology		1.31	0.43	0.43		
75741	TC	Artery x-rays, lung	Radiology	a	0.00	12.64	12.64		
75743	26	Artery x-rays, lungs	Radiology		1.66	0.54	0.54		
75743	TC	Artery x-rays, lungs	Radiology	a	0.00	12.64	12.64		
75746	26	Artery x-rays, lung	Radiology		1.14	0.38	0.38		
75746	TC	Artery x-rays, lung	Radiology	a	0.00	12.64	12.64		
75756	26	Artery x-rays, chest	Radiology		1.14	0.45	0.45		
75756	TC	Artery x-rays, chest	Radiology	a	0.00	12.64	12.64		
75774	26	Artery x-ray, each vessel	Radiology		0.36	0.12	0.12		
75774	TC	Artery x-ray, each vessel	Radiology	a	0.00	12.64	12.64		
75790	26	Visualize A-V shunt	Radiology		1.84	0.60	0.60		
75790	TC	Visualize A-V shunt	Radiology	a	0.00	1.35	1.35		
75801	26	Lymph vessel x-ray, arm/leg	Radiology		0.81	0.27	0.27		
75801	TC	Lymph vessel x-ray, arm/leg	Radiology	a	0.00	5.43	5.43		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 86 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
75803	26	Lymph vessel x-ray, arms/legs	Radiology		1.17	0.38	0.38		
75803	TC	Lymph vessel x-ray, arms/legs	Radiology	a	0.00	5.43	5.43		
75805	26	Lymph vessel x-ray, trunk	Radiology		0.81	0.27	0.27		
75805	TC	Lymph vessel x-ray, trunk	Radiology	a	0.00	6.12	6.12		
75807	26	Lymph vessel x-ray, trunk	Radiology		1.17	0.38	0.38		
75809	26	Nonvascular shunt, x-ray	Radiology		0.47	0.15	0.15		
75809	TC	Nonvascular shunt, x-ray	Radiology	a	0.00	0.78	0.78		
75810	26	Vein x-ray, spleen/liver	Radiology		1.14	0.37	0.37		
75810	TC	Vein x-ray, spleen/liver	Radiology	a	0.00	12.64	12.64		
75820	26	Vein x-ray, arm/leg	Radiology		0.70	0.23	0.23		
75820	TC	Vein x-ray, arm/leg	Radiology	a	0.00	0.95	0.95		
75822	26	Vein x-ray, arms/legs	Radiology		1.06	0.35	0.35		
75822	TC	Vein x-ray, arms/legs	Radiology	a	0.00	1.48	1.48		
75825	26	Vein x-ray, trunk	Radiology		1.14	0.37	0.37		
75825	TC	Vein x-ray, trunk	Radiology	a	0.00	12.64	12.64		
75827	26	Vein x-ray, chest	Radiology		1.14	0.37	0.37		
75827	TC	Vein x-ray, chest	Radiology	a	0.00	12.64	12.64		
75831	26	Vein x-ray, kidney	Radiology		1.14	0.37	0.37		
75831	TC	Vein x-ray, kidney	Radiology	a	0.00	12.64	12.64		
75833	26	Vein x-ray, kidneys	Radiology		1.49	0.49	0.49		
75833	TC	Vein x-ray, kidneys	Radiology	a	0.00	12.64	12.64		
75840	26	Vein x-ray, adrenal gland	Radiology		1.14	0.38	0.38		
75840	TC	Vein x-ray, adrenal gland	Radiology	a	0.00	12.64	12.64		
75842	26	Vein x-ray, adrenal glands	Radiology		1.49	0.48	0.48		
75842	TC	Vein x-ray, adrenal glands	Radiology	a	0.00	12.64	12.64		
75860	26	Vein x-ray, neck	Radiology		1.14	0.39	0.39		
75860	TC	Vein x-ray, neck	Radiology	a	0.00	12.64	12.64		
75870	26	Vein x-ray, skull	Radiology		1.14	0.39	0.39		
75870	TC	Vein x-ray, skull	Radiology	a	0.00	12.64	12.64		
75872	26	Vein x-ray, skull	Radiology		1.14	0.37	0.37		
75872	TC	Vein x-ray, skull	Radiology	a	0.00	12.64	12.64		
75880	26	Vein x-ray, eye socket	Radiology		0.70	0.23	0.23		
75880	TC	Vein x-ray, eye socket	Radiology	a	0.00	0.95	0.95		
75885	26	Vein x-ray, liver	Radiology		1.44	0.47	0.47		
75885	TC	Vein x-ray, liver	Radiology	a	0.00	12.64	12.64		
75887	26	Vein x-ray, liver	Radiology		1.44	0.47	0.47		
75887	TC	Vein x-ray, liver	Radiology	a	0.00	12.64	12.64		
75889	26	Vein x-ray, liver	Radiology		1.14	0.37	0.37		
75889	TC	Vein x-ray, liver	Radiology	a	0.00	12.64	12.64		
75891	26	Vein x-ray, liver	Radiology		1.14	0.37	0.37		
75891	TC	Vein x-ray, liver	Radiology	a	0.00	12.64	12.64		
75893	26	Venous sampling by catheter	Radiology		0.54	0.18	0.18		
75893	TC	Venous sampling by catheter	Radiology	a	0.00	12.64	12.64		
75894	26	X-rays, transcath therapy	Radiology		1.31	0.43	0.43		
75894	TC	X-rays, transcath therapy	Radiology	a	0.00	24.20	24.20		
75896	26	X-rays, transcath therapy	Radiology		1.31	0.45	0.45		
75896	TC	X-rays, transcath therapy	Radiology	a	0.00	21.05	21.05		
75898	26	Follow-up angiography	Radiology		1.65	0.55	0.55		
75898	TC	Follow-up angiography	Radiology	a	0.00	1.05	1.05		
75900	26	Arterial catheter exchange	Radiology		0.49	0.16	0.16		
75901	26	Remove cva device obstruct	Radiology		0.49	0.16	0.16		
75901	TC	Remove cva device obstruct	Radiology	a	0.00	1.31	1.31		
75902	26	Remove cva lumen obstruct	Radiology		0.39	0.13	0.13		
75902	TC	Remove cva lumen obstruct	Radiology	a	0.00	1.31	1.31		
75940	26	X-ray placement, vein filter	Radiology		0.54	0.18	0.18		
75940	TC	X-ray placement, vein filter	Radiology	a	0.00	12.64	12.64		
75945	26	Intravascular us	Radiology		0.40	0.14	0.14		
75945	TC	Intravascular us	Radiology	a	0.00	4.57	4.57		
75946	26	Intravascular us adq-on	Radiology		0.40	0.14	0.14		
75946	TC	Intravascular us adq-on	Radiology	a	4.49	1.49	1.49		
75952	26	Endovasc repair abdom aorta	Radiology					23.49	
75952	TC	Endovasc repair abdom aorta	Radiology	a					
75953	26	Abdom aneurysm endovas rpr	Radiology		1.36	0.45	0.45		
75953	TC	Abdom aneurysm endovas rpr	Radiology	a				21.33	
75954	26	Iliac aneurysm endovas rpr	Radiology		2.25	0.78	0.78		
75954	TC	Iliac aneurysm endovas rpr	Radiology	a				23.49	
75960	26	Transcatheter intro, stent	Radiology		0.82	0.28	0.28		
75960	TC	Transcatheter intro, stent	Radiology	a	0.00	14.94	14.94		
75961	26	Retrieval, broken catheter	Radiology		4.24	1.39	1.39		
75961	TC	Retrieval, broken catheter	Radiology	a	0.00	10.53	10.53		
75962	26	Repair arterial blockage	Radiology		0.54	0.18	0.18		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 87 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
75962	TC	Repair arterial blockage	Radiology	a	0.00	15.79	15.79		
75964	26	Repair artery blockage, each	Radiology		0.36	0.12	0.12		
75964	TC	Repair artery blockage, each	Radiology	a	0.00	8.41	8.41		
75966	26	Repair arterial blockage	Radiology		1.31	0.46	0.46		
75966	TC	Repair arterial blockage	Radiology	a	0.00	15.79	15.79		
75968	26	Repair artery blockage, each	Radiology		0.36	0.13	0.13		
75968	TC	Repair artery blockage, each	Radiology	a	0.00	8.41	8.41		
75970	26	Vascular biopsy	Radiology		0.83	0.28	0.28		
75970	TC	Vascular biopsy	Radiology	a	0.00	11.57	11.57		
75978	26	Repair venous blockage	Radiology		0.54	0.18	0.18		
75978	TC	Repair venous blockage	Radiology	a	0.00	15.79	15.79		
75980	26	Contrast xray exam bile duct	Radiology		1.44	0.47	0.47		
75980	TC	Contrast xray exam bile duct	Radiology	a	0.00	5.43	5.43		
75982	26	Contrast xray exam bile duct	Radiology		1.44	0.47	0.47		
75984	26	Xray control catheter change	Radiology		0.72	0.23	0.23		
75984	TC	Xray control catheter change	Radiology	a	0.00	1.96	1.96		
75989	26	Abscess drainage under x-ray	Radiology		1.19	0.39	0.39		
75989	TC	Abscess drainage under x-ray	Radiology	a	0.00	3.16	3.16		
75992	26	Atherectomy, x-ray exam	Radiology		0.54	0.19	0.19		
75992	TC	Atherectomy, x-ray exam	Radiology	a	0.00	15.79	15.79		
75993	26	Atherectomy, x-ray exam	Radiology		0.36	0.13	0.13		
75994	26	Atherectomy, x-ray exam	Radiology		1.31	0.46	0.46		
75995	26	Atherectomy, x-ray exam	Radiology		1.31	0.47	0.47		
75996	26	Atherectomy, x-ray exam	Radiology		0.36	0.12	0.12		
75998	26	Fluoroguide for vein device	Radiology		0.38	0.13	0.13		
75998	TC	Fluoroguide for vein device	Radiology	a	0.00	1.31	1.31		
76000	26	Fluoroscope examination	Radiology		0.17	0.05	0.05		
76000	TC	Fluoroscope examination	Radiology	a	0.00	1.31	1.31		
76001	26	Fluoroscope exam, extensive	Radiology		0.67	0.22	0.22		
76001	TC	Fluoroscope exam, extensive	Radiology	a	0.00	2.63	2.63		
76003	26	Needle localization by x-ray	Radiology		0.54	0.17	0.17		
76003	TC	Needle localization by x-ray	Radiology	a	0.00	1.31	1.31		
76005	26	Fluoroguide for spine inject	Radiology		0.60	0.15	0.15		
76005	TC	Fluoroguide for spine inject	Radiology	a	0.00	1.31	1.31		
76006		X-ray stress view	Radiology		0.41	0.18	0.18		
76010	26	X-ray, nose to rectum	Radiology		0.18	0.06	0.06		
76010	TC	X-ray, nose to rectum	Radiology	a	0.00	0.52	0.52		
76012	26	Percut vertebroplasty fluor	Radiology		1.31	0.47	0.47	5.38	
76012	TC	Percut vertebroplasty fluor	Radiology	a					
76013	26	Percut vertebroplasty, ct	Radiology		1.38	0.48	0.48		
76013	TC	Percut vertebroplasty, ct	Radiology	a				7.77	
76020	26	X-rays for bone age	Radiology		0.19	0.06	0.06		
76020	TC	X-rays for bone age	Radiology	a	0.00	0.52	0.52		
76040	26	X-rays, bone evaluation	Radiology		0.27	0.09	0.09		
76040	TC	X-rays, bone evaluation	Radiology	a	0.00	0.78	0.78		
76061	26	X-rays, bone survey	Radiology		0.45	0.15	0.15		
76061	TC	X-rays, bone survey	Radiology	a	0.00	1.00	1.00		
76062	26	X-rays, bone survey	Radiology		0.54	0.18	0.18		
76062	TC	X-rays, bone survey	Radiology	a	0.00	1.44	1.44		
76065	26	X-rays, bone evaluation	Radiology		0.70	0.23	0.23		
76065	TC	X-rays, bone evaluation	Radiology	a	0.00	0.73	0.73		
76066	26	Joint survey, single view	Radiology		0.31	0.10	0.10		
76066	TC	Joint survey, single view	Radiology	a	0.00	1.11	1.11		
76070	26	Ct bone density, axial	Radiology		0.25	0.08	0.08		
76070	TC	Ct bone density, axial	Radiology	a	0.00	2.96	2.96		
76071	26	Ct bone density, peripheral	Radiology		0.22	0.07	0.07		
76071	TC	Ct bone density, peripheral	Radiology	a	0.00	2.96	2.96		
76075	26	Dexa, axial skeleton study	Radiology		0.30	0.10	0.10		
76075	TC	Dexa, axial skeleton study	Radiology	a	0.00	3.10	3.10		
76076	26	Dexa, peripheral study	Radiology		0.22	0.08	0.08		
76076	TC	Dexa, peripheral study	Radiology	a	0.00	0.75	0.75		
76077	26	Dxa bone density/v-fracture	Radiology		0.17	0.06	0.06		
76077	TC	Dxa bone density/v-fracture	Radiology	a	0.00	0.75	0.75		
76078	26	Radiographic absorptiometry	Radiology		0.23	0.07	0.07		
76078	TC	Radiographic absorptiometry	Radiology	a	0.00	0.75	0.75		
76080	26	X-ray exam of fistula	Radiology		0.54	0.18	0.18		
76080	TC	X-ray exam of fistula	Radiology	a	0.00	1.05	1.05		
76082	26	Computer mammogram add-on	Radiology		0.06	0.02	0.02		
76082	TC	Computer mammogram add-on	Radiology	a	0.00	0.42	0.42		
76083	26	Computer mammogram add-on	Radiology		0.06	0.02	0.02		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 88 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
76083	TC	Computer mammogram add-on	Radiology	a	0.00	0.42	0.42		
76086	26	X-ray of mammary duct	Radiology		0.36	0.12	0.12		
76086	TC	X-ray of mammary duct	Radiology	a	0.00	2.63	2.63		
76088	26	X-ray of mammary ducts	Radiology		0.45	0.15	0.15		
76088	TC	X-ray of mammary ducts	Radiology	a	0.00	3.67	3.67		
76090	26	Mammogram, one breast	Radiology		0.70	0.23	0.23		
76090	TC	Mammogram, one breast	Radiology	a	0.00	1.05	1.05		
76091	26	Mammogram, both breasts	Radiology		0.87	0.28	0.28		
76091	TC	Mammogram, both breasts	Radiology	a	0.00	1.31	1.31		
76092	26	Mammogram, screening	Radiology		0.70	0.23	0.23		
76092	TC	Mammogram, screening	Radiology	a	0.00	1.23	1.23		
76093	26	Magnetic image, breast	Radiology		1.63	0.53	0.53		
76093	TC	Magnetic image, breast	Radiology	a	0.00	17.67	17.67		
76094	26	Magnetic image, both breasts	Radiology		1.63	0.53	0.53		
76094	TC	Magnetic image, both breasts	Radiology	a	0.00	23.98	23.98		
76095	26	Stereotactic breast biopsy	Radiology		1.59	0.52	0.52		
76095	TC	Stereotactic breast biopsy	Radiology	a	0.00	7.18	7.18		
76096	26	X-ray of needle wire, breast	Radiology		0.56	0.18	0.18		
76096	TC	X-ray of needle wire, breast	Radiology	a	0.00	1.31	1.31		
76098	26	X-ray exam, breast specimen	Radiology		0.16	0.05	0.05		
76098	TC	X-ray exam, breast specimen	Radiology	a	0.00	0.42	0.42		
76100	26	X-ray exam of body section	Radiology		0.58	0.19	0.19		
76100	TC	X-ray exam of body section	Radiology	a	0.00	1.25	1.25		
76101	26	Complex body section x-ray	Radiology		0.58	0.19	0.19		
76101	TC	Complex body section x-ray	Radiology	a	0.00	1.42	1.42		
76102	26	Complex body section x-rays	Radiology		0.58	0.19	0.19		
76102	TC	Complex body section x-rays	Radiology	a	0.00	1.74	1.74		
76120	26	Cine/video x-rays	Radiology		0.38	0.13	0.13		
76120	TC	Cine/video x-rays	Radiology	a	0.00	1.05	1.05		
76125	26	Cine/video x-rays add-on	Radiology		0.27	0.09	0.09		
76125	TC	Cine/video x-rays add-on	Radiology	a	0.00	0.78	0.78		
76140		X-ray consultation	Radiology					0.69	
76150		X-ray exam, dry process	Radiology	a	0.00	0.42	0.42		
76350	26	Special x-ray contrast study	Radiology					0.27	
76350	TC	Special x-ray contrast study	Radiology	a				1.10	
76355	26	CAT scan for localization	Radiology		1.21	0.40	0.40		
76355	TC	CAT scan for localization	Radiology	a	0.00	8.28	8.28		
76360	26	CAT scan for needle biopsy	Radiology		1.16	0.38	0.38		
76360	TC	CAT scan for needle biopsy	Radiology	a	0.00	8.28	8.28		
76362	26	Cat scan for tissue ablation	Radiology		3.99	1.30	1.30		
76362	TC	Cat scan for tissue ablation	Radiology	a	0.00	8.28	8.28		
76370	26	CAT scan for therapy guide	Radiology		0.85	0.28	0.28		
76370	TC	CAT scan for therapy guide	Radiology	a	0.00	2.96	2.96		
76376	26	3d render w/o postprocess	Radiology		0.20	0.07	0.07		RBRVS
76376	TC	3d render w/o postprocess	Radiology	a	0.00	3.43	3.43		RBRVS
76377	26	3d rendering w/postprocess	Radiology		0.79	0.27	0.27		RBRVS
76377	TC	3d rendering w/postprocess	Radiology	a	0.00	3.43	3.43		RBRVS
76380	26	CAT scan follow-up study	Radiology		0.98	0.32	0.32		
76380	TC	CAT scan follow-up study	Radiology	a	0.00	3.51	3.51		
76390	26	Mr spectroscopy	Radiology		1.40	0.47	0.47		
76390	TC	Mr spectroscopy	Radiology	a	0.00	11.04	11.04		
76393	26	Mr guidance for needle place	Radiology		1.50	0.50	0.50		
76393	TC	Mr guidance for needle place	Radiology	a	0.00	11.23	11.23		
76394	26	Mri for tissue ablation	Radiology		4.24	1.38	1.38		
76394	TC	Mri for tissue ablation	Radiology	a	0.00	11.23	11.23		
76400	26	Magnetic image, bone marrow	Radiology		1.60	0.52	0.52		
76400	TC	Magnetic image, bone marrow	Radiology	a	0.00	11.23	11.23		
76496		Fluoroscopic procedure	Radiology					1.53	
76497		Ct procedure	Radiology					7.50	
76498		Mri procedure	Radiology					13.37	
76499		Radiographic procedure	Radiology					0.91	
76506	26	Echo exam of head	Radiology		0.63	0.24	0.24		
76506	TC	Echo exam of head	Radiology	a	0.00	1.42	1.42		
76510	26	Ophth us, b & quant a	Radiology		1.55	0.58	0.58		
76510	TC	Ophth us, b & quant a	Radiology	a	0.00	2.19	2.19		
76511	26	Echo exam of eye	Radiology		0.94	0.40	0.40		
76511	TC	Echo exam of eye	Radiology	a	0.00	2.04	2.04		
76512	26	Echo exam of eye	Radiology		0.94	0.42	0.42		
76512	TC	Echo exam of eye	Radiology	a	0.00	1.82	1.82		
76513	26	Echo exam of eye, water bath	Radiology		0.66	0.29	0.29		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 89 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
76513	TC	Echo exam of eye, water bath	Radiology	a	0.00	1.52	1.52		
76514	26	Echo exam of eye, thickness	Radiology		0.17	0.08	0.08		
76514	TC	Echo exam of eye, thickness	Radiology	a	0.00	0.05	0.05		
76516	26	Echo exam of eye	Radiology		0.54	0.24	0.24		
76516	TC	Echo exam of eye	Radiology	a	0.00	1.22	1.22		
76519	26	Echo exam of eye	Radiology		0.54	0.24	0.24		
76519	TC	Echo exam of eye	Radiology	a	0.00	1.31	1.31		
76529	26	Echo exam of eye	Radiology		0.57	0.24	0.24		
76529	TC	Echo exam of eye	Radiology	a	0.00	1.13	1.13		
76536	26	Us exam of head and neck	Radiology		0.56	0.18	0.18		
76536	TC	Us exam of head and neck	Radiology	a	0.00	1.42	1.42		
76604	26	Us exam, chest, b-scan	Radiology		0.55	0.18	0.18		
76604	TC	Us exam, chest, b-scan	Radiology	a	0.00	1.31	1.31		
76645	26	Us exam, breast(s)	Radiology		0.54	0.18	0.18		
76645	TC	Us exam, breast(s)	Radiology	a	0.00	1.05	1.05		
76700	26	Us exam, abdom, complete	Radiology		0.81	0.27	0.27		
76700	TC	Us exam, abdom, complete	Radiology	a	0.00	1.98	1.98		
76705	26	Echo exam of abdomen	Radiology		0.59	0.19	0.19		
76705	TC	Echo exam of abdomen	Radiology	a	0.00	1.42	1.42		
76770	26	Us exam abdo back wall, comp	Radiology		0.74	0.24	0.24		
76770	TC	Us exam abdo back wall, comp	Radiology	a	0.00	1.98	1.98		
76775	26	Us exam abdo back wall, lim	Radiology		0.58	0.19	0.19		
76775	TC	Us exam abdo back wall, lim	Radiology	a	0.00	1.42	1.42		
76778	26	Us exam kidney transplant	Radiology		0.74	0.24	0.24		
76778	TC	Us exam kidney transplant	Radiology	a	0.00	1.98	1.98		
76800	26	Us exam, spinal canal	Radiology		1.13	0.34	0.34		
76800	TC	Us exam, spinal canal	Radiology	a	0.00	1.42	1.42		
76801	26	Ob us < 14 wks, single fetus	Radiology		0.99	0.34	0.34		
76801	TC	Ob us < 14 wks, single fetus	Radiology	a	0.00	2.11	2.11		
76802	26	Ob us < 14 wks, addl fetus	Radiology		0.83	0.29	0.29		
76802	TC	Ob us < 14 wks, addl fetus	Radiology	a	0.00	1.05	1.05		
76805	26	Ob us >= 14 wks, snql fetus	Radiology		0.99	0.34	0.34		
76805	TC	Ob us >= 14 wks, snql fetus	Radiology	a	0.00	2.11	2.11		
76810	26	Ob us >= 14 wks, addl fetus	Radiology		0.98	0.34	0.34		
76810	TC	Ob us >= 14 wks, addl fetus	Radiology	a	0.00	1.05	1.05		
76811	26	Ob us, detailed, snql fetus	Radiology		1.90	0.71	0.71		
76811	TC	Ob us, detailed, snql fetus	Radiology	a	0.00	3.54	3.54		
76812	26	Ob us, detailed, addl fetus	Radiology		1.78	0.66	0.66		
76812	TC	Ob us, detailed, addl fetus	Radiology	a	0.00	1.05	1.05		
76815	26	Ob us, limited, fetus(s)	Radiology		0.65	0.23	0.23		
76815	TC	Ob us, limited, fetus(s)	Radiology	a	0.00	1.42	1.42		
76816	26	Ob us, follow-up, per fetus	Radiology		0.85	0.32	0.32		
76816	TC	Ob us, follow-up, per fetus	Radiology	a	0.00	1.11	1.11		
76817	26	Transvaginal us, obstetric	Radiology		0.75	0.26	0.26		
76817	TC	Transvaginal us, obstetric	Radiology	a	0.00	1.52	1.52		
76818	26	Fetal biophys profile w/nst	Radiology		1.05	0.39	0.39		
76818	TC	Fetal biophys profile w/nst	Radiology	a	0.00	1.61	1.61		
76819	26	Fetal biophys profil w/o nst	Radiology		0.77	0.28	0.28		
76819	TC	Fetal biophys profil w/o nst	Radiology	a	0.00	1.61	1.61		
76820	26	Umbilical artery echo	Radiology		0.50	0.19	0.19		
76820	TC	Umbilical artery echo	Radiology	a	0.00	1.61	1.61		
76821	26	Middle cerebral artery echo	Radiology		0.70	0.27	0.27		
76821	TC	Middle cerebral artery echo	Radiology	a	0.00	1.61	1.61		
76825	26	Echo exam of fetal heart	Radiology		1.67	0.60	0.60		
76825	TC	Echo exam of fetal heart	Radiology	a	0.00	1.98	1.98		
76826	26	Echo exam of fetal heart	Radiology		0.83	0.29	0.29		
76826	TC	Echo exam of fetal heart	Radiology	a	0.00	0.71	0.71		
76827	26	Echo exam of fetal heart	Radiology		0.58	0.21	0.21		
76827	TC	Echo exam of fetal heart	Radiology	a	0.00	1.72	1.72		
76828	26	Echo exam of fetal heart	Radiology		0.56	0.22	0.22		
76828	TC	Echo exam of fetal heart	Radiology	a	0.00	1.11	1.11		
76830	26	Transvaginal us, non-ob	Radiology		0.69	0.23	0.23		
76830	TC	Transvaginal us, non-ob	Radiology	a	0.00	1.52	1.52		
76831	26	Echo exam, uterus	Radiology		0.72	0.25	0.25		
76831	TC	Echo exam, uterus	Radiology	a	0.00	1.52	1.52		
76856	26	Us exam, pelvic, complete	Radiology		0.69	0.23	0.23		
76856	TC	Us exam, pelvic, complete	Radiology	a	0.00	1.52	1.52		
76857	26	Us exam, pelvic, limited	Radiology		0.38	0.12	0.12		
76857	TC	Us exam, pelvic, limited	Radiology	a	0.00	1.71	1.71		
76870	26	Us exam, scrotum	Radiology		0.64	0.21	0.21		

NOTES: CPT Codes and descriptions only are copyright 2005 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 90 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
76870	TC	Us exam, scrotum	Radiology	a	0.00	1.52	1.52		
76872	26	Echo exam, transrectal	Radiology		0.69	0.22	0.22		
76872	TC	Echo exam, transrectal	Radiology	a	0.00	2.03	2.03		
76873	26	Echograp trans r, pros study	Radiology		1.55	0.50	0.50		
76873	TC	Echograp trans r, pros study	Radiology	a	0.00	2.11	2.11		
76880	26	Us exam, extremity	Radiology		0.59	0.19	0.19		
76880	TC	Us exam, extremity	Radiology	a	0.00	1.42	1.42		
76885	26	Us exam infant hips, dynamic	Radiology		0.74	0.24	0.24		
76885	TC	Us exam infant hips, dynamic	Radiology	a	0.00	1.52	1.52		
76886	26	Us exam infant hips, static	Radiology		0.62	0.20	0.20		
76886	TC	Us exam infant hips, static	Radiology	a	0.00	1.42	1.42		
76930	26	Echo guide, cardiocentesis	Radiology		0.67	0.25	0.25		
76930	TC	Echo guide, cardiocentesis	Radiology	a	0.00	1.52	1.52		
76932	26	Echo guide for heart biopsy	Radiology		0.67	0.25	0.25		
76932	TC	Echo guide for heart biopsy	Radiology	a	0.00	1.52	1.52		
76936	26	Echo guide for artery repair	Radiology		1.99	0.66	0.66		
76936	TC	Echo guide for artery repair	Radiology	a	0.00	6.31	6.31		
76937		Us guide, vascular access	Radiology		0.30	0.48	0.48		
76937		Us guide, vascular access	Radiology		0.30	0.48	0.48		
76937		Us guide, vascular access	Radiology		0.30	0.48	0.48		
76940		Us guide, tissue ablation	Radiology		2.00	2.17	2.17		
76940		Us guide, tissue ablation	Radiology	a	2.00	2.17	2.17		
76940		Us guide, tissue ablation	Radiology	a	2.00	2.17	2.17		
76941	26	Echo guide for transfusion	Radiology		1.34	0.47	0.47		
76941	TC	Echo guide for transfusion	Radiology	a	0.00	1.53	1.53		
76942	26	Echo guide for biopsy	Radiology		0.67	0.22	0.22		
76942	TC	Echo guide for biopsy	Radiology	a	0.00	2.82	2.82		
76945	26	Echo guide, villus sampling	Radiology		0.67	0.22	0.22		
76945	TC	Echo guide, villus sampling	Radiology	a	0.00	1.53	1.53		
76946	26	Echo guide for amniocentesis	Radiology		0.38	0.14	0.14		
76946	TC	Echo guide for amniocentesis	Radiology	a	0.00	1.52	1.52		
76948	26	Echo guide, ova aspiration	Radiology		0.38	0.13	0.13		
76948	TC	Echo guide, ova aspiration	Radiology	a	0.00	1.52	1.52		
76950	26	Echo guidance radiotherapy	Radiology		0.58	0.19	0.19		
76950	TC	Echo guidance radiotherapy	Radiology	a	0.00	1.31	1.31		
76965	26	Echo guidance radiotherapy	Radiology		1.34	0.43	0.43		
76965	TC	Echo guidance radiotherapy	Radiology	a	0.00	5.59	5.59		
76970	26	Ultrasound exam follow-up	Radiology		0.40	0.13	0.13		
76970	TC	Ultrasound exam follow-up	Radiology	a	0.00	1.05	1.05		
76975	26	GI endoscopic ultrasound	Radiology		0.81	0.28	0.28		
76975	TC	GI endoscopic ultrasound	Radiology	a	0.00	1.52	1.52		
76977	26	Us bone density measure	Radiology		0.05	0.02	0.02		
76977	TC	Us bone density measure	Radiology	a	0.00	0.82	0.82		
76986	26	Ultrasound guide intraoper	Radiology		1.20	0.40	0.40		
76986	TC	Ultrasound guide intraoper	Radiology	a	0.00	2.63	2.63		
76999		Echo examination procedure	Radiology					2.44	
77261		Radiation therapy planning	Radiology		1.39	0.51	0.51		
77262		Radiation therapy planning	Radiology		2.11	0.75	0.75		
77263		Radiation therapy planning	Radiology		3.14	1.11	1.11		
77280	26	Set radiation therapy field	Radiology		0.70	0.22	0.22		
77280	TC	Set radiation therapy field	Radiology	a	0.00	3.48	3.48		
77285	26	Set radiation therapy field	Radiology		1.05	0.34	0.34		
77285	TC	Set radiation therapy field	Radiology	a	0.00	5.59	5.59		
77290	26	Set radiation therapy field	Radiology		1.56	0.50	0.50		
77290	TC	Set radiation therapy field	Radiology	a	0.00	6.53	6.53		
77295	26	Set radiation therapy field	Radiology		4.56	1.46	1.46		
77295	TC	Set radiation therapy field	Radiology	a	0.00	28.01	28.01		
77299		Radiation therapy planning	Radiology					8.58	
77300	26	Radiation therapy dose plan	Radiology		0.62	0.20	0.20		
77300	TC	Radiation therapy dose plan	Radiology	a	0.00	1.34	1.34		
77301	26	Radiotherapy dose plan, imrt	Radiology		7.99	2.57	2.57		
77301	TC	Radiotherapy dose plan, imrt	Radiology	a	0.00	28.01	28.01		
77305	26	Telebx isodose plan simple	Radiology		0.70	0.23	0.23		
77305	TC	Telebx isodose plan simple	Radiology	a	0.00	1.87	1.87		
77310	26	Telebx isodose plan intermed	Radiology		1.05	0.34	0.34		
77310	TC	Telebx isodose plan intermed	Radiology	a	0.00	2.34	2.34		
77315	26	Telebx isodose plan complex	Radiology		1.56	0.50	0.50		
77315	TC	Telebx isodose plan complex	Radiology	a	0.00	2.67	2.67		
77321	26	Special telebx port plan	Radiology		0.95	0.30	0.30		
77321	TC	Special telebx port plan	Radiology	a	0.00	4.05	4.05		

NOTES: CPT Codes and descriptions only are copyright 2005 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 91 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
77326	26	Brachytx isodose calc simp	Radiology		0.93	0.30	0.30		
77326	TC	Brachytx isodose calc simp	Radiology	a	0.00	2.37	2.37		
77327	26	Brachytx isodose calc interm	Radiology		1.39	0.44	0.44		
77327	TC	Brachytx isodose calc interm	Radiology	a	0.00	3.48	3.48		
77328	26	Brachytx isodose plan compl	Radiology		2.09	0.67	0.67		
77328	TC	Brachytx isodose plan compl	Radiology	a	0.00	4.97	4.97		
77331	26	Special radiation dosimetry	Radiology		0.87	0.28	0.28		
77331	TC	Special radiation dosimetry	Radiology	a	0.00	0.50	0.50		
77332	26	Radiation treatment aid(s)	Radiology		0.54	0.17	0.17		
77332	TC	Radiation treatment aid(s)	Radiology	a	0.00	1.34	1.34		
77333	26	Radiation treatment aid(s)	Radiology		0.84	0.27	0.27		
77333	TC	Radiation treatment aid(s)	Radiology	a	0.00	1.90	1.90		
77334	26	Radiation treatment aid(s)	Radiology		1.24	0.40	0.40		
77334	TC	Radiation treatment aid(s)	Radiology	a	0.00	3.26	3.26		
77336		Radiation physics consult	Radiology	a	0.00	2.99	2.99		
77370		Radiation physics consult	Radiology	a	0.00	3.50	3.50		
77399		External radiation dosimetry	Radiology					2.99	
77401		Radiation treatment delivery	Radiology	a	0.00	1.78	1.78		
77402		Radiation treatment delivery	Radiology	a	0.00	1.78	1.78		
77403		Radiation treatment delivery	Radiology	a	0.00	1.78	1.78		
77404		Radiation treatment delivery	Radiology	a	0.00	1.78	1.78		
77406		Radiation treatment delivery	Radiology	a	0.00	1.78	1.78		
77407		Radiation treatment delivery	Radiology	a	0.00	2.10	2.10		
77408		Radiation treatment delivery	Radiology	a	0.00	2.10	2.10		
77409		Radiation treatment delivery	Radiology	a	0.00	2.10	2.10		
77411		Radiation treatment delivery	Radiology	a	0.00	2.10	2.10		
77412		Radiation treatment delivery	Radiology	a	0.00	2.34	2.34		
77413		Radiation treatment delivery	Radiology	a	0.00	2.34	2.34		
77414		Radiation treatment delivery	Radiology	a	0.00	2.34	2.34		
77416		Radiation treatment delivery	Radiology	a	0.00	2.34	2.34		
77417		Radiology port film(s)	Radiology	a	0.00	0.59	0.59		
77418		Radiation tx delivery, imrt	Radiology	a	0.00	18.07	18.07		
77421	26	Stereoscopic x-ray guidance	Radiology		0.39	0.13	0.13		
77421	TC	Stereoscopic x-ray guidance	Radiology	a	0.00	3.36	3.36		RBRVS
77422		Neutron beam tx, simple	Radiology	a	0.00	1.71	1.71		RBRVS
77423		Neutron beam tx, complex	Radiology	a	0.00	2.26	2.26		RBRVS
77427		Radiation tx management, x5	Radiology		3.31	1.06	1.06		
77431		Radiation therapy management	Radiology		1.81	0.68	0.68		
77432		Stereotactic radiation tmt	Radiology		7.92	2.91	2.91		
77470	26	Special radiation treatment	Radiology		2.09	0.67	0.67		
77470	TC	Special radiation treatment	Radiology	a	0.00	11.18	11.18		
77499		Radiation therapy management	Radiology					4.36	
77520		Proton tmt, simple w/o comp	Radiology	a				22.19	
77522		Proton tmt, simple w/comp	Radiology	a				23.39	
77600	26	Hyperthermia treatment	Radiology		1.56	0.50	0.50		
77600	TC	Hyperthermia treatment	Radiology	a	0.00	3.06	3.06		
77605	26	Hyperthermia treatment	Radiology		2.09	0.66	0.66		
77605	TC	Hyperthermia treatment	Radiology	a	0.00	4.07	4.07		
77610	26	Hyperthermia treatment	Radiology		1.56	0.51	0.51		
77610	TC	Hyperthermia treatment	Radiology	a	0.00	3.06	3.06		
77615	26	Hyperthermia treatment	Radiology		2.09	0.66	0.66		
77615	TC	Hyperthermia treatment	Radiology	a	0.00	4.07	4.07		
77620	26	Hyperthermia treatment	Radiology		1.56	0.52	0.52		
77620	TC	Hyperthermia treatment	Radiology	a	0.00	3.06	3.06		
77750	26	Infuse radioactive materials	Radiology		4.90	1.58	1.58		
77750	TC	Infuse radioactive materials	Radiology	a	0.00	1.33	1.33		
77761	26	Apply intrcav radiat simple	Radiology		3.80	1.09	1.09		
77761	TC	Apply intrcav radiat simple	Radiology	a	0.00	2.51	2.51		
77762	26	Apply intrcav radiat interm	Radiology		5.71	1.84	1.84		
77762	TC	Apply intrcav radiat interm	Radiology	a	0.00	3.62	3.62		
77763	26	Apply intrcav radiat compl	Radiology		8.56	2.75	2.75		
77763	TC	Apply intrcav radiat compl	Radiology	a	0.00	4.50	4.50		
77776	26	Apply interstit radiat simpl	Radiology		4.65	0.95	0.95		
77776	TC	Apply interstit radiat simpl	Radiology	a	0.00	2.19	2.19		
77777	26	Apply interstit radiat inter	Radiology		7.47	2.38	2.38		
77777	TC	Apply interstit radiat inter	Radiology	a	0.00	4.24	4.24		
77778	26	Apply interstit radiat compl	Radiology		11.17	3.58	3.58		
77778	TC	Apply interstit radiat compl	Radiology	a	0.00	5.14	5.14		
77781	26	High intensity brachytherapy	Radiology		1.66	0.53	0.53		
77781	TC	High intensity brachytherapy	Radiology	a	0.00	20.36	20.36		

NOTES. CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARSDFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 92 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
77782	26	High intensity brachytherapy	Radiology		2.49	0.80	0.80		
77782	TC	High intensity brachytherapy	Radiology	a	0.00	20.36	20.36		
77783	26	High intensity brachytherapy	Radiology		3.72	1.19	1.19		
77783	TC	High intensity brachytherapy	Radiology	a	0.00	20.36	20.36		
77784	26	High intensity brachytherapy	Radiology		5.60	1.80	1.80		
77784	TC	High intensity brachytherapy	Radiology	a	0.00	20.36	20.36		
77789	26	Apply surface radiation	Radiology		1.12	0.37	0.37		
77789	TC	Apply surface radiation	Radiology	e	0.00	0.45	0.45		
77790	26	Radiation handling	Radiology		1.05	0.34	0.34		
77790	TC	Radiation handling	Radiology	e	0.00	0.50	0.50		
77799		Radium/radioscope therapy	Radiology					19.86	
78000	26	Thyroid, single uptake	Radiology		0.19	0.06	0.06		
78000	TC	Thyroid, single uptake	Radiology	e	0.00	0.97	0.97		
78001	26	Thyroid, multiple uptakes	Radiology		0.26	0.09	0.09		
78001	TC	Thyroid, multiple uptakes	Radiology	a	0.00	1.31	1.31		
78003	26	Thyroid suppress/stimul	Radiology		0.33	0.11	0.11		
78003	TC	Thyroid suppress/stimul	Radiology	a	0.00	0.97	0.97		
78006	26	Thyroid imaging with uptake	Radiology		0.49	0.16	0.16		
78006	TC	Thyroid imaging with uptake	Radiology	e	0.00	2.39	2.39		
78007	26	Thyroid image, mult uptakes	Radiology		0.50	0.17	0.17		
78007	TC	Thyroid image, mult uptakes	Radiology	a	0.00	2.58	2.58		
78010	26	Thyroid imaging	Radiology		0.39	0.13	0.13		
78010	TC	Thyroid imaging	Radiology	a	0.00	1.83	1.83		
78011	26	Thyroid imaging with flow	Radiology		0.45	0.15	0.15		
78011	TC	Thyroid imaging with flow	Radiology	a	0.00	2.42	2.42		
78015	26	Thyroid met imaging	Radiology		0.67	0.23	0.23		
78015	TC	Thyroid met imaging	Radiology	a	0.00	2.58	2.58		
78016	26	Thyroid met imaging/studies	Radiology		0.82	0.28	0.28		
78016	TC	Thyroid met imaging/studies	Radiology	e	0.00	3.49	3.49		
78018	26	Thyroid met imaging, body	Radiology		0.86	0.30	0.30		
78018	TC	Thyroid met imaging, body	Radiology	e	0.00	5.44	5.44		
78020	26	Thyroid met uptake	Radiology		0.60	0.21	0.21		
78020	TC	Thyroid met uptake	Radiology	e	0.00	1.31	1.31		
78070	26	Parathyroid nuclear imaging	Radiology		0.82	0.28	0.28		
78070	TC	Parathyroid nuclear imaging	Radiology	a	0.00	4.28	4.28		
78075	26	Adrenal nuclear imaging	Radiology		0.74	0.26	0.26		
78075	TC	Adrenal nuclear imaging	Radiology	a	0.00	5.44	5.44		
78099		Endocrine nuclear procedure	Radiology					3.05	
78102	26	Bone marrow imaging, ltd	Radiology		0.55	0.19	0.19		
78102	TC	Bone marrow imaging, ltd	Radiology	a	0.00	2.05	2.05		
78103	26	Bone marrow imaging, mult	Radiology		0.75	0.26	0.26		
78103	TC	Bone marrow imaging, mult	Radiology	e	0.00	3.18	3.18		
78104	26	Bone marrow imaging, body	Radiology		0.80	0.27	0.27		
78104	TC	Bone marrow imaging, body	Radiology	a	0.00	4.08	4.08		
78110	26	Plasma volume, single	Radiology		0.19	0.07	0.07		
78110	TC	Plasma volume, single	Radiology	a	0.00	0.95	0.95		
78111	26	Plasma volume, multiple	Radiology		0.22	0.08	0.08		
78111	TC	Plasma volume, multiple	Radiology	a	0.00	2.58	2.58		
78120	26	Red cell mass, single	Radiology		0.23	0.08	0.08		
78120	TC	Red cell mass, single	Radiology	e	0.00	1.74	1.74		
78121	26	Red cell mass, multiple	Radiology		0.32	0.11	0.11		
78121	TC	Red cell mass, multiple	Radiology	a	0.00	2.92	2.92		
78122	26	Blood volume	Radiology		0.45	0.16	0.16		
78122	TC	Blood volume	Radiology	e	0.00	4.61	4.61		
78130	26	Red cell survival study	Radiology		0.61	0.21	0.21		
78130	TC	Red cell survival study	Radiology	a	0.00	2.86	2.86		
78135	26	Red cell survival kinetics	Radiology		0.64	0.22	0.22		
78135	TC	Red cell survival kinetics	Radiology	e	0.00	4.88	4.88		
78140	26	Red cell sequestration	Radiology		0.61	0.20	0.20		
78140	TC	Red cell sequestration	Radiology	e	0.00	3.94	3.94		
78185	26	Spleen imaging	Radiology		0.40	0.14	0.14		
78185	TC	Spleen imaging	Radiology	a	0.00	2.37	2.37		
78190	26	Platelet survival, kinetics	Radiology		1.09	0.39	0.39		
78190	TC	Platelet survival, kinetics	Radiology	a	0.00	5.73	5.73		
78191	26	Platelet survival	Radiology		0.61	0.20	0.20		
78191	TC	Platelet survival	Radiology	a	0.00	7.36	7.36		
78195	26	Lymph system imaging	Radiology		1.20	0.41	0.41		
78195	TC	Lymph system imaging	Radiology	a	0.00	4.08	4.08		
78199		Blood/lymph nuclear exam	Radiology					5.70	
78201	26	Liver imaging	Radiology		0.44	0.15	0.15		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 93 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usaga Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
78201	TC	Liver imaging	Radiology	a	0.00	2.37	2.37		
78202	26	Liver imaging with flow	Radiology		0.51	0.17	0.17		
78202	TC	Liver imaging with flow	Radiology	a	0.00	2.89	2.89		
78205	26	Liver imaging (3D)	Radiology		0.71	0.24	0.24		
78205	TC	Liver imaging (3D)	Radiology	a	0.00	5.93	5.93		
78206	26	Liver image (3d) with flow	Radiology		0.96	0.33	0.33		
78206	TC	Liver image (3d) with flow	Radiology	a	0.00	5.93	5.93		
78215	26	Liver and spleen imaging	Radiology		0.49	0.16	0.16		
78215	TC	Liver and spleen imaging	Radiology	a	0.00	2.95	2.95		
78216	26	Liver & spleen image/flow	Radiology		0.57	0.19	0.19		
78216	TC	Liver & spleen image/flow	Radiology	a	0.00	3.49	3.49		
78220	26	Liver function study	Radiology		0.49	0.16	0.16		
78220	TC	Liver function study	Radiology	a	0.00	3.73	3.73		
78223	26	Hepatobiliary imaging	Radiology		0.84	0.28	0.28		
78223	TC	Hepatobiliary imaging	Radiology	a	0.00	3.67	3.67		
78230	26	Salivary gland imaging	Radiology		0.45	0.15	0.15		
78230	TC	Salivary gland imaging	Radiology	a	0.00	2.19	2.19		
78231	26	Serial salivary imaging	Radiology		0.52	0.18	0.18		
78231	TC	Serial salivary imaging	Radiology	a	0.00	3.18	3.18		
78232	26	Salivary gland function exam	Radiology		0.47	0.16	0.16		
78232	TC	Salivary gland function exam	Radiology	a	0.00	3.55	3.55		
78258	26	Esophageal motility study	Radiology		0.74	0.25	0.25		
78258	TC	Esophageal motility study	Radiology	a	0.00	2.89	2.89		
78261	26	Gastric mucosa imaging	Radiology		0.69	0.24	0.24		
78261	TC	Gastric mucosa imaging	Radiology	a	0.00	4.11	4.11		
78262	26	Gastroesophageal reflux exam	Radiology		0.68	0.23	0.23		
78262	TC	Gastroesophageal reflux exam	Radiology	a	0.00	4.26	4.26		
78264	26	Gastric emptying study	Radiology		0.78	0.26	0.26		
78264	TC	Gastric emptying study	Radiology	a	0.00	4.14	4.14		
78270	26	Vit B-12 absorption exam	Radiology		0.20	0.07	0.07		
78270	TC	Vit B-12 absorption exam	Radiology	a	0.00	1.55	1.55		
78271	26	Vit b-12 absp exam, int fac	Radiology		0.20	0.07	0.07		
78271	TC	Vit b-12 absp exam, int fac	Radiology	a	0.00	1.64	1.64		
78272	26	Vit B-12 absorp, combined	Radiology		0.27	0.09	0.09		
78272	TC	Vit B-12 absorp, combined	Radiology	a	0.00	2.33	2.33		
78278	26	Acute GI blood loss imaging	Radiology		0.99	0.33	0.33		
78278	TC	Acute GI blood loss imaging	Radiology	a	0.00	4.88	4.88		
78282	26	GI protein loss exam	Radiology		0.38	0.13	0.13		
78282	TC	GI protein loss exam	Radiology	a				2.89	
78290	26	Meckel's divert exam	Radiology		0.68	0.23	0.23		
78290	TC	Meckel's divert exam	Radiology	a	0.00	3.05	3.05		
78291	26	Leveen/shunt patency exam	Radiology		0.88	0.30	0.30		
78291	TC	Leveen/shunt patency exam	Radiology	a	0.00	3.07	3.07		
78299		GI nuclear procedura	Radiology					4.80	
78300	26	Bone imaging, limited area	Radiology		0.62	0.21	0.21		
78300	TC	Bone imaging, limited area	Radiology	a	0.00	2.49	2.49		
78305	26	Bone imaging, multiple areas	Radiology		0.83	0.28	0.28		
78305	TC	Bone imaging, multiple areas	Radiology	a	0.00	3.67	3.67		
78306	26	Bone imaging, whole body	Radiology		0.86	0.29	0.29		
78306	TC	Bone imaging, whole body	Radiology	a	0.00	4.28	4.28		
78315	26	Bone imaging, 3 phase	Radiology		1.02	0.34	0.34		
78315	TC	Bone imaging, 3 phase	Radiology	a	0.00	4.79	4.79		
78320	26	Bone imaging (3D)	Radiology		1.04	0.36	0.36		
78320	TC	Bone imaging (3D)	Radiology	a	0.00	5.93	5.93		
78350	26	Bone mineral, single photon	Radiology		0.22	0.07	0.07		
78350	TC	Bone mineral, single photon	Radiology	a	0.00	0.75	0.75		
78351	26	Bone mineral, dual photon	Radiology					0.58	
78351	TC	Bone mineral, dual photon	Radiology	a				3.44	
78399		Musculoskeletal nuclear exam	Radiology					5.44	
78414	26	Non-imaging heart function	Radiology		0.45	0.16	0.16		
78414	TC	Non-imaging heart function	Radiology	a				1.22	
78428	26	Cardiac shunt imaging	Radiology		0.78	0.29	0.29		
78428	TC	Cardiac shunt imaging	Radiology	a	0.00	2.26	2.26		
78445	26	Vascular flow imaging	Radiology		0.49	0.17	0.17		
78445	TC	Vascular flow imaging	Radiology	a	0.00	1.87	1.87		
78456	26	Acute venous thrombus image	Radiology		1.00	0.34	0.34		
78456	TC	Acute venous thrombus image	Radiology	a	0.00	3.99	3.99		
78457	26	Venous thrombosis imaging	Radiology		0.77	0.26	0.26		
78457	TC	Venous thrombosis imaging	Radiology	a	0.00	2.67	2.67		
78458	26	Ven thrombosis images, bilat	Radiology		0.90	0.32	0.32		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/OFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 94 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
78458	TC	Ven thrombosis images, bilat	Radiology	a	0.00	4.03	4.03		
78459	26	Heart muscle imaging (PET)	Radiology		1.50	0.57	0.57		
78459	TC	Heart muscle imaging (PET)	Radiology	a				27.72	
78460	26	Heart muscle blood, single	Radiology		0.86	0.29	0.29		
78460	TC	Heart muscle blood, single	Radiology	a	0.00	2.37	2.37		
78461	26	Heart muscle blood, multiple	Radiology		1.23	0.43	0.43		
78461	TC	Heart muscle blood, multiple	Radiology	a	0.00	4.73	4.73		
78464	26	Heart image (3d), single	Radiology		1.09	0.38	0.38		
78464	TC	Heart image (3d), single	Radiology	a	0.00	7.09	7.09		
78465	26	Heart image (3d), multiple	Radiology		1.46	0.52	0.52		
78465	TC	Heart image (3d), multiple	Radiology	a	0.00	11.82	11.82		
78466	26	Heart infarct image	Radiology		0.69	0.24	0.24		
78466	TC	Heart infarct image	Radiology	a	0.00	2.63	2.63		
78468	26	Heart infarct image (ef)	Radiology		0.80	0.27	0.27		
78468	TC	Heart infarct image (ef)	Radiology	a	0.00	3.67	3.67		
78469	26	Heart infarct image (3D)	Radiology		0.92	0.31	0.31		
78469	TC	Heart infarct image (3D)	Radiology	a	0.00	5.24	5.24		
78472	26	Gated heart, planar, single	Radiology		0.98	0.34	0.34		
78472	TC	Gated heart, planar, single	Radiology	a	0.00	5.53	5.53		
78473	26	Gated heart, multiple	Radiology		1.47	0.51	0.51		
78473	TC	Gated heart, multiple	Radiology	a	0.00	8.28	8.28		
78478	26	Heart wall motion add-on	Radiology		0.62	0.23	0.23		
78478	TC	Heart wall motion add-on	Radiology	a	0.00	1.56	1.56		
78480	26	Heart function add-on	Radiology		0.62	0.22	0.22		
78480	TC	Heart function add-on	Radiology	a	0.00	1.56	1.56		
78481	26	Heart first pass, single	Radiology		0.98	0.36	0.36		
78481	TC	Heart first pass, single	Radiology	a	0.00	5.24	5.24		
78483	26	Heart first pass, multiple	Radiology		1.47	0.54	0.54		
78483	TC	Heart first pass, multiple	Radiology	a	0.00	7.89	7.89		
78491	26	Heart image (pet), single	Radiology		1.50	0.59	0.59		
78491	TC	Heart image (pet), single	Radiology	a				16.06	
78492	26	Heart image (pet), multiple	Radiology		1.87	0.74	0.74		
78492	TC	Heart image (pet), multiple	Radiology	a				20.04	
78494	26	Heart image, spect	Radiology		1.19	0.42	0.42		
78494	TC	Heart image, spect	Radiology	a	0.00	7.09	7.09		
78496	26	Heart first pass add-on	Radiology		0.50	0.18	0.18		
78496	TC	Heart first pass add-on	Radiology	a	0.00	7.09	7.09		
78499		Cardiovascular nuclear exam	Radiology					2.41	
78580	26	Lung perfusion imaging	Radiology		0.74	0.25	0.25		
78580	TC	Lung perfusion imaging	Radiology	a	0.00	3.44	3.44		
78584	26	Lung V/Q image single breath	Radiology		0.99	0.33	0.33		
78584	TC	Lung V/Q image single breath	Radiology	a	0.00	3.21	3.21		
78585	26	Lung V/Q imaging	Radiology		1.09	0.36	0.36		
78585	TC	Lung V/Q imaging	Radiology	a	0.00	5.66	5.66		
78586	26	Aerosol lung image, single	Radiology		0.40	0.13	0.13		
78586	TC	Aerosol lung image, single	Radiology	a	0.00	2.60	2.60		
78587	26	Aerosol lung image, multiple	Radiology		0.49	0.17	0.17		
78587	TC	Aerosol lung image, multiple	Radiology	a	0.00	2.81	2.81		
78588	26	Perfusion lung image	Radiology		1.09	0.36	0.36		
78588	TC	Perfusion lung image	Radiology	a	0.00	3.21	3.21		
78591	26	Vent image, 1 breath, 1 proj	Radiology		0.40	0.13	0.13		
78591	TC	Vent image, 1 breath, 1 proj	Radiology	a	0.00	2.86	2.86		
78593	26	Vent image, 1 proj, gas	Radiology		0.49	0.16	0.16		
78593	TC	Vent image, 1 proj, gas	Radiology	a	0.00	3.46	3.46		
78594	26	Vent image, mult proj, gas	Radiology		0.53	0.18	0.18		
78594	TC	Vent image, mult proj, gas	Radiology	a	0.00	4.99	4.99		
78596	26	Lung differential function	Radiology		1.27	0.42	0.42		
78596	TC	Lung differential function	Radiology	a	0.00	7.09	7.09		
78599		Respiratory nuclear exam	Radiology					4.67	
78600	26	Brain imaging, ltd static	Radiology		0.44	0.15	0.15		
78600	TC	Brain imaging, ltd static	Radiology	a	0.00	2.89	2.89		
78601	26	Brain imaging, ltd w/ flow	Radiology		0.51	0.17	0.17		
78601	TC	Brain imaging, ltd w/ flow	Radiology	a	0.00	3.41	3.41		
78605	26	Brain imaging, complete	Radiology		0.53	0.18	0.18		
78605	TC	Brain imaging, complete	Radiology	a	0.00	3.41	3.41		
78606	26	Brain imaging, compl w/flow	Radiology		0.64	0.21	0.21		
78606	TC	Brain imaging, compl w/flow	Radiology	a	0.00	3.88	3.88		
78607	26	Brain imaging (3D)	Radiology		1.23	0.43	0.43		
78607	TC	Brain imaging (3D)	Radiology	a	0.00	6.57	6.57		
78608		Brain imaging (PET)	Radiology					49.17	

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 95 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
78609		Brain imaging (PET)	Radiology					35.76	
78610	26	Brain flow imaging only	Radiology		0.30	0.11	0.11		
78610	TC	Brain flow imaging only	Radiology	a	0.00	1.58	1.58		
78615	26	Cerebral vascular flow image	Radiology		0.42	0.15	0.15		
78615	TC	Cerebral vascular flow image	Radiology	a	0.00	3.86	3.86		
78630	26	Cerebrospinal fluid scan	Radiology		0.68	0.23	0.23		
78630	TC	Cerebrospinal fluid scan	Radiology	a	0.00	5.05	5.05		
78635	26	CSF ventriculography	Radiology		0.61	0.23	0.23		
78635	TC	CSF ventriculography	Radiology	a	0.00	2.55	2.55		
78645	26	CSF shunt evaluation	Radiology		0.57	0.19	0.19		
78645	TC	CSF shunt evaluation	Radiology	a	0.00	3.44	3.44		
78647	26	Cerebrospinal fluid scan	Radiology		0.90	0.31	0.31		
78647	TC	Cerebrospinal fluid scan	Radiology	a	0.00	5.93	5.93		
78650	26	CSF leakage imaging	Radiology		0.61	0.21	0.21		
78650	TC	CSF leakage imaging	Radiology	a	0.00	4.65	4.65		
78660	26	Nuclear exam of tear flow	Radiology		0.53	0.18	0.18		
78660	TC	Nuclear exam of tear flow	Radiology	a	0.00	2.13	2.13		
78699		Nervous system nuclear exam	Radiology					5.96	
78700	26	Kidney imaging, static	Radiology		0.45	0.15	0.15		
78700	TC	Kidney imaging, static	Radiology	a	0.00	3.06	3.06		
78701	26	Kidney imaging with flow	Radiology		0.49	0.16	0.16		
78701	TC	Kidney imaging with flow	Radiology	a	0.00	3.57	3.57		
78704	26	Imaging renogram	Radiology		0.74	0.25	0.25		
78704	TC	Imaging renogram	Radiology	a	0.00	3.96	3.96		
78707	26	Kidney flow/function image	Radiology		0.96	0.32	0.32		
78707	TC	Kidney flow/function image	Radiology	a	0.00	4.48	4.48		
78708	26	Kidney flow/function image	Radiology		1.21	0.41	0.41		
78708	TC	Kidney flow/function image	Radiology	a	0.00	4.48	4.48		
78709	26	Kidney flow/function image	Radiology		1.41	0.47	0.47		
78709	TC	Kidney flow/function image	Radiology	a	0.00	4.48	4.48		
78710	26	Kidney imaging (3D)	Radiology		0.66	0.22	0.22		
78710	TC	Kidney imaging (3D)	Radiology	a	0.00	5.93	5.93		
78715	26	Renal vascular flow exam	Radiology		0.30	0.11	0.11		
78715	TC	Renal vascular flow exam	Radiology	a	0.00	1.58	1.58		
78725	26	Kidney function study	Radiology		0.38	0.13	0.13		
78725	TC	Kidney function study	Radiology	a	0.00	1.79	1.79		
78730	26	Urinary bladder retention	Radiology		0.36	0.12	0.12		
78730	TC	Urinary bladder retention	Radiology	a	0.00	1.46	1.46		
78740	26	Ureteral reflux study	Radiology		0.57	0.19	0.19		
78740	TC	Ureteral reflux study	Radiology	a	0.00	2.13	2.13		
78760	26	Testicular imaging	Radiology		0.66	0.22	0.22		
78760	TC	Testicular imaging	Radiology	a	0.00	2.69	2.69		
78761	26	Testicular imaging/flow	Radiology		0.71	0.24	0.24		
78761	TC	Testicular imaging/flow	Radiology	a	0.00	3.21	3.21		
78799		Genitourinary nuclear exam	Radiology					5.77	
78800	26	Tumor imaging, limited area	Radiology		0.66	0.22	0.22		
78800	TC	Tumor imaging, limited area	Radiology	a	0.00	3.41	3.41		
78801	26	Tumor imaging, mult areas	Radiology		0.79	0.27	0.27		
78801	TC	Tumor imaging, mult areas	Radiology	a	0.00	4.23	4.23		
78802	26	Tumor imaging, whole body	Radiology		0.86	0.29	0.29		
78802	TC	Tumor imaging, whole body	Radiology	a	0.00	5.55	5.55		
78803	26	Tumor imaging (3D)	Radiology		1.09	0.38	0.38		
78803	TC	Tumor imaging (3D)	Radiology	a	0.00	6.57	6.57		
78804	26	Tumor imaging, whole body	Radiology		1.07	0.37	0.37		
78804	TC	Tumor imaging, whole body	Radiology	a	0.00	11.09	11.09		
78805	26	Abscess imaging, ltd area	Radiology		0.73	0.25	0.25		
78805	TC	Abscess imaging, ltd area	Radiology	a	0.00	3.41	3.41		
78806	26	Abscess imaging, whole body	Radiology		0.86	0.29	0.29		
78806	TC	Abscess imaging, whole body	Radiology	a	0.00	6.45	6.45		
78807	26	Nuclear localization/abscess	Radiology		1.09	0.39	0.39		
78807	TC	Nuclear localization/abscess	Radiology	a	0.00	6.57	6.57		
78811	26	Tumor imaging (pet), limited	Radiology		1.54	0.53	0.53		
78812	26	Tumor image (pet)/skul-thigh	Radiology		1.93	0.66	0.66		
78813	26	Tumor image (pet) full body	Radiology		2.00	0.69	0.69		
78814	26	Tumor image pet/ct, limited	Radiology		2.20	0.76	0.76		
78815	26	Tumor image pet/ct skul-thigh	Radiology		2.44	0.84	0.84		
78816	26	Tumor image pet/ct full body	Radiology		2.50	0.86	0.86		
78890	26	Nuclear medicine data proc	Radiology		0.05	0.02	0.02		
78890	TC	Nuclear medicine data proc	Radiology	a	0.00	1.31	1.31		
78891	26	Nuclear med data proc	Radiology		0.10	0.04	0.04		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DARS apply.
See end of the table for note regarding Charge Methodology

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 96 of 119.

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
78891	TC	Nuclear med data proc	Radiology	a	0.00	2.63	2.63		
78999		Nuclear diagnostic exam	Radiology					1.81	
79005	26	Nuclear rx, oral admin	Radiology		1.80	0.60	0.60		
79005	TC	Nuclear rx, oral admin	Radiology	a	0.00	2.63	2.63		
79101	26	Nuclear rx, iv admin	Radiology		1.96	0.67	0.67		
79101	TC	Nuclear rx, iv admin	Radiology	a	0.00	2.63	2.63		
79200	26	Intracavitary nuclear trmt	Radiology		1.99	0.69	0.69		
79200	TC	Intracavitary nuclear trmt	Radiology	a	0.00	2.63	2.63		
79300	26	Interstitial nuclear therapy	Radiology		1.60	0.56	0.56		
79300	TC	Interstitial nuclear therapy	Radiology	a				1.70	
79403	26	Hematopoietic nuclear therapy	Radiology		2.25	0.89	0.89		
79403	TC	Hematopoietic nuclear therapy	Radiology	a	0.00	4.28	4.28		
79440	26	Nuclear joint therapy	Radiology		1.99	0.72	0.72		
79440	TC	Nuclear joint therapy	Radiology	a	0.00	2.63	2.63		
79445	26	Nuclear rx, intra-arterial	Radiology		2.40	0.82	0.82		
79999		Nuclear medicine therapy	Radiology					5.02	BRVS
80500		Lab pathology consultation	Pathology		0.37	0.16	0.21		
80502		Lab pathology consultation	Pathology		1.33	0.54	0.54		
83020	26	Hemoglobin electrophoresis	Pathology		0.37	0.15	0.15		
83912	26	Genetic examination	Pathology		0.37	0.12	0.12		
84165	26	Assay of serum proteins	Pathology		0.37	0.14	0.14		
84166	26	Protein e-phoresis/urine/csf	Pathology		0.37	0.14	0.14		
84181	26	Western blot test	Pathology		0.37	0.14	0.14		
84182	26	Protein, western blot test	Pathology		0.37	0.16	0.16		
85060		Blood smear interpretation	Pathology		0.45	0.18	0.18		
85097		Bone marrow interpretation	Pathology		0.94	0.41	1.92		
85396		Clotting assay, whole blood	Pathology		0.37	0.16	0.16		
85576	26	Blood platelet aggregation	Pathology		0.37	0.16	0.16		
86077		Physician blood bank service	Pathology		0.94	0.39	0.39		
86078		Physician blood bank service	Pathology		0.94	0.40	0.46		
86079		Physician blood bank service	Pathology		0.94	0.41	0.45		
86320	26	Serum immunoelectrophoresis	Pathology		0.37	0.15	0.15		
86325	26	Other immunoelectrophoresis	Pathology		0.37	0.13	0.13		
86327	26	Immunoelectrophoresis assay	Pathology		0.42	0.18	0.18		
86334	26	Immunofixation procedure	Pathology		0.37	0.15	0.15		
86490		Coccidioidomycosis skin test	Pathology	a	0.00	0.29	0.29		
86510		Histoplasmosis skin test	Pathology	a	0.00	0.32	0.32		
86580		TB intradermal test	Pathology	a	0.00	0.25	0.25		
87164	26	Dark field examination	Pathology		0.37	0.12	0.12		
88104	26	Cytopathology, fluids	Pathology		0.56	0.24	0.24		
88104	TC	Cytopathology, fluids	Pathology	a	0.00	0.61	0.61		
88106	26	Cytopathology, fluids	Pathology		0.56	0.24	0.24		
88106	TC	Cytopathology, fluids	Pathology	a	0.00	1.11	1.11		
88107	26	Cytopathology, fluids	Pathology		0.76	0.33	0.33		
88107	TC	Cytopathology, fluids	Pathology	a	0.00	1.21	1.21		
88108	26	Cytopath, concentrate tech	Pathology		0.56	0.24	0.24		
88108	TC	Cytopath, concentrate tech	Pathology	a	0.00	0.97	0.97		
88112	26	Cytopath, cell enhance tech	Pathology		1.18	0.51	0.51		
88112	TC	Cytopath, cell enhance tech	Pathology	a	0.00	1.46	1.46		
88125	26	Forensic cytopathology	Pathology		0.26	0.11	0.11		
88125	TC	Forensic cytopathology	Pathology	a	0.00	0.16	0.16		
88141		Cytopath, c/v, interpret	Pathology		0.42	0.15	0.15		
88160	26	Cytopath smear, other source	Pathology		0.50	0.21	0.21		
88160	TC	Cytopath smear, other source	Pathology	a	0.00	0.62	0.62		
88161	26	Cytopath smear, other source	Pathology		0.50	0.21	0.21		
88161	TC	Cytopath smear, other source	Pathology	a	0.00	0.73	0.73		
88162	26	Cytopath smear, other source	Pathology		0.76	0.33	0.33		
88162	TC	Cytopath smear, other source	Pathology	a	0.00	0.69	0.69		
88172	26	Cytopathology eval of fna	Pathology		0.60	0.26	0.26		
88172	TC	Cytopathology eval of fna	Pathology	a	0.00	0.47	0.47		
88173	26	Cytopath eval, fna, report	Pathology		1.39	0.59	0.59		
88173	TC	Cytopath eval, fna, report	Pathology	a	0.00	1.55	1.55		
88182	26	Cell marker study	Pathology		0.77	0.33	0.33		
88182	TC	Cell marker study	Pathology	a	0.00	1.65	1.65		
88184		Flowcytometry/ tc, 1 marker	Pathology	a	0.00	1.32	1.32		
88185		Flowcytometry/tc, add-on	Pathology	a	0.00	0.64	0.64		
88187		Flowcytometry/read, 2-8	Pathology	a	1.36	0.45	0.45		
88188		Flowcytometry/read, 9-15	Pathology	a	1.69	0.57	0.57		
88189		Flowcytometry/read, 16 & >	Pathology		2.23	0.75	0.75		
88291		Cyto/molecular report	Pathology		0.52	0.17	0.17		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPSC CODE

PAGE 97 of 119

CPT/ HCPSC Code	Modifier	CPT/HCPSC Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
88300		Surgical path, gross	Pathology		0.08	0.03	0.03		
88300	TC	Surgical path, gross	Pathology		0.00	0.42	0.42		
88302	26	Tissue exam by pathologist	Pathology	a	0.13	0.06	0.06		
88302	TC	Tissue exam by pathologist	Pathology		0.00	0.97	0.97		
88304	26	Tissue exam by pathologist	Pathology	a	0.22	0.09	0.09		
88304	TC	Tissue exam by pathologist	Pathology		0.00	1.23	1.23		
88305	26	Tissue exam by pathologist	Pathology	a	0.75	0.33	0.33		
88305	TC	Tissue exam by pathologist	Pathology		0.00	1.58	1.58		
88307	26	Tissue exam by pathologist	Pathology	a	1.59	0.68	0.68		
88307	TC	Tissue exam by pathologist	Pathology		0.00	2.48	2.48		
88309	26	Tissue exam by pathologist	Pathology	a	2.28	0.97	0.97		
88309	TC	Tissue exam by pathologist	Pathology		0.00	3.43	3.43		
88311	26	Decalcify tissue	Pathology		0.24	0.10	0.10		
88311	TC	Decalcify tissue	Pathology	a	0.00	0.13	0.13		
88312	26	Special stains	Pathology		0.54	0.23	0.23		
88312	TC	Special stains	Pathology	a	0.00	1.29	1.29		
88313	26	Special stains	Pathology		0.24	0.10	0.10		
88313	TC	Special stains	Pathology	a	0.00	1.15	1.15		
88314	26	Histochemical stain	Pathology		0.45	0.19	0.19		
88314	TC	Histochemical stain	Pathology	a	0.00	1.88	1.88		
88318	26	Chemical histochemistry	Pathology		0.42	0.18	0.18		
88318	TC	Chemical histochemistry	Pathology	a	0.00	1.47	1.47		
88319	26	Enzyme histochemistry	Pathology		0.53	0.22	0.22		
88319	TC	Enzyme histochemistry	Pathology	a	0.00	3.20	3.20		
88321		Microslide consultation	Pathology		1.30	0.56	0.79		
88323	26	Microslide consultation	Pathology		1.35	0.57	0.57		
88323	TC	Microslide consultation	Pathology	a	0.00	1.21	1.21		
88325		Comprehensive review of data	Pathology		2.22	0.95	2.94		
88329		Path consult intro	Pathology		0.67	0.29	0.65		
88331	26	Path consult intraop, 1 bloc	Pathology		1.19	0.51	0.51		
88331	TC	Path consult intraop, 1 bloc	Pathology	a	0.00	0.59	0.59		
88332	26	Path consult intraop, add	Pathology		0.59	0.25	0.25		
88332	TC	Path consult intraop, add	Pathology	a	0.00	0.21	0.21		
88333		Intraop cyto path consult, 1	Pathology	a	1.20	1.08	1.08		RBRVS
88334		Intraop cyto path consult, 2	Pathology	a	0.59	0.60	0.60		RBRVS
88342	26	Immunocytochemistry	Pathology		0.85	0.36	0.36		
88342	TC	Immunocytochemistry	Pathology	a	0.00	1.10	1.10		
88346	26	Immunofluorescent study	Pathology		0.86	0.36	0.36		
88346	TC	Immunofluorescent study	Pathology	a	0.00	1.21	1.21		
88347	26	Immunofluorescent study	Pathology		0.86	0.35	0.35		
88347	TC	Immunofluorescent study	Pathology	a	0.00	0.91	0.91		
88348	26	Electron microscopy	Pathology		1.51	0.64	0.64		
88348	TC	Electron microscopy	Pathology	a	0.00	8.74	8.74		
88349	26	Scanning electron microscopy	Pathology		0.76	0.33	0.33		
88349	TC	Scanning electron microscopy	Pathology	a	0.00	3.24	3.24		
88355	26	Analysis, skeletal muscle	Pathology		1.85	0.79	0.79		
88355	TC	Analysis, skeletal muscle	Pathology	a	0.00	8.00	8.00		
88356	26	Analysis, nerve	Pathology		3.02	1.26	1.26		
88356	TC	Analysis, nerve	Pathology	a	0.00	2.93	2.93		
88358	26	Analysis, tumor	Pathology		0.95	0.40	0.40		
88358	TC	Analysis, tumor	Pathology	a	0.00	0.44	0.44		
88360	26	Tumor immunohistochem/manual	Pathology		1.10	0.47	0.47		
88360	TC	Tumor immunohistochem/manual	Pathology	a	0.00	1.26	1.26		
88361	26	Immunohistochemistry, tumor	Pathology		1.18	0.49	0.49		
88361	TC	Immunohistochemistry, tumor	Pathology	a	0.00	2.54	2.54		
88362	26	Nerve teasing preparations	Pathology		2.17	0.92	0.92		
88362	TC	Nerve teasing preparations	Pathology	a	0.00	3.78	3.78		
88365	26	Tissue hybridization	Pathology		1.20	0.51	0.51		
88365	TC	Tissue hybridization	Pathology	a	0.00	1.62	1.62		
88367	26	Insitu hybridization, auto	Pathology		1.30	0.54	0.54		
88367	TC	Insitu hybridization, auto	Pathology	a	0.00	3.50	3.50		
88368	26	Insitu hybridization, manual	Pathology		1.40	0.60	0.60		
88368	TC	Insitu hybridization, manual	Pathology	a	0.00	1.80	1.80		
88371	26	Protein, western blot tissue	Pathology		0.37	0.13	0.13		
88372	26	Protein analysis w/probe	Pathology		0.37	0.16	0.16		
88380	26	Microdissection	Pathology		0.24	0.10	0.10		
89049		Chct for mal hyperthermia	Pathology	a	1.40	0.27	3.56		CALC RBRVS
89100		Sample intestinal contents	Pathology		0.60	0.21	1.84		
89105		Sample intestinal contents	Pathology		0.50	0.17	2.23		
89130		Sample stomach contents	Pathology		0.45	0.13	1.75		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 98 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
89132		Sample stomach contents	Pathology		0.19	0.06	1.55		
89135		Sample stomach contents	Pathology		0.79	0.25	1.90		
89136		Sample stomach contents	Pathology		0.21	0.09	1.74		
89140		Sample stomach contents	Pathology		0.94	0.27	2.09		
89141		Sample stomach contents	Pathology		0.85	0.33	2.80		
89220		Sputum specimen collection	Pathology	a	0.00	0.43	0.43		
89230		Collect sweat for test	Pathology	a	0.00	0.11	0.11		
90281		Human iq, im	Therapeutic Injections					0.77	
90283		Human iq, iv	Therapeutic Injections					2.16	
90287		Botulinum antitoxin	Therapeutic Injections					0.55	
90371		Hep b iq, im	Therapeutic Injections					4.56	
90375		Rabies iq, im/sc	Therapeutic Injections					5.22	
90376		Rabies iq, heat treated	Therapeutic Injections					4.98	
90378		Rsv iq, im, 50mg	Therapeutic Injections					22.71	
90379		Rsv iq, iv	Therapeutic Injections					27.49	
90384		Rh iq, full-dose, im	Therapeutic Injections					3.10	
90385		Rh iq, minidose, im	Therapeutic Injections					1.73	
90386		Rh iq, iv	Therapeutic Injections					6.95	
90389		Tetanus iq, im	Therapeutic Injections					3.85	
90396		Varicella-zoster iq, im	Therapeutic Injections					2.75	
90399		Immune globulin	Therapeutic Injections					4.56	
90455		Immune admin 1 inj, < 8 yrs	Immunizations		0.17	0.31	0.31		
90466		Immune admin addl inj, < 8 y	Immunizations		0.15	0.13	0.13		
90467		Immune admin o or n, < 8 yrs	Immunizations	a, b	0.17	0.09	0.17		RBRVS CALC
90468		Immune admin o/n, addl < 8 y	Immunizations	a, b	0.15	0.13	0.13		
90471		Immunization admin	Immunizations		0.17	0.31	0.31		
90472		Immunization admin, each add	Immunizations		0.15	0.13	0.13		
90473		Immune admin oral/nasal	Immunizations					0.36	
90474		Immune admin oral/nasal addl	Immunizations					0.36	
90476		Adenovirus vaccine, type 4	Immunizations					1.05	
90477		Adenovirus vaccine, type 7	Immunizations					0.41	
90581		Anthrax vaccine, sc	Immunizations					2.97	
90585		Bcg vaccine, percut	Immunizations					4.00	
90586		Bcg vaccine, intravesical	Immunizations					3.19	
90632		Hep a vaccine, adult im	Immunizations					1.21	
90633		Hep a vacc, ped/adol, 2 dose	Immunizations					0.96	
90634		Hep a vacc, ped/adol, 3 dose	Immunizations					0.96	
90636		Hep a/hep b vacc, adult im	Immunizations					1.73	
90645		Hib vaccine, hboc, im	Immunizations					0.57	
90646		Hib vaccine, prp-d, im	Immunizations					0.61	
90647		Hib vaccine, prp-omp, im	Immunizations					0.57	
90648		Hib vaccine, prp-t, im	Immunizations					0.64	
90657		Flu vaccine, 6-35 mo, im	Immunizations					0.25	
90658		Flu vaccine, 3 yrs, im	Immunizations					0.25	
90660		Flu vaccine, nasal	Immunizations					0.34	
90665		Lyme disease vaccine, im	Immunizations					1.41	
90669		Pneumococcal vacc, ped <5	Immunizations					1.27	
90675		Rabies vaccine, im	Immunizations					2.80	
90676		Rabies vaccine, id	Immunizations					2.75	
90680		Rotavirus vaccine, oral	Immunizations					0.76	
90690		Typhoid vaccine, oral	Immunizations					0.78	
90691		Typhoid vaccine, im	Immunizations					0.93	
90692		Typhoid vaccine, h-p, sc/d	Immunizations					0.85	
90693		Typhoid vaccine, akd, sc	Immunizations					0.76	
90700		Dtap vaccine, im	Immunizations					0.61	
90701		Dtp vaccine, im	Immunizations					0.51	
90702		Dt vaccine < 7, im	Immunizations					0.32	
90703		Tetanus vaccine, im	Immunizations					0.32	
90704		Mumps vaccine, sc	Immunizations					0.57	
90705		Measles vaccine, sc	Immunizations					0.51	
90706		Rubella vaccine, sc	Immunizations					0.51	
90707		Mmr vaccine, sc	Immunizations					0.83	
90708		Measles-rubella vaccine, sc	Immunizations					0.70	
90710		Mmr vaccine, sc	Immunizations					0.99	
90712		Oral poliovirus vaccine	Immunizations					0.47	
90713		Poliovirus, ipv, sc	Immunizations					0.57	
90716		Chicken pox vaccine, sc	Immunizations					1.10	
90717		Yellow fever vaccine, sc	Immunizations					1.27	
90718		Td vaccine > 7, im	Immunizations					0.33	
90719		Diphtheria vaccine, im	Immunizations					0.32	

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 99 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
90720		Dtp/hib vaccine, im	Immunizations					0.89	
90721		Dtap/hib vaccine, im	Immunizations					0.96	
90723		Dtap-hep b-ipv vaccine, im	Immunizations					1.47	
90725		Cholera vaccine, injectable	Immunizations					0.40	
90727		Plague vaccine, im	Immunizations					0.38	
90732		Pneumococcal vaccine	Immunizations					0.41	
90733		Meningococcal vaccine, sc	Immunizations					1.34	
90735		Encephalitis vaccine, sc	Immunizations					1.53	
90740		Hepb vacc, ill pat 3 dose im	Immunizations					5.05	
90743		Hep b vacc, adol, 2 dose, im	Immunizations					1.02	
90744		Hepb vacc ped/adol 3 dose im	Immunizations					0.76	
90746		Hep b vaccine, adult, im	Immunizations					1.15	
90747		Hepb vacc, ill pat 4 dose im	Immunizations					4.31	
90748		Hep b/hib vaccine, im	Immunizations					1.07	
90749		Vaccine toxoid	Immunizations					0.61	
90760		Hydration iv infusion, init	Therapeutic Injections	b	0.17	1.43	1.43		RBRVS
90761		Hydrate iv infusion, add-on	Therapeutic Injections	b	0.09	0.40	0.40		RBRVS
90765		Ther/proph/diaq iv inf, init	Therapeutic Injections	b	0.21	1.76	1.76		RBRVS
90766		Ther/proph/dq iv inf, add-on	Therapeutic Injections	b	0.18	0.46	0.46		RBRVS
90767		Tx/proph/dq addl seq iv inf	Therapeutic Injections	b	0.19	0.89	0.89		RBRVS
90768		Ther/diaq concurrent inf	Therapeutic Injections	b	0.17	0.44	0.44		RBRVS
90772		Ther/proph/diaq inj, sc/im	Therapeutic Injections	a	0.17	0.31	0.31		RBRVS
90773		Ther/proph/diaq inj, ia	Therapeutic Injections	a	0.17	0.32	0.32		RBRVS
90774		Ther/proph/diaq inj, iv push	Therapeutic Injections	b	0.18	1.30	1.30		RBRVS
90775		Ther/proph/diaq inj add-on	Therapeutic Injections	b	0.10	0.57	0.57		RBRVS
90801		Psy dx interview	OP Psych./A/c. & Drug Abuse		2.80	0.93	1.17		
90802		Intac psy dx interview	OP Psych./A/c. & Drug Abuse		3.01	0.98	1.20		
90804		Psytx, office, 20-30 min	OP Psych./A/c. & Drug Abuse		1.21	0.38	0.49		
90805		Psytx, off, 20-30 min w/e&m	OP Psych./A/c. & Drug Abuse		1.37	0.42	0.50		
90806		Psytx, off, 45-50 min	OP Psych./A/c. & Drug Abuse		1.86	0.60	0.70		
90807		Psytx, off, 45-50 min w/e&m	OP Psych./A/c. & Drug Abuse		2.02	0.63	0.70		
90808		Psytx, office, 75-80 min	OP Psych./A/c. & Drug Abuse		2.79	0.90	1.03		
90809		Psytx, off, 75-80, w/e&m	OP Psych./A/c. & Drug Abuse		2.95	0.92	1.00		
90810		Intac psytx, off, 20-30 min	OP Psych./A/c. & Drug Abuse		1.32	0.42	0.51		
90811		Intac psytx, 20-30, w/e&m	OP Psych./A/c. & Drug Abuse		1.48	0.46	0.57		
90812		Intac psytx, off, 45-50 min	OP Psych./A/c. & Drug Abuse		1.97	0.64	0.79		
90813		Intac psytx, 45-50 min w/e&m	OP Psych./A/c. & Drug Abuse		2.13	0.67	0.77		
90814		Intac psytx, off, 75-80 min	OP Psych./A/c. & Drug Abuse		2.90	0.98	1.10		
90815		Intac psytx, 75-80 w/e&m	OP Psych./A/c. & Drug Abuse		3.06	0.95	1.05		
90816		Psytx, hosp, 20-30 min	OP Psych./A/c. & Drug Abuse		1.25	0.46	0.46		
90817		Psytx, hosp, 20-30 min w/e&m	OP Psych./A/c. & Drug Abuse		1.41	0.46	0.46		
90818		Psytx, hosp, 45-50 min	OP Psych./A/c. & Drug Abuse		1.89	0.69	0.69		
90819		Psytx, hosp, 45-50 min w/e&m	OP Psych./A/c. & Drug Abuse		2.05	0.65	0.65		
90821		Psytx, hosp, 75-80 min	OP Psych./A/c. & Drug Abuse		2.83	1.01	1.01		
90822		Psytx, hosp, 75-80 min w/e&m	OP Psych./A/c. & Drug Abuse		2.99	0.95	0.95		
90823		Intac psytx, hosp, 20-30 min	OP Psych./A/c. & Drug Abuse		1.36	0.48	0.48		
90824		Intac psytx, hsp 20-30 w/e&m	OP Psych./A/c. & Drug Abuse		1.52	0.49	0.49		
90826		Intac psytx, hosp, 45-50 min	OP Psych./A/c. & Drug Abuse		2.01	0.72	0.72		
90827		Intac psytx, hsp 45-50 w/e&m	OP Psych./A/c. & Drug Abuse		2.16	0.68	0.68		
90828		Intac psytx, hosp, 75-80 min	OP Psych./A/c. & Drug Abuse		2.94	1.06	1.06		
90829		Intac psytx, hsp 75-80 w/e&m	OP Psych./A/c. & Drug Abuse		3.10	0.98	0.98		
90845		Psychoanalysis	OP Psych./A/c. & Drug Abuse		1.79	0.55	0.58		
90846		Family psytx w/o patient	OP Psych./A/c. & Drug Abuse		1.83	0.65	0.65		
90847		Family psytx w/patient	OP Psych./A/c. & Drug Abuse		2.21	0.76	0.82		
90849		Multiple family group psytx	OP Psych./A/c. & Drug Abuse		0.59	0.24	0.27		
90853		Group psychotherapy	OP Psych./A/c. & Drug Abuse		0.59	0.23	0.25		
90857		Intac group psytx	OP Psych./A/c. & Drug Abuse		0.63	0.25	0.29		
90862		Medication management	OP Psych./A/c. & Drug Abuse		0.95	0.32	0.40		
90865		Narcosisynthesis	OP Psych./A/c. & Drug Abuse		2.84	0.91	1.36		
90870		Electroconvulsive therapy	OP Psych./A/c. & Drug Abuse		1.88	0.59	1.94		
90875		Psychophysiological therapy	OP Psych./A/c. & Drug Abuse		1.20	0.46	0.90		
90876		Psychophysiological therapy	OP Psych./A/c. & Drug Abuse		1.90	0.73	1.16		
90880		Hypnotherapy	OP Psych./A/c. & Drug Abuse		2.19	0.69	1.04		
90882		Environmental manipulation	OP Psych./A/c. & Drug Abuse					3.32	
90885		Psy evaluation of records	OP Psych./A/c. & Drug Abuse		0.97	0.37	0.37		
90887		Consultation with family	OP Psych./A/c. & Drug Abuse		1.48	0.56	0.82		
90889		Preparation of report	OP Psych./A/c. & Drug Abuse					2.86	
90899		Psychiatric service/therapy	OP Psych./A/c. & Drug Abuse					2.56	
90901		Biofeedback train, any meth	Miscellaneous Medical		0.41	0.14	0.65		
90911		Biofeedback peri/urorectal	Miscellaneous Medical		0.89	0.31	1.56		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 100 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
90918		ESRD related services, month	Miscellaneous Medical		11.16	6.13	6.13		
90919		ESRD related services, month	Miscellaneous Medical		8.53	4.01	4.01		
90920		ESRD related services, month	Miscellaneous Medical		7.26	3.76	3.76		
90921		ESRD related services, month	Miscellaneous Medical		4.46	2.45	2.45		
90922		ESRD related services, day	Miscellaneous Medical		0.37	0.21	0.21		
90923		Esr related services, day	Miscellaneous Medical		0.28	0.13	0.13		
90924		Esr related services, day	Miscellaneous Medical		0.24	0.12	0.12		
90925		Esr related services, day	Miscellaneous Medical		0.15	0.08	0.08		
90935		Hemodialysis, one evaluation	Miscellaneous Medical		1.22	0.67	0.67		
90937		Hemodialysis, repeated eval	Miscellaneous Medical		2.11	0.97	0.97		
90940	26	Hemodialysis access study	Miscellaneous Medical					0.92	
90940	TC	Hemodialysis access study	Miscellaneous Medical					1.37	
90945		Dialysis, one evaluation	Miscellaneous Medical	a	1.28	0.69	0.69		
90947		Dialysis, repeated eval	Miscellaneous Medical		2.16	0.99	0.99		
90989		Dialysis training, complete	Miscellaneous Medical					14.95	
90993		Dialysis training, incompl	Miscellaneous Medical					2.52	
90997		Hemoperfusion	Miscellaneous Medical		1.84	0.66	0.66		
90999		Dialysis procedure	Miscellaneous Medical					3.09	
91000	26	Esophageal intubation	Miscellaneous Medical		0.73	0.25	0.25		
91000	TC	Esophageal intubation	Miscellaneous Medical	a	0.00	0.08	0.08		
91010	26	Esophagus motility study	Miscellaneous Medical		1.25	0.44	0.44		
91010	TC	Esophagus motility study	Miscellaneous Medical	a	0.00	3.98	3.98		
91011	26	Esophagus motility study	Miscellaneous Medical		1.50	0.53	0.53		
91011	TC	Esophagus motility study	Miscellaneous Medical	a	0.00	4.71	4.71		
91012	26	Esophagus motility study	Miscellaneous Medical		1.46	0.51	0.51		
91012	TC	Esophagus motility study	Miscellaneous Medical	a	0.00	5.26	5.26		
91020	26	Gastric motility	Miscellaneous Medical		1.44	0.49	0.49		
91020	TC	Gastric motility	Miscellaneous Medical	a	0.00	4.04	4.04		
91022	26	Duodenal motility study	Miscellaneous Medical		1.44	0.51	0.51		
91022	TC	Duodenal motility study	Miscellaneous Medical	a	0.00	3.90	3.90		RBRVS
91030	26	Acid perfusion of esophagus	Miscellaneous Medical		0.91	0.32	0.32		
91030	TC	Acid perfusion of esophagus	Miscellaneous Medical	a	0.00	2.12	2.12		RBRVS
91034	26	Gastroesophageal reflux test	Miscellaneous Medical		0.97	0.34	0.34		
91034	TC	Gastroesophageal reflux test	Miscellaneous Medical	a	0.00	4.91	4.91		
91035	26	G-esoph reflx tst w/electrod	Miscellaneous Medical		1.59	0.56	0.56		
91035	TC	G-esoph reflx tst w/electrod	Miscellaneous Medical	a	0.00	10.27	10.27		
91037	26	Esoph impeded function test	Miscellaneous Medical		0.97	0.34	0.34		
91037	TC	Esoph impeded function test	Miscellaneous Medical	a	0.00	2.60	2.60		
91038	26	Esoph impeded funct test > 1h	Miscellaneous Medical		1.10	0.39	0.39		
91038	TC	Esoph impeded funct test > 1h	Miscellaneous Medical	a	0.00	1.84	1.84		
91040	26	Esoph balloon distension tst	Miscellaneous Medical		0.97	0.34	0.34		
91040	TC	Esoph balloon distension tst	Miscellaneous Medical	a	0.00	10.82	10.82		
91052	26	Gastric analysis test	Miscellaneous Medical		0.79	0.28	0.28		
91052	TC	Gastric analysis test	Miscellaneous Medical	a	0.00	2.18	2.18		
91055	26	Gastric intubation for smear	Miscellaneous Medical		0.94	0.27	0.27		
91055	TC	Gastric intubation for smear	Miscellaneous Medical	a	0.00	2.68	2.68		
91060	26	Gastric saline load test	Miscellaneous Medical		0.45	0.14	0.14		
91060	TC	Gastric saline load test	Miscellaneous Medical	a	0.00	1.83	1.83		
91065	26	Breath hydrogen test	Miscellaneous Medical		0.20	0.07	0.07		
91065	TC	Breath hydrogen test	Miscellaneous Medical	a	0.00	1.39	1.39		
91100		Pass intestine bleeding tube	Miscellaneous Medical		1.08	0.28	2.80		
91105		Gastric intubation treatment	Miscellaneous Medical		0.37	0.09	2.11		
91110		Gi tract capsule endoscopy	Miscellaneous Medical		3.64	22.24	22.24		
91110		Gi tract capsule endoscopy	Miscellaneous Medical		3.64	22.24	22.24		
91120		Rectal sensation test	Miscellaneous Medical	a	0.97	11.01	11.01		
91120		Rectal sensation test	Miscellaneous Medical	a	0.97	11.01	11.01		
91120		Rectal sensation test	Miscellaneous Medical	a	0.97	11.01	11.01		
91122	26	Anal pressure record	Miscellaneous Medical		1.77	0.60	0.60		
91122	TC	Anal pressure record	Miscellaneous Medical	a	0.00	4.51	4.51		
91123		Irrigate fecal impaction	Miscellaneous Medical					2.04	
91132	26	Electrogastrography	Miscellaneous Medical		0.52	0.18	0.18		RBRVS
91133	26	Electrogastrography w/test	Miscellaneous Medical		0.66	0.23	0.23		RBRVS
91299		Gastroenterology procedure	Miscellaneous Medical					3.96	
92002		Eye exam, new patient	Vision Exams		0.88	0.34	0.97		
92004		Eye exam, new patient	Vision Exams		1.67	0.68	1.70		
92012		Eye exam established pat	Vision Exams		0.67	0.29	1.03		
92014		Eye exam & treatment	Vision Exams		1.10	0.47	1.41		
92015		Refraction	Vision Exams		0.38	0.15	1.49		
92018		New eye exam & treatment	Miscellaneous Medical		2.50	1.07	1.07		
92019		Eye exam & treatment	Miscellaneous Medical		1.31	0.56	0.56		

NOTES: CPT Codes and descriptions only are copyright 2005 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 101 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
92020		Special eye evaluation	Miscellaneous Medical		0.37	0.16	0.34		
92060		Special eye evaluation	Miscellaneous Medical		0.69	0.73	0.73		
92060		Special eye evaluation	Miscellaneous Medical		0.69	0.73	0.73		
92065		Orthoptic/pleoptic training	Miscellaneous Medical		0.37	0.53	0.53		
92065		Orthoptic/pleoptic training	Miscellaneous Medical		0.37	0.53	0.53		
92070		Fitting of contact lens	Miscellaneous Medical		0.70	0.32	1.07		
92081	26	Visual field examination(s)	Miscellaneous Medical		0.36	0.15	0.15		
92081	TC	Visual field examination(s)	Miscellaneous Medical	a	0.00	0.79	0.79		
92082	26	Visual field examination(s)	Miscellaneous Medical		0.44	0.19	0.19		
92082	TC	Visual field examination(s)	Miscellaneous Medical	a	0.00	1.04	1.04		
92083	26	Visual field examination(s)	Miscellaneous Medical		0.50	0.22	0.22		
92083	TC	Visual field examination(s)	Miscellaneous Medical	a	0.00	1.21	1.21		
92100		Serial tonometry exam(s)	Miscellaneous Medical		0.92	0.36	1.35		
92120		Tonography & eye evaluation	Miscellaneous Medical		0.81	0.32	1.07		
92130		Water provocation tonography	Miscellaneous Medical		0.81	0.37	1.28		
92135	26	Ophthalmic dx imaging	Miscellaneous Medical		0.35	0.15	0.15		
92135	TC	Ophthalmic dx imaging	Miscellaneous Medical	a	0.00	0.64	0.64		
92136	26	Ophthalmic biometry	Miscellaneous Medical		0.54	0.24	0.24		
92136	TC	Ophthalmic biometry	Miscellaneous Medical	a	0.00	1.41	1.41		
92140		Glaucoma provocative tests	Miscellaneous Medical		0.50	0.21	0.99		
92225		Special eye exam, initial	Miscellaneous Medical		0.38	0.16	0.22		
92226		Special eye exam, subsequent	Miscellaneous Medical		0.33	0.14	0.21		
92230		Eye exam with photos	Miscellaneous Medical		0.60	0.20	1.53		
92235	26	Eye exam with photos	Miscellaneous Medical		0.81	0.37	0.37		
92235	TC	Eye exam with photos	Miscellaneous Medical	a	0.00	2.25	2.25		
92240	26	Icg angiography	Miscellaneous Medical		1.10	0.50	0.50		
92240	TC	Icg angiography	Miscellaneous Medical	a	0.00	5.62	5.62		
92250	26	Eye exam with photos	Miscellaneous Medical		0.44	0.19	0.19		
92250	TC	Eye exam with photos	Miscellaneous Medical	a	0.00	1.34	1.34		
92260		Ophthalmoscopy/dynamometry	Miscellaneous Medical		0.20	0.09	0.26		
92265	26	Eye muscle evaluation	Miscellaneous Medical		0.81	0.28	0.28		
92265	TC	Eye muscle evaluation	Miscellaneous Medical	a	0.00	1.21	1.21		
92270	26	Electro-oculography	Miscellaneous Medical		0.81	0.33	0.33		
92270	TC	Electro-oculography	Miscellaneous Medical	a	0.00	1.20	1.20		
92275	26	Electroretinography	Miscellaneous Medical		1.01	0.43	0.43		
92275	TC	Electroretinography	Miscellaneous Medical	a	0.00	1.51	1.51		
92283		Color vision examination	Miscellaneous Medical		0.17	0.84	0.84		
92283		Color vision examination	Miscellaneous Medical		0.17	0.84	0.84		
92284		Dark adaptation eye exam	Miscellaneous Medical		0.24	1.89	1.89		
92284		Dark adaptation eye exam	Miscellaneous Medical		0.24	1.89	1.89		
92285	26	Eye photography	Miscellaneous Medical		0.20	0.09	0.09		
92285	TC	Eye photography	Miscellaneous Medical	a	0.00	0.90	0.90		
92286	26	Internal eye photography	Miscellaneous Medical		0.66	0.29	0.29		
92286	TC	Internal eye photography	Miscellaneous Medical	a	0.00	2.77	2.77		
92287	26	Internal eye photography	Miscellaneous Medical		0.66	0.29	0.29	1.50	
92287	TC	Internal eye photography	Miscellaneous Medical	a	0.00	2.77	2.77	2.00	
92310		Contact lens fitting	Vision Exams		1.17	0.45	1.12		
92311		Contact lens fitting	Miscellaneous Medical		1.08	0.35	1.09		
92312		Contact lens fitting	Miscellaneous Medical		1.26	0.50	1.08		
92313		Contact lens fitting	Miscellaneous Medical		0.92	0.29	1.06		
92314		Prescription of contact lens	Vision Exams		0.69	0.27	0.94		
92315		Prescription of contact lens	Miscellaneous Medical		0.45	0.16	0.85		
92316		Prescription of contact lens	Miscellaneous Medical		0.68	0.29	0.91		
92317		Prescription of contact lens	Miscellaneous Medical		0.45	0.15	0.94		
92325		Modification of contact lens	Vision Exams		0.00	0.40	0.40		
92326		Replacement of contact lens	Vision Exams		0.00	1.63	1.63		
92340		Fitting of spectacles	Vision Exams		0.37	0.14	0.70		
92341		Fitting of spectacles	Vision Exams		0.47	0.18	0.74		
92342		Fitting of spectacles	Vision Exams		0.53	0.21	0.76		
92352		Special spectacles fitting	Miscellaneous Medical		0.37	0.14	0.68		
92353		Special spectacles fitting	Miscellaneous Medical		0.50	0.19	0.73		
92354		Special spectacles fitting	Miscellaneous Medical		0.00	8.89	8.89		
92355		Special spectacles fitting	Miscellaneous Medical		0.00	4.34	4.34		
92358		Eye prosthesis service	Miscellaneous Medical		0.00	0.97	0.97		
92370		Repair & adjust spectacles	Vision Exams		0.32	0.13	0.55		
92371		Repair & adjust spectacles	Miscellaneous Medical		0.00	0.62	0.62		
92499		Eye service or procedure	Miscellaneous Medical					1.15	
92502		Ear and throat examination	Miscellaneous Medical		1.51	1.11	1.11		
92504		Ear microscopy examination	Miscellaneous Medical		0.18	0.09	0.50		
92506		Speech/hearing evaluation	Hearing/Speech Exams		0.86	0.40	2.60		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for notes regarding Charge Methodology.

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 102 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
92507		Speech/hearing therapy	Hearing/Speech Exams		0.52	0.23	1.11		
92508		Speech/hearing therapy	Hearing/Speech Exams		0.26	0.12	0.51		
92511		Nasopharyngoscopy	Miscellaneous Medical		0.84	0.78	3.32		
92512		Nasal function studies	Miscellaneous Medical		0.55	0.18	1.14		
92516		Facial nerve function test	Miscellaneous Medical		0.43	0.22	1.20		
92520		Laryngeal function studies	Miscellaneous Medical		0.75	0.39	0.51		
92526		Oral function therapy	Miscellaneous Medical		0.55	0.20	1.64		
92531		Spontaneous nystagmus study	Miscellaneous Medical					0.64	
92532		Positional nystagmus test	Miscellaneous Medical					0.75	
92533		Caloric vestibular test	Miscellaneous Medical					1.20	
92534		Optokinetic nystagmus test	Miscellaneous Medical					0.53	
92541	26	Spontaneous nystagmus test	Miscellaneous Medical		0.40	0.19	0.19		
92541	TC	Spontaneous nystagmus test	Miscellaneous Medical	a	0.00	0.84	0.84		
92542	26	Positional nystagmus test	Miscellaneous Medical		0.33	0.16	0.16		
92542	TC	Positional nystagmus test	Miscellaneous Medical	a	0.00	0.98	0.98		
92543	26	Caloric vestibular test	Miscellaneous Medical		0.10	0.05	0.05		
92543	TC	Caloric vestibular test	Miscellaneous Medical	a	0.00	0.52	0.52		
92544	26	Optokinetic nystagmus test	Miscellaneous Medical		0.26	0.12	0.12		
92544	TC	Optokinetic nystagmus test	Miscellaneous Medical	a	0.00	0.78	0.78		
92545	26	Oscillating tracking test	Miscellaneous Medical		0.23	0.11	0.11		
92545	TC	Oscillating tracking test	Miscellaneous Medical	a	0.00	0.69	0.69		
92546	26	Sinusoidal rotational test	Miscellaneous Medical		0.29	0.13	0.13		
92546	TC	Sinusoidal rotational test	Miscellaneous Medical	a	0.00	1.86	1.86		
92547		Supplemental electrical test	Miscellaneous Medical	a	0.00	0.08	0.08		
92548		Posturography	Miscellaneous Medical		0.50	2.26	2.26		
92548		Posturography	Miscellaneous Medical		0.50	2.26	2.26		
92551		Pure tone hearing test, air	Hearing/Speech Exams					0.39	
92552		Pure tone audiometry, air	Hearing/Speech Exams	a	0.00	0.44	0.44		
92553		Audiometry, air & bone	Hearing/Speech Exams	a	0.00	0.66	0.66		
92555		Speech threshold audiometry	Hearing/Speech Exams	a	0.00	0.38	0.38		
92556		Speech audiometry, complete	Hearing/Speech Exams	a	0.00	0.57	0.57		
92557		Comprehensive hearing test	Hearing/Speech Exams	a	0.00	1.19	1.19		
92559		Group audiometric testing	Hearing/Speech Exams					1.26	
92560		Bekesy audiometry, screen	Hearing/Speech Exams					0.75	
92561		Bekesy audiometry, diagnosis	Hearing/Speech Exams	a	0.00	0.72	0.72		
92562		Loudness balance test	Hearing/Speech Exams	a	0.00	0.41	0.41		
92563		Tone decay hearing test	Hearing/Speech Exams	a	0.00	0.38	0.38		
92564		Sisi hearing test	Hearing/Speech Exams	a	0.00	0.47	0.47		
92565		Stenger test, pure tone	Hearing/Speech Exams	a	0.00	0.40	0.40		
92567		Tympanometry	Hearing/Speech Exams	a	0.00	0.52	0.52		
92568		Acoustic reflex testing	Hearing/Speech Exams	a	0.00	0.38	0.38		
92569		Acoustic reflex decay test	Hearing/Speech Exams	a	0.00	0.41	0.41		
92571		Filtered speech hearing test	Hearing/Speech Exams	a	0.00	0.39	0.39		
92572		Staggered spondaic word test	Hearing/Speech Exams	a	0.00	0.09	0.09		
92573		Lombard test	Hearing/Speech Exams	a	0.00	0.35	0.35		
92575		Sensorineural acuity test	Hearing/Speech Exams	a	0.00	0.30	0.30		
92576		Synthetic sentence test	Hearing/Speech Exams	a	0.00	0.44	0.44		
92577		Stenger test, speech	Hearing/Speech Exams	a	0.00	0.72	0.72		
92579		Visual audiometry (vra)	Hearing/Speech Exams	a	0.00	0.73	0.73		
92582		Conditioning play audiometry	Hearing/Speech Exams	a	0.00	0.73	0.73		
92583		Select picture audiometry	Hearing/Speech Exams	a	0.00	0.89	0.89		
92584		Electrocochleography	Hearing/Speech Exams	a	0.00	2.48	2.48		
92585	26	Auditor evoke potent, compre	Hearing/Speech Exams		0.50	0.21	0.21		
92585	TC	Auditor evoke potent, compre	Hearing/Speech Exams	a	0.00	1.86	1.86		
92586		Auditor evoke potent, limit	Hearing/Speech Exams	a	0.00	1.86	1.86		
92587	26	Evoked auditory test	Hearing/Speech Exams		0.13	0.06	0.06		
92587	TC	Evoked auditory test	Hearing/Speech Exams	a	0.00	1.31	1.31		
92588	26	Evoked auditory test	Hearing/Speech Exams		0.36	0.16	0.16		
92588	TC	Evoked auditory test	Hearing/Speech Exams	a	0.00	1.47	1.47		
92590		Hearing aid exam, one ear	Hearing/Speech Exams					1.51	
92591		Hearing aid exam, both ears	Hearing/Speech Exams					2.26	
92592		Hearing aid check, one ear	Hearing/Speech Exams					0.66	
92593		Hearing aid check, both ears	Hearing/Speech Exams					0.99	
92594		Electro hearing aid test, one	Hearing/Speech Exams					0.72	
92595		Electro hearing aid test, both	Hearing/Speech Exams					1.08	
92596		Ear protector evaluation	Hearing/Speech Exams	a	0.00	0.59	0.59		
92597		Oral speech device eval	Hearing/Speech Exams		0.86	0.45	1.69		
92601		Cochlear implt f/up exam < 7	Miscellaneous Medical		0.00	3.51	3.51		
92602		Reprogram cochlear implt < 7	Miscellaneous Medical		0.00	2.39	2.39		
92603		Cochlear implt f/up exam 7 >	Miscellaneous Medical		0.00	2.15	2.15		

NOTES. CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 103 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
92604		Reprogram cochlear implt 7 >	Miscellaneous Medical		0.00	1.35	1.35		
92607		Ex for speech device rx, 1hr	Miscellaneous Medical		0.00	3.09	3.09		
92608		Ex for speech device rx, addl	Miscellaneous Medical		0.00	0.55	0.55		
92609		Use of speech device service	Miscellaneous Medical		0.00	1.59	1.59		
92610		Evaluate swallowing function	Miscellaneous Medical		0.00	3.44	3.44		
92611		Motion fluoroscopy/swallow	Miscellaneous Medical		0.00	3.44	3.44		
92612		Endoscopy swallow tst (fees)	Miscellaneous Medical		1.27	0.66	2.75		
92613		Endoscopy swallow tst (fees)	Miscellaneous Medical		0.71	0.39	0.40		
92614		Laryngoscopic sensory test	Miscellaneous Medical		1.27	0.66	2.51		
92615		Eval laryngoscopy sense tst	Miscellaneous Medical		0.63	0.35	0.35		
92616		Fees w/laryngeal sense test	Miscellaneous Medical		1.88	0.99	3.40		
92617		Interprt fees/laryngeal test	Miscellaneous Medical		0.79	0.44	0.44		
92620		Auditory function, 60 min	Hearing/Speech Exams		0.00	1.14	1.14		
92621		Auditory function, + 15 min	Hearing/Speech Exams		0.00	0.25	0.25		
92625		Tinnitus assessment	Hearing/Speech Exams		0.00	1.12	1.12		
92626		Eval aud rehab status	Miscellaneous Medical	a	0.00	0.55	0.55		RBRVS
92700		Ent procedure/service	Miscellaneous Medical					0.46	
92950		Heart/lung resuscitation cpr	Cardiovascular		3.79	0.97	4.21		
92953		Temporary external pacinq	Cardiovascular		0.23	0.07	0.07		
92960		Cardioversion electric, ext	Cardiovascular		2.25	1.17	6.33		
92961	26	Cardioversion, electric, int	Cardiovascular					3.67	
92961	TC	Cardioversion, electric, int	Cardiovascular	a				3.01	
92970		Cardioassist, internal	Cardiovascular		3.51	1.06	1.06		
92971		Cardioassist, external	Cardiovascular		1.77	0.85	0.85		
92973		Percut coronary thrombectomy	Surgery		3.28	1.29	1.29		
92974		Cath place, cardio brachytx	Surgery		3.00	1.18	1.18		
92975		Dissolve dot, heart vessel	Cardiovascular		7.24	2.82	2.82		
92977		Dissolve dot, heart vessel	Cardiovascular		0.00	8.07	8.07		
92978	26	Intravasc us, heart add-on	Cardiovascular		1.80	0.71	0.71		
92978	TC	Intravasc us, heart add-on	Cardiovascular	a	0.00	4.57	4.57		
92979	26	Intravasc us, heart add-on	Cardiovascular		1.44	0.56	0.56		
92979	TC	Intravasc us, heart add-on	Cardiovascular	a	0.00	2.30	2.30		
92980		Insert intracoronary stent	Surgery		14.82	6.07	6.07		
92981		Insert intracoronary stent	Surgery		4.16	1.63	1.63		
92982		Coronary artery dilation	Surgery		10.96	4.54	4.54		
92984		Coronary artery dilation	Surgery		2.97	1.16	1.16		
92986		Revision of aortic valve	Surgery		21.77	11.86	11.86		
92987		Revision of mitral valve	Surgery		22.67	12.25	12.25		
92990		Revision of pulmonary valve	Surgery		17.31	9.82	9.82		
92992		Revision of heart chamber	Surgery					36.93	
92993		Revision of heart chamber	Surgery					25.88	
92995		Coronary atherectomy	Surgery		12.07	4.97	4.97		
92996		Coronary atherectomy add-on	Surgery		3.26	1.27	1.27		
92997		Pul art balloon repr, percut	Surgery		11.98	4.83	4.83		
92998		Pul art balloon repr, percut	Surgery		5.99	2.21	2.21		
93000		Electrocardiogram, complete	Cardiovascular	a	0.17	0.51	0.51		
93005		Electrocardiogram, tracing	Cardiovascular	a	0.00	0.45	0.45		
93010		Electrocardiogram report	Cardiovascular		0.17	0.06	0.06		
93012		Transmission of ecg	Cardiovascular		0.00	6.03	6.03		
93014		Report on transmitted ecg	Cardiovascular		0.52	0.19	0.19		
93015		Cardiovascular stress test	Cardiovascular	a	0.75	1.96	1.96		
93016		Cardiovascular stress test	Cardiovascular		0.45	0.17	0.17		
93017		Cardiovascular stress test	Cardiovascular	a	0.00	1.68	1.68		
93018		Cardiovascular stress test	Cardiovascular		0.30	0.11	0.11		
93024	26	Cardiac drug stress test	Cardiovascular		1.17	0.45	0.45		
93024	TC	Cardiac drug stress test	Cardiovascular	a	0.00	1.12	1.12		
93025	TC	Microvolt t-wave assess	Cardiovascular		0.00	7.32	7.32		
93025		Microvolt t-wave assess	Cardiovascular		0.75	7.61	7.61		
93025		Microvolt t-wave assess	Cardiovascular		0.75	7.61	7.61		
93040		Rhythm ECG with report	Cardiovascular	a	0.16	0.20	0.20		
93041		Rhythm ECG, tracing	Cardiovascular	a	0.00	0.15	0.15		
93042		Rhythm ECG, report	Cardiovascular		0.16	0.05	0.05		
93224		ECG monitor/report, 24 hrs	Cardiovascular	a	0.52	3.62	3.62		
93225		ECG monitor/record, 24 hrs	Cardiovascular	a	0.00	1.24	1.24		
93226		ECG monitor/report, 24 hrs	Cardiovascular	a	0.00	2.19	2.19		
93227		ECG monitor/review, 24 hrs	Cardiovascular		0.52	0.19	0.19		
93230		ECG monitor/report, 24 hrs	Cardiovascular	a	0.52	3.90	3.90		
93231		Ecq monitor/record, 24 hrs	Cardiovascular	a	0.00	1.52	1.52		
93232		ECG monitor/report, 24 hrs	Cardiovascular		0.00	2.19	2.19		
93233		ECG monitor/review, 24 hrs	Cardiovascular		0.52	0.19	0.19		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/OFARS apply. See end of the table for notes regarding Charge Methodology

TABLE G -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 104 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
93235		ECG monitor/report, 24 hrs	Cardiovascular	a	0.45	2.79	2.79		
93236		ECG monitor/report, 24 hrs	Cardiovascular	a	0.00	2.63	2.63		
93237		ECG monitor/review, 24 hrs	Cardiovascular		0.45	0.16	0.16		
93268		ECG record/review	Cardiovascular	a	0.52	7.46	7.46		
93270		ECG recording	Cardiovascular	a	0.00	1.24	1.24		
93271		ECG/monitoring and analysis	Cardiovascular	a	0.00	6.03	6.03		
93272		ECG/review, interpret only	Cardiovascular		0.52	0.19	0.19		
93278	26	ECG/signal-averaged	Cardiovascular		0.25	0.10	0.10		
93278	TC	ECG/signal-averaged	Cardiovascular	a	0.00	1.15	1.15		
93303	26	Echo transthoracic	Cardiovascular		1.30	0.48	0.48		
93303	TC	Echo transthoracic	Cardiovascular	a	0.00	3.87	3.87		
93304	26	Echo transthoracic	Cardiovascular		0.75	0.28	0.28		
93304	TC	Echo transthoracic	Cardiovascular	a	0.00	1.95	1.95		
93307	26	Echo exam of heart	Cardiovascular		0.92	0.35	0.35		
93307	TC	Echo exam of heart	Cardiovascular	a	0.00	3.87	3.87		
93308	26	Echo exam of heart	Cardiovascular		0.53	0.20	0.20		
93308	TC	Echo exam of heart	Cardiovascular	a	0.00	1.95	1.95		
93312	26	Echo transesophageal	Cardiovascular		2.20	0.79	0.79		
93312	TC	Echo transesophageal	Cardiovascular	a	0.00	3.79	3.79		
93313		Echo transesophageal	Cardiovascular		0.95	0.21	0.21		
93314	26	Echo transesophageal	Cardiovascular		1.25	0.47	0.47		
93314	TC	Echo transesophageal	Cardiovascular	a	0.00	3.79	3.79		
93315	26	Echo transesophageal	Cardiovascular		2.78	1.01	1.01		
93315	TC	Echo transesophageal	Cardiovascular	a				4.19	
93316		Echo transesophageal	Cardiovascular		0.95	0.24	0.24		
93317	26	Echo transesophageal	Cardiovascular		1.83	0.67	0.67		
93317	TC	Echo transesophageal	Cardiovascular	a				3.43	
93318	26	Echo transesophageal intraop	Cardiovascular		2.20	0.48	0.48		
93318	TC	Echo transesophageal intraop	Cardiovascular	a				3.61	
93320	26	Doppler echo exam, heart	Cardiovascular		0.38	0.15	0.15		
93320	TC	Doppler echo exam, heart	Cardiovascular	a	0.00	1.71	1.71		
93321	26	Doppler echo exam, heart	Cardiovascular		0.15	0.06	0.06		
93321	TC	Doppler echo exam, heart	Cardiovascular	a	0.00	1.11	1.11		
93325	26	Doppler color flow add-on	Cardiovascular		0.07	0.03	0.03		
93325	TC	Doppler color flow add-on	Cardiovascular	a	0.00	2.91	2.91		
93350	26	Echo transthoracic	Cardiovascular		1.48	0.57	0.57		
93350	TC	Echo transthoracic	Cardiovascular	a	0.00	1.77	1.77		
93501	26	Right heart catheterization	Surgery		3.02	1.15	1.15		
93501	TC	Right heart catheterization	Surgery	a	0.00	16.95	16.95		
93503		Insert/place heart catheter	Surgery		2.91	0.68	0.68		
93505	26	Biopsy of heart lining	Surgery		4.37	1.68	1.68		
93505	TC	Biopsy of heart lining	Surgery	a	0.00	1.99	1.99		
93508	26	Cath placement, angiography	Surgery		4.09	2.09	2.09		
93508	TC	Cath placement, angiography	Surgery	a	0.00	12.64	12.64		
93510	26	Left heart catheterization	Surgery		4.32	2.18	2.18		
93510	TC	Left heart catheterization	Surgery	a	0.00	37.06	37.06		
93511	26	Left heart catheterization	Surgery		5.02	2.45	2.45		
93511	TC	Left heart catheterization	Surgery	a	0.00	36.07	36.07		
93514	26	Left heart catheterization	Surgery		7.04	3.13	3.13		
93524	26	Left heart catheterization	Surgery		6.94	3.18	3.18		
93524	TC	Left heart catheterization	Surgery	a	0.00	47.14	47.14		
93526	26	Rt & Lt heart catheters	Surgery		5.98	2.82	2.82		
93526	TC	Rt & Lt heart catheters	Surgery	a	0.00	48.43	48.43		
93527	26	Rt & Lt heart catheters	Surgery		7.27	3.32	3.32		
93527	TC	Rt & Lt heart catheters	Surgery	a	0.00	47.14	47.14		
93528	26	Rt & Lt heart catheters	Surgery		8.99	4.04	4.04		
93528	TC	Rt & Lt heart catheters	Surgery	a	0.00	47.14	47.14		
93529	26	Rt, lt heart catheterization	Surgery		4.79	2.28	2.28		
93529	TC	Rt, lt heart catheterization	Surgery	a	0.00	47.14	47.14		
93530	26	Rt heart cath, congenital	Surgery		4.22	1.94	1.94		
93530	TC	Rt heart cath, congenital	Surgery	a	0.00	16.95	16.95		
93531	26	R & I heart cath, congenital	Surgery		8.34	3.59	3.59		
93531	TC	R & I heart cath, congenital	Surgery	a	0.00	48.43	48.43		
93532	26	R & I heart cath, congenital	Surgery		9.99	4.26	4.26		
93533	26	R & I heart cath, congenital	Surgery		6.69	2.80	2.80		
93539		Injection, cardiac cath	Cardiovascular		0.40	0.16	0.16		
93540		Injection, cardiac cath	Cardiovascular		0.43	0.17	0.17		
93541		Injection for lung angiogram	Cardiovascular		0.29	0.11	0.11		
93542		Injection for heart x-rays	Cardiovascular		0.29	0.11	0.11		
93543		Injection for heart x-rays	Cardiovascular		0.29	0.11	0.11		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 105 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
93544		Injection for aortography	Cardiovascular		0.25	0.10	0.10		
93545		Inject for coronary x-rays	Cardiovascular		0.40	0.16	0.16		
93555	26	Imaging, cardiac cath	Cardiovascular		0.81	0.32	0.32		
93555	TC	Imaging, cardiac cath	Cardiovascular	a	0.00	6.29	6.29		
93556	26	Imaging, cardiac cath	Cardiovascular		0.83	0.32	0.32		
93556	TC	Imaging, cardiac cath	Cardiovascular	a	0.00	9.92	9.92		
93561	26	Cardiac output measurement	Surgery		0.50	0.16	0.16		
93561	TC	Cardiac output measurement	Surgery	a	0.00	0.52	0.52		
93562	26	Cardiac output measurement	Surgery		0.16	0.05	0.05		
93562	TC	Cardiac output measurement	Surgery	a	0.00	0.32	0.32		
93571		Heart flow reserve measure	Surgery		1.80	5.25	5.25		
93571		Heart flow reserve measure	Surgery		1.80	5.25	5.25		
93572	26	Heart flow reserve measure	Surgery		1.44	0.50	0.50		
93580		Transcath closure of asd	Surgery		17.97	7.40	7.40		RRBS
93581		Transcath closure of vsd	Surgery		24.39	9.42	9.42		
93600	26	Bundle of His recording	Cardiovascular		2.12	0.83	0.83		
93600	TC	Bundle of His recording	Cardiovascular	e	0.00	1.96	1.96		
93602	26	Intra-atrial recording	Cardiovascular		2.12	0.82	0.82		
93602	TC	Intra-atrial recording	Cardiovascular	a	0.00	1.11	1.11		
93603	26	Right ventricular recording	Cardiovascular		2.12	0.81	0.81		
93603	TC	Right ventricular recording	Cardiovascular	e	0.00	1.68	1.68		
93609	26	Map tachycardia, add-on	Cardiovascular		4.99	1.96	1.96		
93609	TC	Map tachycardia, add-on	Cardiovascular	a	0.00	2.73	2.73		
93610	26	Intra-atrial pacing	Cardiovascular		3.02	1.16	1.16		
93610	TC	Intra-atrial pacing	Cardiovascular	a	0.00	1.35	1.35		
93612	26	Intraventricular pacing	Cardiovascular		3.02	1.16	1.16		
93612	TC	Intraventricular pacing	Cardiovascular	a	0.00	1.61	1.61		
93613	26	Electrophys map 3d, add-on	Cardiovascular					5.36	
93613	TC	Electrophys map 3d, add-on	Cardiovascular	a				0.98	
93615	26	Esophageal recording	Cardiovascular		0.99	0.27	0.27		
93615	TC	Esophageal recording	Cardiovascular	a	0.00	0.32	0.32		
93616	26	Esophageal recording	Cardiovascular		1.49	0.43	0.43		
93618	26	Heart rhythm pacing	Cardiovascular		4.25	1.67	1.67		
93618	TC	Heart rhythm pacing	Cardiovascular	a	0.00	3.97	3.97		
93619	26	Electrophysiology evaluation	Cardiovascular		7.31	3.19	3.19		
93619	TC	Electrophysiology evaluation	Cardiovascular	a	0.00	7.72	7.72		
93620	26	Electrophysiology evaluation	Cardiovascular		11.57	4.85	4.85		
93620	TC	Electrophysiology evaluation	Cardiovascular	a				11.47	
93621	26	Electrophysiology evaluation	Cardiovascular		2.10	0.82	0.82		
93621	TC	Electrophysiology evaluation	Cardiovascular	a				3.89	
93622	26	Electrophysiology evaluation	Cardiovascular		3.10	1.21	1.21		
93622	TC	Electrophysiology evaluation	Cardiovascular	a				3.89	
93623	26	Stimulation, pacing heart	Cardiovascular		2.85	1.11	1.11		
93623	TC	Stimulation, pacing heart	Cardiovascular	a				3.53	
93624	26	Electrophysiologic study	Cardiovascular		4.80	2.20	2.20		
93624	TC	Electrophysiologic study	Cardiovascular	a	0.00	1.99	1.99		
93631	26	Heart pacing, mapping	Cardiovascular		7.59	2.78	2.78		
93640	26	Evaluation heart device	Cardiovascular		3.51	1.36	1.36		
93640	TC	Evaluation heart device	Cardiovascular	a	0.00	7.19	7.19		
93641	26	Electrophysiology evaluation	Cardiovascular		5.92	2.32	2.32		
93641	TC	Electrophysiology evaluation	Cardiovascular	a	0.00	7.19	7.19		
93642	26	Electrophysiology evaluation	Cardiovascular		4.88	2.22	2.22		
93642	TC	Electrophysiology evaluation	Cardiovascular	a	0.00	7.19	7.19		
93650		Ablate heart dysrhythm focus	Cardiovascular		10.49	4.44	4.44		
93651		Ablate heart dysrhythm focus	Cardiovascular		16.23	6.34	6.34		
93652		Ablate heart dysrhythm focus	Cardiovascular		17.65	6.90	6.90		
93660	26	Tilt table evaluation	Cardiovascular		1.89	0.74	0.74		
93660	TC	Tilt table evaluation	Cardiovascular	a	0.00	1.68	1.68		
93662	26	Intracardiac ecg (ice)	Cardiovascular		2.80	1.11	1.11		
93662	TC	Intracardiac ecg (ice)	Cardiovascular	a				4.40	
93668		Peripheral vascular rehab	Cardiovascular					1.83	
93701		Bioimpedance, thoracic	Cardiovascular		0.17	0.98	0.98		
93701		Bioimpedance, thoracic	Cardiovascular		0.17	0.98	0.98		
93720		Total body plethysmography	Cardiovascular		0.17	0.76	0.76		
93721		Plethysmography tracing	Cardiovascular		0.00	0.71	0.71		
93722		Plethysmography report	Cardiovascular		0.17	0.05	0.05		
93724	26	Analyze pacemaker system	Cardiovascular		4.88	1.92	1.92		
93724	TC	Analyze pacemaker system	Cardiovascular	e	0.00	3.97	3.97		
93727		Analyze ilr system	Cardiovascular		0.52	0.20	0.20		
93731	26	Analyze pacemaker system	Cardiovascular		0.45	0.17	0.17		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARIS/DFARS apply. See end of the table for notes regarding Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 106 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
93731	TC	Analyze pacemaker system	Cardiovascular	a	0.00	0.49	0.49		
93732	26	Analyze pacemaker system	Cardiovascular		0.92	0.35	0.35		
93732	TC	Analyze pacemaker system	Cardiovascular	a	0.00	0.51	0.51		
93733	26	Telephone analy, pacemaker	Cardiovascular		0.17	0.07	0.07		
93733	TC	Telephone analy, pacemaker	Cardiovascular	a	0.00	0.73	0.73		
93734	26	Analyze pacemaker system	Cardiovascular		0.38	0.15	0.15		
93734	TC	Analyze pacemaker system	Cardiovascular	a	0.00	0.35	0.35		
93735	26	Analyze pacemaker system	Cardiovascular		0.74	0.28	0.28		
93735	TC	Analyze pacemaker system	Cardiovascular	a	0.00	0.44	0.44		
93736	26	Telephone analy, pacemaker	Cardiovascular		0.15	0.06	0.06		
93736	TC	Telephone analy, pacemaker	Cardiovascular	a	0.00	0.63	0.63		
93740	26	Temperature gradient studies	Cardiovascular		0.16	0.04	0.04		
93740	TC	Temperature gradient studies	Cardiovascular	a	0.00	0.15	0.15		
93741	26	Analyze ht pace device snql	Cardiovascular		0.80	0.31	0.31		
93741	TC	Analyze ht pace device snql	Cardiovascular	a	0.00	0.67	0.67		
93742	26	Analyze ht pace device snql	Cardiovascular		0.91	0.36	0.36		
93742	TC	Analyze ht pace device snql	Cardiovascular	a	0.00	0.67	0.67		
93743	26	Analyze ht pace device dual	Cardiovascular		1.03	0.40	0.40		
93743	TC	Analyze ht pace device dual	Cardiovascular	a	0.00	0.73	0.73		
93744	26	Analyze ht pace device dual	Cardiovascular		1.18	0.46	0.46		
93744	TC	Analyze ht pace device dual	Cardiovascular	a	0.00	0.67	0.67		
93760	26	Cephalic thermogram	Cardiovascular					0.44	
93760	TC	Cephalic thermogram	Cardiovascular	a				1.74	
93762	26	Peripheral thermogram	Cardiovascular					0.64	
93762	TC	Peripheral thermogram	Cardiovascular	a				2.56	
93770	26	Measure venous pressura	Cardiovascular		0.16	0.05	0.05		
93770	TC	Measure venous pressure	Cardiovascular	a	0.00	0.03	0.03		
93784		Ambulatory BP monitoring	Cardiovascular	a	0.38	1.55	1.55		
93786		Ambulatory BP recording	Cardiovascular	a	0.00	0.91	0.91		
93788		Ambulatory BP analysis	Cardiovascular	a	0.00	0.51	0.51		
93790		Review/report BP recording	Cardiovascular		0.38	0.13	0.13		
93797		Cardiac rehab	Cardiovascular		0.18	0.07	0.07		
93798		Cardiac rehab/monitor	Cardiovascular		0.28	0.11	0.11		
93799		Cardiovascular procedure	Cardiovascular					0.68	
93875	26	Extracranial study	Miscellaneous Medical		0.22	0.08	0.08		
93875	TC	Extracranial study	Miscellaneous Medical	a	0.00	2.26	2.26		
93880	26	Extracranial study	Miscellaneous Medical		0.60	0.20	0.20		
93880	TC	Extracranial study	Miscellaneous Medical	a	0.00	5.37	5.37		
93882	26	Extracranial study	Miscellaneous Medical		0.40	0.14	0.14		
93882	TC	Extracranial study	Miscellaneous Medical	a	0.00	3.37	3.37		
93886	26	Intracranial study	Miscellaneous Medical		0.94	0.37	0.37		
93886	TC	Intracranial study	Miscellaneous Medical	a	0.00	6.39	6.39		
93888	26	Intracranial study	Miscellaneous Medical		0.62	0.23	0.23		
93888	TC	Intracranial study	Miscellaneous Medical	a	0.00	4.02	4.02		
93890	26	Tcd, vasoreactivity study	Cardiovascular		1.00	0.40	0.40		
93890	TC	Tcd, vasoreactivity study	Cardiovascular	a	0.00	4.51	4.51		
93892	26	Tcd, emboli detect w/o inj	Cardiovascular		1.15	0.46	0.46		
93892	TC	Tcd, emboli detect w/o inj	Cardiovascular	a	0.00	4.71	4.71		
93893	26	Tcd, emboli detect w/inj	Cardiovascular		1.15	0.46	0.46		
93893	TC	Tcd, emboli detect w/inj	Cardiovascular	a	0.00	4.58	4.58		
93922	26	Extremity study	Miscellaneous Medical		0.25	0.08	0.08		
93922	TC	Extremity study	Miscellaneous Medical	a	0.00	2.61	2.61		
93923	26	Extremity study	Miscellaneous Medical		0.45	0.15	0.15		
93923	TC	Extremity study	Miscellaneous Medical	a	0.00	3.89	3.89		
93924	26	Extremity study	Miscellaneous Medical		0.50	0.17	0.17		
93924	TC	Extremity study	Miscellaneous Medical	a	0.00	4.63	4.63		
93925	26	Lower extremity study	Miscellaneous Medical		0.58	0.20	0.20		
93925	TC	Lower extremity study	Miscellaneous Medical	a	0.00	6.60	6.60		
93926	26	Lower extremity study	Miscellaneous Medical		0.39	0.13	0.13		
93926	TC	Lower extremity study	Miscellaneous Medical	a	0.00	3.93	3.93		
93930	26	Upper extremity study	Miscellaneous Medical		0.46	0.16	0.16		
93930	TC	Upper extremity study	Miscellaneous Medical	a	0.00	5.21	5.21		
93931	26	Upper extremity study	Miscellaneous Medical		0.31	0.10	0.10		
93931	TC	Upper extremity study	Miscellaneous Medical	a	0.00	3.39	3.39		
93965	26	Extremity study	Miscellaneous Medical		0.35	0.12	0.12		
93965	TC	Extremity study	Miscellaneous Medical	a	0.00	2.68	2.68		
93970	26	Extremity study	Miscellaneous Medical		0.68	0.23	0.23		
93970	TC	Extremity study	Miscellaneous Medical	a	0.00	5.03	5.03		
93971	26	Extremity study	Miscellaneous Medical		0.45	0.15	0.15		
93971	TC	Extremity study	Miscellaneous Medical	a	0.00	3.45	3.45		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 107 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
93975	26	Vascular study	Miscellaneous Medical		1.80	0.60	0.60		
93975	TC	Vascular study	Miscellaneous Medical		0.00	7.05	7.05		
93976	26	Vascular study	Miscellaneous Medical		1.21	0.40	0.40		
93976	TC	Vascular study	Miscellaneous Medical	a	0.00	3.94	3.94		
93978	26	Vascular study	Miscellaneous Medical		0.65	0.22	0.22		
93978	TC	Vascular study	Miscellaneous Medical	a	0.00	4.30	4.30		
93979	26	Vascular study	Miscellaneous Medical		0.44	0.15	0.15		
93979	TC	Vascular study	Miscellaneous Medical	a	0.00	3.07	3.07		
93980	26	Penile vascular study	Miscellaneous Medical		1.25	0.41	0.41		
93980	TC	Penile vascular study	Miscellaneous Medical	a	0.00	2.45	2.45		
93981	26	Penile vascular study	Miscellaneous Medical		0.44	0.14	0.14		
93981	TC	Penile vascular study	Miscellaneous Medical	a	0.00	2.74	2.74		
93990	26	Doppler flow testing	Miscellaneous Medical		0.25	0.09	0.09		
93990	TC	Doppler flow testing	Miscellaneous Medical	a	0.00	3.91	3.91		
94010	26	Breathing capacity test	Miscellaneous Medical		0.17	0.05	0.05		
94010	TC	Breathing capacity test	Miscellaneous Medical	a	0.00	0.62	0.62		
94014		Patient recorded spirometry	Miscellaneous Medical	a	0.52	0.76	0.76		
94015		Patient recorded spirometry	Miscellaneous Medical	a	0.00	0.59	0.59		
94016		Review patient spirometry	Miscellaneous Medical		0.52	0.17	0.17		
94060	26	Evaluation of wheezing	Miscellaneous Medical		0.31	0.09	0.09		
94060	TC	Evaluation of wheezing	Miscellaneous Medical	a	0.00	0.98	0.98		
94070	26	Evaluation of wheezing	Miscellaneous Medical		0.60	0.18	0.18		
94070	TC	Evaluation of wheezing	Miscellaneous Medical	a	0.00	0.64	0.64		
94150	26	Vital capacity test	Miscellaneous Medical		0.07	0.03	0.03		
94150	TC	Vital capacity test	Miscellaneous Medical	a	0.00	0.44	0.44		
94200	26	Lung function test (MBC/MVV)	Miscellaneous Medical		0.11	0.03	0.03		
94200	TC	Lung function test (MBC/MVV)	Miscellaneous Medical	a	0.00	0.41	0.41		
94240	26	Residual lung capacity	Miscellaneous Medical		0.26	0.08	0.08		
94240	TC	Residual lung capacity	Miscellaneous Medical	a	0.00	0.58	0.58		
94250	26	Expired gas collection	Miscellaneous Medical		0.11	0.03	0.03		
94250	TC	Expired gas collection	Miscellaneous Medical	a	0.00	0.61	0.61		
94260	26	Thoracic gas volume	Miscellaneous Medical		0.13	0.04	0.04		
94260	TC	Thoracic gas volume	Miscellaneous Medical	a	0.00	0.54	0.54		
94350	26	Lung nitrogen washout curve	Miscellaneous Medical		0.26	0.08	0.08		
94350	TC	Lung nitrogen washout curve	Miscellaneous Medical	a	0.00	0.68	0.68		
94360	26	Measure airflow resistance	Miscellaneous Medical		0.26	0.08	0.08		
94360	TC	Measure airflow resistance	Miscellaneous Medical	a	0.00	0.62	0.62		
94370	26	Breath airway closing volume	Miscellaneous Medical		0.26	0.08	0.08		
94370	TC	Breath airway closing volume	Miscellaneous Medical	a	0.00	0.64	0.64		
94375	26	Respiratory flow volume loop	Miscellaneous Medical		0.31	0.09	0.09		
94375	TC	Respiratory flow volume loop	Miscellaneous Medical	a	0.00	0.51	0.51		
94400	26	CO2 breathing response curve	Miscellaneous Medical		0.40	0.12	0.12		
94400	TC	CO2 breathing response curve	Miscellaneous Medical	a	0.00	0.72	0.72		
94450	26	Hypoxia response curve	Miscellaneous Medical		0.40	0.12	0.12		
94450	TC	Hypoxia response curve	Miscellaneous Medical	a	0.00	0.73	0.73		
94452	26	Hast w/report	Miscellaneous Medical		0.31	0.09	0.09		
94452	TC	Hast w/report	Miscellaneous Medical	a	0.00	0.93	0.93		
94453	26	Hast w/oxygen titrate	Miscellaneous Medical		0.40	0.12	0.12		
94453	TC	Hast w/oxygen titrate	Miscellaneous Medical	a	0.00	1.39	1.39		
94620	26	Pulmonary stress test/simple	Miscellaneous Medical		0.64	0.20	0.20		
94620	TC	Pulmonary stress test/simple	Miscellaneous Medical	a	0.00	2.30	2.30		
94621	26	Pulm stress test/complex	Miscellaneous Medical		1.42	0.44	0.44		
94621	TC	Pulm stress test/complex	Miscellaneous Medical	a	0.00	1.77	1.77		
94640		Airway inhalation treatment	Miscellaneous Medical		0.00	0.30	0.30		
94642		Aerosol inhalation treatment	Miscellaneous Medical					2.30	
94656		Initial ventilator mgmt	Miscellaneous Medical		1.22	0.32	1.16		
94657		Continued ventilator mgmt	Miscellaneous Medical		0.83	0.25	0.98		
94660		Pos airway pressure, CPAP	Miscellaneous Medical		0.76	0.23	0.65		
94662		Neg press ventilation, cnp	Miscellaneous Medical		0.76	0.23	0.23		
94664		Evaluate pt use of inhaler	Miscellaneous Medical		0.00	0.31	0.31		
94667		Chest wall manipulation	Miscellaneous Medical		0.00	0.52	0.52		
94668		Chest wall manipulation	Miscellaneous Medical		0.00	0.45	0.45		
94680	26	Exhaled air analysis, o2	Miscellaneous Medical		0.26	0.08	0.08		
94680	TC	Exhaled air analysis, o2	Miscellaneous Medical	a	0.00	1.79	1.79		
94681	26	Exhaled air analysis, o2/co2	Miscellaneous Medical		0.20	0.06	0.06		
94681	TC	Exhaled air analysis, o2/co2	Miscellaneous Medical	a	0.00	2.47	2.47		
94690	26	Exhaled air analysis	Miscellaneous Medical		0.07	0.02	0.02		
94690	TC	Exhaled air analysis	Miscellaneous Medical	a	0.00	1.98	1.98		
94720	26	Monoxide diffusing capacity	Miscellaneous Medical		0.26	0.08	0.08		
94720	TC	Monoxide diffusing capacity	Miscellaneous Medical	a	0.00	0.92	0.92		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 108 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
94725	26	Membrane diffusion capacity	Miscellaneous Medical		0.26	0.08	0.08		
94725	TC	Membrane diffusion capacity	Miscellaneous Medical		0.00	2.84	2.84		
94750	26	Pulmonary compliance study	Miscellaneous Medical		0.23	0.07	0.07		
94750	TC	Pulmonary compliance study	Miscellaneous Medical	a	0.00	1.27	1.27		
94760		Measure blood oxygen level	Miscellaneous Medical		0.00	0.04	0.04		
94761		Measure blood oxygen level	Miscellaneous Medical		0.00	0.07	0.07		
94762		Measure blood oxygen level	Miscellaneous Medical		0.00	0.47	0.47		
94770	26	Exhaled carbon dioxide test	Miscellaneous Medical		0.15	0.04	0.04		
94770	TC	Exhaled carbon dioxide test	Miscellaneous Medical	a	0.00	0.71	0.71		
94799		Pulmonary service/procedure	Miscellaneous Medical					0.55	
95004		Percut allergy skin tests	Allergy Testing		0.00	0.10	0.10		
95010		Percut allergy titrate test	Allergy Testing		0.15	0.06	0.32		
95015		Id allergy titrate-drug/bug	Allergy Testing		0.15	0.06	0.14		
95024		Id allergy test, drug/bug	Allergy Testing		0.00	0.15	0.15		
95027		Id allergy titrate-airborne	Allergy Testing	a	0.00	0.15	0.15		
95028		Id allergy test-delayed type	Allergy Testing	a	0.00	0.23	0.23		
95044		Allergy patch tests	Allergy Testing		0.00	0.20	0.20		
95052		Photo patch test	Allergy Testing		0.00	0.25	0.25		
95056		Photosensitivity tests	Allergy Testing		0.00	0.17	0.17		
95060		Eye allergy tests	Allergy Testing	a	0.00	0.35	0.35		
95065		Nose allergy test	Allergy Testing	a	0.00	0.20	0.20		
95070		Bronchial allergy tests	Allergy Testing	a	0.00	2.29	2.29		
95071		Bronchial allergy tests	Allergy Testing	a	0.00	2.93	2.93		
95075		Ingestion challenge test	Allergy Testing		0.95	0.38	0.82		
95078		Provocative testing	Allergy Testing	a	0.00	0.25	0.25		
95115		Immunotherapy, one injection	Allergy Immunotherapy		0.00	0.39	0.39		
95117		Immunotherapy injections	Allergy Immunotherapy		0.00	0.50	0.50		
95120		Immunotherapy, one injection	Allergy Immunotherapy					0.54	
95125		Immunotherapy, many antigens	Allergy Immunotherapy					0.66	
95130		Immunotherapy, insect venom	Allergy Immunotherapy					0.93	
95131		Immunotherapy, insect venoms	Allergy Immunotherapy					1.18	
95132		Immunotherapy, insect venoms	Allergy Immunotherapy					1.43	
95133		Immunotherapy, insect venoms	Allergy Immunotherapy					1.72	
95134		Immunotherapy, insect venoms	Allergy Immunotherapy					2.07	
95144		Antigen therapy services	Allergy Immunotherapy		0.06	0.02	0.19		
95145		Antigen therapy services	Allergy Immunotherapy		0.06	0.02	0.32		
95146		Antigen therapy services	Allergy Immunotherapy		0.06	0.03	0.44		
95147		Antigen therapy services	Allergy Immunotherapy		0.06	0.02	0.42		
95148		Antigen therapy services	Allergy Immunotherapy		0.06	0.03	0.58		
95149		Antigen therapy services	Allergy Immunotherapy		0.06	0.03	0.80		
95165		Antigen therapy services	Allergy Immunotherapy		0.06	0.02	0.19		
95170		Antigen therapy services	Allergy Immunotherapy		0.06	0.03	0.13		
95180		Rapid desensitization	Allergy Immunotherapy		2.01	0.93	2.04		
95199		Allergy immunology services	Allergy Immunotherapy					0.26	
95250		Glucose monitoring, cont	Miscellaneous Medical	a	0.00	4.11	4.11		
95251		Gluc monitor, cont, phys i&r	Miscellaneous Medical	b	0.52	0.19	0.19		RBRVS
95805	26	Multiple sleep latency test	Miscellaneous Medical		1.88	0.66	0.66		
95805	TC	Multiple sleep latency test	Miscellaneous Medical	a	0.00	16.65	16.65		
95806	26	Sleep study, unattended	Miscellaneous Medical		1.66	0.54	0.54		
95806	TC	Sleep study, unattended	Miscellaneous Medical	a	0.00	2.80	2.80		
95807	26	Sleep study, attended	Miscellaneous Medical		1.66	0.53	0.53		
95807	TC	Sleep study, attended	Miscellaneous Medical	a	0.00	11.35	11.35		
95808	26	Polysomnography, 1-3	Miscellaneous Medical		2.65	0.92	0.92		
95808	TC	Polysomnography, 1-3	Miscellaneous Medical	a	0.00	12.31	12.31		
95810	26	Polysomnography, 4 or more	Miscellaneous Medical		3.52	1.18	1.18		
95810	TC	Polysomnography, 4 or more	Miscellaneous Medical	a	0.00	16.36	16.36		
95811	26	Polysomnography w/cpap	Miscellaneous Medical		3.79	1.27	1.27		
95811	TC	Polysomnography w/cpap	Miscellaneous Medical	a	0.00	17.97	17.97		
95812	26	Eq, 41-60 minutes	Miscellaneous Medical		1.08	0.45	0.45		
95812	TC	Eq, 41-60 minutes	Miscellaneous Medical	a	0.00	3.59	3.59		
95813	26	Eq, over 1 hour	Miscellaneous Medical		1.73	0.70	0.70		
95813	TC	Eq, over 1 hour	Miscellaneous Medical	a	0.00	4.33	4.33		
95816	26	Eq, awake and drowsy	Miscellaneous Medical		1.08	0.46	0.46		
95816	TC	Eq, awake and drowsy	Miscellaneous Medical	a	0.00	3.26	3.26		
95819	26	Eq, awake and asleep	Miscellaneous Medical		1.08	0.46	0.46		
95819	TC	Eq, awake and asleep	Miscellaneous Medical	a	0.00	2.53	2.53		
95822	26	Eq, coma or sleep only	Miscellaneous Medical		1.08	0.46	0.46		
95822	TC	Eq, coma or sleep only	Miscellaneous Medical	a	0.00	4.15	4.15		
95824	26	Eq, cerebral death only	Miscellaneous Medical		0.74	0.31	0.31		
95824	TC	Eq, cerebral death only	Miscellaneous Medical	a				1.64	

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/OFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 109 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
95827	26	Eqg, all night recording	Miscellaneous Medical		1.08	0.41	0.41		
95827	TC	Eqg, all night recording	Miscellaneous Medical		0.00	2.30	2.30		
95829	26	Surgery electrocorticogram	Miscellaneous Medical		6.20	2.32	2.32		
95829	TC	Surgery electrocorticogram	Miscellaneous Medical	a	0.00	28.77	28.77		
95830		Insert electrodes for EEG	Miscellaneous Medical		1.70	0.73	3.30		
95831		Limb muscle testing, manual	Miscellaneous Medical		0.28	0.13	0.46		
95832		Hand muscle testing, manual	Miscellaneous Medical		0.29	0.12	0.33		
95833		Body muscle testing, manual	Miscellaneous Medical		0.47	0.23	0.58		
95834		Body muscle testing, manual	Miscellaneous Medical		0.60	0.28	0.63		
95851		Range of motion measurements	Miscellaneous Medical		0.16	0.08	0.36		
95852		Range of motion measurements	Miscellaneous Medical		0.11	0.05	0.26		
95857		Tension test	Miscellaneous Medical		0.53	0.23	0.60		
95860	26	Muscle test, one limb	Miscellaneous Medical		0.96	0.42	0.42		
95860	TC	Muscle test, one limb	Miscellaneous Medical	a	0.00	1.00	1.00		
95861	26	Muscle test, 2 limbs	Miscellaneous Medical		1.54	0.68	0.68		
95861	TC	Muscle test, 2 limbs	Miscellaneous Medical	a	0.00	0.73	0.73		
95863	26	Muscle test, 3 limbs	Miscellaneous Medical		1.87	0.80	0.80		
95863	TC	Muscle test, 3 limbs	Miscellaneous Medical	a	0.00	0.94	0.94		
95864	26	Muscle test, 4 limbs	Miscellaneous Medical		1.99	0.87	0.87		
95864	TC	Muscle test, 4 limbs	Miscellaneous Medical	a	0.00	1.79	1.79		
95865	26	Muscle test, larynx	Miscellaneous Medical		1.57	0.77	0.77		
95865	TC	Muscle test, larynx	Miscellaneous Medical	a	0.00	0.68	0.68		RBRVS
95866	26	Muscle test, hemidiaphragm	Miscellaneous Medical		1.25	0.56	0.56		RBRVS
95866	TC	Muscle test, hemidiaphragm	Miscellaneous Medical	a	0.00	0.20	0.20		RBRVS
95867	26	Muscle test cran nerv unilat	Miscellaneous Medical		0.79	0.35	0.35		
95867	TC	Muscle test cran nerv unilat	Miscellaneous Medical	a	0.00	0.58	0.58		
95868	26	Muscle test cran nerve bilat	Miscellaneous Medical		1.18	0.51	0.51		
95868	TC	Muscle test cran nerve bilat	Miscellaneous Medical	a	0.00	0.70	0.70		
95869	26	Muscle test, thor paraspinal	Miscellaneous Medical		0.37	0.16	0.16		
95869	TC	Muscle test, thor paraspinal	Miscellaneous Medical	a	0.00	0.21	0.21		
95870	26	Muscle test, nonparaspinal	Miscellaneous Medical		0.37	0.16	0.16		
95870	TC	Muscle test, nonparaspinal	Miscellaneous Medical	a	0.00	0.21	0.21		
95872	26	Muscle test, one fiber	Miscellaneous Medical		1.50	0.63	0.63		
95872	TC	Muscle test, one fiber	Miscellaneous Medical	a	0.00	0.60	0.60		
95873	26	Guide nerv destr, elec stim	Miscellaneous Medical		0.37	0.16	0.16		RBRVS
95873	TC	Guide nerv destr, elec stim	Miscellaneous Medical	a	0.00	0.20	0.20		RBRVS
95874	26	Guide nerv destr, needle emg	Miscellaneous Medical		0.37	0.17	0.17		RBRVS
95874	TC	Guide nerv destr, needle emg	Miscellaneous Medical	a	0.00	0.20	0.20		RBRVS
95875	26	Limb exercise test	Miscellaneous Medical		1.10	0.47	0.47		
95875	TC	Limb exercise test	Miscellaneous Medical	a	0.00	0.98	0.98		
95900	26	Motor nerve conduction test	Miscellaneous Medical		0.42	0.18	0.18		
95900	TC	Motor nerve conduction test	Miscellaneous Medical	a	0.00	1.08	1.08		
95903	26	Motor nerve conduction test	Miscellaneous Medical		0.60	0.26	0.26		
95903	TC	Motor nerve conduction test	Miscellaneous Medical	a	0.00	0.93	0.93		
95904	26	Sense nerve conduction test	Miscellaneous Medical		0.34	0.15	0.15		
95904	TC	Sense nerve conduction test	Miscellaneous Medical	a	0.00	0.94	0.94		
95920	26	Intraop nerve test add-on	Miscellaneous Medical		2.11	0.93	0.93		
95920	TC	Intraop nerve test add-on	Miscellaneous Medical	a	0.00	1.31	1.31		
95921		Autonomic nerv function test	Miscellaneous Medical		0.90	0.71	0.71		
95921		Autonomic nerv function test	Miscellaneous Medical		0.90	0.71	0.71		
95922		Autonomic nerv function test	Miscellaneous Medical		0.96	0.78	0.78		
95922		Autonomic nerv function test	Miscellaneous Medical		0.96	0.78	0.78		
95923		Autonomic nerv function test	Miscellaneous Medical		0.90	1.94	1.94		
95923		Autonomic nerv function test	Miscellaneous Medical		0.90	1.94	1.94		
95925	26	Somatosensory testing	Miscellaneous Medical		0.54	0.22	0.22		
95925	TC	Somatosensory testing	Miscellaneous Medical	a	0.00	0.91	0.91		
95926	26	Somatosensory testing	Miscellaneous Medical		0.54	0.23	0.23		
95926	TC	Somatosensory testing	Miscellaneous Medical	a	0.00	0.91	0.91		
95927	26	Somatosensory testing	Miscellaneous Medical		0.54	0.25	0.25		
95927	TC	Somatosensory testing	Miscellaneous Medical	a	0.00	0.91	0.91		
95928	26	C motor evoked, uppr limbs	Miscellaneous Medical		1.50	0.65	0.65		
95928	TC	C motor evoked, uppr limbs	Miscellaneous Medical	a	0.00	2.38	2.38		
95929	26	C motor evoked, lwr limbs	Miscellaneous Medical		1.50	0.65	0.65		
95929	TC	C motor evoked, lwr limbs	Miscellaneous Medical	a	0.00	2.57	2.57		
95930	26	Visual evoked potential test	Miscellaneous Medical		0.35	0.15	0.15		
95930	TC	Visual evoked potential test	Miscellaneous Medical	a	0.00	2.10	2.10		
95933	26	Blink reflex test	Miscellaneous Medical		0.59	0.24	0.24		
95933	TC	Blink reflex test	Miscellaneous Medical	a	0.00	0.78	0.78		
95934	26	H-reflex test	Miscellaneous Medical		0.51	0.22	0.22		
95934	TC	H-reflex test	Miscellaneous Medical	a	0.00	0.21	0.21		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 110 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/CAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
95936	26	H-reflex test	Miscellaneous Medical		0.55	0.24	0.24		
95936	TC	H-reflex test	Miscellaneous Medical		0.00	0.21	0.21		
95937	26	Neuromuscular junction test	Miscellaneous Medical	a	0.65	0.27	0.27		
95937	TC	Neuromuscular junction test	Miscellaneous Medical		0.00	0.34	0.34		
95950	26	Ambulatory eeg monitoring	Miscellaneous Medical		1.51	0.64	0.64		
95950	TC	Ambulatory eeg monitoring	Miscellaneous Medical	a	0.00	3.30	3.30		
95951	26	EEG monitoring/viderecord	Miscellaneous Medical		5.99	2.56	2.56		
95951	TC	EEG monitoring/viderecord	Miscellaneous Medical	a				6.12	
95953	26	EEG monitoring/computer	Miscellaneous Medical		3.08	1.29	1.29		
95953	TC	EEG monitoring/computer	Miscellaneous Medical	a	0.00	6.35	6.35		
95954	26	EEG monitoring/giving drugs	Miscellaneous Medical		2.45	1.04	1.04		
95954	TC	EEG monitoring/giving drugs	Miscellaneous Medical	a	0.00	3.19	3.19		
95955	26	EEG during surgery	Miscellaneous Medical		1.01	0.36	0.36		
95955	TC	EEG during surgery	Miscellaneous Medical	a	0.00	1.97	1.97		
95956	26	Eeg monitoring, cable/radio	Miscellaneous Medical		3.08	1.30	1.30		
95956	TC	Eeg monitoring, cable/radio	Miscellaneous Medical	a	0.00	14.15	14.15		
95957	26	EEG digital analysis	Miscellaneous Medical		1.98	0.85	0.85		
95957	TC	EEG digital analysis	Miscellaneous Medical	a	0.00	1.70	1.70		
95958	26	EEG monitoring/function test	Miscellaneous Medical		4.24	1.75	1.75		
95958	TC	EEG monitoring/function test	Miscellaneous Medical	a	0.00	1.75	1.75		
95961	26	Electrode stimulation, brain	Miscellaneous Medical		2.97	1.32	1.32		
95961	TC	Electrode stimulation, brain	Miscellaneous Medical	a	0.00	1.31	1.31		
95962	26	Electrode stim, brain add-on	Miscellaneous Medical		3.21	1.39	1.39		
95962	TC	Electrode stim, brain add-on	Miscellaneous Medical	a	0.00	1.31	1.31		
95965	26	Meq, spontaneous	Miscellaneous Medical		7.99	3.43	3.43		
95965		Meq, spontaneous	Miscellaneous Medical	a				45.64	
95965		Meq, spontaneous	Miscellaneous Medical	a				57.05	
95966	26	Meq, evoked, single	Miscellaneous Medical		3.99	1.71	1.71		
95966		Meq, evoked, single	Miscellaneous Medical	a				22.88	
95966		Meq, evoked, single	Miscellaneous Medical	a				28.60	
95967	26	Meq, evoked, each addl	Miscellaneous Medical		3.49	1.18	1.18		
95967		Meq, evoked, each addl	Miscellaneous Medical	a				19.28	
95967		Meq, evoked, each addl	Miscellaneous Medical	a				24.10	
95970		Analyze neurostim, no prog	Miscellaneous Medical		0.45	0.14	0.85		
95971		Analyze neurostim, simple	Miscellaneous Medical		0.78	0.22	0.68		
95972		Analyze neurostim, complex	Miscellaneous Medical		1.50	0.49	1.21		
95973		Analyze neurostim, complex	Miscellaneous Medical		0.92	0.34	0.62		
95974		Cranial neurostim, complex	Miscellaneous Medical		3.00	1.30	1.70		
95975		Cranial neurostim, complex	Miscellaneous Medical		1.70	0.73	0.89		
95978		Analyze neurostim brain/1h	Miscellaneous Medical		3.50	1.30	1.94		
95979		Analyze neurostim brain add-on	Miscellaneous Medical		1.64	0.69	0.87		
95990		Spin/brain pump refill & main	Miscellaneous Medical		0.00	1.50	1.50		
95991		Spin/brain pump refill & main	Miscellaneous Medical		0.77	0.17	1.46		
95999		Neurological procedure	Miscellaneous Medical					1.81	
96000		Motion analysis, video/3d	Miscellaneous Medical		1.80	0.53	0.53		
96001		Motion test w/ft press meas	Miscellaneous Medical		2.15	0.66	0.66		
96002		Dynamic surface emg	Miscellaneous Medical		0.41	0.15	0.15		
96003		Dynamic fine wire emg	Miscellaneous Medical		0.37	0.12	0.12		
96004		Phys review of motion tests	Miscellaneous Medical		2.14	0.94	0.94		
96101		Psycho testing by psych/phys	Miscellaneous Medical	a	1.86	0.63	0.65		RBRVS
96102		Psycho testing by technician	Miscellaneous Medical	a	0.50	0.17	0.66		RBRVS
96103		Psycho testing admin by comp	Miscellaneous Medical	a	0.51	0.17	0.21		RBRVS
96105		Assessment of aphasia	Miscellaneous Medical		0.00	1.77	1.77		
96110		Developmental test, lim	Miscellaneous Medical		0.00	0.18	0.18		
96111		Developmental test, extend	Miscellaneous Medical		2.60	1.05	1.05		
96116		Neurobehavioral status exam	Miscellaneous Medical	a	1.86	0.84	0.83		RBRVS
96118		Neuropsych tst by psych/phys	Miscellaneous Medical	a	1.86	0.63	1.39		RBRVS
96119		Neuropsych testing by tech	Miscellaneous Medical	a	0.55	0.19	1.02		RBRVS
96120		Neuropsych tst admin w/comp	Miscellaneous Medical	a	0.51	0.17	0.74		RBRVS
96150		Assess hlt/behav, init	Miscellaneous Medical		0.50	0.18	0.18		
96151		Assess hlt/behav, subseq	Miscellaneous Medical		0.48	0.17	0.18		
96152		Intervene hlt/behav, indiv	Miscellaneous Medical		0.46	0.16	0.17		
96153		Intervene hlt/behav, group	Miscellaneous Medical		0.10	0.03	0.04		
96154		Interv hlt/behav, fam w/pt	Miscellaneous Medical		0.45	0.16	0.17		
96155		Interv hlt/behav fam no pt	Miscellaneous Medical		0.44	0.17	0.18		
96401		Chemo, anti-neopl, sq/im	Miscellaneous Medical	a	0.21	1.53	1.53		RBRVS
96402		Chemo hormon antineopl sq/im	Miscellaneous Medical	a	0.19	0.74	0.74		RBRVS
96405		Intralesional chemo admin	Miscellaneous Medical		0.52	0.24	2.78		
96406		Intralesional chemo admin	Miscellaneous Medical		0.80	0.29	3.08		
96409		Chemo, iv push, snqj drug	Miscellaneous Medical	b	0.24	2.93	2.93		RBRVS

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G.—PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 111 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
96411		Chemo, iv push, addl drug	Miscellaneous Medical	b	0.20	1.61	1.61		RBRVS
96413		Chemo, iv infusion, 1 hr	Miscellaneous Medical	b	0.28	4.20	4.20		RBRVS
96415		Chemo, iv infusion, addl hr	Miscellaneous Medical	b	0.19	0.77	0.77		RBRVS
96416		Chemo prolong infuse w/pump	Miscellaneous Medical	a	0.21	4.61	4.61		RBRVS
96417		Chemo iv infus each addl seq	Miscellaneous Medical	b	0.21	1.95	1.95		RBRVS
96420		Chemotherapy, push technique	Miscellaneous Medical		0.17	2.66	2.66		
96422		Chemotherapy,infusion method	Miscellaneous Medical		0.17	4.84	4.84		
96423		Chemo, infuse method add-on	Miscellaneous Medical		0.17	1.89	1.89		
96425		Chemotherapy,infusion method	Miscellaneous Medical		0.17	4.48	4.48		
96440		Chemotherapy, intracavitary	Miscellaneous Medical		2.37	1.23	8.04		
96445		Chemotherapy, intracavitary	Miscellaneous Medical		2.20	1.18	8.05		
96450		Chemotherapy, into CNS	Miscellaneous Medical		1.53	1.29	6.96		
96521		Refill/maint, portable pump	Miscellaneous Medical	a	0.21	3.77	3.77		RBRVS
96522		Refill/maint pump/resvt syst	Miscellaneous Medical	a	0.21	2.65	2.65		RBRVS
96523		Imrg drug delivery device	Miscellaneous Medical	a	0.04	0.69	0.69		RBRVS
96542		Chemotherapy injection	Miscellaneous Medical		0.75	0.66	4.24	3.08	
96549		Chemotherapy, unspecified	Miscellaneous Medical						
96567		Photodynamic tx, skin	Miscellaneous Medical		0.00	1.96	1.96		
96570		Photodynamic tx, 30 min	Miscellaneous Medical		1.10	0.37	0.37		
96571		Photodynamic tx, addl 15 min	Miscellaneous Medical		0.55	0.19	0.19		
96900		Ultraviolet light therapy	Miscellaneous Medical		0.00	0.44	0.44		
96902		Trichogram	Miscellaneous Medical		0.41	0.16	0.18		
96910		Photochemotherapy with UV-B	Miscellaneous Medical		0.00	0.99	0.99		
96912		Photochemotherapy with UV-A	Miscellaneous Medical		0.00	1.26	1.26		
96913		Photochemotherapy, UV-A or B	Miscellaneous Medical		0.00	1.68	1.68		
96920		Laser tx, skin < 250 sq cm	Miscellaneous Medical		1.15	0.56	2.54		
96921		Laser tx, skin 250-500 sq cm	Miscellaneous Medical		1.17	0.57	2.61		
96922		Laser tx, skin > 500 sq cm	Miscellaneous Medical		2.10	0.62	3.49		
96999		Dermatological procedure	Miscellaneous Medical					1.07	
97001		Pt evaluation	Physical Medicine		1.20	0.45	0.75		
97002		Pt re-evaluation	Physical Medicine		0.60	0.23	0.44		
97003		Ot evaluation	Physical Medicine		1.20	0.40	0.88		
97004		Ot re-evaluation	Physical Medicine		0.60	0.19	0.67		
97005		Athletic train eval	Physical Medicine					1.45	
97006		Athletic train reeval	Physical Medicine					0.72	
97010		Hot or cold packs therapy	Physical Medicine		0.06	0.05	0.05		
97012		Mechanical traction therapy	Physical Medicine		0.25	0.13	0.13		
97014		Electric stimulation therapy	Physical Medicine		0.18	0.19	0.19		
97016		Vasopneumatic device therapy	Physical Medicine		0.18	0.18	0.18		
97018		Paraffin bath therapy	Physical Medicine		0.06	0.10	0.10		
97022		Whirlpool therapy	Physical Medicine		0.17	0.21	0.21		
97024		Diathermy treatment	Physical Medicine		0.06	0.07	0.07		
97026		Infrared therapy	Physical Medicine		0.06	0.06	0.06		
97028		Ultraviolet therapy	Physical Medicine		0.08	0.07	0.07		
97032		Electrical stimulation	Physical Medicine		0.25	0.16	0.16		
97033		Electric current therapy	Physical Medicine		0.26	0.27	0.27		
97034		Contrast bath therapy	Physical Medicine		0.21	0.15	0.15		
97035		Ultrasound therapy	Physical Medicine		0.21	0.10	0.10		
97036		Hydrotherapy	Physical Medicine		0.28	0.32	0.32		
97110		Therapeutic exercises	Physical Medicine		0.45	0.27	0.27		
97112		Neuromuscular reeducation	Physical Medicine		0.45	0.31	0.31		
97113		Aquatic therapy/exercises	Physical Medicine		0.44	0.39	0.39		
97116		Gait training therapy	Physical Medicine		0.40	0.24	0.24		
97124		Massage therapy	Physical Medicine		0.35	0.23	0.23		
97140		Manual therapy	Physical Medicine		0.43	0.25	0.25		
97150		Group therapeutic procedures	Physical Medicine		0.27	0.18	0.18		
97530		Therapeutic activities	Physical Medicine		0.44	0.32	0.32		
97532		Cognitive skills development	Physical Medicine		0.44	0.20	0.20		
97533		Sensory integration	Physical Medicine		0.44	0.24	0.24		
97535		Self care mgmt training	Physical Medicine		0.45	0.33	0.33		
97537		Community/work reintegration	Physical Medicine		0.45	0.26	0.26		
97542		Wheelchair mgmt training	Physical Medicine		0.45	0.28	0.28		
97545		Work hardening	Physical Medicine					2.68	
97546		Work hardening add-on	Physical Medicine					1.07	
97597		Active wound care/20 cm or <	Physical Medicine		0.58	0.66	0.66		
97598		Active wound care > 20 cm	Physical Medicine		0.80	0.79	0.79		
97602		Wound(s) care non-selective	Physical Medicine					0.39	
97750		Physical performance test	Physical Medicine		0.45	0.32	0.32		
97755		Assistive technology assess	Physical Medicine		0.62	0.28	0.28		
97760		Orthotic mgmt and training	Physical Medicine		0.45	0.20	0.34		RBRVS

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology

TABLE G. -- PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPSC CODE

PAGE 112 of 119

CPT/ HCPSC Code	Modifier	CPT/HCPSC Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
97761		Prosthetic training	Physical Medicine		0.45	0.19	0.28		
97762		C/o for orthotic/prosth use	Physical Medicine		0.25	0.19	0.42		
97799		Physical medicine procedure	Physical Medicine					0.76	RBRVS RBRVS
97802		Medical nutrition, indiv, in	Miscellaneous Medical		0.00	0.47	0.47		
97803		Med nutrition, indiv, subseq	Miscellaneous Medical		0.00	0.47	0.47		
97804		Medical nutrition, group	Miscellaneous Medical		0.00	0.18	0.18		
97810		Acupunct w/o stimul 15 min	Physical Medicine		0.60	0.23	0.38		
97811		Acupunct w/o stimul addl 15m	Physical Medicine		0.50	0.19	0.25		
97813		Acupunct w/stimul 15 min	Physical Medicine		0.65	0.25	0.40		
97814		Acupunct w/stimul addl 15m	Physical Medicine		0.55	0.21	0.30		
98925		Osteopathic manipulation	Physical Medicine		0.45	0.14	0.32		
98926		Osteopathic manipulation	Physical Medicine		0.65	0.25	0.41		
98927		Osteopathic manipulation	Physical Medicine		0.87	0.29	0.50		
98928		Osteopathic manipulation	Physical Medicine		1.03	0.34	0.59		
98929		Osteopathic manipulation	Physical Medicine		1.19	0.37	0.67		
98940		Chiropractic manipulation	Chiropractor		0.45	0.12	0.23		
98941		Chiropractic manipulation	Chiropractor		0.65	0.17	0.30		
98942		Chiropractic manipulation	Chiropractor		0.87	0.23	0.36		
98943		Chiropractic manipulation	Chiropractor		0.40	0.16	0.24		
98960		Self-mgmt educ & train, 1 pt	Miscellaneous Medical	b	0.00	0.83	0.83		CALC
98961		Self-mgmt educ/train, 2-4 pt	Miscellaneous Medical	b	0.00	0.48	0.48		CALC
98962		Self-mgmt educ/train, 5-8 pt	Miscellaneous Medical	b	0.00	0.48	0.48		CALC
99000		Specimen handling	Miscellaneous Medical					0.22	
99001		Specimen handling	Miscellaneous Medical					0.25	
99002		Device handling	Miscellaneous Medical					0.37	
99026		In-hospital on call service	Miscellaneous Medical					2.10	
99027		Out-of-hosp on call service	Miscellaneous Medical	b				2.10	CALC
99050		Medical services after hrs	Miscellaneous Medical					0.69	
99056		Non-office medical services	Miscellaneous Medical					0.90	
99058		Office emergency care	Miscellaneous Medical					0.93	
99075		Medical testimony	Miscellaneous Medical					5.27	
99078		Group health education	Miscellaneous Medical					0.90	
99080		Special reports or forms	Miscellaneous Medical					0.72	
99082		Unusual physician travel	Miscellaneous Medical					0.47	
99090		Computer data analysis	Miscellaneous Medical					1.50	
99091		Collect/review data from pt	Miscellaneous Medical					1.50	
99100		Special anesthesia service	Surgery					0.08	
99116		Anesthesia with hypothermia	Surgery					0.50	
99135		Special anesthesia procedure	Surgery					0.63	
99140		Emergency anesthesia	Surgery					0.39	
99170		Anogenital exam, child	Miscellaneous Medical		1.75	0.55	1.77		
99172	26	Ocular function screen	Vision Exams					0.28	
99172	TC	Ocular function screen	Vision Exams	a				1.10	
99173		Visual acuity screen	Vision Exams					0.69	
99175		Induction of vomiting	Miscellaneous Medical						
99183		Hyperbaric oxygen therapy	Miscellaneous Medical		0.00	1.39	1.39		
99185	26	Regional hypothermia	Miscellaneous Medical		2.34	0.72	3.25		
99185	TC	Regional hypothermia	Miscellaneous Medical	a				0.25	
99186	26	Total body hypothermia	Miscellaneous Medical					0.39	
99186	TC	Total body hypothermia	Miscellaneous Medical	a				1.19	
99190		Special pump services	Miscellaneous Medical					1.78	
99191		Special pump services	Miscellaneous Medical					14.50	
99192		Special pump services	Miscellaneous Medical					10.87	
99195		Phlebotomy	Miscellaneous Medical		0.00	0.44	0.44	7.25	
99199		Special service/proc/report	Miscellaneous Medical					0.32	
99201		Office/outpatient visit, new	Office/Home/Urgent Care Visits		0.45	0.15	0.49		
99202		Office/outpatient visit, new	Office/Home/Urgent Care Visits		0.88	0.31	0.79		
99203		Office/outpatient visit, new	Office/Home/Urgent Care Visits		1.34	0.48	1.13		
99204		Office/outpatient visit, new	Office/Home/Urgent Care Visits		2.00	0.71	1.50		
99205		Office/outpatient visit, new	Office/Home/Urgent Care Visits		2.67	0.95	1.78		
99211		Office/outpatient visit, est	Office/Home/Urgent Care Visits		0.17	0.06	0.39		
99212		Office/outpatient visit, est	Office/Home/Urgent Care Visits		0.45	0.16	0.54		
99213		Office/outpatient visit, est	Office/Home/Urgent Care Visits		0.67	0.24	0.69		
99214		Office/outpatient visit, est	Office/Home/Urgent Care Visits		1.10	0.41	1.03		
99215		Office/outpatient visit, est	Office/Home/Urgent Care Visits		1.77	0.65	1.32		
99217		Observation care discharge	Emergency Room Visits		1.28	0.53	0.53		
99218		Observation care	Emergency Room Visits		1.28	0.44	0.44		
99219		Observation care	Emergency Room Visits		2.14	0.72	0.72		
99220		Observation care	Emergency Room Visits		2.99	1.03	1.03		
99221		Initial hospital care	Inpatient Visits		1.28	0.45	0.45		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 113 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
99222		Initial hospital care	Inpatient Visits		2.14	0.74	0.74		
99223		Initial hospital care	Inpatient Visits		2.99	1.03	1.03		
99231		Subsequent hospital care	Inpatient Visits		0.64	0.23	0.23		
99232		Subsequent hospital care	Inpatient Visits		1.06	0.37	0.37		
99233		Subsequent hospital care	Inpatient Visits		1.51	0.52	0.52		
99234		Observ/hosp same date	Inpatient Visits		2.56	0.89	0.89		
99235		Observ/hosp same date	Inpatient Visits		3.41	1.15	1.15		
99236		Observ/hosp same date	Inpatient Visits		4.26	1.44	1.44		
99238		Hospital discharge day	Inpatient Visits		1.28	0.54	0.54		
99239		Hospital discharge day	Inpatient Visits		1.75	0.73	0.73		
99241		Office consultation	Consults		0.64	0.22	0.64		
99242		Office consultation	Consults		1.29	0.46	1.04		
99243		Office consultation	Consults		1.72	0.63	1.39		
99244		Office consultation	Consults		2.58	0.92	1.83		
99245		Office consultation	Consults		3.42	1.24	2.28		
99251		Initial inpatient consult	Consults		0.66	0.24	0.24		
99252		Initial inpatient consult	Consults		1.32	0.50	0.50		
99253		Initial inpatient consult	Consults		1.82	0.68	0.68		
99254		Initial inpatient consult	Consults		2.64	0.98	0.98		
99255		Initial inpatient consult	Consults		3.64	1.35	1.35		
99281		Emergency dept visit	Emergency Room Visits		0.33	0.09	0.09		
99282		Emergency dept visit	Emergency Room Visits		0.55	0.14	0.14		
99283		Emergency dept visit	Emergency Room Visits		1.24	0.31	0.31		
99284		Emergency dept visit	Emergency Room Visits		1.95	0.47	0.47		
99285		Emergency dept visit	Emergency Room Visits		3.06	0.72	0.72		
99288		Direct advanced life support	Emergency Room Visits					1.26	
99289		Ped crit care transport	Inpatient Visits		4.79	1.45	1.45		
99290		Ped crit care transport addl	Inpatient Visits		2.40	0.81	0.81		
99291		Critical care, first hour	Inpatient Visits		3.99	1.28	2.58		
99292		Critical care, addl 30 min	Inpatient Visits		2.00	0.64	0.90		
99293		Ped critical care, initial	Inpatient Visits		15.98	4.76	4.76		
99294		Ped critical care, subseq	Inpatient Visits		7.99	2.41	2.41		
99295		Neonate crit care, initial	Inpatient Visits		18.46	5.39	5.39		
99296		Neonate critical care subseq	Inpatient Visits		7.99	2.55	2.55		
99298		Ic for lbw infant < 1500 gm	Inpatient Visits		2.75	0.93	0.93		
99299		Ic, lbw infant 1500-2500 gm	Inpatient Visits		2.50	0.86	0.86		
99300		Ic, infant pbw 2501-5000 gm	Inpatient Visits		2.40	0.84	0.84		RBRVS
99304		Nursing facility care, init	Office/Home/Urgent Care Visits	b	1.20	0.49	0.49		RBRVS
99305		Nursing facility care, init	Office/Home/Urgent Care Visits	b	1.61	0.63	0.63		RBRVS
99306		Nursing facility care, init	Office/Home/Urgent Care Visits	b	2.01	0.75	0.75		RBRVS
99307		Nursing fac care, subseq	Office/Home/Urgent Care Visits	b	0.60	0.27	0.27		RBRVS
99308		Nursing fac care, subseq	Office/Home/Urgent Care Visits	b	1.00	0.45	0.45		RBRVS
99309		Nursing fac care, subseq	Office/Home/Urgent Care Visits	b	1.42	0.62	0.62		RBRVS
99310		Nursing fac care, subseq	Office/Home/Urgent Care Visits	b	1.77	0.78	0.78		RBRVS
99315		Nursing fac discharge day	Inpatient Visits		1.13	0.45	0.45		
99316		Nursing fac discharge day	Inpatient Visits		1.50	0.59	0.59		
99318		Annual nursing fac assessment	Office/Home/Urgent Care Visits	b	1.20	0.49	0.49		RBRVS
99324		Domicil/r-home visit new pat	Office/Home/Urgent Care Visits	b	1.01	0.38	0.49		RBRVS
99325		Domicil/r-home visit new pat	Office/Home/Urgent Care Visits	b	1.52	0.55	0.68		RBRVS
99326		Domicil/r-home visit new pat	Office/Home/Urgent Care Visits	b	2.27	0.78	0.92		RBRVS
99327		Domicil/r-home visit new pat	Office/Home/Urgent Care Visits	b	3.03	1.05	1.17		RBRVS
99328		Domicil/r-home visit new pat	Office/Home/Urgent Care Visits	b	3.78	1.31	1.42		RBRVS
99334		Domicil/r-home visit est pat	Office/Home/Urgent Care Visits	b	0.76	0.26	0.40		RBRVS
99335		Domicil/r-home visit est pat	Office/Home/Urgent Care Visits	b	1.26	0.43	0.58		RBRVS
99336		Domicil/r-home visit est pat	Office/Home/Urgent Care Visits	b	2.02	0.66	0.82		RBRVS
99337		Domicil/r-home visit est pat	Office/Home/Urgent Care Visits	b	3.03	0.98	1.15		RBRVS
99341		Home visit, new patient	Office/Home/Urgent Care Visits		1.01	0.48	0.48		
99342		Home visit, new patient	Office/Home/Urgent Care Visits		1.52	0.68	0.68		
99343		Home visit, new patient	Office/Home/Urgent Care Visits		2.27	0.94	0.94		
99344		Home visit, new patient	Office/Home/Urgent Care Visits		3.03	1.18	1.18		
99345		Home visit, new patient	Office/Home/Urgent Care Visits		3.78	1.43	1.43		
99347		Home visit, est patient	Office/Home/Urgent Care Visits		0.76	0.40	0.40		
99348		Home visit, est patient	Office/Home/Urgent Care Visits		1.26	0.58	0.58		
99349		Home visit, est patient	Office/Home/Urgent Care Visits		2.02	0.83	0.83		
99350		Home visit, est patient	Office/Home/Urgent Care Visits		3.03	1.18	1.18		
99354		Prolonged service, office	Office/Home/Urgent Care Visits		1.77	0.66	0.77		
99355		Prolonged service, office	Office/Home/Urgent Care Visits		1.77	0.62	0.75		
99356		Prolonged service, inpatient	Inpatient Visits		1.71	0.62	0.62		
99357		Prolonged service, inpatient	Inpatient Visits		1.71	0.63	0.63		
99358		Prolonged serv, w/o contact	Office/Home/Urgent Care Visits					4.36	

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 114 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
99359		Prolonged serv, w/o contact	Office/Home/Urgent Care Visits					2.18	
99360		Physician standby services	Miscellaneous Medical					2.02	
99374		Home health care supervision	Office/Home/Urgent Care Visits		1.10	0.42	0.70		
99375		Home health care supervision	Office/Home/Urgent Care Visits		1.73	1.55	1.55		
99377		Hospice care supervision	Office/Home/Urgent Care Visits		1.10	0.42	0.70		
99378		Hospice care supervision	Office/Home/Urgent Care Visits		1.73	1.95	1.95		
99379		Nursing fac care supervision	Office/Home/Urgent Care Visits		1.10	0.42	0.70		
99380		Nursing fac care supervision	Office/Home/Urgent Care Visits		1.73	0.66	0.99		
99381		Prev visit, new, infant	Well Baby Exams		1.19	0.45	1.50		
99382		Prev visit, new, age 1-4	Physical Exams		1.36	0.52	1.54		
99383		Prev visit, new, age 5-11	Physical Exams		1.36	0.52	1.48		
99384		Prev visit, new, age 12-17	Physical Exams		1.53	0.59	1.55		
99385		Prev visit, new, age 18-39	Physical Exams		1.53	0.59	1.55		
99386		Prev visit, new, age 40-64	Physical Exams		1.88	0.72	1.75		
99387		Prev visit, new, 65 & over	Physical Exams		2.06	0.79	1.88		
99391		Prev visit, est, infant	Well Baby Exams		1.02	0.39	1.02		
99392		Prev visit, est, age 1-4	Physical Exams		1.19	0.45	1.09		
99393		Prev visit, est, age 5-11	Physical Exams		1.19	0.45	1.06		
99394		Prev visit, est, age 12-17	Physical Exams		1.36	0.52	1.13		
99395		Prev visit, est, age 18-39	Physical Exams		1.36	0.52	1.16		
99396		Prev visit, est, age 40-64	Physical Exams		1.53	0.59	1.25		
99397		Prev visit, est, 65 & over	Physical Exams		1.71	0.66	1.36		
99401		Preventive counseling, indiv	Physical Exams		0.48	0.19	0.62		
99402		Preventive counseling, indiv	Physical Exams		0.98	0.37	0.87		
99403		Preventive counseling, indiv	Physical Exams		1.46	0.56	1.09		
99404		Preventive counseling, indiv	Physical Exams		1.95	0.75	1.32		
99411		Preventive counseling, group	Physical Exams		0.15	0.06	0.18		
99412		Preventive counseling, group	Physical Exams		0.25	0.10	0.25		
99420		Health risk assessment test	Physical Exams					1.83	
99429		Unlisted preventive service	Physical Exams					2.46	
99431		Initial care, normal newborn	Inpatient Visits		1.17	0.38	0.38		
99432		Newborn care, not in hosp	Well Baby Exams		1.26	0.40	0.93		
99433		Normal newborn care/hospital	Inpatient Visits		0.62	0.20	0.20		
99435		Newborn discharge day hosp	Inpatient Visits		1.50	0.59	0.59		
99436		Attendance, birth	Inpatient Visits		1.50	0.47	0.47		
99440		Newborn resuscitation	Inpatient Visits		2.93	0.93	0.93		
99450		Life/disability evaluation	Office/Home/Urgent Care Visits					1.68	
99455		Disability examination	Office/Home/Urgent Care Visits					4.23	
99456		Disability examination	Office/Home/Urgent Care Visits					11.47	
99499		Unlisted adm service	Office/Home/Urgent Care Visits					1.37	
99500		Home visit, prenatal	Office/Home/Urgent Care Visits					2.91	
99501		Home visit, postnatal	Office/Home/Urgent Care Visits					3.32	
99502		Home visit, nb care	Office/Home/Urgent Care Visits					4.85	
99503		Home visit, resp therapy	Office/Home/Urgent Care Visits					1.94	
99504		Home visit mech ventilator	Office/Home/Urgent Care Visits					5.64	
99505		Home visit, stoma care	Office/Home/Urgent Care Visits					1.99	
99506		Home visit, im injection	Office/Home/Urgent Care Visits					0.79	
99507		Home visit, cath maintain	Office/Home/Urgent Care Visits					1.41	
99509		Home visit day life activity	Office/Home/Urgent Care Visits					1.91	
99510		Home visit, sing/m/fam couns	Physical Exams	b	0.48	0.19	0.62		CALC
99511		Home visit, fecal/enema mgmt	Office/Home/Urgent Care Visits					0.81	
99512		Home visit, hemodialysis	Office/Home/Urgent Care Visits					7.06	
99600		Home visit nos	Office/Home/Urgent Care Visits					2.21	
99601		Home infusion/visit, 2 hrs	Office/Home/Urgent Care Visits					2.21	
99602		Home infusion, each addtl hr	Office/Home/Urgent Care Visits	b				2.21	CALC
0017T		Photocoagulat macular drusen	Surgery	a	5.19	4.87	5.87		CALC
0028T		Dexa body composition study	Radiology	a	0.30	0.10	0.10		CALC
0042T		Ct perfusion w/contrast, cbf	Radiology	a	1.13	-0.37	0.37		CALC
0043T		Co expired gas analysis	Miscellaneous Medical	a	0.11	0.64	0.64		CALC
0044T		Whole body photography	Miscellaneous Medical	a				1.07	CALC
0045T		Whole body photography	Miscellaneous Medical	a				1.07	CALC
0064T		Spectroscop eval expired gas	Miscellaneous Medical						CALC
0066T	26	Ct colonography,screen	Radiology		0.11	0.64	0.64		CALC
0067T	26	Ct colonography,dx	Radiology		1.19	6.07	6.07		CALC
0082T		Stereotactic rad delivery	Radiology	a, b	1.54	0.53	0.53		CALC
0090T		Cervical artific disc	Surgery		19.38	12.12	12.12		CALC
0091T		Lumbar artific disc	Surgery		21.41	12.83	12.83		CALC
0092T		Artific disc addtl	Surgery		4.04	2.06	2.06		CALC
0093T		Cervical artific disectomy	Surgery		19.38	12.12	12.12		CALC
0094T		Lumbar artific disectomy	Surgery		21.41	12.83	12.83		CALC

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 115 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
0095T		Artific diskectomy addl	Surgery		4.04	2.06	2.06		CALC
0096T		Rev cervical artific disc	Surgery		19.38	12.12	12.12		CALC
0097T		Rev lumbar artific disc	Surgery		21.41	12.83	12.83		CALC
0098T		Rev artific disc addl	Surgery		4.04	2.06	2.06		CALC
0104T		At rest cardio gas rebreathe	Miscellaneous Medical		0.98	5.87	5.87		CALC
0105T		Exerc cardio gas rebreathe	Miscellaneous Medical		0.98	5.87	5.87		CALC
G0008		Admin influenza virus vac	Immunizations					0.22	
G0009		Admin pneumococcal vaccine	Immunizations					0.22	
G0010		Admin hepatitis b vaccine	Immunizations					0.22	
G0101		CA screen;pelvic/breast exam	Physical Exams		0.45	0.17	0.52		
G0102		Prostate ca screening; dre	Physical Exams		0.17	0.06	0.39		
G0104		CA screen;flexi sigmoidscope	Surgery		0.96	0.50	2.28		
G0105		Colorectal scm; hi nsk ind	Surgery		3.69	1.47	6.16		
G0106	26	Colon CA screen;barium enema	Surgery		0.99	0.32	0.32		
G0106	TC	Colon CA screen;barium enema	Surgery	a	0.00	2.24	2.24		
G0108		Diab manage tm per indiv	Miscellaneous Medical		0.00	0.83	0.83		
G0109		Diab manage tm ind/group	Miscellaneous Medical		0.00	0.48	0.48		
G0117		Glaucoma scm hqh risk direc	Miscellaneous Medical		0.45	0.19	0.72		
G0118		Glaucoma scm hqh risk direc	Miscellaneous Medical		0.17	0.06	0.53		
G0120	26	Colon ca scm; barium enema	Surgery		0.99	0.32	0.32		
G0120	TC	Colon ca scm; barium enema	Surgery	a	0.00	2.24	2.24		
G0121		Colon ca scm not hi rsk ind	Surgery		3.69	1.47	6.16		
G0122	26	Colon ca scm; barium enema	Radiology		0.99	0.38	0.38		
G0122	TC	Colon ca scm; barium enema	Radiology	a	0.00	2.20	2.20		
G0124		Screen cv thin layer by MD	Pathology		0.42	0.15	0.15		
G0127		Trim nail(s)	Surgery		0.17	0.07	0.25		
G0128		CORF skilled nursing service	Miscellaneous Medical		0.08	0.03	0.03		
G0130	26	Single energy x-ray study	Radiology		0.22	0.07	0.07		
G0130	TC	Single energy x-ray study	Radiology	a	0.00	0.80	0.80		
G0141		Scr cv cyto,autosys and md	Pathology		0.42	0.15	0.15		
G0151		HHCP-serv of pt,ea 15 min	Physical Medicine	b	0.45	0.27	0.27		CALC
G0152		HHCP-serv of ot,ea 15 min	Physical Medicine	b	0.45	0.33	0.33		CALC
G0153		HHCP-svs of sl path,ea 15mn	Hearing/Speech Exams	b	0.26	0.12	0.51		CALC
G0154		HHCP-svs of m,ea 15 min	Office/Home/Urgent Care Visits	b				1.41	CALC
G0155		HHCP-svs of csw,ea 15 min	Physical Exams	b	0.48	0.19	0.62		CALC
G0156		HHCP-svs of aide,ea 15 min	Office/Home/Urgent Care Visits	b				1.91	CALC
G0166		Extrnl counterpulse, per tx	Miscellaneous Medical		0.07	0.03	3.58		
G0168		Wound closure by adhesive	Surgery		0.45	0.22	1.94		
G0179		MD recertification HHA PT	Office/Home/Urgent Care Visits		0.45	1.03	1.03		
G0180		MD certification HHA patient	Office/Home/Urgent Care Visits		0.67	1.26	1.26		
G0181		Home health care supervision	Office/Home/Urgent Care Visits		1.73	1.48	1.48		
G0182		Hospice care supervision	Office/Home/Urgent Care Visits		1.73	1.66	1.66		
G0186		Dstry eye lesn, fdr vssl tech	Miscellaneous Medical					18.47	
G0202	26	Screen mammography film digital	Radiology		0.70	0.23	0.23		
G0202	TC	Screen mammography film digital	Radiology	a	0.00	2.55	2.55		
G0204	26	Diagnostic mammography digital	Radiology		0.87	0.28	0.28		
G0204	TC	Diagnostic mammography digital	Radiology	a	0.00	2.51	2.51		
G0206	26	Diagnostic mammography digital	Radiology		0.70	0.23	0.23		
G0206	TC	Diagnostic mammography digital	Radiology	a	0.00	2.03	2.03		
G0219	26	PET imq wholebod melano nonco	Radiology		2.00	0.69	0.69		CALC
G0219	TC	PET imq wholebod melano nonco	Radiology	a, b				29.31	CALC
G0235		PET not otherwise specified	Radiology	a, b	0.22	0.08	0.08		CALC
G0237		Therapeutic procd strq endur	Miscellaneous Medical		0.00	0.47	0.47		CALC
G0238		Oth resp proc, indiv	Miscellaneous Medical					0.20	
G0239		Oth resp proc, group	Miscellaneous Medical					0.38	
G0245		Initial foot exam pt tops	Office/Home/Urgent Care Visits		0.88	0.31	0.79		
G0246		Followup eval of foot pt lop	Office/Home/Urgent Care Visits		0.45	0.16	0.54		
G0247		Routine footcare pt w tops	Office/Home/Urgent Care Visits		0.50	0.21	0.52		
G0248		Demonstrate use home inr mon	Cardiovascular	a	0.00	6.63	6.63		
G0249		Provide test material, equipm	Cardiovascular	a	0.00	3.97	3.97		
G0250		MD review interpret of test	Cardiovascular		0.18	0.06	0.06		
G0259		Inject for sacroiliac joint	Surgery	a	1.40	0.33	4.36		CALC
G0268		Removal of impacted wax md	Surgery		0.61	0.24	0.63		
G0270		MNT subs tx for change dx	Miscellaneous Medical		0.00	0.47	0.47		
G0271		Group MNT 2 or more 30 mins	Miscellaneous Medical		0.00	0.18	0.18		
G0275		Renal anqjo, cardiac cath	Radiology		0.25	0.10	0.10		
G0278		Iliac art anqjo, cardiac cath	Radiology		0.25	0.10	0.10		
G0281		Elec stim unattend for press	Physical Medicine		0.18	0.11	0.11		
G0282		Elec stim wound care not pd	Physical Medicine	b	0.18	0.11	0.11		CALC
G0283		Elec stim other than wound	Physical Medicine		0.18	0.11	0.11		

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 116 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
G0288		Recon, CTA for surq plan	Radiology	a	0.00	10.64	10.64		
G0289		Arthro, loose body + chondro	Surgery		1.48	0.80	0.80		
G0295		Electromagnetic therapy onc	Physical Medicine	b	0.06	0.02	0.14		CALC
G0308		ESRD related svc 4+mo<2yrs	Miscellaneous Medical		12.74	8.56	8.56		
G0309		ESRD related svc 2-3mo<2yrs	Miscellaneous Medical		10.61	7.12	7.12		
G0310		ESRD related svc 1 visit<2yr	Miscellaneous Medical		8.49	5.70	5.70		
G0311		ESRD related svcs 4+mo 2-11yr	Miscellaneous Medical		9.73	4.73	4.73		
G0312		ESRD relate svcs 2-3 mo 2-11y	Miscellaneous Medical		8.11	3.93	3.93		
G0313		ESRD related svcs 1 mon 2-11y	Miscellaneous Medical		6.49	3.15	3.15		
G0314		ESRD related svcs 4+ mo 12-19	Miscellaneous Medical		8.28	4.43	4.43		
G0315		ESRD related svcs 2-3mo 12-19	Miscellaneous Medical		6.90	3.68	3.68		
G0316		ESRD relate svcs 1 visit 12-19	Miscellaneous Medical		5.52	2.95	2.95		
G0317		ESRD related svcs 4+mo 20+yr	Miscellaneous Medical		5.09	2.87	2.87		
G0318		ESRD related svcs 2-3 mo 20+y	Miscellaneous Medical		4.24	2.39	2.39		
G0319		ESRD related svcs 1 visit 20+	Miscellaneous Medical		3.39	1.91	1.91		
G0320		ESRD related svcs home under2	Miscellaneous Medical		10.61	7.12	7.12		
G0321		ESRD related svcs home mo<2yrs	Miscellaneous Medical		8.11	3.93	3.93		
G0322		ESRD relate svcs home mo12-19	Miscellaneous Medical		6.90	3.68	3.68		
G0323		ESRD related svcs home mo 20+	Miscellaneous Medical		4.24	2.39	2.39		
G0324		ESRD related svcs home/dy<2y	Miscellaneous Medical		0.35	0.24	0.24		
G0325		ESRD relate home/dy 2-11 yr	Miscellaneous Medical		0.23	0.12	0.12		
G0326		ESRD relate home/dy 12-19y	Miscellaneous Medical		0.27	0.13	0.13		
G0327		ESRD relate home/dy 20+yr	Miscellaneous Medical		0.14	0.08	0.08		
G0329		Electromagntc tx for ulcers	Physical Medicine		0.06	0.02	0.14		
G0337		Hospice evaluation preselect	Office/Home/Urgent Care Visits		1.34	0.51	0.51		
G0341		Percutaneous islet celltrans	Surgery		6.98	2.60	5.75		
G0342		Laparoscopy islet cell trans	Surgery		11.92	5.31	5.31		
G0343		Laparotomy islet cell transp	Surgery		19.85	8.78	8.78		
G0344		Initial preventive exam	Office/Home/Urgent Care Visits		1.34	0.48	1.13		
G0364		Bone marrow aspirate & biopsy	Surgery		0.16	0.06	0.14		
G0365		Vessel mapping hemo access	Miscellaneous Medical	a	0.25	0.09	0.09		
G0365		Vessel mapping hemo access	Miscellaneous Medical	e	0.00	3.91	3.91		
G0365		Vessel mapping hemo access	Miscellaneous Medical	e	0.25	4.00	4.00		
G0366		EKG for initial prevent exam	Office/Home/Urgent Care Visits	b	0.17	0.51	0.51		
G0368		EKG interpret & report preve	Office/Home/Urgent Care Visits	b	0.17	0.06	0.06		
G0375		Smoke/tobacco counselng 3-10	Miscellaneous Medical	e	0.24	0.09	0.09		RBRVS
G0376		Smoke/tobacco counseling >10	Miscellaneous Medical	e	0.48	0.17	0.18		RBRVS
G9001		MCCD, initial rate	Miscellaneous Medical					1.79	
G9002		MCCD, maintenance rate	Miscellaneous Medical					2.13	
G9003		MCCD, risk adj hi, initial	Miscellaneous Medical					2.69	
G9004		MCCD, risk adj lo, initial	Miscellaneous Medical					2.41	
G9005		MCCD, risk adj, maintenance	Miscellaneous Medical					3.19	
G9006		MCCD, Home monitoring	Miscellaneous Medical	b				0.32	CALC
G9007		MCCD, sch team conf	Miscellaneous Medical	b				0.32	CALC
G9008		Mccd,phys coor-care ovrsght	Miscellaneous Medical					4.67	
G9009		MCCD, risk adj, level 3	Miscellaneous Medical					4.67	
G9010		MCCD, risk adj, level 4	Miscellaneous Medical	b				4.67	CALC
G9011		MCCD, risk adj, level 5	Miscellaneous Medical	b				4.67	CALC
G9012		Other Specified Case Mgmt	Miscellaneous Medical	b				4.67	CALC
G9016		Demo-smoking cessation coun	Miscellaneous Medical	a, b	0.24	0.09	0.09		CALC
H0004		Alcohol and/or drug services	OP Psych./Alc. & Drug Abuse					0.51	
H0020		Alcohol and/or drug services	OP Psych./Alc. & Drug Abuse					0.41	
M0064		Visit for drug monitoring	OP Psych./Alc. & Drug Abuse		0.37	0.12	0.34		
M0076		Prolotherapy	Miscellaneous Medical					2.08	
M0300		IV chelationtherapy	Cardiovascular					0.94	
P3001		Screening pap smear by phys	Pathology		0.42	0.15	0.15		
P9010		Whole blood for transfusion	Miscellaneous Medical					1.41	
P9011		Blood split unit	Miscellaneous Medical					2.02	
P9016		RBC leukocytes reduced	Miscellaneous Medical					3.03	
P9019		Platelets, each unit	Miscellaneous Medical					0.93	
P9020		Platelet rich plasma unit	Miscellaneous Medical					1.35	
P9021		Red blood cells unit	Miscellaneous Medical					3.20	
P9022		Washed red blood cells unit	Miscellaneous Medical					4.36	
P9041		Albumin (human), 5%, 50ml	Miscellaneous Medical					0.77	
P9043		Plasma protein fract, 5%, 50ml	Miscellaneous Medical					0.58	
P9045		Albumin (human), 5%, 250 ml	Miscellaneous Medical					1.35	
P9046		Albumin (human), 25%, 20 ml	Miscellaneous Medical					0.73	
P9047		Albumin (human), 25%, 50ml	Miscellaneous Medical					1.35	
P9048		Plasmaprotein fract, 5%, 250ml	Miscellaneous Medical					1.69	
P9603		One-way allow prorated miles	Miscellaneous Medical					0.01	

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for notes regarding Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPSC CODE

PAGE 117 of 119

CPT/ HCPSC Code	Modifier	CPT/HCPSC Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
P9604		One-way allow prorated trip	Miscellaneous Medical					0.11	
Q0035	26	Cardiokymography	Radiology		0.17	0.06	0.06		
Q0035	TC	Cardiokymography	Radiology		0.00	0.39	0.39		
Q0091		Obtaining screen pap smear	Pathology		0.37	0.14	0.67		
Q0092		Set up port xray equipment	Radiology		0.00	0.32	0.32		
Q3031		Collagen skin test	Allergy Testing	a	0.15	0.06	0.32		CALC
S0220		Med Conf Md W/Team Hlth Prof;30 Min	Office/Home/Urgent Care Visits	a	1.10	0.41	1.03		CALC
S0221		Med Conf Md W/Team Hlth Prof;60 Min	Office/Home/Urgent Care Visits	a	1.10	0.41	1.03		CALC
S0255		By Nurse Social Worker Or Other Designated Staff	Physical Exams	a	0.48	0.19	0.62		CALC
S0257		Cnsl&Discuss Ad/Eol Pt&Surrogate	Office/Home/Urgent Care Visits	a	1.77	0.66	0.77		CALC
S0260		Hx & Phys Related To Surgical Proc	Office/Home/Urgent Care Visits	a	0.17	0.39	0.06		CALC
S0265		Genetic Counseling Phys Supervision Ea 15 Mins	Office/Home/Urgent Care Visits	a	0.17	0.39	0.06		CALC
S0315		Dz Mgmt Progm; Init Assess&Init Pro	Office/Home/Urgent Care Visits	a	0.17	0.39	0.06		CALC
S0316		Disease Mgmt Progm; F/U/Reassess	Office/Home/Urgent Care Visits	a	0.17	0.39	0.06		CALC
S0390		Routine Foot Care; Per Visit	Office/Home/Urgent Care Visits	a	0.50	0.21	0.52		CALC
S0400		Globl Fee Xtracorp Shock Wave Lith	Surgery	a	9.08	4.12	12.43		CALC
S0592		Comp Contact Lens Evaluation	Miscellaneous Medical	a	1.08	0.35	1.09		CALC
S0601		Screening Proctoscopy	Surgery	a	0.50	0.34	1.56		CALC
S0613		Annual Gyn Examn Clin Breast Exam W/O Pelv Exam	Office/Home/Urgent Care Visits	a	0.45	0.17	0.52		CALC
S0618		Audiometry For Hearing Aid Eval	Hearing/Speech Exams	a				0.39	CALC
S0622		Physical Exam College New/Est Pt	Office/Home/Urgent Care Visits	a	0.17	0.39	0.06		CALC
S0625		Retinal Telesc Digtl Imag Mx Diff Fundus Areas	Vision Exams	a	0.44	0.19	0.19		CALC
S0810		Photorefractive Keratectomy	Surgery	a	0.92	0.71	1.00		CALC
S0812		Phototherapeutic Keratectomy	Surgery	a	0.92	0.71	1.00		CALC
S2053		Tpint Sm Intestine&Liver Allogfts	Surgery	a	81.40	31.59	31.59		CALC
S2060		Lobar Lung Transplantation	Surgery	a	38.57	27.74	27.74		CALC
S2070		Cysto; Laser Tx Ureteral Calc	Surgery	a	6.87	2.51	2.51		CALC
S2080		Laser-Assisted Uvulopalatoplasty	Surgery	a	8.04	7.51	7.51		CALC
S2082		Lap Surg; Adj Gastric Band	Surgery	a	16.71	7.73	7.73		CALC
S2090		Ablat Open 1/> Renal Tumor; Cryosurg	Surgery	a	14.64	7.76	7.76		CALC
S2091		Ablat Perq 1/> Renal Tumor; Cryosurg	Surgery	a	2.63	1.29	1.29		CALC
S2095		Trmscath Ocd/Emboliz Tumor Destruc	Surgery	a	18.11	5.92	5.92		CALC
S2102		Islet Cell Tiss Tpint Panc; Allogen	Surgery					56.97	CALC
S2115		Osteot Periarticular W/Intrf Fix	Surgery		20.55	13.29	13.29		CALC
S2120		Ldl Aphares Hepam Xtrorp Ldl Precp	Surgery	a	1.22	0.48	84.29		CALC
S2135		Neurolysis Inj Mt Neuroma/Interdig	Surgery	a	1.27	0.48	1.24		CALC
S2140		Cord Bld Harvest Tpint Allogenic	Surgery	a	1.50	0.67	0.67		CALC
S2142		Cord Blood Stem-Cell Tpint Allogen	Surgery	a	2.24	1.03	1.03		CALC
S2150		Bn Marw/Stem Cell Harv Tpint&Comp;	Surgery	a	2.24	1.03	1.03		CALC
S2202		Echocardiography	Surgery	a	1.09	0.73	2.69		CALC
S2205		Min Invas Dir Cab; Art Gft 1 Caq	Surgery		29.96	16.51	16.51		CALC
S2206		Min Invas Dir Cab; Art Gft 2 Caq	Surgery		32.15	17.76	17.76		CALC
S2207		Min Invas Dir Cab; Ven Only 1 Cvq	Surgery		28.96	16.38	16.38		CALC
S2215		Uqi Endo; Inj Impl Lw Esoph Sphinct	Surgery	a	2.92	1.22	6.42		CALC
S2225		Myringotomy Laser-Assisted	Surgery	a	1.33	1.59	3.16		CALC
S2230		Impl Magnt Cmpnt Semi-Impl Hear Dvc	Surgery	a				18.06	CALC
S2235		Impl Audity Brain Stem Implant	Surgery	a	7.99	6.37	6.37		CALC
S2250		Uterine Art Emboliz Uterine Fibroids	Surgery	a	18.11	5.92	5.92		CALC
S2260		Induced Ab 17-24 Weeks Any Surg Meth	Surgery		5.90	3.26	3.26		CALC
S2262		Ab Maternal Indication 25 Weeks/>	Surgery		5.90	3.26	3.26		CALC
S2265		Ab Fetal Indication 25-28 Weeks	Surgery		5.90	3.26	3.26		CALC
S2266		Ab Fetal Indication 29-31 Weeks	Surgery		5.90	3.26	3.26		CALC
S2267		Ab Fetal Indication 32 Weeks/>	Surgery		5.90	3.26	3.26		CALC
S2300		Scope Shldr;W/Therm-Induced Cpslrr	Surgery	a				14.57	CALC
S2340		Chemodenervat Abductr Musc Vocd Cord	Surgery	a	3.86	2.39	5.69		CALC
S2341		Chemodenervat Adductr Musc Vocal Crd	Surgery	a	3.86	2.39	5.69		CALC
S2342		Nasl Endo Postop Debrid Uni/Bil	Surgery	a	2.98	1.89	5.21		CALC
S2348		Decomp Perq Disc Rf 1/Mx Lumb	Surgery	a	8.07	5.57	5.57		CALC
S2350		Diskect Ant-Osteophyt;Lumb 1 Intrsp	Surgery		21.41	12.83	12.83		CALC
S2351		Dskct Ant-Osteophyt;Lumb Add Intrsp	Surgery		3.28	1.64	1.64		CALC
S2360		Perq Vertiplsty 1 Vert Uni/Bil; Cerv	Surgery	a	5.90	5.11	61.84		CALC
S2361		Each Add Cervical Vertebral Body	Surgery	a	4.30	1.68	1.68		CALC
S2362		Kyphplsty 1 Vert Bdy Uni/Bil Inj	Surgery	a	8.54	5.71	5.71		CALC
S2363		Kyphplsty 1 Vert Bdy Uni/Bil Inj	Surgery	a	4.47	2.28	2.28		CALC
S2370		Intradiscal Electrothml Therapy; Single Intrsp	Surgery	a	8.33	4.96	56.13		CALC
S2371		Each Additional Interspace	Surgery	a	4.30	1.68	1.68		CALC
S3005		Performance Msr Eval Pt Self Assess Depression	Office/Home/Urgent Care Visits	a	0.17	0.39	0.06		CALC
S3708		Gastrointestinal Fat Absorption Study	Radiology	a	0.78	0.26	0.26		CALC
S3900		Surface Electromyography	Miscellaneous Medical	a	0.41	0.15	0.15		CALC
S4005		Interim Labor Facility Global	Maternity - Non-Deliveries	a	0.53	0.21	0.21		CALC

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARSD/FARS apply
See end of the table for note regarding Charge Methodology

TABLE G. - PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 118 of 119

CPT/HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non-Facility Practice Expense RVUs	Total Expense RVUs	Charge Methodology (1)
S4981		Instr Levonorgestrel Intrauterine Sys	Surgery	a	1.01	0.38	1.42		CALC
S5035		Home Infus Tx Routine Infus Devc	Therapeutic Injections		0.18	0.46	0.46		CALC
S5108		Home Care Tm Home Care Client 15 Min	Physical Medicine		0.45	0.33	0.33		CALC
S5109		Home Care Tm Home Care Client Sess	Physical Medicine		0.45	0.33	0.33		CALC
S5110		Home Care Training Fam; Per 15 Min	Physical Medicine		0.45	0.33	0.33		CALC
S5111		Home Care Training Fam; Per Session	Office/Home/Urgent Care Visits					2.21	CALC
S5115		Home Care Tm Non-Fam; Per 15 Min	Office/Home/Urgent Care Visits					2.21	CALC
S5116		Home Care Tm Non-Fam; Per Session	Office/Home/Urgent Care Visits					2.21	CALC
S5180		Home Health Resp Tx Init Evaluation	Office/Home/Urgent Care Visits					1.94	CALC
S5181		Home Health Resp Tx Nos Per Diem	Office/Home/Urgent Care Visits					1.94	CALC
S5190		Wellness Assessment Performed By Non-Physician	Physical Exams	a	0.48	0.19	0.62		CALC
S5522		Home Infus Tx Insertion Proc Nrs Svc Only	Surgery		1.82	0.57	7.36		CALC
S5523		Hit Insert Midline Cvc Nrs Svc Only	Surgery		1.82	0.57	7.36		CALC
S8030		Scleral Application Tantalum Ring	Surgery	a	8.65	9.20	9.20		CALC
S8037		Mr Cholangiopancreatography	Radiology	a				13.37	CALC
S8040		Topographic Brain Mapping	Miscellaneous Medical	a	2.97	2.63	2.63		CALC
S8049		Intraoperative Radiation Therapy	Radiology	a	0.00	1.78	1.78		CALC
S8055		Us Guid Mxifeti Pg Rduc Tech Cmpnt	Radiology	a	1.20	0.40	0.40		CALC
S8075		Cmpt Analy Full-Field Digtl Mammogm	Radiology	a	0.06	0.02	0.02		CALC
S8080		Scintimammo Uni W/Spl Radiopharm	Radiology	a				1.81	CALC
S8093		Ct Angio Cor Art W/Contrst Matl	Radiology	a	1.92	13.05	13.05		CALC
S8950		Complex Lymphedema Tx Ea 15 Min	Physical Medicine		0.43	0.25	0.25		CALC
S8950		Complex Lymphedema Tx Ea 15 Min	Physical Medicine		0.43	0.25	0.25		CALC
S9024		Paranasal Sinus Ultrasound	Radiology	a				2.44	CALC
S9034		Eswl For Gall Stones	Surgery	a	9.08	4.12	12.43		CALC
S9061		Home Admin Aerosolized Drug Tx Diem	Miscellaneous Medical		0.00	0.30	0.30		CALC
S9083		Global Fee Urgent Care Centers	Office/Home/Urgent Care Visits	a	0.17	0.06	0.39		CALC
S9092		Canolith Repositioning Per Visit	Office/Home/Urgent Care Visits	a	0.17	0.06	0.39		CALC
S9097		Home Visit For Wound Care	Office/Home/Urgent Care Visits					2.21	CALC
S9117		Back School Per Visit	Office/Home/Urgent Care Visits	a	0.17	0.39	0.06		CALC
S9141		Diab Mgmt Prog F/U Visit Md Prov	Miscellaneous Medical		0.00	0.83	0.83		CALC
S9141		Diab Mgmt Prog F/U Visit Md Prov	Miscellaneous Medical		0.00	0.83	0.83		CALC
S9145		Insulin Pump Init Instruct Use Pump	Miscellaneous Medical		0.00	0.83	0.83		CALC
S9145		Insulin Pump Init Instruct Use Pump	Miscellaneous Medical		0.00	0.83	0.83		CALC
S9208		Home Mgmt Preterm Labor Per Diem	Office/Home/Urgent Care Visits					2.91	CALC
S9209		Home Management Pprom Diem	Office/Home/Urgent Care Visits					2.91	CALC
S9211		Home Mgmt Gestational Htn; Diem	Office/Home/Urgent Care Visits					2.91	CALC
S9212		Home Management Postpartum Htn Diem	Office/Home/Urgent Care Visits					2.91	CALC
S9213		Home Management Preeclampsia; Diem	Office/Home/Urgent Care Visits					2.91	CALC
S9214		Home Mgmt Gestational Diabetes;Diem	Office/Home/Urgent Care Visits					2.91	CALC
S9335		Home Tx Hd; Admin Spl & Eqp Per Diem	Office/Home/Urgent Care Visits					2.91	CALC
S9339		Home Tx; Periton Dialysis Per Diem	Office/Home/Urgent Care Visits					2.91	CALC
S9401		Anticoagulat Clin No Lab Per Sess	Office/Home/Urgent Care Visits	a	0.17	0.39	0.06		CALC
S9453		Smoking Cessation Classes Non-Physician Per Sess	Miscellaneous Medical	a	0.24	0.09	0.09		CALC
S9474		Entrstml Tx Registered Nrs Cert Entrstml Tx-Diem	Office/Home/Urgent Care Visits	a				1.99	CALC
S9475		Amb Set Sbtinc Abs Tx/Dtox Svc Day	OP Psych/Alic. & Drug Abuse	a	2.79	0.90	1.03		CALC
S9480		Intensive Op Psyc Services Per Diem	OP Psych/Alic. & Drug Abuse	a	2.79	0.90	1.03		CALC
S9484		Crisis Intervent Mentl Hlth Svc-Hr	OP Psych/Alic. & Drug Abuse	a	1.86	0.60	0.70		CALC
S9485		Crisis Intervent Mental Health Serv	OP Psych/Alic. & Drug Abuse	a	1.86	0.60	0.70		CALC
S9590		Home Tx Iriq Tx; W/Admn-Per Diem	Office/Home/Urgent Care Visits					2.21	CALC
V5362		Speech screening	Physical Medicine	b	0.86	0.40	2.60		CALC
V5362		Speech screening	Physical Medicine	b	0.86	0.40	2.60		CALC
V5363		Language screening	Physical Medicine	b	0.86	0.40	2.60		CALC
V5363		Language screening	Physical Medicine	b	0.86	0.40	2.60		CALC
V5364		Dysphagia screening	Miscellaneous Medical	b	0.00	3.44	3.44		CALC
V5364		Dysphagia screening	Miscellaneous Medical	b	0.00	3.44	3.44		CALC
15431		Apply acellular xgrefit add	HCPCS - Non-Drug	a				\$337.81 (2)	OPPS
45499		Laparoscope proc, rectum	HCPCS - Non-Drug	a				\$2,029.72 (2)	OPPS
51999		Laparoscope proc, bladder	HCPCS - Non-Drug	a				\$2,029.72 (2)	OPPS
86923		Compatibility test, electric	HCPCS - Non-Drug	a				\$13.81 (2)	OPPS
86960		Vol reduction of blood/prod	HCPCS - Non-Drug	a				\$13.81 (2)	OPPS
88384		Eval molecular probes, 11-50	HCPCS - Non-Drug	a				\$15.88 (2)	OPPS
88385		Eval molec probes, 51-250	HCPCS - Non-Drug	a				\$29.00 (2)	OPPS
88386		Eval molec probes, 251-500	HCPCS - Non-Drug	a				\$48.29 (2)	OPPS
90291		Cmv iq, iv	HCPCS - Non-Drug	a				\$462.03 (2)	OPPS
90714		Td vaccine no prsr >= 7 im	HCPCS - Non-Drug	a				\$37.45 (2)	OPPS
90779		Ther(prop)/diag ini/inf proc	HCPCS - Non-Drug	a				\$8.71 (2)	OPPS
G0332		Preadmin IV immunoglobulin	HCPCS - Non-Drug	a				\$80.25 (2)	OPPS

NOTES: CPT Codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUs) BY CPT/HCPCS CODE

PAGE 119 of 119

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology (1)
-----------------------	----------	----------------------------	---------------------------------------	-------------------------------	-------------------------	---	---	-----------------------	--------------------------------

Key to Status/Usage indicators for new items:

a: Cannot be billed by VA hospital outpatients and provider-based clinics because the service is separately priced as an outpatient facility charge. (See Table F for these charges.)

b: Cannot be billed by VA hospital outpatients and provider-based clinics because a different code is used for facility billing.

No entry: Can be billed at all VA locations.

For all CPT/HCPCS codes retained from V2.4, the status/usage indicator was retained from V2.4.

Charge Methodology

No entry: Charge based upon Version 2.4 fees trended forward.

CALC: Charge based upon a calculation or data provided by VA (e.g., cost).

RBRVS: Charge based upon 1-1-2006 RBRVS fee schedule.

OPPS: Charge based upon 1-1-2006 OPPS Addendum B.

All other entries: See Supplementary Table 1, Reasonable Charges Data Sources - V2.6

TABLE H. - PROFESSIONAL ANESTHESIA NATIONWIDE BASE UNITS BY CPT CODE
PAGE 1 of 5

CPT Code	CPT Code Description	Base Units
00100	Anes-Proc Salivary Glands Incl Bx	5.0
00102	Anes-Proc Plastic Repair Cleft Lip	6.0
00103	Anes-Reconstructive Proc Eyelid	5.0
00104	Anes-Electroconvulsive Therapy	4.0
00120	Anes-Ext Mid&Innr Ear W/Bx; Nos	5.0
00124	Anes-Ext Mid&Innr Ear W/Bx; Otscopy	4.0
00126	Anes-Ext Mid&Innr Ear W/Bx; Tympanot	4.0
00140	Anesthesia Procedures On Eye; Nos	5.0
00142	Anesthesia Proc Eye; Lens Surgery	4.0
00144	Anes-Proc Eye; Corneal Transplant	6.0
00145	Anes-Proc Eye; Vitreoretinal Surg	6.0
00147	Anesthesia Proc Eye; Inidectomy	4.0
00148	Anesthesia Proc Eye; Ophthalmoscopy	4.0
00160	Anes-Proc Nose&Access Sinuses; Nos	5.0
00162	Anes-Nse&Acsc Sinuses; Radl Surg	7.0
00164	Anes-Nse&Acsc Sinuses; Bx Sft Tiss	4.0
00170	Anes-Intraoral Including Bx; Nos	5.0
00172	Anes-Intraoral W/Bx; Repr Cit Palate	6.0
00174	Anes-Intraoral W/Bx; Exc Tumor	6.0
00176	Anes-Intraoral Incl Bx; Radl Surgery	7.0
00190	Anes-Proc Facial Bones/Skull; Nos	5.0
00192	Anes-Proc Fce Bns/Skull; Radl Surg	7.0
00210	Anes-Intracran; Nos	11.0
00212	Anes-Intracran; Subdural Taps	5.0
00214	Anes-Cran; Burr Holes-Ventricraph	9.0
00215	Anes-Intracran; Elev Skl Fx-Xtradurl	9.0
00216	Anes-Intracran; Vascular Procedures	15.0
00218	Anes-Intracran; Proc Sitting Pstn	13.0
00220	Anes-Intracran; Cerebrosp Fl Shnting	10.0
00222	Anes-Intracran; Elec-Coag Cran Nerv	6.0
00300	Anes-Integ-Musc&Nerv-Head-Trunk; Nos	5.0
00320	Anes-Esoph Thyrd Trachea; Nos 1 Yr/ >	6.0
00322	Anes-Esoph Thyroid Trach; Bx Thyroid	3.0
00326	Anes-Larynx&Trach Chld < 1 Yr Age	7.0
00350	Anes-Proc Major Vessels Neck; Nos	10.0
00352	Anes-Proc Maj Ves Neck; Simple Liq	5.0
00400	Anes-Integ Extrem Trmk Perin; Nos	3.0
00402	Anes-Integ Extrem Trmk; Brst Recon	5.0
00404	Anes-Integ Trunk; Radl Breast Proc	5.0
00406	Anes-Integ; Radl Brst W/Node Dissect	13.0
00410	Anes-Integ Extrm Trmk; Convrt Arryth	4.0
00450	Anes-Proc Clavicle&Scapula; Nos	5.0
00452	Anes-Proc Clav&Scapula; Radl Surg	6.0
00454	Anes-Proc Clav&Scapula; Bx Clav	3.0
00470	Anes-Partial Rib Resection; Nos	6.0
00472	Anes-Part Rib Res; Thoracoplasty	10.0
00474	Anes-Part Rib Resection; Radl Proc	13.0
00500	Anes-On Esophagus	15.0
00520	Anes-Closed Chest; Nos	6.0
00522	Anes-Closed Chest; Needle Bx Pleura	4.0
00524	Anes-Closed Chest; Pneumocentesis	4.0
00528	Anes-Clo Chst; Mediastnscop No 1 Lung	8.0
00529	Anes-Clos Chst; Mediastnscopy 1 Lung	11.0
00530	Anes-Perm Trhs Pacemkr Insertion	4.0
00532	Anes-Access Cntrl Venous Circ	4.0
00534	Anes-Tms Insr/Repl Pacing Defib	7.0
00537	Anes-Card Eps Incl Radiofreq Ablat	7.0
00539	Anes-Tracheobronchial Reconstruct	18.0
00540	Anes-Thoracot; Nos	12.0
00541	Anes-Thoracot; Util 1 Lung Vent	15.0
00542	Anes-Thoracot; Decortication	15.0
00546	Anes-Thoracot Lungq; Thoracoplasty	15.0

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

TABLE H. - PROFESSIONAL ANESTHESIA NATIONWIDE BASE UNITS BY CPT CODE
PAGE 2 of 5

CPT Code	CPT Code Description	Base Units
00548	Anes-Thoracot Lung;Intrathor Trach	17.0
00550	Anesthesia For Sternal Debridement	10.0
00560	Anes-Hrt Pericard Sac; W/O Oxygnr	15.0
00561	Anesth, heart surg < age 1	25.0
00562	Anes-Hrt Pericard Sac; W/Oxygnr	20.0
00563	Anes-Hrt Pericard Sac;Oxygnr&Arrst	25.0
00566	Anes-Direct Cabq W/O Pump Oxygenatr	25.0
00580	Anes-Hrt Tplnt/Hrt/Lung Tplnt	20.0
00600	Anesthesia Proc C-Spine&Cord; Nos	10.0
00604	Anes-Cerv Spine&Cord; Pt Sit Pstn	13.0
00620	Anesthesia Proc T-Spine&Cord; Nos	10.0
00622	Anes-Thoracic;Thoracolum Sympathect	13.0
00630	Anesthesia Proc Lumbar Region; Nos	8.0
00632	Anes-Proc Lumb Rqn; Lumb Sympathect	7.0
00634	Anes-Lumb Rqn; Chemonucleolysis	10.0
00635	Anes-Lumb Rqn; Dx/Tx Lumb Punct	4.0
00640	Anes-Manip Spn/Clos Proc Spn	3.0
00670	Anes-Exten Spine & Spinal Cord	13.0
00700	Anes-Proc Upper Ant Abd Wall; Nos	4.0
00702	Anes-Up Ant Abd Wall; Perq Livr Bx	4.0
00730	Anes-Proc Upper Posterior Abd Wall	5.0
00740	Anes-Uqi Endoscopy-Intro Prox Duod	5.0
00750	Anes-Hernia Repairs Upper Abd; Nos	4.0
00752	Anes-Hernia Repr Up Abd; &Dehis	6.0
00754	Anes-Hem Repr Up Abd; Omphalocele	7.0
00756	Anes-Hernia Repr Up Abd;Transabd	7.0
00770	Anes-On Major Abd Blood Vessels	15.0
00790	Anes-Intraper Up Abd W/Lap;Nos	7.0
00792	Anes-Intraper Up Abd W/Lap;Hepatec	13.0
00794	Anes-Intraper Up W/Lap;Pancreatect	8.0
00796	Anes-Intraper Up W/Lap;Liver Tplnt	30.0
00797	Anes-Intraper W/Lap; Gastr Restirct	8.0
00800	Anes-Proc Lower Ant Abd Wall; Nos	4.0
00802	Anes-Lw Ant Abd Wall; Panniculect	5.0
00810	Anes-Low Intest Endo-Dist To Duod	5.0
00820	Anes-Proc Lower Posterior Abd Wall	5.0
00830	Anes-Hernia Repairs Lower Abd; Nos	4.0
00832	Anes-Hern Rep ; Ventral&Inci Hem S	6.0
00834	Anes-Hern Repr Nos Under 1 Yr Age	5.0
00836	Anes-Hern Nos<37Wk Brth &<50Wk Surg	6.0
00840	Anes-Intraper W/Laparscopy; Nos	6.0
00842	Anes-Intraper W/Laparscopy; Amnio	4.0
00844	Anes-Intraper;Abd-Perinl Resection	7.0
00846	Anes-Intraper Low W/Lap;Radl Hyst	8.0
00848	Anes-Intraper W/Lap;Pelv Exentratn	8.0
00851	Anes-Intraper W/Lap; Tubal Liq	6.0
00860	Anes-Xtraper W/Unin Tract; Nos	6.0
00862	Anes-Xtraper;Up 1/3 Ureter/Nephrect	7.0
00864	Anes-Xtraper Low Abd;Tot Cystect	8.0
00865	Anes-Xtraper Low;Radl Prostatact	7.0
00866	Anes-Xtraper Low Abd;Adrenalectomy	10.0
00868	Anes-Xtraper Low Abd;Renal Trsplnt	10.0
00870	Anes-Xtraper Low Abd;Cystolithotomy	5.0
00872	Anes-Lith Etracorp;W/Water Bath	7.0
00873	Anes-Lith Xtracorp;W/O Water Bath	5.0
00880	Anes-Proc Major Lower Abd Ves; Nos	15.0
00882	Anes-Maj Ves; Inf Vena Cava Liq	10.0
00902	Anesthesia For; Anorectal Procedure	5.0
00904	Anes-For; Radical Perineal Proc	7.0
00906	Anesthesia For; Vulvectomy	4.0
00908	Anes-For; Perineal Prostatactomy	6.0
00910	Anes-Transurethral; Nos	3.0

NOTES: CPT codes and descriptions only are copyright 2005 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

TABLE H. - PROFESSIONAL ANESTHESIA NATIONWIDE BASE UNITS BY CPT CODE
PAGE 3 of 5

CPT Code	CPT Code Description	Base Units
00912	Anes-Tmsureth;Resect Bladder Tumor	5.0
00914	Anes-Transurethral ; Turp	5.0
00916	Anes-Tmsureth;Post Resection Bleed	5.0
00918	Anes-Tmsureth;W/Manip&/Remv Calcu	5.0
00920	Anesthesia Proc Male Genitalia; Nos	3.0
00921	Anes-Male Gnt; Vasect Unilat/Bilat	3.0
00922	Anes-Proc Male Gnt; Seminl Vesicles	6.0
00924	Anes-Male;Undescend Testis Uni/Bil	4.0
00926	Anes-Male Gnt; Radl Orchest Inq	4.0
00928	Anes-Male Gnt; Radl Orchest Abd	6.0
00930	Anes-Male Genit;Orchiopexy Uni/Bil	4.0
00932	Anes-Proc Male Gnt; Cmpl Amp Penis	4.0
00934	Anes-Male;Radl Amp Penis-Inq Lymph	6.0
00936	Anes Male;Radl Amp Penis-Inq&Iliac	8.0
00938	Anes-Male Genit;Insrp Penile Prosth	4.0
00940	Anes-Vaq; Not Otherwise Specified	3.0
00942	Anes-Vaq; Colpot Vaginect&Opn Ureth	4.0
00944	Anes-Vaq; Vaginal Hysterectomy	6.0
00948	Anes-Vaq; Cervical Cerclage	4.0
00950	Anes-Vaq ; Culdoscopy	5.0
00952	Anes-Vaq;Hysteroscopy&Salpingraphy	4.0
01112	Anes-Bn Marrow Asp&Bx Iliac Crest	5.0
01120	Anesthesia Procedures Bony Pelvis	6.0
01130	Anes-Body Cast Application/Rev	3.0
01140	Anesthesia Interpelviabd Amputation	15.0
01150	Anes-Radl Tumor Pelv No Hndqtr Amp	10.0
01160	Anes-Clos Proc Invlv Pubis/Si Jnt	4.0
01170	Anes-Open Proc Invlv Pubis/Si Jnt	8.0
01173	Anes-Opn Rep Fx Pelv/Column Acetab	12.0
01180	Anes-Obtur Neurectomy; Extrapelvic	3.0
01190	Anes-Obtur Neurectomy; Intrapelvic	4.0
01200	Anes-All Clos Proc Invlv Hip Joint	4.0
01202	Anes-Arthroscopic Proc Hip Joint	4.0
01210	Anes-Open Proc Invlv Hip Joint; Nos	6.0
01212	Anes-Open Proc Invlv Hip;Disartic	10.0
01214	Anes-Opn Hip Jnt; Tot Hip Arthplsty	8.0
01215	Anes-Open Invlv Hip;Total Hip Rev	10.0
01220	Anes-All Clos Proc Invlv Up 2/3 Fem	4.0
01230	Anes-Open Invlv Upper 2/3 Femur;Nos	6.0
01232	Anes-Open Invlv Upper 2/3 Femur;Amp	5.0
01234	Anes-Open Upper 2/3 Femur;Radl Res	8.0
01250	Anes-All Nerv Musc Tend Fasc Up Leq	4.0
01260	Anes-Invlv Vns Upper Leq Incl Expl	3.0
01270	Anes-Invlv Artery Up Leq W/Gft;Nos	8.0
01272	Anes-Invlv Art Up Leq W/Gft;Fem Liq	4.0
01274	Anes-Invlv Art Up Leq W/Gft;Fem Emb	6.0
01320	Anes-Nerv Musc Fasc Burs Knee&/Pop	4.0
01340	Anes-All Clos Proc Lower 1/3 Femur	4.0
01360	Anes-All Open Proc Lower 1/3 Femur	5.0
01380	Anes-All Closed Proc Knee Joint	3.0
01382	Anes-Dx Arthroscopic Proc Knee Jnt	3.0
01390	Anes-All Clos Up Ends Tib Fib&/Pat	3.0
01392	Anes-All Open Up Ends Tib Fib&/Pat	4.0
01400	Anes-Open/Scope Proc Knee Jnt; Nos	4.0
01402	Anes-Open/Scope Knee Jnt; Tot Plsty	7.0
01404	Anes-Open/Scope Knee Jnt; Disartic	5.0
01420	Anes-All Cast Applic/Repr W/Knee	3.0
01430	Anes-Proc Veins Knee&Pop Area; Nos	3.0
01432	Anes-Vns Knee&Pop Area; Av Fist	6.0
01440	Anes-Proc Art Knee&Pop Area; Nos	8.0
01442	Anes-Art Knee;Pop Thrombendarct	8.0
01444	Anes-Art Knee;Pop Exc Occl/Aneur	8.0

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

TABLE H. -- PROFESSIONAL ANESTHESIA NATIONWIDE BASE UNITS BY CPT CODE
PAGE 4 of 5

CPT Code	CPT Code Description	Base Units
01462	Anes-All Clos Proc Low Leg Ank&Foot	3.0
01464	Anes-Arthroscopic Proc Ank &Or Foot	3.0
01470	Anes-Nerv Musc Fasc Leg Ank&Ft;Nos	3.0
01472	Anes-Nerv Musc Leg&Ft;Repr Achilles	5.0
01474	Anes-Nrv Musc Leg&Ft;Gastroc Recess	5.0
01480	Anes-Open Bones Low Leg Ank&Ft;Nos	3.0
01482	Anes-Open Bones Lw Leg;Radl Res/Amp	4.0
01484	Anes-Open Bns Lw Leg;Osteot Tib Fib	4.0
01486	Anes-Open Bones Lw Leg;Tot Ank Repl	7.0
01490	Anes-Lw Leg Cast Applic Remov/Repr	3.0
01500	Anes-Art Lw Leg W/Byps Gft; Nos	8.0
01502	Anes-Art Low Leg W/Gft;Emboleectomy	6.0
01520	Anes-Proc Veins Lower Leg; Nos	3.0
01522	Anes-Veins Lw Leg;Thrombect Direct	5.0
01610	Anes-Nerv Musc Tend Fasc Burs Shldr	5.0
01620	Anes-All Clos Hum Sc Ac&Shldr Jnt	4.0
01622	Anes-Dx Arthroscopic Proc Shldr Jnt	4.0
01630	Anes-Open/Scope Hum Sc Ac&Shldr;Nos	5.0
01632	Anes-Oprn/Scope Hum Sc&Shldr;Rad Res	6.0
01634	Anes-Oprn/Scope Hum Sc&Shldr;Disartic	9.0
01636	Anes-Oprn/Scope Hum Sc Ac&Shldr; Amp	15.0
01638	Anes-Open/Scope Hum Ac&Shldr; Repl	10.0
01650	Anes-Proc Art Shoulder&Axilla; Nos	6.0
01652	Anes-Art Shldr&Ax; Ax-Brach Aneur	10.0
01654	Anes-Proc Art Shldr&Ax; Byps Graft	8.0
01656	Anes-Art Shldr&Ax; Ax-Fem Byps Gft	10.0
01670	Anes-On Veins Of Shoulder&Axilla	4.0
01680	Anes-Shldr Cast Applic/Remv/Repr;Nos	3.0
01682	Anes-Shldr Cast Applic/Remv;Spica	4.0
01710	Anes-Nrv Musc Burs Up Arm&Elb;Nos	3.0
01712	Anes-Nrv Musc Burs Up Arm&Elb;Tenot	5.0
01714	Anes-Nrv Musc Up Arm&Elb;Tenoplasty	5.0
01716	Anes-Nrv Musc Up Arm&Elb;Tenodesis	5.0
01730	Anes-All Closed Proc Humerus&Elbow	3.0
01732	Anes-Dx Arthroscopic Proc Elb Joint	3.0
01740	Anes-Open/Surg Scope Proc Elb; Nos	4.0
01742	Anes-Open/Scope Proc Elb;Osteot Hum	5.0
01744	Anes-Open/Scope Elb;Rep Non/Mal Hum	5.0
01756	Anes-Open/Scope Proc Elb; Radl Proc	6.0
01758	Anes-Oprn/Scope Elb;Exc Cyst/Tum Hum	5.0
01760	Anes-Open/Scope Elb; Tot Elb Repl	7.0
01770	Anes-Proc Art Upper Arm&Elbow; Nos	6.0
01772	Anes-Proc Art Upper Arm&Elb; Embo	6.0
01780	Anes-Proc Veins Upper Arm&Elb; Nos	3.0
01782	Anes-Proc Vns Up Arm&Elb; Phleborr	4.0
01810	Anes-All Nerv Musc Forarm Wrst&Hnd	3.0
01820	Anes-Clos Radius Ulna Wrst/Hnd Bone	3.0
01829	Anes-Dx Arthroscopic Proc Wrst	3.0
01830	Anes-Oprn/Scope/Endo Wrst/Hnd; Nos	3.0
01832	Anes-Open/Scope/Endo Wrst/Hnd; Tot	6.0
01840	Anes-Proc Art Forarm Wrst&Hand; Nos	6.0
01842	Anes-Proc Art Forarm Wrst&Hnd; Embo	6.0
01844	Anes-Vasc Shnt/Shnt Rev Any Type	6.0
01850	Anes-Proc Vns Forarm Wrst&Hand; Nos	3.0
01852	Anes-Vns Forarm Wrst&Hnd; Phleborr	4.0
01860	Anes-Forarm/Hand Cast Applic/Remv	3.0
01905	Anes-Myelqrph Diskqrph Vertplsty	5.0
01916	Anes-Diagnostic Artrqrph/Venography	5.0
01920	Anes-Card Cath Cor Anqio&Ventrqrph	7.0
01922	Anes-Non-Invasive Imaging/Rad Tx	7.0
01924	Anes-Tx Intrvn Rad Art Sys; Nos	5.0
01925	Anes-Tx Intrvn Rad Art; Carotid/Cor	7.0

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

TABLE H. - PROFESSIONAL ANESTHESIA NATIONWIDE BASE UNITS BY CPT CODE
PAGE 5 of 5

CPT Code	CPT Code Description	Base Units
01926	Anes-Tx Rad Art;Intrcran -Card/Aort	8.0
01930	Anes-Tx Intrvn Rad Venus/Lymph; Nos	5.0
01931	Anes-Tx Rad Venus; Intrahep/Portal	7.0
01932	Anes-Tx Rad Venus; Intrathr/Juqular	6.0
01933	Anes-Tx Rad Venus/Lymph; Intracran	7.0
01951	Anes-2&3 Deg Bm Exc/Debrid; < 4%	3.0
01952	Anes-2&3 Deg Bm Exc/Debrid; 4-9%	5.0
01953	Anes-2-3 Deg Exc/Debrid;Ea Add 9%	1.0
01958	Anes-External Cephalic Version Proc	5.0
01960	Anesthesia Vaginal Delivery Only	5.0
01961	Anesthesia Cesarean Delivery Only	7.0
01962	Anes-Urgent Hyst Follow Deliv	8.0
01963	Anes-C/S Hyst W/O Labr Analq/Anes	8.0
01965	Anesth, inc/missed ab proc	4.0
01966	Anesth, induced ab procedure	4.0
01967	Neurax Labr Anlq/Anes-Plan Vaq Del	5.0
01968	Anes-Cd Flw Neurax Labr Analq/Anes	2.0
01969	Anes-C/S Hyst Flw Neurax Labr Analq	5.0
01990	Physioloq Supp-Harv Org-Brain Dead	7.0
01991	Anes-Dx/Tx Nrv Blks&Inj; Not Prone	3.0
01992	Anes-Dx/Tx Nrv Blks&Inj; Prone Pstn	5.0
01995	Rqn Iv Admn Loc Anes Aqt/Oth Med	5.0
01996	Daily Hos Epidurl/Subarach Cont Rx	3.0
01999	Unlisted Anesthesia Procedure (s)	5.0

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE

PAGE 1 of 9

HCPCS Code	HCPCS Code Description	Charge	GAAP Category
D0120	Periodic oral evaluation	\$42.29	I
D0140	Limit oral eval probim focus	\$64.76	I
D0150	Comprehensve oral evaluation	\$71.21	I
D0160	Extensv oral eval prob focus	\$153.27	I
D0170	Re-eval,est pt,problem focus	\$58.18	I
D0180	Comp periodontal evaluation	\$82.28	I
D0210	Intraor complete film senes	\$115.89	I
D0220	Intraoral periapical first f	\$24.36	I
D0230	Intraoral periapical ea add	\$19.62	I
D0240	Intraoral occlusal film	\$35.53	I
D0250	Extraoral first film	\$50.26	I
D0260	Extraoral ea additional film	\$44.95	I
D0270	Dental bitewing single film	\$24.39	I
D0272	Dental bitewings two films	\$38.18	I
D0274	Dental bitewings four films	\$55.21	I
D0277	Vert bitewings-sev to eight	\$82.85	I
D0290	Dental film skull/facial bon	\$125.83	I
D0310	Dental saligraphy	\$348.99	I
D0320	Dental tmj arthrogram incl i	\$563.60	I
D0321	Dental other tmj films	\$192.49	I
D0322	Dental tomographic survey	\$468.86	I
D0330	Dental panoramic film	\$99.05	I
D0340	Dental cephalometric film	\$111.69	I
D0350	Oral/facial images	\$57.56	I
D0415	Bacteriologic study	\$30.35	I
D0416	Viral culture	\$1.40	I
D0425	Canes susceptibility test	\$27.73	I
D0431	Diag tst detect mucos abnorm	\$27.73	I
D0460	Pulp vitality test	\$47.63	I
D0470	Diagnostic casts	\$97.61	I
D0472	Gross exam, prep & report	\$82.07	I
D0473	Micro exam, prep & report	\$133.62	I
D0474	Micro w exam of surg margins	\$154.35	I
D0475	Decalcification procedure	\$0.39	I
D0476	Spec stains for microorganis	\$0.88	I
D0477	Spec stains not for microorg	\$0.39	I
D0478	Immunohistochemical stains	\$1.38	I
D0479	Tissue in-situ hybridization	\$1.96	I
D0480	Cytopath smear prep & report	\$126.29	I
D0481	Electron microscopy diagnost	\$2.46	I
D0482	Direct immunofluorescence	\$1.40	I
D0483	Indirect immunofluorescence	\$1.38	I
D0484	Consult slides prep elsewhere	\$2.40	I
D0485	Consult inc prep of slides	\$2.19	I
D0502	Other oral pathology procedu	\$149.78	I
D0999	Unspecified diagnostic proce	\$1,255.45	I
D1110	Dental prophylaxis adult	\$81.00	I
D1120	Dental prophylaxis child	\$58.86	I
D1201	Topical fluor w proph child	\$84.79	I
D1203	Topical fluor w/o proph chi	\$33.54	I
D1204	Topical fluor w/o proph adu	\$32.72	I
D1205	Topical fluoride w/ proph a	\$98.98	I
D1310	Nutri counsel-control canes	\$49.71	I
D1320	Tobacco counseling	\$58.45	I
D1330	Oral hygiene instruction	\$52.47	I
D1351	Dental sealant per tooth	\$47.33	I
D1510	Space maintainer fxd unilat	\$299.71	II
D1515	Fixed bilat space maintainer	\$424.66	II
D1520	Remove unilat space maintain	\$378.72	II
D1525	Remove bilat space maintain	\$502.05	II
D1550	Recement space maintainer	\$67.81	II
D2140	Amalgam one surface permanen	\$115.86	II
D2150	Amalgam two surfaces permane	\$145.91	II
D2160	Amalgam three surfaces perma	\$176.68	II
D2161	Amalgam 4 or > surfaces perm	\$213.82	II

NOTES: CDT-4 Codes copyright American Dental Association. All rights reserved.

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE

PAGE 2 of 9

HCPCS Code	HCPCS Code Description	Charge	GAAP Category
D2330	Resin one surface-anterior	\$133.75	II
D2331	Resin two surfaces-anterior	\$165.94	II
D2332	Resin three surfaces-anterior	\$204.00	II
D2335	Resin 4/> surf or w incis an	\$244.45	II
D2390	Ant resin-based cmpst crown	\$309.05	II
D2391	Post 1 srfc resinbased cmpst	\$148.94	II
D2392	Post 2 srfc resinbased cmpst	\$198.97	II
D2393	Post 3 srfc resinbased cmpst	\$245.89	II
D2394	Post >=4srfc resinbase cmpst	\$289.60	II
D2410	Dental gold foil one surface	\$199.54	III
D2420	Dental gold foil two surface	\$484.27	III
D2430	Dental gold foil three surfa	\$876.74	III
D2510	Dental inlay metallic 1 surf	\$726.70	III
D2520	Dental inlay metallic 2 surf	\$818.40	III
D2530	Dental inlay metl 3/more sur	\$901.43	III
D2542	Dental onlay metallic 2 surf	\$896.20	III
D2543	Dental onlay metallic 3 surf	\$940.70	III
D2544	Dental onlay metl 4/more sur	\$975.59	III
D2610	Inlay porcelain/ceramic 1 su	\$810.63	III
D2620	Inlay porcelain/ceramic 2 su	\$866.95	III
D2630	Dental onlay porc 3/more sur	\$911.52	III
D2642	Dental onlay porcelain 2 surf	\$921.03	III
D2643	Dental onlay porcelain 3 surf	\$954.93	III
D2644	Dental onlay porc 4/more sur	\$998.70	III
D2650	Inlay composite/resin one su	\$654.21	III
D2651	Inlay composite/resin two su	\$739.77	III
D2652	Dental inlay resin 3/mre sur	\$786.93	III
D2662	Dental onlay resin 2 surface	\$786.92	III
D2663	Dental onlay resin 3 surface	\$829.22	III
D2664	Dental onlay resin 4/mre sur	\$868.70	III
D2710	Crown resin laboratory	\$536.52	III
D2712	Crown 3/4 resin-based compos	\$536.52	III
D2720	Crown resin w/ high noble me	\$976.50	III
D2721	Crown resin w/ base metal	\$852.96	III
D2722	Crown resin w/ noble metal	\$898.34	III
D2740	Crown porcelain/ceramic subs	\$1,014.90	III
D2750	Crown porcelain w/ h noble m	\$971.16	III
D2751	Crown porcelain fused base m	\$887.57	III
D2752	Crown porcelain w/ noble met	\$925.96	III
D2780	Crown 3/4 cast hi noble met	\$972.37	III
D2781	Crown 3/4 cast base metal	\$921.73	III
D2782	Crown 3/4 cast noble metal	\$934.85	III
D2783	Crown 3/4 porcelain/ceramic	\$991.22	III
D2790	Crown full cast high noble m	\$952.20	III
D2791	Crown full cast base metal	\$888.23	III
D2792	Crown full cast noble metal	\$914.02	III
D2794	Crown-titanium	\$913.99	III
D2799	Provisional crown	\$367.25	III
D2910	Dental recement inlay	\$91.19	III
D2915	Recement cast or prefab post	\$298.64	III
D2920	Dental recement crown	\$91.20	III
D2930	Prefab stnlss steel crwn pri	\$236.95	III
D2931	Prefab stnlss steel crown pe	\$272.55	III
D2932	Prefabncated resin crown	\$297.87	III
D2933	Prefab stainless steel crown	\$318.51	III
D2934	Prefab steel crown primary	\$318.54	III
D2940	Dental sedative filling	\$95.49	III
D2950	Core build-up incl any pins	\$236.42	III
D2951	Tooth pin retention	\$52.27	III
D2952	Post and core cast + crown	\$372.65	III
D2953	Each addtl cast post	\$222.25	III
D2954	Prefab post/core + crown	\$298.68	III
D2955	Post removal	\$258.45	III
D2957	Each addtl prefab post	\$158.20	III
D2960	Laminate labial veneer	\$597.74	III

NOTES: CDT-4 Codes copyright American Dental Association. All rights reserved.

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE

PAGE 3 of 9

HCPCS Code	HCPCS Code Description	Charge	GAAP Category
D2961	Lab labial veneer resin	\$864.91	III
D2962	Lab labial veneer porcelain	\$950.73	III
D2971	Add pruc construct new crown	\$242.78	III
D2975	Coping	\$635.79	III
D2980	Crown repair	\$242.77	III
D2999	Dental unspc restorative pr	\$1,270.84	III
D3110	Pulp cap direct	\$69.09	II
D3120	Pulp cap indirect	\$61.82	II
D3220	Therapeutic pulpotomy	\$158.49	II
D3221	Gross pulpal debridement	\$179.76	II
D3230	Pulpal therapy anterior prim	\$203.49	II
D3240	Pulpal therapy posterior pri	\$229.26	II
D3310	Anterior	\$653.96	II
D3320	Root canal therapy 2 canals	\$779.11	II
D3330	Root canal therapy 3 canals	\$979.49	II
D3331	Non-surg tx root canal obs	\$311.12	II
D3332	Incomplete endodontic tx	\$423.48	II
D3333	Internal root repair	\$223.08	II
D3346	Retreat root canal anterior	\$838.85	II
D3347	Retreat root canal bicuspid	\$963.91	II
D3348	Retreat root canal molar	\$1,148.63	II
D3351	Apexification/recalc initial	\$338.13	II
D3352	Apexification/recalc interim	\$189.39	II
D3353	Apexification/recalc final	\$550.04	II
D3410	Apicoect/peri-rad surg anter	\$715.18	II
D3421	Root surgery bicuspid	\$777.63	II
D3425	Root surgery molar	\$884.70	II
D3426	Root surgery ea add root	\$321.36	II
D3430	Retrograde filling	\$234.63	II
D3450	Root amputation	\$472.23	II
D3460	Endodontic endosseous implan	\$1,796.18	II
D3470	Intentional replantation	\$837.01	II
D3910	Isolation- tooth w rubb dam	\$177.04	II
D3920	Tooth splitting	\$386.26	II
D3950	Canal prep/fitting of dowel	\$178.44	II
D3999	Endodontic procedure	\$1,299.24	II
D4210	Gingivectomy/plasty per quad	\$580.00	II
D4211	Gingivectomy/plasty per tooth	\$219.99	II
D4240	Gingival flap proc w/ planin	\$708.21	II
D4241	Gingiv flap w rootplan 1-3 th	\$470.14	II
D4245	Apically positioned flap	\$628.42	II
D4249	Crown lengthen hard tissue	\$783.33	II
D4260	Osseous surgery per quadrant	\$1,058.96	II
D4261	Osseous surgl-3teethperquad	\$768.50	II
D4263	Bone replce graft first site	\$475.95	II
D4264	Bone replce graft each add	\$201.98	II
D4265	Bio mtrix to aid soft/os reg	\$444.52	II
D4266	Guided tiss regen resorb	\$566.02	II
D4267	Guided tiss regen nonresorb	\$678.21	II
D4268	Surgical revision procedure	\$667.34	II
D4270	Pedicle soft tissue graft pr	\$814.33	II
D4271	Free soft tissue graft proc	\$870.31	II
D4273	Subepithelial tissue graft	\$974.87	II
D4274	Distal/proximal wedge proc	\$441.16	II
D4275	Soft tissue allograft	\$718.91	II
D4276	Con tissue w dble ped graft	\$1,003.17	II
D4320	Provision splnt intracoronal	\$412.80	II
D4321	Provisional splint extracoro	\$362.78	II
D4341	Periodontal scaling & root	\$226.80	II
D4342	Periodontal scaling 1-3teeth	\$147.07	II
D4355	Full mouth debridement	\$152.99	II
D4381	Localized chemo delivery	\$122.90	II
D4910	Periodontal maint procedures	\$126.57	II
D4920	Unscheduled dressing change	\$101.50	II
D4999	Unspecified periodontal proc	\$1,189.19	II

NOTES: CDT-4 Codes copyright American Dental Association. All rights reserved.

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE

PAGE 4 of 9

HCPCS Code	HCPCS Code Description	Charge	GAAF Category
D5110	Dentures complete maxillary	\$1,320.07	III
D5120	Dentures complete mandible	\$1,315.58	III
D5130	Dentures immediat maxillary	\$1,444.80	III
D5140	Dentures immediat mandible	\$1,429.70	III
D5211	Dentures maxill part resin	\$1,055.56	III
D5212	Dentures mand part resin	\$1,149.73	III
D5213	Dentures maxill part metal	\$1,449.53	III
D5214	Dentures mandibl part metal	\$1,460.75	III
D5225	Maxillary part denture flex	\$1,449.53	III
D5226	Mandibular part denture flex	\$1,460.76	III
D5281	Removable partial denture	\$820.48	III
D5410	Dentures adjust cmplt maxil	\$75.05	III
D5411	Dentures adjust cmplt mand	\$74.65	III
D5421	Dentures adjust part maxill	\$75.05	III
D5422	Dentures adjust part mandbl	\$75.05	III
D5510	Dentur repr broken compl bas	\$163.01	III
D5520	Replace denture teeth complt	\$138.84	III
D5610	Dentures repair resin base	\$163.72	III
D5620	Rep part denture cast frame	\$206.75	III
D5630	Rep partial denture clasp	\$211.19	III
D5640	Replace part denture teeth	\$146.17	III
D5650	Add tooth to partial denture	\$182.50	III
D5660	Add clasp to partial denture	\$219.11	III
D5670	Replc th&acric on mtl frmwk	\$539.15	III
D5671	Replc th&acric mandibular	\$566.76	III
D5710	Dentures rebase cmplt maxil	\$498.91	III
D5711	Dentures rebase cmplt mand	\$491.30	III
D5720	Dentures rebase part maxill	\$480.99	III
D5721	Dentures rebase part mandbl	\$485.36	III
D5730	Denture reln cmplt maxil ch	\$307.53	III
D5731	Denture reln cmplt mand chr	\$307.53	III
D5740	Denture reln part maxil chr	\$292.97	III
D5741	Denture reln part mand chr	\$292.93	III
D5750	Denture reln cmplt max lab	\$398.72	III
D5751	Denture reln cmplt mand lab	\$397.15	III
D5760	Denture reln part maxil lab	\$397.22	III
D5761	Denture reln part mand lab	\$397.22	III
D5810	Denture interm cmplt maxill	\$647.06	III
D5811	Denture interm cmplt mandbl	\$672.14	III
D5820	Denture interm part maxill	\$537.48	III
D5821	Denture interm part mandbl	\$552.13	III
D5850	Denture tiss conditn maxill	\$145.56	III
D5851	Denture tiss conditn mandbl	\$147.15	III
D5860	Overdenture complete	\$2,034.44	III
D5861	Overdenture partial	\$1,763.67	III
D5862	Precision attachment	\$548.13	III
D5867	Replacement of precision att	\$203.10	III
D5875	Prosthesis modification	\$391.41	III
D5899	Removable prosthodontic proc	\$1,188.00	III
D5911	Facial moulage sectionai	\$634.44	III
D5912	Facial moulage complete	\$634.44	III
D5913	Nasal prosthesis	\$3,818.55	III
D5914	Auricular prosthesis	\$3,818.55	III
D5915	Orbital prosthesis	\$4,999.47	III
D5916	Ocular prosthesis	\$1,682.29	III
D5919	Facial prosthesis	\$951.35	III
D5922	Nasal septal prosthesis	\$951.35	III
D5923	Ocular prosthesis interim	\$951.35	III
D5924	Cranial prosthesis	\$1,106.36	III
D5925	Facial augmentation implant	\$233.11	III
D5926	Replacement nasal prosthesis	\$951.35	III
D5927	Auricular replacement	\$951.35	III
D5928	Orbital replacement	\$951.35	III
D5929	Facial replacement	\$951.35	III
D5931	Surgical obturator	\$2,275.60	III

NOTES: CDT-4 Codes copyright American Dental Association. All rights reserved.

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE

PAGE 5 of 9

HCPCS Code	HCPCS Code Description	Charge	GAAP Category
D5932	Postsurgical obturator	\$3,841.96	III
D5933	Refitting of obturator	\$951.35	III
D5934	Mandibular flange prosthesis	\$3,543.88	III
D5935	Mandibular denture prosth	\$3,145.30	III
D5936	Temp obturator prosthesis	\$3,474.23	III
D5937	Trismus appliance	\$629.15	III
D5951	Feeding aid	\$965.62	III
D5952	Pediatric speech aid	\$2,066.60	III
D5953	Adult speech aid	\$3,497.07	III
D5954	Superimposed prosthesis	\$3,275.49	III
D5955	Palatal lift prosthesis	\$3,065.36	III
D5958	Intraoral con def inter plt	\$951.35	III
D5959	Intraoral con def mod palat	\$951.35	III
D5960	Modify speech aid prosthesis	\$343.15	III
D5982	Surgical stent	\$473.86	III
D5983	Radiation applicator	\$1,229.45	III
D5984	Radiation shield	\$1,229.45	III
D5985	Radiation cone locator	\$1,229.45	III
D5986	Fluoride applicator	\$162.28	III
D5987	Commisssure splint	\$1,606.92	III
D5988	Surgical splint	\$626.80	III
D5999	Maxillofacial prosthesis	\$951.35	III
D6010	Odonics endosteal implant	\$2,002.53	III
D6040	Odonics eposteal implant	\$8,683.95	III
D6050	Odonics tranosteal implnt	\$5,623.11	III
D6053	Implnt/abtmnt spprt rmv dnt	\$2,012.82	III
D6054	Implnt/abtmnt spprt rmvprtl	\$1,844.52	III
D6055	Implant connecting bar	\$679.67	III
D6056	Prefabricated abutment	\$677.49	III
D6057	Custom abutment	\$878.88	III
D6058	Abutment supported crown	\$1,307.82	III
D6059	Abutment supported mtl crown	\$1,319.61	III
D6060	Abutment supported mtl crown	\$1,161.93	III
D6061	Abutment supported mtl crown	\$1,241.63	III
D6062	Abutment supported mtl crown	\$1,267.80	III
D6063	Abutment supported mtl crown	\$1,260.29	III
D6064	Abutment supported mtl crown	\$1,276.23	III
D6065	Implant supported crown	\$1,395.07	III
D6066	Implant supported mtl crown	\$1,367.93	III
D6067	Implant supported mtl crown	\$1,317.69	III
D6068	Abutment supported retainer	\$1,264.46	III
D6069	Abutment supported retainer	\$1,282.18	III
D6070	Abutment supported retainer	\$1,024.42	III
D6071	Abutment supported retainer	\$1,290.81	III
D6072	Abutment supported retainer	\$1,321.25	III
D6073	Abutment supported retainer	\$1,159.62	III
D6074	Abutment supported retainer	\$1,193.77	III
D6075	Implant supported retainer	\$1,394.46	III
D6076	Implant supported retainer	\$1,306.04	III
D6077	Implant supported retainer	\$1,356.28	III
D6078	Implnt/abut suprtid fixd dent	\$5,007.27	III
D6079	Implnt/abut suprtid fixd dent	\$2,405.87	III
D6080	Implant maintenance	\$111.63	III
D6090	Repair implant	\$480.72	III
D6094	Abut support crown titanium	\$1,267.80	III
D6095	Odonics repr abutment	\$533.47	III
D6100	Removal of implant	\$643.54	III
D6190	Radio/surgical implant index	\$0.31	III
D6194	Abut support retainer titani	\$1,321.25	III
D6199	Implant procedure	\$1,292.14	III
D6205	Pontic-indirect resin based	\$892.27	III
D6210	Prosthodont high noble metal	\$944.07	III
D6211	Bridge base metal cast	\$868.29	III
D6212	Bridge noble metal cast	\$900.05	III
D6214	Pontic titanium	\$900.08	III

NOTES: CDT-4 Codes copyright American Dental Association. All rights reserved.

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE

PAGE 6 of 9

HCPCS Code	HCPCS Code Description	Charge	GAFF Category
D6240	Bridge porcelain high noble	\$958.47	III
D6241	Bridge porcelain base metal	\$867.09	III
D6242	Bridge porcelain noble metal	\$915.85	III
D6245	Bridge porcelain/ceramic	\$973.80	III
D6250	Bridge resin w/high noble	\$942.40	III
D6251	Bridge resin base metal	\$864.49	III
D6252	Bridge resin w/noble metal	\$892.29	III
D6253	Provisional pontic	\$349.60	III
D6545	Dental retainr cast metl	\$514.34	III
D6548	Porcelain/ceramic retainer	\$628.87	III
D6600	Porcelain/ceramic inlay 2srf	\$830.58	III
D6601	Porc/ceram inlay >= 3 surfac	\$902.37	III
D6602	Cst hgh nble mtl inlay 2 srf	\$871.79	III
D6603	Cst hgh nble mtl inlay >=3sr	\$915.10	III
D6604	Cst bse mtl inlay 2 surfaces	\$854.15	III
D6605	Cst bse mtl inlay >= 3 surfa	\$1,022.64	III
D6606	Cast noble metal inlay 2 sur	\$822.72	III
D6607	Cst noble mtl inlay >=3 surf	\$1,033.84	III
D6608	Onlay porc/crmc 2 surfaces	\$884.87	III
D6609	Onlay porc/crmc >=3 surfaces	\$1,007.23	III
D6610	Onlay cst hgh nbl mtl 2 srfc	\$935.27	III
D6611	Onlay cst hgh nbl mtl >=3srf	\$1,048.14	III
D6612	Onlay cst base mtl 2 surface	\$1,011.02	III
D6613	Onlay cst base mtl >=3 surfa	\$1,092.92	III
D6614	Onlay cst nbl mtl 2 surfaces	\$1,036.49	III
D6615	Onlay cst nbl mtl >=3 surfac	\$1,109.41	III
D6624	Inlay titanium	\$871.79	III
D6634	Onlay titanium	\$935.27	III
D6710	Crown-indirect resin based	\$536.52	III
D6720	Retain crown resin w hi noble	\$979.39	III
D6721	Crown resin w/base metal	\$887.29	III
D6722	Crown resin w/noble metal	\$964.78	III
D6740	Crown porcelain/ceramic	\$1,033.05	III
D6750	Crown porcelain high noble	\$1,001.38	III
D6751	Crown porcelain base metal	\$908.50	III
D6752	Crown porcelain noble metal	\$954.02	III
D6780	Crown 3/4 high noble metal	\$971.12	III
D6781	Crown 3/4 cast based metal	\$939.81	III
D6782	Crown 3/4 cast noble metal	\$899.96	III
D6783	Crown 3/4 porcelain/ceramic	\$990.69	III
D6790	Crown full high noble metal	\$971.15	III
D6791	Crown full base metal cast	\$906.03	III
D6792	Crown full noble metal cast	\$941.10	III
D6793	Provisional retainer crown	\$372.97	III
D6794	Crown titanium	\$941.07	III
D6920	Dental connector bar	\$173.86	III
D6930	Dental recement bridge	\$131.57	III
D6940	Stress breaker	\$315.72	III
D6950	Precision attachment	\$550.24	III
D6970	Post & core plus retainer	\$366.48	III
D6971	Cast post bridge retainer	\$334.17	III
D6972	Prefab post & core plus reta	\$285.80	III
D6973	Core build up for retainer	\$230.53	III
D6975	Coping metal	\$635.79	III
D6976	Each addtntl cast post	\$192.29	III
D6977	Each additl prefab post	\$140.12	III
D6980	Bridge repair	\$313.52	III
D6985	Pediatric partial denture fx	\$663.30	III
D6999	Fixed prosthodontic proc	\$1,188.00	III
D7111	Coronal remnnts deciduous t	\$113.66	II
D7140	Extraction erupted tooth/exr	\$134.02	II
D7210	Rem imp tooth w mucoper flap	\$237.12	II
D7220	Impact tooth remov soft tiss	\$285.50	II
D7230	Impact tooth remov part bony	\$368.32	II
D7240	Impact tooth remov comp bony	\$437.52	II

NOTES: CDT-4 Codes copyright American Dental Association. All rights reserved.

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE

PAGE 7 of 9

HCPCS Code	HCPCS Code Description	Charge	GAAP Category
D7241	Impact tooth rem bony w/comp	\$526.92	
D7250	Tooth root removal	\$260.35	
D7260	Oral antral fistula closure	\$1,918.29	
D7261	Primary closure sinus perf	\$651.51	
D7270	Tooth reimplantation	\$468.50	
D7272	Tooth transplantation	\$625.48	
D7280	Exposure impact tooth orthod	\$515.08	
D7282	Mobilize erupted/malpos tooth	\$186.11	
D7283	Place device impacted tooth	\$186.11	
D7285	Biopsy of oral tissue hard	\$618.79	
D7286	Biopsy of oral tissue soft	\$328.29	
D7287	Cytology sample collection	\$130.22	
D7288	Brush biopsy	\$132.38	
D7290	Repositioning of teeth	\$428.59	
D7291	Transseptal fibrotomy	\$191.12	
D7310	Alveoplasty w/ extraction	\$252.17	
D7311	Alveoplasty w/extract 1-3	\$1,484.39	
D7320	Alveoplasty w/o extraction	\$429.14	
D7321	Alveoplasty not w/extracts	\$1,484.39	
D7340	Vestibuloplasty ridge extens	\$1,462.93	
D7350	Vestibuloplasty exten graft	\$2,282.64	
D7410	Rad exc lesion up to 1.25 cm	\$548.94	
D7411	Excision benign lesion>1.25c	\$593.50	
D7412	Excision benign lesion compl	\$708.03	
D7413	Excision malig lesion<=1.25c	\$951.85	
D7414	Excision malig lesion>1.25cm	\$1,226.20	
D7415	Excision malig les complicat	\$1,330.32	
D7440	Malig tumor exc to 1.25 cm	\$657.71	
D7441	Malig tumor > 1.25 cm	\$969.59	
D7450	Rem odontogen cyst to 1.25cm	\$600.40	
D7451	Rem odontogen cyst > 1.25 cm	\$959.69	
D7460	Rem nonodonto cyst to 1.25cm	\$588.01	
D7461	Rem nonodonto cyst > 1.25 cm	\$976.13	
D7465	Lesion destruction	\$367.73	
D7471	Rem exostosis any site	\$687.96	
D7472	Removal of torus palatinus	\$822.49	
D7473	Remove torus mandibularis	\$773.92	
D7485	Surg reduct osseoustuberosit	\$678.90	
D7490	Mandible resection	\$7,331.02	
D7510	I&d abscc intraoral soft tiss	\$219.39	
D7511	Incision/drain abscess intra	\$1,023.54	
D7520	I&d abscess extraoral	\$998.97	
D7521	Incision/drain abscess extra	\$132.38	
D7530	Removal fb skin/areolar tiss	\$341.59	
D7540	Removal of fb reaction	\$497.35	
D7550	Removal of sloughed off bone	\$356.99	
D7560	Maxillary sinusotomy	\$1,697.66	
D7610	Maxilla open reduct simple	\$3,836.26	
D7620	Clsd reduct simpl maxilla fx	\$2,635.81	
D7630	Open red simpl mandible fx	\$4,640.12	
D7640	Clsd red simpl mandible fx	\$3,002.91	
D7650	Open red simp malar/zygom fx	\$2,356.60	
D7660	Clsd red simp malar/zygom fx	\$1,303.99	
D7670	Closed rductn splint alveolus	\$1,207.41	
D7671	Alveolus open reduction	\$933.86	
D7680	Reduct simple facial bone fx	\$6,472.47	
D7710	Maxilla open reduct compound	\$4,162.37	
D7720	Clsd reduct compd maxilla fx	\$2,421.29	
D7730	Open reduct compd mandible fx	\$5,325.87	
D7740	Clsd reduct compd mandible fx	\$3,147.72	
D7750	Open red comp malar/zygma fx	\$3,838.64	
D7760	Clsd red comp malar/zygma fx	\$1,418.21	
D7770	Open reduct compd alveolus fx	\$2,031.90	
D7771	Alveolus clsd reduct stblz te	\$1,438.03	
D7780	Reduct compnd facial bone fx	\$8,846.78	

NOTES: CDT-4 Codes copyright American Dental Association. All rights reserved.

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE

PAGE 8 of 9

HCPCS Code	HCPCS Code Description	Charge	GAAF Category
D7810	Tmj open reduct-dislocation	\$3,954.38	II
D7820	Closed tmp manipulation	\$593.97	II
D7830	Tmj manipulation under anest	\$493.61	II
D7840	Removal of tmj condyle	\$5,224.30	II
D7850	Tmj meniscectomy	\$4,878.44	II
D7852	Tmj repair of joint disc	\$5,297.12	II
D7854	Tmj excision of joint membrane	\$5,395.06	II
D7856	Tmj cutting of a muscle	\$3,598.52	II
D7858	Tmj reconstruction	\$6,427.56	II
D7860	Tmj cutting into joint	\$3,090.30	II
D7865	Tmj reshaping components	\$4,606.25	II
D7870	Tmj aspiration joint fluid	\$304.23	II
D7871	Lysis + lavage w catheters	\$875.21	II
D7872	Tmj diagnostic arthroscopy	\$2,020.35	II
D7873	Tmj arthroscopy lysis adhesn	\$2,307.93	II
D7874	Tmj arthroscopy disc reposit	\$3,044.95	II
D7875	Tmj arthroscopy synovectomy	\$3,277.42	II
D7876	Tmj arthroscopy discectomy	\$3,485.78	II
D7877	Tmj arthroscopy debridement	\$3,148.27	II
D7880	Occlusal orthotic appliance	\$766.48	II
D7899	Tmj unspecified therapy	\$1,222.33	II
D7910	Dent sutur recent wnd to 5cm	\$290.54	II
D7911	Dental suture wound to 5 cm	\$632.32	II
D7912	Suture complicate wnd > 5 cm	\$1,195.71	II
D7920	Dental skin graft	\$2,466.56	II
D7940	Reshaping bone orthognathic	\$2,592.56	II
D7941	Bone cutting ramus closed	\$8,156.66	II
D7943	Cutting ramus open w/graft	\$8,455.05	II
D7944	Bone cutting segmented	\$7,002.85	II
D7945	Bone cutting body mandible	\$7,244.21	II
D7946	Reconstruction maxilla total	\$8,729.08	II
D7947	Reconstruct maxilla segment	\$8,069.57	II
D7948	Reconstruct midface no graft	\$11,603.26	II
D7949	Reconstruct midface w/graft	\$15,024.43	II
D7950	Mandible graft	\$2,286.49	II
D7953	Bone replacement graft	\$475.95	II
D7955	Repair maxillofacial defects	\$2,262.93	II
D7960	Frenulectomy/frenulotomy	\$468.87	II
D7963	Frenuloplasty	\$516.00	II
D7970	Excision hyperplastic tissue	\$488.80	II
D7971	Excision pericoronal gingiva	\$193.16	II
D7972	Surg reduct fibrous tuberosit	\$624.06	II
D7980	Sialolithotomy	\$682.92	II
D7981	Excision of salivary gland	\$467.39	II
D7982	Sialodochoplasty	\$1,611.67	II
D7983	Closure of salivary fistula	\$1,485.23	II
D7990	Emergency tracheotomy	\$1,426.35	II
D7991	Dental coronoidectomy	\$4,108.31	II
D7995	Synthetic graft facial bones	\$429.53	II
D7996	Implant mandible for augmnt	\$1,821.07	II
D7997	Appliance removal	\$238.96	II
D7999	Oral surgery procedure	\$1,222.33	II
D8010	Limited dental tx primary	\$1,486.14	III
D8020	Limited dental tx transition	\$1,643.84	III
D8030	Limited dental tx adolescent	\$1,766.18	III
D8040	Limited dental tx adult	\$1,864.40	III
D8050	Intercep dental tx primary	\$1,854.30	III
D8060	Intercep dental tx transiti	\$2,020.98	III
D8070	Compre dental tx transition	\$3,179.32	III
D8080	Compre dental tx adolescent	\$3,227.03	III
D8090	Compre dental tx adult	\$3,361.73	III
D8210	Orthodontic rem appliance tx	\$1,018.65	III
D8220	Fixed appliance therapy habt	\$1,075.90	III
D8660	Preorthodontic tx visit	\$164.88	III
D8670	Periodic orthodontic tx visit	\$195.18	III

NOTES: COT-4 Codes copyright American Dental Association. All rights reserved.

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE

PAGE 9 of 9

HCPCS Code	HCPCS Code Description	Charge	GAAP Category
D8680	Orthodontic retention	\$476.74	III
D8690	Orthodontic treatment	\$208.17	III
D8691	Repair ortho appliance	\$143.93	III
D8692	Replacement retainer	\$254.73	III
D8999	Orthodontic procedure	\$1,245.98	III
D9110	Tx dental pain minor proc	\$101.47	II
D9210	Dent anesthesia w/o surgery	\$28.85	II
D9211	Regional block anesthesia	\$32.32	II
D9212	Trigeminal block anesthesia	\$69.97	II
D9215	Local anesthesia	\$27.06	II
D9220	General anesthesia	\$352.68	II
D9221	General anesthesia ea ad 15m	\$143.94	II
D9230	Analgesia	\$54.30	II
D9241	Intravenous sedation	\$331.00	II
D9242	IV sedation ea ad 30 m	\$126.40	II
D9248	Sedation (non-iv)	\$74.81	II
D9310	Dental consultation	\$137.00	I
D9410	Dental house call	\$229.13	I
D9420	Hospital call	\$289.71	I
D9430	Office visit during hours	\$66.81	I
D9440	Office visit after hours	\$130.94	I
D9450	Case presentation tx plan	\$58.91	I
D9610	Dent therapeutic drug inject	\$74.89	III
D9630	Other drugs/medicaments	\$43.00	III
D9910	Dent appl desensitizing med	\$46.18	III
D9911	Appl desensitizing resin	\$63.53	III
D9920	Behavior management	\$124.83	III
D9930	Treatment of complications	\$104.98	III
D9940	Dental occlusal guard	\$557.40	III
D9941	Fabrication athletic guard	\$172.89	III
D9950	Occlusion analysis	\$266.83	III
D9951	Limited occlusal adjustment	\$129.84	III
D9952	Complete occlusal adjustment	\$630.16	III
D9970	Enamel microabrasion	\$48.87	III
D9971	Odontoplasty 1-2 teeth	\$64.76	III
D9972	Extrl bleaching per arch	\$303.44	III
D9973	Extrl bleaching per tooth	\$39.47	III
D9974	Intrl bleaching per tooth	\$246.06	III
D9999	Adjunctive procedure	\$1,183.28	III

NOTES: CDT-4 Codes copyright American Dental Association. All rights reserved.

TABLE J. -- PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUs)

PAGE 1 of 20

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Methodology (1)
78267		Breath 1st attain/anal c-14	Pathology	0.37	
78268		Breath test analysis, c-14	Pathology	3.14	
80048		Basic metabolic panel	Pathology	0.40	
80050		General health panel	Pathology	1.42	
80051		Electrolyte panel	Pathology	0.33	
80053		Comprehen metabolic panel	Pathology	0.49	
80055		Obstetric panel	Pathology	1.29	
80061		Lipid panel	Pathology	0.63	
80069		Renal function panel	Pathology	0.41	
80074		Acute hepatitis panel	Pathology	2.22	
80076		Hepatic function panel	Pathology	0.38	
80100		Druq screen, qualitate/multi	Pathology	0.68	
80101		Druq screen, single	Pathology	0.64	
80102		Druq confirmation	Pathology	0.62	
80103		Druq analysis, tissue prep	Pathology	0.44	
80150		Assay of amikacin	Pathology	0.70	
80152		Assay of amitriptyline	Pathology	0.84	
80154		Assay of benzodiazepines	Pathology	0.86	
80156		Assay, carbamazepine, total	Pathology	0.68	
80157		Assay, carbamazepine, free	Pathology	0.62	
80158		Assay of cyclosporine	Pathology	0.84	
80160		Assay of desipramine	Pathology	0.80	
80162		Assay of diqoxin	Pathology	0.62	
80164		Assay, dipropylacetic acid	Pathology	0.63	
80166		Assay of doxepin	Pathology	0.72	
80168		Assay of ethosuximide	Pathology	0.76	
80170		Assay of gentamicin	Pathology	0.76	
80172		Assay of gold	Pathology	0.76	
80173		Assay of haloperidol	Pathology	0.68	
80174		Assay of imipramine	Pathology	0.80	
80176		Assay of lidocaine	Pathology	0.69	
80178		Assay of lithium	Pathology	0.31	
80182		Assay of nortriptyline	Pathology	0.63	
80184		Assay of phenobarbital	Pathology	0.53	
80185		Assay of phenytoin, total	Pathology	0.62	
80186		Assay of phenytoin, free	Pathology	0.64	
80188		Assay of prnmidone	Pathology	0.77	
80190		Assay of procainamide	Pathology	0.78	
80192		Assay of procainamide	Pathology	0.78	
80194		Assay of quinidine	Pathology	0.68	
80196		Assay of salicylate	Pathology	0.33	
80197		Assay of tacrolimus	Pathology	0.64	
80198		Assay of theophylline	Pathology	0.66	
80200		Assay of tobramycin	Pathology	0.75	
80201		Assay of topiramate	Pathology	0.56	
80202		Assay of vancomycin	Pathology	0.63	
80299		Quantitative assay, druq	Pathology	0.64	
80400		Acth stimulation panel	Pathology	1.52	
80402		Acth stimulation panel	Pathology	4.06	
80406		Acth stimulation panel	Pathology	3.65	
80408		Aldosterone suppression eval	Pathology	5.86	
80410		Calcitonin stimul panel	Pathology	3.75	
80412		CRH stimulation panel	Pathology	15.38	
80414		Testosterone response	Pathology	2.41	
80415		Estradiol response panel	Pathology	2.61	
80416		Renin stimulation panel	Pathology	6.16	
80417		Renin stimulation panel	Pathology	2.05	
80418		Pituitary evaluation panel	Pathology	27.05	
80420		Dexamethasone panel	Pathology	3.36	
80422		Glucagon tolerance panel	Pathology	2.15	

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE J. - PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUs)

PAGE 2 of 20

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Methodology (1)
80424		Glucagon tolerance panel	Pathology	2.36	
80426		Gonadotropin hormone panel	Pathology	6.93	
80428		Growth hormone panel	Pathology	3.11	
80430		Growth hormone panel	Pathology	3.66	
80432		Insulin suppression panel	Pathology	6.30	
80434		Insulin tolerance panel	Pathology	4.72	
80435		Insulin tolerance panel	Pathology	4.81	
80436		Metyrapone panel	Pathology	4.25	
80438		TRH stimulation panel	Pathology	2.35	
80439		TRH stimulation panel	Pathology	3.14	
80440		TRH stimulation panel	Pathology	2.71	
81000		Urinalysis, nonauto w/scope	Pathology	0.15	
81001		Urinalysis, auto w/scope	Pathology	0.15	
81002		Urinalysis nonauto w/o scope	Pathology	0.12	
81003		Urinalysis, auto, w/o scope	Pathology	0.10	
81005		Urinalysis	Pathology	0.10	
81007		Urine screen for bacteria	Pathology	0.12	
81015		Microscopic exam of urine	Pathology	0.14	
81020		Urinalysis, glass test	Pathology	0.17	
81025		Urine pregnancy test	Pathology	0.30	
81050		Urinalysis, volume measure	Pathology	0.14	
81099		Urinalysis test procedure	Pathology	0.15	
82000		Assay of blood acetaldehyde	Pathology	0.58	
82003		Assay of acetaminophen	Pathology	0.94	
82009		Test for acetone/ketones	Pathology	0.21	
82010		Acetone assay	Pathology	0.38	
82013		Acetylcholinesterase assay	Pathology	0.52	
82016		Acylcarnitines, qual	Pathology	0.65	
82017		Acylcarnitines, quant	Pathology	0.79	
82024		Assay of acth	Pathology	1.80	
82030		Assay of adp & amp	Pathology	1.20	
82040		Assay of serum albumin	Pathology	0.23	
82042		Assay of urine albumin	Pathology	0.24	
82043		Microalbumin, quantitative	Pathology	0.27	
82044		Microalbumin, semiquant	Pathology	0.21	
82045		Albumin, ischemia modified	Pathology	1.58	
82055		Assay of ethanol	Pathology	0.50	
82075		Assay of breath ethanol	Pathology	0.56	
82085		Assay of aldolase	Pathology	0.45	
82088		Assay of aldosterone	Pathology	1.90	
82101		Assay of urine alkaloids	Pathology	1.40	
82103		Alpha-1-antitrypsin, total	Pathology	0.63	
82104		Alpha-1-antitrypsin, pheno	Pathology	0.67	
82105		Alpha-fetoprotein, serum	Pathology	0.78	
82106		Alpha-fetoprotein, amniotic	Pathology	0.78	
82108		Assay of aluminum	Pathology	1.19	
82120		Amines, vaginal fluid qual	Pathology	0.18	
82127		Amino acid, single qual	Pathology	0.65	
82128		Amino acids, mult qual	Pathology	0.65	
82131		Amino acids, single quant	Pathology	0.79	
82135		Assay, aminolevulinic acid	Pathology	0.77	
82136		Amino acids, quant, 2-5	Pathology	0.79	
82139		Amino acids, quan, 6 or more	Pathology	0.79	
82140		Assay of ammonia	Pathology	0.68	
82143		Amniotic fluid scan	Pathology	0.32	
82145		Assay of amphetamines	Pathology	0.73	
82150		Assay of amylase	Pathology	0.30	
82154		Androstenediol glucuronide	Pathology	1.35	
82157		Assay of androstenedione	Pathology	1.37	
82160		Assay of androsterone	Pathology	1.17	

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE J. - PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUs)

PAGE 3 of 20

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Methodology (1)
82163		Assay of angiotensin II	Pathology	0.96	
82164		Angiotensin I enzyme test	Pathology	0.68	
82172		Assay of apolipoprotein	Pathology	0.72	
82175		Assay of arsenic	Pathology	0.89	
82180		Assay of ascorbic acid	Pathology	0.46	
82190		Atomic absorption	Pathology	0.70	
82205		Assay of barbiturates	Pathology	0.53	
82232		Assay of beta-2 protein	Pathology	0.76	
82239		Bile acids, total	Pathology	0.80	
82240		Bile acids, cholyglycine	Pathology	1.24	
82247		Bilirubin, total	Pathology	0.23	
82248		Bilirubin, direct	Pathology	0.23	
82252		Fecal bilirubin test	Pathology	0.21	
82261		Assay of biotinidase	Pathology	0.79	
82270		Test for blood, feces	Pathology	0.15	
82274		Assay test for blood, fecal	Pathology	0.60	
82286		Assay of bradykinin	Pathology	0.32	
82300		Assay of cadmium	Pathology	1.08	
82306		Assay of vitamin D	Pathology	1.38	
82307		Assay of vitamin D	Pathology	1.50	
82308		Assay of calcitonin	Pathology	1.25	
82310		Assay of calcium	Pathology	0.24	
82330		Assay of calcium	Pathology	0.64	
82331		Calcium infusion test	Pathology	0.24	
82340		Assay of calcium in urine	Pathology	0.28	
82355		Calculus analysis, qual	Pathology	0.54	
82360		Calculus assay, quant	Pathology	0.60	
82365		Calculus spectroscopy	Pathology	0.60	
82370		X-ray assay, calculus	Pathology	0.58	
82373		Assay, c-d transfer measure	Pathology	0.84	
82374		Assay, blood carbon dioxide	Pathology	0.23	
82375		Assay, blood carbon monoxide	Pathology	0.58	
82376		Test for carbon monoxide	Pathology	0.28	
82378		Carcinoembryonic antigen	Pathology	0.89	
82379		Assay of carnitine	Pathology	0.79	
82380		Assay of carotene	Pathology	0.43	
82382		Assay, urine catecholamines	Pathology	0.80	
82383		Assay, blood catecholamines	Pathology	1.17	
82384		Assay, three catecholamines	Pathology	1.18	
82387		Assay of cathepsin-d	Pathology	0.97	
82390		Assay of ceruloplasmin	Pathology	0.50	
82397		Chemiluminescent assay	Pathology	0.66	
82415		Assay of chloramphenicol	Pathology	0.59	
82435		Assay of blood chloride	Pathology	0.21	
82436		Assay of urine chloride	Pathology	0.23	
82438		Assay, other fluid chlorides	Pathology	0.23	
82441		Test for chlorohydrocarbons	Pathology	0.28	
82465		Assay, bid/serum cholesterol	Pathology	0.20	
82480		Assay, serum cholinesterase	Pathology	0.37	
82482		Assay, rbc cholinesterase	Pathology	0.36	
82485		Assay, chondroitin sulfate	Pathology	0.96	
82486		Gas/liquid chromatography	Pathology	0.84	
82487		Paper chromatography	Pathology	0.74	
82488		Paper chromatography	Pathology	1.00	
82489		Thin layer chromatography	Pathology	0.86	
82491		Chromatography, quant, sing	Pathology	0.84	
82492		Chromatography, quant, mult	Pathology	0.84	
82495		Assay of chromium	Pathology	0.95	
82507		Assay of citrate	Pathology	1.30	
82520		Assay of cocaine	Pathology	0.71	

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE J. - PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUs)

PAGE 4 of 20

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Methodology (1)
82523		Collagen crosslinks	Pathology	0.87	
82525		Assay of copper	Pathology	0.58	
82528		Assay of corticosterone	Pathology	1.05	
82530		Cortisol, free	Pathology	0.78	
82533		Total cortisol	Pathology	0.76	
82540		Assay of creatine	Pathology	0.22	
82541		Column chromatography, qual	Pathology	0.84	
82542		Column chromatography, quant	Pathology	0.84	
82543		Column chromatograph/isotope	Pathology	0.84	
82544		Column chromatograph/isotope	Pathology	0.84	
82550		Assay of ck (cpk)	Pathology	0.30	
82552		Assay of cpk in blood	Pathology	0.63	
82553		Creatine, MB fraction	Pathology	0.54	
82554		Creatine, isoforms	Pathology	0.55	
82565		Assay of creatinine	Pathology	0.24	
82570		Assay of urine creatinine	Pathology	0.24	
82575		Creatinine clearance test	Pathology	0.44	
82585		Assay of cryofibrinogen	Pathology	0.40	
82595		Assay of cryoglobulin	Pathology	0.30	
82600		Assay of cyanide	Pathology	0.91	
82607		Vitamin B-12	Pathology	0.70	
82608		B-12 binding capacity	Pathology	0.67	
82615		Test for urine cystines	Pathology	0.38	
82626		Dehydroepiandrosterone	Pathology	1.18	
82627		Dehydroepiandrosterone	Pathology	1.04	
82633		Deoxycorticosterone	Pathology	1.45	
82634		Deoxycortisol	Pathology	1.37	
82638		Assay of dibucaine number	Pathology	0.57	
82646		Assay of dihydrocodeinone	Pathology	0.96	
82649		Assay of dihydromorphinone	Pathology	1.20	
82651		Assay of dihydrotestosterone	Pathology	1.20	
82652		Assay of dihydroxyvitamin d	Pathology	1.80	
82654		Assay of dimethadione	Pathology	0.65	
82656		Pancreatic elastase, fecal	Pathology	0.54	
82657		Enzyme cell activity	Pathology	0.84	
82658		Enzyme cell activity, ra	Pathology	0.84	
82664		Electrophoretic test	Pathology	1.60	
82666		Assay of epiandrosterone	Pathology	1.00	
82668		Assay of erythropoietin	Pathology	0.88	
82670		Assay of estradiol	Pathology	1.30	
82671		Assay of estrogens	Pathology	1.51	
82672		Assay of estrogen	Pathology	1.01	
82677		Assay of estriol	Pathology	1.13	
82679		Assay of estrone	Pathology	1.17	
82690		Assay of ethchlorvynol	Pathology	0.81	
82693		Assay of ethylene glycol	Pathology	0.70	
82696		Assay of etiocholanolone	Pathology	1.10	
82705		Fats/lipids, feces, qual	Pathology	0.24	
82710		Fats/lipids, feces, quant	Pathology	0.78	
82715		Assay of fecal fat	Pathology	0.80	
82725		Assay of blood fatty acids	Pathology	0.62	
82726		Long chain fatty acids	Pathology	0.84	
82728		Assay of ferritin	Pathology	0.64	
82731		Assay of fetal fibronectin	Pathology	3.01	
82735		Assay of fluoride	Pathology	0.87	
82742		Assay of flurazepam	Pathology	0.92	
82746		Blood folic acid serum	Pathology	0.69	
82747		Assay of folic acid, rbc	Pathology	0.81	
82757		Assay of semen fructose	Pathology	0.81	
82759		Assay of rbc galactokinase	Pathology	1.00	

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE J. - PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUs)

PAGE 5 of 20

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Methodology (1)
82760		Assay of galactose	Pathology	0.52	
82775		Assay galactose transferase	Pathology	0.98	
82776		Galactose transferase test	Pathology	0.39	
82784		Assay of gamma globulin igm	Pathology	0.43	
82785		Assay of gamma globulin igc	Pathology	0.77	
82787		Igg 1, 2, 3 or 4, each	Pathology	0.37	
82800		Blood pH	Pathology	0.40	
82803		Blood gases: pH, pO2 & pCO2	Pathology	0.90	
82805		Blood gases W/O2 saturation	Pathology	1.32	
82810		Blood gases, O2 sat only	Pathology	0.41	
82820		Hemoglobin-oxygen affinity	Pathology	0.47	
82926		Assay of gastric acid	Pathology	0.25	
82928		Assay of gastric acid	Pathology	0.31	
82938		Gastrin test	Pathology	0.83	
82941		Assay of gastrin	Pathology	0.82	
82943		Assay of glucagon	Pathology	0.67	
82945		Glucose other fluid	Pathology	0.18	
82946		Glucagon tolerance test	Pathology	0.70	
82947		Assay, glucose, blood quant	Pathology	0.18	
82948		Reagent strip/blood glucose	Pathology	0.15	
82950		Glucose test	Pathology	0.22	
82951		Glucose tolerance test (GTT)	Pathology	0.60	
82952		GTT-added samples	Pathology	0.18	
82953		Glucose-tolbutamide test	Pathology	0.71	
82955		Assay of g6pd enzyme	Pathology	0.45	
82960		Test for G6PD enzyme	Pathology	0.28	
82962		Glucose blood test	Pathology	0.11	
82963		Assay of glucosidase	Pathology	1.00	
82965		Assay of qdh enzyme	Pathology	0.36	
82975		Assay of glutamine	Pathology	0.74	
82977		Assay of GGT	Pathology	0.34	
82978		Assay of glutathione	Pathology	0.67	
82979		Assay, rbc glutathione	Pathology	0.32	
82980		Assay of glutethimide	Pathology	0.86	
82985		Glycated protein	Pathology	0.70	
83001		Gonadotropin (FSH)	Pathology	0.87	
83002		Gonadotropin (LH)	Pathology	0.86	
83003		Assay, growth hormone (hgh)	Pathology	0.78	
83008		Assay of guanosine	Pathology	0.78	
83009		H pylori (c-13), blood	Pathology	3.14	
83010		Assay of haptoglobin, quant	Pathology	0.59	
83012		Assay of haptoglobins	Pathology	0.80	
83013		H pylori analysis	Pathology	3.14	
83014		H pylori drug admin/collect	Pathology	0.37	
83015		Heavy metal screen	Pathology	0.88	
83018		Quantitative screen, metals	Pathology	1.02	
83020	TC	Hemoglobin electrophoresis	Pathology	0.60	
83021		Hemoglobin chromatography	Pathology	0.84	
83026		Hemoglobin, copper sulfate	Pathology	0.11	
83030		Fetal hemoglobin, chemical	Pathology	0.39	
83033		Fetal hemoglobin assay, qual	Pathology	0.28	
83036		Glycated hemoglobin test	Pathology	0.45	
83037		Glycosylated hb, home device	Pathology	0.45	CALC
83045		Blood methemoglobin test	Pathology	0.23	
83050		Blood methemoglobin assay	Pathology	0.34	
83051		Assay of plasma hemoglobin	Pathology	0.34	
83055		Blood sulhemoglobin test	Pathology	0.23	
83060		Blood sulhemoglobin assay	Pathology	0.39	
83065		Assay of hemoglobin heat	Pathology	0.32	
83068		Hemoglobin stability screen	Pathology	0.40	

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology

TABLE J. - PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUs)

PAGE 6 of 20

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Methodology (1)
83069		Assay of urine hemoglobin	Pathology	0.18	
83070		Assay of hemosiderin, qual	Pathology	0.22	
83071		Assay of hemosidenn, quant	Pathology	0.32	
83080		Assay of b hexosaminidase	Pathology	0.79	
83088		Assay of histamine	Pathology	1.38	
83090		Assay of homocystine	Pathology	0.79	
83150		Assay of for hva	Pathology	0.90	
83491		Assay of corticosteroids	Pathology	0.82	
83497		Assay of 5-hiaa	Pathology	0.60	
83498		Assay of progesterone	Pathology	1.27	
83499		Assay of progesterone	Pathology	1.18	
83500		Assay, free hydroxyproline	Pathology	1.06	
83505		Assay, total hydroxyproline	Pathology	1.13	
83516		Immunoassay, nonantibody	Pathology	0.54	
83518		Immunoassay, dipstick	Pathology	0.40	
83519		Immunoassay, nonantibody	Pathology	0.63	
83520		Immunoassay, RIA	Pathology	0.60	
83525		Assay of insulin	Pathology	0.53	
83527		Assay of insulin	Pathology	0.60	
83528		Assay of intrinsic factor	Pathology	0.74	
83540		Assay of iron	Pathology	0.30	
83550		Iron binding test	Pathology	0.41	
83570		Assay of idh enzyme	Pathology	0.41	
83582		Assay of ketogenic steroids	Pathology	0.66	
83586		Assay 17- ketosteroids	Pathology	0.60	
83593		Fractionation, ketosteroids	Pathology	1.23	
83605		Assay of lactic acid	Pathology	0.50	
83615		Lactate (LD) (LDH) enzyme	Pathology	0.28	
83625		Assay of idh enzymes	Pathology	0.60	
83630		Lactoferrin, fecal (qual)	Pathology	0.54	
83632		Placental lactogen	Pathology	0.94	
83633		Test urine for lactose	Pathology	0.26	
83634		Assay of urine for lactose	Pathology	0.54	
83655		Assay of lead	Pathology	0.56	
83661		L/S ratio, fetal lung	Pathology	1.03	
83662		Foam stability, fetal lung	Pathology	0.88	
83663		Fluoro polanze, fetal lung	Pathology	0.88	
83664		Lamellar bdy, fetal lung	Pathology	0.88	
83670		Assay of lap enzyme	Pathology	0.43	
83690		Assay of lipase	Pathology	0.32	
83718		Assay of lipoprotein	Pathology	0.38	
83719		Assay of blood lipoprotein	Pathology	0.54	
83721		Assay of blood lipoprotein	Pathology	0.45	
83727		Assay of lrh hormone	Pathology	0.80	
83735		Assay of magnesium	Pathology	0.31	
83775		Assay of md enzyme	Pathology	0.34	
83785		Assay of manqanese	Pathology	1.15	
83788		Mass spectrometry qual	Pathology	0.84	
83789		Mass spectrometry quant	Pathology	0.84	
83805		Assay of meprobamate	Pathology	0.82	
83825		Assay of mercury	Pathology	0.76	
83835		Assay of metanephriines	Pathology	0.79	
83840		Assay of methadone	Pathology	0.76	
83857		Assay of methemalbumin	Pathology	0.50	
83858		Assay of methsuximide	Pathology	0.69	
83864		Mucopolysaccharides	Pathology	0.93	
83866		Mucopolysaccharides screen	Pathology	0.46	
83872		Assay synovial fluid mucin	Pathology	0.27	
83873		Assay of csf protein	Pathology	0.80	
83874		Assay of myoqlobin	Pathology	0.60	

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE J. - PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUs)

PAGE 7 of 20

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Methodology (1)
83880		Natriuretic peptide	Pathology	1.58	
83883		Assay, nephelometry not spec	Pathology	0.63	
83885		Assay of nickel	Pathology	1.14	
83887		Assay of nicotine	Pathology	1.11	
83890		Molecule isolate	Pathology	0.19	
83891		Molecule isolate nucleic	Pathology	0.19	
83892		Molecular diagnostics	Pathology	0.19	
83893		Molecule dot/slot/blot	Pathology	0.19	
83894		Molecule gel electrophor	Pathology	0.19	
83896		Molecular diagnostics	Pathology	0.19	
83897		Molecule nucleic transfer	Pathology	0.19	
83898		Molecule nucleic ampli	Pathology	0.78	
83901		Molecule nucleic ampli	Pathology	0.78	
83902		Molecular diagnostics	Pathology	0.66	
83903		Molecule mutation scan	Pathology	0.78	
83904		Molecule mutation identify	Pathology	0.78	
83905		Molecule mutation identify	Pathology	0.78	
83906		Molecule mutation identify	Pathology	0.78	
83912	TC	Genetic examination	Pathology	0.19	
83915		Assay of nucleotidase	Pathology	0.52	
83916		Oligoclonal bands	Pathology	0.94	
83918		Organic acids, total, quant	Pathology	0.77	
83919		Organic acids, qual, each	Pathology	0.77	
83921		Organic acid, single, quant	Pathology	0.77	
83925		Assay of opiates	Pathology	0.91	
83930		Assay of blood osmolality	Pathology	0.31	
83935		Assay of urine osmolality	Pathology	0.32	
83937		Assay of osteocalcin	Pathology	1.39	
83945		Assay of oxalate	Pathology	0.60	
83950		Oncoprotein, her-2/neu	Pathology	3.01	
83970		Assay of parathormone	Pathology	1.93	
83986		Assay of body fluid acidity	Pathology	0.17	
83992		Assay for phenacyclidine	Pathology	0.69	
84022		Assay of phenothiazine	Pathology	0.73	
84030		Assay of blood pku	Pathology	0.26	
84035		Assay of phenylketones	Pathology	0.17	
84060		Assay acid phosphatase	Pathology	0.34	
84061		Phosphatase, forensic exam	Pathology	0.37	
84066		Assay prostate phosphatase	Pathology	0.45	
84075		Assay alkaline phosphatase	Pathology	0.24	
84078		Assay alkaline phosphatase	Pathology	0.34	
84080		Assay alkaline phosphatases	Pathology	0.69	
84081		Amniotic fluid enzyme test	Pathology	0.77	
84085		Assay of rbc p66 enzyme	Pathology	0.31	
84087		Assay phosphohexose enzymes	Pathology	0.48	
84100		Assay of phosphorus	Pathology	0.22	
84105		Assay of urine phosphorus	Pathology	0.24	
84106		Test for porphobilinogen	Pathology	0.20	
84110		Assay of porphobilinogen	Pathology	0.39	
84119		Test urine for porphyrins	Pathology	0.40	
84120		Assay of urine porphyrins	Pathology	0.69	
84126		Assay of feces porphyrins	Pathology	1.19	
84127		Assay of feces porphyrins	Pathology	0.54	
84132		Assay of serum potassium	Pathology	0.21	
84133		Assay of urine potassium	Pathology	0.20	
84134		Assay of prealbumin	Pathology	0.68	
84135		Assay of pregnanediol	Pathology	0.89	
84138		Assay of pregnanetriol	Pathology	0.88	
84140		Assay of pregnenolone	Pathology	0.97	
84143		Assay of 17-hydroxyprogreno	Pathology	1.07	

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE J. -- PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUs)

PAGE 8 of 20

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Methodology (1)
84144		Assay of progesterone	Pathology	0.97	
84146		Assay of prolactin	Pathology	0.90	
84150		Assay of prostaglandin	Pathology	1.17	
84152		Assay of psa, complexed	Pathology	0.86	
84153		Assay of psa, total	Pathology	0.86	
84154		Assay of psa, free	Pathology	0.86	
84155		Assay of protein	Pathology	0.17	
84156		Assay of protein, urine	Pathology	0.17	
84157		Assay of protein, other	Pathology	0.17	
84160		Assay of serum protein	Pathology	0.24	
84163		Pappa, serum	Pathology	0.70	
84165	TC	Assay of serum proteins	Pathology	0.50	
84166	TC	Protein e-phoresis/urine/csf	Pathology	0.81	
84181	TC	Western blot test	Pathology	0.80	
84182	TC	Protein, western blot test	Pathology	0.84	
84202		Assay RBC protoporphyrin	Pathology	0.67	
84203		Test RBC protoporphyrin	Pathology	0.40	
84206		Assay of proinsulin	Pathology	0.83	
84207		Assay of vitamin b-6	Pathology	1.31	
84210		Assay of pyruvate	Pathology	0.51	
84220		Assay of pyruvate kinase	Pathology	0.44	
84228		Assay of quinine	Pathology	0.54	
84233		Assay of estrogen	Pathology	3.01	
84234		Assay of progesterone	Pathology	3.03	
84235		Assay of endocrine hormone	Pathology	2.44	
84238		Assay, nonendocrine receptor	Pathology	1.71	
84244		Assay of renin	Pathology	1.03	
84252		Assay of vitamin b-2	Pathology	0.94	
84255		Assay of selenium	Pathology	1.19	
84260		Assay of serotonin	Pathology	1.45	
84270		Assay of sex hormone globul	Pathology	1.01	
84275		Assay of sialic acid	Pathology	0.63	
84285		Assay of silica	Pathology	1.10	
84295		Assay of serum sodium	Pathology	0.22	
84300		Assay of urine sodium	Pathology	0.23	
84302		Assay of sweat sodium	Pathology	0.23	
84305		Assay of somatomedin	Pathology	0.99	
84307		Assay of somatostatin	Pathology	0.85	
84311		Spectrophotometry	Pathology	0.33	
84315		Body fluid specific gravity	Pathology	0.12	
84375		Chromatogram assay, sugars	Pathology	0.91	
84376		Sugars, single, qual	Pathology	0.26	
84377		Sugars, multiple, qual	Pathology	0.26	
84378		Sugars single quant	Pathology	0.54	
84379		Sugars multiple quant	Pathology	0.54	
84392		Assay of urine sulfate	Pathology	0.22	
84402		Assay of testosterone	Pathology	1.19	
84403		Assay of total testosterone	Pathology	1.21	
84425		Assay of vitamin b-1	Pathology	0.99	
84430		Assay of thiocyanate	Pathology	0.54	
84432		Assay of thyroglobulin	Pathology	0.75	
84436		Assay of total thyroxine	Pathology	0.32	
84437		Assay of neonatal thyroxine	Pathology	0.30	
84439		Assay of free thyroxine	Pathology	0.42	
84442		Assay of thyroid activity	Pathology	0.69	
84443		Assay thyroid stim hormone	Pathology	0.78	
84445		Assay of tsi	Pathology	2.37	
84446		Assay of vitamin e	Pathology	-0.66	
84449		Assay of transcortin	Pathology	0.84	
84450		Transferase (AST) (SGOT)	Pathology	0.24	

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE J. - PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUs)

PAGE 9 of 20

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Methodology (1)
84460		Alanine amino (ALT) (SGPT)	Pathology	0.25	
84466		Assay of transferrin	Pathology	0.60	
84478		Assay of triglycerides	Pathology	0.27	
84479		Assay of thyroid (t3 or t4)	Pathology	0.30	
84480		Assay, triiodothyronine (t3)	Pathology	0.66	
84481		Free assay (FT-3)	Pathology	0.79	
84482		T3 reverse	Pathology	0.74	
84484		Assay of troponin, quant	Pathology	0.46	
84485		Assay duodenal fluid trypsin	Pathology	0.35	
84488		Test feces for trypsin	Pathology	0.34	
84490		Assay of feces for trypsin	Pathology	0.36	
84510		Assay of tyrosine	Pathology	0.49	
84512		Assay of troponin, qual	Pathology	0.36	
84520		Assay of urea nitrogen	Pathology	0.18	
84525		Urea nitrogen semi-quant	Pathology	0.18	
84540		Assay of urine/urea-n	Pathology	0.22	
84545		Urea-N clearance test	Pathology	0.31	
84550		Assay of blood/uric acid	Pathology	0.21	
84560		Assay of urine/uric acid	Pathology	0.22	
84577		Assay of feces/urobilinogen	Pathology	0.58	
84578		Test urine urobilinogen	Pathology	0.15	
84580		Assay of urine urobilinogen	Pathology	0.33	
84583		Assay of urine urobilinogen	Pathology	0.23	
84585		Assay of urine vma	Pathology	0.72	
84586		Assay of vip	Pathology	1.65	
84588		Assay of vasopressin	Pathology	1.58	
84590		Assay of vitamin a	Pathology	0.54	
84591		Assay of nos vitamin	Pathology	0.54	
84597		Assay of vitamin k	Pathology	0.64	
84600		Assay of volatiles	Pathology	0.75	
84620		Xylose tolerance test	Pathology	0.55	
84630		Assay of zinc	Pathology	0.53	
84681		Assay of c-peptide	Pathology	0.97	
84702		Chorionic gonadotropin test	Pathology	0.70	
84703		Chorionic gonadotropin assay	Pathology	0.35	
84830		Ovulation tests	Pathology	0.47	
84999		Clinical chemistry test	Pathology	0.24	
85002		Bleeding time test	Pathology	0.21	
85004		Automated diff wbc count	Pathology	0.30	
85007		Bl smear w/diff wbc count	Pathology	0.16	
85008		Bl smear w/o diff wbc count	Pathology	0.16	
85009		Manual diff wbc count b-coat	Pathology	0.17	
85013		Spun microhematocrit	Pathology	0.11	
85014		Hematocrit	Pathology	0.11	
85018		Hemoglobin	Pathology	0.11	
85025		Complete cbc w/auto diff wbc	Pathology	0.36	
85027		Complete cbc, automated	Pathology	0.30	
85032		Manual cell count, each	Pathology	0.20	
85041		Automated rbc count	Pathology	0.14	
85044		Manual reticulocyte count	Pathology	0.20	
85045		Automated reticulocyte count	Pathology	0.19	
85046		Reticyte/hqb concentrate	Pathology	0.26	
85048		Automated leukocyte count	Pathology	0.12	
85049		Automated platelet count	Pathology	0.21	
85055		Reticulated platelet assay	Pathology	1.25	
85130		Chromogenic substrate assay	Pathology	0.56	
85170		Blood clot retraction	Pathology	0.17	
85175		Blood clot lysis time	Pathology	0.21	
85210		Blood clot factor II test	Pathology	0.61	
85220		Blood clot factor V test	Pathology	0.82	

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE J. - PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUs)

PAGE 10 of 20

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Methodology (1)
85230		Blood clot factor VII test	Pathology	0.84	
85240		Blood clot factor VIII test	Pathology	0.84	
85244		Blood clot factor VIII test	Pathology	0.95	
85245		Blood clot factor VIII test	Pathology	1.07	
85246		Blood clot factor VIII test	Pathology	1.07	
85247		Blood clot factor VIII test	Pathology	1.07	
85250		Blood clot factor IX test	Pathology	0.89	
85260		Blood clot factor X test	Pathology	0.84	
85270		Blood clot factor XI test	Pathology	0.84	
85280		Blood clot factor XII test	Pathology	0.90	
85290		Blood clot factor XIII test	Pathology	0.76	
85291		Blood clot factor XIII test	Pathology	0.41	
85292		Blood clot factor assay	Pathology	0.88	
85293		Blood clot factor assay	Pathology	0.88	
85300		Antithrombin III test	Pathology	0.55	
85301		Antithrombin III test	Pathology	0.50	
85302		Blood clot inhibitor antigen	Pathology	0.56	
85303		Blood clot inhibitor test	Pathology	0.65	
85305		Blood clot inhibitor assay	Pathology	0.54	
85306		Blood clot inhibitor test	Pathology	0.72	
85307		Assay activated protein c	Pathology	0.72	
85335		Factor inhibitor test	Pathology	0.60	
85337		Thrombomodulin	Pathology	0.49	
85345		Coagulation time	Pathology	0.20	
85347		Coagulation time	Pathology	0.20	
85348		Coagulation time	Pathology	0.17	
85360		Euqlobulin lysis	Pathology	0.39	
85362		Fibrin degradation products	Pathology	0.32	
85366		Fibrinogen test	Pathology	0.40	
85370		Fibrinogen test	Pathology	0.53	
85378		Fibrin degrade, semiquant	Pathology	0.33	
85379		Fibrin degradation, quant	Pathology	0.48	
85380		Fibrin degradation, vte	Pathology	0.48	
85384		Fibrinogen	Pathology	0.40	
85385		Fibrinogen	Pathology	0.40	
85390		Fibrinolysins screen	Pathology	0.24	
85400		Fibrinolytic plasmin	Pathology	0.41	
85410		Fibrinolytic antiplasmin	Pathology	0.36	
85415		Fibrinolytic plasminogen	Pathology	0.80	
85420		Fibrinolytic plasminogen	Pathology	0.30	
85421		Fibrinolytic plasminogen	Pathology	0.48	
85441		Heinz bodies, direct	Pathology	0.20	
85445		Heinz bodies, induced	Pathology	0.32	
85460		Hemoglobin, fetal	Pathology	0.36	
85461		Hemoglobin, fetal	Pathology	0.31	
85475		Hemolysin	Pathology	0.41	
85520		Heparin assay	Pathology	0.61	
85525		Heparin neutralization	Pathology	0.55	
85530		Heparin-protamine tolerance	Pathology	0.66	
85536		Iron stain peripheral blood	Pathology	0.30	
85540		Wbc alkaline phosphatase	Pathology	0.40	
85547		RBC mechanical fragility	Pathology	0.40	
85549		Muramidase	Pathology	0.88	
85555		RBC osmotic fragility	Pathology	0.31	
85557		RBC osmotic fragility	Pathology	0.62	
85576	TC	Blood platelet aggregation	Pathology	1.00	
85597		Platelet neutralization	Pathology	0.84	
85610		Prothrombin time	Pathology	0.18	
85611		Prothrombin test	Pathology	0.18	
85612		Viper venom prothrombin time	Pathology	0.45	

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE J. -- PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUs)

PAGE 11 of 20

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Methodology (1)
85613		Russell viper venom, diluted	Pathology	0.45	
85635		Reptilase test	Pathology	0.46	
85651		Rbc sed rate, nonautomated	Pathology	0.17	
85652		Rbc sed rate, automated	Pathology	0.13	
85660		RBC sickle cell test	Pathology	0.26	
85670		Thrombin time, plasma	Pathology	0.27	
85675		Thrombin time, liter	Pathology	0.32	
85705		Thromboplastin inhibition	Pathology	0.45	
85730		Thromboplastin time, partial	Pathology	0.28	
85732		Thromboplastin time, partial	Pathology	0.30	
85810		Blood viscosity examination	Pathology	0.55	
85999		Hematology procedure	Pathology	0.30	
86000		Agglutinins, febrile	Pathology	0.33	
86001		Allergen specific igg	Pathology	0.24	
86003		Allergen specific IgE	Pathology	0.24	
86005		Allergen specific IgE	Pathology	0.37	
86021		WBC antibody identification	Pathology	0.70	
86022		Platelet antibodies	Pathology	0.86	
86023		Immunoglobulin assay	Pathology	0.58	
86038		Antinuclear antibodies	Pathology	0.56	
86039		Antinuclear antibodies (ANA)	Pathology	0.52	
86060		Antistreptolysin o, titer	Pathology	0.34	
86063		Antistreptolysin o, screen	Pathology	0.27	
86140		C-reactive protein	Pathology	0.24	
86141		C-reactive protein, hs	Pathology	0.60	
86146		Glycoprotein antibody	Pathology	1.19	
86147		Cardiolipin antibody	Pathology	1.19	
86148		Phospholipid antibody	Pathology	0.75	
86155		Chemotaxis assay	Pathology	0.75	
86156		Cold agglutinin, screen	Pathology	0.31	
86157		Cold agglutinin, titer	Pathology	0.38	
86160		Complement, antigen	Pathology	0.56	
86161		Complement/function activity	Pathology	0.56	
86162		Complement, total (CH50)	Pathology	0.95	
86171		Complement fixation, each	Pathology	0.47	
86185		Counterimmunoelectrophoresis	Pathology	0.42	
86215		Deoxyribonuclease, antibody	Pathology	0.62	
86225		DNA antibody	Pathology	0.64	
86226		DNA antibody, single strand	Pathology	0.57	
86235		Nuclear antigen antibody	Pathology	0.84	
86243		Fc receptor	Pathology	0.96	
86255		Fluorescent antibody, screen	Pathology	0.56	
86256		Fluorescent antibody, titer	Pathology	0.56	
86277		Growth hormone antibody	Pathology	0.73	
86280		Hemagglutination inhibition	Pathology	0.38	
86294		Immunoassay, tumor qual	Pathology	0.92	
86300		Immunoassay, tumor ca 15-3	Pathology	0.97	
86301		Immunoassay, tumor ca 19-9	Pathology	0.97	
86304		Immunoassay, tumor, ca 125	Pathology	0.97	
86308		Heterophile antibodies	Pathology	0.24	
86309		Heterophile antibodies	Pathology	0.30	
86310		Heterophile antibodies	Pathology	0.34	
86316		Immunoassay, tumor other	Pathology	0.97	
86317		Immunoassay, infectious agent	Pathology	0.70	
86318		Immunoassay, infectious agent	Pathology	0.60	
86320	TC	Serum immunoelectrophoresis	Pathology	1.05	
86325	TC	Other immunoelectrophoresis	Pathology	1.04	
86327	TC	Immunoelectrophoresis assay	Pathology	1.06	
86329		Immunodiffusion	Pathology	0.66	
86331		Immunodiffusion oucherlony	Pathology	0.56	

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE J. - PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUs)

PAGE 12 of 20

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Methodology (1)
86332		Immune complex assay	Pathology	1.14	
86334	TC	Immunofixation procedure	Pathology	1.04	
86335	26	Immunfix e-phorsis/unine/csf	Pathology	1.35	
86335	TC	Immunfix e-phorsis/unine/csf	Pathology	1.35	
86336		Inhibin A	Pathology	0.73	
86337		Insulin antibodies	Pathology	1.00	
86340		Intrinsic factor antibody	Pathology	0.70	
86341		Islet cell antibody	Pathology	0.92	
86343		Leukocyte histamine release	Pathology	0.58	
86344		Leukocyte phagocytosis	Pathology	0.37	
86353		Lymphocyte transformation	Pathology	2.29	
86359		T cells, total count	Pathology	1.76	
86360		T cell, absolute count/ratio	Pathology	2.19	
86361		T cell, absolute count	Pathology	1.25	
86376		Microsomal antibody	Pathology	0.68	
86378		Migration inhibitory factor	Pathology	0.92	
86382		Neutralization test, viral	Pathology	0.79	
86384		Nitroblue tetrazolium dye	Pathology	0.53	
86403		Particle agglutination test	Pathology	0.48	
86406		Particle agglutination test	Pathology	0.50	
86430		Rheumatoid factor test	Pathology	0.26	
86431		Rheumatoid factor, quant	Pathology	0.26	
86485		Skin test, candida	Pathology	0.28	
86586		Skin test, unlisted	Pathology	0.26	
86590		Streptokinase, antibody	Pathology	0.51	
86592		Blood serology, qualitative	Pathology	0.20	
86593		Blood serology, quantitative	Pathology	0.21	
86602		Antinomyces antibody	Pathology	0.48	
86603		Adenovirus antibody	Pathology	0.60	
86606		Aspergillus antibody	Pathology	0.70	
86609		Bacterium antibody	Pathology	0.60	
86611		Bartonella antibody	Pathology	0.48	
86612		Blastomyces antibody	Pathology	0.60	
86615		Bordetella antibody	Pathology	0.62	
86617		Lyme disease antibody	Pathology	0.72	
86618		Lyme disease antibody	Pathology	0.80	
86619		Borrelia antibody	Pathology	0.62	
86622		Brucella antibody	Pathology	0.42	
86625		Campylobacter antibody	Pathology	0.61	
86628		Candida antibody	Pathology	0.56	
86631		Chlamydia antibody	Pathology	0.55	
86632		Chlamydia igm antibody	Pathology	0.59	
86635		Coccidioides antibody	Pathology	0.54	
86638		Q fever antibody	Pathology	0.57	
86641		Cryptococcus antibody	Pathology	0.67	
86644		CMV antibody	Pathology	0.67	
86645		CMV antibody, IgM	Pathology	0.79	
86648		Diphtheria antibody	Pathology	0.71	
86651		Encephalitis antibody	Pathology	0.62	
86652		Encephalitis antibody	Pathology	0.62	
86653		Encephalitis antibody	Pathology	0.62	
86654		Encephalitis antibody	Pathology	0.62	
86658		Enterovirus antibody	Pathology	0.61	
86663		Epstein-barr antibody	Pathology	0.61	
86664		Epstein-barr antibody	Pathology	0.71	
86665		Epstein-barr antibody	Pathology	0.85	
86666		Ehrlichia antibody	Pathology	0.48	
86668		Francisella tularensis	Pathology	0.49	
86671		Fungus antibody	Pathology	0.57	
86674		Giardia lamblia antibody	Pathology	0.69	

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE J. -- PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUs)

PAGE 13 of 20

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Methodology (1)
86677		Helicobacter pylori	Pathology	0.68	
86682		Helminth antibody	Pathology	0.61	
86684		Hemophilus influenza	Pathology	0.74	
86687		Htlv-i antibody	Pathology	0.39	
86688		Htlv-ii antibody	Pathology	0.65	
86689		HTLV/HIV confirmatory test	Pathology	0.90	
86692		Hepatitis, delta agent	Pathology	0.80	
86694		Herpes simplex test	Pathology	0.67	
86695		Herpes simplex test	Pathology	0.62	
86696		Herpes simplex type 2	Pathology	0.90	
86698		Histoplasma	Pathology	0.58	
86701		HIV-1	Pathology	0.41	
86702		HIV-2	Pathology	0.63	
86703		HIV-1/HIV-2, single assay	Pathology	0.64	
86704		Hep b core antibody, total	Pathology	0.56	
86705		Hep b core antibody, igm	Pathology	0.55	
86706		Hep b surface antibody	Pathology	0.50	
86707		Hep be antibody	Pathology	0.54	
86708		Hep a antibody, total	Pathology	0.58	
86709		Hep a antibody, igm	Pathology	0.53	
86710		Influenza virus antibody	Pathology	0.63	
86713		Legionella antibody	Pathology	0.71	
86717		Leishmania antibody	Pathology	0.57	
86720		Leptospira antibody	Pathology	0.62	
86723		Listeria monocytogenes ab	Pathology	0.62	
86727		Lymph-choriomeningitis ab	Pathology	0.60	
86729		Lympho venereum antibody	Pathology	0.56	
86732		Mucormycosis antibody	Pathology	0.62	
86735		Mumps antibody	Pathology	0.61	
86738		Mycoplasma antibody	Pathology	0.62	
86741		Neisseria meningitidis	Pathology	0.62	
86744		Nocardia antibody	Pathology	0.62	
86747		Parvovirus antibody	Pathology	0.70	
86750		Malania antibody	Pathology	0.62	
86753		Protozoa antibody nos	Pathology	0.58	
86756		Respiratory virus antibody	Pathology	0.60	
86757		Rickettsia antibody	Pathology	0.90	
86759		Rotavirus antibody	Pathology	0.62	
86762		Rubella antibody	Pathology	0.67	
86765		Rubeola antibody	Pathology	0.60	
86768		Salmonella antibody	Pathology	0.62	
86771		Shigella antibody	Pathology	0.62	
86774		Tetanus antibody	Pathology	0.69	
86777		Toxoplasma antibody	Pathology	0.67	
86778		Toxoplasma antibody, igm	Pathology	0.67	
86781		Treponema pallidum, confirm	Pathology	0.62	
86784		Trichinella antibody	Pathology	0.59	
86787		Varicella-zoster antibody	Pathology	0.60	
86790		Virus antibody nos	Pathology	0.60	
86793		Yersinia antibody	Pathology	0.62	
86800		Thyroglobulin antibody	Pathology	0.74	
86803		Hepatitis c ab test	Pathology	0.67	
86804		Hep c ab test, confirm	Pathology	0.72	
86805		Lymphocytotoxicity assay	Pathology	2.44	
86806		Lymphocytotoxicity assay	Pathology	2.22	
86807		Cytotoxic antibody screening	Pathology	1.85	
86808		Cytotoxic antibody screening	Pathology	1.39	
86812		HLA typing, A, B, or C	Pathology	1.20	
86813		HLA typing, A, B, or C	Pathology	2.71	
86816		HLA typing, DR/DQ	Pathology	1.30	

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE J. - PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUs)

PAGE 14 of 20

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Methodology (1)
86817		HLA typing, DR/DQ	Pathology	3.00	
86821		Lymphocyte culture, mixed	Pathology	2.64	
86822		Lymphocyte culture, primed	Pathology	1.71	
86849		Immunology procedure	Pathology	0.48	
86850		RBC antibody screen	Pathology	0.41	
86860		RBC antibody elution	Pathology	0.41	
86870		RBC antibody identification	Pathology	0.71	
86880		Coombs test, direct	Pathology	0.25	
86885		Coombs test, indirect, qual	Pathology	0.27	
86886		Coombs test, indirect, titer	Pathology	0.24	
86890		Autologous blood process	Pathology	1.63	
86891		Autologous blood, op salvage	Pathology	2.55	
86900		Blood typing, ABO	Pathology	0.14	
86901		Blood typing, Rh (D)	Pathology	0.20	
86903		Blood typing, antigen screen	Pathology	0.44	
86904		Blood typing, patient serum	Pathology	0.44	
86905		Blood typing, RBC antigens	Pathology	0.18	
86906		Blood typing, Rh phenotype	Pathology	0.36	
86910		Blood typing, paternity test	Pathology	0.45	
86911		Blood typing, antigen system	Pathology	0.35	
86920		Compatibility test	Pathology	0.45	
86921		Compatibility test	Pathology	0.41	
86922		Compatibility test	Pathology	0.25	
86927		Plasma, fresh frozen	Pathology	0.22	
86930		Frozen blood prep	Pathology	2.04	
86931		Frozen blood thaw	Pathology	2.25	
86932		Frozen blood freeze/thaw	Pathology	2.45	
86940		Hemolysins/agglutinins, auto	Pathology	0.38	
86941		Hemolysins/agglutinins	Pathology	0.57	
86945		Blood product/irradiation	Pathology	0.61	
86950		Leukocyte transfusion	Pathology	1.12	
86965		Pooling blood platelets	Pathology	0.29	
86970		RBC pretreatment	Pathology	0.33	
86971		RBC pretreatment	Pathology	0.33	
86972		RBC pretreatment	Pathology	0.31	
86975		RBC pretreatment, serum	Pathology	0.20	
86976		RBC pretreatment, serum	Pathology	0.16	
86977		RBC pretreatment, serum	Pathology	0.20	
86978		RBC pretreatment, serum	Pathology	0.45	
86985		Split blood or products	Pathology	0.43	
86999		Transfusion procedure	Pathology	0.20	
87001		Small animal inoculation	Pathology	0.62	
87003		Small animal inoculation	Pathology	0.79	
87015		Specimen concentration	Pathology	0.31	
87040		Blood culture for bacteria	Pathology	0.48	
87045		Feces culture, bacteria	Pathology	0.44	
87046		Stool cultr, bacteria, each	Pathology	0.44	
87070		Culture, bacteria, other	Pathology	0.40	
87071		Culture bacteria aerobic othr	Pathology	0.44	
87073		Culture bacteria anaerobic	Pathology	0.44	
87075		Culture bacteria anaerobic	Pathology	0.44	
87076		Culture anaerobe ident, each	Pathology	0.38	
87077		Culture aerobic identify	Pathology	0.38	
87081		Culture screen only	Pathology	0.31	
87084		Culture of specimen by kit	Pathology	0.40	
87086		Urine culture/colony count	Pathology	0.38	
87088		Urine bacteria culture	Pathology	0.38	
87101		Skin fungi culture	Pathology	0.36	
87102		Fungus isolation culture	Pathology	0.39	
87103		Blood fungus culture	Pathology	0.42	

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE J. -- PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUs)

PAGE 15 of 20

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Methodology (1)
87106		Fungi identification, yeast	Pathology	0.48	
87107		Fungi identification, mold	Pathology	0.48	
87109		Mycoplasma	Pathology	0.72	
87110		Chlamydia culture	Pathology	0.91	
87116		Mycobacteria culture	Pathology	0.50	
87118		Mycobacteric identification	Pathology	0.51	
87140		Culture type immunofluoresc	Pathology	0.26	
87143		Culture typing, q/c/hpic	Pathology	0.58	
87147		Culture type, immunologic	Pathology	0.24	
87149		Culture type, nucleic acid	Pathology	0.94	
87152		Culture type pulse field gel	Pathology	0.24	
87158		Culture typing, added method	Pathology	0.24	
87164	TC	Dark field examination	Pathology	0.50	
87166		Dark field examination	Pathology	0.53	
87168		Macroscopic exam arthropod	Pathology	0.20	
87169		Macroscopic exam parasite	Pathology	0.20	
87172		Pinworm exam	Pathology	0.20	
87176		Tissue homogenization, cultr	Pathology	0.27	
87177		Ova and parasites smears	Pathology	0.42	
87181		Microbe susceptible, diffuse	Pathology	0.22	
87184		Microbe susceptible, disk	Pathology	0.32	
87185		Microbe susceptible, enzyme	Pathology	0.22	
87186		Microbe susceptible, mic	Pathology	0.40	
87187		Microbe susceptible, mic	Pathology	0.48	
87188		Microbe suscept, macrobroth	Pathology	0.31	
87190		Microbe suscept, mycobacteri	Pathology	0.26	
87197		Bactericidal level, serum	Pathology	0.70	
87205		Smear, gram stain	Pathology	0.20	
87206		Smear, fluorescent/acid stai	Pathology	0.25	
87207		Smear, special stain	Pathology	0.28	
87210		Smear, wet mount, saline/ink	Pathology	0.20	
87220		Tissue exam for fungi	Pathology	0.20	
87230		Assay, toxin or antitoxin	Pathology	0.92	
87250		Virus inoculate, eggs/animal	Pathology	0.91	
87252		Virus inoculation, tissue	Pathology	1.22	
87253		Virus inoculate tissue, addl	Pathology	0.94	
87254		Virus inoculation, shell via	Pathology	0.91	
87255		Genet virus isolate, hsv	Pathology	1.58	
87260		Adenovirus aq, if	Pathology	0.56	
87265		Pertussis aq, if	Pathology	0.56	
87267		Enterovirus antibody, dfa	Pathology	0.56	
87269		Giardia aq, if	Pathology	0.56	
87270		Chlamydia trachomatis aq, if	Pathology	0.56	
87271		Cryptosporidium/giardia aq, if	Pathology	0.56	
87272		Cryptosporidium/giardia aq, if	Pathology	0.56	
87273		Herpes simplex 2, aq, if	Pathology	0.56	
87274		Herpes simplex 1, aq, if	Pathology	0.56	
87275		Influenza b, aq, if	Pathology	0.56	
87276		Influenza a, aq, if	Pathology	0.56	
87277		Legionella micdadei, aq, if	Pathology	0.56	
87278		Legion pneumophilia aq, if	Pathology	0.56	
87279		Parainfluenza, aq, if	Pathology	0.56	
87280		Respiratory syncytial aq, if	Pathology	0.56	
87281		Pneumocystis carinii, aq, if	Pathology	0.56	
87283		Rubeola, aq, if	Pathology	0.56	
87285		Treponema pallidum, aq, if	Pathology	0.56	
87290		Varicella zoster, aq, if	Pathology	0.56	
87299		Antibody detection, nos, if	Pathology	0.56	
87300		Aq detection, polyval, if	Pathology	0.56	
87301		Adenovirus aq, eia	Pathology	0.56	

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology

TABLE J. - PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUs)

PAGE 16 of 20

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Methodology (1)
87320		Chylmd trach aq, eia	Pathology	0.56	
87324		Clostridium aq, eia	Pathology	0.56	
87327		Cryptococcus neoform aq, eia	Pathology	0.56	
87328		Cryptospor aq, eia	Pathology	0.56	
87329		Giardia aq, eia	Pathology	0.56	
87332		Cytomegalovirus aq, eia	Pathology	0.56	
87335		E coli 0157 aq, eia	Pathology	0.56	
87336		Entamoeb hist displ, aq, eia	Pathology	0.56	
87337		Entamoeb hist group, aq, eia	Pathology	0.56	
87338		Hpylori, stool, eia	Pathology	0.67	
87339		H pylori aq, eia	Pathology	0.56	
87340		Hepatitis b surface aq, eia	Pathology	0.48	
87341		Hepatitis b surface, aq, eia	Pathology	0.48	
87350		Hepatitis be aq, eia	Pathology	0.54	
87360		Hepatitis delta aq, eia	Pathology	0.77	
87385		Histoplasma capsul aq, eia	Pathology	0.56	
87390		Hiv-1 aq, eia	Pathology	0.82	
87391		Hiv-2 aq, eia	Pathology	0.82	
87400		Influenza a/b, aq, eia	Pathology	0.56	
87420		Resp syncytial aq, eia	Pathology	0.56	
87425		Rotavirus aq, eia	Pathology	0.56	
87427		Shiga-like toxin aq, eia	Pathology	0.56	
87430		Strep a aq, eia	Pathology	0.56	
87449		Aq detect nos, eia, mult	Pathology	0.56	
87450		Aq detect nos, eia, single	Pathology	0.45	
87451		Aq detect polyval, eia, mult	Pathology	0.45	
87470		Bartonella, dna, dir probe	Pathology	0.94	
87471		Bartonella, dna, amp probe	Pathology	1.64	
87472		Bartonella, dna, quant	Pathology	2.00	
87475		Lyme dis, dna, dir probe	Pathology	0.94	
87476		Lyme dis, dna, amp probe	Pathology	1.64	
87477		Lyme dis, dna, quant	Pathology	2.00	
87480		Candida, dna, dir probe	Pathology	0.94	
87481		Candida, dna, amp probe	Pathology	1.64	
87482		Candida, dna, quant	Pathology	1.95	
87485		Chylmd pneum, dna, dir probe	Pathology	0.94	
87486		Chylmd pneum, dna, amp probe	Pathology	1.64	
87487		Chylmd pneum, dna, quant	Pathology	2.00	
87490		Chylmd trach, dna, dir probe	Pathology	0.94	
87491		Chylmd trach, dna, amp probe	Pathology	1.64	
87492		Chylmd trach, dna, quant	Pathology	1.63	
87495		Cytomeg, dna, dir probe	Pathology	0.94	
87496		Cytomeg, dna, amp probe	Pathology	1.64	
87497		Cytomeg, dna, quant	Pathology	2.00	
87510		Gardner vag, dna, dir probe	Pathology	0.94	
87511		Gardner vag, dna, amp probe	Pathology	1.64	
87512		Gardner vag, dna, quant	Pathology	1.95	
87515		Hepatitis b, dna, dir probe	Pathology	0.94	
87516		Hepatitis b, dna, amp probe	Pathology	1.64	
87517		Hepatitis b, dna, quant	Pathology	2.00	
87520		Hepatitis c, ma, dir probe	Pathology	0.94	
87521		Hepatitis c, ma, amp probe	Pathology	1.64	
87522		Hepatitis c, ma, quant	Pathology	2.00	
87525		Hepatitis q, dna, dir probe	Pathology	0.94	
87526		Hepatitis q, dna, amp probe	Pathology	1.64	
87527		Hepatitis q, dna, quant	Pathology	1.95	
87528		Hsv, dna, dir probe	Pathology	0.94	
87529		Hsv, dna, amp probe	Pathology	1.64	
87530		Hsv, dna, quant	Pathology	2.00	
87531		Hhv-6, dna, dir probe	Pathology	0.94	

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE J. -- PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUs)

PAGE 17 of 20

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Methodology (1)
87532		Hhv-6, dna, amp probe	Pathology	1.64	
87533		Hhv-6, dna, quant	Pathology	1.95	
87534		Hiv-1, dna, dir probe	Pathology	0.94	
87535		Hiv-1, dna, amp probe	Pathology	1.64	
87536		Hiv-1, dna, quant	Pathology	3.97	
87537		Hiv-2, dna, dir probe	Pathology	0.94	
87538		Hiv-2, dna, amp probe	Pathology	1.64	
87539		Hiv-2, dna, quant	Pathology	2.00	
87540		Legion pneumo, dna, dir prob	Pathology	0.94	
87541		Legion pneumo, dna, amp prob	Pathology	1.64	
87542		Legion pneumo, dna, quant	Pathology	1.95	
87550		Mycobacteria, dna, dir probe	Pathology	0.94	
87551		Mycobacteria, dna, amp probe	Pathology	1.64	
87552		Mycobacteria, dna, quant	Pathology	2.00	
87555		M.tuberculo, dna, dir probe	Pathology	0.94	
87556		M.tuberculo, dna, amp probe	Pathology	1.64	
87557		M.tuberculo, dna, quant	Pathology	2.00	
87560		M.avium-intra, dna, dir prob	Pathology	0.94	
87561		M.avium-intra, dna, amp prob	Pathology	1.64	
87562		M.avium-intra, dna, quant	Pathology	2.00	
87580		M.pneumon, dna, dir probe	Pathology	0.94	
87581		M.pneumon, dna, amp probe	Pathology	1.64	
87582		M.pneumon, dna, quant	Pathology	1.95	
87590		N.gonorrhoeae, dna, dir prob	Pathology	0.94	
87591		N.gonorrhoeae, dna, amp prob	Pathology	1.64	
87592		N.gonorrhoeae, dna, quant	Pathology	2.00	
87620		Hpv, dna, dir probe	Pathology	0.94	
87621		Hpv, dna, amp probe	Pathology	1.64	
87622		Hpv, dna, quant	Pathology	1.95	
87650		Strep a, dna, dir probe	Pathology	0.94	
87651		Strep a, dna, amp probe	Pathology	1.64	
87652		Strep a, dna, quant	Pathology	1.95	
87660		Trichomonas vagin, dir probe	Pathology	0.94	
87797		Detect agent nos, dna, dir	Pathology	0.94	
87798		Detect agent nos, dna, amp	Pathology	1.64	
87799		Detect agent nos, dna, quant	Pathology	2.00	
87800		Detect agent mult, dna, direc	Pathology	1.87	
87801		Detect agent mult, dna, ampli	Pathology	3.28	
87802		Strep b assay w/optic	Pathology	0.56	
87803		Clostridium toxin a w/optic	Pathology	0.56	
87804		Influenza assay w/optic	Pathology	0.56	
87807		Rsv assay w/optic	Pathology	0.56	
87810		Chylmd trach assay w/optic	Pathology	0.56	
87850		N. gonorrhoeae assay w/optic	Pathology	0.56	
87880		Strep a assay w/optic	Pathology	0.56	
87899		Agent nos assay w/optic	Pathology	0.56	
87901		Genotype, dna, hiv reverse t	Pathology	12.02	
87902		Genotype, dna, hepatitis C	Pathology	12.02	
87903		Phenotype, dna hiv w/culture	Pathology	22.81	
87904		Phenotype, dna hiv w/clt add	Pathology	1.22	
87999		Microbiology procedure	Pathology	0.40	
88000		Autopsy (necropsy), gross	Pathology	8.10	
88005		Autopsy (necropsy), gross	Pathology	9.00	
88007		Autopsy (necropsy), gross	Pathology	9.90	
88012		Autopsy (necropsy), gross	Pathology	7.46	
88014		Autopsy (necropsy), gross	Pathology	7.46	
88016		Autopsy (necropsy), gross	Pathology	9.07	
88020		Autopsy (necropsy), complete	Pathology	11.64	
88025		Autopsy (necropsy), complete	Pathology	12.54	
88027		Autopsy (necropsy), complete	Pathology	13.44	

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE J. -- PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUs)

PAGE 18 of 20

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Methodology (1)
88028		Autopsy (necropsy), complete	Pathology	7.46	
88029		Autopsy (necropsy), complete	Pathology	7.46	
88036		Limited autopsy	Pathology	4.82	
88037		Limited autopsy	Pathology	3.54	
88040		Forensic autopsy (necropsy)	Pathology	19.29	
88045		Coroner's autopsy (necropsy)	Pathology	1.61	
88099		Necropsy (autopsy) procedure	Pathology	12.54	
88130		Sex chromatin identification	Pathology	0.70	
88140		Sex chromatin identification	Pathology	0.37	
88142		Cytopath, c/v, thin layer	Pathology	0.95	
88143		Cytopath c/v thin layer redo	Pathology	0.95	
88147		Cytopath, c/v, automated	Pathology	0.53	
88148		Cytopath, c/v, auto rescreen	Pathology	0.71	
88150		Cytopath, c/v, manual	Pathology	0.49	
88152		Cytopath, c/v, auto redo	Pathology	0.49	
88153		Cytopath, c/v, redo	Pathology	0.49	
88154		Cytopath, c/v, select	Pathology	0.49	
88155		Cytopath, c/v, index add-on	Pathology	0.28	
88164		Cytopath tbs, c/v, manual	Pathology	0.49	
88165		Cytopath tbs, c/v, redo	Pathology	0.49	
88166		Cytopath tbs, c/v, auto redo	Pathology	0.49	
88167		Cytopath tbs, c/v, select	Pathology	0.49	
88174		Cytopath, c/v auto, in fluid	Pathology	1.00	
88175		Cytopath c/v auto fluid redo	Pathology	1.24	
88199		Cytopathology procedure	Pathology	0.49	
88230		Tissue culture, lymphocyte	Pathology	5.44	
88233		Tissue culture, skin/biopsy	Pathology	6.57	
88235		Tissue culture, placenta	Pathology	6.87	
88237		Tissue culture, bone marrow	Pathology	5.90	
88239		Tissue culture, tumor	Pathology	6.89	
88240		Cell cryopreserve/storage	Pathology	0.47	
88241		Frozen cell preparation	Pathology	0.47	
88245		Chromosome analysis, 20-25	Pathology	6.95	
88248		Chromosome analysis, 50-100	Pathology	8.08	
88249		Chromosome analysis, 100	Pathology	8.08	
88261		Chromosome analysis, 5	Pathology	8.25	
88262		Chromosome analysis, 15-20	Pathology	5.82	
88263		Chromosome analysis, 45	Pathology	7.01	
88264		Chromosome analysis, 20-25	Pathology	5.82	
88267		Chromosome analys, placenta	Pathology	8.39	
88269		Chromosome analys, amniotic	Pathology	7.76	
88271		Cyto genetics, dna probe	Pathology	1.00	
88272		Cyto genetics, 3-5	Pathology	1.25	
88273		Cyto genetics, 10-30	Pathology	1.50	
88274		Cyto genetics, 25-99	Pathology	1.62	
88275		Cyto genetics, 100-300	Pathology	1.87	
88280		Chromosome karyotype study	Pathology	1.17	
88283		Chromosome banding study	Pathology	3.20	
88285		Chromosome count, additional	Pathology	0.89	
88289		Chromosome study, additional	Pathology	1.61	
88299		Cyto genetic study	Pathology	5.82	
88371	TC	Protein, western blot tissue	Pathology	1.04	
88372	TC	Protein analysis w/probe	Pathology	1.06	
88380	TC	Microdissection	Pathology	2.49	CALC
88399		Surgical pathology procedure	Pathology	2.49	
88400		Bilirubin total transcut	Pathology	0.23	
89050		Body fluid cell count	Pathology	0.22	
89051		Body fluid cell count	Pathology	0.26	
89055		Leukocyte count, fecal	Pathology	0.20	
89060		Exam, synovial fluid crystals	Pathology	0.33	

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of the table for note regarding Charge Methodology.

TABLE J. - PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUs)

PAGE 19 of 20

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Methodology (1)
89125		Specimen fat stain	Pathology	0.20	
89160		Exam feces for meat fibers	Pathology	0.17	
89190		Nasal smear for eosinophils	Pathology	0.22	
89225		Starch granules, feces	Pathology	0.16	
89235		Water load test	Pathology	0.26	
89240		Pathology lab procedure	Pathology	0.26	
89250		Cultr oocyte/embryo <4 days	Pathology	14.03	
89300		Semen analysis w/huhner	Pathology	0.42	
89310		Semen analysis w/count	Pathology	0.40	
89320		Semen analysis, complete	Pathology	0.56	
89321		Semen analysis & motility	Pathology	0.56	
89325		Sperm antibody test	Pathology	0.50	
89329		Sperm evaluation test	Pathology	0.98	
89330		Evaluation, cervical mucus	Pathology	0.46	
0026T		Measure remnant lipoproteins	Pathology	0.38	CALC
0030T		Antiprothrombin antibody	Pathology	0.40	CALC
0041T		Detect ur infect aqnt w/cpas	Pathology	0.10	CALC
0103T		Holotranscobalamin	Pathology	0.67	CALC
0111T		Rbc membranes fatty acids	Pathology	0.84	CALC
0140T		Exhaled breath condensate ph	Pathology	0.17	CALC
G0027		Semen analysis	Pathology	0.30	
G0103		Psa, total screening	Pathology	0.86	
G0107		CA screen; fecal blood test	Pathology	0.15	
G0123		Screen cerv/vag thin layer	Pathology	0.95	
G0143		Scr c/v cyto,thinlayer, rescr	Pathology	0.95	
G0144		Scr c/v cyto,thinlayer, rescr	Pathology	1.00	
G0145		Scr c/v cyto,thinlayer, rescr	Pathology	1.24	
G0147		Scr c/v cyto, automated sys	Pathology	0.53	
G0148		Scr c/v cyto, autosys, rescr	Pathology	0.71	
G0265		Cryopreservation Freeze+stora	Pathology	0.47	
G0266		Thawing + expansion froz cel	Pathology	0.47	
G0306		CBC/diffwbc w/o platelet	Pathology	0.36	
G0307		CBC without platelet	Pathology	0.30	
G0328		Fecal blood scm immunoassay	Pathology	0.60	
P2038		Blood mucoprotein	Pathology	0.23	
P3000		Screen pap by tech w md supv	Pathology	0.49	
P7001		Culture bacterial urine	Pathology	0.48	
P9612		Catheterize for urine spec	Pathology	0.10	
P9615		Urine specimen collect mult	Pathology	0.10	
Q0111		Wet mounts/ w preparations	Pathology	0.20	
Q0112		Potassium hydroxide preps	Pathology	0.20	
Q0113		Pinworm examinations	Pathology	0.25	
Q0114		Fern test	Pathology	0.33	
Q0115		Post-coital mucous exam	Pathology	0.46	
S3625		Maternl Serum Triple Markr Scr W/Afp Estriol&Hcg	Pathology	0.78	CALC
S3630		Eosinophil Count Blood Direct	Pathology	0.2	CALC
S3645		Hiv-1 Antibody Testinq Oral Mucosal Transudate	Pathology	0.41	CALC
S3650		Saliva Test Hormone Level; During Menopause	Pathology	3.01	CALC
S3652		Saliva Tst Hormone Lev; Assess Prterm Labr Risk	Pathology	2.44	CALC
S3655		Antisperm Antibodies Test	Pathology	0.5	CALC
S3701		Immunoassay Nuclear Matrix Prot 22 Quantitative	Pathology	0.15	CALC
80195		Assay of sirolimus	HCPCS - Non-Drug	\$20.51 (2)	LAB
82271		Occult blood, feces, single	HCPCS - Non-Drug	\$4.86 (2)	LAB
82272		Blood occult peroxidase	HCPCS - Non-Drug	\$4.86 (2)	LAB
83631		Lactoferrin, fecal (quant)	HCPCS - Non-Drug	\$29.34 (2)	LAB
83695		Assay of lipoprotein(a)	HCPCS - Non-Drug	\$19.36 (2)	LAB
83700		Lipopro bld, electrophoretic	HCPCS - Non-Drug	\$16.83 (2)	LAB
83701		Lipoprotein bld, hr fraction	HCPCS - Non-Drug	\$37.11 (2)	LAB
83704		Lipoprotein, bld, by nmr	HCPCS - Non-Drug	\$47.17 (2)	LAB
83900		Molecule nucleic ampli 2 seq	HCPCS - Non-Drug	\$50.12 (2)	LAB

NOTES: CPT codes and descriptions only are copyright 2006 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.
See end of the table for note regarding Charge Methodology.

TABLE J. - PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUs)

PAGE 20 of 20

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Methodology (1)
83907		Lyse cells for nucleic ext	HCPCS - Non-Drug	\$19.97 (2)	LAB
83908		Nucleic acid, signal ampli	HCPCS - Non-Drug	\$25.06 (2)	LAB
83909		Nucleic acid, high resolute	HCPCS - Non-Drug	\$25.06 (2)	LAB
83914		Mutation ident ola/sbce/aspe	HCPCS - Non-Drug	\$25.06 (2)	LAB
86200		Ccp antibody	HCPCS - Non-Drug	\$19.36 (2)	LAB
86355		B cells, total count	HCPCS - Non-Drug	\$56.39 (2)	LAB
86357		Nk cells, total count	HCPCS - Non-Drug	\$56.39 (2)	LAB
86367		Stem cells, total count	HCPCS - Non-Drug	\$56.39 (2)	LAB
86480		Tb test, cell immun measure	HCPCS - Non-Drug	\$92.65 (2)	LAB
87209		Smear, complex stain	HCPCS - Non-Drug	\$26.87 (2)	LAB
87900		Phenotype, infect agent drug	HCPCS - Non-Drug	\$194.86 (2)	LAB

Charge Methodology:

No entry: RVUs based on 1-1-2006 RBRVS fee schedule.

CALC: Charge based upon a calculation or data provided by VA (e.g., cost).

LAB: Charge based upon 1-1-2006 clinical laboratory fee schedule.

All other entries: See Supplementary Table 1, Reasonable Charges Data Sources - V2.6.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 1 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
A4206		1 CC sterile syringe&needle		\$0.72	HCPCS - Non-Drug
A4207		2 CC sterile syringe&needle		\$0.72	HCPCS - Non-Drug
A4208		3 CC sterile syringe&needle		\$0.72	HCPCS - Non-Drug
A4209		5+ CC sterile syringe&needle		\$0.72	HCPCS - Non-Drug
A4210		Nonneedle injection device	a	\$1,794.37	HCPCS - Non-Drug
A4211		Supp for self-adm injections		\$0.92	HCPCS - Non-Drug
A4212		Non coring needle or stylet		\$17.30	HCPCS - Non-Drug
A4213		20+ CC syringe only		\$2.17	HCPCS - Non-Drug
A4215		Sterile needle		\$0.41	HCPCS - Non-Drug
A4216		Sterile water/saline, 10 ml		\$2.17	HCPCS - Non-Drug
A4217		Sterile water/saline, 500 ml		\$22.30	HCPCS - Non-Drug
A4220		Infusion pump refill kit		\$32.64	HCPCS - Non-Drug
A4221		Maint drug infus cath per wk	a	\$38.43	HCPCS - Non-Drug
A4222		Drug infusion pump supplies	a	\$78.62	HCPCS - Non-Drug
A4230		Infus insulin pump non needl		\$19.58	HCPCS - Non-Drug
A4231		Infusion insulin pump needle		\$10.70	HCPCS - Non-Drug
A4232		Syringe w/needle insulin 3cc	a	\$6.87	HCPCS - Non-Drug
A4244		Alcohol or peroxide per pint		\$2.17	HCPCS - Non-Drug
A4245		Alcohol wipes per box		\$5.80	HCPCS - Non-Drug
A4246		Betadine/phisohex solution		\$6.53	HCPCS - Non-Drug
A4247		Betadine/iodine swabs/wipes		\$10.15	HCPCS - Non-Drug
A4250		Urine reagent strips/tablets		\$36.55	HCPCS - Non-Drug
A4253		Blood glucose/reagent strips	a	\$62.42	HCPCS - Non-Drug
A4255		Glucose monitor platforms		\$10.50	HCPCS - Non-Drug
A4256		Calibrator solution/chips		\$21.54	HCPCS - Non-Drug
A4257		Replace Lensshield Cartridge		\$23.52	HCPCS - Non-Drug
A4258		Lancet device each		\$31.51	HCPCS - Non-Drug
A4259		Lancets per box	a	\$23.51	HCPCS - Non-Drug
A4261		Cervical cap contraceptive		\$49.38	HCPCS - Non-Drug
A4262		Temporary tear duct plug		\$0.72	HCPCS - Non-Drug
A4263		Permanent tear duct plug		\$82.90	HCPCS - Non-Drug
A4265		Paraffin		\$5.56	HCPCS - Non-Drug
A4267		Male condom		\$0.72	HCPCS - Non-Drug
A4269		Spermicide		\$2.17	HCPCS - Non-Drug
A4270		Disposable endoscope sheath		\$35.14	HCPCS - Non-Drug
A4280		Brst prsths adhsv attachmnt		\$8.75	HCPCS - Non-Drug
A4284		Replcmnt breast pump shield		\$37.27	HCPCS - Non-Drug
A4285		Replcmnt breast pump bottle		\$7.42	HCPCS - Non-Drug
A4290		Sacral nerve stim test lead		\$226.09	HCPCS - Non-Drug
A4300		Cath impl vasc access portal		\$17.58	HCPCS - Non-Drug
A4301		Implantable access syst perc		\$79.29	HCPCS - Non-Drug
A4305		Drug delivery system >=50 ML		\$27.29	HCPCS - Non-Drug
A4306		Drug delivery system <=5 ML		\$37.99	HCPCS - Non-Drug
A4310		Insert tray w/o bag/cath		\$12.66	HCPCS - Non-Drug
A4311		Catheter w/o bag 2-way latex		\$24.16	HCPCS - Non-Drug
A4312		Cath w/o bag 2-way silicone		\$29.33	HCPCS - Non-Drug
A4313		Catheter w/bag 3-way		\$30.11	HCPCS - Non-Drug
A4314		Cath w/drainage 2-way latex		\$41.05	HCPCS - Non-Drug
A4315		Cath w/drainage 2-way silcne		\$42.81	HCPCS - Non-Drug
A4316		Cath w/drainage 3-way		\$46.08	HCPCS - Non-Drug
A4320		Irrigation tray		\$8.75	HCPCS - Non-Drug
A4321		Cath therapeutic iriq agent		\$2.81	HCPCS - Non-Drug
A4322		Irrigation syringe		\$4.99	HCPCS - Non-Drug
A4326		Male external catheter		\$17.62	HCPCS - Non-Drug
A4327		Fem urinary collect dev cup		\$72.29	HCPCS - Non-Drug
A4328		Fem urinary collect pouch		\$17.08	HCPCS - Non-Drug
A4330		Stool collection pouch		\$11.75	HCPCS - Non-Drug
A4331		Extension drainage tubing		\$5.22	HCPCS - Non-Drug
A4332		Lubricant for cath insertion		\$0.18	HCPCS - Non-Drug
A4333		Urinary cath anchor device		\$3.24	HCPCS - Non-Drug
A4334		Urinary cath leg strap		\$7.25	HCPCS - Non-Drug
A4335		Incontinence supply		\$1.86	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 2 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
A4338		Indwelling catheter latex		\$20.00	HCPCS - Non-Drug
A4340		Indwelling catheter special		\$51.49	HCPCS - Non-Drug
A4344		Cath indw foley 2 way silicon		\$26.08	HCPCS - Non-Drug
A4346		Cath indw foley 3 way		\$31.83	HCPCS - Non-Drug
A4348		Male ext cath extended wear		\$45.14	HCPCS - Non-Drug
A4349		Disposable male external cat		\$2.16	HCPCS - Non-Drug
A4351		Straight tip urine catheter		\$2.97	HCPCS - Non-Drug
A4352		Coude tip urinary catheter		\$10.53	HCPCS - Non-Drug
A4353		Intermittent urinary cath		\$11.50	HCPCS - Non-Drug
A4354		Cath insertion tray w/bag		\$19.26	HCPCS - Non-Drug
A4355		Bladder irrigation tubing		\$14.58	HCPCS - Non-Drug
A4356		Ext ureth clamp or compr dvc		\$73.92	HCPCS - Non-Drug
A4357		Bedside drainage bag		\$15.85	HCPCS - Non-Drug
A4358		Urinary leg or abdomen bag		\$10.89	HCPCS - Non-Drug
A4359		Urinary suspensory w/o leg b		\$49.67	HCPCS - Non-Drug
A4361		Ostomy face plate		\$29.87	HCPCS - Non-Drug
A4362		Solid skin barrier		\$5.68	HCPCS - Non-Drug
A4364		Adhesive, liquid or equal		\$4.31	HCPCS - Non-Drug
A4365		Adhesive remover wipes		\$18.49	HCPCS - Non-Drug
A4366		Ostomy vent		\$55.53	HCPCS - Non-Drug
A4367		Ostomy belt		\$12.05	HCPCS - Non-Drug
A4368		Ostomy filter		\$0.43	HCPCS - Non-Drug
A4369		Skin barrier liquid per oz		\$3.97	HCPCS - Non-Drug
A4371		Skin barrier powder per oz		\$6.00	HCPCS - Non-Drug
A4372		Skin barrier solid 4x4 equiv		\$6.87	HCPCS - Non-Drug
A4373		Skin barrier with flange		\$10.31	HCPCS - Non-Drug
A4375		Drainable plastic pch w fcpl		\$27.95	HCPCS - Non-Drug
A4376		Drainable rubber pch w fcpl		\$77.06	HCPCS - Non-Drug
A4377		Drainable plastic pch w/o fp		\$7.05	HCPCS - Non-Drug
A4378		Drainable rubber pch w/o fp		\$49.87	HCPCS - Non-Drug
A4379		Urinary plastic pouch w fcpl		\$24.46	HCPCS - Non-Drug
A4380		Urinary rubber pouch w fcpl		\$60.49	HCPCS - Non-Drug
A4381		Urinary plastic pouch w/o fp		\$7.58	HCPCS - Non-Drug
A4382		Urinary hvv plastic pch w/o fp		\$39.98	HCPCS - Non-Drug
A4383		Urinary rubber pouch w/o fp		\$45.73	HCPCS - Non-Drug
A4384		Ostomy facepl/silicone ring		\$15.73	HCPCS - Non-Drug
A4385		Ost skin barrier sld ext wear		\$8.38	HCPCS - Non-Drug
A4387		Ost clsd pouch w att st barr		\$4.89	HCPCS - Non-Drug
A4388		Drainable pch w ex wear barr		\$7.16	HCPCS - Non-Drug
A4389		Drainable pch w st wear barr		\$10.22	HCPCS - Non-Drug
A4390		Drainable pch ex wear convex		\$15.71	HCPCS - Non-Drug
A4391		Urinary pouch w ex wear barr		\$11.61	HCPCS - Non-Drug
A4392		Urinary pouch w st wear barr		\$13.41	HCPCS - Non-Drug
A4393		Urine pch w ex wear bar conv		\$14.79	HCPCS - Non-Drug
A4394		Ostomy pouch liq deodorant		\$4.23	HCPCS - Non-Drug
A4395		Ostomy pouch solid deodorant		\$0.07	HCPCS - Non-Drug
A4396		Peristomal hernia support bit		\$65.59	HCPCS - Non-Drug
A4397		Irrigation supply sleeve		\$7.86	HCPCS - Non-Drug
A4398		Ostomy irrigation bag		\$22.58	HCPCS - Non-Drug
A4399		Ostomy irrig cone/cath w brs		\$20.00	HCPCS - Non-Drug
A4400		Ostomy irrigation set		\$79.15	HCPCS - Non-Drug
A4402		Lubricant per ounce		\$2.62	HCPCS - Non-Drug
A4404		Ostomy ring each		\$2.77	HCPCS - Non-Drug
A4405		Nonpectin based ostomy paste		\$5.59	HCPCS - Non-Drug
A4406		Pectin based ostomy paste		\$9.43	HCPCS - Non-Drug
A4407		Ext wear ost skin barr <=4sq"		\$14.34	HCPCS - Non-Drug
A4408		Ext wear ost skin barr >4sq"		\$16.14	HCPCS - Non-Drug
A4409		Ost skin barr w flng <=4 sq"		\$10.22	HCPCS - Non-Drug
A4410		Ost skin barr w flng >4sq"		\$14.79	HCPCS - Non-Drug
A4413		2 pc drainable ost pouch		\$9.03	HCPCS - Non-Drug
A4414		Ostomy skin barr w flng <=4sq"		\$8.09	HCPCS - Non-Drug
A4415		Ostomy skin barr w flng >4sq"		\$9.85	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 3 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
A4416		Ost pch clsd w barrier/filtr		\$4.06	HCPCS - Non-Drug
A4417		Ost pch w bar/bltinconv/fltr		\$5.49	HCPCS - Non-Drug
A4418		Ost pch clsd w/o bar w filtr		\$2.66	HCPCS - Non-Drug
A4419		Ost pch for bar w flange/fltr		\$2.57	HCPCS - Non-Drug
A4420		Ost pch clsd for bar w lk fl		\$2.57	HCPCS - Non-Drug
A4421		Ostomy supply misc		\$0.62	HCPCS - Non-Drug
A4422		Ost pouch absorbent material		\$0.18	HCPCS - Non-Drug
A4423		Ost pch for bar w lk fl/fltr		\$2.57	HCPCS - Non-Drug
A4424		Ost pch drain w bar & filter		\$6.99	HCPCS - Non-Drug
A4425		Ost pch drain for barrier fl		\$5.28	HCPCS - Non-Drug
A4426		Ost pch drain 2 piece system		\$3.48	HCPCS - Non-Drug
A4427		Ost pch drain/barr lk flng/fl		\$5.28	HCPCS - Non-Drug
A4428		Urine ost pouch w faucet/tap		\$9.59	HCPCS - Non-Drug
A4429		Urine ost pouch w bltinconv		\$12.13	HCPCS - Non-Drug
A4430		Ost urine pch w b/ltin conv		\$12.54	HCPCS - Non-Drug
A4431		Ost pch urine w barrier/tapv		\$9.16	HCPCS - Non-Drug
A4432		Os pch urine w bar/flange/tap		\$5.29	HCPCS - Non-Drug
A4433		Urine ost pch bar w lock fln		\$4.91	HCPCS - Non-Drug
A4434		Ost pch urine w lock flng/flt		\$5.54	HCPCS - Non-Drug
A4450		Non-waterproof tape		\$0.14	HCPCS - Non-Drug
A4452		Waterproof tape		\$0.59	HCPCS - Non-Drug
A4455		Adhesive remover per ounce		\$2.35	HCPCS - Non-Drug
A4462		Abdmnl drssng holder/binder ¹		\$5.40	HCPCS - Non-Drug
A4465		Non-elastic extremity binder		\$19.44	HCPCS - Non-Drug
A4470		Gravlee jet washer		\$13.02	HCPCS - Non-Drug
A4480		Vabra aspirator		\$10.87	HCPCS - Non-Drug
A4481		Tracheostoma filter		\$1.69	HCPCS - Non-Drug
A4483		Moisture exchanger		\$13.58	HCPCS - Non-Drug
A4490		Above knee surgical stocking		\$14.46	HCPCS - Non-Drug
A4495		Thigh length surq stocking		\$14.46	HCPCS - Non-Drug
A4500		Below knee surgical stocking		\$10.87	HCPCS - Non-Drug
A4510		Full length surq stocking		\$25.86	HCPCS - Non-Drug
A4550		Surgical trays	a	\$61.51	HCPCS - Non-Drug
A4554		Disposable underpads	a	\$6.53	HCPCS - Non-Drug
A4556		Electrodes, pair	a	\$22.59	HCPCS - Non-Drug
A4557		Lead wires, pair		\$36.10	HCPCS - Non-Drug
A4558		Conductive paste or gel		\$12.51	HCPCS - Non-Drug
A4561		Pessary rubber, any type		\$36.95	HCPCS - Non-Drug
A4562		Pessary, non rubber, any type		\$91.63	HCPCS - Non-Drug
A4565		Slings		\$15.16	HCPCS - Non-Drug
A4570		Splint		\$35.85	HCPCS - Non-Drug
A4575		Hyperbaric o2 chamber disps		\$772.89	HCPCS - Non-Drug
A4580		Cast supplies (plaster)		\$32.89	HCPCS - Non-Drug
A4590		Special casting material	a	\$80.76	HCPCS - Non-Drug
A4595		TENS suppl 2 lead per month		\$47.74	HCPCS - Non-Drug
A4605		Trach suction cath close sys		\$17.55	HCPCS - Non-Drug
A4608		Transtracheal oxygen cath		\$98.13	HCPCS - Non-Drug
A4611		Heavy duty battery		\$364.14	HCPCS - Non-Drug
A4612		Battery cables		\$105.74	HCPCS - Non-Drug
A4613		Battery charger		\$188.38	HCPCS - Non-Drug
A4614		Hand-held PEFR meter		\$38.61	HCPCS - Non-Drug
A4615		Cannula nasal		\$3.66	HCPCS - Non-Drug
A4616		Tubing (oxygen) per foot		\$1.57	HCPCS - Non-Drug
A4617		Mouth piece		\$24.56	HCPCS - Non-Drug
A4618		Breathing circuits		\$14.55	HCPCS - Non-Drug
A4619		Face tent		\$2.57	HCPCS - Non-Drug
A4620		Variable concentration mask		\$7.84	HCPCS - Non-Drug
A4623		Tracheostomy inner cannula		\$10.76	HCPCS - Non-Drug
A4624		Tracheal suction tube	a	\$8.27	HCPCS - Non-Drug
A4625		Trach care kit for new trach		\$11.38	HCPCS - Non-Drug
A4626		Tracheostomy cleaning brush		\$5.24	HCPCS - Non-Drug
A4627		Spacer bag/reservoir		\$37.52	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 4 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAF Category
A4628		Oropharyngeal suction cath	a	\$6.14	HCPCS - Non-Drug
A4629		Tracheostomy care kit		\$7.61	HCPCS - Non-Drug
A4630		Repl bat t.e.n.s. own by pt		\$13.72	HCPCS - Non-Drug
A4632		Infus pump rplcmnt battery		\$35.31	HCPCS - Non-Drug
A4633		Uvl replacement bulb		\$67.77	HCPCS - Non-Drug
A4635		Underarm crutch pad		\$12.02	HCPCS - Non-Drug
A4636		Handcap for cane etc		\$10.65	HCPCS - Non-Drug
A4637		Repl tip cane/crutch/walker		\$7.50	HCPCS - Non-Drug
A4639		Infrared ht sys replcmnt pad		\$537.21	HCPCS - Non-Drug
A4640		Alternating pressure pad		\$110.26	HCPCS - Non-Drug
A4641		Diagnostic imaging agent		\$62.71	HCPCS - Non-Drug
A4642		Satumomab pendetide per dose	a	\$13.14	HCPCS - Non-Drug
A4649		Surgical supplies		\$2.65	HCPCS - Non-Drug
A4651		Calibrated microcap tube		\$3.26	HCPCS - Non-Drug
A4652		Microcapillary tube sealant		\$4.89	HCPCS - Non-Drug
A4657		Syringe w/wo needle		\$0.77	HCPCS - Non-Drug
A4660		Sphyg/bp app w cuff and stet		\$48.29	HCPCS - Non-Drug
A4663		Dialysis blood pressure cuff		\$54.01	HCPCS - Non-Drug
A4670		Automatic bp monitor, dial		\$130.70	HCPCS - Non-Drug
A4680		Activated carbon filter, ea		\$185.52	HCPCS - Non-Drug
A4690		Dialyzer, each		\$1,328.49	HCPCS - Non-Drug
A4706		Bicarbonate conc sol per gal		\$20.39	HCPCS - Non-Drug
A4707		Bicarbonate conc pow per pac		\$6.73	HCPCS - Non-Drug
A4708		Acetate conc sol per gallon		\$15.64	HCPCS - Non-Drug
A4709		Acid conc sol per gallon		\$15.64	HCPCS - Non-Drug
A4714		Treated water per gallon		\$21.23	HCPCS - Non-Drug
A4719		"Y set" tubing		\$13.93	HCPCS - Non-Drug
A4720		Dialysat sol fld vol > 249cc		\$19.37	HCPCS - Non-Drug
A4721		Dialysat sol fld vol > 999cc		\$38.74	HCPCS - Non-Drug
A4722		Dialys sol fld vol > 1999cc		\$46.94	HCPCS - Non-Drug
A4723		Dialys sol fld vol > 2999cc		\$47.55	HCPCS - Non-Drug
A4724		Dialys sol fld vol > 3999cc		\$47.64	HCPCS - Non-Drug
A4725		Dialys sol fld vol > 4999cc		\$50.43	HCPCS - Non-Drug
A4726		Dialys sol fld vol > 5999cc		\$56.04	HCPCS - Non-Drug
A4730		Fistula cannulation set, ea		\$2.79	HCPCS - Non-Drug
A4736		Topical anesthetic, per gram		\$9.82	HCPCS - Non-Drug
A4737		Inj anesthetic per 10 ml		\$14.11	HCPCS - Non-Drug
A4740		Shunt accessory		\$1.63	HCPCS - Non-Drug
A4750		Art or venous blood tubing		\$19.61	HCPCS - Non-Drug
A4755		Comb art/venous blood tubing		\$29.46	HCPCS - Non-Drug
A4760		Dialysate sol test kit, each		\$40.82	HCPCS - Non-Drug
A4765		Dialysate conc pow per pack		\$13.06	HCPCS - Non-Drug
A4766		Dialysate conc sol add 10 ml		\$6.54	HCPCS - Non-Drug
A4770		Blood collection tube/vacuum		\$28.85	HCPCS - Non-Drug
A4772		Blood glucose test strips		\$45.04	HCPCS - Non-Drug
A4773		Occult blood test strips		\$30.87	HCPCS - Non-Drug
A4774		Ammonia test strips		\$16.33	HCPCS - Non-Drug
A4802		Protamine sulfate per 50 mg		\$9.67	HCPCS - Non-Drug
A4860		Disposable catheter tips		\$6.71	HCPCS - Non-Drug
A4870		Plumb/elec wk hm hemo equip		\$171.47	HCPCS - Non-Drug
A4890		Repair/maint cont hemo equip		\$171.47	HCPCS - Non-Drug
A4911		Drain bag/bottle		\$19.22	HCPCS - Non-Drug
A4913		Misc dialysis supplies noc		\$15.22	HCPCS - Non-Drug
A4918		Venous pressure clamp		\$1.63	HCPCS - Non-Drug
A4927		Non-sterile gloves		\$7.38	HCPCS - Non-Drug
A4928		Surgical mask		\$0.46	HCPCS - Non-Drug
A4929		Toumiquet for dialysis, ea		\$0.29	HCPCS - Non-Drug
A4930		Sterile, gloves per pair		\$1.72	HCPCS - Non-Drug
A5051		Pouch clsd w barr attached		\$3.39	HCPCS - Non-Drug
A5052		Clsd ostomy pouch w/o barr		\$2.45	HCPCS - Non-Drug
A5053		Clsd ostomy pouch faceplate		\$2.87	HCPCS - Non-Drug
A5054		Clsd ostomy pouch w/flange		\$2.94	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 5 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
A5055		Stoma cap		\$2.36	HCPCS - Non-Drug
A5061		Pouch drainable w barrier at		\$5.77	HCPCS - Non-Drug
A5062		Dmble ostomy pouch w/o barr		\$3.65	HCPCS - Non-Drug
A5063		Drain ostomy pouch w/flange		\$3.66	HCPCS - Non-Drug
A5071		Urinary pouch w/barrier		\$9.88	HCPCS - Non-Drug
A5072		Urinary pouch w/o barrier		\$5.77	HCPCS - Non-Drug
A5073		Urinary pouch on barr w/flng		\$5.22	HCPCS - Non-Drug
A5081		Continent stoma plug		\$5.41	HCPCS - Non-Drug
A5082		Continent stoma catheter		\$19.40	HCPCS - Non-Drug
A5093		Ostomy accessory convex inse		\$3.20	HCPCS - Non-Drug
A5102		Bedside drain btl w/wo tube		\$36.66	HCPCS - Non-Drug
A5105		Urinary suspensory		\$66.05	HCPCS - Non-Drug
A5112		Urinary leg bag		\$56.13	HCPCS - Non-Drug
A5113		Latex leg strap		\$7.73	HCPCS - Non-Drug
A5114		Foam/fabric leg strap		\$14.64	HCPCS - Non-Drug
A5121		Solid skin barrier 6x6		\$12.25	HCPCS - Non-Drug
A5122		Solid skin barrier 8x8		\$20.95	HCPCS - Non-Drug
A5126		Disk/foam pad +or- adhesive		\$2.17	HCPCS - Non-Drug
A5131		Appliance cleaner		\$25.81	HCPCS - Non-Drug
A5200		Percutaneous catheter anchor		\$18.45	HCPCS - Non-Drug
A5500		Diab shoe for density insert		\$106.97	HCPCS - Non-Drug
A5501		Diabetic custom molded shoe		\$318.23	HCPCS - Non-Drug
A5503		Diabetic shoe w/roller/rockr		\$57.47	HCPCS - Non-Drug
A5504		Diabetic shoe with wedge		\$51.15	HCPCS - Non-Drug
A5505		Diab shoe w/metatarsal bar		\$63.09	HCPCS - Non-Drug
A5506		Diabetic shoe w/off set heel		\$51.46	HCPCS - Non-Drug
A5507		Modification diabetic shoe		\$101.96	HCPCS - Non-Drug
A5508		Diabetic deluxe shoe		\$51.19	HCPCS - Non-Drug
A5510		Compression form shoe insert		\$50.46	HCPCS - Non-Drug
A6000		Wound warming wound cover		\$36.33	HCPCS - Non-Drug
A6010		Collagen based wound filler		\$50.22	HCPCS - Non-Drug
A6011		Collagen gel/paste wound fil		\$3.75	HCPCS - Non-Drug
A6021		Collagen dressinq <=16 sq in		\$34.15	HCPCS - Non-Drug
A6022		Collagen drsq>6<=48 sq in		\$34.15	HCPCS - Non-Drug
A6023		Collagen dressinq >48 sq in		\$307.66	HCPCS - Non-Drug
A6024		Collagen dsq wound filler		\$10.17	HCPCS - Non-Drug
A6025		Silicone gel sheet, each		\$50.83	HCPCS - Non-Drug
A6154		Wound pouch each		\$23.42	HCPCS - Non-Drug
A6196		Alginate dressinq <=16 sq in		\$12.05	HCPCS - Non-Drug
A6197		Alginate drsq >16 <=48 sq in		\$26.75	HCPCS - Non-Drug
A6198		alginate dressinq > 48 sq in		\$33.44	HCPCS - Non-Drug
A6199		Alginate drsq wound filler		\$8.69	HCPCS - Non-Drug
A6200		Compos drsq <=16 no border		\$15.54	HCPCS - Non-Drug
A6201		Compos drsq >16<=48 no bdr		\$33.80	HCPCS - Non-Drug
A6202		Compos drsq >48 no border		\$56.54	HCPCS - Non-Drug
A6203		Composite drsq <= 16 sq in		\$5.50	HCPCS - Non-Drug
A6204		Composite drsq >16<=48 sq in		\$10.23	HCPCS - Non-Drug
A6205		Composite drsq > 48 sq in		\$12.79	HCPCS - Non-Drug
A6206		Contact layer <= 16 sq in		\$9.42	HCPCS - Non-Drug
A6207		Contact layer >16<= 48 sq in		\$12.04	HCPCS - Non-Drug
A6208		Contact layer > 48 sq in		\$15.05	HCPCS - Non-Drug
A6209		Foam drsq <=16 sq in w/o bdr		\$12.28	HCPCS - Non-Drug
A6210		Foam drq >16<=48 sq in w/o b		\$32.37	HCPCS - Non-Drug
A6211		Foam drq > 48 sq in w/o brdr		\$47.65	HCPCS - Non-Drug
A6212		Foam drq <=16 sq in w/border		\$15.85	HCPCS - Non-Drug
A6213		Foam drq >16<=48 sq in w/bdr		\$16.81	HCPCS - Non-Drug
A6214		Foam drq > 48 sq in w/border		\$16.81	HCPCS - Non-Drug
A6216		Non-sterile gauze<=16 sq in		\$0.07	HCPCS - Non-Drug
A6217		Non-sterile gauze>16<=48 sq		\$0.72	HCPCS - Non-Drug
A6218		Non-sterile gauze > 48 sq in		\$0.72	HCPCS - Non-Drug
A6219		Gauze <= 16 sq in w/border		\$1.56	HCPCS - Non-Drug
A6220		Gauze >16 <=48 sq in w/border		\$4.23	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE - CHARGES BY HCPCS CODE

PAGE 6 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
A6221		Gauze > 48 sq in w/border		\$5.29	HCPCS - Non-Drug
A6222		Gauze <=16 in no w/sal w/o b		\$3.49	HCPCS - Non-Drug
A6223		Gauze >16<=48 no w/sal w/o b		\$3.97	HCPCS - Non-Drug
A6224		Gauze > 48 in no w/sal w/o b		\$5.93	HCPCS - Non-Drug
A6228		Gauze <= 16 sq in water/sal		\$4.34	HCPCS - Non-Drug
A6229		Gauze >16<=48 sq in watr/sal		\$5.93	HCPCS - Non-Drug
A6230		Gauze > 48 sq in water/saline		\$6.53	HCPCS - Non-Drug
A6231		Hydroqel dsq<=16 sq in		\$7.69	HCPCS - Non-Drug
A6232		Hydroqel dsq>16<=48 sq in		\$11.29	HCPCS - Non-Drug
A6233		Hydroqel dressing >48 sq in		\$31.19	HCPCS - Non-Drug
A6234		Hydrocolld drq <=16 w/o bdr		\$10.74	HCPCS - Non-Drug
A6235		Hydrocolld drq >16<=48 w/o b		\$27.36	HCPCS - Non-Drug
A6236		Hydrocolld drq > 48 in w/o b		\$44.21	HCPCS - Non-Drug
A6237		Hydrocolld drq <=16 in w/bdr		\$12.98	HCPCS - Non-Drug
A6238		Hydrocolld drq >16<=48 w/bdr		\$37.01	HCPCS - Non-Drug
A6239		Hydrocolld drq > 48 in w/bdr		\$46.27	HCPCS - Non-Drug
A6240		Hydrocolld drq filler paste		\$19.97	HCPCS - Non-Drug
A6241		Hydrocolloid drq filler dry		\$4.22	HCPCS - Non-Drug
A6242		Hydroqel drq <=16 in w/o bdr		\$9.97	HCPCS - Non-Drug
A6243		Hydroqel drq >16<=48 w/o bdr		\$20.08	HCPCS - Non-Drug
A6244		Hydroqel drq >48 in w/o bdr		\$63.64	HCPCS - Non-Drug
A6245		Hydroqel drq <= 16 in w/bdr		\$11.93	HCPCS - Non-Drug
A6246		Hydroqel drq >16<=48 in w/b		\$16.21	HCPCS - Non-Drug
A6247		Hydroqel drq > 48 sq in w/b		\$38.61	HCPCS - Non-Drug
A6248		Hydroqel drsq gel filler		\$26.43	HCPCS - Non-Drug
A6250		Skin seal protect moisturizr		\$2.50	HCPCS - Non-Drug
A6251		Absorpt drq <=16 sq in w/o b		\$3.26	HCPCS - Non-Drug
A6252		Absorpt drq >16 <=48 w/o bdr		\$5.34	HCPCS - Non-Drug
A6253		Absorpt drq > 48 sq in w/o b		\$10.40	HCPCS - Non-Drug
A6254		Absorpt drq <=16 sq in w/bdr		\$1.99	HCPCS - Non-Drug
A6255		Absorpt drq >16<=48 in w/bdr		\$4.98	HCPCS - Non-Drug
A6256		Absorpt drq > 48 sq in w/bdr		\$6.21	HCPCS - Non-Drug
A6257		Transparent film <= 16 sq in		\$2.50	HCPCS - Non-Drug
A6258		Transparent film >16<=48 in		\$7.06	HCPCS - Non-Drug
A6259		Transparent film > 48 sq in		\$17.86	HCPCS - Non-Drug
A6260		Wound cleanser any type/size		\$2.17	HCPCS - Non-Drug
A6261		Wound filler gel/paste /oz		\$8.70	HCPCS - Non-Drug
A6262		Wound filler dry form / gram		\$2.17	HCPCS - Non-Drug
A6266		Impreg gauze no h20/sal/yard		\$3.15	HCPCS - Non-Drug
A6402		Sterile gauze <= 16 sq in		\$0.18	HCPCS - Non-Drug
A6403		Sterile gauze>16 <= 48 sq in		\$0.71	HCPCS - Non-Drug
A6404		Sterile gauze > 48 sq in		\$1.44	HCPCS - Non-Drug
A6410		Sterile eye pad		\$0.64	HCPCS - Non-Drug
A6411		Non-sterile eye pad		\$0.72	HCPCS - Non-Drug
A6412		Occlusive eye patch		\$0.72	HCPCS - Non-Drug
A6441		Pad band w>=3' <5'/yd		\$0.72	HCPCS - Non-Drug
A6442		Conform band n/s w<3'/yd		\$0.18	HCPCS - Non-Drug
A6443		Conform band n/s w>=3' <5'/yd		\$0.31	HCPCS - Non-Drug
A6444		Conform band n/s w>=5'/yd		\$0.60	HCPCS - Non-Drug
A6445		Conform band s w <3'/yd		\$0.34	HCPCS - Non-Drug
A6446		Conform band s w>=3' <5'/yd		\$0.44	HCPCS - Non-Drug
A6447		Conform band s w >=5'/yd		\$0.72	HCPCS - Non-Drug
A6448		Lt compres band <3'/yd		\$1.24	HCPCS - Non-Drug
A6449		Lt compres band >=3' <5'/yd		\$1.87	HCPCS - Non-Drug
A6452		High compres band w>=3' <5'/yd		\$6.32	HCPCS - Non-Drug
A6453		Self-adher band w <3'/yd		\$0.65	HCPCS - Non-Drug
A6454		Self-adher band w>=3' <5'/yd		\$0.82	HCPCS - Non-Drug
A6455		Self-adher band >=5'/yd		\$1.49	HCPCS - Non-Drug
A6456		Zinc paste band w >=3' <5'/yd		\$1.37	HCPCS - Non-Drug
A6550		Neq pres wound ther drsq set		\$45.65	HCPCS - Non-Drug
A7000		Disposable canister for pump	a	\$18.68	HCPCS - Non-Drug
A7001		Nondisposable pump canister		\$54.15	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 7 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
A7002		Tubing used w suction pump	a	\$10.07	HCPCS - Non-Drug
A7003		Nebulizer administration set		\$8.43	HCPCS - Non-Drug
A7004		Disposable nebulizer sml vol		\$7.01	HCPCS - Non-Drug
A7005		Nondisposable nebulizer set		\$50.78	HCPCS - Non-Drug
A7006		Filtered nebulizer admin set		\$18.68	HCPCS - Non-Drug
A7007		Lq vol nebulizer disposable		\$11.26	HCPCS - Non-Drug
A7008		Disposable nebulizer refill		\$20.88	HCPCS - Non-Drug
A7009		Nebulizer reservoir bottle		\$69.68	HCPCS - Non-Drug
A7010		Disposable corrugated tubing		\$39.87	HCPCS - Non-Drug
A7011		Nondispos corrugated tubing		\$61.12	HCPCS - Non-Drug
A7012		Nebulizer water collec devic		\$9.99	HCPCS - Non-Drug
A7013		Disposable compressor filter		\$3.69	HCPCS - Non-Drug
A7014		Compressor nondispos filter		\$11.06	HCPCS - Non-Drug
A7015		Aerosol mask used w nebulize	a	\$7.14	HCPCS - Non-Drug
A7016		Nebulizer dome & mouthpiece		\$15.23	HCPCS - Non-Drug
A7017		Nebulizer not used w oxygen		\$181.19	HCPCS - Non-Drug
A7018		Water distilled w/nebulizer		\$1.69	HCPCS - Non-Drug
A7025		Replace chest compress vest		\$818.91	HCPCS - Non-Drug
A7026		Replace chst cmprss sys hose		\$47.64	HCPCS - Non-Drug
A7030		CPAP full face mask		\$349.24	HCPCS - Non-Drug
A7031		Replacement facemask interfa		\$122.58	HCPCS - Non-Drug
A7032	NU	Replacement nasal cushion		\$66.80	HCPCS - Non-Drug
A7033	NU	Replacement nasal pillows		\$47.13	HCPCS - Non-Drug
A7034	NU	Nasal application device		\$213.85	HCPCS - Non-Drug
A7035	NU	Pos airway press headgear		\$65.31	HCPCS - Non-Drug
A7036	NU	Pos airway press chinstrap		\$31.74	HCPCS - Non-Drug
A7037	NU	Pos airway pressure tubing		\$67.73	HCPCS - Non-Drug
A7038	NU	Pos airway pressure filter		\$12.42	HCPCS - Non-Drug
A7039	NU	Filter, non disposable w nap		\$27.41	HCPCS - Non-Drug
A7040		One way chest drain valve		\$48.15	HCPCS - Non-Drug
A7041		Water seal drain container		\$90.47	HCPCS - Non-Drug
A7042		Implanted pleural catheter		\$329.93	HCPCS - Non-Drug
A7043		Vacuum drainagebottle/tubing		\$47.40	HCPCS - Non-Drug
A7044	NU	PAP oral interface		\$220.09	HCPCS - Non-Drug
A7045		Repl exhalation port for PAP		\$2.09	HCPCS - Non-Drug
A7046	NU	Repl water chamber, PAP dev		\$20.88	HCPCS - Non-Drug
A7501		Tracheostoma valve w diaphra		\$169.89	HCPCS - Non-Drug
A7502		Replacement diaphragm/plate		\$80.83	HCPCS - Non-Drug
A7503		HMES filter holder or cap		\$18.50	HCPCS - Non-Drug
A7504		Tracheostoma HMES filter		\$1.09	HCPCS - Non-Drug
A7505		HMES or trach valve housing		\$7.69	HCPCS - Non-Drug
A7506		HMES/trachvalve adhesivedisk		\$0.55	HCPCS - Non-Drug
A7507		Integrated filter & holder		\$4.09	HCPCS - Non-Drug
A7508		Housing & Integrated Adhesiv		\$4.71	HCPCS - Non-Drug
A7509		Heat & moisture exchange sys		\$2.31	HCPCS - Non-Drug
A7520		Trach/laryn tube non-cuffed		\$50.80	HCPCS - Non-Drug
A7521		Trach/laryn tube cuffed		\$50.34	HCPCS - Non-Drug
A7522		Trach/laryn tube stainless		\$48.32	HCPCS - Non-Drug
A7523		Tracheostomy shower protect		\$22.86	HCPCS - Non-Drug
A7524		Tracheostoma stent/stud/btn		\$82.82	HCPCS - Non-Drug
A7525		Tracheostomy mask		\$3.04	HCPCS - Non-Drug
A7526		Tracheostomy tube collar		\$3.61	HCPCS - Non-Drug
A7527		Trach/laryn tube plug/stop		\$3.83	HCPCS - Non-Drug
A9150		Misc/exper non-prescript dru		\$10.36	HCPCS - Drug
A9270		Non-covered item or service	a	\$45.57	HCPCS - Non-Drug
A9280		Alert device, noc		\$303.85	HCPCS - Non-Drug
A9300		Exercise equipment	a	\$5.82	HCPCS - Non-Drug
A9500		Technetium TC 99m sestamibi	a	\$157.46	HCPCS - Non-Drug
A9502		Technetium TC99M tetrofosmin	a	\$176.50	HCPCS - Non-Drug
A9503		Technetium TC 99m medronate		\$40.94	HCPCS - Non-Drug
A9504		Technetium tc 99m apcitide		\$73.08	HCPCS - Non-Drug
A9505		Thallous chloride TL 201/mci	a	\$69.10	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 8 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
A9507		Iodium/111 capromab pendetid	a	\$2,966.31	HCPCS - Non-Drug
A9508		Iobenquane sulfate I-131	a	\$33.82	HCPCS - Non-Drug
A9510		Technetium TC99m Disofenin		\$117.25	HCPCS - Non-Drug
A9600		Strontium-89 chloride	a	\$1,080.65	HCPCS - Non-Drug
A9605		Samarium sm153 leixidronamm	a	\$535.20	HCPCS - Non-Drug
A9700		Echocardiography Contrast		\$213.88	HCPCS - Non-Drug
A9900		Supply/accessory/service		\$23.47	HCPCS - Non-Drug
A9901		Delivery/set up/dispensing		\$19.44	HCPCS - Non-Drug
B4034		Enter feed supkit syr by day		\$9.84	HCPCS - Non-Drug
B4035		Enteral feed supp pump per d		\$19.10	HCPCS - Non-Drug
B4036		Enteral feed sup kit grav by		\$12.86	HCPCS - Non-Drug
B4081		Enteral nq tubing w/ stylet		\$38.22	HCPCS - Non-Drug
B4082		Enteral nq tubing w/o stylet		\$27.61	HCPCS - Non-Drug
B4083		Enteral stomach tube levine		\$3.97	HCPCS - Non-Drug
B4086		Gastrostomy/jejunostomy tube		\$65.27	HCPCS - Non-Drug
B4149		EF blenderized foods		\$1.64	HCPCS - Non-Drug
B4150		Enteral formulae category i		\$1.09	HCPCS - Non-Drug
B4152		Enteral formulae category ii		\$0.93	HCPCS - Non-Drug
B4153		Enteral formulae category iii		\$3.08	HCPCS - Non-Drug
B4154		Enteral formulae category IV		\$1.98	HCPCS - Non-Drug
B4155		Enteral formulae category v		\$1.55	HCPCS - Non-Drug
B4164		Parenteral 50% dextrose solu		\$28.37	HCPCS - Non-Drug
B4168		Parenteral sol amino acid 3.		\$42.80	HCPCS - Non-Drug
B4172		Parenteral sol amino acid 5.		\$64.39	HCPCS - Non-Drug
B4176		Parenteral sol amino acid 7.		\$85.97	HCPCS - Non-Drug
B4178		Parenteral sol amino acid >		\$103.89	HCPCS - Non-Drug
B4180		Parenteral sol carb > 50%		\$42.07	HCPCS - Non-Drug
B4189		Parenteral sol amino acid &		\$327.89	HCPCS - Non-Drug
B4193		Parenteral sol 52-73 gm prot		\$424.69	HCPCS - Non-Drug
B4197		Parenteral sol 74-100 gm pro		\$517.75	HCPCS - Non-Drug
B4199		Parenteral sol > 100gm prote		\$592.13	HCPCS - Non-Drug
B4216		Parenteral nutrition additiv		\$12.06	HCPCS - Non-Drug
B4220		Parenteral supply kit premix		\$12.49	HCPCS - Non-Drug
B4222		Parenteral supply kit homemi		\$15.40	HCPCS - Non-Drug
B4224		Parenteral administration ki		\$43.27	HCPCS - Non-Drug
B5000		Parenteral sol renal-amirosy		\$18.81	HCPCS - Non-Drug
B5100		Parenteral sol hepatic-fream		\$7.27	HCPCS - Non-Drug
B5200		Parenteral sol stres-bmch c		\$582.82	HCPCS - Non-Drug
B9000	NU	Enter infusion pump w/o alm		\$2,353.86	HCPCS - Non-Drug
B9000	RR	Enter infusion pump w/o alm		\$213.27	HCPCS - Non-Drug
B9000	UE	Enter infusion pump w/o alm		\$1,764.57	HCPCS - Non-Drug
B9002	NU	Enteral infusion pump w/ ala		\$2,353.86	HCPCS - Non-Drug
B9002	RR	Enteral infusion pump w/ ala		\$224.97	HCPCS - Non-Drug
B9004	NU	Parenteral infus pump portab		\$4,698.62	HCPCS - Non-Drug
B9004	RR	Parenteral infus pump portab		\$741.03	HCPCS - Non-Drug
B9004	UE	Parenteral infus pump portab		\$3,523.11	HCPCS - Non-Drug
B9006	NU	Parenteral infus pump statio		\$4,698.62	HCPCS - Non-Drug
B9006	RR	Parenteral infus pump statio		\$741.03	HCPCS - Non-Drug
B9006	UE	Parenteral infus pump statio		\$3,523.11	HCPCS - Non-Drug
B9998		Enteral supp not otherwise c		\$9.66	HCPCS - Non-Drug
B9999		Parenteral supp not othrws c		\$288.42	HCPCS - Non-Drug
E0100	NU	Cane adjust/fixd with tip		\$36.06	HCPCS - Non-Drug
E0100	RR	Cane adjust/fixd with tip		\$13.25	HCPCS - Non-Drug
E0100	UE	Cane adjust/fixd with tip		\$29.62	HCPCS - Non-Drug
E0105	NU	Cane adjust/fixd quad/3 pro		\$83.16	HCPCS - Non-Drug
E0105	RR	Cane adjust/fixd quad/3 pro		\$17.67	HCPCS - Non-Drug
E0105	UE	Cane adjust/fixd quad/3 pro		\$61.73	HCPCS - Non-Drug
E0110	NU	Crutch forearm pair		\$137.47	HCPCS - Non-Drug
E0110	RR	Crutch forearm pair		\$28.42	HCPCS - Non-Drug
E0110	UE	Crutch forearm pair		\$100.46	HCPCS - Non-Drug
E0111	NU	Crutch forearm each		\$91.08	HCPCS - Non-Drug
E0111	RR	Crutch forearm each		\$17.01	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 9 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
E0111	UE	Crutch forearm each		\$67.88	HCPCS - Non-Drug
E0112	NU	Crutch underarm pair wood		\$60.07	HCPCS - Non-Drug
E0112	RR	Crutch underarm pair wood		\$19.27	HCPCS - Non-Drug
E0112	UE	Crutch underarm pair wood		\$46.84	HCPCS - Non-Drug
E0113	NU	Crutch underarm each wood		\$36.14	HCPCS - Non-Drug
E0113	RR	Crutch underarm each wood		\$12.07	HCPCS - Non-Drug
E0113	UE	Crutch underarm each wood		\$28.21	HCPCS - Non-Drug
E0114	NU	Crutch underarm pair no wood		\$79.50	HCPCS - Non-Drug
E0114	RR	Crutch underarm pair no wood		\$17.22	HCPCS - Non-Drug
E0114	UE	Crutch underarm pair no wood		\$58.08	HCPCS - Non-Drug
E0116	NU	Crutch underarm each no wood		\$46.12	HCPCS - Non-Drug
E0116	RR	Crutch underarm each no wood		\$12.43	HCPCS - Non-Drug
E0116	UE	Crutch underarm each no wood		\$35.78	HCPCS - Non-Drug
E0117	NU	Underarm springassist crutch		\$357.01	HCPCS - Non-Drug
E0117	RR	Underarm springassist crutch		\$33.33	HCPCS - Non-Drug
E0117	UE	Underarm springassist crutch		\$265.18	HCPCS - Non-Drug
E0130	NU	Walker rigid adjust/fixd ht		\$123.42	HCPCS - Non-Drug
E0130	RR	Walker rigid adjust/fixd ht		\$29.65	HCPCS - Non-Drug
E0130	UE	Walker rigid adjust/fixd ht		\$93.88	HCPCS - Non-Drug
E0135	NU	Walker folding adjust/fixd		\$149.39	HCPCS - Non-Drug
E0135	RR	Walker folding adjust/fixd		\$30.31	HCPCS - Non-Drug
E0135	UE	Walker folding adjust/fixd		\$112.17	HCPCS - Non-Drug
E0140	NU	Walker w trunk support		\$385.96	HCPCS - Non-Drug
E0140	RR	Walker w trunk support		\$385.96	HCPCS - Non-Drug
E0140	UE	Walker w trunk support		\$385.96	HCPCS - Non-Drug
E0141	NU	Rigid wheeled walker adj/fix		\$209.36	HCPCS - Non-Drug
E0141	RR	Rigid wheeled walker adj/fix		\$38.01	HCPCS - Non-Drug
E0141	UE	Rigid wheeled walker adj/fix		\$154.42	HCPCS - Non-Drug
E0143	NU	Walker folding wheeled w/o s		\$218.78	HCPCS - Non-Drug
E0143	RR	Walker folding wheeled w/o s		\$36.84	HCPCS - Non-Drug
E0143	UE	Walker folding wheeled w/o s		\$161.11	HCPCS - Non-Drug
E0144	NU	Enclosed walker w rear seat		\$596.78	HCPCS - Non-Drug
E0144	RR	Enclosed walker w rear seat		\$52.33	HCPCS - Non-Drug
E0144	UE	Enclosed walker w rear seat		\$444.96	HCPCS - Non-Drug
E0147	NU	Walker variable wheel resist		\$1,085.64	HCPCS - Non-Drug
E0147	RR	Walker variable wheel resist		\$99.14	HCPCS - Non-Drug
E0147	UE	Walker variable wheel resist		\$811.65	HCPCS - Non-Drug
E0148	NU	Heavyduty walker no wheels		\$231.80	HCPCS - Non-Drug
E0148	RR	Heavyduty walker no wheels		\$23.48	HCPCS - Non-Drug
E0148	UE	Heavyduty walker no wheels		\$171.21	HCPCS - Non-Drug
E0149	NU	Heavy duty wheeled walker		\$415.15	HCPCS - Non-Drug
E0149	RR	Heavy duty wheeled walker		\$37.95	HCPCS - Non-Drug
E0149	UE	Heavy duty wheeled walker		\$308.73	HCPCS - Non-Drug
E0153	NU	Forearm crutch platform atta		\$121.82	HCPCS - Non-Drug
E0153	RR	Forearm crutch platform atta		\$16.11	HCPCS - Non-Drug
E0153	UE	Forearm crutch platform atta		\$88.74	HCPCS - Non-Drug
E0154	NU	Walker platform attachment		\$123.97	HCPCS - Non-Drug
E0154	RR	Walker platform attachment		\$17.21	HCPCS - Non-Drug
E0154	UE	Walker platform attachment		\$91.66	HCPCS - Non-Drug
E0155	NU	Walker wheel attachment,pair		\$51.87	HCPCS - Non-Drug
E0155	RR	Walker wheel attachment,pair		\$10.10	HCPCS - Non-Drug
E0155	UE	Walker wheel attachment,pair		\$40.56	HCPCS - Non-Drug
E0156	NU	Walker seat attachment		\$44.15	HCPCS - Non-Drug
E0156	RR	Walker seat attachment		\$9.39	HCPCS - Non-Drug
E0156	UE	Walker seat attachment		\$34.23	HCPCS - Non-Drug
E0157	NU	Walker crutch attachment		\$145.73	HCPCS - Non-Drug
E0157	RR	Walker crutch attachment		\$17.85	HCPCS - Non-Drug
E0157	UE	Walker crutch attachment		\$106.70	HCPCS - Non-Drug
E0158	NU	Walker leg extenders set of4		\$52.82	HCPCS - Non-Drug
E0158	RR	Walker leg extenders set of4		\$9.65	HCPCS - Non-Drug
E0158	UE	Walker leg extenders set of4		\$40.92	HCPCS - Non-Drug
E0159	NU	Brake for wheeled walker		\$31.24	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE - CHARGES BY HCPCS CODE

PAGE 10 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
E0159	RR	Brake for wheeled walker		\$7.09	HCPCS - Non-Drug
E0159	UE	Brake for wheeled walker		\$24.49	HCPCS - Non-Drug
E0160	NU	Sitz type bath or equipment		\$54.13	HCPCS - Non-Drug
E0160	RR	Sitz type bath or equipment		\$10.83	HCPCS - Non-Drug
E0160	UE	Sitz type bath or equipment		\$41.63	HCPCS - Non-Drug
E0161	NU	Sitz bath/equipment w/faucet		\$43.84	HCPCS - Non-Drug
E0161	RR	Sitz bath/equipment w/faucet		\$9.68	HCPCS - Non-Drug
E0161	UE	Sitz bath/equipment w/faucet		\$33.90	HCPCS - Non-Drug
E0162	NU	Sitz bath chair		\$267.36	HCPCS - Non-Drug
E0162	RR	Sitz bath chair		\$27.35	HCPCS - Non-Drug
E0162	UE	Sitz bath chair		\$204.99	HCPCS - Non-Drug
E0163	NU	Commode chair stationry fxd		\$199.83	HCPCS - Non-Drug
E0163	RR	Commode chair stationry fxd		\$41.12	HCPCS - Non-Drug
E0163	UE	Commode chair stationry fxd		\$151.72	HCPCS - Non-Drug
E0164	NU	Commode chair mobile fixed a		\$335.43	HCPCS - Non-Drug
E0164	RR	Commode chair mobile fixed a		\$44.15	HCPCS - Non-Drug
E0164	UE	Commode chair mobile fixed a		\$248.97	HCPCS - Non-Drug
E0166	NU	Commode chair mobile detach		\$427.47	HCPCS - Non-Drug
E0166	RR	Commode chair mobile detach		\$51.23	HCPCS - Non-Drug
E0166	UE	Commode chair mobile detach		\$341.06	HCPCS - Non-Drug
E0167	NU	Commode chair pail or pan		\$22.38	HCPCS - Non-Drug
E0167	RR	Commode chair pail or pan		\$5.61	HCPCS - Non-Drug
E0167	UE	Commode chair pail or pan		\$17.92	HCPCS - Non-Drug
E0168	NU	Heavyduty/wide commode chair		\$277.31	HCPCS - Non-Drug
E0168	RR	Heavyduty/wide commode chair		\$27.17	HCPCS - Non-Drug
E0168	UE	Heavyduty/wide commode chair		\$205.35	HCPCS - Non-Drug
E0175		Commode chair foot rest		\$82.44	HCPCS - Non-Drug
E0180		Press pad alternating w pump		\$336.35	HCPCS - Non-Drug
E0181		Press pad alternating w/ pum		\$441.75	HCPCS - Non-Drug
E0182		Pressure pad alternating pum		\$455.01	HCPCS - Non-Drug
E0184		Dry pressure mattress		\$274.26	HCPCS - Non-Drug
E0185		Gel pressure mattress pad		\$457.65	HCPCS - Non-Drug
E0186		Air pressure mattress		\$409.18	HCPCS - Non-Drug
E0187		Water pressure mattress		\$335.61	HCPCS - Non-Drug
E0188		Synthetic sheepskin pad		\$42.90	HCPCS - Non-Drug
E0189		Lambswool sheepskin pad		\$84.13	HCPCS - Non-Drug
E0190		Positioning cushion		\$168.84	HCPCS - Non-Drug
E0191		Protector heel or elbow		\$19.36	HCPCS - Non-Drug
E0193	RR	Powered air flotation bed		\$1,387.47	HCPCS - Non-Drug
E0194	RR	Air fluidized bed		\$4,963.87	HCPCS - Non-Drug
E0194	UE	Air fluidized bed		\$36,115.71	HCPCS - Non-Drug
E0194		Air fluidized bed		\$48,140.76	HCPCS - Non-Drug
E0196	RR	Gel pressure mattress		\$56.14	HCPCS - Non-Drug
E0196	UE	Gel pressure mattress		\$422.65	HCPCS - Non-Drug
E0196		Gel pressure mattress		\$563.80	HCPCS - Non-Drug
E0197		Air pressure pad for mattres		\$360.69	HCPCS - Non-Drug
E0198		Water pressure pad for mattre		\$310.15	HCPCS - Non-Drug
E0199		Dry pressure pad for mattres		\$40.53	HCPCS - Non-Drug
E0200		Heat lamp without stand		\$102.97	HCPCS - Non-Drug
E0202	RR	Phototherapy light w/ photom		\$108.89	HCPCS - Non-Drug
E0203		Therapeutic lightbox tabletp		\$562.16	HCPCS - Non-Drug
E0205		Heat lamp with stand		\$267.05	HCPCS - Non-Drug
E0210		Electric heat pad standard		\$41.20	HCPCS - Non-Drug
E0215		Electric heat pad moist		\$90.86	HCPCS - Non-Drug
E0217		Water circ heat pad w pump		\$699.51	HCPCS - Non-Drug
E0218		Water circ cold pad w pump		\$687.04	HCPCS - Non-Drug
E0220		Hot water bottle		\$13.85	HCPCS - Non-Drug
E0221		Infrared heating pad system		\$3,012.22	HCPCS - Non-Drug
E0225		Hydrocollator unit		\$545.35	HCPCS - Non-Drug
E0230		Ice cap or collar		\$13.86	HCPCS - Non-Drug
E0231	RR	Wound warming device		\$17.19	HCPCS - Non-Drug
E0231		Wound warming device		\$166.76	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 11 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
E0235	RR	Paraffin bath unit portable		\$30.31	HCPCS - Non-Drug
E0235	UE	Paraffin bath unit portable		\$228.85	HCPCS - Non-Drug
E0235		Paraffin bath unit portable		\$304.93	HCPCS - Non-Drug
E0236	RR	Pump for water circulating p		\$73.89	HCPCS - Non-Drug
E0236	UE	Pump for water circulating p		\$305.75	HCPCS - Non-Drug
E0236		Pump for water circulating p		\$381.90	HCPCS - Non-Drug
E0238		Heat pad non-electric moist		\$45.06	HCPCS - Non-Drug
E0239		Hydrocollator unit portable		\$632.92	HCPCS - Non-Drug
E0240		Bath/shower chair		\$106.95	HCPCS - Non-Drug
E0241		Bath tub wall rail		\$42.96	HCPCS - Non-Drug
E0242		Bath tub rail floor		\$99.34	HCPCS - Non-Drug
E0243		Toilet rail		\$77.03	HCPCS - Non-Drug
E0244		Toilet seat raised		\$56.53	HCPCS - Non-Drug
E0245		Tub stool or bench		\$98.47	HCPCS - Non-Drug
E0246		Transfer tub rail attachment		\$138.80	HCPCS - Non-Drug
E0247		Trans bench w/wo comm open		\$96.76	HCPCS - Non-Drug
E0248		HDtrans bench w/wo comm open		\$164.72	HCPCS - Non-Drug
E0249		Pad water circulating heat u		\$179.45	HCPCS - Non-Drug
E0250	RR	Hosp bed fixed ht w/ mattres		\$161.75	HCPCS - Non-Drug
E0250	UE	Hosp bed fixed ht w/ mattres		\$1,396.16	HCPCS - Non-Drug
E0250		Hosp bed fixed ht w/ mattres		\$2,155.73	HCPCS - Non-Drug
E0251	RR	Hosp bed fixed ht w/o mattres		\$124.52	HCPCS - Non-Drug
E0251	UE	Hosp bed fixed ht w/o mattres		\$999.27	HCPCS - Non-Drug
E0251		Hosp bed fixed ht w/o mattres		\$1,249.09	HCPCS - Non-Drug
E0255	RR	Hospital bed var ht w/ matr		\$191.77	HCPCS - Non-Drug
E0255	UE	Hospital bed var ht w/ matr		\$1,644.93	HCPCS - Non-Drug
E0255		Hospital bed var ht w/ matr		\$2,196.89	HCPCS - Non-Drug
E0256	RR	Hospital bed var ht w/o matt		\$139.75	HCPCS - Non-Drug
E0256	UE	Hospital bed var ht w/o matt		\$1,116.47	HCPCS - Non-Drug
E0256		Hospital bed var ht w/o matt		\$1,395.98	HCPCS - Non-Drug
E0260	RR	Hosp bed semi-elect w/ matt		\$268.52	HCPCS - Non-Drug
E0260	UE	Hosp bed semi-elect w/ matt		\$1,683.43	HCPCS - Non-Drug
E0260		Hosp bed semi-elect w/ matt		\$2,179.41	HCPCS - Non-Drug
E0261	RR	Hosp bed semi-elect w/o mat		\$221.37	HCPCS - Non-Drug
E0261	UE	Hosp bed semi-elect w/o mat		\$1,417.94	HCPCS - Non-Drug
E0261		Hosp bed semi-elect w/o mat		\$2,126.90	HCPCS - Non-Drug
E0265	RR	Hosp bed total electr w/ mat		\$317.13	HCPCS - Non-Drug
E0265	UE	Hosp bed total electr w/ mat		\$1,705.92	HCPCS - Non-Drug
E0265		Hosp bed total electr w/ mat		\$2,635.34	HCPCS - Non-Drug
E0266	RR	Hosp bed total elec w/o matt		\$283.20	HCPCS - Non-Drug
E0266	UE	Hosp bed total elec w/o matt		\$1,945.01	HCPCS - Non-Drug
E0266		Hosp bed total elec w/o matt		\$2,829.11	HCPCS - Non-Drug
E0270	RR	Hospital bed institutional t		\$60.25	HCPCS - Non-Drug
E0270	UE	Hospital bed institutional t		\$438.37	HCPCS - Non-Drug
E0270		Hospital bed institutional t		\$584.32	HCPCS - Non-Drug
E0271		Mattress innerspring		\$276.92	HCPCS - Non-Drug
E0272		Mattress foam rubber		\$242.83	HCPCS - Non-Drug
E0273	RR	Bed board		\$19.78	HCPCS - Non-Drug
E0273	UE	Bed board		\$36.83	HCPCS - Non-Drug
E0273		Bed board		\$46.06	HCPCS - Non-Drug
E0274	RR	Over-bed table		\$33.28	HCPCS - Non-Drug
E0274	UE	Over-bed table		\$59.53	HCPCS - Non-Drug
E0274		Over-bed table		\$73.03	HCPCS - Non-Drug
E0275		Bed pan standard		\$21.61	HCPCS - Non-Drug
E0276		Bed pan fracture		\$20.16	HCPCS - Non-Drug
E0277	RR	Powered pres-redu air mattrs		\$1,168.26	HCPCS - Non-Drug
E0277	UE	Powered pres-redu air mattrs		\$8,499.91	HCPCS - Non-Drug
E0277		Powered pres-redu air mattrs		\$11,330.03	HCPCS - Non-Drug
E0280		Bed cradle		\$49.84	HCPCS - Non-Drug
E0290	RR	Hosp bed fx ht w/o rails w/m		\$125.60	HCPCS - Non-Drug
E0290	UE	Hosp bed fx ht w/o rails w/m		\$1,033.90	HCPCS - Non-Drug
E0290		Hosp bed fx ht w/o rails w/m		\$1,292.00	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 12 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAF Category
E0291	RR	Hosp bed fx ht w/o rail w/o		\$92.00	HCPCS - Non-Drug
E0291	UE	Hosp bed fx ht w/o rail w/o		\$678.22	HCPCS - Non-Drug
E0291		Hosp bed fx ht w/o rail w/o		\$916.20	HCPCS - Non-Drug
E0292	RR	Hosp bed var ht w/o rail w/o		\$140.88	HCPCS - Non-Drug
E0292	UE	Hosp bed var ht w/o rail w/o		\$1,127.80	HCPCS - Non-Drug
E0292		Hosp bed var ht w/o rail w/o		\$1,410.33	HCPCS - Non-Drug
E0293	RR	Hosp bed var ht w/o rail w/		\$120.29	HCPCS - Non-Drug
E0293	UE	Hosp bed var ht w/o rail w/		\$877.25	HCPCS - Non-Drug
E0293		Hosp bed var ht w/o rail w/		\$1,200.58	HCPCS - Non-Drug
E0294	RR	Hosp bed semi-elect w/ matr		\$211.79	HCPCS - Non-Drug
E0294	UE	Hosp bed semi-elect w/ matr		\$1,412.90	HCPCS - Non-Drug
E0294		Hosp bed semi-elect w/ matr		\$2,055.59	HCPCS - Non-Drug
E0295	RR	Hosp bed semi-elect w/o matt		\$206.77	HCPCS - Non-Drug
E0295	UE	Hosp bed semi-elect w/o matt		\$1,228.23	HCPCS - Non-Drug
E0295		Hosp bed semi-elect w/o matt		\$1,892.95	HCPCS - Non-Drug
E0296	RR	Hosp bed total elect w/ matt		\$262.83	HCPCS - Non-Drug
E0296	UE	Hosp bed total elect w/ matt		\$2,100.48	HCPCS - Non-Drug
E0296		Hosp bed total elect w/ matt		\$2,626.15	HCPCS - Non-Drug
E0297	RR	Hosp bed total elect w/o mat		\$227.02	HCPCS - Non-Drug
E0297	UE	Hosp bed total elect w/o mat		\$1,520.21	HCPCS - Non-Drug
E0297		Hosp bed total elect w/o mat		\$2,271.06	HCPCS - Non-Drug
E0300		Enclosed ped crib hosp grade		\$284.93	HCPCS - Non-Drug
E0301		HD hosp bed, 350-600 lbs		\$3,418.16	HCPCS - Non-Drug
E0302		Ex hd hosp bed > 600 lbs		\$765.52	HCPCS - Non-Drug
E0303		Hosp bed hvy dty xtra wide		\$475.48	HCPCS - Non-Drug
E0304		Hosp bed xtra hvy dty x wide		\$1,185.45	HCPCS - Non-Drug
E0305	RR	Rails bed side half length		\$31.97	HCPCS - Non-Drug
E0305	UE	Rails bed side half length		\$227.15	HCPCS - Non-Drug
E0305		Rails bed side half length		\$316.53	HCPCS - Non-Drug
E0310		Rails bed side full length		\$236.54	HCPCS - Non-Drug
E0315		Bed accessory brd/tbl/supprt		\$55.69	HCPCS - Non-Drug
E0316		Bed safety enclosure		\$334.46	HCPCS - Non-Drug
E0325		Urinal male iug-type		\$14.39	HCPCS - Non-Drug
E0326		Urinal female iug-type		\$16.17	HCPCS - Non-Drug
E0352		Disposable pack w/bowel syst		\$66.83	HCPCS - Non-Drug
E0370		Air elevator for heel		\$23.25	HCPCS - Non-Drug
E0371		Nonpower mattress overlay		\$837.10	HCPCS - Non-Drug
E0372		Powered air mattress overlay		\$1,018.02	HCPCS - Non-Drug
E0373		Nonpowered pressure mattress		\$1,161.27	HCPCS - Non-Drug
E0424	RR	Stationary compressed gas O2		\$554.68	HCPCS - Non-Drug
E0425	NU	Gas system stationary compre		\$7,565.58	HCPCS - Non-Drug
E0430	NU	Oxygen system gas portable		\$3,427.95	HCPCS - Non-Drug
E0430	UE	Oxygen system gas portable		\$2,572.60	HCPCS - Non-Drug
E0431	RR	Portable gaseous O2		\$91.07	HCPCS - Non-Drug
E0434		Portable liquid O2		\$91.07	HCPCS - Non-Drug
E0435	NU	Oxygen system liquid portabl		\$2,358.53	HCPCS - Non-Drug
E0435	UE	Oxygen system liquid portabl		\$1,769.53	HCPCS - Non-Drug
E0439	RR	Stationary liquid O2		\$554.68	HCPCS - Non-Drug
E0440	NU	Oxygen system liquid station		\$4,783.48	HCPCS - Non-Drug
E0440	UE	Oxygen system liquid station		\$3,588.77	HCPCS - Non-Drug
E0441		Oxygen contents, gaseous		\$396.44	HCPCS - Non-Drug
E0442		Oxygen contents, liquid		\$396.44	HCPCS - Non-Drug
E0443		Portable O2 contents, gas		\$54.00	HCPCS - Non-Drug
E0444		Portable O2 contents, liquid		\$54.00	HCPCS - Non-Drug
E0445		Oximeter non-invasive		\$130.42	HCPCS - Non-Drug
E0450	NU	Volume vent stationary/porta		\$17,551.15	HCPCS - Non-Drug
E0450	RR	Volume vent stationary/porta		\$1,809.72	HCPCS - Non-Drug
E0450	UE	Volume vent stationary/porta		\$13,167.06	HCPCS - Non-Drug
E0457	NU	Chest shell		\$1,161.34	HCPCS - Non-Drug
E0457	RR	Chest shell		\$106.70	HCPCS - Non-Drug
E0457	UE	Chest shell		\$868.34	HCPCS - Non-Drug
E0459	NU	Chest wrap		\$862.94	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 13 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
E0459	RR	Chest wrap		\$86.56	HCPCS - Non-Drug
E0459	UE	Chest wrap		\$647.54	HCPCS - Non-Drug
E0460	NU	Neg press vent portabl/statn		\$13,464.89	HCPCS - Non-Drug
E0460	RR	Neg press vent portabl/statn		\$1,388.39	HCPCS - Non-Drug
E0460	UE	Neg press vent portabl/statn		\$10,101.51	HCPCS - Non-Drug
E0461	RR	Vol vent noninvasive interfa		\$1,900.36	HCPCS - Non-Drug
E0462	NU	Rocking bed w/ or w/o side r		\$4,561.59	HCPCS - Non-Drug
E0462	RR	Rocking bed w/ or w/o side.r		\$456.34	HCPCS - Non-Drug
E0462	UE	Rocking bed,w/ or w/o side r		\$3,421.65	HCPCS - Non-Drug
E0463	RR	Press supp vent invasive int		\$1,504.83	HCPCS - Non-Drug
E0464	RR	Press supp vent noninv int		\$1,504.83	HCPCS - Non-Drug
E0470	RR	RAD w/o backup non-inv intfc		\$478.84	HCPCS - Non-Drug
E0471	RR	RAD w/backup non inv intfc		\$1,214.11	HCPCS - Non-Drug
E0472	RR	RAD w backup invasive intfc		\$1,214.11	HCPCS - Non-Drug
E0480	NU	Percussor elect/pneum home m		\$708.59	HCPCS - Non-Drug
E0480	RR	Percussor elect/pneum home m		\$73.31	HCPCS - Non-Drug
E0480	UE	Percussor elect/pneum home m		\$621.70	HCPCS - Non-Drug
E0481		Intrpulumny percuss vent sys		\$1,162.37	HCPCS - Non-Drug
E0482	RR	Cough stimulating device		\$809.54	HCPCS - Non-Drug
E0483	RR	Chest compression gen system		\$2,016.85	HCPCS - Non-Drug
E0484	NU	Non-elec oscillatory pep dvc		\$59.95	HCPCS - Non-Drug
E0484	RR	Non-elec oscillatory pep dvc		\$9.87	HCPCS - Non-Drug
E0484	UE	Non-elec oscillatory pep dvc		\$46.05	HCPCS - Non-Drug
E0500	NU	Ippb all types		\$2,187.36	HCPCS - Non-Drug
E0500	RR	Ippb all types		\$198.85	HCPCS - Non-Drug
E0500	UE	Ippb all types		\$1,441.46	HCPCS - Non-Drug
E0550	NU	Humidif extens suppl w ippb		\$517.54	HCPCS - Non-Drug
E0550	RR	Humidif extens suppl w ippb		\$85.11	HCPCS - Non-Drug
E0550	UE	Humidif extens suppl w ippb		\$414.03	HCPCS - Non-Drug
E0555	NU	Humidifier for use w/ regula		\$17.24	HCPCS - Non-Drug
E0555	RR	Humidifier for use w/ regula		\$12.02	HCPCS - Non-Drug
E0555	UE	Humidifier for use w/ regula		\$14.10	HCPCS - Non-Drug
E0560	NU	Humidifier supplemental w/i		\$316.59	HCPCS - Non-Drug
E0560	RR	Humidifier supplemental w/i		\$34.60	HCPCS - Non-Drug
E0560	UE	Humidifier supplemental w/i		\$234.82	HCPCS - Non-Drug
E0561	NU	Humidifier nonheated w PAP		\$193.56	HCPCS - Non-Drug
E0561	RR	Humidifier nonheated w PAP		\$20.40	HCPCS - Non-Drug
E0561	UE	Humidifier nonheated w PAP		\$142.53	HCPCS - Non-Drug
E0562	NU	Humidifier heated used w PAP		\$563.93	HCPCS - Non-Drug
E0562	RR	Humidifier heated used w PAP		\$49.69	HCPCS - Non-Drug
E0562	UE	Humidifier heated used w PAP		\$420.31	HCPCS - Non-Drug
E0565	NU	Compressor air power source		\$1,059.37	HCPCS - Non-Drug
E0565	RR	Compressor air power source		\$105.86	HCPCS - Non-Drug
E0565	UE	Compressor air power source		\$745.89	HCPCS - Non-Drug
E0570	NU	Nebulizer with compression		\$311.85	HCPCS - Non-Drug
E0570	RR	Nebulizer with compression		\$34.03	HCPCS - Non-Drug
E0570	UE	Nebulizer with compression		\$125.05	HCPCS - Non-Drug
E0571	RR	Aerosol compressor for svneb		\$49.48	HCPCS - Non-Drug
E0572	RR	Aerosol compressor adjust pr		\$98.10	HCPCS - Non-Drug
E0574	RR	Ultrasonic generator w svneb		\$103.43	HCPCS - Non-Drug
E0575	NU	Nebulizer ultrasonic		\$1,848.01	HCPCS - Non-Drug
E0575	RR	Nebulizer ultrasonic		\$185.52	HCPCS - Non-Drug
E0575	UE	Nebulizer ultrasonic		\$1,204.07	HCPCS - Non-Drug
E0580	NU	Nebulizer for use w/ regulat		\$245.12	HCPCS - Non-Drug
E0580	RR	Nebulizer for use w/ regulat		\$24.49	HCPCS - Non-Drug
E0580	UE	Nebulizer for use w/ regulat		\$181.19	HCPCS - Non-Drug
E0585	NU	Nebulizer w/ compressor & he		\$569.41	HCPCS - Non-Drug
E0585	RR	Nebulizer w/ compressor & he		\$57.17	HCPCS - Non-Drug
E0585	UE	Nebulizer w/ compressor & he		\$367.41	HCPCS - Non-Drug
E0590		Dispensing fee dme neb drug		\$8.55	HCPCS - Non-Drug
E0600	NU	Suction pump portab hom modl		\$696.81	HCPCS - Non-Drug
E0600	RR	Suction pump portab hom modl		\$76.84	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. -- DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 14 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAF Category
E0600	UE	Suction pump portab hom modl		\$417.63	HCPCS - Non-Drug
E0601	NU	Cont airway pressure device		\$1,866.44	HCPCS - Non-Drug
E0601	RR	Cont airway pressure device		\$202.54	HCPCS - Non-Drug
E0601	UE	Cont airway pressure device		\$1,117.58	HCPCS - Non-Drug
E0602	NU	Manual breast pump		\$48.80	HCPCS - Non-Drug
E0602	RR	Manual breast pump		\$8.76	HCPCS - Non-Drug
E0602	UE	Manual breast pump		\$37.66	HCPCS - Non-Drug
E0603	NU	Electric breast pump		\$144.80	HCPCS - Non-Drug
E0603	RR	Electric breast pump		\$44.98	HCPCS - Non-Drug
E0603	UE	Electric breast pump		\$113.92	HCPCS - Non-Drug
E0604	NU	Hosp grade elec breast pump		\$436.51	HCPCS - Non-Drug
E0604	RR	Hosp grade elec breast pump		\$161.11	HCPCS - Non-Drug
E0604	UE	Hosp grade elec breast pump		\$324.11	HCPCS - Non-Drug
E0605	NU	Vaporizer room type		\$44.15	HCPCS - Non-Drug
E0605	RR	Vaporizer room type		\$8.92	HCPCS - Non-Drug
E0605	UE	Vaporizer room type		\$37.12	HCPCS - Non-Drug
E0606	NU	Drainage board postural		\$388.77	HCPCS - Non-Drug
E0606	RR	Drainage board postural		\$38.88	HCPCS - Non-Drug
E0606	UE	Drainage board postural		\$291.58	HCPCS - Non-Drug
E0607	NU	Blood glucose monitor home		\$89.03	HCPCS - Non-Drug
E0607	RR	Blood glucose monitor home		\$12.44	HCPCS - Non-Drug
E0607	UE	Blood glucose monitor home		\$78.74	HCPCS - Non-Drug
E0610	NU	Pacemaker monitr audible/vis		\$443.11	HCPCS - Non-Drug
E0610	RR	Pacemaker monitr audible/vis		\$42.13	HCPCS - Non-Drug
E0610	UE	Pacemaker monitr audible/vis		\$329.76	HCPCS - Non-Drug
E0615	NU	Pacemaker monitr digital/vis		\$902.61	HCPCS - Non-Drug
E0615	RR	Pacemaker monitr digital/vis		\$101.07	HCPCS - Non-Drug
E0615	UE	Pacemaker monitr digital/vis		\$674.34	HCPCS - Non-Drug
E0616		Cardiac event recorder		\$410.22	HCPCS - Non-Drug
E0617	RR	Automatic ext defibrillator		\$569.33	HCPCS - Non-Drug
E0618	RR	Apnea monitor		\$524.14	HCPCS - Non-Drug
E0618		Apnea monitor		\$554.05	HCPCS - Non-Drug
E0620	NU	Cap bld skin piercing laser		\$1,656.93	HCPCS - Non-Drug
E0620	RR	Cap bld skin piercing laser		\$156.24	HCPCS - Non-Drug
E0620	UE	Cap bld skin piercing laser		\$1,240.08	HCPCS - Non-Drug
E0621	NU	Patient lift sling or seat		\$172.57	HCPCS - Non-Drug
E0621	RR	Patient lift sling or seat		\$18.23	HCPCS - Non-Drug
E0621	UE	Patient lift sling or seat		\$127.50	HCPCS - Non-Drug
E0625	NU	Patient lift bathroom or toi		\$1,525.23	HCPCS - Non-Drug
E0625	RR	Patient lift bathroom or toi		\$157.27	HCPCS - Non-Drug
E0625	UE	Patient lift bathroom or toi		\$1,144.25	HCPCS - Non-Drug
E0627	NU	Seat lift incorp lift-chair		\$632.76	HCPCS - Non-Drug
E0627	RR	Seat lift incorp lift-chair		\$55.16	HCPCS - Non-Drug
E0627	UE	Seat lift incorp lift-chair		\$471.97	HCPCS - Non-Drug
E0628	NU	Seat lift for pt fum-electr		\$632.76	HCPCS - Non-Drug
E0628	RR	Seat lift for pt fum-electr		\$55.16	HCPCS - Non-Drug
E0628	UE	Seat lift for pt fum-electr		\$471.97	HCPCS - Non-Drug
E0629	NU	Seat lift for pt fum-non-el		\$620.15	HCPCS - Non-Drug
E0629	RR	Seat lift for pt fum-non-el		\$54.15	HCPCS - Non-Drug
E0629	UE	Seat lift for pt fum-non-el		\$462.46	HCPCS - Non-Drug
E0630	NU	Patient lift hydraulic		\$1,973.01	HCPCS - Non-Drug
E0630	RR	Patient lift hydraulic		\$183.82	HCPCS - Non-Drug
E0630	UE	Patient lift hydraulic		\$1,402.30	HCPCS - Non-Drug
E0635	NU	Patient lift electric		\$2,226.63	HCPCS - Non-Drug
E0635	RR	Patient lift electric		\$222.85	HCPCS - Non-Drug
E0635	UE	Patient lift electric		\$1,519.38	HCPCS - Non-Drug
E0636	RR	PT support & positioning sys		\$2,000.50	HCPCS - Non-Drug
E0637		Combination sit to stand sys		\$84.55	HCPCS - Non-Drug
E0638		Standing frame sys		\$1,595.80	HCPCS - Non-Drug
E0650	NU	Pneuma compresor non-segment		\$1,362.93	HCPCS - Non-Drug
E0650	RR	Pneuma compresor non-segment		\$159.00	HCPCS - Non-Drug
E0650	UE	Pneuma compresor non-segment		\$1,019.57	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 15 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
E0651	NU	Pneum compressor segmental		\$1,740.89	HCPCS - Non-Drug
E0651	RR	Pneum compressor segmental		\$168.43	HCPCS - Non-Drug
E0651	UE	Pneum compressor segmental		\$1,303.07	HCPCS - Non-Drug
E0652	NU	Pneum compres w/cal pressure		\$10,099.10	HCPCS - Non-Drug
E0652	RR	Pneum compres w/cal pressure		\$988.65	HCPCS - Non-Drug
E0652	UE	Pneum compres w/cal pressure		\$7,564.92	HCPCS - Non-Drug
E0655	NU	Pneumatic appliance half arm		\$195.32	HCPCS - Non-Drug
E0655	RR	Pneumatic appliance half arm		\$23.42	HCPCS - Non-Drug
E0655	UE	Pneumatic appliance half arm		\$144.08	HCPCS - Non-Drug
E0660	NU	Pneumatic appliance full leg		\$294.13	HCPCS - Non-Drug
E0660	RR	Pneumatic appliance full leg		\$29.36	HCPCS - Non-Drug
E0660	UE	Pneumatic appliance full leg		\$217.98	HCPCS - Non-Drug
E0665	NU	Pneumatic appliance full arm		\$250.75	HCPCS - Non-Drug
E0665	RR	Pneumatic appliance full arm		\$25.52	HCPCS - Non-Drug
E0665	UE	Pneumatic appliance full arm		\$185.70	HCPCS - Non-Drug
E0666	NU	Pneumatic appliance half leg		\$252.83	HCPCS - Non-Drug
E0666	RR	Pneumatic appliance half leg		\$25.74	HCPCS - Non-Drug
E0666	UE	Pneumatic appliance half leg		\$187.07	HCPCS - Non-Drug
E0667	NU	Seq pneumatic appl full leg		\$606.94	HCPCS - Non-Drug
E0667	RR	Seq pneumatic appl full leg		\$59.41	HCPCS - Non-Drug
E0667	UE	Seq pneumatic appl full leg		\$452.58	HCPCS - Non-Drug
E0668	NU	Seq pneumatic appl full arm		\$832.16	HCPCS - Non-Drug
E0668	RR	Seq pneumatic appl full arm		\$72.69	HCPCS - Non-Drug
E0668	UE	Seq pneumatic appl full arm		\$621.52	HCPCS - Non-Drug
E0669	NU	Seq pneumatic appli half leg		\$339.08	HCPCS - Non-Drug
E0669	RR	Seq pneumatic appli half leg		\$31.95	HCPCS - Non-Drug
E0669	UE	Seq pneumatic appli half leg		\$251.75	HCPCS - Non-Drug
E0671	NU	Pressure pneum appl full leg		\$781.56	HCPCS - Non-Drug
E0671	RR	Pressure pneum appl full leg		\$68.73	HCPCS - Non-Drug
E0671	UE	Pressure pneum appl full leg		\$583.54	HCPCS - Non-Drug
E0672	NU	Pressure pneum appl full arm		\$604.95	HCPCS - Non-Drug
E0672	RR	Pressure pneum appl full arm		\$52.97	HCPCS - Non-Drug
E0672	UE	Pressure pneum appl full arm		\$451.10	HCPCS - Non-Drug
E0673	NU	Pressure pneum appl half leg		\$500.90	HCPCS - Non-Drug
E0673	RR	Pressure pneum appl half leg		\$44.73	HCPCS - Non-Drug
E0673	UE	Pressure pneum appl half leg		\$373.09	HCPCS - Non-Drug
E0675	RR	Pneumatic compression device		\$820.05	HCPCS - Non-Drug
E0691	NU	Uvl pnl 2 sq ft or less		\$1,703.08	HCPCS - Non-Drug
E0691	RR	Uvl pnl 2 sq ft or less		\$160.87	HCPCS - Non-Drug
E0691	UE	Uvl pnl 2 sq ft or less		\$1,274.68	HCPCS - Non-Drug
E0692	NU	Uvl sys panel 4 ft		\$2,141.26	HCPCS - Non-Drug
E0692	RR	Uvl sys panel 4 ft		\$204.67	HCPCS - Non-Drug
E0692	UE	Uvl sys panel 4 ft		\$1,603.34	HCPCS - Non-Drug
E0693	NU	Uvl sys panel 6 ft		\$2,642.04	HCPCS - Non-Drug
E0693	RR	Uvl sys panel 6 ft		\$254.78	HCPCS - Non-Drug
E0693	UE	Uvl sys panel 6 ft		\$1,978.92	HCPCS - Non-Drug
E0694	NU	Uvl md cabinet sys 6 ft		\$8,432.21	HCPCS - Non-Drug
E0694	RR	Uvl md cabinet sys 6 ft		\$833.79	HCPCS - Non-Drug
E0694	UE	Uvl md cabinet sys 6 ft		\$6,321.59	HCPCS - Non-Drug
E0700		Safety equipment		\$49.29	HCPCS - Non-Drug
E0701	NU	Helmet w face quard prefab		\$281.95	HCPCS - Non-Drug
E0710		Restraints any type		\$17.44	HCPCS - Non-Drug
E0720	NU	Tens two lead		\$690.47	HCPCS - Non-Drug
E0720	RR	Tens two lead		\$198.95	HCPCS - Non-Drug
E0720	UE	Tens two lead		\$379.70	HCPCS - Non-Drug
E0730	NU	Tens four lead		\$696.15	HCPCS - Non-Drug
E0730	RR	Tens four lead		\$236.72	HCPCS - Non-Drug
E0730	UE	Tens four lead		\$383.07	HCPCS - Non-Drug
E0731	NU	Conductive garment for tens/		\$669.70	HCPCS - Non-Drug
E0731	RR	Conductive garment for tens/		\$69.06	HCPCS - Non-Drug
E0740	NU	Incontinence treatment systm		\$986.59	HCPCS - Non-Drug
E0740	RR	Incontinence treatment systm		\$89.24	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 16 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
E0744	NU	Neuromuscular stim for scoli		\$1,096.17	HCPCS - Non-Drug
E0744	RR	Neuromuscular stim for scoli		\$164.14	HCPCS - Non-Drug
E0744	UE	Neuromuscular stim for scoli		\$994.13	HCPCS - Non-Drug
E0745	NU	Neuromuscular stim for shock		\$1,553.73	HCPCS - Non-Drug
E0745	RR	Neuromuscular stim for shock		\$160.21	HCPCS - Non-Drug
E0745	UE	Neuromuscular stim for shock		\$1,165.63	HCPCS - Non-Drug
E0746	NU	Electromyograph biofeedback		\$215.06	HCPCS - Non-Drug
E0746	RR	Electromyograph biofeedback		\$22.18	HCPCS - Non-Drug
E0746	UE	Electromyograph biofeedback		\$161.35	HCPCS - Non-Drug
E0747	NU	Elec osteogen stim not spine		\$6,715.72	HCPCS - Non-Drug
E0747	RR	Elec osteogen stim not spine		\$657.92	HCPCS - Non-Drug
E0747	UE	Elec osteogen stim not spine		\$4,986.95	HCPCS - Non-Drug
E0748	NU	Elec osteogen stim spinal		\$6,672.11	HCPCS - Non-Drug
E0748	RR	Elec osteogen stim spinal		\$657.76	HCPCS - Non-Drug
E0748	UE	Elec osteogen stim spinal		\$5,001.50	HCPCS - Non-Drug
E0749		Elec osteogen stim implanted		\$6,526.22	HCPCS - Non-Drug
E0760	NU	Osteogen ultrasound stimtor		\$5,542.63	HCPCS - Non-Drug
E0765	NU	Nerve stimulator for tx n&v		\$149.95	HCPCS - Non-Drug
E0776	NU	Iv pole		\$262.52	HCPCS - Non-Drug
E0776	RR	Iv pole		\$32.41	HCPCS - Non-Drug
E0776	UE	Iv pole		\$190.37	HCPCS - Non-Drug
E0779	RR	Amb infusion pump mechanical		\$29.52	HCPCS - Non-Drug
E0780	NU	Mech amb infusion pump <8hrs		\$19.93	HCPCS - Non-Drug
E0781	RR	External ambulatory infus pu		\$494.61	HCPCS - Non-Drug
E0782	NU	Non-programble infusion pump		\$7,363.84	HCPCS - Non-Drug
E0783	NU	Programmable infusion pump		\$14,051.22	HCPCS - Non-Drug
E0784	RR	Ext amb infusn pump insulin		\$785.81	HCPCS - Non-Drug
E0784		Ext amb infusn pump insulin		\$5,778.95	HCPCS - Non-Drug
E0785		Replacement impl pump cathet		\$801.08	HCPCS - Non-Drug
E0786		Implantable pump replacement		\$10,276.78	HCPCS - Non-Drug
E0791	RR	Parenteral infusion pump sta		\$653.76	HCPCS - Non-Drug
E0791	UE	Parenteral infusion pump sta		\$4,766.55	HCPCS - Non-Drug
E0791		Parenteral infusion pump sta		\$6,340.29	HCPCS - Non-Drug
E0830		Ambulatory traction device		\$2,542.69	HCPCS - Non-Drug
E0840		Tract frame attach headboard		\$93.04	HCPCS - Non-Drug
E0849		Cervical pneum trac equip		\$55.14	HCPCS - Non-Drug
E0850		Traction stand free standing		\$132.26	HCPCS - Non-Drug
E0855		Cervical traction equipment		\$708.37	HCPCS - Non-Drug
E0860		Tract equip cervical tract		\$51.25	HCPCS - Non-Drug
E0870		Tract frame attach footboard		\$146.33	HCPCS - Non-Drug
E0880		Trac stand free stand extrem		\$157.60	HCPCS - Non-Drug
E0890		Traction frame attach pelvic		\$160.60	HCPCS - Non-Drug
E0900		Trac stand free stand pelvic		\$159.27	HCPCS - Non-Drug
E0910	RR	Trapeze bar attached to bed		\$35.61	HCPCS - Non-Drug
E0910	UE	Trapeze bar attached to bed		\$266.50	HCPCS - Non-Drug
E0910		Trapeze bar attached to bed		\$355.55	HCPCS - Non-Drug
E0920	RR	Fracture frame attached to b		\$78.59	HCPCS - Non-Drug
E0920	UE	Fracture frame attached to b		\$652.44	HCPCS - Non-Drug
E0920		Fracture frame attached to b		\$785.89	HCPCS - Non-Drug
E0930	RR	Fracture frame free standing		\$77.85	HCPCS - Non-Drug
E0930	UE	Fracture frame free standing		\$574.24	HCPCS - Non-Drug
E0930		Fracture frame free standing		\$780.03	HCPCS - Non-Drug
E0935	RR	Exercise device passive moti		\$38.56	HCPCS - Non-Drug
E0940	RR	Trapeze bar free standing		\$59.90	HCPCS - Non-Drug
E0940	UE	Trapeze bar free standing		\$398.61	HCPCS - Non-Drug
E0940		Trapeze bar free standing		\$563.32	HCPCS - Non-Drug
E0941	NU	Gravity assisted traction de		\$739.48	HCPCS - Non-Drug
E0941	RR	Gravity assisted traction de		\$74.10	HCPCS - Non-Drug
E0941	UE	Gravity assisted traction de		\$559.11	HCPCS - Non-Drug
E0942	NU	Cervical head harness/halter		\$35.37	HCPCS - Non-Drug
E0944	NU	Pelvic belt/harness/boot		\$67.27	HCPCS - Non-Drug
E0945	NU	Belt/harness extremity		\$65.11	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 17 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAF Category
E0946	NU	Fracture frame dual w cross		\$1,003.21	HCPCS - Non-Drug
E0946	RR	Fracture frame dual w cross		\$99.98	HCPCS - Non-Drug
E0946	UE	Fracture frame dual w cross		\$752.92	HCPCS - Non-Drug
E0947	NU	Fracture frame attachmnts pe		\$935.65	HCPCS - Non-Drug
E0947	RR	Fracture frame attachmnts pe		\$106.12	HCPCS - Non-Drug
E0947	UE	Fracture frame attachmnts pe		\$704.98	HCPCS - Non-Drug
E0948	NU	Fracture frame attachmnts ce		\$905.41	HCPCS - Non-Drug
E0948	RR	Fracture frame attachmnts ce		\$99.14	HCPCS - Non-Drug
E0948	UE	Fracture frame attachmnts ce		\$642.41	HCPCS - Non-Drug
E0950	NU	Tray		\$151.16	HCPCS - Non-Drug
E0950	RR	Tray		\$18.15	HCPCS - Non-Drug
E0950	UE	Tray		\$113.53	HCPCS - Non-Drug
E0951	NU	Loop heel		\$30.02	HCPCS - Non-Drug
E0951	RR	Loop heel		\$4.21	HCPCS - Non-Drug
E0951	UE	Loop heel		\$23.42	HCPCS - Non-Drug
E0952	NU	Toe loop/holder, each		\$29.81	HCPCS - Non-Drug
E0952	RR	Toe loop/holder, each		\$4.21	HCPCS - Non-Drug
E0952	UE	Toe loop/holder, each		\$23.30	HCPCS - Non-Drug
E0955	NU	Cushioned headrest		\$216.33	HCPCS - Non-Drug
E0955	RR	Cushioned headrest		\$216.33	HCPCS - Non-Drug
E0955	UE	Cushioned headrest		\$216.33	HCPCS - Non-Drug
E0956	NU	W/c lateral trunk/hip suppor		\$105.48	HCPCS - Non-Drug
E0956	RR	W/c lateral trunk/hip suppor		\$105.48	HCPCS - Non-Drug
E0956	UE	W/c lateral trunk/hip suppor		\$105.48	HCPCS - Non-Drug
E0957	NU	W/c medial thigh support		\$147.59	HCPCS - Non-Drug
E0957	RR	W/c medial thigh support		\$147.59	HCPCS - Non-Drug
E0957	UE	W/c medial thigh support		\$147.59	HCPCS - Non-Drug
E0958	NU	Whlchr att- conv 1 arm drive		\$640.64	HCPCS - Non-Drug
E0958	RR	Whlchr att- conv 1 arm drive		\$64.16	HCPCS - Non-Drug
E0958	UE	Whlchr att- conv 1 arm drive		\$480.73	HCPCS - Non-Drug
E0959	NU	Amputee adapter		\$64.96	HCPCS - Non-Drug
E0959	RR	Amputee adapter		\$9.53	HCPCS - Non-Drug
E0959	UE	Amputee adapter		\$50.07	HCPCS - Non-Drug
E0960	NU	W/c shoulder harness/straps		\$97.35	HCPCS - Non-Drug
E0960	RR	W/c shoulder harness/straps		\$97.35	HCPCS - Non-Drug
E0960	UE	W/c shoulder harness/straps		\$97.35	HCPCS - Non-Drug
E0961	NU	Wheelchair brake extension		\$44.91	HCPCS - Non-Drug
E0961	RR	Wheelchair brake extension		\$6.67	HCPCS - Non-Drug
E0961	UE	Wheelchair brake extension		\$24.31	HCPCS - Non-Drug
E0966	NU	Wheelchair head rest extensi		\$103.97	HCPCS - Non-Drug
E0966	RR	Wheelchair head rest extensi		\$13.48	HCPCS - Non-Drug
E0966	UE	Wheelchair head rest extensi		\$78.10	HCPCS - Non-Drug
E0967	NU	Wheelchair hand rims		\$95.74	HCPCS - Non-Drug
E0967	RR	Wheelchair hand rims		\$12.83	HCPCS - Non-Drug
E0967	UE	Wheelchair hand rims		\$71.94	HCPCS - Non-Drug
E0968	NU	Wheelchair commode seat		\$288.19	HCPCS - Non-Drug
E0968	RR	Wheelchair commode seat		\$28.57	HCPCS - Non-Drug
E0968	UE	Wheelchair commode seat		\$183.46	HCPCS - Non-Drug
E0969	NU	Wheelchair narrowing device		\$227.47	HCPCS - Non-Drug
E0969	RR	Wheelchair narrowing device		\$25.21	HCPCS - Non-Drug
E0969	UE	Wheelchair narrowing device		\$170.76	HCPCS - Non-Drug
E0970	NU	Wheelchair no. 2 footplates		\$75.01	HCPCS - Non-Drug
E0970	RR	Wheelchair no. 2 footplates		\$9.94	HCPCS - Non-Drug
E0970	UE	Wheelchair no. 2 footplates		\$57.38	HCPCS - Non-Drug
E0971	NU	Wheelchair anti-tipping devi		\$95.82	HCPCS - Non-Drug
E0971	RR	Wheelchair anti-tipping devi		\$14.06	HCPCS - Non-Drug
E0971	UE	Wheelchair anti-tipping devi		\$72.02	HCPCS - Non-Drug
E0973	NU	W/Ch access det adj amrest		\$167.11	HCPCS - Non-Drug
E0973	RR	W/Ch access det adj amrest		\$18.89	HCPCS - Non-Drug
E0973	UE	W/Ch access det adj amrest		\$125.49	HCPCS - Non-Drug
E0974	NU	W/Ch access anti-rollback		\$114.17	HCPCS - Non-Drug
E0974	RR	W/Ch access anti-rollback		\$15.23	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 18 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
E0974	UE	W/Ch access anti-rollback		\$86.40	HCPCS - Non-Drug
E0977	NU	Wheelchair wedge cushion		\$95.33	HCPCS - Non-Drug
E0977	RR	Wheelchair wedge cushion		\$12.45	HCPCS - Non-Drug
E0977	UE	Wheelchair wedge cushion		\$71.71	HCPCS - Non-Drug
E0978	NU	W/C acc,saf belt pelv strap		\$62.87	HCPCS - Non-Drug
E0978	RR	W/C acc,saf belt pelv strap		\$9.19	HCPCS - Non-Drug
E0978	UE	W/C acc,saf belt pelv strap		\$47.57	HCPCS - Non-Drug
E0980	NU	Wheelchair safety vest		\$49.51	HCPCS - Non-Drug
E0980	RR	Wheelchair safety vest		\$7.08	HCPCS - Non-Drug
E0980	UE	Wheelchair safety vest		\$37.89	HCPCS - Non-Drug
E0981	NU	Seat upholstery, replacement		\$69.04	HCPCS - Non-Drug
E0981	RR	Seat upholstery, replacement		\$10.30	HCPCS - Non-Drug
E0981	UE	Seat upholstery, replacement		\$53.17	HCPCS - Non-Drug
E0982	NU	Back upholstery, replacement		\$75.23	HCPCS - Non-Drug
E0982	RR	Back upholstery, replacement		\$10.86	HCPCS - Non-Drug
E0982	UE	Back upholstery, replacement		\$57.25	HCPCS - Non-Drug
E0983	RR	Add pwr joystick		\$362.62	HCPCS - Non-Drug
E0984	NU	Add pwr tiller		\$2,768.12	HCPCS - Non-Drug
E0984	RR	Add pwr tiller		\$257.84	HCPCS - Non-Drug
E0984	UE	Add pwr tiller		\$2,136.12	HCPCS - Non-Drug
E0985	NU	W/c seat lift mechanism		\$217.05	HCPCS - Non-Drug
E0985	RR	W/c seat lift mechanism		\$217.05	HCPCS - Non-Drug
E0985	UE	W/c seat lift mechanism		\$217.05	HCPCS - Non-Drug
E0986	NU	Man w/c push-rim pow assist		\$5,204.74	HCPCS - Non-Drug
E0986	RR	Man w/c push-rim pow assist		\$5,204.74	HCPCS - Non-Drug
E0986	UE	Man w/c push-rim pow assist		\$5,204.74	HCPCS - Non-Drug
E0990	NU	Wheelchair elevating leg res		\$170.69	HCPCS - Non-Drug
E0990	RR	Wheelchair elevating leg res		\$22.04	HCPCS - Non-Drug
E0990	UE	Wheelchair elevating leg res		\$133.49	HCPCS - Non-Drug
E0992	NU	Wheelchair solid seat insert		\$138.42	HCPCS - Non-Drug
E0992	RR	Wheelchair solid seat insert		\$16.53	HCPCS - Non-Drug
E0992	UE	Wheelchair solid seat insert		\$103.97	HCPCS - Non-Drug
E0994	NU	Wheelchair arm rest		\$28.14	HCPCS - Non-Drug
E0994	RR	Wheelchair arm rest		\$3.82	HCPCS - Non-Drug
E0994	UE	Wheelchair arm rest		\$22.05	HCPCS - Non-Drug
E0995	NU	Wheelchair calf rest		\$45.84	HCPCS - Non-Drug
E0995	RR	Wheelchair calf rest		\$6.54	HCPCS - Non-Drug
E0995	UE	Wheelchair calf rest		\$35.28	HCPCS - Non-Drug
E0997	NU	Wheelchair caster w/ a fork		\$96.93	HCPCS - Non-Drug
E0997	RR	Wheelchair caster w/ a fork		\$13.60	HCPCS - Non-Drug
E0997	UE	Wheelchair caster w/ a fork		\$72.86	HCPCS - Non-Drug
E0998	NU	Wheelchair caster w/o a fork		\$56.74	HCPCS - Non-Drug
E0998	RR	Wheelchair caster w/o a fork		\$8.49	HCPCS - Non-Drug
E0998	UE	Wheelchair caster w/o a fork		\$43.52	HCPCS - Non-Drug
E0999	NU	Wheelchr pneumatic tire w/wh		\$167.11	HCPCS - Non-Drug
E0999	RR	Wheelchr pneumatic tire w/wh		\$19.67	HCPCS - Non-Drug
E0999	UE	Wheelchr pneumatic tire w/wh		\$125.49	HCPCS - Non-Drug
E1002		Pwr seat tilt		\$440.12	HCPCS - Non-Drug
E1003		Pwr seat recline		\$469.88	HCPCS - Non-Drug
E1004		Pwr seat recline mech		\$520.98	HCPCS - Non-Drug
E1005		Pwr seat recline pwr		\$563.92	HCPCS - Non-Drug
E1006		Pwr seat combo w/o shear		\$690.74	HCPCS - Non-Drug
E1007		Pwr seat combo w/shear		\$935.32	HCPCS - Non-Drug
E1008		Pwr seat combo pwr shear		\$935.40	HCPCS - Non-Drug
E1009		Add mech leg elevation		\$111.34	HCPCS - Non-Drug
E1010		Add pwr leg elevation		\$1,650.76	HCPCS - Non-Drug
E1014	NU	Reclining back add ped w/c		\$529.51	HCPCS - Non-Drug
E1015	NU	Shock absorber for man w/c		\$166.74	HCPCS - Non-Drug
E1016	NU	Shock absorber for power w/c		\$190.80	HCPCS - Non-Drug
E1020	NU	Residual limb support system		\$353.17	HCPCS - Non-Drug
E1020	UE	Residual limb support system		\$265.01	HCPCS - Non-Drug
E1028		W/c manual swingaway		\$22.10	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 19 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAF Category
E1029		W/c vent tray fixed		\$39.54	HCPCS - Non-Drug
E1030		W/c vent tray gimbaled		\$124.69	HCPCS - Non-Drug
E1031	NU	Rollabout chair with casters		\$735.77	HCPCS - Non-Drug
E1031	RR	Rollabout chair with casters		\$73.76	HCPCS - Non-Drug
E1031	UE	Rollabout chair with casters		\$551.97	HCPCS - Non-Drug
E1035	RR	Patient transfer system		\$888.84	HCPCS - Non-Drug
E1037		Transport chair, ped size		\$157.74	HCPCS - Non-Drug
E1038		Transport chair, adult size		\$59.15	HCPCS - Non-Drug
E1039		Transport chair pt wt >300lb		\$36.59	HCPCS - Non-Drug
E1050	NU	Wheelchr fxd full length arms		\$1,661.54	HCPCS - Non-Drug
E1050	RR	Wheelchr fxd full length arms		\$148.11	HCPCS - Non-Drug
E1050	UE	Wheelchr fxd full length arms		\$1,246.29	HCPCS - Non-Drug
E1060	NU	Wheelchair detachable arms		\$2,170.50	HCPCS - Non-Drug
E1060	RR	Wheelchair detachable arms		\$183.21	HCPCS - Non-Drug
E1060	UE	Wheelchair detachable arms		\$1,627.54	HCPCS - Non-Drug
E1070	NU	Wheelchair detachable foot r		\$1,957.79	HCPCS - Non-Drug
E1070	RR	Wheelchair detachable foot r		\$159.24	HCPCS - Non-Drug
E1070	UE	Wheelchair detachable foot r		\$1,468.05	HCPCS - Non-Drug
E1083	NU	Hemi-wheelchair fixed arms		\$1,144.74	HCPCS - Non-Drug
E1083	RR	Hemi-wheelchair fixed arms		\$114.64	HCPCS - Non-Drug
E1083	UE	Hemi-wheelchair fixed arms		\$835.23	HCPCS - Non-Drug
E1084	NU	Hemi-wheelchair detachable a		\$1,744.65	HCPCS - Non-Drug
E1084	RR	Hemi-wheelchair detachable a		\$142.68	HCPCS - Non-Drug
E1084	UE	Hemi-wheelchair detachable a		\$1,246.27	HCPCS - Non-Drug
E1085	NU	Hemi-wheelchair fixed arms		\$1,147.49	HCPCS - Non-Drug
E1085	RR	Hemi-wheelchair fixed arms		\$115.28	HCPCS - Non-Drug
E1085	UE	Hemi-wheelchair fixed arms		\$824.16	HCPCS - Non-Drug
E1086	NU	Hemi-wheelchair detachable a		\$1,397.61	HCPCS - Non-Drug
E1086	RR	Hemi-wheelchair detachable a		\$127.48	HCPCS - Non-Drug
E1086	UE	Hemi-wheelchair detachable a		\$1,015.10	HCPCS - Non-Drug
E1087	NU	Wheelchair lightwt fixed arm		\$1,839.72	HCPCS - Non-Drug
E1087	RR	Wheelchair lightwt fixed arm		\$183.84	HCPCS - Non-Drug
E1087	UE	Wheelchair lightwt fixed arm		\$1,341.62	HCPCS - Non-Drug
E1088	NU	Wheelchair lightweight det a		\$2,195.14	HCPCS - Non-Drug
E1088	RR	Wheelchair lightweight det a		\$218.99	HCPCS - Non-Drug
E1088	UE	Wheelchair lightweight det a		\$1,505.95	HCPCS - Non-Drug
E1089	NU	Wheelchair lightwt fixed arm		\$1,854.53	HCPCS - Non-Drug
E1089	RR	Wheelchair lightwt fixed arm		\$186.04	HCPCS - Non-Drug
E1089	UE	Wheelchair lightwt fixed arm		\$1,390.89	HCPCS - Non-Drug
E1090	NU	Wheelchair lightweight det a		\$1,911.88	HCPCS - Non-Drug
E1090	RR	Wheelchair lightweight det a		\$186.04	HCPCS - Non-Drug
E1090	UE	Wheelchair lightweight det a		\$1,397.61	HCPCS - Non-Drug
E1092	NU	Wheelchair wide w/ leg rests		\$2,060.05	HCPCS - Non-Drug
E1092	RR	Wheelchair wide w/ leg rests		\$186.74	HCPCS - Non-Drug
E1092	UE	Wheelchair wide w/ leg rests		\$1,505.75	HCPCS - Non-Drug
E1093	NU	Wheelchair wide w/ foot rest		\$1,571.00	HCPCS - Non-Drug
E1093	RR	Wheelchair wide w/ foot rest		\$160.68	HCPCS - Non-Drug
E1093	UE	Wheelchair wide w/ foot rest		\$1,169.00	HCPCS - Non-Drug
E1100	NU	Whchr s-recl fxd arm leg res		\$1,507.96	HCPCS - Non-Drug
E1100	RR	Whchr s-recl fxd arm leg res		\$150.96	HCPCS - Non-Drug
E1100	UE	Whchr s-recl fxd arm leg res		\$1,131.38	HCPCS - Non-Drug
E1110	NU	Wheelchair semi-recl detach		\$1,475.89	HCPCS - Non-Drug
E1110	RR	Wheelchair semi-recl detach		\$147.83	HCPCS - Non-Drug
E1110	UE	Wheelchair semi-recl detach		\$1,073.21	HCPCS - Non-Drug
E1130	NU	Whlchr stand fxd arm ft rest		\$735.70	HCPCS - Non-Drug
E1130	RR	Whlchr stand fxd arm ft rest		\$74.40	HCPCS - Non-Drug
E1130	UE	Whlchr stand fxd arm ft rest		\$559.39	HCPCS - Non-Drug
E1140	NU	Wheelchair standard detach a		\$1,059.03	HCPCS - Non-Drug
E1140	RR	Wheelchair standard detach a		\$106.73	HCPCS - Non-Drug
E1140	UE	Wheelchair standard detach a		\$750.34	HCPCS - Non-Drug
E1150	NU	Wheelchair standard w/ leg r		\$1,228.02	HCPCS - Non-Drug
E1150	RR	Wheelchair standard w/ leg r		\$118.75	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 20 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
E1150	UE	Wheelchair standard w/ leg r		\$813.05	HCPCS - Non-Drug
E1160	NU	Wheelchair fixed arms		\$995.07	HCPCS - Non-Drug
E1160	RR	Wheelchair fixed arms		\$91.11	HCPCS - Non-Drug
E1160	UE	Wheelchair fixed arms		\$694.85	HCPCS - Non-Drug
E1161	NU	Manual adult wc w tiltspac		\$3,427.95	HCPCS - Non-Drug
E1161	UE	Manual adult wc w tiltspac		\$2,571.15	HCPCS - Non-Drug
E1170	NU	Whlchr ampu fxd arm leg rest		\$1,298.46	HCPCS - Non-Drug
E1170	RR	Whlchr ampu fxd arm leg rest		\$129.96	HCPCS - Non-Drug
E1170	UE	Whlchr ampu fxd arm leg rest		\$974.14	HCPCS - Non-Drug
E1171	NU	Wheelchair amputee w/o leg r		\$1,163.88	HCPCS - Non-Drug
E1171	RR	Wheelchair amputee w/o leg r		\$116.68	HCPCS - Non-Drug
E1171	UE	Wheelchair amputee w/o leg r		\$872.92	HCPCS - Non-Drug
E1172	NU	Wheelchair amputee detach ar		\$1,421.32	HCPCS - Non-Drug
E1172	RR	Wheelchair amputee detach ar		\$142.47	HCPCS - Non-Drug
E1172	UE	Wheelchair amputee detach ar		\$1,066.12	HCPCS - Non-Drug
E1180	NU	Wheelchair amputee w/ foot r		\$1,474.97	HCPCS - Non-Drug
E1180	RR	Wheelchair amputee w/ foot r		\$147.38	HCPCS - Non-Drug
E1180	UE	Wheelchair amputee w/ foot r		\$1,105.95	HCPCS - Non-Drug
E1190	NU	Wheelchair amputee w/ leg re		\$1,702.91	HCPCS - Non-Drug
E1190	RR	Wheelchair amputee w/ leg re		\$170.16	HCPCS - Non-Drug
E1190	UE	Wheelchair amputee w/ leg re		\$1,243.39	HCPCS - Non-Drug
E1195	NU	Wheelchair amputee heavy dut		\$1,825.68	HCPCS - Non-Drug
E1195	RR	Wheelchair amputee heavy dut		\$182.56	HCPCS - Non-Drug
E1195	UE	Wheelchair amputee heavy dut		\$1,369.79	HCPCS - Non-Drug
E1200	NU	Wheelchair amputee fixed arm		\$1,264.24	HCPCS - Non-Drug
E1200	RR	Wheelchair amputee fixed arm		\$126.62	HCPCS - Non-Drug
E1200	UE	Wheelchair amputee fixed arm		\$947.92	HCPCS - Non-Drug
E1220		Whlchr special size/constrc		\$3,678.20	HCPCS - Non-Drug
E1221	NU	Wheelchair spec size w foot		\$695.93	HCPCS - Non-Drug
E1221	RR	Wheelchair spec size w foot		\$69.54	HCPCS - Non-Drug
E1221	UE	Wheelchair spec size w foot		\$522.10	HCPCS - Non-Drug
E1222	NU	Wheelchair spec size w/ leg		\$990.84	HCPCS - Non-Drug
E1222	RR	Wheelchair spec size w/ leg		\$98.78	HCPCS - Non-Drug
E1222	UE	Wheelchair spec size w/ leg		\$712.91	HCPCS - Non-Drug
E1223	NU	Wheelchair spec size w foot		\$1,074.90	HCPCS - Non-Drug
E1223	RR	Wheelchair spec size w foot		\$107.80	HCPCS - Non-Drug
E1223	UE	Wheelchair spec size w foot		\$768.85	HCPCS - Non-Drug
E1224	NU	Wheelchair spec size w/ leg		\$1,241.61	HCPCS - Non-Drug
E1224	RR	Wheelchair spec size w/ leg		\$118.13	HCPCS - Non-Drug
E1224	UE	Wheelchair spec size w/ leg		\$833.19	HCPCS - Non-Drug
E1225	NU	Wheelchair spec sz semi-recl		\$663.34	HCPCS - Non-Drug
E1225	RR	Wheelchair spec sz semi-recl		\$66.34	HCPCS - Non-Drug
E1225	UE	Wheelchair spec sz semi-recl		\$497.77	HCPCS - Non-Drug
E1226	NU	W/C access fully reclineback		\$790.98	HCPCS - Non-Drug
E1226	RR	W/C access fully reclineback		\$81.94	HCPCS - Non-Drug
E1226	UE	W/C access fully reclineback		\$593.33	HCPCS - Non-Drug
E1227	NU	Wheelchair spec sz spec ht a		\$402.56	HCPCS - Non-Drug
E1227	RR	Wheelchair spec sz spec ht a		\$42.16	HCPCS - Non-Drug
E1227	UE	Wheelchair spec sz spec ht a		\$302.10	HCPCS - Non-Drug
E1228	NU	Wheelchair spec sz spec ht b		\$423.73	HCPCS - Non-Drug
E1228	RR	Wheelchair spec sz spec ht b		\$42.54	HCPCS - Non-Drug
E1228	UE	Wheelchair spec sz spec ht b		\$317.66	HCPCS - Non-Drug
E1230	NU	Power operated vehicle		\$3,276.88	HCPCS - Non-Drug
E1230	RR	Power operated vehicle		\$322.82	HCPCS - Non-Drug
E1230	UE	Power operated vehicle		\$2,591.74	HCPCS - Non-Drug
E1232	NU	Folding ped wc tilt-in-space		\$3,098.15	HCPCS - Non-Drug
E1232	UE	Folding ped wc tilt-in-space		\$2,323.77	HCPCS - Non-Drug
E1233	NU	Riq ped wc tltnspc w/o seat		\$3,210.15	HCPCS - Non-Drug
E1233	UE	Riq ped wc tltnspc w/o seat		\$2,407.75	HCPCS - Non-Drug
E1234	NU	Fld ped wc tltnspc w/o seat		\$2,794.74	HCPCS - Non-Drug
E1234	UE	Fld ped wc tltnspc w/o seat		\$2,096.17	HCPCS - Non-Drug
E1235	NU	Riqid ped wc adjustable		\$2,691.15	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 21 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAF Category
E1235	UE	Rigid ped wc adjustable		\$2,018.49	HCPCS - Non-Drug
E1236	NU	Folding ped wc adjustable		\$2,374.34	HCPCS - Non-Drug
E1236	UE	Folding ped wc adjustable		\$1,780.91	HCPCS - Non-Drug
E1237	NU	Rqd ped wc adjustabl w/o seat		\$2,395.08	HCPCS - Non-Drug
E1237	UE	Rqd ped wc adjustabl w/o seat		\$1,796.49	HCPCS - Non-Drug
E1238	NU	Fld ped wc adjustabl w/o seat		\$2,497.20	HCPCS - Non-Drug
E1238	UE	Fld ped wc adjustabl w/o seat		\$1,873.02	HCPCS - Non-Drug
E1240	NU	Whchr litwt det arm leg rest		\$1,498.10	HCPCS - Non-Drug
E1240	RR	Whchr litwt det arm leg rest		\$149.81	HCPCS - Non-Drug
E1240	UE	Whchr litwt det arm leg rest		\$1,072.21	HCPCS - Non-Drug
E1250	NU	Wheelchair lightwt fixed arm		\$1,132.85	HCPCS - Non-Drug
E1250	RR	Wheelchair lightwt fixed arm		\$103.68	HCPCS - Non-Drug
E1250	UE	Wheelchair lightwt fixed arm		\$897.37	HCPCS - Non-Drug
E1260	NU	Wheelchair lightwt foot rest		\$1,323.79	HCPCS - Non-Drug
E1260	RR	Wheelchair lightwt foot rest		\$132.97	HCPCS - Non-Drug
E1260	UE	Wheelchair lightwt foot rest		\$1,044.38	HCPCS - Non-Drug
E1270	NU	Wheelchair lightweight leg r		\$1,151.78	HCPCS - Non-Drug
E1270	RR	Wheelchair lightweight leg r		\$114.94	HCPCS - Non-Drug
E1270	UE	Wheelchair lightweight leg r		\$845.70	HCPCS - Non-Drug
E1280	NU	Whchr h-duty det arm leg res		\$1,908.58	HCPCS - Non-Drug
E1280	RR	Whchr h-duty det arm leg res		\$190.73	HCPCS - Non-Drug
E1280	UE	Whchr h-duty det arm leg res		\$1,368.08	HCPCS - Non-Drug
E1285	NU	Wheelchair heavy duty fixed		\$1,706.30	HCPCS - Non-Drug
E1285	RR	Wheelchair heavy duty fixed		\$171.39	HCPCS - Non-Drug
E1285	UE	Wheelchair heavy duty fixed		\$1,250.58	HCPCS - Non-Drug
E1290	NU	Wheelchair hvy duty detach a		\$1,764.85	HCPCS - Non-Drug
E1290	RR	Wheelchair hvy duty detach a		\$176.89	HCPCS - Non-Drug
E1290	UE	Wheelchair hvy duty detach a		\$1,287.18	HCPCS - Non-Drug
E1295	NU	Wheelchair heavy duty fixed		\$1,765.37	HCPCS - Non-Drug
E1295	RR	Wheelchair heavy duty fixed		\$176.54	HCPCS - Non-Drug
E1295	UE	Wheelchair heavy duty fixed		\$1,282.73	HCPCS - Non-Drug
E1296	NU	Wheelchair special seat heiq		\$712.79	HCPCS - Non-Drug
E1296	RR	Wheelchair special seat heiq		\$72.92	HCPCS - Non-Drug
E1296	UE	Wheelchair special seat heiq		\$534.73	HCPCS - Non-Drug
E1297	NU	Wheelchair special seat dept		\$152.12	HCPCS - Non-Drug
E1297	RR	Wheelchair special seat dept		\$19.82	HCPCS - Non-Drug
E1297	UE	Wheelchair special seat dept		\$114.23	HCPCS - Non-Drug
E1298	NU	Wheelchair spec seat depth/w		\$614.27	HCPCS - Non-Drug
E1298	RR	Wheelchair spec seat depth/w		\$63.77	HCPCS - Non-Drug
E1298	UE	Wheelchair spec seat depth/w		\$460.83	HCPCS - Non-Drug
E1300	NU	Whirlpool portable		\$140.92	HCPCS - Non-Drug
E1300	RR	Whirlpool portable		\$14.53	HCPCS - Non-Drug
E1300	UE	Whirlpool portable		\$105.72	HCPCS - Non-Drug
E1310	NU	Whirlpool non-portable		\$4,084.50	HCPCS - Non-Drug
E1310	RR	Whirlpool non-portable		\$339.77	HCPCS - Non-Drug
E1310	UE	Whirlpool non-portable		\$3,060.76	HCPCS - Non-Drug
E1340		Repair for DME, per 15 min		\$19.45	HCPCS - Non-Drug
E1353	NU	Oxygen supplies regulator		\$183.15	HCPCS - Non-Drug
E1353	RR	Oxygen supplies regulator		\$9.93	HCPCS - Non-Drug
E1353	UE	Oxygen supplies regulator		\$147.64	HCPCS - Non-Drug
E1355	NU	Oxygen supplies stand/rack		\$125.94	HCPCS - Non-Drug
E1355	RR	Oxygen supplies stand/rack		\$14.10	HCPCS - Non-Drug
E1355	UE	Oxygen supplies stand/rack		\$102.26	HCPCS - Non-Drug
E1372	NU	Oxy suppl heater for nebuliz		\$300.39	HCPCS - Non-Drug
E1372	RR	Oxy suppl heater for nebuliz		\$40.02	HCPCS - Non-Drug
E1372	UE	Oxy suppl heater for nebuliz		\$219.64	HCPCS - Non-Drug
E1390	NU	Oxygen concentrator		\$4,218.59	HCPCS - Non-Drug
E1390	RR	Oxygen concentrator		\$554.68	HCPCS - Non-Drug
E1391		Oxygen concentrator, dual		\$554.68	HCPCS - Non-Drug
E1399		Durable medical equipment mi		\$3.27	HCPCS - Non-Drug
E1405	NU	O2/water vapor enrich w/heat		\$5,574.74	HCPCS - Non-Drug
E1405	RR	O2/water vapor enrich w/heat		\$574.83	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 22 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAF Category
E1405	UE	O2/water vapor enrich w/heat		\$4,182.23	HCPCS - Non-Drug
E1406	NU	O2/water vapor enrich w/o he		\$2,350.37	HCPCS - Non-Drug
E1406	RR	O2/water vapor enrich w/o he		\$242.36	HCPCS - Non-Drug
E1406	UE	O2/water vapor enrich w/o he		\$1,763.26	HCPCS - Non-Drug
E1510	NU	Kidney dialysate delivry sys		\$7,206.00	HCPCS - Non-Drug
E1510	RR	Kidney dialysate delivry sys		\$743.02	HCPCS - Non-Drug
E1510	UE	Kidney dialysate delivry sys		\$5,406.03	HCPCS - Non-Drug
E1520	NU	Heparin infusion pump		\$976.13	HCPCS - Non-Drug
E1520	RR	Heparin infusion pump		\$100.64	HCPCS - Non-Drug
E1520	UE	Heparin infusion pump		\$732.31	HCPCS - Non-Drug
E1530	NU	Replacement air bubble detec		\$1,412.27	HCPCS - Non-Drug
E1530	RR	Replacement air bubble detec		\$145.63	HCPCS - Non-Drug
E1530	UE	Replacement air bubble detec		\$1,059.50	HCPCS - Non-Drug
E1540	NU	Replacement pressure alarm		\$875.04	HCPCS - Non-Drug
E1540	RR	Replacement pressure alarm		\$90.22	HCPCS - Non-Drug
E1540	UE	Replacement pressure alarm		\$656.47	HCPCS - Non-Drug
E1550	NU	Bath conductivity meter		\$570.15	HCPCS - Non-Drug
E1550	RR	Bath conductivity meter		\$58.79	HCPCS - Non-Drug
E1550	UE	Bath conductivity meter		\$427.72	HCPCS - Non-Drug
E1560	NU	Replace blood leak detector		\$1,606.44	HCPCS - Non-Drug
E1560	RR	Replace blood leak detector		\$165.64	HCPCS - Non-Drug
E1560	UE	Replace blood leak detector		\$1,205.17	HCPCS - Non-Drug
E1570	NU	Adjustable chair for esrd pt		\$633.49	HCPCS - Non-Drug
E1570	RR	Adjustable chair for esrd pt		\$65.32	HCPCS - Non-Drug
E1570	UE	Adjustable chair for esrd pt		\$475.26	HCPCS - Non-Drug
E1575	NU	Transducer protect/flid bar		\$84.25	HCPCS - Non-Drug
E1575	RR	Transducer protect/flid bar		\$8.69	HCPCS - Non-Drug
E1575	UE	Transducer protect/flid bar		\$63.22	HCPCS - Non-Drug
E1590	NU	Hemodialysis machine		\$1,579.68	HCPCS - Non-Drug
E1590	RR	Hemodialysis machine		\$162.89	HCPCS - Non-Drug
E1590	UE	Hemodialysis machine		\$1,185.10	HCPCS - Non-Drug
E1594	NU	Cycler dialysis machine		\$7,251.29	HCPCS - Non-Drug
E1594	RR	Cycler dialysis machine		\$747.68	HCPCS - Non-Drug
E1594	UE	Cycler dialysis machine		\$5,440.00	HCPCS - Non-Drug
E1600		Del/install chrg hemo equip		\$233.01	HCPCS - Non-Drug
E1610	NU	Reverse osmosis h2o puri sys		\$5,543.07	HCPCS - Non-Drug
E1610	RR	Reverse osmosis h2o puri sys		\$571.56	HCPCS - Non-Drug
E1610	UE	Reverse osmosis h2o puri sys		\$4,158.48	HCPCS - Non-Drug
E1635		Compact travel hemodialyzer		\$672.89	HCPCS - Non-Drug
E1636		Sorbent cartridges per 10		\$248.69	HCPCS - Non-Drug
E1637		Hemostats for dialysis, each		\$8.52	HCPCS - Non-Drug
E1639		Dialysis scale		\$160.66	HCPCS - Non-Drug
E1699		Dialysis equipment noc		\$87.48	HCPCS - Non-Drug
E1700	NU	Jaw motion rehab system		\$647.10	HCPCS - Non-Drug
E1701		Repl cushions for jaw motion		\$20.29	HCPCS - Non-Drug
E1702		Repl measr scales jaw motion		\$38.32	HCPCS - Non-Drug
E1800	RR	Adjust elbow ext/flex device		\$223.12	HCPCS - Non-Drug
E1801	RR	SPS elbow device		\$235.52	HCPCS - Non-Drug
E1802		Adjust forearm pro/sup device		\$612.70	HCPCS - Non-Drug
E1805	RR	Adjust wrist ext/flex device		\$230.44	HCPCS - Non-Drug
E1806	RR	SPS wrist device		\$191.48	HCPCS - Non-Drug
E1810	RR	Adjust knee ext/flex device		\$227.10	HCPCS - Non-Drug
E1811	RR	SPS knee device		\$245.28	HCPCS - Non-Drug
E1815	RR	Adjust ankle ext/flex device		\$230.44	HCPCS - Non-Drug
E1816	RR	SPS ankle device		\$249.31	HCPCS - Non-Drug
E1818	RR	SPS forearm device		\$254.76	HCPCS - Non-Drug
E1820	NU	Soft interface material		\$145.39	HCPCS - Non-Drug
E1820	RR	Soft interface material		\$16.62	HCPCS - Non-Drug
E1820	UE	Soft interface material		\$106.44	HCPCS - Non-Drug
E1821	NU	Replacement interface SPSPD		\$190.22	HCPCS - Non-Drug
E1821	RR	Replacement interface SPSPD		\$20.15	HCPCS - Non-Drug
E1821	UE	Replacement interface SPSPD		\$140.07	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE - CHARGES BY HCPCS CODE

PAGE 23 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
E1825	RR	Adjust finger ext/flex devc		\$230.44	HCPCS - Non-Drug
E1830	RR	Adjust toe ext/flex device		\$230.44	HCPCS - Non-Drug
E1840	RR	Adj shoulder ext/flex device		\$719.33	HCPCS - Non-Drug
E1841		Static str shldr dev rom adj		\$484.71	HCPCS - Non-Drug
E1902		AAC non-electronic board		\$435.23	HCPCS - Non-Drug
E2000	RR	Gastric suction pump hme mdl		\$88.36	HCPCS - Non-Drug
E2100		Bld glucose monitor w voice		\$909.43	HCPCS - Non-Drug
E2101		Bld glucose monitor w lance		\$259.20	HCPCS - Non-Drug
E2120		Pulse gen sys tx endolymp fl		\$303.37	HCPCS - Non-Drug
E2201		Man w/ch acc seat w>=20"<24"		\$39.92	HCPCS - Non-Drug
E2202		Seat width 24-27 in		\$50.72	HCPCS - Non-Drug
E2203		Frame depth less than 22 in		\$51.24	HCPCS - Non-Drug
E2204		Frame depth 22 to 25 in		\$87.04	HCPCS - Non-Drug
E2205		Manual wc accessory, handrim		\$3.48	HCPCS - Non-Drug
E2206		Complete wheel lock assembly		\$4.34	HCPCS - Non-Drug
E2300		Pwr seat elevation sys		\$11,452.39	HCPCS - Non-Drug
E2310	NU	Electro connect btw control		\$1,674.00	HCPCS - Non-Drug
E2310	RR	Electro connect btw control		\$1,674.00	HCPCS - Non-Drug
E2310	UE	Electro connect btw control		\$1,674.00	HCPCS - Non-Drug
E2311	NU	Electro connect btw 2 sys		\$87.81	HCPCS - Non-Drug
E2311	RR	Electro connect btw 2 sys		\$87.81	HCPCS - Non-Drug
E2311	UE	Electro connect btw 2 sys		\$87.81	HCPCS - Non-Drug
E2320		Hand chin control		\$225.55	HCPCS - Non-Drug
E2321		Hand interface joystick		\$432.53	HCPCS - Non-Drug
E2322		Multi mech switches		\$196.58	HCPCS - Non-Drug
E2323	NU	Special joystick handle		\$85.11	HCPCS - Non-Drug
E2323	RR	Special joystick handle		\$85.11	HCPCS - Non-Drug
E2323	UE	Special joystick handle		\$85.11	HCPCS - Non-Drug
E2324	NU	Chin cup interface		\$46.89	HCPCS - Non-Drug
E2324	RR	Chin cup interface		\$46.89	HCPCS - Non-Drug
E2324	UE	Chin cup interface		\$46.89	HCPCS - Non-Drug
E2325	NU	Sip and puff interface		\$429.35	HCPCS - Non-Drug
E2325	RR	Sip and puff interface		\$429.35	HCPCS - Non-Drug
E2325	UE	Sip and puff interface		\$429.35	HCPCS - Non-Drug
E2326	NU	Breath tube kit		\$371.44	HCPCS - Non-Drug
E2326	RR	Breath tube kit		\$371.44	HCPCS - Non-Drug
E2326	UE	Breath tube kit		\$371.44	HCPCS - Non-Drug
E2327		Head control interface mech		\$279.53	HCPCS - Non-Drug
E2328	NU	Head/extremity control inter		\$5,302.19	HCPCS - Non-Drug
E2328	RR	Head/extremity control inter		\$5,302.19	HCPCS - Non-Drug
E2328	UE	Head/extremity control inter		\$5,302.19	HCPCS - Non-Drug
E2329	NU	Head control nonproportional		\$1,889.76	HCPCS - Non-Drug
E2329	RR	Head control nonproportional		\$1,889.76	HCPCS - Non-Drug
E2329	UE	Head control nonproportional		\$1,889.76	HCPCS - Non-Drug
E2330	NU	Head control proximity switc		\$3,661.64	HCPCS - Non-Drug
E2330	RR	Head control proximity switc		\$3,661.64	HCPCS - Non-Drug
E2330	UE	Head control proximity switc		\$3,661.64	HCPCS - Non-Drug
E2331		Attendant control		\$14.34	HCPCS - Non-Drug
E2340	NU	W/c width 20-23 in seat frame		\$383.45	HCPCS - Non-Drug
E2340	RR	W/c width 20-23 in seat frame		\$383.45	HCPCS - Non-Drug
E2340	UE	W/c width 20-23 in seat frame		\$383.45	HCPCS - Non-Drug
E2341	NU	W/c width 24-27 in seat frame		\$575.21	HCPCS - Non-Drug
E2341	RR	W/c width 24-27 in seat frame		\$575.21	HCPCS - Non-Drug
E2341	UE	W/c width 24-27 in seat frame		\$575.21	HCPCS - Non-Drug
E2342	NU	W/c depth 20-21 in seat frame		\$479.34	HCPCS - Non-Drug
E2342	RR	W/c depth 20-21 in seat frame		\$479.34	HCPCS - Non-Drug
E2342	UE	W/c depth 20-21 in seat frame		\$479.34	HCPCS - Non-Drug
E2343	NU	W/c depth 22-25 in seat frame		\$766.95	HCPCS - Non-Drug
E2343	RR	W/c depth 22-25 in seat frame		\$766.95	HCPCS - Non-Drug
E2343	UE	W/c depth 22-25 in seat frame		\$766.95	HCPCS - Non-Drug
E2351	NU	Electronic SGD interface		\$189.17	HCPCS - Non-Drug
E2351	RR	Electronic SGD interface		\$189.17	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 24 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage - Indicator (1)	Charge	GAAF Category
E2351	UE	Electronic SGD interface		\$189.17	HCPCS - Non-Drug
E2360		22mf nonsealed leadacid		\$163.31	HCPCS - Non-Drug
E2361		22mf sealed leadacid battery		\$202.60	HCPCS - Non-Drug
E2362		Gr24 nonsealed leadacid		\$133.81	HCPCS - Non-Drug
E2363		Gr24 sealed leadacid battery		\$270.01	HCPCS - Non-Drug
E2364		U1nonsealed leadacid battery		\$163.31	HCPCS - Non-Drug
E2365		U1 sealed leadacid battery		\$163.07	HCPCS - Non-Drug
E2366		Battery charger, single mode		\$382.45	HCPCS - Non-Drug
E2367		Battery charger, dual mode		\$607.63	HCPCS - Non-Drug
E2368		Power wc motor replacement		\$55.29	HCPCS - Non-Drug
E2369		Pwr wc gear box replacement		\$48.15	HCPCS - Non-Drug
E2370		Pwr wc motor/gear box combo		\$85.91	HCPCS - Non-Drug
E2402		Neq press wound therapy pump		\$3,262.73	HCPCS - Non-Drug
E2500		SGD digitized pre-rec <=8min		\$548.80	HCPCS - Non-Drug
E2502		SGD prerec msq >8min <=20min		\$1,699.77	HCPCS - Non-Drug
E2504		SGD prerec msq >20min <=40min		\$2,245.51	HCPCS - Non-Drug
E2506		SGD prerec msq > 40 min		\$3,297.48	HCPCS - Non-Drug
E2508		SGD spelling phys contact		\$5,104.84	HCPCS - Non-Drug
E2510		SGD w multi methods msq/accs		\$9,669.52	HCPCS - Non-Drug
E2511	NU	SGD sftwre prqrm for PC/PDA		\$3,326.87	HCPCS - Non-Drug
E2511	RR	SGD sftwre prqrm for PC/PDA		\$3,326.87	HCPCS - Non-Drug
E2511	UE	SGD sftwre prqrm for PC/PDA		\$3,326.87	HCPCS - Non-Drug
E2512	NU	SGD accessory, mounting sys		\$384.78	HCPCS - Non-Drug
E2512	RR	SGD accessory, mounting sys		\$384.78	HCPCS - Non-Drug
E2512	UE	SGD accessory, mounting sys		\$384.78	HCPCS - Non-Drug
E2599		SGD accessory noc		\$225.48	HCPCS - Non-Drug
E2601		Gen w/c cushion wdth < 22 in		\$52.53	HCPCS - Non-Drug
E2602		Gen w/c cushion wdth >=22 in		\$17.33	HCPCS - Non-Drug
E2603		Skin protect wc cus wd <22in		\$23.87	HCPCS - Non-Drug
E2604		Skin protect wc cus wd >=22in		\$33.78	HCPCS - Non-Drug
E2605		Position wc cush wdth <22 in		\$34.44	HCPCS - Non-Drug
E2606		Position wc cush wdth >=22 in		\$46.66	HCPCS - Non-Drug
E2607		Skin pro/pos wc cus wd <22in		\$31.63	HCPCS - Non-Drug
E2608		Skin pro/pos wc cus wd >=22in		\$37.90	HCPCS - Non-Drug
E2611		Gen use back cush wdth <22in		\$34.42	HCPCS - Non-Drug
E2612		Gen use back cush wdth >=22in		\$45.21	HCPCS - Non-Drug
E2613		Position back cush wd <22in		\$42.06	HCPCS - Non-Drug
E2614		Position back cush wd >=22in		\$58.21	HCPCS - Non-Drug
E2615		Pos back post/lat wdth <22in		\$48.41	HCPCS - Non-Drug
E2616		Pos back post/lat wdth >=22in		\$65.12	HCPCS - Non-Drug
E2618		Wc acc solid seat supp base		\$16.44	HCPCS - Non-Drug
E2619		Replace cover w/c seat cush		\$34.03	HCPCS - Non-Drug
E2620		WC planar back cush wd <22in		\$61.49	HCPCS - Non-Drug
E2621		WC planar back cush wd >=22in		\$58.60	HCPCS - Non-Drug
G9018		Zanamivir, inhalation pwd 10m		\$37.06	HCPCS - Drug
G9020		Rimantadine HCL 100mq oral		\$143.75	HCPCS - Drug
G9033		Amantadine HCL, oral, brand		\$46.45	HCPCS - Drug
G9034		Zanamivir powder via inhaler		\$37.06	HCPCS - Drug
G9036		Rimantadine HCL 100mq		\$143.75	HCPCS - Drug
J0120		Tetracyclin injection		\$137.46	HCPCS - Drug
J0130		Abciximab injection	a	\$905.24	HCPCS - Drug
J0132		Acetylcysteine injection		\$29.00	HCPCS - Drug
J0150		Injection adenosine 6 MG	a	\$80.03	HCPCS - Drug
J0170		Adrenalin epinephrin inject		\$5.47	HCPCS - Drug
J0200		Alatrofloxacin mesylate		\$44.84	HCPCS - Drug
J0205		Alglucerase injection	a	\$84.38	HCPCS - Drug
J0207		Amifostine	a	\$885.82	HCPCS - Drug
J0210		Methyldopate hcl injection		\$27.12	HCPCS - Drug
J0215		Alefacept	a	\$28.42	HCPCS - Drug
J0256		Alpha 1 proteinase inhibitor	a	\$5.47	HCPCS - Drug
J0270		Alprostadil for injection		\$0.54	HCPCS - Drug
J0275		Alprostadil urethral suppos		\$47.80	HCPCS - Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 25 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
J0278		Amikacin sulfate injection		\$29.00	HCPCS - Drug
J0280		Aminophyllin 250 MG inj		\$1.52	HCPCS - Drug
J0282		Amiodarone HCl		\$14.33	HCPCS - Drug
J0285		Amphotericin B		\$24.16	HCPCS - Drug
J0287		Amphotericin b lipid complex	a	\$50.24	HCPCS - Drug
J0288		Ampho b cholesteryl sulfate	a	\$35.00	HCPCS - Drug
J0289		Amphotericin b liposome inj	a	\$74.93	HCPCS - Drug
J0290		Ampicillin 500 MG inj		\$3.50	HCPCS - Drug
J0295		Ampicillin sodium per 1.5 gm		\$17.27	HCPCS - Drug
J0300		Amobarbital 125 MG inj		\$5.47	HCPCS - Drug
J0330		Succinylcholine chloride inj		\$0.54	HCPCS - Drug
J0360		Hydralazine hcl injection		\$36.97	HCPCS - Drug
J0365		Aprotonin, 10,000 kiu		\$24.94	HCPCS - Drug
J0380		Inj metaraminol bitartrate		\$2.51	HCPCS - Drug
J0390		Chloroquine injection		\$55.32	HCPCS - Drug
J0456		Azithromycin		\$56.77	HCPCS - Drug
J0460		Atropine sulfate injection		\$1.52	HCPCS - Drug
J0470		Dimecaprol injection		\$53.87	HCPCS - Drug
J0475		Baclofen 10 MG injection		\$387.30	HCPCS - Drug
J0476		Baclofen intrathecal trial		\$151.21	HCPCS - Drug
J0480		Basiliximab		\$22.77	HCPCS - Drug
J0500		Dicyclomine injection		\$39.92	HCPCS - Drug
J0515		Inj benzotropine mesylate		\$8.41	HCPCS - Drug
J0530		Penicillin g benzathine inj		\$28.11	HCPCS - Drug
J0540		Penicillin g benzathine inj		\$53.14	HCPCS - Drug
J0550		Penicillin q benzathine inj		\$99.64	HCPCS - Drug
J0560		Penicillin q benzathine inj		\$23.19	HCPCS - Drug
J0570		Penicillin g benzathine inj		\$45.83	HCPCS - Drug
J0580		Penicillin q benzathine inj		\$81.48	HCPCS - Drug
J0585		Botulinum toxin a per unit	a	\$11.37	HCPCS - Drug
J0587		Botulinum toxin type B	a	\$20.23	HCPCS - Drug
J0592		Buprenorphine hydrochloride		\$1.52	HCPCS - Drug
J0600		Edetate calcium disodium inj		\$89.46	HCPCS - Drug
J0610		Calcium gluconate injection		\$1.52	HCPCS - Drug
J0620		Calcium glycer & lact/10 ML		\$14.33	HCPCS - Drug
J0630		Calcitonin salmon injection		\$79.29	HCPCS - Drug
J0636		Inj calcitriol per 0.1 mcg		\$0.54	HCPCS - Drug
J0637		Caspofungin acetate	a	\$69.85	HCPCS - Drug
J0640		Leucovorin calcium injection		\$7.43	HCPCS - Drug
J0670		Inj mepivacaine HCL/10 ml		\$4.48	HCPCS - Drug
J0690		Cefazolin sodium injection		\$4.48	HCPCS - Drug
J0692		Cefepime HCl for injection		\$1.52	HCPCS - Drug
J0694		Cefoxitin sodium injection		\$25.15	HCPCS - Drug
J0696		Ceftriaxone sodium injection		\$35.00	HCPCS - Drug
J0697		Sterile cefuroxime injection		\$7.43	HCPCS - Drug
J0698		Cefotaxime sodium injection		\$22.20	HCPCS - Drug
J0702		Betamethasone acet&sod phosph		\$11.37	HCPCS - Drug
J0704		Betamethasone sod phosph/4 MG		\$2.51	HCPCS - Drug
J0706		Caffeine citrate injection		\$7.43	HCPCS - Drug
J0710		Cephapirin sodium injection		\$17.23	HCPCS - Drug
J0713		Inj ceftazidime per 500 mg		\$15.30	HCPCS - Drug
J0715		Ceftizoxime sodium / 500 MG		\$11.37	HCPCS - Drug
J0720		Chloramphenicol sodium iniec		\$16.29	HCPCS - Drug
J0725		Chorionic gonadotropin/1000u		\$5.47	HCPCS - Drug
J0735		Clonidine hydrochloride		\$108.35	HCPCS - Drug
J0740		Cidofovir injection		\$1,481.30	HCPCS - Drug
J0743		Cilastatin sodium injection		\$36.97	HCPCS - Drug
J0744		Ciprofloxacin iv		\$32.05	HCPCS - Drug
J0745		Inj codeine phosphate /30 MG		\$0.54	HCPCS - Drug
J0760		Colchicine injection		\$16.29	HCPCS - Drug
J0770		Colistimethate sodium inj		\$106.89	HCPCS - Drug
J0780		Prochlorperazine injection		\$9.39	HCPCS - Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 26 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAF Category
J0795		Corticoirelin ovine triflital		\$21.73	HCPCS - Drug
J0800		Corticotropin injection		\$174.45	HCPCS - Drug
J0835		Inj cosyntropin per 0.25 MG		\$42.87	HCPCS - Drug
J0850		Cytomegalovirus imm IV /vial	a	\$1,251.75	HCPCS - Drug
J0881		Darbepoetin alfa, non-esrd		\$15.88	HCPCS - Drug
J0885		Epoetin alfa, non-esrd		\$15.88	HCPCS - Drug
J0895		Deferoxamine mesylate inj		\$35.98	HCPCS - Drug
J0900		Testosterone enanthate inj		\$3.50	HCPCS - Drug
J0945		Brompheniramine maleate inj		\$1.52	HCPCS - Drug
J0970		Estradiol valerate injection		\$3.50	HCPCS - Drug
J1000		Depo-estradiol cypionate inj		\$4.48	HCPCS - Drug
J1020		Methylprednisolone 20 MG inj		\$5.47	HCPCS - Drug
J1030		Methylprednisolone 40 MG inj		\$9.39	HCPCS - Drug
J1040		Methylprednisolone 80 MG inj		\$19.25	HCPCS - Drug
J1051		Medroxyprogesterone inj		\$11.37	HCPCS - Drug
J1055		Medroxyprogester acetate inj		\$130.14	HCPCS - Drug
J1056		MA/EC contraceptive injection		\$55.32	HCPCS - Drug
J1060		Testosterone cypionate 1 ML		\$10.39	HCPCS - Drug
J1070		Testosterone cypionate 100 MG		\$11.37	HCPCS - Drug
J1080		Testosterone cypionate 200 MG		\$22.20	HCPCS - Drug
J1094		Inj dexamethasone acetate		\$1.52	HCPCS - Drug
J1100		Dexamethasone sodium phos		\$0.54	HCPCS - Drug
J1110		Inj dihydroergotamine mesylt		\$82.93	HCPCS - Drug
J1120		Acetazolamid sodium injectio		\$47.80	HCPCS - Drug
J1160		Digoxin injection		\$3.50	HCPCS - Drug
J1162		Digoxin immune fab (ovine)		\$13.81	HCPCS - Drug
J1165		Phenytoin sodium injection		\$1.52	HCPCS - Drug
J1170		Hydromorphone injection		\$3.50	HCPCS - Drug
J1180		Dyphylline injection		\$21.22	HCPCS - Drug
J1190		Dexrazoxane HCl injection	a	\$419.99	HCPCS - Drug
J1200		Diphenhydramine hcl injection		\$3.50	HCPCS - Drug
J1205		Chlorothiazide sodium inj		\$24.16	HCPCS - Drug
J1212		Dimethyl sulfoxide 50% 50 ML		\$90.19	HCPCS - Drug
J1230		Methadone injection		\$1.52	HCPCS - Drug
J1240		Dimenhydrinate injection		\$0.54	HCPCS - Drug
J1245		Dipyridamole injection	a	\$13.34	HCPCS - Drug
J1250		Inj dobutamine HCL/250 mq		\$10.39	HCPCS - Drug
J1260		Dolasetron mesylate		\$44.32	HCPCS - Drug
J1270		Injection, doxercalciferol		\$12.36	HCPCS - Drug
J1320		Amitriptyline injection		\$6.44	HCPCS - Drug
J1325		Epoprostenol injection		\$28.68	HCPCS - Drug
J1327		Eptifibatide injection	a	\$30.08	HCPCS - Drug
J1330		Ergonovine maleate injection	a	\$35.43	HCPCS - Drug
J1364		Erythro lactobionate /500 MG		\$7.43	HCPCS - Drug
J1380		Estradiol valerate 10 MG inj		\$0.54	HCPCS - Drug
J1390		Estradiol valerate 20 MG inj		\$2.51	HCPCS - Drug
J1410		Inj estrogen conjugate 25 MG		\$119.24	HCPCS - Drug
J1430		Ethanolamine oleate 100 mq		\$13.81	HCPCS - Drug
J1435		Injection estrone per 1 MG		\$0.54	HCPCS - Drug
J1436		Etidronate disodium inj		\$146.13	HCPCS - Drug
J1438		Etanercept injection	a	\$282.69	HCPCS - Drug
J1440		Filgrastim 300 mcq injection	a	\$321.19	HCPCS - Drug
J1441		Filgrastim 480 mcq injection	a	\$533.31	HCPCS - Drug
J1450		Fluconazole		\$179.54	HCPCS - Drug
J1451		Fomepizole, 15 mq		\$13.61	HCPCS - Drug
J1452		Intraocular Fomivirsen na		\$1,666.55	HCPCS - Drug
J1455		Foscarnet sodium injection		\$30.08	HCPCS - Drug
J1460		Gamma globulin 1 CC inj		\$26.14	HCPCS - Drug
J1470		Gamma globulin 2 CC inj		\$52.42	HCPCS - Drug
J1480		Gamma globulin 3 CC inj		\$72.02	HCPCS - Drug
J1490		Gamma globulin 4 CC inj		\$91.65	HCPCS - Drug
J1500		Gamma globulin 5 CC inj		\$111.98	HCPCS - Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 27 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
J1510		Gamma globulin 6 CC inj		\$131.60	HCPCS - Drug
J1520		Gamma globulin 7 CC inj		\$151.21	HCPCS - Drug
J1530		Gamma globulin 8 CC inj		\$171.55	HCPCS - Drug
J1540		Gamma globulin 9 CC inj		\$191.16	HCPCS - Drug
J1550		Gamma globulin 10 CC inj		\$210.78	HCPCS - Drug
J1560		Gamma globulin > 10 CC inj		\$21.28	HCPCS - Drug
J1565		RSV-ivig	a	\$38.94	HCPCS - Drug
J1566		Immune globulin, powder		\$13.38	HCPCS - Drug
J1567		Immune globulin, liquid		\$12.71	HCPCS - Drug
J1570		Ganciclovir sodium injection	a	\$73.48	HCPCS - Drug
J1580		Garamycin gentamicin inj		\$4.48	HCPCS - Drug
J1590		Gatifloxacin injection		\$1.52	HCPCS - Drug
J1595		Injection glatiramer acetate	a	\$704.65	HCPCS - Drug
J1600		Gold sodium thiomaleate inj		\$31.06	HCPCS - Drug
J1610		Glucagon hydrochloride/1 MG		\$91.65	HCPCS - Drug
J1620		Gonadorelin hydrochl/ 100 mcq		\$364.06	HCPCS - Drug
J1626		Granisetron HCl injection	a	\$40.91	HCPCS - Drug
J1630		Haloperidol injection		\$15.30	HCPCS - Drug
J1631		Haloperidol decanoate inj		\$21.22	HCPCS - Drug
J1640		Hemin, 1 mg		\$12.63	HCPCS - Drug
J1642		Inj heparin sodium per 10 u		\$0.54	HCPCS - Drug
J1644		Inj heparin sodium per 1000u		\$0.54	HCPCS - Drug
J1645		Dalteparin sodium		\$36.97	HCPCS - Drug
J1650		Inj enoxaparin sodium		\$14.33	HCPCS - Drug
J1652		Fondaparinux sodium		\$19.25	HCPCS - Drug
J1655		Tinzaparin sodium injection		\$8.41	HCPCS - Drug
J1670		Tetanus immune globulin inj		\$219.50	HCPCS - Drug
J1700		Hydrocortisone acetate inj		\$0.54	HCPCS - Drug
J1710		Hydrocortisone sodium ph inj		\$16.29	HCPCS - Drug
J1720		Hydrocortisone sodium succ i		\$4.48	HCPCS - Drug
J1730		Diazoxide injection		\$226.77	HCPCS - Drug
J1742		Ibutilide fumarate injection		\$449.77	HCPCS - Drug
J1745		Infliximab injection	a	\$126.51	HCPCS - Drug
J1751		Iron dextran 185 injection		\$11.77	HCPCS - Drug
J1752		Iron dextran 267 injection		\$10.91	HCPCS - Drug
J1756		Iron sucrose injection		\$1.52	HCPCS - Drug
J1785		Injection imiglucerase /unit	a	\$9.39	HCPCS - Drug
J1790		Droperidol injection		\$6.44	HCPCS - Drug
J1800		Propranolol injection		\$27.12	HCPCS - Drug
J1810		Droperidol/fentanyl inj		\$14.23	HCPCS - Drug
J1815		Insulin injection		\$0.54	HCPCS - Drug
J1817		Insulin for insulin pump use		\$6.44	HCPCS - Drug
J1825		Interferon beta-1a	a	\$596.51	HCPCS - Drug
J1830		Interferon beta-1b / .25 MG	a	\$129.42	HCPCS - Drug
J1835		Itraconazole injection		\$76.39	HCPCS - Drug
J1840		Kanamycin sulfate 500 MG inj		\$7.43	HCPCS - Drug
J1850		Kanamycin sulfate 75 MG inj		\$0.54	HCPCS - Drug
J1885		Ketorolac tromethamine inj		\$8.41	HCPCS - Drug
J1890		Cephalothin sodium injection		\$24.16	HCPCS - Drug
J1940		Furosemide injection		\$1.52	HCPCS - Drug
J1945		Lepirudin		\$9.87	HCPCS - Drug
J1950		Leuprolide acetate /3.75 MG	a	\$895.08	HCPCS - Drug
J1955		Inj levocarnitine per 1 gm		\$72.02	HCPCS - Drug
J1956		Levofloxacin injection		\$48.78	HCPCS - Drug
J1960		Levorphanol tartrate inj		\$8.41	HCPCS - Drug
J1980		Hyoscyamine sulfate inj		\$20.23	HCPCS - Drug
J1990		Chlordiazepoxide injection		\$56.05	HCPCS - Drug
J2010		Lincomycin injection		\$7.43	HCPCS - Drug
J2020		Linezolid injection	a	\$76.39	HCPCS - Drug
J2060		Lorazepam injection		\$7.43	HCPCS - Drug
J2150		Mannitol injection		\$7.43	HCPCS - Drug
J2175		Meperidine hydrochl /100 MG		\$0.54	HCPCS - Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 28 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
J2180		Mependine/promethazine inj		\$10.39	HCPCS - Drug
J2210		Methylergonovin maleate inj		\$9.39	HCPCS - Drug
J2250		Inj midazolam hydrochloride		\$2.51	HCPCS - Drug
J2260		Inj milrinone lactate / 5 MG	a	\$102.54	HCPCS - Drug
J2270		Morphine sulfate injection		\$1.52	HCPCS - Drug
J2271		Morphine sulfate injection 100mq		\$10.39	HCPCS - Drug
J2275		Morphine sulfate injection		\$4.48	HCPCS - Drug
J2278		Ziconotide injection		\$8.90	HCPCS - Drug
J2300		Inj nalbuphine hydrochloride		\$3.50	HCPCS - Drug
J2310		Inj naloxone hydrochloride		\$5.47	HCPCS - Drug
J2320		Nandrolone decanoate 50 MG		\$8.41	HCPCS - Drug
J2321		Nandrolone decanoate 100 MG		\$16.29	HCPCS - Drug
J2322		Nandrolone decanoate 200 MG		\$36.97	HCPCS - Drug
J2325		Nesiritide injection		\$8.71	HCPCS - Drug
J2355		Oprelvekin injection	a	\$478.83	HCPCS - Drug
J2360		Orphenadrine injection		\$12.36	HCPCS - Drug
J2370		Phenylephrine hcl injection		\$2.51	HCPCS - Drug
J2400		Chloroprocaine hcl injection		\$14.33	HCPCS - Drug
J2405		Ondansetron hcl injection		\$14.33	HCPCS - Drug
J2410		Oxymorphone hcl injection		\$6.44	HCPCS - Drug
J2425		Palifermin injection		\$7.70	HCPCS - Drug
J2430		Pamidronate disodium /30 MG	a	\$475.20	HCPCS - Drug
J2440		Papaverin hcl injection		\$7.43	HCPCS - Drug
J2460		Oxytetracycline injection		\$1.52	HCPCS - Drug
J2501		Paricalcitol		\$11.37	HCPCS - Drug
J2503		Pegaptanib sodium injection		\$6.90	HCPCS - Drug
J2504		Pegademase bovine, 25 iu		\$6.84	HCPCS - Drug
J2510		Penicillin q procaine inj		\$22.20	HCPCS - Drug
J2513		Pentastarch 10% solution		\$6.59	HCPCS - Drug
J2515		Pentobarbital sodium inj		\$2.51	HCPCS - Drug
J2540		Penicillin q potassium inj		\$0.54	HCPCS - Drug
J2543		Piperacillin/tazobactam		\$11.37	HCPCS - Drug
J2545		Pentamidine isethionel/300mq	a	\$90.19	HCPCS - Drug
J2550		Promethazine hcl injection		\$6.44	HCPCS - Drug
J2560		Phenobarbital sodium inj		\$3.50	HCPCS - Drug
J2590		Oxytocin injection		\$2.51	HCPCS - Drug
J2597		Inj desmopressin acetate		\$7.43	HCPCS - Drug
J2650		Prednisolone acetate inj		\$0.54	HCPCS - Drug
J2670		Totazoline hcl injection		\$8.41	HCPCS - Drug
J2675		Inj progesterone per 50 MG		\$8.41	HCPCS - Drug
J2680		Fluphenazine decanoate 25 MG		\$20.23	HCPCS - Drug
J2690		Procainamide hcl injection		\$2.51	HCPCS - Drug
J2700		Oxacillin sodium injection		\$1.52	HCPCS - Drug
J2710		Neostigmine methylsulfite inj		\$1.52	HCPCS - Drug
J2720		Inj protamine sulfate/10 MG		\$1.52	HCPCS - Drug
J2725		Inj protirelin per 250 mcq		\$54.59	HCPCS - Drug
J2730		Pralidoxime chloride inj		\$191.89	HCPCS - Drug
J2760		Phentolaine mesylate inj		\$67.67	HCPCS - Drug
J2765		Metoclopramide hcl injection		\$3.50	HCPCS - Drug
J2770		Quinupristin/dalfopristin		\$212.23	HCPCS - Drug
J2780		Ranitidine hydrochloride inj		\$2.51	HCPCS - Drug
J2788		Rho d immune globulin 50 mcq	a	\$101.82	HCPCS - Drug
J2790		Rho d immune globulin inj	a	\$186.80	HCPCS - Drug
J2792		Rho(D) immune globulin h, sd	a	\$47.80	HCPCS - Drug
J2795		Ropivacaine HCl injection		\$0.54	HCPCS - Drug
J2800		Methocarbamol injection		\$8.41	HCPCS - Drug
J2805		Sinacalide injection		\$6.59	HCPCS - Drug
J2810		Inj theophylline per 40 MG		\$1.48	HCPCS - Drug
J2820		Sargramostim injection	a	\$60.40	HCPCS - Drug
J2850		Inj secretin synthetic human		\$6.59	HCPCS - Drug
J2910		Aurothiogluucose injection		\$39.92	HCPCS - Drug
J2912		Sodium chloride injection		\$0.54	HCPCS - Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 29 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
J2916		Na ferric gluconate complex		\$19.25	HCPCS - Drug
J2920		Methylprednisolone injection		\$3.50	HCPCS - Drug
J2930		Methylprednisolone injection		\$4.48	HCPCS - Drug
J2940		Somatrem injection		\$91.65	HCPCS - Drug
J2941		Somatropin injection	a	\$92.37	HCPCS - Drug
J2950		Promazine hcl injection		\$0.54	HCPCS - Drug
J2993		Reteplase injection	a	\$2,286.18	HCPCS - Drug
J2995		Inj streptokinase /250000 IU	a	\$167.19	HCPCS - Drug
J2997		Alteplase recombinant	a	\$76.39	HCPCS - Drug
J3000		Streptomycin injection		\$14.33	HCPCS - Drug
J3010		Fentanyl citrate injection		\$1.52	HCPCS - Drug
J3030		Sumatriptan succinate / 6 MG		\$58.95	HCPCS - Drug
J3070		Pentazocine injection		\$12.36	HCPCS - Drug
J3100		Tenecteplase injection	a	\$4,696.48	HCPCS - Drug
J3105		Terbutaline sulfate inj		\$63.31	HCPCS - Drug
J3110		Teriparalide injection	a	\$368.20	HCPCS - Drug
J3120		Testosterone enanthate inj		\$21.22	HCPCS - Drug
J3130		Testosterone enanthate inj		\$41.90	HCPCS - Drug
J3140		Testosterone suspension inj		\$14.41	HCPCS - Drug
J3150		Testosteron propionate inj		\$3.50	HCPCS - Drug
J3230		Chlorpromazine hcl injection		\$10.39	HCPCS - Drug
J3240		Thyrotropin injection	a	\$1,087.68	HCPCS - Drug
J3250		Trimethobenzamide hcl inj		\$3.50	HCPCS - Drug
J3260		Tobramycin sulfate injection		\$10.39	HCPCS - Drug
J3265		Injection torsemide 10 mg/ml		\$3.50	HCPCS - Drug
J3280		Thiethylperazine maleate inj		\$13.34	HCPCS - Drug
J3285		Treprostinil injection		\$6.59	HCPCS - Drug
J3301		Triamcinolone acetonide inj		\$3.50	HCPCS - Drug
J3302		Triamcinolone diacetate inj		\$0.54	HCPCS - Drug
J3303		Triamcinolone hexacetonl inj		\$1.52	HCPCS - Drug
J3305		Inj trimetrexate gluconate	a	\$260.17	HCPCS - Drug
J3310		Perphenazine injection		\$21.22	HCPCS - Drug
J3315		Triptorelin pamoate	a	\$706.21	HCPCS - Drug
J3320		Spectinomycin di-hcl inj		\$61.86	HCPCS - Drug
J3350		Urea injection		\$202.79	HCPCS - Drug
J3355		Urofollitropin, 75 iu		\$6.59	HCPCS - Drug
J3360		Diazepam injection		\$1.52	HCPCS - Drug
J3364		Urokinase 5000 IU injection		\$24.16	HCPCS - Drug
J3365		Urokinase 250,000 IU inj	a	\$903.07	HCPCS - Drug
J3370		Vancomycin hcl injection		\$6.44	HCPCS - Drug
J3400		Triflupromazine hcl inj		\$82.09	HCPCS - Drug
J3410		Hydroxyzine hcl injection		\$2.51	HCPCS - Drug
J3420		Vitamin b12 injection		\$0.54	HCPCS - Drug
J3430		Vitamin k phytonadione inj		\$4.48	HCPCS - Drug
J3470		Hyaluronidase injection		\$59.68	HCPCS - Drug
J3471		Ovine, up to 999 USP units		\$5.35	HCPCS - Drug
J3472		Ovine, 1000 USP units		\$5.35	HCPCS - Drug
J3475		Inj magnesium sulfate		\$0.54	HCPCS - Drug
J3480		Inj potassium chloride		\$0.54	HCPCS - Drug
J3485		Zidovudine		\$1.52	HCPCS - Drug
J3487		Zoledronic acid	a	\$390.92	HCPCS - Drug
J3490		Drugs unclassified injection		\$16.04	HCPCS - Drug
J3520		Edetate disodium per 150 mg		\$0.54	HCPCS - Drug
J3535		Metered dose inhaler drug		\$2.20	HCPCS - Drug
J3570		Laetrile amygdalin vit B17		\$39.53	HCPCS - Drug
J7030		Normal saline solution infus		\$19.25	HCPCS - Drug
J7040		Normal saline solution infus		\$10.39	HCPCS - Drug
J7042		5% dextrose/normal saline		\$22.20	HCPCS - Drug
J7050		Normal saline solution infus		\$3.50	HCPCS - Drug
J7060		5% dextrose/water		\$20.23	HCPCS - Drug
J7070		D5w infusion		\$25.15	HCPCS - Drug
J7100		Dextran 40 infusion		\$56.05	HCPCS - Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 30 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAF Category
J7110		Dextran 75 infusion		\$33.02	HCPCS - Drug
J7120		Ringers lactate infusion		\$27.12	HCPCS - Drug
J7130		Hypertonic saline solution		\$0.54	HCPCS - Drug
J7188		Inj Vonwillebrand factor iu		\$4.32	HCPCS - Drug
J7189		Factor viia		\$4.27	HCPCS - Drug
J7190		Factor viii	a	\$1.52	HCPCS - Drug
J7191		Factor VIII (porcine)	a	\$4.48	HCPCS - Drug
J7192		Factor viii recombinant	a	\$2.51	HCPCS - Drug
J7193		Factor IX non-recombinant	a	\$2.51	HCPCS - Drug
J7194		Factor ix complex	a	\$0.54	HCPCS - Drug
J7195		Factor IX recombinant	a	\$2.51	HCPCS - Drug
J7197		Antithrombin iii injection		\$3.50	HCPCS - Drug
J7198		Anti-inhibitor	a	\$3.50	HCPCS - Drug
J7300		Intraut copper contraceptive		\$510.70	HCPCS - Drug
J7302		Levonorgestrel iu contraceptive		\$859.48	HCPCS - Drug
J7308		Aminolevulinic acid hcl top		\$188.26	HCPCS - Drug
J7310		Ganciclovir long act implant	a	\$8,281.39	HCPCS - Drug
J7318		Hyaluron/deriv intra-art inj		\$4.02	HCPCS - Drug
J7330		Cultured chondrocytes implnt		\$26,406.51	HCPCS - Drug
J7340		Metabolic active D/E tissue		\$63.31	HCPCS - Drug
J7341		Non-human, metabolic tissue		\$3.26	HCPCS - Drug
J7342		Metabolically active tissue		\$26.57	HCPCS - Non-Drug
J7343		Nonmetabolic act d/e tissue	a	\$11.44	HCPCS - Drug
J7344		Nonmetabolic active tissue	a	\$67.81	HCPCS - Non-Drug
J7500		Azathioprine oral 50mg		\$2.51	HCPCS - Drug
J7501		Azathioprine parenteral		\$116.34	HCPCS - Drug
J7502		Cyclosporine oral 100 mg	a	\$12.36	HCPCS - Drug
J7504		Lymphocyte immune globulin	a	\$497.72	HCPCS - Drug
J7505		Monoclonal antibodies	a	\$1,787.12	HCPCS - Drug
J7506		Prednisone oral		\$0.54	HCPCS - Drug
J7507		Tacrolimus oral per 1 MG	a	\$7.43	HCPCS - Drug
J7509		Methylprednisolone oral		\$0.54	HCPCS - Drug
J7510		Prednisolone oral per 5 mg		\$0.54	HCPCS - Drug
J7511		Antithymocyte globulin rabbit	a	\$635.01	HCPCS - Drug
J7513		Daclizumab, parenteral	a	\$752.69	HCPCS - Drug
J7515		Cyclosporine oral 25 mg		\$2.51	HCPCS - Drug
J7516		Cyclosporin parenteral 250mg		\$69.85	HCPCS - Drug
J7517		Mycophenolate mofetil oral	a	\$6.44	HCPCS - Drug
J7520		Sirolimus, oral	a	\$16.29	HCPCS - Drug
J7525		Tacrolimus injection	a	\$219.50	HCPCS - Drug
J7599		Immunosuppressive drug noc		\$6.75	HCPCS - Drug
J7608		Acetylcysteine inh sol u d		\$62.58	HCPCS - Drug
J7612		Levalbuterol concentrated		\$49.77	HCPCS - Drug
J7622		Beclomethasone inhalatn sol		\$0.54	HCPCS - Drug
J7624		Betamethasone inhalation sol		\$1.74	HCPCS - Drug
J7626		Budesonide inhalation sol		\$10.39	HCPCS - Drug
J7628		Bitolterol mes inhal sol con		\$0.61	HCPCS - Drug
J7629		Bitolterol mes inh sol u d		\$1.52	HCPCS - Drug
J7631		Cromolyn sodium inh sol u d		\$0.54	HCPCS - Drug
J7633		Budesonide concentrated sol		\$0.54	HCPCS - Drug
J7635		Atropine inhal sol con		\$0.54	HCPCS - Drug
J7636		Atropine inhal sol unit dose		\$0.54	HCPCS - Drug
J7637		Dexamethasone inhal sol con		\$0.54	HCPCS - Drug
J7638		Dexamethasone inhal sol u d		\$0.54	HCPCS - Drug
J7639		Dornase alpha inhal sol u d		\$38.94	HCPCS - Drug
J7641		Flunisolide, inhalation sol		\$0.54	HCPCS - Drug
J7642		Glycopyrrolate inhal sol con		\$0.54	HCPCS - Drug
J7643		Glycopyrrolate inhal sol u d	a	\$0.54	HCPCS - Drug
J7644		Ipratropium brom inh sol u d	a	\$7.43	HCPCS - Drug
J7649		Isoetharine hcl inh sol u d		\$1.52	HCPCS - Drug
J7658		Isoproterenolhcl inh sol con		\$8.41	HCPCS - Drug
J7659		Isoproterenol hcl inh sol ud		\$8.41	HCPCS - Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 31 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAF Category
J7668		Metaproterenol inh sol con		\$0.16	HCPCS - Drug
J7669		Metaproterenol inh sol u d		\$2.65	HCPCS - Drug
J7680		Terbutaline so4 inh sol con		\$0.54	HCPCS - Drug
J7681		Terbutaline so4 inh sol u d		\$0.54	HCPCS - Drug
J7682		Tobramycin inhalation sol		\$118.52	HCPCS - Drug
J7683		Triamcinolone inh sol con		\$0.54	HCPCS - Drug
J7684		Triamcinolone inh sol u d		\$0.54	HCPCS - Drug
J7699		Inhalation solution for DME	a	\$19.41	HCPCS - Drug
J7799		Non-inhalation drug for DME	a	\$68.74	HCPCS - Drug
J8499		Oral prescrip drug non chemo	a	\$2.46	HCPCS - Drug
J8501		Oral aprepitant	a	\$322.99	HCPCS - Drug
J8510		Oral busulfan	a	\$7.19	HCPCS - Drug
J8520		Capecitabine, oral, 150 mg	a	\$9.58	HCPCS - Drug
J8521		Capecitabine, oral, 500 mg	a	\$33.54	HCPCS - Drug
J8530		Cyclophosphamide oral 25 MG		\$8.39	HCPCS - Drug
J8540		Oral dexamethasone		\$3.22	HCPCS - Drug
J8560		Etoposide oral 50 MG	a	\$178.88	HCPCS - Drug
J8565		Gefitinib oral	a	\$1,267.69	HCPCS - Drug
J8600		Melphalan oral 2 MG		\$8.39	HCPCS - Drug
J8610		Methotrexate oral 2.5 MG		\$11.98	HCPCS - Drug
J8700		Temozolomide	a	\$23.96	HCPCS - Drug
J8999		Oral prescription drug chemo		\$19.27	HCPCS - Drug
J9000		Doxorubic hcl 10 MG v1 chemo	a	\$27.55	HCPCS - Drug
J9001		Doxorubicin hcl liposome inj	a	\$697.49	HCPCS - Drug
J9010		Alemtuzumab injection	a	\$1,030.19	HCPCS - Drug
J9015		Aldesleukin/single use vial	a	\$1,348.51	HCPCS - Drug
J9017		Arsenic trioxide	a	\$9.58	HCPCS - Drug
J9020		Asparaginase injection	a	\$154.33	HCPCS - Drug
J9025		Azacitidine injection		\$2.47	HCPCS - Drug
J9027		Clofarabine injection		\$1.09	HCPCS - Drug
J9031		Bcq live intravesical vac	a	\$375.27	HCPCS - Drug
J9040		Bleomycin sulfate injection	a	\$393.23	HCPCS - Drug
J9045		Carboplatin injection	a	\$333.73	HCPCS - Drug
J9050		Carmus bischi nitro inj		\$320.51	HCPCS - Drug
J9060		Cisplatin 10 MG injection	a	\$43.13	HCPCS - Drug
J9062		Cisplatin 50 MG injection		\$184.54	HCPCS - Drug
J9065		Inj cladribine per 1 MG	a	\$133.56	HCPCS - Drug
J9070		Cyclophosphamide 100 MG inj	a	\$16.77	HCPCS - Drug
J9080		Cyclophosphamide 200 MG inj		\$31.15	HCPCS - Drug
J9090		Cyclophosphamide 500 MG inj		\$64.62	HCPCS - Drug
J9091		Cyclophosphamide 1.0 qm inj		\$116.56	HCPCS - Drug
J9092		Cyclophosphamide 2.0 qm inj		\$219.48	HCPCS - Drug
J9093		Cyclophosphamide lyophilized	a	\$16.77	HCPCS - Drug
J9094		Cyclophosphamide lyophilized		\$33.54	HCPCS - Drug
J9095		Cyclophosphamide lyophilized		\$64.62	HCPCS - Drug
J9096		Cyclophosphamide lyophilized	a	\$116.56	HCPCS - Drug
J9097		Cyclophosphamide lyophilized		\$225.15	HCPCS - Drug
J9100		Cytarabine hcl 100 MG inj	a	\$23.96	HCPCS - Drug
J9110		Cytarabine hcl 500 MG inj		\$23.96	HCPCS - Drug
J9120		Dactinomycin actinomycin d		\$39.54	HCPCS - Drug
J9130		Dacarbazine 100 mg inj	a	\$32.35	HCPCS - Drug
J9140		Dacarbazine 200 MG inj		\$62.73	HCPCS - Drug
J9150		Daunorubicin	a	\$180.76	HCPCS - Drug
J9151		Daunorubicin citrate liposom	a	\$159.04	HCPCS - Drug
J9160		Denileukin diftitox, 300 mcq	a	\$2,329.05	HCPCS - Drug
J9165		Diethylstilbestrol injection		\$41.93	HCPCS - Drug
J9170		Docetaxel	a	\$695.24	HCPCS - Drug
J9181		Etoposide 10 MG inj	a	\$4.79	HCPCS - Drug
J9182		Etoposide 100 MG inj	a	\$49.11	HCPCS - Drug
J9185		Fludarabine phosphate inj	a	\$726.79	HCPCS - Drug
J9190		Fluorouracil injection		\$5.99	HCPCS - Drug
J9200		Floxuridine injection	a	\$327.12	HCPCS - Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 32 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAF Category
J9201		Gemcitabine HCl	a	\$270.46	HCPCS - Drug
J9202		Goserelin acetate implant	a	\$832.35	HCPCS - Drug
J9206		Innotecan injection	a	\$323.35	HCPCS - Drug
J9208		Ifosfomide injection	a	\$352.62	HCPCS - Drug
J9209		Mesna injection	a	\$92.01	HCPCS - Drug
J9211		Idarubicin hcl injection	a	\$831.67	HCPCS - Drug
J9212		Interferon alfacon-1		\$9.39	HCPCS - Drug
J9213		Interferon alfa-2a inj	a	\$92.01	HCPCS - Drug
J9214		Interferon alfa-2b inj	a	\$43.13	HCPCS - Drug
J9215		Interferon alfa-n3 inj	a	\$22.77	HCPCS - Drug
J9216		Interferon gamma 1-b inj	a	\$485.49	HCPCS - Drug
J9217		Leuprolide acetate suspnion	a	\$1,061.30	HCPCS - Drug
J9218		Leuprolide acetate injecton	a	\$71.23	HCPCS - Drug
J9219		Leuprolide acetate implant	a	\$9,012.15	HCPCS - Drug
J9225		Histrelin implant		\$1.08	HCPCS - Drug
J9230		Mechlorethamine hcl inj		\$34.74	HCPCS - Drug
J9245		Inj melphalan hydrochl 50 MG	a	\$832.35	HCPCS - Drug
J9250		Methotrexate sodium inj		\$1.20	HCPCS - Drug
J9260		Methotrexate sodium inj	a	\$13.17	HCPCS - Drug
J9263		Oxaliplatin	a	\$636.92	HCPCS - Drug
J9264		Paclitaxel injection		\$0.93	HCPCS - Drug
J9265		Paclitaxel injection	a	\$366.77	HCPCS - Drug
J9266		Pegaspargase/singl dose vial		\$2,486.40	HCPCS - Drug
J9268		Pentostatin injection	a	\$3,160.91	HCPCS - Drug
J9270		Plicamycin (mithramycin) inj	a	\$225.15	HCPCS - Drug
J9280		Mitomycin 5 MG inj	a.	\$157.16	HCPCS - Drug
J9290		Mitomycin 20 MG inj		\$481.97	HCPCS - Drug
J9291		Mitomycin 40 MG inj		\$610.25	HCPCS - Drug
J9293		Mitoxantrone hydrochl / 5 MG	a	\$732.28	HCPCS - Drug
J9300		Gemtuzumab ozogamicin	a	\$3,729.17	HCPCS - Drug
J9310		Rituximab cancer treatment	a	\$926.27	HCPCS - Drug
J9320		Streptozocin injection	a	\$332.79	HCPCS - Drug
J9340		Thiolepa injection	a	\$224.20	HCPCS - Drug
J9350		Topotecan	a	\$1,438.32	HCPCS - Drug
J9355		Trastuzumab	a	\$113.43	HCPCS - Drug
J9357		Valrubicin, 200 mq	a	\$929.21	HCPCS - Drug
J9360		Vinblastine sulfate inj		\$9.58	HCPCS - Drug
J9370		Vincristine sulfate 1 MG inj		\$51.51	HCPCS - Drug
J9375		Vincristine sulfate 2 MG inj		\$129.77	HCPCS - Drug
J9380		Vincristine sulfate 5 MG inj		\$214.76	HCPCS - Drug
J9390		Vinorelbine tartrate/10 mq	a	\$205.32	HCPCS - Drug
J9600		Porfimer sodium	a	\$4,418.77	HCPCS - Drug
J9999		Chemotherapy drug		\$33.24	HCPCS - Drug
K0001	NU	Standard wheelchair		\$790.26	HCPCS - Non-Drug
K0001	RR	Standard wheelchair		\$79.70	HCPCS - Non-Drug
K0001	UE	Standard wheelchair		\$592.69	HCPCS - Non-Drug
K0002	NU	Stnd hemi (low seat) whlchr		\$943.68	HCPCS - Non-Drug
K0002	RR	Stnd hemi (low seat) whlchr		\$119.12	HCPCS - Non-Drug
K0002	UE	Stnd hemi (low seat) whlchr		\$740.88	HCPCS - Non-Drug
K0003	NU	Lightweight wheelchair		\$1,482.89	HCPCS - Non-Drug
K0003	RR	Lightweight wheelchair		\$130.36	HCPCS - Non-Drug
K0003	UE	Lightweight wheelchair		\$1,112.87	HCPCS - Non-Drug
K0004	NU	High strength ltwt whlchr		\$2,312.24	HCPCS - Non-Drug
K0004	RR	High strength ltwt whlchr		\$194.17	HCPCS - Non-Drug
K0004	UE	High strength ltwt whlchr		\$1,733.99	HCPCS - Non-Drug
K0005	NU	Ultralightweight wheelchair		\$2,678.57	HCPCS - Non-Drug
K0005	RR	Ultralightweight wheelchair		\$268.36	HCPCS - Non-Drug
K0005	UE	Ultralightweight wheelchair		-\$2,009.05	HCPCS - Non-Drug
K0006	NU	Heavy duty wheelchair		\$1,659.72	HCPCS - Non-Drug
K0006	RR	Heavy duty wheelchair		\$182.24	HCPCS - Non-Drug
K0006	UE	Heavy duty wheelchair		\$1,250.97	HCPCS - Non-Drug
K0007	NU	Extra heavy duty wheelchair		\$2,589.40	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 33 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
K0007	RR	Extra heavy duty wheelchair		\$259.15	HCPCS - Non-Drug
K0007	UE	Extra heavy duty wheelchair		\$2,535.33	HCPCS - Non-Drug
K0009		Other manual wheelchair/base		\$606.96	HCPCS - Non-Drug
K0010	NU	Stnd wt frame power whlchr		\$6,174.75	HCPCS - Non-Drug
K0010	RR	Stnd wt frame power whlchr		\$617.65	HCPCS - Non-Drug
K0010	UE	Stnd wt frame power whlchr		\$4,632.10	HCPCS - Non-Drug
K0011	NU	Stnd wt pwr whlchr w control		\$10,404.89	HCPCS - Non-Drug
K0011	RR	Stnd wt pwr whlchr w control		\$767.80	HCPCS - Non-Drug
K0012	RR	Ltwt portbl power whlchr		\$471.24	HCPCS - Non-Drug
K0012		Ltwt portbl power whlchr		\$4,483.25	HCPCS - Non-Drug
K0014		Other power whlchr base		\$5.39	HCPCS - Non-Drug
K0015	NU	Detach non-adjus hght armrst		\$263.79	HCPCS - Non-Drug
K0015	RR	Detach non-adjus hght armrst		\$28.91	HCPCS - Non-Drug
K0015	UE	Detach non-adjus hght armrst		\$197.98	HCPCS - Non-Drug
K0017	NU	Detach adjust armrest base		\$74.61	HCPCS - Non-Drug
K0017	RR	Detach adjust armrest base		\$10.81	HCPCS - Non-Drug
K0017	UE	Detach adjust armrest base		\$56.81	HCPCS - Non-Drug
K0018	NU	Detach adjust armrst upper		\$43.27	HCPCS - Non-Drug
K0018	RR	Detach adjust armrst upper		\$6.10	HCPCS - Non-Drug
K0018	UE	Detach adjust armrst upper		\$33.41	HCPCS - Non-Drug
K0019	NU	Arm pad each		\$27.61	HCPCS - Non-Drug
K0019	RR	Arm pad each		\$3.70	HCPCS - Non-Drug
K0019	UE	Arm pad each		\$21.64	HCPCS - Non-Drug
K0020	NU	Fixed adjust armrest pair		\$68.08	HCPCS - Non-Drug
K0020	RR	Fixed adjust armrest pair		\$9.98	HCPCS - Non-Drug
K0020	UE	Fixed adjust armrest pair		\$51.97	HCPCS - Non-Drug
K0037	NU	High mount flip-up footrest		\$70.43	HCPCS - Non-Drug
K0037	RR	High mount flip-up footrest		\$9.23	HCPCS - Non-Drug
K0037	UE	High mount flip-up footrest		\$53.77	HCPCS - Non-Drug
K0038	NU	Leq strap each		\$37.33	HCPCS - Non-Drug
K0038	RR	Leq strap each		\$5.21	HCPCS - Non-Drug
K0038	UE	Leq strap each		\$28.93	HCPCS - Non-Drug
K0039	NU	Leq strap h style each		\$78.63	HCPCS - Non-Drug
K0039	RR	Leq strap h style each		\$11.20	HCPCS - Non-Drug
K0039	UE	Leq strap h style each		\$59.71	HCPCS - Non-Drug
K0040	NU	Adjustable angle footplate		\$108.75	HCPCS - Non-Drug
K0040	RR	Adjustable angle footplate		\$14.05	HCPCS - Non-Drug
K0040	UE	Adjustable angle footplate		\$81.69	HCPCS - Non-Drug
K0041	NU	Large size footplate each		\$77.23	HCPCS - Non-Drug
K0041	RR	Large size footplate each		\$11.07	HCPCS - Non-Drug
K0041	UE	Large size footplate each		\$58.70	HCPCS - Non-Drug
K0042	NU	Standard size footplate each		\$54.18	HCPCS - Non-Drug
K0042	RR	Standard size footplate each		\$7.80	HCPCS - Non-Drug
K0042	UE	Standard size footplate each		\$41.56	HCPCS - Non-Drug
K0043	NU	First lower extension tube		\$30.77	HCPCS - Non-Drug
K0043	RR	First lower extension tube		\$4.18	HCPCS - Non-Drug
K0043	UE	First lower extension tube		\$24.03	HCPCS - Non-Drug
K0044	NU	First upper hanger bracket		\$26.77	HCPCS - Non-Drug
K0044	RR	First upper hanger bracket		\$3.60	HCPCS - Non-Drug
K0044	UE	First upper hanger bracket		\$21.00	HCPCS - Non-Drug
K0045	NU	Footrest complete assembly		\$82.60	HCPCS - Non-Drug
K0045	RR	Footrest complete assembly		\$11.81	HCPCS - Non-Drug
K0045	UE	Footrest complete assembly		\$62.54	HCPCS - Non-Drug
K0045		Footrest complete assembly		\$30.77	HCPCS - Non-Drug
K0046	NU	Elevat legrst low extension		\$4.18	HCPCS - Non-Drug
K0046	RR	Elevat legrst low extension		\$24.03	HCPCS - Non-Drug
K0046	UE	Elevat legrst low extension		\$111.38	HCPCS - Non-Drug
K0047	NU	Elevat legrst up hangr brack		\$14.35	HCPCS - Non-Drug
K0047	RR	Elevat legrst up hangr brack		\$83.64	HCPCS - Non-Drug
K0047	UE	Elevat legrst up hangr brack		\$48.74	HCPCS - Non-Drug
K0050	NU	Ratchet assembly		\$6.96	HCPCS - Non-Drug
K0050	RR	Ratchet assembly		\$37.50	HCPCS - Non-Drug
K0050	UE	Ratchet assembly			HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 34 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAF Category
K0051	NU	Cam release assem frst/lgrst		\$76.79	HCPCS - Non-Drug
K0051	RR	Cam release assem frst/lgrst		\$11.05	HCPCS - Non-Drug
K0051	UE	Cam release assem frst/lgrst		\$58.36	HCPCS - Non-Drug
K0052	NU	Swingaway detach footrest		\$134.49	HCPCS - Non-Drug
K0052	RR	Swingaway detach footrest		\$16.52	HCPCS - Non-Drug
K0052	UE	Swingaway detach footrest		\$101.01	HCPCS - Non-Drug
K0053	NU	Elevate footrest articulate		\$148.34	HCPCS - Non-Drug
K0053	RR	Elevate footrest articulate		\$17.84	HCPCS - Non-Drug
K0053	UE	Elevate footrest articulate		\$111.42	HCPCS - Non-Drug
K0056	NU	Seat ht <17 or >=21 lwt wc		\$138.35	HCPCS - Non-Drug
K0056	RR	Seat ht <17 or >=21 lwt wc		\$16.90	HCPCS - Non-Drug
K0056	UE	Seat ht <17 or >=21 lwt wc		\$103.93	HCPCS - Non-Drug
K0065	NU	Spoke protectors		\$65.31	HCPCS - Non-Drug
K0065	RR	Spoke protectors		\$9.53	HCPCS - Non-Drug
K0065	UE	Spoke protectors		\$49.90	HCPCS - Non-Drug
K0069	NU	Rear whl complete solid tire		\$145.32	HCPCS - Non-Drug
K0069	RR	Rear whl complete solid tire		\$18.15	HCPCS - Non-Drug
K0069	UE	Rear whl complete solid tire		\$109.14	HCPCS - Non-Drug
K0070	NU	Rear whl compl pneum tire		\$265.91	HCPCS - Non-Drug
K0070	RR	Rear whl compl pneum tire		\$29.10	HCPCS - Non-Drug
K0070	UE	Rear whl compl pneum tire		\$199.57	HCPCS - Non-Drug
K0071	NU	Front castr compl pneum tire		\$158.83	HCPCS - Non-Drug
K0071	RR	Front castr compl pneum tire		\$18.86	HCPCS - Non-Drug
K0071	UE	Front castr compl pneum tire		\$119.25	HCPCS - Non-Drug
K0072	NU	Fmt cstr compl sem-pneum tir		\$95.84	HCPCS - Non-Drug
K0072	RR	Fmt cstr compl sem-pneum tir		\$12.83	HCPCS - Non-Drug
K0072	UE	Fmt cstr compl sem-pneum tir		\$72.04	HCPCS - Non-Drug
K0073	NU	Caster pin lock each		\$51.93	HCPCS - Non-Drug
K0073	RR	Caster pin lock each		\$7.46	HCPCS - Non-Drug
K0073	UE	Caster pin lock each		\$39.88	HCPCS - Non-Drug
K0077	NU	Front caster assem complete		\$85.84	HCPCS - Non-Drug
K0077	RR	Front caster assem complete		\$11.87	HCPCS - Non-Drug
K0077	UE	Front caster assem complete		\$64.86	HCPCS - Non-Drug
K0090	NU	Rear tire power wheelchair		\$110.94	HCPCS - Non-Drug
K0090	RR	Rear tire power wheelchair		\$14.28	HCPCS - Non-Drug
K0090	UE	Rear tire power wheelchair		\$83.35	HCPCS - Non-Drug
K0091	NU	Rear tire tube power whlchr		\$32.50	HCPCS - Non-Drug
K0091	RR	Rear tire tube power whlchr		\$4.44	HCPCS - Non-Drug
K0091	UE	Rear tire tube power whlchr		\$25.31	HCPCS - Non-Drug
K0092	NU	Rear assem cmplt powr whlchr		\$352.77	HCPCS - Non-Drug
K0092	RR	Rear assem cmplt powr whlchr		\$37.39	HCPCS - Non-Drug
K0092	UE	Rear assem cmplt powr whlchr		\$264.73	HCPCS - Non-Drug
K0093	NU	Rear zero pressure tire tube		\$220.59	HCPCS - Non-Drug
K0093	RR	Rear zero pressure tire tube		\$24.77	HCPCS - Non-Drug
K0093	UE	Rear zero pressure tire tube		\$165.58	HCPCS - Non-Drug
K0094	NU	Wheel tire for power base		\$72.29	HCPCS - Non-Drug
K0094	RR	Wheel tire for power base		\$10.58	HCPCS - Non-Drug
K0094	UE	Wheel tire for power base		\$55.13	HCPCS - Non-Drug
K0095	NU	Wheel tire tube each base		\$72.29	HCPCS - Non-Drug
K0095	RR	Wheel tire tube each base		\$10.58	HCPCS - Non-Drug
K0095	UE	Wheel tire tube each base		\$55.13	HCPCS - Non-Drug
K0096	NU	Wheel assem powr base complt		\$397.90	HCPCS - Non-Drug
K0096	RR	Wheel assem powr base complt		\$41.71	HCPCS - Non-Drug
K0096	UE	Wheel assem powr base complt		\$298.58	HCPCS - Non-Drug
K0097	NU	Wheel zero presure tire tube		\$91.97	HCPCS - Non-Drug
K0097	RR	Wheel zero presure tire tube		\$12.47	HCPCS - Non-Drug
K0097	UE	Wheel zero presure tire tube		\$69.25	HCPCS - Non-Drug
K0098	NU	Drive belt power wheelchair		\$41.42	HCPCS - Non-Drug
K0098	RR	Drive belt power wheelchair		\$5.84	HCPCS - Non-Drug
K0098	UE	Drive belt power wheelchair		\$31.96	HCPCS - Non-Drug
K0099	NU	Pwr wheelchair front caster		\$117.79	HCPCS - Non-Drug
K0099	RR	Pwr wheelchair front caster		\$14.96	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 35 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
K0099	UE	Pwr wheel chair front caster		\$88.48	HCPCS - Non-Drug
K0108		W/c component-accessory NOS		\$101.43	HCPCS - Non-Drug
K0195	RR	Elevating wheelchair leg rests		\$32.90	HCPCS - Non-Drug
K0195		Elevating wheelchair leg rests		\$162.25	HCPCS - Non-Drug
K0455	RR	Pump uninterrupted infusion		\$494.61	HCPCS - Non-Drug
K0552		Supply/ext inf pump syr type		\$8.30	HCPCS - Non-Drug
K0601		Repl batt silver oxide 1.5 v		\$4.86	HCPCS - Non-Drug
K0602		Repl batt silver oxide 3 v		\$13.89	HCPCS - Non-Drug
K0603		Repl batt alkaline 1.5 v		\$2.53	HCPCS - Non-Drug
K0604		Repl batt lithium 3.6 v		\$13.48	HCPCS - Non-Drug
K0605		Repl batt lithium 4.5 v		\$26.32	HCPCS - Non-Drug
K0607		Repl batt for AED		\$359.91	HCPCS - Non-Drug
K0608		Repl garment for AED		\$220.67	HCPCS - Non-Drug
K0609		Repl electrode for AED		\$1,526.70	HCPCS - Non-Drug
L0100		Cranial orthosis/helmet mold		\$750.70	HCPCS - Non-Drug
L0110		Cranial orthosis/helmet nonm		\$176.92	HCPCS - Non-Drug
L0112		Cranial cervical orthosis		\$1,436.05	HCPCS - Non-Drug
L0120		Cerv flexible non-adjustable		\$34.78	HCPCS - Non-Drug
L0130		Flex thermoplastic collar mo		\$200.57	HCPCS - Non-Drug
L0140		Cervical semi-rigid adjustab		\$80.26	HCPCS - Non-Drug
L0150		Cerv semi-rig adj molded chn		\$133.72	HCPCS - Non-Drug
L0160		Cerv semi-rig wire occ/mand		\$192.65	HCPCS - Non-Drug
L0170		Cervical collar molded to pt		\$846.62	HCPCS - Non-Drug
L0172		Cerv col themplas foam 2 pi		\$156.65	HCPCS - Non-Drug
L0174		Cerv col foam 2 piece w thor		\$335.97	HCPCS - Non-Drug
L0180		Cerv post col occ/man sup adj		\$466.03	HCPCS - Non-Drug
L0190		Cerv collar supp adj cerv ba		\$639.19	HCPCS - Non-Drug
L0200		Cerv col supp adj bar & thor		\$668.36	HCPCS - Non-Drug
L0210		Thoracic nb belt		\$56.31	HCPCS - Non-Drug
L0220		Thor rib belt custom fabrica		\$151.21	HCPCS - Non-Drug
L0430		Dewall posture protector		\$1,439.00	HCPCS - Non-Drug
L0450		TLSO flex prefab thoracic		\$213.51	HCPCS - Non-Drug
L0452		tiso flex custom fab thoraci		\$14.24	HCPCS - Non-Drug
L0454		TLSO flex prefab sacrococ-T9		\$411.68	HCPCS - Non-Drug
L0456		TLSO flex prefab		\$1,270.11	HCPCS - Non-Drug
L0458		TLSO 2Mod symphis-xipho pre		\$1,133.96	HCPCS - Non-Drug
L0460		TLSO 2Mod symphysis-stem pre		\$1,282.35	HCPCS - Non-Drug
L0462		TLSO 3Mod sacro-scap pre		\$1,281.08	HCPCS - Non-Drug
L0464		TLSO 4Mod sacro-scap pre		\$1,921.92	HCPCS - Non-Drug
L0466		TLSO rigid frame pre soft ap		\$470.31	HCPCS - Non-Drug
L0468		TLSO rigid frame prefab pelv		\$587.89	HCPCS - Non-Drug
L0470		TLSO rigid frame pre subclav		\$836.43	HCPCS - Non-Drug
L0472		TLSO rigid frame hyperex pre		\$512.94	HCPCS - Non-Drug
L0480		TLSO rigid plastic custom fa		\$1,927.22	HCPCS - Non-Drug
L0482		TLSO rigid lined custom fab		\$2,103.05	HCPCS - Non-Drug
L0484		TLSO rigid plastic cust fab		\$2,417.12	HCPCS - Non-Drug
L0486		TLSO rigid lined cust fab two		\$2,567.34	HCPCS - Non-Drug
L0488		TLSO rigid lined pre one pie		\$1,282.35	HCPCS - Non-Drug
L0490		TLSO rigid plastic pre one		\$330.56	HCPCS - Non-Drug
L0700		Citso a-p-l control molded		\$2,756.35	HCPCS - Non-Drug
L0710		Citso a-p-l control w/ inter		\$2,849.02	HCPCS - Non-Drug
L0810		Halo cervical into jckt vest		\$3,529.95	HCPCS - Non-Drug
L0820		Halo cervical into body jack		\$2,948.29	HCPCS - Non-Drug
L0830		Halo cerv into milwaukee typ		\$4,301.69	HCPCS - Non-Drug
L0861		Halo repl liner/interface		\$221.15	HCPCS - Non-Drug
L0960		Post surgical support pads		\$86.41	HCPCS - Non-Drug
L0970		Tlso corset front		\$141.28	HCPCS - Non-Drug
L0972		Lso corset front		\$127.47	HCPCS - Non-Drug
L0974		Tlso full corset		\$219.86	HCPCS - Non-Drug
L0976		Lso full corset		\$196.62	HCPCS - Non-Drug
L0978		Axillary crutch extension		\$236.19	HCPCS - Non-Drug
L0980		Peroneal straps pair		\$23.76	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. -- DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 36 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
L0982		Stocking supp grips set of f		\$22.33	HCPCS - Non-Drug
L0984		Protective body sock each		\$75.22	HCPCS - Non-Drug
L0999		Add to spinal orthosis NOS		\$307.54	HCPCS - Non-Drug
L1000		Cltso milwaukee initial model		\$2,768.20	HCPCS - Non-Drug
L1005		Tension based scoliosis orth		\$4,193.62	HCPCS - Non-Drug
L1010		Cltso axilla sling		\$84.03	HCPCS - Non-Drug
L1020		Kyphosis pad		\$107.47	HCPCS - Non-Drug
L1025		Kyphosis pad floating		\$153.92	HCPCS - Non-Drug
L1030		Lumbar bolster pad		\$79.78	HCPCS - Non-Drug
L1040		Lumbar or lumbar rib pad		\$97.26	HCPCS - Non-Drug
L1050		Sternal pad		\$103.62	HCPCS - Non-Drug
L1060		Thoracic pad		\$118.63	HCPCS - Non-Drug
L1070		Trapezius sling		\$111.77	HCPCS - Non-Drug
L1080		Outrigger		\$69.73	HCPCS - Non-Drug
L1085		Outrigger bil w/ vert extens		\$189.38	HCPCS - Non-Drug
L1090		Lumbar sling		\$113.82	HCPCS - Non-Drug
L1100		Ring flange plastic/leather		\$195.56	HCPCS - Non-Drug
L1110		Ring flange plas/leather mol		\$312.53	HCPCS - Non-Drug
L1120		Covers for upright each		\$50.78	HCPCS - Non-Drug
L1200		Fumsh initial orthosis only		\$2,125.42	HCPCS - Non-Drug
L1210		Lateral thoracic extension		\$320.12	HCPCS - Non-Drug
L1220		Anterior thoracic extension		\$271.44	HCPCS - Non-Drug
L1230		Milwaukee type superstructure		\$740.57	HCPCS - Non-Drug
L1240		Lumbar derotation pad		\$96.81	HCPCS - Non-Drug
L1250		Anterior asis pad		\$90.27	HCPCS - Non-Drug
L1260		Anterior thoracic derotation		\$94.37	HCPCS - Non-Drug
L1270		Abdominal pad		\$96.61	HCPCS - Non-Drug
L1280		Rib gusset (elastic) each		\$107.27	HCPCS - Non-Drug
L1290		Lateral trochanteric pad		\$97.96	HCPCS - Non-Drug
L1300		Body jacket mold to patient		\$2,269.12	HCPCS - Non-Drug
L1310		Post-operative body jacket		\$2,336.31	HCPCS - Non-Drug
L1499		Spinal orthosis NOS		\$305.54	HCPCS - Non-Drug
L1500		Thkao mobility frame		\$2,586.80	HCPCS - Non-Drug
L1510		Thkao standing frame		\$1,618.92	HCPCS - Non-Drug
L1520		Thkao swivel walker		\$3,116.55	HCPCS - Non-Drug
L1600		Abduct hip flex frejka w cvr		\$158.97	HCPCS - Non-Drug
L1610		Abduct hip flex frejka covr		\$55.85	HCPCS - Non-Drug
L1620		Abduct hip flex pavlik hame		\$165.19	HCPCS - Non-Drug
L1630		Abduct control hip semi-flex		\$208.22	HCPCS - Non-Drug
L1640		Pelv band/spread bar thigh c		\$592.12	HCPCS - Non-Drug
L1650		HO abduction hip adjustable		\$283.56	HCPCS - Non-Drug
L1652		HO bi thighcuffs w sprdr bar		\$424.48	HCPCS - Non-Drug
L1660		HO abduction static plastic		\$210.27	HCPCS - Non-Drug
L1680		Pelvic & hip control thigh c		\$1,642.15	HCPCS - Non-Drug
L1685		Post-op hip abduct custom fa		\$1,601.98	HCPCS - Non-Drug
L1686		HO post-op hip abduction		\$1,217.37	HCPCS - Non-Drug
L1690		Combination bilateral HO		\$2,514.70	HCPCS - Non-Drug
L1700		Leg perthes orth toronto typ		\$2,070.32	HCPCS - Non-Drug
L1710		Legq perthes orth newington		\$2,431.70	HCPCS - Non-Drug
L1720		Legq perthes orthosis triatl		\$1,779.86	HCPCS - Non-Drug
L1730		Legq perthes orth scottish r		\$1,521.98	HCPCS - Non-Drug
L1755		Legq perthes patten bottom t		\$2,148.17	HCPCS - Non-Drug
L1800		Knee orthoses elas w stays		\$83.31	HCPCS - Non-Drug
L1810		Ko elastic with joints		\$122.10	HCPCS - Non-Drug
L1815		Elastic with condylar pads		\$120.14	HCPCS - Non-Drug
L1820		Ko elas w/ condyle pads & jo		\$159.92	HCPCS - Non-Drug
L1825		Ko elastic knee cap		\$69.30	HCPCS - Non-Drug
L1830		Ko immobilizer canvas longit		\$108.74	HCPCS - Non-Drug
L1831		Knee orth pos locking joint		\$301.98	HCPCS - Non-Drug
L1832		KO adj jnt pos rigid support		\$795.38	HCPCS - Non-Drug
L1834		Ko w/o joint rigid molded to		\$1,028.82	HCPCS - Non-Drug
L1836		Rigid KO wo joints		\$157.28	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. -- DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 37 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
L1840		Ko derot ant cruciate custom		\$1,227.48	HCPCS - Non-Drug
L1843		KO single upright custom fit		\$1,141.16	HCPCS - Non-Drug
L1844		Ko w/adj jt rot cntrl molded		\$2,157.66	HCPCS - Non-Drug
L1845		Ko w/ adj flex/ext rotat cus		\$1,085.81	HCPCS - Non-Drug
L1846		Ko w adj flex/ext rotat mold		\$1,424.75	HCPCS - Non-Drug
L1847		KO adjustable w air chambers		\$714.29	HCPCS - Non-Drug
L1850		Ko swedish type		\$351.90	HCPCS - Non-Drug
L1855		Ko plas doub upright jint mol		\$1,476.32	HCPCS - Non-Drug
L1858		Ko polycentric pneumatic pad		\$1,614.16	HCPCS - Non-Drug
L1860		Ko supracondylar socket mold		\$1,440.49	HCPCS - Non-Drug
L1870		Ko doub upright lacers molde		\$1,403.69	HCPCS - Non-Drug
L1880		Ko doub upright cuffs/lacers		\$933.85	HCPCS - Non-Drug
L1900		Afo spmq wir drsflx calf bd		\$329.97	HCPCS - Non-Drug
L1901		Prefab ankle orthosis		\$23.08	HCPCS - Non-Drug
L1902		Afo ankle gauntlet		\$99.45	HCPCS - Non-Drug
L1904		Afo molded ankle gauntlet		\$604.36	HCPCS - Non-Drug
L1906		Afo multiligamentus ankle su		\$148.54	HCPCS - Non-Drug
L1907		AFO supramalleolar custom		\$577.34	HCPCS - Non-Drug
L1910		Afo sinq bar clasp attach sh		\$327.12	HCPCS - Non-Drug
L1920		Afo sinq upright w/ adjust s		\$437.00	HCPCS - Non-Drug
L1930		Afo plastic		\$289.67	HCPCS - Non-Drug
L1932		Afo rig ant tib prefab TCF/=		\$915.58	HCPCS - Non-Drug
L1940		Afo molded to patient plasti		\$638.06	HCPCS - Non-Drug
L1945		Afo molded plas rig ant tib		\$1,236.10	HCPCS - Non-Drug
L1950		Afo spiral molded to pt plas		\$985.25	HCPCS - Non-Drug
L1951		AFO spiral prefabricated		\$861.69	HCPCS - Non-Drug
L1960		Afo pos solid ank plastic mo		\$720.92	HCPCS - Non-Drug
L1970		Afo plastic molded w/ankle i		\$939.09	HCPCS - Non-Drug
L1971		AFO w/ankle joint, prefab		\$480.92	HCPCS - Non-Drug
L1980		Afo sinq solid stirrup calf		\$461.14	HCPCS - Non-Drug
L1990		Afo doub solid stirrup calf		\$570.36	HCPCS - Non-Drug
L2000		Kafo sinq fre stirr thi/calf		\$1,358.97	HCPCS - Non-Drug
L2005		KAFO snq/dbl mechanical act		\$3,693.35	HCPCS - Non-Drug
L2010		Kafo snq solid stirrup w/o i		\$1,234.60	HCPCS - Non-Drug
L2020		Kafo dbl solid stirrup band/		\$1,571.72	HCPCS - Non-Drug
L2030		Kafo dbl solid stirrup w/o i		\$1,357.26	HCPCS - Non-Drug
L2035		KAFO plastic pediatric size		\$204.69	HCPCS - Non-Drug
L2036		Kafo plas doub free knee mol		\$2,525.59	HCPCS - Non-Drug
L2037		Kafo plas sinq free knee mol		\$2,262.41	HCPCS - Non-Drug
L2038		Kafo w/o joint multi-axis an		\$1,935.24	HCPCS - Non-Drug
L2040		Hkafo torsion bil rot straps		\$218.04	HCPCS - Non-Drug
L2050		Hkafo torsion cable hip pelv		\$612.83	HCPCS - Non-Drug
L2060		Hkafo torsion ball bearing i		\$757.41	HCPCS - Non-Drug
L2070		Hkafo torsion unilat rot str		\$165.79	HCPCS - Non-Drug
L2080		Hkafo unilat torsion cable		\$450.98	HCPCS - Non-Drug
L2090		Hkafo unilat torsion ball br		\$560.31	HCPCS - Non-Drug
L2106		Afo tib fx cast plaster mold		\$895.17	HCPCS - Non-Drug
L2108		Afo tib fx cast molded to pt		\$1,434.12	HCPCS - Non-Drug
L2112		Afo tibial fracture soft		\$599.22	HCPCS - Non-Drug
L2114		Afo tib fx semi-rigid		\$757.20	HCPCS - Non-Drug
L2116		Afo tibial fracture rigid		\$939.55	HCPCS - Non-Drug
L2126		Kafo fem fx cast thermoplas		\$1,613.07	HCPCS - Non-Drug
L2128		Kafo fem fx cast molded to p		\$2,330.56	HCPCS - Non-Drug
L2132		Kafo femoral fx cast soft		\$1,071.01	HCPCS - Non-Drug
L2134		Kafo fem fx cast semi-rigid		\$1,293.63	HCPCS - Non-Drug
L2136		Kafo femoral fx cast rigid		\$1,592.45	HCPCS - Non-Drug
L2180		Plas shoe insert w ank joint		\$144.69	HCPCS - Non-Drug
L2182		Drop lock knee		\$113.81	HCPCS - Non-Drug
L2184		Limited motion knee joint		\$152.91	HCPCS - Non-Drug
L2186		Adj motion knee jint lerman t		\$185.27	HCPCS - Non-Drug
L2188		Quadrilateral brim		\$367.50	HCPCS - Non-Drug
L2190		Waist belt		\$108.56	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. -- DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE - CHARGES BY HCPCS CODE

PAGE 38 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
L2192		Pelvic band & belt thigh fla		\$446.65	HCPCS - Non-Drug
L2200		Limited ankle motion ea jnt		\$60.27	HCPCS - Non-Drug
L2210		Dorsiflexion assist each joi		\$84.16	HCPCS - Non-Drug
L2220		Dorsi & plantar flex ass/res		\$101.96	HCPCS - Non-Drug
L2230		Split flat caliper stirr & p		\$95.70	HCPCS - Non-Drug
L2240		Round caliper and plate atta		\$104.07	HCPCS - Non-Drug
L2250		Foot plate molded stirrup at		\$444.95	HCPCS - Non-Drug
L2260		Reinforced solid stirrup		\$245.85	HCPCS - Non-Drug
L2265		Long tongue stirrup		\$145.50	HCPCS - Non-Drug
L2270		Varus/valgus strap padded/li		\$67.74	HCPCS - Non-Drug
L2275		Plastic mod low ext pad/line		\$154.79	HCPCS - Non-Drug
L2280		Molded inner boot		\$580.18	HCPCS - Non-Drug
L2300		Abduction bar jointed adjust		\$329.32	HCPCS - Non-Drug
L2310		Abduction bar-straight		\$151.88	HCPCS - Non-Drug
L2320		Non-molded lacer		\$252.27	HCPCS - Non-Drug
L2330		Lacer molded to patient mode		\$496.74	HCPCS - Non-Drug
L2335		Anterior swing band		\$278.27	HCPCS - Non-Drug
L2340		Pre-tibial shell molded to p		\$572.02	HCPCS - Non-Drug
L2350		Prosthetic type socket molde		\$1,188.05	HCPCS - Non-Drug
L2360		Extended steel shank		\$65.37	HCPCS - Non-Drug
L2370		Patten bottom		\$314.12	HCPCS - Non-Drug
L2375		Torsion ank & half solid sti		\$139.71	HCPCS - Non-Drug
L2380		Torsion straight knee joint		\$151.98	HCPCS - Non-Drug
L2385		Straight knee joint heavy du		\$165.12	HCPCS - Non-Drug
L2390		Offset knee joint each		\$135.41	HCPCS - Non-Drug
L2395		Offset knee joint heavy duty		\$192.45	HCPCS - Non-Drug
L2397		Suspension sleeve lower ext		\$138.97	HCPCS - Non-Drug
L2405		Knee joint drop lock ea jnt		\$103.66	HCPCS - Non-Drug
L2415		Knee joint cam lock each joi		\$143.41	HCPCS - Non-Drug
L2425		Knee disc/dial lock/adj flex		\$168.77	HCPCS - Non-Drug
L2430		Knee jnt ratchet lock ea jnt		\$168.77	HCPCS - Non-Drug
L2492		Knee lift loop drop lock rin		\$126.33	HCPCS - Non-Drug
L2500		Thi/gluti/schia wgt bearing		\$389.66	HCPCS - Non-Drug
L2510		Th/wght bear quad-lat brim m		\$959.63	HCPCS - Non-Drug
L2520		Th/wght bear quad-lat brim c		\$591.08	HCPCS - Non-Drug
L2525		Th/wght bear nar m-l brim mo		\$1,642.92	HCPCS - Non-Drug
L2526		Th/wght bear nar m-l brim cu		\$902.16	HCPCS - Non-Drug
L2530		Thigh/wght bear lacer non-mo		\$287.71	HCPCS - Non-Drug
L2540		Thigh/wght bear lacer molded		\$538.51	HCPCS - Non-Drug
L2550		Thigh/wght bear high roll cu		\$351.12	HCPCS - Non-Drug
L2570		Hip clevis type 2 posit jnt		\$612.76	HCPCS - Non-Drug
L2580		Pelvic control pelvic sling		\$595.82	HCPCS - Non-Drug
L2600		Hip clevis/thrust bearing fr		\$251.82	HCPCS - Non-Drug
L2610		Hip clevis/thrust bearing lo		\$297.29	HCPCS - Non-Drug
L2620		Pelvic control hip heavy dut		\$327.06	HCPCS - Non-Drug
L2622		Hip joint adjustable flexion		\$377.44	HCPCS - Non-Drug
L2624		Hip adj flex ext abduct cont		\$411.40	HCPCS - Non-Drug
L2627		Plastic mold recipro hip & c		\$2,329.95	HCPCS - Non-Drug
L2628		Metal frame recipro hip & ca		\$2,276.00	HCPCS - Non-Drug
L2630		Pelvic control band & belt u		\$303.09	HCPCS - Non-Drug
L2640		Pelvic control band & belt b		\$418.22	HCPCS - Non-Drug
L2650		Pelv & thor control gluteal		\$148.22	HCPCS - Non-Drug
L2660		Thoracic control thoracic ba		\$228.77	HCPCS - Non-Drug
L2670		Thorac cont paraspinial uprig		\$209.59	HCPCS - Non-Drug
L2680		Thorac cont lat support upri		\$192.48	HCPCS - Non-Drug
L2750		Plating chrome/nickel pr bar		\$104.03	HCPCS - Non-Drug
L2755		Carbon graphite lamination		\$154.07	HCPCS - Non-Drug
L2760		Extension per extension per		\$76.31	HCPCS - Non-Drug
L2768		Ortho sidebar disconnect		\$153.65	HCPCS - Non-Drug
L2770		Low ext orthosis per bar/jnt		\$77.51	HCPCS - Non-Drug
L2780		Non-corrosive finish		\$84.71	HCPCS - Non-Drug
L2785		Drop lock retainer each		\$41.05	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 39 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
L2795		Knee control full kneecap		\$105.69	HCPCS - Non-Drug
L2800		Knee cap medial or lateral p		\$132.02	HCPCS - Non-Drug
L2810		Knee control condylar pad		\$97.36	HCPCS - Non-Drug
L2820		Soft interface below knee se		\$107.97	HCPCS - Non-Drug
L2830		Soft interface above knee se		\$116.60	HCPCS - Non-Drug
L2840		Tibial length sock fx or equ		\$55.60	HCPCS - Non-Drug
L2850		Femoral lgth sock fx or equa		\$77.71	HCPCS - Non-Drug
L2860		Torsion mechanism knee/ankle		\$464.45	HCPCS - Non-Drug
L2999		Lower extremity orthosis NOS		\$62.68	HCPCS - Non-Drug
L3000		Ft insert ucb berkeley shell		\$291.69	HCPCS - Non-Drug
L3001		Foot insert remov molded spe		\$173.01	HCPCS - Non-Drug
L3002		Foot insert plastazote or eq		\$143.18	HCPCS - Non-Drug
L3003		Foot insert silicone gel eac		\$175.44	HCPCS - Non-Drug
L3010		Foot longitudinal arch suppo		\$227.17	HCPCS - Non-Drug
L3020		Foot longitud/metatarsal sup		\$287.43	HCPCS - Non-Drug
L3030		Foot arch support remov prem		\$287.43	HCPCS - Non-Drug
L3031		Foot lamin/prepreg composite		\$1,529.36	HCPCS - Non-Drug
L3040		Ft arch suprt premold longit		\$53.09	HCPCS - Non-Drug
L3050		Foot arch supp premold metal		\$49.44	HCPCS - Non-Drug
L3060		Foot arch supp longitud/meta		\$93.26	HCPCS - Non-Drug
L3070		Arch suprt att to sho longit		\$30.58	HCPCS - Non-Drug
L3080		Arch supp att to shoe metata		\$14.08	HCPCS - Non-Drug
L3090		Arch supp att to shoe long/m		\$20.23	HCPCS - Non-Drug
L3100		Hallus-valgus nght dynamic s		\$31.79	HCPCS - Non-Drug
L3140		Abduction rotation bar shoe		\$87.79	HCPCS - Non-Drug
L3150		Abduct rotation bar w/o shoe		\$73.79	HCPCS - Non-Drug
L3160		Shoe styled positioning dev		\$24.49	HCPCS - Non-Drug
L3170		Foot plastic heel stabilizer		\$39.70	HCPCS - Non-Drug
L3201		Oxford w supinat/pronator inf		\$87.18	HCPCS - Non-Drug
L3202		Oxford w/ supinat/pronator c		\$85.35	HCPCS - Non-Drug
L3203		Oxford w/ supinator/pronator		\$83.53	HCPCS - Non-Drug
L3204		Hightop w/ suppl/pronator inf		\$83.53	HCPCS - Non-Drug
L3206		Hightop w/ suppl/pronator chi		\$86.56	HCPCS - Non-Drug
L3207		Hightop w/ suppl/pronator jun		\$87.79	HCPCS - Non-Drug
L3208		Surgical boot each infant		\$47.63	HCPCS - Non-Drug
L3209		Surgical boot each child		\$65.88	HCPCS - Non-Drug
L3211		Surgical boot each junior		\$70.14	HCPCS - Non-Drug
L3212		Benesch boot pair infant		\$96.92	HCPCS - Non-Drug
L3213		Benesch boot pair child		\$116.39	HCPCS - Non-Drug
L3214		Benesch boot pair junior		\$123.70	HCPCS - Non-Drug
L3215		Orthopedic ftwear ladies oxf		\$156.57	HCPCS - Non-Drug
L3216		Orthoped ladies shoes dpth i		\$188.82	HCPCS - Non-Drug
L3217		Ladies shoes hightop depth i		\$204.65	HCPCS - Non-Drug
L3219		Orthopedic mens shoes oxford		\$175.44	HCPCS - Non-Drug
L3221		Orthopedic mens shoes dpth i		\$210.13	HCPCS - Non-Drug
L3222		Mens shoes hightop depth inl		\$232.04	HCPCS - Non-Drug
L3224		Woman's shoe oxford brace		\$73.94	HCPCS - Non-Drug
L3225		Man's shoe oxford brace		\$84.67	HCPCS - Non-Drug
L3230		Custom shoes depth inlay		\$272.21	HCPCS - Non-Drug
L3250		Custom mold shoe remov prost		\$552.45	HCPCS - Non-Drug
L3251		Shoe molded to pt silicone s		\$75.01	HCPCS - Non-Drug
L3252		Shoe molded plastazote cust		\$289.86	HCPCS - Non-Drug
L3253		Shoe molded plastazote cust		\$74.40	HCPCS - Non-Drug
L3254		Orth foot non-standard size/w		\$25.34	HCPCS - Non-Drug
L3255		Orth foot non-standard size/		\$28.15	HCPCS - Non-Drug
L3257		Orth foot add charge split s		\$54.92	HCPCS - Non-Drug
L3260		Ambulatory surgical boot eac		\$31.79	HCPCS - Non-Drug
L3265		Plastazote sandal each		\$34.23	HCPCS - Non-Drug
L3300		Sho lift taper to metatarsal		\$39.10	HCPCS - Non-Drug
L3310		Shoe lift elev heel/sole neo		\$76.23	HCPCS - Non-Drug
L3320		Shoe lift elev heel/sole cor		\$196.74	HCPCS - Non-Drug
L3330		Lifts elevation metal extens		\$317.26	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 40 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAF Category
L3332		Shoe lifts tapered to one-ha		\$24.49	HCPCS - Non-Drug
L3334		Shoe lifts elevation heel fi		\$24.49	HCPCS - Non-Drug
L3340		Shoe wedge sach		\$55.53	HCPCS - Non-Drug
L3350		Shoe heel wedge		\$36.05	HCPCS - Non-Drug
L3360		Shoe sole wedge outside sole		\$27.53	HCPCS - Non-Drug
L3370		Shoe sole wedge between sole		\$32.40	HCPCS - Non-Drug
L3380		Shoe clubfoot wedge		\$54.31	HCPCS - Non-Drug
L3390		Shoe outflare wedge		\$74.40	HCPCS - Non-Drug
L3400		Shoe metatarsal bar wedge ro		\$71.36	HCPCS - Non-Drug
L3410		Shoe metatarsal bar between		\$119.44	HCPCS - Non-Drug
L3420		Full sole/heel wedge btween		\$39.70	HCPCS - Non-Drug
L3430		Sho heel count plast reinfor		\$96.31	HCPCS - Non-Drug
L3440		Heel leather reinforced		\$65.88	HCPCS - Non-Drug
L3450		Shoe heel sach cushion type		\$53.70	HCPCS - Non-Drug
L3455		Shoe heel new leather standa		\$23.88	HCPCS - Non-Drug
L3460		Shoe heel new rubber standar		\$39.70	HCPCS - Non-Drug
L3465		Shoe heel thomas with wedge		\$28.75	HCPCS - Non-Drug
L3470		Shoe heel thomas extend to b		\$67.10	HCPCS - Non-Drug
L3480		Shoe heel pad & depress for		\$46.40	HCPCS - Non-Drug
L3485		Shoe heel pad removable for		\$31.79	HCPCS - Non-Drug
L3500		Ortho shoe add leather insol		\$34.84	HCPCS - Non-Drug
L3510		Orthopedic shoe add rub insl		\$32.40	HCPCS - Non-Drug
L3520		O shoe add felt w leath insl		\$51.88	HCPCS - Non-Drug
L3530		Ortho shoe add half sole		\$17.18	HCPCS - Non-Drug
L3540		Ortho shoe add full sole		\$56.74	HCPCS - Non-Drug
L3550		O shoe add standard toe tap		\$10.38	HCPCS - Non-Drug
L3560		O shoe add horseshoe toe tap		\$14.08	HCPCS - Non-Drug
L3570		O shoe add instep extension		\$51.27	HCPCS - Non-Drug
L3580		O shoe add instep velcro clo		\$74.40	HCPCS - Non-Drug
L3590		O shoe convert to sof counte		\$58.58	HCPCS - Non-Drug
L3595		Ortho shoe add march bar		\$19.01	HCPCS - Non-Drug
L3600		Trans shoe calip plate exist		\$93.26	HCPCS - Non-Drug
L3610		Trans shoe caliper plate new		\$149.27	HCPCS - Non-Drug
L3620		Trans shoe solid stirrup exi		\$93.26	HCPCS - Non-Drug
L3630		Trans shoe solid stirrup new		\$113.97	HCPCS - Non-Drug
L3640		Shoe dennis browne splint bo		\$39.10	HCPCS - Non-Drug
L3649		Orthopedic shoe modifca NOS		\$25.37	HCPCS - Non-Drug
L3650		Slider fig 8 abduct restrain		\$73.01	HCPCS - Non-Drug
L3651		Prefab shoulder orthosis		\$72.06	HCPCS - Non-Drug
L3652		Prefab dbl shoulder orthosis		\$211.97	HCPCS - Non-Drug
L3660		Abduct restrainer canvas&web		\$124.63	HCPCS - Non-Drug
L3670		Acromio/clavicular canvas&we		\$136.87	HCPCS - Non-Drug
L3675		Canvas vest SO		\$187.75	HCPCS - Non-Drug
L3677		SO hard plastic stabilizer		\$215.00	HCPCS - Non-Drug
L3700		Elbow orthoses elas w stays		\$85.46	HCPCS - Non-Drug
L3701		Prefab elbow orthosis		\$24.06	HCPCS - Non-Drug
L3710		Elbow elastic with metal joi		\$149.38	HCPCS - Non-Drug
L3720		Forearm/arm cuffs free motio		\$839.88	HCPCS - Non-Drug
L3730		Forearm/arm cuffs ext/flex a		\$1,175.65	HCPCS - Non-Drug
L3740		Cuffs adj lock w/ active con		\$1,402.73	HCPCS - Non-Drug
L3760		EO withjoint, Prefabricated		\$555.21	HCPCS - Non-Drug
L3762		Rigid EO wo joints		\$116.03	HCPCS - Non-Drug
L3800		Whfo short opponen no attach		\$240.04	HCPCS - Non-Drug
L3805		Whfo long opponens no attach		\$386.34	HCPCS - Non-Drug
L3807		WHFO,no joint, prefabricated		\$266.42	HCPCS - Non-Drug
L3810		Whfo thumb abduction bar		\$79.54	HCPCS - Non-Drug
L3815		Whfo second m.p. abduction a		\$74.02	HCPCS - Non-Drug
L3820		Whfo ip ext asst w/ mp ext s		\$125.30	HCPCS - Non-Drug
L3825		Whfo m.p. extension stop		\$79.59	HCPCS - Non-Drug
L3830		Whfo m.p. extension assist		\$103.11	HCPCS - Non-Drug
L3835		Whfo m.p. spring extension a		\$111.56	HCPCS - Non-Drug
L3840		Whfo spring swivel thumb		\$77.22	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 41 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAF Category
L3845		Whfo thumb ip ext ass w/ mp		\$98.98	HCPCS - Non-Drug
L3850		Action wrist w/ dorsiflex as		\$140.29	HCPCS - Non-Drug
L3855		Whfo adj m.p. flexion contro		\$141.39	HCPCS - Non-Drug
L3860		Whfo adj m.p. flex ctrl & i.		\$192.58	HCPCS - Non-Drug
L3890		Torsion mechanism wrist/elbo		\$340.10	HCPCS - Non-Drug
L3900		Hinge extension/flex wrist/ff		\$1,708.40	HCPCS - Non-Drug
L3901		Hinge ext/flex wrist finger		\$2,133.36	HCPCS - Non-Drug
L3902		Whfo ext power compress gas		\$3,424.21	HCPCS - Non-Drug
L3904		Whfo electric custom fitted		\$3,926.96	HCPCS - Non-Drug
L3906		Wrist gauntlet molded to pt		\$488.42	HCPCS - Non-Drug
L3907		Whfo wrst gauntlt thmb spica		\$641.56	HCPCS - Non-Drug
L3908		Wrist cock-up non-molded		\$73.73	HCPCS - Non-Drug
L3909		Prefab wrist orthosis		\$17.49	HCPCS - Non-Drug
L3910		Whfo swanson design		\$461.21	HCPCS - Non-Drug
L3911		Prefab hand finger orthosis		\$23.13	HCPCS - Non-Drug
L3912		Flex glove w/elastic finger		\$115.20	HCPCS - Non-Drug
L3914		WHO wrist extension cock-up		\$104.37	HCPCS - Non-Drug
L3916		Whfo wrist extens w/ outrigg		\$153.41	HCPCS - Non-Drug
L3917		Prefab metacarp l fx orthosis		\$98.63	HCPCS - Non-Drug
L3918		HFO knuckle bender		\$95.65	HCPCS - Non-Drug
L3920		Knuckle bender with outrigg		\$118.89	HCPCS - Non-Drug
L3922		Knuckle bend 2 seq to flex j		\$118.71	HCPCS - Non-Drug
L3923		HFO, no joint, prefabricated		\$43.63	HCPCS - Non-Drug
L3924		Oppenheimer		\$129.19	HCPCS - Non-Drug
L3926		Thomas suspension		\$112.83	HCPCS - Non-Drug
L3928		Finger extension w/ clock sp		\$71.70	HCPCS - Non-Drug
L3930		Finger extension with wrist		\$75.63	HCPCS - Non-Drug
L3932		Safety pin spring wire		\$58.39	HCPCS - Non-Drug
L3934		Safety pin modified		\$59.79	HCPCS - Non-Drug
L3936		Palmer		\$108.35	HCPCS - Non-Drug
L3938		Dorsal wrist		\$113.35	HCPCS - Non-Drug
L3940		Dorsal wrist w/ outrigger at		\$130.24	HCPCS - Non-Drug
L3942		Reverse knuckle bender		\$90.88	HCPCS - Non-Drug
L3944		Reverse knuckle bend w/ outr		\$119.20	HCPCS - Non-Drug
L3946		HFO composite elastic		\$107.82	HCPCS - Non-Drug
L3948		Finger knuckle bender		\$68.02	HCPCS - Non-Drug
L3950		Oppenheimer w/ knuckle bend		\$180.66	HCPCS - Non-Drug
L3952		Oppenheimer w/ rev knuckle 2		\$200.23	HCPCS - Non-Drug
L3954		Spreading hand		\$133.72	HCPCS - Non-Drug
L3956		Add joint upper ext orthosis		\$50.66	HCPCS - Non-Drug
L3960		Sewho airplan desiq abdu pos		\$949.61	HCPCS - Non-Drug
L3962		Sewho erbs palsey design abd		\$925.96	HCPCS - Non-Drug
L3964		Seo mobile arm sup att to wc		\$595.81	HCPCS - Non-Drug
L3965		Arm supp att to wc rancho ty		\$979.37	HCPCS - Non-Drug
L3966		Mobile arm supports reclinin		\$725.98	HCPCS - Non-Drug
L3968		Friction dampening arm supp		\$931.44	HCPCS - Non-Drug
L3969		Monosuspension arm/hand supp		\$636.92	HCPCS - Non-Drug
L3970		Elevat proximal arm support		\$242.27	HCPCS - Non-Drug
L3972		Offset/lat rocker arm w/ ela		\$154.99	HCPCS - Non-Drug
L3974		Mobile arm support supinator		\$131.85	HCPCS - Non-Drug
L3980		Upp ext fx orthosis humeral		\$371.69	HCPCS - Non-Drug
L3982		Upper ext fx orthosis rad/ul		\$458.79	HCPCS - Non-Drug
L3984		Upper ext fx orthosis wrist		\$419.27	HCPCS - Non-Drug
L3985		Forearm hand fx orth w/ wr h		\$745.42	HCPCS - Non-Drug
L3986		Humeral rad/ulna wrist fx or		\$712.87	HCPCS - Non-Drug
L3995		Sock fracture or equal each		\$41.42	HCPCS - Non-Drug
L3999		Upper limb orthosis NOS		\$39.30	HCPCS - Non-Drug
L4000		Repl girdle milwaukee orth		\$1,720.69	HCPCS - Non-Drug
L4010		Replace trilateral socket br		\$882.97	HCPCS - Non-Drug
L4020		Replace quadlat socket brim		\$1,146.82	HCPCS - Non-Drug
L4030		Replace socket brim cust fit		\$652.39	HCPCS - Non-Drug
L4040		Replace molded thigh lacer		\$518.28	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 42 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
L4045		Replace non-molded thigh lac		\$407.09	HCPCS - Non-Drug
L4050		Replace molded calf lacer		\$524.73	HCPCS - Non-Drug
L4055		Replace non-molded calf lace		\$327.01	HCPCS - Non-Drug
L4060		Replace high roll cuff		\$392.89	HCPCS - Non-Drug
L4070		Replace prox & dist upright		\$344.10	HCPCS - Non-Drug
L4080		Repl met band kafo-af0 prox		\$125.33	HCPCS - Non-Drug
L4090		Repl met band kafo-af0 calf		\$112.18	HCPCS - Non-Drug
L4100		Repl leath cuff kafo prox th		\$129.16	HCPCS - Non-Drug
L4110		Repl leath cuff kafo-af0 cal		\$105.49	HCPCS - Non-Drug
L4130		Replace pretibial shell		\$640.26	HCPCS - Non-Drug
L4205		Ortho dvc repair per 15 min		\$35.30	HCPCS - Non-Drug
L4210		Orth dev repair/repl minor p		\$47.11	HCPCS - Non-Drug
L4350		Ankle control orthosi prefab		\$111.06	HCPCS - Non-Drug
L4360		Pneumati walking boot prefab		\$338.60	HCPCS - Non-Drug
L4370		Pneumatic full leg splint		\$231.69	HCPCS - Non-Drug
L4380		Pneumatic knee splint		\$132.94	HCPCS - Non-Drug
L4386		Non-pneum walk boot prefab		\$186.40	HCPCS - Non-Drug
L4392		Replace AFO soft interface		\$29.81	HCPCS - Non-Drug
L4394		Replace foot drop spint		\$22.45	HCPCS - Non-Drug
L4396		Static AFO		\$196.81	HCPCS - Non-Drug
L4398		Foot drop splint recumbent		\$91.98	HCPCS - Non-Drug
L5000		Sho insert w arch toe filler		\$698.72	HCPCS - Non-Drug
L5010		Mold socket ank hqt w/ toe f		\$1,751.16	HCPCS - Non-Drug
L5020		Tibial tubercle hqt w/ toe f		\$2,880.65	HCPCS - Non-Drug
L5050		Ank symes mold sock sach ft		\$3,343.50	HCPCS - Non-Drug
L5060		Symes met fr leath socket ar		\$4,033.70	HCPCS - Non-Drug
L5100		Molded socket shin sach foot		\$3,386.66	HCPCS - Non-Drug
L5105		Plast socket its/thgh lacer		\$5,085.78	HCPCS - Non-Drug
L5150		Mold sock ext knee shin sach		\$5,141.54	HCPCS - Non-Drug
L5160		Mold socket bent knee shin s		\$5,596.57	HCPCS - Non-Drug
L5200		Kne sinq axis fric shin sach		\$4,833.86	HCPCS - Non-Drug
L5210		No knee/ankle joints w/ ft b		\$3,538.01	HCPCS - Non-Drug
L5220		No knee joint with artic ali		\$4,028.13	HCPCS - Non-Drug
L5230		Fem focal defic constant fri		\$5,573.78	HCPCS - Non-Drug
L5250		Hip canad sinq axi cons fric		\$7,619.58	HCPCS - Non-Drug
L5270		Tilt table locking hip sinq		\$7,552.41	HCPCS - Non-Drug
L5280		Hemipelvect canad sinq axis		\$7,476.41	HCPCS - Non-Drug
L5301		BK mold socket SACH ft endo		\$3,345.09	HCPCS - Non-Drug
L5311		Knee disart, SACH ft, endo		\$4,826.50	HCPCS - Non-Drug
L5321		AK open end SACH		\$4,809.08	HCPCS - Non-Drug
L5331		Hip disart canadian SACH ft		\$6,824.91	HCPCS - Non-Drug
L5341		Hemipelvectomy canadian SACH		\$7,420.67	HCPCS - Non-Drug
L5400		Postop dress & 1 cast chq bk		\$1,730.64	HCPCS - Non-Drug
L5410		Postop dsq bk ea add cast ch		\$569.52	HCPCS - Non-Drug
L5420		Postop dsq & 1 cast chq ak/d		\$2,198.33	HCPCS - Non-Drug
L5430		Postop dsq ak ea add cast ch		\$695.70	HCPCS - Non-Drug
L5450		Postop app non-wqt bear dsq		\$554.12	HCPCS - Non-Drug
L5460		Postop app non-wqt bear dsq		\$757.88	HCPCS - Non-Drug
L5500		Init bk ptb plaster direct		\$1,850.02	HCPCS - Non-Drug
L5505		Init ak ischal plstr direct		\$2,522.41	HCPCS - Non-Drug
L5510		Prep BK ptb plaster molded		\$2,103.51	HCPCS - Non-Drug
L5520		Prep BK ptb thermopls direct		\$2,077.19	HCPCS - Non-Drug
L5530		Prep BK ptb thermopls molded		\$2,504.54	HCPCS - Non-Drug
L5535		Prep BK ptb open end socket		\$2,458.09	HCPCS - Non-Drug
L5540		Prep BK ptb laminated socket		\$2,626.79	HCPCS - Non-Drug
L5560		Prep AK ischial plast molded		\$2,824.25	HCPCS - Non-Drug
L5570		Prep AK ischial direct form		\$2,938.13	HCPCS - Non-Drug
L5580		Prep AK ischial thermo mold		\$3,438.08	HCPCS - Non-Drug
L5585		Prep AK ischial open end		\$3,733.05	HCPCS - Non-Drug
L5590		Prep AK ischial laminated		\$3,504.55	HCPCS - Non-Drug
L5595		Hip disartic sach thermopls		\$5,902.33	HCPCS - Non-Drug
L5600		Hip disart sach laminat mold		\$6,522.94	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 43 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
L5610		Above knee hydracade		\$3,011.64	HCPCS - Non-Drug
L5611		Ak 4 bar link w/fric swing		\$2,333.04	HCPCS - Non-Drug
L5613		Ak 4 bar link w/hydraul swiq		\$3,573.65	HCPCS - Non-Drug
L5614		4-bar link above knee w/swing		\$2,192.69	HCPCS - Non-Drug
L5616		Ak univ multiplex sys frict		\$1,959.12	HCPCS - Non-Drug
L5617		AK/BK self-aligning unit ea		\$699.76	HCPCS - Non-Drug
L5618		Test socket symes		\$367.67	HCPCS - Non-Drug
L5620		Test socket below knee		\$362.92	HCPCS - Non-Drug
L5622		Test socket knee disarticula		\$487.80	HCPCS - Non-Drug
L5624		Test socket above knee		\$489.33	HCPCS - Non-Drug
L5626		Test socket hip disarticulat		\$656.66	HCPCS - Non-Drug
L5628		Test socket hemipelvectomy		\$565.57	HCPCS - Non-Drug
L5629		Below knee acrylic socket		\$421.72	HCPCS - Non-Drug
L5630		Syme typ expandabl wall sockt		\$615.29	HCPCS - Non-Drug
L5631		Ak/knee disartic acrylic soc		\$601.37	HCPCS - Non-Drug
L5632		Symes type ptb brim design s		\$289.66	HCPCS - Non-Drug
L5634		Symes type poster opening so		\$401.59	HCPCS - Non-Drug
L5636		Symes type medial opening so		\$332.02	HCPCS - Non-Drug
L5637		Below knee total contact		\$378.97	HCPCS - Non-Drug
L5638		Below knee leather socket		\$671.25	HCPCS - Non-Drug
L5639		Below knee wood socket		\$1,608.93	HCPCS - Non-Drug
L5640		Knee disarticulat leather so		\$897.01	HCPCS - Non-Drug
L5642		Above knee leather socket		\$867.65	HCPCS - Non-Drug
L5643		Hip flex inner socket ext fr		\$2,252.15	HCPCS - Non-Drug
L5644		Above knee wood socket		\$824.92	HCPCS - Non-Drug
L5645		Bk flex inner socket ext fra		\$1,131.16	HCPCS - Non-Drug
L5646		Below knee cushion socket		\$761.77	HCPCS - Non-Drug
L5647		Below knee suction socket		\$1,127.58	HCPCS - Non-Drug
L5648		Above knee cushion socket		\$925.00	HCPCS - Non-Drug
L5649		Isch containmt/narrow m-l so		\$2,765.65	HCPCS - Non-Drug
L5650		Tot contact ak/knee disart s		\$673.50	HCPCS - Non-Drug
L5651		Ak flex inner socket ext fra		\$1,726.76	HCPCS - Non-Drug
L5652		Suction susp ak/knee disart		\$596.35	HCPCS - Non-Drug
L5653		Knee disart expand wall sock		\$812.13	HCPCS - Non-Drug
L5654		Socket insert symes		\$442.16	HCPCS - Non-Drug
L5655		Socket insert below knee		\$345.51	HCPCS - Non-Drug
L5656		Socket insert knee articulat		\$500.27	HCPCS - Non-Drug
L5658		Socket insert above knee		\$489.40	HCPCS - Non-Drug
L5661		Multi-durometer symes		\$851.37	HCPCS - Non-Drug
L5665		Multi-durometer below knee		\$708.73	HCPCS - Non-Drug
L5666		Below knee cuff suspension		\$93.08	HCPCS - Non-Drug
L5668		Socket insert w/o lock lower		\$133.14	HCPCS - Non-Drug
L5670		Bk molded supracondylar susp		\$353.40	HCPCS - Non-Drug
L5671		BK/AK locking mechanism		\$687.13	HCPCS - Non-Drug
L5672		Bk removable medial brim sus		\$392.72	HCPCS - Non-Drug
L5673		Socket insert w lock mech		\$939.55	HCPCS - Non-Drug
L5676		Bk knee joints single axis p		\$487.58	HCPCS - Non-Drug
L5677		Bk knee joints polycentric p		\$680.69	HCPCS - Non-Drug
L5678		Bk joint covers pair		\$53.92	HCPCS - Non-Drug
L5679		Socket insert w/o lock mech		\$774.94	HCPCS - Non-Drug
L5680		Bk thigh lacer non-molded		\$401.88	HCPCS - Non-Drug
L5681		Intl custm cong/latyp insert		\$1,699.10	HCPCS - Non-Drug
L5682		Bk thigh lacer glut/ischia m		\$876.26	HCPCS - Non-Drug
L5683		Initial custom socket insert		\$1,699.10	HCPCS - Non-Drug
L5684		Bk fork strap		\$64.80	HCPCS - Non-Drug
L5685		Below knee sus/seal sleeve		\$246.51	HCPCS - Non-Drug
L5686		Bk back check		\$68.63	HCPCS - Non-Drug
L5688		Bk waist belt webbing		\$81.54	HCPCS - Non-Drug
L5690		Bk waist belt padded and lin		\$129.10	HCPCS - Non-Drug
L5692		Ak pelvic control belt light		\$174.38	HCPCS - Non-Drug
L5694		Ak pelvic control belt pad/l		\$237.13	HCPCS - Non-Drug
L5695		Ak sleeve susp neoprene/equa		\$213.43	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 44 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
L5696		Ak/knee disartic pelvic join		\$241.80	HCPCS - Non-Drug
L5697		Ak/knee disartic pelvic band		\$106.36	HCPCS - Non-Drug
L5698		Ak/knee disartic silesian ba		\$137.44	HCPCS - Non-Drug
L5699		Shoulder harness		\$243.65	HCPCS - Non-Drug
L5700		Replace socket below knee		\$3,999.03	HCPCS - Non-Drug
L5701		Replace socket above knee		\$4,976.68	HCPCS - Non-Drug
L5702		Replace socket hip		\$6,372.49	HCPCS - Non-Drug
L5704		Custom shape cover BK		\$730.20	HCPCS - Non-Drug
L5705		Custom shape cover AK		\$1,324.81	HCPCS - Non-Drug
L5706		Custom shape cvr knee disart		\$1,298.84	HCPCS - Non-Drug
L5707		Custom shape cvr hip disart		\$1,780.15	HCPCS - Non-Drug
L5710		Knee-shin exo sng axi mnl loc		\$483.58	HCPCS - Non-Drug
L5711		Knee-shin exo mnl lock ultra		\$723.69	HCPCS - Non-Drug
L5712		Knee-shin exo frict swg & st		\$588.84	HCPCS - Non-Drug
L5714		Knee-shin exo variable frict		\$570.19	HCPCS - Non-Drug
L5716		Knee-shin exo mech stance ph		\$1,029.14	HCPCS - Non-Drug
L5718		Knee-shin exo frct swg & sta		\$1,298.28	HCPCS - Non-Drug
L5722		Knee-shin pneum swg frct exo		\$1,286.32	HCPCS - Non-Drug
L5724		Knee-shin exo fluid swing ph		\$2,182.65	HCPCS - Non-Drug
L5726		Knee-shin ext jnts fld swg e		\$2,522.76	HCPCS - Non-Drug
L5728		Knee-shin fluid swg & stance		\$3,468.42	HCPCS - Non-Drug
L5780		Knee-shin pneum/hydra pneum		\$1,643.99	HCPCS - Non-Drug
L5781		Lower limb pros vacuum pump		\$5,264.85	HCPCS - Non-Drug
L5782		HD low limb pros vacuum pump		\$4,336.38	HCPCS - Non-Drug
L5785		Exoskeletal bk ultralt mater		\$719.86	HCPCS - Non-Drug
L5790		Exoskeletal ak ultra-light m		\$1,014.63	HCPCS - Non-Drug
L5795		Exoskel hip ultra-light mate		\$1,538.75	HCPCS - Non-Drug
L5810		Endoskel knee-shin mnl lock		\$671.54	HCPCS - Non-Drug
L5811		Endo knee-shin mnl lck ultra		\$1,029.84	HCPCS - Non-Drug
L5812		Endo knee-shin frct swg & st		\$787.46	HCPCS - Non-Drug
L5814		Endo knee-shin hydral swg ph		\$4,883.35	HCPCS - Non-Drug
L5816		Endo knee-shin polyc mch sta		\$1,208.84	HCPCS - Non-Drug
L5818		Endo knee-shin frct swg & st		\$1,371.22	HCPCS - Non-Drug
L5822		Endo knee-shin pneum swg frc		\$2,468.56	HCPCS - Non-Drug
L5824		Endo knee-shin fluid swing p		\$2,218.32	HCPCS - Non-Drug
L5826		Miniature knee joint		\$4,124.69	HCPCS - Non-Drug
L5828		Endo knee-shin fluid swg/sta		\$4,125.21	HCPCS - Non-Drug
L5830		Endo knee-shin pneum/swg pha		\$2,756.19	HCPCS - Non-Drug
L5840		Multi-axial knee/shin system		\$4,960.83	HCPCS - Non-Drug
L5845		Knee-shin sys stance flexion		\$2,331.98	HCPCS - Non-Drug
L5848		Knee-shin sys hydraul stance		\$1,379.88	HCPCS - Non-Drug
L5850		Endo ak/hip knee extens assi		\$167.99	HCPCS - Non-Drug
L5855		Mech hip extension assist		\$408.46	HCPCS - Non-Drug
L5856		Elec knee-shin swing/stance		\$24,714.45	HCPCS - Non-Drug
L5857		Elec knee-shin swing only		\$8,792.66	HCPCS - Non-Drug
L5910		Endo below knee alignable sy		\$487.29	HCPCS - Non-Drug
L5920		Endo ak/hip alignable system		\$736.15	HCPCS - Non-Drug
L5925		Above knee manual lock		\$448.61	HCPCS - Non-Drug
L5930		High activity knee frame		\$4,449.98	HCPCS - Non-Drug
L5940		Endo bk ultra-light material		\$693.34	HCPCS - Non-Drug
L5950		Endo ak ultra-light material		\$1,101.80	HCPCS - Non-Drug
L5960		Endo hip ultra-light materia		\$1,376.70	HCPCS - Non-Drug
L5962		Below knee flex cover system		\$820.70	HCPCS - Non-Drug
L5964		Above knee flex cover system		\$1,336.04	HCPCS - Non-Drug
L5966		Hip flexible cover system		\$1,715.58	HCPCS - Non-Drug
L5968		Multiaxial ankle w dorsiflex		\$4,777.21	HCPCS - Non-Drug
L5970		Foot external keel sach foot		\$265.17	HCPCS - Non-Drug
L5972		Flexible keel foot		\$472.88	HCPCS - Non-Drug
L5974		Foot single axis ankle/foot		\$303.87	HCPCS - Non-Drug
L5975		Combo ankle/foot prosthesis		\$567.64	HCPCS - Non-Drug
L5976		Energy storing foot		\$779.66	HCPCS - Non-Drug
L5978		Ft prosth multiaxial anklft		\$383.34	HCPCS - Non-Drug

NOTES: See end of the table for notes regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 45 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
L5979		Multi-axial ankle/ft prosth		\$3,324.00	HCPCS - Non-Drug
L5980		Flex foot system		\$5,431.23	HCPCS - Non-Drug
L5981		Flex-walk sys low ext prosth		\$4,208.32	HCPCS - Non-Drug
L5982		Exoskeletal axial rotation u		\$806.39	HCPCS - Non-Drug
L5984		Endoskeletal axial rotation		\$793.92	HCPCS - Non-Drug
L5985		Lwr ext dynamic prosth pylon		\$332.73	HCPCS - Non-Drug
L5986		Multi-axial rotation unit		\$888.52	HCPCS - Non-Drug
L5987		Shank ft w vert load pylon		\$9,503.94	HCPCS - Non-Drug
L5988		Vertical shock reducing pylo		\$2,604.62	HCPCS - Non-Drug
L5990		User adjustable heel height		\$2,360.97	HCPCS - Non-Drug
L5995		Lower ext pros heavyduty fea		\$496.24	HCPCS - Non-Drug
L5999		Lowr extremity prothes NOS		\$248.00	HCPCS - Non-Drug
L6000		Par hand robin-aids thum rem		\$1,915.59	HCPCS - Non-Drug
L6010		Hand robin-aids little/ring		\$2,137.13	HCPCS - Non-Drug
L6020		Part hand robin-aids no finq		\$1,989.29	HCPCS - Non-Drug
L6025		Part hand disart myoelectric		\$10,577.66	HCPCS - Non-Drug
L6050		Wrst Mld sock flx hng tri pad		\$2,759.27	HCPCS - Non-Drug
L6055		Wrst mold sock w/exp interfa		\$3,864.60	HCPCS - Non-Drug
L6100		Elb mold sock flex hinge pad		\$2,796.20	HCPCS - Non-Drug
L6110		Elbow mold sock suspension t		\$2,968.76	HCPCS - Non-Drug
L6120		Elbow mold doub split soc ste		\$3,467.59	HCPCS - Non-Drug
L6130		Elbow stump activated lock h		\$3,777.61	HCPCS - Non-Drug
L6200		Elbow mold outsid lock hinge		\$3,983.57	HCPCS - Non-Drug
L6205		Elbow molded w/ expand inter		\$5,333.49	HCPCS - Non-Drug
L6250		Elbow inter loc elbow forarm		\$3,920.42	HCPCS - Non-Drug
L6300		Shldr disart int lock elbow		\$5,457.71	HCPCS - Non-Drug
L6310		Shoulder passive restor comp		\$4,436.52	HCPCS - Non-Drug
L6320		Shoulder passive restor cap		\$2,477.50	HCPCS - Non-Drug
L6350		Thoracic intern lock elbow		\$5,740.40	HCPCS - Non-Drug
L6360		Thoracic passive restor comp		\$4,659.05	HCPCS - Non-Drug
L6370		Thoracic passive restor cap		\$2,953.54	HCPCS - Non-Drug
L6380		Postop dsq cast chq wrst/elb		\$1,651.91	HCPCS - Non-Drug
L6382		Postop dsq cast chq elb dis/		\$2,140.17	HCPCS - Non-Drug
L6384		Postop dsq cast chq shldr/ft		\$2,769.61	HCPCS - Non-Drug
L6386		Postop ea cast chq & realign		\$545.53	HCPCS - Non-Drug
L6388		Postop applicat rigid dsq on		\$601.74	HCPCS - Non-Drug
L6400		Below elbow prosth tiss shap		\$3,381.08	HCPCS - Non-Drug
L6450		Elb disart prosth tiss shap		\$4,508.18	HCPCS - Non-Drug
L6500		Above elbow prosth tiss shap		\$4,511.90	HCPCS - Non-Drug
L6550		Shldr disar prosth tiss shap		\$5,587.20	HCPCS - Non-Drug
L6570		Scap thorac prosth tiss shap		\$6,420.11	HCPCS - Non-Drug
L6580		Wrist/elbow bowden cable mol		\$2,262.07	HCPCS - Non-Drug
L6582		Wrist/elbow bowden cbl dir f		\$1,985.94	HCPCS - Non-Drug
L6584		Elbow fair lead cable molded		\$2,976.78	HCPCS - Non-Drug
L6586		Elbow fair lead cable dir fo		\$2,735.35	HCPCS - Non-Drug
L6588		Shdr fair lead cable molded		\$4,129.02	HCPCS - Non-Drug
L6590		Shdr fair lead cable direct		\$3,839.96	HCPCS - Non-Drug
L6600		Polycentric hinge pair		\$245.09	HCPCS - Non-Drug
L6605		Single pivot hinge pair		\$242.03	HCPCS - Non-Drug
L6610		Flexible metal hinge pair		\$217.83	HCPCS - Non-Drug
L6615		Disconnect locking wrist uni		\$227.19	HCPCS - Non-Drug
L6616		Disconnect insert locking wr		\$86.43	HCPCS - Non-Drug
L6620		Flexion/extension wrist unit		\$400.15	HCPCS - Non-Drug
L6623		Spring-ass rot wrst w/ latch		\$900.02	HCPCS - Non-Drug
L6625		Rotation wrst w/ cable lock		\$738.04	HCPCS - Non-Drug
L6628		Quick disconn hook adapter o		\$660.01	HCPCS - Non-Drug
L6629		Lamination collar w/ couplin		\$191.74	HCPCS - Non-Drug
L6630		Stainless steel any wrist		\$281.23	HCPCS - Non-Drug
L6632		Latex suspension sleeve each		\$86.57	HCPCS - Non-Drug
L6635		Lift assist for elbow		\$230.31	HCPCS - Non-Drug
L6637		Nudge control elbow lock		\$494.70	HCPCS - Non-Drug
L6638		Elec lock on manual pw elbow		\$3,272.56	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 46 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
L6640		Shoulder abduction joint pai		\$366.01	HCPCS - Non-Drug
L6641		Excursion amplifier pulley t		\$210.00	HCPCS - Non-Drug
L6642		Excursion amplifier lever ty		\$283.72	HCPCS - Non-Drug
L6645		Shoulder flexion-abduction j		\$423.83	HCPCS - Non-Drug
L6646		Multiplo locking shoulder jnt		\$4,139.95	HCPCS - Non-Drug
L6647		Shoulder lock actuator		\$641.52	HCPCS - Non-Drug
L6648		Ext pwrdr shlder lock/unlock		\$4,271.27	HCPCS - Non-Drug
L6650		Shoulder universal joint		\$452.28	HCPCS - Non-Drug
L6655		Standard control cable extra		\$99.70	HCPCS - Non-Drug
L6660		Heavy duty control cable		\$121.25	HCPCS - Non-Drug
L6665		Teflon or equal cable lining		\$62.11	HCPCS - Non-Drug
L6670		Hook to hand cable adapter		\$64.57	HCPCS - Non-Drug
L6672		Harness chest/shlder saddle		\$220.58	HCPCS - Non-Drug
L6675		Harness figure of 8 sinq con		\$157.85	HCPCS - Non-Drug
L6676		Harness figure of 8 dual con		\$159.38	HCPCS - Non-Drug
L6680		Test sock wrist disart/bel e		\$302.56	HCPCS - Non-Drug
L6682		Test sock elbw disart/abov		\$334.23	HCPCS - Non-Drug
L6684		Test socket shldr disart/tho		\$467.18	HCPCS - Non-Drug
L6686		Suction socket		\$824.50	HCPCS - Non-Drug
L6687		Frame typ socket bel elbow/w		\$804.47	HCPCS - Non-Drug
L6688		Frame typ sock above elb/dis		\$734.91	HCPCS - Non-Drug
L6689		Frame typ socket shoulder di		\$947.81	HCPCS - Non-Drug
L6690		Frame typ sock interscap-tho		\$968.21	HCPCS - Non-Drug
L6691		Removable insert each		\$462.19	HCPCS - Non-Drug
L6692		Silicone gel insert or equal		\$778.49	HCPCS - Non-Drug
L6693		Lockingelbow forearm cntrbal		\$3,721.72	HCPCS - Non-Drug
L6700		Terminal device model #3		\$718.64	HCPCS - Non-Drug
L6705		Terminal device model #5		\$402.12	HCPCS - Non-Drug
L6710		Terminal device model #5x		\$462.10	HCPCS - Non-Drug
L6715		Terminal device model #5xa		\$458.70	HCPCS - Non-Drug
L6720		Terminal device model #6		\$1,212.77	HCPCS - Non-Drug
L6725		Terminal device model #7		\$562.43	HCPCS - Non-Drug
L6730		Terminal device model #7lo		\$896.39	HCPCS - Non-Drug
L6735		Terminal device model #8		\$392.40	HCPCS - Non-Drug
L6740		Terminal device model #8x		\$526.15	HCPCS - Non-Drug
L6745		Terminal device model #88x		\$477.37	HCPCS - Non-Drug
L6750		Terminal device model #10p		\$471.28	HCPCS - Non-Drug
L6755		Terminal device model #10x		\$469.80	HCPCS - Non-Drug
L6765		Terminal device model #12p		\$492.98	HCPCS - Non-Drug
L6770		Terminal device model #99x		\$473.52	HCPCS - Non-Drug
L6775		Terminal device model#555		\$569.92	HCPCS - Non-Drug
L6780		Terminal device model #ss555		\$612.50	HCPCS - Non-Drug
L6790		Hooks-accu hook or equal		\$619.82	HCPCS - Non-Drug
L6795		Hooks-2 load or equal		\$1,780.97	HCPCS - Non-Drug
L6800		Hooks-apri vc or equal		\$1,449.37	HCPCS - Non-Drug
L6805		Modifier wrist flexion unit		\$454.86	HCPCS - Non-Drug
L6806		Trs grip vc or equal		\$2,099.55	HCPCS - Non-Drug
L6807		Term device grip1/2 or equal		\$1,899.40	HCPCS - Non-Drug
L6808		Term device infant or child		\$1,614.89	HCPCS - Non-Drug
L6809		Trs super sport passive		\$500.40	HCPCS - Non-Drug
L6810		Pincher tool otto bock or eq		\$243.76	HCPCS - Non-Drug
L6825		Hands dorrance vo		\$1,476.73	HCPCS - Non-Drug
L6830		Hand aprl vc		\$1,953.26	HCPCS - Non-Drug
L6835		Hand sierra vo		\$1,695.30	HCPCS - Non-Drug
L6840		Hand becker imperial		\$1,163.13	HCPCS - Non-Drug
L6845		Hand becker lock grip		\$1,076.31	HCPCS - Non-Drug
L6850		Term dvc-hand becker plylite		\$970.27	HCPCS - Non-Drug
L6855		Hand robin-aids vo		\$1,247.11	HCPCS - Non-Drug
L6860		Hand robin-aids vo soft		\$934.25	HCPCS - Non-Drug
L6865		Hand passive hand		\$433.28	HCPCS - Non-Drug
L6867		Hand detroit infant hand		\$1,371.79	HCPCS - Non-Drug
L6868		Passive inf hand steeper/hos		\$312.57	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. -- DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 47 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAF Category
L6870		Hand child mitt		\$309.89	HCPCS - Non-Drug
L6872		Hand nyu child hand		\$1,343.86	HCPCS - Non-Drug
L6873		Hand mech inf steeper or equ		\$643.37	HCPCS - Non-Drug
L6875		Hand back vc		\$1,100.69	HCPCS - Non-Drug
L6880		Hand back vo		\$697.23	HCPCS - Non-Drug
L6881		Autograsp feature ul term dv		\$5,380.46	HCPCS - Non-Drug
L6882		Microprocessor control uplmb		\$4,069.77	HCPCS - Non-Drug
L6890		Production glove		\$222.49	HCPCS - Non-Drug
L6895		Custom glove		\$777.25	HCPCS - Non-Drug
L6900		Hand restorat thumb/1 finger		\$2,184.20	HCPCS - Non-Drug
L6905		Hand restoration multiple fi		\$2,121.76	HCPCS - Non-Drug
L6910		Hand restoration no fingers		\$2,065.78	HCPCS - Non-Drug
L6915		Hand restoration replacmnt q		\$877.20	HCPCS - Non-Drug
L6920		Wrist disarticul switch ctrl		\$9,814.34	HCPCS - Non-Drug
L6925		Wrist disart myoelectronic c		\$11,337.90	HCPCS - Non-Drug
L6930		Below elbow switch control		\$9,875.49	HCPCS - Non-Drug
L6935		Below elbow myoelectronic ct		\$11,551.06	HCPCS - Non-Drug
L6940		Elbow disarticulation switch		\$12,917.66	HCPCS - Non-Drug
L6945		Elbow disart myoelectronic c		\$15,036.03	HCPCS - Non-Drug
L6950		Above elbow switch control		\$14,689.29	HCPCS - Non-Drug
L6955		Above elbow myoelectronic ct		\$17,601.90	HCPCS - Non-Drug
L6960		Shldr disartic switch contro		\$17,753.25	HCPCS - Non-Drug
L6965		Shldr disartic myoelectronic		\$20,895.99	HCPCS - Non-Drug
L6970		Interscapular-thor switch ct		\$21,505.30	HCPCS - Non-Drug
L6975		Interscap-thor myoelectronic		\$23,567.58	HCPCS - Non-Drug
L7010		Hand otto back steeper/eq sw		\$5,349.42	HCPCS - Non-Drug
L7015		Hand sys teknik village swit		\$8,528.86	HCPCS - Non-Drug
L7020		Electronic greifer switch ct		\$4,980.80	HCPCS - Non-Drug
L7025		Electron hand myoelectronic		\$5,026.81	HCPCS - Non-Drug
L7030		Hand sys teknik vill myoelec		\$7,712.14	HCPCS - Non-Drug
L7035		Electron greifer myoelectro		\$5,149.18	HCPCS - Non-Drug
L7040		Prehensile actuator hosmer s		\$4,118.18	HCPCS - Non-Drug
L7045		Electron hook child michigan		\$2,340.64	HCPCS - Non-Drug
L7170		Electronic elbow hosmer swit		\$8,617.01	HCPCS - Non-Drug
L7180		Electronic elbow utah myoele		\$48,226.67	HCPCS - Non-Drug
L7185		Electron elbow adolescent sw		\$8,726.48	HCPCS - Non-Drug
L7186		Electron elbow child switch		\$13,023.80	HCPCS - Non-Drug
L7190		Elbow adolescent myoelectron		\$11,115.84	HCPCS - Non-Drug
L7191		Elbow child myoelectronic ct		\$13,611.26	HCPCS - Non-Drug
L7260		Electron wrist rotator otto		\$2,860.36	HCPCS - Non-Drug
L7261		Electron wrist rotator utah		\$5,246.28	HCPCS - Non-Drug
L7266		Servo control steeper or equ		\$1,415.17	HCPCS - Non-Drug
L7272		Analoque control unb or equa		\$2,935.33	HCPCS - Non-Drug
L7274		Proportional ctl 12 volt uta		\$8,439.80	HCPCS - Non-Drug
L7360		Six volt bat otto bock/eq ea		\$296.58	HCPCS - Non-Drug
L7362		Battery chrgr six volt otto		\$326.52	HCPCS - Non-Drug
L7364		Twelve volt battery utah/equ		\$540.93	HCPCS - Non-Drug
L7366		Battery chrgr 12 volt utah/e		\$745.30	HCPCS - Non-Drug
L7367		Replacemnt lithium ionbatter		\$469.02	HCPCS - Non-Drug
L7368		Lithium ion battery charger		\$622.21	HCPCS - Non-Drug
L7499		Upper extremity prosthes NOS		\$157.71	HCPCS - Non-Drug
L7500		Prosthetic dvc repair hourly		\$112.59	HCPCS - Non-Drug
L7510		Prosthetic device repair rep		\$33.50	HCPCS - Non-Drug
L7520		Repair prosthesis per 15 min		\$35.98	HCPCS - Non-Drug
L7900		Male vacuum erection system		\$664.17	HCPCS - Non-Drug
L8000		Mastectomy bra		\$49.79	HCPCS - Non-Drug
L8001		Breast prosthesis bra & form		\$148.28	HCPCS - Non-Drug
L8002		Brst prsth bra & bilat form		\$194.24	HCPCS - Non-Drug
L8010		Mastectomy sleeve		\$68.31	HCPCS - Non-Drug
L8015		Ext breastprosthesis garment		\$72.36	HCPCS - Non-Drug
L8020		Mastectomy form		\$261.96	HCPCS - Non-Drug
L8030		Breast prosthesis silicone/e		\$418.28	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 48 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
L8035		Custom breast prosthesis		\$4,816.64	HCPCS - Non-Drug
L8039		Breast prosthesis NOS		\$270.80	HCPCS - Non-Drug
L8040	KM	Nasal prosthesis		\$3,076.28	HCPCS - Non-Drug
L8040	KN	Nasal prosthesis		\$1,267.53	HCPCS - Non-Drug
L8041	KM	Midfacial prosthesis		\$3,717.80	HCPCS - Non-Drug
L8041	KN	Midfacial prosthesis		\$1,537.65	HCPCS - Non-Drug
L8042	KM	Orbital prosthesis		\$4,183.22	HCPCS - Non-Drug
L8042	KN	Orbital prosthesis		\$1,733.60	HCPCS - Non-Drug
L8043	KM	Upper facial prosthesis		\$4,690.97	HCPCS - Non-Drug
L8043	KN	Upper facial prosthesis		\$1,947.39	HCPCS - Non-Drug
L8044	KM	Hemi-facial prosthesis		\$5,198.71	HCPCS - Non-Drug
L8044	KN	Hemi-facial prosthesis		\$2,161.18	HCPCS - Non-Drug
L8045	KM	Auricular prosthesis		\$3,404.37	HCPCS - Non-Drug
L8045	KN	Auricular prosthesis		\$1,405.68	HCPCS - Non-Drug
L8046	KM	Partial facial prosthesis		\$3,337.01	HCPCS - Non-Drug
L8046	KN	Partial facial prosthesis		\$1,377.31	HCPCS - Non-Drug
L8047	KM	Nasal septal prosthesis		\$1,686.87	HCPCS - Non-Drug
L8047	KN	Nasal septal prosthesis		\$682.51	HCPCS - Non-Drug
L8048		Unspec maxillofacial prosth		\$32.99	HCPCS - Non-Drug
L8049		Repair maxillofacial prosth		\$42.46	HCPCS - Non-Drug
L8300		Truss single w/ standard pad		\$111.64	HCPCS - Non-Drug
L8310		Truss double w/ standard pad		\$174.77	HCPCS - Non-Drug
L8320		Truss addition to std pad wa		\$71.69	HCPCS - Non-Drug
L8330		Truss add to std pad scrotal		\$66.41	HCPCS - Non-Drug
L8400		Sheath below knee		\$22.92	HCPCS - Non-Drug
L8410		Sheath above knee		\$29.36	HCPCS - Non-Drug
L8415		Sheath upper limb		\$30.28	HCPCS - Non-Drug
L8417		Pros sheath/sock w gel cushn		\$89.91	HCPCS - Non-Drug
L8420		Prosthetic sock multi ply BK		\$27.71	HCPCS - Non-Drug
L8430		Prosthetic sock multi ply AK		\$31.19	HCPCS - Non-Drug
L8435		Pros sock multi ply upper lm		\$29.77	HCPCS - Non-Drug
L8440		Shrinker below knee		\$56.66	HCPCS - Non-Drug
L8460		Shrinker above knee		\$88.75	HCPCS - Non-Drug
L8465		Shrinker upper limb		\$65.63	HCPCS - Non-Drug
L8470		Pros sock single ply BK		\$10.51	HCPCS - Non-Drug
L8480		Pros sock single ply AK		\$14.48	HCPCS - Non-Drug
L8485		Pros sock single ply upper l		\$16.96	HCPCS - Non-Drug
L8499		Unlisted misc prosthetic ser		\$54.55	HCPCS - Non-Drug
L8500		Artificial larynx		\$927.35	HCPCS - Non-Drug
L8501		Tracheostomy speaking valve		\$158.76	HCPCS - Non-Drug
L8505		Artificial larynx, accessory		\$31.54	HCPCS - Non-Drug
L8507		Trach-esoph voice pros pt in		\$51.23	HCPCS - Non-Drug
L8509		Trach-esoph voice pros md in		\$129.45	HCPCS - Non-Drug
L8510		Voice amplifier		\$296.13	HCPCS - Non-Drug
L8511		Indwelling trach insert		\$74.77	HCPCS - Non-Drug
L8512		Gel cap for trach voice pros		\$2.24	HCPCS - Non-Drug
L8513		Trach pros cleaning device		\$5.34	HCPCS - Non-Drug
L8514		Repl trach puncture dilator		\$96.95	HCPCS - Non-Drug
L8515		Gel cap app device for trach		\$64.90	HCPCS - Non-Drug
L8600		Implant breast silicone/eq		\$874.87	HCPCS - Non-Drug
L8603		Collagen imp urinary 2.5 ml		\$681.44	HCPCS - Non-Drug
L8606		Synthetic implnt urinary 1ml		\$341.81	HCPCS - Non-Drug
L8610		Ocular implant		\$817.03	HCPCS - Non-Drug
L8612		Aqueous shunt prosthesis		\$850.61	HCPCS - Non-Drug
L8613		Ossicular implant		\$335.04	HCPCS - Non-Drug
L8614		Cochlear device/system		\$25,634.89	HCPCS - Non-Drug
L8615		Coch implant headset replace		\$463.77	HCPCS - Non-Drug
L8616		Coch implant microphone repl		\$108.02	HCPCS - Non-Drug
L8617		Coch implant trans coil repl		\$94.34	HCPCS - Non-Drug
L8618		Coch implant tran cable repl		\$26.95	HCPCS - Non-Drug
L8619		Replace cochlear processor		\$10,976.15	HCPCS - Non-Drug
L8621		Repl zinc air battery		\$0.64	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE - CHARGES BY HCPCS CODE

PAGE 49 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAF Category
L8622		Repl alkaline battery		\$0.34	HCPCS - Non-Drug
L8630		Metacarpophalangeal implant		\$449.94	HCPCS - Non-Drug
L8631		MCP joint repl 2 pc or more		\$2,874.09	HCPCS - Non-Drug
L8641		Metatarsal joint implant		\$469.36	HCPCS - Non-Drug
L8642		Hallux implant		\$371.64	HCPCS - Non-Drug
L8658		Interphalangeal joint spacer		\$403.10	HCPCS - Non-Drug
L8659		Interphalangeal joint repl		\$2,514.95	HCPCS - Non-Drug
L8670		Vascular graft, synthetic		\$692.41	HCPCS - Non-Drug
L8699		Prosthetic implant NOS		\$342.12	HCPCS - Non-Drug
L9900		O&P supply/accessory/service		\$49.04	HCPCS - Non-Drug
Q0081		Infusion ther other than che	a	\$94.31	HCPCS - Non-Drug
Q0083		Chemo by other than infusion	a	\$243.08	HCPCS - Drug
Q0084		Chemotherapy by infusion	a	\$405.49	HCPCS - Drug
Q0085		Chemo by both infusion and o	a	\$462.45	HCPCS - Drug
Q0144		Azithromycin dihydrate, oral		\$34.02	HCPCS - Drug
Q0163		Diphenhydramine HCl 50mg		\$1.20	HCPCS - Drug
Q0164		Prochlorperazine maleate 5mg		\$1.20	HCPCS - Drug
Q0165		Prochlorperazine maleate 10mg		\$2.40	HCPCS - Drug
Q0166		Granisetron HCl 1 mg oral	a	\$113.73	HCPCS - Drug
Q0167		Dronabinol 2.5mg oral		\$9.58	HCPCS - Drug
Q0168		Dronabinol 5mg oral		\$25.16	HCPCS - Drug
Q0169		Promethazine HCl 12.5mg oral		\$1.20	HCPCS - Drug
Q0170		Promethazine HCl 25 mg oral		\$1.20	HCPCS - Drug
Q0171		Chlorpromazine HCl 10mg oral		\$1.20	HCPCS - Drug
Q0172		Chlorpromazine HCl 25mg oral		\$1.20	HCPCS - Drug
Q0173		Trimethobenzamide HCl 250mg		\$1.20	HCPCS - Drug
Q0174		Thiethylperazine maleate 10mg		\$2.40	HCPCS - Drug
Q0175		Perphenazine 4mg oral		\$1.20	HCPCS - Drug
Q0176		Perphenazine 8mg oral		\$2.40	HCPCS - Drug
Q0177		Hydroxyzine pamoate 25mg		\$1.20	HCPCS - Drug
Q0178		Hydroxyzine pamoate 50mg		\$1.20	HCPCS - Drug
Q0179		Ondansetron HCl 8mg oral		\$81.62	HCPCS - Drug
Q0180		Dolasetron mesylate oral	a	\$176.99	HCPCS - Drug
Q0181		Unspecified oral anti-emetic		\$0.90	HCPCS - Drug
Q0480		Driver pneumatic vad, rep	a	\$92,612.14	HCPCS - Non-Drug
Q0481		Microprcsr cu elec vad, rep	a	\$14,941.90	HCPCS - Non-Drug
Q0482		Microprcsr cu combo vad, rep	a	\$4,680.07	HCPCS - Non-Drug
Q0483		Monitor elec vad, rep	a	\$19,279.83	HCPCS - Non-Drug
Q0484		Monitor elec or comb vad rep	a	\$3,744.08	HCPCS - Non-Drug
Q0485		Monitor cable elec vad, rep	a	\$361.49	HCPCS - Non-Drug
Q0486		Mon cable elec/pneum vad rep	a	\$300.86	HCPCS - Non-Drug
Q0487		Leads any type vad, rep only	a	\$351.01	HCPCS - Non-Drug
Q0489		Pwr pck base combo vad, rep	a	\$16,714.58	HCPCS - Non-Drug
Q0490		Emr pwr source elec vad, rep	a	\$723.00	HCPCS - Non-Drug
Q0491		Emr pwr source combo vad rep	a	\$1,136.63	HCPCS - Non-Drug
Q0492		Emr pwr cbl elec vad, rep	a	\$91.58	HCPCS - Non-Drug
Q0493		Emr pwr cbl combo vad, rep	a	\$260.74	HCPCS - Non-Drug
Q0494		Emr hd pmp elec/combo, rep	a	\$220.63	HCPCS - Non-Drug
Q0495		Charger elec/combo vad, rep	a	\$4,295.23	HCPCS - Non-Drug
Q0496		Battery elec/combo vad, rep	a	\$1,541.63	HCPCS - Non-Drug
Q0497		Bat clips elec/comb vad, rep	a	\$481.39	HCPCS - Non-Drug
Q0498		Holster elec/combo vad, rep	a	\$528.19	HCPCS - Non-Drug
Q0499		Bell/vest elec/combo vad rep	a	\$171.62	HCPCS - Non-Drug
Q0500		Filters elec/combo vad, rep	a	\$31.40	HCPCS - Non-Drug
Q0501		Shwr cov elec/combo vad, rep	a	\$525.16	HCPCS - Non-Drug
Q0502		Mobility cart pneum vad, rep	a	\$668.58	HCPCS - Non-Drug
Q0503		Battery pneum vad replacemnt	a	\$1,337.17	HCPCS - Non-Drug
Q0504		Pwr adpt pneum vad, rep veh	a	\$705.59	HCPCS - Non-Drug
Q2004		Bladder calculi irriq sol		\$58.23	HCPCS - Drug
Q2009		Fosphenytoin, 50 mg	a	\$14.33	HCPCS - Drug
Q2017		Teniposide, 50 mg	a	\$560.89	HCPCS - Drug
Q3001		Brachytherapy Radioelements		\$77.05	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 50 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
Q3014		Telehealth facility fee		\$39.85	HCPCS - Non-Drug
Q3019		ALS emer trans no ALS serv		\$531.52	HCPCS - Non-Drug
Q3020		ALS nonemer trans no ALS ser		\$528.10	HCPCS - Non-Drug
Q3025		IM inj interferon beta 1-a	a	\$160.66	HCPCS - Drug
Q4001		Cast sup body cast plaster		\$288.28	HCPCS - Non-Drug
Q4002		Cast sup body cast fiberglas		\$613.45	HCPCS - Non-Drug
Q4003		Cast sup shoulder cast plstr		\$156.36	HCPCS - Non-Drug
Q4004		Cast sup shoulder cast fibrq		\$332.49	HCPCS - Non-Drug
Q4005		Cast sup long arm adult plst		\$86.47	HCPCS - Non-Drug
Q4006		Cast sup long arm adult fibrq		\$183.46	HCPCS - Non-Drug
Q4007		Cast sup long arm ped plster		\$42.98	HCPCS - Non-Drug
Q4008		Cast sup long arm ped fibrq		\$91.46	HCPCS - Non-Drug
Q4009		Cast sup sht arm adult plstr		\$66.51	HCPCS - Non-Drug
Q4010		Cast sup sht arm adult fibrq		\$141.39	HCPCS - Non-Drug
Q4011		Cast sup sht arm ped plaster		\$32.99	HCPCS - Non-Drug
Q4012		Cast sup sht arm ped fibrq		\$70.78	HCPCS - Non-Drug
Q4013		Cast sup gauntlet plaster		\$62.23	HCPCS - Non-Drug
Q4014		Cast sup gauntlet fiberglas		\$133.55	HCPCS - Non-Drug
Q4015		Cast sup gauntlet ped plster		\$31.57	HCPCS - Non-Drug
Q4016		Cast sup gauntlet ped fibrq		\$66.51	HCPCS - Non-Drug
Q4017		Cast sup lng arm splint plst		\$54.39	HCPCS - Non-Drug
Q4018		Cast sup lng arm splint fibrq		\$116.43	HCPCS - Non-Drug
Q4019		Cast sup lng arm splint ped p		\$27.29	HCPCS - Non-Drug
Q4020		Cast sup lng arm splint ped f		\$58.67	HCPCS - Non-Drug
Q4021		Cast sup sht arm splint plst		\$54.39	HCPCS - Non-Drug
Q4022		Cast sup sht arm splint fibrq		\$116.43	HCPCS - Non-Drug
Q4023		Cast sup sht arm splint ped p		\$27.29	HCPCS - Non-Drug
Q4024		Cast sup sht arm splint ped f		\$58.67	HCPCS - Non-Drug
Q4025		Cast sup hip spica plaster		\$242.64	HCPCS - Non-Drug
Q4026		Cast sup hip spica fiberglas		\$515.76	HCPCS - Non-Drug
Q4027		Cast sup hip spica ped plstr		\$121.41	HCPCS - Non-Drug
Q4028		Cast sup hip spica ped fibrq		\$258.34	HCPCS - Non-Drug
Q4029		Cast sup long leg plaster		\$119.99	HCPCS - Non-Drug
Q4030		Cast sup long leg fiberglas		\$254.05	HCPCS - Non-Drug
Q4031		Cast sup lng leg ped plaster		\$60.09	HCPCS - Non-Drug
Q4032		Cast sup lng leg ped fibrq		\$127.12	HCPCS - Non-Drug
Q4033		Cast sup lng leg cylinder pl		\$102.15	HCPCS - Non-Drug
Q4034		Cast sup lng leg cylinder fb		\$216.26	HCPCS - Non-Drug
Q4035		Cast sup lng leg cylindr ped p		\$50.83	HCPCS - Non-Drug
Q4036		Cast sup lng leg cylindr ped f		\$107.87	HCPCS - Non-Drug
Q4037		Cast sup shrt leg plaster		\$137.11	HCPCS - Non-Drug
Q4038		Cast sup shrt leg fiberglas		\$291.14	HCPCS - Non-Drug
Q4039		Cast sup shrt leg ped plster		\$68.64	HCPCS - Non-Drug
Q4040		Cast sup shrt leg ped fibrq		\$145.66	HCPCS - Non-Drug
Q4041		Cast sup lng leg splnt plstr		\$78.62	HCPCS - Non-Drug
Q4042		Cast sup lng leg splnt fibrq		\$166.34	HCPCS - Non-Drug
Q4043		Cast sup lng leg splnt ped p		\$39.41	HCPCS - Non-Drug
Q4044		Cast sup lng leg splnt ped f		\$83.62	HCPCS - Non-Drug
Q4045		Cast sup sht leg splnt plstr		\$50.83	HCPCS - Non-Drug
Q4046		Cast sup sht leg splnt fibrq		\$107.87	HCPCS - Non-Drug
Q4047		Cast sup sht leg splnt ped p		\$25.15	HCPCS - Non-Drug
Q4048		Cast sup sht leg splnt ped f		\$54.39	HCPCS - Non-Drug
Q4049		Finger splint, static		\$66.51	HCPCS - Non-Drug
Q4050		Cast supplies unlisted		\$31.35	HCPCS - Non-Drug
Q4051		Splint supplies misc	a	\$27.99	HCPCS - Non-Drug
Q4079		Injection, Natalizumab, 1 MG	a	\$0.24	HCPCS - Drug
Q9955		Inj perflhexane lip micros,ml	a	\$14.18	HCPCS - Non-Drug
Q9957		Inj perflutren lip micros,ml	a	\$375.31	HCPCS - Non-Drug
R0070		Transport portable x-ray		\$156.31	HCPCS - Non-Drug
R0075		Transport port x-ray multipl		\$81.63	HCPCS - Non-Drug
R0076		Transport portable EKG		\$159.76	HCPCS - Non-Drug
S0012		Butorphanol tartrate, nasal		\$174.26	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. -- DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 51 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
S0014		Tacrine hydrochloride, 10 mg		\$2.46	HCPCS - Non-Drug
S0016		Injection, amikacin sulfate		\$59.71	HCPCS - Non-Drug
S0017		Injection, aminocaproic acid		\$4.31	HCPCS - Non-Drug
S0020		Injection, bupivacaine hydro		\$4.75	HCPCS - Non-Drug
S0023		Injection, cimetidine hydroc		\$9.83	HCPCS - Non-Drug
S0028		Injection, famotidine, 20 mg		\$10.69	HCPCS - Non-Drug
S0030		Injection, metronidazole		\$29.83	HCPCS - Non-Drug
S0032		Injection, nafcillin sodium		\$11.34	HCPCS - Non-Drug
S0039		Injection, sulfamethoxazole		\$21.43	HCPCS - Non-Drug
S0040		Injection, ticarcillin disod		\$31.80	HCPCS - Non-Drug
S0071		Injection, acyclovir sodium		\$4.53	HCPCS - Non-Drug
S0072		Injection, amikacin sulfate		\$238.68	HCPCS - Non-Drug
S0073		Injection, aztreonam, 500 mg		\$30.61	HCPCS - Non-Drug
S0074		Injection, cefotetan disodiu		\$14.39	HCPCS - Non-Drug
S0077		Injection, clindamycin phosph		\$21.26	HCPCS - Non-Drug
S0078		Inj Fosphenytoin Sodium 750 mg	a	\$332.87	HCPCS - Non-Drug
S0080		Injection, pentamidine iseth		\$175.12	HCPCS - Non-Drug
S0081		Injection, piperacillin sodi		\$76.82	HCPCS - Non-Drug
S0088		Imatinib 100 mg		\$25.44	HCPCS - Non-Drug
S0090		Sildenafil citrate, 25 mg		\$17.98	HCPCS - Non-Drug
S0091		Granisetron 1mg		\$395.93	HCPCS - Non-Drug
S0092		Hydromorphone 250 mg		\$180.08	HCPCS - Non-Drug
S0093		Morphine 500 mg		\$21.44	HCPCS - Non-Drug
S0104		Zidovudine, oral, 100 mg		\$4.61	HCPCS - Non-Drug
S0107		Injection Omalizumab 25 mg	a	\$349.59	HCPCS - Non-Drug
S0108		Mercaptopurine 50 mg		\$8.49	HCPCS - Non-Drug
S0114		Injection Treprostinil Sodium 05 mg	a	\$4,092.74	HCPCS - Non-Drug
S0116		Bevacizumab 100 mg	a	\$440.51	HCPCS - Non-Drug
S0118		Injection Ziconotide Intrathecal Infusion 1 mcq	a	\$479.61	HCPCS - Drug
S0122		Inj menotropins 75 iu		\$155.04	HCPCS - Non-Drug
S0126		Inj follitropin alfa 75 iu		\$204.70	HCPCS - Non-Drug
S0128		Inj follitropin beta 75 iu		\$197.31	HCPCS - Non-Drug
S0132		Injection Ganirelix Acetate 250 mcq	a	\$33.10	HCPCS - Non-Drug
S0133		Histerelin Implant 50 mg	a	\$2,312.00	HCPCS - Drug
S0136		Clozapine 25 mg	a	\$31.46	HCPCS - Non-Drug
S0137		Didanosine 25 mg	a	\$114.60	HCPCS - Non-Drug
S0155		Epoprostenol dilutant		\$23.97	HCPCS - Non-Drug
S0156		Exemestane, 25 mg		\$14.51	HCPCS - Non-Drug
S0157		Becaplermin Gel 0.01% 0.5 gm	a	\$342.75	HCPCS - Non-Drug
S0158		Injection Laronidase 0.58 mg	a	\$439.99	HCPCS - Non-Drug
S0159		Injection Agalsidase Beta 35 mg	a	\$3,082.41	HCPCS - Non-Drug
S0161		Calcitrol 0.25 mg	a	\$78.04	HCPCS - Non-Drug
S0164		Injection Pantoprazole Sodium 40 mg	a	\$64.52	HCPCS - Non-Drug
S0167		Injection Apomorphine Hydrochloride 1 mg	a	\$63.43	HCPCS - Non-Drug
S0168		Injection Azacitidine 100 mg	a	\$297.42	HCPCS - Non-Drug
S0170		Anastrozole 1 mg		\$13.13	HCPCS - Non-Drug
S0171		Bumetanide 0.5 mg		\$2.92	HCPCS - Non-Drug
S0172		Chlorambucil 2 mg		\$3.35	HCPCS - Non-Drug
S0173		Dexamethasone 4 mg		\$1.96	HCPCS - Non-Drug
S0174		Dolasetron 50 mg		\$130.42	HCPCS - Non-Drug
S0175		Flutamide 125 mg		\$4.00	HCPCS - Non-Drug
S0176		Hydroxyurea 500 mg		\$2.59	HCPCS - Non-Drug
S0177		Levamisole 50 mg		\$12.89	HCPCS - Non-Drug
S0178		Lomustine 10 mg		\$12.97	HCPCS - Non-Drug
S0179		Megestrol 20 mg		\$1.35	HCPCS - Non-Drug
S0181		Ondansetron 4 mg		\$33.85	HCPCS - Non-Drug
S0182		Procarbazine 5 mg		\$1.41	HCPCS - Non-Drug
S0183		Prochlorperazine 5 mg		\$1.13	HCPCS - Non-Drug
S0187		Tamoxifen 10 mg		\$4.48	HCPCS - Non-Drug
S0195		Pneumococcl Coniugat Vac Im 5-9 Yr Not Prev Recvd	a	\$243.87	HCPCS - Non-Drug
S0198		Injection Pegaptanib Sodium 0.3 mg	a	\$813.18	HCPCS - Drug
S0209		WC van mileage per mi		\$1.54	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. -- DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 52 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAF Category
S0215		Nonemerg transp mileage		\$1.54	HCPCS - Non-Drug
S0302		Completed EPSDT		\$72.20	HCPCS - Non-Drug
S0395		Impression casting ft		\$76.82	HCPCS - Non-Drug
S0500		Dispos cont lens		\$138.27	HCPCS - Non-Drug
S0504		Singl prscrp lens		\$19.40	HCPCS - Non-Drug
S0506		Bifoc prscrp lens		\$33.34	HCPCS - Non-Drug
S0508		Trifoc prscrp lens		\$43.07	HCPCS - Non-Drug
S0510		Non-prscrp lens		\$27.41	HCPCS - Non-Drug
S0512		Daily cont lens		\$246.55	HCPCS - Non-Drug
S0514		Color cont lens		\$282.61	HCPCS - Non-Drug
S0515		Scleral Lens Lqd Bandge Device-Lens		\$297.46	HCPCS - Non-Drug
S0516		Safety frames		\$80.22	HCPCS - Non-Drug
S0518		Sunglass frames		\$46.38	HCPCS - Non-Drug
S0580		Polycarb lens		\$38.41	HCPCS - Non-Drug
S0581		Nonstandard Lens		\$297.46	HCPCS - Non-Drug
S0605		Digital rectal examination,		\$23.04	HCPCS - Non-Drug
S0610		Annual gynecological examina		\$161.30	HCPCS - Non-Drug
S0612		Annual gynecological examina		\$122.90	HCPCS - Non-Drug
S0620		Routine ophthalmological exa		\$84.49	HCPCS - Non-Drug
S0621		Routine ophthalmological exa		\$93.71	HCPCS - Non-Drug
S0630		Removal of sutures		\$58.38	HCPCS - Non-Drug
S0800		Laser in situ keratomileusis		\$1,758.99	HCPCS - Non-Drug
S0820		Computerized corneal topogra		\$124.43	HCPCS - Non-Drug
S1015		IV tubing extension set		\$38.52	HCPCS - Non-Drug
S1016		Non-pvc intravenous administ		\$24.58	HCPCS - Non-Drug
S1040		Cranil Remold Orthos Riqd W/Sft Int		\$618.32	HCPCS - Non-Drug
S3620		Newborn metabolic screening		\$46.10	HCPCS - Non-Drug
S4993		Contraceptive pills for bc		\$36.87	HCPCS - Non-Drug
S5000		Prescription drug, generic		\$16.90	HCPCS - Non-Drug
S5001		Prescription drug,brand name		\$72.20	HCPCS - Non-Drug
S5010		5% dextrose and 0.45% saline		\$12.29	HCPCS - Non-Drug
S5497		HIT cath care noc		\$22.52	HCPCS - Non-Drug
S5498		HIT simple cath care		\$23.04	HCPCS - Non-Drug
S5501		HIT complex cath care		\$30.72	HCPCS - Non-Drug
S5502		HIT interim cath care		\$13.84	HCPCS - Non-Drug
S8085		Fluorine-18 fluorodeoxygluco		\$789.63	HCPCS - Non-Drug
S8092		Electron beam computed tomoq		\$606.81	HCPCS - Non-Drug
S8095		Wiq (for medically-induced h		\$460.87	HCPCS - Non-Drug
S8096		Portable peak flow meter		\$30.72	HCPCS - Non-Drug
S8100		Hold Chamb W/Inhal/Nebulizr;No Mask		\$182.63	HCPCS - Non-Drug
S8101		Hold Chamb W/Inhal/Nebulizr; W/Mask		\$18.38	HCPCS - Non-Drug
S8110		Peak expiratory flow rate (p		\$29.19	HCPCS - Non-Drug
S8185		Flutter device		\$56.14	HCPCS - Non-Drug
S8186		Swivel adaptor		\$52.23	HCPCS - Non-Drug
S8189		Trach supply noc		\$27.65	HCPCS - Non-Drug
S8190		Electronic spirometer		\$51.41	HCPCS - Non-Drug
S8260		Oral orthotic for treatment		\$1,451.75	HCPCS - Non-Drug
S8420		Custom gradient sleeve/glov		\$190.44	HCPCS - Non-Drug
S8421		Ready gradient sleeve/glov		\$36.50	HCPCS - Non-Drug
S8422		Custom grad sleeve med		\$126.81	HCPCS - Non-Drug
S8423		Custom grad sleeve heavy		\$118.10	HCPCS - Non-Drug
S8424		Ready gradient sleeve		\$64.63	HCPCS - Non-Drug
S8425		Custom grad glove med		\$30.73	HCPCS - Non-Drug
S8427		Ready gradient glove		\$16.52	HCPCS - Non-Drug
S8428		Gradient Press Aid Gauntlet Rdy Made		\$49.34	HCPCS - Non-Drug
S8429		Gradient pressure wrap		\$235.01	HCPCS - Non-Drug
S8450		Splint digit		\$10.75	HCPCS - Non-Drug
S8451		Splint wrist or ankle		\$43.01	HCPCS - Non-Drug
S8452		Splint elbow		\$83.28	HCPCS - Non-Drug
S9001		Home uterine monitor with or		\$113.69	HCPCS - Non-Drug
S9015		Automated EEG monitoring		\$135.19	HCPCS - Non-Drug
S9075		Smoking cessation treatment		\$268.85	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 53 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
S9088		Services provided in urgent		\$138.27	HCPCS - Non-Drug
S9090		Vertebral axial decompressio		\$99.85	HCPCS - Non-Drug
S9122		Home health aide or certifie		\$66.17	HCPCS - Non-Drug
S9123		Nursing care in home RN		\$112.83	HCPCS - Non-Drug
S9124		Nursing care, in the home; b		\$59.91	HCPCS - Non-Drug
S9126		Hospice care, in the home, p		\$307.25	HCPCS - Non-Drug
S9127		Social work visit, in the ho		\$237.20	HCPCS - Non-Drug
S9128		Speech Therapy In The Home Per Diem		\$196.67	HCPCS - Non-Drug
S9129		Occupational therapy, in the		\$201.16	HCPCS - Non-Drug
S9131		PT in the home per diem		\$196.63	HCPCS - Non-Drug
S9140		Diabetic Management Program,		\$97.11	HCPCS - Non-Drug
S9325		HIT pain mgmt per diem		\$361.02	HCPCS - Non-Drug
S9326		HIT cont pain per diem		\$145.95	HCPCS - Non-Drug
S9327		Hit Intermitt Pain Mgmt Infus; Diem		\$384.06	HCPCS - Non-Drug
S9328		Hit Implanted Pump Pain Mgmt; Diem		\$335.83	HCPCS - Non-Drug
S9329		Hit Chemotherapy Infusion; Per Diem		\$335.83	HCPCS - Non-Drug
S9330		HIT cont chem diem		\$138.27	HCPCS - Non-Drug
S9331		HIT intermit chemo diem		\$384.06	HCPCS - Non-Drug
S9336		Hit Cont Anticoagulant Infus Tx Diem		\$145.95	HCPCS - Non-Drug
S9338		HIT immunotherapy diem		\$184.34	HCPCS - Non-Drug
S9340		HIT enteral per diem		\$192.03	HCPCS - Non-Drug
S9341		Ht; Enteral Nutrit Via Gravity; Diem		\$192.03	HCPCS - Non-Drug
S9342		HIT enteral pump diem		\$70.67	HCPCS - Non-Drug
S9343		Ht; Enteral Nutrit Via Bolus; Diem		\$192.03	HCPCS - Non-Drug
S9345		Hit Anti-Hemophilic Agent; Per Diem		\$335.83	HCPCS - Non-Drug
S9346		Hit Alpha-1-Protenas Inhibitr; Diem		\$184.34	HCPCS - Non-Drug
S9347		HIT longterm infusion diem		\$99.85	HCPCS - Non-Drug
S9348		HIT sympathomim diem		\$13.84	HCPCS - Non-Drug
S9349		HIT tocolysis diem		\$307.25	HCPCS - Non-Drug
S9351		Hit Cont Anti-Emetic; Per Diem		\$145.95	HCPCS - Non-Drug
S9353		Home Infus Tx Cont Insulin; Diem		\$145.95	HCPCS - Non-Drug
S9355		Home Infus Tx Chelation; Per Diem		\$184.34	HCPCS - Non-Drug
S9357		Hit Enzyme Repl Iv Tx; Per Diem		\$335.83	HCPCS - Non-Drug
S9359		Hit Anti-Tumr Necros Factor Iv Tx;		\$335.83	HCPCS - Non-Drug
S9361		Hit Diuretic Iv Tx; Per Diem		\$335.83	HCPCS - Non-Drug
S9363		Hit Anti-Spasmotic Tx; Per Diem		\$184.34	HCPCS - Non-Drug
S9364		HIT tpn total diem		\$661.35	HCPCS - Non-Drug
S9365		HIT tpn 1 liter diem		\$661.35	HCPCS - Non-Drug
S9366		HIT tpn 2 liter diem		\$661.35	HCPCS - Non-Drug
S9367		HIT tpn 3 liter diem		\$661.35	HCPCS - Non-Drug
S9368		HIT tpn over 3l diem		\$661.35	HCPCS - Non-Drug
S9370		Ht Intermittent Anti-Emetic Inj Tx;		\$76.82	HCPCS - Non-Drug
S9372		Ht; Intermitt Anticoagulant Inj Tx;		\$76.82	HCPCS - Non-Drug
S9373		HIT hydra total diem		\$335.83	HCPCS - Non-Drug
S9374		HIT hydra 1 liter diem		\$335.83	HCPCS - Non-Drug
S9375		HIT hydra 2 liter diem		\$335.83	HCPCS - Non-Drug
S9376		HIT hydra 3 liter diem		\$335.83	HCPCS - Non-Drug
S9377		HIT hydra over 3l diem		\$335.83	HCPCS - Non-Drug
S9379		HIT noc per diem		\$335.83	HCPCS - Non-Drug
S9435		Medical foods for inbom err		\$15.37	HCPCS - Non-Drug
S9452		Nutrition Classes Non-Physician Per Session	a	\$86.03	HCPCS - Non-Drug
S9455		Diabetic Management Program,		\$76.82	HCPCS - Non-Drug
S9460		Diabetic Management Program,		\$107.54	HCPCS - Non-Drug
S9465		Diabetic Management Program,		\$95.57	HCPCS - Non-Drug
S9470		Nutritional counseling, diet		\$85.99	HCPCS - Non-Drug
S9490		Hit Corticosteroid Infus; Admn Srvc		\$335.83	HCPCS - Non-Drug
S9494		HIT antibiotic total diem		\$4.61	HCPCS - Non-Drug
S9497		HIT antibiotic q3h diem		\$314.92	HCPCS - Non-Drug
S9500		HIT antibiotic q24h diem		\$161.30	HCPCS - Non-Drug
S9501		HIT antibiotic q12h diem		\$248.87	HCPCS - Non-Drug
S9502		HIT antibiotic q8h diem		\$268.85	HCPCS - Non-Drug
S9503		HIT antibiotic q6h diem		\$291.89	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 54 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
S9504		HIT antibiotic q4h diem		\$314.92	HCPCS - Non-Drug
S9529		Venipuncture home/snf		\$184.34	HCPCS - Non-Drug
S9537		HT hem horn inj diem		\$76.82	HCPCS - Non-Drug
S9542		Home injectable Therapy Noc-Diem		\$6.14	HCPCS - Non-Drug
S9558		HT inj growth horn diem		\$6.14	HCPCS - Non-Drug
S9559		Home Infus Tx Interferon Per Diem		\$6.14	HCPCS - Non-Drug
S9560		Home Inj Tx; Hormonal Therapy Diem		\$6.14	HCPCS - Non-Drug
S9562		Horn Inj Tx Palivizumab-Per Diem		\$6.14	HCPCS - Non-Drug
V2020		Vision svcs frames purchases		\$91.77	HCPCS - Non-Drug
V2025		Eyeglasses delux frames		\$126.50	HCPCS - Non-Drug
V2100		Lens spher single plano 4.00		\$53.86	HCPCS - Non-Drug
V2101		Single vis:n sphere 4.12-7.00		\$56.62	HCPCS - Non-Drug
V2102		Singl visn sphere 7.12-20.00		\$78.59	HCPCS - Non-Drug
V2103		Spherocylindr 4.00d/12-2.00d		\$47.12	HCPCS - Non-Drug
V2104		Spherocylindr 4.00d/2.12-4d		\$51.90	HCPCS - Non-Drug
V2105		Spherocylindr 4.00d/4.25-6d		\$56.27	HCPCS - Non-Drug
V2106		Spherocylindr 4.00d/>6.00d		\$62.16	HCPCS - Non-Drug
V2107		Spherocylindr 4.25d/12-2d		\$59.25	HCPCS - Non-Drug
V2108		Spherocylindr 4.25d/2.12-4d		\$61.25	HCPCS - Non-Drug
V2109		Spherocylindr 4.25d/4.25-6d		\$67.50	HCPCS - Non-Drug
V2110		Spherocylindr 4.25d/over 6d		\$66.63	HCPCS - Non-Drug
V2111		Spherocylindr 7.25d/2.25-2.25		\$69.35	HCPCS - Non-Drug
V2112		Spherocylindr 7.25d/2.25-4d		\$75.47	HCPCS - Non-Drug
V2113		Spherocylindr 7.25d/4.25-6d		\$84.37	HCPCS - Non-Drug
V2114		Spherocylindr over 12.00d		\$89.87	HCPCS - Non-Drug
V2115		Lens lenticular bifocal		\$96.17	HCPCS - Non-Drug
V2118		Lens aniseikonic single		\$95.50	HCPCS - Non-Drug
V2121		Lenticular lens, single		\$97.98	HCPCS - Non-Drug
V2199		Lens single vision not oth c		\$103.54	HCPCS - Non-Drug
V2200		Lens spher bifoc plano 4.00d		\$69.70	HCPCS - Non-Drug
V2201		Lens sphere bifocal 4.12-7.0		\$75.73	HCPCS - Non-Drug
V2202		Lens sphere bifocal 7.12-20.		\$87.54	HCPCS - Non-Drug
V2203		Lens sphcyl bifocal 4.00d/1		\$70.29	HCPCS - Non-Drug
V2204		Lens sphcyl bifocal 4.00d/2.1		\$73.37	HCPCS - Non-Drug
V2205		Lens sphcyl bifocal 4.00d/4.2		\$79.13	HCPCS - Non-Drug
V2206		Lens sphcyl bifocal 4.00d/ove		\$84.43	HCPCS - Non-Drug
V2207		Lens sphcyl bifocal 4.25-7/d.		\$77.38	HCPCS - Non-Drug
V2208		Lens sphcyl bifocal 4.25-7/2.		\$81.10	HCPCS - Non-Drug
V2209		Lens sphcyl bifocal 4.25-7/4.		\$86.28	HCPCS - Non-Drug
V2210		Lens sphcyl bifocal 4.25-7/ov		\$93.25	HCPCS - Non-Drug
V2211		Lens sphcyl bifo 7.25-12/1/25-		\$96.04	HCPCS - Non-Drug
V2212		Lens sphcyl bifo 7.25-12/2.2		\$98.55	HCPCS - Non-Drug
V2213		Lens sphcyl bifo 7.25-12/4.2		\$99.37	HCPCS - Non-Drug
V2214		Lens sphcyl bifocal over 12.		\$106.42	HCPCS - Non-Drug
V2215		Lens lenticular bifocal		\$107.74	HCPCS - Non-Drug
V2218		Lens aniseikonic bifocal		\$124.70	HCPCS - Non-Drug
V2219		Lens bifocal seq width over		\$60.87	HCPCS - Non-Drug
V2220		Lens bifocal add over 3.25d		\$49.86	HCPCS - Non-Drug
V2221		Lenticular lens, bifocal		\$111.24	HCPCS - Non-Drug
V2299		Lens bifocal speciality		\$72.23	HCPCS - Non-Drug
V2300		Lens sphere trifocal 4.00d		\$87.01	HCPCS - Non-Drug
V2301		Lens sphere trifocal 4.12-7.		\$99.27	HCPCS - Non-Drug
V2302		Lens sphere trifocal 7.12-20		\$104.59	HCPCS - Non-Drug
V2303		Lens sphcyl trifocal 4.0/12-		\$85.92	HCPCS - Non-Drug
V2304		Lens sphcyl trifocal 4.0/2.25		\$89.05	HCPCS - Non-Drug
V2305		Lens sphcyl trifocal 4.0/4.25		\$100.24	HCPCS - Non-Drug
V2306		Lens sphcyl trifocal 4.00/>6		\$102.66	HCPCS - Non-Drug
V2307		Lens sphcyl trifocal 4.25-7/1.		\$98.19	HCPCS - Non-Drug
V2308		Lens sphc trifocal 4.25-7/2.		\$102.00	HCPCS - Non-Drug
V2309		Lens sphc trifocal 4.25-7/4.		\$109.47	HCPCS - Non-Drug
V2310		Lens sphc trifocal 4.25-7/>6		\$108.39	HCPCS - Non-Drug
V2311		Lens sphc trifo 7.25-12/25-		\$112.04	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 55 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
V2312		Lens sphc trifo 7.25-12/2.25		\$112.57	HCPCS - Non-Drug
V2313		Lens sphc trifo 7.25-12/4.25		\$123.57	HCPCS - Non-Drug
V2314		Lens sphcyl trifocal over 12		\$131.33	HCPCS - Non-Drug
V2315		Lens lenticular trifocal		\$143.77	HCPCS - Non-Drug
V2318		Lens aniseikonic trifocal		\$172.52	HCPCS - Non-Drug
V2319		Lens trifocal seq width > 28		\$67.59	HCPCS - Non-Drug
V2320		Lens trifocal add over 3.25d		\$71.18	HCPCS - Non-Drug
V2321		Lenticular lens, trifocal		\$141.98	HCPCS - Non-Drug
V2399		Lens trifocal speciality		\$72.23	HCPCS - Non-Drug
V2410		Lens variab asphericity sing		\$112.64	HCPCS - Non-Drug
V2430		Lens variable asphericity bi		\$131.96	HCPCS - Non-Drug
V2499		Variable asphericity lens		\$44.52	HCPCS - Non-Drug
V2500		Contact lens pmma spherical		\$103.84	HCPCS - Non-Drug
V2501		Cntct lens pmma-toric/prism		\$148.48	HCPCS - Non-Drug
V2502		Contact lens pmma bifocal		\$178.63	HCPCS - Non-Drug
V2503		Cntct lens pmma color vision		\$165.98	HCPCS - Non-Drug
V2510		Cntct gas permeable spherid		\$134.99	HCPCS - Non-Drug
V2511		Cntct toric prism ballast		\$185.87	HCPCS - Non-Drug
V2512		Cntct lens gas permbl bifocl		\$216.29	HCPCS - Non-Drug
V2513		Contact lens extended wear		\$184.55	HCPCS - Non-Drug
V2520		Contact lens hydrophilic		\$128.00	HCPCS - Non-Drug
V2521		Cntct lens hydrophilic toric		\$209.13	HCPCS - Non-Drug
V2522		Cntct lens hydrophil bifocl		\$204.01	HCPCS - Non-Drug
V2523		Cntct lens hydrophil extend		\$176.59	HCPCS - Non-Drug
V2530		Contact lens gas impermeable		\$252.66	HCPCS - Non-Drug
V2531		Contact lens gas permeable		\$532.56	HCPCS - Non-Drug
V2599		Contact lens/es other type		\$73.37	HCPCS - Non-Drug
V2600		Hand held low vision aids		\$66.83	HCPCS - Non-Drug
V2610		Single lens spectacle mount		\$339.19	HCPCS - Non-Drug
V2615		Telescop/otr compound lens		\$1,440.00	HCPCS - Non-Drug
V2623		Plastic eye prosth custom		\$2,388.33	HCPCS - Non-Drug
V2624		Polishing artificial eye		\$87.13	HCPCS - Non-Drug
V2625		Enlargemnt of eye prosthesis		\$893.61	HCPCS - Non-Drug
V2626		Reduction of eye prosthesis		\$440.20	HCPCS - Non-Drug
V2627		Scleral cover shell		\$3,495.89	HCPCS - Non-Drug
V2628		Fabrication & fitting		\$706.98	HCPCS - Non-Drug
V2629		Prosthetic eye other type		\$770.88	HCPCS - Non-Drug
V2630		Anter chamber intraocul lens		\$297.48	HCPCS - Non-Drug
V2632		Post chmbr intraocular lens		\$403.08	HCPCS - Non-Drug
V2700		Balance lens		\$59.94	HCPCS - Non-Drug
V2702		Deluxe lens feature		\$59.94	HCPCS - Non-Drug
V2710		Glass/plastic slab off prism		\$85.81	HCPCS - Non-Drug
V2715		Prism lens/es		\$17.80	HCPCS - Non-Drug
V2718		Fresnell prism press-on lens		\$39.96	HCPCS - Non-Drug
V2730		Special base curve		\$30.20	HCPCS - Non-Drug
V2744		Tint photochromatic lens/es		\$24.06	HCPCS - Non-Drug
V2745		Tint, any color/solid/grad		\$16.05	HCPCS - Non-Drug
V2750		Anti-reflective coating		\$27.57	HCPCS - Non-Drug
V2755		UV lens/es		\$24.34	HCPCS - Non-Drug
V2760		Scratch resistant coating		\$23.56	HCPCS - Non-Drug
V2761		Mirror coating		\$18.94	HCPCS - Non-Drug
V2762		Polarization, any lens		\$18.89	HCPCS - Non-Drug
V2770		Occluder lens/es		\$28.14	HCPCS - Non-Drug
V2780		Oversize lens/es		\$19.00	HCPCS - Non-Drug
V2781		Progressive lens per lens		\$167.14	HCPCS - Non-Drug
V2782		Lens, 1.54-1.65 p/1.60-1.79q		\$66.17	HCPCS - Non-Drug
V2783		Lens, >= 1.66 p/>=1.80 q		\$74.62	HCPCS - Non-Drug
V2784		Lens polycarb or equal		\$48.52	HCPCS - Non-Drug
V2785		Corneal tissue processing		\$3,004.78	HCPCS - Non-Drug
V2790		Amniotic membrane		\$53.96	HCPCS - Non-Drug
V2799		Miscellaneous vision service		\$62.77	HCPCS - Non-Drug
V5008		Hearing screening		\$76.90	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 56 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAFF Category
V5010		Assessment for hearing aid		\$100.24	HCPCS - Non-Drug
V5011		Hearing aid fitting/checking		\$156.54	HCPCS - Non-Drug
V5014		Hearing aid repair/modifying		\$188.80	HCPCS - Non-Drug
V5020		Conformity evaluation		\$87.88	HCPCS - Non-Drug
V5030		Body-worn hearing aid air		\$1,975.21	HCPCS - Non-Drug
V5040		Body-worn hearing aid bone		\$1,461.27	HCPCS - Non-Drug
V5050		Hearing aid monaural in ear		\$1,716.13	HCPCS - Non-Drug
V5060		Behind ear hearing aid		\$1,406.28	HCPCS - Non-Drug
V5070		Glasses air conduction		\$707.29	HCPCS - Non-Drug
V5080		Glasses bone conduction		\$2,030.20	HCPCS - Non-Drug
V5090		Hearing aid dispensing fee		\$614.23	HCPCS - Non-Drug
V5100		Body-worn bilat hearing aid		\$3,358.40	HCPCS - Non-Drug
V5110		Hearing aid dispensing fee		\$626.91	HCPCS - Non-Drug
V5120		Body-worn binaur hearing aid		\$2,914.25	HCPCS - Non-Drug
V5130		In ear binaural hearing aid		\$3,110.94	HCPCS - Non-Drug
V5140		Behind ear binaur hearing ai		\$3,242.07	HCPCS - Non-Drug
V5150		Glasses binaural hearing aid		\$3,472.60	HCPCS - Non-Drug
V5160		Dispensing fee binaural		\$784.48	HCPCS - Non-Drug
V5170		Within ear cros hearing aid		\$2,364.36	HCPCS - Non-Drug
V5180		Behind ear cros hearing aid		\$1,975.21	HCPCS - Non-Drug
V5190		Glasses cros hearing aid		\$2,336.87	HCPCS - Non-Drug
V5200		Cros hearing aid dispens fee		\$620.58	HCPCS - Non-Drug
V5210		In ear bicros hearing aid		\$2,584.32	HCPCS - Non-Drug
V5220		Behind ear bicros hearing ai		\$2,476.45	HCPCS - Non-Drug
V5230		Glasses bicros hearing aid		\$2,565.28	HCPCS - Non-Drug
V5240		Dispensing fee bicros		\$648.07	HCPCS - Non-Drug
V5241		Dispensing fee, monaural		\$124.07	HCPCS - Non-Drug
V5242		Hearing aid, monaural, cic		\$1,430.41	HCPCS - Non-Drug
V5243		Hearing aid, monaural, itc		\$1,506.62	HCPCS - Non-Drug
V5244		Hearing aid, proq, mon, cic		\$3,367.75	HCPCS - Non-Drug
V5245		Hearing aid, proq, mon, itc		\$2,658.76	HCPCS - Non-Drug
V5246		Hearing aid, proq, mon, ite		\$1,644.90	HCPCS - Non-Drug
V5247		Hearing aid, proq, mon, bte		\$2,279.50	HCPCS - Non-Drug
V5248		Hearing aid, binaural, cic		\$1,810.30	HCPCS - Non-Drug
V5249		Hearing aid, binaural, itc		\$2,300.71	HCPCS - Non-Drug
V5250		Hearing aid, proq, bin, cic		\$6,363.28	HCPCS - Non-Drug
V5251		Hearing aid, proq, bin, itc		\$6,008.77	HCPCS - Non-Drug
V5252		Hearing aid, proq, bin, ite		\$5,672.00	HCPCS - Non-Drug
V5253		Hearing aid, proq, bin, bte		\$2,570.12	HCPCS - Non-Drug
V5254		Hearing aid, digit, mon, cic		\$3,988.13	HCPCS - Non-Drug
V5255		Hearing aid, digit, mon, itc		\$3,155.06	HCPCS - Non-Drug
V5256		Hearing aid, digit, mon, ite		\$3,766.56	HCPCS - Non-Drug
V5257		Hearing aid, digit, mon, bte		\$2,765.09	HCPCS - Non-Drug
V5258		Hearing aid, digit, bin, cic		\$6,024.73	HCPCS - Non-Drug
V5259		Hearing aid, digit, bin, itc		\$7,090.00	HCPCS - Non-Drug
V5260		Hearing aid, digit, bin, ite		\$8,153.50	HCPCS - Non-Drug
V5261		Hearing aid, digit, bin, bte		\$6,735.50	HCPCS - Non-Drug
V5262		Hearing aid, disp, monaural		\$138.25	HCPCS - Non-Drug
V5263		Hearing aid, disp, binaural		\$69.13	HCPCS - Non-Drug
V5264		Ear mold/insert		\$87.39	HCPCS - Non-Drug
V5265		Ear mold/insert, disp		\$12.41	HCPCS - Non-Drug
V5266		Battery for hearing device		\$2.43	HCPCS - Non-Drug
V5267		Hearing aid supply/accessory		\$26.59	HCPCS - Non-Drug
V5268		ALD Telephone Amplifier		\$375.56	HCPCS - Non-Drug
V5269		Alerting device, any type		\$549.82	HCPCS - Non-Drug
V5270		ALD, TV amplifier, any type		\$671.03	HCPCS - Non-Drug
V5271		ALD, TV caption decoder		\$3,486.23	HCPCS - Non-Drug
V5272		Tdd		\$789.80	HCPCS - Non-Drug
V5273		ALD for cochlear implant		\$521.04	HCPCS - Non-Drug
V5274		ALD unspecified		\$1,155.11	HCPCS - Non-Drug
V5275		Ear impression		\$53.17	HCPCS - Non-Drug
V5298		Hearing aid noc		\$3,374.75	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. -- DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 57 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAP Category
V5299		Hearing service		\$865.67	HCPCS - Non-Drug
V5336		Repair communication device		\$308.32	HCPCS - Non-Drug

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE K. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE NATIONWIDE- CHARGES BY HCPCS CODE

PAGE 58 of 58

HCPCS	Modifier	HCPCS Code Description	Status/ Usage Indicator (1)	Charge	GAAF Category
-------	----------	------------------------	-----------------------------------	--------	---------------

Key to Status/Usage Indicators for new items:

a: Cannot be billed by VA hospital outpatients and provider-based clinics because the service is separately priced as an outpatient facility charge. (See Table F for these charges.)

No entry: Can be billed at all VA locations.

For all HCPCS codes retained from V2.4, the status/usage indicator was retained from V2.4.

NOTES: See end of the table for note regarding Status/Usage Indicator.

TABLE L. - PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

2 of 20

Zip Code	RVU GAAFs											Conversion Factor GAAFs By Category															
	Work Expense	Practice Expense	Total Unit Value	Inpatient Visits	Office/Home/Urgent Care Visits	Therapeutic Injections	Allergy Testing	Allergy Immunotherapy	Misc. Medical Visits	ER Visits	Consults	Physical Medicine	Cardiovascular	Immunizations	Well Baby Exams	Vision Exams	Hearing/Speech Exams	Physical Exams	Chiropractic	Psych/Alcohol/Drug Abuse	Surgery	Radiology	Pathology	Anesthesia	Normal Delivery	Cesarean Delivery	Non-Delivery
049	1.000	0.810	0.95	0.90	0.99	0.83	0.84	1.09	0.94	0.87	1.03	0.92	0.73	0.27	1.12	0.91	1.15	1.07	0.91	0.97	0.98	1.03	0.86	0.80	1.02	1.10	0.86
050	1.000	0.880	0.99	0.89	0.87	0.62	1.03	1.02	0.68	0.78	0.85	0.80	0.73	0.61	0.96	0.83	1.24	0.92	0.89	0.82	0.89	0.86	0.78	0.84	0.89	0.95	0.70
051	1.000	0.880	0.99	0.89	0.87	0.62	1.03	1.02	0.68	0.78	0.85	0.80	0.73	0.61	0.96	0.83	1.24	0.92	0.89	0.82	0.89	0.86	0.78	0.84	0.89	0.95	0.70
052	1.000	0.880	0.99	0.89	0.87	0.62	1.03	1.02	0.68	0.78	0.85	0.80	0.73	0.61	0.96	0.83	1.24	0.92	0.89	0.82	0.89	0.86	0.78	0.84	0.89	0.95	0.70
053	1.000	0.880	0.99	0.89	0.87	0.62	1.03	1.02	0.68	0.78	0.85	0.80	0.73	0.61	0.96	0.83	1.24	0.92	0.89	0.82	0.89	0.86	0.78	0.84	0.89	0.95	0.70
054	1.000	0.868	0.99	0.87	0.95	1.08	0.70	1.00	1.32	0.85	0.85	0.84	0.90	0.60	1.15	0.91	1.00	0.83	0.83	1.17	1.34	0.85	0.91	1.18	1.17	1.12	0.86
055	1.010	1.129	1.08	0.68	0.85	0.82	1.26	1.19	1.04	0.91	0.85	1.11	0.90	1.01	0.55	1.08	0.92	1.11	1.00	0.92	0.87	0.95	1.02	0.94	0.91	1.07	0.86
056	1.000	0.880	0.99	0.89	0.87	0.62	1.03	1.02	0.68	0.78	0.85	0.80	0.73	0.61	0.96	0.83	1.24	0.92	0.89	0.82	0.89	0.86	0.78	0.84	0.89	0.95	0.70
057	1.000	0.880	0.99	0.89	0.87	0.62	1.03	1.02	0.68	0.78	0.85	0.80	0.73	0.61	0.96	0.83	1.24	0.92	0.89	0.82	0.89	0.86	0.78	0.84	0.89	0.95	0.70
058	1.000	0.880	0.99	0.89	0.87	0.62	1.03	1.02	0.68	0.78	0.85	0.80	0.73	0.61	0.96	0.83	1.24	0.92	0.89	0.82	0.89	0.86	0.78	0.84	0.89	0.95	0.70
059	1.000	0.880	0.99	0.89	0.87	0.62	1.03	1.02	0.68	0.78	0.85	0.80	0.73	0.61	0.96	0.83	1.24	0.92	0.89	0.82	0.89	0.86	0.78	0.84	0.89	0.95	0.70
060	1.050	1.156	1.11	0.81	0.96	0.94	1.12	1.12	0.90	0.85	0.94	0.96	1.02	0.51	1.20	1.02	1.02	1.02	1.02	1.02	1.19	1.01	1.00	0.86	1.49	1.57	1.00
061	1.050	1.156	1.11	0.81	0.96	0.94	1.12	1.12	0.90	0.85	0.94	0.96	1.02	0.51	1.20	1.02	1.02	1.02	1.02	1.19	1.01	1.00	0.86	1.49	1.57	1.00	1.00
062	1.050	1.156	1.11	0.81	0.96	0.94	1.12	1.12	0.90	0.85	0.94	0.96	1.02	0.51	1.20	1.02	1.02	1.02	1.19	1.01	1.00	0.86	1.49	1.57	1.00	1.00	1.00
063	1.050	1.156	1.11	0.81	0.96	0.94	1.12	1.12	0.90	0.85	0.94	0.96	1.02	0.51	1.20	1.02	1.02	1.02	1.19	1.01	1.00	0.86	1.49	1.57	1.00	1.00	1.00
064	1.050	1.156	1.11	0.81	0.96	0.94	1.12	1.12	0.90	0.85	0.94	0.96	1.02	0.51	1.20	1.02	1.02	1.02	1.19	1.01	1.00	0.86	1.49	1.57	1.00	1.00	1.00
065	1.050	1.156	1.11	0.81	0.96	0.94	1.12	1.12	0.90	0.85	0.94	0.96	1.02	0.51	1.20	1.02	1.02	1.02	1.19	1.01	1.00	0.86	1.49	1.57	1.00	1.00	1.00
066	1.050	1.156	1.11	0.81	0.96	0.94	1.12	1.12	0.90	0.85	0.94	0.96	1.02	0.51	1.20	1.02	1.02	1.02	1.19	1.01	1.00	0.86	1.49	1.57	1.00	1.00	1.00
067	1.050	1.156	1.11	0.81	0.96	0.94	1.12	1.12	0.90	0.85	0.94	0.96	1.02	0.51	1.20	1.02	1.02	1.02	1.19	1.01	1.00	0.86	1.49	1.57	1.00	1.00	1.00
068	1.050	1.156	1.11	0.81	0.96	0.94	1.12	1.12	0.90	0.85	0.94	0.96	1.02	0.51	1.20	1.02	1.02	1.02	1.19	1.01	1.00	0.86	1.49	1.57	1.00	1.00	1.00
069	1.050	1.156	1.11	0.81	0.96	0.94	1.12	1.12	0.90	0.85	0.94	0.96	1.02	0.51	1.20	1.02	1.02	1.02	1.19	1.01	1.00	0.86	1.49	1.57	1.00	1.00	1.00
070	1.058	1.193	1.13	0.97	0.96	0.90	1.21	1.07	1.00	1.17	0.86	1.04	1.08	1.06	1.18	0.84	1.21	1.05	1.22	1.34	1.22	1.34	1.02	1.05	1.48	1.23	1.40
071	1.058	1.193	1.13	0.97	0.96	0.90	1.21	1.07	1.00	1.17	0.86	1.04	1.08	1.06	1.18	0.84	1.21	1.05	1.22	1.34	1.22	1.34	1.02	1.05	1.48	1.23	1.40
072	1.058	1.193	1.13	0.97	0.96	0.90	1.21	1.07	1.00	1.17	0.86	1.04	1.08	1.06	1.18	0.84	1.21	1.05	1.22	1.34	1.22	1.34	1.02	1.05	1.48	1.23	1.40
073	1.058	1.193	1.13	0.97	0.96	0.90	1.21	1.07	1.00	1.17	0.86	1.04	1.08	1.06	1.18	0.84	1.21	1.05	1.22	1.34	1.22	1.34	1.02	1.05	1.48	1.23	1.40
074	1.058	1.193	1.13	0.97	0.96	0.90	1.21	1.07	1.00	1.17	0.86	1.04	1.08	1.06	1.18	0.84	1.21	1.05	1.22	1.34	1.22	1.34	1.02	1.05	1.48	1.23	1.40
075	1.058	1.193	1.13	0.97	0.96	0.90	1.21	1.07	1.00	1.17	0.86	1.04	1.08	1.06	1.18	0.84	1.21	1.05	1.22	1.34	1.22	1.34	1.02	1.05	1.48	1.23	1.40
076	1.058	1.193	1.13	0.97	0.96	0.90	1.21	1.07	1.00	1.17	0.86	1.04	1.08	1.06	1.18	0.84	1.21	1.05	1.22	1.34	1.22	1.34	1.02	1.05	1.48	1.23	1.40
077	1.029	1.110	1.07	1.01	0.96	0.84	1.14	1.14	0.97	1.20	0.93	0.97	0.99	1.01	0.95	0.90	0.90	0.90	0.90	1.07	1.09	1.27	1.06	1.28	1.18	1.12	1.35
078	1.058	1.193	1.13	0.97	0.96	0.90	1.21	1.07	1.00	1.17	0.86	1.04	1.08	1.06	1.18	0.84	1.21	1.05	1.22	1.34	1.22	1.34	1.02	1.05	1.48	1.23	1.40
079	1.058	1.193	1.13	0.97	0.96	0.90	1.21	1.07	1.00	1.17	0.86	1.04	1.08	1.06	1.18	0.84	1.21	1.05	1.22	1.34	1.22	1.34	1.02	1.05	1.48	1.23	1.40
080	1.029	1.110	1.07	0.97	0.90	1.14	0.90	1.02	0.95	1.44	0.89	1.15	1.43	1.13	1.01	0.89	1.18	0.97	1.07	1.07	1.15	1.03	0.95	1.18	0.90	0.91	1.17
081	1.029	1.110	1.07	0.97	0.90	1.14	0.90	1.02	0.95	1.44	0.89	1.15	1.43	1.13	1.01	0.89	1.18	0.97	1.07	1.07	1.15	1.03	0.95	1.18	0.90	0.91	1.17
082	1.029	1.110	1.07	0.97	0.90	1.14	0.90	1.02	0.95	1.44	0.89	1.15	1.43	1.13	1.01	0.89	1.18	0.97	1.07	1.07	1.15	1.03	0.95	1.18	0.90	0.91	1.17
083	1.029	1.110	1.07	0.97	0.90	1.14	0.90	1.02	0.95	1.44	0.89	1.15	1.43	1.13	1.01	0.89	1.18	0.97	1.07	1.07	1.15	1.03	0.95	1.18	0.90	0.91	1.17
084	1.029	1.110	1.07	0.97	0.90	1.14	0.90	1.02	0.95	1.44	0.89	1.15	1.43	1.13	1.01	0.89	1.18	0.97	1.07	1.07	1.15	1.03	0.95	1.18	0.90	0.91	1.17
085	1.029	1.110	1.07	0.97	0.90	1.14	0.90	1.02	0.95	1.44	0.89	1.15	1.43	1.13	1.01	0.89	1.18	0.97	1.07	1.07	1.15	1.03	0.95	1.18	0.90	0.91	1.17
086	1.029	1.110	1.07	0.97	0.90	1.14	0.90	1.02	0.95	1.44	0.89	1.15	1.43	1.13	1.01	0.89	1.18	0.97	1.07	1.07	1.15	1.03	0.95	1.18	0.90	0.91	1.17
087	1.029	1.110	1.07	0.97	0.90	1.14	0.90	1.02	0.95	1.44	0.89	1.15	1.43	1.13	1.01	0.89	1.18	0.97	1.07	1.07	1.15	1.03	0.95	1.18	0.90	0.91	1.17
088	1.058	1.193	1.13	0.90	0.91	0.83	1.06	1.02	0.92	1.23	0.90	1.07	1.04	0.89	0.92	0.85	0.90	0.92	1.02	1.15	1.18	1.00	0.95	1.49	1.20	1.46	1.68
089	1.058	1.193	1.13	0.90	0.91	0.83	1.06	1.02	0.92	1.23	0.90	1.07	1.04	0.89	0.92	0.85	0.90	0.92	1.02	1.15	1.18	1.00	0.95	1.49	1.20	1.46	1.68
090	1.094	1.351	1.24	1.39	1.47	1.18	1.24	1.40	1.10	0.97	1.20	1.23	0.99	1.00	1.12	1.37	0.92	1.18	1.41	1.13	1.57	0.83	1.06	1.57	1.83	1.76	1.30
100	1.094	1.351	1.24	1.39	1.47	1.18	1.24	1.40	1.10	0.97	1.20	1.23	0.99	1.00	1.12	1.37	0.92	1.18	1.41	1.13	1.57	0.83	1.06	1.57	1.83	1.76	1.30
101	1.094	1.351	1.24	1.39	1.47	1.18	1.24	1.40	1.10	0.97	1.20	1.23	0.99	1.00	1.12	1.37	0.92	1.18	1.41	1.13	1.57	0.83	1.06	1.57	1.83	1.76	1.30
102	1.094	1.351	1.24	1.39	1.47	1.18	1.24	1.40	1.10	0.97	1.20	1.23	0.99	1.00	1.12	1.37	0.92	1.18	1.41	1.13	1.57	0.83	1.06	1.57	1.83	1.76	1.30
103	1.068	1.251	1.17	0.92	1.06	1.09	1.00	1.32	0.85	0.95	1.00	1.09	0.68	1.06	0.91	1.12	0.84	1.05	1.12	1.05	1.30	0					

TABLE L. -- PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU)
AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

3 of 20

Zip Code	RVU GAAFs							Conversion Factor GAAFs By Category																				
	Work Expense	Practice Expense	Total Unit Value	Inpatient Visits	Office/Home/ Urgent Care Visits	Therapeutic Injections	Allergy Testing	Allergy Medication	Misc. Medication	ER Visits	Copays	Phys. Med. Exam	Cardiovascular	Immunizations	Well Baby Exams	Missed/ Speech Exams	Physical Exams	Chiropractor	Psych/ Alcohol/ Drug Abuse	Surgey	Radiology	Pathology	Anesthesia	Normal Delivered	Cesarean Delivered	Non-Delivered		
108	1.066	1.251	1.17	0.96	1.15	1.41	1.20	1.49	1.00	0.80	1.10	1.37	0.70	0.90	0.80	1.04	0.87	1.05	1.21	1.14	1.19	0.84	0.87	1.35	1.50	1.44	0.86	
107	1.066	1.251	1.17	0.96	1.00	1.04	1.35	1.12	0.95	0.83	1.01	0.93	0.73	0.98	0.83	1.03	0.84	1.10	1.00	1.10	1.28	0.92	0.85	1.39	1.53	1.49	0.86	
109	1.066	1.251	1.17	0.94	0.92	0.93	1.05	1.11	0.95	0.83	0.91	1.02	0.68	0.80	0.80	1.03	0.77	0.84	1.00	0.68	1.18	0.75	0.95	1.65	1.22	1.32	1.31	
110	1.066	1.251	1.17	0.92	1.05	1.09	1.00	1.32	0.85	0.95	1.00	1.09	0.68	1.06	0.91	1.12	0.84	1.05	1.12	1.05	1.30	0.86	1.03	1.66	1.64	1.54	1.46	
111	1.058	1.251	1.17	0.83	1.10	1.11	1.02	1.35	0.86	0.97	1.01	1.11	0.70	1.10	0.92	1.14	0.86	1.13	1.06	1.32	0.87	1.04	1.58	1.67	1.56	1.52	1.52	
112	1.058	1.251	1.17	0.84	1.09	1.49	0.80	1.13	0.86	0.93	1.02	1.08	1.11	1.18	1.03	1.10	0.91	0.96	1.16	0.93	1.33	0.79	1.00	2.15	1.59	1.56	1.71	
113	1.058	1.251	1.17	0.85	1.10	1.51	0.90	1.15	0.80	0.94	1.03	1.10	1.13	1.18	1.04	1.12	0.93	1.00	1.17	0.94	1.36	0.80	1.00	2.15	1.62	1.56	1.74	
114	1.058	1.251	1.17	0.85	1.10	1.32	1.08	1.13	0.87	0.90	1.00	1.07	0.86	0.98	0.93	1.03	0.81	0.98	1.19	1.05	1.32	0.81	1.10	1.63	1.51	1.44	1.64	
115	1.066	1.251	1.17	0.95	1.03	1.34	1.06	1.15	0.86	0.91	1.01	1.09	0.89	1.00	0.86	0.98	0.83	1.03	1.05	1.32	0.81	1.10	1.63	1.51	1.44	1.64		
116	1.066	1.251	1.17	0.93	1.01	1.32	1.08	1.13	0.87	0.90	1.00	1.07	0.86	0.98	0.83	1.03	0.81	0.98	1.19	1.05	1.32	0.81	1.10	1.63	1.51	1.44	1.64	
117	1.066	1.251	1.17	0.93	1.01	1.32	1.06	1.13	0.87	0.90	1.00	1.07	0.86	0.98	0.83	1.03	0.81	0.98	1.19	1.05	1.32	0.81	1.10	1.63	1.51	1.44	1.64	
118	1.066	1.251	1.17	0.93	1.01	1.32	1.06	1.13	0.87	0.90	1.00	1.07	0.86	0.98	0.83	1.03	0.81	0.98	1.19	1.05	1.32	0.81	1.10	1.63	1.51	1.44	1.64	
119	1.066	1.251	1.17	0.93	1.01	1.32	1.06	1.13	0.87	0.90	1.00	1.07	0.86	0.98	0.83	1.03	0.81	0.98	1.19	1.05	1.32	0.81	1.10	1.63	1.51	1.44	1.64	
120	1.066	1.251	1.17	0.93	1.01	1.32	1.06	1.13	0.87	0.90	1.00	1.07	0.86	0.98	0.83	1.03	0.81	0.98	1.19	1.05	1.32	0.81	1.10	1.63	1.51	1.44	1.64	
121	1.000	0.844	0.97	0.89	0.99	1.44	0.92	1.00	0.96	0.89	0.93	0.87	0.70	1.16	1.12	1.12	0.95	1.07	0.92	0.94	0.96	1.00	0.94	0.92	1.03	1.04	0.98	
122	1.000	0.844	0.97	0.89	0.99	1.44	0.92	1.00	0.96	0.89	0.93	0.87	0.70	1.16	1.12	1.12	0.95	1.07	0.92	0.94	0.96	1.00	0.94	0.92	1.03	1.04	0.98	
123	1.000	0.844	0.97	0.89	0.99	1.44	0.92	1.00	0.96	0.89	0.93	0.87	0.70	1.16	1.12	1.12	0.95	1.07	0.92	0.94	0.96	1.00	0.94	0.92	1.03	1.04	0.98	
124	1.011	1.075	1.05	0.85	0.92	1.28	0.78	0.88	0.80	0.84	0.86	0.81	0.81	1.02	1.04	1.02	0.85	0.99	0.67	0.89	0.89	0.89	0.92	0.82	0.93	0.87	0.84	
125	1.011	1.075	1.05	0.84	1.02	0.85	0.91	1.18	1.18	0.91	0.91	0.93	0.84	0.81	1.10	1.11	1.08	0.85	1.12	0.95	0.98	1.18	1.03	0.91	1.59	1.49	1.33	1.45
126	1.011	1.075	1.05	0.84	1.02	0.85	0.91	1.18	1.18	0.91	0.91	0.93	0.84	0.81	1.10	1.11	1.08	0.85	1.12	0.95	0.98	1.18	1.03	0.91	1.59	1.49	1.33	1.45
127	1.011	1.075	1.05	0.84	1.02	0.85	0.91	1.18	1.18	0.91	0.91	0.93	0.84	0.81	1.10	1.11	1.08	0.85	1.12	0.95	0.98	1.18	1.03	0.91	1.59	1.49	1.33	1.45
128	1.000	0.844	0.97	0.86	0.97	0.81	1.07	1.17	1.06	0.86	0.86	1.02	1.04	1.05	1.06	1.07	0.82	1.01	0.90	0.98	0.98	1.07	0.88	0.91	1.52	1.27	1.27	1.27
129	1.000	0.844	0.97	0.86	0.97	0.81	1.07	1.17	1.06	0.86	0.86	1.02	1.04	1.05	1.06	1.07	0.82	1.01	0.90	0.98	0.98	1.07	0.88	0.91	1.52	1.27	1.27	1.27
130	1.000	0.844	0.97	0.91	0.99	0.94	0.94	1.00	0.94	0.94	0.96	0.82	0.83	1.02	1.05	1.00	0.98	1.05	0.82	0.95	1.09	0.94	0.80	1.00	1.20	1.20	1.02	1.02
131	1.000	0.844	0.97	0.91	0.99	0.94	0.94	1.00	0.94	0.94	0.96	0.82	0.83	1.02	1.05	1.00	0.98	1.05	0.82	0.95	1.09	0.94	0.80	1.00	1.20	1.20	1.02	1.02
132	1.000	0.844	0.97	0.91	0.99	0.94	0.94	1.00	0.94	0.94	0.96	0.82	0.83	1.02	1.05	1.00	0.98	1.05	0.82	0.95	1.09	0.94	0.80	1.00	1.20	1.20	1.02	1.02
133	1.000	0.844	0.97	0.92	0.90	0.94	0.92	1.25	0.95	0.97	0.95	0.92	0.70	1.06	1.08	1.23	0.86	1.01	0.86	0.91	0.98	1.22	0.90	0.98	1.03	1.05	1.01	1.01
134	1.000	0.844	0.97	0.92	0.90	0.94	0.92	1.25	0.95	0.97	0.95	0.92	0.70	1.06	1.08	1.23	0.86	1.01	0.86	0.91	0.98	1.22	0.90	0.98	1.03	1.05	1.01	1.01
135	1.000	0.844	0.97	0.92	0.90	0.94	0.92	1.25	0.95	0.97	0.95	0.92	0.70	1.06	1.08	1.23	0.86	1.01	0.86	0.91	0.98	1.22	0.90	0.98	1.03	1.05	1.01	1.01
136	1.000	0.844	0.97	0.92	0.90	0.94	0.92	1.25	0.95	0.97	0.95	0.92	0.70	1.06	1.08	1.23	0.86	1.01	0.86	0.91	0.98	1.22	0.90	0.98	1.03	1.05	1.01	1.01
137	1.000	0.844	0.97	0.92	0.90	0.94	0.92	1.25	0.95	0.97	0.95	0.92	0.70	1.06	1.08	1.23	0.86	1.01	0.86	0.91	0.98	1.22	0.90	0.98	1.03	1.05	1.01	1.01
138	1.000	0.844	0.97	0.92	0.90	0.94	0.92	1.25	0.95	0.97	0.95	0.92	0.70	1.06	1.08	1.23	0.86	1.01	0.86	0.91	0.98	1.22	0.90	0.98	1.03	1.05	1.01	1.01
139	1.000	0.844	0.97	0.92	0.90	0.94	0.92	1.25	0.95	0.97	0.95	0.92	0.70	1.06	1.08	1.23	0.86	1.01	0.86	0.91	0.98	1.22	0.90	0.98	1.03	1.05	1.01	1.01
140	1.000	0.844	0.97	0.92	0.90	0.94	0.92	1.25	0.95	0.97	0.95	0.92	0.70	1.06	1.08	1.23	0.86	1.01	0.86	0.91	0.98	1.22	0.90	0.98	1.03	1.05	1.01	1.01
141	1.000	0.844	0.97	0.92	0.90	0.94	0.92	1.25	0.95	0.97	0.95	0.92	0.70	1.06	1.08	1.23	0.86	1.01	0.86	0.91	0.98	1.22	0.90	0.98	1.03	1.05	1.01	1.01
142	1.000	0.844	0.97	0.92	0.90	0.94	0.92	1.25	0.95	0.97	0.95	0.92	0.70	1.06	1.08	1.23	0.86	1.01	0.86	0.91	0.98	1.22	0.90	0.98	1.03	1.05	1.01	1.01
143	1.000	0.844	0.97	0.92	0.90	0.94	0.92	1.25	0.95	0.97	0.95	0.92	0.70	1.06	1.08	1.23	0.86	1.01	0.86	0.91	0.98	1.22	0.90	0.98	1.03	1.05	1.01	1.01
144	1.000	0.844	0.97	0.92	0.90	0.94	0.92	1.25	0.95	0.97	0.95	0.92	0.70	1.06	1.08	1.23	0.86	1.01	0.86	0.91	0.98	1.22	0.90	0.98	1.03	1.05	1.01	1.01
145	1.000	0.844	0.97	0.92	0.90	0.94	0.92	1.25	0.95	0.97	0.95	0.92	0.70	1.06	1.08	1.23	0.86	1.01	0.86	0.91	0.98	1.22	0.90	0.98	1.03	1.05	1.01	1.01
146	1.000	0.844	0.97	0.92	0.90	0.94	0.92	1.25	0.95	0.97	0.95	0.92	0.70	1.06	1.08	1.23	0.86	1.01	0.86	0.91	0.98	1.22	0.90	0.98	1.03	1.05	1.01	1.01
147	1.000	0.844	0.97	0.92	0.90	0.94	0.92	1.25	0.95	0.97	0.95	0.92	0.70	1.06	1.08	1.23	0.86	1.01	0.86	0.91	0.98	1.22	0.90	0.98	1.03	1.05	1.01	1.01
148	1.000	0.844	0.97	0.92	0.90	0.94	0.92	1.25	0.95	0.97	0.95	0.92	0.70	1.06	1.08	1.23	0.86	1.01	0.86	0.91	0.98	1.22	0.90	0.98	1.03	1.05	1.01	1.01
149	1.000	0.844	0.97	0.92	0.90	0.94	0.92	1.25	0.95	0.97	0.95	0.92	0.70	1.06	1.08	1.23	0.86	1.01	0.86	0.91	0.98	1.22	0.90	0.98	1.03	1.05	1.01	1.01
150	1.000	0.844	0.97	0.92	0.90	0.94	0.92	1.25	0.95	0.97	0.95	0.92	0.70	1.06	1.08	1.23	0.86	1.01	0.86	0.91	0.98	1.22	0.90	0.98	1.03	1.05	1.01	1.01
151	1.000	0.829	0.96	0.89	0.90	1.46	0.85	0.82	0.99	0.98	0.80	0.87	1.56	1.01	0.81	0.93	1.12	0.76	1.06	0.87	1.01	0.91	0.97	0.94	0.94			

TABLE L. — PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

4 of 20

Zip Code	RVU GAAFs											Conversion Factor GAAFs By Category															
	Work Expense	Practice Expense	Total Unit Value	Inpatient Visits	Office/Home/Urgent Care Visits	Therapeutic Injections	Allegry Testing	Allegry Immunotherapy	Misc. Medical	ER Visits	Consults	Physical Medicine	Cardiovascular	Immunizations	Well Baby Exams	Vision Exams	Hearing/Speech Exams	Physiological Exams	Chiropractor	Psych/Alcohol/Drug Abuse	Surgery	Rehabilitation	Pathology	Anesthesia	Normal Diagnostics	Casualty Diagnostics	Non-Diagnostic
153	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.82	0.77	0.86	1.17	1.02	0.80	0.85	0.96	0.73	0.96	0.85	0.83	0.80	0.81	0.85	1.21	1.19	1.26
154	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.82	0.77	0.86	1.17	1.02	0.80	0.85	0.96	0.73	0.96	0.85	0.83	0.80	0.81	0.85	1.21	1.19	1.26
155	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.82	0.77	0.86	1.17	1.02	0.80	0.85	0.96	0.73	0.96	0.85	0.83	0.80	0.81	0.85	1.21	1.19	1.26
156	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
157	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
158	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
159	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
160	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
161	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
162	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
163	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
164	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
165	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
166	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
167	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
168	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
169	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
170	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
171	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
172	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
173	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
174	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
175	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
176	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
177	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
178	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
179	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
180	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
181	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
182	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
183	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
184	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
185	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
186	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
187	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
188	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
189	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
190	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
191	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
192	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
193	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
194	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
195	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
196	1.000	0.929	0.96	0.81	0.86	1.09	0.83	0.77	0.83	0.80	0.79	1.00	0.96	1.01	0.83	0.89	1.05	0.71	0.84	0.85	0.85	1.06	0.82	0.86	1.22	1.20	1.26
197	1.019	1.035	1.03	0.85	0.94	1.10	0.85	0.82	0.85	0.84	1.13	1.06	1.35	0.96	0.87	0.92	1.11	0.86	1.06	0.84	1.05	0.90	1.09	1.09	0.86	1.30	1.30
198	1.019	1.035	1.03	0.85	0.94	1.10	0.85	0.82	0.85	0.84	1.13	1.06	1.35	0.96	0.87	0.92	1.11	0.86	1.06	0.84	1.0						

TABLE L—PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU)
AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

5 of 20

Zip Code	RVU GAAFs										Conversion Factor GAAFs By Category																	
	Work Expense	Practice Expense	Total Unit Value	Independent Visits	Office/Home/Urgent Care Visits	Therapeutic Injections	Allergy Testing	Allergy Immunotherapy	Misc. Medical	ER	Consults	Physical Medicine	Cardiovascular	Immunizations	Well Baby Exams	Vision Exams	Hearing/Speech Exams	Physical Exams	Chiropractor	Psych/Alcohol/Drug Abuse	Surgery	Radiology	Pathology	Anesthesia	Normal Deliv-eries	Cesar-ean Deliv-eries	Non-Deliv-eries	
200	1.000	1.186	1.111	1.17	1.05	1.28	1.06	0.76	1.03	0.81	0.96	0.90	1.16	0.93	1.03	0.84	1.01	0.97	1.12	1.07	1.04	1.00	1.02	1.25	1.23	1.42		
201	1.000	1.038	0.97	1.25	1.12	1.12	0.94	1.02	1.12	0.96	1.01	0.97	1.02	1.21	0.99	1.09	0.84	1.01	0.97	1.12	1.07	1.04	1.00	1.02	1.22	1.19	1.37	
202	1.000	1.166	1.11	1.17	1.05	1.28	1.06	0.76	1.03	0.81	0.96	0.90	1.16	0.93	1.03	0.84	1.01	0.97	1.12	1.07	1.04	1.00	1.02	1.25	1.23	1.42		
203	1.000	1.166	1.11	1.17	1.05	1.28	1.06	0.76	1.03	0.81	0.96	0.90	1.16	0.93	1.03	0.84	1.01	0.97	1.12	1.07	1.04	1.00	1.02	1.25	1.23	1.42		
204	1.000	1.166	1.11	1.17	1.05	1.28	1.06	0.76	1.03	0.81	0.96	0.90	1.16	0.93	1.03	0.84	1.01	0.97	1.12	1.07	1.04	1.00	1.02	1.25	1.23	1.42		
205	1.000	1.186	1.11	1.17	1.05	1.28	1.06	0.76	1.03	0.81	0.96	0.90	1.16	0.93	1.03	0.84	1.01	0.97	1.12	1.07	1.04	1.00	1.02	1.25	1.23	1.42		
206	1.000	1.072	0.96	0.98	1.02	1.09	0.89	0.93	0.97	0.86	0.87	1.30	0.84	0.98	0.84	0.96	0.84	0.89	0.92	0.88	1.01	1.04	0.86	0.91	1.13	1.17	1.51	
207	1.000	1.166	1.11	0.98	1.00	1.03	1.21	0.82	0.90	0.85	0.87	1.30	0.84	0.98	0.84	0.96	0.84	0.89	0.92	0.88	1.01	1.04	0.86	0.91	1.13	1.17	1.51	
208	1.000	1.166	1.11	1.08	0.97	1.18	0.85	0.92	1.01	0.93	0.91	0.99	0.78	1.05	0.86	1.01	0.85	0.88	0.93	1.01	0.86	0.78	0.89	1.02	1.06	1.17	1.17	
209	1.000	1.186	1.11	1.06	0.97	1.18	0.85	0.92	1.01	0.93	0.91	0.99	0.78	1.05	0.86	1.01	0.85	0.88	0.93	1.01	0.86	0.78	0.89	1.02	1.06	1.17	1.17	
210	1.021	1.038	1.03	0.96	0.93	0.97	0.93	0.92	0.97	1.02	0.88	0.98	1.11	0.99	0.92	1.02	0.95	0.98	0.98	0.93	1.01	1.10	0.89	0.93	1.09	1.07	1.18	
211	1.021	1.038	1.03	0.96	0.93	0.97	0.93	0.92	0.97	1.02	0.88	0.98	1.11	0.99	0.92	1.02	0.95	0.98	0.98	0.93	1.01	1.10	0.89	0.93	1.09	1.07	1.18	
212	1.021	1.038	1.03	1.21	1.06	1.09	0.96	0.92	1.15	0.86	1.05	1.40	1.07	1.14	1.10	1.13	1.10	1.03	1.00	1.06	1.07	1.06	0.84	1.16	1.16	1.24	1.18	
214	1.021	1.038	1.03	0.98	0.93	0.97	0.93	0.92	0.97	1.02	0.88	0.98	1.11	0.99	0.92	1.02	0.95	0.98	0.98	0.93	1.01	1.10	0.89	0.93	1.09	1.07	1.18	
215	1.000	0.972	0.88	0.90	0.90	0.86	0.85	1.15	0.86	0.71	0.83	0.95	1.03	0.82	0.87	0.99	0.90	0.90	0.80	0.84	0.92	0.88	0.72	1.02	1.05	1.09	1.13	
218	1.000	0.972	0.88	0.81	0.90	0.89	0.78	0.97	0.74	0.87	0.89	0.85	0.99	0.77	0.83	0.83	0.81	0.85	1.05	0.92	0.90	0.79	0.73	0.94	0.96	0.92	0.92	
217	1.000	0.972	0.88	0.80	0.90	0.86	0.86	1.15	0.86	0.71	0.83	0.95	1.03	0.82	0.87	0.99	0.90	0.90	0.80	0.84	0.92	0.88	0.72	1.02	1.05	1.09	1.13	
218	1.000	0.972	0.88	0.81	0.90	0.89	0.76	0.97	0.74	0.87	0.89	0.85	0.99	0.77	0.83	0.83	0.81	0.85	1.05	0.92	0.90	0.79	0.73	0.94	0.96	0.92	0.92	
219	1.000	0.972	0.88	0.81	0.97	0.93	1.00	0.99	1.03	1.08	0.92	1.02	1.18	1.08	0.97	1.02	0.92	1.00	0.86	1.05	0.92	0.90	0.79	0.73	0.94	0.96	0.92	0.92
220	1.000	1.166	1.11	1.13	0.97	0.85	0.74	0.82	0.83	0.89	0.86	0.83	0.96	1.06	0.94	0.81	0.82	1.00	0.86	1.05	0.92	0.90	0.79	0.73	0.94	0.96	0.92	0.92
221	1.000	1.166	1.11	1.13	0.97	0.85	0.74	0.82	0.83	0.89	0.86	0.83	0.96	1.06	0.94	0.81	0.82	1.00	0.86	1.05	0.92	0.90	0.79	0.73	0.94	0.96	0.92	0.92
222	1.000	1.166	1.11	0.95	0.99	1.03	1.07	0.83	0.93	0.82	0.93	0.92	0.81	0.93	1.05	1.03	0.84	1.05	0.95	0.84	1.00	0.97	1.06	0.94	1.07	1.13	1.14	1.14
223	1.050	1.186	1.11	0.95	0.99	1.03	1.07	0.83	0.93	0.82	0.93	0.92	0.81	0.93	1.05	1.03	0.84	1.05	0.95	0.84	1.00	0.97	1.06	0.94	1.07	1.13	1.14	1.14
224	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0.86
225	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0.86
226	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0.86
227	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0.86
228	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0.86
229	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0.86
230	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0.86
231	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0.86
232	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0.86
233	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0.86
234	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0.86
235	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0.86
236	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0.86
237	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0.86
238	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0.86
239	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0.86
240	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0.86
241	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0.86
242	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0.86
243	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0.86
244	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0.86
245	1.000	0.938	0.97	0.86	1.04	0.78	1.07	0.95	1.00	0.89	1.00	0.90	0.85	1.01	1.13	1.06	0.99	1.07	0.91	0.86	0.90	0.81	0.86	0.86	0.95	0.92	0.81	0

TABLE L -- PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

6 of 20

Zip Code	RVU GAAFs															Conversion Factor GAAFs By Category														
	Work Expense	Practice Expense	Total Unit Value	Inpatient Visits	Office/Home/ Urgent Care Visits	Therapeutic/ Injections	Allergy Testing	Allergy Immunotherapy	Misc Medical	ER Visits	Con- sults	Physi- cal Medi- cine	Cardio- vascular	Immun- izations	Well Baby Exams	Vision Exams	Hear- ing/ Speech Exams	Physi- cal Exams	Chro- nic Pro- ce- dures	Physi- cal/ Alcohol & Drug Abuse	Sur- gery	Radi- ology	Path- ology	Anes- thesia	Normal Deliv- ery	Caes- aran Deliv- ery	Non- Deliv- ery			
248	1.000	0.850	0.92	0.98	1.01	0.90	0.90	1.12	1.20	0.99	1.00	1.13	1.38	1.22	1.07	1.06	1.01	1.23	0.92	1.03	1.10	1.12	1.29	1.17	1.00	1.01	1.13			
249	1.000	0.850	0.92	0.98	1.01	0.90	0.90	1.12	1.20	0.99	1.00	1.13	1.38	1.22	1.07	1.06	1.01	1.23	0.92	1.03	1.10	1.12	1.29	1.17	1.00	1.01	1.13			
250	1.000	0.850	0.92	0.98	1.01	0.90	0.90	1.12	1.20	0.99	1.00	1.13	1.38	1.22	1.07	1.06	1.01	1.23	0.92	1.03	1.10	1.12	1.29	1.17	1.00	1.01	1.13			
251	1.000	0.850	0.92	0.98	1.01	0.90	0.90	1.12	1.20	0.99	1.00	1.13	1.38	1.22	1.07	1.06	1.01	1.23	0.92	1.03	1.10	1.12	1.29	1.17	1.00	1.01	1.13			
252	1.000	0.850	0.92	0.98	1.01	0.90	0.90	1.12	1.20	0.99	1.00	1.13	1.38	1.22	1.07	1.06	1.01	1.23	0.92	1.03	1.10	1.12	1.29	1.17	1.00	1.01	1.13			
253	1.000	0.850	0.92	0.98	1.01	0.90	0.90	1.12	1.20	0.99	1.00	1.13	1.38	1.22	1.07	1.06	1.01	1.23	0.92	1.03	1.10	1.12	1.29	1.17	1.00	1.01	1.13			
254	1.000	0.850	0.92	0.98	1.01	0.90	0.90	1.12	1.20	0.99	1.00	1.13	1.38	1.22	1.07	1.06	1.01	1.23	0.92	1.03	1.10	1.12	1.29	1.17	1.00	1.01	1.13			
255	1.000	0.850	0.92	0.98	1.01	0.90	0.90	1.12	1.20	0.99	1.00	1.13	1.38	1.22	1.07	1.06	1.01	1.23	0.92	1.03	1.10	1.12	1.29	1.17	1.00	1.01	1.13			
256	1.000	0.850	0.92	0.98	1.01	0.90	0.90	1.12	1.20	0.99	1.00	1.13	1.38	1.22	1.07	1.06	1.01	1.23	0.92	1.03	1.10	1.12	1.29	1.17	1.00	1.01	1.13			
257	1.000	0.850	0.92	0.98	1.01	0.90	0.90	1.12	1.20	0.99	1.00	1.13	1.38	1.22	1.07	1.06	1.01	1.23	0.92	1.03	1.10	1.12	1.29	1.17	1.00	1.01	1.13			
258	1.000	0.850	0.92	0.98	1.01	0.90	0.90	1.12	1.20	0.99	1.00	1.13	1.38	1.22	1.07	1.06	1.01	1.23	0.92	1.03	1.10	1.12	1.29	1.17	1.00	1.01	1.13			
259	1.000	0.850	0.92	0.98	1.01	0.90	0.90	1.12	1.20	0.99	1.00	1.13	1.38	1.22	1.07	1.06	1.01	1.23	0.92	1.03	1.10	1.12	1.29	1.17	1.00	1.01	1.13			
260	1.000	0.850	0.92	0.98	1.01	0.90	0.90	1.12	1.20	0.99	1.00	1.13	1.38	1.22	1.07	1.06	1.01	1.23	0.92	1.03	1.10	1.12	1.29	1.17	1.00	1.01	1.13			
261	1.000	0.850	0.92	0.93	1.04	0.75	1.10	1.06	1.19	0.85	0.98	1.10	0.83	1.22	1.18	0.91	1.01	0.96	0.87	0.90	0.83	0.86	1.00	0.98	1.08	1.03	0.90			
262	1.000	0.850	0.92	0.93	1.04	0.75	1.10	1.06	1.19	0.85	0.98	1.10	0.83	1.22	1.18	0.91	1.01	0.96	0.87	0.90	0.83	0.86	1.00	0.98	1.08	1.03	0.90			
263	1.000	0.850	0.92	0.93	1.04	0.75	1.10	1.06	1.19	0.85	0.98	1.10	0.83	1.22	1.18	0.91	1.01	0.96	0.87	0.90	0.83	0.86	1.00	0.98	1.08	1.03	0.90			
264	1.000	0.850	0.92	0.93	1.04	0.75	1.10	1.06	1.19	0.85	0.98	1.10	0.83	1.22	1.18	0.91	1.01	0.96	0.87	0.90	0.83	0.86	1.00	0.98	1.08	1.03	0.90			
265	1.000	0.850	0.92	0.93	1.04	0.75	1.10	1.06	1.19	0.85	0.98	1.10	0.83	1.22	1.18	0.91	1.01	0.96	0.87	0.90	0.83	0.86	1.00	0.98	1.08	1.03	0.90			
266	1.000	0.850	0.92	0.98	1.01	0.90	0.90	1.12	1.20	0.99	1.00	1.13	1.38	1.22	1.07	1.06	1.01	1.23	0.92	1.03	1.10	1.12	1.29	1.17	1.00	1.01	1.13			
267	1.000	0.850	0.92	0.98	1.01	0.90	0.90	1.12	1.20	0.99	1.00	1.13	1.38	1.22	1.07	1.06	1.01	1.23	0.92	1.03	1.10	1.12	1.29	1.17	1.00	1.01	1.13			
268	1.000	0.850	0.92	0.98	1.01	0.90	0.90	1.12	1.20	0.99	1.00	1.13	1.38	1.22	1.07	1.06	1.01	1.23	0.92	1.03	1.10	1.12	1.29	1.17	1.00	1.01	1.13			
269	1.000	0.850	0.92	0.98	1.01	0.90	0.90	1.12	1.20	0.99	1.00	1.13	1.38	1.22	1.07	1.06	1.01	1.23	0.92	1.03	1.10	1.12	1.29	1.17	1.00	1.01	1.13			
270	1.000	0.831	0.96	0.97	1.05	1.03	0.89	0.76	1.03	0.86	1.04	1.01	1.04	0.53	0.87	0.84	1.31	1.18	0.99	1.14	0.95	0.96	1.08	1.17	0.97	1.01	1.11			
271	1.000	0.831	0.96	0.97	1.05	1.03	0.89	0.76	1.03	0.86	1.04	1.01	1.04	0.53	0.87	0.84	1.31	1.18	0.99	1.14	0.95	0.96	1.08	1.17	0.97	1.01	1.11			
272	1.000	0.831	0.96	0.97	1.05	1.03	0.89	0.76	1.03	0.86	1.04	1.01	1.04	0.53	0.87	0.84	1.31	1.18	0.99	1.14	0.95	0.96	1.08	1.17	0.97	1.01	1.11			
273	1.000	0.831	0.96	0.97	1.05	1.03	0.89	0.76	1.03	0.86	1.04	1.01	1.04	0.53	0.87	0.84	1.31	1.18	0.99	1.14	0.95	0.96	1.08	1.17	0.97	1.01	1.11			
274	1.000	0.831	0.96	0.97	1.05	1.03	0.89	0.76	1.03	0.86	1.04	1.01	1.04	0.53	0.87	0.84	1.31	1.18	0.99	1.14	0.95	0.96	1.08	1.17	0.97	1.01	1.11			
275	1.000	0.831	0.96	0.97	1.05	1.03	0.89	0.76	1.03	0.86	1.04	1.01	1.04	0.53	0.87	0.84	1.31	1.18	0.99	1.14	0.95	0.96	1.08	1.17	0.97	1.01	1.11			
276	1.000	0.831	0.96	0.97	1.05	1.03	0.89	0.76	1.03	0.86	1.04	1.01	1.04	0.53	0.87	0.84	1.31	1.18	0.99	1.14	0.95	0.96	1.08	1.17	0.97	1.01	1.11			
277	1.000	0.831	0.96	1.31	1.22	1.23	1.10	1.10	0.93	1.27	1.08	1.12	0.84	1.40	0.55	1.12	0.96	1.02	1.15	0.95	1.00	1.09	1.23	1.08	1.07	1.11	1.13	1.04		
278	1.000	0.831	0.96	1.31	1.22	1.23	1.10	1.10	0.93	1.27	1.08	1.12	0.84	1.40	0.55	1.12	0.96	1.02	1.15	0.95	1.00	1.09	1.23	1.08	1.07	1.11	1.13	1.04		
279	1.000	0.831	0.96	1.03	1.01	0.85	1.02	0.86	1.02	0.93	1.08	0.79	1.10	0.58	0.95	0.90	1.01	1.01	0.85	1.00	1.00	1.11	1.08	1.09	1.26	1.24	1.40	0.98		
280	1.000	0.831	0.96	1.03	1.01	0.85	1.02	0.86	1.02	0.93	1.08	0.79	1.10	0.58	0.95	0.90	1.01	1.01	0.85	1.00	1.00	1.11	1.08	1.09	1.26	1.24	1.40	0.98		
281	1.000	0.831	0.96	1.07	1.04	1.12	1.39	0.99	1.19	0.92	1.14	0.88	1.05	0.76	1.26	0.84	-0.79	1.20	0.84	0.98	1.08	1.13	1.07	1.14	0.90	0.82	0.90	0.90		
282	1.000	0.831	0.96	1.07	1.04	1.12	1.39	0.99	1.19	0.92	1.14	0.88	1.05	0.76	1.26	0.84	-0.79	1.20	0.84	0.98	1.08	1.13	1.07	1.14	0.90	0.82	0.90	0.90		
283	1.000	0.831	0.96	1.15	1.11	1.94	1.02	0.71	1.35	1.00	1.17	0.90	0.96	0.74	1.29	1.19	0.99	1.23	0.97	0.96	1.04	1.08	1.09	0.97	1.08	1.03	0.93	0.93		
284	1.000	0.831	0.96	1.03	1.01	0.95	1.02	0.86	1.02	0.93	1.08	0.79	1.10	0.58	0.95	0.90	1.01	1.01	0.85	1.00	1.00	1.11	1.08	1.09	1.06	1.04	0.96	0.96		
285	1.000	0.831	0.96	1.03	1.01	0.95	1.02	0.86	1.02	0.93	1.08	0.79	1.10	0.58	0.95	0.90	1.01	1.01	0.85	1.00	1.00	1.11	1.08	1.09	1.06	1.04	0.96	0.96		
286	1.000	0.831	0.96	0.96	0.99	0.97	1.10	0.99	1.08	0.84	1.00	0.97	1.21	0.70	0.92	0.93	1.13	1.01	0.90	0.95	0.97	1.01	0.86	1.04	1.03	0.99	0.95	0.95		
287	1.000	0.831	0.96	0.98	0.99	0.97	1.10	0.99	1.08	0.84	1.00	0.97	1.21	0.70	0.92	0.93	1.13	1.01	0.90	0.95	0.97	1.01	0.86	1.04	1.03	0.99	0.95	0.95		
288	1.000	0.831	0.96	0.98	0.99	0.97	1.10	0.99	1.08	0.84	1.00	0.97	1.21	0.70	0.92	0.93	1.13	1.01	0.90	0.95	0.97	1.01	0.86	1.04	1.03	0.99	0.95	0.95		
289	1.000	0.831	0.96	0.96	0.99	0.97	1.10	0.99	1.08	0.84	1.00	0.97	1.21	0.70	0.92	0.93	1.13	1.01	0.90	0.95	0.97	1.01	0.86	1.04	1.03	0.99	0.95	0.95		
290	1.000	0.804	0.95	0.96	0.95	0.83	0.97	1.01	1.05	1.39	0.96	0.96	1.03	1.26	0.77	0.92	1.34	0.79	1.02	0.89	0.98	1.02	1.10	0.84	0.95	0.83	1.15	1.15		
291	1.000	0.804	0.95	0.96	0.95	0.83	0.97	1.01	1.05	1.39	0.96	0.96	1.03	1.26	0.77	0.92	1.34	0.79	1.02	0.89	0.98	1.02	1.10	0.84	0.95	0.83	1.15	1.15		
292	1.000	0.804	0.95	0.97	1.00	0.96	1.26	1.16	1.27	0.93	0.98	0.84	1.07	0.95	0.84	0.96	1.07	0.86	0.82	0.87	1.00	1.03	0.98	1.07	0.87	0.80	1.01	0.97		
293	1.000	0.904	0.95	0.99																										

TABLE L.—PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

7 of 20

Zip Code	RVU GAAFs															Conversion Factor GAAFs By Category														
	Work Expense	Practice Expense	Total Unit Value	Inpatient Visits	Office/Home/Urgent Care Visits	Therapeutic Injections	Allergy Testing	Immunotherapy	Misc. Medical	ER Visits	Consults	Physiological Medicine	Cardiovascular	Immunizations	Well Baby Exams	Vision Exams	Hearing/Speech Exams	Physiological Exams	Chiropractor	Psych/Alcohol/Drug Abuse	Subsidiary	Redology	Pathology	Anesthesia	Normal Delivered	Cesarean Delivered	Non-Delivered			
286	1.000	0.604	0.95	0.99	0.86	1.50	0.87	0.90	1.16	0.84	0.99	1.26	1.13	0.67	0.89	0.97	0.89	0.89	0.90	0.83	0.97	1.13	1.07	0.81	0.83	0.84	1.02			
297	1.000	0.604	0.95	0.99	0.86	1.50	0.87	0.90	1.16	0.84	0.99	1.26	1.13	0.67	0.89	0.97	0.89	0.89	0.90	0.83	0.97	1.13	1.07	0.81	0.83	1.01	0.97			
298	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.31	1.13			
299	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
300	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
301	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
302	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
303	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
304	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
305	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
306	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
307	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
308	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
309	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
310	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
311	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
312	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
313	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
314	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
315	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
316	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
317	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
318	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
319	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
320	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
321	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
322	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
323	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
324	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
325	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
326	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
327	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
328	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
329	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
330	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
331	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
332	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
333	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
334	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
335	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
336	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
337	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
338	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
339	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
341	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11	0.88	1.03	1.32	1.13	1.13			
342	1.000	0.604	0.95	1.08	1.04	0.99	1.28	0.85	1.02	0.95	0.99	1.00	1.27	0.62	0.96	1.10	0.88	1.03	0.85	1.02	1.09	1.11								

TABLE L -- PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

8 of 20

Zip Code	RVU GAAFs			Conversion Factor GAAFs By Category																							
	Work Expenses	Practices	Total Unit Value	Inpatient Visits	Office/Home/Urgent Care Visits	Therapeutic Injections	Allergy Testing	Allergy Immunotherapy	Misc Medical	ER Visits	Consultants	Physical Medicine	Cardiovascular	Immunizations	Well Elderly Exams	Vision Exams	Hearing/Speech Exams	Physician Exams	Chiropractor	Psych/Alcohol/Drug Abuse	Surgeory	Radiology	Pathology	Anesthesia	Normal Deliveries	Cesarean Deliveries	Non-Deliveries
346	1000	0.946	0.97	0.08	0.95	0.93	0.91	1.02	0.87	1.40	0.99	0.99	0.75	1.10	1.09	0.94	1.02	1.03	1.00	1.03	0.94	0.88	0.71	1.06	0.96	0.92	1.03
347	1000	0.946	0.97	0.83	1.01	1.00	0.88	1.08	0.93	1.04	1.05	1.06	0.87	1.21	1.03	0.95	0.90	1.08	1.11	1.02	0.85	0.97	0.85	1.00	0.96	0.97	0.88
349	1000	1.016	1.01	1.08	0.99	0.92	1.31	1.27	0.89	1.04	1.03	1.07	0.80	1.42	1.10	0.95	0.93	0.99	1.06	1.06	0.97	0.85	1.06	1.00	1.14	1.09	0.88
350	1000	0.870	0.83	0.70	0.81	0.88	1.24	0.81	0.86	0.95	0.80	0.95	1.08	0.90	0.80	0.84	0.93	0.56	0.83	1.01	0.85	1.00	0.78	0.91	0.87	0.78	0.69
351	1000	0.870	0.83	0.70	0.81	0.88	1.24	0.81	0.86	0.95	0.80	0.95	1.08	0.90	0.80	0.84	0.93	0.56	0.83	1.01	0.85	1.00	0.78	0.91	0.87	0.78	0.69
352	1000	0.870	0.83	0.70	0.81	0.88	1.24	0.81	0.86	0.95	0.80	0.95	1.08	0.90	0.80	0.84	0.93	0.56	0.83	1.01	0.85	1.00	0.78	0.91	0.87	0.78	0.69
353	1000	0.870	0.83	0.70	0.81	0.88	1.24	0.81	0.86	0.95	0.80	0.95	1.08	0.90	0.80	0.84	0.93	0.56	0.83	1.01	0.85	1.00	0.78	0.91	0.87	0.78	0.69
354	1000	0.870	0.83	0.70	0.81	0.88	1.24	0.81	0.86	0.95	0.80	0.95	1.08	0.90	0.80	0.84	0.93	0.56	0.83	1.01	0.85	1.00	0.78	0.91	0.87	0.78	0.69
355	1000	0.870	0.83	0.70	0.81	0.88	1.24	0.81	0.86	0.95	0.80	0.95	1.08	0.90	0.80	0.84	0.93	0.56	0.83	1.01	0.85	1.00	0.78	0.91	0.87	0.78	0.69
356	1000	0.870	0.83	0.70	0.81	0.88	1.24	0.81	0.86	0.95	0.80	0.95	1.08	0.90	0.80	0.84	0.93	0.56	0.83	1.01	0.85	1.00	0.78	0.91	0.87	0.78	0.69
357	1000	0.870	0.83	0.70	0.81	0.88	1.24	0.81	0.86	0.95	0.80	0.95	1.08	0.90	0.80	0.84	0.93	0.56	0.83	1.01	0.85	1.00	0.78	0.91	0.87	0.78	0.69
358	1000	0.870	0.83	0.70	0.81	0.88	1.24	0.81	0.86	0.95	0.80	0.95	1.08	0.90	0.80	0.84	0.93	0.56	0.83	1.01	0.85	1.00	0.78	0.91	0.87	0.78	0.69
359	1000	0.870	0.83	0.70	0.81	0.88	1.24	0.81	0.86	0.95	0.80	0.95	1.08	0.90	0.80	0.84	0.93	0.56	0.83	1.01	0.85	1.00	0.78	0.91	0.87	0.78	0.69
360	1000	0.870	0.83	0.69	0.81	0.84	0.82	0.81	0.96	0.87	0.76	1.04	1.34	1.04	0.50	0.83	1.18	0.53	0.80	0.91	0.93	1.09	0.88	0.91	0.89	0.82	0.88
361	1000	0.870	0.83	0.69	0.81	0.84	0.82	0.81	0.96	0.87	0.76	1.04	1.34	1.04	0.50	0.83	1.18	0.53	0.80	0.91	0.93	1.09	0.88	0.91	0.89	0.82	0.88
362	1000	0.870	0.83	0.75	0.81	0.84	0.82	0.81	0.96	0.87	0.76	1.04	1.34	1.04	0.50	0.83	1.18	0.53	0.80	0.91	0.93	1.09	0.88	0.91	0.89	0.82	0.88
363	1000	0.870	0.83	0.69	0.81	0.84	0.82	0.81	0.96	0.87	0.76	1.04	1.34	1.04	0.50	0.83	1.18	0.53	0.80	0.91	0.93	1.09	0.88	0.91	0.89	0.82	0.88
364	1000	0.870	0.83	0.69	0.81	0.84	0.82	0.81	0.96	0.87	0.76	1.04	1.34	1.04	0.50	0.83	1.18	0.53	0.80	0.91	0.93	1.09	0.88	0.91	0.89	0.82	0.88
365	1000	0.870	0.83	0.73	0.80	0.70	0.99	0.80	0.72	0.79	0.75	0.99	0.97	1.09	0.52	0.96	0.99	0.52	0.85	1.03	0.92	0.86	0.75	0.78	0.69	0.82	0.88
366	1000	0.870	0.83	0.73	0.80	0.70	0.99	0.80	0.72	0.79	0.75	0.99	0.97	1.09	0.52	0.96	0.99	0.52	0.85	1.03	0.92	0.86	0.75	0.78	0.69	0.82	0.88
367	1000	0.870	0.83	0.69	0.81	0.84	0.82	0.81	0.96	0.87	0.76	1.04	1.34	1.04	0.50	0.83	1.18	0.53	0.80	0.91	0.93	1.09	0.88	0.91	0.89	0.82	0.88
368	1000	0.870	0.83	0.69	0.81	0.84	0.82	0.81	0.96	0.87	0.76	1.04	1.34	1.04	0.50	0.83	1.18	0.53	0.80	0.91	0.93	1.09	0.88	0.91	0.89	0.82	0.88
369	1000	0.870	0.83	0.69	0.81	0.84	0.82	0.81	0.96	0.87	0.76	1.04	1.34	1.04	0.50	0.83	1.18	0.53	0.80	0.91	0.93	1.09	0.88	0.91	0.89	0.82	0.88
370	1000	0.900	0.84	0.96	0.97	0.78	0.93	1.01	1.08	0.98	0.95	1.12	1.12	1.01	1.15	0.91	1.04	1.03	0.91	1.00	0.97	1.03	1.07	0.97	0.94	0.90	0.95
371	1000	0.900	0.84	0.96	0.97	0.78	0.93	1.01	1.08	0.98	0.95	1.12	1.12	1.01	1.15	0.91	1.04	1.03	0.91	1.00	0.97	1.03	1.07	0.97	0.94	0.90	0.95
372	1000	0.900	0.84	1.03	1.08	0.85	1.05	0.82	1.04	1.20	1.10	1.22	0.87	1.12	1.17	1.00	1.03	1.10	1.01	0.99	0.86	1.02	1.26	1.19	0.98	0.98	1.00
373	1000	0.900	0.84	0.96	1.01	0.99	0.75	1.12	1.15	1.21	1.03	1.04	1.00	1.27	1.19	0.89	1.05	1.12	0.89	1.04	1.03	1.04	1.08	1.12	0.92	0.91	1.00
374	1000	0.900	0.84	0.96	1.01	0.99	0.75	1.12	1.15	1.21	1.03	1.04	1.00	1.27	1.19	0.89	1.05	1.12	0.89	1.04	1.03	1.04	1.08	1.12	0.92	0.91	1.00
375	1000	0.900	0.84	1.04	1.09	1.14	1.02	0.98	0.98	0.93	1.10	1.25	1.16	1.27	1.19	1.33	1.01	1.16	0.97	1.08	1.02	1.07	1.12	0.96	0.95	0.93	0.94
376	1000	0.900	0.84	0.96	1.01	0.99	0.75	1.12	1.15	1.21	1.03	1.04	1.00	1.27	1.19	0.89	1.05	1.12	0.89	1.04	1.03	1.04	1.08	1.12	0.92	0.91	1.00
377	1000	0.900	0.84	0.96	1.01	0.99	0.75	1.12	1.15	1.21	1.03	1.04	1.00	1.27	1.19	0.89	1.05	1.12	0.89	1.04	1.03	1.04	1.08	1.12	0.92	0.91	1.00
378	1000	0.900	0.84	0.96	1.01	0.99	0.75	1.12	1.15	1.21	1.03	1.04	1.00	1.27	1.19	0.89	1.05	1.12	0.89	1.04	1.03	1.04	1.08	1.12	0.92	0.91	1.00
379	1000	0.900	0.84	1.07	0.97	0.94	0.87	1.03	0.94	1.28	1.10	1.03	0.91	1.07	1.25	1.09	1.00	1.23	1.00	0.99	1.04	1.03	1.08	1.12	0.92	0.91	1.00
380	1000	0.900	0.84	1.04	1.08	0.47	1.05	1.15	0.90	1.04	1.11	1.15	1.14	1.01	1.15	0.95	1.25	1.06	0.94	1.05	1.02	1.12	0.90	1.00	0.92	0.89	0.94
381	1000	0.900	0.84	1.04	1.09	1.14	1.02	0.88	0.96	0.93	1.10	1.25	1.16	1.27	1.19	1.33	1.01	1.16	0.97	1.08	1.02	1.12	0.96	0.95	0.93	0.95	0.95
382	1000	0.900	0.84	0.95	0.98	0.84	0.97	1.11	0.86	0.89	0.93	1.13	1.06	1.05	1.13	1.14	1.00	1.04	0.88	0.94	1.00	1.03	1.04	0.92	0.88	0.92	0.79
383	1000	0.900	0.84	0.95	0.98	0.84	0.97	1.11	0.86	0.89	0.93	1.13	1.06	1.05	1.13	1.14	1.00	1.04	0.88	0.94	1.00	1.03	1.04	0.92	0.88	0.92	0.79
384	1000	0.900	0.84	0.96	0.97	0.79	0.93	1.01	1.08	0.96	0.95	1.12	1.12	1.01	1.15	0.91	1.04	1.03	0.91	1.00	0.97	1.03	1.07	0.94	0.90	0.95	0.95
385	1000	0.900	0.84	0.98	1.01	0.99	0.75	1.12	1.15	1.21	1.03	1.04	1.00	1.27	1.19	0.89	1.05	1.12	0.89	1.04	1.03	1.04	1.08	1.12	0.92	0.91	1.00
386	1000	0.837	0.81	0.95	1.00	1.05	1.84	0.83	1.19	1.13	1.01	1.00	1.12	1.10	0.86	0.35	1.13	0.90	0.90	1.01	1.01	1.28	1.04	0.81	0.96	0.97	0.97
387	1000	0.837	0.81	0.99	0.90	0.88	0.89	0.94	1.04	0.90	1.08	1.05	1.14	1.23	0.82	0.86	0.85	0.80	0.85	0.84	0.96	1.03	0.96	0.86	0.88	0.89	0.86
388	1000	0.837	0.81	0.99	0.90	0.88	0.89	0.94	1.04	0.90	1.08	1.05	1.14	1.23	0.82	0.86	0.85	0.80	0.85	0.84	0.96	1.03	0.96	0.86	0.88	0.89	0.86
389	1000	0.837	0.81	0.91	0.89	1.04	1.34	0.85	1.15	0.97	0.90	1.04	1.44	1.02	0.71	0.80	0.99	0.80	0.92	1.09	1.03	1.14	1.05	0.79	0.96	1.09	0.92
390	1000	0.837	0.81	0.91	0.89	1.04	1.34	0.85	1.15	0.97	0.90	1.04	1.44	1.02	0.71	0.80	0.99	0.80	0.92	1.09	1.03	1.14	1.05	0.79	0.96	1.09	0.92
391	1000	0.837	0.81	0.91	0.89	1.04	1.34	0.85	1.15	0.97	0.90	1.04	1.44	1.02	0.71	0.80	0.99	0.80	0.92	1.09	1.03	1.14	1.05	0.79	0.96	1.09	0.92
392	1000	0.837	0.81	0.90	0.92	0.93	1.41	1.41	1.14	0.83	0.94	1.06	1.25	0.85	0.77	0.85	0.96	0.83	0.78	1.12	1.00	1.06	1.04	0.89	0.77	0.95	

TABLE L.—PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

9 of 20

Zip Code	RVU GAAFs															Conversion Factor GAAFs By Category														
	Work Expense	Practice Expense	Total Unit Value	Impatient Visits	Office/Home/Urgent Care Visits	Therapeutic Injections	Allergy Testing	Allergy Immunotherapy	Misc Medication	ER Visits	Consults	Physicall Med- ical	Cardio-vascular	Immunizations	Well Baby Exams	Vision Exams	Hear- ing/ Speech Exams	Physi- cian Exams	Chiro- practor	Psych/ Alcohol & Drug Abuse	Sur- gery	Radi- ology	Path- ology	Area- thesia	Normal Deliv- eries	Cesar- ean Deliv- eries	Non- Deliv- eries			
395	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
396	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
397	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
398	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
399	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
400	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
401	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
402	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
403	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
404	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
405	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
406	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
407	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
408	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
409	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
410	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
411	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
412	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
413	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
414	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
415	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
416	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
417	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
418	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
419	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
420	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
421	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
422	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
423	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
424	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
425	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
426	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
427	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
428	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
429	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
430	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
431	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
432	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
433	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
434	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
435	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
436	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
437	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
438	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
439	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12	1.00	1.00	1.07	1.00	1.12	1.00	0.76	0.83	0.96	0.94			
440	1.000	0.837	0.91	0.92	0.87	0.92	1.06	1.30	1.06	0.72	0.95	0.86	0.88	0.90	1.07	1.00	1.12</													

TABLE L -- PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

10 of 20

Zip Code	RVU GAAFs		Conversion Factor GAAFs By Category																	Normal Deliv-eries	Cesar-ian Deliv-eries	Non-Deliv-eries					
	Work Expendi-ture	Practice Expendi-ture	Total Unit Value	Inpa-tient Visits	Offi-cial/Home/Upport Care Visits	Therap-eutic Injec-tions	Allergy Test-ing	Allergy Immu-nization	Misc. Med-ical	ER Visits	Con-sults	Phys-ical Med-icine	Cardio-vascular	Immu-nizations	Neel-Rally Exams	Visi-on Exams	Hear-ing/Speech Exams	Phys-ical Exams	Cher-acter				Psych/Alcohol & Drug Abuse	Sur-gery	Radi-ology	Path-ology	Anes-thesia
446	1.000	0.944	0.97	0.81	0.92	0.84	0.90	0.89	0.93	0.90	0.88	0.95	1.12	0.98	0.83	0.65	0.83	0.85	0.93	0.84	0.91	0.86	0.97	0.82	0.80	0.90	0.80
447	1.000	0.944	0.97	0.81	0.92	0.84	0.90	0.89	0.93	0.90	0.88	0.95	1.12	0.98	0.83	0.65	0.83	0.85	0.93	0.84	0.91	0.86	0.97	0.82	0.80	0.90	0.80
448	1.000	0.944	0.97	0.81	0.92	0.84	0.90	0.89	0.93	0.90	0.88	0.95	1.12	0.98	0.83	0.65	0.83	0.85	0.93	0.84	0.91	0.86	0.97	0.82	0.80	0.90	0.80
449	1.000	0.944	0.97	0.81	0.92	0.84	0.90	0.89	0.93	0.90	0.88	0.95	1.12	0.98	0.83	0.65	0.83	0.85	0.93	0.84	0.91	0.86	0.97	0.82	0.80	0.90	0.80
450	1.000	0.944	0.97	0.81	0.92	0.84	0.90	0.89	0.93	0.90	0.88	0.95	1.12	0.98	0.83	0.65	0.83	0.85	0.93	0.84	0.91	0.86	0.97	0.82	0.80	0.90	0.80
451	1.000	0.944	0.97	0.81	0.92	0.84	0.90	0.89	0.93	0.90	0.88	0.95	1.12	0.98	0.83	0.65	0.83	0.85	0.93	0.84	0.91	0.86	0.97	0.82	0.80	0.90	0.80
452	1.000	0.944	0.97	0.81	0.92	0.84	0.90	0.89	0.93	0.90	0.88	0.95	1.12	0.98	0.83	0.65	0.83	0.85	0.93	0.84	0.91	0.86	0.97	0.82	0.80	0.90	0.80
453	1.000	0.944	0.97	0.81	0.92	0.84	0.90	0.89	0.93	0.90	0.88	0.95	1.12	0.98	0.83	0.65	0.83	0.85	0.93	0.84	0.91	0.86	0.97	0.82	0.80	0.90	0.80
454	1.000	0.944	0.97	0.81	0.92	0.84	0.90	0.89	0.93	0.90	0.88	0.95	1.12	0.98	0.83	0.65	0.83	0.85	0.93	0.84	0.91	0.86	0.97	0.82	0.80	0.90	0.80
455	1.000	0.944	0.97	0.81	0.92	0.84	0.90	0.89	0.93	0.90	0.88	0.95	1.12	0.98	0.83	0.65	0.83	0.85	0.93	0.84	0.91	0.86	0.97	0.82	0.80	0.90	0.80
456	1.000	0.944	0.97	0.81	0.92	0.84	0.90	0.89	0.93	0.90	0.88	0.95	1.12	0.98	0.83	0.65	0.83	0.85	0.93	0.84	0.91	0.86	0.97	0.82	0.80	0.90	0.80
457	1.000	0.944	0.97	0.81	0.92	0.84	0.90	0.89	0.93	0.90	0.88	0.95	1.12	0.98	0.83	0.65	0.83	0.85	0.93	0.84	0.91	0.86	0.97	0.82	0.80	0.90	0.80
458	1.000	0.944	0.97	0.81	0.92	0.84	0.90	0.89	0.93	0.90	0.88	0.95	1.12	0.98	0.83	0.65	0.83	0.85	0.93	0.84	0.91	0.86	0.97	0.82	0.80	0.90	0.80
459	1.000	0.944	0.97	0.81	0.92	0.84	0.90	0.89	0.93	0.90	0.88	0.95	1.12	0.98	0.83	0.65	0.83	0.85	0.93	0.84	0.91	0.86	0.97	0.82	0.80	0.90	0.80
460	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
461	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
462	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
463	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
464	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
465	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
466	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
467	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
468	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
470	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
471	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
472	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
473	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
474	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
475	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
476	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
477	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
478	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
479	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
480	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
481	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
482	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
483	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
484	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
485	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
486	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
487	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
488	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
489	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
490	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
491	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10	0.98	0.87	0.90	0.92	0.87	0.87	1.03	1.15	1.05	-0.87	0.87	0.87	1.04
492	1.000	0.922	0.96	1.00	0.93	1.13	1.45	1.03	1.21	0.91	1.03	1.01	1.03	1.10													

TABLE L.—PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU)
AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

11 of 20

Zip Code	RVU GAAFs										Conversion Factor GAAFs By Category																
	Work Expense	Precise Expense	Total Unit Value	Inpatient Visits	Office/Home/Urgent Care Visits	Therapeutic Injections	Allergy Testing	Allergy Immunotherapy	Misc Medical	ER Visits	Consults	Phys-Med	Cardio-vascular	Immunizations	Well Baby Exams	Vision Exams	Hearing/Speech Exams	Physical Exams	Chemopreventor	Psych/Alcohol/Drug Abuse	Surgery	Redi-ology	Pathology	Anesthesia	Normal Deliv-eries	Cesarean Deliv-eries	Non-Deliv-eries
483	1.000	0.938	0.997	0.82	0.85	1.14	0.87	0.82	0.80	0.82	0.83	0.96	0.91	1.00	0.93	0.93	0.89	0.93	0.91	0.89	0.82	0.79	0.77	0.83	0.75	0.75	0.78
484	1.000	0.938	0.997	0.82	0.85	1.14	0.87	0.82	0.80	0.82	0.83	0.96	0.91	1.00	0.93	0.93	0.89	0.93	0.91	0.89	0.82	0.79	0.77	0.83	0.75	0.75	0.76
485	1.000	0.938	0.997	0.82	0.85	1.14	0.87	0.82	0.80	0.82	0.83	0.96	0.91	1.00	0.93	0.93	0.89	0.93	0.91	0.89	0.82	0.79	0.77	0.83	0.75	0.75	0.76
486	1.000	0.938	0.997	0.82	0.85	1.14	0.87	0.82	0.80	0.82	0.83	0.96	0.91	1.00	0.93	0.93	0.89	0.93	0.91	0.89	0.82	0.79	0.77	0.83	0.75	0.75	0.76
487	1.000	0.938	0.997	0.82	0.85	1.14	0.87	0.82	0.80	0.82	0.83	0.96	0.91	1.00	0.93	0.93	0.89	0.93	0.91	0.89	0.82	0.79	0.77	0.83	0.75	0.75	0.76
488	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
489	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
490	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
500	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
501	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
502	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
503	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
504	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
505	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
506	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
507	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
508	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
509	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
510	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
511	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
512	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
513	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
514	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
515	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
516	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
517	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
518	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
519	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
520	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
521	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
522	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
523	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
524	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
525	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
526	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
527	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
528	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
529	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
530	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
531	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
532	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
533	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
534	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
535	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
537	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75	0.92	0.95	0.79	1.01	0.85	0.85	0.84	0.86	1.11	0.99	1.06	1.05	0.95
538	1.000	0.938	0.997	0.80	0.84	0.60	1.00	0.99	0.83	0.95	0.80	0.86	1.15	0.75													

TABLE L. - PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU)
AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

12 of 20

Zip Code	RVU GAAFs										Conversion Factor GAAFs By Category														
	Work Expense	Practices Expense	Total Net Value	High-Care Value	Office/Home Care Value	Therapeutic Appointments	Alteryg Therapy	Misc. Medical	ER Visits	Com-Sults	Physi-Med. Sults	Casib-Subs	Immun-izations	Walt Baby Exams	Walt Vision Exams	Heer-Physi-Spachi Exams	Physi-Chio-Practor	Physi/Alcohol & Drug Abuse	Sur-gery	Radi-ology	Path-ology	Area-Health	Normal-Health	Casib-Health	Non-Health
545	1.000	0.920	0.98	1.32	1.09	0.98	0.82	1.32	1.44	1.42	1.22	1.55	0.93	0.70	1.40	1.32	1.22	1.33	1.34	1.89	1.36	0.95	1.07	1.17	1.30
547	1.000	0.929	0.96	1.27	1.20	1.19	1.12	1.19	1.09	1.09	1.12	1.13	1.07	1.02	1.31	1.09	1.05	1.05	1.17	1.18	1.46	1.05	1.01	1.07	1.07
548	1.000	0.929	0.96	1.15	1.05	1.06	1.13	1.11	1.11	1.11	1.07	1.08	1.01	0.93	1.29	0.97	1.01	1.20	1.10	1.23	1.15	1.06	1.06	1.04	1.04
549	1.000	0.974	0.99	1.20	1.20	1.20	1.22	1.13	0.97	1.04	1.16	1.38	1.03	0.75	1.23	1.18	1.15	0.95	1.14	1.21	1.07	1.02	0.89	1.04	1.02
550	1.000	0.974	0.99	1.20	1.20	1.20	1.22	1.13	0.97	1.04	1.16	1.38	1.03	0.75	1.23	1.18	1.15	0.95	1.14	1.21	1.07	1.02	0.89	1.04	1.02
551	1.000	0.974	0.99	1.10	1.19	1.35	1.03	0.94	1.10	1.23	1.22	0.96	0.78	1.09	1.30	0.99	1.18	1.24	0.89	0.90	1.06	0.66	1.01	1.03	0.86
553	1.000	0.974	0.99	1.11	1.19	1.23	0.92	1.02	1.21	1.13	1.09	1.07	1.07	1.21	1.18	1.25	1.18	1.24	0.89	0.87	1.04	0.66	1.01	1.03	0.86
554	1.000	0.974	0.99	1.20	1.30	1.25	1.22	1.23	1.01	1.07	1.27	1.11	1.02	0.92	1.25	1.21	1.18	1.25	0.89	0.87	1.04	0.66	1.01	1.03	0.86
555	1.000	0.974	0.99	1.11	1.11	1.23	0.92	1.02	1.21	1.13	1.09	1.07	1.07	1.21	1.18	1.25	1.18	1.24	0.89	0.87	1.04	0.66	1.01	1.03	0.86
556	1.000	0.974	0.99	1.11	1.11	1.23	0.92	1.02	1.21	1.13	1.09	1.07	1.07	1.21	1.18	1.25	1.18	1.24	0.89	0.87	1.04	0.66	1.01	1.03	0.86
557	1.000	0.974	0.99	1.03	0.98	0.85	1.06	1.20	1.07	0.82	1.10	0.99	0.97	0.83	1.06	0.91	1.04	0.97	1.02	0.94	1.04	0.78	0.86	0.86	0.81
558	1.000	0.974	0.99	1.03	0.98	0.85	1.06	1.20	1.07	0.82	1.10	0.99	0.97	0.83	1.06	0.91	1.04	0.97	1.02	0.94	1.04	0.78	0.86	0.86	0.81
559	1.000	0.974	0.99	1.01	1.11	0.87	1.06	1.43	1.00	0.85	1.02	1.09	1.02	0.83	0.89	1.04	1.24	0.85	0.86	1.03	1.02	0.62	0.87	1.13	1.01
560	1.000	0.974	0.99	1.06	1.15	1.25	1.38	1.91	1.36	0.86	1.14	1.11	1.14	0.85	1.27	1.27	1.33	1.06	0.90	1.20	1.08	1.22	0.86	1.18	1.14
561	1.000	0.974	0.99	1.07	1.03	1.00	1.53	1.04	1.03	0.95	1.07	0.86	1.04	0.86	0.86	0.86	0.86	0.86	0.86	1.23	1.02	1.03	1.17	1.07	1.10
562	1.000	0.974	0.99	1.05	1.09	0.78	1.03	1.06	0.78	0.89	1.09	0.80	1.04	0.84	0.81	1.17	0.91	0.78	1.20	0.86	1.06	0.97	0.77	0.97	1.26
563	1.000	0.974	0.99	1.05	1.09	0.78	1.03	1.06	0.78	0.89	1.09	0.80	1.04	0.84	0.81	1.17	0.91	0.78	1.20	0.86	1.06	0.97	0.77	0.97	1.26
564	1.000	0.974	0.99	1.20	1.05	1.04	1.06	1.11	0.83	0.93	1.24	1.12	0.84	1.23	1.34	0.85	0.85	1.17	0.80	1.13	0.89	0.89	0.92	1.09	0.89
565	1.000	0.974	0.99	1.03	0.96	0.85	1.06	1.20	1.07	0.82	1.10	0.99	0.97	0.83	1.06	0.91	1.04	0.97	0.82	1.03	1.02	0.84	1.04	0.78	0.86
566	1.000	0.974	0.99	1.03	0.96	0.85	1.06	1.20	1.07	0.82	1.10	0.99	0.97	0.83	1.06	0.91	1.04	0.97	0.82	1.03	1.02	0.84	1.04	0.78	0.86
567	1.000	0.974	0.99	1.03	0.96	0.85	1.06	1.20	1.07	0.82	1.10	0.99	0.97	0.83	1.06	0.91	1.04	0.97	0.82	1.03	1.02	0.84	1.04	0.78	0.86
570	1.000	0.878	0.83	0.96	1.01	0.99	0.85	0.81	0.97	0.85	1.06	0.96	1.05	0.49	0.88	0.88	1.05	0.65	0.83	1.01	1.14	0.87	0.88	1.03	0.97
571	1.000	0.878	0.83	1.11	1.20	0.81	1.23	0.81	0.85	0.79	1.14	0.80	1.11	0.74	0.82	0.95	1.07	0.80	0.86	1.06	1.08	1.07	0.86	1.10	1.11
572	1.000	0.878	0.83	0.96	1.01	0.99	0.85	0.81	0.97	0.85	1.06	0.96	1.05	0.49	0.88	0.88	1.05	0.65	0.83	0.91	1.01	1.14	0.87	0.88	1.03
573	1.000	0.878	0.83	0.96	1.01	0.99	0.85	0.81	0.97	0.85	1.06	0.96	1.05	0.49	0.88	0.88	1.05	0.65	0.83	0.91	1.01	1.14	0.87	0.88	1.03
574	1.000	0.878	0.83	0.96	1.01	0.99	0.85	0.81	0.97	0.85	1.06	0.96	1.05	0.49	0.88	0.88	1.05	0.65	0.83	0.91	1.01	1.14	0.87	0.88	1.03
575	1.000	0.878	0.83	0.96	1.01	0.99	0.85	0.81	0.97	0.85	1.06	0.96	1.05	0.49	0.88	0.88	1.05	0.65	0.83	0.91	1.01	1.14	0.87	0.88	1.03
576	1.000	0.878	0.83	0.96	1.01	0.99	0.85	0.81	0.97	0.85	1.06	0.96	1.05	0.49	0.88	0.88	1.05	0.65	0.83	0.91	1.01	1.14	0.87	0.88	1.03
577	1.000	0.878	0.83	0.96	1.01	0.99	0.85	0.81	0.97	0.85	1.06	0.96	1.05	0.49	0.88	0.88	1.05	0.65	0.83	0.91	1.01	1.14	0.87	0.88	1.03
578	1.000	0.878	0.83	0.96	1.01	0.99	0.85	0.81	0.97	0.85	1.06	0.96	1.05	0.49	0.88	0.88	1.05	0.65	0.83	0.91	1.01	1.14	0.87	0.88	1.03
579	1.000	0.880	0.83	0.97	1.05	0.87	1.05	1.24	0.92	0.74	0.99	0.95	0.87	0.42	0.78	1.15	1.25	0.87	0.87	1.27	0.86	0.86	0.84	0.83	0.88
580	1.000	0.880	0.83	0.97	1.05	0.87	1.05	1.24	0.92	0.74	0.99	0.95	0.87	0.42	0.78	1.15	1.25	0.87	0.87	1.27	0.86	0.86	0.84	0.83	0.88
581	1.000	0.880	0.83	1.07	1.00	0.89	1.05	1.24	0.92	0.74	0.99	0.95	0.87	0.42	0.78	1.15	1.25	0.87	0.87	1.27	0.86	0.86	0.84	0.83	0.88
582	1.000	0.880	0.83	0.97	1.05	0.87	1.05	1.24	0.92	0.74	0.99	0.95	0.87	0.42	0.78	1.15	1.25	0.87	0.87	1.27	0.86	0.86	0.84	0.83	0.88
583	1.000	0.880	0.83	0.97	1.05	0.87	1.05	1.24	0.92	0.74	0.99	0.95	0.87	0.42	0.78	1.15	1.25	0.87	0.87	1.27	0.86	0.86	0.84	0.83	0.88
584	1.000	0.880	0.83	0.97	1.05	0.87	1.05	1.24	0.92	0.74	0.99	0.95	0.87	0.42	0.78	1.15	1.25	0.87	0.87	1.27	0.86	0.86	0.84	0.83	0.88
585	1.000	0.880	0.83	0.97	1.05	0.87	1.05	1.24	0.92	0.74	0.99	0.95	0.87	0.42	0.78	1.15	1.25	0.87	0.87	1.27	0.86	0.86	0.84	0.83	0.88
586	1.000	0.880	0.83	0.97	1.05	0.87	1.05	1.24	0.92	0.74	0.99	0.95	0.87	0.42	0.78	1.15	1.25	0.87	0.87	1.27	0.86	0.86	0.84	0.83	0.88
587	1.000	0.880	0.83	0.97	1.05	0.87	1.05	1.24	0.92	0.74	0.99	0.95	0.87	0.42	0.78	1.15	1.25	0.87	0.87	1.27	0.86	0.86	0.84	0.83	0.88
588	1.000	0.880	0.83	0.97	1.05	0.87	1.05	1.24	0.92	0.74	0.99	0.95	0.87	0.42	0.78	1.15	1.25	0.87	0.87	1.27	0.86	0.86	0.84	0.83	0.88
589	1.000	0.878	0.83	0.93	1.05	0.79	1.12	0.99	0.86	0.79	1.06	0.84	0.83	0.81	0.99	0.99	1.13	1.06	0.94	0.98	0.95	1.18	0.78	0.88	0.82
590	1.000	0.878	0.83	1.04	1.05	1.29	0.97	0.59	0.82	0.74	1.06	0.99	1.18	0.79	1.09	1.02	1.13	1.06	0.94	0.98	0.95	1.18	0.78	0.88	0.82
591	1.000	0.878	0.83	0.93	1.05	0.79	1.12	0.99	0.86	0.79	1.06	0.84	0.83	0.81	0.99	0.99	1.13	1.06	0.94	0.98	0.95	1.18	0.78	0.88	0.82
592	1.000	0.878	0.83	0.93	1.05	0.79	1.12	0.99	0.86	0.79	1.06	0.84	0.83	0.81	0.99	0.99	1.13	1.06	0.94	0.98	0.95	1.18	0.78	0.88	0.82
593	1.000	0.878	0.83	0.93	1.05	0.79	1.12	0.99	0.86	0.79	1.06	0.84	0.83	0.81	0.99	0.99	1.13	1.06	0.94	0.98	0.95	1.18	0.78	0.88	0.82
594	1.000	0.878	0.83	0.93	1.05	0.79	1.12	0.99	0.86	0.79	1.06	0.84	0.83	0.81	0.99	0.99	1.13	1.06	0.94	0.98	0.95	1.18	0.78	0.88	0.82
595	1.000	0.878	0.83	0.93	1.05	0.79	1.12	0.99	0.86	0.79	1.06	0.84	0.83	0.81	0.99	0.99	1.13	1.06	0.94	0.98	0.95	1.18	0.78	0.88	0.82
596	1.000	0.878	0.83	0.93	1.05	0.79	1.12	0.99	0.86	0.79	1.06	0.84	0.83	0.81	0.99	0.99	1.13	1.06	0.94	0.98	0.95	1.18	0.78	0.88	0.82
597	1.000	0.878	0.83	0.93	1.05	0.79	1.12	0.99	0.86	0.79	1.06	0.84	0.83	0.81	0.99	0.99	1.13	1.06	0.94	0.98	0.95	1.18	0.78	0.88	0.82
598	1.000	0.878	0.83																						

TABLE L.—PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU)
AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

13 of 20

Conversion Factor GAAFs By Category

Zip Code	RVU GAAFs										Conversion Factor GAAFs By Category															
	Work Expense	Practice Expense	Total Unit Value	Inpatient Visits	Office/Home/Care Visits	Therapeutic/Allergy/Testing	Allergy/Immunotherapy	Misc. Medical	ER Visits	Consultations	Physician/MD/MDA/MDM/MDO/MDOP/MDPP/MDPPA/MDPPS/MDPPSA/MDPPSS/MDPPSSA/MDPPSSS/MDPPSSSA/MDPPSSSS/MDPPSSSSA/MDPPSSSSS	Cardiovascular	Immunizations	Well Baby Exams	Vision Exams	Hearing/Speech Exams	Physical Exams	Chiropractor	Psych/Alcohol/Drug Abuse	Subsidiary	Resiology	Pathology	Anesthesia	Normal Delivery	Cesarean Delivery	Non-Delivery
599	1.000	0.076	0.93	0.83	1.05	1.12	0.99	0.86	0.78	1.05	0.84	0.83	0.91	0.99	0.89	1.07	0.87	0.85	0.89	0.86	0.86	0.80	0.75	0.84	1.01	0.86
600	1.028	1.092	1.06	1.01	1.01	1.12	0.97	0.84	1.01	1.10	0.87	0.87	1.16	0.86	1.16	0.88	0.88	0.95	0.87	1.09	0.97	1.06	1.27	0.97	0.98	1.16
601	1.006	1.071	1.04	1.07	1.00	1.71	0.92	0.95	1.11	1.00	1.16	0.95	1.23	1.00	0.93	0.85	0.99	0.92	0.98	1.15	0.95	1.26	1.14	1.02	0.81	1.02
602	1.028	1.092	1.06	1.06	1.05	1.51	0.90	0.71	1.00	1.00	1.08	0.83	1.07	0.91	1.01	0.99	1.00	0.99	0.94	1.05	0.91	1.08	1.20	1.00	1.00	1.02
603	1.028	1.092	1.06	1.06	1.05	1.51	0.90	0.71	1.00	1.00	1.08	0.83	1.07	0.91	1.01	0.99	1.00	0.99	0.94	1.05	0.91	1.08	1.20	1.00	1.00	1.02
604	1.028	1.092	1.06	1.06	1.05	1.51	0.90	0.71	1.00	1.00	1.08	0.83	1.07	0.91	1.01	0.99	1.00	0.99	0.94	1.05	0.91	1.08	1.20	1.00	1.00	1.02
605	1.006	1.071	1.04	1.07	1.00	1.00	1.02	0.81	1.01	1.18	1.00	1.03	1.00	1.11	1.01	0.94	0.87	0.86	0.96	1.08	0.88	1.20	1.12	1.03	1.03	1.05
606	1.028	1.092	1.06	1.17	1.07	1.84	1.22	0.89	1.13	0.83	1.08	1.20	1.03	1.06	1.05	1.03	1.01	1.08	1.19	1.04	1.21	1.21	1.14	1.19	1.32	1.32
607	1.028	1.092	1.06	1.17	1.07	1.84	1.22	0.89	1.13	0.83	1.08	1.20	1.03	1.06	1.05	1.03	1.01	1.08	1.19	1.04	1.21	1.21	1.14	1.19	1.32	1.32
608	1.028	1.092	1.06	1.17	1.07	1.84	1.22	0.89	1.13	0.83	1.08	1.20	1.03	1.06	1.05	1.03	1.01	1.08	1.19	1.04	1.21	1.21	1.14	1.19	1.32	1.32
609	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
610	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
611	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
612	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
613	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
614	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
615	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
616	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
617	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
618	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
619	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
620	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
621	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
622	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
623	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
624	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
625	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
626	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
627	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
628	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
629	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
630	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
631	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
632	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
633	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
634	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
635	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
636	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
637	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
638	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
639	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
640	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
641	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
644	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
645	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
648	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
647	1.000	0.889	0.94	0.97	1.02	0.83	0.84	0.96	1.01	0.85	0.96	1.15	0.91	0.88	0.91	1.12	1.04	1.02	0.84	1.08	1.04	1.25	1.14	1.38	1.09	1.11
648	1.000	0.889	0.94	0.97																						

TABLE L. -- PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

15 of 20

Zip Code	RVU GAAFs											Conversion Factor GAAFs By Category															
	Work Expense	Practice Expense	Total Unit Value	Inpatient Visits	Office Home Urgent Care Visits	Therapeutic Injections	Diagnostic Injections	Allergy Immunotherapy	Misc. Medical	ER Visits	Consults	Phys. Med. - Diagnostic	Cardio-vascular	Immunizations	Well Baby Exams	Vision Exams	Hearing Speech Exams	Phys. - Diagnostic Exams	Chronic Practitioner	Psych./Alcohol & Drug Abuse	Sur-gery	Radiology	Pathology	Anesthesia	Normal Deliveries	Cesarean Deliveries	Non-Deliveries
707	1.000	0.870	0.93	0.98	0.98	1.20	1.28	0.93	1.02	0.94	0.95	1.01	0.81	1.01	1.16	0.93	1.08	1.06	1.24	0.91	0.92	0.93	0.83	0.81	0.85	0.85	1.04
708	1.000	0.870	0.93	0.98	0.98	1.20	1.28	0.93	1.02	0.94	0.98	1.01	0.81	1.01	1.16	0.93	1.08	1.06	1.24	0.91	0.92	0.93	0.83	0.81	0.85	0.85	1.04
710	1.000	0.870	0.93	0.98	0.98	1.04	1.40	0.93	1.02	0.94	0.98	1.01	0.81	1.01	1.16	0.93	1.08	1.06	1.24	0.91	0.92	0.93	0.83	0.81	0.85	0.85	1.04
711	1.000	0.870	0.93	0.98	0.98	1.04	1.40	0.93	1.02	0.94	0.98	1.01	0.81	1.01	1.16	0.93	1.08	1.06	1.24	0.91	0.92	0.93	0.83	0.81	0.85	0.85	1.04
712	1.000	0.870	0.93	0.98	0.98	1.04	1.40	0.93	1.02	0.94	0.98	1.01	0.81	1.01	1.16	0.93	1.08	1.06	1.24	0.91	0.92	0.93	0.83	0.81	0.85	0.85	1.04
713	1.000	0.870	0.93	0.98	0.98	1.04	1.40	0.93	1.02	0.94	0.98	1.01	0.81	1.01	1.16	0.93	1.08	1.06	1.24	0.91	0.92	0.93	0.83	0.81	0.85	0.85	1.04
714	1.000	0.870	0.93	0.98	0.98	1.04	1.40	0.93	1.02	0.94	0.98	1.01	0.81	1.01	1.16	0.93	1.08	1.06	1.24	0.91	0.92	0.93	0.83	0.81	0.85	0.85	1.04
718	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
717	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
716	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
719	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
720	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
721	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
722	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
723	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
724	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
725	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
726	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
727	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
728	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
729	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
730	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
731	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
733	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
734	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
735	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
736	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
737	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
738	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
739	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
740	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
741	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
743	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
744	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
745	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
746	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
747	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
748	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
749	1.000	0.847	0.92	0.78	0.83	0.67	1.09	0.84	1.05	0.97	0.93	0.98	1.17	1.07	0.96	0.86	1.22	0.94	1.04	1.10	0.95	1.15	0.88	0.75	1.05	0.85	0.99
750	1.010	1.065	1.04	1.06	1.04	1.06	1.19	1.06	1.10	0.84	1.02	1.01	0.93	1.24	1.23	1.09	0.87	1.19	1.00	0.99	1.01	1.00	1.19	1.01	1.00	1.10	1.06
751	1.010	1.065	1.04	1.06	1.04	1.06	1.19	1.06	1.10	0.84	1.02	1.01	0.93	1.24	1.23	1.09	0.87	1.19	1.00	0.99	1.01	1.00	1.19	1.01	1.00	1.10	1.06
752	1.010	1.065	1.04	1.06	1.04	1.06	1.19	1.06	1.10	0.84	1.02	1.01	0.93	1.24	1.23	1.09	0.87	1.19	1.00	0.99	1.01	1.00	1.19	1.01	1.00	1.10	1.06
753	1.010	1.065	1.04	1.06	1.04	1.06	1.19	1.06	1.10	0.84	1.02	1.01	0.93	1.24	1.23	1.09	0.87	1.19	1.00	0.99	1.01	1.00	1.19	1.01	1.00	1.10	1.06
754	1.000	0.860	0.93	1.02	1.01	1.38	1.10	1.17	1.13	0.97	1.08	1.07	1.30	1.27	0.99	1.02	1.02	1.05	0.89	0.91	1.03	1.17	0.97	1.01	1.00	1.01	1.01
755	1.000	0.860	0.93	1.02	1.01	1.38	1.10	1.17	1.13	0.97	1.08	1.07	1.30	1.27	0.99	1.02	1.02	1.05	0.89	0.91	1.03	1.17	0.97	1.01	1.00	1.01	1.01
756	1.000	0.860	0.93	1.02	1.01	1.38	1.10	1.17	1.13	0.97	1.08	1.07	1.30	1.27	0.99	1.02	1.02	1.05	0.89	0.							

TABLE L -- PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

16 of 20

Zip Code	RVU GAAFs											Conversion Factor GAAFs By Category											Normal Deliv-eries	Cesar-ain Deliv-eries	Non-Deli-areas		
	Work Expen-diture	Prac-tice Expen-diture	Total Unit Value	Impe-rient Vis-its	Offi-cial Home/ Urgent Care Vis-its	Thera-peutic Injec-tions	Allergy Test-ing	Allergy Immu-nother-apy	Misc. Med-ical	ER Vis-its	Con-sults	Phys-ical Med-i-cine	Cardio-vas-cular	Immu-niza-tions	Well Baby Exams	Vision Exams	Hear-ing, Speech Exams	Phys-ical Exams	Chico-proctor	Psych./Alcohol & Drug Abuse	Sur-gery	Radi-ology				Path-ology	Anes-thesia
758	1.00	0.860	0.93	1.02	1.01	1.38	1.10	1.17	1.13	0.87	1.06	1.07	1.30	1.27	0.99	1.02	1.02	1.05	0.89	0.81	1.03	1.17	1.17	0.97	1.01	1.00	1.01
759	1.00	0.860	0.93	1.02	1.01	1.38	1.10	1.17	1.13	0.87	1.06	1.07	1.30	1.27	0.99	1.02	1.02	1.05	0.89	0.81	1.03	1.17	1.17	0.97	1.01	1.00	1.01
760	1.00	0.981	0.99	1.11	1.12	1.12	0.96	1.11	1.00	0.87	1.02	0.99	0.97	1.20	1.41	1.04	0.95	1.21	0.84	0.97	0.97	0.92	1.07	0.98	0.87	0.88	0.96
761	1.00	0.951	0.99	1.11	1.12	1.12	0.96	1.11	1.00	0.87	1.02	0.99	0.97	1.20	1.41	1.04	0.95	1.21	0.84	0.97	0.97	0.92	1.07	0.98	0.87	0.88	0.96
762	1.00	0.860	0.83	1.06	1.17	1.18	0.95	0.92	1.11	0.84	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.90	1.00	1.00	1.08	0.92	1.12	1.10	1.07
763	1.00	0.860	0.83	1.06	1.17	1.18	0.95	0.92	1.11	0.84	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.90	1.00	1.00	1.08	0.92	1.12	1.10	1.07
764	1.00	0.860	0.83	1.06	1.17	1.18	0.95	0.92	1.11	0.84	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.90	1.00	1.00	1.08	0.92	1.12	1.10	1.07
765	1.00	0.860	0.83	1.06	1.17	1.18	0.95	0.92	1.11	0.84	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.90	1.00	1.00	1.08	0.92	1.12	1.10	1.07
766	1.00	0.860	0.83	1.06	1.17	1.18	0.95	0.92	1.11	0.84	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.90	1.00	1.00	1.08	0.92	1.12	1.10	1.07
767	1.00	0.860	0.83	1.06	1.17	1.18	0.95	0.92	1.11	0.84	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.90	1.00	1.00	1.08	0.92	1.12	1.10	1.07
768	1.00	0.860	0.83	1.06	1.17	1.18	0.95	0.92	1.11	0.84	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.90	1.00	1.00	1.08	0.92	1.12	1.10	1.07
769	1.00	0.860	0.83	1.06	1.17	1.18	0.95	0.92	1.11	0.84	1.23	1.10	1.11	1.47	1.47	1.41	1.25	1.25	0.89	0.90	1.00	1.00	1.08	0.92	1.12	1.10	1.07
770	1.00	1.007	1.01	1.21	1.21	1.05	1.03	0.82	0.87	1.09	1.27	1.06	1.03	1.07	1.06	1.06	1.06	1.00	1.07	1.02	1.06	1.15	1.31	1.00	1.03	1.06	
771	1.00	1.007	1.01	1.21	1.21	1.05	1.03	0.82	0.87	1.09	1.27	1.06	1.03	1.07	1.06	1.06	1.06	1.00	1.07	1.02	1.06	1.15	1.31	1.00	1.03	1.06	
772	1.00	1.007	1.01	1.21	1.21	1.05	1.03	0.82	0.87	1.09	1.27	1.06	1.03	1.07	1.06	1.06	1.06	1.00	1.07	1.02	1.06	1.15	1.31	1.00	1.03	1.06	
773	1.00	0.860	0.83	1.06	1.02	1.21	0.95	1.18	1.29	1.45	1.03	1.01	1.14	1.25	1.10	1.05	1.03	1.05	1.05	1.07	1.09	1.37	1.15	0.86	0.84	1.00	1.03
774	1.00	0.860	0.83	1.06	1.02	1.21	0.95	1.18	1.29	1.45	1.03	1.01	1.14	1.25	1.10	1.05	1.03	1.05	1.05	1.07	1.09	1.37	1.15	0.86	0.84	1.00	1.03
775	1.00	1.007	1.01	1.03	1.03	0.94	1.06	0.82	1.01	1.18	1.38	0.86	0.94	1.01	1.09	1.02	0.96	0.90	0.97	1.02	1.00	1.23	1.13	0.86	0.87	0.92	0.84
776	1.00	0.860	0.83	0.96	1.01	1.63	1.01	1.20	1.21	1.19	1.03	1.02	0.86	1.12	1.46	1.11	1.03	0.90	0.91	1.02	1.21	1.13	0.86	1.02	1.04	0.93	0.89
777	1.00	0.860	0.84	0.95	1.00	1.60	0.96	1.17	1.19	1.03	1.02	0.86	1.12	1.46	1.11	1.03	0.90	0.90	0.91	1.02	1.21	1.13	0.86	1.02	1.04	0.93	0.89
778	1.00	0.860	0.83	1.03	1.01	1.10	0.84	0.89	1.32	0.84	1.06	1.07	1.36	1.26	1.13	1.00	1.25	1.03	0.87	0.90	1.00	1.18	1.11	0.89	0.96	1.00	0.89
779	1.00	0.860	0.83	1.03	1.02	1.06	0.85	1.05	1.18	0.93	0.99	0.92	1.05	1.27	1.20	0.90	1.20	1.13	0.89	0.87	0.95	0.92	0.97	0.88	0.88	1.03	1.00
780	1.00	0.860	0.83	1.06	1.02	1.15	0.94	1.12	1.09	1.21	1.06	1.06	1.25	1.43	1.10	1.11	1.02	1.01	0.83	1.05	0.96	1.01	1.20	0.88	0.78	0.84	1.00
781	1.00	0.860	0.83	0.96	1.02	0.86	0.95	1.05	1.18	0.95	0.99	0.92	1.05	1.27	1.20	0.90	1.20	1.13	0.89	0.87	0.95	0.92	0.97	0.88	0.88	0.93	0.90
782	1.00	0.860	0.83	1.09	1.02	1.15	0.94	1.12	1.09	1.21	1.06	1.06	1.25	1.43	1.10	1.11	1.02	1.01	0.83	1.05	0.99	1.01	1.20	0.88	0.76	0.84	1.00
783	1.00	0.860	0.83	1.03	1.03	1.09	1.10	1.25	1.26	1.27	1.03	1.05	1.17	1.39	0.95	1.17	1.18	1.12	1.00	1.01	1.09	1.10	1.21	1.21	1.07	1.05	1.01
784	1.00	0.860	0.83	1.03	1.03	1.09	1.10	1.25	1.26	1.27	1.03	1.05	1.17	1.39	0.95	1.17	1.18	1.12	1.00	1.01	1.09	1.10	1.21	1.21	1.07	1.05	1.01
785	1.00	0.860	0.83	1.03	1.03	1.09	1.10	1.25	1.26	1.27	1.03	1.05	1.17	1.39	0.95	1.17	1.18	1.12	1.00	1.01	1.09	1.10	1.21	1.21	1.07	1.05	1.01
786	1.00	0.860	0.83	1.19	1.09	1.39	0.95	1.01	1.12	0.93	1.11	1.04	0.86	1.33	1.25	1.00	1.04	1.20	0.93	0.93	0.86	1.23	1.37	0.87	0.95	0.94	0.94
787	1.00	0.996	1.00	1.16	1.00	1.39	0.95	0.91	1.13	0.93	1.11	1.04	0.86	1.33	1.25	1.00	1.04	1.20	0.93	0.93	0.86	1.23	1.37	0.87	0.95	0.94	0.94
788	1.00	0.860	0.83	1.02	1.02	1.07	1.18	0.88	1.08	0.97	1.06	0.94	1.50	1.19	1.04	0.94	1.05	0.95	0.87	0.98	1.10	1.18	1.11	0.87	0.98	0.97	0.86
789	1.00	0.860	0.83	1.19	1.09	1.39	0.95	1.01	1.12	0.93	1.11	1.04	0.96	1.33	1.25	1.00	1.04	1.20	0.93	0.93	0.86	1.23	1.37	0.87	0.95	0.94	0.94
790	1.00	0.860	0.83	1.19	1.09	1.39	0.95	1.01	1.12	0.93	1.11	1.04	0.96	1.33	1.25	1.00	1.04	1.20	0.93	0.93	0.86	1.23	1.37	0.87	0.95	0.94	0.94
791	1.00	0.860	0.83	0.96	0.94	1.02	1.11	1.24	1.07	0.92	0.99	0.98	1.15	1.44	1.19	1.06	1.11	1.06	0.84	0.86	0.98	1.11	0.90	0.88	0.85	0.89	1.18
792	1.00	0.860	0.83	0.96	0.94	1.02	1.11	1.24	1.07	0.92	0.99	0.98	1.15	1.44	1.19	1.06	1.11	1.06	0.84	0.86	0.98	1.11	0.90	0.88	0.85	0.89	1.16
793	1.00	0.860	0.83	1.06	1.23	1.57	0.96	0.84	1.16	0.97	1.05	0.97	1.02	1.18	1.53	1.14	0.86	1.42	0.90	0.98	1.03	1.00	0.89	1.34	1.28	0.83	0.83
794	1.00	0.860	0.83	1.06	1.23	1.57	0.96	0.84	1.16	0.97	1.05	0.97	1.02	1.18	1.53	1.14	0.86	1.42	0.90	0.98	1.03	1.00	0.89	1.34	1.28	0.83	0.83
795	1.00	0.860	0.83	1.06	1.23	1.57	0.96	0.84	1.16	0.97	1.05	0.97	1.02	1.18	1.53	1.14	0.86	1.42	0.90	0.98	1.03	1.00	0.89	1.34	1.28	0.83	0.83
796	1.00	0.860	0.83	1.06	1.23	1.57	0.96	0.84	1.16	0.97	1.05	0.97	1.02	1.18	1.53	1.14	0.86	1.42	0.90	0.98	1.03	1.00	0.89	1.34	1.28	0.83	0.83
797	1.00	0.860	0.83	1.02	1.02	1.07	1.18	0.88	1.08	0.97	1.06	0.94	1.50	1.19	1.04	0.94	1.05	0.95	0.87	0.98	1.10	1.18	1.11	0.87	0.98	0.97	0.86
798	1.00	0.860	0.83	1.02	1.02	1.07	1.18	0.88	1.08	0.97	1.06	0.94	1.50	1.19	1.04	0.94	1.05	0.95	0.87	0.98	1.10	1.18	1.11	0.87	0.98	0.97	0.86
799	1.00	0.860	0.83	1.03	1.02	1.07	1.19	0.88	1.08	0.97	1.06	0.94	1.50	1.19	1.04	0.94	1.05	0.95	0.87	0.98	1.10	1.18	1.11	0.87	0.98	0.97	0.86
800	1.00	0.962	1.00	1.01	1.06	0.90	1.00	1.01	0.84	1.02	1.01	1.05	0.98	1.04	1.05	1.02	1.00	1.06	0.99	1.06	1.00	1.06	1.06	0.83	0.86	0.96	1.06
801	1.00	0.962	1.00	1.15	1.01	0.81	1.14	0.95	0.85	0.86	1.06	0.96	0.91	0.99	1.24	0.93	0.82	1.21	1.45	0.98	0.82	0.82	0.78	0.84	0.85	0.89	0.88
802	1.00	0.962	1.00	1.19	1.04	0.92	0.85	1.01	1.20	1.01	0.99	1.04	0.86	1.06	1.27	1.07	0.92	1.21	1.45	1.02	0.87	0.89	1.09	0.88	0.92	0.89	0.88
803	1.00	0.962	1.00	1.01	1.06	0.90	1.00	1.01	0.82	0.86	1.06	0.96	0.91	0.99	1.24	0.93	0.82	1.21	1.45	0.98	0.82	0.					

TABLE L. -- PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

17 of 20

Zip Code	RVU GAAFs										Conversion Factor GAAFs By Category																
	Work Expense	Practice Expense	Total Unit Value	Inpatient Visits	Office/Home/Urgent Care Visits	Therapeutic Injections	Allergy Testing	Allergy Immunotherapy	Misc. Medical	ER Visits	Consults	Physical Medicine	Cardiovascular	Immunizations	Well Baby Exams	Vision Exams	Hearing/Speech Exams	Physical Exams	Cholesterol	Psych/Alcohol/Drug Abuse	Surgery	Radiology	Pathology	Anesthesia	Normal Studies	Cesarean Deliveries	Non-Deliveries
800	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
807	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
808	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
809	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
810	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
811	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
812	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
813	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
814	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
815	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
818	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
820	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
822	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
823	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
824	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
825	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
826	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
827	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
828	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
829	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
830	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
831	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
832	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
833	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
834	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
835	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
836	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
837	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
838	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
839	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
840	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
841	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
842	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
843	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
844	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
845	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
846	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
847	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
848	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
850	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
852	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
853	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
855	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
856	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
857	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98	1.10	1.05	0.89	0.75	0.51	0.53	0.80	0.82	0.83	0.76
859	1.000	0.992	1.000	0.91	0.98	1.00	0.75	0.95	0.98	0.77	0.95	0.99	0.76	0.88	1.13	0.94	0.98										

TABLE L - PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

18 of 20

Zip Code	RVU GAAFs												Conversion Factor GAAFs By Category														
	Work Expense	Practice Expense	Total Unit Value	Inpatient Visits	Office/Home/ Urgent Care Visits	Therapeutic Injections	Allergy Testing	Allergy Immunotherapy	Misc Med. Visits	ER Visits	Consults	Phys-Med	Cardio-vascular	Immunizations	Well Baby Exams	Vision Exams	Hearing/ Speech Exams	Physical Exams	Chronic Proctor	Psych/Alcohol/Drug Abuse	Surgery	Radiology	Pathology	Anesthesia	Normal Deliv-eries	Cesarean Deliv-eries	Non-Deliv-eries
864	1.000	0.978	0.99	0.91	0.98	0.75	1.29	0.96	0.52	1.04	0.95	0.91	0.74	1.17	1.06	0.98	1.29	1.09	0.99	0.95	0.92	1.04	0.87	0.87	0.60	0.78	0.83
865	1.000	0.978	0.99	0.96	0.93	1.17	0.99	1.05	0.90	0.75	0.97	0.97	0.99	1.34	0.96	0.85	0.78	1.03	1.03	1.03	1.04	1.10	0.80	0.94	0.60	0.78	0.83
870	1.000	0.900	0.94	1.00	1.08	1.24	0.91	1.00	1.00	0.97	1.10	1.15	0.65	0.65	1.37	1.15	0.99	1.21	1.15	1.00	1.00	1.22	0.87	0.78	0.88	0.98	0.80
871	1.000	0.900	0.94	1.08	1.60	1.28	0.79	0.87	1.08	1.10	1.10	0.88	0.73	0.77	0.97	1.28	1.11	0.99	1.20	1.14	0.92	1.01	0.72	0.87	1.02	1.09	0.56
872	1.000	0.900	0.94	1.00	1.08	1.24	0.91	1.00	1.00	0.97	1.11	0.90	1.15	0.65	1.37	1.15	0.98	1.21	1.15	1.00	1.00	1.22	0.87	0.78	0.89	0.98	0.80
873	1.000	0.900	0.94	1.00	1.08	1.24	0.91	1.00	1.00	0.97	1.11	0.90	1.15	0.65	1.37	1.15	0.98	1.21	1.15	1.00	1.00	1.22	0.87	0.78	0.89	0.98	0.80
874	1.000	0.900	0.94	1.00	1.08	1.24	0.91	1.00	1.00	0.97	1.11	0.90	1.15	0.65	1.37	1.15	0.98	1.21	1.15	1.00	1.00	1.22	0.87	0.78	0.89	0.98	0.80
875	1.000	0.900	0.94	1.00	1.08	1.24	0.91	1.00	1.00	0.97	1.11	0.90	1.15	0.65	1.37	1.15	0.98	1.21	1.15	1.00	1.00	1.22	0.87	0.78	0.89	0.98	0.80
877	1.000	0.900	0.94	1.00	1.08	1.24	0.91	1.00	1.00	0.97	1.11	0.90	1.15	0.65	1.37	1.15	0.98	1.21	1.15	1.00	1.00	1.22	0.87	0.78	0.89	0.98	0.80
878	1.000	0.900	0.94	1.00	1.08	1.24	0.91	1.00	1.00	0.97	1.11	0.90	1.15	0.65	1.37	1.15	0.98	1.21	1.15	1.00	1.00	1.22	0.87	0.78	0.89	0.98	0.80
879	1.000	0.900	0.94	1.00	1.08	1.24	0.91	1.00	1.00	0.97	1.11	0.90	1.15	0.65	1.37	1.15	0.98	1.21	1.15	1.00	1.00	1.22	0.87	0.78	0.89	0.98	0.80
880	1.000	0.900	0.94	1.00	1.08	1.24	0.91	1.00	1.00	0.97	1.11	0.90	1.15	0.65	1.37	1.15	0.98	1.21	1.15	1.00	1.00	1.22	0.87	0.78	0.89	0.98	0.80
881	1.000	0.900	0.94	1.00	1.08	1.24	0.91	1.00	1.00	0.97	1.11	0.90	1.15	0.65	1.37	1.15	0.98	1.21	1.15	1.00	1.00	1.22	0.87	0.78	0.89	0.98	0.80
882	1.000	0.900	0.94	1.00	1.08	1.24	0.91	1.00	1.00	0.97	1.11	0.90	1.15	0.65	1.37	1.15	0.98	1.21	1.15	1.00	1.00	1.22	0.87	0.78	0.89	0.98	0.80
883	1.000	0.900	0.94	1.00	1.08	1.24	0.91	1.00	1.00	0.97	1.11	0.90	1.15	0.65	1.37	1.15	0.98	1.21	1.15	1.00	1.00	1.22	0.87	0.78	0.89	0.98	0.80
884	1.000	0.900	0.94	1.00	1.08	1.24	0.91	1.00	1.00	0.97	1.11	0.90	1.15	0.65	1.37	1.15	0.98	1.21	1.15	1.00	1.00	1.22	0.87	0.78	0.89	0.98	0.80
885	1.000	0.800	0.93	1.01	1.01	1.43	0.79	0.86	1.08	1.02	1.01	1.05	0.96	1.00	1.04	1.05	1.02	0.99	1.08	1.06	1.00	1.00	1.00	1.00	1.00	0.98	1.08
889	1.005	1.039	1.02	1.15	1.26	1.01	0.93	0.99	1.08	1.24	1.15	0.90	0.98	0.82	1.15	0.99	1.08	1.07	1.05	1.20	1.02	1.02	0.86	1.22	1.21	0.87	0.98
890	1.005	1.039	1.02	1.15	1.26	1.01	0.93	0.99	1.08	1.24	1.15	0.90	0.98	0.82	1.15	0.99	1.08	1.07	1.05	1.20	1.02	1.02	0.86	1.22	1.21	0.87	0.98
891	1.005	1.039	1.02	1.15	1.26	1.01	0.93	0.99	1.08	1.24	1.15	0.90	0.98	0.82	1.15	0.99	1.08	1.07	1.05	1.20	1.02	1.02	0.86	1.22	1.21	0.87	0.98
893	1.005	1.039	1.02	1.15	1.26	1.01	0.93	0.99	1.08	1.24	1.15	0.90	0.98	0.82	1.15	0.99	1.08	1.07	1.05	1.20	1.02	1.02	0.86	1.22	1.21	0.87	0.98
894	1.005	1.039	1.02	1.15	1.26	1.01	0.93	0.99	1.08	1.24	1.15	0.90	0.98	0.82	1.15	0.99	1.08	1.07	1.05	1.20	1.02	1.02	0.86	1.22	1.21	0.87	0.98
895	1.005	1.039	1.02	1.15	1.26	1.01	0.93	0.99	1.08	1.24	1.15	0.90	0.98	0.82	1.15	0.99	1.08	1.07	1.05	1.20	1.02	1.02	0.86	1.22	1.21	0.87	0.98
897	1.005	1.039	1.02	1.15	1.26	1.01	0.93	0.99	1.08	1.24	1.15	0.90	0.98	0.82	1.15	0.99	1.08	1.07	1.05	1.20	1.02	1.02	0.86	1.22	1.21	0.87	0.98
898	1.005	1.039	1.02	1.15	1.26	1.01	0.93	0.99	1.08	1.24	1.15	0.90	0.98	0.82	1.15	0.99	1.08	1.07	1.05	1.20	1.02	1.02	0.86	1.22	1.21	0.87	0.98
900	1.056	1.139	1.10	1.26	1.13	0.96	0.86	1.10	1.06	1.44	1.13	1.03	1.05	1.01	1.15	1.53	1.11	1.08	1.19	1.13	1.08	1.13	1.05	1.05	1.08	1.13	1.07
901	1.056	1.139	1.10	1.26	1.13	0.96	0.86	1.10	1.06	1.44	1.13	1.03	1.05	1.01	1.15	1.53	1.11	1.08	1.19	1.13	1.08	1.13	1.05	1.05	1.08	1.13	1.07
902	1.056	1.139	1.10	1.26	1.13	0.96	0.86	1.10	1.06	1.44	1.13	1.03	1.05	1.01	1.15	1.53	1.11	1.08	1.19	1.13	1.08	1.13	1.05	1.05	1.08	1.13	1.07
903	1.056	1.139	1.10	1.26	1.13	0.96	0.86	1.10	1.06	1.44	1.13	1.03	1.05	1.01	1.15	1.53	1.11	1.08	1.19	1.13	1.08	1.13	1.05	1.05	1.08	1.13	1.07
904	1.056	1.139	1.10	1.26	1.13	0.96	0.86	1.10	1.06	1.44	1.13	1.03	1.05	1.01	1.15	1.53	1.11	1.08	1.19	1.13	1.08	1.13	1.05	1.05	1.08	1.13	1.07
905	1.056	1.139	1.10	1.26	1.13	0.96	0.86	1.10	1.06	1.44	1.13	1.03	1.05	1.01	1.15	1.53	1.11	1.08	1.19	1.13	1.08	1.13	1.05	1.05	1.08	1.13	1.07
906	1.056	1.139	1.10	1.26	1.13	0.96	0.86	1.10	1.06	1.44	1.13	1.03	1.05	1.01	1.15	1.53	1.11	1.08	1.19	1.13	1.08	1.13	1.05	1.05	1.08	1.13	1.07
907	1.056	1.139	1.10	1.26	1.13	0.96	0.86	1.10	1.06	1.44	1.13	1.03	1.05	1.01	1.15	1.53	1.11	1.08	1.19	1.13	1.08	1.13	1.05	1.05	1.08	1.13	1.07
908	1.056	1.139	1.10	1.26	1.13	0.96	0.86	1.10	1.06	1.44	1.13	1.03	1.05	1.01	1.15	1.53	1.11	1.08	1.19	1.13	1.08	1.13	1.05	1.05	1.08	1.13	1.07
910	1.056	1.139	1.10	1.26	1.13	0.96	0.86	1.10	1.06	1.44	1.13	1.03	1.05	1.01	1.15	1.53	1.11	1.08	1.19	1.13	1.08	1.13	1.05	1.05	1.08	1.13	1.07
911	1.056	1.139	1.10	1.26	1.13	0.96	0.86	1.10	1.06	1.44	1.13	1.03	1.05	1.01	1.15	1.53	1.11	1.08	1.19	1.13	1.08	1.13	1.05	1.05	1.08	1.13	1.07
912	1.056	1.139	1.10	1.26	1.13	0.96	0.86	1.10	1.06	1.44	1.13	1.03	1.05	1.01	1.15	1.53	1.11	1.08	1.19	1.13	1.08	1.13	1.05	1.05	1.08	1.13	1.07
913	1.056	1.139	1.10	1.26	1.13	0.96	0.86	1.10	1.06	1.44	1.13	1.03	1.05	1.01	1.15	1.53	1.11	1.08	1.19	1.13	1.08	1.13	1.05	1.05	1.08	1.13	1.07
914	1.056	1.139	1.10	1.26	1.13	0.96	0.86	1.10	1.06	1.44	1.13	1.03	1.05	1.01	1.15	1.53	1.11	1.08	1.19	1.13	1.08	1.13	1.05	1.05	1.08	1.13	1.07
915	1.056	1.139	1.10	1.26	1.13	0.96	0.86	1.10	1.06	1.44	1.13	1.03	1.05	1.01	1.15	1.53	1.11	1.08	1.19	1.13	1.08	1.13	1.05	1.05	1.08	1.13	1.07
918	1.056	1.139	1.10	1.26	1.13	0.96	0.86	1.10	1.06	1.44	1.13	1.03	1.05	1.01	1.15	1.53	1.11	1.08	1.19	1.13	1.08	1.13	1.05	1.05	1.08	1.13	1.07
917	1.056	1.139	1.10	1.26	1.13	0.96	0.86	1.10	1.06	1.44	1.13	1.03	1.05	1.01	1.15	1.53	1.11	1.08	1.19	1.13	1.08	1.13	1.05	1.05	1.08	1.13	1.07
918	1.056	1.139	1.10	1.26	1.13	0.96	0.86	1.10	1.06	1.44	1.13	1.03	1.05	1.01	1.15	1.53	1.11	1.08	1.19	1.13	1.08	1.13	1.05	1.05	1.08	1.13	1.07
919	1.007	1.034	1.02	1.04	0.84	1.02	0.84	0.93	0.80	1.16	0.94	0.77	0.87	1.01	0.92	0.98	1.03	0.96	1.08	1.10	0.89	1.08	0.80	0.99	0.84	0.94	0.87
920	1.007	1.034	1.02	1.04	0.84	1.02	0.84	0.93	0.80	1.16	0.94	0.77	0.87	1.01	0.92	0.98	1.03	0.96	1.08	1.10	0.89	1.08	0.80	0.99	0.84	0.94	0.87
921	1.007	1.034	1.02	1.04	0.84	1.02	0.84	0.93	0.80	1.16	0.94	0.77	0.87	1.01	0.92	0.98	1.03	0.96	1.08	1.10	0.89						

TABLE L. - PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

20 of 20

Zip Code	RVU GAAFs										Conversion Factor GAAFs By Category																
	Work Expense	Practice Expense	Total Unit Value	Inpatient Visits	Office/Home/Urgent Care Visits	Therapeutic Injections	Allergy Testing	Allergy Immunotherapy	Misc. Medical	ER Visits	Consults	Physical Medicine	Cardiovascular	Immunizations	Well Baby Exams	Vision Exams	Hearing/Speech Exams	Physical Exams	Chiropractor	Psych./Alcohol & Drug Abuse	Surgery	Radiology	Pathology	Anesthesia	Normal Deliveries	Cesarean Deliveries	Non-Deliveries
976	1.000	0.933	0.96	0.97	1.19	0.87	1.11	1.18	0.87	0.95	1.16	1.07	0.70	0.65	1.33	1.09	1.28	1.30	0.99	0.99	0.94	0.61	0.69	0.86	1.02	1.01	0.71
977	1.000	0.833	0.96	0.97	1.19	0.87	1.11	1.18	0.87	0.95	1.16	1.07	0.70	0.65	1.33	1.09	1.28	1.30	0.99	0.99	0.94	0.61	0.69	0.86	1.02	1.01	0.71
978	1.000	0.833	0.96	0.88	1.09	0.60	1.10	1.11	0.84	0.81	1.10	0.87	0.72	0.65	1.20	0.88	1.14	1.12	0.93	0.90	0.87	0.92	0.57	0.71	0.96	0.96	0.72
979	1.000	0.833	0.96	0.88	1.09	0.60	1.10	1.11	0.84	0.81	1.10	0.87	0.72	0.65	1.20	0.88	1.14	1.12	0.93	0.90	0.87	0.92	0.57	0.71	0.96	0.96	0.72
980	1.005	1.100	1.06	0.99	0.97	0.75	0.89	1.13	0.83	0.99	1.06	0.83	0.72	0.43	1.07	0.99	0.77	1.07	0.97	0.92	0.79	0.74	0.78	0.78	0.88	0.65	0.75
981	1.005	1.100	1.06	1.13	1.21	1.03	0.99	1.10	0.88	0.95	1.10	1.13	0.71	0.50	1.36	1.06	0.96	1.25	1.00	0.97	0.83	0.89	0.82	0.80	0.94	0.81	0.81
982	1.000	0.972	0.96	1.00	1.04	0.64	0.87	1.13	0.81	0.85	1.07	0.86	0.75	0.53	1.25	1.02	0.92	1.12	0.95	0.91	0.75	0.66	0.69	0.81	0.96	0.95	0.71
983	1.000	0.972	0.96	1.18	1.15	0.78	0.87	1.06	0.79	0.90	1.00	0.84	1.30	0.46	1.21	1.06	1.01	1.33	0.94	0.94	0.65	0.76	0.81	0.84	1.11	1.11	0.85
984	1.000	0.972	0.96	1.10	1.15	0.76	0.87	1.06	0.79	0.90	1.00	0.84	1.30	0.46	1.21	1.09	1.01	1.33	0.94	0.94	0.65	0.76	0.81	0.84	1.11	1.11	0.85
985	1.000	0.972	0.96	1.01	1.22	0.95	0.95	1.05	0.82	0.97	1.06	0.88	1.05	0.49	1.20	1.07	0.76	1.06	0.98	0.92	0.77	0.92	0.91	0.76	0.93	1.05	0.72
986	1.000	0.972	0.96	1.01	1.27	0.96	0.96	1.06	0.86	0.77	1.16	1.03	0.99	0.46	1.18	0.88	0.73	1.31	0.99	1.00	0.78	0.81	0.88	0.78	0.96	0.94	0.73
988	1.000	0.972	0.96	0.96	0.99	0.99	0.96	1.06	1.01	0.86	0.96	0.82	0.86	0.50	0.98	1.07	0.89	1.09	0.86	0.90	0.81	0.86	0.90	0.84	1.02	0.97	0.79
989	1.000	0.972	0.96	0.88	0.99	0.99	0.96	1.06	1.01	0.86	0.96	0.82	0.86	0.50	0.98	1.07	0.89	1.09	0.86	0.90	0.81	0.86	0.90	0.84	1.02	0.97	0.79
990	1.000	0.972	0.96	0.89	0.95	0.82	0.89	0.95	0.86	0.97	0.94	0.80	0.65	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.78	0.88	0.81	0.80	0.84	0.56
991	1.000	0.972	0.96	0.89	0.95	0.82	0.89	0.95	0.86	0.97	0.94	0.80	0.65	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.78	0.88	0.81	0.80	0.84	0.56
992	1.000	0.972	0.96	0.89	0.95	0.82	0.89	0.95	0.86	0.97	0.94	0.80	0.65	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.78	0.88	0.81	0.80	0.84	0.56
993	1.000	0.972	0.96	0.86	0.95	0.82	0.86	0.95	0.86	0.97	0.94	0.80	0.65	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.78	0.88	0.81	0.80	0.84	0.56
994	1.000	0.972	0.96	0.86	0.95	0.82	0.86	0.95	0.86	0.97	0.94	0.80	0.65	0.50	1.05	1.06	1.07	1.05	0.90	0.92	0.77	0.78	0.88	0.81	0.80	0.84	0.56
995	1.670	1.870	1.67	0.88	0.84	0.77	0.88	0.84	0.80	0.64	0.82	0.73	0.72	0.34	0.77	0.63	0.68	0.72	0.73	0.66	0.75	0.62	1.00	1.01	0.60	0.69	0.73
996	1.670	1.870	1.67	0.79	0.74	0.78	0.85	0.84	0.73	0.57	0.74	0.70	0.54	0.32	0.67	0.63	0.51	0.65	0.68	0.57	0.68	0.55	1.10	0.87	0.81	0.60	0.61
997	1.670	1.870	1.67	0.88	0.84	0.77	0.88	0.84	0.80	0.64	0.82	0.73	0.72	0.34	0.77	0.63	0.68	0.72	0.73	0.66	0.75	0.62	1.00	1.01	0.60	0.69	0.73
998	1.870	1.670	1.67	0.79	0.74	0.78	0.85	0.84	0.73	0.57	0.74	0.70	0.54	0.32	0.67	0.63	0.51	0.65	0.66	0.57	0.68	0.55	1.10	0.87	0.81	0.60	0.61
999	1.870	1.870	1.67	0.77	0.71	0.70	0.64	0.59	0.82	0.52	0.66	0.64	0.65	0.84	0.64	0.64	0.56	0.64	0.62	0.49	0.77	0.63	0.94	0.87	0.77	0.77	0.81

TABLE M. — CHARGE ADJUSTMENT FACTORS
FOR PROFESSIONAL SERVICES CHARGE
MODIFIERS

CPT/ HCPCS Code Modifier	Description	Charge Factor
22	Unusual Procedure	1.20
50	Bilateral Procedure	1.54
51	Multiple Procedures	0.94
52	Reduced Services	0.70
53	Discontinued Procedure	0.97
62	Two Surgeons	0.92
80	Assistant Surgeon	0.31

TABLE P. -- OUTPATIENT FACILITY CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

1 of 4

ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF
Nationwide Average	1.00	071	1.13	151	0.95	222	0.90
		072	1.03	152	0.95	223	0.90
		073	1.13	153	0.81	224	0.96
002	0.94	074	0.99	154	0.81	225	0.96
005	0.87	075	0.99	155	0.81	226	0.71
006	0.40	076	0.99	156	0.85	227	0.71
007	0.40	077	1.26	157	0.81	228	0.71
008	0.40	078	0.96	158	0.73	229	0.71
009	0.40	079	0.96	159	0.81	230	0.96
010	0.78	080	1.28	160	0.85	231	0.96
011	0.78	081	1.28	161	0.85	232	0.96
012	0.78	082	1.28	162	0.85	233	0.85
013	0.92	083	1.28	163	0.73	234	0.85
014	0.92	084	1.28	164	0.88	235	0.85
015	0.94	085	1.26	165	0.88	236	0.85
016	0.93	086	1.26	166	0.77	237	0.85
017	1.12	087	1.10	167	0.73	238	0.96
018	0.82	088	1.16	168	0.81	239	0.78
019	0.82	089	1.22	169	0.78	240	0.80
020	0.84	100	0.96	170	0.81	241	0.80
021	0.92	101	0.96	171	0.81	242	0.80
022	1.14	102	0.96	172	0.76	243	0.80
023	0.84	103	0.99	173	0.76	244	0.71
024	0.92	104	0.99	174	0.76	245	0.78
025	0.88	105	0.93	175	0.76	246	0.80
026	0.88	106	0.96	176	0.75	247	0.70
027	0.84	107	0.93	177	0.78	248	0.70
028	0.89	108	0.93	178	0.78	249	0.70
029	0.89	109	1.04	179	0.69	250	0.70
030	0.86	110	0.99	180	0.84	251	0.70
031	0.86	111	0.99	181	0.84	252	0.70
032	0.83	112	0.97	182	0.85	253	0.70
033	0.83	113	0.97	183	0.94	254	0.72
034	0.83	114	0.97	184	0.85	255	0.70
035	0.83	115	0.87	185	0.85	256	0.70
036	0.83	116	0.87	186	0.85	257	0.70
037	0.83	117	0.87	187	0.85	258	0.70
038	0.94	118	0.87	188	0.85	259	0.70
039	0.80	119	0.87	189	1.40	260	0.68
040	0.77	120	0.68	190	1.54	261	0.72
041	0.66	121	0.68	191	1.48	262	0.72
042	0.77	122	0.68	192	1.48	263	0.72
043	0.80	123	0.68	193	1.40	264	0.72
044	0.77	124	0.68	194	1.40	265	0.68
045	0.77	125	0.85	195	0.69	266	0.70
046	0.77	126	0.85	196	0.69	267	0.72
047	0.80	127	0.85	197	0.64	268	0.72
048	0.77	128	0.67	198	0.64	270	0.66
049	0.80	129	0.67	199	0.76	271	0.61
050	0.72	130	0.62	200	0.87	272	0.66
051	0.72	131	0.62	201	0.93	273	0.66
052	0.72	132	0.62	202	0.87	274	0.66
053	0.72	133	0.69	203	0.87	275	0.82
054	0.76	134	0.69	204	0.87	276	0.82
055	0.82	135	0.69	205	0.87	277	0.83
056	0.72	136	0.69	206	0.64	278	0.74
057	0.72	137	0.68	207	0.66	279	0.74
058	0.72	138	0.68	208	0.69	280	0.77
059	0.72	139	0.68	209	0.69	281	0.77
060	0.82	140	0.57	210	0.54	282	0.81
061	0.77	141	0.57	211	0.54	283	0.74

TABLE P. -- OUTPATIENT FACILITY CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE
2 of 4

ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF
062	0.82	142	0.57	212	0.53	284	0.74
063	0.82	143	0.57	214	0.54	285	0.74
064	0.86	144	0.57	215	0.50	286	0.79
065	0.87	145	0.57	216	0.50	287	0.79
066	0.87	146	0.57	217	0.50	288	0.79
067	0.86	147	0.57	218	0.50	289	0.79
068	0.93	148	0.57	219	0.54	290	0.88
069	0.93	149	0.57	220	0.93	291	0.88
070	1.03	150	0.95	221	0.93	292	0.77
293	0.98	368	0.99	442	0.84	512	0.76
294	0.91	369	0.99	443	0.84	513	0.76
295	0.91	370	0.85	444	0.86	514	0.76
296	0.86	371	0.85	445	0.86	515	0.76
297	0.98	372	0.89	446	0.78	516	0.76
298	0.99	373	0.84	447	0.64	520	0.74
299	0.99	374	0.84	448	0.81	521	0.75
300	0.85	375	0.87	449	0.77	522	0.74
301	0.88	376	0.84	450	0.81	523	0.74
302	0.88	377	0.84	451	0.81	524	0.74
303	0.88	378	0.84	452	0.80	525	0.74
304	0.82	379	0.84	453	0.81	526	0.74
305	0.79	380	0.90	454	0.95	527	0.74
306	0.79	381	0.87	455	0.81	528	0.74
307	0.79	382	0.80	456	0.81	530	0.94
308	0.79	383	0.80	457	0.78	531	0.95
309	0.79	384	0.85	458	0.74	532	1.02
310	0.82	385	0.84	459	0.80	534	0.78
311	0.88	386	0.78	460	0.78	535	0.86
312	0.82	387	0.74	461	0.78	537	0.80
313	0.89	388	0.74	462	0.75	538	0.86
314	0.89	389	0.78	463	0.83	539	0.86
315	0.82	390	0.78	464	0.83	540	0.96
316	0.82	391	0.78	465	0.85	541	0.78
317	0.76	392	0.81	466	0.85	542	0.78
318	0.76	393	0.78	467	0.79	543	0.69
319	0.76	394	0.82	468	0.79	544	0.77
320	1.23	395	0.82	469	0.80	545	0.96
321	1.11	396	0.82	470	0.80	546	0.84
322	1.16	397	0.74	471	0.80	547	0.77
323	1.13	399	0.88	472	0.80	548	0.96
324	1.13	400	0.98	473	0.78	549	0.72
325	1.13	401	0.98	474	0.80	550	0.96
326	1.12	402	0.87	475	0.77	551	1.07
327	1.16	403	0.79	476	0.77	553	1.01
328	1.28	404	0.79	477	0.77	554	1.00
329	1.31	405	0.80	478	0.80	555	1.01
330	1.36	406	0.80	479	0.80	556	0.79
331	1.21	407	0.78	480	0.94	557	0.79
332	1.21	408	0.78	481	0.97	558	0.77
333	1.47	409	0.78	482	1.01	559	0.84
334	1.21	410	0.79	483	1.03	560	0.78
335	1.29	411	0.78	484	0.88	561	0.77
336	1.31	412	0.78	485	0.88	562	0.77
337	1.29	413	0.78	486	0.81	563	0.79
338	1.17	414	0.78	487	0.81	564	0.79
339	1.27	415	0.78	488	0.83	565	0.79
341	1.57	416	0.78	489	0.83	566	0.79
342	1.20	417	0.78	490	0.78	567	0.79
344	1.04	418	0.78	491	0.78	570	0.72
346	1.20	420	0.79	492	0.78	571	0.75
347	1.16	421	0.87	493	0.71	572	0.72
349	1.40	422	0.79	494	0.71	573	0.72

TABLE P. - OUTPATIENT FACILITY CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

3 of 4

ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF
350	1.04	423	0.79	495	0.71	574	0.72
351	1.04	424	0.79	496	0.71	575	0.72
352	1.14	425	0.78	497	0.71	576	0.72
354	1.04	426	0.78	498	0.82	577	0.72
355	1.04	427	0.78	499	0.82	580	0.68
356	1.00	430	0.81	500	0.78	581	0.73
357	1.00	431	0.81	501	0.78	582	0.68
358	1.00	432	0.85	502	0.78	583	0.68
359	1.06	433	0.74	503	0.78	584	0.68
360	0.99	434	0.86	504	0.75	585	0.68
361	0.99	435	0.86	505	0.76	586	0.68
362	1.06	436	0.86	506	0.75	587	0.68
363	0.99	437	0.78	507	0.75	588	0.68
364	0.99	438	0.78	508	0.76	590	0.68
365	0.83	439	0.78	509	0.78	591	0.70
366	0.83	440	0.85	510	0.76	592	0.68
367	0.99	441	0.84	511	0.79	593	0.68
594	0.68	670	0.78	752	1.02	826	0.79
595	0.68	671	0.78	753	1.02	827	0.79
596	0.68	672	1.01	754	0.99	828	0.79
597	0.68	673	0.80	755	0.99	829	0.79
598	0.68	674	0.74	756	0.99	830	0.79
599	0.68	675	0.74	757	0.99	831	0.79
600	1.12	676	0.74	758	0.99	832	0.75
601	1.10	677	0.74	759	0.99	833	0.79
602	1.15	678	0.74	760	0.98	834	0.75
603	1.15	679	0.74	761	0.98	835	0.79
604	1.12	680	0.94	762	0.99	836	0.79
605	1.19	681	0.94	763	0.99	837	0.77
606	1.13	683	0.80	764	0.87	838	0.79
607	1.13	684	0.80	765	0.85	840	0.81
608	1.13	685	0.85	766	0.87	841	0.80
609	0.98	686	0.80	767	0.87	842	0.84
610	0.84	687	0.80	768	0.93	843	0.84
611	0.90	688	0.80	769	0.93	844	0.84
612	0.84	689	0.80	770	1.08	845	0.74
613	0.87	690	0.80	772	1.08	846	0.74
614	0.87	691	0.80	773	1.10	847	0.74
615	0.87	692	0.80	774	1.10	850	1.19
616	1.01	693	0.80	775	1.10	852	1.19
617	0.98	700	1.05	776	1.18	853	1.19
618	0.90	701	1.14	777	1.18	855	1.16
619	0.90	703	0.83	778	0.85	856	1.07
620	1.07	704	1.05	779	0.89	857	1.07
622	0.91	705	0.83	780	0.93	859	1.16
623	0.80	706	0.83	781	0.89	860	1.06
624	0.86	707	0.85	782	0.93	863	1.16
625	0.80	708	0.85	783	1.16	864	1.16
626	0.80	710	0.94	784	1.16	865	1.06
627	0.82	711	0.94	785	1.16	870	0.90
628	0.86	712	0.94	786	0.98	871	0.87
629	0.91	713	0.94	787	0.98	872	0.90
630	0.96	714	0.94	788	0.93	873	0.90
631	1.03	716	0.87	789	0.98	874	0.90
633	0.96	717	0.87	790	0.91	875	0.90
634	0.96	718	0.87	791	0.91	877	0.90
635	0.82	719	0.87	792	0.91	878	0.98
636	0.86	720	0.87	793	1.06	879	0.98
637	0.86	721	0.87	794	1.06	880	0.98
638	0.86	722	0.87	795	1.06	881	0.98
639	0.86	723	0.87	796	1.06	882	0.98
640	1.03	724	0.74	797	0.93	883	0.98

TABLE P. - OUTPATIENT FACILITY CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE

4 of 4

ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF
641	1.03	725	0.74	798	0.93	884	0.90
644	0.82	726	0.74	799	1.90	885	1.90
645	0.82	727	0.74	800	1.17	889	1.51
646	0.82	728	0.87	801	1.23	890	1.51
647	0.86	729	0.78	802	1.19	891	1.51
648	0.86	730	0.91	803	1.17	893	1.18
649	1.03	731	0.91	804	1.17	894	1.18
650	0.84	733	0.98	805	0.90	895	1.18
651	0.84	734	0.88	806	0.90	897	1.18
652	0.84	735	0.88	807	0.90	898	1.18
653	0.86	736	0.85	808	1.05	900	1.54
654	0.86	737	0.85	809	1.05	901	1.54
655	0.86	738	0.85	810	1.05	902	1.59
656	0.86	739	0.85	811	0.90	903	1.59
657	0.86	740	0.74	812	0.90	904	1.59
658	0.73	741	0.74	813	0.90	905	1.48
660	0.96	743	0.79	814	0.90	906	1.48
661	0.96	744	0.79	815	0.90	907	1.48
662	1.27	745	0.88	816	0.95	908	1.48
664	0.78	746	0.85	820	0.79	910	1.47
665	0.78	747	0.88	821	0.79	911	1.75
666	0.83	748	0.79	822	0.79	912	1.47
667	0.80	749	0.88	823	0.79	913	1.45
668	0.80	750	1.09	824	0.79	914	1.53
669	0.74	751	1.09	825	0.79	915	1.45
916	1.53	937	1.21	957	1.83	982	0.91
917	1.55	938	1.21	958	1.84	983	0.97
918	1.55	939	1.31	959	1.24	984	0.97
919	1.34	940	1.63	960	1.24	985	0.96
920	1.34	941	1.55	961	1.24	986	0.78
921	1.33	942	1.84	967	0.98	988	0.82
922	1.41	943	1.51	968	0.98	989	0.82
923	1.41	944	1.38	969	0.98	990	0.88
924	1.41	945	1.74	970	0.87	991	0.88
925	1.41	946	1.74	971	0.87	992	0.88
926	1.41	947	1.74	972	0.91	993	0.82
927	1.41	948	1.74	973	0.82	994	0.82
928	1.41	949	1.74	974	0.83	995	1.01
930	1.30	950	1.72	975	0.83	996	0.96
931	1.73	951	1.72	976	0.83	997	1.01
932	1.16	952	1.74	977	0.83	998	0.96
933	1.16	953	1.74	978	0.88	999	1.03
934	1.61	954	1.24	979	0.88		
935	1.16	955	1.24	980	0.86		
936	1.21	956	1.83	981	0.91		

TABLE Q. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE
1 of 6

ZIP Code	GAAF		ZIP Code	GAAF		ZIP Code	GAAF	
	Non-Drug	Drug		Non-Drug	Drug		Non-Drug	Drug
Nationwide Average	1.00	1.00	068	1.07	0.88	145	1.02	0.97
002	1.05	0.61	069	1.07	0.88	146	1.02	0.97
005	1.08	0.80	070	0.91	1.00	147	0.93	0.69
006	1.12	0.57	071	1.13	1.22	148	1.02	0.97
007	1.12	0.57	072	0.91	1.00	149	1.02	0.97
008	1.12	0.57	073	1.13	1.22	150	0.97	0.66
009	1.12	0.57	074	0.99	0.85	151	0.97	0.66
010	0.86	0.72	075	0.99	0.85	152	1.13	0.60
011	0.86	0.72	076	0.99	0.85	153	1.01	0.87
012	0.97	1.02	077	0.97	0.84	154	1.01	0.87
013	1.16	1.16	078	1.00	0.77	155	0.95	0.81
014	1.16	1.16	079	1.00	0.77	156	1.00	0.89
015	1.09	1.08	080	1.15	1.04	157	1.00	0.99
016	0.97	0.96	081	1.15	1.04	158	1.05	1.09
017	0.97	0.89	082	1.15	1.04	159	0.95	0.81
018	0.91	0.76	083	1.15	1.04	160	1.00	0.89
019	0.91	0.76	084	1.15	1.04	161	1.00	0.89
020	0.94	0.88	085	0.97	0.84	162	1.00	0.89
021	1.04	1.19	086	0.97	0.84	163	1.05	1.09
022	0.97	0.95	087	1.11	1.00	164	1.04	0.72
023	0.94	0.88	088	1.01	0.94	165	1.04	0.72
024	1.04	1.19	089	0.91	0.76	166	0.97	1.06
025	0.88	0.89	090	1.23	0.75	167	1.05	1.09
026	0.88	0.89	101	1.23	0.75	168	1.00	0.99
027	0.94	0.88	102	1.23	0.75	169	0.79	0.98
028	0.85	1.21	103	1.14	0.69	170	0.93	0.74
029	0.85	1.21	104	1.14	0.69	171	0.93	0.74
030	0.69	1.02	105	1.02	0.91	172	0.97	0.94
031	0.69	1.02	106	1.20	1.15	173	0.97	0.94
032	1.17	0.82	107	1.02	0.91	174	0.97	0.94
033	1.17	0.82	108	1.02	0.91	175	0.97	0.94
034	1.17	0.82	109	0.91	0.88	176	1.00	1.05
035	1.17	0.82	110	1.14	0.69	177	0.79	0.98
036	1.17	0.82	111	1.14	0.69	178	0.79	0.98
037	1.17	0.82	112	1.08	0.97	179	0.96	0.77
038	1.05	0.61	113	1.08	0.97	180	1.06	0.99
039	0.96	0.90	114	1.08	0.97	181	1.06	0.99
040	1.03	0.69	115	1.08	0.80	182	1.01	1.15
041	1.03	0.82	116	1.08	0.80	183	1.15	0.83
042	1.03	0.69	117	1.08	0.80	184	1.01	1.15
043	0.96	0.90	118	1.08	0.80	185	1.01	1.15
044	0.89	0.55	119	1.08	0.80	186	1.01	1.15
045	0.89	0.55	120	1.08	1.02	187	1.01	1.15
046	0.89	0.55	121	1.08	1.02	188	1.01	1.15
047	0.96	0.90	122	1.08	1.02	189	1.09	0.92
048	0.89	0.55	123	1.08	1.02	190	0.97	0.69
049	0.96	0.90	124	1.08	1.02	191	0.74	0.93
050	1.07	0.77	125	0.80	0.51	192	0.74	0.93
051	1.07	0.77	126	0.80	0.51	193	1.09	0.92
052	1.07	0.77	127	0.80	0.51	194	1.09	0.92
053	1.07	0.77	128	0.91	0.95	195	0.96	0.77
054	1.14	0.72	129	0.91	0.95	196	0.96	0.77
055	1.14	0.72	130	0.99	1.17	197	0.84	0.82
056	1.07	0.77	131	0.99	1.17	198	0.84	0.82
057	1.07	0.77	132	0.99	1.17	199	1.01	0.73
058	1.07	0.77	133	0.98	1.16	200	1.07	1.22
059	1.07	0.77	134	0.98	1.16	201	1.13	0.65
060	0.92	0.60	135	0.98	1.16	202	1.07	1.22
			136	0.98	1.16	203	1.07	1.22
			137	1.08	1.12	204	1.07	1.22

TABLE Q. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

2 of 6

ZIP Code	GAAF		ZIP Code	GAAF		ZIP Code	GAAF	
	Non-Drug	Drug		Non-Drug	Drug		Non-Drug	Drug
061	0.81	0.74	138	1.08	1.12	205	1.07	1.22
062	0.92	0.60	139	1.08	1.12	206	1.03	0.82
063	0.92	0.60	140	0.93	0.69	207	1.02	0.85
064	1.02	0.68	141	0.93	0.69	208	0.90	0.73
065	1.04	0.60	142	0.93	0.69	209	0.90	0.73
066	1.04	0.60	143	0.93	0.69	210	0.92	0.64
067	1.02	0.68	144	1.02	0.97	211	0.92	0.64
212	1.05	1.01	281	1.05	1.02	352	0.99	1.02
214	0.92	0.64	282	1.10	1.06	354	0.83	1.39
215	0.96	0.92	283	1.09	0.96	355	0.83	1.39
216	0.82	0.66	284	1.09	0.96	356	0.88	0.75
217	0.96	0.92	285	1.09	0.96	357	0.88	0.75
218	0.82	0.66	286	0.99	1.08	358	0.88	0.75
219	0.92	0.64	287	0.99	1.08	359	0.98	1.24
220	1.13	0.65	288	0.99	1.08	360	1.05	0.78
221	1.13	0.65	289	0.99	1.08	361	1.05	0.78
222	1.07	0.94	290	1.09	1.02	362	0.98	1.24
223	1.07	0.94	291	1.09	1.02	363	1.05	0.78
224	0.97	1.11	292	1.10	1.18	364	1.05	0.78
225	0.97	1.11	293	0.96	1.48	365	0.79	1.03
226	0.90	0.93	294	1.01	1.00	366	0.79	1.03
227	0.90	0.93	295	1.01	1.00	367	1.05	0.78
228	0.90	0.93	296	1.06	1.01	368	1.05	0.78
229	0.90	0.93	297	0.96	1.48	369	1.05	0.78
230	0.97	1.11	298	0.94	1.05	370	1.00	1.03
231	0.97	1.11	299	0.94	1.05	371	1.00	1.03
232	0.97	1.11	300	0.99	1.12	372	0.93	0.85
233	1.08	1.01	301	1.06	1.12	373	1.01	1.27
234	1.08	1.01	302	1.06	1.12	374	1.01	1.27
235	1.08	1.01	303	1.06	1.12	375	1.01	1.27
236	1.08	1.01	304	0.99	1.24	376	1.01	1.27
237	1.08	1.01	305	0.92	1.14	377	1.01	1.27
238	0.97	1.11	306	0.92	1.14	378	1.01	1.27
239	0.97	0.64	307	0.92	1.14	379	1.08	0.95
240	1.11	1.00	308	0.92	1.14	380	0.92	1.14
241	1.11	1.00	309	0.92	1.14	381	0.97	1.05
242	1.11	1.00	310	0.99	1.12	382	0.90	1.07
243	1.11	1.00	311	1.06	1.12	383	0.90	1.07
244	0.90	0.93	312	0.99	1.12	384	1.00	1.03
245	0.97	0.64	313	1.02	0.87	385	1.01	1.27
246	1.11	1.00	314	1.02	0.87	386	0.99	1.33
247	1.04	0.92	315	0.99	1.24	387	0.96	0.79
248	1.04	0.92	316	0.99	1.24	388	0.96	0.79
249	1.04	0.92	317	1.11	1.12	389	1.10	1.21
250	1.04	0.92	318	1.11	1.12	390	1.10	1.21
251	1.04	0.92	319	1.11	1.12	391	1.10	1.21
252	1.04	0.92	320	0.87	1.11	392	1.04	0.85
253	1.04	0.92	321	0.95	1.38	393	1.10	1.21
254	0.92	0.82	322	0.96	1.01	394	1.01	1.06
255	1.04	0.92	323	0.89	1.05	395	1.01	1.06
256	1.04	0.92	324	0.89	1.05	396	1.01	1.06
257	1.04	0.92	325	0.89	1.05	397	0.96	0.79
258	1.04	0.92	326	0.94	0.71	399	1.11	1.12
259	1.04	0.92	327	0.99	1.33	400	0.91	0.78
260	1.00	1.10	328	1.03	1.41	401	0.91	0.78
261	0.92	0.82	329	1.02	1.00	402	0.91	1.05
262	0.92	0.82	330	1.16	1.38	403	0.92	0.99
263	0.92	0.82	331	1.07	1.11	404	0.92	0.99
264	0.92	0.82	332	1.07	1.11	405	1.08	0.94
265	1.00	1.10	333	1.09	1.11	406	1.08	0.94

TABLE Q. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

3 of 6								
ZIP Code	GAAF		ZIP Code	GAAF		ZIP Code	GAAF	
	Non-Drug	Drug		Non-Drug	Drug		Non-Drug	Drug
266	1.04	0.92	334	1.43	1.34	407	1.01	1.14
267	0.92	0.82	335	1.25	0.92	408	1.01	1.14
268	0.92	0.82	336	0.93	0.90	409	0.82	1.00
270	0.97	1.17	337	1.25	0.92	410	0.92	0.99
271	1.13	1.02	338	1.07	0.93	411	0.82	1.00
272	0.97	1.17	339	1.03	0.77	412	0.82	1.00
273	0.97	1.17	341	1.09	0.72	413	0.82	1.00
274	0.97	1.17	342	1.02	0.99	414	0.82	1.00
275	1.11	1.03	344	0.96	0.96	415	0.82	1.00
276	1.11	1.03	346	1.02	0.99	416	0.82	1.00
277	0.87	1.03	347	0.99	1.33	417	0.82	1.00
278	1.09	0.96	349	1.42	1.09	418	0.82	1.00
279	1.09	0.96	350	0.83	1.39	420	0.98	0.96
280	1.05	1.02	351	0.83	1.39	421	0.90	0.89
422	0.98	0.96	491	0.86	0.83	565	0.91	0.91
423	0.98	0.96	492	0.86	0.83	566	0.91	0.91
424	0.98	0.96	493	0.92	0.71	567	0.91	0.91
425	1.01	1.14	494	0.92	0.71	570	0.93	0.64
426	1.01	1.14	495	0.92	0.71	571	0.75	0.81
427	1.01	1.14	496	0.92	0.71	572	0.93	0.64
430	1.12	0.80	497	0.92	0.71	573	0.93	0.64
431	1.12	0.80	498	1.07	0.67	574	0.93	0.64
432	0.91	1.24	499	1.07	0.67	575	0.93	0.64
433	0.83	0.82	500	0.83	0.88	576	0.93	0.64
434	0.90	0.74	501	0.83	0.88	577	0.93	0.64
435	0.90	0.74	502	0.83	0.88	580	0.98	1.06
436	0.90	0.74	503	0.83	0.88	581	0.90	0.75
437	0.97	1.29	504	0.77	0.91	582	0.98	1.06
438	0.97	1.29	505	0.96	1.33	583	0.98	1.06
439	0.97	1.29	506	0.77	0.91	584	0.98	1.06
440	1.17	0.91	507	0.77	0.91	585	0.98	1.06
441	0.89	0.89	508	0.96	1.33	586	0.98	1.06
442	0.96	1.03	509	0.83	0.88	587	0.98	1.06
443	0.96	1.03	510	0.96	1.33	588	0.98	1.06
444	0.79	0.87	511	0.87	0.77	590	0.97	0.72
445	0.79	0.87	512	0.96	1.33	591	0.85	0.95
446	0.97	1.29	513	0.96	1.33	592	0.97	0.72
447	1.01	1.19	514	0.96	1.33	593	0.97	0.72
448	0.70	0.95	515	0.96	1.33	594	0.97	0.72
449	0.79	0.80	516	0.96	1.33	595	0.97	0.72
450	0.95	0.78	520	0.98	0.81	596	0.97	0.72
451	0.95	0.78	521	0.77	0.91	597	0.97	0.72
452	1.13	0.94	522	0.98	0.81	598	0.97	0.72
453	0.99	1.02	523	0.98	0.81	599	0.97	0.72
454	0.90	1.11	524	0.98	0.81	600	1.11	1.02
455	0.99	1.02	525	0.98	0.81	601	1.06	1.48
456	0.95	0.78	526	0.98	0.81	602	1.21	1.28
457	0.97	1.29	527	0.98	0.81	603	1.21	1.28
458	0.83	0.82	528	0.98	0.81	604	1.06	1.40
459	0.83	0.82	530	1.15	1.06	605	1.06	0.88
460	0.95	1.22	531	1.07	1.04	606	1.02	1.06
461	0.95	1.22	532	1.07	1.04	607	1.02	1.06
462	1.02	0.84	534	1.02	0.98	608	1.02	1.06
463	0.90	1.44	535	0.78	1.03	609	0.96	0.75
464	0.90	1.44	537	0.98	0.52	610	1.07	0.98
465	0.85	1.16	538	0.78	1.03	611	0.91	1.00
466	0.85	1.16	539	0.71	0.67	612	1.07	0.98
467	0.82	0.97	540	0.87	0.94	613	0.86	1.01
468	0.82	0.97	541	0.84	0.93	614	0.86	1.01
469	0.81	0.94	542	0.84	0.93	615	0.86	1.01

TABLE Q. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE
4 of 6

ZIP Code	GAAF		ZIP Code	GAAF		ZIP Code	GAAF	
	Non-Drug	Drug		Non-Drug	Drug		Non-Drug	Drug
470	0.97	0.98	543	0.87	0.68	616	0.84	1.14
471	0.97	0.98	544	1.10	0.92	617	1.13	1.00
472	0.97	0.98	545	0.87	0.94	618	1.02	0.96
473	0.95	1.22	546	0.94	0.85	619	1.01	1.05
474	0.97	0.98	547	1.03	0.93	620	1.07	0.96
475	1.08	0.94	548	0.87	0.94	622	0.88	0.95
476	1.08	0.94	549	0.77	0.80	623	1.01	0.85
477	1.08	0.94	550	0.85	1.00	624	0.94	1.09
478	0.97	0.98	551	1.01	1.01	625	1.01	0.85
479	0.81	0.94	553	0.99	0.68	626	1.01	0.85
480	1.11	0.90	554	0.97	1.00	627	0.98	0.63
481	1.08	0.66	555	0.99	0.68	628	0.94	1.09
482	1.05	1.22	556	0.91	0.91	629	0.88	0.95
483	0.98	0.84	557	0.91	0.91	630	0.86	0.87
484	0.99	0.77	558	0.79	0.82	631	0.95	1.03
485	0.99	0.77	559	1.11	0.67	633	0.86	0.87
486	1.03	0.93	560	0.88	0.86	634	0.86	0.87
487	1.03	0.93	561	0.92	0.67	635	1.01	1.10
488	0.84	0.90	562	0.92	0.67	636	0.90	1.16
489	0.84	0.90	563	1.08	0.74	637	0.90	1.16
490	0.86	0.83	564	1.08	0.74	638	1.03	1.06
639	1.03	1.06	720	0.93	1.00	790	1.08	1.08
640	0.99	1.07	721	0.93	1.00	791	1.08	1.08
641	0.99	1.07	722	0.93	1.00	792	1.08	1.08
644	1.01	1.10	723	0.96	1.08	793	0.97	1.11
645	1.01	1.10	724	1.14	0.92	794	0.97	1.11
646	1.01	1.10	725	1.14	0.92	795	0.97	1.11
647	1.03	1.06	726	1.14	0.92	796	0.97	1.11
648	0.99	1.09	727	1.14	0.92	797	1.03	1.11
649	0.99	1.09	728	0.96	1.08	798	1.03	1.11
650	0.96	1.10	729	1.01	1.11	799	1.24	1.10
651	0.96	1.10	730	1.06	1.17	800	0.91	0.95
652	0.96	1.10	731	1.06	1.17	801	1.13	0.76
653	1.03	1.06	733	1.06	1.17	802	0.91	1.00
654	1.03	1.06	734	1.01	1.17	803	0.91	0.95
655	1.03	1.06	735	1.01	1.17	804	0.91	0.95
656	0.99	1.09	736	0.84	1.13	805	0.88	0.94
657	0.99	1.09	737	0.84	1.13	806	0.88	0.94
658	1.25	0.86	738	0.84	1.13	807	0.88	0.94
660	0.97	1.09	739	0.84	1.13	808	0.94	0.91
661	0.97	1.09	740	1.03	1.39	809	0.94	0.91
662	1.02	1.02	741	1.03	1.39	810	0.94	0.91
664	0.82	0.70	743	0.70	1.45	811	0.91	0.94
665	0.82	0.70	744	0.70	1.45	812	0.91	0.94
666	1.03	0.64	745	1.01	1.17	813	0.91	0.94
667	0.90	1.07	746	0.84	1.13	814	0.91	0.94
668	0.90	1.07	747	1.01	1.17	815	0.91	0.94
669	1.00	1.17	748	0.70	1.45	816	0.98	1.25
670	1.05	1.17	749	1.01	1.17	820	0.95	1.04
671	1.05	1.17	750	1.12	1.06	821	0.95	1.04
672	0.79	0.93	751	1.12	1.06	822	0.95	1.04
673	0.90	1.07	752	1.14	1.06	823	0.95	1.04
674	1.00	1.17	753	1.14	1.06	824	0.95	1.04
675	1.00	1.17	754	1.03	1.00	825	0.95	1.04
676	1.00	1.17	755	1.03	1.00	826	0.95	1.04
677	1.00	1.17	756	1.03	1.00	827	0.95	1.04
678	1.00	1.17	757	1.03	1.00	828	0.95	1.04
679	1.00	1.17	758	1.03	1.00	829	0.95	1.04
680	0.93	0.86	759	1.03	1.00	830	0.95	1.04
681	0.93	0.86	760	0.85	1.11	831	0.95	1.04

TABLE Q. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

5 of 6

ZIP Code	GAAF		ZIP Code	GAAF		ZIP Code	GAAF	
	Non-Drug	Drug		Non-Drug	Drug		Non-Drug	Drug
683	0.92	0.74	761	0.85	1.11	832	0.87	0.75
684	0.92	0.74	762	0.86	1.18	833	0.84	0.79
685	0.82	0.88	763	0.86	1.18	834	0.87	0.75
686	0.92	0.74	764	1.06	1.07	835	0.84	0.79
687	0.93	0.83	765	1.01	1.01	836	0.84	0.79
688	0.92	0.74	766	1.06	1.07	837	0.60	0.68
689	0.92	0.74	767	1.06	1.07	838	0.84	0.79
690	0.92	0.74	768	1.03	1.11	840	0.84	0.89
691	0.92	0.74	769	1.03	1.11	841	0.90	0.66
692	0.92	0.74	770	1.01	1.34	842	0.84	0.75
693	0.92	0.74	772	1.01	1.34	843	0.84	0.75
700	0.93	1.07	773	1.04	1.14	844	0.84	0.75
701	1.02	1.02	774	1.04	1.14	845	1.01	0.89
703	0.94	1.10	775	1.04	1.14	846	1.01	0.89
704	0.93	1.07	776	0.89	1.05	847	1.01	0.89
705	0.94	1.10	777	0.89	1.05	850	1.18	0.95
706	0.94	1.10	778	1.01	1.01	852	0.99	0.77
707	0.83	1.09	779	1.04	1.19	853	0.99	0.77
708	0.83	1.09	780	1.00	1.08	855	1.18	1.04
710	0.98	1.13	781	1.04	1.19	856	0.96	1.03
711	0.98	1.13	782	1.00	1.08	857	0.96	1.03
712	0.98	1.13	783	1.01	0.95	859	1.18	1.04
713	0.98	1.13	784	1.01	0.95	860	0.75	1.01
714	0.98	1.13	785	1.01	0.95	863	1.18	1.04
716	0.96	1.08	786	0.91	1.10	864	1.18	1.04
717	0.96	1.08	787	0.91	1.10	865	0.75	1.01
718	0.96	1.08	788	1.03	1.11	870	0.95	1.01
719	0.96	1.08	789	0.91	1.10	871	1.02	0.97
872	0.95	1.01	918	1.18	1.18	957	1.17	0.87
873	0.95	1.01	919	0.90	0.82	958	1.06	0.92
874	0.95	1.01	920	0.90	0.82	959	0.96	0.91
875	0.95	1.01	921	1.13	0.70	960	0.96	0.91
877	0.95	1.01	922	0.99	0.90	961	0.96	0.91
878	0.97	0.97	923	0.99	0.90	967	0.93	1.30
879	0.97	0.97	924	0.99	0.90	968	0.93	1.30
880	0.97	0.97	925	0.99	0.90	969	0.93	1.30
881	0.97	0.97	926	1.12	0.98	970	1.11	0.97
882	0.97	0.97	927	1.12	0.93	971	1.11	0.97
883	0.97	0.97	928	1.12	0.98	972	0.90	0.89
884	0.95	1.01	930	0.88	0.90	973	0.94	0.56
885	1.24	1.10	931	0.94	0.66	974	0.91	0.95
889	1.12	0.97	932	1.20	1.06	975	0.91	0.95
890	1.12	0.97	933	1.20	1.06	976	0.91	0.95
891	1.12	0.97	934	0.94	0.68	977	0.91	0.95
893	1.31	0.79	935	1.20	1.06	978	0.86	0.99
894	1.31	0.79	936	0.90	0.87	979	0.86	0.99
895	1.31	0.79	937	0.90	0.87	980	1.13	0.74
897	1.31	0.79	938	0.90	0.87	981	1.01	1.07
898	1.31	0.79	939	0.93	0.92	982	0.93	0.97
900	0.93	0.80	940	1.04	0.76	983	0.98	0.77
901	0.93	0.80	941	0.88	0.96	984	0.98	0.77
902	0.95	1.03	942	1.06	0.92	985	1.14	0.65
903	0.95	1.03	943	0.92	0.90	986	1.10	0.98
904	0.95	1.03	944	1.17	0.97	988	1.01	0.76
905	1.15	0.86	945	1.10	0.91	989	1.01	0.76
906	1.15	0.86	946	1.10	0.91	990	1.00	1.01
907	1.15	0.86	947	1.10	0.91	991	1.00	1.01
908	1.15	0.86	948	1.10	0.91	992	1.00	1.01
910	0.70	0.69	949	1.10	0.91	993	1.01	0.76
911	1.05	1.04	950	0.92	0.72	994	1.01	0.76

TABLE Q. - DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE CHARGES GEOGRAPHIC AREA ADJUSTMENT
FACTORS (GAAFS) BY ZIP CODE
6 of 6

ZIP Code	GAAF	
	Non-Drug	Drug
912	0.70	0.69
913	0.96	0.77
914	1.02	0.72
915	0.96	0.77
916	1.02	0.72
917	1.18	1.18

ZIP Code	GAAF	
	Non-Drug	Drug
951	0.92	0.72
952	0.88	1.09
953	0.88	1.09
954	0.96	0.91
955	0.96	0.91
956	1.17	0.87

ZIP Code	GAAF	
	Non-Drug	Drug
995	0.79	0.92
996	1.07	0.90
997	0.79	0.92
998	1.07	0.90
999	1.19	1.04

TABLE R. - OUTPATIENT DENTAL PROFESSIONAL CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE
1 of 5

ZIP Code	GAAF			ZIP Code	GAAF			ZIP Code	GAAF		
	Class I	Class II	Class III		Class I	Class II	Class III		Class I	Class II	Class III
Nationwide Average	1.00	1.00	1.00	069	1.19	1.24	1.30	147	0.85	0.85	0.96
002	1.04	1.10	1.17	070	1.20	1.19	1.19	148	0.81	0.84	0.97
005	1.28	1.14	1.16	071	1.19	1.11	1.14	149	0.81	0.84	0.97
006	0.73	0.56	0.74	072	1.20	1.19	1.19	150	0.84	0.81	0.87
007	0.73	0.56	0.74	073	1.19	1.11	1.14	151	0.84	0.81	0.87
008	0.73	0.56	0.74	074	1.19	1.20	1.20	152	0.84	0.81	0.87
009	0.73	0.56	0.74	075	1.19	1.20	1.20	153	0.82	0.81	0.88
010	0.99	1.04	1.10	076	1.19	1.20	1.20	154	0.82	0.81	0.88
011	0.99	1.04	1.10	077	1.11	1.14	1.12	155	0.72	0.72	0.78
012	0.86	0.94	1.01	078	1.19	1.20	1.19	156	0.82	0.80	0.87
013	1.06	1.11	1.16	079	1.19	1.20	1.19	157	0.86	0.84	0.94
014	1.06	1.11	1.16	080	1.03	1.04	1.05	158	0.81	0.80	0.87
015	1.08	1.10	1.20	081	1.03	1.04	1.05	159	0.72	0.72	0.78
016	1.12	1.16	1.20	082	1.03	1.04	1.05	160	0.82	0.80	0.87
017	1.12	1.16	1.26	083	1.03	1.04	1.05	161	0.82	0.80	0.87
018	1.12	1.14	1.22	084	1.03	1.04	1.05	162	0.82	0.80	0.87
019	1.12	1.14	1.22	085	1.11	1.14	1.12	163	0.81	0.80	0.87
020	1.09	1.12	1.20	086	1.11	1.14	1.12	164	0.81	0.82	0.87
021	1.17	1.17	1.31	087	1.09	1.10	1.09	165	0.81	0.82	0.87
022	1.15	1.17	1.45	088	1.19	1.18	1.17	166	0.79	0.75	0.85
023	1.09	1.12	1.20	089	1.19	1.19	1.16	167	0.81	0.80	0.87
024	1.17	1.17	1.31	100	1.64	1.46	1.46	168	0.86	0.84	0.94
025	1.11	1.14	1.21	101	1.64	1.46	1.46	169	0.83	0.82	0.89
026	1.11	1.14	1.21	102	1.64	1.46	1.46	170	0.86	0.84	0.89
027	1.09	1.12	1.20	103	1.40	1.18	1.20	171	0.86	0.84	0.89
028	1.06	0.97	1.06	104	1.40	1.18	1.20	172	0.86	0.86	0.92
029	1.06	0.97	1.06	105	1.38	1.22	1.26	173	0.86	0.86	0.92
030	1.06	1.14	1.18	106	1.41	1.31	1.34	174	0.86	0.86	0.92
031	1.06	1.14	1.18	107	1.38	1.22	1.26	175	0.86	0.86	0.92
032	1.02	1.08	1.15	108	1.38	1.22	1.26	176	0.85	0.87	0.94
033	1.02	1.08	1.15	109	1.29	1.18	1.21	177	0.83	0.82	0.89
034	1.02	1.08	1.15	110	1.40	1.18	1.20	178	0.83	0.82	0.89
035	1.02	1.08	1.15	111	1.40	1.18	1.20	179	0.87	0.86	0.93
036	1.02	1.08	1.15	112	1.51	1.20	1.21	180	0.92	0.93	0.96
037	1.02	1.08	1.15	113	1.51	1.20	1.21	181	0.92	0.93	0.96
038	1.04	1.10	1.17	114	1.51	1.20	1.21	182	0.86	0.86	0.93
039	0.92	0.97	1.06	115	1.28	1.14	1.16	183	0.99	0.94	1.01
040	0.96	1.07	1.11	116	1.28	1.14	1.16	184	0.86	0.86	0.93
041	0.96	1.11	1.16	117	1.28	1.14	1.16	185	0.86	0.86	0.93
042	0.96	1.07	1.11	118	1.28	1.14	1.16	186	0.86	0.86	0.93
043	0.92	0.97	1.06	119	1.28	1.14	1.16	187	0.86	0.86	0.93
044	0.92	1.00	1.04	120	0.94	0.95	0.99	188	0.86	0.86	0.93
045	0.92	1.00	1.04	121	0.94	0.95	0.99	189	1.04	1.03	1.06
046	0.92	1.00	1.04	122	0.94	0.95	0.99	190	1.05	1.03	1.07
047	0.92	0.97	1.06	123	0.94	0.95	0.99	191	1.08	1.01	1.05
048	0.92	1.00	1.04	124	0.94	0.95	0.99	192	1.08	1.01	1.05
049	0.92	0.97	1.06	125	0.95	0.93	0.99	193	1.04	1.03	1.06
050	0.89	0.97	1.01	126	0.95	0.93	0.99	194	1.04	1.03	1.06
051	0.89	0.97	1.01	127	0.95	0.93	0.99	195	0.87	0.86	0.93
052	0.89	0.97	1.01	128	0.93	0.92	0.98	196	0.87	0.86	0.93
053	0.89	0.97	1.01	129	0.93	0.92	0.98	197	1.16	1.15	1.21
054	0.90	1.01	1.02	130	0.87	0.93	0.97	198	1.16	1.15	1.21
055	1.12	1.14	1.22	131	0.87	0.93	0.97	199	0.94	0.95	1.02
056	0.89	0.97	1.01	132	0.87	0.93	0.97	200	1.16	1.23	1.25
057	0.89	0.97	1.01	133	0.81	0.86	0.91	201	1.09	1.14	1.12
058	0.89	0.97	1.01	134	0.81	0.86	0.91	202	1.16	1.23	1.25
059	0.89	0.97	1.01	135	0.81	0.86	0.91	203	1.16	1.23	1.25
060	1.12	1.13	1.15	136	0.81	0.86	0.91	204	1.16	1.23	1.25
061	1.14	1.13	1.16	137	0.82	0.86	0.95	205	1.16	1.23	1.25
062	1.12	1.13	1.15	138	0.82	0.86	0.95	206	1.05	1.07	1.07
063	1.12	1.13	1.15	139	0.82	0.86	0.95	207	1.09	1.10	1.10
				140	0.85	0.85	0.96	208	1.11	1.14	1.13
				141	0.85	0.85	0.96	209	1.11	1.14	1.13

TABLE R. -- OUTPATIENT DENTAL PROFESSIONAL CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE
2 of 5

ZIP Code	GAAF			ZIP Code	GAAF			ZIP Code	GAAF		
	Class I	Class II	Class III		Class I	Class II	Class III		Class I	Class II	Class III
064	1.13	1.13	1.16	142	0.85	0.85	0.96	210	1.02	1.02	1.06
065	1.17	1.15	1.22	143	0.85	0.85	0.96	211	1.02	1.02	1.06
066	1.17	1.15	1.22	144	0.81	0.84	0.97	212	1.02	0.98	1.04
067	1.13	1.13	1.16	145	0.81	0.84	0.97	214	1.02	1.02	1.06
068	1.19	1.24	1.30	146	0.81	0.84	0.97	215	0.91	0.92	0.96
216	0.97	1.00	0.99	285	0.89	0.92	0.92	358	0.83	0.83	0.82
217	0.91	0.92	0.96	286	0.87	0.96	0.95	359	0.72	0.75	0.75
218	0.97	1.00	0.99	287	0.87	0.96	0.95	360	0.71	0.77	0.77
219	1.02	1.02	1.06	288	0.87	0.96	0.95	361	0.71	0.77	0.77
220	1.09	1.14	1.12	289	0.87	0.96	0.95	362	0.72	0.75	0.75
221	1.09	1.14	1.12	290	0.83	0.91	0.96	363	0.71	0.77	0.77
222	1.11	1.16	1.14	291	0.83	0.91	0.96	364	0.71	0.77	0.77
223	1.11	1.16	1.14	292	0.85	0.95	0.98	365	0.77	0.86	0.86
224	0.99	0.99	1.03	293	0.85	0.89	0.93	366	0.77	0.86	0.86
225	0.99	0.99	1.03	294	0.86	0.90	0.95	367	0.71	0.77	0.77
226	0.97	1.01	1.03	295	0.86	0.90	0.95	368	0.71	0.77	0.77
227	0.97	1.01	1.03	296	0.86	0.88	0.96	369	0.71	0.77	0.77
228	0.97	1.01	1.03	297	0.85	0.89	0.93	370	0.84	0.86	0.89
229	0.97	1.01	1.03	298	0.85	0.91	0.94	371	0.84	0.86	0.89
230	0.99	0.99	1.03	299	0.85	0.91	0.94	372	0.90	0.94	0.95
231	0.99	0.99	1.03	300	0.98	1.06	1.06	373	0.80	0.85	0.85
232	0.99	0.99	1.03	301	0.96	1.03	1.03	374	0.80	0.85	0.85
233	0.94	0.95	0.98	302	0.96	1.03	1.03	375	0.86	0.86	0.91
234	0.94	0.95	0.98	303	1.01	1.11	1.12	376	0.80	0.85	0.85
235	0.94	0.95	0.98	304	0.89	0.95	0.98	377	0.80	0.85	0.85
236	0.94	0.95	0.98	305	0.88	0.98	0.97	378	0.80	0.85	0.85
237	0.94	0.95	0.98	306	0.88	0.98	0.97	379	0.82	0.86	0.87
238	0.99	0.99	1.03	307	0.88	0.98	0.97	380	0.85	0.86	0.90
239	0.88	0.89	0.93	308	0.88	0.98	0.97	381	0.86	0.86	0.91
240	0.81	0.82	0.86	309	0.88	0.98	0.97	382	0.80	0.81	0.82
241	0.81	0.82	0.86	310	0.82	0.91	0.91	383	0.80	0.81	0.82
242	0.81	0.82	0.86	311	1.01	1.11	1.12	384	0.84	0.86	0.89
243	0.81	0.82	0.86	312	0.82	0.91	0.91	385	0.80	0.85	0.85
244	0.97	1.01	1.03	313	0.87	0.91	0.99	386	0.83	0.81	0.84
245	0.88	0.89	0.93	314	0.87	0.91	0.99	387	0.80	0.82	0.82
246	0.81	0.82	0.86	315	0.89	0.95	0.98	388	0.80	0.82	0.82
247	0.79	0.77	0.85	316	0.89	0.95	0.98	389	0.81	0.81	0.85
248	0.79	0.77	0.85	317	0.81	0.89	0.93	390	0.81	0.81	0.85
249	0.79	0.77	0.85	318	0.81	0.89	0.93	391	0.81	0.81	0.85
250	0.79	0.77	0.85	319	0.81	0.89	0.93	392	0.83	0.86	0.87
251	0.79	0.77	0.85	320	0.90	0.94	0.96	393	0.81	0.81	0.85
252	0.79	0.77	0.85	321	0.81	0.89	0.91	394	0.82	0.82	0.83
253	0.79	0.77	0.85	322	0.90	0.96	0.97	395	0.82	0.82	0.83
254	0.93	0.93	0.97	323	0.82	0.90	0.91	396	0.82	0.82	0.83
255	0.79	0.77	0.85	324	0.82	0.90	0.91	397	0.80	0.82	0.82
256	0.79	0.77	0.85	325	0.82	0.90	0.91	399	1.01	1.11	1.12
257	0.79	0.77	0.85	326	0.85	0.98	0.99	400	0.80	0.79	0.84
258	0.79	0.77	0.85	327	0.86	0.92	0.93	401	0.80	0.79	0.84
259	0.79	0.77	0.85	328	0.89	0.93	0.95	402	0.82	0.84	0.87
260	0.75	0.76	0.83	329	0.92	1.01	0.98	403	0.82	0.80	0.86
261	0.93	0.93	0.97	330	1.14	1.14	1.05	404	0.82	0.80	0.86
262	0.93	0.93	0.97	331	1.38	1.32	1.18	405	0.82	0.84	0.88
263	0.93	0.93	0.97	332	1.38	1.32	1.18	406	0.82	0.84	0.88
264	0.93	0.93	0.97	333	1.14	1.16	1.04	407	0.77	0.75	0.79
265	0.75	0.76	0.83	334	0.99	1.08	1.08	408	0.77	0.75	0.79
266	0.79	0.77	0.85	335	0.88	0.98	0.95	409	0.77	0.75	0.79
267	0.93	0.93	0.97	336	0.89	1.00	0.95	410	0.82	0.80	0.86
268	0.93	0.93	0.97	337	0.88	0.98	0.95	411	0.77	0.75	0.79
270	0.90	0.97	0.96	338	0.86	0.91	0.92	412	0.77	0.75	0.79
271	0.93	0.99	0.95	339	0.90	1.00	0.98	413	0.77	0.75	0.79
272	0.90	0.97	0.96	341	0.98	1.08	1.06	414	0.77	0.75	0.79
273	0.90	0.97	0.96	342	0.87	0.98	0.94	415	0.77	0.75	0.79
274	0.90	0.97	0.96	344	0.77	0.88	0.87	416	0.77	0.75	0.79

TABLE R. - OUTPATIENT DENTAL PROFESSIONAL CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE
3 of 5

ZIP Code	GAAF			ZIP Code	GAAF			ZIP Code	GAAF		
	Class I	Class II	Class III		Class I	Class II	Class III		Class I	Class II	Class III
275	0.97	1.01	1.00	346	0.87	0.98	0.94	417	0.77	0.75	0.79
276	0.97	1.01	1.00	347	0.86	0.92	0.93	418	0.77	0.75	0.79
277	0.97	1.02	1.00	349	0.90	1.01	0.98	420	0.78	0.79	0.84
278	0.89	0.92	0.92	350	0.76	0.78	0.77	421	0.80	0.78	0.82
279	0.89	0.92	0.92	351	0.76	0.78	0.77	422	0.78	0.79	0.84
280	0.95	0.98	0.97	352	0.78	0.82	0.80	423	0.78	0.79	0.84
281	0.95	0.98	0.97	354	0.76	0.78	0.77	424	0.78	0.79	0.84
282	0.98	1.03	1.03	355	0.76	0.78	0.77	425	0.77	0.75	0.79
283	0.89	0.92	0.92	356	0.83	0.83	0.82	426	0.77	0.75	0.79
284	0.89	0.92	0.92	357	0.83	0.83	0.82	427	0.77	0.75	0.79
430	0.90	0.95	0.98	498	0.93	0.88	0.92	575	0.85	0.81	0.82
431	0.90	0.95	0.98	499	0.93	0.88	0.92	576	0.85	0.81	0.82
432	0.91	0.97	0.99	500	0.86	0.87	0.88	577	0.85	0.81	0.82
433	0.81	0.86	0.91	501	0.86	0.87	0.88	580	0.84	0.81	0.86
434	0.86	0.89	0.95	502	0.86	0.87	0.88	581	0.88	0.86	0.90
435	0.86	0.89	0.95	503	0.86	0.87	0.88	582	0.84	0.81	0.86
436	0.86	0.89	0.95	504	0.77	0.78	0.80	583	0.84	0.81	0.86
437	0.83	0.85	0.90	505	0.76	0.78	0.81	584	0.84	0.81	0.86
438	0.83	0.85	0.90	506	0.77	0.78	0.80	585	0.84	0.81	0.86
439	0.83	0.85	0.90	507	0.77	0.78	0.80	586	0.84	0.81	0.86
440	0.91	0.94	0.98	508	0.76	0.78	0.81	587	0.84	0.81	0.86
441	0.93	0.97	1.01	509	0.86	0.87	0.88	588	0.84	0.81	0.86
442	0.88	0.92	0.98	510	0.76	0.78	0.81	590	0.90	0.90	0.91
443	0.88	0.92	0.98	511	0.84	0.86	0.87	591	0.92	0.95	0.96
444	0.83	0.83	0.89	512	0.76	0.78	0.81	592	0.90	0.90	0.91
445	0.83	0.83	0.89	513	0.76	0.78	0.81	593	0.90	0.90	0.91
446	0.83	0.85	0.90	514	0.76	0.78	0.81	594	0.90	0.90	0.91
447	0.84	0.88	0.93	515	0.76	0.78	0.81	595	0.90	0.90	0.91
448	0.78	0.83	0.88	516	0.76	0.78	0.81	596	0.90	0.90	0.91
449	0.80	0.84	0.91	520	0.79	0.80	0.83	597	0.90	0.90	0.91
450	0.85	0.88	0.92	521	0.77	0.78	0.80	598	0.90	0.90	0.91
451	0.85	0.88	0.92	522	0.79	0.80	0.83	599	0.90	0.90	0.91
452	0.87	0.91	0.95	523	0.79	0.80	0.83	600	1.03	1.07	1.07
453	0.82	0.84	0.91	524	0.79	0.80	0.83	601	1.01	1.04	1.05
454	0.84	0.88	0.92	525	0.79	0.80	0.83	602	1.05	1.09	1.07
455	0.82	0.84	0.91	526	0.79	0.80	0.83	603	1.05	1.09	1.07
456	0.85	0.88	0.92	527	0.79	0.80	0.83	604	1.00	1.01	1.03
457	0.83	0.85	0.90	528	0.79	0.80	0.83	605	1.02	1.04	1.05
458	0.81	0.86	0.91	530	0.91	0.92	0.95	606	1.08	1.07	1.09
459	0.87	0.91	0.95	531	0.92	0.93	0.94	607	1.08	1.07	1.09
460	0.86	0.91	0.92	532	0.92	0.92	0.95	608	1.08	1.07	1.09
461	0.86	0.91	0.92	534	0.92	0.97	0.95	609	0.99	1.01	1.05
462	0.87	0.93	0.94	535	0.83	0.85	0.89	610	0.86	0.88	0.92
463	0.92	0.94	0.97	537	0.93	0.97	0.96	611	0.89	0.94	0.97
464	0.92	0.94	0.97	538	0.83	0.85	0.89	612	0.86	0.88	0.92
465	0.83	0.89	0.91	539	0.89	0.92	0.92	613	0.89	0.91	0.94
466	0.83	0.89	0.91	540	0.92	0.93	0.95	614	0.89	0.91	0.94
467	0.78	0.84	0.87	541	0.86	0.89	0.93	615	0.89	0.91	0.94
468	0.78	0.84	0.87	542	0.86	0.89	0.93	616	0.85	0.88	0.86
469	0.83	0.88	0.91	543	0.90	0.96	1.00	617	0.85	0.84	0.91
470	0.83	0.85	0.90	544	0.87	0.89	0.92	618	0.85	0.84	0.88
471	0.83	0.85	0.90	545	0.92	0.93	0.95	619	0.87	0.89	0.93
472	0.83	0.85	0.90	546	0.83	0.84	0.89	620	0.85	0.87	0.88
473	0.86	0.91	0.92	547	0.86	0.88	0.92	622	0.86	0.87	0.89
474	0.83	0.85	0.90	548	0.92	0.93	0.95	623	0.85	0.87	0.90
475	0.80	0.85	0.89	549	0.87	0.91	0.93	624	0.86	0.86	0.90
476	0.80	0.85	0.89	550	0.99	1.02	1.00	625	0.85	0.87	0.90
477	0.80	0.85	0.89	551	1.01	1.03	1.04	626	0.85	0.87	0.90
478	0.83	0.85	0.90	553	1.00	1.03	1.03	627	0.83	0.84	0.92
479	0.83	0.88	0.91	554	1.04	1.05	1.06	628	0.86	0.86	0.90
480	1.07	0.96	0.96	555	1.00	1.03	1.03	629	0.86	0.87	0.89
481	1.05	0.96	0.96	556	0.92	0.89	0.92	630	0.92	0.93	0.94
482	1.08	0.95	0.96	557	0.92	0.89	0.92	631	0.92	0.93	0.96

TABLE R. -- OUTPATIENT DENTAL PROFESSIONAL CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE
4 of 5

ZIP Code	GAAF			ZIP Code	GAAF			ZIP Code	GAAF		
	Class I	Class II	Class III		Class I	Class II	Class III		Class I	Class II	Class III
483	1.07	0.97	0.97	558	0.84	0.84	0.88	633	0.92	0.93	0.94
484	1.05	0.94	0.93	559	0.85	0.84	0.90	634	0.92	0.93	0.94
485	1.05	0.94	0.93	560	0.90	0.90	0.93	635	0.79	0.80	0.83
486	0.93	0.89	0.87	561	0.88	0.87	0.89	636	0.82	0.83	0.85
487	0.93	0.89	0.87	562	0.88	0.87	0.89	637	0.82	0.83	0.85
488	0.96	0.91	0.90	563	0.86	0.85	0.90	638	0.79	0.78	0.82
489	0.96	0.91	0.90	564	0.86	0.85	0.90	639	0.79	0.78	0.82
490	0.91	0.89	0.92	565	0.92	0.89	0.92	640	0.89	0.91	0.92
491	0.91	0.89	0.92	566	0.92	0.89	0.92	641	0.89	0.91	0.92
492	0.91	0.89	0.92	567	0.92	0.89	0.92	644	0.79	0.80	0.83
493	0.89	0.88	0.92	570	0.85	0.81	0.82	645	0.79	0.80	0.83
494	0.89	0.88	0.92	571	0.84	0.82	0.82	646	0.79	0.80	0.83
495	0.89	0.88	0.92	572	0.85	0.81	0.82	647	0.79	0.78	0.82
496	0.89	0.88	0.92	573	0.85	0.81	0.82	648	0.79	0.78	0.82
497	0.89	0.88	0.92	574	0.85	0.81	0.82	649	0.89	0.91	0.92
650	0.84	0.87	0.88	730	0.86	0.88	0.90	801	1.08	1.12	1.10
651	0.84	0.87	0.88	731	0.86	0.88	0.90	802	1.07	1.10	1.09
652	0.84	0.87	0.88	733	0.99	1.07	1.06	803	1.06	1.10	1.08
653	0.79	0.78	0.82	734	0.83	0.81	0.84	804	1.06	1.10	1.08
654	0.79	0.78	0.82	735	0.83	0.81	0.84	805	1.01	1.03	1.03
655	0.79	0.78	0.82	736	0.83	0.83	0.86	806	1.01	1.03	1.03
656	0.79	0.78	0.82	737	0.83	0.83	0.86	807	1.01	1.03	1.03
657	0.79	0.78	0.82	738	0.83	0.83	0.86	808	1.02	1.07	1.04
658	0.82	0.83	0.86	739	0.83	0.83	0.86	809	1.02	1.07	1.04
660	0.88	0.90	0.90	740	0.86	0.88	0.90	810	1.02	1.07	1.04
661	0.88	0.90	0.90	741	0.86	0.88	0.90	811	0.97	0.99	0.99
662	0.92	0.95	0.96	743	0.81	0.79	0.82	812	0.97	0.99	0.99
664	0.82	0.83	0.84	744	0.81	0.79	0.82	813	0.97	0.99	0.99
665	0.82	0.83	0.84	745	0.83	0.81	0.84	814	0.97	0.99	0.99
666	0.89	0.89	0.90	746	0.83	0.83	0.86	815	0.97	0.99	0.99
667	0.83	0.82	0.84	747	0.83	0.81	0.84	816	1.05	1.14	1.11
668	0.83	0.82	0.84	748	0.81	0.79	0.82	820	0.82	0.79	0.81
669	0.83	0.82	0.85	749	0.83	0.81	0.84	821	0.82	0.79	0.81
670	0.88	0.84	0.87	750	0.98	1.08	1.06	822	0.82	0.79	0.81
671	0.88	0.84	0.87	751	0.98	1.08	1.06	823	0.82	0.79	0.81
672	0.89	0.90	0.90	752	0.99	1.08	1.09	824	0.82	0.79	0.81
673	0.83	0.82	0.84	753	0.99	1.08	1.09	825	0.82	0.79	0.81
674	0.83	0.82	0.85	754	0.88	0.95	0.97	826	0.82	0.79	0.81
675	0.83	0.82	0.85	755	0.88	0.95	0.97	827	0.82	0.79	0.81
676	0.83	0.82	0.85	756	0.88	0.95	0.97	828	0.82	0.79	0.81
677	0.83	0.82	0.85	757	0.88	0.95	0.97	829	0.82	0.79	0.81
678	0.83	0.82	0.85	758	0.88	0.95	0.97	830	0.82	0.79	0.81
679	0.83	0.82	0.85	759	0.88	0.95	0.97	831	0.82	0.79	0.81
680	0.81	0.85	0.85	760	0.92	1.01	0.99	832	0.87	0.82	0.84
681	0.81	0.85	0.85	761	0.92	1.01	0.99	833	0.93	0.89	0.88
683	0.74	0.79	0.80	762	0.93	1.00	1.00	834	0.87	0.82	0.84
684	0.74	0.79	0.80	763	0.93	1.00	1.00	835	0.93	0.89	0.88
685	0.75	0.81	0.86	764	0.87	0.94	0.96	836	0.93	0.89	0.88
686	0.74	0.79	0.80	765	0.80	0.85	0.87	837	0.95	0.93	0.92
687	0.74	0.79	0.80	766	0.87	0.94	0.96	838	0.93	0.89	0.88
688	0.74	0.79	0.80	767	0.87	0.94	0.96	840	0.81	0.78	0.81
689	0.74	0.79	0.80	768	0.87	0.92	0.94	841	0.84	0.82	0.84
690	0.74	0.79	0.80	769	0.87	0.92	0.94	842	0.80	0.78	0.79
691	0.74	0.79	0.80	770	0.97	1.04	1.04	843	0.80	0.78	0.79
692	0.74	0.79	0.80	772	0.97	1.04	1.04	844	0.80	0.78	0.79

TABLE R. - OUTPATIENT DENTAL PROFESSIONAL CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFs) BY ZIP CODE
5 of 5

ZIP Code	GAAF			ZIP Code	GAAF			ZIP Code	GAAF		
	Class I	Class II	Class III		Class I	Class II	Class III		Class I	Class II	Class III
693	0.74	0.79	0.80	773	0.93	1.02	1.02	845	0.80	0.77	0.81
700	0.80	0.90	0.90	774	0.93	1.02	1.02	846	0.80	0.77	0.81
701	0.83	0.90	0.92	775	0.93	1.02	1.02	847	0.80	0.77	0.81
703	0.77	0.85	0.89	776	0.81	0.85	0.86	850	1.03	1.04	1.01
704	0.80	0.90	0.90	777	0.81	0.85	0.86	852	1.03	1.04	1.01
705	0.77	0.85	0.89	778	0.80	0.85	0.87	853	1.03	1.04	1.01
706	0.77	0.85	0.89	779	0.79	0.87	0.89	855	0.96	0.97	0.97
707	0.80	0.89	0.91	780	0.87	0.91	0.92	856	1.00	1.03	1.00
708	0.80	0.89	0.91	781	0.79	0.87	0.89	857	1.00	1.03	1.00
710	0.79	0.85	0.87	782	0.87	0.91	0.92	859	0.96	0.97	0.97
711	0.79	0.85	0.87	783	0.82	0.89	0.88	860	1.00	0.98	1.01
712	0.79	0.85	0.87	784	0.82	0.89	0.88	863	0.96	0.97	0.97
713	0.79	0.85	0.87	785	0.82	0.89	0.88	864	0.96	0.97	0.97
714	0.79	0.85	0.87	786	0.99	1.07	1.06	865	1.00	0.98	1.01
716	0.76	0.76	0.79	787	0.99	1.07	1.06	870	0.98	0.98	0.99
717	0.76	0.76	0.79	788	0.87	0.92	0.94	871	0.99	1.00	1.00
718	0.76	0.76	0.79	789	0.99	1.07	1.06	872	0.98	0.98	0.99
719	0.76	0.76	0.79	790	0.89	0.93	0.94	873	0.98	0.98	0.99
720	0.84	0.84	0.83	791	0.89	0.93	0.94	874	0.98	0.98	0.99
721	0.84	0.84	0.83	792	0.89	0.93	0.94	875	0.98	0.98	0.99
722	0.84	0.84	0.83	793	0.86	0.93	0.94	877	0.98	0.98	0.99
723	0.76	0.76	0.79	794	0.86	0.93	0.94	878	0.92	0.90	0.93
724	0.84	0.84	0.84	795	0.86	0.93	0.94	879	0.92	0.90	0.93
725	0.84	0.84	0.84	796	0.86	0.93	0.94	880	0.92	0.90	0.93
726	0.84	0.84	0.84	797	0.87	0.92	0.94	881	0.92	0.90	0.93
727	0.84	0.84	0.84	798	0.87	0.92	0.94	882	0.92	0.90	0.93
728	0.76	0.76	0.79	799	0.91	0.93	0.89	883	0.92	0.90	0.93
729	0.84	0.81	0.84	800	1.06	1.10	1.08	884	0.98	0.98	0.99
885	0.91	0.93	0.89	926	1.26	1.22	1.10	961	1.11	1.17	1.03
889	1.12	1.09	1.03	927	1.26	1.22	1.10	967	1.16	1.03	1.00
890	1.12	1.09	1.03	928	1.26	1.22	1.10	968	1.16	1.03	1.00
891	1.12	1.09	1.03	930	1.18	1.14	1.05	969	1.16	1.03	1.00
893	1.12	1.16	1.05	931	1.21	1.32	1.15	970	1.16	1.05	0.99
894	1.12	1.16	1.05	932	1.12	1.07	0.97	971	1.16	1.05	0.99
895	1.12	1.16	1.05	933	1.12	1.07	0.97	972	1.16	1.04	0.98
897	1.12	1.16	1.05	934	1.09	1.10	0.99	973	1.09	0.99	0.96
898	1.12	1.16	1.05	935	1.12	1.07	0.97	974	1.11	0.99	0.95
900	1.34	1.21	1.13	936	1.08	1.02	0.95	975	1.11	0.99	0.95
901	1.34	1.21	1.13	937	1.08	1.02	0.95	976	1.11	0.99	0.95
902	1.29	1.22	1.14	938	1.08	1.02	0.95	977	1.11	0.99	0.95
903	1.29	1.22	1.14	939	1.17	1.19	1.10	978	1.08	0.97	0.95
904	1.29	1.22	1.14	940	1.30	1.32	1.18	979	1.08	0.97	0.95
905	1.26	1.15	1.08	941	1.31	1.36	1.23	980	1.35	1.27	1.17
906	1.26	1.15	1.08	942	1.17	1.16	1.03	981	1.35	1.28	1.19
907	1.26	1.15	1.08	943	1.37	1.37	1.26	982	1.26	1.15	1.10
908	1.26	1.15	1.08	944	1.29	1.32	1.20	983	1.30	1.20	1.11
910	1.20	1.13	1.07	945	1.25	1.27	1.12	984	1.30	1.20	1.11
911	1.23	1.17	1.09	946	1.25	1.27	1.12	985	1.23	1.12	1.06
912	1.20	1.13	1.07	947	1.25	1.27	1.12	986	1.18	1.07	1.02
913	1.22	1.17	1.08	948	1.25	1.27	1.12	988	1.24	1.15	1.07
914	1.28	1.18	1.06	949	1.25	1.27	1.12	989	1.24	1.15	1.07
915	1.22	1.17	1.08	950	1.32	1.29	1.14	990	1.19	1.11	1.02
916	1.28	1.18	1.09	951	1.32	1.29	1.14	991	1.19	1.11	1.02
917	1.27	1.11	1.06	952	1.11	1.10	0.98	992	1.19	1.11	1.02
918	1.27	1.11	1.06	953	1.11	1.10	0.98	993	1.24	1.15	1.07
919	1.15	1.18	1.07	954	1.11	1.17	1.03	994	1.24	1.15	1.07
920	1.15	1.18	1.07	955	1.11	1.17	1.03	995	1.51	1.44	1.22
921	1.16	1.17	1.06	956	1.11	1.13	0.98	996	1.54	1.39	1.21
922	1.15	1.06	1.01	957	1.11	1.13	0.98	997	1.51	1.44	1.22
923	1.15	1.06	1.01	958	1.17	1.16	1.03	998	1.54	1.39	1.21
924	1.15	1.06	1.01	959	1.11	1.17	1.03	999	1.50	1.36	1.18
925	1.15	1.06	1.01	960	1.11	1.17	1.03				

TABLE S. — PROFESSIONAL SERVICES CONVERSION FACTORS

Category	Conversion Factor
Allergy Immunotherapy	\$60.13
Allergy Testing	\$76.49
Anesthesia	\$92.32
Cardiovascular	\$132.03
Chiropractor	\$67.38
Consults	\$69.90
Emergency Room Visits	\$125.13
Hearing/Speech Exams	\$80.64
Immunizations	\$86.04
Inpatient Visits	\$86.86
Maternity - Cesarean Deliveries	\$85.39
Maternity - Non-Deliveries	\$151.17
Maternity - Normal Deliveries	\$80.52
Miscellaneous Medical	\$91.25
Office/Home/Urgent Care Visits	\$62.19
OP Psych./Alc. & Drug Abuse	\$55.24
Pathology	\$113.90
Physical Exams	\$61.86
Physical Medicine	\$72.63
Radiology	\$122.69
Surgery	\$156.89
Therapeutic Injections	\$59.86
Vision Exams	\$42.40
Well Baby Exams	\$55.77
Dental - Class I	\$1.07
Dental - Class II	\$1.07
Dental - Class III	\$1.07
HCPCS - Non-Drug	\$1.07
HCPCS - Drug	\$1.07
Outpatient Facility	\$1.07

Vz06 Data Sources 2006-1-01.xls - Sorted By Charge Type

Supplementary Table 1
Reasonable Charges Data Sources - V2.6

Charge Type	Paragraph (1)	Subject	Data Source	Edition
PH	(d)(2)(ii)	Trending Forward	CPI-U, Outpatient Hospital Services Component, Seasonally Adjusted	August 2005 as of October 2005
Opt	(e)(3)(iii)	Trending Forward	CPI-U, Outpatient Hospital Services Component, Seasonally Adjusted	August 2005 as of October 2005
Opt	(e)(3)(i)	Unit Charges	CMS OPPS-APC Payment Schedule	2006
Opt	(e)(4)	GAAFs	V2.1 Federal Register Table P	May 2004
Opt	(e)(3)(i)	Unit Charges for Screening Mammograms	CMS Medicare Fee Schedule for Mammograms	2006
Phys	(f)(2)(i)(A)	RVUs, code with Medicare RVUs, Work Expense	CMS Medicare Physician Fee Schedule RVUs, work expense	2006
Phys	(f)(s)(ii)	Trending Forward	CPI-U, Physician Services Component, Seasonally Adjusted	August 2005 as of October 2005
Phys	(f)(4)	Modifiers: Charge Adjustment Factors	V2.1 Federal Register Table M	May 2004
Phys	(f)(2)(iv)	GAAFs	V2.1 Federal Register Table L	May 2004
Anes	(g)(2)	RVUs	CMS Anesthesia Base Units	2005
Anes	(G)(3)(ii)	Trending Forward	CPI-U, Physician Services Component, Seasonally Adjusted	August 2005 as of October 2005
Dent	(h)(2)(iii)	Trending Forward	CPI-U, Dental Services Component, Seasonally Adjusted	August 2005 as of October 2005
Dent	(h)(3)	GAAFs	V2.1 Federal Register Table R	May 2004
Lab	(i)(2)(i), (i)(2)(ii), (i)(2)(iii)	RVUs, Existing Codes with Total RVUs	V2.1 VA Host File	May 2004
Lab	(i)(2)(i), (i)(2)(ii), (i)(2)(iii)	RVUs, Codes with Total RVUs	CMS Medicare Laboratory Fee Schedule	2006
Lab	(i)(2)(i)	RVUs, Codes with Medicare-based RVUs	CMS Medicare Physician Fee Schedule Payment Levels	2006
Lab	(i)(3)(ii)	Trending Forward	CPI-U, Physician Services Component, Seasonally Adjusted	August 2005 as of October 2005
Obs	(j)(2)(ii)	Trending Forward	CPI-U, Outpatient Hospital Services Component, Seasonally Adjusted	August 2005 as of October 2005
Amb	(k)(2)(iii)	Trending Forward	CPI-U, Outpatient Hospital Services Component, Seasonally Adjusted	August 2005 as of October 2005
DME	(l)(2)(iv)	Trending Forward	CPI-U, Medical Care Commodities Component, Seasonally Adjusted	August 2005 as of October 2005
DME	(l)(2)(i)	Unit Charges	CMS Medicare DME Fee Schedule	2006
DME	(l)(2)(i)	Unit Charges	CMS Medicare PEN Fee Schedule	2006

Supplementary Table 1
Reasonable Charges Data Sources - VZ.6

Charge Type	Paragraph (1)	Subject	Data Source	Edition
Anes	(g)(2)	RVUs	CMS Anesthesia Base Units	2005
Opt	(e)(3)(i)	Unit Charges for Screening Mammograms	CMS Medicare Fee Schedule for Mammograms	2006
Opt	(e)(3)(ii)	Unit Charges	CMS OPPS-APC Payment Schedule	2006
Dent	(h)(2)(iii)	Trending Forward	CPH-U, Dental Services Component, Seasonally Adjusted	August 2005 as of October 2005
DME	(l)(2)(iv)	Trending Forward	CPH-U, Medical Care Commodities Component, Seasonally Adjusted	August 2005 as of October 2005
PH	(j)(2)(i)	Trending Forward	CPH-U, Outpatient Hospital Services Component, Seasonally Adjusted	August 2005 as of October 2005
Opt	(e)(3)(iii)	Trending Forward	CPH-U, Outpatient Hospital Services Component, Seasonally Adjusted	August 2005 as of October 2005
Obs	(k)(2)(i)	Trending Forward	CPH-U, Outpatient Hospital Services Component, Seasonally Adjusted	August 2005 as of October 2005
Amb	(k)(2)(iii)	Trending Forward	CPH-U, Outpatient Hospital Services Component, Seasonally Adjusted	August 2005 as of October 2005
Phys	(f)(5)(i)	Trending Forward	CPH-U, Physician Services Component, Seasonally Adjusted	August 2005 as of October 2005
Anes	(G)(3)(iii)	Trending Forward	CPH-U, Physician Services Component, Seasonally Adjusted	August 2005 as of October 2005
Lab	(l)(3)(i)	Trending Forward	CPH-U, Physician Services Component, Seasonally Adjusted	August 2005 as of October 2005
DME	(l)(2)(i)	Unit Charges	CMS Medicare DME Fee Schedule	2006
Lab	(l)(2)(i), (l)(2)(ii), (l)(2)(iii)	RVUs, Codes with Total RVUs	CMS Medicare Laboratory Fee Schedule	2006
DME	(l)(2)(iii)	Unit Charges	CMS Medicare PEN Fee Schedule	2006
Lab	(l)(2)(i)	RVUs, Codes with Medicare-based RVUs	CMS Medicare Physician Fee Schedule Payment Levels	2006
Phys	(l)(2)(i)(A)	RVUs, code with Medicare RVUs, Work Expense	CMS Medicare Physician Fee Schedule RVUs, work expense	2006
Phys	(l)(2)(iv)	GAAFs	V2.1 Federal Register Table L	May 2004
Phys	(f)(4)	Modifiers: Charge Adjustment Factors	V2.1 Federal Register Table M	May 2004
Opt	(e)(4)	GAAFs	V2.1 Federal Register Table P	May 2004
Dent	(h)(3)	GAAFs	V2.1 Federal Register Table R	May 2004
Lab	(l)(2)(i), (l)(2)(ii), (l)(2)(iii)	RVUs, Existing Codes with Total RVUs	V2.1 VA Host File	May 2004

Charge Type Abbreviations
 Amb = Ambulance
 Anes = Anesthesia
 Dent = Dental HCPCS Level II
 DME = DME and other HCPCS Level II
 Inpt = Acute Inpatient Facility Charges
 Lab = Pathology and Laboratory
 Obs = Observation Care
 Opt = Outpatient Facility Charges
 PH = Partial Hospitalization
 Phys = Physician and Other Professional Charges
 SNF = Skilled Nursing Facility / Sub-acute Inpatient Facility Charges

Other Abbreviations
 CMS = Centers for Medicare and Medicaid Services
 CPH-U = Consumer Price Index - All Urban Consumers
 DME = Durable Medical Equipment
 OPSS = Outpatient Prospective Payment APC Classification System
 VA = Existing VA Charges

(1) Paragraph References: Federal Register / Vol. 68, No. 191 / Thursday, October 2, 2003 / Proposed Rule

Supplemental Table 2
Reasonable Charges Data Sources - V2.6 - Where To Obtain

Database	Where To Obtain
CMS Anesthesia Base Units	Ingenix, Inc, 2525 Lake Park Blvd, Salt Lake City, UT 84120
CPI-U, various components, seasonally adjusted	Bureau of Labor Statistics Internet Site, CPI Section, http://www.bls.gov/cpi
Ingenix Comprehensive Healthcare payment System, Dental UCR Module	Ingenix, Inc, 2525 Lake Park Blvd, Salt Lake City, UT 84120
Ingenix St. Anthony's RBRVS	Ingenix, Inc, 2525 Lake Park Blvd, Salt Lake City, UT 84120
MDR Database	Ingenix, Inc, 2525 Lake Park Blvd, Salt Lake City, UT 84120
MDR Database, Outpatient Facility Component	CMS Internet Site, http://www.cms.gov/providers/hopps/2006p/1501p.asp
Medicare APC Payment Amount	Federal Register, Vol.68, No. 40, February 28, 2003, pages 9587-9588
Medicare Conversion Factor	CMS Internet Site, files for download section, http://www.cms.hhs.gov/providers/purdownload/default.asp#dme
Medicare DME Fee Schedule	Federal Register, Vol.67, No. 251, December 31, 2002, pages 80170-80172
Medicare Geographic Practice Cost Index, Practice Expense	Federal Register, Vol.67, No. 251, December 31, 2002, pages 80170-80172
Medicare Geographic Practice Cost Index, Work Expense	CMS Internet Site, http://www.cms.hhs.gov/providers/purdownload/default.asp#dme
Medicare Parenteral and Enteral Nutrition Fee Schedule	CMS Internet Site, files for download section, http://www.cms.gov/providers/purdownload/
Medicare Physician Fee Schedule Payment Levels	CMS Internet Site, http://www.cms.hhs.gov/physicians/pfs/default.asp
Medicare Physician Fee Schedule RVUs, Practice Expense	CMS Internet Site, http://www.cms.hhs.gov/physicians/pfs/default.asp
Medicare Physician Fee Schedule RVUs, Work Expense	CMS Internet Site, Files-for-Purchase Directory, at http://www.cms.hhs.gov/data/purchase/default.asp
Medicare SAF 5% Sample, DME Component	CMS Internet Site, Files-for-Purchase Directory, at http://www.cms.hhs.gov/data/purchase/default.asp
Medicare SAF 5% Sample, Outpatient Facility Component	CMS Internet Site, Files-for-Purchase Directory, at http://www.cms.hhs.gov/data/purchase/default.asp
Medicare SAF 5% Sample, Part B Component	CMS Internet Site, Files-for-Purchase Directory, at http://www.cms.hhs.gov/data/purchase/default.asp
Milliman USA, Inc., Dental Health Cost Guidelines	Milliman USA, Inc., 1301 5th Avenue Suite 3800, Seattle, WA 98101-2605
Milliman USA, Inc., Health Cost Guidelines	Milliman USA, Inc., 1301 5th Avenue Suite 3800, Seattle, WA 98101-2605
Milliman USA, Inc., Health Cost Guidelines Fee Survey	Milliman USA, Inc., 1301 5th Avenue Suite 3800, Seattle, WA 98101-2605
Milliman USA, Inc., Optimized HMO Data Sets	Milliman USA, Inc., 1301 5th Avenue Suite 3800, Seattle, WA 98101-2605
National Dental Advisory Service Nationwide Pricing Index	Wasserman Medical Publishers, Ltd, PO Box 510949, Milwaukee, WI 53203
Prevailing Healthcare Charges System	Ingenix, Inc, 2525 Lake Park Blvd, Salt Lake City, UT 84120
VA Nationwide Discharges	Veterans Health Administration
VA Nationwide Distribution of Procedures and Services	Veterans Health Administration
VA Nationwide Distribution of Procedures, Services, Items and Supplies	Veterans Health Administration
Abbreviations	
APC = Ambulatory Payment Classification	
CMS = Centers for Medicare and Medicaid Services	
CPI-U = Consumer Price Index - All Urban Consumers	
DME = Durable Medical Equipment	
HMO = Health Maintenance Organization	
MDR = Medical Data Research	
MedPAR = Medicare Provider Analysis and Review	
RBRVS = Resource-Based Relative Value Sets	
RVU = Relative Value Unit	
SAF = Standard Analytical File	
UCR = Usual, Customary, or Reasonable	
VA = Department of Veterans Affairs	

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations

RC V2.6 Facility List 12/13/2005

Page 1 of 15

Sta #	VA Facility Location	ST	ZIP 3	VN	TYPE	PB
402	TOGUS, ME	ME	043	1	VAMC	PBH
402GA	CARIBOU, ME	ME	047	1	CBOC	NPB
402GB	CALAIS, ME	ME	046	1	CBOC	NPB
402GC	RUMFORD, ME	ME	042	1	CBOC	NPB
402GD	SACO, ME	ME	040	1	CBOC	NPB
402HB	BANGOR, ME	ME	044	1	CBOC	NPB
402HC	PORTLAND, ME	ME	041	1	CBOC	NPB
405	WHITE RIVER JCT, VT	VT	050	1	VAMC	PBH
405GA	BENNINGTON, VT	VT	052	1	CBOC	NPB
405HA	BURLINGTON, VT	VT	054	1	CBOC	NPB
405HC	SAINT JOHNSBURY, VT	VT	058	1	CBOC	NPB
405HD	NEWPORT, VT	VT	058	1	CBOC	NPB
405HF	RUTLAND, VT	VT	057	1	CBOC	NPB
405HG	WILDER, VT	VT	050	1	CBOC	NPB
436	FORT HARRISON, MT	MT	596	19	VAMC	PBH
436GA	ANACONDA, MT	MT	597	19	CBOC	NPB
436GB	GREAT FALLS, MT	MT	594	19	CBOC	NPB
436GC	MISSOULA, MT	MT	598	19	CBOC	NPB
436GD	BOZEMAN, MT	MT	597	19	CBOC	NPB
436GF	KALISPELL, MT	MT	599	19	CBOC	NPB
436GH	BILLINGS, MT	MT	591	19	CBOC	NPB
436GI	GLASGOW, MT	MT	592	19	CBOC	NPB
436GJ	MILES CITY, MT	MT	593	19	CBOC	NPB
436GK	SIDNEY, MT	MT	592	19	CBOC	NPB
437	FARGO, ND	ND	581	23	VAMC	PBH
437GA	GRAFTON, ND	ND	582	23	CBOC	NPB
437GB	BISMARCK, ND	ND	585	23	CBOC	NPB
437GC	FERGUS FALLS, MN	MN	565	23	CBOC	NPB
437GD	MINOT, ND	ND	587	23	CBOC	NPB
438	SIOUX FALLS, SD	SD	571	23	VAMC	PBH
438GC	SIOUX CITY, IA	IA	511	23	CBOC	NPB
438GD	ABERDEEN, SD	SD	574	23	CBOC	NPB
442	CHEYENNE, WY	WY	820	19	VAMC	PBH
442GB	SIDNEY, NE	NE	691	19	CBOC	NPB
442GC	FORT COLLINS, CO	CO	805	19	CBOC	NPB
442GD	GREELEY, CO	CO	806	19	CBOC	NPB
459	HONOLULU, HI	HI	968	21	VAMC	PBH
459GA	KAHULUI, HI	HI	967	21	CBOC	NPB
459GB	HILO, HI	HI	967	21	CBOC	NPB
459GC	KAILUA KONA, HI	HI	967	21	CBOC	NPB
459GD	LIHUE, HI	HI	967	21	CBOC	NPB
459GE	GUAM, GU	GU	969	21	CBOC	NPB
460	WILMINGTON, DE	DE	198	4	VAMC	PBH
460GA	MILLSBORO, DE	DE	199	4	CBOC	NPB
460HE	VENTNOR CITY, NJ	NJ	084	4	CBOC	NPB
460HG	VINELAND, NJ	NJ	083	4	CBOC	PBO
463	ANCHORAGE, AK	AK	995	20	IOC	PBO
463GA	FAIRBANKS, AK	AK	997	20	CBOC	NPB
463GB	KENAI, AK	AK	996	20	CBOC	NPB
501	ALBUQUERQUE, NM	NM	871	18	VAMC	PBH
501G2	LAS VEGAS, NM	NM	875	18	CBOC	NPB
501GA	ARTESIA, NM	NM	882	18	CBOC	NPB
501GB	FARMINGTON, NM	NM	874	18	CBOC	NPB
501GC	SILVER CITY, NM	NM	880	18	CBOC	NPB
501GD	GALLUP, NM	NM	873	18	CBOC	NPB
501GE	ESPANOLA, NM	NM	884	18	CBOC	NPB
501GH	TRUTH OR CONSEQUENCES, NM	NM	879	18	CBOC	NPB
501GI	ALAMOGORDO, NM	NM	883	18	CBOC	NPB

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations

RC V2 6 Facility List 12/13/2005

Page 2 of 15

Sta #	VA Facility Location	ST	ZIP 3	VN	TYPE	PB
501GJ	DURANGO, CO	CO	813	18	CBOC	NPB
501GK	SANTA FE, NM	NM	875	18	CBOC	NPB
501HB	RATON, NM	NM	877	18	CBOC	NPB
502	ALEXANDRIA, LA	LA	713	16	VAMC	PBH
502GA	JENNINGS, LA	LA	705	16	CBOC	NPB
502GB	LAFAYETTE, LA	LA	705	16	CBOC	NPB
502GC	BATON ROUGE, LA	LA	708	16	CBOC	NPB
502GD	HOUMA, LA	LA	703	16	CBOC	NPB
503	ALTOONA, PA	PA	166	4	VAMC	PBH
503GA	JOHNSTOWN, PA	PA	159	4	CBOC	PBO
503GB	DU BOIS, PA	PA	158	4	CBOC	NPB
503GC	STATE COLLEGE, PA	PA	168	4	CBOC	PBO
504	AMARILLO, TX	TX	791	18	VAMC	PBH
504BY	LUBBOCK, TX	TX	794	18	CBOC	NPB
504BZ	CLOVIS, NM	NM	881	18	CBOC	NPB
504GA	CHILDRESS, TX	TX	792	18	CBOC	NPB
504GB	LIBERAL, KS	KS	679	18	CBOC	NPB
504HB	STRATFORD, TX	TX	790	18	CBOC	NPB
506	ANN ARBOR, MI	MI	481	11	VAMC	PBH
506GA	TOLEDO, OH	OH	436	11	CBOC	NPB
506GB	FLINT, MI	MI	485	11	CBOC	NPB
506GC	JACKSON, MI	MI	492	11	CBOC	NPB
508	ATLANTA/DECATUR, GA	GA	300	7	VAMC	PBH
508GA	EAST POINT, GA	GA	303	7	CBOC	PBO
508GE	OAKWOOD/NE CORRIDOR, GA	GA	305	7	CBOC	PBO
508GF	SMYRNA, GA	GA	300	7	CBOC	PBO
508GH	LAWRENCEVILLE, GA	GA	300	7	CBOC	PBO
509	AUGUSTA DOWNTOWN, GA	GA	309	7	VAMC	PBH
509A0	AUGUSTA UPTOWN, GA	GA	309	7	VAMC	PBH
512	BALTIMORE, MD	MD	212	5	VAMC	PBH
512A5	PERRY POINT, MD	MD	219	5	VAMC	PBH
512GA	CAMBRIDGE, MD	MD	216	5	CBOC	NPB
512GC	GLEN BURNIE, MD	MD	210	5	CBOC	PBO
512GD	BALTIMORE/LOCH RAVEN, MD	MD	212	5	CBOC	PBO
512GE	POCOMOKE CITY, MD	MD	218	5	CBOC	NPB
512GF	FORT HOWARD CBOC, MD	MD	210	5	CBOC	PBO
512PA	PERRY POINT RTPS, MD	MD	219	5	CBOC	NPB
515	BATTLE CREEK, MI	MI	490	11	VAMC	PBH
515BY	GRAND RAPIDS, MI	MI	495	11	CBOC	NPB
515GA	MUSKEGON, MI	MI	494	11	CBOC	NPB
515GB	LANSING, MI	MI	489	11	CBOC	NPB
515GC	BENTON HARBOR, MI	MI	490	11	CBOC	NPB
516	BAY PINES, FL	FL	337	8	VAMC	PBH
516BZ	FORT MYERS, FL	FL	339	8	CBOC	NPB
516GA	SARASOTA, FL	FL	342	8	CBOC	NPB
516GB	SAINT PETERSBURG, FL	FL	337	8	CBOC	PBO
516GC	DUNEDIN, FL	FL	346	8	CBOC	PBO
516GD	ELLENTON, FL	FL	342	8	CBOC	PBO
516GE	PORT CHARLOTTE, FL	FL	339	8	CBOC	NPB
516GF	NAPLES, FL	FL	341	8	CBOC	NPB
516GH	AVON PARK, FL	FL	338	8	CBOC	NPB
517	BECKLEY, WV	WV	258	6	VAMC	PBH
517GA	GASSAWAY, WV	WV	266	6	CBOC	NPB
518	BEDFORD, MA	MA	017	1	VAMC	PBH
518GA	LYNN, MA	MA	019	1	CBOC	PBO
518GB	HAVERHILL, MA	MA	018	1	CBOC	PBO
518GC	WINCHINDON, MA	MA	014	1	CBOC	NPB
518GD	LOWELL, MA	MA	018	1	CBOC	PBO

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations

RC V2.6 Facility List 12/13/2005

Page 3 of 15

Sta #	VA Facility Location	ST	ZIP 3	VN	TYPE	PB
518GE	GLOUCESTER, MA	MA	019	1	CBOC	PBO
518GG	FITCHBURG, MA	MA	014	1	CBOC	PBO
519	BIG SPRING, TX	TX	797	18	VAMC	PBH
519GA	ODESSA, TX	TX	797	18	CBOC	NPB
519GB	HOBBS, NM	NM	882	18	CBOC	NPB
519GD	FORT STOCKTON, TX	TX	797	18	CBOC	NPB
519HC	ABILENE, TX	TX	796	18	CBOC	NPB
519HD	STAMFORD, TX	TX	795	18	CBOC	NPB
519HF	SAN ANGELO, TX	TX	769	18	CBOC	NPB
520	BILOXI, MS	MS	395	16	VAMC	PBH
520A0	GULFPORT, MS	MS	395	16	VAMC	PBH
520BZ	PENSACOLA, FL	FL	325	16	CBOC	NPB
520GA	MOBILE, AL	AL	366	16	CBOC	NPB
520GB	PANAMA CITY, FL	FL	324	16	CBOC	NPB
521	BIRMINGHAM, AL	AL	352	7	VAMC	PBH
521GA	HUNTSVILLE, AL	AL	358	7	CBOC	NPB
521GB	DECATUR, AL	AL	356	7	CBOC	NPB
521GC	FLORENCE, AL	AL	356	7	CBOC	NPB
521GD	RAINBOW CITY, AL	AL	359	7	CBOC	NPB
521GE	ANNISTON, AL	AL	362	7	CBOC	NPB
521GF	JASPER, AL	AL	355	7	CBOC	NPB
523	BOSTON, MA	MA	021	1	VAMC	PBH
523A4	WEST ROXBURY, MA	MA	021	1	VAMC	PBH
523A5	BROCKTON, MA	MA	024	1	VAMC	PBH
523BY	LOWELL, MA	MA	018	1	CBOC	PBO
523BZ	BOSTON CBOC, MA	MA	021	1	CBOC	PBO
523GA	FRAMINGHAM, MA	MA	017	1	CBOC	PBO
523GB	WORCESTER, MA	MA	016	1	CBOC	PBO
523GC	QUINCY, MA	MA	021	1	CBOC	PBO
523GD	PLYMOUTH, MA	MA	023	1	CBOC	NPB
523GE	DORCHESTER, MA	MA	021	1	CBOC	PBO
526	BRONX, NY	NY	104	3	VAMC	PBH
526GA	WHITE PLAINS/BRONX, NY	NY	106	3	CBOC	PBO
526GB	YONKERS, NY	NY	107	3	CBOC	PBO
526GC	SOUTH BRONX, NY	NY	104	3	CBOC	PBO
526GD	QUEENS, NY	NY	111	3	CBOC	PBO
528	BUFFALO, NY	NY	142	2	VAMC	PBH
528A4	BATAVIA, NY	NY	140	2	VAMC	PBH
528A5	CANANDAIGUA, NY	NY	144	2	VAMC	PBH
528A6	BATH, NY	NY	148	2	VAMC	PBH
528A7	SYRACUSE, NY	NY	132	2	VAMC	PBH
528A8	ALBANY, NY	NY	122	2	VAMC	PBH
528G1	MALONE, NY	NY	129	2	CBOC	NPB
528G2	ELIZABETHTOWN, NY	NY	129	2	CBOC	NPB
528G3	BAINBRIDGE, NY	NY	137	2	CBOC	NPB
528G4	ELMIRA, NY	NY	149	2	CBOC	PBO
528G5	AUBURN, NY	NY	130	2	CBOC	NPB
528G6	FONDA, NY	NY	120	2	CBOC	NPB
528G7	CATSKILL, NY	NY	124	2	CBOC	NPB
528G8	WELLSVILLE, NY	NY	148	2	CBOC	NPB
528G9	CORTLAND, NY	NY	130	2	CBOC	NPB
528GB	JAMESTOWN, NY	NY	147	2	CBOC	NPB
528GC	DUNKIRK, NY	NY	140	2	CBOC	NPB
528GD	NIAGARA FALLS, NY	NY	143	2	CBOC	NPB
528GE	ROCHESTER, NY	NY	146	2	CBOC	PBO
528GK	LOCKPORT, NY	NY	140	2	CBOC	PBO
528GL	MASSENA, NY	NY	136	2	CBOC	NPB
528GM	ROME, NY	NY	134	2	CBOC	NPB

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations

RC V2.6 Facility List 12/13/2005

Page 4 of 15

Sta #	VA Facility Location	ST	ZIP 3	VN	TYPE	PB
528GN	BINGHAMTON, NY	NY	139	2	CBOC	NPB
528GO	CARTHAGE, NY	NY	136	2	CBOC	NPB
528GP	OSWEGO, NY	NY	131	2	CBOC	NPB
528GQ	LACKAWANNA, NY	NY	142	2	CBOC	NPB
528GR	OLEAN, NY	NY	147	2	CBOC	NPB
528GT	GLENS FALLS, NY	NY	128	2	CBOC	NPB
528GV	PLATTSBURGH, NY	NY	129	2	CBOC	NPB
528GW	SCHENECTADY, NY	NY	123	2	CBOC	NPB
528GX	TROY, NY	NY	121	2	CBOC	NPB
528GY	CLIFTON PARK, NY	NY	120	2	CBOC	PBO
528GZ	KINGSTON, NY	NY	124	2	CBOC	NPB
528JI	WARSAW CBOC, NY	NY	145	2	CBOC	PBO
529	BUTLER, PA	PA	160	4	VAMC	PBH
529GA	MERCER, PA	PA	161	4	CBOC	PBO
529GB	NEW CASTLE, PA	PA	161	4	CBOC	PBO
529GC	KITTANNING, PA	PA	162	4	CBOC	NPB
529GD	KNOX, PA	PA	162	4	CBOC	NPB
529GE	VENANGO CTY, PA	PA	163	4	CBOC	NPB
531	BOISE, ID	ID	837	20	VAMC	PBH
531GD	ONTARIO, OR	OR	979	20	CBOC	NPB
531GE	TWIN FALLS, ID	ID	833	20	CBOC	NPB
534	CHARLESTON, SC	SC	294	7	VAMC	PBH
534BY	SAVANNAH, GA	GA	314	7	CBOC	NPB
534GB	MYRTLE BEACH, SC	SC	295	7	CBOC	NPB
534GC	BEAUFORT, SC	SC	299	7	CBOC	NPB
534GD	GOOSE CREEK, SC	SC	294	7	CBOC	PBO
537	CHICAGO WEST SIDE, IL	IL	606	12	VAMC	PBH
537BY	CROWN POINT, IN	IN	463	12	CBOC	NPB
537GA	CHICAGO HEIGHTS, IL	IL	604	12	CBOC	PBO
537GD	LAKESIDE CBOC, IL	IL	606	12	VAMC	PBO
537HA	CHICAGO/WOODLAWN, IL	IL	606	12	CBOC	PBO
538	CHILLICOTHE, OH	OH	456	10	VAMC	PBH
538GA	ATHENS, OH	OH	457	10	CBOC	NPB
538GB	PORTSMOUTH, OH	OH	456	10	CBOC	NPB
538GC	MARIETTA, OH	OH	457	10	CBOC	NPB
538GD	LANCASTER, OH	OH	431	10	CBOC	PBO
539	CINCINNATI, OH	OH	452	10	VAMC	PBH
539DT	GEORGETOWN, OH	OH	451	10	VAMC	PBH
539GA	BELLEVUE, KY	KY	410	10	CBOC	PBO
539GB	CINCINNATI CBOC, OH	OH	452	10	CBOC	PBO
539GC	LAWRENCEBURG, IN	IN	470	10	CBOC	PBO
540	CLARKSBURG, WV	WV	263	4	VAMC	PBH
540GA	PARSONS, WV	WV	262	4	CBOC	NPB
540GB	PARKERSBURG, WV	WV	261	4	CBOC	NPB
540GC	GASSAWAY, WV	WV	266	4	CBOC	NPB
541	CLEVELAND WADE PARK, OH	OH	441	10	VAMC	PBH
541A0	CLEVELAND BRECKSVILLE, OH	OH	441	10	VAMC	PBH
541BY	CANTON, OH	OH	447	10	CBOC	NPB
541BZ	YOUNGSTOWN, OH	OH	445	10	CBOC	NPB
541GB	LORAIN, OH	OH	440	10	CBOC	PBO
541GC	SANDUSKY, OH	OH	448	10	CBOC	NPB
541GD	MANSFIELD, OH	OH	449	10	CBOC	NPB
541GE	CLEVELAND CBOC, OH	OH	441	10	CBOC	PBO
541GF	PAINESVILLE, OH	OH	440	10	CBOC	PBO
541GG	AKRON, OH	OH	443	10	CBOC	NPB
541GH	EAST LIVERPOOL, OH	OH	439	10	CBOC	NPB
541GI	WARREN, OH	OH	444	10	CBOC	NPB
541GJ	NEW PHILADELPHIA, OH	OH	446	10	CBOC	NPB

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations

RQ V2.6 Facility List 12/13/2005

Page 5 of 15

Sta #	VA Facility Location	ST	ZIP 3	VN	TYPE	PB
541GK	RAVENNA, OH	OH	442	10	CBOC	PBO
542	COATESVILLE, PA	PA	193	4	VAMC	PBH
542GA	SPRINGFIELD, PA	PA	190	4	CBOC	PBO
542GB	PHILADELPHIA CBOC, PA	PA	191	4	CBOC	NPB
542GE	SPRING CITY, PA	PA	194	4	CBOC	PBO
542GG	COATESVILLE MSCEC, PA	PA	193	4	CBOC	PBO
542GH	COATESVILLE CBOC, PA	PA	193	4	CBOC	PBO
544	COLUMBIA, SC	SC	292	7	VAMC	PBH
544BZ	GREENVILLE, SC	SC	296	7	CBOC	NPB
544GB	FLORENCE, SC	SC	295	7	CBOC	NPB
544GC	ROCK HILL, SC	SC	297	7	CBOC	NPB
544GD	ANDERSON, SC	SC	296	7	CBOC	NPB
544GE	ORANGEBURG, SC	SC	291	7	CBOC	NPB
544GF	SUMTER, SC	SC	291	7	CBOC	NPB
546	MIAMI, FL	FL	331	8	VAMC	PBH
546BZ	OAKLAND PARK, FL	FL	333	8	CBOC	PBO
546GA	MIAMI CBOC, FL	FL	331	8	CBOC	PBO
546GB	KEY WEST, FL	FL	330	8	CBOC	NPB
546GC	HOMESTEAD, FL	FL	330	8	CBOC	NPB
546GD	PEMBROKE PINES, FL	FL	330	8	CBOC	PBO
546GE	KEY LARGO, FL	FL	330	8	CBOC	NPB
546GF	HALLANDALE, FL	FL	330	8	CBOC	PBO
546GG	CORAL SPRINGS, FL	FL	330	8	CBOC	NPB
546GH	DEERFIELD BEACH, FL	FL	334	8	CBOC	NPB
548	WEST PALM BEACH, FL	FL	334	8	VAMC	PBH
548GA	FORT PIERCE, FL	FL	349	8	CBOC	NPB
548GB	DELRAY BEACH, FL	FL	334	8	CBOC	NPB
548GC	STUART, FL	FL	349	8	CBOC	NPB
548GD	BOCA RATON, FL	FL	334	8	CBOC	NPB
548GE	VERO BEACH, FL	FL	329	8	CBOC	NPB
548GF	OKEECHOBEE, FL	FL	349	8	CBOC	NPB
549	DALLAS, TX	TX	752	17	VAMC	PBH
549A4	BONHAM, TX	TX	754	17	VAMC	PBH
549BY	FORT WORTH SOC, TX	TX	761	17	CBOC	PBO
549GA	TYLER, TX	TX	757	17	CBOC	NPB
549GC	BONHAM CBOC, TX	TX	754	17	CBOC	NPB
549GD	DENTON, TX	TX	762	17	CBOC	NPB
549GE	DECATUR, TX	TX	762	17	CBOC	NPB
549GF	EASTLAND, TX	TX	764	17	CBOC	NPB
549GH	GREENVILLE, TX	TX	754	17	CBOC	NPB
549GI	CLEBURNE, TX	TX	760	17	CBOC	NPB
549HA	DIAMOND HILL, TX	TX	761	17	CBOC	PBO
550	DANVILLE, IL	IL	618	11	VAMC	PBH
550BY	PEORIA, IL	IL	616	11	CBOC	NPB
550GA	DECATUR, IL	IL	625	11	CBOC	NPB
550GC	LAFAYETTE, IN	IN	479	11	CBOC	NPB
550GD	SPRINGFIELD, IL	IL	627	11	CBOC	NPB
550GE	EFFINGHAM, IL	IL	624	11	CBOC	NPB
552	DAYTON, OH	OH	454	10	VAMC	PBH
552GA	MIDDLETOWN, OH	OH	450	10	CBOC	PBO
552GB	LIMA, OH	OH	458	10	CBOC	NPB
552GC	RICHMOND, IN	IN	473	10	CBOC	NPB
552GD	SPRINGFIELD, OH	OH	455	10	CBOC	PBO
553	DETROIT, MI	MI	482	11	VAMC	PBH
553GA	YALE, MI	MI	480	11	CBOC	NPB
553GB	PONTIAC, MI	MI	483	11	CBOC	NPB
554	DENVER, CO	CO	802	19	VAMC	PBH
554GB	AURORA, CO	CO	800	19	CBOC	PBO

**Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations**

RC V2.8 Facility List 12/13/2005

Page 6 of 15

Sta #	VA Facility Location	ST	ZIP 3	VN	TYPE	PB
554GC	LAKEWOOD, CO	CO	802	19	CBOC	PBO
554GD	PUEBLO, CO	CO	810	19	CBOC	NPB
554GE	COLORADO SPRINGS, CO	CO	809	19	CBOC	NPB
554GF	ALAMOSA, CO	CO	811	19	CBOC	NPB
554GG	LA JUNTA, CO	CO	810	19	CBOC	NPB
554GH	LAMAR, CO	CO	810	19	CBOC	NPB
554HB	FORT MORGAN, CO	CO	807	19	CBOC	NPB
556	NORTH CHICAGO, IL	IL	600	12	VAMC	PBH
556GA	EVANSTON, IL	IL	602	12	CBOC	PBO
556GC	MCHENRY, IL	IL	600	12	CBOC	PBO
556GD	KENOSHA, WI	WI	531	12	CBOC	PBO
557	DUBLIN, GA	GA	310	7	VAMC	PBH
557GA	MACON, GA	GA	312	7	CBOC	NPB
557GB	ALBANY, GA	GA	317	7	CBOC	NPB
558	DURHAM, NC	NC	277	6	VAMC	PBH
558GA	GREENVILLE, NC	NC	278	6	CBOC	NPB
558GB	RALEIGH, NC	NC	276	6	CBOC	NPB
558GC	MOOREHEAD CITY, NC	NC	285	6	CBOC	NPB
561	EAST ORANGE, NJ	NJ	070	3	VAMC	PBH
561A4	LYONS, NJ	NJ	079	3	VAMC	PBH
561BY	NEWARK SAC, NJ	NJ	071	3	CBOC	PBO
561BZ	BRICK, NJ	NJ	087	3	CBOC	NPB
561GA	TRENTON, NJ	NJ	086	3	CBOC	PBO
561GB	ELIZABETH, NJ	NJ	072	3	CBOC	PBO
561GD	HACKENSACK, NJ	NJ	076	3	CBOC	PBO
561GE	JERSEY CITY, NJ	NJ	073	3	CBOC	PBO
561GF	NEW BRUNSWICK, NJ	NJ	089	3	CBOC	PBO
561GG	NEWARK CBOC, NJ	NJ	071	3	CBOC	PBO
561GH	MORRISTOWN, NJ	NJ	079	3	CBOC	PBO
561GI	FORT MONMOUTH, NJ	NJ	077	3	CBOC	PBO
561GJ	PATERSON CBOC, NJ	NJ	075	3	CBOC	PBO
561HB	JAMESBURG, NJ	NJ	088	3	CBOC	PBO
562	ERIE, PA	PA	165	4	VAMC	PBH
562GA	MEADVILLE, PA	PA	163	4	CBOC	PBO
562GB	ASHTABULA, OH	OH	440	4	CBOC	NPB
562GC	SMETHPORT, PA	PA	167	4	CBOC	NPB
562GD	VENANGO CTY, PA	PA	163	4	CBOC	NPB
562GE	WARREN CTY, PA	PA	163	4	CBOC	NPB
564	FAYETTEVILLE, AR	AR	727	16	VAMC	PBH
564BY	MOUNT VERNON, MO	MO	657	16	CBOC	NPB
564GA	HARRISON, AR	AR	726	16	CBOC	NPB
564GB	FORT SMITH, AR	AR	729	16	CBOC	NPB
565	FAYETTEVILLE, NC	NC	283	6	VAMC	PBH
565GA	JACKSONVILLE UCJ, NC	NC	285	6	CBOC	NPB
565GC	WILMINGTON, NC	NC	284	6	CBOC	NPB
568	FORT MEADE, SD	SD	577	23	VAMC	PBH
568A4	HOT SPRINGS, SD	SD	577	23	VAMC	PBH
568GA	RAPID CITY, SD	SD	577	23	CBOC	PBO
568GB	PIERRE, SD	SD	575	23	CBOC	NPB
568HA	NEWCASTLE, WY	WY	827	23	CBOC	NPB
568HB	RUSHVILLE, NE	NE	693	23	CBOC	NPB
568HC	ALLIANCE, NE	NE	693	23	CBOC	NPB
568HF	PINE RIDGE, SD	SD	577	23	CBOC	NPB
568HH	GERING, NE	NE	693	23	CBOC	NPB
568HJ	ROSEBUD, SD	SD	575	23	CBOC	NPB
568HK	MCLAUGHLIN, SD	SD	576	23	CBOC	NPB
568HM	EAGLE BUTTE, SD	SD	576	23	CBOC	NPB
568HN	LAME DEER, MT	MT	590	23	CBOC	NPB

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations

RC V2.6 Facility List 12/13/2005

Page 7 of 15

Sta #	VA Facility Location	ST	ZIP 3	VN	TYPE	PB
568HP	WINNER, SD	SD	575	23	CBOC	NPB
570	FRESNO, CA	CA	937	21	VAMC	PBH
570GA	ATWATER, CA	CA	953	21	CBOC	NPB
570GB	TULARE, CA	CA	932	21	CBOC	NPB
573	GAINESVILLE, FL	FL	326	8	VAMC	PBH
573A4	LAKE CITY, FL	FL	320	8	VAMC	PBH
573BY	JACKSONVILLE, FL	FL	322	8	CBOC	NPB
573BZ	DAYTONA BEACH, FL	FL	321	8	CBOC	NPB
573GA	VALDOSTA, GA	GA	316	8	CBOC	NPB
573GD	OCALA, FL	FL	344	8	CBOC	PBO
573GE	SAINT AUGUSTINE, FL	FL	320	8	CBOC	NPB
573GF	TALLAHASSEE, FL	FL	323	8	CBOC	NPB
573GG	LECANTO, FL	FL	344	8	CBOC	NPB
573GH	LEESBURG, FL	FL	347	8	CBOC	NPB
573GI	THE VILLAGES, FL	FL	321	8	CBOC	NPB
575	GRAND JUNCTION, CO	CO	815	19	VAMC	PBH
575GA	MONTROSE, CO	CO	814	19	CBOC	NPB
578	HINES, IL	IL	601	12	VAMC	PBH
578GA	JOLIET, IL	IL	604	12	CBOC	PBO
578GB	OAK PARK, IL	IL	603	12	CBOC	PBO
578GC	MANTENO, IL	IL	609	12	CBOC	NPB
578GD	AURORA, IL	IL	605	12	CBOC	PBO
578GE	ELGIN, IL	IL	601	12	CBOC	PBO
578GF	LA SALLE, IL	IL	613	12	CBOC	NPB
578GG	OAK LAWN, IL	IL	604	12	CBOC	NPB
580	HOUSTON, TX	TX	770	16	VAMC	PBH
580BY	BEAUMONT, TX	TX	777	16	CBOC	NPB
580BZ	LUFKIN, TX	TX	759	16	CBOC	NPB
580GC	GALVESTON (ISLAND), TX	TX	775	16	CBOC	NPB
581	HUNTINGTON, WV	WV	257	9	VAMC	PBH
581GA	PRESTONSBURG, KY	KY	416	9	CBOC	NPB
581GB	CHARLESTON, WV	WV	253	9	CBOC	NPB
581GD	WILLIAMSON, WV	WV	256	9	CBOC	NPB
583	INDIANAPOLIS, IN	IN	462	11	VAMC	PBH
583GA	TERRE HAUTE, IN	IN	478	11	CBOC	NPB
583GB	BLOOMINGTON, IN	IN	474	11	CBOC	NPB
585	IRON MOUNTAIN, MI	MI	498	12	VAMC	PBH
585GA	HANCOCK/PORTAGE, MI	MI	499	12	CBOC	NPB
585GB	RHINELANDER, WI	WI	545	12	CBOC	NPE
585GC	MENOMINEE, MI	MI	498	12	CBOC	NPB
585GD	IRONWOOD, MI	MI	499	12	CBOC	NPB
585HA	MARQUETTE, MI	MI	498	12	CBOC	NPB
585HB	SAULT SAINTE MARIE, MI	MI	497	12	CBOC	NPB
586	JACKSON, MS	MS	392	16	VAMC	PBH
586GA	KOSCIUSKO, MS	MS	390	16	CBOC	NPB
586GB	MERIDIAN, MS	MS	393	16	CBOC	NPB
586GC	GREENVILLE, MS	MS	387	16	CBOC	NPB
586GD	HATTIESBURG, MS	MS	394	16	CBOC	NPB
586GE	NATCHEZ, MS	MS	391	16	CBOC	NPB
586GF	COLUMBUS, MS	MS	397	16	CBOC	NPB
589	KANSAS CITY, MO	MO	641	15	VAMC	PBH
589A4	COLUMBIA, MO	MO	652	15	VAMC	PBH
589A5	EASTERN KANSAS HCS - TOPEKA, KS	KS	666	15	VAMC	PBH
589A6	EASTERN KANSAS HCS - LEAVENWORTH, KS	KS	660	15	VAMC	PBH
589A7	WICHITA, KS	KS	672	15	VAMC	PBH
589DQ	WICHITA NON-VA HOSP, KS	KS	627	15	CMC	PBH
589DS	KANSAS CITY NON-VA HOSPITALS, KS	KS	641	15	CMC	PBH
589G1	WARRENSBURG, MO	MO	640	15	CBOC	NPB

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations

RC V2.6 Facility List 12/13/2005

Page 8 of 15

Sta #	VA Facility Location	ST	ZIP 3	VN	TYPE	PB
589G2	DODGE CITY, KS	KS	678	15	CBOC	NPB
589G3	LIBERAL, KS	KS	679	15	CBOC	NPB
589G4	HAYS, KS	KS	676	15	CBOC	NPB
589G5	PARSONS, KS	KS	673	15	CBOC	NPB
589G6	SALINA, KS	KS	674	15	CBOC	NPB
589GB	BELTON, MO	MO	640	15	CBOC	PBO
589GC	PAOLA, KS	KS	660	15	CBOC	NPB
589GD	NEVADA, MO	MO	647	15	CBOC	NPB
589GE	KIRKSVILLE, MO	MO	635	15	CBOC	NPB
589GF	FORT LEONARD WOOD, MO	MO	654	15	CBOC	NPB
589GH	CAMDENTON, MO	MO	650	15	CBOC	NPB
589GI	SAINT JOSEPH, MO	MO	645	15	CBOC	PBO
589GJ	KANSAS CITY/WYANDOTTE, KS	KS	661	15	CBOC	PBO
589GK	ABILENE, KS	KS	674	15	CBOC	NPB
589GM	CHANUTE, KS	KS	667	15	CBOC	NPB
589GN	EMPORIA, KS	KS	668	15	CBOC	NPB
589GO	FORT RILEY, KS	KS	664	15	CBOC	NPB
589GP	GARNETT, KS	KS	660	15	CBOC	NPB
589GQ	HOLTON, KS	KS	664	15	CBOC	NPB
589GR	JUNCTION CITY, KS	KS	664	15	CBOC	NPB
589GS	RUSSELL, KS	KS	676	15	CBOC	NPB
589GT	SENECA, KS	KS	665	15	CBOC	NPB
589GU	LAWRENCE, KS	KS	660	15	CBOC	NPB
589GV	FORT SCOTT, KS	KS	667	15	CBOC	NPB
589GW	SALINA, KS	KS	674	15	CBOC	NPB
589GX	MEXICO, MO	MO	652	15	CBOC	PBO
589GY	SAINT JAMES, MO	MO	655	15	CBOC	NPB
589GZ	CAMERON, MO	MO	644	15	CBOC	NPB
590	HAMPTON, VA	VA	236	6	VAMC	PBH
590GA	NORFOLK, VA	VA	235	6	CBOC	PBO
593	LAS VEGAS, NV	NV	891	22	VAMC	PBH
593GA	LAS VEGAS CBOC, NV	NV	891	22	CBOC	PBO
593GB	HENDERSON, NV	NV	890	22	CBOC	PBO
593GC	PAHRUMP, NV	NV	890	22	CBOC	NPB
595	LEBANON, PA	PA	170	4	VAMC	PBH
595GA	CAMP HILL, PA	PA	170	4	CBOC	PBO
595GB	POTTSVILLE/SCHUYLKILL/SHENANDOAH, PA	PA	179	4	CBOC	PBO
595GC	LANCASTER, PA	PA	176	4	CBOC	PBO
595GD	READING, PA	PA	196	4	CBOC	PBO
595GE	YORK, PA	PA	174	4	CBOC	PBO
596	LEXINGTON LEESTOWN, KY	KY	405	9	VAMC	PBH
596AO	LEXINGTON LEESTOWN, KY	KY	405	9	VAMC	PBH
596A4	LEXINGTON COOPER DRIVE, KY	KY	405	9	VAMC	PBH
596GA	SOMERSET, KY	KY	425	9	CBOC	NPB
596HA	LEXINGTON MSORC, KY	KY	405	9	CBOC	PBO
598	LITTLE ROCK, AR	AR	722	16	VAMC	PBH
598A0	NORTH LITTLE ROCK, AR	AR	721	16	VAMC	PBH
598GA	MOUNTAIN HOME, AR	AR	726	16	CBOC	NPB
598GB	EL DORADO, AR	AR	717	16	CBOC	NPB
598GC	HOT SPRINGS, AR	AR	719	16	CBOC	NPB
598GD	MENA CBOC, AR	AR	719	16	CBOC	NPB
600	LONG BEACH, CA	CA	908	22	VAMC	PBH
600GA	ANAHEIM, CA	CA	928	22	CBOC	PBO
600GB	SANTA ANA, CA	CA	927	22	CBOC	PBO
600GC	LONG BEACH CBOC, CA	CA	908	22	CBOC	PBO
600GD	SANTA FE SPRINGS, CA	CA	906	22	CBOC	PBO
603	LOUISVILLE, KY	KY	402	9	VAMC	PBH
603GA	FORT KNOX, KY	KY	401	9	CBOC	NPB

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations

RC V2.6 Facility List 12/13/2005

Page 9 of 15

Sta #	VA Facility Location	ST	ZIP 3	VN	TYPE	PB
603GB	NEW ALBANY, IN	IN	471	9	CBOC	NPB
603GC	LOUISVILLE CBOC, KY	KY	402	9	CBOC	PBO
603GD	DUPONT CBOC, KY	KY	402	9	CBOC	PBO
603GE	STANDIFORD FIELD CBOC, KY	KY	402	9	CBOC	PBO
605	LOMA LINDA, CA	CA	923	22	VAMC	PBH
605GA	VICTORVILLE, CA	CA	923	22	CBOC	PBO
605GB	SUN CITY, CA	CA	923	22	CBOC	PBO
605GC	PALM DESERT, CA	CA	922	22	CBOC	NPB
605GD	CORONA, CA	CA	928	22	CBOC	PBO
605GE	UPLAND, CA	CA	917	22	CBOC	PBO
607	MADISON, WI	WI	537	12	VAMC	PBH
607GC	JANESVILLE, WI	WI	535	12	CBOC	NPB
607GD	BARABOO, WI	WI	539	12	CBOC	PBO
607GE	BEAVER DAM, WI	WI	539	12	CBOC	NPB
607GF	FREEPORT CBOC, IL	IL	610	12	CBOC	NPB
607HA	ROCKFORD, IL	IL	611	12	CBOC	NPB
608	MANCHESTER, NH	NH	031	1	VAMC	PBH
608GA	PORTSMOUTH, NH	NH	038	1	CBOC	PBO
608GC	SOMERSWORTH, NH	NH	038	1	CBOC	PBO
608GD	CONWAY, NH	NH	038	1	CBOC	NPB
608HA	TILTON, NH	NH	032	1	CBOC	PBO
610	MARION, IN	IN	469	11	VAMC	PBH
610A4	FORT WAYNE, IN	IN	468	11	VAMC	PBH
610GA	SOUTH BEND, IN	IN	466	11	CBOC	NPB
610GB	MUNCIE, IN	IN	473	11	CBOC	NPB
612	MARTINEZ, CA	CA	945	21	VAMC	PBH
612A4	SACRAMENTO/MATHER AFB, CA	CA	958	21	VAMC	PBH
612B4	REDDING, CA	CA	960	21	CBOC	NPB
612BY	OAKLAND, CA	CA	946	21	CBOC	PBO
612CZ	TRAVIS AFB, CA	CA	945	21	CBOC	PBO
612GD	FAIRFIELD, CA	CA	945	21	CBOC	PBO
612GE	MARE ISLAND, CA	CA	945	21	CBOC	PBO
612GF	MARTINEZ CBOC, CA	CA	945	21	CBOC	PBO
612GG	CHICO, CA	CA	959	21	CBOC	NPB
612GH	MCCLELLAN AFB, CA	CA	956	21	CBOC	PBO
613	MARTINSBURG, WV	WV	254	5	VAMC	PBH
613GA	CUMBERLAND, MD	MD	215	5	CBOC	NPB
613GB	HAGERSTOWN, MD	MD	217	5	CBOC	PBO
613GC	STEPHENS CITY, VA	VA	226	5	CBOC	PBO
613GD	FRANKLIN, WV	WV	268	5	CBOC	NPB
613GE	PETERSBURG, WV	WV	268	5	CBOC	NPB
613GF	HARRISONBURG, VA	VA	228	5	CBOC	NPB
614	MEMPHIS, TN	TN	381	9	VAMC	PBH
614GA	SMITHVILLE, MS	MS	388	9	CBOC	NPB
614GB	JONESBORO, AR	AR	724	9	CBOC	NPB
614GC	BYHALIA, MS	MS	386	9	CBOC	NPB
614GD	SAVANNAH, TN	TN	383	9	CBOC	NPB
614GE	COVINGTON, TN	TN	381	9	CBOC	PBO
618	MINNEAPOLIS, MN	MN	554	23	VAMC	PBH
618BY	SUPERIOR, WI	WI	548	23	CBOC	NPB
618GA	MANKATO, MN	MN	560	23	CBOC	NPB
618GB	HIBBING, MN	MN	557	23	CBOC	NPB
618GD	SAINT PAUL, MN	MN	551	23	CBOC	PBO
618GE	CHIPPEWA FALLS, WI	WI	547	23	CBOC	NPB
618GG	ROCHESTER, MN	MN	559	23	CBOC	NPB
619	MONTGOMERY, AL	AL	361	7	VAMC	PBH
619A4	TUSKEGEE, AL	AL	360	7	VAMC	PBH
619GA	COLUMBUS, GA	GA	319	7	CBOC	NPB

**Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations**

RC V2 6 Facility List 12/13/2005

Page 10 of 15

Sta #	VA Facility Location	ST	ZIP 3	VN	TYPE	PB
619GB	DOTHAN, AL	AL	363	7	CBOC	NPB
620	MONTROSE, NY	NY	105	3	VAMC	PBH
620A4	CASTLE POINT, NY	NY	125	3	VAMC	PBH
620GA	NEW CITY, NY	NY	109	3	CBOC	PBO
620GB	CARMEL, NY	NY	105	3	CBOC	PBO
620GD	WALLKILL, NY	NY	125	3	CBOC	PBO
620GE	PORT JERVIS, NY	NY	127	3	CBOC	NPB
620GF	HARRIS, NY	NY	127	3	CBOC	NPB
620GG	POUGHKEEPSIE, NY	NY	126	3	CBOC	PBO
620GH	EASTERN DUTCHESS, NY	NY	125	3	CBOC	NPB
621	MOUNTAIN HOME, TN	TN	376	9	VAMC	PBH
621GA	ROGERSVILLE, TN	TN	378	9	CBOC	NPB
621GB	MOUNTAIN CITY, TN	TN	376	9	CBOC	NPB
621GC	NORTON, VA	VA	242	9	CBOC	NPB
621GD	SAINT CHARLES, VA	VA	242	9	CBOC	NPB
623	MUSKOGEE, OK	OK	744	16	VAMC	PBH
623BY	TULSA, OK	OK	741	16	CBOC	NPB
623GA	MCALISTER, OK	OK	745	16	CBOC	NPB
626	NASHVILLE, TN	TN	372	9	VAMC	PBH
626A4	MURFREESBORO, TN	TN	371	9	VAMC	PBH
626BY	KNOXVILLE, TN	TN	379	9	CBOC	NPB
626GA	DOVER, TN	TN	370	9	CBOC	NPB
626GC	BOWLING GREEN, KY	KY	421	9	CBOC	NPB
626GD	FT. CAMPBELL CBOC, KY	KY	422	9	CBOC	NPB
626GE	CLARKSVILLE, TN	TN	370	9	CBOC	NPB
626GF	CHATTANOOGA, TN	TN	374	9	CBOC	NPB
626GG	TULLAHOMA/ARNOLD AFB, TN	TN	373	9	CBOC	NPB
626GH	COOKEVILLE, TN	TN	385	9	CBOC	NPB
626GI	VINE HILL, TN	TN	372	9	CBOC	PBO
629	NEW ORLEANS, LA	LA	701	16	VAMC	PBH
629BY	BATON ROUGE, LA	LA	708	16	CBOC	NPB
629GA	HOUMA CBOC, LA	LA	703	16	CBOC	NPB
630	NEW YORK, NY	NY	100	3	VAMC	PBH
630A4	BROOKLYN, NY	NY	112	3	VAMC	PBH
630A5	SAINT ALBANS, NY	NY	114	3	VAMC	PBH
630B2	NEW YORK SOHO C&P UNIT, NY	NY	100	3	CBOC	PBO
630BZ	NEW YORK METHADONE, NY	NY	100	3	CBOC	PBO
630GA	HARLEM, NY	NY	100	3	CBOC	PBO
630GB	STATEN ISLAND, NY	NY	103	3	CBOC	PBO
630GC	BROOKLYN CHAPEL STREET, NY	NY	112	3	CBOC	PBO
631	NORTHAMPTON, MA	MA	010	1	VAMC	PBH
631BY	SPRINGFIELD SOC, MA	MA	011	1	CBOC	PBO
631GA	NORTHAMPTON CBOC, MA	MA	010	1	CBOC	PBO
631GB	SPRINGFIELD CBOC, MA	MA	011	1	CBOC	PBO
631GC	PITTSFIELD, MA	MA	012	1	CBOC	PBO
631GD	GREENFIELD, MA	MA	013	1	CBOC	PBO
632	NORTHPORT/LONG ISLAND, NY	NY	117	3	VAMC	PBH
632GA	PLAINVIEW, NY	NY	118	3	CBOC	PBO
632HA	LYNBROOK, NY	NY	115	3	CBOC	PBO
632HB	RIVERHEAD, NY	NY	119	3	CBOC	NPB
632HC	ISLIP, NY	NY	117	3	CBOC	PBO
632HD	PATCHOGUE, NY	NY	117	3	CBOC	PBO
632HE	MOUNT SINAI, NY	NY	117	3	CBOC	PBO
632HF	LINDENHURST, NY	NY	117	3	CBOC	PBO
635	OKLAHOMA CITY, OK	OK	731	16	VAMC	PBH
635DZ	LAWTON/FORT SILL, OK	OK	735	16	VAMC	PBH
635GA	LAWTON/FORT SILL, OK	OK	735	16	CBOC	NPB
635GB	WICHITA FALLS, TX	TX	763	16	CBOC	NPB

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations

RC V2.6 Facility List 12/13/2005

Page 11 of 15

Sta #	VA Facility Location	ST	ZIP 3	VN	TYPE	PB
635GC	PONCA CITY, OK	OK	746	16	CBOC	NPB
635GD	KONAWA, OK	OK	748	16	CBOC	NPB
635HB	ARDMORE, OK	OK	734	16	CBOC	NPB
636	OMAHA, NE	NE	681	23	VAMC	PBH
636A4	GRAND ISLAND, NE	NE	688	23	VAMC	PBH
636A5	LINCOLN, NE	NE	685	23	VAMC	PBH
636A6	DES MOINES, IA	IA	503	23	VAMC	PBH
636A7	KNOXVILLE, IA	IA	501	23	VAMC	PBH
636A8	IOWA CITY, IA	IA	522	23	VAMC	PBH
636GA	NORFOLK, NE	NE	687	23	CBOC	NPB
636GB	NORTH PLATTE, NE	NE	691	23	CBOC	NPB
636GC	MASON CITY, IA	IA	504	23	CBOC	NPB
636GF	BETTENDORF, IA	IA	527	23	CBOC	NPB
636GG	QUINCY, IL	IL	623	23	CBOC	NPB
636GH	WATERLOO, IA	IA	507	23	CBOC	NPB
636GI	GALESBURG, IL	IL	614	23	CBOC	NPB
636GJ	DUBUQUE, IA	IA	520	23	CBOC	NPB
636GK	FORT DODGE, IA	IA	505	23	CBOC	NPB
637	ASHEVILLE, NC	NC	288	6	VAMC	PBH
640	PALO ALTO, CA	CA	943	21	VAMC	PBH
640A0	MENLO PARK, CA	CA	940	21	VAMC	PBH
640A4	LIVERMORE, CA	CA	945	21	VAMC	PBH
640BY	SAN JOSE, CA	CA	951	21	CBOC	PBO
640GA	CAPITOLA, CA	CA	950	21	CBOC	PBO
640GB	SONORA, CA	CA	953	21	CBOC	NPB
640HA	STOCKTON, CA	CA	952	21	CBOC	NPB
640HB	MODESTO, CA	CA	953	21	CBOC	NPB
640HC	MONTEREY/FORT ORD, CA	CA	939	21	CBOC	NPB
642	PHILADELPHIA, PA	PA	191	4	VAMC	PBH
642GA	FORT DIX, NJ	NJ	086	4	CBOC	PBO
642GB	CAPE MAY, NJ	NJ	082	4	CBOC	NPB
642GC	WILLOW GROVE, PA	PA	190	4	CBOC	PBO
642GD	GLOUCESTER, NJ	NJ	080	4	CBOC	PBO
644	PHOENIX, AZ	AZ	850	18	VAMC	PBH
644BY	MESA/WILLIAMS AFB, AZ	AZ	852	18	CBOC	PBO
644GA	SUN CITY, AZ	AZ	853	18	CBOC	PBO
644GB	SHOW LOW, AZ	AZ	859	18	CBOC	NPB
644GC	BUCKEYE, AZ	AZ	853	18	CBOC	NPB
644GD	PAYSON, AZ	AZ	855	18	CBOC	NPB
646	PITTSBURGH UNIV DR, PA	PA	152	4	VAMC	PBH
646A4	VA HCS - HEINZ DIVISION, PA	PA	152	4	VAMC	PBH
646A5	PITTSBURGH HIGHLAND DR, PA	PA	152	4	VAMC	PBH
646GA	SAINT CLAIRSVILLE, OH	OH	439	4	CBOC	NPB
646GB	GREENSBURG, PA	PA	156	4	CBOC	PBO
646GC	ALIQUIPPA, PA	PA	150	4	CBOC	PBO
646GD	WASHINGTON, PA	PA	153	4	CBOC	PBO
646GE	UNIONTOWN, PA	PA	154	4	CBOC	NPB
648	PORTLAND, OR	OR	972	20	VAMC	PBH
648A4	VANCOUVER, WA	WA	986	20	VAMC	PBH
648GA	BEND, OR	OR	977	20	CBOC	NPB
648GB	SALEM, OR	OR	973	20	CBOC	NPB
648GD	NORTH COAST, OR	OR	971	20	CBOC	NPB
649	PRESCOTT, AZ	AZ	863	18	VAMC	PBH
649GA	KINGMAN, AZ	AZ	864	18	CBOC	NPB
649GB	BELLEMONT, AZ	AZ	860	18	CBOC	NPB
649GC	LAKE HAVASU CITY, AZ	AZ	864	18	CBOC	NPB
649GD	ANTHEM, AZ	AZ	850	18	CBOC	NPB
649GE	COTTONWOOD, AZ	AZ	863	18	CBOC	PBO

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations

RC V2.6 Facility List 12/13/2005

Page 12 of 15

Sta #	VA Facility Location	ST	ZIP 3	VN	TYPE	PB
650	PROVIDENCE, RI	RI	029	1	VAMC	PBH
650GA	NEW BEDFORD, MA	MA	027	1	CBOC	PBO
650GB	HYANNIS, MA	MA	026	1	CBOC	NPB
650GC	OAK BLUFFS, MA	MA	025	1	CBOC	NPB
650GD	MIDDLETOWN, RI	RI	028	1	CBOC	PBO
650GE	NANTUCKET, MA	MA	025	1	CBOC	NPB
652	RICHMOND, VA	VA	232	6	VAMC	PBH
652GA	FREDERICKSBURG, VA	VA	224	6	CBOC	NPB
653	ROSEBURG, OR	OR	974	20	VAMC	PBH
653BY	EUGENE, OR	OR	974	20	CBOC	NPB
653GA	BANDON, OR	OR	974	20	CBOC	NPB
653GB	BROOKINGS, OR	OR	974	20	CBOC	NPB
654	RENO, NV	NV	895	21	VAMC	PBH
654GA	AUBURN, CA	CA	956	21	CBOC	NPB
654GB	MINDEN, NV	NV	894	21	CBOC	PBO
655	SAGINAW, MI	MI	486	11	VAMC	PBH
655GA	GAYLORD, MI	MI	497	11	CBOC	NPB
655GB	TRAVERSE CITY, MI	MI	496	11	CBOC	NPB
655GC	OSCODA, MI	MI	487	11	CBOC	NPB
656	SAINT CLOUD, MN	MN	563	23	VAMC	PBH
656GA	BRAINERD, MN	MN	564	23	CBOC	NPB
656GB	MONTEVIDEO, MN	MN	562	23	CBOC	NPB
657	SAINT LOUIS JOHN COCHRAN, MO	MO	631	15	VAMC	PBH
657A0	SAINT LOUIS JEFF BARRACKS, MO	MO	631	15	VAMC	PBH
657A4	POPLAR BLUFF, MO	MO	639	15	VAMC	PBH
657A5	MARION, IL	IL	629	15	VAMC	PBH
657DP	MARION NON-VA HOSPITALS, IL	IL	629	15	CMC	PBH
657DS	ST. LOUIS NON-VA HOSPITAL, IL	IL	631	15	CMC	PBH
657GA	BELLEVILLE, IL	IL	622	15	CBOC	PBO
657GB	SAINT LOUIS CBOC, MO	MO	631	15	CBOC	PBO
657GD	SAINT CHARLES, MO	MO	633	15	CBOC	PBO
657GE	SPRINGFIELD, IL	IL	627	15	CBOC	NPB
657GF	WEST PLAINS, MO	MO	657	15	CBOC	NPB
657GG	PARAGOULD, AR	AR	724	15	CBOC	NPB
657GH	CAPE GIRARDEAU, MO	MO	637	15	CBOC	NPB
657GI	FARMINGTON, MO	MO	636	15	CBOC	NPB
657GJ	EVANSVILLE, IN	IN	477	15	CBOC	NPB
657GK	MOUNT VERNON, IL	IL	628	15	CBOC	NPB
657GL	PADUCAH, KY	KY	420	15	CBOC	NPB
657GM	EFFINGHAM, IL	IL	624	15	CBOC	NPB
657GN	SALEM, MO	MO	655	15	CBOC	NPB
657GO	HANSON CBOC, KY	KY	424	15	CBOC	NPB
658	SALEM, VA	VA	241	6	VAMC	PBH
658GA	TAZEWELL, VA	VA	246	6	CBOC	NPB
658GB	DANVILLE, VA	VA	245	6	CBOC	NPB
658HA	STUARTS DRAFT, VA	VA	244	6	CBOC	NPB
658HB	PULASKI, VA	VA	243	6	CBOC	NPB
658HC	LYNCHBURG, VA	VA	245	6	CBOC	NPB
658HD	HILLSVILLE, VA	VA	243	6	CBOC	NPB
658HE	MARTINSVILLE, VA	VA	241	6	CBOC	NPB
658HG	COVINGTON, VA	VA	244	6	CBOC	NPB
658HH	MARION, VA	VA	243	6	CBOC	NPB
659	SALISBURY, NC	NC	281	6	VAMC	PBH
659BY	WINSTON-SALEM, NC	NC	271	6	CBOC	PBO
659GA	CHARLOTTE, NC	NC	282	6	CBOC	NPB
660	SALT LAKE CITY, UT	UT	841	19	VAMC	PBH
660GA	POCATELLO, ID	ID	832	19	CBOC	NPB
660GB	OGDEN, UT	UT	844	19	CBOC	PBO

Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations

RC V2.6 Facility List 12/13/2005

Page 13 of 15


Sta #	VA Facility Location	ST	ZIP 3	VN	TYPE	PB
660GC	ELY, NV	NV	893	19	CBOC	NPB
660GD	ROOSEVELT, UT	UT	840	19	CBOC	NPB
660GE	OREM, UT	UT	840	19	CBOC	PBO
660GF	GREEN RIVER, WY	WY	829	19	CBOC	NPB
660GG	SAINT GEORGE, UT	UT	847	19	CBOC	NPB
660GI	NEPHI, UT	UT	846	19	CBOC	NPB
662	SAN FRANCISCO, CA	CA	941	21	VAMC	PBH
662BU	SAN FRANCISCO HOMELESS CTR, CA	CA	941	21	CBOC	PBO
662GA	SANTA ROSA, CA	CA	954	21	CBOC	NPB
662GC	EUREKA, CA	CA	955	21	CBOC	NPB
662GD	UKIAH, CA	CA	954	21	CBOC	NPB
662GE	SAN BRUNO CBOC, CA	CA	940	21	CBOC	PBO
663	SEATTLE, WA	WA	981	20	VAMC	PBH
663A4	AMERICAN LAKE/TACOMA, WA	WA	984	20	VAMC	PBH
663GA	LYNNWOOD/NORTHGATE, WA	WA	980	20	CBOC	PBO
663GB	BREMERTON, WA	WA	983	20	CBOC	PBO
664	SAN DIEGO, CA	CA	921	22	VAMC	PBH
664BY	SAN DIEGO CBOC, CA	CA	921	22	CBOC	PBO
664GA	EL CENTRO, CA	CA	922	22	CBOC	NPB
664GB	VISTA, CA	CA	920	22	CBOC	PBO
664GC	CHULA VISTA, CA	CA	919	22	CBOC	PBO
664GD	ESCONDIDO, CA	CA	920	22	CBOC	PBO
666	SHERIDAN, WY	WY	828	19	VAMC	PBH
666GB	CASPER, WY	WY	826	19	CBOC	NPB
666GC	RIVERTON, WY	WY	825	19	CBOC	NPB
666GD	POWELL, WY	WY	824	19	CBOC	NPB
666GE	GILLETTE, WY	WY	827	19	CBOC	NPB
666GF	ROCK SPRINGS CBOC, WY	WY	829	19	CBOC	NPB
667	SHREVEPORT, LA	LA	711	16	VAMC	PBH
667GA	TEXARKANA, AR	AR	718	16	CBOC	NPB
667GB	MONROE, LA	LA	712	16	CBOC	NPB
667GC	LONGVIEW, TX	TX	756	16	CBOC	NPB
668	SPOKANE, WA	WA	992	20	VAMC	PBH
668HK	SPOKANE MOC, WA	WA	992	20	CBOC	PBO
671	SAN ANTONIO, TX	TX	782	17	VAMC	PBH
671A4	KERRVILLE, TX	TX	780	17	VAMC	PBH
671B0	MCALLEN, TX	TX	785	17	CBOC	NPB
671BY	SAN ANTONIO CBOC, TX	TX	782	17	CBOC	PBO
671BZ	CORPUS CHRISTI, TX	TX	784	17	CBOC	NPB
671GA	BROWNSVILLE, TX	TX	785	17	CBOC	NPB
671GB	VICTORIA, TX	TX	779	17	CBOC	NPB
671GC	DEL RIO, TX	TX	788	17	CBOC	NPB
671GD	EAGLE PASS, TX	TX	788	17	CBOC	NPB
671GE	LAREDO, TX	TX	780	17	CBOC	NPB
671GF	SOUTH BEXAR COUNTY, TX	TX	782	17	CBOC	PBO
671GG	ALICE, TX	TX	783	17	CBOC	NPB
671GH	BEEVILLE, TX	TX	781	17	CBOC	NPB
671GI	KINGSVILLE, TX	TX	783	17	CBOC	NPB
671GJ	UVALDE, TX	TX	788	17	CBOC	NPB
671GK	SAN ANTONIO CBOC, TX	TX	782	17	CBOC	NPB
671GL	NEW BRAUNFELS, TX	TX	781	17	CBOC	NPB
671GN	SEGUIN CBOC, TX	TX	781	17	CBOC	PBO
672	SAN JUAN, PR	PR	009	8	VAMC	PBH
672B0	PONCE, PR	PR	007	8	CBOC	NPB
672BZ	MAYAGUEZ, PR	PR	006	8	CBOC	NPB
672GA	SAINT CROIX, VI	VI	008	8	CBOC	NPB
672GB	SAINT THOMAS, VI	VI	008	8	CBOC	NPB
672GC	ARECIBO, PR	PR	006	8	CBOC	NPB

**Supplementary Table 3
VA Medical Facility Locations, Three-Digit ZIP Codes,
and Provider-Based/Non-Provider-Based Designations**

RC V2.6 Facility List 12/13/2005

Page 14 of 15

Sta #	VA Facility Location	ST	ZIP 3	VN	TYPE	PB
672GD	KINGSHILL, VI	VI	008	8	CBOC	NPB
672GE	GUAYAMA, PR	PR	007	8	CBOC	PBO
673	TAMPA, FL	FL	336	8	VAMC	PBH
673BY	ORLANDO, FL	FL	328	8	CBOC	NPB
673BZ	PORT RICHEY, FL	FL	346	8	CBOC	NPB
673GA	VIERA/MELBOURNE, FL	FL	329	8	CBOC	NPB
673GB	LAKELAND, FL	FL	338	8	CBOC	PBO
673GC	BROOKSVILLE, FL	FL	346	8	CBOC	NPB
673GD	SANFORD, FL	FL	327	8	CBOC	NPB
673GE	KISSIMMEE, FL	FL	347	8	CBOC	NPB
673GF	ZEPHYRHILLS, FL	FL	335	8	CBOC	NPB
674	TEMPLE, TX	TX	765	17	VAMC	PBH
674A4	WACO, TX	TX	767	17	VAMC	PBH
674A5	MARLIN, TX	TX	766	17	VAMC	PBH
674BY	AUSTIN, TX	TX	787	17	CBOC	NPB
674GA	PALESTINE, TX	TX	758	17	CBOC	NPB
674GB	BROWNWOOD, TX	TX	768	17	CBOC	NPB
674GC	BRYAN/COLLEGE STATION, TX	TX	778	17	CBOC	NPB
674GD	CEDAR PARK, TX	TX	786	17	CBOC	NPB
674GE	MARLIN CBOC, TX	TX	766	17	CBOC	PBO
676	TOMAH, WI	WI	546	12	VAMC	PBH
676GA	WAUSAU, WI	WI	544	12	CBOC	NPB
676GC	LA CROSSE, WI	WI	546	12	CBOC	NPB
676GD	WISCONSIN RAPIDS, WI	WI	544	12	CBOC	NPB
676GE	LOYAL, WI	WI	544	12	CBOC	NPB
676HB	WAUTOMA, WI	WI	549	12	CBOC	NPB
678	TUCSON, AZ	AZ	857	18	VAMC	PBH
678GA	SIERRA VISTA, AZ	AZ	856	18	CBOC	NPB
678GB	YUMA, AZ	AZ	853	18	CBOC	NPB
678GC	CASA GRANDE, AZ	AZ	852	18	CBOC	NPB
678GD	SAFFORD, AZ	AZ	855	18	CBOC	NPB
678GE	GREEN VALLEY, AZ	AZ	856	18	CBOC	PBO
679	TUSCALOOSA, AL	AL	354	7	VAMC	PBH
679PA	TUSCALOOSA PRRT, AL	AL	354	7	CBOC	PBO
687	WALLA WALLA, WA	WA	993	20	VAMC	PBH
687GA	RICHLAND, WA	WA	993	20	CBOC	NPB
687GB	LEWISTON, ID	ID	835	20	CBOC	NPB
687HA	YAKIMA, WA	WA	989	20	CBOC	NPB
688	WASHINGTON, DC	DC	204	5	VAMC	PBH
688GA	ALEXANDRIA, VA	VA	223	5	CBOC	PBO
688GB	WASHINGTON SE, DC	DC	200	5	CBOC	PBO
688GC	LANDOVER, MD	MD	207	5	CBOC	PBO
688GD	CHARLOTTE HALL, MD	MD	206	5	CBOC	PBO
688PA	WASHINGTON CWT/TR DC	DC	204	5	VAMC	PBO
689	WEST HAVEN, CT	CT	065	1	VAMC	PBH
689A4	NEWINGTON, CT	CT	061	1	CBOC	PBO
689GA	WATERBURY, CT	CT	067	1	CBOC	PBO
689GB	STAMFORD, CT	CT	069	1	CBOC	PBO
689GC	WINDHAM, CT	CT	062	1	CBOC	NPB
689GD	WINSTED, CT	CT	060	1	CBOC	NPB
689GE	DANBURY, CT	CT	068	1	CBOC	PBO
689HA	WILLIMANTIC, CT	CT	062	1	CBOC	NPB
689HC	NEW LONDON, CT	CT	063	1	CBOC	NPB
691	WEST LOS ANGELES, CA	CA	900	22	VAMC	PBH
691A4	SEPULVEDA, CA	CA	913	22	CBOC	PBO
691GA	WEST LOS ANGELES CBOC, CA	CA	900	22	CBOC	PBO
691GB	SANTA BARBARA, CA	CA	931	22	CBOC	NPB
691GC	GARDENA, CA	CA	902	22	CBOC	PBO





Federal Register

Friday,
January 6, 2006

Part III

Department of Energy

Federal Energy Regulatory Commission

**18 CFR Parts 2 and 33
Transactions Subject to FPA Section 203;
Final Rule**

DEPARTMENT OF ENERGY**Federal Energy Regulatory Commission****18 CFR Parts 2 and 33****[Docket No. RM05-34-000; Order No. 669]****Transactions Subject to FPA Section 203**

Issued December 23, 2005.

AGENCY: Federal Energy Regulatory Commission.**ACTION:** Final rule.**SUMMARY:** Under Subtitle G (Market Transparency, Enforcement, and Consumer Protection), section 1289

(Merger Review Reform), of Title XII (Electricity Modernization Act of 2005), of the Energy Policy Act of 2005 (EPAct 2005), Public Law 109-58, 119 Stat. 594 (2005), the Federal Energy Regulatory Commission (Commission) amends 18 CFR 2.26 and 18 CFR part 33 to implement amended section 203 of the Federal Power Act (FPA).¹

DATES: *Effective Date:* This Final Rule will become effective on February 8, 2006.

FOR FURTHER INFORMATION CONTACT: Sarah McWane (Legal Information), Office of the General Counsel, Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426. (202) 502-8372.

Phillip Nicholson (Technical Information), Office of Markets, Tariffs and Rates—West, Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC, 20426. (202) 502-8240.

Jan Macpherson (Legal Information), Office of the General Counsel, Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426. (202) 502-8921.

James Akers (Technical Information), Office of Markets, Tariffs and Rates—West, Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426. (202) 502-8101.

SUPPLEMENTARY INFORMATION:

TABLE OF CONTENTS

	Paragraph Nos.
I. Introduction	1.
II. Background	5.
A. Commission Merger Policy Before Effective Date of Amended FPA Section 203	5.
B. Section 203 As Amended By EPAct 2005	15.
C. Notice of Proposed Rulemaking on Transactions Subject to FPA Section 203	25.
III. Discussion	27.
A. Amendments to 18 CFR Part 33	27.
1. Section 33.1(a)—Applicability	28.
2. Section 33.1(b)—Definitions of "Associate Company," "Holding Company," "Holding Company System," "Transmitting Utility," and "Electric Utility Company"	33.
3. Section 33.1(b)—Definition of "Existing Generation Facility"	74.
4. Section 33.1(b)—Definition of "Non-Utility Associate Company"	88.
5. Section 33.1(b)—Definition of "Value"	94.
6. Compliance with Section 203	127.
7. Cash Management Arrangements, Intra-Holding Company System Financing, Securities Under Amended Section 203, and Blanket Authorizations	133.
8. Section 33.2(j)—General Information Requirements Regarding Cross-Subsidization	146.
9. Section 33.11—Commission Procedures for Consideration of Applications under Section 203 of the FPA	172.
B. Amendments to 18 CFR 2.26—The Merger Policy Statement	195.
1. Comments	198.
2. Commission Determination	202.
IV. Information Collection Statement	203.
V. Environmental Analysis	207.
VI. Regulatory Flexibility Act Certification	208.
VII. Document Availability	210.
VIII. Effective Date and Congressional Notification	213.

Before Commissioners: Joseph T. Kelliher, Chairman; Nora Mead Brownell, and Suedeen G. Kelly.

I. Introduction

1. On August 8, 2005, the Energy Policy Act of 2005 (EPAct 2005)² was signed into law. Section 1289 (Merger Review Reform) of Title XII, Subtitle G (Market Transparency, Enforcement, and Consumer Protection),³ of EPAct 2005 amends section 203 of the Federal Power Act (FPA).⁴ Amended section 203: (1) increases (from \$50,000 to greater than \$10 million) the value threshold for certain transactions being subject to section 203; (2) extends the

scope of section 203 to include transactions involving certain transfers of generation facilities and certain holding companies' transactions with a value in excess of \$10 million; (3) limits the Federal Energy Regulatory Commission's (Commission) review of a public utility's acquisition of securities of another public utility to transactions greater than \$10 million; (4) requires that the Commission, when reviewing proposed section 203 transactions, examine cross-subsidization and pledges or encumbrances of utility assets; and (5) directs the Commission to adopt, by rule, procedures for the

expeditious consideration of applications for the approval of dispositions, consolidations, or acquisitions under section 203.

2. As discussed below, on October 3, 2005, the Commission issued a notice of proposed rulemaking (NOPR) in which it proposed certain modifications to 18 CFR 2.26 and 18 CFR part 33 to implement amended section 203.⁵ Numerous comments were filed by a variety of entities.

3. In this Final Rule, the Commission adopts some of the proposals in the

¹ 16 U.S.C. 824b (2000).

² Energy Policy Act of 2005, Pub. L. No. 109-58, 119 Stat. 594 (2005).

³ EPAct 2005 §§ 1281 *et seq.*

⁴ 16 U.S.C. 824b (2000).

⁵ *Transactions Subject to FPA Section 203*, 70 FR 58,636 (October 7, 2005), FERC Stats. & Regs. ¶ 32,589 (2005).

NOPR as well as many of the commenters' recommendations. Specifically, this Final Rule:

(1) Implements the new applicability of amended section 203 of the FPA;

(2) Grants blanket authorizations for certain types of transactions, including foreign utility acquisitions by holding companies, intra-holding company system financing and cash management arrangements, certain internal corporate reorganizations, and certain investments in transmitting utilities and electric utility companies;

(3) Adopts many of the NOPR's proposed defined terms, including "electric utility company," "holding company," and "non-utility associate company," but clarifies the application of these terms to certain entities;

(4) Amends the proposed definition of "existing generation facility;"

(5) Adopts a simpler rule than was proposed in the NOPR with respect to the determination of "value" as it applies to various section 203 transactions;

(6) Clarifies and refines the NOPR's proposal with respect to a section 203 applicant's obligation to file evidentiary support to demonstrate that a proposed transaction will not result in cross-subsidization of a non-utility associate company or pledge or encumbrance of utility assets for the benefit of an associate company; and

(7) Adopts the NOPR's proposal that the Commission provide expeditious consideration of completed applications for the approval of transactions that are not contested, do not involve mergers, and are consistent with Commission precedent.

4. Our goal is to carry out the expanded authorities and requirements contained in the new section 203 amendments to ensure that all jurisdictional transactions subject to section 203 are consistent with the public interest and at the same time ensure that our rules do not impede day-to-day business transactions or stifle timely investment in transmission and generation infrastructure. We believe we have accomplished this result with the rules herein. However, at the technical conference we announced in our final rule implementing the Public Utility Holding Company Act of 2005 (PUHCA 2005),⁶ to be held within the next year,⁷ we will also address

⁶ EPAct 2005 sections 1261 *et seq.* Repeal of the Public Utility Holding Company Act of 1935 and Enactment of the Public Utility Holding Company Act of 2005, Order No. 667, FERC Stats. & Regs. ¶ 31,197 (2005) (PUHCA 2005 Final Rule).

⁷ PUHCA 2005 Final Rule at P 17. Specifically, in the PUHCA Final Rule, the Commission stated that we intend to hold a technical conference no later

than one year after PUHCA 2005 becomes effective to evaluate whether additional exemptions, different reporting requirements, or other regulatory actions need to be considered. The Commission's regulations implementing PUHCA 2005 take effect on February 8, 2006.

II. Background

A. Commission Merger Policy Before Effective Date of Amended FPA Section 203

5. Section 203 of the FPA⁸ currently provides that: No public utility shall sell, lease or otherwise dispose of the whole of its facilities subject to the jurisdiction of the Commission, or any part thereof of a value in excess of \$50,000, or by any means whatsoever, directly or indirectly, merge or consolidate such facilities or any part thereof with those of any other person, or purchase, acquire, or take any security of any other public utility, without first having secured an order of the Commission authorizing it to do so. The Commission shall approve such transactions if they are "consistent with the public interest."

6. In 1996, the Commission issued the Merger Policy Statement⁹ updating and clarifying the Commission's procedures, criteria, and policies concerning public utility mergers. The purpose of the Merger Policy Statement was to ensure that mergers are consistent with the public interest and to provide greater certainty and expedition in the Commission's analysis of merger applications.

7. The Merger Policy Statement sets out three factors the Commission generally considers when analyzing whether a proposed section 203 transaction¹⁰ is consistent with the public interest: Effect on competition; effect on rates; and effect on regulation.

8. With respect to the first factor, the effect on competition, the Merger Policy

Statement adopts the Department of Justice (DOJ)/Federal Trade Commission (FTC) 1992 Horizontal Merger Guidelines (Guidelines)¹¹ as the analytical framework for examining horizontal market power concerns. The Merger Policy Statement also uses an analytical screen (Appendix A analysis) to allow early identification of transactions that clearly do not raise competitive concerns.¹² As part of the screen analysis, applicants must define the relevant products sold by the merging entities, identify the customers and potential suppliers in the geographic markets that are likely to be affected by the proposed transaction, and measure the concentration in those markets. Using the Delivered Price Test to identify alternative competing suppliers, the concentration of potential suppliers included in the defined market is then measured by the Herfindahl-Hirschman Index (HHI) and used as a screen to determine which transactions clearly do not raise market power concerns.

9. The Commission stated in the Merger Policy Statement that it will examine the second factor, the effect on rates, by focusing on customer protections designed to insulate consumers from any harm resulting from the transaction.¹³

10. The Merger Policy Statement set forth a third factor for examination, the effect on regulation. This includes both state regulation and the Commission's regulation, including any potential shift in regulation from the Commission to the Securities and Exchange Commission (SEC) due to a transaction creating a registered public utility holding company under the Public Utility Holding Company Act of 1935 (PUHCA 1935).¹⁴ The Merger Policy Statement explained that, unless applicants commit themselves to abide by this Commission's policies with regard to affiliate transactions involving non-power goods and services, we will set the issue of the effect on regulation for hearing.¹⁵

11 U.S. Department of Justice and Federal Trade Commission, Horizontal Merger Guidelines, 57 FR 41,552 (1992), revised, 4 Trade Reg. Rep. (CCH) ¶ 13,104 (Apr. 8, 1997).

¹² Merger Policy Statement at 30,119–20.

¹³ See *id.* at 30,121–24.

¹⁴ 15 U.S.C. 79a *et seq.* (2000).

¹⁵ Merger Policy Statement at 30,125; see also *Atlantic City Electric Co. and Delmarva Power & Light Co.*, 80 FERC ¶ 61,126 at 61,412, order denying reh'g, 81 FERC ¶ 61,173 (1997). With respect to a transaction's effect on state regulation, where the state commissions have authority to act on the transaction, the Commission stated that it intends to rely on them to exercise their authority to protect state interests.

⁸ EPAct 2005's amendments to FPA section 203 take effect on February 8, 2006. We will generally refer to EPAct 2005's amended section 203 of the FPA as "amended" or "new" section 203. All other references to FPA section 203 are as it exists now.

⁹ *Inquiry Concerning the Commission's Merger Policy Under the Federal Power Act: Policy Statement*, Order No. 592, 61 FR 68,595 (Dec. 30, 1996), FERC Stats. & Regs. ¶ 31,044 (1996), reconsideration denied, Order No. 592-A, 62 FR 33,340 (June 19, 1997), 79 FERC ¶ 61,321 (1997) (Merger Policy Statement).

¹⁰ Although the Commission applies these factors to all section 203 transactions, not just mergers, the filing requirements and the level of detail required may differ. *Id.* at 30,113 n.7. See also 18 CFR 2.26 (2005) (codifying the Merger Policy Statement).

11. The Commission later issued the Filing Requirements Rule,¹⁶ a final rule updating the filing requirements under 18 CFR part 33 of the Commission's regulations for section 203 applications. The Filing Requirements Rule implements the Merger Policy Statement and provides detailed guidance to applicants for preparing applications. The revised filing requirements also assist the Commission in determining whether section 203 transactions are consistent with the public interest, provide more certainty, and expedite the Commission's handling of such applications.

12. Further, the Filing Requirements Rule codified the Commission's screening approach, provided specific filing requirements consistent with Appendix A of the Commission's Merger Policy Statement, established guidelines for vertical competitive analysis, and set forth filing requirements for mergers that may raise vertical market power concerns.

13. The Filing Requirements Rule also reduced the information burden for transactions that clearly raise no competitive concerns. The Commission explained that for certain transactions, abbreviated filing requirements are appropriate because it is relatively easy to determine that they will not harm competition and, thus, a full-fledged horizontal screen analysis or vertical competitive analysis is not required.¹⁷

14. The Commission stated in the Filing Requirements Rule that it intended to continue processing section 203 applications expeditiously, with a goal of issuing an initial order for most mergers within 150 days of a completed application.¹⁸ Further, the Commission stated that it intended to continue processing uncontested non-merger applications within 60 days of filing and protested non-merger applications within 90 days of filing.¹⁹

B. Section 203 as Amended by EAct 2005

15. EAct 2005 revises section 203(a) of the FPA as follows:

16. Amended section 203(a)(1) states that no public utility shall, without first

having secured an order of the Commission authorizing it to do so: (A) Sell, lease, or otherwise dispose of the whole of its facilities subject to the jurisdiction of the Commission, or any part thereof of a value in excess of \$10 million; (B) merge or consolidate, directly or indirectly, such facilities or any part thereof with those of any other person, by any means whatsoever; (C) purchase, acquire, or take any security with a value in excess of \$10 million of any other public utility; or (D) purchase, lease, or otherwise acquire an existing generation facility: (i) That has a value in excess of \$10 million; and (ii) that is used for interstate wholesale sales and over which the Commission has jurisdiction for ratemaking purposes.

17. Section 203(a)(2) adds the entirely new requirement that no holding company in a holding company system that includes a transmitting utility or an electric utility shall purchase, acquire, or take any security with a value in excess of \$10 million of, or, by any means whatsoever, directly or indirectly, merge or consolidate with, a transmitting utility, an electric utility company, or a holding company in a holding company system that includes a transmitting utility, or an electric utility company, with a value in excess of \$10 million without prior Commission authorization.

18. Like the existing section 203(a), amended section 203(a)(3) provides that upon receipt of an application for such approval, the Commission shall give reasonable notice in writing to the Governor and state commission of each of the states in which the physical property affected is situated, and to such other persons as it may deem advisable.

19. Amended section 203(a)(4) states that after notice and opportunity for hearing, the Commission shall approve the proposed disposition, consolidation, acquisition, or change in control if it finds that the transaction will be consistent with the public interest. It also specifically provides that the Commission must find that the transaction will not result in cross-subsidization of a non-utility associate company or pledge or encumbrance of utility assets for the benefit of an associate company, unless that cross-subsidization, pledge, or encumbrance will be consistent with the public interest.

20. Section 203(a)(5) adds the entirely new requirement that the Commission shall: By rule, adopt procedures for the expeditious consideration of applications for the approval of dispositions, consolidations, or acquisitions, under this section. Such

rules shall identify classes of transactions, or specify criteria for transactions, that normally meet the standards established in paragraph (4). The Commission shall provide expedited review for such transactions. The Commission shall grant or deny any other application for approval of a transaction not later than 180 days after the application is filed. If the Commission does not act within 180 days, such application shall be deemed granted unless the Commission finds, based on good cause, that further consideration is required to determine whether the proposed transaction meets the standards of paragraph (4) and issues an order tolling the time for acting on the application for not more than 180 days, at the end of which additional period the Commission shall grant or deny the application.

21. Section 203(a)(6), which is also new, provides that for purposes of this subsection, the terms "associate company," "holding company," and "holding company system" have the meaning given those terms in PUHCA 2005.

22. Section 1289(b) provides that the amendments made by this section shall take effect six months after the date of enactment of EAct 2005, or February 8, 2006. This is the same date on which the repeal of PUHCA 1935 and enactment of the PUHCA 2005, are to take effect.²⁰

23. Section 1289(c) provides that the amendments made by subsection (a) shall not apply to any section 203 application that was filed on or before the date of enactment of EAct 2005.

24. Section 203(b) of the FPA remains unchanged.²¹

C. Notice of Proposed Rulemaking on Transactions Subject to FPA Section 203

25. On October 7, 2005, the Commission's NOPR on *Transactions Subject to FPA Section 203* was published in the *Federal Register*.²² As discussed in more detail below, in the

¹⁶ Revised Filing Requirements Under Part 33 of the Commission's Regulations, Order No. 642, 65 FR 70,983 (Nov. 28, 2000), FERC Stats. & Regs., July 1996-Dec. 2000 ¶ 31,111 (2000), order on reh'g, Order No. 642-A, 66 FR 16,121 (Mar. 23, 2001), 94 FERC ¶ 61,289 (2001) (codified at 18 CFR Part 33 (2005)) (Filing Requirements Rule).

¹⁷ Filing Requirements Rule at 31,902 & 31,907. The Commission clarified that, if it later determined that a filing raised competitive issues, the Commission would evaluate those issues and direct the applicant to submit any data needed to satisfy the Commission's concerns. *Id.* at n.79.

¹⁸ *Id.* at 31,873.

¹⁹ *Id.* at 31,876.

²⁰ *Id.* §§ 1261, 1274. PUHCA 2005 Final Rule at P 1.

²¹ Section 203(b) states:

The Commission may grant any application for an order under this section in whole or in part and upon such terms and conditions as it finds necessary or appropriate to secure the maintenance of adequate service and the coordination in the public interest of facilities subject to the jurisdiction of the Commission. The Commission may from time to time for good cause shown make such orders supplemental to any order made under this section as it may find necessary or appropriate.

²² 70 FR 58,636 (October 7, 2005). On October 19, 2005, an errata notice was published in the *Federal Register* (70 FR 60,748), correcting Paragraph 1, footnote 4 of the NOPR to refer to February 8, 2006, as opposed to February 3, 2006.

NOPR the Commission proposed to revise 18 CFR part 33 and 18 CFR 2.26 of its rules to implement amended section 203 of the FPA. Comments were due on or before November 7, 2005.²³

26. This Final Rule will be effective on the date on which amended section 203 of the FPA takes effect, February 8, 2006.

III. Discussion

A. Amendments to 18 CFR Part 33

27. In the NOPR, the Commission proposed to amend 18 CFR part 33 by: Revising the title to read "Applications Under Federal Power Act Section 203;" amending section 33.1(a) to clarify what transactions are subject to amended section 203 and part 33 as a result of amended sections 203(a)(1)(A)-(D) and (a)(2) of the FPA; adding a new subsection 33.1(b) that defines certain new terms used in amended section 203 that are not defined in EPAAct 2005; adding a new subsection 33.2(j) to implement amended section 203(a)(4) regarding cross-subsidization and pledge or encumbrance issues; and adding new sections 33.11(a) and (b) to implement amended section 203(a)(5) regarding the Commission's procedures for the consideration of applications under section 203 of the FPA.

1. Section 33.1(a)—Applicability

28. Proposed section 33.1(a) clarifies what transactions are subject to amended section 203 and part 33 as a result of amended sections 203(a)(1)(A)-(D) and (a)(2) of the FPA.²⁴

a. Comments

29. Several commenters raise concerns, described in more detail below, regarding the applicability of amended section 203 to transactions involving foreign utility companies (FUCOs), qualifying facilities (QFs), exempt wholesale generators (EWGs),²⁵ rural electric cooperatives, local distribution companies, stand-alone generation and retail sales, as well as intrastate transactions, *i.e.*, transactions wholly within the Electric Reliability Council of Texas (ERCOT), Alaska, or Hawaii. They generally argue that Congress did not intend to expand significantly the Commission's jurisdiction under amended section 203 and, therefore, did not convey to the Commission jurisdiction over these

types of transactions. Commenters also express concern over any potential overlap between the Commission's scope of review under amended section 203 and the scope of review by state commissions. They state that the Commission should not use its new section 203 authority to preempt state regulatory authority over rates and approvals of utility mergers and acquisitions.

30. Electric Power Supply Association (EPSA) requests that the Commission modify the text of proposed section 33.1(a)(1)(ii) to clarify that any merger or consolidation must exceed the \$10 million threshold before section 203 filing approval is required. It states that the Commission should not alter its past practice of applying the statutory dollar threshold to all types of transactions requiring section 203 approval, including mergers and acquisitions. EPSA explains that the mergers and acquisitions clause of the currently effective section 203 and section 203 as amended by EPAAct 2005 are substantially the same and do not specify a value amount. EPSA points out, however, that although the currently effective statutory language, like the newly enacted EPAAct 2005 language, did not codify the monetary threshold with respect to mergers and consolidations, for decades the Commission's regulations (section 33.1(a)(2)) have required section 203 applications for mergers, consolidations and acquisitions only if they meet the \$50,000 threshold (which on February 8, 2006 will become \$10 million). EPSA states that the NOPR provides no reason for the Commission to change its interpretation of section 203.

b. Commission Determination

31. Most of the concerns regarding the applicability of amended section 203 involve new section 203(a)(2) and the Commission's proposed definitions of "electric utility company" and "holding company." Accordingly, these comments are discussed in greater detail in those sections below. Similarly, concerns regarding any potential overlap between the scope of review of the Commission under amended section 203 and that of state commissions are also discussed with the proposed definition of "electric utility company," below.

32. We reject EPSA's request that we revise proposed section 33.1(a)(1)(ii) to clarify that any merger or consolidation must also exceed a monetary threshold before section 203 filing approval is required. The plain language of amended section 203(a)(1)(B) does not permit such an interpretation. Under

amended section 203(a)(1)(B): "No public utility shall * * * merge or consolidate, directly or indirectly, such facilities [facilities subject to the jurisdiction of the Commission] or any part thereof with those of any other person, by any means whatsoever." This provision, on its face, does not impose a dollar threshold on mergers or consolidations and proposed section 33.1(a)(1)(ii) is consistent with the statutory provision. While Congress included a \$10 million threshold for amended subsections 203(a)(1)(A), (C), (D), and 203(a)(2) (dispositions of jurisdictional facilities; acquisitions of securities of public utilities; purchases of existing generation facilities; holding company acquisitions), Congress clearly did not adopt a monetary threshold for mergers and consolidations in amended subsection 203(a)(1)(B). We note that "[w]here Congress includes particular language in one section of a statute but omits it in another section of the same Act, it is generally presumed that Congress acts intentionally and purposely in the disparate inclusion or exclusion."²⁶ In light of the unambiguous statutory language, we are not convinced by EPSA's unsupported assertion that the failure to include a monetary threshold as to mergers and consolidations was an "oversight" and that "Congress did not intend to change [the currently effective] statutory and regulatory structure."²⁷ While our regulations previously applied a dollar threshold to mergers and consolidations, such an approach is no longer tenable, since it is inconsistent with the plain language of amended section 203. Thus, we will not revise section 33.1(a)(1)(ii) to include a \$10 million threshold.

2. Section 33.1(b)—Definitions of "Associate Company," "Holding Company," "Holding Company System," "Transmitting Utility," and "Electric Utility Company"

33. As noted above, section 203(a)(2) adds an entirely new requirement to the FPA:

No holding company in a holding company system that includes a transmitting utility or an electric utility shall purchase, acquire, or take any security with a value in excess of \$10 million of, or, by any means whatsoever, directly or indirectly, merge or consolidate with, a transmitting utility, an electric utility company, or a holding company in a holding company system that includes a transmitting utility, or an electric utility company, with a value in excess of \$10 million without first

²³ The commenters are listed in an appendix to this order.

²⁴ Because proposed section 33.1(a) is almost identical, with minor exceptions, to amended sections 203(a)(1)(A)-(D) and (a)(2), which are summarized in section II.B. above and set forth in the regulatory text, we will not recite that text here.

²⁵ PUHCA 2005 § 1266(a).

²⁶ *Russello v. United States*, 464 U.S. 16, 23 (1983) (internal citations omitted).

²⁷ EPSA Comments at 5.

having secured an order of the Commission authorizing it to do so.

a. Definition of "Electric Utility Company"

34. The scope of amended section 203(a)(2) turns in large part on the Commission's interpretation of the term "electric utility company" which, in turn, affects whether an entity is a holding company subject to section 203(a)(2). The FPA does not include a definition of "electric utility company" and the Commission proposed that the term, as used in amended section 203(a)(2), have the same meaning as in PUHCA 2005, which is "any company that owns or operates facilities used for the generation, transmission, or distribution of electric energy for sale."²⁸

i. Comments

35. The proposed definition of "electric utility company" was one of the most commented-on issues in the NOPR. While certain commenters, including the American Public Power Association and the National Rural Electric Cooperative Association (APPANRECA), Indiana Utility Regulatory Commission (Indiana Commission), and Southern Company Services, Inc. (Southern Companies), support the Commission's adoption of the PUHCA 2005 definition of "electric utility company," several commenters expressed concerns about the scope of the Commission's jurisdiction under the proposed definition. Specifically, they object to the proposed definition of the term "electric utility company" or seek clarification as to what types of entities are considered "electric utility companies," for purposes of amended section 203(a)(2), to determine whether or not they must seek section 203 approval.

36. Many commenters argue that Congress did not intend to give the Commission jurisdiction over acquisitions of foreign companies.²⁹ Certain commenters assert that if Congress had intended the PUHCA 2005 definition to apply to "electric utility company" as used in amended section 203(a)(2), it would have said so as it did for the other terms listed in amended section 203(a)(6). They explain that,

while the term "electric utility" is used once in amended section 203(a)(2) and "electric utility company" is used twice, the terms should be read similarly and should not affect the interpretation of the section. Accordingly, commenters assert that it is reasonable to read the term "electric utility company," not as used in PUHCA 2005, where the term includes foreign utility companies, but rather to have the same meaning as "electric utility," which is defined in the FPA as "a person or Federal or State agency * * * that sells electric energy."³⁰ They argue that the use of the term "electric utility" in the FPA and in the Public Utility Regulatory Policies Act of 1978 (PURPA)³¹ makes clear that "electric utilities" are domestic entities (*i.e.*, ones selling electricity in the U.S.), not foreign.³²

37. Similarly, EEI, Entergy, E.ON, PNM, and Progress Energy maintain that, in order to be consistent with the Commission's FPA jurisdiction, the Commission should define an "electric utility company" as "a person that sells electric energy in interstate commerce." Suez states that, based on an analysis of and the legislative purpose behind EPAct 2005, the Commission should exempt the acquisition of foreign utility assets by jurisdictional holding companies without captive customers by adding the word "jurisdictional" before "transmitting utility" and "electric utility company" at the end of proposed section 33.1(a)(2).

38. Other commenters add that the Commission did not have jurisdiction over foreign acquisitions before EPAct 2005 and that nothing in EPAct 2005 explicitly gives the Commission jurisdiction over foreign acquisitions. Commenters assert that Commission jurisdiction over foreign acquisitions is contrary to Congressional intent and poor public policy, because Commission review will become an impediment to U.S. investment in foreign entities and may discourage international investment in the U.S. utility industry.³³ They assert that the Commission should not review the numerous and/or routine foreign transactions that are not connected to the Commission's role of overseeing U.S. wholesale electric markets and the public interest. Certain commenters maintain that, at minimum,

the Commission should exempt from review a holding company's acquisition of a FUCO where the holding company has no captive U.S. ratepayers.

39. Several commenters argue that if the PUHCA 2005 definition of "electric utility company" is adopted in the Final Rule, the definition should incorporate the exemptions to that definition set forth in the PUHCA 2005, including the exemption for FUCOs.³⁴

40. As indicated above, commenters argue that part II of the FPA applies to interstate commerce; therefore, section 203 should not be read to extend to transactions that are not in interstate commerce.³⁵ Several commenters object to the proposed definition of "electric utility company" if it includes transactions typically reserved for state commission consideration (including transactions involving local distribution companies, stand-alone generation, retail sales and exclusively intrastate transactions), which the commenters maintain are beyond the Commission's jurisdiction.³⁶

41. Specifically, Chairman Barton maintains that Congress did not intend to give the Commission jurisdiction over mergers in ERCOT. EEI, as supported by E.ON, PNM, and Progress Energy, maintains that its alternative definition for "electric utility company," which is "a person that sells electric energy in interstate commerce," would properly exclude local distribution companies from the Commission's authority under amended section 203.

42. Further, many commenters are concerned that the proposed definition of "electric utility company" applies to QFs.³⁷ ACC, EPSA, GE EFS, and Independent Sellers ask that the Commission clarify that QFs continue to be exempt from the Commission's section 203 authority. ACC asks the Commission to exclude QFs that are not affiliated with traditional utilities, transmission providers, or other non-QF power producers in order to ensure that the parent companies of such QFs are not subject to amended section 203.

43. Similarly, EPSA, GE EFS, and Independent Sellers request that we exclude a QF's upstream owners from Commission oversight under amended 203. They state that section 210(e) of

²⁸ EPAct 2005 § 1262(5).

²⁹ *E.g.*, Congressman Joe Barton (Chairman Barton), The AES Corporation (AES), Edison Electric Institute (EEI), Entergy Services, Inc. (Entergy), E.ON AG (E.ON), EPSA, GE Energy Financial Services (GE EFS), Cogentrix Energy, Inc. and The Goldman Sachs Group, Inc. (Independent Sellers), National Grid USA (National Grid), PNM Resources, Inc. (PNM), Progress Energy, Inc. (Progress Energy), Scottish Power plc (Scottish Power), and SUEZ Energy North America (Suez).

³⁰ EPAct 2005 1291(b)(22).

³¹ 16 U.S.C. 824a-3 (2000).

³² *See, e.g.*, AES Comments at 5. For example, AES states that, unless "electric utility" is implicitly defined only to include domestic entities, the provisions of sections 111-117 of PURPA, which relate in part to the actions of state commissions as they affect "electric utilities," become a complete *non sequitur*.

³³ *E.g.*, E.ON, Chairman Barton, and Suez.

³⁴ *E.g.*, EEI, Entergy, E.ON, Independent Sellers, National Grid, Progress Energy, and Scottish Power (*citing, e.g.*, PUHCA 2005 §§ 1264 & 1266).

³⁵ *See, e.g.*, Chairman Barton Comments at 3.

³⁶ *E.g.*, Chairman Barton, EEI, Hawaiian Electric Company, Inc. (HECO), National Association of Regulatory Utility Commissioners (NARUC), National Grid, PNM, and Progress Energy.

³⁷ *E.g.*, American Chemistry Counsel (ACC), APPA/NRECA, EPSA, GE EFS, Independent Sellers, and Transmission Access Policy Study Group (TAPSG).

PURPA³⁸ supports this finding. Independent Sellers also maintain that Congressional testimony suggests that amended 203(a)(2) should regulate only transactions of holding companies with public utilities in their holding company systems.³⁹

44. Several commenters, including GE EFS and Morgan Stanley Capital Group Inc. (Morgan Stanley), express concern about whether the proposed definition of "electric utility company" includes EWGs. Morgan Stanley agrees with the use of the PUHCA 2005 definition of "electric utility company," stating that applying the same definition in both statutes accords with traditional principles of statutory construction. However, it asks the Commission to construe that definition consistent with the exemptions set forth in PUHCA 2005; this would exempt EWGs.

45. APPA/NRECA seek clarification that "a State, any political subdivision of a State, or any agency, authority or instrumentality of a State or political subdivision of a State" is not an "electric utility company" under amended section 203(a)(2).

46. Finally, the Energy Program of Public Citizen, Inc. (Public Citizen) asks the Commission to interpret its jurisdiction under amended FPA section 203 more extensively. It argues that certain "suspect" categories of utility owners are not addressed in the NOPR or in current merger policy. These include investment banks, electric equipment suppliers, natural gas system owners, oil companies, and construction and other "service" companies. Public Citizen also states that the Commission must formulate a policy as to how it will protect American ratepayers if foreign holding companies are allowed to acquire, or continue to own, U.S. public utilities. Public Citizen criticizes the SEC's practice of allowing foreign holding companies to declare their own domestic utilities to be FUCOs under section 33 of PUHCA 1935; even though Congress did not intend to provide for this.⁴⁰ Public Citizen asks for greater protections for domestic ratepayers given the absence of a requirement for "registration for foreign holding companies and comprehensive PUHCA 1935 regulation of their financial transaction with their U.S. public utilities."⁴¹ It also states that the Commission should require a strong showing that acquisition by a foreign company without any experience in

owning utilities is consistent with the public interest.

ii. Commission Determination

47. A number of commenters make various arguments to support the contention that the term "electric utility company," as used in amended section 203(a)(2), should not have the same meaning contained in PUHCA 2005. As discussed in greater detail below, we have carefully considered this issue and will retain the NOPR's proposed definition of the term. Additionally, we continue to believe that the most reasonable interpretation of section 203(a)(2) is that it applies to purchases or acquisitions of foreign utility companies. However, consistent with Congressional intent, we do not want to impede foreign investments and we will grant blanket authorizations of foreign utility company acquisitions subject to certain conditions to protect U.S. captive customers. We also offer further clarifications below regarding the application of the definition of "electric utility company" in specific circumstances and provide blanket authorizations for certain transactions.

48. As noted above, new section 203(a)(2) provides:

No holding company in a holding company system that includes a transmitting utility or an electric utility shall purchase, acquire, or take any security with a value in excess of \$10,000,000 of, or, by any means whatsoever, directly or indirectly, merger or consolidate with, a transmitting utility, an electric utility company, or a holding company in a holding company system that includes a transmitting utility, or an electric utility company, with a value in excess of \$10,000,000 * * *⁴²

Canons of statutory construction require that effect be given to every term used in a statute.⁴³ In new section 203(a)(2), Congress uses the term "electric utility" (already defined in the FPA) one time, and the term "electric utility company" (undefined in the FPA, but defined in both PUHCA 1935 and PUHCA 2005) two times in the same sentence. We cannot ignore the fact that Congress used two different terms within the same sentence. Had Congress intended "electric utility" to be used in three places instead of one, it would have done so.

49. However, the precise meaning of the term "electric utility company" is not clear. It is not a defined term in the FPA. Amended section 203(a)(6) provides that certain other terms used in

amended section 203 ("associate company," "holding company," and "holding company system") are to have the same meanings given those terms in PUHCA 2005, but does not address "electric utility company." Thus there is Congressional silence as to the meaning of the term. We are therefore left to apply a reasonable meaning to the term in light of the simultaneous amendments to FPA section 203 and enactment of PUHCA 2005.

50. One of the arguments commenters raise in seeking an alternative definition of "electric utility company," is that "nothing compels" the Commission to use the PUHCA 2005 definition of the term.⁴⁴ We agree that such a result is not "compelled," because the term is ambiguous. However, in determining what Congress might have meant by "electric utility company," the only reference points the Commission has in the context of federal electric utility regulatory terminology is the meaning of the term as used in PUHCA 1935 and in PUHCA 2005.⁴⁵ Further, while certain commenters maintain that Congress intended to use the term "electric utility" instead of "electric utility company" in section 203(a)(2), there is no reliable legislative history to support this conclusion and, moreover, we do not believe that proper statutory construction permits us to simply substitute a term that Congress did not use.⁴⁶ Additionally, as discussed below, substitution of the FPA term "electric utility" would not by itself resolve the issue as sought by commenters.

51. We conclude that the most reasonable interpretation of "electric utility company," as used in section 203(a)(2) of the FPA, particularly in light of the fact that section 203(a)(2) will become effective simultaneous with the repeal of PUHCA 1935 and enactment of PUHCA 2005, is the meaning in PUHCA 2005: "any company that owns or operates facilities used for the generation, transmission, or distribution of electric energy for sale." We also find that it is reasonable to

⁴⁴ Commenters' alternative proposed definitions are also discussed below in the specific context of the requested exemptions of foreign transactions.

⁴⁵ While both the FPA and PURPA contain definitions of "electric utility," neither contains a definition of "electric utility company."

⁴⁶ See, e.g., *Indiana Michigan Power Co. v. Dept. of Energy*, 88 F.3d 1272, 1276 (DC Cir. 1996) (vacating an agency's decision where the agency's "treatment of [a] statute is not an interpretation but a rewrite"); *United States v. Plaza Health Laboratories, Inc.*, 3 F.3d 643, 655 (2nd Cir. 1993), cert. denied sub nom. *United States v. Villegas*, 512 U.S. 1245 (1994) ("neither agencies nor courts should rewrite the statute to be more 'reasonable' * * * than Congress intended").

³⁸ 16 U.S.C. 824a-3 (2000). Section 210(e) provides certain exemptions for cogeneration and small power producers.

³⁹ Independent Sellers Comments at 9.

⁴⁰ Public Citizen Comments at 10.

⁴¹ *Id.* at 10-11.

⁴² EPA Act 2005 1289(a).

⁴³ See *Reiter v. Sonotone Corp.*, 442 U.S. 330, 339 (1979) (finding that settled principles of statutory construction require giving "effect, if possible, to every word Congress used"); see also 2A *Statutes and Statutory Construction* § 46.06 (N. Singer 6th Ed. 2000 Revision) (a statute must be construed so that no part will be void or insignificant).

interpret section 203(a)(2) as applying to foreign utility acquisitions, in light of the legitimate concern that there be federal oversight to ensure that U.S. captive customers do not cross-subsidize foreign transactions and that U.S. utility assets used to serve captive customers are not encumbered in order to support foreign acquisitions. The legislative history relevant to new section 203(a)(2) evidences this concern.⁴⁷ However, the legislative history also makes clear that the provision was not intended to impede foreign investments, particularly where there are no U.S. captive customers that could be affected. Accordingly, we will interpret "electric utility company" to include foreign utility companies, but, as discussed *infra*, we will grant blanket authorizations for certain foreign acquisitions, with conditions to protect U.S. customers.

52. We reject commenters' specific alternatives to the proposed definition of "electric utility company." We do not believe that those proposed alternative definitions properly resolve the issue as to whether amended section 203(a)(2) applies to acquisitions of foreign utility companies. As noted above, the term "electric utility company" is defined in PУHCA 2005 as "any company that owns or operates facilities used for the generation, transmission, or distribution of electric energy for sale."⁴⁸ In contrast, "electric utility" (which some commenters would have us substitute) is defined in the FPA, as modified by EРAAct 2005, as "a person or Federal or State agency * * * that sells electric energy."⁴⁹ Neither of these terms, on its face, is limited to domestic transactions or even to interstate transactions. "Electric utility," as defined in the FPA, both pre- and post-EРAAct 2005, means persons that sell electric energy. Thus, we reject the argument that the Commission should insert the term "electric utility" into section 203(a)(2) and then re-define it to mean persons that sell electric energy "in interstate commerce." Not only has the modifier in "interstate commerce" not been included in the FPA definition of "electric utility" either pre- or post-EРAAct 2005, but these commenters

would require us to write into the statute words that are not there.⁵⁰

53. We also reject the alternative, proposed by Suez, by which the Commission would exclude foreign acquisitions by jurisdictional holding companies without captive customers by adding the word "jurisdictional" before "transmitting utility" and "electric utility company" at the end of proposed section 33.1(a)(2) (which reflects new section 203(a)(2)). Congress in other provisions of the FPA, including section 203, has specifically limited certain authorizations to jurisdictional facilities, but chose not to do so in section 203(a)(2). We do not believe it is appropriate to insert into the statute modifiers that Congress did not include.

54. A number of commenters raised concerns about the definition of "electric utility company" and the applicability of the Commission's authority under amended section 203 to transactions wholly within ERCOT, Alaska, or Hawaii, transactions involving QFs, local distribution companies, stand-alone generation, retail sales and other intrastate transactions. Several of these commenters rely on the argument, as stated above, that Congress did not intend to expand significantly the Commission's jurisdiction and, therefore, did not convey to the Commission jurisdiction over transactions typically reserved for state commission consideration. Others argue for exemptions from the definition of "electric utility company."

55. While we do not believe it is reasonable to interpret section 203(a)(2) as being limited solely to holding company acquisitions and mergers involving wholesale sales or

transmission in interstate commerce, we nevertheless conclude that commenters have raised valid concerns and that there would be no benefit from the Commission's case-by-case evaluation of certain transactions under section 203(a)(2).⁵¹

56. Our core jurisdiction under part II of the FPA continues to be transmission and sales for resale of electric energy in interstate commerce and we believe that a major impetus behind section 203(a)(2) was to clarify the Commission's jurisdiction over mergers of holding companies that own public utilities as defined in the FPA.⁵² However, the fact is that the language in section 203(a)(2) does more than address this issue, and we must implement the provision in a way that recognizes the expansion of authority, yet retains our primary focus on interstate wholesale energy markets and does not interfere unduly with historical state jurisdiction. Accordingly, we conclude that it is consistent with the public interest to grant blanket authorizations in the Final Rule for the following:

(1) Section 203(a)(2) purchases or acquisitions by holding companies of companies that own, operate, or control facilities used solely for transmission or sales of electric energy in *intrastate* commerce; and

(2) Section 203(a)(2) purchases or acquisitions by holding companies of facilities used solely for local distribution and/or sales at retail regulated by a state commission.

57. We conclude that these blanket authorizations are consistent with the public interest for several reasons. First, the identified categories do not raise concerns with respect to competitive wholesale markets for sales in interstate commerce or protection of wholesale captive customers served by Commission-regulated public utilities—matters within this Commission's core responsibility and expertise. Second, to the extent these categories raise competitive issues in intrastate commerce, *i.e.*, in ERCOT, Hawaii, and Alaska,⁵³ those issues are within the

⁵⁰ In fact, the key FPA provisions in which the term "electric utility" is used are sections 210 and 211. Section 210, both pre- and post-EРAAct 2005, permits the Commission to order an interconnection with the facilities of persons that sell energy in interstate or intrastate commerce. The current interconnection between ERCOT and the interstate grid was pursuant to a Commission order under sections 210 and 211 of the FPA. See *Central Power & Light Co.*, 17 FERC ¶ 61,078 (1981), order on reh'g, 18 FERC ¶ 61,100 (1982). Although commenters are correct that most of part II of the FPA is limited to interstate commerce, Congress has made specific exceptions in certain FPA provisions, and that includes the definition of "electric utility." Cf. *Indiana Michigan Power Co. v. Dept. of Energy*, 88 F.3d 1272, 1276 (DC Cir. 1996) ("The [agency's] treatment of this statute is not an interpretation but a rewrite."); *United States v. Plaza Health Laboratories, Inc.*, 3 F.3d 643, 655 (2d Cir. 1993) (stating "neither agencies nor courts should rewrite the statute to be more 'reasonable' * * * than Congress intended"); *Newman v. Love*, 962 F.2d 1008, 1013 (Fed. Cir. 1992) (rejecting an agency's "attempt to rewrite" a statute to contain costs or to avoid what it views as an inappropriate allocation of benefits).

⁴⁷ The only legislative history on this issue is a colloquy between Senators Bingaman and Domenici, Ranking Member and Chairman, respectively, of the Senate Committee on Energy and Natural Resources. See Senate Floor Statements by Senators Bingaman (D-NM) and Domenici (R-NM), H.R. 6, Energy Policy Act of 2005, 151 Cong. Rec. S9359 (July 29, 2005) (discussing concerns regarding Commission approval of certain foreign transactions outside of the United States).

⁴⁸ EРAAct 2005 § 1262(5).

⁴⁹ *Id.* § 1291(b)(22).

⁵¹ An acquisition or merger involving "any company that owns or operates facilities used for the generation, transmission, or distribution of electric energy for sale" is not on its face limited to interstate facilities.

⁵² *Illinois Power Co.*, 67 FERC ¶ 61,136 (1994) (noting that the Commission does not have jurisdiction over public holding company mergers or consolidations, but concluding that, ordinarily, when public utility holding companies merge, an indirect merger involving their public utility subsidiaries also takes place, and that Commission approval under section 203 would be required).

⁵³ Similarly, although not raised by commenters, the blanket authorization would apply to any organized Territory of the United States.

expertise of, and more appropriately addressed by, state commissions. Third, to the extent retail competition and retail ratepayer protection issues are raised by a holding company acquisition of local distribution or other retail facilities, these issues also are within the expertise of, and more appropriately addressed by, state commissions. We will thus grant the identified blanket authorizations and not impose any type of filing requirement with respect to such transactions.

58. In response to the request of APPA/NRECA that we clarify that "a State, any political subdivision of a State, or any agency, authority or instrumentality of a State or political subdivision of a State" is not an "electric utility company" under amended section 203(a)(2), and therefore, not subject to amended section 203, we clarify that even if a governmental entity were to meet the definitions of "electric utility company" or "holding company," section 203(a)(2) would not impose on the governmental entity any filing requirements under section 203. This is discussed in further detail *infra*. However, if a non-governmental public utility holding company were to seek to acquire a governmental utility (e.g., a municipal utility) that owns interstate transmission facilities or facilities used for wholesale sales in interstate commerce (and thus meets the definitions of "electric utility company"), and turn it into a private company subsidiary, then section 203(a)(2) should apply to the public utility holding company's acquisition. While no section 203 filing requirement would be imposed on the governmental entity, it would be imposed on the private entity.

59. We reject commenters' request that we explicitly exclude QFs and EWGs from the definition of "electric utility company." Regardless of their status under PUHCA 2005, the exemptions set forth under PUHCA 2005 are not dispositive as to the scope of the Commission's amended FPA section 203 authority. These PUHCA 2005 exemptions are set forth in the context of federal access to books and records and, more importantly, unlike PUHCA 2005, FPA section 203 does not give us any express authority to exempt persons or classes of transactions.⁵⁴

60. Additionally, were the Commission to interpret "electric utility company" for purposes of FPA section 203(a)(2) not to include EWGs or QFs,

⁵⁴ While QFs themselves currently are exempt from section 203's filing requirements by virtue of the Commission's PURPA regulations, PURPA does not give us authority to exempt holding companies that own QFs.

this could preclude review of certain acquisitions of securities of EWGs or QFs even by holding companies whose systems contain traditional public utilities with transmission facilities and/or captive customers. We do not believe that such transactions should be excluded from review under section 203 and conclude that it is reasonable to interpret the statute not to exclude them.⁵⁵ We recognize the arguments of some commenters that we should not apply section 203(a)(2) to holding company acquisitions of securities of EWGs and QFs, or at a minimum should not apply it to such acquisitions by holding companies that are holding companies solely by virtue of owning or controlling one or more EWGs, FUCOs, or QFs, because it would impede investments in QFs and EWGs or result in unnecessary regulation of upstream owners of QFs and EWGs.⁵⁶ In response, we believe the blanket authorizations granted herein for certain holding company acquisitions of non-voting securities and up to 9.9 percent of voting securities in electric utility companies will adequately address the concerns raised. To the extent additional blanket authorizations are needed or appropriate, we will consider those on a case-by-case basis.

61. Public Citizen makes broad comments on the scope of the Commission's jurisdiction and the standards articulated in the Commission's existing merger policy. We reject the request that we treat various types of utility owners or transactions as "suspect." As discussed below, the Commission is adopting the definition of "holding company" as required by amended section 203(a)(6), and is adopting a definition of "electric utility company" that is reasonable, in light of the statutory construction of amended section 203 and Congressional silence. We note that several of the scenarios discussed by Public Citizen in its comments fall under the Commission's amended section 203 authority, as clarified herein. As with all such transactions under its review, the Commission will carefully examine the

⁵⁵ We note that a holding company acquisition of securities of an EWG would in some circumstances trigger section 203 review in any event by virtue of section 203(a)(1). This is because the EWG could well be a public utility and, to the extent the holding company acquired "control" of the EWG, we would construe the EWG to be "disposing" of its jurisdictional facilities and thus required to file for approval under section 203(a). A similar situation involving acquisition of securities of a QF would not trigger section 203 review, since QFs currently are exempted from FPA section 203 filing requirements by the Commission's PURPA regulations.

⁵⁶ See, e.g., GE EFS and Independent Sellers.

proposed transaction to ensure it is consistent with the public interest. Moreover, Public Citizen will have an opportunity to present its concerns in these specific cases.

b. Definitions of "Associate Company," "Holding Company," "Holding Company System," and "Transmitting Utility"

62. In the NOPR, the Commission explained that the term "transmitting utility" is already defined in amended section 3 of the FPA⁵⁷ as "an entity (including an entity described in section 201(f)) that owns, operates, or controls facilities used for the transmission of electric energy—(A) in interstate commerce; (B) for the sale of electric energy at wholesale."⁵⁸

63. The Commission also proposed that, consistent with amended section 203(a)(6), the terms "associate company," "holding company," and "holding company system" shall have the meaning given those terms in PUHCA 2005.⁵⁹

i. Comments

64. No comments were filed specifically in response to these proposed definitions of "transmitting utility," "associate company," or "holding company system." However, several commenters object to the proposed definition of "holding company" or seek exemption from that definition for purposes of amended section 203(a)(2). They seek to limit the scope of the Commission's definition of "holding company."⁶⁰ Amended section 203(a)(2) provides explicitly, for the first time, that "holding companies" must seek Commission approval prior to certain mergers and acquisitions. Commenters seek clarification as to the types of entities that meet the definition of "holding company" to confirm whether or not they will be subject to this new filing requirement.

65. GE EFS asks the Commission to construe the term "holding company" to include only companies that own traditional utilities and that would have been deemed to be holding companies under PUHCA 1935. This would exclude companies that are holding companies only by virtue of owning QFs, EWGs, or FUCOs. Industrial

⁵⁷ 16 U.S.C. 796 (2000).

⁵⁸ NOPR at P 38 (citing EPAct 2005 1291(b)(1)(B)(23)).

⁵⁹ *Id.* at P 39 (citing EPAct 2005 1262(2), (8), & (9)).

⁶⁰ E.g., GE EFS, HECO, Independent Sellers, and the Electricity Consumers Resource Council, the American Iron and Steel Institute, the American Chemistry Council, and the PJM Industrial Customer Coalition (collectively, Industrial Consumers).

Consumers also seek to limit the definition of "holding company," asking the Commission to clarify that "industrials and other entities whose on-site generation investment meets the statutory definition of EWGs' are not included in the definition."⁶¹ Independent Sellers asks the Commission to confirm that a "holding company," for purposes of amended section 203(a), does not include entities owning new electric generation facilities that have not yet begun commercial operation.

66. APPA/NRECA seek clarification that "a State, any political subdivision of a State, or any agency, authority or instrumentality of a State or political subdivision of a State," does not meet the definition of "holding company."⁶² It also seeks clarification that rural electric cooperatives are not "holding companies" under amended section 203(a)(2).

67. HECO seeks clarification that an entity that meets the definition of holding company for purposes of section 203(a)(2) solely because it is the upstream owner of an electric utility company that is not a public utility under FPA, and that is not otherwise subject to Commission jurisdiction under any other provision of part II of the FPA, will not be subject to the Commission's merger authority. HECO explains that this would exclude from the Commission's jurisdiction under section 203(a)(2) acquisitions of holding companies with subsidiaries located only in Hawaii, Alaska, ERCOT, and foreign countries. HECO contends that Commission oversight of holding company acquisitions in this context is not necessary to protect the public interest.

ii. Commission Determination

68. Because the term "transmitting utility" is already defined in amended section 3 of the FPA and amended section 203(a)(6) provides that the terms "associated company" and "holding company system" shall have the meaning provided in PUHCA 2005, the Final Rule adopts them, as set forth in the NOPR.⁶³ We also note that no commenters oppose these proposed definitions.

69. The Final Rule also adopts the NOPR's proposed definition of the term

"holding company." Amended section 203(a)(6) mandates that the term "holding company" shall have the meaning provided in PUHCA 2005. This statutory directive is unambiguous.

70. The Commission therefore rejects requests for clarification that only companies that own traditional utilities, and not those that own solely FUCOs, EWGs and/or QFs, should be deemed "holding companies" under amended section 203. "Holding Company" in PUHCA 2005, as reflected in the rules adopted herein, means "any company that directly or indirectly owns, controls, or holds, with the power to vote, 10 percent or more of the outstanding voting securities of a public utility company or of a holding company of any public utility company; * * *"⁶⁴ There is no limitation within the plain words of this definition that can be read to exclude holding companies that own or control EWGs, FUCOs, or QFs. Additionally, even under PUHCA 2005, persons that own or control only EWGs, FUCOs, or QFs are considered holding companies but are explicitly exempted from PUHCA 2005 by section 1266. There is no similar exemption in amended section 203 and we conclude that it is reasonable to interpret section 203(a)(2) review to include acquisitions of generation or transmission facilities or companies by holding companies owning only FUCOs, QFs, and/or EWGs.

71. In response to the clarification sought by HECO, as indicated above, amended section 203(a)(6) mandates the adoption of the PUHCA 2005 definition of "holding company." That definition includes the upstream owners of an electric utility company that is not a public utility under the FPA and that is not otherwise subject to Commission ratemaking jurisdiction under part II of the FPA. As discussed above regarding the definition of "electric utility company," we have concluded that this definition is not limited to interstate commerce. Therefore, holding companies that own "electric utility companies" whose businesses are solely intrastate technically fall under amended section 203(a)(2). However, we agree that reviewing transactions involving Hawaii, Alaska, and ERCOT would involve matters outside our expertise and the core focus of part II of the FPA, and therefore we have granted blanket authorizations, as discussed above.

72. As requested by Independent Sellers, we clarify that a "holding company," for purposes of amended section 203(a), does not include entities

owning new electric generation that have not yet begun commercial operation.

73. We grant APPA/NRECA's request that the Commission clarify that a state or any political subdivision of a state or agency thereof is not a "holding company" under amended section 203(a)(2). While the definition of holding company possibly could be construed to include governmental entities or electric power cooperatives, we believe a more reasonable interpretation is that Congress did not intend to give the Commission authority over acquisitions by such entities. Section 201(f) of the FPA⁶⁵ excludes from most FPA part II provisions governmental entities and electric power cooperatives financed by the Rural Electrification Act of 1936,⁶⁶ and there is no indication that Congress intended to impose any section 203 filing requirements on such entities. Accordingly, we will not interpret section 203(a)(2) to apply to governmental entities and electric power cooperatives.

3. Section 33.1(b)—Definition of "Existing Generation Facility"

74. The Commission proposed that subsection 33.1(b) would define "existing generation facility" for section 203 purposes as a generation facility that is operational at the time the transaction is consummated.⁶⁷ The Commission stated that, as reflected in proposed section 33.1(a)(1)(iv)(b), if such a generation facility is *intended* to be used in whole or in part for wholesale sales in interstate commerce by a public utility, it is subject to our jurisdiction for ratemaking purposes and thus is covered under amended section 203(a)(1)(D). The Commission explained that, although the statute refers to a facility that "is" used for wholesale sales (and over which the Commission has jurisdiction for ratemaking purposes), we believed that a reasonable interpretation is that the provision would apply to newly constructed facilities that have already been energized at the time the transaction is consummated and are intended to be used in whole or in part for wholesale sales in interstate commerce by public utilities. The Commission also noted that if it can be demonstrated that a facility is used exclusively for retail sales, then amended section 203(a)(1)(D) does not apply.

⁶¹ Industrial Consumers Comments at 6.

⁶² APPA/NRECA Comments at 18.

⁶³ We note that, prior to EAct 2005, the FPA term "transmitting utility" was *not* limited to entities that own or operate transmission facilities used "in interstate commerce." EAct 2005, however, modified the definition to, among other things, limit it to facilities used in interstate commerce.

⁶⁴ EAct 2005 1262(8).

⁶⁵ 16 U.S.C. 824(f) (2000).

⁶⁶ 7 U.S.C. 901 *et seq.*

⁶⁷ NOPR at P 37.

a. Comments

75. The definition of "existing generation facility" drew extensive comment from state regulatory commissions, traditional public utilities, public/cooperative entities and retail customer and other groups.

76. One comment raised by EEL and Progress Energy is that the Commission should construe the term "existing" to mean only facilities that existed as of the date of enactment of EPAct 2005 (August 8, 2005). They claim that had Congress meant to apply amended section 203 to facilities that become operational after August 8, 2005, it would have used different language. APPA/NRECA takes the decidedly opposite view that applying amended section 203 only to facilities that existed when EPAct 2005 was enacted would eventually mean the demise of section 203 review, without any indication that Congress intended such a result.

77. Most commenters focused on the term "existing" in its operational and temporal context, as reflected in the NOPR's proposal to assert jurisdiction over transfers of facilities that "are operational at the time the transaction is consummated." Commenters generally focused on whether the facilities are in the construction or development stage, at or near "operation," or in retired or mothballed status. Contrary to most commenters, Kentucky Public Service Commission (Kentucky Commission) and National Association of State Utility Consumer Advocates (NASUCA) would have the Commission assert jurisdiction over transfers of facilities that are under construction or development. NASUCA argues that section 203 should apply if the facilities have received any kind of federal or state permit or have applied for market-based rate authority or generator interconnection status with an independent system operator (ISO) or regional transmission organization (RTO). It contends that such facilities are already influencing the market, particularly if they are being sold to provide future capacity or ancillary services. By the same token, NASUCA and TAPSG want us to assert jurisdiction over transfers of units that are mothballed or retired, especially if the units can be brought back on line and retain the permits or authorities. FirstEnergy Service Company (FirstEnergy) recommends that the Commission clarify its rules to deal with a mothballed facility that is slated to be refurbished and with a facility that is shut down where the site and equipment has been sold. Neither FirstEnergy nor Progress Energy believe that section 203 should apply to

transfers of facilities removed from service and from the Commission's accounting and thus are not physically or otherwise capable of making wholesale sales.

78. Although all commenters agree that section 203 review should encompass facilities that are "operational," they disagree as to how to define "operational" and "ability to make sales." They also disagree as to the point in time at which a jurisdictional determination is to be made, particularly for substantially completed plants that are at or near the "operational stage." APPA/NRECA finds the Commission's proposed approach reasonable, but is concerned that defining a facility on the basis of whether the facility is energized may allow companies to evade section 203 by delaying the interconnection process. NASUCA shares this concern, asserting that whether the plant is producing electricity at the time of the transaction is irrelevant to whether section 203 jurisdiction should apply. NARUC, Progress Energy, and Southern Companies take the view that for a generation facility to be deemed "operational," it must be interconnected and synchronized with the system so that it is capable of making wholesale sales. Other commenters suggest that a facility actually be in service and making jurisdictional sales. Most commenters agree with the Commission's proposal that the jurisdictional determination should be made on the basis of whether the facility is operational, or is projected to be operational when the transaction is (or is expected) to be consummated. NARUC, however, suggests that the jurisdictional determination should be made on the basis of whether the facility is operational at the time the underlying transaction agreement has been entered into and submitted for Commission approval.

79. Wisconsin Electric Power Company (Wisconsin Electric) expresses concern regarding the application of the term "operational." It requests that the Commission clarify either that "consummated" refers to when the transaction, as defined by the lease and associated commitments, is executed or that "operational" is restricted to operations in the ordinary course of the business of the non-acquiring party.

80. EEL and Ameren Services Company (Ameren) argue that the "intent" language in proposed section 33.1(a)(1)(iv)(b) exceeds the statutory authority of amended section 203(a)(1)(D)(ii). They also insist that an "intent" standard is unworkable because "intent" would be difficult to

ascertain. Southern is also concerned that the "intent" language would introduce confusion as to the jurisdictional status of transfers of facilities that are merely under construction. Chairman Barton questions whether requiring only an intent to use facilities in interstate commerce will unduly burden potential transactions and results in unnecessary review, particularly when, after the facilities are placed in service, the Commission has authority under FPA sections 205⁶⁸ and 206⁶⁹ over the facility and its rates. Although not specifically referring to either the "intent" language or the "exclusive use for retail sales" language, the North Carolina Utilities Commission (North Carolina Commission) emphasizes that nothing in amended section 203(a)(1)(D) expands the Commission's jurisdiction to include generation resource adequacy for retail service; EPAct 2005 expressly reserves authority over generation resource adequacy to the states. It urges that the final rule recognize this limitation.

81. Other commenters, such as Utility Workers Union of America, AFL-CIO (UWUA) and APPA/NRECA, generally support the "intent" language. APPA/NRECA and TAPSG, however, believe that a very high standard should be set for demonstrating that a facility is exclusively used for retail sales. TAPSG points out that utilities do not ordinarily dispatch their units separately for wholesale sales and retail sales. Both commenters also contend that amended section 203 should apply to facilities that received an exemption initially from section 203 on the basis of retail use only but that later are used for wholesale sales. Owners of such facilities should be subject to the Commission's expanded penalty authority. APPA/NRECA and TAPSG argue that the Commission should explicitly state that section 203 approval is required for the acquisition of a QF; they ask us to clarify that QFs may be "existing generation facilities" under amended section 203(a)(1)(D).

b. Commission Determination

82. The Commission will clarify and modify a number of aspects of its proposal for determining whether a generation facility is an existing generation facility for purposes of amended section 203(a)(1)(D). We will also address other questions raised by commenters with regard to the NOPR.

83. Initially, the Commission will reject EEL's and Progress Energy's

⁶⁸ 16 U.S.C. 824d (2000).

⁶⁹ 16 U.S.C. 824e (2000).

argument that "existing generation facility" should be construed to encompass only those generation facilities in existence as of the date of enactment of EAct 2005 (*i.e.*, August 8, 2005). They submit that any other interpretation would effectively write "existing" out of the statute and that if Congress had intended amended section 203 to apply to generation facilities that come into existence after August 8, 2005, it would have used plainly different language. We do not agree. First, such an interpretation is not, as Progress Energy suggests, required as a textual matter. Congress could have, but chose not to, use the term "existing on the effective date of this Act." Rather, it simply used the term "existing." Second, such an interpretation would make little sense. It would eventually write amended section 203(a)(1)(D) out of existence as pre-EAct 2005 generation facilities are retired and only post-EAct 2005 generation facilities remain. There is only a brief mention of the term "existing," without any explanation, in the legislative history of amended section 203. However, the legislative history suggests that Congress intended for the Commission to not only continue, but to expand our review of activities that would affect wholesale competition and ratepayers.⁷⁰ Therefore, we reject EEL's and Progress Energy's argument.

84. The Commission adopts the NOPR's proposal that an "existing generation facility" is a generation facility that is operational at or before the time the transaction is consummated. However, we are deleting language in proposed section 33.1(a)(iv)(b) stating that section 203 applies if the generation facility "is intended to be used" in whole or in part for wholesale sales in interstate commerce by a public utility. Below we explain various aspects of this definition.

85. We note first that "the time the transaction is consummated" refers to the point in time when the transaction actually closes and control of the facility changes hands. The Commission will construe "operational" to mean a generation facility for which construction is complete (*i.e.*, it is capable of producing power). An "existing generation facility" would not include generation plants that are only

in the development or construction stage. However, an "existing generation facility" would include a mothballed facility, so long as the facility was operational at any time before the transaction is consummated.

86. With regard to the issue of wholesale versus retail sales, the Commission will eliminate the language "intended to be" from proposed section 33.1(a)(1)(iv)(b). We agree with some commenters that "intent" is difficult to discern and could introduce unnecessary confusion about plants that are under construction and clearly not being used for wholesale sales. Rather, the Commission will adopt a rebuttable presumption that amended section 203(a) applies to the transfer of any existing generation facility unless the utility can demonstrate with substantial evidence that the generator is used exclusively for retail sales. In our experience, utilities do not ordinarily separate the dispatch of their plants for retail sales and wholesale sales; rather, they dispatch all their units on an integrated basis to serve all load (retail and wholesale). Therefore a utility proposing an unusual procedure by which it dispatches certain plants "only" for retail load will have the burden to demonstrate that any particular generating facility will never be used to make wholesale sales.

87. Finally, in response to commenters' requests that section 203 approval be required for the acquisition of a QF, we clarify that if a public utility acquires an existing generation facility used for Commission-jurisdictional sales, whether a QF or any other type of generation facility, the transaction is subject to section 203. Although certain QFs themselves are exempted from any filing requirements under section 203 by virtue of our PURPA regulations, this does not mean that public utilities that acquire QFs are exempt. Additionally, there is no limitation in amended section 203(a)(1)(D) on the type of generation facilities that trigger section 203 review, if they are used for interstate wholesale sales and the Commission has jurisdiction over them for ratemaking purposes. Further, even if the Commission had the discretion to exempt QF acquisitions from section 203 review, we do not think it would be necessarily consistent with the public interest to do so in light of EAct 2005's elimination of QF ownership restrictions.

4. Section 33.1(b)—Definition of "Non-Utility Associate Company"

88. The Commission proposed to interpret the term "non-utility associate company" to mean any associate

company in a holding company system other than a public utility or electric utility company that has wholesale or retail customers served under cost-based regulation.⁷¹ Therefore, we proposed that a non-utility associate company would include, for example, a power marketer, a generator that does not have captive customers, a gas marketer, a fuel supply company or other company that provides inputs to power production, or a company that is involved in business activities not related to the generation, transmission, distribution, or sale of electricity.⁷² This definition is relevant because of the new section 203(a)(4) requirement that we find that a proposed transaction does not result in inappropriate cross-subsidization or pledge or encumbrance of utility assets. The Commission sought comment on whether it should use a narrower definition, for example, whether we should define a "non-utility associate company" as a company that is in a business not related to the generation, transmission, distribution, or sale of electricity.

a. Comments

89. Many state commissions and other commenters from the industry agree that the Commission's proposed broad definition of "non-utility associate company" should be adopted in order to afford the greatest protection against cross-subsidization, as Congress intended in EAct 2005.⁷³ Indiana Commission and NARUC explain that the cross-subsidization of an entity involved in a business unrelated to the electric industry and the cross-subsidization of an entity involved in "unregulated," electricity-related activities are equally inappropriate. On the other hand, FirstEnergy and Southern Companies urge the Commission to adopt the narrower definition.

90. American Electric Power Service Corporation (AEP) asserts that both the Commission's broader definition proposed in the NOPR and the narrower definition (proposed as an alternative) are unnecessarily broad, ensnaring companies that are providing essentially ancillary services to the regulated utility and that thus present no risk of cross-subsidization. AEP maintains that amended section 203(a)(4) is simply designed to ensure that a transaction does not result in cross-subsidization,

⁷⁰ See, e.g., Senate Floor Statement by Senator Bingaman (D-NM), H.R. 6, Energy Policy Act of 2005, Congressional Record at S9258 (July 28, 2005) (stating that "in the area of electric utility mergers, we have expanded the jurisdiction of [the Commission] over mergers involving existing generation plants; that is, plants that are in existence at the time the merger takes place.")

⁷¹ NOPR at P 44.

⁷² These are examples only. This list is not intended to be exhaustive.

⁷³ E.g., APPA/NRECA, Indiana Commission, Kentucky Commission, NARUC, NASUCA, and New Jersey Board of Public Utilities (New Jersey Board).

which, by definition, only occurs when a competitive affiliate of the utility is unduly enriched by use of regulated assets. AEP states that the Commission has already defined these energy affiliate companies in the Standards of Conduct,⁷⁴ and states that we should define a "non-utility associate company" by adopting the same definition used to describe an "energy affiliate" in 18 CFR 358.3(d).

b. Commission Determination

91. We agree with the majority of the commenters that the NOPR's proposed broader definition of the term "non-utility associate company" is reasonable. Our goal in defining this term is to ensure that public utilities with captive customers do not cross-subsidize "non-regulated" associate companies, *i.e.*, companies that are not subject to traditional cost-based regulation.⁷⁵ As it relates to this objective, there is no difference between the propriety of cross-subsidizing associate energy companies that are not subject to traditional cost-based regulation versus an entity that is involved in a business completely unrelated to the energy industry. Since the purpose is to protect customers, whether the company inappropriately subsidized is an associate company in the energy industry or not is irrelevant.

92. We disagree with AEP's contention that cross-subsidization occurs only when using traditionally regulated assets to subsidize a competitive affiliate of the utility company. Congress was concerned with the potential for abuse when a traditionally regulated public utility (*i.e.*, one that is subject to the Commission's traditional cost-based regulation) subsidizes an "unregulated" affiliate company within the same holding company system. Defining a non-utility associate company based on whether or not that "unregulated" affiliate company is a competitor of the utility company is too narrow to prevent abuses; consequently, the Standards of Conduct definition of an "energy affiliate" is not appropriate here.⁷⁶

93. Accordingly, we will adopt the broader definition of a "non-utility associate company," which is any associate company in a holding company system other than a public utility or electric utility company that has wholesale or retail customers served under cost-based regulation. A non-utility associate company would include, among others, a power

marketer, a generator that does not have captive customers, a gas marketer, a fuel supply company or company that provides inputs to power production, or a company that is involved in business activities not related to the generation, transmission, distribution or sale of electricity.

5. Section 33.1(b)—Definition of "Value"

94. In the NOPR, the Commission proposed to generally rely on a "market value" approach for determining whether asset transfers, with the exception of wholesale contracts, meet the value threshold necessary to require approval under amended section 203. This would base value on expected future earnings or profits over the life of the asset. This is in contrast to our current regulations, which define value as original cost undepreciated as defined in the Commission's Uniform System of Accounts; in other words the amount paid for installing an original plant and equipment and additions thereto.⁷⁷ As described below, the Commission proposed certain measures of value for each of four types of asset transactions, inviting comment and suggestions for alternative approaches.

95. Specifically, the Commission proposed that section 33.1(b) would define "value," as applied to jurisdictional facilities and existing generation facilities (addressed by amended subsections 203(a)(1)(A) and (D)), as the market value of such facilities.⁷⁸ The Commission recognized that determining the market value of transmission facilities could be difficult in some instances. We proposed that, in the absence of a readily ascertainable market value, original cost undepreciated would be used. For transactions involving transfers of facilities between non-affiliates, the Commission stated that market value will, in most circumstances, be reflected in the transaction price. For transactions between affiliates, the Commission recognized that we cannot assume that market value will be reflected in transaction price. We suggested undepreciated original cost as a possible alternative measure of value.

96. The Commission also proposed that section 33.1(b) would define "value," with respect to a merger or consolidation with a transmitting utility, an electric utility company, or a holding company in a holding company system that includes a transmitting utility, or an electric utility company, with a value in excess of \$10 million,

as used in amended section 203(a)(2) as "market value." We stated that in most instances market value would be reflected in the transaction price for transactions between non-affiliates.

97. Turning to how to value paper jurisdictional facilities, the Commission proposed that the value of any wholesale contract included in the transaction would be based on total expected contract revenues over the remaining life of the contract.⁷⁹ We noted that market value was an alternative approach and that it could be based on the price or consideration paid for the contract.

98. The Commission proposed to define the "value" of a security, as discussed in amended sections 203(a)(1)(C) and (a)(2), as the market price at the time the security is acquired.⁸⁰ For transactions between non-affiliated companies, the Commission proposed to rebuttably presume that the market value is the agreed-upon transaction price. We sought comments on how to determine value for security transactions involving affiliates if the securities are not widely traded. Further, the Commission sought comments as to whether it should give particular weight to evidence of non-affiliate transactions involving either non-affiliated buyers or sellers of securities of similarly situated utilities or assets.

a. Comments on Definition of "Value" as Applied to Transmission and Generation Facilities

99. Nearly all commenters support the use of market value. Most commenters support using transaction price to measure market value in most situations.⁸¹

100. APPA/NRECA and TAPSG contend that market value should be replaced by "fair" market value. They recommend that the Commission measure "fair" market value based on standards to be adopted by the Financial Accounting Standards Board that use both a market approach and an income approach. Because the market value standard could introduce some

⁷⁴ 18 CFR part 358 (2005).

⁷⁵ NOPR at P 42.

⁷⁶ 18 CFR 358.3(d).

⁷⁷ 18 CFR 33.1(b) (2005).

⁷⁸ NOPR at P 30.

⁷⁹ *Id.* at P 32.

⁸⁰ *Id.* at P 33.

⁸¹ Chairman Barton does not take a position on the appropriate measure of value, but believes that the Commission should consider whether the use of market value, by bringing more transactions under section 203, will unnecessarily increase regulatory burden because of the potential for disputes concerning the market value of transactions. He also suggests that some utilities will make section 203 filings needlessly to show the Commission that section 203 does not apply. He notes that undepreciated original cost value is a simple way to value transactions. Chairman Barton Comments at 6.

uncertainty into the process, FirstEnergy urges the Commission to provide clear guidance to the industry and the investment community explaining how a market value standard would be used in certain situations. It suggests that we create a "safe harbor" that clearly defines methods and components used to assess market value. EEI argues that when a state commission has reviewed or made a determination of value for a particular transaction, a company should be able to rely on that value for purposes of determining value under section 203; the company should not have to pay penalties if the Commission later determines that the value of the transaction exceeds \$10 million.

101. Virtually all commenters recognize that a market value standard, particularly one based on transaction price, may need to be modified or even replaced in some circumstances. As explained below, these circumstances involve transactions that include non-jurisdictional facilities in addition to jurisdictional facilities or generation facilities; transactions where market value may not be ascertainable; and transactions not conducted at arms'-length (such as affiliate transactions). Alternative suggested measures of market value or value are the following: (1) Market value as determined by market-based results of an *Edgar*-type analysis⁸² or independent valuation process; (2) original cost undepreciated; (3) the higher of market value or original cost undepreciated; and (4) net book value (original cost depreciated).

102. Focusing first on transactions between non-affiliates, many commenters agree that, in most circumstances, transaction price is the appropriate measure of market value.⁸³ EEI, Duke Energy Corporation and Cinergy Corp. (Duke/Cinergy), and Progress Energy urge the Commission to rebuttably presume that market value is the agreed-on transaction price. EEI, Duke/Cinergy, Entergy, and FirstEnergy, argue that the market value determination should be based only on the value of jurisdictional transmission assets or generation assets. They state that a single transaction price will not measure the market value for a transaction that also includes assets other than jurisdictional transmission

assets or generation assets. EEI proposes determining the transaction price for the jurisdictional transmission facilities or generation facilities based on their relative net book value (original cost depreciated).

103. Commenters differ significantly as to the appropriate measure of value where the transaction is between affiliates. As a first backstop in scenarios involving affiliated transactions, several commenters contend that transaction price is still a reasonable measure of market value, provided that the transaction price is shown to be consistent with the results of an *Edgar*-type analysis or independent valuation process.⁸⁴ However, other commenters, including the New Jersey Board, NASUCA, and APPA/NRECA, would compare a market value or "fair" market value with original cost undepreciated and select the higher of the two. They argue that the Commission must evaluate the widest possible range of transactions to determine the public interest implications of transactions; utilities will attempt to understate value and thereby avoid section 203 review.

104. When a market-based determination of value is not possible or practical, commenters are divided, mainly between original cost undepreciated and net book value. Commenters who advocate the use of net book value urge the Commission to reject any use of original cost undepreciated, particularly for non-affiliate transactions, since it does not reflect the deterioration (wear) of the facility.⁸⁵ Rather, they would encourage the use of net book value, since it is the basis of transmission rates.

105. Other commenters suggest a modification of the original cost undepreciated and net book value concepts. Missouri Public Utilities Commission (Missouri Commission) would rely on reproduction cost (the costs of replicating the same plant today with the same assets and same technology). As a proxy for this measure, Missouri Commission suggests that the original cost could be escalated by appropriate wholesale price indices. Scottish Power would adjust net book value by converting it to current dollars.

b. Comments on Definition of "Value" as Applied to Transmitting Utilities, Electric Utility Companies, or Holding Companies

106. Nearly all commenters support the market value approach as measured by the transaction price to determine the value of a transaction involving transmitting utilities, electric utility companies, or holding companies. NASUCA proposes the higher of market value or original cost undepreciated to limit the possibility that a merger of two independent transmission companies would escape review. It also asserts that market value is not necessarily the same as market price. FirstEnergy believes that the transaction price should reflect only the value of the underlying jurisdictional or generation facilities. The Commission should also establish other parameters for determining the market price, such as the point in time at which the determination is to be made, such as the date of the agreement, the date of filing of the application, or the date of consummation of the transaction. To the extent the Commission does not adopt transaction price, FirstEnergy urges the Commission to otherwise specifically define market value and specify safe harbor standards.

c. Comments on Definition of "Value" as Applied to Paper Jurisdictional Facilities

107. Many commenters, including state commissions and consumer groups generally favor total expected revenues over the contract's remaining life as the appropriate measure of value for transfers of wholesale contracts.⁸⁶ This is regardless of whether affiliates or non-affiliates are involved. Revenues will be a function of quantities of supply and thus are an indirect measure of the contract's contribution to market supply, in much the same way that the value of generation assets will be related to generator size. These commenters also point out that a revenues approach would be much easier to apply than an expected net profits standard, which can be unpredictable on the basis of varying assumptions and is likely to be measured inaccurately.

108. Constellation adds that the use of nominal revenues avoids confidentiality issues raised by how buyers and sellers value contracts on the basis of transaction price. This is particularly true where it is necessary to determine value for individual contracts that are part of a portfolio of contracts and non-

⁸² *Boston Edison Co. Re: Edgar Electric Energy Co.*, 55 FEREC ¶ 61,382 (1991) (*Edgar*). The *Edgar* standard of review is designed to prevent affiliate abuse and to ensure prices that are consistent with competitive outcomes.

⁸³ E.g., Indiana Commission, Kentucky Commission, New Jersey Board, International Transmission Company (International Transmission), EPSA, Scottish Power, TAPSG, and UWUA.

⁸⁴ E.g., EEI, Duke/Cinergy, TAPSO, Indiana Commission, Kentucky Commission, Progress Energy, and Scottish Power.

⁸⁵ E.g., EEI, Ameren, Progress Energy, Southern Companies, and Duke/Cinergy.

⁸⁶ NARUC, Missouri Commission, the Public Utilities Commission of Ohio (Ohio Commission), APPA/NRECA, NASUCA, and Constellation Energy Group Inc. (Constellation).

jurisdictional assets. Some commenters point out that in some instances, for individual contracts, the seller may actually pay the buyer and the buyer may have the option to buy the power at a market price, which may be lower than contract price. Thus, the transaction price would either be negative or much smaller than under a revenues approach. This would increase the likelihood that the transaction would not fall under section 203.

109. On the other hand, many commenters urge the Commission to adopt transaction price as the measure of value.⁸⁷ They contend that value is closely tied to expected profits, which considers supply costs, unlike the revenue approach, and thus will be more accurately reflected in transaction price than in revenues. FirstEnergy comments that a revenues approach would be difficult to apply if the contract rates are not fixed. If the Commission decides not to use transaction price, commenters suggest a variety of other measures, including discounted value of future cash flows reduced by obligations, net present value of non-fuel revenues, and expected profits.

110. For affiliate transactions, many of these same commenters generally agree that transaction price is appropriate if it is supported by *Edgar*-type evidence. However, another measure favored by EEI, Entergy, and Duke/Cinergy would apply "mark to market" pricing⁸⁸ to determine the value of a contract between affiliates. Entergy, citing Order No. 627,⁸⁹ asserts that the Commission has taken the same approach in requiring utilities to report in Form 1 changes to the fair market value of certain derivative instruments and activities.

d. Comments on Definition of "Value" as Applied to Securities in Excess of \$10 Million

111. Generally all of the commenters from the various segments of the industry, including regulatory commissions, public power, and customer groups, support the

Commission's proposal to value security transactions between non-affiliates at market value. Nearly all appear to accept our proposal to rebuttably presume that price is the appropriate measure of market value. FirstEnergy requests, however, that the Commission provide more specificity as to which price is relevant, *i.e.*, the agreed-to-price or a publicly traded price, and as to what is meant by time of the transaction—the time of agreement or the time of consummation. FirstEnergy also asks whether the transaction value used should take into consideration the fact that non-regulated assets may be included in the transaction as well. EEI and International Transmission argue that to give regulatory certainty to the transacting parties, the relevant price should be the agreed-to price.

112. EEI suggests that for securities transactions between affiliated parties, market price is reasonable when the securities are widely traded. However, several parties support assessing market value based on an application of *Edgar* standards, particularly when the securities are not widely traded. On the other hand, FirstEnergy and NASUCA contend that an *Edgar* approach will not work well because any group of non-affiliate transactions will be vastly different in terms and other factors that affect value or price. When *Edgar*-type evidence is not available, EEI and Ameren propose certain formulaic measures involving company-specific variables;⁹⁰ NARUC suggests that the Commission simply use paid-in capital equity. Indiana Commission suggests that an affiliate transaction be constructed to evade section 203 jurisdiction could be used to subsidize a non-jurisdictional affiliate, but Southern Companies asserts that transaction thresholds are so low there will be no meaningful opportunities to evade jurisdiction by such means.

e. Commission Determination

113. The Commission notes the widespread support for using a market value approach (where feasible). After

considering the comments of numerous parties, we remain convinced that market value is, in most instances, the most effective and reasonable approach (both for potential section 203 applicants and for the Commission) to determine which asset transfers, particularly those that involve acquisitions of physical facilities or securities, require section 203 approval.

114. As one commenter suggests, however, using market value as the measurement standard is not straightforward in all circumstances. For example, where the transaction involves a single asset subject to section 203 being purchased and sold between non-affiliates, the agreed-upon price for the transaction is a straightforward measure of market value. However, there may be non-affiliate transactions that include a bundle of assets, both assets subject to section 203 and assets not subject to section 203, so that the transaction price does not reflect the market value of only the assets subject to section 203. Another example involves transactions between affiliates where the agreed-upon price for the exchange will not necessarily reflect market value. In both instances, other measures of market value would be required.

115. It is important that the Commission provide as much guidance as possible to those contemplating business transactions regarding how the determination of value should be made and thus deciding whether section 203 review is required. Such guidance will enhance parties' certainty and will also contribute stability to investment decision-making by utilities and non-utilities alike.

116. For transfers of physical facilities (transmission and generation facilities) the Commission will adopt market value as the appropriate measure of value. When a transaction occurs between non-affiliates, the Commission will rebuttably presume that market value is the transaction price. The most obvious complicating factor in applying this test is the need to consider only the value of the facilities subject to section 203; many transactions will include other assets not subject to section 203 as well. However, in such situations, the acquiring entity will probably have made a valuation analysis of the constituent parts of the transaction in order to guide its negotiations and/or properly record the value of those facilities on its balance sheet. Almost certainly included in that analysis will be a valuation of the physical facilities. In transactions involving both facilities subject to section 203 and facilities not subject to section 203, companies should rely on such valuations in

⁸⁷ *E.g.*, EEI, First Energy, Ameren, Duke/Cinergy, Entergy, International Transmission, EPSA, Independent Sellers, Scottish Power, Morgan Stanley, Indiana Commission, and Missouri Commission.

⁸⁸ In this context, "mark to market" refers to the process whereby the book value or collateral value of an asset such as a multiyear contract or power purchase agreement is adjusted to reflect current market value for the applicable period.

⁸⁹ *Accounting and Reporting of Financial Instruments, Comprehensive Income, Derivatives and Hedging Activities*, Order No. 627, 67 FR 67,691 (Oct. 10, 2002), FERC Stats. & Regs. ¶ 32,558 (2002).

⁹⁰ For example, EEI proposes that, for securities that are not widely traded, the Commission should allow companies to utilize the *Edgar* guidelines. If the *Edgar* guidelines are not applicable to a particular case, EEI suggests the following: For equity securities, a three part determination should be utilized to determine value: (i) Determining the value of the company that is the issuer of the equity securities based on the depreciated net book value of the company's assets; (ii) determining the fraction of the securities at issue by dividing the number of equity securities involved in the transaction by the total number of outstanding equity securities for the company; and (iii) multiplying (i) by (ii) (*i.e.*, the value of the company multiplied by the fraction of the equity securities at issue). EEI Comments at 11.

deciding whether to file for section 203 approval.

117. If separate valuations of the physical assets were not performed, companies should rely on original cost undepreciated. Several commenters urge the Commission to reject the use of original cost undepreciated and adopt, instead, net book value. Our current regulations use original cost undepreciated as the appropriate measurement standard and we will continue to use that standard in applying amended section 203. Although net book value is a valuation method commonly used to establish cost-based rates, most generating facilities today sell power at market rates, and their market value is driven primarily by factors unrelated to the book depreciation of the facility. For example, many highly depreciated coal-fired assets have commanded significant premiums in generation divestitures. Hence, we believe that the continued use of original cost undepreciated is preferable to net book value.

118. We also cannot rely on transaction price as a measure of market value when a transaction involving physical facilities occurs between affiliates. Instead, here too we will adopt original cost undepreciated. The alternatives to transaction price most frequently supported by commenters include: (1) Value based on an *Edgar*-type analysis (market value), (2) original cost undepreciated, (3) the higher of market value or original cost depreciated, and (4) net book value. As discussed above, as between the choices of original cost undepreciated and net book value, the Commission believes that original cost undepreciated is preferable and should continue to be used.

119. The *Edgar* analysis is applied in section 205 proceedings to determine whether purchases from an affiliate are reasonable in light of other alternatives. The analysis is not intended to provide a bright-line easy-to-apply test of whether jurisdiction to approve a particular transaction exists in the first place. Rather, the analysis is often highly contentious and is used to determine the justness and reasonableness of a particular transaction, not for determining whether jurisdiction exists to review it in the first place. The Commission believes that, for purposes of section 203 applicability, a valuation based on original cost depreciated will be simpler and less ambiguous than one based on *Edgar*, particularly when most transactions will clearly exceed \$10 million by any reasonable measure.

120. With respect to determining value to be applied to transfers of wholesale contracts between non-affiliates, the Commission will rebuttably presume that market value is the transaction price. This is consistent with our use of market value and transaction price for other types of asset transfers. As with transfers of physical facilities, when assets not subject to section 203 are included in the transaction, the acquiring entity should rely on its valuation of the contracts component included in transaction price. The market valuation should be consistent with the value the applicant places on the contract for purposes of its audited financial statements and in keeping with generally accepted accounting principle (GAAP) requirements. One commenter has expressed confidentiality concerns about valuations for individual contracts as part of a portfolio of contracts that could likely arise if a utility's decision not to file for section 203 approval was challenged. We believe that any such concerns can be addressed through our procedures that provide confidential treatment to certain proprietary materials.⁹¹ Furthermore, we note that any measurement standard (such as projected revenue stream) could also raise concerns over confidentiality in certain circumstances.

121. The issue of how to value contract transfers between affiliates is more difficult to resolve, since a transaction price, if it exists at all, will not necessarily reflect market value. For affiliate transfers of contracts, we agree with one commenter that total expected contract revenues are a simple, objective way to assess value and to provide increased certainty as to the need for a section 203 filing. We therefore adopt this standard for valuing jurisdictional contracts between affiliates.

122. Amended sections 203(a)(1)(C) and (a)(2) define the Commission's jurisdiction over certain acquisitions of securities by public utilities and holding companies. With respect to securities transactions between non-affiliates, the Commission will adopt transaction price, as explained more fully herein, for the acquisition of securities by either a public utility or a holding company. The Commission recognizes that the NOPR was not entirely clear as to how to determine the "transaction price." Although we stated that the value of a security would be defined as the market price at the time the security is acquired, we also stated that the market value would be rebuttably presumed to be the agreed-on transaction price.

⁹¹ 18 CFR 1.36 (2005).

Thus, FirstEnergy asks how market price should be defined—a publicly traded price or the price ultimately agreed on. It also asked the Commission to clarify the meaning of "at the time the security is acquired." Specifically, does this language refer to the point in time an agreement is entered into or the actual time of consummation of the transaction?

123. The Commission is mindful of the need to provide parties as much regulatory certainty as possible with respect to decisions as to whether section 203 approval is required for a particular transaction. In this case, the Commission finds that greater regulatory certainty is provided by relying on the agreed-to transaction price at the time the transacting parties enter into an agreement. However, the Commission will reject the argument that the value of securities transactions should be adjusted to reflect the fact that not all of the assets underlying the value of the securities are jurisdictional facilities or generation facilities. Amended section 203 does not permit any such interpretation, as it applies to the purchase of the "security * * * of a * * * public utility," not to the "securities applicable to the jurisdictional facilities of a public utility."

124. For securities transactions between affiliates, however, an agreed-on transaction price will not necessarily be consistent with market price. For that reason, if the securities are widely traded, the Commission will require that affiliates value the transaction based on the market price at the time the securities are acquired. If the securities are not widely traded, we will adopt, in a slightly modified manner, EEI's suggestion. For equity securities, we will utilize a three-part determination to determine value: (i) Determining the value of the company that is the issuer of the equity securities based on the total undepreciated book value of the company's assets; (ii) determining the fraction of the securities at issue by dividing the number of equity securities involved in the transaction by the total number of outstanding equity securities for the company; and (iii) multiplying (i) by (ii) (i.e., the value of the company multiplied by the fraction of the equity securities at issue). This method for securities transactions that are not widely traded is consistent with our use of original cost undepreciated to measure value for transactions between affiliates involving physical assets.

125. Amended section 203(a)(2) addresses holding company mergers or consolidations with a transmitting utility, an electric utility company, or a

holding company in a holding company system that includes a transmitting utility, or an electric utility company, with a value in excess of \$10 million. Regarding transactions between non-affiliates, market value will be the transaction price or consideration paid, as provided for in the agreement between the transacting entities. As with securities, we note there is no statutory provision or legislative history to suggest that the transaction price should be adjusted to reflect the fact that non-jurisdictional assets are also involved, and so we will not allow for such an adjustment.

126. For mergers or consolidations involving affiliates, transaction price will not be an acceptable basis for establishing value. Several commenters recommend the use of an *Edgar*-type analysis to arrive at a market value. However, the *Edgar* approach is not a practical approach to applying the \$10 million jurisdictional threshold for the reasons discussed above. Therefore, the Commission will, instead, use the book cost of all of a company's assets to measure the value of mergers or consolidations of affiliated companies.⁹²

6. Compliance With Section 203

127. Given the increased significance of valuation of a transaction under amended section 203, the Commission solicited comments on whether our existing recordkeeping and reporting requirements, outside the section 203 context, will allow us and the public to effectively monitor jurisdictional entities' determinations of when a section 203 application is required. For example, the Commission asked "do FERC Form 1s or Order No. 652⁹³ market-based rate change in status reports provide sufficient information to monitor compliance with section 203?"⁹⁴

a. Comments

128. Many commenters believe that the Commission's existing record-keeping and reporting requirements will be enough.⁹⁵ Some note that parties often seek section 203 authorization out

⁹² Book cost, as used here, refers to original book cost.

⁹³ *Reporting Requirement for Changes in Status for Public Utilities with Market-Based Rate Authority*, Order No. 652, 70 FR 8,253 (Feb. 18, 2005), FERC Stats. & Regs. ¶ 31,175, order on reh'g, 111 FERC ¶ 61,413 (2005).

⁹⁴ NOPR at P 35.

⁹⁵ E.g., Kentucky Commission, NARUC, Oklahoma Commission, Ameren, Constellation, EEI, FirstEnergy, Progress Energy, and Southern Companies. Some commenters argue that the Commission's existing record-keeping and reporting requirements, including the information supplied under the FERC Form 1, Order No. 652, and Change in Status reports, are more than adequate.

of an abundance of caution, whenever there is a reasonable possibility that section 203 approval is legally required, in order to remove regulatory uncertainty from a transaction, as an entire transaction can be placed at risk if required regulatory approvals are not obtained.

129. However, some commenters suggest that the Commission's current record-keeping and reporting requirements are the minimum necessary for section 203 purposes and should not be reduced. NARUC states that our existing record-keeping and reporting requirements are adequate as they pertain to mergers. However, NARUC suggests that Commission review of merger applications could be enhanced by requiring the applicant to file *pro forma* consolidated financial reports showing the projected financial position of the merged entity after the proposed transaction.⁹⁶

130. APPA/NRECA assert that the Commission's existing record-keeping and reporting requirements do not provide sufficient information on fair market value for the Commission to ensure that companies are not improperly transacting without filing for approval. They state that the Commission should update our reporting requirements, including requiring applicants to adhere to GAAP principles for valuation determinations and to justify exemption from section 203 under both a cost and market value method of valuation. As for reporting requirements that might enable the Commission and the public to police compliance with section 203, APPA/NRECA suggest that the Commission should consider requiring public utilities to file annual reports of all transactions with a value exceeding, for example, \$5 million, to enable the Commission to enforce the \$10 million standard.

b. Commission Determination

131. Most commenters state that the Commission's existing record-keeping and reporting requirements are adequate. We agree and we will not adopt any additional compliance requirements at this time. We intend to keep our regulations as straightforward as possible so as not to increase regulatory burden on the industry while at the same time adequately monitoring jurisdictional entities' determinations of when section 203 applies to their transaction. The Commission agrees that parties have often sought section 203 authorization out of an abundance of caution because of a reasonable

possibility that section 203 approval was legally required. In this way, parties have sought to remove regulatory uncertainty from a transaction, as an entire transaction can be placed at risk if required regulatory approvals are not obtained. This incentive is even greater now that EAct 2005 has authorized civil penalties for violating statutory requirements.⁹⁷

132. Although the majority of commenters assert that the current requirements are adequate, a few suggest that these requirements should be considered the minimum necessary for section 203 purposes and should not be reduced. We agree, and note that the NOPR did not propose to reduce our current requirements. We merely asked whether our existing record keeping and reporting requirements, outside the section 203 context, provide an adequate basis for monitoring jurisdictional entities' determinations of when a section 203 application is required. We believe that those requirements, as well as other publicly available information (e.g., financial statements filed with the SEC), will give interested entities enough information to allow them to monitor compliance with section 203. For example, under SEC disclosure requirements, publicly traded entities must disclose material transactions such as mergers or asset acquisitions. Most of these transactions will easily exceed the \$10 million threshold, so the public will be on notice of transactions that likely should be submitted to the Commission for approval under section 203. We will therefore not adopt the suggestions of NARUC and APPA/NRECA that we impose new and burdensome disclosure requirements for purposes of monitoring compliance with section 203.

7. Cash Management Arrangements, Intra-Holding Company System Financing, Securities Under Amended Section 203, and Blanket Authorizations

133. The NOPR did not specifically address these issues, but we received comments on them. We note that section 203(a)(2) adds the entirely new requirement that no holding company in a holding company system that includes a transmitting utility or an electric utility shall purchase, acquire, or take any security with a value in excess of \$10 million of, or, by any means whatsoever, directly or indirectly, merge or consolidate with, a transmitting utility, an electric utility company, or a holding company in a holding company system that includes a transmitting

⁹⁷ See 16 U.S.C. 8250-1 (2000), as amended by EAct 2005 1284(e).

⁹⁶ NARUC Comments at 7-8.

utility, or an electric utility company, with a value in excess of \$10 million without Commission authorization.

a. Comments

134. Many commenters, including EEL, Duke/Cinergy, and Entergy, request that the Commission clarify that it will continue to interpret section 203 to not apply to cash management⁹⁸ and other financing arrangements routinely used in utility holding company systems. Thus, they request that the Commission continue to distinguish between the acquisition of voting securities and other instruments that confer control, which is subject to review under section 203, and the acquisition of loans and other financial instruments that do not confer control. They state that the issuance of these should remain subject to section 204 of the FPA⁹⁹ and relevant state law, but should not require section 203 approval. EEL, Duke/Cinergy, and Entergy also explain that cash management rules are already in place to monitor any potential cross-subsidization concerns for these types of financial arrangements. Furthermore, they assert that requiring prior approval under section 203 for cash management arrangements would impair the ability of holding companies and their public utility subsidiaries to manage their short-term financing needs efficiently. Applying section 203 to all intra-system financings would be contrary to Congress' intent and would create significant burdens for the Commission and utilities alike. Alternatively, should the Commission determine that section 203 applies to cash management programs, they request that the Commission allow companies to seek pre-approval (similar to the pre-approval process and reporting requirements adopted for cash management agreements) or blanket authorization.

135. MidAmerican Energy Holdings Company (MidAmerican) also urges the Commission to grant a blanket authorization for intra-holding company system financings, contributions, or

⁹⁸ While there are several different types of cash management programs, a cash management program generally involves pooling the cash resources of several affiliated companies into a "money pool." Affiliates can then borrow against the funds in the pool, often at below market rates. Additionally, the parent company is often able to achieve a higher rate of return on its money pool investments than any single affiliate could on its own. For a more detailed discussion of cash management programs. See *Regulation of Cash Management Practices*, Order No. 634, 68 FR 40,500 (July 8, 2003), III FERC Stats. & Regs. ¶ 31,145 (June 26, 2003), Order No. 634-A, 68 FR 61,993 (Oct. 31, 2003), FERC Stats. & Regs. ¶ 31,152 (Oct. 23, 2003) (Cash Management Rule).

⁹⁹ 16 U.S.C. 824c (2000).

equity infusions in excess of \$10 million undertaken by an upper tier company to fund a lower tier holding company, intermediate holding company, or public utility company within the same holding company system. It states that the purpose of these financial transactions is to fund the capital and operating requirements of the lower tier entities and, thus, that these transactions do not raise any cross-subsidization issues. MidAmerican explains that the utility company would still need to obtain Commission authorization under section 204 for the issuance of its own securities.

136. Further, MidAmerican urges the Commission to grant another blanket authorization for the infusion of capital by a passive investor through the acquisition of holding company or public utility company securities, including debt and equity securities, subject to an aggregate limitation that the passive investor acquire less than ten percent of voting equity securities. It explains that one of the main objectives of repealing PUHCA 1935 was to encourage additional investment in the energy infrastructure by non-traditional, or passive investors (who make significant capital infusions in the utility industry either as lenders or equity investors), because existing investors are not providing sufficient money. There is no need for passive investors to follow the traditional section 203 approval process. It states that passive investments will not have any adverse effects on competition, rates, or regulation, and will not result in cross-subsidization. MidAmerican proposes that, to ensure that a passive investor will not be able to exercise control through ownership of a voting equity security, the passive investor be limited to an ownership interest of less than ten percent of voting securities. Further, MidAmerican states that when an investor acquires the debt or equity securities of an entity that has a *de minimis* interest in an electric utility company, we should grant the blanket authorization.

137. MidAmerican suggests that the Commission require those who receive these types of blanket authorizations to report their transactions within 45 days of the closing of the transactions.

138. Many commenters, including EPSCA and Independent Sellers, request that the Commission clarify that the term "securities," as used in amended section 203(a), means only "voting securities," as that term is defined in section 1262(17) of PUHCA 2005, and does not apply, for example, to debt or other nonvoting securities. Alternatively, if the Commission is

unable or unwilling to so clarify, the Commission should request a conforming amendment from Congress.

139. Transmission Agency of Northern California (TANC) urges the Commission to modify its Cash Management Rule to apply to public utility holding companies, which would add an additional layer of protection to utilities and their customers.

b. Commission Determination

140. As noted above, amended section 203(a)(2) expands the Commission's authority to include mergers, acquisitions, and purchases of securities¹⁰⁰ of over \$10 million involving holding companies within certain holding company systems. A major part of the Commission's past practice in reviewing section 203 transactions has been to determine whether a particular merger or acquisition results in a single entity having control over transmission or generation resources that would allow it exercise market power. This would also be a concern under the new section 203(a)(2) provision.

141. However, as several commenters suggest, there are several classes of transactions covered by amended section 203(a)(2) that will not harm competition or captive customers. These include: (1) Routine cash management transactions and intra-holding company system financing transactions; (2) acquisition of non-voting securities (in any amount);¹⁰¹ and (3) acquisition of voting securities that would give the acquiring entity not more than 9.9 percent ownership of the outstanding voting securities. For these transactions, the Commission finds that it is consistent with the public interest to issue a blanket authorization in this Final Rule, for the reasons discussed below.

¹⁰⁰ The term "security" is defined in FPA section 3(16) as "any note, stock, treasury stock, bond, debenture, or other evidence of indebtedness of a corporation * * *."

¹⁰¹ We note, however, that it is possible, in some circumstances, for non-voting securities to convey sufficient "veto" rights over management actions as to convey "control" that triggers section 203. The Commission has addressed similar issues for purposes of evaluating independence of entities that ask for RTO status, and the SEC considered similar issues through its "no action" letter process in applying PUHCA 1935. We anticipate that our treatment of such issues under amended section 203 will generally be consistent with these precedents. If uncertainty exists as to whether significant veto rights could convey control, entities should seek a ruling from the Commission to determine whether section 203 approval is required.

i. Cash Management Programs and Intra-Holding Company Financing Arrangements

142. As several commenters note, cash management programs, money pools, and other intra-holding company financing arrangements are a routine and important tool used by many large companies to lower the cost of capital for their regulated subsidiaries and to improve the rate of return the holding company and its subsidiaries can get on their money.¹⁰² The Commission does not intend to make it more difficult for companies to take advantage of these types of transactions. Since the companies participating in a cash management-type agreement are already affiliated, allowing the transfer of funds between such companies does not generally present competitive problems. Thus, we find that it is consistent with the public interest to grant a blanket authorization to allow holding companies and their subsidiaries to take part in intra-system cash management-type programs, subject to the discussion below.

143. TANC suggests that the Commission modify its Cash Management Rule to cover holding companies themselves. Currently, the Cash Management Rule only covers the cash management practices of a holding company's public utility subsidiaries.¹⁰³ We disagree with TANC that additional generic cash management rules governing holding companies are necessary at this time to safeguard consumers. The focus of amended section 203 is partly to prevent inappropriate cross-subsidization, or encumbrances or pledges of utility assets by public utility subsidiaries. Applicants must adopt sufficient safeguards, including any necessary cash management controls (such as restrictions on upstream transfers of funds, ring fencing, etc.), to prevent any cross-subsidization between holding companies and their new subsidiaries prior to receiving section 203 approval. Such safeguards ensure that consumers are protected, while permitting companies the flexibility to competitively manage their cost of capital via a cash management program. On balance, the Commission believes that the flexibility provided by this approach, combined with our existing cash management policies,¹⁰⁴ is

superior to the one-size-fits-all approach advocated by TANC.

ii. Purchases of Non-Voting Securities by a Qualifying Holding Company

144. We agree with the majority of commenters that there is no need for case-by-case examination of the purchase by a holding company of non-voting securities of a public utility or of another holding company under amended section 203. The purchase of such securities generally does not convey control and hence does not grant the purchasing holding company additional market power, harm competitive markets, or otherwise disadvantage captive customers.¹⁰⁵ This is consistent with the intent of Congress that EPAAct 2005 increase outside investment in the utility sector while protecting customers.¹⁰⁶ As MidAmerican notes, the issuance of securities by a jurisdictional company is also governed by section 204 of the FPA. Thus, for the purposes of amended section 203, we find that it is consistent with the public interest to grant a blanket authorization for the purchase by a holding company of any amount of non-voting securities of a public utility or of another holding company. We will grant this blanket authorization and will not impose any type of filing requirement with respect to such transactions.

iii. Purchases of Voting Securities Amounting to 9.9 Percent or Less of Outstanding Voting Securities

145. As commenters note, a number of investors would like to invest in the utility sector, but have been prevented from doing so by the fear that they would become subject to regulation by the SEC as well as this Commission. To remedy this problem, a number of commenters suggest giving a blanket section 203 approval to institutional investors within holding company systems purchasing less than 10 percent of the outstanding voting securities. Commenters note that the SEC has traditionally given blanket approval to a holding company in a holding company system purchasing up to 9.9 percent of outstanding voting securities of a public utility or a holding company covered by the statute. We agree that this approach makes sense and that it is consistent

with the public interest and Congressional intent in repealing the restrictions of PUHCA 1935 and encouraging incentives for additional investment. We will, however, condition the blanket authorization by requiring the purchaser of such securities to provide the Commission, not more than 45 days after the purchase, with the same information on the same basis that the holding company now provides to the SEC.¹⁰⁷ We will issue notices of these filings for informational purposes only.

8. Section 33.2(j)—General Information Requirements Regarding Cross-Subsidization

146. In the NOPR, the Commission proposed that new section 33.2(j) would implement section 203(a)(4) by requiring applicants to explain how they are providing assurance that the proposed transaction will not result in a cross-subsidization of a non-utility associate company or a pledge or encumbrance of utility assets for the benefit of an associate company. We proposed to require appropriate evidentiary support for that explanation. We proposed that if no such assurance can be provided, applicants must explain how such cross-subsidization, pledge, or encumbrance will be consistent with the public interest.¹⁰⁸ This explanation would be Exhibit M to the applicant's section 203 application. The Commission sought comment on what evidence parties should be required to submit to support any explanation offered under this subsection.

147. The Commission noted that it has sought to guard against potential

¹⁰⁷ Accordingly, the Commission directs that the purchaser of such securities file with the Commission copies of SEC schedules 13D, 13C, and 13F. SEC schedule 13D is required to be filed by any entity acquiring beneficial ownership of more than 5 percent of a class of a company's securities. The schedule 13D filing requires, among other things, a statement of the purpose(s) of the acquisition of the securities of the issuer and a description of any plans or proposals the reporting person may have that relate to or would result in the acquisition of additional securities of the issuer; any extraordinary corporate transactions, such as a merger, reorganization or liquidation of the issuer or its affiliates; and any changes in the board of directors or management of the issuer. Schedule 13C is the same form, but is used when the person or entity is making the purchase for investment only. Institutional investment managers who exercise investment discretion over \$100 million or more must report their holdings on SEC schedule 13F. We note that these schedules required for a grant of blanket authorization under section 203(a)(2) should impose only a *de minimis* burden on the holding company, since we are requiring merely the same information that is filed with the SEC. Should the SEC change its reporting requirements, this information must continue to be filed with the Commission.

¹⁰⁸ NOPR at P 45.

¹⁰⁵ See Cash Management Rule at P 29 (discussing exception for non-voting interests that convey significant veto rights).

¹⁰⁶ See, e.g., Senate Floor Statement by Senators Domenici (R-NM), H.R. 6, Energy Policy Act of 2005, 151 Cong. Rec. S9256 (July 28, 2005) (stating that "this should bring much more capital investment into the utility companies that make up this powerful institution, this entity called the grid of the United States.").

¹⁰² See, e.g., EEI Comments at 27-31.

¹⁰³ See Cash Management Rule at P 29.

¹⁰⁴ We also note that under our existing Cash Management Rule, changes to existing or new cash management agreements (including money pool arrangements and other internal corporate financing arrangements) must be filed with the Commission.

cross-subsidization and affiliate abuse when it reviews applications for cost-based or market-based rate authority under section 205 of the FPA¹⁰⁹ or dispositions of jurisdictional facilities under section 203 involving public utilities (or their affiliates) with captive customers.¹¹⁰ We also noted that the Commission has cash management rules to monitor proprietary capital ratios and money lending or other financial arrangements that can harm regulated companies.¹¹¹ We stated that our primary focus has been on preventing a transfer of benefits from a traditional public utility's captive customers to shareholders of the public utility's holding company due to an intra-system transaction that involves power or energy, generation facilities, or non-power goods and services. Thus, in light of the Congress' clear directive in EPAct 2005 that the Commission make findings regarding cross-subsidization and the pledge or encumbrance of utility assets in a section 203 order, we sought comments on what additional safeguards or conditions may need to be placed on section 203 transactions. Specifically, the Commission solicited comments on the adequacy of its present policies preventing affiliate abuse and cross-subsidization, and whether conditions such as those imposed by state commissions may need to be imposed on section 203 transactions. The Commission also sought comment on whether additional conditions should be placed on section 203 approvals to ensure that there is no pledge or encumbrance that harms utility customers.

a. Comments

148. Many commenters generally support the Commission's proposal but recommend additional conditions or safeguards. They agree that the Commission should impose specific conditions or safeguards to protect against unfair competitive practices, cross-subsidization, and affiliate abuse.¹¹² Some recommend that the Commission consider such protections on a case-by-case basis in consultation with affected state commissions. Proposed conditions include, for example: Utility company subsidiaries shall not loan any funds (or advance any credit or indemnity) to the holding company without appropriate regulatory

approvals; a utility shall not incur any additional indebtedness, issue any additional securities, or pledge any assets to finance any part of a merger of holding companies without prior regulatory approvals; all debt at the holding company level shall be non-recourse to the utility; and the Commission should develop a process for periodic audits of inter-company transactions to be conducted in appropriate instances, as well as procedures for compliance monitoring, investigation, and complaints of cross-subsidization and affiliate abuse.

149. The Oklahoma Corporation Commission (Oklahoma Commission) proposes that applicants provide: A report of the nature of affiliates' operations; description of the business intended to be done by subsidiaries; and an explanation and detailed rationale of any plans to make any material change in investment policy, business, corporate structure, or management.

150. New Jersey Board states that it is not clear that proposed section 33.2(j) requires applicants to provide evidentiary support when claiming that a cross-subsidization, pledge, or encumbrance is consistent with the public interest. Therefore, it proposes that the text be revised to state "An explanation, with appropriate evidentiary support for such explanation (to be identified as Exhibit M to this application)."¹¹³

151. To mitigate cross-subsidization risks to ratepayers, other commenters propose structural conditions on mergers of entities that include both public utility and non-utility businesses, as the facts require. This could include the separation of public utility business within companies that also engage in non-utility business and the separation of a public utility's books and records from those of non-utility affiliates.

152. Finally, Southern Companies request that when a public utility predominately serves customers at retail but has some jurisdictional facilities, the Commission accept as sufficient a showing that the public utility applicant is subject to general supervision by a state commission that has authority to review the transaction, and that such state commission approval is predicated upon a finding that the transaction will not impair the performance of public service obligations or result in cross-subsidy burdening utility assets or service.

153. Other commenters generally state that there is no need to impose

additional conditions or a new evidentiary requirement to ensure that transactions are consistent with the public interest.¹¹⁴ They assert that the Commission already has in ways to guard against cross-subsidization or pledging or encumbering of utility assets, including: (1) Cash management rules; (2) code of conduct restrictions; (3) prior approval for certain power transactions; (4) access to, and auditing of, books and records; (5) expanded jurisdiction under EPAct 2005 with regard to books, accounts, and records; (6) standards of conduct; and (7) the application of *Edgar* standards to ensure that the sale price is not higher than would have been paid to a non-affiliate.

154. Duke/Cinergy, EEI, PNM, and Entergy assert that the Commission should allow applicants to avoid a detailed examination of cross-subsidization and encumbrance concerns by making four verifications on a case-by-case basis that address those issues. These verifications would enable the Commission to quickly determine whether a transaction is consistent with the public interest. The verifications would be that the transaction results in: (1) No transfers of facilities between a traditional utility associate company with wholesale or retail customers served under cost-based rates and an associate company; (2) no new issuance of securities by traditional utility associate companies with wholesale or retail customers served under cost-based rates for the benefit of an associate company; (3) no new pledge or encumbrance of assets of a traditional utility associate company with wholesale or retail customers served under cost-based regulation for the benefit of an associate company; (4) no new affiliate contracts between non-utility associate companies and traditional utility associate companies with wholesale or retail customers served under cost-based rates, other than system allocation agreements subject to review under EPAct 2005 section 1275(b).¹¹⁵ In cases where an applicant is unable to make one or more of the accepted verifications, these commenters state that the applicant should bear the burden of submitting sufficient information in Exhibit M to demonstrate that there is no cross-subsidization issue or, if there is, that the transaction is consistent with the public interest.

¹⁰⁹ 16 U.S.C. 824d (2000).

¹¹⁰ See, e.g., *Sierra Pacific*, 95 FERC ¶ 61,193; *Boston Edison Co.*, 80 FERC ¶ 61,274 (1997).

¹¹¹ NOPR at P 46.

¹¹² E.g., NARUC, New Jersey Board, Ohio Commission, Oklahoma Commission, Indiana Commission, APPA/NRECA, TANC, TAPSG, NASUCA, and UWUA.

¹¹³ New Jersey Board Comments at 6 (emphasis in original).

¹¹⁴ E.g., Duke/Cinergy, Entergy, EEI, AEP, Ameren, FirstEnergy, Progress Energy, International Transmission, National Grid, and Scottish Power.

¹¹⁵ See, e.g., EEI Comments at 20-21; Entergy Comments at 8; Duke/Cinergy Comments at 7.

155. Some commenters generally oppose imposing additional conditions or safeguards beyond or that would conflict with those imposed by state commissions. Many commenters believe that the Commission's current policies are more than adequate to address state commission conditions and that the Commission already imposes most of these conditions directly.¹¹⁶

156. Oklahoma Commission suggests that the Commission allow state commissions to continue to exercise their autonomous authority in addressing possible affiliate abuse and cross-subsidization. Kentucky Commission states that any additional conditions imposed by the Commission should complement, not nullify or preempt, those imposed by state commissions.

157. International Transmission states that because independent transmission companies, by definition, are not affiliated with market participants, concerns regarding transmission-specific cross-subsidization that distort energy markets are minimized. National Grid states that the Commission should impose a merger condition only when it finds a proposed transaction, taken as a whole, is inconsistent with the public interest. Scottish Power states that the Commission should allow applicants to provide their own ways to demonstrate that there is no potential for cross-subsidization, on a case-by-case basis.

158. FirstEnergy contends that a requirement that applications demonstrate that each company within a holding company system is unaffected by cross-subsidization would inundate the Commission with information that has no real import. If the Commission requires such an evidentiary showing, it must clearly define the types of evidentiary support that would be necessary and provide guidance on the types of activities that typically would result in a pledge or encumbrance and those that will be consistent with the public interest. FirstEnergy states that conditions should be placed on section 203 approvals only when the Commission finds that a pledge or encumbrance is not consistent with the public interest.

159. Finally, Independent Sellers request that the Commission adopt a rebuttable presumption that no opportunity for cross-subsidization exists when a transaction involves only entities that are not affiliated with

traditional public utilities with captive ratepayers.

160. In addition, Kentucky Commission, APPA/NRECA, and TAPSG comment that the Commission should require as part of a section 203 application the disclosure of all existing and/or future pledges and future encumbrances of utility assets. They state that applicants should have to explain how these existing pledges or encumbrances do not harm utility customers. However, International Transmission and FirstEnergy do not believe that all existing pledges and encumbrances should be disclosed in section 203 applications because this would be inconsistent with section 33.11(b)(3) of the regulations, which assumes that corporate reorganizations can occur that do not present cross-subsidization issues.

161. Missouri Commission states that the Commission should require, as a condition of approving mergers, the application of a "lower of" or "higher of" "cost or market value" standard. TANC states that requiring associate and affiliated companies to file cost allocation agreements with the Commission will help prevent excessive costs for non-power goods and services from being charged to utility companies and their customers. With regard to cost allocations for non-power goods and services, TANC asserts that the dual approach of a "lower of cost or market" standard has the advantage of ensuring that utilities and customers will not be harmed by an affiliate company relationship, regardless of whether market price exceeds costs for the non-power goods or services, or vice versa.

162. AEP encourages the Commission to retain the "at cost" standard for intra-system non-power goods and services transactions due to the added cost, burden, and inconsistencies that would be created otherwise. It explains that the expense and effort of implementing a "lower of cost or market" standard to the wide range of routine service company administrative and professional services would be immense, would result in lost efficiencies and, ultimately, would produce higher rates for regulated ratepayers. AEP states that the at-cost standard is a fair, verifiable, and workable.¹¹⁷

163. National Grid states that the Commission should continue to allow the use of the SEC's "at no more than cost" standard for pricing of intra-company transactions involving service companies. It explains that such companies were created to allow

efficiently centralized support services for utility and non-utility associate companies within a holding company; therefore, a pricing system based on market prices would not be appropriate.

b. Commission Determination

164. The Commission will adopt, with the modification explained below, our proposal to require section 203 applicants to include an explanation of either: (1) How they are providing assurances that the proposed transaction will not result in cross-subsidization or improper pledges or encumbrances of utility assets; or (2) if such results would occur, how those results are consistent with the public interest. We believe that this approach meets Congress' concern regarding cross-subsidization in section 203 transactions. As we explained in the NOPR, the Commission has previously adopted a number of policies to address affiliate abuse and cross-subsidization activities as it carries out its section 203 and 205 responsibilities. Amended section 203, however, clearly shows that Congress intended that cross-subsidization and related concerns should be a focal point of the Commission's section 203 analysis.

165. We also agree with commenters that certain protections may be necessary, on a case-by-case basis, in order to protect against cross-subsidization, pledge or encumbrance of utility assets, and affiliate abuse. We note that commenters who generally support the Commission's proposal, as well as some who generally do not support the proposal, advocate a case-by-case approach. Commenters suggest many valid conditions that applicants might propose or that the Commission might impose under revised FPA section 203(a)(4). However, many of these conditions may not be appropriate to every section 203 transaction.

166. In our Merger Policy Statement, the Commission explained that, in determining whether a merger is consistent with the public interest, one of the factors we consider is the effect the proposed merger will have on rates. The Commission's main objective in applying this factor is to protect captive customers who are served under cost-based rates that could be adversely affected by a section 203 transaction.¹¹⁸

¹¹⁸ Customers charged under market-based rates escape the potentially deleterious effects of cross-subsidization, or pledge or encumbrance of utility assets, because the prices are constrained by competition, regardless of the seller's costs. In contrast, captive customers (who pay cost-based rates) require protection. See, e.g., *Alpena Power Generation, L.L.C.*, 110 FERC ¶61,199, at P 17

¹¹⁶ E.g., Duke/Cinergy, EEL, Entergy, AEP, Ameren, Progress Energy, PNM, FirstEnergy, International Transmission, National Grid, and Scottish Power (citing NOPR at P 52.).

¹¹⁷ AEP Comments at 6-7.

The new provision in amended section 203(a)(4) concerning cross-subsidization is rooted in similar concerns. In our Merger Policy Statement, we held that an applicant that wishes to avoid a hearing on rate issues should submit a commitment that adequately protects captive customers, such as a hold harmless commitment or an open season. Also, as part of our policy authorizing market-based rates for traditional public utilities or their affiliates, we have required that these utilities adopt a code of conduct that addresses both power and non-power transactions between them.¹¹⁹ We believe that these types of commitments also can, in appropriate circumstances, address concerns regarding the potential that a merger may permit cross-subsidization. We will therefore require applicants to offer protections to their captive customers that address the potential for cross-subsidization. We also note that, in addition to any such commitments, we have continuing jurisdiction over the rates of public utilities under section 205 by which to further protect captive customers.

167. In sum, the concern about cross-subsidization is principally a concern over the effect of a transaction on rates. Accordingly, applicants proposing transactions under section 203 should proffer ratepayer protection mechanisms to assure that captive customers are protected from the effects of cross-subsidization. The applicant bears the burden of proof to demonstrate that customers will be protected.¹²⁰ Applicants should attempt to resolve the matter with customers before filing. Among the types of protection mechanisms that could be proposed by applicants are: A general hold harmless provision, which must be enforceable and administratively manageable, where

(2005) (finding affiliate abuse concerns were addressed with respect to market-based rate authority because, among other factors, there were no captive customers); *Pinnacle West Capital Corp.*, 95 FERC ¶ 61,300, at 62,024 (2001) ("The focus of the Commission's affiliate abuse concerns in cases involving sales between affiliates at market-based rates thus is protection of captive customers."); *Connectiv Energy Supply, Inc.*, 91 FERC ¶ 61,076, at 61,268 (2000) ("As the Commission has explained in previous cases, there is a concern whenever a public utility can transact with an affiliated power marketer in such a way as to transfer benefits from a power sale from captive ratepayers to its shareholders."); *The Detroit Edison Co.*, 84 FERC ¶ 61,197 (1998) (the Commission places no restrictions on power marketer transactions with affiliates that do not have captive customers).

¹¹⁹ NOPR at P 48 and 49.

¹²⁰ See *Central Vermont Pub. Serv. Corp.*, 39 FERC ¶ 61,295, at 61,960 (1987) (stating that in cases where the Commission finds sufficient potential for abuse, the Commission may disapprove the transaction or place appropriate conditions on it).

the applicant commits that it will protect wholesale customers from any adverse rate effects resulting from the transaction for a significant period of time following the transaction; or a moratorium on increases in base rates (rate freeze), where the applicant commits to freezing its rates for wholesale customers under a certain tariff for a significant period of time.¹²¹ The Commission will address the adequacy of the proposed mechanisms on a case-by-case basis. Furthermore, we agree that any additional conditions imposed by the Commission would complement, not nullify, those imposed by state commissions.

168. What constitutes adequate ratepayer protection will depend on the particular circumstances of the transaction. Should parties be unable to reach an agreement on ratepayer protection, the Commission may still be able to approve the transaction on the basis of the parties' filings if we determine that the proposal protects ratepayers from harm, or after imposing conditions specific to the particular circumstances.

169. We also agree with commenters that certain verifications in an application under amended section 203 could streamline the approval process by avoiding a detailed examination of cross-subsidization and encumbrance concerns. Such verifications, considered on a case-by-case basis in light of the given transaction, and explanations relating to those verifications, as well as other explanations of how the transaction will not result in cross-subsidization, pledge, or encumbrance of utility assets for the benefit of an associate company "or if it does result in such, an explanation of how such cross-subsidization, pledge, or encumbrance will be consistent with the public interest" is to be included as Exhibit M to the application. Accordingly, along with any protection mechanisms as discussed above, we may accept on a case-by-case basis, in lieu of or in addition to any other explanation, the following four verifications. The application may verify that the proposed transaction does not result in, at the time of the transaction or in the future: (1) Transfers of facilities between a traditional utility associate company with wholesale or retail customers served under cost-based regulation and an associate company; (2) new issuances of securities by

¹²¹ These protection mechanisms are offered only as examples. Whether these types of protection mechanisms are appropriate in a particular case will depend on the circumstances and the details of the transaction in question. See, e.g., Merger Policy Statement at 30,121-24.

traditional utility associate companies with wholesale or retail customers served under cost-based regulation for the benefit of an associate company; (3) new pledges or encumbrances of assets of a traditional utility associate company with wholesale or retail customers served under cost-based regulation for the benefit of an associate company; (4) new affiliate contracts between non-utility associate companies and traditional utility associate companies with wholesale or retail customers served under cost-based regulation, other than non-power goods and services agreements subject to review under sections 205 and 206 of the FPA.

170. We also agree with New Jersey Board that proposed section 33.2(j) does not clearly require appropriate evidentiary support for the explanation in Exhibit M. We will therefore revise the text to read: "An explanation, with appropriate evidentiary support for such explanation (to be identified as Exhibit M to this application): * * *" Further, the Commission will monitor and periodically audit, where appropriate, to ensure that applicants abide by their commitments in Exhibit M and any requirements contained in Commission orders.

171. With regard to comments on the "at cost" standard versus the "market" standard for transactions involving non-power goods and services, we note that the Commission addressed this issue in the PUHCA 2005 rulemaking.¹²²

9. Section 33.11—Commission Procedures for Consideration of Applications Under Section 203 of the FPA

172. In the NOPR, the Commission proposed new subsections 33.11(a) and (b) to implement amended section 203(a)(5). Specifically, subsection 33.11(a) provides that the Commission will act on a completed application for approval of a transaction (*i.e.*, an application that meets the requirements of Part 33), not later than 180 days after the completed application is filed.¹²³ If the Commission does not act within 180 days, such application shall be deemed granted unless the Commission finds, based on good cause, that further consideration is required and issues an

¹²² PUHCA 2005 Final Rule at P 166-73.

¹²³ As explained in the Merger Policy Statement, a complete application is one that describes the merger being proposed and that contains all the information necessary to explain how the merger is consistent with the public interest, including an evaluation of the merger's effect on competition, rates, and regulation. Merger Policy Statement at 30,127. The Commission's review process will begin when the application is deemed to be complete.

order tolling the time for acting on the application for not more than 180 days, at the end of which additional period the Commission shall grant or deny the application, as required by amended section 203 of the FPA.¹²⁴

173. Proposed subsection 33.11(b) would provide for the expeditious consideration of completed section 203 applications that are not contested, are not mergers, and are consistent with Commission precedent, because they should typically meet the standards established in section 203(a)(4).¹²⁵

174. The Commission also stated that it could not provide a comprehensive description of all the classes or types of transactions that will receive the expedited review. However, the Commission proposed that transactions that would generally warrant expedited review include: (1) A disposition of only transmission facilities, particularly those that both before and after the transaction remain under the functional control of a Commission-approved RTO or independent system operator; (2) transfers involving generation facilities of a size that do not require an Appendix A analysis; (3) internal corporate reorganizations that do not present cross-subsidization issues; and (4) the acquisition of a foreign utility company by a holding company with no captive customers in the United States.¹²⁶

175. With respect to the latter category, the Commission recognized that amended section 203's requirement for regulatory approval could have a chilling effect on investment—particularly if the transaction were subjected to a lengthy regulatory review. The Commission noted that such a transaction would not cause competitive concerns in the United States and, further, that there would be no concerns about cross-subsidization that harms captive customers in the United States. In addition, the Commission stated that even with respect to the acquisition of a foreign utility company by a holding company with captive customers in the United States, there may be safeguards that allow expedited approval of such transactions. Thus, the Commission sought comment on procedures the Commission might adopt, or safeguards it might require, to pre-approve or expedite such transactions while at the

same time protecting U.S. captive customers.

176. Further, the Commission stated that it expects to have a 60-day notice period for section 203 applications that involve, contain, or require a competitive analysis per the part 33 and a 21-day notice period for all other section 203 applications, except for certain applications that may raise cross-subsidization concerns. The Commission stated that it expects to have a 60-day notice period for applications that seek authorization to transfer ownership of a generation plant from one affiliate or associate company to another company within the same corporate structure and for other applications that may raise cross-subsidization or pledge or encumbrance issues.¹²⁷

a. Comments

177. Many commenters, including TAPSG and UWUA, support the Commission's proposal regarding the criteria for expedited consideration (applications that are not contested, are not mergers, and are consistent with Commission precedent). APPA/NRECA and TANC, however, caution that uncontested section 203 applications should still be reviewed to ensure they are consistent with Commission precedent. International Transmission notes that limiting expedited review to non-merger transactions is inconsistent with the Commission's recognition in the NOPR that not all merger transactions require the same level of analysis. Oklahoma Commission suggests that state commissions take over initial transaction review and that the Commission adopt a role of appellate review where there are disagreements between state commissions and the applicant.

178. TAPSG and UWUA agree with the Commission's proposal not to provide a comprehensive description of the classes or types of transactions that generally fall into the expedited review category. However, TANC suggests that the Commission adopt an exhaustive list of section 203 transactions that are eligible for expedited review to provide customers with the utmost protection and certainty. International Transmission recommends that, in order to encourage investment in independent transmission, dispositions, consolidations, or acquisitions by independent transmission companies

should receive expedited review, even if all of the criteria in section 33.11(b) of the proposed regulations are not met. Many commenters recommend that, for all four of the categories, the Commission automatically approve the application upon filing an informational report where the applicants make certain verifications.¹²⁸

179. With respect to proposed section 33.11(b)(4), commenters had a variety of responses on the procedures that the Commission might adopt, or safeguards it might require, to expedite or pre-approve transactions involving the acquisition of a FUCO by a holding company with no captive customers in the U.S. Many commenters request that the Commission not adopt any rules or policies that would impose undue regulatory burdens on holding companies that seek to invest in foreign utility companies.

180. Many traditional public utility commenters and others generally support a 30-day expedited review or pre-approval for transactions involving acquisitions of FUCOs.¹²⁹ Commenters suggest that the Commission automatically approve the application when the applicant provides certain cross-subsidization verifications (similar to those listed in EEI's comments), as well as assurances that the transaction will have no adverse effect on competition, rates, and regulation, if the filing is verified by a duly authorized corporate official of the holding company.¹³⁰ The transaction should be deemed approved upon making such informational filing.

181. State commission commenters, including NARUC, Ohio Commission, and New Jersey Board, generally suggest that, in order to protect domestic customers while expediting or pre-approving foreign utility transactions, the Commission should consider reviewing the financial condition and credit ratings of the acquiring utility holding company and its operating utility companies, or require applicants to submit service agreements, codes of

¹²⁴ NOPR at P 56.

¹²⁵ *Id.* at P 57.

¹²⁶ NOPR at P 59. The Commission noted that PUHCA 1935 exempted from its requirements certain acquisitions of foreign utility companies by a holding company with operations in the United States. 15 U.S.C. 33 (2000); 17 CFR 250.57 (2005). However, amended section 203 appears to provide no such exemption.

¹²⁷ NOPR at P 64–64. The Commission explained that not included in this category are transactions that merely change upstream ownership interests held by parent companies of public utilities or transactions that do not alter the terms of power supply or power supply costs for captive customers.

¹²⁸ See EEI Comments at 22–23. For example, one verification that EEI proposes is that the proposed transaction results in no transfers of facilities between a traditional utility associate company with wholesale or retail customers served under cost-based regulation and an associate company. Thus, a transaction that results in a transfer of facilities into or out of a traditional utility with captive customers could not qualify for automatic approval.

¹²⁹ *E.g.*, EEI, Duke/Cinergy, Entergy, AEP, Progress Energy, Ameren, AES, EPSA, Scottish Power, and E.ON.

¹³⁰ *E.g.*, EEI Comments at 22–23, 25–26; National Grid Comments at 20–22; AES Comments at 15–19; EPSA Comments at 8–9.

conduct, and affiliate rules.¹³¹ They recommend that the Commission also conduct a cursory "due diligence" review of historical information from annual FERC Form 1 filings by the holding company's operating utility companies to examine trends in the holding company's investment in its domestic operating utilities and in their quality of service. The Commission could get this information from state regulatory commissions.

182. Some commenters are cautious of the Commission's proposed expedited procedures for approving the acquisition of FUCOs. TAPSG states that the Commission should not decide in the abstract how reviews of such transactions can be expedited. Public Citizen urges the Commission to protect domestic ratepayers by requiring that a strong showing be made that such a transaction is consistent with the public interest and by evaluating whether attempts by off-shore companies to acquire or hold controlling shares in U.S. public utilities can be found to be consistent with the public interest.

183. With respect to proposed section 33.11(b)(1) and expedited procedures for a disposition of transmission facilities only (particularly those that both before and after the transaction remain under the functional control of a Commission-approved RTO or ISO), TANC comments that expedited review should be used only where the facilities will remain under the functional control of the same Commission-approved RTO or ISO after the transaction is completed. TANC also states that transmission-only dispositions should receive expedited review only when they involve entities that are non-dominant market participants. APPA/NRECA argues that dispositions of transmission-only facilities should not generally receive expedited review.

184. With respect to proposed section 33.11(b)(2) and expedited procedures for transfers involving generation facilities of a size that do not require an Appendix A analysis, many traditional public utility commenters suggest that such expedited review be extended to include all transactions that do not require an Appendix A analysis. They recommend revising the proposed regulations to state: "transactions that do not require an Appendix A analysis."¹³² They also state that, even in cases where an Appendix A analysis is required for a generation facility

acquisition, the Commission should act expeditiously in certain circumstances, setting a 30-day comment period and issuing an order no later than 30 days thereafter. Southern Companies requests that the Commission provide guidance regarding when an Appendix A analysis is required.

185. With regard to proposed section 33.11(b)(3), EEL, Entergy, and Duke/Cinergy support expedited procedures or pre-approval for internal corporate reorganizations that do not present cross-subsidization issues. National Grid, however, requests expedited procedures or pre-approval for internal reorganizations that do involve mergers.¹³³ It requests that the Commission facilitate all internal corporate reorganizations that do not either introduce new third-party interests or cross-subsidization issues, which are routine aspects of a company's financial operations, and do not need to be disrupted by formal proceedings, however expedited, under section 203.

186. EEL, Entergy, and Duke/Cinergy, state that the Commission could streamline the process further by granting blanket authorizations, for FUCO acquisitions involving holding companies that do not have captive customers in the U.S. and for internal corporate reorganizations involving public utility and holding company systems that do not involve traditional utility companies with captive customers.¹³⁴

187. Several commenters also made suggestions regarding notice periods and complete applications. Many commenters support the Commission's expected notice periods. However, some commenters recommend that, except in simple cases, the Commission provide for a 60-day notice period. They suggest that the applicant bear the burden of demonstrating that a shorter notice period is appropriate. TAPSG and UWUA recommend that, where applications are not complete, the Commission should issue deficiency letters. TAPSG also suggests that the Commission not deem an application complete until after it has reviewed any interventions or protests, since they may identify deficiencies in the application. UWUA recommends that the 180-day clock on section 203 applications should not begin to run until a complete application has been submitted. It states that merger applicants should have an increased responsibility to submit complete applications that are supported with full explanations of the

details of the proposed transaction, including testimony.

b. Commission Determination

188. The Commission adopts the proposed criteria for expedited consideration in section 33.11(b). Expedited consideration will be available for applications that are not contested, are not mergers, and are consistent with Commission precedent. With respect to APPA/NRECA and TANC's concerns that the Commission should review even uncontested section 203 applications to ensure that they are consistent with Commission precedent, we note that the Commission has always reviewed section 203 applications, regardless of whether they are contested.

189. Further, while some commenters recommend that the regulations contain an exhaustive list of the types of transactions that would generally warrant expedited review, we continue to believe that doing so could exclude transactions that may warrant expedited review, but that are not listed. Thus, as discussed below, we will not adopt an exhaustive list of such transactions. The Commission will not expressly provide expedited review for mergers or acquisitions involving independent transmission companies, as suggested by International Transmission, as review of such cases would be more appropriately addressed on an individual basis.¹³⁵

190. Commenters have raised many valid arguments regarding the Commission's four proposed categories of transactions generally warranting expedited review. We will adopt the NOPR's proposal in section 33.11(b)(1) and will generally provide expedited review for a disposition of only transmission facilities, particularly those that both before and after the transaction remain under the functional control of a Commission-approved RTO or ISO. We note APPA/NRECA's concern that the consolidation of control of jurisdictional facilities should be carefully evaluated under section 203 and TANC's argument that expedited review should be limited to those facilities that will remain under the functional control of the same Commission-approved RTO or ISO after the transaction is completed. However,

¹³⁵ We note that although the Filing Requirements Rule provided that applicants for a transaction involving only transmission facilities need not provide a competitive analysis under §§ 33.3 or 33.4 of the Commission's regulations, it also states that if the Commission determines that a filing nonetheless raises competitive issues, the Commission will evaluate those issues. Filing Requirements Rule at 31,902.

¹³¹ See, e.g., NARUC Comments at 15-16; Ohio Commission Comments at 8-9; New Jersey Board Comments at 9-10.

¹³² See, e.g., EEL Comments at 24-26; Duke/Cinergy Comments at 10-11; Entergy Comments at 9-11.

¹³³ National Grid Comments at 33.

¹³⁴ See, e.g., EEL Comments at 26-27.

we believe that ISOs and RTOs are pro-competitive and are effective at preventing market power abuse because they have Commission-approved market-monitoring and mitigation measures in place. Further, we continue to believe that, as stated in the Filing Requirements Rule, "the standards set forth in Order No. 2000¹³⁶ require extensive information from RTO applicants that we believe will demonstrate whether the proposal is in the public interest. It also has been our experience that anticompetitive effects are unlikely to arise with regard to internal corporate reorganizations or transactions that only involve the disposition of transmission facilities."¹³⁷ For these reasons, we adopt section 33.11(b)(1) as proposed in the NOPR.

191. With respect to proposed section 33.11(b)(2), the Commission will adopt commenters' proposal and expand that section to generally provide expedited review for "transactions that do not require an Appendix A analysis." On further consideration, the Commission finds that it is not necessary to limit the transactions that will receive expedited review based on the amount of generation that is being transferred in the transaction. First, we note that the amount as well as the type of generation, involved can have different market power consequences, depending on the situation, in different markets. Second, our current regulations, which allow applicants to file an abbreviated competitive analysis (e.g., an analysis that does not include an Appendix A analysis) in certain circumstances, permit us to seek additional information if it is needed to allow us to evaluate the effects of the transaction. Therefore, although in the first instance the applicant must decide whether to perform a full-fledged analysis, it is the Commission that ultimately decides whether such analysis is necessary and thus whether the filing qualifies for expedited review.

192. With respect to proposed section 33.11(b)(3), we agree with commenters that internal corporate reorganizations that do not present cross-subsidization issues are unlikely to cause anticompetitive effects. Thus, instead of providing expedited review for this category, the Commission is granting a blanket authorization for internal

corporate reorganizations that do not present cross-subsidization issues and that do not involve a traditional public utility with captive customers.

193. With respect to the last category, proposed section 33.11(b)(4), we will not adopt the NOPR's proposal to expedite review for transactions involving the acquisition of a FUCO by a holding company with no captive customers in the U.S. Instead, we will grant a blanket authorization for any holding company in a holding company system that includes a transmitting utility or an electric utility company to acquire a foreign utility company. However, if such holding company or any of its affiliates, its subsidiaries, or associate companies within the holding company system have captive customers in the United States, the authorization is conditioned on the holding company verifying by a duly authorized corporate official of the holding company that the proposed transaction will not have any adverse effect on competition, rates, or regulation, and will not result in, at the time of the transaction or in the future: (1) Any transfer of facilities between a traditional utility associate company with wholesale or retail customers served under cost-based regulation and an associate company; (2) any new issuance of securities by traditional utility associate companies with wholesale or retail customers served under cost-based regulation for the benefit of an associate company; (3) any new pledge or encumbrance of assets of a traditional utility associate company with wholesale or retail customers served under cost-based regulation for the benefit of an associate company; or (4) any new affiliate contracts between non-utility associate companies and traditional utility associate companies with wholesale or retail customers served under cost-based regulation, other than non-power goods and services agreements subject to review under sections 205 and 206 of the FPA. Such transactions will be deemed approved only upon making a filing of these verifications.

194. Regarding notice periods, the Final Rule adopts the NOPR approach. Some commenters recommend that the Commission's default rule for all section 203 applications should be to provide the public 60 days to submit comments, and that the applicants should bear the burden or demonstrating that a shorter notice is appropriate. However, the Commission finds that the NOPR notice periods will allow us to continue processing section 203 applications quickly to allow reasonable business goals to be met. Accordingly, we expect to have a 60-day notice period for

section 203 applications that involve, contain, or require a competitive analysis per the revised filing requirements, and a 21-day notice period for all other section 203 applications, except those that may raise cross-subsidization concerns. We will not formalize this policy by rule, so that we can be flexible to deal with varying circumstances. This will allow us to protect against some commenters' concerns that the public notice period would be "unnecessarily short-circuited," and ensure that it will only be streamlined as appropriate.

B. Amendments to 18 CFR 2.26—The Merger Policy Statement

195. When the Commission considers a proposed transaction's effect on federal regulation, section 2.26(e)(1) states that "[w]here the merged entity would be part of a registered public utility holding company, if applicants do not commit in their application to abide by this Commission's policies with regard to affiliate transactions, the Commission will set the issue for a trial-type hearing."

196. However, in the NOPR, the Commission explained that because EPCRA 2005 repeals PUHCA 1935,¹³⁸ activities of registered holding companies that were previously subject to SEC regulation, including inter-company transactions, will no longer be exempt from this Commission's regulation once PUHCA 1935 repeal takes effect on February 8, 2006.¹³⁹ Thus, the Commission stated that there is no longer a concern about any potential shift in regulation from this Commission to the SEC under the effect of regulation factor, and proposed to delete section 2.26(e)(1).¹⁴⁰

197. Proposed new subsection 2.26(f) would state that the Commission will not approve a transaction that will result in cross-subsidization of a non-utility associate company or pledge or encumbrance of utility assets for the benefit of an associate company unless that cross-subsidization, pledge, or encumbrance will be consistent with the public interest.

1. Comments

198. Commenters did not specifically address the Commission's proposed section 2.26(e) and (f) amendments. However, some recommend that the Commission rethink its current merger policy and make important decisions as

¹³⁶ *Regional Transmission Organizations*, Order No. 2000, 65 FR 809 (Jan. 6, 2000), FERC Stats. & Regs. ¶ 31,089, at 31,108 (1999), *order on reh'g*, Order No. 2000-A, 65 FR 12,088 (Mar. 8, 2000), FERC Stats. & Regs. ¶ 31,092 (2000), *aff'd sub nom. Public Utility District No. 1 of Snohomish County, Washington v. FERC*, 272 F.3d 607 (DC Cir. 2001).

¹³⁷ Filing Requirements Rule at 31,902.

¹³⁸ EPCRA 2005 § 1263.

¹³⁹ See 17 CFR part 250 (2005).

¹⁴⁰ NOPR at P 67. However, the Commission reiterated that applicants are still required to address whether the transaction will have any other effect on the Commission's regulation.

to what "consistent with the public interest" means in light of amended section 203 and the repeal of PUHCA 1935. Some comment that the Commission should broaden its public interest inquiry to consider ratepayer benefits on an application-specific basis; namely, applicants could propose an open season guarantee under which their existing wholesale requirements customers could terminate their contracts if the applicants request a rate increase affecting those customers for the first five years after the merger is consummated.

199. Ohio Commission comments that the Commission should consider factors in addition to those listed in section 2.26(b). It recommends that the Commission require that a holding company secure a letter of endorsement, or order, from any affected state regulatory commission in which the holding company has utility operations. It states that a similar endorsement requirement is used by the SEC to implement Rule 53¹⁴¹ regarding authority for registered holding company financings in connection with the acquisition of exempt wholesale generators.

200. Commenters also explain that, in light of amended section 203, the Commission should expect numerous section 203 applications seeking approval of "cross-country" (or interstate) mergers. They state that the Commission's current method for evaluating the effect of a proposed electric utility merger on competition, the Appendix A analysis, was developed when cross-country electric utility mergers were not common, because of PUHCA 1935. The "impact on competition" horizontal screen analysis looks primarily at whether competition will be lessened in the "common" markets where the merger applicants operate. They state that continued use of the Appendix A analysis alone may result in substantial industry consolidation.

201. TAPSG asserts that the Commission almost exclusively relies on the HHI aspect of the Appendix A analysis and fails to examine the other competitive effects of a transaction. It comments that the Commission should require applicants to submit documents and data, beyond those needed to perform the Appendix A analysis, including the kinds of information submitted to the antitrust agencies as part of the initial Hart-Scott-Rodino¹⁴²

notification, and should require applicants to submit supply curve analyses for each relevant market.

2. Commission Determination

202. With respect to commenters' specific concerns regarding the Commission's merger policy, we are not persuaded at this time to change our current policies. Our standard of review is flexible enough to consider any changes in market structure that ultimately result from the EPA Act 2005 and the repeal of PUHCA 1935. However, once the Commission has gained more experience in evaluating section 203 applications under the new statute, we may consider reevaluating our merger policy in general. Accordingly, we adopt the proposal set forth in the NOPR with respect to amended sections 2.26(e) and (f).

IV. Information Collection Statement

203. Office of Management and Budget (OMB) regulations require that OMB approve certain reporting and recordkeeping requirements (collections of information) imposed by an agency.¹⁴³ The information collection requirements in this Final Rule are identified under the Commission's data collection, FERC-519, "Applications Under Federal Power Act Section 203." Under section 3507(d) of the Paperwork Reduction Act of 1995,¹⁴⁴ the reporting requirements in this rulemaking will be submitted to OMB for review.

204. Respondents subject to the filing requirements of this Final Rule will not be penalized for failing to respond to this collection of information unless the collection of information displays a valid OMB control number. "Display" is defined as publishing the OMB control number in regulations, guidelines, forms or other issuances in the *Federal Register* (for example, in the preamble or regulatory text for the Final Rule containing the information collection).¹⁴⁵

Public Reporting Burden: In the NOPR, the Commission stated that the regulations that it proposed should have a minimal impact on the current reporting burden associated with an individual application, as they would not substantially change the filing requirements with which section 203 applicants must currently comply. Further, the Commission stated that it did not expect the total number of section 203 applications to increase

substantially under amended section 203. The Commission received 42 comments on its NOPR and only GE EFS specifically addressed its estimates. GE EFS notes that the "Information Collection Statement" in the NOPR states that "the Commission does not expect the total number of section 203 applications under amended section 203 to increase substantially."¹⁴⁶ GE EFS comments that, unless the Commission limits the overly broad scope of its proposed rules, the Commission will be burdened with applications for acquisitions of securities of QFs, which heretofore were exempted from section 203.¹⁴⁷ As noted above, we believe that the blanket authorizations granted herein for certain holding company acquisitions of non-voting securities and up to 9.9 percent of voting securities in electric utility companies will adequately address GE EFS' concerns. To the extent additional blanket authorizations are needed or appropriate, we will consider those on a case-by-case basis. Thus, we believe that we have lessened the burden on applicants subject to the requirements of amended section 203, including for applicants seeking to acquire securities of QFs. Therefore, the Commission will retain its initial estimates.

The Commission is submitting a copy of this Final Rule to OMB for review and approval. In their notice of December 9, 2005, OMB took no action on the NOPR, instead deferring their approval until review of the Final Rule.

Title: FERC-519, Applications Under Federal Power Act Section 203.

Action: Proposed Information Collection.

OMB Control No: 1902-0082.

Respondents: Businesses or other for profit.

Necessity of the Information: The information collected under the requirements of FERC-519 is used by the Commission to implement section 203 of the Federal Power Act and the Code of Federal Regulations under 18 CFR part 33 and 18 CFR 2.26. This Final Rule is limited to implementing amended section 203 of the FPA, which directs the Commission to adopt a rule to do so. Further, this Final Rule does not substantially change the current filing requirements or regulations that applicants must comply with for transactions subject to FPA section 203.

205. Interested persons may obtain information on this information collection by contacting the following: Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC

Rodino filing requirements and described in 16 CFR part 803 (2005).

¹⁴¹ 17 CFR 250.53 (2005).

¹⁴² TAPSG explains that the Hart-Scott-Rodino notification is a far more limited submission required of all utilities subject to the Hart-Scott-

¹⁴³ 5 CFR 1320.11 (2005).

¹⁴⁴ 44 U.S.C. 3507(d) (2000).

¹⁴⁵ See 1 CFR 21.35; 5 CFR 1320.3(f)(3).

¹⁴⁶ NOPR at P 70.

¹⁴⁷ GE EFS Comments at 2.

20426, Attention: Michael Miller, Officer of the Executive Director, phone: (202) 502-8415, fax: (202) 273-0873, e-mail: michael.miller@ferc.gov.

206. Comments concerning this information collection can be sent to the Office of Management and Budget, Office of Information and Regulatory Affairs, Washington, DC 20503 [Attention: Desk Officer for the Federal Energy Regulatory Commission, phone: (202) 395-4650, fax: (202) 395-7285].

V. Environmental Analysis

207. The Commission is required to prepare an Environmental Assessment or an Environmental Impact Statement for any action that may have a significant adverse effect on the human environment.¹⁴⁸ The Commission concludes that neither an Environmental Assessment or an Environmental Impact Statement is required for this Final Rule under section 380.4(a)(2)(ii) of the Commission regulations, which provides a "categorical exclusion for rules that do not substantively change the effect of legislation."¹⁴⁹

VI. Regulatory Flexibility Act Certification

208. The Regulatory Flexibility Act of 1980 (RFA)¹⁵⁰ generally requires a description and analysis of final rules that will have a significant economic impact on a substantial number of small entities.¹⁵¹ The Commission is not required to make such analyses if a rule would not have such an effect.

209. The Commission adheres to its certification in the NOPR that this rulemaking will not have a significant economic impact upon a substantial number of small entities. As stated in the NOPR, EPA Act 2005 directs the Commission to issue a rule adopting procedures for the expeditious consideration of applications for the approval of dispositions, consolidations, or acquisition, under this section. In accordance with this directive, this rule

implements section 203 of the FPA. In particular, the rule increases the value threshold for filing a section 203 application with the Commission from transactions in excess of \$50,000 to transactions in excess of \$10 million (under amended section 203 of the FPA). Further, the RFA directs agencies to consider four regulatory alternatives to be considered in a rulemaking to lessen the impact on small entities: Tiering or establishment of different compliance or reporting requirements for small entities, classification, consolidation, clarification or simplification of compliance and reporting requirements, performance rather than design standards, and exemptions. In this Final Rule, the Commission has adopted tiering, and classification and simplification by classifying the types of holding acquisitions that qualify for a grant of blanket approval under section 203(a)(2). Further, the rule does not substantially change the current requirements and regulations that applicants must comply with for transactions subject to FPA section 203. Therefore, the Commission certifies that this rule will not have a significant impact on a substantial number of small entities.

VII. Document Availability

210. In addition to publishing the full text of this document in the **Federal Register**, the Commission provides all interested persons an opportunity to view and/or print the contents of this document via the Internet through FERC's Home Page (<http://www.ferc.gov>) and in FERC's Public Reference Room during normal business hours (8:30 a.m. to 5 p.m. Eastern time) at 888 First Street, NE., Room 2A, Washington, DC 20426.

211. From the Commission's Home Page on the Internet, this information is available in the Commission's document management system, eLibrary. The full text of this document is available on eLibrary in PDF and Microsoft Word format for viewing, printing, and/or downloading. To access this document in eLibrary, type "RM05-34" in the docket number field.

212. User assistance is available for eLibrary and the FERC's Web site during normal business hours. For assistance, please contact FERC Online Support at 1-866-208-3676 (toll free) or 202-502-6652 (e-mail at FERCOnlineSupport@FERC.gov), or the Public Reference Room at 202-502-8371, TTY 202-502-8659 (e-mail at public.refenceroom@ferc.gov).

VIII. Effective Date and Congressional Notification

213. This Final Rule will take effect on February 8, 2006. The Commission has determined, with the concurrence of the Administrator of the Office of Information and Regulatory Affairs of OMB, that this rule is not a major rule within the meaning of section 251 of the Small Business Regulatory Enforcement Fairness Act of 1996.¹⁵² The Commission will submit this Final Rule to both houses of Congress and the General Accountability Office.¹⁵³

List of Subjects

18 CFR Part 2

Administrative practice and procedure; Electric power; Natural gas; Pipelines; Reporting and recordkeeping requirements

18 CFR Part 33

Electric utilities; Reporting and recordkeeping requirements; Securities

By Order of the Commission.

Magalie R. Salas,

Secretary.

■ In consideration of the foregoing, the Commission amends Chapter I, Title 18, *Code of Federal Regulations*, as follows:

PART 2—GENERAL POLICY AND INTERPRETATIONS

■ 1. The authority citation for part 2 is revised to read as follows:

Authority: 5 U.S.C. 601; 15 U.S.C. 717-717w, 3301-3432; 16 U.S.C. 792-825y, 2601-2645; 42 U.S.C. 4321-4361, 7101-7352; Pub. L. No. 109-58, 119 Stat. 594.2.

■ 2. Section 2.26 is amended by revising paragraph (e) and by adding paragraph (f) to read as follows:

§ 2.26. Policies concerning review of applications under section 203.

* * * * *

(e) *Effect on regulation.* (1) Where the affected state commissions have authority to act on the transaction, the Commission will not set for hearing whether the transaction would impair effective regulation by the state commissions. The application should state whether the state commissions have this authority.

(2) Where the affected state commissions do not have authority to act on the transaction, the Commission may set for hearing the issue of whether the transaction would impair effective state regulation.

(f) Under section 203(a)(4) of the Federal Power Act (16 U.S.C. 824b), in

¹⁴⁸ Order No. 486, *Regulations Implementing the National Environmental Policy Act*, 52 FR 47,897 (Dec. 17, 1987), FERC Stats. & Regs. ¶ 30,783 (1987).

¹⁴⁹ 18 CFR 380.4(a)(2)(ii) (2005).

¹⁵⁰ 5 U.S.C. 601-12.

¹⁵¹ The RFA definition of "small entity" refers to the definition provided in the Small Business Act, which defines a "small business concern" as a business that is independently owned and operated and that is not dominant in its field of operation. 15 U.S.C. 632. The Small Business Size Standards component of the North American Industry Classification System defines a small electric utility as one that, including its affiliates, is primarily engaged in the generation, transmission, and/or distribution of electric energy for sale and whose total electric output for the preceding fiscal years did not exceed 4 million MWh. 13 CFR 121.201 (2005).

¹⁵² See 5 U.S.C. 804(2).

¹⁵³ See 5 U.S.C. 801(a)(1)(A).

reviewing a proposed transaction subject to section 203, the Commission will also consider whether the proposed transaction will result in cross-subsidization of a non-utility associate company or pledge or encumbrance of utility assets for the benefit of an associate company, unless that cross-subsidization, pledge, or encumbrance will be consistent with the public interest.

PART 33—APPLICATIONS UNDER FEDERAL POWER ACT SECTION 203

■ 3. The authority citation for part 33 is revised to read as follows:

Authority: 16 U.S.C. 791a–825r, 2601–2645; 31 U.S.C. 9701; 42 U.S.C. 7101–7352; Pub. L. No. 109–58, 119 Stat. 594.

■ 4. The heading of part 33 is revised to read as set forth above.

■ 5. Section 33.1 is revised to read as follows:

§ 33.1. Applicability, definitions, and blanket authorizations.

(a) *Applicability.* (1) The requirements of this part will apply to any public utility seeking authorization under section 203 of the Federal Power Act to:

(i) Sell, lease, or otherwise dispose of the whole of its facilities subject to the jurisdiction of the Commission, or any part thereof of a value in excess of \$10 million;

(ii) Merge or consolidate, directly or indirectly, such facilities or any part thereof with those of any other person, by any means whatsoever;

(iii) Purchase, acquire, or take any security with a value in excess of \$10 million of any other public utility; or

(iv) Purchase, lease, or otherwise acquire an existing generation facility:

(A) That has a value in excess of \$10 million; and

(B) That is used in whole or in part for wholesale sales in interstate commerce by a public utility.

(2) The requirements of this part shall also apply to any holding company in a holding company system that includes a transmitting utility or an electric utility if such holding company seeks to purchase, acquire, or take any security with a value in excess of \$10 million of, or, by any means whatsoever, directly or indirectly, merge or consolidate with, a transmitting utility, an electric utility company, or a holding company in a holding company system that includes a transmitting utility, or an electric utility company, with a value in excess of \$10 million.

(b) *Definitions.* For the purposes of this part, as used in section 203 of the Federal Power Act (16 U.S.C. 824b)

(1) *Existing generation facility* means a generation facility that is operational at or before the time the section 203 transaction is consummated. “The time the transaction is consummated” means the point in time when the transaction actually closes and control of the facility changes hands. “Operational” means a generation facility for which construction is complete (*i.e.*, it is capable of producing power). The Commission will rebuttably presume that section 203(a) applies to the transfer of any existing generation facility unless the utility can demonstrate with substantial evidence that the generator is used exclusively for retail sales.

(2) *Non-utility associate company* means any associate company in a holding company system other than a public utility or electric utility company that has wholesale or retail customers served under cost-based regulation.

(3) *Value* when applied to:

(i) Transmission facilities, generation facilities, transmitting utilities, electric utility companies, and holding companies, means the market value of the facilities or companies for transactions between non-affiliated companies; the Commission will rebuttably presume that the market value is the transaction price. For transactions between affiliated companies, value means original cost undepreciated, as defined in the Commission’s Uniform System of Accounts prescribed for public utilities and licensees in part 101 of this chapter, or original book cost, as applicable;

(ii) Wholesale contracts, means the market value for transactions between non-affiliated companies; the Commission will rebuttably presume that the market value is the transaction price. For transactions between affiliated companies, value means total expected nominal contract revenues over the remaining life of the contract; and

(iii) Securities, means market value for transactions between non-affiliated companies; the Commission will rebuttably presume that the market value is the agreed-upon transaction price. For transactions between affiliated companies, value means market value if the securities are widely traded, in which case the Commission will rebuttably presume that market value is the market price at which the securities are being traded at the time the transaction occurs; if the securities are not widely traded, market value is determined by:

(A) Determining the value of the company that is the issuer of the equity securities based on the total

undepreciated book value of the company’s assets;

(B) Determining the fraction of the securities at issue by dividing the number of equity securities involved in the transaction by the total number of outstanding equity securities of the company; and

(C) Multiplying the value determined in paragraph (b)(3)(iii)(A) of this section by the value determined in paragraph (b)(3)(iii)(B) of this section (*i.e.*, the value of the company multiplied by the fraction of the equity securities at issue).

(4) The terms *associate company*, *electric utility company*, *foreign utility company*, *holding company*, and *holding company system* have the meaning given those terms in the Public Utility Holding Company Act of 2005. The term holding company does not include: A State, any political subdivision of a State, or any agency, authority or instrumentality of a State or political subdivision of a State; or an electric power cooperative.

(c) *Blanket Authorizations.* (1) Any holding company in a holding company system that includes a transmitting utility or an electric utility is granted a blanket authorization under section 203(a)(2) of the Federal Power Act to purchase, acquire, or take any security of:

(i) A transmitting utility or company that owns, operates, or controls only facilities used solely for transmission in intrastate commerce and/or sales of electric energy in intrastate commerce;

(ii) A transmitting utility or company that owns, operates, or controls only facilities used solely for local distribution and/or sales of electric energy at retail regulated by a state commission; or

(iii) A transmitting utility or company if the transaction involves an internal corporate reorganization that does not present cross-subsidization issues and does not involve a traditional public utility with captive customers.

(2) Any holding company in a holding company system that includes a transmitting utility or an electric utility is granted a blanket authorization under section 203(a)(2) of the Federal Power Act to purchase, acquire, or take:

(i) Any non-voting security (that does not convey sufficient veto rights over management actions so as to convey control) in a transmitting utility, an electric utility company, or a holding company in a holding company system that includes a transmitting utility or an electric utility company; or

(ii) Any voting security in a transmitting utility, an electric utility company, or a holding company in a holding company system that includes a

transmitting utility or an electric utility company if, after the acquisition, the holding company will own less than 10 percent of the outstanding voting securities; or

(iii) Any security of a subsidiary company within the holding company system.

(3) The blanket authorizations granted under paragraph (c)(2) of this section are subject to the conditions that the holding company shall not:

(i) Borrow from any electric utility company subsidiary in connection with such acquisition; or

(ii) Pledge or encumber the assets of any electric utility company subsidiary in connection with such acquisition;

(4) A holding company granted blanket authorizations in section (c)(2) shall provide the Commission with the same information, on the same basis, that the holding company provides to the Securities and Exchange Commission in connection with any securities purchased, acquired or taken pursuant to this section.

(5) Any holding company in a holding company system that includes a transmitting utility or an electric utility is granted a blanket authorization under section 203(a)(2) of the Federal Power Act to acquire a foreign utility company. However, if such holding company or any of its affiliates, its subsidiaries, or associate companies within the holding company system have captive customers in the United States, the authorization is conditioned on the holding company verifying by a duly authorized corporate official of the holding company that the proposed transaction:

(i) Will not have any adverse effect on competition, rates, or regulation; and
(ii) Will not result in, at the time of the transaction or in the future:

(A) Any transfer of facilities between a traditional utility associate company with wholesale or retail customers served under cost-based regulation and an associate company;

(B) Any new issuance of securities by traditional utility associate companies

with wholesale or retail customers served under cost-based regulation for the benefit of an associate company;

(C) Any new pledge or encumbrance of assets of a traditional utility associate company with wholesale or retail customers served under cost-based regulation for the benefit of an associate company; or

(D) Any new affiliate contracts between non-utility associate companies and traditional utility associate companies with wholesale or retail customers served under cost-based regulation, other than non-power goods and services agreements subject to review under sections 205 and 206 of the Federal Power Act.

(iii) A transaction by a holding company subject to the conditions in paragraphs (c)(5)(i) and (ii) of this section will be deemed approved only upon filing the information required in paragraphs (c)(5)(i) and (ii) of this section.

■ 6. Section 33.2 is amended to add paragraph (j) to read as follows:

§ 33.2. Contents of application—general information requirements.

* * * * *

(j) An explanation, with appropriate evidentiary support for such explanation (to be identified as Exhibit M to the application):

(1) Of how applicants are providing assurance that the proposed transaction will not result in cross-subsidization of a non-utility associate company or pledge or encumbrance of utility assets for the benefit of an associate company; or

(2) If no such assurance can be provided, an explanation of how such cross-subsidization, pledge, or encumbrance will be consistent with the public interest.

■ 7. Section 33.11 is added to read as follows:

§ 33.11. Commission procedures for the consideration of applications under section 203 of the FPA.

(a) The Commission will act on a completed application for approval of a transaction (*i.e.*, one that is consistent with the requirements of this part) not later than 180 days after the completed application is filed. If the Commission does not act within 180 days, such application shall be deemed granted unless the Commission finds, based on good cause, that further consideration is required to determine whether the proposed transaction meets the standards of section 203(a)(4) of the FPA and issues, by the 180th day, an order tolling the time for acting on the application for not more than 180 days, at the end of which additional period the Commission shall grant or deny the application.

(b) The Commission will provide for the expeditious consideration of completed applications for the approval of transactions that are not contested, do not involve mergers, and are consistent with Commission precedent. The transactions that would generally warrant expedited review include:

- (1) A disposition of only transmission facilities, particularly those that both before and after the transaction remain under the functional control of a Commission-approved regional transmission organization or independent system operator; and
- (2) Transactions that do not require an Appendix A analysis.¹

Note: The following appendix will not appear in the Code of Federal Regulations.

Appendix List of Intervenor and Commenters

Intervenors

- California Public Utilities Commission.
- Edison Mission Energy, Edison Mission Marketing & Trading, Inc., and Midwest Generation EME, LLC.
- Public Service Commission of Wisconsin.
- Public Utilities Commission of Ohio.
- Southern California Edison Company.

COMMENTERS

Acronym	Name
ACC	American Chemistry Counsel.
AEP	American Electric Power Service Corporation.
AES	The AES Corporation.
Ameren	Ameren Services Company.
APPA/NRECA	American Public Power Association and the National Rural Electric Cooperative Association.
Chairman Barton	Congressman Joe Barton.
Constellation	Constellation Energy Group Inc.
Duke/Cinergy	Duke Energy Corporation and Cinergy Corporation.
EEL	Edison Electric Institute.

¹ *Inquiry Concerning the Commission's Merger Policy Under the Federal Power Act: Policy Statement*, Order No. 592, 61 FR 68,595 (Dec. 30,

1996), FERC Stats. & Regs. ¶ 31,044 (1996), reconsideration denied, Order No. 592-A, 62 FR

33,340 (June 19, 1997), 79 FERC ¶ 61,321 (1997) (Merger Policy Statement).

COMMENTERS—Continued

Acronym	Name
Entergy	Entergy Services, Inc.
E.ON	E.ON AG.
EPSA	Electric Power Supply Association.
FirstEnergy	FirstEnergy Service Company.
GE EFS	GE Energy Financial Services.
HECO	Hawaiian Electric Company, Inc.
Independent Sellers	Cogentrix Energy, Inc. and The Goldman Sachs Group, Inc.
Indiana Commission	Indiana Utility Regulatory Commission.
Industrial Consumers	Electricity Consumers Resource Council, the American Iron and Steel Institute, the American Chemistry Council, and the PJM Industrial Customer Coalition.
International Transmission	International Transmission Company.
Kentucky Commission	Kentucky Public Service Commission.
MidAmerican	MidAmerican Energy Holdings Company.
Missouri Commission	Missouri Public Utilities Commission.
Morgan Stanley	Morgan Stanley Capital Group Inc.
NAFC	National Alliance for Fair Competition.
NARUC	National Association of Regulatory Utility Commissioners.
NASUCA	National Association of State Utility Consumer Advocates.
National Grid	National Grid USA.
New Jersey Board	New Jersey Board of Public Utilities.
North Carolina Commission	North Carolina Utilities Commission.
Ohio Commission	Public Utilities Commission of Ohio.
Oklahoma Commission	Oklahoma Corporation Commission.
PNM	PNM Resources, Inc.
Progress Energy	Progress Energy, Inc.
Public Citizen	Energy Program of Public Citizen, Inc.
Scottish Power	Scottish Power plc.
Southern Companies	Southern Company Services, Inc.
Suez	SUEZ Energy North America.
TANC	Transmission Agency of Northern California.
TAPSG	Transmission Access Policy Study Group.
UWUA	Utility Workers Union of America, AFL-CIO.
Wisconsin Electric	Wisconsin Electric Power Company.
Xcel	Xcel Energy Services, Inc.

[FR Doc. 06-77 Filed 1-5-06; 8:45 am]

BILLING CODE 6717-01-P



Federal Register

Friday,
January 6, 2006

Part IV

Environmental Protection Agency

40 CFR Part 63

**National Emission Standards for
Hazardous Air Pollutants: Surface Coating
of Metal Cans; Final Rule and Proposed
Rule**

ENVIRONMENTAL PROTECTION AGENCY
40 CFR Part 63
[OAR-2003-0005; FRL-8018-9]
RIN 2060-AM28
National Emission Standards for Hazardous Air Pollutants: Surface Coating of Metal Cans
AGENCY: Environmental Protection Agency (EPA).

ACTION: Direct final rule; amendments.

SUMMARY: EPA is taking direct final action on amendments to the national emission standards for hazardous air pollutants (NESHAP) for surface coating of metal cans, which were promulgated on November 13, 2003, under section 112 of the Clean Air Act (CAA). The direct final rule amendments correct errors and add clarification to sections of the rule. We are issuing the amendments as a direct final rule, without prior proposal, because we view the revisions as noncontroversial and anticipate no adverse comments. However, in the Proposed Rules section of this **Federal Register** notice, we are publishing a separate document that will serve as the proposal to amend the NESHAP for surface coating of metal cans if adverse comments are filed. Any comments on the revisions should be directed to the proposed rule.

DATES: The direct final rule is effective on March 7, 2006 without further notice, unless EPA receives adverse written comment by February 6, 2006. If adverse comments are received, EPA will publish a timely withdrawal in the **Federal Register** indicating which amendments will become effective and which amendments are being withdrawn due to adverse comment.

ADDRESSES: Submit your comments, identified by Docket ID No. OAR-2003-0005, by one of the following methods:

- Federal eRulemaking Portal: <http://www.regulations.gov>. Follow the on-line instructions for submitting comments.
- Agency Web site: <http://docket.epa.gov/edkpub/index.jsp>. EDOCKET, EPA's electronic public docket and comment system, is EPA's preferred method for receiving comments. Follow the on-line instructions for submitting comments.

- E-mail: a-and-r-docket@epa.gov and almodovar.paul@epa.gov.
- Fax: (202) 566-1741 and (919) 541-5689.

- Mail: U.S. Postal Service, send comments to: EPA Docket Center (6102T), Attention Docket ID No. OAR-2003-0005, 1200 Pennsylvania Avenue, NW., Washington, DC 20460. Please include a total of two copies. We request that you also send a separate copy of each comment to the contact person listed below (see **FOR FURTHER INFORMATION CONTACT**).

- Hand Delivery: In person or by courier, deliver comments to: EPA Docket Center (6102T), Attention Docket ID No. OAR-2003-0005, 1301 Constitution Avenue, NW., Room B-108, Washington, DC 20004. Such deliveries are only accepted during the Docket's normal hours of operation, and special arrangements should be made for deliveries of boxed information. Please include a total of two copies. We request that you also send a separate copy of each comment to the contact person listed below (see **FOR FURTHER INFORMATION CONTACT**).

Instructions: Direct your comments to Docket ID No. OAR-2003-0005. The EPA's policy is that all comments received will be included in the public docket without change and may be made available online at <http://docket.epa.gov/edkpub/index.jsp>, including any personal information provided, unless the comment includes information claimed to be confidential business information (CBI) or other information whose disclosure is restricted by statute. Do not submit information that you consider to be CBI or otherwise protected through EDOCKET, regulations.gov, or e-mail. Send or deliver information identified as CBI only to the following address: Mr. Roberto Morales, OAQPS Document Control Officer, EPA (C404-02), Attention Docket ID No. OAR-2003-0005, Research Triangle Park, NC 27711. Clearly mark all of the information that you claim to be CBI. The EPA EDOCKET and the Federal [regulations.gov](http://www.regulations.gov) websites are "anonymous access" systems, which means EPA will not know your identity or contact information unless you provide it in the body of your comment. If you send an e-mail comment directly to EPA without going through EDOCKET or [regulations.gov](http://www.regulations.gov), your e-

mail address will be automatically captured and included as part of the comment that is placed in the public docket and made available on the Internet. If you submit an electronic comment, EPA recommends that you include your name and other contact information in the body of your comment and with any disk or CD-ROM you submit. If EPA cannot read your comment due to technical difficulties and cannot contact you for clarification, EPA may not be able to consider your comment. Electronic files should avoid the use of special characters, any form of encryption, and be free of any defects or viruses. For additional information about EPA's public docket, visit EDOCKET on-line or see the **Federal Register** of May 31, 2002 (67 FR 38102).

Docket: All documents in the docket are listed in the EDOCKET index at <http://docket.epa.gov/edkpub/index.jsp>. Although listed in the index, some information is not publicly available, i.e., CBI or other information whose disclosure is restricted by statute. Certain other material, such as copyrighted material, is not placed on the Internet and will be publicly available only in hard copy form. Publicly available docket materials are available either electronically in EDOCKET or in hardcopy at the EPA Docket Center, Docket ID No. OAR-2003-0005, EPA West Building, Room B-102, 1301 Constitution Ave., NW., Washington, DC. The Public Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday through Friday, excluding legal holidays. The telephone number for the Public Reading Room is (202) 566-1744, and the telephone number for the EPA Docket Center is (202) 566-1742. A reasonable fee may be charged for copying docket materials.

FOR FURTHER INFORMATION CONTACT: For further information, contact Mr. Paul Almodovar, EPA, Office of Air Quality Planning and Standards, Emission Standards Division, Coatings and Consumer Products Group (C539-03), Research Triangle Park, NC 27711; telephone number (919) 541-0283; fax number (919) 541-5689; e-mail address: almodovar.paul@epa.gov.

SUPPLEMENTARY INFORMATION: *Regulated Entities.* Categories and entities potentially regulated by this action include:

Category	NAICS * code	Examples of regulated entities
Industry	332431	Two piece beverage can facilities.
	332431, 332115, 332116, 332812, 332999 332431	Three piece food can facilities, two piece D&I facilities, one piece aerosol can facilities, etc.
	332431	Can assembly facilities.

Category	NAICS* code	Examples of regulated entities
	332431, 332812	End manufacturing facilities.

* North American Industry Classification System

This table is not intended to be exhaustive, but rather provides a guide for readers regarding entities likely to be regulated by this action. To determine whether your facility is regulated by this action, you should examine the applicability criteria in 40 CFR 63.3481 and 40 CFR 63.3482 of the Metal Can NESHAP (68 FR 64432, November 13, 2003). If you have any questions regarding the applicability of this action to a particular entity, consult the person listed in the preceding **FOR FURTHER INFORMATION CONTACT** section.

Comments. We are publishing the direct final rule amendments without prior proposal because we view the amendments as noncontroversial and do not anticipate adverse comments. However, in the Proposed Rules section of this **Federal Register**, we are publishing a separate document that will serve as the proposal to amend the NESHAP for surface coating of metal cans if adverse comments are filed. If we receive any adverse comments on one or more distinct amendments, we will publish a timely withdrawal in the **Federal Register** informing the public which amendments will become effective, and which amendments are being withdrawn due to adverse comment. We will address all public comments in a subsequent final rule, should the Agency determine to issue one. Any of the distinct amendments in today's direct final rule for which we do not receive adverse comment will become effective on the previously mentioned date. We will not institute a second comment period on the direct final rule amendments. Any parties interested in commenting must do so at this time.

Judicial Review. Under section 307(b)(1) of the CAA, judicial review of the direct final rule amendments is available only by filing a petition for review in the United States Court of Appeals for the District of Columbia Circuit by March 7, 2006. Under section 307(d)(7)(B) of the CAA, only an objection to the direct final rule amendments which was raised with reasonable specificity during the period for public comment can be raised during judicial review. Moreover, under section 307(b)(2) of the CAA, the requirements established by the direct final rule amendments may not be challenged separately in any civil or criminal

proceedings brought by EPA to enforce these requirements.

Worldwide Web (WWW). In addition to being available in the docket, an electronic copy of today's direct final rule amendments will also be available on the WWW through the Technology Transfer Network (TTN). Following the Administrator's signature, a copy of this action will be posted on the TTN's policy and guidance page for newly proposed or promulgated rules at <http://www.epa.gov/ttn/oarpg/>. The TTN provides information and technology exchange in various areas of air pollution control.

Outline. The information presented in this preamble is organized as follows:

- I. Background
- II. Amendments to 40 CFR Part 63, Subpart KKKK
- III. Statutory and Executive Order Reviews
 - A. Executive Order 12866, Regulatory Planning and Review
 - B. Paperwork Reduction Act
 - C. Regulatory Flexibility Act
 - D. Unfunded Mandates-Reform Act
 - E. Executive Order 13132, Federalism
 - F. Executive Order 13175, Consultation and Coordination With Indian Tribal Governments
 - G. Executive Order 13045, Protection of Children From Environmental Health Risks and Safety Risks
 - H. Executive Order 13211, Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use
 - I. National Technology Transfer and Advancement Act
 - J. Congressional Review Act

I. Background

EPA promulgated NESHAP for surface coating of metal cans on November 13, 2003 (68 FR 64432). The final rule (40 CFR part 63, subpart KKKK) includes standards for hazardous air pollutants (HAP), as well as monitoring, performance testing, recordkeeping, and reporting requirements related to the standards. After promulgation of the final rule, EPA received numerous questions relating to rule interpretation. The questions pointed out minor inconsistencies in some of the rule language and equations and identified areas where the rule requirements were not clear. Today's action includes direct final rule amendments that resolve inconsistencies and clarify rule language. None of the amendments will have any discernable effect on the stringency of the rule.

II. Amendments to 40 CFR Part 63, Subpart KKKK

In response to the proposed rule (68 FR 2110, January 15, 2003), EPA received a question related to compliance with parametric monitoring after testing but before the compliance date. In the final rule, EPA retained language from the proposed rule that requires affected sources to meet operating limits once the performance test used to establish those limits is complete, even if this occurs before the actual compliance date. EPA failed to make an intended change for the final rule to clarify that existing affected sources do not have to meet the operating limits prior to the compliance date. We have rewritten 40 CFR 63.3492 to state that new and reconstructed sources must meet the operating limits at all times after they have been established during the performance test, and existing sources must meet the operating limits at all times after the compliance date of November 13, 2006.

A question was raised concerning the definition of major source in the final rule versus the definition of major source in the General Provisions of 40 CFR part 63. To be consistent with the definition of major source in 40 CFR 63.2 of the General Provisions, we added the phrase "considering controls" to the description of a major source of HAP emissions in 40 CFR 63.3481(b).

A question was raised about the omission of clarifying text stating that all required calculations and compliance demonstrations may be performed with either metric or English units. In response, we have added language clarifying that all required calculations and all compliance demonstrations may be performed using either metric or English units in 40 CFR 63.3521, 63.3531, and 63.3541, as was intended.

A question was raised about the inclusion of cleaning materials in compliance calculations and equations. EPA erroneously made a change between the proposed and final rule that added cleaning materials as HAP-containing materials and included them in compliance calculations in 40 CFR 63.3541(h). Several other surface coating maximum achievable control technology (MACT) rules include cleaning materials as part of the calculation of total mass of organic HAP; however, as stated in the preamble

to the proposed rule (January 15, 2003, 68 FR 2130), emissions data collected for the metal can industry did not show any significant HAP associated with cleaning materials. Therefore, we have removed references to cleaning materials in the text in 40 CFR 63.3522 and 63.3561, as well as references to cleaning materials in equations which also resulted in modifications to the associated equation numbering in 40 CFR 63.3510, 63.3511, and 63.3512. The term "surface preparation" was removed in 40 CFR 63.3544(b), since this term is defined to mean the use of a cleaning material on a substrate. These revisions are discussed in more detail below.

Section 63.3522, paragraph (c) pertaining to identifying those coating operations for which affected sources use the compliant material option in the semiannual compliance report, was revised to exclude the application of cleaning materials as a coating operation.

Section 63.3561 includes the definition of terms used in this subpart, including the definition of "capture system" which is defined in terms of coatings and cleaning materials. Capture systems will not be required to collect emissions from cleaning materials, so the definition of "capture system" no longer contains a reference to cleaning materials.

Section 63.3510, paragraph (c)(8)(ii), pertaining to the notification of compliance requirements for affected sources using the emission rate without add-on controls option, was revised to reference Equations 1, 1A, 1B, 2, and 3 of 40 CFR 63.3531 for calculating the total mass of organic HAP emissions for each month, the total volume of coating solids used each month, and the 12-month organic HAP emission rate, respectively.

Section 63.3510, paragraph (c)(8)(iii) pertains to affected sources using the emission rate with add-on controls option. The notification of compliance will now require the use of Equations 1, 1A, and 1B of 40 CFR 63.3531 to calculate the total mass of organic HAP emissions for the coatings and thinners used each month. Also, the calculation of the mass of organic HAP emission reduction each month by emission capture systems and add-on control devices will now be performed by using Equations 1 and 1A through 1C of 40 CFR 63.3541, and Equations 2, 3, 3A, and 3B of 40 CFR 63.3541, as applicable.

In 40 CFR 63.3511, which pertains to reporting requirements for affected sources, references to equations to be used to calculate the total mass of

organic HAP emissions for the coatings and thinners used each month were revised in the second sentence of paragraph (a)(6)(ii) to include Equations 1, 1A, 1B, 2, and 3 in 40 CFR 63.3531; and in the second sentence of paragraph (a)(7)(ii) to include Equations 1, 1A, and 1B of 40 CFR 63.3531. In addition, the calculation for the mass of organic HAP emission reduction each month by emission capture systems and add-on control devices will now use Equations 1 and 1A through 1C of 40 CFR 63.3541, and Equations 2, 3, 3A, and 3B of 40 CFR 63.3541, as applicable.

Section 63.3512 contains recordkeeping requirements. References to each equation were revised in paragraph (c)(3) to include Equations 1, 1A, 1B, and 2 of 40 CFR 63.3531 to be used to calculate the total mass of organic HAP emissions for the coatings and thinners used each month for the emission rate without add-on controls option; paragraph (c)(4)(i) was revised to include Equations 1, 1A, and 1B of 40 CFR 63.3531 to be used to calculate the total mass of organic HAP emissions for the coatings and thinners used each month; and paragraph (c)(4)(iii) was revised to include Equations 1 and 1A through 1C, 2, 3, 3A, and 3B of 40 CFR 63.3541 to be used to calculate the mass of organic HAP emission reduction by emission capture systems and add-on control devices.

Section 63.3544, paragraph (b), pertains to measuring capture efficiency during a production run of at least 3 hours and up to 8 hours, where the production run is defined as the time required for a single part to go from the beginning to the end of production. The term production run was redefined to exclude surface preparation activities which involve the use of cleaning materials.

EPA received comments requesting that it include six additional cross-references to the overall subcategory emission limit (OSEL) in the notification, reports, and records sections of this subpart, in 40 CFR 63.3510, 63.3511, and 63.3512, respectively. The OSEL is a 12-month alternative emission limit that can be used if the affected source applies coatings in more than one coating type segment within a subcategory and can be calculated by using Equation 4 in 40 CFR 63.3531(i). We have rewritten five sentences to reference OSEL Equation 4 in addition to the existing formula references and added one new sentence. The same five sentences were also affected by the deletion of the reference to cleaning materials, as discussed above.

A comment was made pertaining to remaining references to 40 CFR 63.3547(g) and 63.3557(g), paragraphs pertaining to requirements for continuous parameter monitoring for emission rate with the add-on controls option and for the control efficiency/outlet concentration option, respectively, that appeared in the proposed rule but were not included in the final rule. We are removing the remaining references to these paragraphs in 40 CFR 63.3547(a) and 63.3557(a). A similar reference to 40 CFR 63.3546(g) remained in Table 4 to Subpart KKKK of Part 63, Item 8.a.i, was also removed.

A comment was made pertaining to redundant language in 40 CFR 63.3547(a)(1) and 63.3557(a)(1), pertaining to continuous parameter monitoring system (CPMS) frequency of data collection. These sections state that the CPMS must complete a minimum of one cycle of operation for each successive 15-minute period. They then state that you must have a minimum of four equally spaced successive cycles of CPMS operation in 1 hour. The second sentence is redundant and is now removed from each section.

A comment was made pertaining to the need to clarify the frequency of data collection for CPMS for permanent total enclosure (PTE) capture systems in Table 4 to Subpart KKKK of Part 63, Item 7, and the number of data points needed to establish the 3-hour average for the non-PTE emission capture operating parameters in Table 4, Item 8. For emission capture systems and add-on control devices, the frequency of data collection and the number of data collection points is specified in 40 CFR 63.3547(a)(1) and (2) and 40 CFR 63.3557(a)(1) and (2), which state that the CPMS must complete a minimum of one cycle of operation for each successive 15-minute period, and the average of all recorded readings must be determined for each successive 3-hour period. These sections apply to emission capture systems (PTE and non-PTE) and add-on control devices. We are, therefore, transferring this language and references to 40 CFR 63.3547(a)(1) and (2) and 40 CFR 63.3557(a)(1) and (2) to Table 4 to Subpart KKKK of Part 63, Items 7 and 8, for clarification.

A question was raised as to whether a bypass line valve indicator or a damper indicator would be acceptable in place of the capture system bypass line flow indicator required in paragraph (b)(1) of 40 CFR 63.3547. The alternate indicators would meet the CPMS requirements by recording the position of the bypass valve damper at least once every 15 minutes to ensure

the bypass line is in the closed position and would not divert emissions away from the add-on control device directly to the atmosphere. We are, therefore, modifying the text to add the two alternate indicators.

A question was raised as to whether static pressure could be measured at the oxidizer inlet as an alternative to the requirement to measure the static pressure in each capture system duct as required by Table 4 to Subpart KKKK of Part 63, Item 8, to show that the capture system is working. EPA agrees that this approach would be acceptable, but consider it critical to address the position of the pressure measurement relative to the flow inducer and that "at the inlet of the oxidizer" is not descriptive enough. We, therefore, added new language requiring measurement of static pressure "upstream of the fan" in the duct of each capture device or "upstream of the fan that is common to multiple capture devices" versus "at the inlet of the oxidizer." Language was also added to differentiate between smaller safety fans (on the outlet of ovens that also act as capture devices) and fans that serve as the primary air movers. This allows for the affected source to monitor pressure downstream of the safety fan, but upstream of the primary fan. Language was also added to refer back to the required performance testing in 40 CFR 63.3546(g) in order to establish the limits for gas volumetric flow rate and duct static pressure. Conforming changes were then made to 40 CFR 63.3546(g).

III. Statutory and Executive Order Reviews

A. Executive Order 12866, Regulatory Planning and Review

Under Executive Order 12866 (58 FR 51735, October 4, 1993), EPA must determine whether the regulatory action is "significant" and, therefore, subject to review by the Office of Management and Budget (OMB) and the requirements of the Executive Order. The Executive Order defines "significant regulatory action" as one that is likely to result in a rule that may:

(1) Have an annual effect on the economy of \$100 million or more or adversely affect in a material way the economy, a sector of the economy, productivity, competition, jobs, the environment, public health or safety, or State, local, or tribal governments or communities;

(2) Create a serious inconsistency or otherwise interfere with an action taken or planned by another agency;

(3) Materially alter the budgetary impact of entitlements, grants, user fees, or loan programs, or the rights and obligations of recipients thereof; or

(4) Raise novel legal or policy issues arising out of legal mandates, the President's priorities, or the principles set forth in the Executive Order.

It has been determined that this rule is not a "significant regulatory action" under the terms of Executive Order 12866 and is, therefore, not subject to OMB review.

B. Paperwork Reduction Act

This action does not impose any new information collection burden under the provisions of the Paperwork Reduction Act, 44 U.S.C. 3501, *et seq.* OMB approved the information collection request (ICR) for the NESHAP for metal can surface coating pursuant to the provisions of the Paperwork Reduction Act and has assigned OMB control number 2060-0541 (EPA ICR No. 2079.02). A copy of the original ICR may be obtained from Susan Auby by mail at the Office of Environmental Information, Collection Strategies Division (2822), EPA, 1200 Pennsylvania Avenue, NW., Washington, DC 20460, by e-mail at auby.susan@epa.gov, or by calling (202) 566-1672. You may also download a copy from the internet at <http://www.epa.gov/icr>. Include the ICR number in any correspondence.

Burden means the total time, effort, or financial resources expended by persons to generate, maintain, retain, or disclose or provide information to or for a Federal agency. This includes the time needed to review instructions; develop, acquire, install, and utilize technology and systems for the purposes of collecting, validating, and verifying information, processing and maintaining information, and disclosing and providing information; adjust the existing ways to comply with any previously applicable instructions and requirements; train personnel to be able to respond to a collection of information; search data sources; complete and review the collection of information; and transmit or otherwise disclose the information.

An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The OMB control numbers for EPA's regulations in 40 CFR are listed in 40 CFR part 9.

C. Regulatory Flexibility Analysis.

EPA has determined that it is not necessary to prepare a regulatory

flexibility analysis in connection with the direct final rule amendments.

For purposes of assessing the impacts of today's direct final rule on small entities, small entity is defined as: (1) A small business as defined by the Small Business Administrations' regulations at 13 CFR 121.201; (2) a small governmental jurisdiction that is a government of a city, county, town, school district or special district with a population of less than 50,000; and (3) a small organization that is any not-for-profit enterprise which is independently owned and operated and is not dominant in its field.

After considering the economic impacts of today's direct final rule amendments on small entities, EPA has concluded that this action will not have a significant economic impact on a substantial number of small entities. We have determined that the direct final rule amendments will not impose any new requirements on small entities.

D. Unfunded Mandates Reform Act

Title II of the Unfunded Mandates Reform Act of 1995 (UMRA), Public Law No. 104-4, establishes requirements for Federal agencies to assess the effects of their regulatory actions on State, local, and tribal governments and the private sector. Under section 202 of the UMRA, EPA generally must prepare a written statement, including a cost-benefit analysis, for proposed and final rules with "Federal mandates" that may result in expenditures to State, local, and tribal governments, in the aggregate, or to the private sector, of \$100 million or more in any 1 year. Before promulgating a rule for which a written statement is needed, section 205 of the UMRA generally requires us to identify and consider a reasonable number of regulatory alternatives and adopt the least costly, most cost-effective, or least burdensome alternative that achieves the objectives of the rule. The provisions of section 205 do not apply when they are inconsistent with applicable law. Moreover, section 205 allows us to adopt an alternative other than the least costly, most cost-effective, or least burdensome alternative if the Administrator publishes with the final rule an explanation why that alternative was not adopted. Before EPA establishes any regulatory requirements that may significantly or uniquely affect small governments, including tribal governments, it must have developed under section 203 of the UMRA a small government agency plan. The plan must provide for notifying potentially affected small governments, enabling officials of affected small governments

to have meaningful and timely input in the development of EPA regulatory proposals with significant Federal intergovernmental mandates, and informing, educating, and advising small governments on compliance with the regulatory requirements.

EPA has determined that the direct final rule amendments do not contain a Federal mandate that may result in expenditures of \$100 million or more for State, local, and tribal governments, in the aggregate, or the private sector in any 1 year. The direct final rule amendments apply only to affected sources in the metal can industry and clarify and correct errors in the final rule and, therefore, add no additional burden on sources. EPA has determined that this rule contains no regulatory requirements that might significantly or uniquely affect small governments. The direct final rule amendments apply only to affected sources in the metal can industry and clarify and correct errors in the final rule. Thus, the direct final rule amendments are not subject to the requirements of sections 202 and 205 of the UMRA.

E. Executive Order 13132, Federalism

Executive Order 13132, entitled "Federalism" (64 FR 43255, August 10, 1999), requires EPA to develop an accountable process to ensure "meaningful and timely input by State and local officials in the development of regulatory policies that have federalism implications." "Policies that have federalism implications" is defined in the Executive Order to include regulations that have "substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government."

The direct final rule amendments do not have federalism implications. They will not have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132. No metal can production facilities subject to the direct final rule amendments are owned or operated by State or local governments. Therefore, State and local governments will not have any direct compliance costs resulting from the direct final rule amendments. Furthermore, the direct final rule amendments do not require these governments, or anyone else, to take on any new responsibilities. Thus, Executive Order 13132 does not apply to the direct final rule amendments.

F. Executive Order 13175, Consultation and Coordination With Indian Tribal Governments

Executive Order 13175, entitled "Consultation and Coordination with Indian Tribal Governments" (65 FR 67249, November 9, 2000), requires EPA to develop an accountable process to ensure "meaningful and timely input by tribal officials in the development of regulatory policies that have tribal implications." The direct final rule amendments do not have tribal implications as specified in Executive Order 13175. They will not have substantial direct effects on tribal governments, on the relationship between the Federal government and Indian tribes, or on the distribution of power and responsibilities between the Federal government and Indian tribes, because we are not aware of any Indian tribal governments or communities affected by the direct final rule amendments. Thus, Executive Order 13175 does not apply to the direct final rule amendments.

G. Executive Order 13045, Protection of Children From Environmental Health Risks and Safety Risks

Executive Order 13045 (62 FR 19885, April 23, 1997) applies to any rule that: (1) Is determined to be "economically significant" as defined under Executive Order 12866, and (2) concerns an environmental health or safety risk that EPA has reason to believe may have a disproportionate effect on children. If the regulatory action meets both criteria, the Agency must evaluate the environmental health or safety effects of the planned rule on children, and explain why the planned regulation is preferable to other potentially effective and reasonably feasible alternatives considered by the Agency.

EPA interprets Executive Order 13045 as applying only to those regulatory actions that are based on health or safety risks, such that the analysis required under section 5-501 of the Executive Order has the potential to influence the regulation. The direct final rule amendments are not subject to Executive Order 13045 because they are based on technology performance and not on health or safety risks.

H. Executive Order 13211, Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use

The direct final rule amendments are not subject to Executive Order 13211 (66 FR 28355, May 22, 2001) because they are not a significant regulatory action under Executive Order 12866.

I. National Technology Transfer and Advancement Act

Section 12(d) of the National Technology Transfer and Advancement Act (NTTAA) of 1995, Public Law No. 104-113, 12(d) (15 U.S.C. 272 note) directs EPA to use voluntary consensus standards (VCS) in its regulatory activities unless to do so would be inconsistent with applicable law or otherwise impractical. The VCS are technical standards (e.g., materials specifications, test methods, sampling procedures, and business practices) that are developed or adopted by VCS bodies. The NTTAA directs EPA to provide Congress, through the OMB, explanations when the Agency decides not to use available and applicable VCS. The direct final rule amendments do not involve technical standards; therefore, EPA is not adopting any VCS.

J. Congressional Review Act

The Congressional Review Act, 5 U.S.C. 801, *et seq.*, as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. EPA will submit a report containing the direct final rule amendments and other required information to the United States Senate, the United States House of Representatives, and the Comptroller General of the United States prior to publication of the direct final rule amendments in the **Federal Register**. A major rule cannot take effect until 60 days after it is published in the **Federal Register**. The direct final rule amendments are not a "major rule" as defined by 5 U.S.C. 804(2). The direct final rule amendments are effective on March 7, 2006.

List of Subjects in 40 CFR Part 63

Environmental protection, Air pollution control, Hazardous substances, and Reporting and recordkeeping requirements.

Dated: December 29, 2005.

Stephen L. Johnson,
Administrator.

■ For the reasons stated in the preamble, title 40, chapter I, part 63 of the Code of the Federal Regulations is amended as follows:

PART 63—[AMENDED]

■ 1. The authority citation for part 63 continues to read as follows:

Authority: 42 U.S.C. 7401, *et seq.*

Subpart KKKK—[AMENDED]

■ 2. Section 63.3481 is amended by revising the second sentence in paragraph (b) to read as follows:

§ 63.3481 Am I subject to this subpart?

(b) * * * A major source of HAP emissions is any stationary source or group of stationary sources located within a contiguous area and under common control that emits or has the potential to emit, considering controls, any single HAP at a rate of 9.07 megagrams (Mg) (10 tons) or more per year or any combination of HAP at a rate of 22.68 Mg (25 tons) or more per year.

■ 3. Section 63.3492 is amended by revising the third sentence in paragraph (b) to read as follows:

§ 63.3492 What operating limits must I meet?

(b) * * * You must establish the operating limits during the initial performance test according to the requirements in § 63.3546 or § 63.3556. New and reconstructed sources must meet the operating limits at all times after they have been established during the performance test, and existing sources must meet the operating limits at all times after the compliance date.

■ 4. Section 63.3510 is amended by revising paragraphs (c)(8)(ii) and (iii) to read as follows:

§ 63.3510 What notifications must I submit?

(ii) For the emission rate without add-on controls option, provide the calculation of the total mass of organic HAP emissions for each month, the calculation of the total volume of coating solids used each month, and the calculation of the 12-month organic HAP emission rate, using Equations 1, 1A, 1B, 2, and 3, respectively, of § 63.3531, or Equation 4 of § 63.3531, if applicable.

(iii) For the emission rate with add-on controls option, provide the calculation of the total mass of organic HAP emissions for the coatings and thinners used each month, using Equations 1, 1A, and 1B of § 63.3531; the calculation of the total volume of coating solids used each month, using Equation 2 of § 63.3531; the calculation of the mass of organic HAP emission reduction each month by emission capture systems and add-on control devices, using Equations

1 and 1A through 1C of § 63.3541, and Equations 2, 3, 3A, and 3B of § 63.3541, as applicable; the calculation of the total mass of organic HAP emissions each month, using Equation 4 of § 63.3541, as applicable; and the calculation of the 12-month organic HAP emission rate, using the applicable equation, Equation 5 of § 63.3541 or Equation 4 of § 63.3531.

■ 5. Section 63.3511 is amended by revising the second sentence of paragraph (a)(6)(ii) and the second sentence of paragraph (a)(7)(ii) to read as follows:

§ 63.3511 What reports must I submit?

(ii) * * * You must provide the calculations for Equations 1, 1A, 1B, 2, and 3 in § 63.3531 or Equation 4 in § 63.3531, if applicable; and, if applicable, the calculation used to determine mass of organic HAP in waste materials according to § 63.3531(e)(3).

(ii) * * * You must provide the calculation of the total mass of organic HAP emissions for the coatings and thinners used each month, using Equations 1, 1A, and 1B of § 63.3531 and, if applicable, the calculation used to determine mass of organic HAP in waste materials according to § 63.3531(e)(3); the calculation of the total volume of coating solids used each month, using Equation 2 of § 63.3531; the calculation of the mass of organic HAP emission reduction each month by emission capture systems and add-on control devices, using Equations 1 and 1A through 1C of § 63.3541, and Equations 2, 3, 3A, and 3B of § 63.3541, as applicable; the calculation of the total mass of organic HAP emissions each month, using Equation 4 of § 63.3541; and the calculation of the 12-month organic HAP emission rate, using Equation 5 of § 63.3541, or Equation 4 in § 63.3531, if applicable.

(ii) * * * You must provide the calculation of the total mass of organic HAP emissions for the coatings and thinners used each month, using Equations 1, 1A, and 1B of § 63.3531 and, if applicable, the calculation used to determine mass of organic HAP in waste materials according to § 63.3531(e)(3); the calculation of the total volume of coating solids used each month, using Equation 2 of § 63.3531; the calculation of the mass of organic HAP emission reduction each month by emission capture systems and add-on control devices, using Equations 1 and 1A through 1C of § 63.3541, and Equations 2, 3, 3A, and 3B of § 63.3541, as applicable; the calculation of the total mass of organic HAP emissions each month, using Equation 4 of § 63.3541; and the calculation of the 12-month organic HAP emission rate, using Equation 5 of § 63.3541, or Equation 4 in § 63.3531, if applicable.

■ 6. Section 63.3512 is amended by:

■ a. Revising paragraphs (c)(3), (c)(4) introductory text, (c)(4)(i), and (c)(4)(iii); and

■ b. Adding paragraph (c)(4)(vi) to read as follows:

§ 63.3512 What records must I keep?

(3) For the emission rate without add-on controls option, a record of the calculation of the total mass of organic

HAP emissions for the coatings and thinners used each month, using Equations 1, 1A, 1B, and 2 of § 63.3531 and, if applicable, the calculation used to determine mass of organic HAP in waste materials according to § 63.3531(e)(3); the calculation of the total volume of coating solids used each month, using Equation 2 of § 63.3531; and the calculation of each 12-month organic HAP emission rate, using Equation 3 of § 63.3531, or Equation 4 in § 63.3531, if applicable.

(4) For the emission rate with add-on controls option, records of the calculations specified in paragraphs (c)(4)(i) through (vi) of this section.

(i) The calculation of the total mass of organic HAP emissions for the coatings and thinners used each month, using Equations 1, 1A, and 1B of § 63.3531 and, if applicable, the calculation used to determine mass of organic HAP in waste materials according to § 63.3531(e)(3).

(iii) The calculation of the mass of organic HAP emission reduction by emission capture systems and add-on control devices, using Equations 1 and 1A through 1C of § 63.3541, and Equations 2, 3, 3A, and 3B of § 63.3541, as applicable.

(vi) The OSEL calculation, if applicable, using Equation 4 of § 63.3531.

■ 7. Section 63.3521 is amended by adding a sentence to the end of the introductory text to read as follows:

§ 63.3521 How do I demonstrate initial compliance with the emission limitations?

* * * All required calculations and compliance demonstrations may be performed with either metric or English units.

■ 8. Section 63.3522 is amended by revising the second sentence in paragraph (c) to read as follows:

§ 63.3522 How do I demonstrate continuous compliance with the emission limitations?

(c) * * * If there were no deviations from the emission limitations set forth in § 63.3490, submit a statement that the coating operation(s) was (were) in compliance with the emission limitations during the reporting period because you used no coating for which the organic HAP content exceeded the applicable emission limit in § 63.3490, and you used no thinner that contained

organic HAP, as determined according to § 63.3521(a).

* * * * *

■ 9. Section 63.3531 is amended by adding a sentence to the end of the introductory text to read as follows:

§ 63.3531 How do I demonstrate initial compliance with the emission limitations?

* * * All required calculations and compliance demonstrations may be performed with either metric or English units.

* * * * *

■ 10. Section 63.3541 is amended by:

- a. Adding a sentence to the end of paragraph (a);
- b. Revising the third sentence and Equation 1 (defined terms) of paragraph (h);
- c. Removing paragraph (h)(3) and Equation 1C and redesignating paragraph (h)(4) as (h)(3) and Equation 1D as Equation 1C, and revising the newly redesignated paragraph (h)(3); and
- d. Revising paragraph (i)(5) to read as follows:

§ 63.3541 How do I demonstrate initial compliance?

(a) * * * All required calculations and compliance demonstrations may be performed with either metric or English units.

* * * * *

(h) Calculate the organic HAP emission reduction for each controlled coating operation not using liquid-liquid material balances. * * * The calculation applies the emission capture system efficiency and add-on control device efficiency to the mass of organic HAP contained in the coatings and thinners that are used in the coating operation served by the emission capture system and add-on control device during each month. * * *

* * * * *

H_{unc} = Total mass of organic HAP in the coatings and thinners used during all deviations specified in § 63.3542(c) and (d) that occurred during the month in the controlled coating operation, kg, as calculated in Equation 1C of this section.

* * * * *

(3) Calculate the mass of organic HAP in the coatings and thinners used in the controlled coating operation during deviations specified in § 63.3542(c) and (d), using Equation 1C of this section.

$$H_{unc} = \sum_{h=1}^q (Vol_h)(D_h)(W_h) \quad (\text{Eq. 1C})$$

Where:

H_{unc} = Total mass of organic HAP in the coatings and thinners used during all deviations specified in § 63.3542(c) and (d) that occurred during the month in the controlled coating operation, kg.

Vol_h = Total volume of coating or thinner, h, used in the controlled coating operation during deviations, liters.

D_h = Density of coating or thinner, h, kg per liter.

W_h = Mass fraction of organic HAP in coating or thinner, h, kg organic HAP per kg coating.

q = Number of different coatings or thinners.

(i) Calculate the organic HAP emission reduction for each controlled coating operation using liquid-liquid material balances. * * *

(5) Measure the volume of each coating and thinner used in the coating operation controlled by the solvent recovery system during the month, liters.

* * * * *

■ 11. Section 63.3544 is amended by revising the fifth sentence in paragraph (b) to read as follows:

§ 63.3544 How do I determine the emission capture system efficiency?

* * * * *

(b) * * * For the purposes of this test, a production run means the time required for a single part to go from the beginning to the end of production, and includes drying or curing time, but excludes surface preparation activities.

* * * * *

■ 12. Section 63.3546 is amended by revising paragraphs (g)(1) and (g)(2) as follows:

§ 63.3546 How do I establish the emission capture system and add-on control device operating limits during the performance test?

* * * * *

(g) * * *
 (1) During the capture efficiency determination required by § 63.3540 and described in §§ 63.3543 and 63.3544, you must monitor and record either the gas volumetric flow rate at a location upstream of the control device, or the duct static pressure at a location upstream of the primary fan in each duct of each capture device or upstream of the fan that is common to multiple capture devices at least once every 15 minutes during each of the three test runs.

(2) Calculate and record the average gas volumetric flow rate or duct static pressure for the three test runs for each capture device or system of multiple

capture devices. The average gas volumetric flow rate is the minimum operating limit for that specific capture device or system of multiple capture devices. The average duct static pressure is the maximum operating limit for that specific capture device or system of multiple capture devices.

■ 13. Section 63.3547 is amended by:

- a. Revising the first sentence of paragraph (a) introductory text,
- b. Removing the second sentence of paragraph (a)(1), and
- c. Revising paragraph (b)(1) to read as follows:

§ 63.3547 What are the requirements for continuous parameter monitoring system installation, operation, and maintenance?

(a) General. You must install, operate, and maintain each CPMS specified in paragraphs (c), (e), and (f) of this section according to paragraphs (a) (1) through (6) of this section. * * *

* * * * *

(b) * * *
 (1) Properly install, maintain, and operate a flow indicator that takes a reading at least once every 15 minutes. The flow indicator shall be installed at the entrance to any bypass line. Alternatively, install, maintain, and operate a bypass line valve indicator or damper indicator that indicates valve position.

* * * * *

■ 14. Section 63.3557 is amended by revising the first sentence of paragraph (a) introductory text and removing the second sentence of paragraph (a)(1) to read as follows:

§ 63.3557 What are the requirements for continuous parameter monitoring system installation, operation, and maintenance?

(a) General. You must install, operate, and maintain each CPMS specified in paragraphs (c), (e), and (f) of this section according to paragraphs (a)(1) through (6) of this section. * * *

* * * * *

■ 15. Section 63.3561 is amended by revising the definition of "capture system" to read as follows:

§ 63.3561 What definitions apply to this subpart?

* * * * *

Capture system means one or more capture devices intended to collect emissions generated by a coating operation in the use of coatings, both at the point of application and at subsequent points where emissions from the coatings occur, such as flash-off, drying, or curing.

* * * * *

■ 16. Table 4 to Subpart KKKK of Part 63 is amended by redesignating Item

7.a.ii as 7.a.iii and adding a new Item 7.a.ii; and revising newly redesignated Item 7.a.iii, and Items 8.a introductory text, 8.a.i, 8.a.ii, and 8.a.iii to read as follows:

**Table 4 to Subpart KKKK of Part 63—
Operating Limits if Using the Emission
Rate With Add-On Controls Option or
the Control Efficiency/Outlet
Concentration Compliance Option**

7. * * *
a. * * *
i. * * *
ii. Reducing the data collected each successive 15-minute period to 3-hour block averages according to § 63.3547(a)(1) and (2) or § 63.3557(a)(1) and (2), as applicable; and
iii. Maintaining the 3-hour block average facial velocity of air flow through all natural draft openings or the pressure drop at or above the facial

velocity limit or pressure drop limit, and maintaining the direction of air flow into the enclosure at all times.

8. * * *
a. The average gas volumetric flow rate at a location upstream of the control device, or duct static pressure at a location upstream (i.e., vacuum side) of the primary fan in each duct of each capture device or upstream of the fan that is common to multiple capture devices in each 3-hour period must not fall below the average volumetric flow rate or above the duct static pressure limit established for that capture device in accordance with § 63.3546 or § 63.3556, as applicable.
i. Measuring the gas volumetric flow at a location upstream of the control device, or duct static pressure at a location upstream (i.e., vacuum side) of the primary fan in each duct of each capture device upstream or upstream of

the fan that is common to multiple capture devices; and

- ii. Reducing the data collected each successive 15-minute period to 3-hour block averages according to § 63.3547(a)(1) and (2) or § 63.3557(a)(1) and (2), as applicable; and
iii. Maintaining the 3-hour block average gas volumetric flow rate at a location upstream of the control device, or duct static pressure at a location upstream (i.e., vacuum side) of the primary fan in each duct of each capture device or upstream of the fan that is common to multiple capture devices at or above the average gas volumetric flow rate or below the duct static pressure limit established in accordance with the performance test described in § 63.3546(g).

[FR Doc. 06-70 Filed 1-5-06; 8:45 am]
BILLING CODE 6560-50-P

**ENVIRONMENTAL PROTECTION
AGENCY**
40 CFR Part 63
[OAR-2003-0005; FRL-8018-8]
RIN 2060-AM28
**National Emission Standards for
Hazardous Air Pollutants: Surface
Coating of Metal Cans**
AGENCY: Environmental Protection
Agency (EPA).

ACTION: Proposed rule; amendments.

SUMMARY: On November 13, 2003, EPA issued national emission standards for hazardous air pollutants (NESHAP) for surface coating of metal cans under section 112 of the Clean Air Act (CAA). This action proposes to amend the final rule to correct errors and clarify sections of the rule.

In the Rules and Regulations section of this **Federal Register**, we are taking direct final action on the proposed amendments because we view the amendments as noncontroversial and anticipate no adverse comments. We have explained our reasons for the amendments in the preamble to the direct final rule. If we receive no adverse comments, the changes set forth in the direct final action will become effective and we will take no further action on the proposed amendments. If we receive adverse comment on one or more distinct amendments, we will publish a timely withdrawal in the **Federal Register** indicating which amendments in the direct final rule will become effective and which amendments are being withdrawn due to adverse comment. If part or all of the direct final rule in the Rules and Regulations section of today's **Federal Register** is withdrawn, all comments pertaining to the amendments will be addressed in a subsequent final rule based on these proposed amendments. We will not institute a second comment period on the subsequent final rule. Any parties interested in commenting must do so at this time.

DATES: *Comments.* Written comments must be received on or before February 6, 2006 unless a public hearing is requested. If requested by January 23, 2006, a hearing will be held on February 6, 2006 and the comment period will be extended until March 7, 2006.

ADDRESSES: Submit your comments, identified by Docket ID No. OAR-2003-0005, by one of the following methods:

- Federal eRulemaking Portal: <http://www.regulations.gov>. Follow the on-line instructions for submitting comments.

- Agency Web site: <http://docket.epa.gov/edkpub/index.jsp>. EDOCKET, EPA's electronic public docket and comment system, is EPA's preferred method for receiving comments. Follow the on-line instructions for submitting comments.

- E-mail: a-and-r-docket@epa.gov and almodovar.paul@epa.gov.

- Fax: (202) 566-1741 and (919) 541-5689.

- Mail: U.S. Postal Service, send comments to: EPA Docket Center (6102T), Attention Docket ID No. OAR-2003-0005, 1200 Pennsylvania Ave., NW., Washington, DC 20460. Please include a total of two copies. We request that you also send a separate copy of each comment to the contact person listed below (see **FOR FURTHER INFORMATION CONTACT**).

- Hand Delivery: In person or by courier, deliver comments to: EPA Docket Center (6102T), Attention Docket ID No. OAR-2003-0005, 1301 Constitution Ave., NW., Room B-108, Washington, DC 20004. Such deliveries are only accepted during the Docket's normal hours of operation, and special arrangements should be made for deliveries of boxed information. Please include a total of two copies. We request that you also send a separate copy of each comment to the contact person listed below (see **FOR FURTHER INFORMATION CONTACT**).

Instructions: Direct your comments to Docket ID No. OAR-2003-0005. The EPA's policy is that all comments received will be included in the public docket without change and may be made available online at <http://docket.epa.gov/edkpub/index.jsp>, including any personal information provided, unless the comment includes information claimed to be confidential business information (CBI) or other information whose disclosure is restricted by statute. Do not submit information that you consider to be CBI or otherwise protected through EDOCKET, regulations.gov, or e-mail. Send or deliver information identified as CBI only to the following address: Mr. Roberto Morales, OAQPS Document Control Officer, EPA (C404-02), Attention Docket ID No. OAR-2003-0005, Research Triangle Park, NC 27711. Clearly mark the part or all of the information that you claim to be CBI. The EPA EDOCKET and the Federal regulations.gov websites are "anonymous access" systems, which means EPA will not know your identity

or contact information unless you provide it in the body of your comment. If you send an e-mail comment directly to EPA without going through EDOCKET or regulations.gov, your e-mail address will be automatically captured and included as part of the comment that is placed in the public docket and made available on the Internet. If you submit an electronic comment, EPA recommends that you include your name and other contact information in the body of your comment and with any disk or CD-ROM you submit. If EPA cannot read your comment due to technical difficulties and cannot contact you for clarification, EPA may not be able to consider your comment. Electronic files should avoid the use of special characters, any form of encryption, and be free of any defects or viruses. For additional information about EPA's public docket, visit EDOCKET on-line or see the **Federal Register** of May 31, 2002 (67 FR 38102).

Docket: All documents in the docket are listed in the EDOCKET index at <http://docket.epa.gov/edkpub/index.jsp>. Although listed in the index, some information is not publicly available, i.e., CBI or other information whose disclosure is restricted by statute. Certain other material, such as copyrighted material, is not placed on the Internet and will be publicly available only in hard copy form. Publicly available docket materials are available either electronically in EDOCKET or in hard copy at the EPA Docket Center, Docket ID No. OAR-2003-0005, EPA West Building, Room B-102, 1301 Constitution Ave., NW., Washington, DC. The Public Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday through Friday, excluding legal holidays. The telephone number for the Public Reading Room is (202) 566-1744, and the telephone number for the EPA Docket Center is (202) 566-1742. A reasonable fee may be charged for copying docket materials.

FOR FURTHER INFORMATION CONTACT: For further information, contact Mr. Paul Almodovar, EPA, Office of Air Quality Planning and Standards, Emission Standards Division, Coatings and Consumer Products Group (C539-03), Research Triangle Park, NC 27711; telephone number (919) 541-0283; fax number (919) 541-5689; e-mail address: almodovar.paul@epa.gov.

SUPPLEMENTARY INFORMATION:

Regulated Entities. Categories and entities potentially regulated by this action include:

Category	NAICS* Code	Examples of regulated entities
Industry	332431	Two piece beverage can facilities.
	332431	Three piece food can facilities, two piece D&I facilities, one piece aerosol can facilities, etc.
	332115	
	332116	
	332812	
	332999	
	332431	Can assembly facilities.
	332431	End manufacturing facilities.
	332812	

*North American Industry Classification System.

This table is not intended to be exhaustive, but rather provides a guide for readers regarding entities likely to be regulated by this action. To determine whether your facility is regulated by this action, you should examine the applicability criteria in 40 CFR 63.3481 and 40 CFR 63.3482 of the Metal Can NESHAP (68 FR 64432, November 13, 2003). If you have any questions regarding the applicability of this action to a particular entity, consult the person listed in the preceding **FOR FURTHER INFORMATION CONTACT** section.

Submitting CBI. Do not submit information which you claim to be CBI to EPA through EDOCKET, regulations.gov, or e-mail. Clearly mark the part or all of the information that you claim to be CBI. For CBI information in a disk or CD ROM that you mail to EPA, mark the outside of the disk or CD ROM as CBI and then identify electronically within the disk or CD ROM the specific information that is claimed as CBI. In addition to one complete version of the comment that includes information claimed as CBI, a copy of the comment that does not contain the information claimed as CBI must be submitted for inclusion in the public docket. Information so marked will not be disclosed except in accordance with procedures set forth in 40 CFR part 2.

Public Hearing. If a public hearing is held, it will be held at 10 a.m. at the EPA Facility Complex in Research Triangle Park, NC, or at an alternate site nearby. Persons interested in presenting oral testimony or inquiring as to whether a hearing is to be held should contact Ms. Janet Eck, EPA, Office of Air Quality Planning and Standards, Emission Standards Division, Coatings and Consumer Products Group (C539-03), Research Triangle Park, NC 27711,

telephone number (919) 541-7946, e-mail address: eck.janet@epa.gov, at least 2 days in advance of the potential date of the public hearing. Persons interested in attending the public hearing must also call Ms. Eck to verify the time, date, and location of the hearing. The public hearing will provide interested parties the opportunity to present data, views, or arguments concerning these proposed emission standards. *World Wide Web (WWW)*. In addition to being available in the docket, an electronic copy of today's proposal will also be available through the WWW. Following the Administrator's signature, a copy of this action will be posted on EPA's Technology Transfer Network (TTN) policy and guidance page for newly proposed or promulgated rules at <http://www.epa.gov/ttn/oarpg/>. The TTN at EPA's web site provides information and technology exchange in various areas of air pollution control.

Statutory and Executive Order Reviews

For a complete discussion of all of the administrative requirements applicable to this action, see the direct final rule in the Rules and Regulations section of today's **Federal Register**.

Regulatory Flexibility Act

The Regulatory Flexibility Act (RFA) generally requires an agency to prepare a regulatory flexibility analysis of any rule subject to notice and comment rulemaking requirements under the Administrative Procedure Act or any other statute unless the agency certifies that the rule will not have a significant economic impact on a substantial number of small entities. Small entities include small businesses, small organizations, and small governmental jurisdictions.

For purposes of assessing the impact of today's technical amendments on small entities, a small entity is defined as: (1) A small business ranging from 500 to 1,000 employees as defined by the Small Business Administration's size standards; (2) a small governmental jurisdiction that is a government of a city, county, town, school district or special district with a population of less than 50,000; and (3) a small organization that is any not-for-profit enterprise which is independently owned and operated and is not dominant in its field.

After considering the economic impacts of today's proposed rule amendments on small entities, I certify that the proposed rule amendments will not have a significant economic impact on a substantial number of small entities. The proposed rule amendments will not impose any new requirements on small entities. We continue to be interested in the potential impacts of the proposed rule on small entities and welcome comments on issues related to such impacts.

For information regarding other administrative requirements for this action, please see the direct final rule action that is located in the Rules and Regulations section of this **Federal Register**.


List of Subjects in 40 CFR Part 63

Environmental protection, Air pollution control, Hazardous substances, Reporting and recordkeeping requirements.

Dated: December 29, 2005.

Stephen L. Johnson,
Administrator.

[FR Doc. 06-68 Filed 1-5-06; 8:45 am]
BILLING CODE 6560-50-P



47 CFR	8.....221	38.....227	49 CFR
73.....245, 246, 247, 877	9.....219, 227	39.....211, 227	571.....877
Proposed Rules:	11.....211, 227	42.....200, 221	
73.....312, 313	12.....211, 219, 220	43.....227	50 CFR
	14.....219	44.....225	223.....834
48 CFR	16.....211	46.....200, 227	224.....834
Ch. 1.....198, 228, 864, 866	17.....219	47.....200	299.....247
1.....200	19.....220, 221	48.....227	600.....27
2.....208, 211	22.....219, 864	50.....227	635.....273
4.....208	25.....219, 221, 223, 224, 227, 864	52.....200, 208, 219, 221, 224, 225, 226, 227, 864	Proposed Rules:
5.....219, 220	27.....227	53.....200	17.....315
6.....219	34.....227	Proposed Rules:	679.....386
7.....208, 211	37.....211	9903.....313	

REMINDERS

The items in this list were editorially compiled as an aid to Federal Register users. Inclusion or exclusion from this list has no legal significance.

RULES GOING INTO EFFECT JANUARY 6, 2006**AGRICULTURE DEPARTMENT****Agricultural Marketing Service**

Melons grown in—

South Texas; published 12-7-05

COMMERCE DEPARTMENT National Oceanic and Atmospheric Administration

Fishery conservation and management:

West Coast States and Western Pacific fisheries—

Highly migratory species; commercial and recreational charter fishing; vessels; data collection requirements; published 11-7-05

ENVIRONMENTAL PROTECTION AGENCY

Air pollution control; new motor vehicles and engines: Diesel fuel sulfur transition provisions; highway and nonroad diesel and Tier 2 gasoline programs; published 11-22-05

GENERAL SERVICES ADMINISTRATION

Federal travel:

2006 privately owned vehicle mileage reimbursement; published 1-6-06

HEALTH AND HUMAN SERVICES DEPARTMENT**Food and Drug Administration**

Animal drugs, feeds, and related products:

Phenylbutazone powder; published 1-6-06

TREASURY DEPARTMENT Fiscal Service

Financial Management Service:

Automated Clearing House; Federal agency participation; published 11-7-05

TREASURY DEPARTMENT Alcohol and Tobacco Tax and Trade Bureau

Alcohol; viticultural area designations:

Ramona Valley, San Diego County, CA; published 12-7-05

Sta. Rita Hills, Santa Barbara County, CA; name change; published 12-7-05

Texoma; Montague, Cooke, Grayson and Fannin Counties, TX; published 12-7-05

Wahluke Slope, Grant County, WA; published 12-7-05

RULES GOING INTO EFFECT JANUARY 7, 2006**COMMERCE DEPARTMENT National Oceanic and Atmospheric Administration**

Fishery conservation and management:

Atlantic highly migratory species—
Atlantic bluefin tuna; published 1-9-06

RULES GOING INTO EFFECT JANUARY 8, 2006**POSTAL SERVICE**

Domestic Mail Manual:

International rate schedules; Marshall Islands and Micronesia; published 11-23-05

Postal rates and fees; published 12-2-05

International Mail Manual:

Marshall Islands and Micronesia; published 11-23-05

Postal rate and fee changes; published 11-23-05

COMMENTS DUE NEXT WEEK**AGRICULTURE DEPARTMENT****Agricultural Marketing Service**

Pears grown in—

Oregon and Washington; comments due by 1-9-06; published 12-9-05 [FR 05-23819]

AGRICULTURE DEPARTMENT**Animal and Plant Health Inspection Service**

Exportation and importation of animals and animal products:

Cattle from Mexico; fever-ticks infestation or

exposure; comments due by 1-9-06; published 11-9-05 [FR 05-22337]

COMMERCE DEPARTMENT National Oceanic and Atmospheric Administration

Fishery conservation and management:

Alaska; fisheries of Exclusive Economic Zone—

Gulf of Alaska groundfish; comments due by 1-13-06; published 11-29-05 [FR 05-23465]

Northeastern United States fisheries—

American lobster; comments due by 1-12-06; published 12-13-05 [FR 05-23984]

Marine mammals:

Taking and importing—

Hawaiian Islands; spinner dolphin protection from human activities; comments due by 1-11-06; published 12-12-05 [FR 05-23928]

DEFENSE DEPARTMENT**Army Department**

Law enforcement and criminal investigations:

Sexual assaults; law enforcement reporting; comments due by 1-9-06; published 12-9-05 [FR 05-23853]

DEFENSE DEPARTMENT

Acquisition regulations:

Contract administration functions; comments due by 1-9-06; published 11-9-05 [FR 05-22113]

ENERGY DEPARTMENT**Federal Energy Regulatory Commission**

Electric utilities (Federal Power Act):

Pricing reform; transmission investment promotion; comments due by 1-11-06; published 11-29-05 [FR 05-23404]

ENVIRONMENTAL PROTECTION AGENCY

Air pollution control:

Alaska alternative low-sulfur diesel fuel transition program; highway, nonroad, locomotive, and marine diesel fuel requirements; comments due by 1-11-06; published 10-13-05 [FR 05-20519]

Air pollution control; new motor vehicles and engines:

Evaporative emissions, dynamometer regulations, and vehicle labeling;

technical amendments; comments due by 1-9-06; published 12-8-05 [FR 05-23713]

Air programs:

Ambient air quality

standards, national—
Fine particulate matter and ozone; interstate transport control measures; reconsideration; comments due by 1-13-06; published 12-2-05 [FR 05-23501]

Air programs; State authority delegations:

New Mexico; comments due by 1-9-06; published 12-9-05 [FR 05-23809]

Oklahoma; comments due by 1-12-06; published 12-13-05 [FR 05-23970]

Air quality implementation plans; approval and promulgation; various States:

Texas; comments due by 1-11-06; published 12-12-05 [FR 05-23915]

Air quality planning purposes; designation of areas:

South Dakota; comments due by 1-9-06; published 12-9-05 [FR 05-23808]

Pesticides; tolerances in food, animal feeds, and raw agricultural commodities:

2-bromo-2-nitro-1,3-propanediol; comments due by 1-9-06; published 11-9-05 [FR 05-22255]

Flucarbazono-sodium; comments due by 1-9-06; published 11-9-05 [FR 05-22254]

Superfund program:

Toxic chemical release reporting; community-right-to-know—

Toxics Release Inventory Program Burden Reduction; comments due by 1-13-06; published 10-4-05 [FR 05-19710]

Toxics Release Inventory Program Burden Reduction; comments due by 1-13-06; published 11-29-05 [FR 05-23416]

Water pollution; effluent guidelines for point source categories:

Meat and poultry products processing facilities; Open for comments until further notice; published 9-8-04 [FR 04-12017]

Water programs:

Oil pollution prevention; non-transportation-related

onshore facilities;
comments due by 1-11-06; published 12-12-05 [FR 05-23916]

EQUAL EMPLOYMENT OPPORTUNITY COMMISSION

Freedom of Information Act (FOIA):

Fee schedule; revision; comments due by 1-11-06; published 12-12-05 [FR E5-07177]

FEDERAL COMMUNICATIONS COMMISSION

Radio stations; table of assignments:

Kentucky and Virginia; comments due by 1-9-06; published 11-23-05 [FR 05-23185]

FEDERAL ELECTION COMMISSION

Coordinated and independent expenditures:

Coordinated communications; comments due by 1-13-06; published 12-14-05 [FR E5-07293]

FEDERAL RESERVE SYSTEM

Equal Employment Opportunity

Rules; non-citizen employees, sensitive information access limitations; comments due by 1-9-06; published 11-8-05 [FR 05-22223]

FEDERAL TRADE COMMISSION

Appliances, consumer; energy consumption and water use information in labeling and advertising:

Energy efficiency labeling; comments due by 1-13-06; published 11-2-05 [FR 05-21817]

HEALTH AND HUMAN SERVICES DEPARTMENT

Centers for Medicare & Medicaid Services

Medicare:

Hospital outpatient prospective payment system and 2006 CY payment rates; comments due by 1-9-06; published 11-10-05 [FR 05-22136]

HEALTH AND HUMAN SERVICES DEPARTMENT

Food and Drug Administration

Food additives:

Direct food additives—
Synthetic fatty alcohols; comments due by 1-9-06; published 12-8-05 [FR 05-23745]

INTERIOR DEPARTMENT

Fish and Wildlife Service

Endangered and threatened species:

Critical habitat designations—
Braunton's milk-vetch and Lyon's pentachaeta; comments due by 1-9-06; published 11-10-05 [FR 05-22191]
Willow monardella; comments due by 1-9-06; published 11-9-05 [FR 05-22190]

Migratory bird permits:

Raptor propagation; comments due by 1-12-06; published 10-14-05 [FR 05-20596]

INTERIOR DEPARTMENT

Minerals Management Service

Outer Continental Shelf; oil, gas, and sulphur operations: Oil and gas activities; costs recovery; comments due by 1-13-06; published 11-14-05 [FR 05-22504]

LABOR DEPARTMENT

Occupational Safety and Health Administration

Construction and occupational safety and health standards:

Electric power generation, transmission, and distribution standard and electrical protective equipment standard; comments due by 1-11-06; published 10-12-05 [FR 05-20421]

ARTS AND HUMANITIES, NATIONAL FOUNDATION

National Foundation on the Arts and the Humanities

Organization, functions, and authority delegations:

Institute of Museum and Library Services; new reauthorization legislation; technical amendments; comments due by 1-13-06; published 12-14-05 [FR 05-24007]

TRANSPORTATION DEPARTMENT

Federal Aviation Administration

Airworthiness directives:

Aerospatiale; comments due by 1-9-06; published 12-13-05 [FR 05-23953]
Airbus; comments due by 1-13-06; published 11-14-05 [FR 05-22213]
BAE Systems (Operations) Ltd.; comments due by 1-9-06; published 12-8-05 [FR 05-23778]

Boeing; Open for comments until further notice; published 8-16-04 [FR 04-18641]

Bombardier; comments due by 1-13-06; published 11-14-05 [FR 05-22309]

Empresa Brasileira de Aeronautica S.A. (EMBRAER); comments due by 1-12-06; published 12-13-05 [FR 05-23954]

Empresa Brasileira de Aeronautica, S.A. (EMBRAER); comments due by 1-13-06; published 11-14-05 [FR 05-22442]

General Electric Co.; comments due by 1-9-06; published 11-9-05 [FR 05-22207]

Rolls-Royce Corp.; comments due by 1-9-06; published 11-10-05 [FR 05-22437]

Class E airspace; comments due by 1-13-06; published 12-14-05 [FR 05-24000]

LIST OF PUBLIC LAWS

This is a continuing list of public bills from the current session of Congress which have become Federal laws. It may be used in conjunction with "PLUS" (Public Laws Update Service) on 202-741-6043. This list is also available online at <http://www.archives.gov/federal-register/laws.html>.

The text of laws is not published in the **Federal Register** but may be ordered in "slip law" (individual pamphlet) form from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 (phone, 202-512-1808). The text will also be made available on the Internet from GPO Access at <http://www.gpoaccess.gov/plaws/index.html>. Some laws may not yet be available.

H.R. 2863/P.L. 109-148

Department of Defense, Emergency Supplemental Appropriations to Address Hurricanes in the Gulf of Mexico, and Pandemic Influenza Act, 2006 (Dec. 30, 2005; 119 Stat. 2680)

H.R. 3010/P.L. 109-149

Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2006. (Dec. 30, 2005; 119 Stat. 2833)

H.R. 4525/P.L. 109-150

Second Higher Education Extension Act of 2005 (Dec. 30, 2005; 119 Stat. 2884)

H.R. 4579/P.L. 109-151

To amend title I of the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to extend by one year provisions requiring parity in the application of certain limits to mental health benefits. (Dec. 30, 2005; 119 Stat. 2886)

S. 205/P.L. 109-152

Buffalo Soldiers Commemoration Act of 2005 (Dec. 30, 2005; 119 Stat. 2887)

S. 652/P.L. 109-153

Benjamin Franklin National Memorial Commemoration Act of 2005 (Dec. 30, 2005; 119 Stat. 2889)

S. 1238/P.L. 109-154

Public Lands Corps Healthy Forests Restoration Act of 2005 (Dec. 30, 2005; 119 Stat. 2890)

S. 1281/P.L. 109-155

National Aeronautics and Space Administration Authorization Act of 2005 (Dec. 30, 2005; 119 Stat. 2895)

S. 1310/P.L. 109-156

Delaware Water Gap National Recreation Area Improvement Act (Dec. 30, 2005; 119 Stat. 2946)

S. 1481/P.L. 109-157

Indian Land Probate Reform Technical Corrections Act of 2005 (Dec. 30, 2005; 119 Stat. 2949)

S. 1892/P.L. 109-158

To amend Public Law 107-153 to modify a certain date. (Dec. 30, 2005; 119 Stat. 2954)

S. 1988/P.L. 109-159

To authorize the transfer of items in the War Reserves Stockpile for Allies, Korea. (Dec. 30, 2005; 119 Stat. 2955)

S. 2167/P.L. 109-160

To amend the USA PATRIOT ACT to extend the sunset of certain provisions of that Act and the lone wolf provision of the Intelligence Reform and Terrorism Prevention Act of 2004 to July 1, 2006. (Dec. 30, 2005; 119 Stat. 2957)

H.R. 4635/P.L. 109-161

TANF and Child Care Continuation Act of 2005 (Dec. 30, 2005; 119 Stat. 2958)

Last List December 28, 2005

**Public Laws Electronic
Notification Service
(PENS)**

PENS is a free electronic mail notification service of newly

enacted public laws. To subscribe, go to <http://listserv.gsa.gov/archives/publaws-l.html>

Note: This service is strictly for E-mail notification of new laws. The text of laws is not available through this service.

PENS cannot respond to specific inquiries sent to this address.

Public Laws

109th Congress

Pamphlet prints of public laws, often referred to as slip laws, are the initial publication of Federal laws upon enactment and are printed as soon as possible after approval by the President. Legislative history references appear on each law. Subscription service includes all public laws, issued irregularly upon enactment, for the 109th Congress.


Individual laws also may be purchased from the Superintendent of Documents, U.S. Government Printing Office. Prices vary. See Reader Aids Section of the Federal Register for announcements of newly enacted laws or access the online database at <http://www.gpoaccess.gov/plaws/index.html>

Superintendent of Documents Subscriptions Order Form

Order Processing Code:

* 6216

YES, enter my subscription(s) as follows:

Charge your order.  
It's Easy!

To fax your orders (202) 512-2250
Phone your orders (202) 512-1800

_____ subscriptions to **PUBLIC LAWS** for the 109th Congress for \$317 per subscription.

The total cost of my order is \$ _____. Price includes regular domestic postage and handling and is subject to change. International customers please add 25%.

Company or personal name (Please type or print)

Additional address/attention line

Street address

City, State, ZIP code

Daytime phone including area code

Purchase order number (optional)

May we make your name/address available to other mailers?

YES NO


Please Choose Method of Payment:

- Check Payable to the Superintendent of Documents
 GPO Deposit Account [] [] [] [] [] [] [] [] - []
 VISA* MasterCard Account
[]
[] [] [] [] (Credit card expiration date) **Thank you for your order!**

Authorizing signature

6/05

Mail To: Superintendent of Documents
P.O. Box 371954, Pittsburgh, PA 15250-7954





Printed on recycled paper

